<SEC-DOCUMENT>0001193125-23-021669.txt : 20230201
<SEC-HEADER>0001193125-23-021669.hdr.sgml : 20230201
<ACCEPTANCE-DATETIME>20230201170718
ACCESSION NUMBER:		0001193125-23-021669
CONFORMED SUBMISSION TYPE:	F-4/A
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20230201
DATE AS OF CHANGE:		20230201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oculis Holding AG
		CENTRAL INDEX KEY:			0001953530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268201
		FILM NUMBER:		23577762

	BUSINESS ADDRESS:	
		STREET 1:		BAHNHOFSTRASSE 7
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		617-937-2423

	MAIL ADDRESS:	
		STREET 1:		BAHNHOFSTRASSE 7
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-4/A
<SEQUENCE>1
<FILENAME>d389734df4a.htm
<DESCRIPTION>F-4/A
<TEXT>
<HTML><HEAD>
<TITLE>F-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on February&nbsp;1, 2023. </B></P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268201</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 4 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">F-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Oculis Holding AG </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Bahnhofstrasse 7</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CH-6300</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Zug, Switzerland</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Tel.: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+41-58-810-0182</FONT></FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal
Executive Offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Corporation Service Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>19 West 44th Street, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10036 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(800) 927-9801 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of
all correspondence to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Michael Davis</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Derek Dostal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Davis&nbsp;Polk&nbsp;&amp; Wardwell&nbsp;LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New&nbsp;York&nbsp;10017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (212) <FONT STYLE="white-space:nowrap">450-4000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Dr.&nbsp;Matthias Staehelin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Vischer AG</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Aeschenvorstadt 4 Postfach</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>4010 Basel, Switzerland</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +41 58 211 33 00</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Katie Kazem</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ryan
Sansom</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston,&nbsp;Massachusetts&nbsp;02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (617) <FONT STYLE="white-space:nowrap">937-2300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Michal Berkner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cooley (UK) LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>22
Bishopsgate</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>London, UK EC2N 4BQ</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +44 20 7583 4055</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this Registration Statement becomes
effective and on completion of the Business Combination described in the enclosed proxy statement/prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">If this form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-l(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8.5pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information contained in this preliminary proxy statement/prospectus is subject to
completion or amendment. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration
statement becomes effective. This preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction in
which such offer, solicitation or sale is not permitted or would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY PROXY STATEMENT AND PROSPECTUS
</B></FONT></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED FEBRUARY&nbsp;1, 2023 </B></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>European Biotech Acquisition Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EPFL Innovation Park, Bat D </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3e Route J-D. Colladon </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
OF EUROPEAN BIOTECH ACQUISITION CORP. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS FOR 44,524,604 ORDINARY SHARES AND 4,403,294 WARRANTS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OCULIS HOLDING AG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear EBAC Shareholder:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend an extraordinary general meeting of the shareholders of European Biotech Acquisition Corp., a Cayman Islands exempted
company (&#147;<I>EBAC</I>&#148;, &#147;<I>we</I>&#148;, &#147;<I>us</I>&#148; or &#147;<I>our</I>&#148;) (the &#147;<I>Extraordinary General Meeting</I>&#148;), which will be held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, at EBAC&#146;s corporate address, located at EPFL Innovation Park, Bat&nbsp;D, 3e&nbsp;Route J-D.
Colladon, CH-1015 Lausanne, Switzerland and virtually via a live webcast at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or at such other time, on such other date and at such other place to which the meeting may be
adjourned. To attend the meeting virtually please visit &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and use a <FONT STYLE="white-space:nowrap">12-digit</FONT> control number assigned by Continental Stock
Transfer&nbsp;&amp; Trust Company included on your proxy card or notice of the Extraordinary General Meeting. To register and receive access to the virtual meeting, registered shareholders and beneficial shareholders (i.e., those holding shares
through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, EBAC and Oculis SA, a stock corporation (<I></I><I>Aktiengesellschaft</I>) incorporated and existing under the laws of Switzerland
(&#147;<I>Oculis</I>&#148; or the &#147;<I>Company</I>&#148;) entered into a Business Combination Agreement (as it may be amended from time to time, the &#147;<I>Business Combination Agreement</I>&#148;), attached hereto as <U>Annex A</U>, pursuant
to which, among other things, shareholders of each of EBAC and Oculis will exchange their securities in those entities for securities of Oculis Holding AG, a stock corporation (<I>Aktiengesellschaft</I>) incorporated and existing under the laws of
Switzerland and that is a direct wholly owned subsidiary of EBAC (&#147;<I>New Parent</I>&#148;<I>)</I>. Following the execution of the Business Combination Agreement, New Parent formed each of Oculis Merger Sub I Company, a Cayman Islands exempted
company and a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 1</I>&#148;), Oculis Merger Sub II Company, a Cayman Islands exempted company and a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 2</I>&#148;) and
Oculis Operations GmbH, a limited liability company (<I>Gesellschaft mit beschr&auml;nkter Haftung</I>) incorporated and existing under the laws of Switzerland and a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 3</I>&#148;) for
the purposes of carrying out the transactions therein and in connection therewith. To effectuate the Business Combination and related transactions contemplated by the Business Combination Agreement (and described therein), among other things and
subject to the terms and conditions therein, the Business Combination Agreement and the Ancillary Agreements (as defined below) provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Investors (as defined below) will transfer $71,188,910 to EBAC in exchange for 7,118,891&nbsp;shares
of EBAC Class&nbsp;A Common Stock (the &#147;<I>PIPE Shares</I>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease and
EBAC will be the surviving company and a wholly owned subsidiary of New Parent (the &#147;<I>First Merger</I>,&#148; and the time at which the First Merger becomes effective, the &#147;<I>First</I> <I>Merger Effective Time</I>&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as part of the First Merger, (i)&nbsp;each share of EBAC Common Stock (including those held by the PIPE
Investors) shall be automatically converted into one class of common stock of EBAC, as the surviving company of the First Merger (the &#147;<I>Surviving EBAC Shares</I>&#148;), (ii) each EBAC Warrant (as defined below) outstanding immediately prior
to the First Merger Effective time will be automatically converted into warrants of EBAC, as the surviving company of the First Merger (&#147;<I>Surviving EBAC Warrants</I>&#148;) and (iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the
Exchange Agent (as defined below) (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms and subject to the conditions set forth in the Business Combination
Agreement and in the Ancillary Agreements (as defined below); </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date (as defined in the Business Combination Agreement) and following
the First Merger Effective Time but prior to the Second Merger Effective Time (as defined below), the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent (the &#147;<I>Exchange Agent
Contribution</I>&#148;) in exchange for (i)&nbsp;New Parent ordinary shares, nominal value CHF 0.01 (&#147;<I>New Parent Shares</I>&#148;) and (ii)&nbsp;a right to acquire New Parent Shares (&#147;<I>New Parent Warrants</I>&#148;), in each case of
(i)&nbsp;and (ii), to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the &#147;<I>New Parent Interests Consideration</I>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to
the Second Merger Effective Time, the Exchange Agent will undertake to distribute the (i)&nbsp;New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii)&nbsp;New Parent Warrants as part of
the New Parent Interests Consideration to the holders of Surviving EBAC Warrants (&#147;<I>Exchange Agent Contribution Actions</I>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution
Actions, at the Second Merger Effective Time, EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent (the
&#147;<I>Second Merger</I>&#148; and the time at which the Second Merger becomes effective, the &#147;<I>Second Merger Effective Time</I>&#148;, and the Second Merger, together with the First Merger, the &#147;<I>EBAC Mergers</I>&#148;), and
following the Acquisition Closing, Merger Sub 2 shall be liquidated and its assets distributed to New Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the Second Merger Effective Time but before the Oculis Share Contribution (as defined below), it is the
intention of the parties to the Convertible Loan Agreements (as defined below) that New Parent will assume the Convertible Loan Agreements, pursuant to which certain Oculis Shareholders (as defined below) (the &#147;<I>Lenders</I>&#148;) granted
Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $19,670,000, and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights
in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing
Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the contribution to New Parent of all Company Share Capital held by such Oculis Shareholders free and clear of all liens
(other than general restrictions on transfer under applicable securities laws or the articles of association of Oculis) in exchange for New Parent Shares on the terms and subject to the conditions set forth in the Business Combination Agreement and
Oculis Shareholders Support Agreement (as defined below); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ix.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately 30 days after the closing of the EBAC Mergers, pursuant to a merger agreement to be entered into
in accordance with Section&nbsp;9.10 of the Business Combination Agreement, Oculis will merge with and into Merger Sub 3, the separate corporate existence of Oculis will cease and Merger Sub 3 will be the surviving company and remain a wholly owned
subsidiary of New Parent (the &#147;<I>Third Merger</I>&#148; and together with the EBAC Mergers, the &#147;<I>Mergers</I>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, certain Oculis equityholders will receive additional consideration in the form of an earnout of, collectively, 4,000,000 newly issued New Parent Shares and options underlying such New Parent Shares (&#147;<I>Earnout Options</I>&#148;),
that will be received pro rata in proportion to their equity interests in Oculis as of the date of the Business Combination Agreement (the &#147;<I>Earnout Consideration</I>&#148;). The Earnout Consideration will be issued to such Oculis
equityholders upon the Acquisition Closing but shall initially be unvested and subject to forfeiture in the event of a failure to achieve the performance targets. The Earnout Consideration will consist of three tranches of New Parent Shares
(&#147;<I>Earnout Shares</I>&#148;), as follows (in the case of each tranche, <I>minus</I> any Earnout Options granted to replace vested options to purchase shares of Oculis common stock): (i) 1,500,000, (ii) 1,500,000 and (iii) 1,000,000, vesting
based on the achievement of post-Acquisition Closing share price targets of New Parent Shares of $15.00, $20.00 and $25.00, respectively, in each case, for any 20 trading days within any consecutive 30 trading day period commencing after the
Acquisition Closing Date and ending on or prior to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fifth anniversary of the Acquisition Closing Date (the &#147;<I>Earnout Period</I>&#148;). A given share price target described above will also be deemed to be achieved (to the extent such
target has not already been achieved) if there is a Change of Control (as defined in the Business Combination Agreement) transaction of New Parent during the Earnout Period. Such Oculis equityholders&#146; right and entitlement to receive the
Earnout Consideration will be forfeited to the extent that the relevant share price targets have not been achieved by the fifth anniversary of the Acquisition Closing Date. The Earnout Shares shall not be entitled to vote on matters submitted to the
holders of New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New Parent Shares, if any, until the achievement of such share price targets specified above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor (as defined below) will forfeit 727,096 of its shares of EBAC Class&nbsp;B Common Stock (as defined below) for no consideration, contingent upon
the consummation of the Acquisition Closing. Furthermore, if as of the Acquisition Closing Date (i)&nbsp;the amount of cash available in the Trust Account (as defined below) following the Extraordinary General Meeting (after deducting the EBAC Share
Redemption Amount (as defined below) but before payment of any transaction expenses of Oculis or EBAC), plus (ii)&nbsp;the PIPE Investment Amount (as defined below) actually received by New Parent (or other financing, including through a convertible
loan, in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing from a PIPE Investor or other investor that in either case has been introduced to Oculis following the date of the Business
Combination Agreement by the Sponsor or its affiliates, is less than $25,500,000, then the Sponsor will forfeit for no consideration an additional number of EBAC Class&nbsp;B Common Stock (the &#147;<I>Additional
<FONT STYLE="white-space:nowrap">At-Risk</FONT> Shares</I>&#148;) proportional to the available cash relative to the $25,500,000 threshold (up to a maximum of 1,594,348 Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Shares); provided
that such amount may be reduced by the number of Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Shares transferred by the Sponsor to EBAC Shareholders in connection with executing a <FONT STYLE="white-space:nowrap">Non-Redemption</FONT>
Agreement or similar arrangement after the date hereof; provided further that, the number of shares transferred to any such shareholder does not exceed 10% of the number of EBAC Class&nbsp;A Common Stock owned by such shareholder as of the date of
such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the foregoing and concurrently with the
execution of the Business Combination Agreement, EBAC entered into subscription agreements with the Initial PIPE Investors (the &#147;<I>Initial Subscription Agreements</I>&#148;), pursuant to which the Initial PIPE Investors have agreed to purchase
from EBAC, severally and not jointly, and EBAC has agreed to issue from treasury and sell to the Initial PIPE Investors, a number of EBAC Class&nbsp;A Common Stock equal to (i)&nbsp;the total subscription amount from the Initial PIPE Investors
<I>divided </I>by (ii) $10.00 (the &#147;<I>Initial PIPE Financing</I>&#148;). Subsequent to the Initial PIPE Financing, in January 2023, EBAC entered into subscription agreements (the &#147;<I>Subsequent Subscription Agreements</I>&#148;, and
together with the Initial Subscription Agreements, the &#147;<I>Subscription Agreements</I>&#148;) with certain subscribers (the &#147;<I>Subsequent PIPE Investors</I>&#148;, and together with the Initial PIPE Investors, the &#147;<I>PIPE
Investors</I>&#148;), pursuant to which the Subsequent PIPE Investors have agreed to subscribe for, and EBAC has agreed to issue to the Subsequent Subscribers, an aggregate of 788,500 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per
share, for aggregate gross proceeds of $7,885,000 (the &#147;<I>Subsequent PIPE Financing</I>&#148;, and together with the Initial PIPE Financing, the &#147;<I>PIPE Financing</I>&#148;). The aggregate amount of EBAC Class&nbsp;A Common Stock to be
issued pursuant to the PIPE Financing is 7,118,891 shares for aggregate gross proceeds of $71,188,910. The shares of EBAC Class&nbsp;A Common Stock to be issued from treasury pursuant to the Subscription Agreements have not been registered under the
Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act (as defined below). Upon the Acquisition Closing, New Parent will grant the PIPE Investors certain customary registration rights in connection with
the PIPE Financing, including demand and piggyback rights, as set forth in the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (as defined below). The PIPE Financing is contingent upon, among other things, the
Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the Sponsor and certain EBAC Shareholders have agreed pursuant to the Shareholder
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, dated as of October&nbsp;17, 2022 (the &#147;<I><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements</I>&#148;) to, among other things, vote in favor of the transactions
contemplated in the Business Combination Agreement for which the approval of EBAC Shareholders is required and have agreed not to redeem or exercise any right to redeem any shares, capital stock or any other equity interests, as applicable, of EBAC
that the Sponsor or such EBAC shareholder, as applicable, holds of record or beneficially, as of the date of executing such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, or acquires thereafter. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, in connection with their entry into the Business Combination Agreement, Oculis, EBAC, and the
Sponsor entered into a Sponsor Support Agreement (the &#147;<I>Sponsor Letter Agreement</I>&#148;), pursuant to which, among other things, the Sponsor has agreed (i)&nbsp;to vote in favor of the Business Combination Agreement and the transactions
contemplated thereby, subject to the terms and conditions contemplated by the Sponsor Letter Agreement and (ii)&nbsp;to be bound by certain transfer restrictions with respect to the equity interests of EBAC held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Extraordinary General Meeting, EBAC Shareholders will be asked to consider and vote upon a proposal, as an ordinary resolution, to approve the Business
Combination Agreement, and the transactions contemplated thereby (the &#147;<I>Business Combination Proposal</I>&#148; or &#147;<I>Proposal No.</I><I></I><I>&nbsp;1</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Shareholders will also be asked to approve and authorize, by special resolution, the form of plan of merger (the &#147;<I>Plan of Merger</I>&#148;), a
copy of which is attached to the accompanying proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease, and EBAC will be the surviving
company and a direct wholly owned subsidiary of New Parent (the &#147;<I>Merger Proposal</I>&#148; or &#147;<I>Proposal No.</I><I></I><I>&nbsp;2</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Shareholders are also being asked to consider and vote upon a proposal, as an ordinary resolution, to adjourn the Extraordinary General Meeting to a
later date or dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of
the Business Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common
Stock such that the Minimum EBAC Cash Condition (as defined below) would not be satisfied (the &#147;<I>Adjournment Proposal&#148; or &#147;Proposal No.</I><I></I><I>&nbsp;3</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Proposal No.&nbsp;1, Proposal No.&nbsp;2 and Proposal No.&nbsp;3 is more fully described in this proxy statement/prospectus, which each shareholder is
encouraged to read carefully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Class&nbsp;A Common Stock, EBAC Public Units (as defined below) and EBAC Public Warrants (as defined below) are
currently listed on the Nasdaq Capital Market under the symbols &#147;EBAC,&#148; &#147;EBACU&#148; and &#147;EBACW,&#148; respectively. Upon the Acquisition Closing, EBAC&#146;s securities will be delisted from the Nasdaq Capital Market. New Parent
has applied to list the New Parent Shares and New Parent Warrants (as defined below) on the Nasdaq Global Market under the symbols &#147;OCS&#148; and &#147;OCSAW,&#148; respectively, upon the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to EBAC and the holders of the EBAC Common Stock, this proxy statement/prospectus serves as a: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proxy statement for the Extraordinary General Meeting being held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 where EBAC Shareholders will vote on, among other things, a proposal to approve the Business Combination Agreement and the transactions contemplated thereby, including
the Business Combination, and to authorize the Plan of Merger; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prospectus for the New Parent Shares and New Parent Warrants that will be issued in connection with the Business
Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and restated memorandum and articles of association, EBAC is providing its public
shareholders with the opportunity to redeem, subject to the Acquisition Closing being completed, any EBAC Class&nbsp;A Common Stock then held by them for the right to receive an amount in cash equal to each EBAC shareholder&#146;s respective pro
rata share of the aggregate amount on deposit (as of two business days prior to the Acquisition Closing) in the Trust Account that holds the proceeds (including interest accrued thereon, which shall be net of taxes payable) of EBAC&#146;s initial
public offering and certain of the proceeds of the sale of the EBAC Private Placement Units (as defined below). Redemptions referred to herein shall take effect as repurchases into treasury under EBAC&#146;s amended and restated memorandum and
articles of association. The EBAC Share Redemption Amount will be distributed, subject to all conditions to the Acquisition Closing being </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
met, by New Parent to shareholders who properly redeem their EBAC Class&nbsp;A Common Stock. The EBAC Share Redemption Amount will not be reduced by the aggregate deferred underwriting fee that
EBAC will pay to the underwriters of EBAC&#146;s initial public offering or the Transaction Expenses (as defined below), which together are estimated to amount to $7.4&nbsp;million. For illustrative purposes, based on the fair value of marketable
securities held in the Trust Account of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, the estimated redemption price per share of EBAC Class&nbsp;A Common Stock would have been approximately $10.052. The redemption rights include
the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to the Transfer Agent (as defined below) in order to validly redeem its shares. <B><U>Public shareholders may
elect to redeem their shares even if they vote for the Business Combination Proposal and the Merger Proposal</U></B>. A public shareholder, together with any of its affiliates or any other person with whom it is acting in concert or as a
&#147;group&#148; (as defined under Section&nbsp;13 of the Exchange Act (as defined below)), will be restricted from redeeming in the aggregate its shares or, if part of such a group, the group&#146;s shares, in excess of 15% of the outstanding EBAC
Class&nbsp;A Common Stock. EBAC has no specified maximum redemption threshold under its amended and restated memorandum and articles of association, other than the aforementioned 15% threshold. Each redemption of EBAC Class&nbsp;A Common Stock by
EBAC&#146;s public shareholders will reduce the amount in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions to the Acquisition Closing are for the sole benefit of the
parties thereto and may be waived by such parties. The Business Combination Agreement provides that the parties&#146; obligation to consummate the Business Combination is conditioned, among other things, on the amount of cash in the Trust Account
(net of the Cash Redemption Amount (as defined below)) together with the proceeds from the PIPE Financing (or other financing in connection with the EBAC Mergers, such as the Convertible Loan Agreement) (after payment of any unpaid transaction
expenses of Oculis and EBAC) being equal to or greater than $100&nbsp;million (such condition, the &#147;<I>Minimum EBAC Cash Condition</I>&#148;). If, as a result of redemptions of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders,
the Minimum EBAC Cash Condition is not met or is not waived by the parties, then either party may elect not to consummate the Business Combination. In addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would
cause its net tangible assets to be less than $5,000,001, as provided in EBAC&#146;s amended and restated memorandum and articles of association. Unless otherwise specified, the information in this proxy statement/prospectus assumes that none of
EBAC&#146;s public shareholders exercise their redemption rights with respect to their EBAC Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Initial Shareholders (as
defined below) and certain other officers and directors of EBAC have agreed, for no consideration in return, to waive their redemption rights with respect to any Founder Shares (as defined below) they may hold in connection with the consummation of
the Business Combination, and the Founder Shares will be excluded from the pro rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. The Sponsor has agreed to vote any EBAC Common Stock (including
Founder Shares and any other public shares of EBAC as of the record date) owned by it in favor of the Business Combination and the transactions contemplated thereby (including by voting in favor of the Business Combination Proposal and the Merger
Proposal and for any other proposal presented to EBAC Shareholders in this proxy statement/prospectus). The Founder Shares are subject to transfer restrictions. EBAC&#146;s amended and restated memorandum and articles of association includes a
conversion adjustment which provides that the Founder Shares will automatically convert, at the time of the Business Combination, into the number of EBAC Class&nbsp;A Common Stock one day after the Acquisition Closing, at a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> conversion rate. However, the Sponsor has agreed to waive such conversion adjustment pursuant to the Sponsor Letter Agreement, and as referenced above, in
connection with the transactions contemplated hereby, such Founder Shares ultimately become New Parent Shares in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is providing this proxy statement/prospectus and accompanying proxy card to its shareholders in connection with the solicitation of proxies to be voted
at the Extraordinary General Meeting and at any adjournments or postponements of the Extraordinary General Meeting. Information about the Extraordinary General Meeting, the Business Combination and other related business to be considered by EBAC
Shareholders at the Extraordinary General Meeting is included in this proxy statement/prospectus. <B><U>Whether or not you plan to attend the Extraordinary General Meeting, all EBAC Shareholders are urged to read carefully this</U></B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>proxy statement/prospectus, including the Annexes and the accompanying financial statements of New</U></B>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><U>Parent, EBAC and Oculis, carefully and in their entirety. In particular, you are urged to read carefully the section entitled &#147;</U></B><B><I><U><A HREF="#toc389734_10">Risk
Factors</A></U></I></B><B><U>.&#148;</U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>After careful consideration, the EBAC Board has approved the Business Combination Proposal and the
Business Combination, and recommends that EBAC Shareholders vote &#147;FOR&#148; adoption of the Business Combination Agreement and approval of the Business Combination and &#147;FOR&#148; any other</U> <U>proposal presented to EBAC Shareholders in
this proxy statement/prospectus. When considering the EBAC</U> <U>Board&#146;s recommendation of these proposals, you should keep in mind that certain EBAC directors</U> <U>and officers have interests in the Business Combination that may conflict
with your interests as</U> <U>shareholders. Please see the section entitled &#147;</U></B><B><I><U>Proposal No.</U></I></B><B></B><B><I><U></U></I></B><B></B><B><I><U>&nbsp;1&#151;The Business Combination Proposal&#151; Interests of Certain Persons
in the Business Combination</U></I></B><B><U>&#148; for additional information.</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires the
affirmative vote of holders of at least a majority of the EBAC Common Stock that are entitled to vote and are voted at the Extraordinary General Meeting. Approval of the Adjournment Proposal requires the affirmative vote of holders of a majority of
the EBAC Common Stock that are entitled to vote and are voted at the Extraordinary General Meeting. Approval of the Merger Proposal requires the affirmative vote of holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the EBAC
Common Stock that are entitled to vote and are voted at the Extraordinary General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Your vote is very important. Whether or not you plan to
attend the Extraordinary General Meeting, please vote as soon as possible by following the instructions in this proxy statement/prospectus to ensure that your shares are represented at the Extraordinary General Meeting. If you hold your shares in
&#147;street name&#148; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the Extraordinary General
Meeting. The transactions contemplated by the Business Combination Agreement will be consummated only if the Business Combination Proposal and the Merger Proposal are approved at the Extraordinary General Meeting. The Acquisition Closing is
conditioned upon the approval of the Business Combination Proposal and the Merger Proposal. If the Business Combination Proposal and the Merger Proposal are not approved by the shareholders of EBAC, the Business Combination will not be consummated.
The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you sign, date
and return your proxy card without indicating how you wish to vote, your proxy will be voted <B>&#147;FOR&#148;</B> each of the proposals presented at the Extraordinary General Meeting. If you fail to return your proxy card or fail to instruct your
bank, broker or other nominee how to vote, and you do not attend the Extraordinary General Meeting in person, your shares will not be counted for purposes of determining whether a quorum is present at the Extraordinary General Meeting. If you are a
shareholder of record and you attend the Extraordinary General Meeting and wish to vote in person, you may withdraw your proxy and vote in person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO
EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND THAT EBAC REDEEM YOUR SHARES FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO THE TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE INITIALLY SCHEDULED VOTE
AT THE EXTRAORDINARY GENERAL MEETING. YOUR REDEMPTION RIGHTS INCLUDE THE REQUIREMENT THAT A HOLDER MUST IDENTIFY ITSELF IN WRITING AS A BENEFICIAL HOLDER AND PROVIDE ITS LEGAL NAME, PHONE NUMBER AND ADDRESS TO THE TRANSFER AGENT IN ORDER TO VALIDLY
REDEEM ITS SHARES. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING DEPOSITORY TRUST COMPANY&#146;S (&#147;<I>DTC</I>&#148;) DEPOSIT WITHDRAWAL AT
CUSTODIAN (&#147;<I>DWAC</I>&#148;) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN YOUR SHARES WILL NOT BE REDEEMED FOR CASH. IF YOU HOLD YOUR SHARES IN &#147;STREET NAME,&#148; YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR
BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the EBAC Board, I would like to thank you for your support of EBAC and look forward to a
successful completion of the Business Combination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Martijn Kleijwegt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the EBAC Board</TD></TR>
</TABLE></DIV>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES OR REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS
PROXY STATEMENT/PROSPECTUS, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED PARTY TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURES IN THIS PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE
CONTRARY CONSTITUTES A CRIMINAL OFFENSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus is dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 and is expected to be first mailed or otherwise delivered to EBAC Shareholders on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No person is authorized to give any information or to make any representation with respect to the matters that this proxy statement/prospectus describes other
than those contained in this proxy statement/prospectus, and, if given or made, such information or representation must not be relied upon as having been authorized by EBAC, Oculis or New Parent. This proxy statement/prospectus does not constitute
an offer to sell or a solicitation of an offer to buy securities or a solicitation of a proxy in any jurisdiction where, or to any person to whom, it is unlawful to make such an offer or a solicitation. Neither the delivery of this proxy
statement/prospectus nor any distribution of securities under this proxy statement/prospectus will, under any circumstances, create an implication that there has been no change in the affairs of EBAC, Oculis or New Parent since the date of this
proxy statement/prospectus or that any information contained herein is correct as of any time subsequent to such date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF EUROPEAN BIOTECH ACQUISITION CORP., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders of EBAC: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that an
extraordinary general meeting of the shareholders of EBAC (the &#147;<I>Extraordinary General Meeting</I>&#148;) will be held on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time, at EBAC&#146;s corporate address, located at EPFL Innovation Park, Bat D, 3e Route J-D. Colladon, CH-1015 Lausanne, Switzerland, and via a live webcast at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or at such other time, on such other date and at such other place to which the meeting may be adjourned. You are cordially invited to attend the Extraordinary General Meeting
to conduct the following items of business and/or consider, and if thought fit, approve the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposal No.&nbsp;1 &#151; <I>Business Combination Proposal</I> <I>&#151;</I> a proposal to approve, as an
ordinary resolution, and adopt the Business Combination Agreement, a copy of which is attached to this proxy statement/prospectus as <U>Annex A</U>, and the transactions contemplated thereby, including the Business Combination;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposal No.&nbsp;2 &#151; <I>Merger Proposal </I>&#151; a proposal to approve and authorize, by special
resolution, the Plan of Merger, a copy of which is attached to the accompanying proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease,
and EBAC will be the surviving company and a direct wholly owned subsidiary of New Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposal No.&nbsp;3 &#151; <I>Adjournment Proposal </I>&#151; a proposal to approve, as an ordinary resolution,
to adjourn the Extraordinary General Meeting to a later date or dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit
additional proxies from EBAC Shareholders in favor of the Business Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC
Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such that the Minimum EBAC Cash Condition would not be satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
attend the meeting virtually please visit &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and use a 12-digit control number assigned by Continental included on your proxy card or notice of the Extraordinary General Meeting.
To register and receive access to the virtual meeting, registered shareholders and beneficial shareholders (i.e., those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions
applicable to them provided in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for the Extraordinary General Meeting that hold their shares in
&#147;street name&#148; is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. For EBAC Shareholders holding their shares in &#147;street name,&#148; only shareholders holding such shares at the close of business on that
date may vote at the Extraordinary General Meeting or any adjournment thereof. For the avoidance of doubt, the record date does not apply to EBAC Shareholders that hold their shares in registered form and are registered as shareholders in
EBAC&#146;s register of members. EBAC Shareholders that hold their shares in registered form are entitled to one vote on each proposal presented at the Extraordinary General Meeting for each share of EBAC Common Stock held on the record date of the
Extraordinary General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As further described in this proxy statement/prospectus, subject to the terms and conditions of the Business Combination
Agreement, in connection with the consummation of the Business Combination, among other things, shareholders of each of EBAC and Oculis will exchange their securities in those entities, as applicable, for securities of New Parent. To effectuate the
Business Combination and related transactions contemplated by the Business Combination Agreement (and described therein), among other things and subject to the terms and conditions therein, the Business Combination Agreement and the Ancillary
Agreements provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Investors will transfer $71,188,910 to EBAC in exchange for 7,118,891 PIPE Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC will undergo the First Merger; and as part of the First Merger, (i)&nbsp;each share of EBAC Common Stock
(including those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares (ii)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
time will be automatically converted into Surviving EBAC Warrants and (iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of
EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms and subject to the conditions set forth in the Business Combination Agreement and in the Ancillary Agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the
Second Merger Effective Time, the Exchange Agent, solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for receipt of the New Parent Interests
Consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to
the Second Merger Effective Time, the Exchange Agent will undertake to distribute (i)&nbsp;the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii)&nbsp;the New Parent Warrants as part
of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution
Actions, at the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence of EBAC will cease, and following the Acquisition Closing, Merger Sub 2 will be liquidated and
its assets distributed to New Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the Second Merger Effective Time but before the Oculis Share Contribution, it is the intention of the
parties to the Convertible Loan Agreements that New Parent will assume the Convertible Loan Agreements, pursuant to which the Lenders granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of
$19,670,000, and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing
the Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the contribution to New Parent of all Company Share Capital held by such Oculis Shareholders free and clear of all
liens (other than general restrictions on transfer under applicable securities laws or the articles of association of Oculis) in exchange for New Parent Shares on the terms and subject to the conditions set forth in the Business Combination
Agreement and Oculis Shareholders Support Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately 30 days after the closing of the EBAC Mergers, Oculis will undergo the Third Merger.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain Oculis equityholders will receive additional Earnout Consideration that will be received pro rata in proportion to
their equity interests in Oculis as of the date of the Business Combination Agreement. The Earnout Consideration will be issued to such Oculis equityholders upon the Acquisition Closing but shall initially be unvested and subject to forfeiture in
the event of a failure to achieve the performance targets. The Earnout Consideration will consist of three tranches of Earnout Shares, as follows (in the case of each tranche, <I>minus</I> any Earnout Options granted to replace vested options to
purchase shares of Oculis common stock): (i) 1,500,000, (ii) 1,500,000 and (iii) 1,000,000, vesting based on the achievement of post-Acquisition Closing share price targets of New Parent Shares of $15.00, $20.00 and $25.00, respectively, in each
case, for any 20 trading days within any consecutive 30 trading day period commencing after the Acquisition Closing Date and ending on or prior to the fifth anniversary of the Acquisition Closing Date. A given share price target described above will
also be deemed to be achieved (to the extent such target has not already been achieved) if there is a Change of Control (as defined in the Business Combination Agreement) transaction of New Parent during the Earnout Period. Such Oculis
equityholders&#146; right and entitlement to receive the Earnout Consideration will be forfeited to the extent that the relevant share price targets have not been achieved by the fifth anniversary of the Acquisition Closing Date. The Earnout Shares
shall not be entitled to vote on matters submitted to the holders of New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New Parent Shares, if any, until the achievement of such share price targets
specified above. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the foregoing and concurrently with the execution of the Business Combination Agreement,
EBAC entered into Initial Subscription Agreements with the Initial PIPE Investors pursuant to which the Initial PIPE Investors have agreed to purchase from EBAC, severally and not jointly, and EBAC has agreed to issue from treasury and sell to the
Initial PIPE Investors, a number of EBAC Class&nbsp;A Common Stock equal to (i)&nbsp;the total subscription amount from the Initial PIPE Investors ($63,303,910) <I>divided </I>by (ii) $10.00. Subsequent to the Initial PIPE Financing, in
January&nbsp;2023, EBAC entered into the Subsequent Subscription Agreements with the Subsequent PIPE Investors, pursuant to which the Subsequent PIPE Investors have agreed to subscribe for, and EBAC has agreed to issue to the Subsequent PIPE
Investors, a number of EBAC Class&nbsp;A Common Stock equal to (i)&nbsp;the total subscription amount from the Subsequent PIPE Investors ($7,885,000) <I>divided </I>by (ii)&nbsp;$10.00. The aggregate amount of EBAC Class&nbsp;A Common Stock to be
issued pursuant to the PIPE Financing is 7,118,891 for aggregate gross proceeds of $71,188,910. The shares of EBAC Class&nbsp;A Common Stock to be issued from treasury to the PIPE Investors pursuant to the Subscription Agreements have not been
registered under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act (as defined below). Upon the Acquisition Closing, New Parent will grant the PIPE Investors certain customary registration
rights in connection with the PIPE Financing, including demand and piggyback rights as set forth in the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. The PIPE Financing is contingent upon, among other things, the
Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the Sponsor and certain EBAC Shareholders have agreed pursuant to the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement to, among other things, vote in favor of the transactions contemplated in the Business Combination Agreement for which the approval of EBAC Shareholders is required and have agreed not
to redeem or exercise any right to redeem any shares, capital stock or any other equity interests, as applicable, of EBAC that Sponsor or such EBAC shareholder, as applicable, holds of record or beneficially, as of the date of executing such <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, or acquires thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with their entry into the Business Combination
Agreement, Oculis, EBAC and the Sponsor entered into the Sponsor Letter Agreement, pursuant to which, among other things, the Sponsor agreed (i)&nbsp;to vote in favor of the Business Combination Agreement and the transactions contemplated thereby,
subject to the terms and conditions contemplated by the Sponsor Letter Agreement and (ii)&nbsp;to be bound by certain transfer restrictions with respect to the equity interests of EBAC held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above matters are more fully described in this proxy statement/prospectus, which also includes, as <U>Annex A</U>, a copy of the Business Combination
Agreement. <B>You are urged to read carefully this proxy statement/prospectus in its entirety, including each of the Annexes hereto and the accompanying financial statements provided herein.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and restated memorandum and articles of association, EBAC is providing its public shareholders with the opportunity to redeem,
subject to the Acquisition Closing being completed, EBAC Class&nbsp;A Common Stock then held by them for the right to receive an amount in cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the
Acquisition Closing) in the Trust Account that holds the proceeds (including interest accrued thereon, which shall be net of taxes payable) of EBAC&#146;s initial public offering and certain of the proceeds of the sale of the EBAC Private Placement
Units. Redemptions referred to herein shall take effect as repurchases into treasury under EBAC&#146;s amended and restated memorandum and articles of association. The EBAC Share Redemption Amount will be distributed, subject to all conditions to
the Acquisition Closing being met, by New Parent to EBAC&#146;s shareholders who properly redeem their EBAC Class&nbsp;A Common Stock. The EBAC Share Redemption Amount will not be reduced by the aggregate deferred underwriting fee that EBAC will pay
to the underwriters of EBAC&#146;s initial public offering or transaction expenses of Oculis and EBAC incurred in connection with the Business Combination, which together are estimated to amount to $7.4&nbsp;million. For illustrative purposes, based
on the fair value of marketable securities held in the Trust Account of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, the estimated redemption price per share of EBAC Class&nbsp;A Common Stock would have been approximately
$10.052.<B></B> The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to the Transfer Agent in order to validly redeem its shares.
<B><U>Public shareholders may elect to redeem their shares even if they vote for the Business Combination Proposal and</U></B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><U>the Merger Proposal</U></B>. A public shareholder, together with any of its affiliates or any other person with whom it is acting in concert or as a &#147;group&#148; (as defined under
Section&nbsp;13 of the Exchange Act (as defined below)), will be restricted from redeeming in the aggregate his, her or its shares or, if part of such a group, the group&#146;s shares, in excess of 15% of the outstanding EBAC Class&nbsp;A Common
Stock. EBAC has no specified maximum redemption threshold under its amended and restated memorandum and articles of association, other than the aforementioned 15% threshold. Each redemption of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public
shareholders will reduce the amount in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions to closing in the Business Combination Agreement are for the sole benefit of the
parties thereto and may be waived by such parties. The Business Combination Agreement provides that the parties&#146; obligation to consummate the Business Combination is conditioned, among other things, on satisfying the Minimum EBAC Cash
Condition. If, as a result of redemptions of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by the parties, then either party may elect not to consummate the Business
Combination. In addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001, as provided in EBAC&#146;s amended and restated memorandum and articles of
association. Unless otherwise specified, the information in this proxy statement/prospectus assumes that none of EBAC&#146;s public shareholders exercise their redemption rights with respect to their EBAC Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Acquisition Closing is conditioned upon the approval of the Business Combination Proposal and the Merger Proposal. If the Business Combination Proposal
and the Merger Proposal are not approved by the shareholders of EBAC, the Business Combination shall not be consummated. The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative
vote of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting.&nbsp;Approval of the Adjournment
Proposal requires an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative vote of the holders of at least a majority of the issued shares of EBAC Class&nbsp;Common Stock who are present in person or
represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting.&nbsp;Approval of the Merger Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting.<B> The EBAC
Board recommends that you vote &#147;FOR&#148; each of these proposals.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the EBAC Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Martijn Kleijwegt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the EBAC Board</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><U>TABLE OF CONTENTS</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_1">About this Proxy Statement/Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_2">Important Information About IFRS and <FONT STYLE="white-space:nowrap">Non-IFRS
</FONT> Financial Measures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_3">Conventions Which Apply to this Proxy Statement/Prospectus and Exchange Rate
 Presentation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_4">Trademarks, Trade Names and Service Marks</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_5">Industry and Market Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_6">Selected Definitions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_7">Questions and Answers About the Business Combination and the Extraordinary
 General Meeting of Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_8">Summary of the Proxy Statement/Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_8a">Selected Unaudited Pro Forma Condensed Combined Financial Information
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_9">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_10">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_11">Extraordinary General Meeting of EBAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_12">Material Tax Considerations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_13">Unaudited Pro Forma Condensed Combined Financial
Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_14">Business of New Parent Before the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_15">Business of Oculis and Certain Information About Oculis</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_16">Oculis Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_17">Business of EBAC and Certain Information About EBAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_18">EBAC Management&#146;s Discussion and Analysis of Financial Condition and
 Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_19">Management of New Parent After the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_20">Management and Executive Officer and Director Compensation of
Oculis</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_21">Description of New Parent Securities and Proposed Articles of Association
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_22">Comparison of Shareholder Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_23">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_24">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_25">Beneficial Ownership of New Parent Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_26">Price Range of Securities and Dividends</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_27">Proposal No.&nbsp;1 &#151; The Business Combination
Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_28">Proposal No.&nbsp;2 &#151; The Merger Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_29">Proposal No.&nbsp;3 &#151; The Adjournment Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_30">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_31">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_32">Shareholder Communications</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_33">Enforcement of Civil Liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_34">Householding Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_35">Transfer Agent and Registrar</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_36">Future Shareholder Proposals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_37">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_38">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANNEXES </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_39">Annex A: Business Combination Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_40">Annex B: Proposed Articles of Association of New Parent</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc389734_41">Annex C: Form of Plan of Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_1"></A>ABOUT THIS PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> filed with the U.S.
Securities and Exchange Commission (the &#147;<I>SEC</I>&#148;) by New Parent, constitutes a prospectus of New Parent under Section&nbsp;5 of the Securities Act (as defined below) with respect to the New Parent Shares and New Parent Warrants to be
issued to EBAC Shareholders if the Business Combination described herein is consummated. This document also constitutes a notice of meeting and a proxy statement under Section&nbsp;14(a) of the Exchange Act (as defined below) with respect to the
Extraordinary General Meeting of EBAC, at which such shareholders will be asked to consider and vote upon a proposal to approve the Business Combination by the approval and adoption of the Business Combination Agreement, among other matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities, or the solicitation of a proxy, in
any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy
statement/prospectus incorporates important business and financial information that is not included in or delivered with this proxy statement/prospectus. This information is available for you to review through the SEC&#146;s website at www.sec.gov.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request copies of this proxy statement/prospectus and any of the documents incorporated by reference into this proxy statement/prospectus or
other publicly available information concerning EBAC, free of charge, by written request to European Biotech Acquisition Corp., EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne,
Switzerland, Tel.: +41-21-711-3970. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order for EBAC Shareholders to receive timely delivery of the documents in advance of the Extraordinary General
Meeting, you must request the information no later than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, or five business days prior to the date of the Extraordinary General Meeting. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_2"></A>IMPORTANT INFORMATION ABOUT IFRS AND <FONT
STYLE="white-space:nowrap">NON-IFRS</FONT> FINANCIAL MEASURES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the unaudited financial statements of EBAC as of September 30, 2022, for the three and nine months ended
September 30, 2022 and for the period from January&nbsp;8, 2021 (inception) through September 30, 2021 prepared in accordance with U.S. generally accepted accounting principles (&#147;<I>U.S. GAAP</I>&#148;) and expressed in U.S. dollars;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the audited financial statements of EBAC as of December&nbsp;31, 2021 and for the period from January&nbsp;8,
2021 (inception) through December&nbsp;31, 2021 prepared in accordance with U.S. GAAP and expressed in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the unaudited condensed interim consolidated financial statements of Oculis as of September 30, 2022 and
December 31, 2021 and for each of the three- and nine-month periods ended September 30, 2022 and 2021 prepared in accordance with International Financial Reporting Standards (&#147;<I>IFRS</I>&#148;) as issued by the International Accounting
Standards Board (&#147;<I>IASB</I>&#148;) and expressed in thousands of Swiss francs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the audited consolidated financial statements of Oculis as of and for the years ended December&nbsp;31, 2021
and 2020 prepared in accordance with IFRS as issued by the IASB and expressed in thousands of Swiss francs (collectively, the &#147;<I>Historical Financial Information</I>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rounding and Negative Amounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain figures in this
proxy statement/prospectus, including financial data, have been rounded. Accordingly, figures shown for the same category presented in different tables may vary slightly, and figures shown as totals in certain tables may not be an exact arithmetic
aggregation of the figures which precede them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the Historical Financial Information, most numerical figures are presented in U.S. dollars
(for EBAC) and thousands of Swiss francs (CHF) for Oculis. For the convenience of the reader of this proxy statement/prospectus, certain numerical figures in this proxy statement/prospectus are rounded to the nearest one million. As a result of this
rounding, certain numerical figures presented herein may vary slightly from the corresponding numerical figures presented in our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The percentages (as a percentage of costs and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-on-period</FONT></FONT> percentage
changes) presented in the textual financial disclosure in this proxy statement/prospectus are derived directly from the financial information contained in our financial statements. Such percentages may be computed using the numerical figures
expressed in either U.S. dollars (for EBAC) or thousands of Swiss francs (for Oculis) in the respective financial statements. Therefore, such percentages are not calculated on the basis of the financial information in the textual disclosure that has
been subjected to rounding adjustments in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In tables, negative amounts are shown between brackets. Otherwise, negative
amounts may also be shown by &#147;&#150;&#148; or &#147;negative&#148; before the amount. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_3"></A>CONVENTIONS WHICH
APPLY TO THIS PROXY STATEMENT/PROSPECTUS AND EXCHANGE RATE PRESENTATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this proxy statement/prospectus, unless otherwise specified or the context
otherwise requires: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;$,&#148; &#147;USD&#148; and &#147;U.S. dollar&#148; each refer to the United States dollar; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CHF&#148; and &#147;Swiss francs&#148; each refer to the Swiss franc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain amounts described herein have been expressed in U.S. dollars for convenience, and when expressed in U.S. dollars in the future, such amounts may be
different from those set forth herein due to intervening exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate fluctuations. The exchange rate used for conversion between U.S. dollars and Swiss francs is based on the historical exchange rate of the Swiss franc released by the Federal Reserve, the
central bank of the United States. Unless otherwise indicated, certain Swiss franc amounts contained in this proxy statement/prospectus have been translated into U.S. dollars at the rate of CHF 1.00 to $1.0198, which was the exchange rate as
reported by the Federal Reserve on September&nbsp;30, 2022. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could actually have been purchased upon exchange of Swiss francs at the dates indicated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_4"></A>TRADEMARKS, TRADE NAMES AND SERVICE MARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus includes trademarks, tradenames and service marks, certain of which belong to Oculis and others that are the property of other
organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this proxy statement/prospectus appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,<SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;TM</SUP>&nbsp;and <SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> symbols, but the absence of those symbols is not intended to indicate, in any way, that the applicable owner will not assert
its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not
be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_5"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains industry and market data which have been obtained from industry publications, market research and other publicly
available information. Certain information regarding market size, market share, market position, growth rates and other industry data pertaining to Oculis and its business contained in this proxy statement/prospectus consists of estimates based on
data compiled by independent professional organizations and on data from other external sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such information is supplemented, where necessary, with
Oculis&#146; own internal estimates, taking into account publicly available information about other industry participants and Oculis&#146; management&#146;s judgment where information is not publicly available. The November 2019 market research
report discussed in this proxy statement/prospectus was commissioned by and prepared in collaboration with Oculis. This information appears in the sections entitled, among others, &#147;<I>Summary</I>,&#148; &#147;<I>Business of Oculis and Certain
Information about Oculis</I>&#148; and &#147;<I>Oculis Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Industry publications and market research generally state that the information they contain has been obtained from sources believed to be reliable, but that
the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on a number of significant assumptions. In some cases, the sources from which this data is derived is not expressly referred to.
While Oculis compiled, extracted and reproduced industry data from these sources, and believes that the information used is reliable, Oculis did not independently verify the data that was extracted or derived from such industry publications or
market reports, and cannot guarantee its accuracy or completeness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The industry and market data that appears in this proxy statement/prospectus is
inherently uncertain, involves a number of assumptions and limitations and may not necessarily be reflective of actual market conditions and you are cautioned not to give undue weight to such industry and market data because it may differ from
current data, may that be due to material changes in market conditions or otherwise. Such statistics are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the respondents, including
judgments about what types of products and transactions should be included in the relevant market. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other
forward-looking statements in this proxy statement/prospectus. These and other factors could cause results to differ materially from those expressed in any forecasts or estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent, EBAC and Oculis do not intend, and none of the foregoing assumes any obligation, to update industry or market data set forth in this proxy
statement/prospectus. Because market behavior, preferences and trends are subject to change, prospective investors should be aware that market and industry information in this proxy statement/prospectus and estimates based on any data therein may
not be reliable indicators of future market performance or Oculis&#146; future results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_6"></A>SELECTED DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this proxy statement/prospectus unless stated otherwise or the context otherwise requires, a reference to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Acquisition Closing&#148; means the closing of the First Merger, Second Merger and Oculis Share
Contribution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Acquisition Transactions&#148; means the transactions contemplated by the First Merger and Second Merger.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Acquisition Closing Date&#148; means the date upon which the Acquisition Closing is to occur.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Adjournment Proposal&#148; means the proposal to adjourn to a later date or dates to the extent reasonable
(i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the Business Combination Proposal and the
Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such that the Minimum EBAC Cash
Condition would not be satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Ancillary Agreements&#148; means the Business Combination Agreement (together with the Oculis Disclosure
Letter and the EBAC Disclosure Letter), the Subscription Agreements, the Convertible Loan Agreements, the Sponsor Support Agreement, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Confidentiality Agreement, dated as of
February&nbsp;22, 2022, by and between Oculis and EBAC, the Oculis Shareholders Support Agreement and when entered into at the Acquisition Closing, the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and the Warrant
Assumption Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Business Combination&#148; means the transactions contemplated by the Business Combination Agreement,
including the Mergers and the Oculis Share Contribution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Business Combination Agreement&#148; means the Business Combination Agreement, dated as of October&nbsp;17,
2022, as may be amended from time to time, by and among EBAC and Oculis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Business Combination Proposal&#148; means the proposal to approve the adoption of the Business Combination
Agreement and the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Cayman Companies Act&#148; means the Companies Act of the Cayman Island (As Revised).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Code&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Combination Period&#148; means the period ending 24 months after the closing of EBAC&#146;s initial public
offering (March 18, 2023, or such later date to which such deadline is extended pursuant to a vote of the EBAC Shareholders) during which time EBAC must either complete its initial business combination or redeem all of the outstanding EBAC
Class&nbsp;A Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Company Share Capital&#148; has the meaning ascribed to such term in the Business Combination Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Continental&#148; means Continental Stock Transfer&nbsp;&amp; Trust Company, EBAC&#146;s transfer agent and
warrant agent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Convertible Loan Agreements&#148; means the convertible loan agreements, dated as of October&nbsp;17, 2022
and January 26, 2023, by and among Oculis and certain lenders party thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;D.F. King&#148; means D.F. King &amp; Co., Inc., our proxy solicitor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Earnout Shares&#148; means the New Parent Shares issued as part of the Earnout Consideration on the terms,
and subject to the conditions set forth in the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC&#148; means European Biotech Acquisition Corp., a Cayman Islands exempted company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Board&#148; means the board of directors of EBAC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Class&nbsp;A Common Stock&#148; means Class&nbsp;A ordinary shares, par value $0.0001 per share, of
EBAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Class&nbsp;B Common Stock&#148; or &#147;Founder Shares&#148; means Class&nbsp;B ordinary shares, par
value $0.0001 per share, of EBAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Common Stock&#148; means EBAC Class&nbsp;A Common Stock and EBAC Class&nbsp;B Common Stock.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Disclosure Letter&#148; means that certain disclosure letter delivered to Oculis by EBAC on the date
of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Initial Shareholders&#148; means the holders of EBAC Class&nbsp;B Common Stock as of the date of the
Business Combination Agreement, together with such holders&#146; ownership of shares of EBAC Class A Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Private Placement Warrants&#148; means a warrant to purchase one share of EBAC Class&nbsp;A Common
Stock at an exercise price of $11.50 issued to the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Public Warrants&#148; means a warrant to purchase one share of EBAC Class&nbsp;A Common Stock at an
exercise price of $11.50 that was included in the units sold as part of EBAC&#146;s initial public offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Shareholders&#148; means the shareholders of EBAC as of any applicable determination time prior to the
Acquisition Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Share Redemption&#148; means the election of an eligible (as determined in accordance with EBAC&#146;s
amended and restated memorandum and articles of association) holder of shares of EBAC Class&nbsp;A Common Stock to redeem all or a portion of the shares of EBAC Class&nbsp;A Common Stock held by such holder in return for the right to receive a <FONT
STYLE="white-space:nowrap">per-share</FONT> price, payable in cash by New Parent, equal to a pro rata share of the aggregate amount on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) (as determined
in accordance with EBAC&#146;s amended and restated memorandum and articles of association) in connection with the Transactions. The redeemed shares of EBAC Class A Common Stock shall be held in treasury for re-issuance to new investors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Share Redemption Amount&#148; means the aggregate amount payable by New Parent with respect to all
EBAC Share Redemptions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Units&#148; means the units issued in EBAC&#146;s initial public offering consisting of one share of
EBAC Class&nbsp;A Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of an EBAC Public Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EBAC Warrants&#148; means the EBAC Public Warrants and the EBAC Private Placement Warrants.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;EMA&#148; means the European Medicines Agency. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Exchange Act&#148; means the Securities Exchange Act of 1934, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Exchange Agent&#148; means a person authorized to act as exchange agent in connection with the Business
Combination, which shall be selected by New Parent, Oculis and EBAC to act on behalf of EBAC, EBAC Shareholders, Oculis and Oculis Shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Exchange Agent Contribution&#148; means the contribution by the Exchange Agent of Surviving EBAC Shares and
Surviving EBAC Warrants to New Parent in exchange for New Parent Shares and New Parent Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Exchange Agent Contribution Actions&#148; means the distribution by the Exchange Agent of New Parent Shares
and New Parent Warrants to the holders of Surviving EBAC Shares and Surviving EBAC Warrants, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Existing Warrant Agreement&#148; means the warrant agreement dated as of March&nbsp;15, 2021, between EBAC
and Continental, as warrant agent, as amended. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;FDA&#148; means the U.S. Food and Drug Administration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;First Merger&#148; means when Merger Sub 1 merges with and into EBAC, with EBAC as the surviving company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;First Merger Effective Time&#148; means the time at which the First Merger becomes effective pursuant to
the filing and registration of the plan of merger with the Cayman Islands Registrar of Companies or at such later time as may be agreed by New Parent and Oculis in writing and specified in such plan of merger. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;GAAP&#148; means United States generally accepted accounting principles. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;IFRS&#148; means the International Financial Reporting Standards as adopted by the International Accounting
Standards Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Initial PIPE Financing&#148; means the private placement pursuant to which the Initial PIPE Investors
subscribed for EBAC Class&nbsp;A Common Stock, for a subscription price of $10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Initial PIPE Investors&#148; means the institutional investors that have committed to subscribe for EBAC
Class&nbsp;A Common Stock in the Initial PIPE Financing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Initial Subscription Agreements&#148; means the subscription agreements, each dated as of October&nbsp;17,
2022, by and among EBAC and the Initial PIPE Investors party thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Lenders&#148; means those certain Oculis Shareholders party to the Convertible Loan Agreements pursuant to
which, among other things, such Oculis Shareholders agreed to grant Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $19,670,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Proposal&#148; means a proposal to approve and authorize, by special resolution, the form of Plan of
Merger, a copy of which is attached to this proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease, and EBAC will be the surviving
company and as a direct wholly owned subsidiary of New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub 1&#148; means Oculis Merger Sub I Company, a Cayman Islands exempted company that is a direct
wholly owned subsidiary of New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub 2&#148; means Oculis Merger Sub II Company, a Cayman Islands exempted company that is a direct
wholly owned subsidiary of New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub 3&#148; means Oculis Operations GmbH, a limited liability company (<I>Gesellschaft mit
beschr&auml;nkter Haftung</I>) incorporated and existing under the laws of Switzerland that is a direct wholly owned subsidiary of New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Minimum EBAC Cash Condition&#148; means (i)&nbsp;the amount of cash or cash equivalents available in the
Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount and payment of the Oculis and EBAC expenses in connection with the Business Combination); (ii) plus the aggregate amount of the PIPE
Financing actually received by New Parent (or other financing in connection with the Business Combination, including the Convertible Loan) prior to or substantially concurrently with the Acquisition Closing, which must be equal to or greater than
$100&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Nasdaq&#148; means The Nasdaq Stock Market LLC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Parent&#148; means Oculis Holding AG, a stock corporation (<I>Aktiengesellschaft</I>) incorporated and
existing under the laws of Switzerland and that is a direct wholly owned subsidiary of EBAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Parent Board&#148; means the board of directors of New Parent following the Acquisition Closing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Parent Shares&#148; means ordinary shares, nominal value CHF 0.01 per share of New Parent.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Parent Interests Consideration&#148; means New Parent Shares, nominal value CHF 0.01 per share and New
Parent Warrants held by the Exchange Agent solely on behalf of holders of Surviving EBAC Shares and Surviving EBAC Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Parent Warrants&#148; means a right to acquire New Parent Shares, on substantially the same terms as
the EBAC Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreements&#148; means the Shareholder <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, each dated as of October&nbsp;17, 2022 by and among EBAC and certain EBAC Shareholders party thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Oculis&#148; means Oculis SA, a stock corporation (<I>Aktiengesellschaft</I>) incorporated and existing
under the laws of Switzerland. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Oculis Disclosure Letter&#148; means that certain disclosure letter delivered to EBAC by Oculis on the date
of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Oculis Shareholders&#148; means, collectively, the holders of shares of Company Share Capital as of any
applicable determination time prior to the Acquisition Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Oculis Shareholders Support Agreement&#148; means that certain agreement entered into concurrently with the
execution of the Business Combination Agreement, dated as of October&nbsp;17, 2022, by and among Oculis, EBAC and the Oculis Shareholders party thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Oculis Share Contribution&#148; means the contribution by the Oculis Shareholders of the full legal and
beneficial ownership of the applicable Company Share Capital to New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Financing&#148; means the Initial PIPE Financing and the Subsequent PIPE Financing, pursuant to which
the PIPE Investors subscribed for EBAC Class&nbsp;A Common Stock, for a subscription price of $10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Investment Amount&#148; means the aggregate proceeds actually received by EBAC prior to or
substantially concurrently with the Acquisition Closing for the shares in the PIPE Financing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Investors&#148; means the Initial PIPE Investors and the Subsequent PIPE Investors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Shares&#148; means the shares of EBAC Class A Common Stock purchased by the PIPE Investors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Private Placement Units&#148; means the units issued to Sponsor in a private placement simultaneously with
the closing of EBAC&#146;s initial public offering, which private placement units consists of EBAC Class&nbsp;A Common Stock and EBAC Private Placement Warrants. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Proposed Articles of Association&#148; means the amended and restated articles of association of New Parent
to be adopted by New Parent, in the form attached as <U>Annex B</U> to this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Prospectus&#148; means the proxy statement/prospectus included in the Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268201)</FONT> filed with the SEC, as amended from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement&#148; means the Amended
and Restated Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, dated as of the Acquisition Closing Date, by and among New Parent, Sponsor and certain Oculis Shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;SEC&#148; means the U.S. Securities and Exchange Commission. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Second Merger&#148; means when EBAC will merge with and into Merger Sub 2, with Merger Sub 2 as the
surviving company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Second Merger Effective Time&#148; means the time at which the Second Merger becomes effective pursuant to
the filing and registration of the plan of merger with the Cayman Islands Registrar of Companies or at such later time as may be agreed by New Parent and Oculis in writing and specified in such plan of merger. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Securities Act&#148; means the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Sponsor&#148; means LSP Sponsor EBAC B.V. a Dutch limited liability company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Sponsor Support Agreement&#148; means the Sponsor Support Agreement, dated October&nbsp;17, 2022, by and
among EBAC, Oculis and Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Subscription Agreements&#148; means the Initial Subscription Agreements and the Subsequent Subscription
Agreements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Subsequent PIPE Financing&#148; means the private placement pursuant to which the Subsequent PIPE Investors
subscribed for EBAC Class&nbsp;A Common Stock, for a subscription price of $10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Subsequent PIPE Investors&#148; means the institutional investors that have committed to subscribe for EBAC
Class&nbsp;A Common Stock in the Subsequent PIPE Financing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Subsequent Subscription Agreements&#148; means the subscription agreements, entered into in January 2023,
by and among EBAC and the Subsequent PIPE Investors party thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Surviving EBAC Shares&#148; means EBAC Common Stock, including those held by the PIPE Investors,
automatically converted into one class of common stock of EBAC, as the surviving company of the First Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Surviving EBAC Warrants&#148; means EBAC Warrants outstanding immediately prior to the First Merger
Effective Time automatically converted into warrants of EBAC, as the surviving company of the First Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Swiss Code of Obligations&#148; means the Swiss Federal Act on the Amendment of the Swiss Civil Code of
March&nbsp;30, 1911. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Third Merger&#148; means when Oculis will merge with and into Merger Sub 3, with Oculis as the surviving
company and wholly owned subsidiary of New Parent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Third Merger Effective Time&#148; means the time at which the Third Merger becomes effective pursuant to
the filing and the registration of the plan of merger in accordance with the provisions of the Swiss Code of Obligations or at such later time as may be agreed by New Parent and Oculis in writing and specified in such plan of merger.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Transaction Proposals&#148; means the Business Combination Proposal, the Merger Proposal the Adjournment
Proposal, and if applicable, the Additional Proposals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Transfer Agent&#148; means Continental. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Trust Account&#148; means that certain trust account with Continental, as trustee, containing the cash
proceeds of EBAC from its initial public offering and private placement of securities (and all accrued interest earned thereon), deposited therein for the benefit of EBAC and EBAC&#146;s public shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Warrant Assumption Agreement&#148; a Warrant Assignment and Assumption Agreement to be entered into among
EBAC, New Parent and the Exchange Agent, in a form to be agreed upon among EBAC, New Parent, Continental, the Exchange Agent and Oculis, to be effective upon the Acquisition Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Warrant Conversion&#148; means the right of the EBAC Warrant holders to receive a New Parent Warrant in
exchange for EBAC Warrants to be transferred immediately to holders of EBAC Warrants pursuant to the Warrant Assumption Agreement, to be effective upon the Acquisition Closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_7"></A>QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The questions and answers below highlight only selected information from this proxy
statement/prospectus and only briefly address some commonly asked questions about the proposals to be presented at the Extraordinary General Meeting, including the Business Combination Proposal and the Merger Proposal. The following questions and
answers do not include all the information that is important to EBAC Shareholders. Shareholders are urged to read carefully this entire proxy statement/prospectus, including the Annexes and the other documents referred to herein, to fully understand
the proposed Business Combination and the voting procedures for the Extraordinary General Meeting, which will be held on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, at EBAC&#146;s corporate address, located at EPFL Innovation Park, Bat D, 3e Route J-D. Colladon, CH-1015 Lausanne, Switzerland, and virtually via live
webcast. To participate in the Extraordinary General Meeting virtually, visit &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and enter the <FONT STYLE="white-space:nowrap">12-digit</FONT> control number assigned by
Continental included on your proxy card or notice of the Extraordinary General Meeting. You may register for the meeting as early as 5:00&nbsp;p.m., Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. If
you hold your shares in &#147;street name&#148; through a bank, broker or other nominee, you will need to take additional steps to participate in the Extraordinary General Meeting, as described in this proxy statement/prospectus.</I> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why am I receiving this proxy statement/prospectus? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Shareholders are being asked to consider and vote upon (i)&nbsp;a proposal to approve and adopt the
Business Combination Agreement, a copy of which is attached to this proxy statement/prospectus as <U>Annex&nbsp;A</U>, and the transactions contemplated thereby, including the Business Combination, (ii)&nbsp;a proposal to approve and authorize, by
special resolution, the Plan of Merger, a copy of which is attached to the accompanying proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1
will cease, and EBAC will be the surviving company and a direct wholly owned subsidiary of New Parent and (iii)&nbsp;a proposal to adjourn the Extraordinary General Meeting to a later date or dates to the extent reasonable (a)&nbsp;to ensure that
any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (b)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the Business Combination Proposal and the Merger Proposal or for any
other reason in connection with the transactions contemplated by the Business Combination Agreement or (c)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such that the Minimum EBAC Cash Condition would not be satisfied.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement provides, among other things, that: (i)&nbsp;EBAC will undergo the First Merger,
pursuant to which, among other things, (a)&nbsp;each share of EBAC Common Stock (including those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares, (b)&nbsp;each EBAC Warrant outstanding immediately prior to
the First Merger Effective Time will be automatically converted into Surviving EBAC Warrants and (c)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC
Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants; (ii)&nbsp;on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time, the Exchange Agent, solely on
behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for the New Parent Interests Consideration; (iii)&nbsp;in connection with the Exchange Agent Contribution,
on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange Agent will (a)&nbsp;undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of
Surviving EBAC Shares and (b)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants; (iv)&nbsp;on the day before the Acquisition Closing Date and following the completion
of the Exchange Agent Contribution Actions, at the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence of EBAC will cease; (v)&nbsp;at approximately 10:00 a.m.
Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing Oculis Shareholders Support Agreements and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
exchange notice contemplated by the Business Combination Agreement shall effect the Oculis Share Contribution; and (vi)&nbsp;approximately 30 days after the closing of the EBAC Mergers, Oculis
will undergo the Third Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EBAC will hold the Extraordinary General Meeting to consider and vote upon these proposals. This proxy
statement/prospectus and its Annexes each contain important information about the proposed Business Combination and the other matters to be acted upon at the Extraordinary General Meeting. You should read this proxy statement/prospectus and its
Annexes carefully and in their entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><U>The EBAC Board believes that each of the Business Combination Proposal, the Merger
Proposal and the Adjournment Proposal to be presented at the Extraordinary General Meeting is in the best interests of EBAC and its shareholders and recommends that its shareholders vote &#147;FOR&#148; each of the proposals.</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">When considering the EBAC Board&#146;s recommendation that EBAC Shareholders vote in favor of the approval of the Business Combination
Proposal and the Merger Proposal, EBAC Shareholders should be aware that, aside from their interests as shareholders, the EBAC Initial Shareholders and EBAC&#146;s other current officers and directors have interests in the Business Combination that
are different from, or in addition to, those of other EBAC Shareholders generally. The EBAC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination, and in recommending to EBAC
Shareholders that they approve the Business Combination Proposal and the Merger Proposal. EBAC Shareholders should take these interests into account in deciding whether to approve the Business Combination Proposal and the Merger Proposal. Please see
the section entitled &#147;<I>Proposal No. 1</I>&#151;<I>The Business Combination Proposal</I>&#151;<I>Interests of Certain Persons in the Business Combination</I>&#148; for a further discussion of these interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><U>Your vote is important. You are encouraged to submit your proxy as soon as possible after carefully reviewing this proxy
statement/prospectus and its Annexes and the accompanying financial statements of EBAC and Oculis, in each case, carefully and in its entirety</U></B><U>.</U><B><U></U></B> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When and where is the Extraordinary General Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Extraordinary General Meeting will be held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time, at EBAC&#146;s corporate address, located at EPFL Innovation Park, Bat D,
3e Route J-D. Colladon, CH-1015 Lausanne, Switzerland, and via a live webcast at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or at such other time, on such other date and at such other place to which the meeting may be adjourned.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who is entitled to vote at the Extraordinary General Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a shareholder of EBAC, you have a right to vote on certain matters affecting EBAC. The proposals that will
be presented at the Extraordinary General Meeting and upon which you are being asked to vote are summarized above and fully set forth in this proxy statement/prospectus. EBAC Shareholders will be entitled to vote or direct votes to be cast at the
Extraordinary General Meeting if they owned EBAC Common Stock at the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, which is the record date for the Extraordinary General Meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How many votes do I have? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Shareholders are entitled to one vote at the Extraordinary General Meeting for each share of EBAC Common
Stock held of record as of the record date. As of the close of business on the record date for the Extraordinary General Meeting, there were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBAC Common Stock outstanding, of
which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are EBAC Class&nbsp;A Common Stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are Founder Shares held by the EBAC Initial Shareholders
(including Founder Shares transferred by the Sponsor in the amount of 25,000 Founder Shares to certain of the Independent Directors, for a total of 50,000 Founder Shares transferred). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the specific proposals on which I am being asked to vote at the Extraordinary General Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Shareholders are being asked to approve the following proposals: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Business Combination Proposal</I> &#151; a proposal to approve and adopt the Business Combination Agreement,
a copy of which is attached to this proxy statement/prospectus as <U>Annex A</U>, and the transactions contemplated thereby (including, for the avoidance of doubt, the Plan of Merger), including the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Merger Proposal</I> &#151; a proposal to approve and authorize, by special resolution, the Plan of Merger, a
copy of which is attached to this proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease, and EBAC will be the surviving company and as
a direct wholly owned subsidiary of New Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Adjournment Proposal</I> &#151; a proposal to adjourn the Extraordinary General Meeting to a later date or
dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the Business
Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such
that the Minimum EBAC Cash Condition would not be satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the recommendations of the EBAC Board? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After careful consideration, the EBAC Board has approved the Business Combination Agreement and the Business
Combination, and recommends that EBAC Shareholders vote &#147;<B>FOR</B>&#148; adoption of the Business Combination Agreement and approval of the Business Combination, &#147;<B>FOR</B>&#148; the Merger Proposal, &#147;<B>FOR</B>&#148; the
Adjournment Proposal and &#147;<B>FOR</B>&#148; any other proposal presented to EBAC Shareholders in this proxy statement/prospectus. When you consider the EBAC Board&#146;s recommendation of these proposals, you should keep in mind that certain
EBAC directors and officers have interests in the Business Combination that may conflict with your interests as a shareholder. Please see the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1&#151; The Business Combination Proposal &#151;
Interests of Certain Persons in the Business Combination</I>&#148; for additional information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do the Proposed Articles of Association differ materially from the current constitutional documents of EBAC?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Business Combination Agreement contemplates, among other things, the replacement of EBAC&#146;s amended and
restated memorandum and articles of association under the Cayman Companies Act with the Proposed Articles of Association of New Parent, which differ materially from the current constitutional documents of EBAC in the certain respects. Please see the
section entitled &#147;<I>Comparison of Shareholder Rights</I>&#148; for more information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is EBAC proposing the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of
effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The EBAC Board sought to do this by utilizing the networks and industry experience of
both the Sponsor and the EBAC Board to identify, acquire and operate one or more businesses. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In determining to approve
entry into the Business Combination Agreement and Ancillary Agreements and the transactions contemplated thereby, the EBAC Board considered, among others, the following factors (although not weighted or in any order of significance): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team and New Parent Board. </I></B>The EBAC Board believes that Oculis&#146;
management team has extensive experience in the biopharma industry in general and the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
ophthalmology market in particular. The EBAC Board is confident in the management team&#146;s deep industry knowledge and strategic vision and believes that the EBAC and Oculis teams (together
with the new incoming directors of the New Parent Board who have extensive executive experience working in the biopharma industry) will form a collaborative and effective long-term partnership that is positioned to create and enhance shareholder
value going forward. For additional information regarding Oculis&#146; executive officers, please see the section entitled &#147;<I>Management of New Parent After the Business Combination</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced and diversified pipeline. </I></B>The EBAC Board considered that the current pipeline of Oculis
provides multiple product candidates that may be developed in several indications where the existing unmet medical need could provide significant market opportunities and long-term shareholder value. For additional information regarding Oculis&#146;
pipeline, please see the section entitled &#147;<I>Business of Oculis and Certain Information about Oculis</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Upcoming milestones.</I></B> The EBAC Board considered that with the funds that Oculis is expected to
receive with the proposed transaction, it may be able to reach significant clinical and regulatory milestones for all three of its product candidates, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and
<FONT STYLE="white-space:nowrap">OCS-05,</FONT> in a total of five different indications. These milestones could provide opportunity for potential uplifts in valuation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Benefit for Oculis of being U.S. listed</I></B>. As a result of the proposed transaction, Oculis will
become a public company listed on Nasdaq (via New Parent). By having access to the largest biotech capital market, Oculis will be better positioned to have the capacity to raise additional funds in the future if and when needed.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Investment by Third Parties</I></B><B>. </B>The EBAC Board considered that certain sophisticated investors
(x)&nbsp;subscribed for the PIPE Financing in the aggregate amount of approximately $71.2&nbsp;million and (y)&nbsp;agreed to grant Oculis a right to receive a convertible loan with certain conversion rights in the aggregate amount of approximately
$19.7&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Terms of the Business Combination Agreement and the Ancillary Agreements</I></B><B>. </B>The EBAC Board
considered the terms and conditions of the Business Combination Agreement and the Ancillary Agreements, including the transactions contemplated thereby, each party&#146;s representations, warranties and covenants, the conditions to each party&#146;s
obligation to close and the termination provisions, as well as EBAC&#146;s and Oculis&#146; strong commitment to complete the Business Combination. The EBAC Board determined that such terms and conditions are reasonable and were the product of
extensive <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between EBAC and Oculis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continued Ownership of Oculis Shareholders</I></B><B>.</B> The EBAC Board considered that the Oculis
Shareholders would be receiving a significant amount of New Parent Shares in the proposed Business Combination. Oculis Shareholders have demonstrated confidence in the long-term prospects of New Parent by agreeing not to transfer their New Parent
Shares for 180 days following the Acquisition Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>The Role of the Independent Directors</I></B><B>.</B> In connection with the Business Combination,
EBAC&#146;s Independent Directors evaluated the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements, and unanimously approved, as members of the EBAC Board, the Business Combination
Agreement, the Ancillary Agreements, and the transactions contemplated thereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Alternatives</I></B><B>. </B>The EBAC Board believes, after a thorough review of other business
combination opportunities reasonably available to or explored by EBAC, that the proposed Business Combination represents the optimal potential business combination for EBAC and its shareholders based upon the process utilized to evaluate and assess
other potential acquisition targets, and the EBAC Board&#146;s belief that such processes had not presented a better alternative. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;The EBAC Board&#146;s Reasons for the
Business Combination</I>&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Although the EBAC Board believes that the Business Combination presents a compelling
business combination opportunity and is in the best interests of EBAC and its shareholders, the EBAC Board did consider certain potentially material negative factors in arriving at that conclusion. These factors are discussed in greater detail in
the sections entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;The EBAC Board&#146;s Reasons for the Business Combination</I>&#148; and &#147;<I>Risk Factors&#151;Risks Related to Oculis&#146; Business</I>.&#148; </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is EBAC providing shareholders with the opportunity to vote on the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The approval of the Business Combination by shareholders is required under EBAC&#146;s amended and restated
memorandum and articles of association and under Cayman Islands law. In addition, such approval is also a condition to the Acquisition Closing. Additionally, under EBAC&#146;s amended and restated memorandum and articles of association, EBAC must
provide all holders of EBAC Class&nbsp;A Common Stock with the opportunity to have their EBAC Class&nbsp;A Common Stock redeemed upon the consummation of its initial business combination either in conjunction with a tender offer or in conjunction
with a shareholder vote. For business and other reasons, EBAC has elected to provide its shareholders with the opportunity to have their EBAC Class&nbsp;A Common Stock redeemed in connection with a shareholder vote rather than a tender offer.
Therefore, EBAC is seeking to obtain the approval of its shareholders of the proposals contemplated by this proxy statement/prospectus and also allow its public shareholders to effectuate redemptions of their EBAC Class&nbsp;A Common Stock in
connection with the Acquisition Closing in accordance with EBAC&#146;s amended and restated memorandum and articles of association. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen in the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Business Combination Agreement, and upon the terms and subject to the conditions therein, among
other things: (i)&nbsp;EBAC will undergo the First Merger, pursuant to which, among other things, (a)&nbsp;each share of EBAC Common Stock (including those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares
(b)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into Surviving EBAC Warrants and (c)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely
on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants; (ii)&nbsp;on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second
Merger Effective Time, the Exchange Agent, solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for the New Parent Interests Consideration;
(iii)&nbsp;in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange Agent will (a)&nbsp;undertake to distribute the New Parent Shares as part of
the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (b)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants; (iv)&nbsp;on the day before
the Acquisition Closing Date and following the completion of the Exchange Agent Contribution Actions, at the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence
of EBAC will cease; (v)&nbsp;at approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination
Agreement shall effect the Oculis Share Contribution; and (vi)&nbsp;approximately 30 days after the closing of the EBAC Mergers, Oculis will undergo the Third Merger. Please see the section entitled &#147;<I>Proposal No. 1&#151;The Business
Combination Proposal</I>&#148; for additional information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How has the announcement of the Business Combination affected the trading price of the EBAC Class&nbsp;A
Common Stock? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On October&nbsp;14, 2022, the trading date before the public announcement of the Business Combination, the EBAC
Public Units, EBAC Class&nbsp;A Common Stock and EBAC Public Warrants closed at $9.93, $9.92 and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
$0.12, respectively. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the trading date immediately prior to the date of this proxy statement/prospectus, the EBAC
Public Units, EBAC Class&nbsp;A Common Stock and EBAC Public Warrants closed at $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively.
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Following the Business Combination, will EBAC&#146;s securities continue to trade on a stock exchange?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. EBAC anticipates that, following consummation of the Business Combination, the EBAC Public Units will
automatically separate into their component parts, the EBAC Class&nbsp;A Common Stock and the EBAC Public Warrants will be delisted from the Nasdaq Capital Market and EBAC will be deregistered under the Exchange Act. However, New Parent has applied
to list the New Parent Shares and New Parent Warrants on the Nasdaq Global Market under the symbols &#147;OCS&#148; and &#147;OCSAW,&#148; respectively, upon the Acquisition Closing. The approval of New Parent&#146;s listing application by the
Nasdaq Global Market is a condition to the Acquisition Closing: New Parent&#146;s initial listing application with the Nasdaq Global Market in connection with the transactions contemplated by the Business Combination Agreement shall have been
conditionally approved and, immediately following the Acquisition Closing, New Parent shall satisfy any applicable initial and continuing listing requirements of the Nasdaq with regard to the listing of New Parent Shares and New Parent Warrants.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Is the Business Combination the first step in a &#147;going private&#148; transaction?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. EBAC does not intend for the Business Combination to be the first step in a &#147;going private&#148;
transaction. One of the primary purposes of the Business Combination is to provide a platform for Oculis to access the U.S. public markets. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will the executive management team of Oculis change in the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The current executive officers of Oculis are Riad Sherif (Chief Executive Officer), Sylvia Cheung (Chief
Financial Officer) and P&aacute;ll Ragnar J&oacute;hannesson (Chief Strategy Officer). These individuals are expected to continue to serve as New Parent&#146;s executive officers upon consummation of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the transactions contemplated by the Business Combination Agreement, New Parent will initially be governed through a
single-tiered board of directors comprised of up to seven members, with each director serving terms of one year. The initial board of directors at the Acquisition Closing will be comprised of (i)&nbsp;two individuals designated as the Sponsor
director nominees and (ii)&nbsp;up to five individuals designated by Oculis, one of whom shall be the chief executive of Oculis and at least three of whom, who in each case will be subject to the prior approval of the Sponsor (not to be unreasonably
withheld) shall qualify as &#147;independent&#148; under applicable SEC and Nasdaq listing rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please see the section entitled
&#147;<I>Management of New Parent After the Business Combination</I>&#148; for additional information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will holders of EBAC Common Stock and EBAC Public Warrants and the Oculis Shareholders each receive in
the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Closing, after giving effect to the transactions contemplated by the Business Combination Agreement and
as more fully described in the Business Combination Agreement, the Ancillary Agreements and elsewhere in this proxy statement/prospectus: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Investors will transfer $71,188,910 to EBAC in exchange for 7,118,891 PIPE Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC will undergo the First Merger; and as part of the First Merger, (a)&nbsp;each share of EBAC Common Stock
(including those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares, (b)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into Surviving
EBAC Warrants and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(c)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and
Surviving EBAC Warrants on the terms, and subject to the conditions set forth in the Business Combination Agreement and in the Ancillary Agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the
Second Merger Effective Time, the Exchange Agent, solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for receipt of the New Parent Interests
Consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to
the Second Merger Effective Time, the Exchange Agent will undertake to distribute (a)&nbsp;the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (b)&nbsp;the New Parent Warrants as part
of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution
Actions, at the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence of EBAC will cease, and following the Acquisition Closing, Merger Sub 2 shall be liquidated
and its assets distributed to New Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the Second Merger Effective Time but before the Oculis Share Contribution, it is the intention of the
parties to the Convertible Loan Agreements that New Parent will assume the Convertible Loan Agreements, pursuant to which the Lenders agreed to grant Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount
of $19,670,000, and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing
Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the Oculis Share Contribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately 30 days after the closing of the EBAC Mergers, Oculis will undergo the Third Merger.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates varying ownership levels in New Parent immediately following the consummation of the
Business Combination, assuming (i)&nbsp;no redemptions by EBAC&#146;s public shareholders and (ii)&nbsp;the maximum number of redemptions by EBAC&#146;s public shareholders such that the Minimum EBAC Cash Condition will still be satisfied. The
Earnout Consideration, potential future exercises of New Parent Warrants to purchase New Parent Shares and options to acquire New Parent Shares are excluded from the calculations presented below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Share Ownership in New Parent </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Assuming&nbsp;Maximum&nbsp;Redemptions<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC public shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,828,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,465,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC Initial Shareholders<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,761,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors and Lenders under the CLA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,085,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,085,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oculis Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma Ordinary Shares Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,033,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34,588,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ownership amounts ascribed to the EBAC Initial Shareholders include New Parent Shares owned by such
shareholders as a result of the transactions contemplated by the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ownership amounts reflect 727,096 Founder Shares that will be forfeited upon the Acquisition Closing and 74,078
Founder Shares transferred to EBAC Shareholders in connection with executing Non-Redemption Agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that EBAC&#146;s public shareholders exercise redemption rights with respect to 10,363,709 of
EBAC&#146;s public shares, which represents redemptions of approximately 81% of EBAC&#146;s public shares and which is the maximum number of redemptions which may occur such that the Minimum EBAC Cash Condition would still be satisfied at a
redemption price of approximately $10.052 per share, excluding EBAC public shares subject to <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, and assuming total transaction expenses of $15 million. The estimated <FONT
STYLE="white-space:nowrap">per-share</FONT> redemption value of $10.052 was calculated by dividing the Trust Account balance of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBAC Class&nbsp;A Common Stock outstanding on the record date. Reflects the additional sponsor forfeiture amount of 80,869 Founder Shares as described elsewhere in this proxy
statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What equity stake will the current holders of public shares of EBAC, the EBAC Initial Shareholders, the PIPE
Investors and the Oculis Shareholders hold in New Parent after the consummation of the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is anticipated that, upon completion of the Business Combination: (i)&nbsp;EBAC&#146;s public shareholders
will own approximately 29% of New Parent; (ii)&nbsp;the EBAC Initial Shareholders will own approximately 6% of New Parent (as a result of the Business Combination and the PIPE Financing); (iii) the PIPE Investors and Lenders under the Convertible
Loan Agreements (excluding the EBAC Initial Shareholders) will own approximately 20% of New Parent; and (iv)&nbsp;the Oculis Shareholders will own approximately 45% of New Parent. These levels of ownership interests assume that (a)&nbsp;no EBAC
Class&nbsp;A Common Stock are elected to be redeemed by EBAC&#146;s public shareholders, (b) 7,118,891 shares of EBAC Class&nbsp;A Common Stock are issued to the PIPE Investors in connection with the PIPE Financing and (c) 1,967,000 New Parent
Shares are issued to the Lenders in connection with the Convertible Loan Agreements. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ownership percentages with
respect to New Parent following the Business Combination do not take into account the Earnout Consideration or warrants to purchase New Parent Shares that will be outstanding immediately following the Business Combination, but do include Founder
Shares, which will ultimately become New Parent Shares in connection with the consummation of the transactions contemplated hereby, including effecting the Exchange Agent Contribution and the Exchange Agent Contribution Actions. If the actual facts
are different than these assumptions (which they are likely to be), the ownership percentages in New Parent will be different. For more information, please see the sections entitled &#147;<I>Beneficial Ownership</I><I></I><I>&nbsp;of New Parent
Securities</I>&#148; and &#147;<I>Unaudited</I><I></I><I>&nbsp;Pro Forma Condensed Combined Financial</I><I></I><I>&nbsp;Information&#151;Redemption</I><I></I><I>&nbsp;Scenarios.</I>&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alternatively, assuming (i)&nbsp;the maximum number of redemptions by EBAC&#146;s public shareholders such that the Minimum EBAC Cash Condition
will still be satisfied, (ii)&nbsp;that 7,118,891 shares of EBAC Class&nbsp;A Common Stock are issued to the PIPE Investors in connection with the PIPE Financing and (iii) 1,967,000 New Parent Shares are issued to the Lenders in connection with the
Convertible Loan Agreements, the levels of ownership will be as follows: (a)&nbsp;the EBAC public shareholders will own approximately 7% of New Parent; (b)&nbsp;the EBAC Initial Shareholders will own approximately 8% of New Parent (as a result of
the Business Combination and the PIPE Financing); (c) the PIPE Investors and Lenders under the Convertible Loan Agreements (excluding the EBAC Initial Shareholders) will own approximately 26% of New Parent; and (d)&nbsp;the Oculis Shareholders will
own approximately 59% of New Parent, resulting in an amount of 34,588,901 total New Parent Shares outstanding, of which all will be New Parent Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The below sensitivity table shows the potential impact of redemptions on the pro forma book value per share of the shares owned by
non-redeeming shareholders in a no redemption scenario, a 50% of maximum redemption scenario and a maximum redemption scenario. The sensitivity table below also sets forth the potential additional dilutive impact of each of the below additional
dilution sources in each redemption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
scenario, and the effective underwriting fee incurred in connection with the Business Combination in each redemption scenario. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Assuming&nbsp;No<BR>Redemptions&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Assuming&nbsp;50%&nbsp;of&nbsp;the<BR>Maximum<BR>Redemptions (4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Assuming<BR>Maximum<BR>Redemptions&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;%&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;%&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;%&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,828,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,647,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,465,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued to Oculis shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued to EBAC&#146;s initial stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,761,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued to PIPE investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued in connection with closing of the Convertible Loan Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total shares outstanding excluding Additional Dilution Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,033,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,851,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,588,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total pro forma book value&nbsp;(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>178,790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>127,715</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Pro forma book value per share&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.49</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3.69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Additional Dilution Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares underlying public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,251,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,251,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,251,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares underlying private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Earnout Shares (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Oculis vested options (6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">983,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">983,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">983,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Oculis unvested options (6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">779,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">779,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">779,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total Additional Dilution Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,166,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,166,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,166,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total Shares Outstanding Excluding Additional Dilution Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,033,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,851,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,588,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total Shares Outstanding Including Additional Dilution Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,199,782</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,017,928</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,755,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting<BR>fee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting<BR>fee&nbsp;as&nbsp;a&nbsp;%&nbsp;of<BR>the
trust<BR>account<BR>following&nbsp;the<BR>redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Underwriting<BR>fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting<BR>fee&nbsp;as&nbsp;a&nbsp;%&nbsp;of<BR>the
trust<BR>account<BR>following&nbsp;the<BR>redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Underwriting<BR>fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting<BR>fee&nbsp;as&nbsp;a&nbsp;%&nbsp;of<BR>the
trust<BR>account<BR>following&nbsp;the<BR>redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Underwriting fee (7) </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,377,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,377,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,377,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; for pro forma book value
(i.e., total assets <I>minus</I> total liabilities) in the no redemption scenario and the maximum redemption scenario. Pro forma book value for the 50% of maximum redemption scenario is the midpoint between the no redemption and maximum redemption
scenarios pro forma book values. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma book value per share is a result of pro forma book value divided by total shares outstanding
excluding Additional Dilution Sources. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Equity % with respect to each Additional Dilution Sources set forth above, including the Total Additional
Dilution Sources, includes the full amount of shares issuable with respect to the applicable Additional Dilution Sources in both the numerator and denominator. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The no redemption scenario assumes that no EBAC Ordinary Shares are redeemed by the Public Shareholders, the
maximum redemption scenario assumes that 10,363,709 EBAC Ordinary Shares are redeemed by the Public Shareholders and the 50% of the maximum redemption scenario assumes that 5,181,854 EBAC Ordinary Shares are redeemed by the Public Shareholders.
Refer the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; for more information on the no redemption scenario and maximum redemption scenario. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; for more information on the
Earnout Consideration in the form of New Parent Shares (Earnout Shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represent the numbers of vested and unvested options that will be outstanding after the Business Combination
where Oculis options will convert from options to purchase Oculis stock into options to purchase New Parent stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the payment of EBAC&#146;s deferred underwriting fee payable as of September 30, 2022 of CHF 4.4
million incurred in connection with the EBAC initial public offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What income and profits and losses has Oculis generated in the last two years? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the years ended December&nbsp;31, 2021 and December&nbsp;31, 2020, Oculis had grant income of CHF
1.0&nbsp;million and CHF 1.0&nbsp;million, and loss from operating activities of CHF 13.2&nbsp;million and CHF 12.3&nbsp;million, respectively. For the years ended December&nbsp;31, 2021 and December&nbsp;31, 2020, Oculis&#146; total assets were CHF
58.0&nbsp;million and CHF 16.4&nbsp;million, respectively, and its total liabilities, predominantly related to accounting of preferred shares, were CHF 119.0&nbsp;million and CHF 60.0&nbsp;million, respectively. For additional information, please
see the section entitled &#147;<I>Oculis Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Oculis estimates that it had cash and cash equivalents of approximately $21 million as of December 31, 2022. This estimate was prepared by
Oculis&#146; management in good faith based upon internal reporting, is preliminary and unaudited, and may be revised as a result of Oculis&#146; management&#146;s further review of Oculis&#146; results as of and for the year ended December 31,
2022. Oculis has not yet completed its normal audit procedures as of and for the year ended December 31, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preliminary financial
data above has been prepared by, and is the responsibility of, Oculis&#146; management. PricewaterhouseCoopers SA has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data.
Accordingly, PricewaterhouseCoopers SA does not express an opinion or any other form of assurance with respect thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the PIPE Financing? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the Business Combination and concurrently with the execution of the Business Combination
Agreement, EBAC entered into Initial Subscription Agreements with the Initial PIPE Investors pursuant to which the Initial PIPE Investors have agreed to purchase from EBAC, severally and not jointly, and EBAC has agreed to issue from treasury and
sell to the Initial PIPE Investors, a number of shares of EBAC Class&nbsp;A Common Stock equal to (i)&nbsp;the total subscription amount from the Initial PIPE Investors ($63,303,910) <I>divided </I>by (ii) $10.00. Subsequent to the Initial PIPE
Financing, in January 2023, EBAC entered into the Subsequent Subscription Agreements with the Subsequent PIPE Investors, pursuant to which the Subsequent PIPE Investors have agreed to subscribe for, and EBAC has agreed to issue to the Subsequent
PIPE Investors, a number of EBAC Class&nbsp;A Common Stock equal to (i)&nbsp;the total subscription amount from the Subsequent PIPE Investors ($7,885,000) <I>divided </I>by (ii) $10.00. The aggregate amount of EBAC Class&nbsp;A Common Stock to be
issued pursuant to the PIPE Financing is 7,118,891 for aggregate gross proceeds of $71,188,910. The shares of EBAC Class&nbsp;A Common Stock to be issued from treasury to the PIPE Investors pursuant to the Subscription Agreements have not been
registered under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act. New Parent will grant the PIPE Investors certain customary registration rights in connection with the PIPE Financing,
including demand and piggyback rights. The PIPE Financing is contingent upon, among other things, the Acquisition Closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless waived by the parties, the Business Combination Agreement provides that the
parties&#146; obligation to consummate the Business Combination is conditioned on the amount of cash in the Trust Account (net of the Cash Redemption Amount) together with the proceeds from the PIPE Financing (or other financing in connection with
the EBAC Mergers) (after any payment of any unpaid transaction expenses of Oculis and EBAC) being equal to or greater than $100&nbsp;million. The conditions to closing in the Business Combination Agreement are for the sole benefit of the parties
thereto and may be waived by such parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Convertible Loan? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the Business Combination and concurrently with the execution of the Business Combination
Agreement, Oculis entered into a convertible loan agreement with certain Lenders, pursuant to which, among other things, the Lenders party thereto granted Oculis a convertible loan with certain conversion rights in an aggregate amount of
$12,670,000. Subsequent to the execution of the Business Combination Agreement, on January 26, 2023, Oculis and the Lender party thereto entered into an additional convertible loan agreement in substantially the same form as the initial convertible
loan agreement, pursuant to which, among other things, the Lender party thereto has granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $7,000,000. The aggregate amount raised under the
Convertible Loan Agreements is $19,670,000. Following the Second Merger Effective Time, it is the intention<B> </B>of the parties thereto that New Parent will assume the Convertible Loan Agreements, and that immediately after such assumption but
before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors. The Convertible Loan Agreements provide that, upon conversion,
the Lenders will be granted certain customary registration rights, substantially on the same terms as those offered pursuant to the Subscription Agreements. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is EBAC proposing the Adjournment Proposal? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC is proposing the Adjournment Proposal to allow it to adjourn the Extraordinary General Meeting to a later
date or dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the
Business Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common
Stock such that the Minimum EBAC Cash Condition would not be satisfied. Please see the sections entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;3 &#151; The Adjournment Proposal</I>&#148; and &#147;<I>Risk Factors&#151;Risks if the Adjournment
Proposal is Not Approved</I>&#148; for additional information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I sell my EBAC Common Stock before the Extraordinary General Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The record date for the Extraordinary General Meeting is earlier than the date that the Business Combination is
expected to be completed. If you transfer your EBAC public shares after the applicable record date but before the Extraordinary General Meeting, unless the transferee obtains from you a proxy to vote those shares, you will retain your right to vote
at the Extraordinary General Meeting. However, you will not be able to seek redemption of your EBAC Common Stock because you will no longer be able to deliver them for cancellation upon consummation of the Business Combination. If you transfer your
EBAC Common Stock prior to the applicable record date, you will have no right to vote those shares at the Extraordinary General Meeting or redeem those shares for a pro rata portion of the proceeds held in the Trust Account. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What vote is required to approve the proposals presented at the Extraordinary General Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being,
where a quorum is present, the affirmative vote of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General
Meeting. Approval of the Merger Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote
at the Extraordinary General Meeting. Approval of the Adjournment Proposal an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative vote of the holders of at least a majority of the issued shares of EBAC
Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Accordingly, an EBAC shareholder&#146;s failure to vote by proxy or to vote in person (including virtually
by visiting &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) at the Extraordinary General Meeting will not be counted towards the number of shares of EBAC Common Stock required to validly establish a quorum, and if a valid
quorum is otherwise established, such failure to vote will have no effect on the outcome of any vote on any proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted in connection with the determination of
whether a valid quorum is established, but will have no effect on any proposal. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How will the EBAC Initial Shareholders and EBAC&#146;s other current directors and officers vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to EBAC&#146;s initial public offering, EBAC entered into certain agreements with the EBAC Initial
Shareholders, including the Sponsor, and certain other officers and directors of EBAC, pursuant to which each of the parties agreed to vote any EBAC Common Stock owned by them in favor of an initial business combination. All such persons agreed to
vote all of the Founder Shares and such other public shares held by the EBAC Initial Shareholders and such other officers and directors of EBAC in favor of the Business Combination Proposal and the Merger Proposal, and for any other proposal
presented to EBAC Shareholders in this proxy statement/prospectus. As of the record date, the EBAC Initial Shareholders and such other current directors and officers of EBAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; own Founder Shares,
representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the EBAC Common Stock then outstanding and entitled to vote at the Extraordinary General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You should keep in mind that certain EBAC directors and officers have interests in the Business Combination that may conflict with your
interests as a shareholder. Please see the sections entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;Interests of Certain Persons in the Business Combination</I>&#148; and &#147;<I>Risk Factors&#151;Risks Related to
Oculis&#146; Business&#151;The Sponsor has entered into a letter agreement with EBAC to vote in favor of the Business Combination, regardless of how EBAC public shareholders vote&#148;</I> for additional information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What interests do the EBAC Initial Shareholders and EBAC&#146;s other current officers and directors have in
the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The EBAC Initial Shareholders and EBAC&#146;s other current officers and directors have interests in the
Business Combination that are different from or in addition to (and which may conflict with) your interests. You should take these interests into account in deciding whether to approve the Business Combination Proposal and the Merger Proposal. These
interests include, among other things, the following considerations: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed not to redeem any EBAC
Common Stock held by them in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $25,000 for the Founder Shares. The Founder Shares had an estimated aggregate
market value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based upon the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per public share on the Nasdaq Capital Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor transferred Founder Shares to two independent directors prior to EBAC&#146;s initial
public offering and such securities would be worthless if a business combination is not consummated within the Combination Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to any Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period and, in the event EBAC fails to complete an initial business
combination within the Combination Period, the Founder Shares would have no value; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be entered into with
the Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $4.55&nbsp;million for its 455,096 Private Placement Units and that such
Private Placement Units (and the underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The Private Placement Units had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit on the Nasdaq Capital Market on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other
shareholders experience a negative rate of return in the post-business combination company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor will own 2,842,618 New Parent Shares, which collectively will represent approximately
6.3% of outstanding New Parent Shares and have a value of approximately $28,426,180 based on an implied value of $10.00 per New Parent Share and assuming that the maximum number of EBAC Class&nbsp;A Common Stock are redeemed while still satisfying
the Minimum EBAC Cash Condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the anticipated designation by EBAC of Martijn Kleijwegt and Geraldine O&#146;Keeffe as directors of New Parent
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued indemnification of EBAC&#146;s existing directors and officers and the continuation of
EBAC&#146;s directors&#146; and officers&#146; liability insurance after the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LSP 7 Co&ouml;peratief U.A. (&#147;<I>LSP 7</I>&#148;), an affiliate of the Sponsor, previously invested
$2,104,007 into Oculis on July&nbsp;22, 2022 prior to the execution of the Business Combination Agreement. In connection with the Oculis Share Contribution, LSP 7 will receive 233,405 New Parent Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an affiliate of the Sponsor has also entered into a Subscription Agreement in connection with the PIPE
Financing, pursuant to which such affiliate has agreed to subscribe for and purchase, and EBAC has agreed to issue from treasury to such affiliate, a certain number of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share for an aggregate
purchase price of $37.90&nbsp;million. Certain of EBAC&#146;s directors also hold a personal financial interest in such affiliate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and EBAC&#146;s officers and directors will lose their entire investment in EBAC and will not be
reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated within the Combination Period; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Trust Account is liquidated, including in the event EBAC is unable to complete an initial business
combination within the required time period, the Sponsor has agreed to indemnify EBAC to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account
on the liquidation date, by the claims of prospective target businesses with which EBAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to EBAC, but only if such a vendor or target
business has not executed a waiver of any and all rights to seek access to the Trust Account. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">These interests may
influence EBAC&#146;s directors in making their recommendation that EBAC Shareholders vote in favor of the approval of the Business Combination. Please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination
Proposal&#151;Interests of Certain Persons in the Business Combination</I>&#148; for additional information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if the Business Combination Proposal or the Merger Proposal is not approved?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Business Combination Proposal or the Merger Proposal does not receive the requisite votes
for approval, EBAC will not consummate the Business Combination. If EBAC does not consummate the Business Combination and fails to complete an initial business combination within the Combination Period, EBAC will be required to dissolve and
liquidate the Trust Account by returning the then-remaining funds in such account to its public shareholders. Please see the section entitled &#147;<I>Risk Factors&#151;Risks if the Business Combination is not Consummated</I>&#148; for additional
information<I>.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What constitutes a quorum at the Extraordinary General Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One or more shareholders who together hold a majority of the issued and outstanding EBAC Common Stock entitled
to vote at the Extraordinary General Meeting must be present, in person (including virtual presence by visiting &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) or represented by proxy, at the Extraordinary General Meeting
to constitute a quorum and in order to conduct business at the Extraordinary General Meeting. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted as present for the purpose of determining a quorum. The EBAC
Initial Shareholders and other officers and directors of EBAC, who owned &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the issued and outstanding EBAC Common Stock as of the record date, will count towards this quorum. In the absence of a
quorum, the chairman of the Extraordinary General Meeting has power to adjourn the Extraordinary General Meeting. As of the record date for the Extraordinary General Meeting, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
EBAC Common Stock would be required to achieve a quorum. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I vote against any of the proposals contemplated by this proxy statement/prospectus?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you vote against the Business Combination Proposal or the Merger Proposal but the Business Combination
Proposal and the Merger Proposal still obtain the requisite vote of holders of EBAC Common Stock to approve the Business Combination Proposal and the Merger Proposal, then the Business Combination Proposal and the Merger Proposal will be approved
and, assuming the satisfaction or waiver of the other conditions to the Acquisition Closing, the Business Combination and the transactions contemplated thereby will be consummated in accordance with the terms of the Business Combination Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being, where a
quorum is present, the affirmative vote of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting.
Approval of the Merger Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the issued shares of EBAC Common
Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Approval of the Adjournment Proposal an ordinary resolution under Cayman Islands law, being, where a quorum is
present, the affirmative vote of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting.
Accordingly, an EBAC shareholder&#146;s failure to vote by proxy or to vote in person (including virtually by visiting &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) at the Extraordinary General Meeting will not be counted towards the number of
EBAC Common Stock required to validly establish a quorum, and if a valid quorum is otherwise established, such failure to vote will have no effect on the outcome of any vote on any proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
and abstentions will be counted in connection with the determination of whether a valid quorum is established, but will have no effect on any proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Acquisition Closing is conditioned upon the approval of the Business Combination Proposal and the Merger Proposal. The Adjournment Proposal
is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is important for you to note
that, in the event that either the Business Combination Proposal or the Merger Proposal does not receive the requisite votes for approval, EBAC will not consummate the Business Combination. If EBAC does not consummate the Business Combination and
fails to complete an initial business combination within the Combination Period, EBAC will be required to dissolve and liquidate the Trust Account by returning the then-remaining funds in such account to its public shareholders.<B> </B> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do I have redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to EBAC&#146;s amended and restated memorandum and articles of association, holders of EBAC public
shares may elect to have their shares redeemed for the right to receive an amount in cash at the applicable redemption price per share calculated in accordance with EBAC&#146;s amended and restated
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
memorandum and articles of association. As of September&nbsp;30, 2022, this would have amounted to approximately $10.00 per share. If a holder of EBAC public shares exercises its redemption
rights, then such holder will, subject to the Acquisition Closing being completed, be exchanging its EBAC Class&nbsp;A Common Stock for the right to receive an amount in cash and will not own shares of New Parent following the closing of the
transactions contemplated by the Business Combination Agreement, including the Business Combination. Such a holder will be entitled to receive cash for its public shares only if it properly demands redemption and delivers its shares (either
physically or electronically) to the Transfer Agent in accordance with the procedures described herein. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name,
phone number and address to the Transfer Agent in order to validly redeem its shares. Notwithstanding the foregoing, a holder of the public shares, together with any affiliate of his, her, it or any other person with whom he, she or it is acting in
concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock. Accordingly, all public shares
in excess of the 15% threshold beneficially owned by a public shareholder or group will not be redeemed for cash. The EBAC Initial Shareholders and certain other officers and directors of EBAC have agreed, for no consideration in return, to waive
their redemption rights with respect to any Founder Shares and other EBAC Common Stock they may hold in connection with the consummation of the Business Combination, and the Founder Shares and such other EBAC Common Stock will be excluded from the
pro rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally,
the Sponsor and certain EBAC Shareholders have agreed pursuant to that certain <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement to, among other things, not to redeem or exercise any right to redeem any shares, capital stock or any
other equity interests, as applicable, of EBAC that the Sponsor or such EBAC shareholder, as applicable, holds of record or beneficially, as of the date of executing such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, or acquires
thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of EBAC public shares, together with any affiliate or any other person with whom it is
acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock. Accordingly, all
public shares in excess of the 15% threshold beneficially owned by a public shareholder or group will not be redeemed for cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EBAC has
no specified maximum redemption threshold under its amended and restated memorandum and articles of association, other than the aforementioned 15% threshold. Each redemption of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders will
reduce the amount in the Trust Account, which held marketable securities with a fair value of approximately $128.3&nbsp;million as of September&nbsp;30, 2022. The conditions to the Acquisition Closing are for the sole benefit of the parties thereto
and may be waived by such parties. If, as a result of redemptions of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by the parties to the Business Combination Agreement,
then either of the parties thereto may elect not to consummate the Business Combination. In addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001,
as provided in EBAC&#146;s amended and restated memorandum and articles of association. Under these circumstances, EBAC Shareholders may exercise their redemption rights with respect to a maximum of 10,363,709 shares of redeemable EBAC Class&nbsp;A
Common Stock upon consummation of the Business Combination at a redemption price of approximately $10.052 per share. The estimated per share redemption value of $10.052 was calculated by dividing the Trust Account balance of approximately
$128.3&nbsp;million as of September&nbsp;30, 2022, by 12,754,784 shares of EBAC Class&nbsp;A Common Stock outstanding and subject to redemption. Please see the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial
Information&#151;Redemption Scenarios</I>.&#148; EBAC Shareholders who wish to redeem their public shares for cash must refer to and follow the procedures set forth in the section entitled &#147;<I>Extraordinary General Meeting of EBAC
Shareholders&#151;Redemption Rights</I>&#148; in order to properly redeem their public shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Holders of EBAC Warrants will not have
redemption rights with respect to such warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a holder of EBAC public shares exercises its redemption rights, then such holder will,
subject to the Acquisition Closing being completed, be exchanging its EBAC Class&nbsp;A Common Stock for the right to receive an amount in cash and will not own shares of New Parent following the closing of the transactions contemplated by the
Business Combination Agreement, including the Business Combination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Can the EBAC Initial Shareholders redeem their Founder Shares in connection with consummation of the
Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. The EBAC Initial Shareholders and certain other officers and directors of EBAC have agreed, for no
consideration in return, to waive their redemption rights with respect to any Founder Shares held by them in connection with the consummation of an initial business combination. Additionally, the EBAC Initial Shareholders have agreed, for no
consideration in return, to waive their redemption rights with respect to their Founder Shares if EBAC fails to consummate an initial business combination within the Combination Period. However, if the EBAC Initial Shareholders and the other current
officers and directors of EBAC acquire public shares, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if EBAC fails to consummate an initial business combination within the prescribed time
frame. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Is there a limit on the total number of EBAC public shares that may be redeemed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. A holder of EBAC Common Stock, together with any affiliate of his, her, it or any other person with whom
he, she or it is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock.
Accordingly, all public shares in excess of the 15% threshold beneficially owned by a public shareholder or group will not be redeemed for cash. In addition, EBAC&#146;s amended and restated memorandum and articles of association provide that in no
event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless waived by either of the parties to the Business Combination Agreement, the Business Combination Agreement provides the parties&#146;
obligation to consummate the Business Combination is conditioned on the amount of cash in the Trust Account (net of the Cash Redemption Amount) together with the proceeds from the PIPE Financing (or other financing in connection with the EBAC
Mergers) (after any payment of any unpaid transaction expenses of Oculis and EBAC) being equal to or greater than $100&nbsp;million. The conditions to closing in the Business Combination Agreement are for the sole benefit of the parties thereto and
may be waived by such parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will how I vote affect my ability to exercise redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. You may exercise your redemption rights whether you vote your EBAC Class&nbsp;A Common Stock for or
against, or whether you abstain from voting on, the Business Combination Proposal, the Merger Proposal, the Adjournment Proposal or any other proposal described by this proxy statement/prospectus. As a result, the Business Combination Agreement can
be approved by EBAC Shareholders who will redeem their shares and will not be shareholders of New Parent after the consummation of the transactions contemplated by the Business Combination Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do I exercise my redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In order to exercise your redemption rights, you must: (i)&nbsp;if you hold EBAC Units, separate the underlying
EBAC Class&nbsp;A Common Stock and EBAC Public Warrants; (ii)&nbsp;prior to 5:00 p.m., Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the scheduled Extraordinary General
Meeting), identify yourself in writing as a beneficial holder and provide your legal name, phone number and address to the Transfer Agent in order to validly redeem your shares and tender your shares physically or electronically and submit a request
in writing that EBAC redeem your public shares for cash to Continental at the following address: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Continental Stock Transfer&nbsp;&amp; Trust Company, 1 State Street, New York, New York 10004, Attention: &nbsp;&nbsp;&nbsp;&nbsp;; and (iii)&nbsp;deliver your public shares either physically or
electronically through DTC&#146;s DWAC system to the Transfer Agent at least two business days before the initially scheduled Extraordinary General Meeting. Shareholders seeking to exercise their redemption rights and opting to deliver physical
certificates should allot sufficient time to obtain physical certificates from the Transfer Agent and time to effect delivery. Shareholders should generally allot at least two weeks to obtain physical certificates from the Transfer Agent. However,
it may take longer than two weeks. Shareholders who hold their shares in &#147;street name&#148; will have to coordinate with their bank, broker or other nominee to have the shares certificated or delivered electronically. If you do not submit a
written request and deliver your public shares as described above, your shares will not be redeemed. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You do not have to be a
shareholder on the record date in order to exercise your redemption rights. Shareholders seeking to exercise their redemption rights, whether they are registered holders or hold their shares in &#147;street name&#148; are required to either tender
their certificates to the Transfer Agent prior to the date </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">set forth in this proxy statement/prospectus, or up to two business days prior
to the initially scheduled vote on the Business Combination Proposal and the Merger Proposal at the Extraordinary General Meeting, or to deliver their shares to the Transfer Agent electronically using DTC&#146;s DWAC system, at such
shareholder&#146;s option. <B><U>The requirement for physical or electronic delivery prior to the Extraordinary General Meeting ensures that a redeeming shareholder&#146;s election to redeem is irrevocable once the Business Combination is
approved</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold EBAC Units registered in your own name, you must deliver the certificate for such units to the Transfer
Agent with written instructions to separate such units into EBAC Class&nbsp;A Common Stock and EBAC Public Warrants. This must be completed far enough in advance to permit the mailing of the public share certificates back to you so that you may then
exercise your redemption rights upon the separation of the EBAC Class&nbsp;A Common Stock from the EBAC Units. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a broker, dealer,
commercial bank, trust company or other nominee holds your EBAC Units, you must instruct such nominee to separate your units. Your nominee must send written instructions by facsimile to the Transfer Agent. Such written instructions must include the
number of units to be split and the nominee holding such units. Your nominee must also initiate electronically, using DTC&#146;s DWAC system, a withdrawal of the relevant units and a deposit of an equal number of EBAC Class&nbsp;A Common Stock and
EBAC Public Warrants. This must be completed far enough in advance to permit your nominee to exercise your redemption rights upon the separation of the public shares from the EBAC Units. While this is typically done electronically on the same
business day, you should allow at least one full business day to accomplish the separation. If you fail to cause your EBAC Units to be separated in a timely manner, you will likely not be able to exercise your redemption rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any demand for redemption, once made, may be withdrawn at any time until the vote is taken with respect to the Business Combination. If you
delivered your shares for redemption to the Transfer Agent and decide within the required timeframe not to exercise your redemption rights, you may request that the Transfer Agent return the shares (physically or electronically). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them
through the DWAC system. The Transfer Agent will typically charge a tendering broker a fee and it is in the broker&#146;s discretion whether or not to pass this cost on to the redeeming shareholder. However, this fee would be incurred regardless of
whether or not shareholders seeking to exercise redemption rights are required to tender their shares, as the need to deliver shares is a requirement to exercising redemption rights, regardless of the timing of when such delivery must be
effectuated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><U>If you exercise your redemption rights, your shares of EBAC Class</U></B><B><U></U></B><B><U>&nbsp;A Common Stock will
be repurchased by EBAC into treasury immediately prior to the First Merger Effective Time and in return you will obtain the right to receive a pro rata share of the aggregate amount then on deposit in the Trust Account</U></B><B><U>, subject to the
Acquisition Closing being completed</U></B>. You will no longer own those shares and you will not receive any New Parent Shares in the Business Combination. You will have no right to participate in, or have any interest in, the future growth of New
Parent, if any. You will be entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
receive the right for an amount in cash for your EBAC Class&nbsp;A Common Stock only if you properly and timely demand redemption. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the U.S. federal income tax consequences of U.S. Holders of EBAC Class&nbsp;A Common Stock
exercising their redemption rights? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is expected that a U.S. Holder (as defined in the section entitled &#147;<I>Material Tax
Considerations&#151;United States Federal Income Tax Considerations to U.S. Holders</I>&#148;) that exercises its redemption rights to receive an amount in cash from the Trust Account in exchange for its shares of EBAC Class&nbsp;A Common Stock will
generally be treated as selling such shares, resulting in the recognition of capital gain or capital loss. There may be certain circumstances, however, in which the redemption may be treated as a distribution for U.S. federal income tax purposes
depending on the amount of shares that such U.S. Holder owns or is deemed to own (including through the ownership of warrants). For a more complete discussion of the U.S. federal income tax considerations of an exercise of redemption rights, please
see the section entitled &#147;<I>Material Tax Considerations&#151;United States Federal Income Tax Considerations to U.S. Holders&#151;Consequences of the Business Combination to U.S. Holders of EBAC Securities&#151;Redemption of EBAC
Class</I><I></I><I>&nbsp;A Common Stock</I>.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All U.S. Holders considering exercising their redemption rights are
urged to consult their tax advisors regarding the tax consequences to them of an exercise of redemption rights, including the applicability and effect of U.S. federal, state, and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the U.S. federal income tax consequences as a result of the Business Combination to U.S. Holders of
EBAC Common Stock and EBAC Warrants? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As discussed more fully in the section entitled &#147;<I>Material Tax Considerations&#151;United States Federal
Income Tax Considerations to U.S. Holders</I>,&#148; it is intended that the EBAC Mergers qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(l)(F) of the Code. Assuming that the EBAC Mergers so qualify, U.S. Holders
(as defined in the section entitled &#147;<I>Material Tax Considerations&#151;United States Federal Income Tax Considerations to U.S. Holders</I>&#148;) will generally not recognize gain or loss for U.S. federal income tax purposes on the exchange
of EBAC Common Stock and EBAC Warrants for New Parent Shares and New Parent Warrants, as applicable, in the EBAC Mergers. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The discussion of the U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general
discussion and is not a complete analysis or description of all of the U.S. federal income tax considerations that are applicable to a U.S. Holder in respect of the Business Combination, nor does it address any tax considerations arising under U.S.
state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. All U.S. Holders are urged to consult their tax advisors regarding the potential tax consequences to them of the Business Combination, including the applicability and
effect of U.S. federal, state, and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am an EBAC warrant holder, can I exercise redemption rights with respect to my EBAC Public Warrants?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. There will be no redemption rights or liquidating distributions with respect to EBAC Public Warrants, which
will expire worthless if EBAC fails to complete its initial business combination within the Combination Period. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do the EBAC Public Warrants differ from the EBAC Private Placement Warrants and what are the related
risks for any holders of EBAC Public Warrants following the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The EBAC Private Placement Warrants are identical to the EBAC Public Warrants in all material respects, except
that the EBAC Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of the Business Combination and they will not be redeemable by EBAC (except as described in the notes to EBAC&#146;s
financial statements included elsewhere in this proxy statement/</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
prospectus) so long as they are held by the Sponsor or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the EBAC Private Placement Warrants on a
cashless basis. If the EBAC Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the EBAC Private Placement Warrants are redeemable by EBAC in all redemption scenarios and exercisable by the holders on
the same basis as the EBAC Public Warrants. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As a result, following the Business Combination, New Parent may redeem your EBAC
Public Warrants prior to their exercise at a time that is disadvantageous to you, thereby significantly impairing the value of such warrants. New Parent will have the ability to redeem outstanding New Parent Warrants at any time after they become
exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the closing price of the New Parent Shares equals or exceeds $18.00 per share (as adjusted for share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT>
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which a notice of redemption is sent to the warrantholders. New
Parent will not redeem the New Parent Warrants as described above unless a registration statement under the Securities Act covering the New Parent Shares issuable upon exercise of such warrants is effective and a current prospectus relating to those
New Parent Shares is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. If and when the New Parent Warrants become redeemable by New Parent, it may exercise its redemption right even if it is unable to
register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding New Parent Warrants could force you (i)&nbsp;to exercise your New Parent Warrants and pay the exercise price therefor at
a time when it may be disadvantageous for you to do so, (ii)&nbsp;to sell your New Parent Warrants at the then-current market price when you might otherwise wish to hold your New Parent Warrants or (iii)&nbsp;to accept the nominal redemption price
which, at the time the outstanding New Parent Warrants are called for redemption, is likely to be substantially less than the market value of your New Parent Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, New Parent will have the ability to redeem the outstanding New Parent Warrants at any time after they become exercisable and prior
to their expiration, at a price of $0.10 per warrant if, among other things, the closing price of the New Parent Shares equals or exceeds $10.00 per share (as adjusted for share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT> share dividends,
rights issuances, subdivisions, reorganizations, recapitalizations and the like) on the trading day prior to the date on which a notice of redemption is sent to the warrant holders. Recent trading prices for the EBAC Class&nbsp;A Common Stock have
generally not exceeded the $10.00 per share threshold at which the New Parent Warrants would become redeemable. In such a case, the holders will be able to exercise their New Parent Warrants prior to redemption for a number of New Parent Shares
determined based on the redemption date and the fair market value of the New Parent Shares. Please see the notes to EBAC&#146;s financial statements included elsewhere in this proxy statement/prospectus for more information. The value received upon
exercise of the New Parent Warrants (i)&nbsp;may be less than the value the holders would have received if they had exercised their New Parent Warrants at a later time where the underlying share price is higher and (ii)&nbsp;may not compensate the
holders for the value of the New Parent Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In each case, New Parent may only call the New Parent Warrants for redemption upon a
minimum of 30 days&#146; prior written notice of redemption to each holder, provided that holders will be able to exercise their New Parent Warrants prior to the time of redemption and, at New Parent&#146;s election, any such exercise may be
required to be on a cashless basis. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do I have appraisal rights or dissenters&#146; rights if I object to the proposed Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the holders of EBAC Warrants have appraisal rights in connection with the Business Combination under
the Cayman Companies Act. EBAC Shareholders may be entitled to give notice to EBAC prior to the meeting that they wish to dissent to the Business Combination and to receive payment of fair market value for their EBAC Common Stock if they follow the
procedures set forth in the Cayman Companies Act, noting that any such dissention rights may be limited pursuant to Section&nbsp;239 of the Cayman Companies Act, which states that no such dissention rights shall be available in respect of shares of
any class for which an open market exists on a recognized stock exchange at the expiry date of the period allowed for written </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
notice of an election to dissent provided that the merger consideration constitutes, inter alia, shares of any company which at the effective date of the merger are listed on a national
securities exchange. It is the view of the EBAC Board that such fair market value would equal the amount which EBAC Shareholders would obtain if they exercise their redemption rights as described herein. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to the Oculis Shareholders in connection with the Business Combination. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens to the funds held in the Trust Account upon consummation of the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The conditions to closing in the Business Combination Agreement are for the sole benefit of the parties thereto
and may be waived by such parties. The Business Combination Agreement provides that Oculis&#146; obligation to consummate the Business Combination is conditioned, among other things, on satisfying the Minimum EBAC Cash Condition. If, as a result of
redemptions of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by EBAC or Oculis, then either party may elect not to consummate the Business Combination. For more
information, please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;Sources and Uses of Funds for the Business Combination</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if the Business Combination Agreement is terminated or the Business Combination is not
consummated? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The conditions to closing in the Business Combination Agreement are for the sole benefit of the parties thereto
and may be waived by such parties. The Business Combination Agreement is subject to the satisfaction or waiver of certain customary closing conditions including, among others: (i)&nbsp;approval by EBAC Shareholders of the Business Combination
Proposal and the Merger Proposal, (ii)&nbsp;effectiveness of the registration statement of which this proxy statement/prospectus forms a part, and there being no order suspending the effectiveness of the registration statement and no proceeding for
that purpose initiated or threatened by the SEC, (iii)&nbsp;receipt of approval for listing on the Nasdaq Global Market of the shares and warrants of New Parent to be issued in connection with the transactions contemplated by the Business
Combination Agreement, (iv)&nbsp;absence of any injunctions or adoption of any laws making illegal or otherwise prohibiting the Business Combination Agreement and the transactions contemplated thereby, (v)&nbsp;that the Minimum EBAC Cash Condition
is met, (vi)&nbsp;EBAC having net tangible assets of at least $5,000,001, and (vii)&nbsp;satisfaction of customary bringdowns of the representations, warranties and covenants of the parties therein. Please see the section entitled &#147;<I>Proposal
No.</I><I></I><I>&nbsp;1&#151;The Business Combination Proposal&#151;The Business Combination Agreement</I>&#148; for information regarding the parties&#146; specific termination rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If EBAC has not completed its initial business combination within the Combination Period, EBAC will: (i)&nbsp;cease all operations except for
the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible, but not more than 10 business days thereafter, redeem its public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), <I>divided</I> by the number of then issued and outstanding public
shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such
redemption, subject to the approval of EBAC&#146;s remaining shareholders and the EBAC Board, liquidate and dissolve, subject, in each case, to EBAC&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. There will be no redemption rights or liquidating distributions with respect to EBAC Public Warrants, which will expire worthless if EBAC fails to complete its initial business combination within the Combination Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The EBAC Initial Shareholders and the other current officers and directors of EBAC have entered into an agreement with EBAC, pursuant to which
they have waived their rights to liquidating distributions from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Trust Account with respect to their Founder Shares if EBAC fails to complete its initial business combination within the Combination Period. However, if the EBAC Initial Shareholders and the
other current officers and directors of EBAC acquire public shares, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if EBAC fails to complete its initial business combination within the
Combination Period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your vote is very important. You should read carefully this entire proxy statement/prospectus, including the
Annexes and accompanying financial statements of Oculis and EBAC to fully understand the proposed Business Combination before voting on the proposals to be considered at the Extraordinary General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Whether or not you plan to attend the Extraordinary General Meeting, please vote as soon as possible by following the instructions in this
proxy statement/prospectus to ensure that your shares are represented at the Extraordinary General Meeting. The transactions contemplated by the Business Combination Agreement will be consummated only if the Business Combination Proposal and the
Merger Proposal are approved at the Extraordinary General Meeting. The Acquisition Closing is conditioned upon the approval of the Business Combination Proposal and the Merger Proposal. The Adjournment Proposal is not conditioned on the approval of
any other proposal set forth in this proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you hold your shares in &#147;street name&#148; and are a EBAC shareholder of record, you may vote by mail
or in person at the Extraordinary General Meeting. Each share of EBAC Common Stock that you own in your name entitles you to one vote on each of the proposals for the Extraordinary General Meeting. Your one or more proxy cards show the number of
EBAC Common Stock that you own. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Voting by Mail</B>. You can vote your shares by completing, signing, dating and
returning the enclosed proxy card in the postage-paid envelope provided. By signing the proxy card and returning it in the enclosed <FONT STYLE="white-space:nowrap">pre-paid</FONT> and addressed envelope, you are authorizing the individuals named on
the proxy card to vote your shares at the Extraordinary General Meeting in the manner you indicate. You are encouraged to sign and return the proxy card even if you plan to attend the Extraordinary General Meeting so that your shares will be voted
if you are unable to attend the Extraordinary General Meeting. If you receive more than one proxy card, it is an indication that your shares are held in multiple accounts. Please sign and return all proxy cards to ensure that all of your shares are
voted. If you hold your shares in &#147;street name&#148; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at
the Extraordinary General Meeting. If you sign and return the proxy card but do not give instructions on how to vote your shares, your EBAC Common Stock will be voted as recommended by the EBAC Board. The EBAC Board recommends voting
&#147;<B>FOR</B>&#148; the Business Combination Proposal, &#147;<B>FOR</B>&#148; the Merger Proposal, and &#147;<B>FOR</B>&#148; the Adjournment Proposal. Votes submitted by mail must be received by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Voting in Person at the Meeting</B>. If you attend the Extraordinary General Meeting and plan to vote in person, you will be provided with a
ballot at the Extraordinary General Meeting. If your shares are registered directly in your name, you are considered the shareholder of record and you have the right to vote in person at the Extraordinary General Meeting. If you hold your shares in
&#147;street name,&#148; which means your shares are held of record by a broker, bank or other nominee, you should follow the instructions provided by your broker, bank or nominee to ensure that votes related to the shares you beneficially own are
properly counted. In this regard, you must provide the record holder of your shares with instructions on how to vote your shares or, if you wish to attend the Extraordinary General Meeting and vote in person, you will need to bring to the
Extraordinary General Meeting a legal proxy from your broker, bank or nominee authorizing you to vote these shares. That is the only way EBAC can be sure that the broker, bank or nominee has not already voted your EBAC Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Voting Virtually at the Meeting</B>. If your shares are registered in your name with
Continental and you attend the Extraordinary General Meeting and plan to vote virtually, you must visit &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, enter the <FONT STYLE="white-space:nowrap">12-digit</FONT> control
number assigned by Continental included on your proxy card or notice of the Extraordinary General Meeting and click on the &#147;Click here to preregister for the virtual meeting&#148; link at the top of the page. Just prior to the start of the
Extraordinary General Meeting you will need to log back into the Extraordinary General Meeting site using your control number. <FONT STYLE="white-space:nowrap">Pre-registration</FONT> is recommended but is not required in order to attend. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in an account at a brokerage firm, bank or other nominee, then you are the beneficial owner of shares held in
&#147;street name&#148; and this proxy statement/prospectus is being sent to you by that broker, bank or other nominee. The broker, bank or other nominee holding your account is considered to be the shareholder of record for purposes of voting at
the Extraordinary General Meeting. As a beneficial owner, you have the right to direct your broker, bank or other nominee regarding how to vote the shares in your account by following the instructions that the broker, bank or other nominee provides
you along with this proxy statement/prospectus. As a beneficial owner, if you wish to vote at the Extraordinary General Meeting, you will need to bring to the Extraordinary General Meeting a legal proxy from your broker, bank or other nominee
authorizing you to vote those shares. Please see the section entitled &#147;&#151;<I>Attending the Extraordinary General Meeting</I>&#148; below for more details. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen if I abstain from voting or fail to vote at the Extraordinary General Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Extraordinary General Meeting, a properly executed proxy marked &#147;ABSTAIN&#148; with respect to a
particular proposal will be counted as present for purposes of determining whether a quorum is present. For purposes of approval, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the Business
Combination Proposal, the Merger Proposal or the Adjournment Proposal (other than as counted for purposes of determining whether a quorum is present). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you fail to take any action with respect to the Extraordinary General Meeting and the Business Combination is approved by EBAC Shareholders
and the Business Combination is consummated, you will become a shareholder or warrant holder of New Parent. If you fail to take any action with respect to the Extraordinary General Meeting and the Business Combination is not approved, you will
remain a shareholder or warrant holder of EBAC. However, even if you fail to vote with respect to the Extraordinary General Meeting, you will nonetheless be able to elect to redeem your EBAC public shares in connection with the Business Combination.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen if I sign and return my proxy card without indicating how I wish to vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted
<B>&#147;FOR&#148;</B> each of the proposals presented at the Extraordinary General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am not going to attend the Extraordinary General Meeting, should I return my proxy card instead?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. Whether you plan to attend the Extraordinary General Meeting or not, please read this proxy
statement/prospectus carefully in its entirety, and vote your shares by completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EBAC intends to hold the Extraordinary General Meeting in person as well as virtually, via a live webcast at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, EBAC is sensitive to the public health and travel concerns its shareholders may have and recommendations that public health officials may issue in light of the
evolving novel coronavirus disease (&#147;<I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I>&#148;) situation. As a result, EBAC may impose additional procedures or limitations on meeting attendees or may decide to hold the meeting in a
different location. EBAC plans to announce any such updates on its proxy website at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and encourages you to check this website prior to the meeting if you plan to attend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If my shares are held in &#147;street name,&#148; will my broker, bank or nominee automatically vote my
shares for me? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the
&#147;beneficial holder&#148; of the shares held for you in what is known as &#147;street name.&#148; If this is the case, this proxy statement/prospectus may have been forwarded to you by your brokerage firm, bank or other nominee, or its agent,
and you may need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker, bank or other nominee as to how to vote your shares. Under the rules of
various national and regional securities exchanges, your broker, bank or other nominee cannot vote your shares with respect to <FONT STYLE="white-space:nowrap">non-discretionary</FONT> matters unless you provide instructions on how to vote in
accordance with the information and procedures provided to you by your broker, bank or other nominee. EBAC believes all the proposals presented to its shareholders will be considered <FONT STYLE="white-space:nowrap">non-discretionary</FONT> and
therefore your broker, bank or nominee cannot vote your shares without your instruction. Your bank, broker or other nominee can vote your shares only if you provide instructions on how to vote. As the beneficial holder, you have the right to direct
your broker, bank or other nominee as to how to vote your shares and you should instruct your broker, bank or other nominee to vote your shares in accordance with directions you provide. If you do not provide voting instructions to your broker, bank
or other nominee on a particular proposal on which your broker does not have discretionary authority to vote, your shares will not be voted on that proposal. This is called a &#147;broker <FONT STYLE="white-space:nowrap">non-vote.&#148;</FONT>
Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary General Meeting, and otherwise will have no effect on a
particular proposal. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I change my vote after I have mailed my signed proxy card? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. You may change your vote by (i)&nbsp;sending a later-dated, signed proxy card (ii)&nbsp;sending notice to
EBAC&#146;s Secretary in writing before the Extraordinary General Meeting that you have revoked your proxy (in the case of clauses (i)&nbsp;and (ii), so that such card or notice is received prior to the vote at the Extraordinary General Meeting
scheduled to take place on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023) or (iii)&nbsp;attending the Extraordinary General Meeting, revoking your proxy and voting in person (including by virtual means).
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What should I do with my share certificates, warrant certificates or unit certificates?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Shareholders who exercise their redemption rights must deliver (either physically or electronically) their
share certificates to Continental prior to the Extraordinary General Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Holders must complete the procedures for
electing to redeem their public shares in the manner described in the section entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Redemption Rights</I>&#148; prior to 5:00 p.m., Eastern Time, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the scheduled Extraordinary General Meeting) in order for such shares to be redeemed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EBAC&#146;s warrant holders should not submit the certificates relating to their EBAC Public Warrants. Public shareholders who do not elect to
have their EBAC public shares redeemed for the pro rata share of the Trust Account should not submit the certificates relating to their EBAC public shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon the Acquisition Closing and the transactions contemplated thereby, holders of EBAC Units, EBAC Common Stock and EBAC Public Warrants will
receive New Parent Shares and New Parent Warrants, as the case may be, without needing to take any action and, accordingly, such holders should not submit any certificates relating to their EBAC Units, EBAC Class&nbsp;A Common Stock (unless such
holder elects to redeem the either their EBAC Units or EBAC Class&nbsp;A Common Stock in accordance with the procedures set forth below), or EBAC Public Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What should I do if I receive more than one set of voting materials? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You may receive more than one set of voting materials, including multiple copies of this proxy
statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold
shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to
cast your vote with respect to all of your EBAC Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will solicit and pay the cost of soliciting proxies for the Extraordinary General Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC and Oculis will each bear <FONT STYLE="white-space:nowrap">one-half</FONT> of the entire cost of the proxy
solicitation, including the preparation, assembly, printing, mailing and distribution of this proxy statement/prospectus and the related proxy materials. EBAC has engaged D.F. King &amp; Co., Inc. (&#147;D.F. King&#148;), to assist in the
solicitation of proxies for the Extraordinary General Meeting. EBAC will pay D.F. King a fee of $25,000 <I>plus</I> disbursements and indemnify D.F. King and its affiliates against certain claims, liabilities, losses, damages and expenses for their
services as EBAC&#146;s proxy solicitor. EBAC will reimburse brokerage firms and other custodians for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for forwarding this proxy
statement/prospectus and the related proxy materials to EBAC Shareholders. Directors, officers and employees of EBAC who solicit proxies will not be paid any additional compensation for soliciting. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have questions about the Business Combination or the proposals included in this proxy
statement/prospectus or if you need additional copies of this proxy statement/prospectus or the enclosed proxy card you should contact: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">D.F. King &amp; Co., Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">48
Wall Street, 22nd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Individuals (toll-free): (877) 732-3619 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Banks and Brokerage Firms, please call collect at (212) 269-5550 or email at EBAC@dfking.com. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To obtain timely delivery, EBAC Shareholders must request the materials no later than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 or five business days prior to the Extraordinary General Meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may also obtain additional information about EBAC from documents filed with the SEC by following the instructions in the section entitled
&#147;<I>Where You Can Find More Information</I>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of EBAC public shares and intend to seek redemption of such
shares, you will need to deliver your public shares (either physically or electronically) to the Transfer Agent. Holders must complete the procedures for electing to redeem such shares in the manner described in the section entitled
&#147;<I>Redemption Rights</I>&#148; prior to 5:00 p.m., New York City time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the scheduled Extraordinary General Meeting) in order for such
shares to be redeemed. If you have questions regarding the certification of your position or delivery of your public shares, please contact the Transfer Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 State Street, 30th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, New York 10004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_8"></A>SUMMARY OF THE PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained in this proxy statement/prospectus and does not contain all of the information that is important to
you. You should read carefully this entire proxy statement/prospectus, including the Annexes and accompanying financial statements of Oculis and EBAC to fully understand the proposed Business Combination (as described below) before voting on the
proposals to be considered at the Extraordinary General Meeting (as described below). Please see the section entitled &#147;Where You Can Find More Information.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parties to the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Oculis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis is a stock
corporation (<I>Aktiengesellschaft</I>) that was incorporated under the laws of Switzerland on December&nbsp;11, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis is registered with the
commercial register of the Canton de Vaud under company registration number <FONT STYLE="white-space:nowrap">CHE-237.826.774.</FONT> The mailing address of Oculis&#146; principal executive office prior to and after the Acquisition Closing is Oculis
SA, EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. Neither the Oculis articles of association nor the operation of law limit the duration of Oculis. Oculis&#146; telephone
number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+41-21-711-3970</FONT></FONT></FONT> and its website is www.oculis.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>New Parent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent is a stock
corporation (<I>Aktiengesellschaft</I>) that was incorporated on October&nbsp;31, 2022. To date, New Parent has not conducted any material activities other than those incident to its formation and the pending Business Combination and only has
nominal assets consisting of cash and cash equivalents. Accordingly, no financial statements of New Parent have been included in this proxy statement/prospectus. New Parent has applied to list the New Parent Shares and New Parent Warrants under the
Exchange Act and on the Nasdaq Global Market under the symbols &#147;OCS&#148; and &#147;OCSAW,&#148; respectively, upon the Acquisition Closing. All New Parent Shares shall be of the same class of shares and consist only of New Parent Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of New Parent&#146;s principal executive office prior to the Acquisition Closing is Oculis Holding AG, Bahnhofstrasse 7, <FONT
STYLE="white-space:nowrap">CH-6300</FONT> Zug, Switzerland. The mailing address of New Parent&#146;s principal executive office is expected to move within two months after the Acquisition Closing to Oculis Holding AG, EPFL Innovation Park, Bat D 3e
Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. Neither the Proposed Articles of Association nor the operation of law limit the duration of New Parent. New Parent&#146;s telephone number is currently <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+41-58-810-0182.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>EBAC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is a blank check
company incorporated as a Cayman Islands exempted company on January&nbsp;8, 2021 for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more
businesses or entities. EBAC consummated its initial public offering on March&nbsp;18, 2021, generating net proceeds of $127.5&nbsp;million, which includes the partial exercise of the underwriter&#146;s option to purchase an additional 754,784 units
at the initial public offering price to cover over-allotments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Class&nbsp;A Common Stock, EBAC Units and EBAC Public Warrants are traded on the
Nasdaq Capital Market under the ticker symbols, &#147;EBAC,&#148; &#147;EBACU,&#148; and &#147;EBACW,&#148; respectively. Upon the Acquisition Closing, EBAC&#146;s securities will be delisted from the Nasdaq Capital Market. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of EBAC&#146;s registered office is European Biotech Acquisition Corp., EPFL Innovation
Park Building, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Merger Sub 1 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub 1 is a Cayman Islands exempted company and a direct, wholly owned subsidiary of New Parent that was incorporated on January 3, 2023 to facilitate
the consummation of the Business Combination. In the Business Combination, at the First Merger Effective Time, Merger Sub 1 will merge with and into EBAC, with EBAC continuing as the surviving company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of Merger Sub 1 registered office is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Merger Sub 2 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub 2 is
a Cayman Islands exempted company and a direct, wholly owned subsidiary of New Parent that was incorporated on January 3, 2023 to facilitate the consummation of the Business Combination. In the Business Combination, at the Second Merger Effective
Time, EBAC will merge with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of Merger Sub 2 registered
office is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Merger Sub 3
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub 3 is a limited liability company (<I>Gesellschaft mit beschr</I><I>&auml;</I><I>nkter Haftung</I>) incorporated and existing under the
laws of Switzerland and a direct, wholly owned subsidiary of New Parent that was incorporated on December&nbsp;30, 2022 to facilitate the consummation of the Business Combination. In the Business Combination, at the Third Merger Effective Time,
Oculis will merge with and into Merger Sub 3, with Merger Sub 3 continuing as the surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of Merger Sub 3 registered office
is Bahnhofstrasse&nbsp;7, 6300 Zug, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, EBAC entered into the Business Combination Agreement with Oculis. Pursuant to the Business Combination Agreement and the Ancillary
Agreements, and subject to the terms and conditions contained therein, the Business Combination will be effected in the following steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Investors will transfer $71,188,910 to EBAC in exchange for 7,118,891 PIPE Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC will undergo the First Merger; and as part of the First Merger, (a)&nbsp;each share of EBAC Common Stock
(including those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares, (b)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into Surviving
EBAC Warrants and (c)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms, and
subject to the conditions set forth in the Business Combination Agreement and in the Ancillary Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the
Second Merger Effective Time, the Exchange Agent, solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for receipt of the New Parent Interests
Consideration; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to
the Second Merger Effective Time, the Exchange Agent will undertake to distribute (i)&nbsp;the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii)&nbsp;the New Parent Warrants as part
of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution
Actions, at the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence of EBAC will cease, and following the Acquisition Closing, Merger Sub 2 shall be liquidated
and its assets distributed to New Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the Second Merger Effective Time but before the Oculis Share Contribution, it is the intention of the
parties to the Convertible Loan Agreements that New Parent will assume the Convertible Loan Agreements, pursuant to which the Lenders have granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of
$19,670,000, and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing
Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the Oculis Share Contribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately 30 days after the closing of the EBAC Mergers, Oculis will undergo the Third Merger.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Business Combination are contained in the Business Combination Agreement, a copy of which is attached
to this proxy statement/prospectus as <U>Annex A</U>. You are encouraged to read the Business Combination Agreement carefully, as it is the legal document that governs the Business Combination. For more information on the Business Combination
Agreement, please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;The Business Combination Agreement</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The First Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub 1 will be
merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease and EBAC will be the surviving company and a wholly owned subsidiary of New Parent. As part of the First Merger, (i)&nbsp;each share of EBAC Common Stock (including
those held by the PIPE Investors) shall be automatically converted into one class of common stock of EBAC, as the surviving company of the First Merger, (ii)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time
will be automatically converted into warrants of EBAC, as the surviving company of the First Merger and (iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and
EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms, and subject to the conditions set forth in the Business Combination Agreement and in the Ancillary Agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Exchange Agent Contribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the
day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time, the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in exchange
for (i)&nbsp;New Parent Shares and (ii)&nbsp;New Parent Warrants, in each case of (i)&nbsp;and (ii), to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Exchange Agent Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange
Agent will (i)&nbsp;undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares (as defined in the Business Combination Agreement) and (ii)&nbsp;distribute the New Parent
Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Second Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution Actions, at the Second Merger Effective Time,
EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Oculis Share Contribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the
contribution to New Parent of all Company Share Capital held by such Oculis shareholder free and clear of all liens (other than general restrictions on transfer under applicable securities laws or the articles of association of Oculis) in exchange
for New Parent Shares on the terms, and subject to the conditions set forth in the Business Combination Agreement and Oculis Shareholders Support Agreements; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Third Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 30 days
after the Acquisition Closing Date, pursuant to a merger agreement to be entered into in accordance with the Business Combination Agreement, Oculis will merge with and into Merger Sub 3, the separate corporate existence of Oculis will cease and
Merger Sub 3 will be the surviving company and remain a wholly owned subsidiary of New Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Conditions to Closing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the Parties to the Business Combination Agreement to consummate the Business Combination are subject to the satisfaction or waiver (where
permissible) at or prior to the Acquisition Closing Date of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of EBAC Shareholders shall have been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC&#146;s net tangible assets shall be at least $5,000,001; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement of which this proxy statement/prospectus forms a part shall have become effective
under the Securities Act and no stop order suspending the effectiveness of such registration statement shall have been issued and no proceedings for that purpose shall have been initiated or threatened by the SEC and not withdrawn;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the New Parent Shares to be issued in connection with the transactions contemplated by the Business Combination
Agreement shall have been approved for listing on the Nasdaq Global Market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) The amount of cash or cash equivalents available in the Trust Account following the Extraordinary General
Meeting (after deducting the EBAC Share Redemption Amount and payment of any transaction expenses of Oculis and EBAC); plus (ii)&nbsp;(a) the cash actually received by New Parent pursuant to the Convertible Loan Agreements from the respective lender
parties thereto and (b)&nbsp;the PIPE Investment Amount actually received by New Parent (or other financing in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing is equal to or greater
than $100&nbsp;million; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall not be in force any governmental order enjoining or prohibiting the consummation of any of the
Business Combination or the Acquisition Transactions or any law that makes the consummation of any of the Business Combination or the Acquisition Transactions illegal or otherwise prohibited; provided that the governmental authority issuing such
governmental order has jurisdiction over the parties thereto with respect to the Transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of EBAC to consummate
the Business Combination are subject to the satisfaction or waiver (where permissible) of the following additional conditions as of the dates set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain of Oculis&#146; representations and warranties being true and correct in all respects as of the date of
the Business Combination Agreement and the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material
respects at and as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company Fundamental Representations (as defined in the Business Combination Agreement) shall be true and
correct in all material respects as of the date of the Business Combination Agreement and the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and
warranties shall be true and correct in all material respects at and as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Oculis, other than the Company Fundamental Representations, (disregarding
any qualifications and exceptions contained therein relating to materiality, material adverse effect and Company Material Adverse Effect or any similar qualification or exception) shall be true and correct as of the date of the Business Combination
Agreement and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct at and as of such date, except for, in
each case, inaccuracies or omissions that have not had, and would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the covenants of Oculis to be performed as of or prior to the Acquisition Closing shall have been
performed in all material respects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall not have occurred a Company Material Adverse Effect after the date of the Business Combination
Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Oculis to consummate the Business Combination are subject to the satisfaction or waiver (where
permissible) of the following additional conditions as of the dates set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain of EBAC&#146;s representations and warranties being true and correct in all respects as of the
Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all respects at and as of such date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the EBAC Fundamental Representations (as defined below) shall be true and correct in all material respects as of
the date of the Business Combination Agreement and the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all
material respects at and as of such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 in Article 5
and Article 6 of the Business Combination Agreement (other than the EBAC Fundamental Representations and the representations and warranties set forth in the first sentence of each of Section&nbsp;5.03(a) and Section&nbsp;6.13(a) of the Business
Combination Agreement) (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect or any similar qualification or exception) shall be true and correct as of the date of the Business Combination
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Agreement and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true
and correct as of such date, except for, in each case, inaccuracies or omissions that have not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the
Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the covenants of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to be performed as of or
prior to the Acquisition Closing shall have been performed in all material respects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall not have occurred a material adverse effect with respect to EBAC after the date of the Business
Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mutual termination rights</I>. The Business Combination Agreement may be terminated and the transactions contemplated thereby abandoned: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by the mutual written consent of Oculis and EBAC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if the Acquisition Closing Date has not occurred by March&nbsp;18, 2023 (the &#147;<I>Agreement
End Date</I>&#148;); provided, that if an Extension Proposal (as defined in the Business Combination Agreement) shall be approved at an Extension Shareholders&#146; Meeting (as defined in the Business Combination Agreement) then to the last day of
the extended time period for EBAC to consummate a business combination; provided, further, however, that a party shall not be entitled to terminate the Business Combination Agreement pursuant to Section&nbsp;11.01(b) of the Business Combination
Agreement if such party&#146;s breach of the Business Combination Agreement has prevented the consummation of the Acquisition Closing Date at or prior to such time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if any governmental order which has become final and
<FONT STYLE="white-space:nowrap">non-appealable</FONT> has the effect of making consummation of any of the Acquisition Transactions illegal or otherwise preventing or prohibiting consummation of any of the Acquisition Transactions or if there shall
be adopted any law that permanently makes consummation of any of the Acquisition Transactions illegal or otherwise prohibited; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if the approval of EBAC Shareholders has not been obtained due to the failure to obtain the
required vote at the Extraordinary General Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Oculis termination rights</I>. The Business Combination Agreement may be
terminated and the transactions contemplated thereby abandoned: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis if there has been a Modification in Recommendation (as defined below); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by written notice to EBAC upon the occurrence of a Terminating EBAC Breach (as defined below) which is not cured
within the time period beginning on the date of such Terminating EBAC Breach and ending on the earlier of (a) 45 days after EBAC&#146;s receipt of Oculis&#146; notice of such breach or (b)&nbsp;the Agreement End Date, provided that Oculis is not
then in material breach of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EBAC termination rights</I>. The Business Combination Agreement may
be terminated and the transactions contemplated thereby abandoned: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by written notice to Oculis upon the occurrence of a Terminating Company Breach (as defined below) which is not
cured within the time period beginning on the date of such Terminating Company Breach </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and ending on the earlier of (i) 45 days after Oculis&#146; receipt of EBAC&#146;s notice of such breach or (ii)&nbsp;the Agreement End Date; provided that EBAC is not then in material breach of
the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information about the Business Combination Agreement and the Business Combination and
other transactions contemplated thereby, please see the section entitled &#147;</B><B><I>Proposal No. 1&#151;The Business Combination Proposal&#151;The Business Combination Agreement</I></B><B>.&#148; </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ancillary Documents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The
Subscription Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, EBAC entered into Initial Subscription Agreements
with the Initial PIPE Investors, including LSP 7, certain existing Oculis Shareholders as well as certain other investors, pursuant to which the Initial PIPE Investors have agreed to subscribe for and purchase, and EBAC has agreed to issue from
treasury to such PIPE Investors, an aggregate of 6,330,391 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share, for the aggregate purchase price of $63,303,910. Subsequent to the Initial PIPE Financing, in January 2023, EBAC
entered into the Subsequent Subscription Agreements with the Subsequent PIPE Investors, pursuant to which the Subsequent PIPE Investors have agreed to subscribe for, and EBAC has agreed to issue to the Subsequent PIPE Investors, an aggregate of
788,500 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share, for the aggregate purchase price of $7,885,000. The aggregate amount of EBAC Class&nbsp;A Common Stock to be issued pursuant to the PIPE Financing is 7,118,891 for
aggregate gross proceeds of $71,188,910. Pursuant to the transactions contemplated in the Business Combination Agreement, EBAC Class&nbsp;A Common Stock will ultimately convert into New Parent Shares. The Subscription Agreements contain
substantially the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the PIPE Financing is subject to, among other customary closing conditions, the substantially concurrent
consummation of the Business Combination. The Subscription Agreements provide that EBAC will cause New Parent to grant the PIPE Investors certain customary registration rights in connection with the PIPE Financing, including demand and piggyback
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Convertible Loan Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Oculis and the Lenders party thereto entered into a convertible loan agreement, pursuant
to which, among other things, the Lenders party thereto have granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $12,670,000. Subsequent to the execution of the Business Combination
Agreement, on January 26, 2023, Oculis and an additional Lender entered into a convertible loan agreement in substantially the same form as the initial convertible loan agreement, pursuant to which, among other things, the Lender party thereto has
granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $7,000,000. The aggregate amount raised under the Convertible Loan Agreements is $19,670,000. Following the Second Merger Effective Time,
it is the intention of the parties thereto that New Parent will assume the Convertible Loan Agreements, and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in
exchange for New Parent Shares at $10.00 per share, on substantially the same terms as the PIPE Investors. The Convertible Loan Agreements provide that, upon conversion, the Lenders will be granted certain customary registration rights,
substantially on the same terms as those offered pursuant to the Subscription Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Oculis Shareholders Support
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Oculis, EBAC, and certain Oculis Shareholders entered into the
Oculis Shareholders Support Agreements, pursuant to which such Oculis </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shareholders agreed to, among other things, (i)&nbsp;adopt the Business Combination Agreement and approve and consent to the Mergers and the consummation of the transactions contemplated therein,
(ii)&nbsp;execute and deliver the exchange notice agreeing to transfer to the Exchange Agent all Company Share Capital held by such Shareholder and (iii)&nbsp;provide a release of claims against Oculis and its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Sponsor Support Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Sponsor, EBAC and Oculis entered into the Sponsor Support Agreement, pursuant to which
Sponsor agreed to, among other things, (i)&nbsp;vote to adopt and approve the Business Combination Agreement and the other documents contemplated thereby and the transactions contemplated thereby, (ii)&nbsp;not transfer its shares of EBAC Common
Stock and EBAC Warrants, in each case, until the consummation of the Acquisition Closing (subject to certain customary exceptions), (iii) waive certain anti-dilution adjustments, and (iv)&nbsp;waive certain redemption rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the Business Combination, New Parent will enter into the Registration Rights and
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with Sponsor and certain Oculis Shareholders. Pursuant to the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, Sponsor and such Oculis Shareholders may not
transfer New Parent Shares (subject to certain exceptions) until: (i)&nbsp;with respect to the New Parent Shares held by the Oculis Shareholders party thereto upon the Acquisition Closing, 180 days from the Acquisition Closing, and (ii)&nbsp;with
respect to the New Parent Shares held by Sponsor upon the Acquisition Closing, 270 days after the Acquisition Closing, in each case subject to earlier release if the New Parent Shares trade at or above a volume weighted average price of $15.00 for
20 trading days during any 30 trading day period commencing at least 150 days following the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registration Rights and <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement provides Sponsor and the Oculis Shareholders party thereto certain customary registration rights, including demand and piggyback registration rights, subject to customary requirements and
conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, EBAC, Sponsor and certain EBAC Shareholders have entered into <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, pursuant to which, among other things, such EBAC Shareholder has agreed to (i)&nbsp;vote in favor of the transactions contemplated in the Business Combination Agreement, for which the
approval of such EBAC Shareholder is required, (ii)&nbsp;not to redeem, or exercise any right to redeem, any EBAC equity securities held by such EBAC Shareholder as of the date of the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement,
or acquired thereafter and (iii)&nbsp;not to transfer any EBAC equity securities until 90 days after the Acquisition Closing. In consideration of such EBAC Shareholder&#146;s performance of its obligations under the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, Sponsor has agreed to transfer to such EBAC Shareholder one New Parent Share for every 10 shares of EBAC Class&nbsp;A Common Stock held by such EBAC Shareholder. As of the record
date, &nbsp;&nbsp;&nbsp;&nbsp;shares of EBAC Class&nbsp;A Common Stock are subject <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
additional information about the ancillary agreements related to the Business Combination, please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;Certain Agreements Related to the Business
Combination</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The EBAC Board&#146;s Reasons for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business
combination with one or more businesses. The EBAC Board sought to do this by utilizing the networks and industry experience of both the Sponsor and the EBAC Board to identify, acquire and operate one or more businesses. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the EBAC Board considered the following factors (although not weighted or in any order of
significance) in deciding to approve the proposed Business Combination: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team and New Parent Board. </I></B>The EBAC Board believes that Oculis&#146;
management team has extensive experience in the biopharma industry in general and the ophthalmology market in particular. The EBAC Board is confident in the management team&#146;s deep industry knowledge and strategic vision and believes that the
EBAC and Oculis teams (together with the new incoming directors of the New Parent Board who have extensive executive experience working in the biopharma industry) will form a collaborative and effective long-term partnership that is positioned to
create and enhance shareholder value going forward. For additional information regarding Oculis&#146; executive officers, please see the section entitled &#147;<I>Management of New Parent After the Business Combination</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced and diversified pipeline. </I></B>The EBAC Board considered that the current pipeline of Oculis
provides multiple product candidates that may be developed in several indications where the existing unmet medical need could provide significant market opportunities and long-term shareholder value. For additional information regarding Oculis&#146;
pipeline, please see the section entitled &#147;<I>Business of Oculis and Certain Information about Oculis</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Upcoming milestones.</I></B> The EBAC Board considered that with the funds that Oculis is expected to
receive with the proposed transaction, it may be able to reach significant clinical and regulatory milestones for all three of its product candidates, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and
<FONT STYLE="white-space:nowrap">OCS-05,</FONT> in a total of five different indications. These milestones could provide opportunity for potential uplifts in valuation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Benefit for Oculis of being U.S. listed</I></B>. As a result of the proposed transaction, Oculis will
become a public company listed on the Nasdaq Global Market (via New Parent). By having access to the largest biotech capital market, Oculis will be better positioned to have the capacity to raise additional funds in the future if and when needed.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Investment by Third Parties</I></B><B>. </B>The EBAC Board considered that certain sophisticated investors
(i)&nbsp;subscribed for the PIPE Financing in the aggregate amount of approximately $71.2&nbsp;million and (ii)&nbsp;agreed to grant Oculis a right to receive a convertible loan with certain conversion rights in the aggregate amount of approximately
$19.7&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Terms of the Business Combination Agreement and the Ancillary Agreements</I></B><B>. </B>The EBAC Board
considered the terms and conditions of the Business Combination Agreement and the Ancillary Agreements, including the transactions contemplated thereby, each party&#146;s representations, warranties and covenants, the conditions to each party&#146;s
obligation to close and the termination provisions, as well as EBAC&#146;s and Oculis&#146; strong commitment to complete the Business Combination. The EBAC Board determined that such terms and conditions are reasonable and were the product of
extensive <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between EBAC and Oculis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continued Ownership of Oculis Shareholders</I></B><B>.</B> The EBAC Board considered that the Oculis
Shareholders would be receiving a significant amount of New Parent Shares in the proposed Business Combination. Oculis Shareholders have demonstrated confidence in the long-term prospects of New Parent by agreeing not to transfer their New Parent
Shares for 180 days following the Acquisition Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>The Role of the Independent Directors</I></B><B>.</B> In connection with the Business Combination,
EBAC&#146;s Independent Directors evaluated the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements, and unanimously approved, as members of the EBAC Board, the Business Combination
Agreement, the Ancillary Agreements, and the transactions contemplated thereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Alternatives</I></B><B>. </B>The EBAC Board believes, after a thorough review of other business
combination opportunities reasonably available to or explored by EBAC, that the proposed Business Combination </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
represents the optimal potential business combination for EBAC and its shareholders based upon the process utilized to evaluate and assess other potential acquisition targets, and the EBAC
Board&#146;s belief that such processes had not presented a better alternative. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more complete description of the EBAC
Board&#146;s reasons for approving the Business Combination, including other factors and risks considered by the EBAC Board, please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;The Business Combination
Agreement&#151;The EBAC Board&#146;s Reasons for the Business Combination.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This explanation of EBAC&#146;s reasons for the EBAC Board&#146;s
approval of the Business Combination, and all other information presented in this summary is not intended to be exhaustive, but includes material factors considered by the EBAC Board and is forward-looking in nature and, therefore, should be read in
light of the factors discussed under the section entitled &#147;<I>Cautionary Note Regarding Forward-Looking Statements</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Extraordinary
General Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Date, Time and Place of Extraordinary General Meeting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary General Meeting will be held on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, at EBAC&#146;s corporate address, located at EPFL Innovation Park, Bat D, 3e Route J-D. Colladon, CH-1015 Lausanne, Switzerland, and
via a live webcast at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or at such other time, on such other date and at such other place to which the meeting may be adjourned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC intends to hold the Extraordinary General Meeting in person as well as virtually, via a live webcast at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, EBAC is sensitive to the public health and travel concerns our shareholders may have and recommendations that public health officials may
issue in light of the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation. As a result, EBAC may impose additional procedures or limitations on meeting attendees or may decide to hold the meeting in a different location. EBAC plans
to announce any such updates on its proxy website at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and encourages you to check this website prior to the meeting if you plan to attend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To attend the meeting virtually please visit &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and use a
12-digit control number assigned by Continental included on your proxy card or notice of the Extraordinary General Meeting. To register and receive access to the virtual meeting, registered shareholders and beneficial shareholders (i.e., those
holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Proposals of the Extraordinary General Meeting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Extraordinary General Meeting, EBAC Shareholders will be asked to consider and vote on the following proposals:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Business Combination Proposal</I> &#151; a proposal to approve and adopt the Business Combination Agreement,
a copy of which is attached to this proxy statement/prospectus as <U>Annex A</U>, and the transactions contemplated thereby, including the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Merger Proposal</I> &#151; a proposal to approve and authorize, by special resolution, the Plan of Merger, a
copy of which is attached to this proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with and into EBAC, the separate entity existence of Merger Sub 1 will cease, and EBAC will be the surviving company and
wholly owned subsidiary of New Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Adjournment Proposal</I> &#151; a proposal to adjourn the Extraordinary General Meeting to a later date or
dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC&#146;s
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shareholders in favor of the Business Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement
or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such that the Minimum EBAC Cash Condition would not be satisfied. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please see the sections entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal</I>&#148;, &#147;<I>Proposal No.
2&#151;The Merger Proposal</I>&#148; and &#147;<I>Proposal No. 3&#151;The Adjournment Proposal</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Registering for the
Extraordinary General Meeting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder wishing to attend the Extraordinary General Meeting virtually should register for the Extraordinary
General Meeting by &nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp;. To register for the Extraordinary General Meeting, please follow these instructions as applicable to the nature of your ownership of EBAC shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If your shares are registered in your name with Continental and you attend the Extraordinary General Meeting
and plan to vote virtually, go to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, enter the <FONT STYLE="white-space:nowrap">12-digit</FONT> control number included on your proxy card or notice of the
Extraordinary General Meeting and click on the &#147;Click here to preregister for the virtual meeting&#148; link at the top of the page. Just prior to the start of the Extraordinary General Meeting you will need to log back into the Extraordinary
General Meeting site using your control number. <FONT STYLE="white-space:nowrap">Pre-registration</FONT> is recommended but is not required in order to attend. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Beneficial shareholders (i.e., those holding shares through a stock brokerage account or by a bank or other
holder of record) who wish to attend the virtual meeting must obtain a legal proxy by contacting their account representative at the bank, broker or other nominee that holds their shares and email a copy (a legible photograph is sufficient) of their
legal proxy to proxy@continentalstock.com. Beneficial shareholders who email a valid legal proxy will be issued a <FONT STYLE="white-space:nowrap">12-digit</FONT> control number that will allow them to register to attend and participate in the
Extraordinary General Meeting. After contacting Continental, a beneficial holder will receive an email prior to the Extraordinary General Meeting with a link and instructions for entering the virtual meeting. Beneficial shareholders should contact
Continental at least five business days prior to the Extraordinary General Meeting date in order to ensure access. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Power; Record Date </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
shareholder of EBAC, you have a right to vote on certain matters affecting EBAC. The proposals that will be presented at the Extraordinary General Meeting and upon which you are being asked to vote are summarized above and fully set forth in this
proxy statement/prospectus. If you are a shareholder that holds your shares in &#147;street name,&#148; you will be entitled to vote or direct votes to be cast at the Extraordinary General Meeting if you owned EBAC Common Stock at the close of
business on &nbsp;&nbsp;&nbsp;&nbsp;, 2023, which is the record date for the Extraordinary General Meeting. You are entitled to one vote for each share of EBAC Common Stock that you owned as of the close of business on the record date. If your
shares are held in &#147;street name&#148; through a broker, bank or other nominee, or are in a margin or similar account, you should contact your broker, bank or other nominee to ensure that votes related to the shares you beneficially own are
properly counted. On the record date, there were &nbsp;&nbsp;&nbsp;&nbsp; shares of EBAC Common Stock outstanding, of which &nbsp;&nbsp;&nbsp;&nbsp; are shares of EBAC Class&nbsp;A Common Stock and &nbsp;&nbsp;&nbsp;&nbsp; are shares of EBAC
Class&nbsp;B Common Stock held by the EBAC Initial Shareholders (including Founder Shares transferred by the Sponsor in the amount of 25,000 Founder Shares to certain of the Independent Directors, for a total of 50,000 Founder Shares transferred).
For the avoidance of doubt, the record date does not apply to EBAC Shareholders that hold their shares in registered form and are registered as shareholders in EBAC&#146;s register of members. EBAC Shareholders that hold their shares in registered
form are entitled to one vote on each proposal presented at the Extraordinary General Meeting for each share of EBAC Common Stock held on the record date of the Extraordinary General Meeting. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Vote of EBAC Initial Shareholders and the Other Directors and Officers of EBAC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to EBAC&#146;s initial public offering, EBAC entered into certain agreements with the EBAC Initial Shareholders and other officers and directors of EBAC,
pursuant to which each of the parties agreed to vote any EBAC Common Stock owned by them in favor of an initial business combination. These agreements apply to the EBAC Initial Shareholders and other officers and directors of EBAC, including the
Sponsor, as it relates to the Founder Shares and any other public shares held by the EBAC Initial Shareholders and other officers and directors of EBAC. As of the record date, the EBAC Initial Shareholders and the other current directors and
officers of EBAC owned &nbsp;&nbsp;&nbsp;&nbsp; Founder Shares, representing &nbsp;&nbsp;&nbsp;&nbsp;% of the EBAC Common Stock then outstanding and entitled to vote at the Extraordinary General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Initial Shareholders and the other current officers and directors of EBAC have entered into a letter agreement with EBAC, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if EBAC fails to complete its initial business combination within the Combination Period. However, if EBAC Initial Shareholders and the
other current officers and directors of EBAC acquire public shares, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if EBAC fails to complete its initial business combination within the
Combination Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Quorum and Required Vote for Proposals at the Extraordinary General Meeting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative vote
of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Approval of the Merger Proposal
requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the issued shares of EBAC Common Stock who are present in person
or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Approval of the Adjournment Proposal an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative vote of
the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Accordingly, an EBAC shareholder&#146;s
failure to vote by proxy or to vote in person (including virtually by visiting &nbsp;&nbsp;&nbsp;&nbsp;) at the Extraordinary General Meeting will not be counted towards the number of EBAC Common Stock required to validly establish a quorum, and if
a valid quorum is otherwise established, such failure to vote will have no effect on the outcome of any vote on the Business Combination Proposal, the Merger Proposal or the Adjournment Proposal. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted in connection with the determination of whether a valid quorum is established, but will have no effect on the Business Combination Proposal, the Merger Proposal or the
Adjournment Proposal. The Sponsor and each member of EBAC&#146;s management team have agreed to vote any EBAC Common Stock (including Founder Shares and any other public shares of EBAC as of the record date) owned by them in favor of the Business
Combination and the transactions contemplated thereby (including by voting in favor of the Business Combination Proposal, the Merger Proposal and for any other proposal presented to EBAC Shareholders in this proxy statement/prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from the votes cast by the EBAC Initial Shareholders, at least &nbsp;&nbsp;&nbsp;&nbsp; votes will be required to approve the Business Combination
Proposal, and at least &nbsp;&nbsp;&nbsp;&nbsp; votes will be required to approve the Merger Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more shareholders who together hold a
majority of the issued and outstanding EBAC Common Stock entitled to vote at the Extraordinary General Meeting must be present, in person or represented by proxy, at the Extraordinary General Meeting to constitute a quorum and in order to conduct
business at the Extraordinary General Meeting. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted as present for the purpose of determining a quorum. The EBAC Initial Shareholders and other officers and
directors of EBAC, who owned &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the issued and outstanding EBAC Common Stock as of the record date, will count towards this quorum. In the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">absence of a quorum, the chairman of the Extraordinary General Meeting has power to adjourn the
Extraordinary General Meeting. As of the record date for the Extraordinary General Meeting, &nbsp;&nbsp;&nbsp;&nbsp; EBAC Common Stock would be required to achieve a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Acquisition Closing is conditioned upon the approval of the Business Combination Proposal and the Merger Proposal. The Adjournment Proposal is not
conditioned on the approval of any other proposal set forth in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is important for you to note that, in the event
that the Business Combination Proposal or the Merger Proposal do not receive the requisite votes for approval, EBAC will not consummate the Business Combination. If EBAC does not consummate the Business Combination and fails to complete an initial
business combination within the Combination Period, EBAC will be required to dissolve and liquidate the Trust Account by returning the then-remaining funds in such account to the public shareholders. </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation to EBAC Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board
believes that each of the Business Combination Proposal, the Merger Proposal and the Adjournment Proposal to be presented at the Extraordinary General Meeting is in the best interests of EBAC and its shareholders and recommends that its shareholders
vote &#147;FOR&#148; each of the proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Certain Persons in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the EBAC Board&#146;s recommendation that EBAC Shareholders vote in favor of the approval of the Business Combination Proposal and the Merger
Proposal, EBAC Shareholders should be aware that aside from their interests as shareholders, the EBAC Initial Shareholders and EBAC&#146;s other current officers and directors have interests in the Business Combination that are different from, or in
addition to, those of other EBAC Shareholders generally. For example, such interests may incentivize the Sponsor to complete the Business Combination with Oculis, or an alternative initial business combination with a less favorable company or on
terms less favorable to EBAC Shareholders, rather than to liquidate, in which case the Sponsor would lose its entire investment. The EBAC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the
Business Combination, and in recommending to EBAC Shareholders that they approve the Business Combination Proposal and the Merger Proposal. EBAC Shareholders should take these interests into account in deciding whether to approve the Business
Combination Proposal and the Merger Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These interests include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed not to redeem any EBAC
Common Stock held by them in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $25,000 for the Founder Shares. The Founder Shares had an estimated aggregate
market value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;based upon the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
public share on the Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor transferred Founder Shares to two independent directors prior to EBAC&#146;s initial
public offering and such securities would be worthless if a business combination is not consummated within the Combination Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to any Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period and, in the event EBAC fails to complete an initial business
combination within the Combination Period, the Founder Shares would have no value; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be entered into by
the Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $4.55&nbsp;million for its 455,096 Private Placement Units and that such
Private Placement Units (and the underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The Private Placement Units had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit on the Nasdaq
Capital Market on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $227,548.50 for its 151,699 EBAC Private Placement Warrants and that such EBAC
Private Placement Warrants will expire worthless if a business combination is not consummated within the Combination Period. The EBAC Private Placement Warrants had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant on the
Nasdaq Capital Market on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other
shareholders experience a negative rate of return in the post-business combination company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor will own 2,842,618 New Parent Shares, which collectively will represent approximately
6.3% of outstanding New Parent Shares and have a value of approximately $28,426,180 based on an implied value of $10.00 per New Parent Share and assuming that the maximum number of EBAC Class&nbsp;A Common Stock are redeemed while still satisfying
the Minimum EBAC Cash Condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right of EBAC Initial Shareholders and the other directors and officers of EBAC to receive New Parent
Shares, subject to certain lock-up periods (it being understood that no contractual selling restrictions apply to any shares issued in connection with the PIPE Financing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the anticipated designation by EBAC of Martijn Kleijwegt and Geraldine O&#146;Keeffe as directors of New Parent
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued indemnification of EBAC&#146;s existing directors and officers and the continuation of
EBAC&#146;s directors&#146; and officers&#146; liability insurance after the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LSP 7, an affiliate of the Sponsor, previously invested $2,104,007 into Oculis on July&nbsp;22, 2022 prior to
the execution of the Business Combination Agreement. In connection with the Oculis Share Contribution, LSP 7 will receive 233,405 New Parent Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an affiliate of the Sponsor has also entered into a Subscription Agreement in connection with the PIPE
Financing, pursuant to which such affiliate has agreed to subscribe for and purchase, and EBAC has agreed to issue from treasury to such affiliate, a certain number of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share for an aggregate
purchase price of $37.896&nbsp;million. Certain of EBAC&#146;s directors also hold a personal financial interest in such affiliate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and EBAC&#146;s officers and directors will lose their entire investment in EBAC and will not be
reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated within the Combination Period. If the Business Combination is consummated
within the Combination Period, pursuant to the Business Combination Agreement, the reimbursement of out-of-pocket expenses incurred by the Sponsor and its affiliates and EBAC&#146;s officers and directors in connection with activities on EBAC&#146;s
behalf. The aggregate value of all out-of-pocket expenses for which the Sponsor and EBAC&#146;s officers and directors are entitled to reimbursement as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting, is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Trust Account is liquidated, including in the event EBAC is unable to complete an initial business
combination within the Combination Period, the Sponsor has agreed to indemnify EBAC to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on
the liquidation date, by the claims of prospective target businesses with which EBAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to EBAC, but only if such a vendor or target business
has not executed a waiver of any and all rights to seek access to the Trust Account; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the consummation of the transactions contemplated hereby, each of the Founder Shares held by
the Sponsor and by certain other directors of EBAC will ultimately be exchanged and converted into a number of New Parent Shares on a one-to-one basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These interests may influence EBAC&#146;s directors in making their recommendation that EBAC Shareholders vote in favor of the approval of the
Business Combination. Please see the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1&#151; The Business Combination Proposal&#151; Interests of Certain Persons in the Business Combination</I>&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and
restated memorandum and articles of association, holders of EBAC public shares may elect to have their shares redeemed for the right to receive an amount in cash at the applicable redemption price per share calculated in accordance with EBAC&#146;s
amended and restated memorandum and articles of association. As of September&nbsp;30, 2022, this would have amounted to approximately $10.00 per share. If a holder of EBAC public shares exercises its redemption rights, then such holder will, subject
to the Acquisition Closing being completed, be exchanging its EBAC Class&nbsp;A Common Stock for the right to receive an amount in cash and will not own shares of New Parent following the closing of the transactions contemplated by the Business
Combination Agreement, including the Business Combination. Such a holder will be entitled to receive the right for an amount in cash for its public shares subject to the Acquisition Closing being completed and only if it properly demands redemption
and delivers its shares (either physically or electronically) to the Transfer Agent in accordance with the procedures described herein. The EBAC Share Redemption Amount will be distributed, subject to all conditions to the Acquisition Closing being
met, by New Parent. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to the Transfer Agent in order to validly redeem its shares.
Notwithstanding the foregoing, a holder of the public shares, together with any affiliate of his, her, it or any other person with whom he, she or it is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act)
will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock. Accordingly, all public shares in excess of the 15% threshold beneficially owned by a public shareholder or group will
not be redeemed for cash. The EBAC Initial Shareholders and certain other officers and directors of EBAC have agreed, for no consideration in return, to waive their redemption rights with respect to any Founder Shares and other EBAC Common Stock
they may hold in connection with the consummation of the Business Combination, and the Founder Shares and such other EBAC Common Stock will be excluded from the pro rata calculation used to determine the
<FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has no specified maximum redemption threshold under its amended and restated
memorandum and articles of association, other than the aforementioned 15% threshold. Each redemption of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders will reduce the amount in the Trust Account, which held marketable securities
with a fair value of approximately $128.3&nbsp;million as of September&nbsp;30, 2022. The conditions to the Acquisition Closing are for the sole benefit of the parties thereto and may be waived by such parties. If, as a result of redemptions of EBAC
Class&nbsp;A Common Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by the parties to the Business Combination Agreement, then either of the parties thereto may elect not to consummate the
Business Combination. In addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001, as provided in EBAC&#146;s amended and restated memorandum and
articles of association. Under these circumstances, EBAC Shareholders may exercise their redemption rights with respect to a maximum of 10,363,709 shares of redeemable EBAC Class&nbsp;A Common Stock upon consummation of the Business Combination at a
redemption price of approximately $10.052 per share. The estimated per share redemption value of $10.052 was calculated by dividing the Trust Account balance of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, by 12,754,784 EBAC
Class&nbsp;A Common Stock outstanding and subject to redemption. Please see the section entitled &#147;<I>Unaudited Pro Forma</I> <I>Condensed</I> <I>Combined Financial Information&#151;Redemption</I>
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Scenarios</I>.&#148; EBAC Shareholders who wish to redeem their public shares for cash must refer to and follow the procedures set forth in the section entitled &#147;<I>Extraordinary General
Meeting of EBAC&#151;Redemption Rights</I>&#148; in order to properly redeem their public shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of EBAC Public Warrants will not have
redemption rights with respect to such warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material United States Federal Income Tax Considerations of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a description of certain material U.S. federal income tax consequences of (i)&nbsp;the Business Combination generally applicable to U.S. Holders of EBAC
Common Stock and EBAC Warrants, (ii)&nbsp;the exercise of redemption rights by U.S. Holders of EBAC Class&nbsp;A Common Stock and (iii)&nbsp;the subsequent ownership and disposition of New Parent Shares and New Parent Warrants following the Business
Combination, please see the section entitled &#147;<I>Material Tax Considerations&#151;United States Federal Income Tax Considerations to U.S. Holders</I>.&#148;<I> </I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Swiss Tax and certain Dutch Withholding Tax Considerations of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a description of certain material Swiss tax and certain Dutch withholding tax consequences of the ownership and disposition of New Parent Shares and/or New
Parent Warrants, please see the sections entitled &#147;<I>Material Tax Considerations&#151;</I><I>Material</I><I> Swiss Tax Considerations&#148;</I> and &#147;<I>Material Tax Considerations&#151;Dutch Withholding Tax</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anticipated Accounting Treatment of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a capital reorganization. Under this method of accounting, EBAC will be treated as the acquired company for
financial reporting purposes, whereas Oculis will be treated as the accounting acquiror. In accordance with this accounting method, the Business Combination will be treated as the equivalent of Oculis issuing stock for the net assets of EBAC,
accompanied by a recapitalization. The net assets of Oculis will be stated at historical cost, with no goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of Oculis. Oculis has been determined
to be the accounting acquiror for purposes of the Business Combination based on an evaluation of the following facts and circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After the Acquisition Closing, persons affiliated with Oculis are expected to control a majority of the New
Parent Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis Shareholders have the largest voting interest under both redemption scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis is the largest entity based on the entity&#146;s operations and number of employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; operations prior to the Business Combination will comprise the ongoing operations of New Parent; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; existing executive officers and senior management team will comprise the executive officers and
senior management team of New Parent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination, which is not within the scope of IFRS 3 since EBAC does not meet the
definition of a business in accordance with IFRS 3, is accounted for within the scope of IFRS 2. Any excess of fair value of New Parent Shares issued over the fair value of EBAC&#146;s identifiable net assets acquired represents compensation for the
service of a stock exchange listing for its shares and is expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination and the transactions contemplated by the Business Combination Agreement are not subject to any regulatory requirement or approval,
except for (i)&nbsp;filings with the Cayman Registrar of Companies, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Commercial Register of the Canton of Zug, Switzerland and the Commercial Register of the Canton of Vaud, Switzerland to effect the Mergers and New Parent Share Capital Increase and
(ii)&nbsp;filings required with the SEC pursuant to the reporting requirements applicable to EBAC, and the requirements of the Securities Act and the Exchange Act, including the requirement to file the registration statement of which this proxy
statement/prospectus forms a part and to disseminate this proxy statement/prospectus to EBAC Shareholders. EBAC must comply with applicable United States federal and state securities laws in connection with the PIPE Financing, and with the Nasdaq
continued listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the holders of EBAC Warrants have appraisal rights in connection with the Business Combination under the Companies Act. EBAC Shareholders may be
entitled to give notice to EBAC prior to the meeting that they wish to dissent to the Business Combination and to receive payment of fair market value for his, her or its EBAC Common Stock if they follow the procedures set forth in the Cayman
Companies Act, noting that any such dissention rights may be limited pursuant to Section&nbsp;239 of the Cayman Companies Act, which states that no such dissention rights shall be available in respect of shares of any class for which an open market
exists on a recognized stock exchange at the expiry date of the period allowed for written notice of an election to dissent provided that the merger consideration constitutes inter alia shares of any company which at the effective date of the merger
are listed on a national securities exchange. It is the view of the EBAC Board that such fair market value would equal the amount which EBAC Shareholders would obtain if they exercise their redemption rights as described herein. For more
information, please see the section entitled &#147;<I>Proposal No. 1</I>&#151;<I>The Business Combination Proposal</I>&#151;<I>Appraisal Rights</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to Oculis Shareholders in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies may be solicited by mail, via
telephone or via email or other electronic correspondence. EBAC has engaged D.F. King to assist in the solicitation of proxies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an EBAC shareholder
grants a proxy, such shareholder may still vote its shares in person if it revokes its proxy before the Extraordinary General Meeting. An EBAC shareholder may also change its vote by submitting a later-dated proxy, as described in the section
entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Revoking Your Proxy</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating the proposals set forth in this proxy statement/prospectus, you should carefully read this proxy statement/prospectus, including the Annexes, and
especially consider the factors discussed in the section entitled &#147;<I>Risk Factors</I>.&#148; The occurrence of one or more of the events or circumstances described in the section entitled &#147;<I>Risk Factors</I>,&#148; alone or in
combination with other events or circumstances, may have a material adverse effect on (i)&nbsp;the ability of EBAC and Oculis to complete the Business Combination, (ii)&nbsp;the business, financial condition and operating results of Oculis prior to
the Acquisition Closing and (iii)&nbsp;the business, financial condition and operating results of New Parent following the Acquisition Closing. The risks of Oculis listed below will apply to New Parent after the Acquisition Closing. Some of the more
significant challenges and risks related to Oculis, EBAC, the Business Combination and the New Parent Shares are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis has a very limited operating history and no products approved for commercial sale, which may make it
difficult to evaluate its current business and predict its future success and viability.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis has incurred significant net losses in each period since its inception and anticipates that it will
continue to incur significant and increasing net losses for the foreseeable future.</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. Oculis has never
generated any revenue from product sales and may never generate revenue or be profitable.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Oculis fails to obtain additional financing, it may be unable to complete the development and, if approved,
commercialization of its product candidates.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis has identified material weaknesses in its internal control over financial reporting and may identify
additional material weaknesses in the future or fail to maintain effective internal control over financial reporting. If Oculis is unable to maintain an effective system of internal controls in the future, its ability to accurately or timely report
its financial condition or results of operations may be adversely affected, which could hurt Oculis&#146; business, lessen investor confidence and depress the market price of its securities.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis has not yet successfully completed any Phase 3 clinical trials, received any marketing approvals or
commercialized any pharmaceutical products, which may make it difficult to evaluate Oculis&#146; future prospects.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis depends significantly on its product candidates, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT
STYLE="white-space:nowrap">OCS-02,</FONT> and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> which it is developing for treatment of multiple diseases. If Oculis is unable to complete the clinical development of any of these product candidates, if
is unable to obtain marketing approvals for any of these product candidates, or if any of these product candidates are approved and Oculis fails to successfully commercialize the product candidate or experience significant delays in doing so, its
business will be materially harmed.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; product candidates may cause undesirable side effects, such as an increase in intraocular pressure
caused by <FONT STYLE="white-space:nowrap">OCS-01,</FONT> or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action. <FONT
STYLE="white-space:nowrap">OCS-05</FONT> was placed on a clinical hold with the FDA in 2016. If Oculis is unable to establish a NOAEL, or if its studies otherwise do not satisfy the FDA&#146;s requirements,
<FONT STYLE="white-space:nowrap">OCS-05</FONT> may not receive clearance from the FDA to proceed with human clinical trials, may never receive regulatory approval from the FDA, and Oculis may not be able to market and commercialize <FONT
STYLE="white-space:nowrap">OCS-05</FONT> in the United States, which could materially adversely affect its business, financial condition, results of operations and growth prospects.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacture of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> a biologic, is highly complex, costly and
requires substantial lead time to produce.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and
patient adoption and use necessary for commercial success.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if Oculis receives marketing approval for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT
STYLE="white-space:nowrap">OCS-02,</FONT> <FONT STYLE="white-space:nowrap">OCS-05,</FONT> or any future product candidate, Oculis may not be able to successfully commercialize its product candidates due to unfavorable pricing regulations or
third-party coverage and reimbursement policies, which could make it difficult for Oculis to sell its product candidates profitably.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis faces substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than Oculis does.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis relies completely on third-party contractors to supply, manufacture and distribute clinical drug supplies
for its product candidates, which may include sole-source suppliers and manufacturers; Oculis intends to rely on third parties for commercial supply, manufacturing and distribution if any of its product candidates receives regulatory approval and
for any future product candidates.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; rights to develop and commercialize its technology are subject, in part, to the terms and conditions
of licenses granted to Oculis by others. In particular, Oculis depends on licenses for </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
development and commercialization rights to <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT> If these rights are terminated or Oculis fails to
comply with its obligations under these agreements or any other license, collaboration or other agreement, Oculis may be required to pay damages and it could lose intellectual property rights that are necessary for the development and protection of
its product candidates.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Oculis is unable to obtain,&nbsp;maintain, protect and enforce patent or other intellectual property
protection for its current and future technology and products, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, Oculis may not be able to compete effectively in its
markets.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities are highly complex, lengthy, and inherently unpredictable. If Oculis is unable to obtain regulatory approval for its product candidates, or to do so in a timely manner, Oculis will be unable to generate product revenue and its business
will be substantially harmed.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the FDA does not conclude that <FONT STYLE="white-space:nowrap">OCS-01</FONT> satisfies the requirements for
the Section&nbsp;505(b)(2) regulatory approval pathway, or if the requirements under Section&nbsp;505(b)(2) are not as Oculis expects, the approval pathway for <FONT STYLE="white-space:nowrap">OCS-01</FONT> will likely take significantly longer,
cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent is a Swiss stock corporation. The rights of its shareholders may be different from the rights of
shareholders in companies governed by the laws of U.S. jurisdictions.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against New Parent or its
executive officers or members of the New Parent Board.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since the Sponsor and EBAC&#146;s directors and executive officers have interests that are different from, or in
addition to (and which may conflict with), the interests of EBAC Shareholders, a conflict of interest may have existed in determining whether the Business Combination with Oculis is appropriate as EBAC&#146;s initial business combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is no assurance that the due diligence undertaken in relation to the Business Combination would uncover all
material issues in relation to the business or financial condition of Oculis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC has not obtained a fairness opinion from an independent investment banking firm, and consequently, there is
no assurance from an independent source that the Business Combination is fair to its shareholders from a financial point of view. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is no guarantee that a public shareholder&#146;s decision whether to redeem is shares for a pro rata
portion of the Trust Account will put the public shareholder in a better future economic position </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If EBAC is not able to complete the Business Combination with Oculis within the Combination Period, EBAC would
cease all operations except for the purpose of winding up and EBAC would redeem its EBAC Class&nbsp;A Common Stock and liquidate the Trust Account, in which case EBAC&#146;s public shareholders may only receive approximately $10.00 per share and
EBAC Public Warrants will expire worthless. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses of Funds for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the sources and uses for funding the Business Combination. All of the sources and uses below are for illustrative purposes only.
Where actual amounts are not known or knowable, the figures below represent EBAC&#146;s good faith estimate of such amounts. The maximum redemption scenario represents the maximum amount of shares of EBAC Class A Common Stock that can be redeemed
such that the Minimum EBAC Cash Condition can still be satisfied. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Redemption Scenario<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt"><B>Sources</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing<SUP STYLE="font-size:75%; vertical-align:top">(3)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Expenses<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that none of EBAC&#146;s outstanding public shares are redeemed in connection with the Business
Combination. Excludes interest earned in the Trust Account. The actual amount of cash in the Trust Account is subject to change depending on actual interest earned. Approximately $7.4&nbsp;million in
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements has been committed from existing EBAC investors as of the announcement of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approximately $19.7&nbsp;million of the PIPE Financing is in the form of convertible loan agreements at zero
percent interest and convertible at the Acquisition Closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Company Equity Value under the terms of the Business Combination Agreement, with a <FONT
STYLE="white-space:nowrap">pro-forma</FONT> number of approximately 20.3&nbsp;million New Parent Shares to be issued to Oculis Shareholders as rollover equity. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Parent Shares issued to Oculis Shareholders and PIPE Investors are at a deemed value of $10.00 per share.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximum Redemption Scenario<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt"><B>Sources</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing<SUP STYLE="font-size:75%; vertical-align:top">(3)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Expenses<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that EBAC&#146;s public shareholders exercise redemption rights with respect to 10,363,709 of
EBAC&#146;s public shares, which represents redemptions of approximately 81% of EBAC&#146;s public shares and which is the maximum number of redemptions which may occur such that the Minimum EBAC Cash Condition would still be satisfied at a
redemption price of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and excluding EBAC public shares subject to Non-Redemption Agreements. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approximately $19.7&nbsp;million of the PIPE Financing is in the form of convertible loan agreements at zero
percent interest and convertible at the Acquisition Closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Company Equity Value under the terms of the Business Combination Agreement, with a <FONT
STYLE="white-space:nowrap">pro-forma</FONT> number of approximately 20.3&nbsp;million New Parent Shares to be issued to Oculis Shareholders as rollover equity. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Parent Shares issued to Oculis Shareholders and PIPE Investors are at a deemed value of $10.00 per share.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_8a"></A>SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following selected unaudited pro forma condensed combined financial data is derived from and should be read in conjunction with the
unaudited pro forma condensed combined statement of financial position and unaudited pro forma condensed combined statements of operations included elsewhere in this proxy statement/prospectus and is provided to aid you in your analysis of the
financial aspects of the Business Combination, the consummation of the PIPE Financing and Convertible Loan Agreements, which are collectively referred to as the &#147;<I>Pro Forma Transactions</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are based on the EBAC historical financial statements and the Oculis historical consolidated
financial statements as adjusted to give effect to the Pro Forma Transactions. The unaudited pro forma condensed combined statement of financial position gives pro forma effect to the Pro Forma Transactions as if they had been consummated on
September 30, 2022. The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2022 and the year ended December&nbsp;31, 2021 gives effect to the Pro Forma Transactions as if they had occurred on
January&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements were prepared in accordance with Article 11 of SEC Regulation <FONT
STYLE="white-space:nowrap">S-X.</FONT> The adjustments presented in the unaudited pro forma condensed combined financial statements have been identified and presented to provide relevant information necessary for an understanding of New Parent
reflecting the Pro Forma Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been derived from and should be read in
conjunction with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of EBAC as of September 30, 2022, for the three and
nine&nbsp;months ended September 30, 2022, and for the period from January&nbsp;8, 2021 (inception) through September 30, 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of EBAC as of December&nbsp;31, 2021 and for the period from
January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed interim consolidated financial statements of Oculis as of September&nbsp;30,
2022 and December&nbsp;31, 2021 and for each of the three- and nine-month periods ended September&nbsp;30, 2022 and 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited consolidated financial statements of Oculis as of and for the years ended
December&nbsp;31, 2021 and 2020 included elsewhere in this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections entitled &#147;<I>EBAC Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations,</I>&#148; &#147;<I>Oculis Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&#148; and other financial information relating to EBAC and Oculis included elsewhere in this proxy
statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical consolidated financial statements of Oculis have been prepared in accordance with IFRS as issued
by the IASB and in its presentation currency of CHF. The historical financial statements of EBAC have been prepared in accordance with US&nbsp;GAAP in its presentation currency of US dollars. The historical financial information of EBAC has been
adjusted to give effect to the differences between US&nbsp;GAAP and IFRS for the purposes of the combined pro forma financial information, which included the only adjustment to reclassify the carrying value of EBAC&#146;s Class&nbsp;A Common Stock
subject to possible redemption to <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities under </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IFRS. The adjustments presented in the pro forma combined financial information have been identified and presented to provide relevant information necessary for an accurate understanding of New
Parent after giving effect to the Pro Forma Transactions. The historical financial statements of EBAC have been translated into CHF for the purposes of presentation in the unaudited pro forma condensed combined financial statements
(<I>&#147;</I><I>As Converted</I><I>&#148;</I>) using the following exchange rates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the period end exchange rate as of September 30, 2022 of $1.00 to CHF 0.98054 for the unaudited pro forma
condensed combined statement of financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average exchange rate for the period from January&nbsp;1, 2022 through September 30, 2022 of $1.00 to CHF
0.95162 for the unaudited pro forma condensed combined statement of operations for the nine&nbsp;months ended September 30, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average exchange rate for the period from January&nbsp;8, 2021 through December&nbsp;31, 2021 of $1.00 to CHF
0.91416 for the unaudited pro forma condensed combined pro forma statement of operations for the period from January&nbsp;8, 2021 through December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined financial data below presents two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming No Redemptions (Scenario 1)</B>: This presentation assumes that no EBAC public shareholders exercise
their right to redeem their shares of EBAC Class&nbsp;A Common Stock for their pro rata share of the Trust Account, and thus, the full amount held in the Trust Account as of the Acquisition Closing is available for the Pro Forma Transactions. This
redemption scenario also reflects the Sponsor&#146;s forfeiture of 727,096 shares of EBAC Class&nbsp;B Common Stock pursuant to the terms of the Business Combination Agreement and 74,078 shares of EBAC Class B Common Stock transferred to EBAC public
shareholders in connection with executing a Non-Redemption Agreement. Up to an additional 1,594,348 shares of EBAC Class&nbsp;B Common Stock are subject to forfeiture if the Sponsor fails to ensure $25.5&nbsp;million in combined cash through (i)
additional PIPE Investment Amount from specified investors and (ii) the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount) but before payment of any
transaction expenses of Oculis or EBAC as described elsewhere in the accompanying proxy statement/prospectus. As of January 27, 2023, none of these additional shares would be forfeited in the no redemption scenario; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming Maximum Redemptions (Scenario 2):</B> This presentation assumes that 10,363,709 shares of EBAC Class
A Common Stock are redeemed at a per share redemption price of CHF 9.86 or $10.052, which represents the maximum amount of redemptions of CHF 102.1&nbsp;million or $104.2&nbsp;million that would allow consummation of the Pro Forma Transactions that
would still satisfy the Minimum EBAC Cash Condition in the Business Combination Agreement of CHF 98.1 million or $100.0 million available for use as primary capital net of any redemptions by the EBAC public shareholders and payment of any
transaction expenses. The maximum redemption scenario includes all adjustments contained in the no redemption scenario and presents additional adjustments to reflect the effect of maximum redemptions. This redemption scenario also reflects the
Sponsor&#146;s forfeiture of 727,096 shares of EBAC Class B Common Stock pursuant to the terms of the Business Combination Agreement and 74,078 shares of EBAC Class B Common Stock transferred to EBAC public shareholders in connection with executing
Non-Redemption Agreements. Up to an additional 1,594,348 shares of EBAC Class B Common Stock are subject to forfeiture if the Sponsor fails to obtain an additional $25.5 million in combined cash through (i) additional PIPE Investment Amount from
specified investors and (ii) the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount) but before payment of any transaction expenses of Oculis or EBAC. 80,969 of
these additional shares would be forfeited in the maximum redemption scenario as of January 27, 2023 as described elsewhere in the </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
accompanying proxy statement/prospectus. As of January&nbsp;27, 2023, 740,789 shares of EBAC Class A Common Stock held by the EBAC public shareholders are subject to non-redemption agreements
contingent upon the Acquisition Closing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is for illustrative purposes
only and is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination taken place on the dates indicated, nor are they indicative of the future consolidated results of
operations or financial position of New Parent. The actual level of redemptions by EBAC&#146;s public shareholders is unknowable prior to the shareholder vote with respect to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets out summary data derived from the unaudited pro forma condensed combined statements of financial position as of September 30, 2022
and the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2022 and year ended December&nbsp;31, 2021 under the two redemption scenarios. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unaudited Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unaudited Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September 30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming&nbsp;No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming&nbsp;No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Combined Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,729</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Class A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unaudited Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>September 30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming&nbsp;No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Combined Statements of Financial Position:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_9"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this proxy statement/prospectus may constitute &#147;forward-looking statements&#148; for purposes of the federal securities laws.
Forward-looking statements include, but are not limited to, statements regarding our or our management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;would&#148; and
similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this proxy statement/prospectus may include, for example, statements
about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to consummate the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent&#146;s financial performance following the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain or maintain the listing of New Parent Shares or New Parent Warrants on the Nasdaq Global
Market, following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and expected outcomes of clinical trials, preclinical studies, regulatory submissions and approvals, as
well as commercial outcomes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expected benefits of Oculis&#146; business and scientific approach and technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential safety and efficacy of Oculis&#146; product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; ability to successfully develop, advance and commercialize its pipeline of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness and profitability of Oculis&#146; collaborations and partnerships, is ability to maintain
current collaborations and partnerships and enter into new collaborations and partnerships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expectations related to future milestone and royalty payments and other economic terms under Oculis&#146;
collaborations and partnerships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates regarding future revenue, expenses, capital requirements and need for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of market opportunity for Oculis&#146; product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; strategic advantages and the impact those advantages may have on future financial and operational
results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; expansion plans and opportunities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; ability to grow its business in a cost-effective manner; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; expectations regarding its ability to obtain and maintain intellectual property protection and not
infringe on the rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> macroeconomic factors and
other global events, such as the Russia-Ukraine conflict, on Oculis&#146; business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any known and unknown litigation and regulatory proceedings; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed in this proxy statement/prospectus in the section entitled
&#147;<I>Risk Factors</I>.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By their nature, forward-looking statements involve known and unknown risks and uncertainties because
they relate to events and depend on circumstances that may or may not occur in the future and are based on potentially inaccurate assumptions. Forward-looking statements are not guarantees of future performance. The risks outlined above and others
described in the section entitled &#147;<I>Risk Factors</I>&#148; are not exhaustive. Other sections of this proxy statement/prospectus describe additional factors that could adversely affect the results of operations, financial condition, liquidity
and the development of EBAC, Oculis and New Parent, the industry Oculis operates in and risks relating to the Business Combination. New risks can emerge from time to time, and it is not possible to predict all such risks, nor can it be assessed the
impact of all such risks on Oculis&#146; business or to the extent which any such risks or combinations of risks and other factors may cause actual results to differ materially from those contained in any forward-looking statements. Given these
results and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, you should not place undue
reliance on these forward-looking statements, which speak only as of the date of this proxy statement/prospectus. Neither EBAC, Oculis nor New Parent undertakes any obligation to publicly revise any forward-looking statement to reflect circumstances
or events after the date of this proxy statement/prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks described in the reports filed by EBAC (prior to the Acquisition Closing) or New
Parent (after the Acquisition Closing) from time to time with the SEC after the date of this proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_10"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In addition to the other information contained in (or incorporated by reference into) this proxy statement/prospectus, including the matters addressed
under the heading &#147;Cautionary Note Regarding Forward-Looking Statements,&#148; you should carefully consider the following risk factors in deciding how to vote on the proposals presented in this proxy statement/prospectus. The occurrence of one
or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on the business, reputation, revenue, financial condition, results of operations
and future prospects of Oculis (which will be the business of New Parent after the Acquisition Closing), in which event the market price of the New Parent Shares could decline, and you could lose part or all of your investment. Unless otherwise
indicated, reference in this section and elsewhere in this proxy statement/prospectus to the Oculis business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, the business,
reputation, financial condition, results of operations, revenue and future prospects of New Parent, and references to &#147;we&#148;, &#147;our&#148; or &#147;us&#148; refer to Oculis or New Parent, as the case may be. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our business, financial condition, capital requirements, or financial operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and
predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat ophthalmic
diseases. We commenced operations in December 2017, have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To
date, we have not completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product, or conducted sales and marketing activities necessary for successful product commercialization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to
significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and
difficulties. If we do not address these risks and difficulties successfully, our business, financial condition, results of operations and growth prospects may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing net
losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each reporting period since our inception, including net losses of CHF
29.5&nbsp;million and CHF 13.0 million for the nine months ended September 30, 2022 and 2021, respectively, and CHF 18.6&nbsp;million and CHF 14.9&nbsp;million for the fiscal years ended December&nbsp;31, 2021 and 2020, respectively. As of September
30, 2022, we had an accumulated deficit of CHF 101.8 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested significant financial resources in research and development activities,
including for our product candidates. We do not expect to generate revenue from product sales in the foreseeable future, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and our ability to
generate revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;period-to-period&nbsp;comparison</FONT></FONT> of our
results of operations may not be a good indication of our future performance quarter to quarter or year to year due to factors including the timing of clinical trials, any litigation that we may file or that may be filed against us, the execution of
collaboration, licensing or other agreements and the timing of any payments we make or receive thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant and
increasingly higher expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress our current and any future product candidates through preclinical and clinical development;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">work with our contract manufacturers to scale up the manufacturing processes for our product candidates, if
approved, or, in the future, establish and operate a manufacturing facility; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and discovery activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and conduct additional preclinical, clinical or other studies for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add contract manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals and marketing authorizations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments due under any current or future collaboration or license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, expand, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter other issues related to our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur costs associated with becoming a public company if the Business Combination is consummated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet the requirements and demands of being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against any product liability claims or other lawsuits related to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our prior losses and expected future losses have had and will continue to have an adverse effect on our shareholders&#146; deficit and working capital. In any
particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause the share price of New Parent Shares to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, we had cash and cash equivalents of CHF 28.5 million. We believe that these cash and cash equivalents will be sufficient to enable
us to fund our current operations for at least the next twelve months period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development is a highly uncertain undertaking and involves a
substantial degree of risk. We have never generated any revenue from product sales, and we may never generate revenue or be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no
products approved for commercial sale and have not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory
approval for the commercial sale of a product candidate, if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue, alone or with strategic collaboration, and achieve
profitability depends significantly on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully completing research, preclinical and clinical development of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully
complete clinical development and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing
and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and any commercial demand for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, assessing, acquiring and/or developing new product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing
approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining an adequate price for our product candidates, both in the United States and in other
countries where our products are commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining adequate reimbursement for our product candidates from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance of our product candidates as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including
patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we
will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product candidates. Even if one or
more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable, and we will need to obtain additional funding
through one or more debt or equity financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for
which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we
anticipate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant
revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our failure to become and remain profitable could decrease the value of our company and could impair our ability to raise capital, expand our business,
maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of the New Parent Shares, all or any of which may adversely affect our viability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating and financial results are subject to concentration risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operational and financial results are subject to concentration risk. Our success will depend significantly on the development of <FONT
STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> their regulatory approval in a limited number of jurisdictions and their commercialization by a limited
number of commercial partners. Even if we are successful in developing and commercializing all of these products, our revenue will be dependent on a limited number of products that would account for a significant majority of our revenues. This
concentration risk would increase to the extent we are successful in developing and commercializing fewer products as we would be dependent on a lower number of products for the significant majority of our revenues. Unfavorable changes or the <FONT
STYLE="white-space:nowrap">non-occurrence</FONT> of certain anticipated events with respect to any of these limited number of products, jurisdictions or commercial partners may disproportionally affect our global results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain additional financing, we may be unable to complete the development and, if
approved, commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception. To date, we have
financed our operations primarily through the sale of equity securities. Developing our product candidates is expensive, and we expect to substantially increase our spending as we advance our product candidates in clinical trials. Even if we are
successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding beyond the net proceeds from the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, we had CHF 28.5 million in cash and cash equivalents. On a pro forma basis as of September 30, 2022, assuming the consummation of
the Business Combination, the PIPE Investment and Convertible Loan Agreements, we estimate that the future company would have CHF 223.1 million in cash assuming no redemptions by EBAC&#146;s Shareholders and CHF 121.0&nbsp;million in cash assuming
maximum redemption by EBAC&#146;s Shareholders such that the Minimum EBAC Cash Condition would still be satisfied. Although we believe that our existing cash and cash equivalents will be sufficient to fund our projected operations through at least
the next 12&nbsp;months, our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove inaccurate, and we could use our available capital resources sooner
than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our
control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
require additional capital for the further development and, if approved, commercialization of our product candidates. Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of
additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back or discontinue our research and development programs or the commercialization of any product candidates, if
approved, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations and cause the price of the New
Parent Shares to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified
personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical and business development expertise of our chief executive officer as
well as other principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laws and regulations on executive compensation, including legislation in our home country, Switzerland, may restrict our ability to attract, motivate and
retain the required level of qualified personnel. In Switzerland, legislation affecting public companies is in force that, among other things, (i)&nbsp;imposes an annual binding shareholders&#146; &#147;say on pay&#148; vote with respect to the
compensation of our executive committee and board of directors, (ii)&nbsp;generally prohibits severance, advances, transaction premiums and similar payments to members of our executive committee and board of directors, and (iii)&nbsp;requires
companies to specify certain compensation-related matters in their articles of association, thus requiring them to be approved by a shareholders&#146; vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the
services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of
individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire,
train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high
quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant expenses and devote other significant
resources and management time as a result of being a public company, which may negatively impact our financial performance and could cause our results of operations and financial condition to suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incur significant legal, accounting, insurance and other expenses as a result of being a public company. The rules implemented by the SEC, and by the
Nasdaq and Swiss corporate law require changes in corporate governance practices of public companies. We expect that compliance with these laws, rules and regulations and the move from a private to a public company will substantially increase our
expenses, including our legal, accounting and information technology costs and expenses, and make some activities more time consuming and costly, and these new obligations will require attention from our executive officers and senior management and
could divert their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;day-to-day&nbsp;management</FONT></FONT> of our business. We also expect these laws, rules and regulations and the move from a private
to a public company to make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.
Due to increased risks and exposure it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as officers. As a result of the foregoing, we expect a substantial increase in legal, accounting,
insurance and certain other expenses in the future, which will negatively impact our financial performance and could cause our results of operations and financial condition to suffer. Furthermore, if we are unable to satisfy our obligations as a
public company, we could be subject to delisting of the New Parent Shares, fines, sanctions and other regulatory action and potentially civil litigation, which could adversely impact our business, results of operation, financial condition and the
price of the New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have been and will need to continue to expand our organization and we may experience difficulties in managing
this growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, we had 32 employees. Additionally, we may rely on a number of
temporary workers and contractors <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;time-to-time&nbsp;as</FONT></FONT> needed. As our development and commercialization plans and strategies develop, we expect to need
additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of our attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">our&nbsp;day-to-day&nbsp;activities</FONT></FONT> and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion
of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. In addition, our success depends on our ability to
attract and retain a talented workforce with a specialized set of skills. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and
potential future product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over financial reporting, and we may
identify additional material weaknesses in the future or fail to maintain effective internal control over financial reporting. If we are unable to maintain an effective system of internal controls in the future, our ability to accurately or timely
report our financial condition or results of operations may be adversely affected, which could hurt our business, lessen investor confidence and depress the market price of our securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal executive and
principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited internal accounting
personnel to address our internal controls and procedures. As of December&nbsp;31, 2021, we had two designated finance and accounting employees and rely primarily on third-party accounting professional service firms to provide accounting,
bookkeeping and administrative services. Our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. However, in connection with the preparation of our consolidated financial
statements for the years ended December&nbsp;31, 2020 and 2021, we identified material weaknesses in our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
material weaknesses identified are related to (i)&nbsp;a lack of sufficient internal accounting personnel to support an efficient and structured financial statement close process and allow for the appropriate monitoring of financial reporting
matters; and (ii)&nbsp;the maintenance of effective controls over information technology general controls for IT accounting and financial reporting systems. Specifically, IT systems and related operations are outsourced to third parties and
therefore, we were not in a position to maintain user access controls, program change management controls, and testing and approval controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
identified control deficiencies did not result in a material misstatement to the Company&#146;s financial statements. However, each of these control deficiencies could result in a misstatement of our accounts or disclosures that would result in a
material misstatement of our annual or interim financial statements that would not be prevented or detected, and accordingly, we determined that these control deficiencies constitute material weaknesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are presently a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which
to address our internal control over financial reporting. We are progressing with the activities necessary to implement the appropriate accounting policies, processes and controls required to comply with Section&nbsp;404 of the Sarbanes-Oxley Act.
We intend and have taken steps to remediate the material weaknesses described above through hiring additional qualified accounting and financial reporting personnel, and further enhance our accounting policies, procedures, and controls. In
particular, in 2021 and 2022, we have hired additional staff for the finance and legal functions. Also, we are in the process of implementing an ERP system along with related IT general controls, which we believe will enhance our internal control
over financial reporting. While we will not be able to fully remediate these material weaknesses until these steps have been completed, we have been operating effectively for a sufficient period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot provide assurance that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control
deficiencies that led to these material weaknesses in our internal control over financial reporting nor that they will prevent or avoid potential future material weaknesses. In addition, we cannot provide assurance that all of our existing material
weaknesses have been identified, or that we will not in the future identify additional material weaknesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays or the failure to implement our ERP system may result in a material adverse effect on our
ability to report our financial results on a timely basis and in an accurate manner. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are in the process of implementing a global ERP system
that will upgrade and standardize our information system. The ERP implementation started in 2021 and is expected to continue to occur in phases. Any delays or the failure to achieve our implementation goals may adversely impact our financial
results. In addition, the failure to either complete or deliver the application on time or anticipate the necessary readiness and training needs could lead to business disruption and loss of business. Failure or abandonment of any part of the ERP
system could result in a <FONT STYLE="white-space:nowrap">write-off</FONT> of part or all of the costs that have been capitalized on the project, which could adversely affect our results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Economic, financial, geopolitical, epidemiological, or other conditions could result in business disruptions which could seriously harm our future
revenue and financial condition and increase our costs and expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concerns over inflation, geopolitical issues, the U.S. financial markets,
foreign exchange rates, capital and exchange controls, unstable global credit markets and financial conditions, <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, supply chain disruptions and economic issues, have led to periods of
significant economic instability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth going forward, and increased unemployment rates. Our
general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. If these conditions continue to deteriorate or do not improve,
it may make any necessary debt or equity financing more difficult to complete, more costly and more dilutive. In addition, there is a risk that one or more of our current or future service providers, manufacturers, suppliers and other partners could
be negatively affected by difficult economic times, which could adversely affect our ability to attain our operating goals on schedule and on budget or meet our business and financial objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations, and those of our contract research organizations (<I>&#147;CROs&#148;</I>), contract manufacturing organizations (<I>&#147;CMOs&#148;</I>),
suppliers, and other third-party contractors and consultants upon which we rely, could be subject to wildfires, earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political
crises, such as terrorism, war (including trade wars), political instability or other conflicts, and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or other events outside of our control that could disrupt our business.
In February 2022, armed conflict escalated between Russia and Ukraine. The sanctions announced by the United States and other countries, following Russia&#146;s invasion of Ukraine, against Russia to date include restrictions on selling or importing
goods, services or technology in or from affected regions and travel bans and asset freezes impacting connected individuals and political, military, business and financial organizations in Russia. The United States and other countries could impose
wider sanctions and take other actions should the conflict further escalate. It is not possible to predict the broader consequences of this conflict, which could include further sanctions, embargoes, regional instability, geopolitical shifts and
adverse effects on macroeconomic conditions, currency exchange rates and financial markets, all of which could impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. For
example, we rely on third-party manufacturers to produce our product candidates. Our ability to obtain supplies of our product candidates, or other necessary supplies, could be disrupted if the operations of our suppliers are affected by a <FONT
STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications
failure, unauthorized entry or other events could cause us to cease or delay the marketing or development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage, our business,
financial condition, and results of operations may be seriously harmed should the losses we suffer as a result of such property damage and/or business interruption substantially exceed our insurance coverage and we are required to make up for this
shortfall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business, financial condition and results of operations would suffer in the event of computer
system failures, security breaches or other disruptions to our information technology systems. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we collect,
store and transmit sensitive data, including protected health information (&#147;<I>PHI</I>&#148;), intellectual property, proprietary business information and other personal information. We rely on information technology systems, networks and
services, some of which are managed, hosted or provided by third parties, to assist in conducting our business. While we have not previously experienced a security breach or computer failure resulting in destruction, theft, or other loss of this
information, and we and our service providers have implemented a number of security measures designed to protect against security breaches, these measures could fail or may be insufficient, resulting in the unauthorized disclosure, modification,
misuse, unavailability, destruction, or loss of confidential information or personal information we collect, store and transmit. Despite the implementation of security measures, our internal computer systems, and those of our contract research
organizations, or CROs, and other third parties on which we rely, are vulnerable to attack, damage or interruption from computer viruses, unauthorized access, cyberattacks, employee theft or misuse, human error, hacking, fraud, natural disasters,
fire, terrorism, war and telecommunication and electrical failures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyberattacks are increasing in their frequency, sophistication and intensity.
Cyberattacks could include the deployment of harmful malware,&nbsp;&#147;phishing attacks&#148;, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service&nbsp;attacks,</FONT></FONT> social engineering and other means to
affect service reliability and threaten the confidentiality, integrity and availability of information. The use of cloud-based computing also creates opportunities for the unintentional dissemination or intentional destruction of confidential
information stored in our or our third-party providers&#146; systems, portable media or storage devices. Furthermore, as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may also face increased cybersecurity risks due to
our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant disruptions of our information technology systems or security breaches could adversely affect our business operations and/or result in the loss,
misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and
could result in financial, legal, business and reputational harm to us.&nbsp;If such disruptions were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the
loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Despite our efforts to ensure the
security, privacy, integrity, confidentiality, availability, and authenticity of our information technology networks and systems, processing and information, we may not be able to anticipate or to implement effective preventive and remedial measures
against all data security and privacy threats. We cannot guarantee that the recovery systems, security protocols, network protection mechanisms and other security measures that we or our third-party providers have integrated into our or their
systems, networks and physical facilities, which are designed to protect against, detect and minimize security breaches will be adequate to prevent or detect service interruption, system failures, data loss or theft, or other material adverse
consequences. No security solution, strategy, or measures can address all possible security threats or block all methods of penetrating a network or otherwise perpetrating a security incident. The risk of unauthorized circumvention of our security
measures has been heightened by advances in computer and software capabilities and the increasing sophistication of hackers who employ complex techniques, including without limitation, the theft or misuse of personal and financial information,
counterfeiting, &#147;phishing&#148; or social engineering, ransomware, extortion, publicly announcing security breaches, account takeover attacks, denial or degradation of service attacks, malware, fraudulent payment and identity theft.
Furthermore, because the techniques used to sabotage, disrupt or to obtain unauthorized access to our systems, networks, or physical facilities in which data is stored or through which data is transmitted change frequently and often are not
recognized until launched against a target, we or our third-party providers may be unable to implement adequate preventative measures or stop security breaches while they are occurring. We or our third-party providers may also experience security
breaches that may remain undetected for an extended period. Even if identified, we or our third-party providers may be unable to adequately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate
forensic evidence, or we or our third-party providers may be unable to repair our or their systems in an efficient and timely manner. In addition, laws, regulations, government guidance, and industry standards and practices are rapidly evolving to
combat these threats. We may face increased compliance burdens regarding such requirements from regulators and incur additional costs for oversight and monitoring of security risks relating to our own supply chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our third-party providers were to experience a significant cybersecurity breach of our or their information systems or data, the costs associated
with the investigation, remediation and potential notification of the breach to counterparties and data subjects could be material. Unauthorized access to our systems, networks, or physical facilities could result in litigation with our customers or
other relevant stakeholders, which may adversely affect our business. These proceedings could force us to spend money in defense or settlement, divert management&#146;s time and attention, increase our costs of doing business, or adversely affect
our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we may not have adequate insurance coverage for security incidents or breaches, including fines, judgments, settlements,
penalties, costs, attorney fees and other impacts that arise out of incidents or breaches. Depending on the facts and circumstances of such an incident, the damages, penalties and costs could be significant and may not be covered by insurance or
could exceed our applicable insurance coverage limits. If the impacts of a security incident or breach, or the successful assertion of one or more large claims against us, exceeds our available insurance coverage, or results in changes to our
insurance policies (including premium increases or the imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements), it could have an adverse effect on our business. In addition, we cannot be sure that our
existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms, or at all, or that our insurers will not deny coverage as to all or part of any future claim or loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in a significant number of our employees and partners working remotely,
which increases the risk of a data breach or issues with data and cybersecurity. To the extent that any disruption or security breach results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability and the further development of our future product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to
numerous laws, regulations, standards and other requirements related to personal information, privacy and data protection. Our actual or perceived failure to comply with such laws, regulations, standards and other requirements could negatively
affect our business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving, and we are subject to
numerous federal, state and foreign laws, regulations, standards and other requirements governing the collection, use, disclosure, retention and security of personal information, such as information that we may collect in connection with clinical
trials in the United States and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards or requirements may have
on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations
in our contracts, result in liability or impose additional costs on us. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal or external policies and procedures or our contracts governing
our processing of personal information could result in negative publicity, government investigations, enforcement actions, claims by third parties or damage to our reputation, any of which could have a material adverse effect on our business,
results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, numerous federal and state laws and regulations, including data breach notification
laws, health information privacy laws, and consumer protection laws and regulations that govern the collection, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processing, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, in the United States,
the Health Insurance Portability and Accountability Act of 1996 (&#147;<I>HIPAA</I>&#148;) imposes among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health
information. Entities that are found to be in violation of HIPAA, whether as the result of a breach of unsecured PHI, a complaint about privacy practices, or an audit by the U.S. Department of Health and Human Services, or HHS, may be subject to
significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA <FONT
STYLE="white-space:nowrap">non-compliance.</FONT> Depending on the facts and circumstances, we could be subject to penalties if we violate HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even
when HIPAA does not apply, according to the Federal Trade Commission (the <I>&#147;FTC&#148;</I>) failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce
in violation of the Federal Trade Commission Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its
business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which may
be more stringent, broader in scope or offer greater individual rights with respect to protected health information than HIPAA, many of which may differ from each other, thus, complicating compliance efforts. Such laws and regulations will be
subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California enacted the California Consumer Privacy Act, (&#147;<I>CCPA</I>&#148;), which creates individual privacy rights for California
consumers, including the right to opt out of certain disclosures of their information, and places increased privacy and security obligations on entities handling certain personal data of consumers or households and may apply to us in the future. The
CCPA provides for civil penalties for violations and also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, the California Privacy Rights
Act, or CPRA, significantly amends the CCPA and will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt
outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the
provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in
the U.S., as other states or the federal government may follow California&#146;s lead and increase protections for U.S. residents, which creates the potential for a patchwork of overlapping but different state laws and could increase our potential
liability and adversely affect our business, financial condition and results of operations. For example, the Virginia Consumer Data Protection Act, a comprehensive privacy statute that shares similarities with the CCPA, CPRA and legislation proposed
in other states, will take effect on January&nbsp;1, 2023. Colorado enacted a similar law, the Colorado Privacy Act, which becomes effective on July&nbsp;1, 2023. Similar laws have been passed and proposed in other states and at the federal level,
reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could add layers of complexity to compliance in the U.S. market, increase our compliance costs and adversely affect our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we are subject to international data protection laws and regulations, including the European Union General
Data Protection Regulation and applicable national supplementing laws, or GDPR, which may apply to health-related and other personal information obtained outside of the United States. The GDPR imposes strict
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements for collection, control, sharing, disclosure, transfer, use and other processing of the personal data of individuals located in the European Economic Area (the
&#147;<I>EEA</I>&#148;), including clinical trial data, as well as potential fines for noncompliant companies. The GDPR also imposes strict requirements relating to obtaining consent, providing information to individuals regarding data processing
activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, taking certain measures when engaging third-party processors. Compliance with the GDPR may increase our cost
of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our activities carried out in the
context of our EEA operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the
European Economic Area, or EEA, to the United States. On July&nbsp;16, 2020, in a case known as Schrems II, the Court of Justice of the European Union, or CJEU, invalidated the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework
under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the Standard Contractual Clauses (a standard form of contract approved by the
European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual
clauses must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance
laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place. Additionally, new Standard Contractual Clauses that repealed the Standard Contractual Clauses adopted under the Data Protection
Directive have been adopted on June&nbsp;4, 2021 by the European Commission. As supervisory authorities issue further guidance on personal data export mechanisms, including on the new Standard Contractual Clauses, and/or start taking enforcement
action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we conduct clinical trials, it could affect
our business. U.S. President Joseph Biden and the President of the European Commission announced on March&nbsp;25, 2022 that they had reached an agreement in principle for a Trans-Atlantic Data Privacy Framework, which would allow personal data to
flow freely and safely between the EU and participating U.S. companies. To that end, U.S. President Joseph Biden signed the Executive Order on Enhancing Safeguard for United States Signals Intelligence Activities, or EO, on October&nbsp;7, 2022. The
EO answers to certain shortcomings identified by the EU but it does not yet allow for the free transfers of personal data to the United States. Organizations must continue to implement a valid compliance mechanism for cross-border data transfers,
such as the Standard Contractual Clauses, and conduct an assessment of the U.S. laws prior to transferring personal data to the United States. As the EO introduces safeguards for U.S. intelligence services&#146; access to European personal
information, certain supplementary measures that have been implemented and are linked to these practices could be softened and the overall risk associated to the data transfer could be lowered. It is expected that a new <FONT
STYLE="white-space:nowrap">EU-US</FONT> data transfer framework will not be ready before Spring 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Relatedly, following the United Kingdom&#146;s
withdrawal from the EEA and the EU, we are required to comply with both the GDPR and, separately, the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR sets out the <FONT
STYLE="white-space:nowrap">UK-specific</FONT> requirements related to data protection, including with respect to transfer of personal data outside of the UK, which increases our regulatory compliance burden. Further, in July 2022, the UK government
published a Data Reform Bill that will amend the UK GPDR. This creates uncertainty with regard to the data protection regulatory regime in the United Kingdom and could result in the introduction of data privacy laws that materially deviate from the
EU GDPR. This would expose us to two parallel regimes. Further, the entry into force of the <FONT STYLE="white-space:nowrap">US-UK</FONT> Data Access Agreement on 3&nbsp;October 2022 may put at risk the European Commission&#146;s adequacy decision
granted to the UK. If such adequacy decision were to be withdrawn, personal data would not flow freely between the UK and the EU and additional safeguards would need to be adopted, which could result in additional costs for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure or perceived failure by us to comply with our legal obligations concerning privacy, data
protection or information security could result in claims by data subjects, governmental investigations and enforcement action against us, including fines, enforcement orders, imprisonment of company officials and public censure, (individual and
collective) claims for damages by affected individuals and damage to our reputation, any of which could have a material adverse effect on our business, financial condition, and operating results. Companies that must comply with the GDPR and UK GDPR
face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#128;20&nbsp;million or 4% of the annual global revenues of the noncompliant
company, whichever is greater, litigation (including private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests), regulatory
investigations, enforcement actions that require us to change the way we use personal data, and/or prohibitions on the use of personal data. Such penalties may be in addition to any civil litigation claims by data subjects. We may not be successful
in avoiding potential liability or disruption of business resulting from the failure to comply with these laws and, even if we comply with laws, we may be subject to liability because of a security incident. Further, complying with the applicable
notification requirements in the event of a security breach could result in significant costs. Furthermore, future interpretations of existing data protection laws or regulations could be inconsistent with our current interpretations, increase our
compliance burden, make it more difficult to comply, and/or increase our risk of regulatory investigations and fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EU data protection laws also
require <FONT STYLE="white-space:nowrap">opt-in</FONT> consent to send marketing emails or use cookies and similar technologies for advertising, analytics and other purposes &#150; activities on which our marketing strategies may rely. Enforcement
of these requirements has increased and a new regulation that has been proposed in the EU, known as the Privacy Regulation, may make these requirements more stringent and increase the penalties for violating them. Such restrictions could increase
our exposure to regulatory enforcement action, increase our compliance costs, and adversely affect our business. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how
UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure. On
June&nbsp;28, 2021, the European Commission adopted an adequacy decision permitting flows of personal data between the EU and the UK to continue without additional requirements. However, the UK adequacy decision will automatically expire in June
2025 unless the European Commission <FONT STYLE="white-space:nowrap">re-assesses</FONT> and renews or extends that decision and remains under review by the European Commission during this period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we contract with, and are accountable for, third-party service providers we engage to process personal data on our behalf, including our CROs.
We cannot assure you that our service providers with access to our or our customers&#146;, suppliers&#146;, trial patients&#146; and employees&#146; personal information, including health data and other sensitive or confidential information, will
not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof. If they were to breach their contractual obligations or experience a security incident, such event could have an adverse
effect on our business, including putting us in breach of our obligations under privacy laws and regulations, which could in turn adversely affect our business, financial conditions and results of operations. We cannot assure you that our
contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Swiss Federal Act on Data Protection, or DPA, also applies to the collection and processing of personal data by companies located in Switzerland, or in
certain circumstances, by companies located outside of Switzerland. The DPA has been revised and adopted by the Swiss Parliament, and the revised version and its revised ordinances will enter into force on September 1, 2023. This revised law may
lead to an increase in our costs of compliance, risk of noncompliance and penalties for noncompliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security laws, we
may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We may also be bound by other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles,
regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by
regulators, or other adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with applicable United States and foreign data protection, privacy and security laws, regulations
and standards could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our ability, or our that of
our partners or suppliers, to operate in certain jurisdictions. Each of these constantly evolving laws can also be subject to varying interpretations. Any failure or perceived failure to comply could result in government investigations and
enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity, and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain
information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection
laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits of acquired assets or other strategic transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or product candidates, intellectual property, or
technologies as well as pursue joint ventures or investments in complementary businesses. The success of any future strategic transaction depends on various risks and uncertainties, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated liabilities related to investee companies or joint ventures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conflicts in economic or business interests with our joint ventures or investee companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties integrating acquired personnel, technologies, and operations into our existing business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s time and focus from operating our business to management of strategic alliances or
joint ventures or acquisition integration challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increases in our expenses and reductions in our cash available for operations and other uses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption in or termination of our relationships with collaborators or suppliers as a result of such a
transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible write-offs or impairment charges relating to investee companies or joint ventures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign acquisitions and joint ventures are subject to additional risks, including those related to regulatory or compliance issues,
integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations, and the particular economic, political, and regulatory risks associated with specific countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities,
or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We could also incur losses resulting from undiscovered liabilities that are not covered by the indemnification we may obtain from the seller. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates or products or acquire
businesses, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we
will achieve the results, revenue, or specific net income that justifies the transaction. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities, or
amortization expenses or write-offs of goodwill, any of which could harm our financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in late 2019, may continue to affect our ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt our manufacturing and
supply chain or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse
effects on our business and operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in December 2019, caused many
governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny and other measures. The outbreak and government measures taken in response have also had a significant impact,
both directly and indirectly, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical services and
supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the outbreak and its effects on our business and operations are uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business, operations and clinical development timelines and plans had been and could in the future be adversely affected by
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> and could be adversely impacted by other health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the
operations of CROs upon whom we rely. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has affected multiple countries worldwide, including those where we have planned and ongoing preclinical studies and clinical trials. In addition, in
response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, many state, local and foreign governments put in place quarantines, executive orders,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders and similar government orders and restrictions in order to control the spread of the disease. Such orders or restrictions, and the perception
that such orders or restrictions could continue or, after being lifted, be reinstated for a period of time, have resulted in business closures, work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of
events, among other effects that could negatively impact productivity and disrupt our business and operations. While some of the orders and restrictions have been lifted, we cannot be certain that such orders and restrictions will not be reinstated
in the future, particularly with the emergence of new variant strains of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus. We may take further actions that alter our operations as may be required by federal, state or local authorities, or
which we determine are in the best interests of our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, our clinical development timelines and plans could be affected by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic as we and the third-party manufacturers and clinical research organizations that we engage may face disruptions. Site initiation and patient enrollment could be delayed or suspended due to
prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or patients not having a desire to enroll in clinical trials due to concerns regarding <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We
cannot be certain that we will not experience future delays in enrollment. In addition, some patients may not be able to comply with clinical trial protocols and the ability to conduct follow up visits with treated patients may be limited if
patients do not want to participate in follow up visits due to concerns regarding <FONT STYLE="white-space:nowrap">COVID-19</FONT> or if quarantines impede patient movement or interrupt healthcare services. There may be shortages in the raw
materials used in the manufacturing of our product candidates or laboratory supplies for our preclinical studies and clinical trials, in each case, because of ongoing efforts to address the outbreak. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure that the inability to collect such clinical data would not have an adverse impact on our clinical trial results. Similarly, our ability to
recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19</FONT> could be adversely impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience disruptions that could severely impact our business, preclinical studies, and clinical
trials, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials, including
receiving any required IND or similar approval to initiate clinical trials from regulatory bodies in other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing disruptions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the transport of clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties recruiting or retaining patients for our planned clinical trials if patients are affected by the
virus or are fearful of visiting or traveling to clinical trial sites because of the outbreak; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of or changes in key clinical trial activities, such as clinical trial site monitoring,
implementation of virtual monitoring, use of local testing labs, or home delivery of study drugs, due to limitations on travel imposed or recommended by federal or state governments, employers and others, use of new digital technologies for subject
visits or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in our clinical trials will acquire
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulators which may impact review and approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in regulatory approvals for our product candidates due to the FDA or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators focusing on clinical trials related to therapies and vaccines targeting <FONT STYLE="white-space:nowrap">COVID-19;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators to accept data, including from
clinical trials in affected geographies or failure to comply with updated guidance and expectations of the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators related to the conduct of clinical trials during the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays to our sourced discovery and clinical activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may redirect resources with respect to regulatory matters in a way that would
adversely impact our ability to pursue marketing approvals. In addition, we may face impediments to regulatory meetings and potential approvals due to measures intended to limit <FONT STYLE="white-space:nowrap">in-person</FONT> interactions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Furthermore, third parties, including manufacturers, medical institutions, clinical investigators, CROs and consultants with whom we conduct business, are similarly adjusting their operations and
assessing their capacity in light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If these third parties continue to experience shutdowns or business disruptions, our ability to conduct our business in the manner and on the
timelines presently planned could be materially and negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic impacts our business, clinical trials, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration of the pandemic, its
severity, the actions to contain the virus or address its impact, and how quickly and to what extent government orders and mandates are lifted and normal economic and operating activities can resume. Further, while the potential economic impact
brought by and the duration of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in significant disruptions of global financial markets,
which could reduce our ability to access capital, which could in the future negatively affect our liquidity. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business, clinical trials, results of
operations and financial condition, it may also have the effect of heightening many of the other risks described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ultimate impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to
securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline
in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs
and a diversion of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to development and regulatory approval of
our investigational therapies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The success of our product candidates, and our ability to generate revenue in the future, will depend upon a
number of factors, many of which are beyond our control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business, including our ability to finance and generate revenue in the
future, primarily depends on the successful development, regulatory approval and commercialization of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT>
The clinical and commercial success of our product candidates depend on a number of factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biopharmaceutical company with no approved products. We have not yet successfully
completed any Phase 3 clinical trials nor commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our innovations to the treatments of retinal diseases, dry eye and glaucoma are unproven, and we do not know
whether we will be able to successfully develop these products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug development is a lengthy, highly uncertain undertaking and involves a substantial degree of risk. The
outcome of preclinical testing and earlier clinical trials may not be predictive of the success of later clinical trials. In addition, the regulatory approval processes of the Food and Drug Administration (&#147;<I>FDA</I>&#148;), and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities are highly complex, lengthy, and inherently unpredictable, and the results of our clinical trials may not satisfy the requirements of the FDA or other regulatory authorities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business depends on the successful development and commercialization of
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> <FONT STYLE="white-space:nowrap">OCS-05</FONT> and our other product candidates. To the extent the pipeline products are not commercially successful, our
business, financial condition, and results of operations may be adversely affected. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our products may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and
others in the medical community necessary for commercial success, and the market opportunity for these products may be smaller than we estimated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have no experience manufacturing any of our product candidates at a commercial scale. We, or our CMOs, may be
unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> a biologic, and certain of our other product
candidates are complex and highly regulated, and there are particular risks associated with manufacturing the products to commercial scale, including our reliance on third parties and the risk that we will not have sufficient quantities of our
products or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair the commercialization or development efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our patent position does not adequately protect our product candidates, others could compete against us more
directly, which would harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations under any license, collaboration or other agreements, including our
license agreements with Novartis Technology LLC (&#147;<I>Novartis</I>&#148;) and Accure Therapeutics SL (&#147;<I>Accure</I>&#148;), such agreements may be terminated, we may be required to pay damages and we could lose intellectual property rights
that are necessary for the development and protection of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional funding to support our operations and pursue our growth strategy. If we are
unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate future commercialization efforts or one or more of our research and development programs. In addition, raising additional capital may cause
dilution to New Parent&#146;s shareholders or restrict our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant losses and negative cash flows from operations
since our formation, and we anticipate that we will continue to incur losses for the foreseeable future, which may make it difficult for investors to evaluate our current business and predict our future success and viability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Business Combination, New Parent will qualify as an &#147;emerging growth company&#148; and we
cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make New Parent Shares less attractive to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may from time to time report the results of clinical trials and some of those results may not meet our or
market expectations. For instance, we expect to receive readouts from <FONT STYLE="white-space:nowrap">OCS-01</FONT> trials as soon as in <FONT STYLE="white-space:nowrap">mid-2023.</FONT> Any results that we report that do not meet our or market
expectations may negatively affect the trading price of New Parent Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sizes of the market opportunities for our product
candidates have not been established with precision and may be smaller than we estimate, possibly materially. If our estimates of the sizes overestimate these markets, our sales growth may be adversely affected. We may also not be able to grow the
markets for our product candidates as intended or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our assessment of the potential market opportunity the product candidates that we
develop is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties and our own internal epidemiology and market research studies. Industry publications and
third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these
industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Similarly, although the studies we have conducted are based on information that we believe to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be complete and reliable, we cannot guarantee that such information is accurate or complete. The potential market opportunities of our product candidates are difficult to precisely estimate.
Therefore, our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and our own epidemiology studies and market
research, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions and the bases of the studies and research we have conducted are reasonable, no independent source
has verified such assumptions or bases. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for our product candidates may be smaller than we expect, and as a
result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend,
in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets where we lack familiarity with local
regulations, environment and procedures and for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in other foreign markets. We are not
permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates.
To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other
things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product
candidates in foreign markets, we would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our customers&#146; ability to obtain reimbursement for our product candidates in foreign markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to directly control commercial activities if we are relying on third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">import or export licensing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer accounts receivable collection times; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer lead times for shipping; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">language barriers for technical training and the need for language translations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection of intellectual property rights in some foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional potentially relevant third-party intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of restrictions on currency conversion or the transfer of funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anti-competitive policies or anti-competitive practices which are condoned and the imposition of restrictions on
investments and other measures that may be taken to protect the local industry in these foreign markets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions by <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, governments, companies, or other entities
which prevent us from entering into or benefiting from licensing agreements or other collaborations with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> companies, universities, research institutes, or other entities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the treatment of retinal disease with <FONT STYLE="white-space:nowrap">OCS-01</FONT>
is unproven, and we do not know whether we will be able to successfully develop <FONT STYLE="white-space:nowrap">OCS-01.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">OCS-01&nbsp;is</FONT> designed to deliver therapeutic drug levels to the retinal tissue by a topical route of administration as an eye drop formulation. There are currently
<FONT STYLE="white-space:nowrap">no&nbsp;FDA-approved&nbsp;therapies</FONT> that treat retinal diseases by a topical route of administration. Our future success partially depends on the successful development of
<FONT STYLE="white-space:nowrap">OCS-01</FONT> which is&nbsp;based on this novel therapeutic approach. We have not yet demonstrated efficacy and safety <FONT STYLE="white-space:nowrap">for&nbsp;OCS-01&nbsp;or</FONT> any other product candidates in a
pivotal trial or obtained marketing approval of any product <FONT STYLE="white-space:nowrap">candidate.&nbsp;OCS-01&nbsp;may</FONT> not demonstrate in patients any or all of the pharmacological benefits we believe it may possess. If we are
unsuccessful in our development efforts, we may not be able to advance the development and commercialization <FONT STYLE="white-space:nowrap">of&nbsp;OCS-01.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our potential approach to use <FONT STYLE="white-space:nowrap">OCS-02</FONT> for the treatment of dry eye disease in patients identified with a
biomarker is unproven, and we do not know whether we will be able to successfully confirm the role of the biomarker and successfully develop <FONT STYLE="white-space:nowrap">OCS-02.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">OCS-02&nbsp;is</FONT> in development for treating ophthalmic diseases including dry eye disease. One of our potential
strategies for <FONT STYLE="white-space:nowrap">OCS-02</FONT> is also to develop it for patients identified with a biomarker to predict patients that may respond well to <FONT STYLE="white-space:nowrap">OCS-02</FONT> treatment. There are currently <FONT
STYLE="white-space:nowrap">no&nbsp;FDA-approved&nbsp;therapies</FONT> that treat dry eye disease in this &#147;precision medicine&#148; way. If we choose to utilize this biomarker strategy, then our future success partially depends on the successful
development of both <FONT STYLE="white-space:nowrap">OCS-02</FONT> and a companion diagnostic for the biomarker and our ability to demonstrate that patients with that biomarker are likely to respond well to
<FONT STYLE="white-space:nowrap">OCS-02</FONT> treatment. We have not yet demonstrated efficacy and safety <FONT STYLE="white-space:nowrap">for&nbsp;OCS-02&nbsp;or</FONT> any other product candidates in patients with or without a biomarker in a
pivotal trial or obtained marketing approval of any of our product <FONT STYLE="white-space:nowrap">candidates.&nbsp;OCS-02&nbsp;may</FONT> not demonstrate in patients with or without the biomarker any or all of the pharmacological benefits we
believe it may possess. If we are unsuccessful in our development efforts, we may not be able to advance the development and commercialization <FONT STYLE="white-space:nowrap">of&nbsp;OCS-02.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the treatment of ophthalmic disease with <FONT STYLE="white-space:nowrap">OCS-05</FONT> is unproven, and we do not know whether we will
be able to successfully develop <FONT STYLE="white-space:nowrap">OCS-05.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">OCS-05&nbsp;is</FONT> intended to
prevent or reverse nerve damage (<I>&#147;neuroprotection&#148;</I>) in ophthalmic diseases in which patients lose vision due to nerve damage. There are currently <FONT STYLE="white-space:nowrap">no&nbsp;FDA-approved&nbsp;therapies</FONT> that treat
ophthalmic diseases in this &#147;neuroprotective&#148; way. Our future success partially depends on the successful development of <FONT STYLE="white-space:nowrap">OCS-05</FONT> which is&nbsp;based on this novel therapeutic approach. We have not yet
demonstrated efficacy and safety <FONT STYLE="white-space:nowrap">for&nbsp;OCS-05&nbsp;or</FONT> any other product candidates in a pivotal trial or obtained marketing approval of any product
<FONT STYLE="white-space:nowrap">candidate.&nbsp;OCS-05&nbsp;may</FONT> not demonstrate in patients any or all of the pharmacological benefits we believe it may possess. If we are unsuccessful in our development efforts, we may not be able to
advance the development and commercialization <FONT STYLE="white-space:nowrap">of&nbsp;OCS-05.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We in-licensed OCS-05 from Accure in 2022. Accure
was previously unable to establish a no-observed-adverse-effect-level (&#147;<I>NOAEL</I>&#148;) for the product candidate. We have engaged Toxicodynamix International LLC to manage toxicology studies relating to OCS-05. If our studies do not
satisfy the FDA&#146;s requirements, OCS-05 may not receive clearance from the FDA to proceed with human clinical trials, may never receive clearance from the FDA to proceed with human clinical trials and may never receive regulatory approval from
the FDA, and we may be unable to market and commercialize OCS-05 in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet successfully completed any Phase 3 clinical
trials, received any marketing approvals or commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations to date have been limited to financing and staffing our company, developing our technology and conducting preclinical research as well as Phase
1 and Phase 2 clinical trials for our product candidates. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not yet demonstrated an ability to successfully complete Phase 3 clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our
behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by
clinical-stage biopharmaceutical companies such as ours. Any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and
commercializing pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in
achieving our business objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend significantly on our product candidates, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and <FONT
STYLE="white-space:nowrap">OCS-05,</FONT> which we are developing for treatment of multiple diseases. If we are unable to complete the clinical development of any of these product candidates, if we are unable to obtain marketing approvals for any of
these product candidates, or if any of these product candidates are approved and we fail to successfully commercialize the product candidate or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend significantly on the success of our lead product candidate, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> which we are developing for the treatment
of patients with diabetic macular edema, and also for the treatment of patients with pain or inflammation following ocular surgery. In addition, we also depend on the success of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> which we are developing
for the treatment of dry eye disease and <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis and on the success of <FONT STYLE="white-space:nowrap">OCS-05,</FONT> which we are initially developing for the treatment of Acute Optic
Neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our efforts and financial resources in the development of
<FONT STYLE="white-space:nowrap">OCS-01</FONT> for the treatment of patients with diabetic macular edema as well as for the treatment of patients with pain or inflammation following ocular surgery. There remains a significant risk that we will fail
to successfully develop <FONT STYLE="white-space:nowrap">OCS-01</FONT> in one or both of these indications. The results of our Phase&nbsp;2 clinical trials in each indication may not be predictive of the results of our Phase&nbsp;3 clinical programs
due, in part, to the fact that (i)&nbsp;we have no clinical data on <FONT STYLE="white-space:nowrap">OCS-01</FONT> therapy in diabetic macular edema in any clinical trial with treatment longer than 12&nbsp;weeks, (ii)&nbsp;we have modified the
methodology used to determine a patient&#146;s eligibility under certain of the inclusion and exclusion criteria for our Phase&nbsp;3 clinical trial as compared to our Phase&nbsp;2 clinical trial, (iii)&nbsp;we have no clinical data from a trial of
similar size to that anticipated for our Phase 3 clinical trial, and (iv)&nbsp;we plan to conduct our Phase&nbsp;3 clinical trials at many clinical centers that were not included in our Phase&nbsp;2 clinical trial. The results of our Phase&nbsp;2
clinical trials for inflammation and pain following ocular surgery may not be predictive of the results of the planned Phase&nbsp;3 clinical study, due, in part, to the fact that we plan to conduct our Phase 3 clinical trial at clinical centers that
were not included in our Phase 2 clinical trial. Furthermore, despite consultation with regulatory authorities, no assurance can be provided that the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities would consider the
planned Phase 3 clinical trials to be sufficient to serve as the basis for approval in either indication, or that the Phase 2 study for inflammation and pain following ocular surgery may be considered as one of the two required adequate and
well-controlled trials to support a New Drug Application (NDA) submission, with such a final determination only made by the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities following review of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot accurately predict when or if any of our product candidates will prove effective or safe in humans or whether these product candidates will receive
marketing approval. Our ability to generate product revenues sufficient to achieve profitability will depend heavily on our obtaining marketing approval for and <FONT STYLE="white-space:nowrap">commercializing&nbsp;OCS-01,</FONT> <FONT
STYLE="white-space:nowrap">OCS-02,</FONT> or <FONT STYLE="white-space:nowrap">OCS-05.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success
<FONT STYLE="white-space:nowrap">of&nbsp;OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> <FONT STYLE="white-space:nowrap">OCS-05&nbsp;and</FONT> other product candidates will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully and timely completing preclinical studies and clinical trials that demonstrate to the satisfaction
of the FDA, the European Medicines Agency, or EMA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities that our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of the label that may be approved by applicable regulatory authorities, including the specific
indication for which the product may be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are required by the FDA or similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agency
to conduct additional studies beyond those planned to support the approval and commercialization of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors,
including relative to alternative and competing treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of our products both prior to and following any marketing
approval of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating consistent therapeutic efficacy of our products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining coverage and adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applying for and receiving marketing approvals from applicable regulatory authorities for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain
compliance with their contractual obligations and with all regulatory requirements applicable to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scaling up our manufacturing processes and capabilities to support additional or larger clinical trials of our
product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, validating and maintaining a commercially viable manufacturing process that is compliant with current
good manufacturing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and expanding our sales, marketing and distribution capabilities and launching commercial sales of our
product candidates, if and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">minimizing and managing any delay or disruption to our ongoing or planned clinical trials, and any adverse
impacts to the U.S. and global market for pharmaceutical products, as a result of the <FONT STYLE="white-space:nowrap">ongoing&nbsp;COVID-19&nbsp;pandemic;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory
exclusivity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting and enforcing our rights in our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully
commercialize our product candidates, which would materially harm our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not
satisfy the requirements of the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from the prior
preclinical studies and clinical trials for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and <FONT STYLE="white-space:nowrap">OCS-05</FONT> may not necessarily be predictive of the results of future
preclinical studies or clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our current development timelines, the results from our prior clinical trials of our product candidates may
not be replicated in these future trials. Many companies in the pharmaceutical and biotechnology industries (including those with greater resources and experience than us) have suffered significant setbacks in late-stage clinical trials after
achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported
adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials
nonetheless have failed to obtain FDA or <FONT STYLE="white-space:nowrap">non-U.S.-regulatory</FONT> authority approval. If we fail to produce positive results in our clinical trials of any of our product candidates, the development timelines,
regulatory approvals and commercialization prospects for our product candidates, as well as our business and financial prospects, would be adversely affected. Further, our product candidates may not be approved even if they achieve their respective
primary endpoints in Phase 3 registration trials. The FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may disagree with our trial designs or our interpretation of data from preclinical studies and clinical trials. In
addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in
approval by the FDA or another regulatory authority. Furthermore, any of these regulatory authorities may also approve our product candidates for fewer or more limited indications than it requests or may grant approval contingent on the performance
of costly post-marketing clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our clinical data results come from previous trials of less than 100 patients each, including a
Phase&nbsp;2a clinical trial of <FONT STYLE="white-space:nowrap">OCS-02</FONT> for the treatment of dry eye disease, a Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">OCS-02</FONT> for the treatment of
<FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis, and a Phase 1 dose-ranging study of <FONT STYLE="white-space:nowrap">OCS-05</FONT> in healthy volunteers, making it difficult to predict whether the favorable results from such
trials will be repeatable in larger, more advanced clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you
that the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities would consider our completed and planned clinical trials used for an NDA submission to be sufficient to serve as the basis for approval of our product candidates
for any indication. Even if the results of future Phase 3 clinical trials are positive, the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities retain broad discretion in evaluating the results of our clinical trials and
in determining whether the results demonstrate that our product candidates are safe and effective. If we are required to conduct clinical trials of our product candidates in addition to those we have planned prior to approval, we will need
substantial additional funds, and cannot assure you that the results of any such outcomes trial or other clinical trials will be sufficient for approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization
of our product candidates could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials
that could delay or prevent our ability to receive marketing approval or commercialize any product candidate that we may develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may not produce statistically significant, conclusive, or anticipated
results, and we may decide, or regulators may require us, to conduct additional clinical trials or amend product development programs, or abandon product development programs entirely; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contractors may fail to comply with regulatory requirements or meet their obligations to us in a timely
manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or
clinical trial protocols with prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may decide, or regulators, IRBs, or ethics committees may require us, to suspend or terminate clinical
research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our clinical trial material or other materials necessary to conduct clinical trials of
our product candidates may be insufficient or inadequate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of
our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these trials or other tests are not favorable or are only
modestly favorable or if there are safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining or unable to obtain marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our preclinical
studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right
to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required, or choose, to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, the trials are not well-designed, or research participants experience adverse safety outcomes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory agencies, IRBs, or data safety monitoring boards may at any time recommend the temporary or permanent discontinuation of our clinical trials or
request that we cease using investigators in the clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to
participants. Clinical trials must be conducted in accordance with GCPs and other applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority guidelines. Clinical trials are subject to oversight by the FDA, <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities and IRBs at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced in accordance with applicable
current good manufacturing practices. Clinical trials may be placed on a full or partial clinical hold by the FDA, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, or us for various reasons, including, but not limited to:
deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols; deficiencies in the clinical trial operations or trial sites; deficiencies in the
trial designs necessary to demonstrate efficacy; fatalities or other adverse effects arising during a clinical trial due to medical problems that may or may not be related to clinical trial treatments; the product candidates may not appear to be
more effective than current therapies; or the quality or stability of the product candidates may fall below acceptable standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect or are
forced to suspend or terminate a clinical trial of any of our current or future product candidates, the commercial prospects for that product may be harmed and our ability to generate product revenue from that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product may be delayed or eliminated. Furthermore, any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could
substantially increase the costs of commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products either by us or by our collaboration partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional SAEs could result in the FDA delaying our clinical trials or denying or delaying clearance or approval of a product. Even though an adverse
effect may not be the result of the failure of our drug candidate, the FDA or an IRB could delay or halt a clinical trial for an indefinite period of time while an adverse effect is reviewed, and likely would do so in the event of multiple such
events. Any delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to
continue to participate in a clinical trial, and delays or termination of clinical trials as a result of protocol modifications or adverse effects during the trials, may cause an increase in costs and delays in the submission of any New Drug
Applications, or NDAs, to the FDA, delay the approval and commercialization of our products or result in the failure of the clinical trial, which could adversely affect our business, financial condition, results of operations and growth prospects.
Lengthy delays in the completion of clinical trials of our products would adversely affect our business and prospects and could cause us to cease operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If preliminary data demonstrate that any of our product candidates has an unfavorable safety profile and is unlikely to receive regulatory approval or be
successfully commercialized, we may voluntarily suspend or terminate future development of such product candidate. Any one or a combination of these events could prevent us from obtaining approval and achieving or maintaining market acceptance of
the affected product or could substantially increase the costs and expenses of commercializing the product candidate, which in turn could delay or prevent us from generating significant revenues from the sale of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects, such as an increase in intraocular pressure caused by
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action. <FONT
STYLE="white-space:nowrap">OCS-05</FONT> was placed on a clinical hold with the FDA in 2016. If we are unable to establish a NOAEL, or if our studies otherwise do not satisfy the FDA&#146;s requirements,
<FONT STYLE="white-space:nowrap">OCS-05</FONT> may not receive clearance from the FDA to proceed with human clinical trials, may never receive regulatory approval from the FDA, and we may not be able to market and commercialize <FONT
STYLE="white-space:nowrap">OCS-05</FONT> in the United States, which could materially adversely affect our business, financial condition, results of operations and growth prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unforeseen side effects varying in severity (from minor reactions to death) and frequency (infrequent or prevalent) from
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> or <FONT STYLE="white-space:nowrap">OCS-05</FONT> could arise either during clinical development or, if approved, after marketing. Undesirable side
effects could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend, modify, delay or halt clinical trials and could result in a more restrictive or narrower label or the delay or denial of regulatory
approval by the FDA or comparable foreign authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the conduct of clinical trials, subjects report changes in their health, including
illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer
and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as
conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases,
after they are made available to subjects on a commercial scale after approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT
STYLE="white-space:nowrap">OCS-02</FONT> or <FONT STYLE="white-space:nowrap">OCS-05</FONT> or any of our other product candidates are associated with serious adverse events, or SAEs, or other undesirable side effects in clinical trials or have
characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SAEs, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, <FONT STYLE="white-space:nowrap">OCS-05</FONT> was placed on a clinical hold by the FDA in 2016. We licensed
<FONT STYLE="white-space:nowrap">OCS-05</FONT> from Accure in 2022. Accure had conducted a limited set of animal regulatory toxicology studies in 2016 and submitted them to the FDA in an IND requesting the initiation of human testing. Upon review,
the FDA found the data insufficient and asked for more animal toxicology data to be generated prior to human studies, thereby placing OCS-05 on the regulatory status of &#147;clinical hold&#148; pending the availability of the requested data. In
response, Accure chose to withdraw the IND in 2017 rather than invest in further toxicology studies to address the FDA&#146;s request. Upon our license of OCS-05 from Accure in 2022, we reactivated the IND and plan to meet with the FDA in the first
half of 2023 to agree on a comprehensive toxicology plan to satisfy the FDA&#146;s request. Other health authorities where clinical studies have been proposed, including the UK and France, have authorized us to commence clinical studies of selected
doses and reinforced safety measures as in our European Phase 1 trial in AON. We have engaged Toxicodynamix International LLC to manage toxicology studies relating to <FONT STYLE="white-space:nowrap">OCS-05.</FONT> If our studies do not satisfy the
FDA&#146;s requirements, <FONT STYLE="white-space:nowrap">OCS-05</FONT> may not receive clearance from the FDA to proceed with human clinical trials, may never receive regulatory approval from the FDA, and we may be unable to market and
commercialize <FONT STYLE="white-space:nowrap">OCS-05</FONT> in the United States, and our business, financial condition, results of operations and growth prospects could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or
terminated, and the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. Such adverse
event findings also could require us or our collaboration partners to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits which would harm our business, financial condition,
results of operations and growth prospects. In such an event, we could be required by the FDA or other comparable regulatory authorities to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which
we have not planned or anticipated or our studies could be suspended or terminated, and the FDA or comparable regulatory authorities could order us to cease further development of or deny, vary, or withdraw approval of our product candidates for any
and all intended indications. The drug-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial. There can be no assurance that we will resolve any issues related to any product-related
adverse events to the satisfaction of the FDA or any comparable regulatory agency in a timely manner, if ever, and any of these occurrences may harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by a product after obtaining U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approval, a number of potentially negative consequences could result, including but not limited to, regulatory authorities suspending, withdrawing or varying approvals of such product, regulatory
authorities requiring additional warnings on the label or otherwise requiring labeling to be updated or narrowed, us becoming liable for harm caused to patients and the diminution of our reputation, which could prevent us or our potential partners
from achieving or maintaining market acceptance of the product candidate, if approved, and could substantially increase the costs of commercializing such product, which would have a material adverse effect on our business, results of operation,
financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates receives approval, regulatory agencies including the FDA and other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies will require that we regularly report certain information, including information about adverse events that may have caused or contributed by those products. The timing of adverse event
reporting obligations would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe especially if it is not reported to
us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or other regulatory agencies could take action that may include
criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or suspension of market approval, and delay in approval or clearance of future products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our clinical trials may change as more patient data becomes
available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may
publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions may be subject to change
following a more comprehensive review of the data. We also may use assumptions and estimates as part of our preliminary analyses of the data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Topline data
also remain subject to audit and verification procedures before they can be finalized. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of
available information. For example, we may report interim analyses of only certain of the endpoints of the clinical trial, rather than all of the endpoints. Additional disclosure of interim data by us or by our competitors in the future could result
in volatility in the price of the New Parent Shares. Further, investors may not agree with what we determine is the material or otherwise appropriate information to include in our public disclosures, and any information we determine not to disclose
may ultimately be deemed significant by us or, if subsequently disclosed, by investors, with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. Further, others,
including regulatory agencies and investors may not accept our conclusions regarding such preliminary or interim analyses, which could impact the value of a particular program or the approvability or commercialization of the particular product
candidate, or result in volatility in the price of the New Parent Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The topline results that we report may differ significantly from the final
results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. As a result, topline and interim data from clinical trials are subject to the risk that
one or more of the reported clinical outcomes may materially change, and should be viewed with caution until the final data are available. If the preliminary or topline data that we report differ from the final results, or if others, including
regulatory authorities, disagree with our conclusions, then our ability to obtain approval for, and to successfully commercialize our product candidates may be harmed, which could materially affect our business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical
trials on the timelines we expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that
any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application, or IND, or a clinical trial application, or CTA, will result in the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, or any other regulatory authority as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that
could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any difficulties we experience relating to the initiation or completion of patient visits in clinical trials, including as a result of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;SARS-CoV-2</FONT></FONT> virus, could delay regulatory approval for our product candidates. Identifying and qualifying subjects to participate in clinical trials of our product
candidates is critical to our success. The timing of clinical trials depends on our ability to recruit subjects to participate, as well as the completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. Patients may be
unwilling to participate in clinical trials because of negative publicity from adverse events related to the biotechnology or pharmaceutical fields, competitive clinical trials for similar patient populations, the existence of current treatments or
for other reasons. The timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed, which could result in increased costs, delays in advancing our product candidates, delays in
testing the effectiveness of our product candidates or termination of the clinical trials altogether. Patient enrollment for any of our future clinical trials may be affected by other factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other<I>&nbsp;in vivo</I>&nbsp;or<I>&nbsp;in
vitro</I>&nbsp;data to support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory agencies on study design; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the determination by the reviewing regulatory authority to require more costly or lengthy clinical trials than we
currently anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required IRB, or ethics committee approval at each clinical trial site;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including
after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical
trial operations or study sites; developments on trials conducted by competitors for related technology that raises FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, or any other regulatory authority
concerns about risk to patients of the technology broadly; or if the FDA, EMA, National Medical Products Administration, or NMPA, or any other regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its
stated objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and
delays caused by patients withdrawing from clinical trials or failing to return for <FONT STYLE="white-space:nowrap">post-treatment&nbsp;follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s current good
clinical practices, or cGCPs, requirements, or applicable regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of competing treatments and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate, including as a result of
volatility in currency exchange rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by a CMO or by us, and delays or failure
by our CMOs or us to make any necessary changes to such manufacturing process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any inability to successfully initiate
or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods
during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by
the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, or any other regulatory authority, or if the IRBs or ethics committees of the institutions in which such trials are being conducted suspend or terminate
the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory
requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue
the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delays in the commencement or completion of any clinical trial of our product candidates will increase our costs, slow down our
product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do, and may in the future, conduct
clinical trials for our product candidates outside the United States, and the FDA and applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may not accept data from such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and investigator sponsors have conducted clinical trials, are conducting clinical trials, and may in the future choose to conduct one or more clinical
trials outside of the United States. Although the FDA or applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority may accept data from clinical trials conducted outside the United States or the applicable jurisdiction,
acceptance of such study data by the FDA or applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority may be subject to certain conditions or exclusions. Where data from foreign clinical trials are intended to serve as the
basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless such data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical
investigators of recognized competence; and the data are considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to
validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. Many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory bodies have similar requirements. In addition, such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> studies would be subject to the applicable local laws of the jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authority will accept data from trials conducted outside of the United States or the applicable home country. If the FDA or applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority does not accept such data, it
would likely result&nbsp;in the need for additional trials, which would be costly and time-consuming and delay aspects of our business&nbsp;plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on and expect to continue to rely on third-party CROs and other third parties to conduct and oversee our clinical trials. If these third parties
do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on, and expect to continue to rely on, third-party CROs to conduct and oversee our clinical trials and other aspects of product development. We also
expect to rely on various medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and applicable regulatory requirements, including the FDA&#146;s regulations and good
clinical practice, or GCP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements, and equivalent <FONT STYLE="white-space:nowrap">non-U.S.</FONT> and international standards, which are international standards meant to protect the rights and health of patients and
to define the roles of clinical trial sponsors, administrators and monitors, and national, supranational, and state regulations governing the handling, storage, security and recordkeeping for drug and biologic products. These CROs and other third
parties are expected to play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We expect to rely heavily on these parties for the execution of our clinical trials and
preclinical studies and will control only certain aspects of their activities. We and our CROs and other third-party contractors will be required to comply with GCP and good laboratory practice, or GLP, requirements, which are regulations and
guidelines enforced by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Regulatory authorities enforce these GCP and GLP requirements through periodic inspections of trial sponsors, principal
investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP requirements, or reveal noncompliance from an audit or inspection, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA or other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may require us to perform additional clinical trials before approving our or our partners&#146; marketing applications. We cannot
provide assurance that upon inspection by a given regulatory authority, such regulatory authority will determine whether or not any of our clinical or preclinical trials comply with applicable GCP and GLP requirements. In addition, our clinical
trials generally must be conducted with product produced under current good manufacturing practices, or cGMP, regulations. Our failure to comply with these regulations and policies may require us to repeat clinical trials, which would delay the
regulatory approval process, and adversely affect our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our CROs or clinical trial sites terminate their involvement in one of our
clinical trials for any reason, we may not be able to enter into arrangements with alternative CROs or clinical trial sites or do so on commercially reasonable terms. In addition, if our relationship with clinical trial sites is terminated, we may
experience the loss of <FONT STYLE="white-space:nowrap">follow-up</FONT> information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition,
principal investigators for our clinical trials may serve as scientific advisors or consultants to it from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related
compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities, which could delay the regulatory approval process and adversely affect our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for a
product candidate, our products will remain subject to continuous subsequent regulatory obligations and scrutiny. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our product candidates are
approved, they will be subject to ongoing regulatory requirements for pharmacovigilance, manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies (if any) and submission of
other post-market information, including both federal and state requirements in the United States and equivalent requirements of comparable regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA, and comparable regulatory authority requirements, including
ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP regulations and adherence to
commitments made in any marketing authorization application, or MAA. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we or our collaboration partners receive for our product candidates may be subject to limitations on the approved
conditions of use for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional data generation, including clinical trials. We will be required to report certain adverse
reactions and production problems, if any, to the FDA and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable regulatory authorities, and to conduct surveillance to monitor the safety and efficacy of the product candidate. Any new legislation addressing drug safety or biologics issues could
result in delays in product development or commercialization or increased costs to assure compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will have to comply with requirements concerning
advertising and promotion for our product candidates, if approved. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions that vary throughout the world and must be consistent with
the information in the product&#146;s approved label. As such, we may promote our products in ways that are not consistent <FONT STYLE="white-space:nowrap">with&nbsp;FDA-approved&nbsp;labeling,</FONT> e.g., for indications or uses for which they do
not have approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a regulatory authority discovers previously unknown problems with one of our products such as adverse events of unanticipated
severity or frequency, or if there are problems with the facility where the product is manufactured or the regulatory authority disagrees with the advertising, promotion, marketing or labeling of a product, such regulatory agency may impose
restrictions on that product or us. If we fail to comply with applicable regulatory requirements, a regulatory authority such as FDA may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refer a case to the U.S. Department of Justice to impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin proceedings to suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue an import alert; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend our ongoing clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications (including supplements to approved applications) submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ask us to initiate a product recall; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refer a case to the U.S. Department of Justice to seize and forfeit products or obtain an injunction imposing
restrictions on our operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law or regulations could require us to expend
significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products.
If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of us and our operating results will be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not successful in discovering, developing, and commercializing additional product candidates beyond our current portfolio, our ability to
expand our business and achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to discover, develop, and potentially
commercialize additional product candidates beyond our current portfolio to treat various conditions in a variety of therapeutic areas. We intend to do so by investing in our own drug discovery efforts, exploring potential strategic alliances for
the development of new products, and <FONT STYLE="white-space:nowrap">in-licensing</FONT> technologies. Identifying new product candidates requires substantial technical, financial, and human resources. We may fail to identify promising product
candidates and, even if we do identify such product candidates, we may fail to successfully develop and commercialize such product candidates for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates we develop may be covered by third parties&#146; patents or other intellectual property and
proprietary rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be incapable of producing a product candidate in commercial quantities at an acceptable cost, or at all;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an approved product may not be accepted as safe and effective by patients, the medical community or third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have several early-stage programs in preclinical development as we seek to expand our pipeline. Preclinical development
programs in the biotechnology industry carry high risk of failure. If any of these programs fails due to, among others, adverse formulation, pharmacokinetic, pharmacodynamics, or safety, we may need to terminate the program. If we are unsuccessful
in identifying and developing additional product candidates and progressing those into clinical development, our potential for growth may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we
focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates
for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate
through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. As a result of the foregoing, our
business, operations and prospects could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may choose to discontinue developing or commercializing any of our
product candidates, or may choose to not commercialize product candidates in approved indications, at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time, we may decide to discontinue the development of any of our product candidates for a variety of reasons, including the appearance of
new technologies that make our product candidates obsolete, competition from a competing product, cost concerns, manufacturing challenges, analysis of preclinical and clinical trial results or changes in or failure to comply with applicable
regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to have allocated those resources to potentially more
productive uses. As a result, our business, financial condition, results of operations and growth prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related
to our manufacturing activities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience manufacturing any of our product candidates at a commercial scale. If we or any of our
third-party manufacturers encounter difficulties in production, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be
delayed or stopped, or we may be unable to establish a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product
candidates, or supply commercial products, if approved, we need to manufacture them in small and large quantities. The manufacturing processes for <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05</FONT> have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
never been tested at commercial scale, and the process validation requirement (the requirement to consistently produce the active pharmaceutical ingredient used in&nbsp;these drug candidates in
commercial quantities and of specified quality on a repeated basis and document our ability to do so) for each of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and
<FONT STYLE="white-space:nowrap">OCS-05</FONT> has not yet been satisfied. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at
all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If our manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and
quantity, the development, testing and clinical trials of our product candidates may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly
harm our business. The same risks would apply to any internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process for any products that we may develop is subject to FDA, European Commission, NMPA and other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority approval processes and continuous oversight. We will need to contract with manufacturers who can meet all applicable FDA, European Commission, EMA, NMPA and other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority requirements, including complying with current good manufacturing practices, or cGMPs, regulations on an ongoing basis. If we or our third-party manufacturers are unable to reliably
produce products to specifications acceptable to the FDA, European Commission, EMA, NMPA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for
any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, NMPA or other regulatory authorities, to produce it in sufficient
quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more
clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> a biologic, is highly complex, costly and requires substantial lead
time to produce. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing <FONT STYLE="white-space:nowrap">OCS-02,</FONT> a biologic, involves complex processes, including developing cells
or cell systems to produce the biologic, growing large quantities of such cells, and harvesting and purifying the biologic produced by them. These processes require specialized facilities, highly specific raw materials and other production
constraints. As a result, the cost to manufacture a biologic is generally far higher than traditional small molecule chemical compounds, and the biologics manufacturing process is less reliable and is difficult to reproduce. Because of the complex
nature of this product candidate, we need to oversee manufacture of multiple components that require a diverse knowledge base and specialized personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as <FONT STYLE="white-space:nowrap">OCS-02</FONT> generally
cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple
steps to attempt to control our manufacturing process to assure that the process works and the product or product candidate is made strictly and consistently in compliance with the process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor
or operator error, improper storage or transfer, inconsistency in yields and variability in product characteristics. Even minor deviations from normal manufacturing, distribution or storage processes could result in reduced production yields,
product defects and other supply disruptions. Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A
material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates could adversely impact or disrupt commercialization. Production of additional drug substance and drug product for <FONT STYLE="white-space:nowrap">OCS-02</FONT> may require
substantial lead time. In the event of significant product loss and materials shortages, we may be unable to produce adequate amounts of our product candidates or products for our operational needs, which would materially adversely affect our
business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, as product candidates are developed through preclinical studies to late-stage clinical
trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that
they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. We and our third-party
manufacturing partner are engaged in efforts to reduce the expected costs for <FONT STYLE="white-space:nowrap">OCS-02.</FONT> In the future, if the proposed manufacturing plans to reduce <FONT STYLE="white-space:nowrap">OCS-02</FONT> costs does not
succeed when producing <FONT STYLE="white-space:nowrap">OCS-02</FONT> at commercial scale, we may not be able to proceed with <FONT STYLE="white-space:nowrap">OCS-02</FONT> commercialization, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of the foregoing could potentially materially adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our future commercialization activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for
commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial successes of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> or
<FONT STYLE="white-space:nowrap">OCS-05,</FONT> if approved, will depend significantly on attaining broad adoption and use of the products by physicians and patients for approved indications, and any of these product candidates may not be
commercially successful even if shown to be effective in clinical trials. The degree and rate of physician and patient adoption of a product, if approved, will depend on a number of factors, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient demand for approved products that treat the indication for which they are approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efficacy and potential advantages compared to alternative treatments, including the existing standard of care;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments and willingness to pay on the part of patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurers&#146; willingness to see the applicable indication as a disease worth treating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proper administration by physicians or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient satisfaction with the results, administration and overall treatment experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or contraindications, warnings, precautions or approved indications for use different than those
sought by us that are contained in the final <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities-approved labeling for the applicable product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority&#146;s requirement to
undertake a risk evaluation and mitigation strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, and
distribution efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about a product or favorable publicity about competitive products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new government regulations and programs, including price controls and/or limits or prohibitions on ways to
commercialize drugs, such as increased scrutiny on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of pharmaceuticals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims or other product-related litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> <FONT
STYLE="white-space:nowrap">OCS-05,</FONT> or any future product candidate, we may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could
make it difficult for us to sell our product candidates profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement approval for a product from a government
or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data to the payor. There may be significant delays in obtaining such coverage and reimbursement
for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Moreover, eligibility for coverage
and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new
products, if applicable, may also not be sufficient to cover costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels
already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any
future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors in the United States often
rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Pricing and reimbursement outside of
the United States vary widely and are constantly evolving, with requirements and limitations becoming increasingly strict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement by
a third-party payor or competent foreign authority may depend upon a number of factors, including the third-party payor&#146;s or competent foreign authority&#146;s determination that use of a product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available,
what the level of reimbursement will be. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our
operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand
for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors or competent foreign authorities to reimburse all or
part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and
adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or
subsequently become available. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures in connection with the
sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly
prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and
implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed and the pricing review period only
begins after marketing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available
therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a
particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that
country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any
product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not
have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we
must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities
with our collaborators for, some of our product candidates if and when they are approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own
commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch.
If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred
these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any approved product on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs and other support personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product
revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our
product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively.
If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved, which would materially adversely affect
our business, results of operations, financial condition and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in others
discovering, developing or commercializing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug
products are highly competitive. We face competition with respect to our product candidates that we may seek to develop or commercialize, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.
Potential competitors may also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development,
manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The diabetic macular edema market is already served by multiple approved products, such as ranimizumab, aflibercept,
brolucizumab, faricimab VEGF inhibitors as well as dexamethasone and fluocinolone acetonide intravitreal implants. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it
difficult to convince these parties to switch <FONT STYLE="white-space:nowrap">to&nbsp;OCS-01.&nbsp;Companies</FONT> that we are aware are developing therapeutics for diabetic macular edema include large companies with significant financial
resources, such as Roche (Genentech), Novartis, Bayer, Regeneron, Abbvie (Allergan), and Alimera Sciences. In addition, <FONT STYLE="white-space:nowrap">OCS-01</FONT> will compete with the current status quo practice of treating diabetic macular
edema, which is often observing and not treating milder patients before they often progress to invasive treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-operative inflammation and
pain market is already served by multiple approved steroid products, such as difluprednate ophthalmic emulsion, loteprednol etabonate ophthalmic gel and suspension, prednisolone acetate ophthalmic suspension, among others. These drugs are well
established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch <FONT STYLE="white-space:nowrap">to&nbsp;OCS-01.&nbsp;Companies</FONT> that we are aware
are developing therapeutics for post-operative inflammation and pain include large companies with significant financial resources, such as Bausch and Lomb, Kala Pharmaceuticals, Alcon Laboratories, Abbvie (Allergan), TEVA, Novartis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dry eye disease market is already served by multiple approved products, such as Cyclosporine ophthalmic
emulsion and solution, lifitegrast ophthalmic solution, loteprednol etabonate ophthalmic suspension, varenicline solution. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may
make it difficult to convince these parties to switch <FONT STYLE="white-space:nowrap">to&nbsp;OCS-02.&nbsp;Companies</FONT> that we are aware are developing therapeutics for dry eye disease include large companies with significant financial
resources, such as Abbvie (Allergan), Sun Pharmaceuticals, Novartis, Kala Pharmaceuticals and Oyster points. In addition, over the counter products are currently available for the treatment of dry eye disease which may impact sales of our products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis market is already served by multiple approved steroid products indicated to
treat inflammation of the eyes, such as prednisolone acetate suspension, loteprednol etabonate ophthalmic formulations, dexamethasone sodium phosphate formulations, fluorometholone ophthalmic suspension, among others. These drugs are well
established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch <FONT STYLE="white-space:nowrap">to&nbsp;OCS-02.&nbsp;Companies</FONT> that we are aware
are developing therapeutics for <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis include large companies with significant financial resources, such as Abbvie (Allergan), Bausch and Lomb, Novartis, among others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The glaucoma market is already served by multiple approved drug classes to reduce elevated intraocular pressure, such as Alpha Agonists, Beta Blockers
Carbonic Anhydrase Inhibitors, Cholinergic (Myotic), Prostaglandin Analogs, Rho Kinase Inhibitors and combination products. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may
make it difficult to convince these parties to switch <FONT STYLE="white-space:nowrap">to&nbsp;OCS-05.&nbsp;Companies</FONT> that we are aware are developing therapeutics for glaucoma include large companies with significant financial resources,
such as Novartis, Abbvie (Allergan), Bausch and Lomb, Akorn, Teva Pharmaceuticals, Pfizer, Merck, Sun Ophthalmics, Pharmaceuticals, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to competition from other companies targeting the diseases which we target, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies or drug delivery devices. Our commercial
opportunity for any of our product candidates could also be reduced or eliminated if our competitors develop and commercialize new products that are safer, more effective, are more convenient, or are less expensive than our products. The competitors
also may obtain FDA or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approval for their products more rapidly than we may obtain approval for our candidates, which could result in competitors establishing a strong market position
before we are able to enter the market for a new product candidate. If our product candidates are not perceived as more effective, safe, cost-effective, or otherwise medically beneficial than current practices or products in their respective target
market segments, then our commercial opportunities will be negatively impacted. If we are unable to demonstrate the value of our product candidates based on our clinical data, patient experience, or real-world evidence, future successful
commercialization of such product candidates could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our ability to compete may be affected in many cases by insurers
or other third-party payors, including Medicare and equivalent foreign health insurance programs, seeking to encourage the use of generic products. For example, a generic version of
Restasis<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;to treat dry eye disease received FDA approval in February 2022. Generic products are generally offered at lower prices than branded products, and consequently, after the
introduction of a generic competitor, a significant percentage of the sales of any branded product may be lost to the generic product. Accordingly, competition from generic products could have a material adverse impact on our ability to successfully
commercialize <FONT STYLE="white-space:nowrap">OCS-02</FONT> for dry eye disease or any other product candidate or indication, if approved, or negatively impact sales or pricing of our products or our ability to gain market acceptance or market
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our current and future competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant
competitors, including through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and
patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability
lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an
inherent risk of product liability exposure related to the use of our product candidates that we develop in clinical trials. We face an even greater risk for any products we develop and sell commercially.
<FONT STYLE="white-space:nowrap">Off-label</FONT> use or misuse of our products if and when commercialized may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, or subject us to penalties if we
fail to comply with regulatory requirements or experience unanticipated problems with any product. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial
liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal or delay of recruitment or decreased enrollment rates of clinical trial participants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or increased government regulation of clinical trial sites or entire trial programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recall or withdrawal from the market or labeling, marketing or promotional restrictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant delays in product launch; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced time and attention of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may need to purchase insurance coverage as we expand our clinical trials and should we eventually realize sales of any product candidate for which we
obtain marketing approval. Insurance coverage is increasingly expensive, restrictive and narrow. We may not be able to maintain insurance coverage at a reasonable cost, upon adequate terms or in a sufficient amount necessary to protect us against
losses due to product liability or other similar legal actions that may arise. A successful product liability claim or series of claims brought against us which substantially exceeds our insurance coverage will require us to make up the shortfall,
which may in turn require us to drawdown on our cash reserve, and harm our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our reliance on third parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may enter into collaborations with third parties for the development and commercialization of&nbsp;our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may enter into a combination of exclusive and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> collaboration arrangements with
third parties to develop or commercialize some or all of our product candidates. We also may enter into arrangements with third parties to perform these services in the United States and other jurisdictions if we do not establish our own sales,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing and distribution capabilities in the United States and other jurisdictions for our product candidates or if we determine that such arrangements are otherwise beneficial. We also may
seek collaborators for development and commercialization of other product candidates. Our likely collaborators for any sales, marketing, distribution, development, licensing or broader collaboration arrangements include large <FONT
STYLE="white-space:nowrap">and&nbsp;mid-size&nbsp;pharmaceutical</FONT> companies, regional and national pharmaceutical companies and biotechnology companies. While we are not currently party to any such arrangement, our ability to generate revenues
from these arrangements will depend on our collaborators&#146; abilities and efforts to successfully perform the functions assigned to them in the future in these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations that we enter into may pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may have significant discretion in determining the amount and timing of efforts and resources that
they will apply to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates that receive marketing
approval or may elect not to continue or renew development or commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an
acquisition, that divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights,
contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product
candidates, or might result in litigation or arbitration, any of which would divert management attention and resources and be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property or proprietary rights or may use our
intellectual property or proprietary rights in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary rights or expose us to potential litigation and liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third
parties, which may expose us to litigation and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most
efficient manner, or at all. If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future
research funding or milestone or royalty payments, or be able to recover any costs and expenses incurred by us under the collaboration arrangement. If we do not receive the funding we expect, or recover any costs and expenses incurred under these
agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described
herein also apply to the activities of our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to
be involved in a business combination, it might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult
to attract new collaborators and our perception in the business and financial communities could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely completely on third-party
contractors to supply, manufacture and distribute clinical drug supplies for our product candidates, which may include sole-source suppliers and manufacturers; we intend to rely on third parties for commercial supply, manufacturing and distribution
if any of our product candidates receives regulatory approval and for any future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have, nor do we plan to
acquire, the infrastructure or capability to supply, store, manufacture or distribute preclinical, clinical or commercial quantities of drug substances or products. Additionally, we have not entered into a long-term commercial supply agreement to
provide us with such drug substances or products. As a result, our ability to develop our product candidates is dependent, and our ability to supply our products commercially will depend, in part, on our ability to obtain the active pharmaceutical
ingredients, or APIs, and other substances and materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient
quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply and other technical relationships with these third parties, and if we are unable to seek suitable replacements in a timely manner or at
all, we may face delays or be unable to continue to develop or commercialize our products and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have direct control over
whether or not our contract suppliers and manufacturers will maintain current pricing terms, be willing to continue supplying us with APIs and finished products or maintain adequate capacity and capabilities to serve our needs, including quality
control, quality assurance and qualified personnel. We are dependent on our contract suppliers and manufacturers for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> compliance with applicable laws and cGMP
regulations for production of both APIs and finished products. If the safety or quality of any product or product candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to
commercialize or obtain regulatory approval for the affected product or product candidate successfully, and we may be held liable for injuries sustained as a result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to establish any further agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party or us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible early termination of the agreement by us at a time that requires us to pay a cancellation fee;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and
related reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to produce required volume in a timely manner and to quality standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the
failure of our third-party manufacturers, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of
approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and harm our business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have
arrangements in place for redundant supply for any of our product candidates. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in
identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By relying on third-party manufacturers for outsourced, custom manufacturing, we may encounter difficulties in production, particularly with respect to
formulation, process development or scaling up of manufacturing capabilities. If we, or our CMOs, encounter such difficulties, our ability to provide supply of our product candidates for preclinical studies, clinical trials or our products for
patients, if approved, could be delayed or halted, or we may be unable to maintain a commercially viable cost structure, which would materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third-party suppliers on which we rely fail to successfully scale up their production of our product candidates, we may face delays and lost
opportunities with our development or future commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to conduct larger or late-stage clinical trials for a product
candidate and supply sufficient commercial quantities of the resulting drug product and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce our drug substances and product
candidates in larger quantities more cost-effectively and, in certain cases, at higher yields than they currently achieve. If our third-party contractors are unable to scale up the manufacture of any of our product candidates successfully in
sufficient quality and quantity and at commercially reasonable prices, or are shut down or put on clinical hold by government regulators, and we are unable to find one or more replacement suppliers or manufacturers capable of production at a
substantially equivalent cost in substantially equivalent volumes and quality, and we are unable to transfer the processes successfully on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any
resulting products may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements do not
guarantee that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any damage to or destruction of our third-party manufacturer&#146;s or suppliers&#146; facilities or equipment, may significantly impair
our ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers and suppliers further exposes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us to the possibility that they, or third parties with access to their facilities, will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the
manufacturing facilities of certain of our suppliers may be located outside of the United States. This may give rise to difficulties in importing our products or product candidates or their components into the United States or other countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their
inability to supply us with adequate raw materials could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers for the raw materials required for
the production of our product candidates. Our reliance on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality
and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the
quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product
candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our
suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our technology are subject, in part, to the terms and conditions of licenses granted to us by others. In
particular, we depend on licenses for development and commercialization rights to <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT> If these rights are terminated or we fail to comply with our
obligations under these agreements or any other license, collaboration or other agreement, we may be required to pay damages and we could lose intellectual property rights that are necessary for the development and protection of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently and may in the future license from third parties certain intellectual property relating to current and future product
candidates. For example, we are party to various license agreements, including with Novartis and Accure, that we depend on for rights to <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> respectively.
These agreements impose, and other potential agreements we may enter into with third parties may impose, diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. Under the Novartis
Agreement (as defined below) and Accure Agreement (as defined below), for example, we are obligated to make payments to the counterparty upon us achieving certain development or commercialization milestones and to make royalty payments to Novartis
and Accure on net product sales of <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
also have diligence and development obligations under the Novartis Agreement and Accure Agreement. Generally, these diligence obligations require us to use commercially reasonable efforts to develop, manufacture, seek regulatory approval for and
commercialize the licensed products. If we fail to comply with our obligations under current or future license agreements, use the licensed intellectual property in an unauthorized manner or otherwise breach a license agreement, our counterparties
may have the right to terminate these agreements, in which event we might not have the rights or the financial resources to develop, manufacture or market any licensed product that is covered by these agreements. Future counterparties also may have
the right to convert an exclusive license to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> in the territory in which we fail to satisfy our diligence obligations, which could materially adversely affect the value of the product candidate
being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, seek alternative
sources of financing or cause us to lose our rights under these agreements, including our rights to <FONT STYLE="white-space:nowrap">OCS-02,</FONT> <FONT STYLE="white-space:nowrap">OCS-05</FONT> or other important intellectual property or
technology. Any of the foregoing could prevent us from commercializing <FONT STYLE="white-space:nowrap">OCS-02</FONT> or <FONT STYLE="white-space:nowrap">OCS-05</FONT> or cause a competitor to gain access to the licensed technology, which could have
a material adverse effect on our operating results and overall financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our license agreements are, and future license agreements are likely to be, complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Disputes
may arise between us and our licensors or future licensors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license, or to sublicense patents and other intellectual property rights to
third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations and what activities satisfy those diligence obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by any of our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed from third parties prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing or acquisition of third-party
intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies
may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be harmed. If we are unable to obtain a necessary license, we may be unable to develop or
commercialize the affected product candidates, which could harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting sales or an obligation on our part to pay royalties and/or other
forms of compensation. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the
sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-licensed.</FONT> Some of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are sublicensed to us pursuant to parent license agreements we are not a
party to. If any such parent licenses terminate, whether due to our licensor&#146;s breach of the parent license agreement or for other reasons outside of our control, we could lose our rights to such sublicensed patent rights. Furthermore, if other
third parties have ownership rights to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, the license granted to us in jurisdictions where the consent of a <FONT STYLE="white-space:nowrap">co-owner</FONT> is necessary to grant such a
license may not be valid, in any case, and such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, certain of our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights. If one
or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be adversely affected. Any of these events could have a material adverse
effect on our competitive position, business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future licenses may not provide
us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology. Patents licensed to us could be put at risk of being invalidated or interpreted
narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be
able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses. Some of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are subject
to <FONT STYLE="white-space:nowrap">pre-existing</FONT> rights granted by the licensor to third parties and our acquired technologies and current or future licensed technology may also be subject to retained rights. Our predecessors or licensors may
retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or future licensors limit their use of the technology to these uses, and we could incur substantial
expenses to enforce our rights to our licensed technology in the event of misuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain of our current or future agreements with third
parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. If we are limited in our ability to utilize acquired technologies or
current or future licensed technologies, or if we lose our rights to critical acquired or <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, we may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT>
market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies, and current or future licensed technology, into commercial products.
Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, <FONT STYLE="white-space:nowrap">out-license</FONT> or market and sell our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on our license agreements with third parties, please see the section entitled &#147;<I>Business of Oculis&#151;Material Licenses,
Partnerships and Collaborations</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our intellectual property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain, maintain, protect and enforce patent or other intellectual property protection for our current and future technology and
products, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements to protect the intellectual property related to our development
programs and product candidates. These legal measures afford only limited protection, and competitors or others may gain access to our intellectual property and proprietary information. Our success depends in part on our ability to obtain, maintain,
expand, enforce and defend the scope of our intellectual property protection in the United States and other countries with respect to our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have sought and will continue to seek to protect our proprietary position by filing patent applications in the United States and abroad related to our
development programs and product candidates. However, the patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents or patent applications
at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. Additionally, in some instances, we have submitted and expect to
submit provisional patent applications. Corresponding <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications must be filed not later than 12 months after the provisional application filing date. While we intend to timely file <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with competitive
advantage. Any failure to obtain or maintain patent and other intellectual property protection with respect to our product candidates could harm our business, financial condition and results of operations. Additionally, although we seek to enter
into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and development output, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, our owned and exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio included 10 issued U.S.
patents, five issued European patents validated in multiple jurisdictions, and 42 issued patents in other foreign jurisdictions, as well as five pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent applications, 66 foreign
pending patent applications, including four pending European patent applications, and one pending PCT application related to our different product candidates, namely, <FONT STYLE="white-space:nowrap">OCS-01,</FONT>
<FONT STYLE="white-space:nowrap">OCS-02,</FONT> OCS-03, <FONT STYLE="white-space:nowrap">OCS-04</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT> Please see the section entitled &#147;<I>Business of Oculis and Certain Information about
Oculis &#150; Intellectual Property</I>&#148; for further details on our intellectual property portfolio. The patents and patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with
claims that protect our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a
patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or
scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful
commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our licensors will be
successful in protecting our product candidates by obtaining, maintaining, enforcing and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Patent and Trademark office, or USPTO, and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of
patent rights in the relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise
may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our products and product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also choose not to
seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in
scope. For example, we currently do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents or pending patent applications relating to <FONT STYLE="white-space:nowrap">OCS-03,</FONT> other than a pending PCT application. PCT
applications do not issue directly as patents, and national phases of such PCT application must be filed within 30 months after the earliest priority date of such PCT application. There can be no assurance that any national phases of such PCT
application will result in an issued patent, or that the claims in national phases of such PCT application will not be narrowed during prosecution or, even if issued, be broad enough to adequately cover
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">OCS-03.</FONT> It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent
protection. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we are, and
could become in the future, a licensee of a third party&#146;s patents or patent applications and we may not have the right to control the preparation, filing or prosecution of such patent applications, or to maintain, enforce or protect the patents
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from those third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, any licensed
patents or patent applications may not be prosecuted, maintained, enforced or protected in a manner consistent with the best interests of our business. We also cannot be certain that patent prosecution and maintenance activities by any of our
licensors will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If any of our licensors fail to do so, this could
cause us to lose rights in any applicable intellectual property, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and
selling competing products. In addition, even where we have the right to control the prosecution of patents and patent applications under a license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our
predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. If our current or future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of
any patent rights, such patent rights could be compromised. If disputes over intellectual property that we license prevents or impairs our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop
and commercialize the affected product candidates. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the patent applications we own, license, or may own or license in the future with respect to our development programs and product candidates fail to issue,
if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our
ability to commercialize our product candidates, if approved. Any such outcome could have a materially adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent
position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign
countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications in scientific literature often lag behind the
actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, there is a risk that we cannot know with certainty whether we
or our licensors were the first to make the inventions claimed in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or pending patent applications, or that we or our licensors were the first to file for patent protection of
such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are highly uncertain. Our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents or narrow the scope of patent protection for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we or our licensors may be subject to a third-party <FONT
STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights or the patent rights of others. In particular, the costs of defending patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be
substantial and the outcome can be uncertain. An adverse determination in any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such submission, proceeding or litigation could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, allow third parties to
commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength
of protection provided by our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications is threatened, it could dissuade companies from collaborating to license, develop or commercialize current or future product
candidates. We may not be aware of all third-party intellectual property rights potentially relating to our products, product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the
patentability of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. We cannot ensure
that we do not infringe, misappropriate or otherwise violate any patents or other intellectual property or proprietary rights held by others or that we will not infringe, misappropriate or otherwise violate intellectual property or proprietary
rights held by others in the future. If our products were found to infringe, misappropriate or otherwise violate any proprietary intellectual property or right of another party, we could be required to pay significant damages or license fees to such
party and/or cease production, marketing and distribution of those products. Litigation may also be necessary to defend infringement, misappropriation or other violation claims of third parties or to enforce patent or other intellectual property
rights we hold or protect trade secrets or techniques or other intellectual property we own. Further, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may
need to defend and/or assert our patents or other intellectual property, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents invalid, unenforceable, or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar. Even if we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and patents in which we or our licensors have an
interest may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from
the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, patent terms can be adjusted to recapture a portion of delay incurred by the USPTO in examining the patent application (patent term
adjustment). The scope of patent protection may also be limited. In addition, the laws of foreign jurisdictions may not protect our rights to the same extent as the laws of the U.S. For example, certain countries outside of the U.S. do not allow
patents for methods of treating the human body. This may preclude us from obtaining method patents outside of the U.S. having similar scope to those we have obtained or may obtain in the future in the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. The acquisition or licensing of third-party intellectual property rights is a
competitive area, and our competitors may pursue strategies to acquire or license third-party intellectual property rights that we may consider attractive or necessary, and our competitors could market competing products and technology. Our
competitors may have a competitive advantage due to their size, capital resources and greater development and commercialization capabilities. In addition, companies may be unwilling to assign or license rights to us. We also may be unable to acquire
or license third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or
maintain the existing intellectual property rights we have, we may have to abandon development of the relevant product, and our customers may be forced to stop using the relevant products. If we or our current or future licensors fail to establish,
maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to
prevent competition from third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without patent protection for our current or future product
candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval of future product candidates, one or more of our U.S. patents may be eligible for
limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal
expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). A
patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval. This extension is based on the first approved use of a product and is limited to only one patent that covers the approved product,
the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authority in other countries, may not agree with our
assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within
applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. If
we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and
preclinical data to obtain approval of competing products following our patent expiration and launch our product earlier than might otherwise be the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining intellectual property, including patent protection, depends on compliance with various procedural, document submission, fee
payment, and other requirements imposed by governmental agencies, and our intellectual property, including patent protection, could be reduced or eliminated for noncompliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming and complex. Periodic maintenance, renewal, annuity and various other fees on any issued patent are
due to be paid to the USPTO and other foreign governmental agencies in several stages over the lifetime of the intellectual property. The USPTO and various national or international agencies require compliance with a number of procedural,
documentary, fee payment, and other similar provisions during the application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in
which noncompliance can result in abandonment or lapse of the intellectual property, resulting in partial or complete loss of rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of rights include, but
are not limited to, failure to timely file national and regional stage patent applications based on our international application, failure to respond to official actions within prescribed time limits,
<FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the intellectual property covering our product candidates, our competitors may
be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of
our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party
patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current and future product candidates in any jurisdiction. The scope of a patent claim is determined by an
interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability
to market our product candidates, if approved. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#146;s pending application will issue with claims of relevant
scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to
develop and market our products. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. As the
number of competitors in the market grows and the number of patents issued in this area increases, the possibility of patent infringement claims escalates. Moreover, in recent years, individuals and groups that are
<FONT STYLE="white-space:nowrap">non-practicing</FONT> entities, commonly referred to as &#147;patent trolls,&#148; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract
settlements. From time to time, we may receive threatening letters, notices or &#147;invitations to license,&#148; or may be the subject of claims that our products and business operations infringe, misappropriate or otherwise violate the
intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management&#146;s attention and resources, damage our reputation and brand and cause us to incur significant expenses
or make substantial payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to third-party claims or litigation alleging infringement, misappropriation or other violation
of such third party&#146;s patents or other intellectual property or proprietary rights, or seeking to invalidate our patents or other intellectual property or proprietary rights, which could be costly, time consuming, and, if successfully asserted
against us, may delay or prevent the development and commercialization of any of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on
us and our licensors avoiding infringement, misappropriation and other violations of the patents and other intellectual property or proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S.,
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant
review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole
or in part, which could limit our ability to stop others from using or commercializing similar or identical products and techniques without payment, or limit the duration of the patent protection of our technology. Numerous U.S. and foreign issued
patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are
issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of
third parties. Third parties may assert that we are infringing, misappropriating or otherwise violating their patents or other intellectual property or proprietary rights or employing their proprietary technology without authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods of treatment related
to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future
product candidates may infringe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, third parties may obtain patent rights in the future and claim that use of our technologies
infringes upon their rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process, methods of treating
certain diseases or conditions that we are pursuing with our product candidates, our formulations including combination therapies, or any final product itself, the holders of any such patents may be able to block our ability to commercialize such
product candidate unless we obtained a license under the applicable patents, or until such patents expire. Such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are
infringing, misappropriating or otherwise violating other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use
intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and
commercialize one or more of our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In
the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third
parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on
commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We
may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business
significantly. We cannot provide any assurances that third-party patents or other intellectual property or proprietary rights do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting sales,
or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the course of any
intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard
these announcements as negative, the perceived value of our existing product candidates, programs or intellectual property could be diminished. Accordingly, the market price of New Parent Shares may decline. Such announcements could also harm our
reputation or the market for future products, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lawsuits or other proceedings to protect
or enforce our patents, the patents of any licensors or our other intellectual property rights could be expensive, time consuming, and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or
unauthorized use or misappropriations, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more patents of us or any of our current or future
licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings
could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring
counterclaims against us, such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or lack of statutory subject matter. Grounds for an unenforceability
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during
prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, post-grant review or oppositions or similar proceedings outside the U.S., in parallel
with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. Additionally, for any patents and patent applications that we license from third parties, we may have limited or no right to participate in the defense of such licensed patents against challenge by a third-party. If
a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could harm our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if our patents or other intellectual property or proprietary rights are found to be valid and infringed, a court may refuse
to grant injunctive relief against the infringer and instead award us monetary damages or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#146;s competition in
the market. Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our current or future owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, any patents that may be issued as
a result of our current or future owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not
in the best interest of us or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or
solution. Moreover, even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the
infringement and the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, third parties may assert infringement claims against our customers. These claims may require us to
initiate or defend protracted and costly litigation on behalf of our customers or indemnify our customers for any costs associated with their own initiation or defense of infringement claims, regardless of the merits of these claims. If any of these
claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms
or at all, our customers may be forced to stop using our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, infringement,
misappropriation or other violation of our intellectual property or other proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the
prevailing party does not offer us a license on commercially reasonable terms or at all. Any litigation or other proceedings to enforce our intellectual property or proprietary rights may fail, and even if successful, may result in substantial costs
and distract the management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of the New Parent Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. or foreign patent laws or their interpretations could diminish the value of patents in general, thereby impairing our ability to protect
our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States government has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on
several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.
Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or
that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent
laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
2011, the Leahy-Smith America Invents Act (the &#147;<I>Leahy-Smith Act</I>&#148;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications
are prosecuted and also affect patent litigation. These also include provisions that switched the U.S. from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity
of a patent by the USPTO administered post grant proceedings. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor
to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the
Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. A third-party that files a patent application in
the USPTO after March 2013, but before the Company could therefore be awarded a patent covering an invention even if the Company had made the invention before it was made by such third-party. This will require the Company to be cognizant of the time
from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, the Company cannot be certain that it was the first to file any
patent application related to its products or invent any of the inventions claimed in its patents or patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Leahy-Smith Act also
includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared
to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate the Company&#146;s patent claims that would not have been invalidated if first
challenged by the third-party as a defendant in a district court action. Therefore, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of the Company&#146;s patent applications and the
enforcement or defense of our issued patents. In addition, future actions by the U.S. Congress, the federal courts and the USPTO could cause the laws and regulations governing patents to change in unpredictable ways. The Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on the Company&#146;s business,
financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world, which could
impair our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents covering our product candidates throughout the world would be prohibitively
expensive. Furthermore, the requirements for patentability and obtaining other intellectual property protection may differ in certain countries, particularly developing countries. In addition, the laws of many foreign countries will not protect our
intellectual property or other proprietary rights to the same extent as the laws of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States. Competitors may use our technologies in jurisdictions where we have not obtained patent or other intellectual property protection to develop their own products and, further, may
export otherwise infringing products to territories where we may have or obtain patent or other intellectual property protection, but where patent or other intellectual property enforcement is not as strong as that in the United States. These
unauthorized products may compete with our products in such jurisdictions and take away our market share where we do not have any issued or licensed patents or other intellectual property protection and any future patent claims or other intellectual
property rights may not be effective or sufficient to prevent them from so competing. Our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that
our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we rely on third parties for a wide variety of services, including the manufacture
and continuing development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our trade secrets in part by entering into agreements containing confidentiality and use restrictions and obligations prior to
disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third
parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in
violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or
disclosure could impair our competitive position and may have an adverse effect on business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite our efforts to protect our
trade secrets, our competitors may discover our trade secrets, either through breach of agreements with third parties, independent development or publication of information by any of the third-party collaborators. A competitor&#146;s discovery of
our trade secrets could impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to protect the confidentiality of
our trade secrets and other proprietary information, the value of our product candidates and our business and competitive position may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information that is not patentable or that we elect not to patent. Trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade
secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of
their relationship with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements
with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. In addition, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants
and other third parties who have access to such intellectual property or other proprietary rights is difficult. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such
employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. There can be no assurance that such employees, consultants, advisors or third parties will not breach their agreements with us,
that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have infringed,
misappropriated or otherwise violated the intellectual property of a third party, including trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> of their former employers or other third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information of third
parties. We employ individuals who were previously employed at other biotechnology or pharmaceutical companies, or at research institutions. Some of these employees, consultants and contractors may have executed proprietary rights, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the
intellectual property rights, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us and seek to protect our ownership of intellectual property rights by ensuring that our agreements
with employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent
contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former employers or other third parties. To the extent that our employees, consultants or contractors use intellectual property rights or
proprietary information owned by others in their work for us, disputes may arise as to the rights in any related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. We may also be subject to claims that former employers or
other third parties have an ownership interest in our patents or other intellectual property or proprietary rights. Litigation may be necessary to defend against any of these claims. There is no guarantee of success in defending these claims, and if
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. In addition, we may lose personnel as a
result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. Even if we are successful, litigation could result in substantial cost and be a
distraction to our management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to validly execute invention assignment agreements with our employees and contractors
involved in the development of intellectual property, the value of our products, business and competitive position may be harmed. Our patent rights and other intellectual property may also be subject to priority, ownership or inventorship disputes,
interferences, and similar proceedings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To maintain the confidentiality of our trade secrets, proprietary information and other intellectual
property rights, we generally have confidentiality and invention assignment provisions in place with our employees, consultants, suppliers, contract manufacturers, collaborators, and others upon the commencement of a relationship. However, we may
not enter into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes or who conceives or develops intellectual property rights that we regard as our own. Moreover, even when we
obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing, and we may be forced to bring claims against third parties or defend claims that they may bring against us to
determine the ownership of what we regard as our intellectual property. There can be no assurance that such agreements will be upheld in the face of a potential challenge or that third parties will not breach their agreements with us, or that we
will have adequate remedies for any breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be subject to claims that former employees, collaborators, or other third parties have an
interest in our current or future patents and patent applications or other intellectual property rights, including as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> If we are unable to obtain an exclusive license to any such
third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents and patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> rights may be subject, or in the future subject, to assignment or license to
other third parties, including competitors. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> to enforce any such patents and any patents issuing from such patent applications against third
parties, and such cooperation may not be provided. Additionally, we may be subject to claims from third parties challenging our ownership interest in or inventorship of intellectual property we regard as our own, for example, based on claims that
our agreements with employees or consultants obligating them to assign intellectual property rights to us are ineffective or in conflict with prior or competing contractual obligations to assign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inventions to another employer, to a former employer, or to another person or entity, despite the inclusion of valid, present-tense intellectual property assignment obligations. Litigation may be
necessary to defend against claims, and it may be necessary or we may desire to enter into a license to settle any such claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors are
unsuccessful in any priority, validity (including any patent oppositions), ownership or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our patents, or such
patent claims may be narrowed, invalidated, or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. In the event of loss of patent
rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be
available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of
one or more of the product candidates we may develop. An inability to incorporate technologies, features or other intellectual property that are important or essential to our products could have a material adverse effect on our business and
competitive position. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we are successful in priority,
inventorship or ownership disputes, such disputes could result in substantial costs and be a distraction to management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with
independent sales representatives. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to our current and future product candidates we intend to
commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any of our future licensors or collaborators might not have been the first to make the inventions covered
by the issued patents or pending patent applications that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any of our current or future licensors or collaborators might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing, misappropriating or otherwise violating our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may have access to the same intellectual property rights licensed to us on a nonexclusive basis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our future patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may not provide us with any
competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major
commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to seek patent protection for some of our proprietary technology to maintain certain trade
secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our current and future trademarks and trade names are not adequately protected, then we may not
be able to build name recognition in our markets and markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use registered
or unregistered trademarks or trade names to brand and market our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our
rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in the markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the
USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In the event that our trademarks are successfully challenged, we could be forced to
rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third
parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.
At times, competitors may adopt trade names or trademarks similar to us, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims
brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how
trademarks and trade names may be used, a breach of these agreements or misuse of such trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to
enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could
adversely affect our business, growth prospects, operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to government regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities are highly complex, lengthy, and
inherently unpredictable. If we are unable to obtain regulatory approval for our product candidates, or to do so in a timely manner, we will be unable to generate product revenue and our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The processes that must be followed to obtain approval by the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to market a
pharmaceutical product are highly complex and unpredictable, and typically take many years following the commencement of clinical trials. A company&#146;s ability to obtain such an approval, and the time necessary to obtain it, depends
upon<B><I></I></B>&nbsp;numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during
the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval
process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any
regulatory filing for our product candidates, the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally
requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, development of a company&#146;s product candidates and/or regulatory approval may be impacted or delayed by events beyond our
control. For example, events such as a U.S. federal government shutdown or budget </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sequestration, such as ones that occurred during 2013, 2018 and 2019, or the FDA&#146;s diversion of resources to handle
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;SARS-CoV-2</FONT></FONT> virus public health emergency and pandemic, may result in significant reductions to the FDA&#146;s budget, employees and operations, and could lead
to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. In addition, the impact
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;SARS-CoV-2</FONT></FONT> virus pandemic&nbsp;may cause the FDA to allocate additional resources to product candidates focused on treating related illnesses, which could lead
to longer approval processes for our product candidates. Moreover, our competitors may file citizens&#146; petitions with the FDA in an attempt to persuade the FDA that our product candidates, or the clinical trials that support their approval,
contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any of our NDAs or biologics license applications, or BLAs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may disagree with the design,
implementation, or results of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may determine that our product
candidates are not safe and effective, are insufficiently effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy
and safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may disagree with our
interpretation of data from preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities that a product candidate&#146;s risk-benefit ratio for our proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may fail to approve the
manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities may significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This complex and lengthy
approval process, as well as the unpredictability of the results of clinical trials, may result in us failing to obtain regulatory approval to market any of our product candidates, or a failure to obtain such approval in a timely manner, which could
materially adversely affect our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face difficulties in
commercializing and achieving reimbursement of our products from changes to current regulations and future legislation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the
European Union and other jurisdictions there have been a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. We cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are unable to maintain regulatory compliance, we may be unable to successfully commercialize our products, and may not achieve or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
Education Reconciliation Act of 2010 (or collectively, the &#147;<I>ACA</I>&#148;), substantially affects the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA
contains provisions that can reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D
beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. There have been extensive judicial, Congressional and executive branch challenges to certain aspects of the ACA, as well as efforts
and proposals to revise or repeal the law and its application, to control the prices at which pharmaceutical products are sold, and to implement other healthcare reform measures. Such efforts can be expected to continue in the future, but it is
unclear what measures will be enacted or implemented, or how they might affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative and administrative changes
have been adopted in the United States in recent years, and others continue to be proposed. These changes include reductions to payments made under the Medicare program. In addition, during 2021, the Biden administration proposed additional
potential legislative and administrative actions to, among other things, reform drug pricing. For example, in July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple
provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, the U.S Department of Health and Human Services (&#147;<I>HHS</I>&#148;) released a Comprehensive Plan for Addressing High Drug Prices
that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or
administrative actions have been finalized to implement these principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These recent laws, administrative decisions and proposals, and any new ones
that follow, may result in additional reductions in Medicare payments and other healthcare funding, which could have a material adverse effect on customers for our products and product candidates, if approved, and accordingly, on our results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform measures that have been adopted, or may be adopted in the future, could
result in more rigorous healthcare insurance coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a
similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if
approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union and other countries, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or
obstacles that may increase our operating costs. In most EU member states, healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with
ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to
commercialize our product candidates, if approved. Moreover, in the European Union, some EU member states may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product to currently available
therapies. This Health Technology Assessment, or HTA, which is currently governed by the national laws of the individual EU member states, is the procedure according to which the assessment of the public health impact, therapeutic impact and the
economic and societal impact of use of a given medicinal product in the national </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal product will often influence the pricing and reimbursement status granted to these
products by the competent authorities of individual EU member states. On December&nbsp;15, 2021, the Health Technology Regulation, or HTA Regulation, was adopted. The HTA Regulation is intended to boost cooperation among EU member states in
assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. When it enters into application in 2025, the HTA Regulation will be intended to
harmonize the clinical benefit assessment of HTA across the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval
requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA, European Union, or other jurisdictions&#146; regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by, for example, United States Congress of the FDA approval process may
significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not conclude that <FONT STYLE="white-space:nowrap">OCS-01</FONT> satisfies the requirements for the Section&nbsp;505(b)(2) regulatory
approval pathway, or if the requirements under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for <FONT STYLE="white-space:nowrap">OCS-01</FONT> will likely take significantly longer, cost significantly more and entail
significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to seek FDA approval through the
Section&nbsp;505(b)(2) regulatory pathway for <FONT STYLE="white-space:nowrap">OCS-01.</FONT> The Hatch-Waxman Amendments added Section&nbsp;505(b)(2) (&#147;<I>Section 505(b)(2)</I>&#148;) to the Federal Food, Drug and Cosmetic Act (the
&#147;<I>FDCA</I>&#148;). Section&nbsp;505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not
obtained a right of reference. Section&nbsp;505(b)(2), if applicable to us under the FDCA, would allow an NDA to rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and effectiveness of approved drug
products, which could expedite the development program for <FONT STYLE="white-space:nowrap">OCS-01</FONT> by potentially decreasing the amount of preclinical or clinical data that we would need to generate in order to obtain FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot pursue the Section&nbsp;505(b)(2) regulatory pathway for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> we may need to conduct additional
clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> and complications and risks associated with <FONT STYLE="white-space:nowrap">OCS-01,</FONT> would likely substantially increase. Moreover, our inability to pursue the Section&nbsp;505(b)(2) regulatory
pathway would likely result in new competitive products reaching the market more quickly than <FONT STYLE="white-space:nowrap">OCS-01,</FONT> which would likely adversely impact our competitive position and prospects. Even if we can pursue the
Section&nbsp;505(b)(2) regulatory pathway, we cannot assure you that <FONT STYLE="white-space:nowrap">OCS-01</FONT> will receive the requisite approvals for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the approval of products by the FDA under Section&nbsp;505(b)(2), certain pharmaceutical companies and others have objected to
the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If the FDA&#146;s interpretation of Section&nbsp;505(b)(2) is successfully challenged, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from
approving any NDA that we submit under Section&nbsp;505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of
previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to thirty (30)&nbsp;months or longer depending on the outcome of
any litigation. It is not uncommon for the owner of the NDA of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such
petitions could significantly delay, or even prevent, the approval of a new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considers and responds to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to earlier
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, even if <FONT STYLE="white-space:nowrap">OCS-01</FONT> is approved under Section&nbsp;505(b)(2), the approval may be subject to
limitations on the indicated uses for which the product may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The U.S. Government and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities actively enforce laws and regulations regarding the
promotion of pharmaceutical products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other U.S. Government agencies and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities strictly regulate the manner in which prescription products may be marketed. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s
approved labeling. In addition, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such laws, and the application of those laws, are complex and
evolving. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted the sale of any of our product candidates, if approved, such as through the promotion of the <FONT
STYLE="white-space:nowrap">off-label</FONT> use of those products, or through kickbacks or fraud, or through any other conduct or activity deemed to be unlawful, then we may become subject to significant liability. For example, if we receive
marketing approval for a product as a treatment for a disease, physicians may nevertheless choose to prescribe the product for their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent
injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely
affect our business, growth prospects, operating results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, the advertising and promotion of medicinal products are
subject to both EU and EU member states&#146; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. Although general
requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in individual EU member states and can differ from one country to another. For example, applicable laws
require that promotional materials and advertising in relation to medicinal products comply with the product&#146;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities in connection with a marketing authorization.
The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT> and is
prohibited in the EU. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicinal products is also prohibited in all EU member states. The competent regulatory authorities
in the EU actively enforce the laws and regulations governing promotion of medicinal products. If we are found to have undertaken improper promotional activities we may be subject to significant civil, criminal and administrative penalties, which
could materially adversely affect our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent
contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers,
vendors and other third parties with which we do business may engage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in misconduct or other improper activities. Misconduct by these parties could include failures to comply with federal and state health care fraud and abuse laws and regulations and equivalent
foreign laws, FDA regulations and equivalent regulation of foreign authorities, requirements to provide accurate information to the FDA or equivalent foreign authorities, data privacy and security laws and requirements to accurately report financial
information or data or to disclose unauthorized activities to us. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm
to our reputation. Although we have adopted a code of business conduct and ethics with respect to our employees, agents and contractors, it is not always possible to identify and deter misconduct by these parties, and the precautions we take to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion
from participation in government funded healthcare programs, such as Medicare and Medicaid and equivalent foreign health insurance programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits
and future earnings and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates
in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. The FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may not accept data
from trials conducted in locations outside of their jurisdiction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product candidates in one
jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA approves a drug candidate for an indication in the U.S., comparable regulatory authorities in
foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product in those countries. In addition, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the U.S., including additional preclinical studies or clinical trials,
since clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for
sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals and establishing and maintaining compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements could result in significant difficulties and costs for us and
could delay or prevent the introduction of our product candidates, if approved, in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing
approvals, then our target market will be reduced and our ability to realize the full market potential of our product candidates, if approved, will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and future relationships with healthcare professionals, clinical investigators, consultants, patient organizations,
customers, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health
information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished
profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product
candidates for which we obtain marketing approval. Our current and future arrangements with healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
professionals, including physicians, clinical investigators, CROs, third-party payors and customers may expose it to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and
regulations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good
or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by
private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for
payment that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Food Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of
drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, state laws that require biotechnology
companies to comply with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws that require biotechnology companies to report information on the pricing of certain drug products, state and local laws that require the
registration of pharmaceutical sales representatives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things,
executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value
to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals as well as information regarding
ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their
implementing regulations, also imposes obligations, including mandatory contractual terms, on &#147;covered entities,&#148; including certain healthcare providers, health plans, healthcare clearinghouses, and their respective &#147;business
associates&#148; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information, as well as analogous state and foreign laws that govern the privacy and security of health </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some state laws require biotechnology companies to comply with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require
biotechnology companies to report information on the pricing of certain drug products. Certain state and local jurisdictions require the registration of pharmaceutical sales representatives. State, federal and foreign laws also govern the privacy
and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will
involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including the provision of compensation for consulting services to physicians and other healthcare providers, some of whom may
be in a position to recommend, purchase and/or prescribe our product candidates, if approved, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations, contractual
damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel
resources. Therefore, even if we are successful in defending against any such actions that may be brought against it, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do
business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which could have an adverse effect on our business
and reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities are subject to the FCPA and similar anti-bribery and anti-corruption laws of other countries in which we
operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate
them. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may conduct clinical trials in countries other than the United States. In addition, we have entered into a license agreement with Accure,
a biotechnology company headquartered in Barcelona, Spain. Our business activities are subject to the U.S. Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of Switzerland and other
countries in which we operate. Anti-corruption laws, including the FCPA, generally prohibit offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a government official in order to influence
official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system
of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, potentially including officials of foreign governments. Additionally, although none of our product candidates is
yet approved for sale in any country, in many countries other than the U.S., the healthcare providers who prescribe pharmaceuticals like our product candidates are employed by their government, and the purchasers of pharmaceuticals are government
entities. Therefore, any future dealings by us with these prescribers and purchasers may be subject to regulation under the FCPA and other applicable anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC and Department of Justice have increased their FCPA enforcement activities with respect to
biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable <FONT STYLE="white-space:nowrap">anti-corruption</FONT> laws and
regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, the closing down of our facilities, cessation
of business activities in certain countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products, if approved, in one or more
countries and could materially damage our reputation, our brand, international activities, our ability to attract and retain employees and our business, growth prospects, operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the
import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory
requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, export control laws and
economic sanctions may prohibit the shipment of certain products and services to specified countries, governments, and persons. If we fail to comply with export and import regulations and such economic sanctions, we may be fined or other penalties
could be imposed, including a denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or
technologies targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export products to existing or potential customers with international operations. Any decreased use of our products or
limitation on our ability to export or sell access to our products could adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA, the SEC and other
government agencies and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to review and approve
new products can be affected by a variety of factors, including government budget and funding levels, our ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory, and policy changes, and other events that
may otherwise affect the ability of the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to perform routine functions. Average review times at the FDA and comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund
research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA, other
agencies, and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may slow the time necessary for new drugs to be reviewed or approved, which could adversely affect our business. For example, in recent years, including
in 2013, 2018 and 2019, the U.S. government shut down several times, and in 2020 and 2021 the FDA diverted significant resources to handle <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;SARS-CoV-2</FONT></FONT> virus
public health emergency and pandemic. Certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees for a time, and to stop critical activities in response to such events, and may be
required to do so again in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If such disruptions recur, or if a prolonged government shutdown occurs, it could significantly impact the ability
of the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a
public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, future government disruptions or shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that
could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal,
state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials
and waste; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive
materials. Our operations also may produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating
to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our
research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or waste. Although we maintain workers&#146; compensation insurance to cover us
for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not currently maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with storage or disposal of hazardous and flammable materials, including chemicals and biological materials. Accordingly, in the event of contamination or
injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on business, financial
condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future
environmental, health and safety laws and regulations. These current or future laws and regulations may impair research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial
fines, penalties or other sanctions that could have a material adverse effect on our business, reputation and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to
domicile in Switzerland and being foreign private issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Parent is a Swiss stock corporation. The rights of its shareholders may be
different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent is a Swiss stock corporation. Its
corporate affairs are governed by its articles of association and by the laws governing companies, including listed companies, incorporated in Switzerland. The rights of its shareholders and the responsibilities of members of the New Parent Board
may be different from the rights and obligations of shareholders and directors of companies governed by the laws of the United States. In the performance of its duties, its board of directors is required by Swiss law to consider the interests of New
Parent, and may also have regard to the interests of its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have
interests that are different from, or in addition to, your interests as a shareholder. Swiss corporate law limits the ability of New Parent&#146;s shareholders to challenge resolutions made or other actions taken by its board of directors in court.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent&#146;s shareholders generally are not permitted to file a suit to reverse a decision or an action
taken by the New Parent Board, but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of New Parent&#146;s board of directors for breach of fiduciary duty would
have to be brought to the competent courts at the registered office of the New Parent, currently in Zug, Switzerland,. In addition, under Swiss law, any claims by its shareholders against New Parent must be brought exclusively to the competent
courts at the registered office of New Parent, currently in Zug, Switzerland. U.S.-style class actions and derivative actions are not available under Swiss law. A further summary of applicable Swiss corporate law is included in this prospectus,
please see the sections entitled &#147;<I>Description of New Parent Securities and Proposed Articles of Association</I>&#148; and &#147;<I>Comparison of Shareholder Rights</I>.&#148; There can be no assurance that Swiss law will not change in the
future, which could adversely affect the rights of our shareholders, or that Swiss law will protect New Parent&#146;s shareholders in a similar fashion as under U.S. corporate law principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The registration of share capital increases in the commercial register may be blocked and the shareholders&#146; resolutions regarding the ordinary and
authorized share capital increases may be challenged. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the completion of the Business Combination, our shareholders will
approve an ordinary share capital increase and the introduction of a capital band as well as conditional share capital. The execution of the share capital increases by our board of directors and the related filings will be made prior to the
completion of this offering. As with all share capital increases in Switzerland, the shareholders&#146; resolutions regarding such share capital increases may be challenged in court within two months after such shareholders&#146; meeting and/or the
registration of the capital increases in the commercial register may be blocked temporarily by a preliminary injunction or permanently by order of a competent court. Either action would prevent or delay the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The New Parent Shares are not listed in Switzerland, our home jurisdiction. As a result, certain Swiss law provisions designed to protect shareholders
in the event of a public takeover offer or change of control transaction will not apply. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Swiss rules that require investors to disclose their
interest in a company if they reach, exceed or fall below certain ownership thresholds only applies to issuers that have a listing (including a secondary listing) for their equity securities in Switzerland. Since the New Parent Shares will be listed
exclusively on The Nasdaq Global Market, a U.S. market, the disclosure obligations regarding major shareholdings according to art. 120 of the Swiss Financial Markets Infrastructure Act and its implementing provisions do not apply to New Parent.
Likewise, the Swiss takeover regime does not apply to New Parent. In particular, the duty to make a mandatory bid offer for all outstanding listed equity securities of a company by any person or group of persons that acquires more than one third of
a company&#146;s voting rights does not apply to New Parent. In addition, the Swiss takeover regime imposes certain restrictions and obligations on bidders in a voluntary public takeover offer that are designed to protect shareholders. However,
these protections are applicable only to issuers that list their equity securities in Switzerland and, because the New Parent Shares will be listed exclusively on The Nasdaq Global Market, will not be applicable to New Parent. Furthermore, since
Swiss law restricts New Parent&#146;s ability to implement rights plans or U.S.-style &#147;poison pills,&#148; New Parent&#146;s ability to resist an unsolicited takeover attempt or to protect minority shareholders in the event of a change of
control transaction may be limited. Therefore, New Parent&#146;s shareholders may not be protected in the same degree in a public takeover offer or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT>
transaction as are shareholders in a Swiss company listed in Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. shareholders may not be able to obtain judgments or enforce civil
liabilities against New Parent or its executive officers or members of the New Parent Board. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent is a corporation organized and
incorporated under the laws of Switzerland with registered office and domicile in Zug, Switzerland, and the majority of its assets are located within Switzerland. Moreover, a number of New Parent&#146;s directors and executive officers are not
residents of the United States, and all or a substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
portion of the assets of such persons are or may be located outside the United States. As a result, investors may not be able to effect service of process within the United States upon New Parent
or upon such persons, or to enforce judgments obtained against New Parent or such persons in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. There is
doubt that a lawsuit based upon United States federal or state securities laws could be brought in an original action in Switzerland and that a judgment of a U.S. court based upon United States securities laws would be enforced in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and Switzerland currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration
awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, may not be enforceable in Switzerland, please see the section
entitled &#147;<I>Enforcement of Civil Liabilities</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Parent&#146;s status as a Swiss stock corporation means that its shareholders
enjoy certain rights that may limit its flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law
reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and the cancellation of treasury shares must be approved by
shareholders. Swiss law also requires that New Parent&#146;s shareholders themselves resolve to, or authorize its board of directors to, increase our share capital. While its shareholders may introduce a capital band pursuant to which share capital
that can be issued by its board of directors without additional shareholder approval, Swiss law limits this capital band to 50% of the share capital registered in the commercial register at the time of the introduction of the capital band. The
capital band, furthermore, has a limited duration of up to five years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital. Additionally, subject to specified exceptions, including
exceptions explicitly described in New Parent&#146;s articles of association, Swiss law grants <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights to existing shareholders to subscribe for new issuances of shares, which may be limited or
withdrawn under certain conditions. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different classes of shares as do the laws of some other jurisdictions. These Swiss law requirements
relating to our capital management may limit New Parent&#146;s flexibility, and situations may arise where greater flexibility would have provided benefits to its shareholders. Please see the sections entitled &#147;<I>Description of New Parent
Securities and Proposed Articles of Association</I>&#148; and &#147;<I>Comparison of Shareholder Rights</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders outside of the
United States may not be able to exercise <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights in future issuances of equity or other securities that are convertible into equity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss corporate law, shareholders may receive certain <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights to subscribe on a <FONT
STYLE="white-space:nowrap">pro-rata</FONT> basis for issuances of equity securities or other securities that are convertible into equity securities. Due to the laws and regulations in certain jurisdictions, however, shareholders who are not
residents of the United States may not be able to exercise such rights unless New Parent takes action to register or otherwise qualify the rights offering, including, for example, by complying with prospectus requirements under the laws of that
jurisdiction. There can be no assurance that New Parent will take any action to register or otherwise qualify an offering of subscription rights or shares under the laws of any jurisdiction other than the United States where the offering of such
rights is restricted. If shareholders in such jurisdictions were unable to exercise their subscription rights, their ownership interest in New Parent will be diluted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in the Proposed Articles of Association could make an acquisition of New Parent, which may be beneficial to its shareholders,
more difficult. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Articles of Association may contain provisions that may have the effect of discouraging, delaying or preventing a
change in control of New Parent that shareholders may consider favorable, including transactions in which its shareholders may receive a premium for their shares. The Proposed Articles of Association, which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will become effective immediately prior to the completion of the Business Combination, may include provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in certain cases, allow the New Parent Board to place such number of new ordinary shares corresponding to up to
23,808,596 New Parent Shares and to place rights to acquire such number of new shares corresponding to up to an additional 5,000,000 of new ordinary shares respectively, of the expected outstanding share capital after completion of the Business
Combination, with affiliates or third parties, without existing shareholders having statutory <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights in relation to this share placement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the New Parent Board not to record any acquirer of ordinary shares, or several acquirers acting in concert,
in New Parent&#146;s share register as a shareholder with voting rights with respect to more than 15% of New Parent&#146;s share capital registered in the commercial register; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrict shareholders from exercising voting rights with respect to own or represented shares in excess of 15% of
New Parent&#146;s share capital registered in the commercial register; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the size of the New Parent Board to nine members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes represented at a general meeting of
shareholders for amending or repealing the above-mentioned registration and voting restrictions, the provision setting a maximum board size, and the provision for indemnification of the members of New Parent Board and its executive committee as set
forth in New Parent&#146;s articles of association, and for dismissing the chairman or any member of the New Parent Board or any member of New Parent&#146;s remuneration committee before the end of his or her term of office. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other provisions of New Parent&#146;s articles of association, alone or together, could delay or prevent takeovers and changes in control. Please
see the sections entitled &#147;<I>Description of New Parent Securities and Proposed Articles of Association</I>&#148; and &#147;<I>Comparison of Shareholder Rights</I>.&#148; Any provision of the Proposed Articles of Association that has the effect
of delaying or preventing a change in control could limit the opportunity for shareholders to receive a premium for their shares of New Parent&#146;s share capital and could also affect the price that some investors are willing to pay for New Parent
Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Parent is a foreign private issuer and, as a result, it will not be subject to U.S. proxy rules and will be subject to Exchange Act
reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
consummation of the Business Combination, New Parent will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private issuer status. Because New Parent qualifies as a foreign private issuer under
the Exchange Act, it is exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations
in respect of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made
in a short period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or
current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> until four months after the end of each financial year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material
information. As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer and as permitted by the listing requirements of Nasdaq, New Parent will
have the option to follow certain home country governance practices rather than the corporate governance requirements of Nasdaq. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
closing of the Business Combination, New Parent will be a foreign private issuer. As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), it may choose to comply with home country governance requirements and certain exemptions thereunder
rather than complying with certain of the corporate governance requirements of the Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law does not require that a majority of New
Parent&#146;s board of directors consist of independent directors. Its board of directors therefore may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, it is not subject
to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings at which only independent directors are present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Swiss law also requires that New Parent set up a remuneration committee, it may follow home country requirements with respect to such committee.
Among other things, Swiss law does not require that all or a majority of the remuneration committee consist of independent directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent&#146;s
articles of association provide for an independent proxy elected by its shareholders, who may represent its shareholders of record at a general meeting of shareholders, and it must provide shareholders of record with an agenda and other relevant
documents for the general meeting of shareholders. However, Swiss law does not have a regulatory regime for the solicitation of proxies, thus New Parent&#146;s practice may vary from the requirement of Nasdaq Listing Rule 5620(b), which sets forth
certain requirements regarding the solicitation of proxies. Furthermore, in accordance with Swiss law and generally accepted business practices, New Parent&#146;s articles of association do not provide quorum requirements generally applicable to
general meetings of shareholders. New Parent&#146;s practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less
than <FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For an overview of New Parent&#146;s corporate governance
principles, please see the section entitled &#147;<I>Description of New Parent Securities and Proposed Articles of Association</I>.&#148; As a result of the above, you may not have the same protections afforded to shareholders of companies that are
not foreign private issuers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following the closing of the Business Combination, New Parent may lose its foreign private issuer status, which would
then require it to comply with the domestic reporting requirements of the Exchange Act and cause it to incur significant legal, accounting and other expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, New Parent will be a foreign private issuer and therefore will not be required to comply with all of
the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. In order to maintain New Parent&#146;s status as a foreign private issuer, either (i)&nbsp;a majority of its ordinary shares must be
either directly or indirectly owned of record by <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States; or (ii) (a) a majority of its executive officers or directors may not be United States citizens or residents, (b)&nbsp;more
than 50% of its assets cannot be located in the United States and (c)&nbsp;its business must be administered principally outside the United States. If it lost this status, it would be required to comply with the Exchange Act reporting and other
requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. Among other things, New Parent would be required under current SEC rules to prepare its financial statements
in accordance with generally accepted accounting principles in the United States, rather than IFRS, which would involve significant time and cost and could result in variations, which could be material, between historical financial results reported
under IFRS and as reported under US&nbsp;GAAP. It may also be required to make changes in its corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to New
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent under U.S. securities laws if it is required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost it would incur as a
foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase New Parent&#146;s legal and financial compliance costs and would make some activities highly time-consuming and costly. If it loses its
foreign private issuer status and is unable to devote adequate funding and the resources needed to maintain compliance with U.S. securities laws, while continuing its operations, New Parent could be forced to deregister with the SEC. A
deregistration would substantially reduce or effectively terminate the trading of its securities in the United States. We also expect that if New Parent were required to comply with the rules and regulations applicable to U.S. domestic issuers, it
would make it more difficult and expensive for it to obtain director and officer liability insurance, and it may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also
make it more difficult for New Parent to attract and retain qualified members of the New Parent Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax authorities may challenge EBAC&#146;s
tax residency, which could adversely affect its tax burden and financial position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has registered as a resident of Switzerland for Swiss tax
purposes as of October 2022 and has deregistered as a taxpayer for Dutch corporate income tax and Dutch dividend withholding tax purposes, but no confirmation has been obtained from the Dutch tax authorities that EBAC is no longer considered a Dutch
tax resident. EBAC&#146;s tax residency primarily depends upon EBAC&#146;s place of effective management, which is a question of fact based on all circumstances. Because the determination of EBAC&#146;s residency is highly fact sensitive, no
assurance can be given regarding the definitive determination of EBAC&#146;s tax residency. If the Dutch tax authorities were to assert that EBAC continues to be a tax resident of the Netherlands, the Dutch tax authorities may seek to impose Dutch
corporate income tax in respect of any income or gains realized by EBAC and/or Dutch dividend withholding tax in respect of any distributions made by or on behalf of EBAC (including the payment of the EBAC Share Redemption Amount to the extent that
it exceeds the aggregate recognised paid-in capital per redeemed share). If the Dutch tax authorities would be successful in such assertion, this could affect EBAC&#146;s tax burden and financial position and following the Acquisition Closing, our
tax burden and financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We urge our shareholders to consult with their legal and tax advisors with respect to the potential tax consequences
of investing in or holding New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a result of changes in tax laws, treaties, rulings, regulations or agreements, or their
interpretation, of Switzerland or any other country in which we operate, the loss of a major tax dispute or a successful challenge to our operating structure, intercompany pricing policies or the taxable presence of our key subsidiaries in certain
countries, or other factors, our effective income tax rates may increase in the future, which could adversely affect our net income and cash flows. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We operate in multiple jurisdictions and our profits are taxed pursuant to the tax laws of these jurisdictions. The tax laws applicable to our business
activities, however, are subject to changes in interpretation. Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax
authorities in jurisdictions in which we do business. Our effective income tax rate may be affected by changes in or interpretations of tax laws, treaties, rulings, regulations or agreements in any given jurisdiction, the resolution of issues
arising from any future tax audits with various tax authorities, utilization of net operating loss and tax credit carryforwards, changes in geographical allocation of income and expense, and changes in management&#146;s assessment of matters such as
the realizability of deferred tax assets. In the past, we have experienced fluctuations in our effective income tax rate. Our actual tax rate may vary from our expectation and that variance may be material. Our effective income tax rate in a given
fiscal year reflects a variety of factors that may not be present in the succeeding fiscal year or years. There is no assurance that our effective income tax rate will not change in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file Swiss and <FONT STYLE="white-space:nowrap">non-Swiss</FONT> tax returns. We are subject to tax
audits, examinations and assessments in various jurisdictions. If any tax authority successfully challenges our operational structure, allocation of income by tax jurisdiction, or amounts paid between our affiliated companies pursuant to our
intercompany arrangements or transfer pricing policies, if any tax authority successfully asserts that we are subject to income, withholding or other taxes in a jurisdiction by reason of our activities and operations or our other taxable presence in
such jurisdiction, if the terms of certain income tax treaties are interpreted in a manner that is adverse to our structure, or if we lose a material tax dispute in any country, our effective income tax rate could increase. A tax authority may take
the position that material income or other tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful
in disputing the assessment, the implications could increase our anticipated effective tax rate, which could adversely affect our profitability. If our effective income tax rate increases in future periods, our net income and cash flows could be
adversely affected, including in future tax years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the Swiss corporate tax law reform that took effect on January&nbsp;1, 2020, all Swiss cantons,
including the Canton of Vaud, have abolished the cantonal tax privileges. Therefore, since January&nbsp;1, 2020, we are subject to standard cantonal taxation. The standard effective corporate tax rate in Lausanne, Canton of Vaud, can change from
time to time. The standard combined (federal, cantonal, communal) effective corporate income tax rate, except for dividend income for which New Parent could claim a participation exemption, for 2022 in Vaud will be approximately 13.79%. The Federal
Counsel of Switzerland has submitted on 23&nbsp;June 2022 a proposal for a minimum tax of 15&nbsp;percent for groups of companies with annual sales of at least 750&nbsp;million euros on the basis of an internationally standardized assessment base.
This proposal would implement the <FONT STYLE="white-space:nowrap">so-called</FONT> GloBE rules (Global Anti-Base Erosion Rules) of the OECD. The minimum tax rate must be achieved in each country. Switzerland plans to implement these rules with a
supplementary direct tax to become effective on January 1, 2024, which - if adopted - will result in a minimum tax rate of 15&nbsp;percent on large corporate groups that achieve a worldwide turnover of at least 750&nbsp;million euros. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We urge our shareholders to consult with their legal and tax advisors with respect to the potential tax consequences of investing in or holding the New Parent
Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in exchange rates of several
currencies, particularly regarding U.S. dollars, euros, British pounds and Swiss francs. Our functional currency is the Swiss franc and the majority of our operating expenses are paid in Swiss francs, but we also may receive payments from our
business partners, including Amgen and AbbVie, in U.S. dollars or euros and we regularly acquire services, consumables and materials in U.S. dollars and Swiss francs. Further, potential future revenue may be derived from abroad, particularly from
the United States and the European Union. As a result, our business and share price may be affected by fluctuations in foreign exchange rates between the Swiss franc, the euro, the U.S. dollar and these other currencies, which may also have a
significant impact on our reported results of operations and cash flows from period to period. Besides our natural hedging, currently, we do not have any exchange rate hedging arrangements in place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the possible abandonment of the euro by one or more members of the European Union could materially affect our business in the future. Despite
measures taken by the European Union to provide funding to certain European Union member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro
could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the <FONT STYLE="white-space:nowrap">re-introduction</FONT> of individual currencies in one or more European Union member states, or in more
extreme circumstances, the abandonment of the euro or the dissolution of the European Union. The effects on our business of a potential dissolution of the European Union, the exit of one or more European Union member states from the European Union
or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Business Combination and EBAC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>During the <FONT STYLE="white-space:nowrap">pre-closing</FONT> period, (i)&nbsp;EBAC and Oculis are prohibited from entering into certain transactions
that might otherwise be beneficial to EBAC, Oculis or their respective shareholders and (ii)&nbsp;uncertainties about whether the Business Combination will be consummated may cause third parties to delay or defer decisions concerning Oculis or seek
to change existing arrangements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until the earlier of the consummation of the Business Combination or termination of the Business Combination
Agreement, EBAC and Oculis are subject to certain limitations on the operations of their businesses. Please see the section entitled &#147;<I>Proposal No. 1&#151;The Business Combination Proposal&#151;The Business Combination
Agreement&#151;Covenants and Agreements</I>&#148; for additional information. The limitations on EBAC&#146;s and Oculis&#146; conduct of their businesses during this period could have the effect of delaying or preventing other strategic transactions
and may, in some cases, make it impossible to pursue business opportunities that are available only for a limited time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may also be uncertainty
regarding whether the Business Combination will occur. This uncertainty may cause third parties to delay or defer decisions concerning Oculis, which could negatively affect Oculis&#146; business. Third parties may seek to change existing agreements
with Oculis as a result of the Business Combination for these or other reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to successfully effect the Business Combination and to
be successful thereafter will be dependent upon the efforts of key personnel of New Parent, including those from Oculis. The loss of key personnel or the hiring of ineffective personnel after the Business Combination could negatively impact the
operations and profitability of New Parent. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to successfully effect the Business Combination and be successful thereafter will be
dependent upon the efforts of New Parent&#146;s key personnel. EBAC expects Oculis&#146; current management to remain in place. EBAC cannot assure you that New Parent will be successful in integrating and retaining such key personnel, or in
identifying and recruiting additional key individuals New Parent determines may be necessary following the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Sponsor has
entered into a letter agreement with EBAC to vote in favor of the Business Combination, regardless of how EBAC public shareholders vote. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike
some other blank check companies in which the initial shareholders agree to vote their shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, the Sponsor, pursuant to
the Sponsor Support Agreement, has agreed, among other things, to vote in favor of all the proposals being presented at the extraordinary general meeting, including the Business Combination Proposal and the Merger Proposal and the transactions
contemplated thereby (including the Mergers). As of the date of this proxy statement/prospectus, the Sponsor owns approximately 21.92% of the issued and outstanding ordinary shares (excluding the private placement shares underlying the EBAC Private
Placement Warrants). Accordingly, the agreement by the Sponsor to vote in favor of each of the proposals being presented at the Extraordinary General Meeting will increase the likelihood that EBAC will receive the requisite shareholder approval for
the Business Combination and the transactions contemplated thereby (including the Mergers). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The consummation of the Business Combination is subject
to a number of conditions and if those conditions are not satisfied or waived, the Business Combination Agreement may be terminated in accordance with its terms and the Business Combination may not be completed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consummation of the Business Combination is conditioned upon, among other things: (i)&nbsp;the approval by EBAC Shareholders of the Transaction Proposals;
(ii)&nbsp;the lack of any Governmental Order in force, enjoining or prohibiting the consummation of the Business Combination, or any Law making the consummation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination illegal or otherwise prohibited; (iii)&nbsp;EBAC having at least $5,000,001 of net tangible assets (as determined in accordance with Rule
<FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing; (iv)&nbsp;EBAC having an amount of cash equal to or greater
than $100&nbsp;million prior to or substantially concurrently with the Acquisition Closing after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing (or other financing in connection with the
EBAC Mergers, such as the Convertible Loan Agreements) and after payment of the EBAC Share Redemption Amount and any unpaid transaction expenses of Oculis and EBAC; (v)&nbsp;the approval by Nasdaq of Oculis&#146; initial listing application in
connection with the Business Combination; and (vi)&nbsp;the Registration Statement becoming effective under the Securities Act and no stop order suspending the effectiveness of the Registration Statement having been issued. Therefore, unless these
conditions are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited pro forma financial information included elsewhere in this proxy statement/prospectus may not be indicative of what New Parent&#146;s
actual financial position or results of operations would have been. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information in this proxy
statement/prospectus is presented for illustrative purposes only and has been prepared based on a number of assumptions including Oculis being considered the accounting acquirer in the Business Combination and the number of public shares that are
redeemed in connection with the Business Combination. Accordingly, such pro forma financial information may not be indicative of New Parent&#146;s future operating or financial performance and New Parent&#146;s actual financial condition and results
of operations may vary materially from the pro forma results of operations and balance sheet contained elsewhere in this proxy statement/prospectus, including as a result of such assumptions not being accurate. Please see the section entitled
&#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of New Parent Shares and New Parent Warrants may be
volatile. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, the price of New Parent Shares and New Parent Warrants may fluctuate due to a variety of
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the industry in which New Parent operates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition from existing products or new products that may emerge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by New Parent or its competitors of significant acquisitions, strategic partnerships, joint
ventures, collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays in New Parent&#146;s or any of its competitors&#146;
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval for any of New Parent&#146;s
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or amendment of a strategic alliance, partnership or collaboration or the inability to establish
additional strategic alliances, partnerships or collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments related to proprietary rights, including patents, litigation matters and our
ability to obtain patent and other intellectual property protection for New Parent&#146;s technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and
any announcements relating to coverage policies or reimbursement levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in its operating performance and the performance of its competitors in general; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in New Parent&#146;s quarterly or annual results of operation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports by securities analysts about New Parent or its competitors or its industry;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public&#146;s reaction to New Parent&#146;s press releases, its other public announcements, and its filings
with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent&#146;s failure or the failure of its competitors to meet analysts&#146; projections or guidance that
New Parent or its competitors may give to the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws and regulations affecting New Parent&#146;s business or industry in which it operates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or involvement in, litigation involving New Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in New Parent&#146;s capital structure, such as future issuances of securities or the incurrence of
additional debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in executive officers, senior management or key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential acquisitions or strategic partnerships by New Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume of New Parent Shares available for public sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of New Parent Shares by the PIPE and CLA Investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material and adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the other
macroeconomic conditions such as the ongoing Ukraine-Russia conflict and the raising of benchmark interest rates by the Federal Reserve to combat historically high levels of inflation in the United States, on the markets and the broader global
economy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency
fluctuations, international tariffs, social, political, and economic risks, and acts of war or terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These market and industry
factors may materially reduce the market price of New Parent Shares and New Parent Warrants regardless of the operating performance of New Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of New Parent&#146;s total outstanding shares after the Acquisition Closing will be restricted from immediate resale but may be
sold into the market in the near future. This could cause the market price of New Parent Shares to drop significantly, even if New Parent&#146;s business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of New Parent Shares in the public market could occur at any time after the Acquisition Closing. These sales, or the perception
in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of New Parent Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that,
upon completion of the Business Combination, based on the assumptions below, (i)&nbsp;the Oculis Shareholders will own approximately 45.0% of the outstanding New Parent Shares and (ii)&nbsp;the Sponsor will own approximately 6.3% of the outstanding
New Parent Shares, in each case, assuming that none of EBAC&#146;s outstanding public shares are redeemed in connection with the Business Combination, or approximately 58.6% and 8.0%, respectively, assuming maximum redemption of the EBAC
Class&nbsp;A Common Stock in connection with the Business Combination such that the Minimum EBAC Cash Condition would still be satisfied. These percentages assume that (i)&nbsp;all existing Oculis ordinary shares have been converted into New Parent
Shares; (ii)&nbsp;7,118,891 shares of EBAC Class&nbsp;A Common Stock (that will ultimately be converted into New Parent Shares in connection with the Business Combination) will be issued from treasury and replaced in the PIPE Financing; (iii)
1,967,000 New Parent Shares will be issued to the Lenders pursuant to the Convertible Loan Agreements and (iv)&nbsp;no vested or unvested options to acquire New Parent Shares that will be held by Oculis Equityholders immediately following the
Acquisition Closing have been exercised. In addition, the numbers of shares and percentages set forth above do not take into account (i)&nbsp;potential future exercises of warrants to purchase New Parent Shares that will be outstanding immediately
following the Acquisition Closing and (ii)&nbsp;the Earnout </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Consideration. If the actual facts are different than these assumptions, the ownership percentages in New Parent will be different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Sponsor and certain Oculis Shareholders will be subject to certain restrictions regarding the transfer of New Parent Shares, these shares may be
sold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> under the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. New Parent intends to file one or more registration statements shortly
after the Acquisition Closing to provide for the resale of such shares from time to time. As restrictions on resale end and the registration statements are available for use, the market price of New Parent Shares could decline if the holders of
currently restricted shares sell such shares or are perceived by the market as intending to sell such shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Since the Sponsor and EBAC&#146;s
directors and executive officers have interests that are different from, or in addition to (and which may conflict with), the interests of EBAC Shareholders, a conflict of interest may have existed in determining whether the Business Combination
with Oculis is appropriate as EBAC&#146;s initial business combination. Such interests include that the Sponsor, as well as EBAC&#146;s executive officers and directors, will lose their entire investment in EBAC if the Business Combination is not
completed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the EBAC Board in favor of approval of the Business Combination Proposal and the Merger
Proposal, you should keep in mind that the Sponsor and EBAC&#146;s directors and executive officers have interests in such proposal that are different from, or in addition to, those of EBAC Shareholders and EBAC warrant holders generally. These
interests include, among other things, the interests listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor has agreed not to redeem any EBAC Class&nbsp;A Common Stock held by it in connection
with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor paid an aggregate of $25,000 for 2,875,000 EBAC Class&nbsp;B Common Stock (which
underwent a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-for-5</FONT></FONT> stock split on March&nbsp;15, 2021), of which the Sponsor currently owns 3,138,696 EBAC Class&nbsp;B Common Stock and two of the independent
directors each own 25,000 shares of EBAC Class&nbsp;B Common Stock, and such securities will have a significantly higher value at the time of the Business Combination; as described further below: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>EBAC&nbsp;Class&nbsp;B<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;EBAC<BR>Class&nbsp;B&nbsp;Common<BR>Stock<BR>implied&nbsp;by&nbsp;the<BR>Business<BR>Combination<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of<BR>EBAC&nbsp;Class&nbsp;B<BR>Common<BR>Stock<BR>based
on<BR>recent<BR>trading&nbsp;price<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,937,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,937,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Wegter<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,937,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volkert Doeksen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Onno van de Stolpe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All officers and directors as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,437,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported above are held in the name of our sponsor. MRMJ Holding B.V., a Dutch limited liability
company, is the majority owner of our sponsor and as such, MRMJ Holding B.V. has voting and investment discretion with respect to the shares held of record by our sponsor and may be deemed to have shared beneficial ownership of the shares held by
our sponsor. Ren&#233; Kuijten, Joachim Rothe, Martijn Kleijwegt and Mark Wegter who are directors of MRMJ Holding B.V. have voting and investment discretion with respect to the shares owned by MRMJ Holding B.V. and may be deemed to have indirect
shared beneficial ownership of the shares held by our sponsor. Ren&#233; Kuijten, Joachim Rothe, Martijn Kleijwegt and Mark Wegter each disclaim beneficial ownership over the founder shares except to the extent of their pecuniary interest therein.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.00 per share, the deemed value of the EBAC Class&nbsp;B Common Stock in the Business
Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the
closing price of the EBAC Class&nbsp;A Common Stock on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor paid an aggregate of $4,550,960 for 455,096 EBAC Private Placement Units, containing
151,699 Private Placement Warrants, as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>private<BR>placement<BR>warrants<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;EBAC<BR>Private<BR>Placement<BR>Warrants<BR>implied&nbsp;by&nbsp;the<BR>Business<BR>Combination<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value
of<BR>EBAC<BR>Private<BR>Placement<BR>Warrants<BR>based<BR>on&nbsp;recent<BR>trading<BR>price<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interests shown consist solely of EBAC Private Placement Warrants. Such warrants will automatically convert
into warrants to acquire New Parent Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sponsor is the record holder of the warrants reported herein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $0.00 per warrant, which reflects that the exercise price of the warrants ($11.50 per
warrant) exceeds the value of the underlying ordinary shares in the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant, the
closing price of the warrant on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that given the differential in the purchase price that the Sponsor paid for the founder shares as
compared to the price of the public shares sold in the initial public offering, the Sponsor and its affiliates may earn a positive rate of return on their investment even if the EBAC Class&nbsp;A Common Stock trade below the price initially paid for
the public shares in the initial public offering and the public shareholders experience a negative rate of return following the completion of the Business Combination. It is not practicable to quantify the Sponsor and its affiliates&#146; rate of
return because, among other things, the timing (including as a result of the nine months <FONT STYLE="white-space:nowrap">lock-up</FONT> applicable to the founder shares) and the price at which the Sponsor sells New Parent Shares and other equity
securities of New Parent are uncertain, both of which would have a material impact on the applicable rate of return; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if a business combination is not consummated within the Combination Period, the Sponsor and
EBAC&#146;s officers and directors will lose their entire investment in EBAC, which investment included a capital contribution of $25,000 for the Sponsor&#146;s EBAC Class&nbsp;B Common Stock and $4,550,960 for the Sponsor&#146;s EBAC Private
Placement Units, and will not be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses from any amounts held in the Trust Account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and EBAC&#146;s current officers and directors have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to any ordinary shares (other than public shares) held by them if EBAC fails to complete an initial business combination within the Combination Period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be
entered into by the Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor transferred 25,000 EBAC Class&nbsp;B Common Stock to each of two of EBAC&#146;s
independent directors prior to EBAC&#146;s initial public offering, and such securities would be worthless if a business combination is not consummated within the Combination Period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor will own 2,761,649 New Parent Shares, which collectively will represent approximately
8.0% of outstanding New Parent Shares and have a value of approximately $27,616,490 based on an implied value of $10.00 per New Parent Share and assuming that the maximum number of EBAC Class&nbsp;A Common Stock are redeemed while still satisfying
the Minimum EBAC Cash Condition; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated designation by EBAC of Martijn Kleijwegt and Geraldine O&#146;Keeffe as directors of New Parent
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of EBAC&#146;s directors and officers and the continuation of EBAC&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (i.e., a &#147;tail policy&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if the Trust Account is liquidated, including in the event EBAC is unable to complete an initial
business combination within the Combination Period, the Sponsor has agreed to indemnify EBAC to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust
Account on the liquidation date, by the claims of prospective target businesses with which EBAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to EBAC, but only if such a vendor or
target business has not executed a waiver of any and all rights to seek access to the Trust Account. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, the
Sponsor may be incentivized to complete the Business Combination with Oculis, or an alternative initial business combination with a less favorable company or on terms less favorable to EBAC Shareholders, rather than to liquidate, in which case the
Sponsor would lose its entire investment. As a result, the existence of financial and personal interests of the Sponsor and EBAC&#146;s directors and executive officers may result in a conflict of interest between what they may believe is best for
EBAC and EBAC Shareholders and what they may believe is best for themselves in determining whether the Business Combination with Oculis is appropriate as EBAC&#146;s initial business combination, and accordingly the interests of the Sponsor and
EBAC&#146;s directors and executive officers may not be aligned with the interests of EBAC Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the section entitled
&#147;<I>Business Combination Proposal&#151;Interests of Certain Persons in the Business Combination</I>&#148; for additional information on interests of EBAC&#146;s directors and executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration, at a price of
$0.01 per warrant, provided that the last reported sales price of the New Parent Shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations, and
the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-trading-day</FONT></FONT> period ending on the third trading day prior to the date EBAC sends the notice of redemption to the
warrant-holders. If and when the public warrants become redeemable by EBAC, EBAC may exercise its redemption right even if EBAC is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of the outstanding public warrants could force you to: (i)&nbsp;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (ii)&nbsp;sell your warrants at the then-current market
price when you might otherwise wish to hold your warrants; or (iii)&nbsp;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, EBAC may redeem your warrants at any time after they become exercisable and prior to their expiration at a price of $0.10 per
warrant upon a minimum of 30 days&#146; prior written notice of redemption provided that holders will be able to exercise their warrants prior to redemption for a number of EBAC Class&nbsp;A Common Stock determined based on the redemption date and
the fair market value of EBAC Class&nbsp;A Common Stock. The value received upon exercise of the public warrants (i)&nbsp;may be less than the value the holders would have received if they had exercised their warrants at a later time where the
underlying share price is higher and (ii)&nbsp;may not compensate the holders for the value of the warrants. None of the EBAC Private Placement Warrants will be redeemable by EBAC, subject to certain circumstances, so long as they are held by the
Sponsor or its permitted transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC is subject to, and New Parent will be subject to following the Business Combination, changing law
and regulations regarding regulatory matters, corporate governance, and public disclosure that have increased both EBAC&#146;s costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> and will increase both New Parent&#146;s
costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is, and New Parent will be following the Business Combination,
subject to rules and regulations by various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory
measures under applicable law. EBAC&#146;s efforts to comply with new and changing laws and regulations have resulted in, and New Parent&#146;s efforts to comply likely will result in, increased general and administrative expenses and a diversion of
management time and attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, because these laws, regulations, and standards are subject to varying interpretations, their application in
practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to New Parent&#146;s disclosure and governance
practices. If either EBAC or New Parent fails to address and comply with these regulations and any subsequent changes, EBAC or New Parent may be subject to penalty and EBAC&#146;s or New Parent&#146;s business may be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of the Business Combination Agreement could negatively impact EBAC. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is not completed for any reason, the ongoing business of EBAC may be adversely impacted and, without realizing any of the
anticipated benefits of completing the transactions, EBAC would be subject to a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC may experience negative reactions from the financial markets, including negative impacts on its stock price
(including to the extent that the current market price reflects a market assumption that the Business Combination will be completed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC will have incurred substantial expenses and will be required to pay certain costs relating to the Business
Combination, whether or not the transaction is completed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is terminated and the EBAC Board seeks
another merger or business combination, EBAC Shareholders cannot be certain that EBAC will be able to find another acquisition target that would constitute a business combination or that such other merger or business combination will be completed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC&#146;s independent directors may decide not to enforce the indemnification obligations of the Sponsor, resulting in a reduction in the amount
of funds in the Trust Account available for distribution to the holders of EBAC Class&nbsp;A Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the
Trust Account are reduced below the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in
the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, and the Sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim,
EBAC&#146;s independent directors would determine whether to take legal action against the Sponsor to enforce its indemnification obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While EBAC
currently expects that its independent directors would take legal action on its behalf against the Sponsor to enforce its indemnification obligations to EBAC, it is possible that EBAC&#146;s independent directors in exercising their business
judgment and subject to their fiduciary duties may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent directors to be too high relative to the amount recoverable or if the
independent directors determine that a favorable outcome is not likely. If EBAC&#146;s independent directors choose not to enforce these indemnification obligations, the amount of funds in the Trust Account available for distribution to the holders
of EBAC Class&nbsp;A Common Stock may be reduced below $10.00 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exercise of EBAC&#146;s directors&#146; and executive officers&#146; discretion in agreeing to
changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in EBAC Shareholders&#146;
best interest. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the period leading up to the Acquisition Closing, events may occur that, pursuant to the Business Combination Agreement, would
require EBAC to agree to amend the Business Combination Agreement, to consent to certain actions taken by Oculis, or to waive rights that EBAC is entitled to under the Business Combination Agreement. Such events could arise because of changes in the
course of Oculis&#146; business, a request by Oculis to undertake actions that would otherwise be prohibited by the terms of the Business Combination Agreement, or the occurrence of other events that would have a material adverse effect on
Oculis&#146; business and would entitle EBAC to terminate the Business Combination Agreement. In any of such circumstances, it would be at EBAC&#146;s discretion, acting through the EBAC Board, to grant its consent or waive those rights. The
existence of financial and personal interests of one or more of the directors described in the preceding risk factors may result in a conflict of interest on the part of such director(s) between what he or she or they may believe is best for EBAC
and EBAC Shareholders and what he or she or they may believe is best for himself or herself or themselves in determining whether or not to take the requested action. As of the date of this proxy statement/prospectus, EBAC does not believe there will
be any changes or waivers that EBAC&#146;s directors and executive officers would be likely to make after shareholder approval of the Business Combination Proposal and the Merger Proposal have been obtained. While certain changes could be made
without further shareholder approval, EBAC will circulate a new or amended proxy statement/prospectus and resolicit EBAC Shareholders if changes to the terms of the transaction that would have a material impact on EBAC Shareholders are required
prior to the vote on the Business Combination Proposal and the Merger Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance that the due diligence undertaken in relation
to the Business Combination would uncover all material issues in relation to the business or financial condition of Oculis. Accordingly, following the Acquisition Closing, New Parent may be required to write-down or
<FONT STYLE="white-space:nowrap">write-off,</FONT> restructure its operations or incur impairment or other charges that could have a significant negative effect on New Parent&#146;s financial condition, results of operations and stock price, which
could cause you to lose some or all of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Going public through a merger rather than an underwritten public offering, as Oculis is
seeking to do through the Business Combination, presents risks to unaffiliated investors. Such risks include the absence of a due diligence investigation conducted by an independent third-party underwriter that would be subject to potential
liability for any material misstatements or omissions in a registration statement under the Securities Act, the rules of Financial Industry Regulatory Authority, Inc. (&#147;<I>FINRA</I>&#148;) and the national securities exchange where such
securities are listed, had the transaction been otherwise undertaken as an underwritten public offering. Although EBAC believes it has conducted due diligence on Oculis which is customary for such transactions, EBAC cannot assure you that this
diligence revealed all material issues that may be present in Oculis&#146; business or financial condition, that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of EBAC&#146;s
or New Parent&#146;s control will not later arise. As a result, New Parent may be required following the Business Combination to write down or write off assets, restructure its operations, or incur impairment or other charges that could have a
significant negative effect on New Parent&#146;s financial condition, results of operations and stock price. Even if the due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a
manner not consistent with EBAC&#146;s preliminary risk analysis. Accordingly, any EBAC shareholder who chooses to remain a shareholder of New Parent following the Acquisition Closing could suffer a reduction in the value of their EBAC shares. Such
EBAC Shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by EBAC&#146;s officers or directors of a duty of care or other fiduciary duty owed to
them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation relating to the Business Combination contained an actionable material misstatement or material omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third parties bring claims against EBAC, the proceeds held in the Trust Account could be reduced
and the per share redemption amount received by EBAC Shareholders may be less than $10.00 per share (which was the offering price in EBAC&#146;s initial public offering). </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s placing of funds in the Trust Account may not protect those funds from third-party claims against EBAC. Although EBAC will seek to have all
vendors, service providers (other than EBAC&#146;s independent registered public accounting firm), prospective target businesses, or other entities with which EBAC does business, execute agreements with EBAC waiving any right, title, interest, or
claim of any kind in or to any monies held in the Trust Account, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the Trust Account,
including fraudulent inducement, breach of fiduciary duty or responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case, in order to gain advantage with respect to a claim against EBAC&#146;s
assets, including the funds held in the Trust Account. If any third party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, EBAC&#146;s management will consider whether competitive alternatives are
reasonably available to EBAC and will only enter into an agreement with such third party if management believes that such third party&#146;s engagement would be in the best interests of EBAC under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Examples of possible instances where EBAC may engage a third party that refuses to execute a waiver include the engagement of a third-party consultant whose
particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver.
Marcum LLC, EBAC&#146;s independent registered public accounting firm, and the underwriters of EBAC&#146;s initial public offer have not executed agreements with EBAC waiving such claims to the monies held in the Trust Account. In addition, there is
no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts, or agreements with EBAC and will not seek recourse against the Trust Account for any reason.
In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to EBAC if and to the extent any claims by a third party (other than Marcum LLC, EBAC&#146;s independent registered public accounting firm) for
services rendered or products sold to EBAC, or a prospective target business with which EBAC has entered into a written letter of intent, confidentiality, or other similar agreement or business combination agreement, reduce the amount of funds in
the Trust Account to below the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions
in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account
(whether or not such waiver is enforceable) nor will it apply to any claims under EBAC&#146;s indemnity of the underwriters of EBAC&#146;s initial public offering against certain liabilities, including liabilities under the Securities Act. However,
EBAC has not asked the Sponsor to reserve for such indemnification obligations, nor has EBAC independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations, and EBAC believes that the Sponsor&#146;s only assets
are securities of EBAC. Therefore, EBAC cannot assure you that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the Trust Account, the funds available for the Business Combination
and redemptions could be reduced to less than $10.00 per public share. In such event, EBAC may not be able to complete the Business Combination, and you would receive such lesser amount per share in connection with any redemption of your public
shares. None of EBAC&#146;s officers or directors will indemnify EBAC for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if EBAC is forced to file a bankruptcy case or insolvency petition or an involuntary bankruptcy case or insolvency filing is filed against EBAC
which is not dismissed, or if EBAC otherwise enters compulsory or court supervised liquidation, the proceeds held in the Trust Account could be subject to applicable bankruptcy or insolvency law, and may be included in EBAC&#146;s bankruptcy estate
and subject to the claims of third parties with priority over the claims of EBAC Shareholders. To the extent any bankruptcy claims deplete the Trust </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Account, EBAC may not be able to return to the public shareholders $10.00 per share (which was the offering price in the initial public offering). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC Shareholders may be held liable for claims by third parties against EBAC to the extent of distributions received by them upon redemption of their
shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC is forced to enter into an insolvent liquidation, any distributions received by EBAC Shareholders could be viewed as an unlawful
payment if it was proved that immediately following the date on which the distribution was made, EBAC was unable to pay EBAC&#146;s debts as they fall due in the ordinary course of business. As a result, a liquidator could seek to recover all
amounts received by EBAC Shareholders. Furthermore, EBAC directors may be viewed as having breached their fiduciary duties to EBAC or EBAC&#146;s creditors and/or may have acted in bad faith, and thereby exposing themselves and EBAC to claims, by
paying public shareholders from the Trust Account prior to addressing the claims of creditors. Claims may be brought against EBAC for these reasons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC is, and New Parent is expected to be, an emerging growth company and if EBAC and New Parent rely on certain exemptions from disclosure requirements
available to &#147;emerging growth companies,&#148; this could make EBAC&#146;s or New Parent&#146;s securities less attractive to investors and may make it more difficult to compare EBAC&#146;s or New Parent&#146;s performance with other public
companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is, and New Parent is expected to be, an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified
by the JOBS Act, and EBAC and New Parent may rely on certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including not being required to comply with
the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in EBAC&#146;s and New Parent&#146;s periodic reports and proxy statements, and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, EBAC Shareholders and New Parent&#146;s shareholders may not have access to
certain information they may deem important. After the Acquisition Closing, New Parent could be an emerging growth company for up to five years from the last day of the fiscal year of EBAC&#146;s initial public offering, although circumstances could
cause New Parent to lose that status earlier, including if the market value of New Parent Shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of any June 30th before that time, in which case New Parent
would no longer be an emerging growth company as of the following December 31st. EBAC cannot predict whether investors will find EBAC&#146;s or New Parent&#146;s securities less attractive because EBAC or New Parent will rely on these exemptions. If
some investors find EBAC&#146;s or New Parent&#146;s securities less attractive as a result of reliance on these exemptions, the trading prices of EBAC&#146;s or New Parent&#146;s securities may be lower than they otherwise would be, there may be a
less active trading market for EBAC&#146;s or New Parent&#146;s securities and the trading prices of EBAC&#146;s or New Parent&#146;s securities may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any
such election to opt out is irrevocable. EBAC has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, EBAC, as an
emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of EBAC&#146;s financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, EBAC is a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. Following the Business
Combination, EBAC expects that New Parent will no longer be a smaller reporting company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of additional New Parent Shares will significantly
dilute the equity interests of existing holders of EBAC securities, and may adversely affect prevailing market prices of New Parent Shares and/or New Parent warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants will become exercisable for New Parent Shares, which would increase the number of shares eligible for future resale in the public market and
result in dilution to New Parent shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is completed, outstanding warrants to purchase an aggregate of
4,403,294 New Parent Shares will become exercisable in accordance with the terms of the warrant agreement governing those securities. These warrants will become exercisable 30 days after the completion of the Business Combination. The exercise price
of these warrants will be $11.50 per share. To the extent such warrants are exercised, additional New Parent Shares will be issued, which will result in dilution to the holders of New Parent Shares and increase the number of shares eligible for
resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the prevailing market prices of New Parent Shares. However, there is no guarantee
that the New Parent Warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. See below risk factor entitled, &#147;<I>&#151;Even if the Business Combination is consummated, the EBAC Public
Warrants may never be in the money, and they may expire worthless and the terms of the EBAC Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then-outstanding EBAC Public Warrants approve of such
amendment</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if the Business Combination is consummated, the EBAC Public Warrants may never be in the money, and they may expire
worthless and the terms of the EBAC Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then-outstanding EBAC Public Warrants approve of such amendment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Public Warrants were issued in registered form under the Existing Warrant Agreement, which will be assumed by New Parent in the Business Combination.
The Existing Warrant Agreement provides that the terms of the EBAC Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the
holders of at least 50% of the then-outstanding EBAC Public Warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, EBAC may amend the terms of the EBAC Public Warrants in a manner
adverse to a holder if holders of at least 50% of the then-outstanding EBAC Public Warrants approve of such amendment. Although EBAC&#146;s ability to amend the terms of the EBAC Public Warrants with the consent of at least 50% of the
then-outstanding EBAC Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the EBAC Public Warrants, convert the EBAC Public Warrants into cash, shorten the exercise
period, or decrease the number of New Parent Shares purchasable upon exercise of a public warrant and private warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Nasdaq Global Market may
not list New Parent&#146;s securities on its exchange, which could limit investors&#146; ability to make transactions in New Parent&#146;s securities and subject New Parent to additional trading restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An active trading market for New Parent&#146;s securities following the Business Combination may never develop or, if developed, it may not be sustained. In
connection with the Business Combination, in order to list New Parent&#146;s securities on the Nasdaq Global Market, New Parent will be required to demonstrate compliance with Nasdaq&#146;s listing requirements. New Parent has applied to have New
Parent&#146;s securities listed on the Nasdaq Global Market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon consummation of the Business Combination. EBAC cannot assure you that New Parent will be able to meet all listing requirements. Even if New Parent&#146;s securities are listed on the Nasdaq
Global Market, New Parent may be unable to maintain the listing of its securities in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If New Parent fails to meet the listing requirements and
the Nasdaq Global Market does not list its securities on its exchange, either party would not be required to consummate the Business Combination. In the event that Oculis or EBAC elected to waive this condition, and the Business Combination was
consummated without New Parent&#146;s securities being listed on the Nasdaq Global Market or on another national securities exchange, New Parent could face significant material adverse consequences, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for New Parent&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced liquidity for New Parent&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination that New Parent Shares is a &#147;penny stock&#148; which will require brokers trading in New
Parent Shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for New Parent&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to issue additional securities or obtain additional financing in the future.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating
the sale of certain securities, which are referred to as &#147;covered securities.&#148; If New Parent&#146;s securities were not listed on the Nasdaq Global Market, such securities would not qualify as covered securities and EBAC would be subject
to regulation in each state in which EBAC offers New Parent&#146;s securities because states are not preempted from regulating the sale of securities that are not covered securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, after EBAC distributes the proceeds in the Trust Account to the public shareholders, EBAC files a bankruptcy or insolvency petition or an
involuntary bankruptcy or insolvency petition is filed against EBAC that is not dismissed, a bankruptcy or insolvency court may seek to recover such proceeds, and EBAC and the EBAC Board may be exposed to claims of punitive damages. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, after EBAC distributes the proceeds in the Trust Account to the public shareholders, EBAC files a bankruptcy or insolvency petition or an involuntary
bankruptcy or insolvency petition is filed against EBAC that is not dismissed, any distributions received by public shareholders could be viewed under applicable debtor/creditor and/or bankruptcy and/or insolvency laws as either a &#147;preferential
transfer&#148; or a &#147;fraudulent conveyance.&#148; As a result, a bankruptcy or insolvency court could seek to recover all amounts received by EBAC Shareholders. In addition, the EBAC Board may be viewed as having breached its fiduciary duties
to EBAC&#146;s creditors and/or having acted in bad faith, thereby potentially exposing it and EBAC to claims of punitive damages, by paying public shareholders from the Trust Account prior to addressing the claims of creditors. EBAC cannot assure
you that claims will not be brought against EBAC for these reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, before distributing the proceeds in the Trust Account to the public
shareholders, EBAC files a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against EBAC that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of EBAC
Shareholders and the per share amount that would otherwise be received by EBAC Shareholders in connection with EBAC&#146;s liquidation may be reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, before distributing the proceeds in the Trust Account to the public shareholders, EBAC files a bankruptcy or insolvency petition or an involuntary
bankruptcy or insolvency petition is filed against EBAC that is not dismissed, the proceeds held in the Trust Account could be subject to applicable bankruptcy or insolvency law, and may be included in EBAC&#146;s bankruptcy estate and subject to
the claims of third parties with priority over the claims of public shareholders. To the extent any bankruptcy or insolvency claims deplete the Trust Account, the per share amount that would otherwise be received by EBAC Shareholders in connection
with EBAC&#146;s liquidation may be reduced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for New Parent to
effectuate its initial business combination, require substantial financial and management resources, and increase the time and costs of completing an initial business combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, prior to the Business Combination, Oculis is not a publicly reporting company required to comply with Section&nbsp;404 of the Sarbanes-Oxley Act
(&#147;<I>Section</I><I></I><I>&nbsp;404</I>&#148;) and New Parent management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting obligations that
will be applicable to New Parent after the Business Combination, including the requirement to document and test New Parent&#146;s internal control over financial reporting so that New Parent&#146;s management can certify as to the effectiveness of
its internal control over financial reporting. These regulatory compliance and reporting obligations as a public company are likely to place a considerable strain on New Parent&#146;s financial and management systems, processes and controls, as well
as on its personnel. If New Parent is not able to implement the requirements of Section&nbsp;404, including any additional requirements once New Parent is no longer an emerging growth company, in a timely manner or with adequate compliance, New
Parent may not be able to assess whether its internal control over financial reporting are effective, which may subject New Parent to adverse regulatory consequences and could harm investor confidence and the market price of New Parent Shares.
Additionally, once New Parent is no longer an emerging growth company, New Parent will be required to comply with the independent registered public accounting firm attestation requirement on New Parent&#146;s internal control over financial
reporting. Until New Parent ceases to be an emerging growth company, shareholders will not have the benefit of an independent assessment of the effectiveness of New Parent&#146;s internal control environment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC&#146;s warrants are accounted for as liabilities and the changes in value of EBAC&#146;s warrants (and, following the Acquisition Closing, the New
Parent Warrants) could have a material effect on New Parent&#146;s financial results and thus may have an adverse effect on the market price of EBAC&#146;s (and, following the Acquisition Closing, New Parent&#146;s) securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2021, the staff of the SEC (the &#147;<I>SEC Staff</I>&#148;) issued a public statement entitled &#147;Staff Statement on Accounting and
Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies&#148; (&#147;<I>SPACs</I>&#148;) (the &#147;<I>SEC Staff Statement</I>&#148;). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and
conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC&#146;s balance sheet as opposed to equity. As a result of the SEC Staff Statement, EBAC reevaluated the accounting treatment of the EBAC Public
Warrants and EBAC Private Placement Warrants, and determined to classify the warrants as derivative liabilities measured at fair value, with changes in fair value each period reported in earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Accounting Standards Board&#146;s Accounting Standards Codification Topic 815, &#147;Derivatives and Hedging&#148; (&#147;<I>ASC 815</I>&#148;),
provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting <FONT STYLE="white-space:nowrap">non-cash</FONT> gain or loss related to the change in the fair value being recognized in earnings in
the statement of operations. As a result of the recurring fair value measurement, EBAC&#146;s financial statements and results of operations may fluctuate quarterly, based on factors, which are outside of EBAC&#146;s control. Due to the recurring
fair value measurement, EBAC (and, following the Acquisition Closing, New Parent) expects that it will recognize <FONT STYLE="white-space:nowrap">non-cash</FONT> gains or losses on its warrants each reporting period and that the amount of such gains
or losses could be material. The impact of changes in fair value on earnings may have an adverse effect on the market price of EBAC&#146;s (and, following the Acquisition Closing, New Parent&#146;s) securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC has identified a material weakness in its internal control over financial reporting as of
December&nbsp;31, 2021. If EBAC (and, following the Acquisition Closing, New Parent) is unable to develop and maintain an effective system of internal control over financial reporting, EBAC (and, following the Acquisition Closing, New Parent) may
not be able to accurately report its financial results in a timely manner, which may adversely affect investor confidence in EBAC or New Parent, as applicable, and materially and adversely affect EBAC&#146;s or New Parent&#146;s, as applicable,
business and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has identified a material weakness in its internal control over financial reporting related to EBAC&#146;s
accounting and reporting of complex financial instruments, including application of ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99-3A</FONT></FONT></FONT> to its accounting
classification of public shares. As a result of this material weakness, EBAC&#146;s management has concluded that its disclosure controls and procedures were not effective as of December&nbsp;31, 2021. EBAC remediated the material weakness in the
second quarter of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. Effective internal controls are necessary for us to provide reliable
financial reports and prevent fraud. We continue to evaluate steps to remediate the material weakness. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended
effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC or New Parent, as applicable, identify any new material weaknesses in the future, any such newly identified material weakness could
limit EBAC&#146;s or New Parent&#146;s, as applicable, ability to prevent or detect a misstatement of its accounts or disclosures that could result in a material misstatement of its annual or interim financial statements. In such case, EBAC or New
Parent, as applicable, may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in its financial
reporting and EBAC&#146;s or New Parent&#146;s stock price, as applicable, may decline as a result. Neither EBAC nor, following the Acquisition Closing, New Parent can assure you that any measures it may take in the future will be sufficient to
avoid potential future material weaknesses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC has not obtained a fairness opinion from an independent investment banking firm, and consequently,
there is no assurance from an independent source that the Business Combination is fair to its shareholders from a financial point of view.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is
not required to, and has not, obtained a fairness opinion from an independent investment banking firm that the Business Combination is fair to EBAC Shareholders from a financial point of view. The fair market value of Oculis has been determined by
the EBAC Board based upon the financial skills and background of its directors, and EBAC Shareholders will be relying on the judgment of the EBAC Board with respect to such matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC may be deemed a &#147;foreign person&#148; under the regulations relating to the Committee on Foreign Investment in the United States
(&#147;CFIUS&#148;) and its failure to obtain any conceivable approvals within the requisite time period may require EBAC to liquidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor is
controlled by, and has substantial ties with non-U.S. persons, but EBAC does not believe that any of the facts or relationships with respect to the Business Combination would subject the proposed Business Combination to regulatory review by a U.S.
government entity or authority, including review by CFIUS. Nor does EBAC believe that if such a review were conceivable that the Business Combination ultimately would be prohibited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if the Business Combination were to become subject to CFIUS review, CFIUS could decide to block or delay the Business Combination, impose conditions
with respect to the Business Combination or request the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
President of the United States to order EBAC to divest all or a portion of any U.S. target business of the Business Combination that EBAC acquired without first obtaining CFIUS approval. The time
required for CFIUS to conduct its review and any remedy imposed by CFIUS could prevent EBAC from completing its initial business combination and require EBAC to liquidate. In that case, EBAC would as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses
and which interest shall be net of taxes payable), <I>divided</I> by the number of then issued and outstanding public shares, which redemption will completely extinguish EBAC Shareholders&#146; rights as shareholders (including the right to receive
further liquidation distributions, if any), subject to applicable law. Moreover, investors would lose the investment opportunity in a target company, any price appreciation in the combined companies, and the warrants would expire worthless. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For so long as Sponsor retains a material ownership interest in EBAC, we may be deemed a &#147;foreign person&#148; under the regulations relating to CFIUS.
As such, an initial business combination with a U.S. business or foreign business with U.S. subsidiaries that EBAC may wish to pursue may be subject to CFIUS review. If a particular proposed initial business combination with a U.S. business falls
within CFIUS&#146;s jurisdiction, EBAC may determine that it is required to make a mandatory filing or that it will submit to CFIUS review on a voluntary basis, or to proceed with the transaction without submitting to CFIUS and risk CFIUS
intervention, before or after closing the transaction. CFIUS may decide to block or delay EBAC&#146;s proposed initial business combination, impose conditions with respect to such initial business combination or request the President of the United
States to order EBAC to divest all or a portion of the U.S. target business of its initial business combination that EBAC acquired without first obtaining CFIUS approval, which may limit the attractiveness of, delay or prevent EBAC from pursuing
certain target companies that EBAC believes would otherwise be beneficial to us and our shareholders. In addition, certain federally licensed businesses may be subject to rules or regulations that limit foreign ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of government review, whether by CFIUS or otherwise, could be lengthy. Because EBAC has only a limited time to complete its initial business
combination, its failure to obtain any required approvals within the requisite time period may require EBAC to liquidate. If EBAC is unable to complete an initial business combination within the Combination Period, including as a result of extended
regulatory review of a potential initial business combination, EBAC will, as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), <I>divided</I> by the number of then outstanding public shares,
which redemption will completely extinguish EBAC Shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law. In such event, EBAC Shareholders will miss the
opportunity to benefit from an investment in a target company and the appreciation in value of such investment. Additionally, the warrants will be worthless. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>The EBAC Mergers may be a taxable event for U.S. Holders of EBAC Common Stock and EBAC Warrants</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limitations and qualifications described in the section entitled &#147;<I>Material Tax Considerations &#151; U.S. Federal Income Tax
Considerations to U.S. Holders &#151; Consequences of the Business Combination to U.S. Holders of EBAC Securities,</I>&#148; EBAC intends to treat the EBAC Mergers as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(F) of
the Code. If this treatment applies, a U.S. Holder (as defined in the section entitled &#147;<I>Material Tax Considerations &#151; U.S. Federal Income Tax Considerations to U.S. Holders</I>&#148;) of EBAC Common Stock and EBAC Warrants will
generally not recognize gain or loss for U.S. federal income tax purposes on the exchange of EBAC Common Stock and EBAC Warrants for New Parent Shares and New Parent Warrants, respectively, pursuant to the Business Combination. However, there can be
no assurance that the United States Internal Revenue Service (the &#147;<I>IRS</I>&#148;) will not assert that the EBAC Mergers do not qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(F) of the Code, or otherwise
as a <FONT STYLE="white-space:nowrap">tax-free</FONT> transaction. U.S. Holders of EBAC Common Stock and EBAC Warrants should consult their tax advisors regarding the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
federal income tax consequences of the EBAC Mergers, including in the event that they do not qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Parent (or its predecessor EBAC) may be or become a passive foreign investment company for U.S. federal income tax purposes, which could result in
adverse U.S. federal income tax consequences to U.S. Holders of New Parent Shares or New Parent Warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a foreign (<I>i.e.</I>, <FONT
STYLE="white-space:nowrap">non-U.S.)</FONT> corporation will be a passive foreign investment company (&#147;<I>PFIC</I>&#148;) for U.S. federal income tax purposes if at least 75% of its gross income in a taxable year of the foreign corporation,
including its pro rata share of the gross income of any Look-Through Subsidiary (as defined below), is passive income. Alternatively, a foreign corporation will be a PFIC if at least 50% of its assets in a taxable year of the foreign corporation,
ordinarily determined for based on fair market value and averaged quarterly over the year, including such foreign corporation&#146;s pro rata share of the assets of any Look-Through Subsidiary (and excluding the value of the shares held in such
corporation), are held for the production of, or produce, passive income. Passive income generally includes dividends (excluding any dividends received from a Look-Through Subsidiary), interest, rents and royalties (other than certain rents or
royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets. Cash and cash equivalents are generally passive assets. The value of goodwill will generally be treated as an active or passive
asset based on the nature of the income produced in the activity to which the goodwill is attributable. For purposes of the PFIC rules, a foreign corporation that owns, directly or indirectly, at least 25% by value of the stock of another
corporation is treated as if it held its proportionate share of the assets of the other corporation, and received directly its proportionate share of the income of the other corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because New Parent&#146;s PFIC status for any taxable year is an annual determination that can be made only after the end of such taxable year and may depend
in part on the value of its unbooked goodwill (which may be determined in large part by reference to the market price of New Parent Shares from time to time, which could be volatile), there can be no assurance that New Parent will not be a PFIC for
the taxable year ending on December&nbsp;31, 2022 or any future taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the PFIC status of EBAC may affect U.S. Holders that own New
Parent Shares or New Parent Warrants. Assuming the EBAC Mergers qualify as an F Reorganization (as defined below), New Parent will be treated as the successor to EBAC for U.S. federal income tax purposes, including for purposes of the PFIC rules.
Because EBAC is a blank-check company with no current active business, based upon the composition of EBAC&#146;s income and assets, EBAC believes it would qualify as a PFIC for its taxable year ending December&nbsp;31, 2022, and, if the Business
Combination is not completed in 2022, would likely qualify as a PFIC for its taxable year ending December&nbsp;31, 2023. In the event that EBAC qualifies as a PFIC for its taxable year ending December&nbsp;31, 2022, New Parent should also qualify as
a PFIC for that same taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, there can be no assurance with respect to New Parent or EBAC&#146;s PFIC status for any taxable
year. Additionally, although a foreign corporation&#146;s PFIC status is determined annually, a determination that EBAC or New Parent is a PFIC for a taxable year in which a U.S. Holder holds shares in such entity will generally continue to apply to
such U.S. Holder for subsequent taxable years in which the holder continues to hold shares in such entity (including a successor entity), whether or not such entity continues to be a PFIC. As such, if EBAC was a PFIC during the holding period of a
U.S. Holder, any New Parent Shares received in exchange for EBAC Common Stock in the EBAC Mergers (or on the exercise of New Parent Warrants exchanged for EBAC Warrants) may, in the absence of certain elections described below, be treated as stock
of a PFIC, even if New Parent is not a PFIC for the taxable year ending December&nbsp;31, 2022, or future taxable years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If New Parent is treated as a
PFIC for any taxable year during which a U.S. Holder owns New Parent Shares or New Parent Warrants, the U.S. Holder generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and
certain &#147;excess distributions&#148; and additional reporting requirements. U.S. Holders of New Parent Shares or New Parent Warrants should consult their tax advisors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the application of the PFIC rules to New Parent and the risks of owning equity securities in a company that may be a PFIC. See &#147;<I>Material Taxation Considerations&#151;United
States Federal Income Tax Considerations to U.S. Holders&#151;U.S. Federal Income Tax Considerations of Owning and Disposing of New Parent Securities Following the Business Combination&#151;Passive Foreign Investment Company Rules</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future changes to tax laws could materially and adversely affect New Parent and reduce net returns to New Parent&#146;s shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent&#146;s tax treatment is subject to changes in tax laws, regulations, and treaties, or the interpretation thereof, tax policy initiatives and reforms
under consideration, and the practices of tax authorities in jurisdictions in which New Parent operates. The income and other tax rules in the jurisdictions in which New Parent operates are constantly under review by taxing authorities and other
governmental bodies. Changes to tax laws (which changes may have retroactive application) could adversely affect New Parent or its shareholders. New Parent is unable to predict what tax proposals may be proposed or enacted in the future or what
effect such changes would have on New Parent&#146;s business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect New Parent&#146;s financial position and overall or effective tax
rates in the future in countries where New Parent has operations and where New Parent is organized or resident for tax purposes, and increase the complexity, burden and cost of tax compliance. New Parent urges investors to consult with their legal
and tax advisors regarding the implication of potential changes in tax laws on an investment in New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other macroeconomic conditions which may delay or prevent the consummation of the Business Combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over two years after the World Health Organization declared <FONT STYLE="white-space:nowrap">COVID-19</FONT> a pandemic, the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to impact worldwide economic activity and financial markets. Variants of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have caused and may continue to cause waves of increased
infections and governments around the world have responded by implementing a range of measures in affected regions intended to contain the pandemic and subsequent variants of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus which impact
commercial activities and businesses, and may in turn delay or prevent the consummation of the Business Combination. Given the ongoing and dynamic nature of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> crisis, it is difficult to predict the
impact on the businesses of EBAC, Oculis, and New Parent, and there is no guarantee that efforts by EBAC, Oculis, and New Parent to address the adverse impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> will be effective. If EBAC or Oculis
are unable to recover from a business disruption on a timely basis, the Business Combination and New Parent&#146;s business and financial conditions and results of operations following the completion of the Business Combination could be adversely
affected. The Business Combination may also be delayed and adversely affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and become more costly. Each of EBAC and Oculis may also incur additional costs to remedy damages caused by such
disruptions, which could adversely affect their respective financial condition and results of operations. In February 2022, armed conflict escalated between Russia and Ukraine. The sanctions announced by the U.S. and other countries, following
Russia&#146;s invasion of Ukraine, against Russia as a result include restrictions on selling or importing goods, services, or technology in or from affected regions and travel bans and asset freezes impacting connected individuals and political,
military, business, and financial organizations in Russia. The United States and other countries could impose wider sanctions and take other actions should the conflict further escalate. It is not possible to predict the broader consequences of this
conflict, which could include further sanctions, embargoes, regional instability, threats of cyberattacks, prolonged periods of higher inflation, geopolitical shifts, and adverse effects on macroeconomic conditions, currency exchange rates, and
financial markets, all of which could have a material adverse effect on each of EBAC and Oculis&#146; business, financial condition, and results of operations and could delay or adverse effect the consummation of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks if the Adjournment Proposal is Not Approved </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Adjournment Proposal is not approved, and an insufficient number of votes have been obtained to authorize the consummation of the Business
Combination, the EBAC Board will not have the ability to adjourn the Extraordinary General Meeting to a later date in order to, among other things, solicit further votes. As a result the Business Combination will not be approved, and, therefore, the
Business Combination may not be consummated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board is seeking approval, as an ordinary resolution, to adjourn the Extraordinary General
Meeting to a later date or dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC
Shareholders in favor of the Business Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of
EBAC Class&nbsp;A Common Stock such that the Minimum EBAC Cash Condition would not be satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved, the EBAC
Board will not have the ability to adjourn the Extraordinary General Meeting to a later date and, therefore, will not have more time to take actions in furtherance of consummating the transactions contemplated by the Business Combination Agreement,
including solicit votes. In such events, the Business Combination may not be completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks if the Business Combination is Not Consummated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If EBAC is not able to complete the Business Combination with Oculis within the Combination Period, EBAC would cease all operations except for the
purpose of winding up and EBAC would redeem its EBAC Class&nbsp;A Common Stock and liquidate the Trust Account, in which case EBAC&#146;s public shareholders may only receive approximately $10.00 per share and the EBAC Public Warrants will expire
worthless. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s ability to complete the Business Combination may be negatively impacted by general market conditions, volatility in the
capital markets and the other risks described herein, including as a result of terrorist attacks, natural disaster or a significant outbreak of infectious diseases. For example, the outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
continues in the United States and, while the extent of the impact of the outbreak on EBAC may depend on future developments, it could limit EBAC&#146;s ability to complete the Business Combination, including as a result of increased market
volatility. Additionally, the continued outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other events (such as terrorist attacks, natural disasters or a significant outbreak of infectious diseases) may negatively impact the business
of New Parent following the Business Combination, as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC is not able to complete the Business Combination with Oculis within the
Combination Period, EBAC will: (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible, but not more than 10 business days thereafter, redeem the public shares, at a <FONT
STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net
of taxes payable), divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if
any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of EBAC&#146;s remaining shareholders and the EBAC Board, liquidate and dissolve, subject in each case to EBAC&#146;s obligations under Cayman
Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to EBAC Public Warrants, which will expire worthless if EBAC fails to complete
its initial business combination within the Combination Period. Initial shareholders of EBAC and the other officers and directors of EBAC have agreed to waive their rights to liquidating distributions from the Trust Account with respect to any
Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period, and therefore would not be entitled to the same consideration as the other public shares in the event an initial business
combination is not completed within the Combination Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will not have any rights or interests in funds from the Trust Account, except under certain
limited circumstances. To liquidate your investment, therefore, you may be forced to sell your EBAC Class&nbsp;A Common Stock and/or EBAC Public Warrants, potentially at a loss. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s public shareholders will be entitled to receive funds from the Trust Account only upon the earliest to occur of: (i)&nbsp;completion of an initial
business combination (including the Acquisition Closing), and then only in connection with those EBAC Class&nbsp;A Common Stock that such shareholder properly elected to redeem, subject to the limitations described herein; (ii)&nbsp;the redemption
of any public shares properly submitted in connection with a shareholder vote to amend EBAC&#146;s amended and restated memorandum and articles of association (a)&nbsp;to modify the substance or timing of EBAC&#146;s obligation to allow redemption
in connection with its initial business combination or to redeem 100% of EBAC&#146;s public shares if it does not complete an initial business combination within the Combination Period, or (b)&nbsp;with respect to any other provision relating to
shareholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> business combination activity; and (iii)&nbsp;the redemption of EBAC&#146;s public shares if it has not completed an initial business combination within the Combination
Period, subject to applicable law. In no other circumstances will a shareholder have any right or interest of any kind to or in the Trust Account. Holders of public warrants will not have any right to the proceeds held in the Trust Account with
respect to such warrants. Accordingly, to liquidate your investment, you may be forced to sell your public shares and/or public warrants, potentially at a loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If EBAC has not completed its initial business combination, its public shareholders may not receive any redemption from the Trust Account until after
the Combination Period. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC is not able to complete the Business Combination with Oculis within the Combination Period, EBAC will:
(i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible, but not more than 10 business days thereafter, redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), <I>divided</I> by the
number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any); and (iii)&nbsp;as promptly
as reasonably possible following such redemption, subject to the approval of EBAC&#146;s remaining shareholders and the EBAC Board, liquidate and dissolve, subject in each case to EBAC&#146;s obligations under Cayman Islands law to provide for
claims of creditors and the requirements of other applicable law. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less
than the initial public offering price per unit in EBAC&#146;s initial public offering. In addition, if EBAC fails to complete any initial business combination within the Combination Period, there will be no redemption rights or liquidating
distributions with respect to EBAC Public Warrants, which will expire worthless if EBAC fails to complete its initial business combination within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to redemption rights, holders of EBAC Class&nbsp;B Common Stock have different incentives than holders of EBAC Class&nbsp;A Common Stock with
respect to the completion of any proposed business combination (including the Business Combination) and/or the exercise of any right to redeem. In particular, holders of EBAC Class&nbsp;B Common Stock are not entitled to participate in any
redemption with respect to such shares. The value of the EBAC Class&nbsp;B Common Stock is dependent on the consummation of an initial business combination. In the event no initial business combination is consummated within the Combination Period,
the EBAC Class&nbsp;B Common Stock would be rendered valueless. Holders of EBAC Class&nbsp;A Common Stock, on the other hand, are entitled to exercise redemption rights and receive the value of their redeemed shares even if an initial business
combination is not completed. Therefore, the interests of holders of EBAC Class&nbsp;A Common Stock and EBAC Class&nbsp;B Common Stock may not be aligned. Holders of EBAC Class&nbsp;A Common Stock should form their own independent views as to
whether or not to redeem or whether or not to vote in favor of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC has not completed its initial business combination
within the Combination Period, EBAC will distribute the aggregate amount then on deposit in the Trust Account, including interest (<I>less</I> up to $100,000 of interest to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pay dissolution expenses and which interest shall be net of taxes payable), <I>divided</I> by the number of then issued and outstanding public shares, which redemption will completely extinguish
public shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any) and cease all operations except for the purposes of winding up of EBAC&#146;s affairs, as further described in this proxy
statement/prospectus. If EBAC is required to <FONT STYLE="white-space:nowrap">wind-up,</FONT> liquidate the Trust Account and distribute such amount therein, pro rata, to its public shareholders, as part of any liquidation process, such winding up,
liquidation and distribution must comply with the applicable provisions of the Cayman Companies Act. In that case, investors may be forced to wait beyond the Combination Period before the redemption proceeds of the Trust Account become available to
them, and they receive the return of their pro rata portion of the proceeds from the Trust Account. EBAC has no obligation to return funds to investors prior to the date of its redemption or liquidation unless, prior thereto, EBAC consummates an
initial business combination (including the Business Combination) or amends certain provisions of EBAC&#146;s amended and restated memorandum and articles of association, and only then in cases where investors have properly sought to redeem their
public shares. Only upon EBAC&#146;s redemption or any liquidation will public shareholders be entitled to distributions if EBAC has not completed an initial business combination within the Combination Period and does not amend certain provisions of
EBAC&#146;s amended and restated memorandum and articles of association prior thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC&#146;s public shareholders who wish to redeem their public shares for a pro rata portion of the Trust Account must comply with specific requirements
for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If EBAC Shareholders fail to comply with the redemption requirements specified in this proxy statement/prospectus, they will not be
entitled to redeem their public shares for the right to receive a pro rata portion of the funds held in the Trust Account. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A public shareholder
will be entitled to receive the right for an amount in cash for any public shares to be redeemed only if such public shareholder: (i)(a) holds public shares, or (b)&nbsp;holds public shares through units and elects to separate its units into the
underlying public shares and public warrants prior to exercising its redemption rights with respect to the public shares; (ii)&nbsp;submits a written request to Continental, EBAC&#146;s transfer agent, in which it (a)&nbsp;requests that EBAC redeem
all or a portion of its public shares for the right to receive an amount in cash, and (b)&nbsp;identifies itself as a beneficial holder of the public shares and provides its legal name, phone number, and address; and (iii)&nbsp;delivers its share
certificates (if any) and other redemption forms (as applicable) to Continental physically or electronically through DTC. Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00 PM,
Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Extraordinary General Meeting) in order for their shares to be redeemed. In order to obtain a
physical share certificate, a public shareholder&#146;s broker and/or clearing broker, DTC and Continental, will need to act to facilitate this request. It is EBAC&#146;s understanding that public shareholders should generally allot at least two
weeks to obtain physical certificates from the transfer agent. However, because EBAC does not have any control over this process or over DTC, it may take significantly longer than two weeks to obtain a physical stock certificate. If it takes longer
than anticipated to obtain a physical certificate, public shareholders who wish to redeem their public shares may be unable to obtain physical certificates by the deadline for exercising their redemption rights and thus will be unable to redeem
their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is consummated, and if a public shareholder has properly exercised its right to redeem all or a portion of the
public shares that it holds and timely delivers its share certificates (if any) and other redemption forms (as applicable) to Continental, EBAC will redeem such public shares for the right to receive a
<FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash by New Parent, equal to the pro rata portion of the Trust Account established at the consummation of the initial public offering, calculated as of two business days prior to
the consummation of the Business Combination. Please see the section entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Redemption Rights</I>&#148; for additional information on how to exercise your redemption rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a public shareholder fails to receive notice of EBAC&#146;s offer to redeem public shares in
connection with the Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If,
despite EBAC&#146;s compliance with the proxy rules, a public shareholder fails to receive EBAC&#146;s proxy materials, such public shareholder may not become aware of the opportunity to redeem its public shares. In addition, the proxy materials
that EBAC is furnishing to holders of public shares in connection with the Business Combination describe the various procedures that must be complied with in order to validly redeem the public shares. In the event that a public shareholder fails to
comply with these procedures, its public shares may not be redeemed. Please see the section entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Redemption Rights</I>&#148; for additional information on how to exercise your redemption
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC does not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for EBAC to
complete the Business Combination even though a substantial portion of EBAC Shareholders do not agree. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum
and articles of association do not provide a specified maximum redemption threshold, except that EBAC will not redeem public shares in an amount that would cause EBAC&#146;s net tangible assets to be less than $5,000,001 after giving effect to the
transactions contemplated by the Business Combination Agreement and the PIPE Financing, including the proceeds received from the Lenders to the Convertible Loan Agreements (as determined in accordance with Rule
<FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, EBAC may be able to complete the Business Combination even though
a substantial portion of public shareholders do not agree with the transaction and have redeemed their shares or have entered into privately negotiated agreements to sell their shares to the Sponsor, its director or officers, or their respective
affiliates. As of the date of this proxy statement/prospectus, no agreements with respect to the private purchase of public shares by EBAC or the persons described above have been entered into with any such investor or holder. EBAC will file a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be presented at
the Extraordinary General Meeting or the redemption threshold. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you or a &#147;group&#148; of shareholders of which you are a part are deemed to hold an aggregate of more than 15% of the public shares, you (or, if
a member of such a group, all of the members of such group in the aggregate) will lose the ability to redeem all such shares in excess of 15% of the public shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A public shareholder, together with any of his, her or its affiliates or any other person with whom it is acting in concert or as a &#147;group&#148; (as
defined under Section&nbsp;13 of the Exchange Act), will be restricted from redeeming in the aggregate his, her or its shares or, if part of such a group, the group&#146;s shares, in excess of 15% of the public shares. In order to determine whether
a shareholder is acting in concert or as a group with another shareholder, EBAC will require each public shareholder seeking to exercise redemption rights to certify to EBAC whether such shareholder is acting in concert or as a group with any other
shareholder. Such certifications, together with other public information relating to stock ownership available to EBAC at that time, such as Section&nbsp;13D, Section&nbsp;13G, and Section&nbsp;16 filings under the Exchange Act, will be the sole
basis on which EBAC makes the above-referenced determination. Your inability to redeem any such excess shares will reduce your influence over EBAC&#146;s ability to consummate the Business Combination and you could suffer a material loss on your
investment in EBAC if you sell such excess shares in open market transactions. Additionally, you will not receive redemption distributions with respect to such excess shares if EBAC consummates the Business Combination. As a result, you will
continue to hold that number of shares aggregating to more than 15% of the public shares and, in order to dispose of such excess shares, would be required to sell your stock in open market transactions, potentially at a loss. EBAC cannot assure you
that the value of such excess shares will appreciate over time following the Business Combination or that the market price of the public shares will exceed the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. Notwithstanding the foregoing, shareholders may challenge EBAC&#146;s determination as to whether a shareholder is acting in
concert or as a group with another shareholder in a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, EBAC Shareholders&#146; ability to vote all of their shares
(including such excess shares) for or against the Business Combination is not restricted by this limitation on redemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no guarantee
that a public shareholder&#146;s decision whether to redeem its shares for a pro rata portion of the Trust Account will put the public shareholder in a better future economic position. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC can give no assurance as to the price at which a public shareholder may be able to sell its public shares in the future following the completion of the
Business Combination or any alternative business combination. Certain events following the consummation of any initial business combination, including the Business Combination, may cause an increase in EBAC share price, and may result in a lower
value realized now than a public shareholder might realize in the future had the public shareholder not redeemed its shares. Similarly, if a public shareholder does not redeem its shares, the public shareholder will bear the risk of ownership of the
public shares after the consummation of any initial business combination, and there can be no assurance that a public shareholder can sell its shares in the future for a greater amount than the redemption price set forth in this proxy
statement/prospectus. A public shareholder should consult the public shareholder&#146;s own financial advisor for assistance on how this may affect his, her, or its individual situation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_11"></A>EXTRAORDINARY GENERAL MEETING OF EBAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus is being
provided to EBAC Shareholders as part of a solicitation of proxies by the EBAC Board for use at the Extraordinary General Meeting to be held on &nbsp;&nbsp;&nbsp;&nbsp;, 2023, and at any adjournment or postponement thereof. This proxy
statement/prospectus contains important information regarding the Extraordinary General Meeting, the proposals on which you are being asked to vote and information you may find useful in determining how to vote and voting procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus is being first mailed on or about &nbsp;&nbsp;&nbsp;&nbsp;, 2023 to all shareholders of record of EBAC as of
&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting for EBAC Shareholders that hold their shares in &#147;street name.&#148; For &#147;street name&#148; shareholders, all shareholders of record who owned EBAC Common
Stock at the close of business on the record date are entitled to receive notice of, attend and vote at the Extraordinary General Meeting. On the record date, there were &nbsp;&nbsp;&nbsp;&nbsp; EBAC Common Stock outstanding. EBAC Shareholders that
hold their shares in registered form on the day of the Extraordinary General Meeting are entitled to vote their shares at the Extraordinary General Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place of Extraordinary General Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary General Meeting will be held on &nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, at EBAC&#146;s corporate
address, located at EPFL Innovation Park, Bat D, 3e Route J-D. Colladon, CH-1015 Lausanne, Switzerland, and via a live webcast at &nbsp;&nbsp;&nbsp;&nbsp;, or at such other time, on such other date and at such other place to which the meeting may be
adjourned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to hold the Extraordinary General Meeting in person as well as virtually, via a live webcast at &nbsp;&nbsp;&nbsp;&nbsp;. However,
we are sensitive to the public health and travel concerns our shareholders may have and recommendations that public health officials may issue in light of the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation. As a result, we may
impose additional procedures or limitations on meeting attendees or may decide to hold the meeting in a different location. We plan to announce any such updates on our proxy website at &nbsp;&nbsp;&nbsp;&nbsp;, and we encourage you to check this
website prior to the meeting if you plan to attend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To attend the meeting virtually please visit <B>&nbsp;&nbsp;&nbsp;&nbsp;</B> and use a <FONT
STYLE="white-space:nowrap">12-digit</FONT> control number assigned by Continental included on your proxy card or notice of the Extraordinary General Meeting. To register and receive access to the virtual meeting, registered shareholders and
beneficial shareholders (i.e., those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposals at the Extraordinary General Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the
Extraordinary General Meeting, EBAC Shareholders will vote on the following proposals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Business Combination Proposal</I> &#151; a proposal to approve and adopt the Business Combination Agreement,
a copy of which is attached to this proxy statement/prospectus as <U>Annex A</U>, and the transactions contemplated thereby, including the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Merger Proposal</I> &#150; a proposal to approve and authorize, by special resolution, the Plan of Merger, a
copy of which is attached to this proxy statement/prospectus as <U>Annex C</U>, pursuant to which Merger Sub 1 will be merged with EBAC, the separate entity existence of Merger Sub 1 will cease, and EBAC will be the surviving company and wholly
owned subsidiary of New Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Adjournment Proposal</I> &#151; a proposal to adjourn the Extraordinary General Meeting to a later date or
dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the Business
Combination Proposal and the Merger Proposal or for any other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such that the
Minimum EBAC Cash Condition would not be satisfied. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registering for the Extraordinary General Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder wishing to attend the Extraordinary General Meeting virtually should register for the Extraordinary General Meeting by
&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at &nbsp;&nbsp;&nbsp;&nbsp;. To register for the Extraordinary General Meeting, please follow these instructions as applicable to the nature of your ownership of EBAC shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If your shares are registered in your name with Continental and you attend the Extraordinary General Meeting
and plan to vote virtually, go to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, enter the <FONT STYLE="white-space:nowrap">12-digit</FONT> control number assigned by Continental included on your
proxy card or notice of the Extraordinary General Meeting and click on the &#147;Click here to preregister for the virtual meeting&#148; link at the top of the page. Just prior to the start of the Extraordinary General Meeting you will need to log
back into the Extraordinary General Meeting site using your control number. <FONT STYLE="white-space:nowrap">Pre-registration</FONT> is recommended but is not required in order to attend. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Beneficial shareholders (i.e., those holding shares through a stock brokerage account or by a bank or other
holder of record) who wish to attend the virtual meeting must obtain a legal proxy by contacting their account representative at the bank, broker or other nominee that holds their shares and email a copy (a legible photograph is sufficient) of their
legal proxy to proxy@continentalstock.com. Beneficial shareholders who email a valid legal proxy will be issued a <FONT STYLE="white-space:nowrap">12-digit</FONT> control number that will allow them to register to attend and participate in the
Extraordinary General Meeting. After contacting Continental, a beneficial holder will receive an email prior to the Extraordinary General Meeting with a link and instructions for entering the virtual meeting. Beneficial shareholders should contact
Continental at least five business days prior to the Extraordinary General Meeting date in order to ensure access. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE EBAC BOARD RECOMMENDS THAT YOU VOTE &#147;FOR&#148; EACH OF THESE PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Power; Record Date </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a shareholder of EBAC, you
have a right to vote on certain matters affecting EBAC. The proposals that will be presented at the Extraordinary General Meeting and upon which you are being asked to vote are summarized above and fully set forth in this proxy statement/prospectus.
If you are a shareholder that holds your shares in &#147;street name,&#148; you will be entitled to vote or direct votes to be cast at the Extraordinary General Meeting if you owned EBAC Common Stock at the close of business on
&nbsp;&nbsp;&nbsp;&nbsp;, 2023, which is the record date for the Extraordinary General Meeting. You are entitled to one vote for each share of EBAC Common Stock that you owned as of the close of business on the record date. If your shares are held
in &#147;street name&#148; through a bank, broker or other nominee, or are in a margin or similar account, you should contact your broker, bank or other nominee to ensure that votes related to the shares you beneficially own are properly counted.
For the avoidance of doubt, the record date does not apply to EBAC Shareholders that hold their shares in registered form and are registered as shareholders in EBAC&#146;s register of members. EBAC Shareholders that hold their shares in registered
form are entitled to one vote on each proposal presented at the Extraordinary General Meeting for each share of EBAC Common Stock held on the record date of the Extraordinary General Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote of the EBAC Initial Shareholders and Other Directors and Officers of EBAC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the record date, there were &nbsp;&nbsp;&nbsp;&nbsp; shares of EBAC Common Stock outstanding, of which &nbsp;&nbsp;&nbsp;&nbsp; are shares of EBAC
Class&nbsp;A Common Stock and &nbsp;&nbsp;&nbsp;&nbsp; are shares of EBAC Class&nbsp;B Common Stock held by the EBAC Initial Shareholders (including Founder Shares transferred by the Sponsor in the amount of 25,000 Founder Shares to certain of the
Independent Directors, for a total of 50,000 Founder Shares transferred). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to EBAC&#146;s initial public offering, EBAC entered into certain agreements with the EBAC Initial
Shareholders and other officers and directors of EBAC, pursuant to which each of the parties agreed to vote any EBAC Common Stock owned by them in favor of an initial business combination. These agreements apply to the EBAC Initial Shareholders and
other officers and directors of EBAC, including the Sponsor, as it relates to the Founder Shares and any other public shares held by the EBAC Initial Shareholders and other officers and directors of EBAC. As of the record date, the EBAC Initial
Shareholders and the other current directors and officers of EBAC owned &nbsp;&nbsp;&nbsp;&nbsp; Founder Shares, representing &nbsp;&nbsp;&nbsp;&nbsp;% of the EBAC Common Stock then outstanding and entitled to vote at the Extraordinary General
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Initial Shareholders and the other current officers and directors of EBAC have entered into a letter agreement with EBAC, pursuant to which
they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if EBAC fails to complete its initial business combination within the Combination Period. However, if EBAC Initial Shareholders
and the other current officers and directors of EBAC acquire public shares, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if EBAC fails to complete its initial business combination
within the Combination Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association includes a conversion adjustment which provides
that the Founder Shares will automatically convert, at the time of the Business Combination, into the number of EBAC Class&nbsp;A Common Stock one day after the Acquisition Closing, at a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-to-one</FONT></FONT> conversion rate. However, the Sponsor has agreed to waive such conversion adjustment pursuant to the Sponsor Support Agreement, and as referenced above, in connection with the transactions
contemplated hereby, such Founder Shares will ultimately become New Parent Shares in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum and Required Vote for Proposals for the Extraordinary General Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative vote
of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Approval of the Merger Proposal
requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the issued shares of EBAC Common Stock who are present in person
or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being, where a quorum is present, the affirmative
vote of the holders of at least a majority of the issued shares of EBAC Common Stock who are present in person or represented by proxy and entitled to vote thereon and who vote at the Extraordinary General Meeting. Accordingly, an EBAC
shareholder&#146;s failure to vote by proxy or to vote in person (including virtually by visiting &nbsp;&nbsp;&nbsp;&nbsp;) at the Extraordinary General Meeting will not be counted towards the number of EBAC Common Stock required to validly
establish a quorum, and if a valid quorum is otherwise established, such failure to vote will have no effect on the outcome of any vote on the Business Combination Proposal, the Merger Proposal or the Adjournment Proposal. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted in connection with the determination of whether a valid quorum is established, but will have no effect on the Business Combination Proposal, the Merger Proposal or the
Adjournment Proposal. The EBAC Initial Shareholders and other officers and directors of EBAC have agreed to vote any EBAC Common Stock (including Founder Shares and any other public shares of EBAC as of the record date) owned by them in favor of the
Business Combination and the transactions contemplated thereby (including by voting in favor of the Business Combination Proposal, the Merger Proposal and for any other proposal presented to EBAC Shareholders in this proxy statement/prospectus).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from the votes cast by the EBAC Initial Shareholders and other officers and directors of EBAC, at least &nbsp;&nbsp;&nbsp;&nbsp; votes will be
required to approve the Business Combination Proposal, and at least &nbsp;&nbsp;&nbsp;&nbsp; votes will be required to approve the Merger Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or more shareholders who together hold a majority of the issued and outstanding EBAC Common Stock
entitled to vote at the Extraordinary General Meeting must be present, in person or represented by proxy, at the Extraordinary General Meeting to constitute a quorum and in order to conduct business at the Extraordinary General Meeting. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be counted as present for the purpose of determining a quorum. The EBAC Initial Shareholders and other officers and directors of EBAC, who currently own 21.92% of the issued and
outstanding EBAC Common Stock, will count towards this quorum. In the absence of a quorum, the chairman of the Extraordinary General Meeting has power to adjourn the Extraordinary General Meeting. As of the record date for the Extraordinary General
Meeting, &nbsp;&nbsp;&nbsp;&nbsp; shares of EBAC Common Stock would be required to achieve a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Acquisition Closing is conditioned upon the
approval of the Business Combination Proposal and the Merger Proposal. The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is important for you to note that, in the event that the Business Combination Proposal or the Merger Proposal do not receive the requisite votes for
approval, EBAC will not consummate the Business Combination. If EBAC does not consummate the Business Combination and fails to complete an initial business combination within the Combination Period, EBAC will be required to dissolve and liquidate
the Trust Account by returning the then-remaining funds in the Trust Account to the public shareholders. </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation to EBAC Shareholders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The EBAC Board believes that each of the Business Combination Proposal, the Merger Proposal and the Adjournment Proposal to be presented at the
Extraordinary General Meeting is in the best interests of EBAC and its shareholders and recommends that its shareholders vote &#147;FOR&#148; each of the proposals. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the EBAC Board in favor of approval of the Business Combination Proposal and the Merger Proposal, you should keep in
mind that the Sponsor and certain members of the EBAC Board and officers of EBAC have interests in the Business Combination that are different from or in addition to (or which may conflict with) your interests as a shareholder. Shareholders should
take these interests into account in deciding whether to approve the proposals presented at the Extraordinary General Meeting, including the Business Combination Proposal and the Merger Proposal. These interests include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed not to redeem any EBAC
Common Stock held by them in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $25,000 for the Founder Shares. The Founder Shares had an estimated aggregate
market value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;based upon the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
public share on the Nasdaq Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor transferred Founder Shares to two independent directors prior to EBAC&#146;s initial
public offering and such securities would be worthless if a business combination is not consummated within the Combination Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to any Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period, and, in the event EBAC fails to complete an initial business
combination within the Combination Period, the Founder Shares would have no value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be entered into by
the Sponsor, the EBAC Initial Shareholders and the other officers and directors of EBAC; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $4.55&nbsp;million for its 455,096 Private Placement Units and that such
Private Placement Units (and the underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The Private Placement Units had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per unit on the Nasdaq
Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $4,550,960 for its EBAC Private Placement Units and that such EBAC Private
Placement Units (and the underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The EBAC Private Placement Warrants had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per warrant on the Nasdaq
Capital Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other
shareholders experience a negative rate of return in the post-business combination company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor will own 2,842,618 New Parent Shares, which collectively will represent approximately
6.3% of outstanding New Parent Shares and have a value of approximately $28,426,180 based on an implied value of $10.00 per New Parent Share and assuming that the maximum number of EBAC Class&nbsp;A Common Stock are redeemed while still satisfying
the Minimum EBAC Cash Condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right of EBAC Initial Shareholders and the other directors and officers of EBAC to receive New Parent
Shares, subject to certain <FONT STYLE="white-space:nowrap">lock-up</FONT> periods (it being understood that no contractual selling restrictions apply to any shares issued in connection with the PIPE Financing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the anticipated designation by EBAC of Martijn Kleijwegt and Geraldine O&#146;Keeffe as directors of New Parent
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued indemnification of EBAC&#146;s existing directors and officers and the continuation of
EBAC&#146;s directors&#146; and officers&#146; liability insurance after the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LSP 7, an affiliate of the Sponsor, previously invested $2,104,007 into Oculis on July&nbsp;22, 2022 prior to
the execution of the Business Combination Agreement. In connection with the Oculis Share Contribution, LSP 7 will receive 233,405 New Parent Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an affiliate of the Sponsor has also entered into a Subscription Agreement in connection with the PIPE
Financing, pursuant to which such affiliate has agreed to subscribe for and purchase, and EBAC has agreed to issue from treasury to such affiliate, a certain number of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share for an aggregate
purchase price of $37.896&nbsp;million. Certain of EBAC&#146;s directors also hold a personal financial interest in such affiliate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and EBAC&#146;s officers and directors will lose their entire investment in EBAC and will not be
reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated within the Combination Period. If the Business Combination is consummated
within the Combination Period, pursuant to the Business Combination Agreement, the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the Sponsor and its affiliates and
EBAC&#146;s officers and directors in connection with activities on EBAC&#146;s behalf. The aggregate value of all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for which the Sponsor and
EBAC&#146;s officers and directors are entitled to reimbursement as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting, is
$&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Trust Account is liquidated, including in the event EBAC is unable to complete an initial business
combination within the Combination Period, the Sponsor has agreed to indemnify EBAC to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on
the liquidation date, by the claims of prospective target businesses with which EBAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to EBAC, but only if such a vendor or target business
has not executed a waiver of any and all rights to seek access to the Trust Account; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the consummation of the transactions contemplated hereby, each of the Founder Shares held by
the Sponsor and by certain other directors of EBAC will ultimately be exchanged and converted into a number of New Parent Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Broker <FONT STYLE="white-space:nowrap">Non-Votes</FONT> and Abstentions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions are considered present for the purposes of establishing a quorum, but will have no
effect on the Business Combination Proposal, the Merger Proposal or the Adjournment Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, if your shares are held in &#147;street
name&#148; and you do not instruct your broker, bank or other nominee on a timely basis on how to vote your shares, your broker, bank or other nominee, in its sole discretion, may either leave your shares unvoted or vote your shares on routine
matters, but not on any <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the proposals at the Extraordinary General Meeting are
routine matters. As such, without your voting instructions, your brokerage firm cannot vote your shares on any proposal to be voted on at the Extraordinary General Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Your Shares &#151; Shareholders of Record </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
hold your shares in &#147;street name&#148; and are an EBAC shareholder of record, you may vote by mail or in person at the Extraordinary General Meeting. Each share of EBAC Common Stock that you own in your name entitles you to one vote on each of
the proposals for the Extraordinary General Meeting. Your one or more proxy cards show the number of EBAC Common Stock that you own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting by
Mail</B>. You can vote your shares by completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. By signing the proxy card and returning it in the enclosed
<FONT STYLE="white-space:nowrap">pre-paid</FONT> and addressed envelope, you are authorizing the individuals named on the proxy card to vote your shares at the Extraordinary General Meeting in the manner you indicate. You are encouraged to sign and
return the proxy card even if you plan to attend the Extraordinary General Meeting so that your shares will be voted if you are unable to attend the Extraordinary General Meeting. If you receive more than one proxy card, it is an indication that
your shares are held in multiple accounts. Please sign and return all proxy cards to ensure that all of your shares are voted. If you hold your shares in &#147;street name&#148; through a bank, broker or other nominee, you will need to follow the
instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the Extraordinary General Meeting. If you sign and return the proxy card but do not give instructions on how to vote your
shares, your EBAC Common Stock will be voted as recommended by the EBAC Board. The EBAC Board recommends voting &#147;<B>FOR</B>&#148; the Business Combination Proposal, &#147;<B>FOR</B>&#148; the Merger Proposal and &#147;<B>FOR</B>&#148; the
Adjournment Proposal. Votes submitted by mail must be received by &nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting in Person at the Meeting</B>. If you attend the Extraordinary General Meeting and plan to vote in person, you will be provided with a ballot at the
Extraordinary General Meeting. If your shares are registered directly in your name, you are considered the shareholder of record and you have the right to vote in person at the Extraordinary General Meeting. If you hold your shares in &#147;street
name,&#148; which means your shares are held of record by a broker, bank or other nominee, you should follow the instructions provided by your broker, bank or nominee to ensure that votes related to the shares you beneficially own are properly
counted. In this regard, you must provide the record holder of your shares with instructions on how to vote your shares or, if you wish to attend the Extraordinary General Meeting and vote in person, you will need to bring to the Extraordinary
General Meeting a legal proxy from your broker, bank or nominee authorizing you to vote these shares. That is the only way EBAC can be sure that the broker, bank or nominee has not already voted your EBAC Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Virtually at the Meeting</B>: If your shares are registered in your name with Continental and you attend the Extraordinary General Meeting and plan
to vote virtually, you must visit &nbsp;&nbsp;&nbsp;&nbsp;, enter the <FONT STYLE="white-space:nowrap">12-digit</FONT> control number </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assigned by Continental included on your proxy card or notice of the Extraordinary General Meeting and click on the &#147;Click here to preregister for the virtual meeting&#148; link at the top
of the page. Just prior to the start of the Extraordinary General Meeting you will need to log back into the Extraordinary General Meeting site using your control number. <FONT STYLE="white-space:nowrap">Pre-registration</FONT> is recommended but is
not required in order to attend. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Your Shares &#151; Beneficial Owners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in an account at a brokerage firm, bank or other nominee, then you are the beneficial owner of shares held in &#147;street name&#148;
and this proxy statement/prospectus is being sent to you by that broker, bank or other nominee. The broker, bank or other nominee holding your account is considered to be the shareholder of record for purposes of voting at the Extraordinary General
Meeting. As a beneficial owner, you have the right to direct your broker, bank or other nominee regarding how to vote the shares in your account by following the instructions that the broker, bank or other nominee provides you along with this proxy
statement/prospectus. As a beneficial owner, if you wish to vote at the Extraordinary General Meeting, you will need to bring to the Extraordinary General Meeting a legal proxy from your broker, bank or other nominee authorizing you to vote those
shares. Please see the section entitled &#147;&#151;<I>Attending the Extraordinary General Meeting</I>&#148; below for more details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the
Extraordinary General Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only EBAC Shareholders on the record date (if the shares are held in &#147;street name&#148;) or their legal proxy
holders may attend the Extraordinary General Meeting. To be admitted to the Extraordinary General Meeting, you will need a form of photo identification and valid proof of ownership of EBAC Common Stock or a valid legal proxy. If you have a legal
proxy from a shareholder of record, you must bring a form of photo identification and the legal proxy to the Extraordinary General Meeting. If you have a legal proxy from a &#147;street name&#148; shareholder, you must bring a form of photo
identification, a legal proxy from the record holder (that is, the bank, broker or other holder of record) to the &#147;street name&#148; shareholder that is assignable, and the legal proxy from the &#147;street name&#148; shareholder to you.
Shareholders may appoint only one proxy holder to attend on their behalf. Shareholders that hold their shares in registered form on the record date of the Extraordinary General Meeting are entitled to attend and vote at the Extraordinary General
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial shareholders (i.e., those holding shares through a stock brokerage account or by a bank or other holder of record) who wish to attend
the virtual meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and email a copy (a legible photograph is sufficient) of their legal proxy to
proxy@continentalstock.com. Beneficial shareholders who email a valid legal proxy will be issued a <FONT STYLE="white-space:nowrap">12-digit</FONT> control number that will allow them to register to attend and participate in the virtual meeting.
After contacting Continental, a beneficial holder will receive an email prior to the Extraordinary General Meeting with a link and instructions for entering the virtual meeting. Beneficial shareholders should contact Continental at least five
business days prior to the Extraordinary General Meeting date in order to ensure access. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revoking Your Proxy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a shareholder and you submit a proxy to vote your shares or warrants and wish to change your vote, you may revoke it at any time before the
Extraordinary General Meeting or at the Extraordinary General Meeting by doing any one of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you may send another proxy card with a later date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you may notify EBAC&#146;s Secretary in writing before the Extraordinary General Meeting that you have revoked
your proxy; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">you may attend the Extraordinary General Meeting, revoke your proxy, and vote in person (including by virtual
means), as indicated above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Additional Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary General Meeting has been called only to consider the approval of the Business Combination Proposal, the Merger Proposal and the Adjournment
Proposal. Under EBAC&#146;s amended and restated memorandum and articles of association, other than procedural matters incident to the conduct of the Extraordinary General Meeting, no other matters may be considered at the Extraordinary General
Meeting if they are not included in this proxy statement/prospectus, which serves as the notice of the Extraordinary General Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can Answer
Your Questions About Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about how to vote or direct a vote in respect of your EBAC Common Stock, you may call D.F. King,
EBAC&#146;s proxy solicitor, at (877) 732-3619 (toll free), or banks and brokerage firms, please call collect at (212) 269-5550 or email at EBAC@dfking.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and
restated memorandum and articles of association, any holders of EBAC public shares may demand that such shares be redeemed in exchange for the right to receive a pro rata share of the aggregate amount on deposit in the Trust Account, less taxes
payable, calculated as of two business days prior to the consummation of the Business Combination. If demand is properly made and the Business Combination is consummated, these shares, immediately prior to the First Merger Effective Time, will be
repurchased by EBAC into treasury and in return the right will be granted to receive a pro rata share of the aggregate amount on deposit in the Trust Account which holds the proceeds of EBAC&#146;s initial public offering and a portion of the
proceeds from the sale of the EBAC Private Placement Units (calculated as of two business days prior to the consummation of the Business Combination, less taxes payable), subject to the Acquisition Closing being completed. For illustrative purposes,
based on the fair value of marketable securities held in the Trust Account of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, the estimated per share redemption price would have been approximately $10.052. The EBAC Share Redemption
Amount will be distributed, subject to all conditions being met, by New Parent </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a holder of EBAC public shares exercises its redemption rights, then
such holder will be exchanging its EBAC Class&nbsp;A Common Stock for the right to receive an amount in cash and will not own shares of New Parent following the closing of the transactions contemplated by the Business Combination Agreement,
including the Business Combination. Such a holder will be entitled to receive the right for an amount in cash for its public shares subject to the Acquisition Closing being completed and only if it properly demands redemption and delivers its shares
(either physically or electronically) to the Transfer Agent in accordance with the procedures described herein. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal
name, phone number and address to the Transfer Agent in order to validly redeem its shares. Notwithstanding the foregoing, a holder of the public shares, together with any of its affiliate or any other person with whom it is acting in concert or as
a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock. Accordingly, all public shares in excess of
the 15% threshold beneficially owned by a public shareholder or group will not be redeemed for cash. The EBAC Initial Shareholders and certain other officers and directors of EBAC have agreed, for no consideration in return, to waive their
redemption rights with respect to any Founder Shares and other EBAC Common Stock they may hold in connection with the consummation of the Business Combination, and the Founder Shares and such other EBAC Common Stock will be excluded from the pro
rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise your redemption rights, you must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if you hold EBAC Public Units, separate the underlying EBAC Class&nbsp;A Common Stock and EBAC Public Warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to 5:00 p.m., Eastern Time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the scheduled Extraordinary General Meeting), identify yourself in writing as a beneficial holder and provide your
legal name, phone number and address to the Transfer Agent in order to validly redeem your shares and tender your shares physically or electronically and submit a request in writing that EBAC redeem your public shares for cash to Continental at the
following address: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 State Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New
York 10004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deliver your public shares either physically or electronically through DTC&#146;s DWAC system to the Transfer
Agent at least two business days before the initially scheduled Extraordinary General Meeting. Shareholders seeking to exercise their redemption rights and opting to deliver physical certificates should allot sufficient time to obtain physical
certificates from the Transfer Agent and time to effect delivery. Shareholders should generally allot at least two weeks to obtain physical certificates from the Transfer Agent. However, it may take longer than two weeks. Shareholders who hold their
shares in &#147;street name&#148; will have to coordinate with their bank, broker or other nominee to have the shares certificated or delivered electronically. If you do not submit a written request and deliver your public shares as described above,
your shares will not be redeemed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You do not have to be a record date holder in order to exercise your redemption rights. Shareholders
seeking to exercise their redemption rights, whether they are registered holders or hold their shares in &#147;street name&#148; are required to either tender their certificates to the Transfer Agent prior to the date set forth in this proxy
statement/prospectus, or up to two business days prior to the initially scheduled vote on the Business Combination Proposal and the Merger Proposal at the Extraordinary General Meeting, or to deliver their shares to the Transfer Agent electronically
using DTC&#146;s DWAC system, at such shareholder&#146;s option. <B><U>The requirement for physical or electronic delivery prior to the Extraordinary General Meeting ensures that a redeeming shareholder&#146;s election to redeem is irrevocable once
the Business Combination is approved</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of outstanding EBAC Public Units must separate the underlying EBAC Class&nbsp;A Common Stock and
EBAC Public Warrants prior to exercising redemption rights with respect to the public shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold EBAC Public Units registered in your own name,
you must deliver the certificate for such units to the Transfer Agent with written instructions to separate such units into EBAC Class&nbsp;A Common Stock and EBAC Public Warrants. This must be completed far enough in advance to permit the mailing
of the public share certificates back to you so that you may then exercise your redemption rights upon the separation of the EBAC Class&nbsp;A Common Stock from the EBAC Public Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a broker, dealer, commercial bank, trust company or other nominee holds your EBAC Public Units, you must instruct such nominee to separate your units. Your
nominee must send written instructions by facsimile to the Transfer Agent. Such written instructions must include the number of units to be split and the nominee holding such units. Your nominee must also initiate electronically, using DTC&#146;s
DWAC system, a withdrawal of the relevant units and a deposit of an equal number of EBAC Class&nbsp;A Common Stock and EBAC Public Warrants. This must be completed far enough in advance to permit your nominee to exercise your redemption rights upon
the separation of the public shares from the EBAC Public Units. While this is typically done electronically on the same business day, you should allow at least one full business day to accomplish the separation. If you fail to cause your EBAC Public
Units to be separated in a timely manner, you will likely not be able to exercise your redemption rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each redemption of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders will reduce the amount
in the Trust Account, which held marketable securities with a fair value of approximately $128.3&nbsp;million as of September&nbsp;30, 2022. The conditions to closing in the Business Combination Agreement are for the sole benefit of the parties
thereto and may be waived by such parties. If, as a result of redemptions of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by Oculis or EBAC, then either party may
elect not to consummate the Business Combination. In addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001, as provided in EBAC&#146;s amended and
restated memorandum and articles of association. Under these circumstances, EBAC Shareholders may exercise their redemption rights with respect to a maximum of 10,363,709 redeemable shares of EBAC Class&nbsp;A Common Stock upon consummation of the
Business Combination at a redemption price of approximately $10.052 per share. The estimated per share redemption value of $10.052 was calculated by dividing the Trust Account balance of approximately $128.3&nbsp;million as of September&nbsp;30,
2022, by 12,754,784 shares of EBAC Class&nbsp;A Common Stock outstanding and subject to redemption. Please see the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information&#151;Redemption Scenarios</I>.&#148; EBAC
Shareholders who wish to redeem their public shares for cash must refer to and follow the procedures set forth in the section entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Redemption Rights</I>&#148; in order to properly redeem their
public shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to redemption rights, holders of EBAC Class&nbsp;B Common Stock have different incentives than holders of EBAC Class&nbsp;A
Common Stock with respect to the completion of any proposed business combination (including the Business Combination) and/or the exercise of any right to redeem. In particular, holders of EBAC Class&nbsp;B Common Stock are not entitled to
participate in any redemption with respect to such shares. The value of the EBAC Class&nbsp;B Common Stock is dependent on the consummation of an initial business combination. In the event no initial business combination is consummated within the
Combination Period, the EBAC Class&nbsp;B Common Stock would be rendered valueless. Holders of EBAC Class&nbsp;A Common Stock, on the other hand, are entitled to exercise redemption rights and receive the value of their redeemed shares even if an
initial business combination is not completed. Therefore, the interests of holders of EBAC Class&nbsp;A Common Stock and EBAC Class&nbsp;B Common Stock may not be aligned. Holders of EBAC Class&nbsp;A Common Stock should form their own independent
views as to whether or not to redeem or whether or not to vote in favor of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to exercising redemption rights, EBAC
Shareholders should verify the market price of the EBAC Class&nbsp;A Common Stock, as shareholders may receive higher proceeds from the sale of their EBAC Class&nbsp;A Common Stock in the public market than from exercising their redemption rights if
the market price per share is higher than the redemption price. There is no assurance that you will be able to sell your EBAC Class&nbsp;A Common Stock in the open market, even if the market price per share is higher than the redemption price stated
above, as there may not be sufficient liquidity in the EBAC Class&nbsp;A Common Stock when you wish to sell your shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you exercise your
redemption rights, your EBAC Class</B><B></B><B>&nbsp;A Common Stock will be repurchased by EBAC into treasury immediately prior to the First Merger Effective Time and in return you will obtain the right to receive a pro rata share of the aggregate
amount then on deposit in the Trust Account, subject to the Acquisition Closing being completed.</B> You will no longer own those shares and you will not receive any New Parent Shares in the Business Combination. You will have no right to
participate in, or have any interest in, the future growth of New Parent, if any. You will be entitled to receive the right for an amount in cash for your EBAC Class&nbsp;A Common Stock only if you properly and timely demand redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is not approved and EBAC does not consummate an initial business combination within the Combination Period, EBAC will be required
to dissolve and liquidate the Trust Account by returning the then-remaining funds in such account to the public shareholders and all of EBAC&#146;s Warrants will expire worthless. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the holders of EBAC Warrants have appraisal rights in connection with the Business Combination under the Cayman Companies Act. EBAC Shareholders may
be entitled to give notice to EBAC prior to the meeting that they wish to dissent to the Business Combination and to receive payment of fair market value for his, her or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its EBAC Common Stock if they follow the procedures set forth in the Cayman Companies Act, noting that any such dissention rights may be limited pursuant to Section&nbsp;239 of the Cayman
Companies Act, which states that no such dissention rights shall be available in respect of shares of any class for which an open market exists on a recognized stock exchange at the expiry date of the period allowed for written notice of an election
to dissent provided that the merger consideration constitutes inter alia shares of any company which at the effective date of the merger are listed on a national securities exchange. It is the view of the EBAC Board that such fair market value would
equal the amount which EBAC Shareholders would obtain if they exercise their redemption rights as described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to
Oculis Shareholders in connection with the Business Combination. For more information, please see the section entitled &#147;<I>Proposal No. 1</I>&#151;<I>The Business Combination Proposal</I>&#151;<I>Appraisal Rights</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is soliciting proxies on
behalf of the EBAC Board. This proxy solicitation is being made by mail, but also may be made by telephone or in person. EBAC has engaged D.F. King to assist in the solicitation of proxies for the Extraordinary General Meeting. EBAC and its
directors, officers and employees may also solicit proxies in person. EBAC will ask banks, brokers and other institutions, nominees and fiduciaries to forward this proxy statement/prospectus and the related proxy materials to their principals and to
obtain their authority to execute proxies and voting instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis and EBAC will each bear <FONT STYLE="white-space:nowrap">one-half</FONT> of the
costs of the proxy solicitation, including the preparation, assembly, printing, mailing and distribution of this proxy statement/prospectus and the related proxy materials. Oculis and EBAC will each pay D.F. King
<FONT STYLE="white-space:nowrap">one-half</FONT> of a fee of $25,000, plus disbursements and indemnify D.F.&nbsp;King and its affiliates against certain claims, liabilities, losses, damages and expenses for their services as EBAC&#146;s proxy
solicitor. Oculis and EBAC will each bear <FONT STYLE="white-space:nowrap">one-half</FONT> of the reimbursement costs to brokerage firms and other custodians for their reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for forwarding this proxy statement/prospectus and the related proxy materials to EBAC Shareholders. Directors, officers and employees of EBAC who
solicit proxies will not be paid any additional compensation for soliciting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_12"></A>MATERIAL TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States Federal Income Tax Considerations to U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are certain material U.S. federal income tax consequences of (i)&nbsp;the Business Combination generally applicable to U.S. Holders (as defined
below) of EBAC Common Stock and EBAC Warrants (together, &#147;<I>EBAC Securities</I>&#148;), (ii) the exercise of redemption rights by U.S. Holders of EBAC Class&nbsp;A Common Stock, and (iii)&nbsp;the subsequent ownership and disposition of New
Parent Shares and New Parent Warrants (together, &#147;<I>New Parent Securities</I>&#148;) following the Business Combination. This discussion is limited to U.S. federal income tax considerations relevant to U.S. Holders that hold EBAC Securities
and, after the completion of the Business Combination, will hold New Parent Securities, as capital assets within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not discuss all aspects of
U.S. federal income taxation that may be relevant to U.S. Holders in light of their particular circumstances or status, including without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Sponsor or its officers or directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions or financial services entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that are subject to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> tax accounting rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governments or agencies or instrumentalities thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that actually or constructively own five percent (5%) or more of the shares of EBAC or, following the
Business Combination, New Parent, by vote or value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired EBAC Securities pursuant to an exercise of employee share options, in connection with
employee share incentive plans, or otherwise as compensation or in connection with services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold EBAC Securities or will hold New Parent Securities, in connection with a trade or business,
permanent establishment, or fixed place of business conducted outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold EBAC Securities or will hold New Parent Shares, as part of a straddle, constructive sale,
hedging, conversion, or other integrated or similar transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency is not the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, proposed, temporary, and final Treasury Regulations promulgated under the Code, and judicial and administrative
interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S. federal taxes other
than those pertaining to U.S. federal income taxation (such as estate or gift taxes), the alternative minimum tax, the special tax accounting rules under Section&nbsp;451(b) of the Code, or the Medicare contribution tax on investment income, nor
does it address any aspects of U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not and do not intend to seek
any rulings from the IRS regarding the Business Combination or an exercise of redemption rights. There can be no assurance that the IRS will not take positions inconsistent with the tax considerations discussed below or that any such positions would
not be sustained by a court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not consider the tax treatment of partnerships or other pass-through entities or
persons that hold EBAC Securities or New Parent Securities through such entities. If a partnership (or any entity or arrangement so characterized for U.S. federal income tax purposes) holds EBAC Securities or New Parent Securities, the tax treatment
of such partnership and a person treated as a partner of such partnership will generally depend on the status of the partner and the activities of the partnership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partnerships holding EBAC Securities or New Parent Securities and persons that are treated as partners of such partnerships should consult their tax advisors
as to the particular U.S. federal income tax consequences of the Business Combination and an exercise of redemption rights with respect to the EBAC Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH U.S. HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE BUSINESS COMBINATION AND AN
EXERCISE OF REDEMPTION RIGHTS, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used herein, a &#147;<I>U.S. Holder</I>&#148; is a beneficial owner of EBAC Securities or New Parent Securities received pursuant to the Business
Combination (as the case may be) who or that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is
created or organized (or treated as created or organized) in or under the laws of the United States or any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;if a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more United States persons (as defined in the Code) have the authority to control all substantial decisions of the trust or (ii)&nbsp;that has in effect a valid election under applicable Treasury Regulations to
be treated as a United States person. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences of the Business Combination to U.S. Holders of EBAC Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Qualification of the EBAC Mergers as a Reorganization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;368(a)(1)(F) of the Code, a reorganization is defined to include a &#147;mere change in identity, form, or place of organization of one
corporation, however effected&#148; (an &#147;<I>F Reorganization</I>&#148;). Pursuant to the EBAC Mergers, Merger Sub 1 will merge with and into EBAC, the separate corporate existence of Merger Sub 1 shall cease, and EBAC will be the surviving
company, after which EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease, and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent. Immediately after the EBAC
Mergers, New Parent will, for U.S. federal income tax purposes, own the same assets and be subject to the same liabilities as EBAC immediately prior to the EBAC Mergers because Merger Sub 2 is disregarded as an entity separate from New Parent for
U.S. federal income tax purposes, and will have the same shareholders as EBAC did immediately prior to the EBAC Mergers. Furthermore, the Oculis Share Contribution and the Third Merger should not adversely affect the U.S. federal income tax
treatment of the EBAC Mergers. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of Davis Polk &amp; Wardwell LLP, it is expected that the EBAC Mergers qualify as an F Reorganization.
If, as expected, the EBAC Mergers qualify as an F Reorganization, U.S. Holders of EBAC Securities will generally not recognize gain or loss for U.S. federal income tax purposes on the EBAC Mergers. The remaining discussion under this section assumes
that the EBAC Mergers qualify as an F Reorganization. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, as expected, the EBAC Mergers qualify as an F Reorganization: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adjusted tax basis of a U.S. Holder in the New Parent Shares received in the EBAC Mergers will equal such
U.S. Holder&#146;s adjusted tax basis in the EBAC Common Stock surrendered in exchange therefor, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adjusted tax basis of a U.S. Holder in the New Parent Warrants received in the EBAC Mergers will equal such
U.S. Holder&#146;s adjusted tax basis in the EBAC Warrants surrendered in exchange therefor, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a U.S. Holder&#146;s holding period in the New Parent Securities received in the exchange will include such U.S.
Holder&#146;s holding period for the EBAC Securities surrendered in exchange therefor. However, it is unclear whether the redemption rights with respect to the EBAC Common Stock may prevent the holding period of the New Parent Shares from commencing
prior to the termination of such rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the EBAC Mergers do not qualify as an F Reorganization, the tax consequences of the EBAC
Mergers will depend on whether the EBAC Mergers or any component thereof would qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under other provisions of the Code. U.S. Holders should consult their tax advisors regarding the
U.S. federal income tax consequences of the EBAC Mergers if they do not qualify as an F Reorganization or otherwise as <FONT STYLE="white-space:nowrap">tax-free</FONT> transactions (including the requirement to recognize gain in that event). In
addition, U.S. Holders should consult their tax advisors regarding whether the PFIC rules could apply to the transfer of their EBAC Securities pursuant to the EBAC Mergers if they do not qualify as an F Reorganization (regardless of whether the EBAC
Mergers otherwise qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All U.S. Holders considering exercising redemption rights with
respect to EBAC Common Stock are urged to consult with their tax advisors with respect to the potential tax consequences of the EBAC Mergers and an exercise of redemption rights to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Redemption of EBAC Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of Davis Polk &amp; Wardwell LLP, the following are the material U.S. federal income tax consequences of the redemption of EBAC Class A Common
Stock by U.S. Holders of EBAC Class A Common Stock. In the event that a U.S. Holder&#146;s shares of EBAC Class&nbsp;A Common Stock are redeemed pursuant to the redemption provisions described in this proxy statement, the treatment of the redemption
for U.S. federal income tax purposes will depend on whether the redemption qualifies as a sale of EBAC Class&nbsp;A Common Stock under Section&nbsp;302 of the Code. If the redemption or purchase by us qualifies as a sale of EBAC Class&nbsp;A Common
Stock, the U.S. Holder will be treated as described under &#147;<I>&#151;Taxation on the Disposition of New Parent Securities</I>&#148; below. If the redemption or purchase by us does not qualify as a sale of EBAC Class&nbsp;A Common Stock, the U.S.
Holder will be treated as receiving a corporate distribution with the tax consequences described below under the section entitled &#147;<I>&#151;Taxation of Dividends and Other Distributions on New Parent Shares</I>.&#148; Whether a redemption or
purchase by us qualifies for sale treatment will depend largely on the total number of EBAC Class&nbsp;A Common Stock treated as held by the U.S. Holder (including any EBAC Class&nbsp;A Common Stock constructively owned by the U.S. Holder as a
result of owning warrants) relative to all of the EBAC Class&nbsp;A Common Stock outstanding both before and after such redemption or purchase. The redemption or purchase by us of EBAC Class&nbsp;A Common Stock generally will be treated as a sale of
EBAC Class&nbsp;A Common Stock (rather than as a corporate distribution) if such redemption or purchase (i)&nbsp;is &#147;substantially disproportionate&#148; with respect to the U.S. Holder, (ii)&nbsp;results in a &#147;complete termination&#148;
of the U.S. Holder&#146;s interest in us, or (iii)&nbsp;is &#147;not essentially equivalent to a dividend&#148; with respect to the U.S. Holder (collectively, the &#147;<I>Section</I><I></I><I>&nbsp;302 tests</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining whether any of the Section&nbsp;302 tests is satisfied, a U.S. Holder takes into account not only shares of EBAC Class&nbsp;A Common Stock
actually owned by the U.S. Holder, but also shares of EBAC Class&nbsp;A Common Stock that are constructively owned by such U.S. Holder under the relevant rules. A U.S. Holder may constructively own, in addition to shares owned directly, shares owned
by certain related individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any shares the U.S. Holder has a right to acquire by exercise of an option, which would generally include
EBAC Class&nbsp;A Common Stock which could be acquired pursuant to the exercise of the EBAC Warrants. In order to meet the substantially disproportionate test, the percentage of EBAC outstanding voting shares actually and constructively owned by the
U.S. Holder immediately following the redemption of EBAC Class&nbsp;A Common Stock must, among other requirements, be less than 80&nbsp;percent of the percentage of EBAC Class&nbsp;A Common Stock by the U.S.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder immediately before the redemption. There will be a complete termination of a U.S. Holder&#146;s interest if either (i)&nbsp;all of the EBAC Class&nbsp;A Common Stock actually and
constructively owned by the U.S. Holder are redeemed or (ii)&nbsp;all of the EBAC Class&nbsp;A Common Stock actually owned by the U.S. Holder are redeemed and the U.S. Holder is eligible to waive, and effectively waives in accordance with specific
rules, the attribution of shares owned by certain family members and the U.S. Holder does not constructively own any other EBAC Class&nbsp;A Common Stock. The redemption of EBAC Class&nbsp;A Common Stock will not be essentially equivalent to a
dividend if such redemption results in a &#147;meaningful reduction&#148; of the U.S. Holder&#146;s proportionate interest in EBAC. Whether the redemption will result in a meaningful reduction in a U.S. Holder&#146;s proportionate interest in EBAC
Class&nbsp;A Common Stock will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority shareholder in a publicly held
corporation who exercises no control over corporate affairs may constitute such a &#147;meaningful reduction.&#148; A U.S. Holder should consult with its own tax advisors as to the tax consequences of a redemption of EBAC Class&nbsp;A Common Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If none of the Section&nbsp;302 tests are satisfied, then the redemption will be treated as a corporate distribution and the tax effects will be as
described under &#147;&#151;<I>Taxation of Dividends and Other Distributions on New Parent Shares</I>&#148; below. After the application of those rules, any remaining tax basis of the U.S. Holder in the redeemed EBAC Class&nbsp;A Common Stock will
be added to the U.S. Holder&#146;s adjusted tax basis in its remaining EBAC Class&nbsp;A Common Stock, or, if it has none, to the U.S. Holder&#146;s adjusted tax basis in its EBAC Warrants or possibly in other shares constructively owned by such
U.S. Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders may be subject to special reporting requirements with respect to a redemption of EBAC Class&nbsp;A Common Stock, and
such holders should consult with their own tax advisors with respect to their reporting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Considerations of Owning
and Disposing of New Parent Securities Following the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Taxation of Dividends and Other Distributions on New
Parent Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, if New Parent makes a distribution of cash or other property to a U.S. Holder of New Parent
Shares, such distribution (including amounts withheld to reflect Swiss withholding taxes) will generally be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of New Parent&#146;s current or
accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends will generally be taxable to a corporate U.S. Holder at regular rates and will not be eligible for the dividends-received deduction generally
allowed to domestic corporations in respect of dividends received from other domestic corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions in excess of such earnings and profits
will generally be applied against and reduce the U.S. Holder&#146;s basis in its New Parent Shares (but not below zero) and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of such New Parent Shares. Because
New Parent does not expect to determine its earnings and profits on the basis of U.S. federal income tax principles, any distribution paid by New Parent will generally be reported as a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders, dividends will generally be taxed at preferential long-term capital gains
rates only if (i)&nbsp;New Parent Shares are readily tradable on an established securities market in the United States or (ii)&nbsp;New Parent is eligible for the benefits of the income tax treaty between the United States and Switzerland (the
&#147;<I>Treaty</I>&#148;), in each case provided that New Parent is not treated as a PFIC in the taxable year in which the dividend was paid or in any previous year and certain holding period and other requirements are met. However, it is unclear
whether the redemption rights with respect to EBAC Common Stock may prevent the holding period of New Parent Shares from commencing prior to the termination of such rights. U.S. Holders should consult their tax advisors regarding the availability of
the preferential rate for any dividends paid with respect to New Parent Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of any dividend paid in Swiss francs (including amounts withheld to reflect Swiss withholding
taxes) will equal the U.S. dollar value of the dividend, calculated by reference to the exchange rate in effect at the time the dividend is actually or constructively received by the U.S. Holder, regardless of whether the payment is in fact
converted into U.S. dollars at that time. A U.S. Holder should not recognize any foreign currency gain or loss in respect of such dividend if such Swiss francs are converted into U.S. dollars on the date received by the U.S. Holder. If the Swiss
francs are not converted into U.S. dollars on the date of receipt, however, gain or loss may be recognized upon a subsequent sale or other disposition of the Swiss francs. Such foreign currency gain or loss, if any, will be U.S. source ordinary
income or loss. U.S. Holders should consult their own tax advisors regarding the tax treatment of any foreign currency gain or loss if any Swiss francs received as a dividend on New Parent Shares are not converted into U.S. dollars on the date of
receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder may be entitled, subject to certain limitations, to a foreign tax credit against its U.S. federal income tax liability, or a
deduction in computing its U.S. federal taxable income, for Swiss withholding taxes withheld by New Parent. To the extent a reduction or refund of the tax withheld is available to a U.S. Holder under Swiss law or under the Treaty, the amount of tax
withheld that could have been reduced or that is refundable will not be eligible for credit against the U.S. Holder&#146;s U.S. federal income tax liability. Dividends will generally constitute foreign source &#147;passive category income&#148; for
purposes of the foreign tax credit. The rules governing foreign tax credits are complex. U.S. Holders should consult their tax advisors concerning the foreign tax credit implications of Swiss withholding taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Taxation on the Disposition of New Parent Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, upon a sale or other taxable disposition of New Parent Securities, a U.S. Holder will generally recognize capital
gain or loss. The amount of gain or loss recognized, if any, will generally be equal to the difference between (i)&nbsp;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&nbsp;the U.S.
Holder&#146;s adjusted tax basis in the securities so disposed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under tax law currently in effect, long-term capital gains recognized by <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders are generally subject to U.S. federal income tax at a reduced rate of tax. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&#146;s holding period for
New Parent Shares exceeds one year. However, it is unclear whether the redemption rights with respect to EBAC Common Stock may prevent the holding period of New Parent Shares from commencing prior to the termination of such rights. The deductibility
of capital losses is subject to various limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Exercise, Lapse, or Redemption of a New Parent Warrant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below and except as discussed below regarding a cashless exercise, a U.S. Holder will generally not recognize gain or loss
upon the exercise of a New Parent Warrant. A New Parent Share acquired pursuant to the exercise of a New Parent Warrant for cash will generally have a tax basis equal to the U.S. Holder&#146;s tax basis in the warrant, increased by the amount paid
to exercise the warrant. It is unclear whether the U.S. Holder&#146;s holding period for such New Parent Share will commence on the date of exercise of the New Parent Warrant or the day following the date of exercise of the warrant; in either case,
the holding period will not include the period during which the U.S. Holder held the warrant. If a New Parent Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to such holder&#146;s tax basis in the
warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the absence of authority specifically addressing the treatment of a cashless exercise of warrants under U.S. federal income tax law,
the treatment of such a cashless exercise is unclear. A cashless exercise may be <FONT STYLE="white-space:nowrap">tax-free,</FONT> either because the exercise is not a realization event or because the exercise is treated as a recapitalization for
U.S. federal income tax purposes. Alternatively, a cashless exercise could be treated as a taxable exchange in which gain or loss would be recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
either <FONT STYLE="white-space:nowrap">tax-free</FONT> situation, a U.S. Holder&#146;s tax basis in the New Parent Shares received would generally equal the U.S. Holder&#146;s tax basis in the New Parent Warrants. If a cashless exercise is not
treated as a realization event, it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is unclear whether a U.S. Holder&#146;s holding period for the New Parent Shares received on exercise will be treated as commencing on the date of exercise of the New Parent Warrants or the
following day. If a cashless exercise is treated as a recapitalization, the U.S. Holder&#146;s holding period for the New Parent Shares received will include the holding period of the New Parent Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a cashless exercise is treated as a taxable exchange, a U.S. Holder could be deemed to have surrendered New Parent Warrants with an aggregate fair market
value equal to the exercise price for the total number of New Parent Warrants to be exercised. In this case, the U.S. Holder would recognize capital gain or loss in an amount equal to the difference, if any, between the fair market value of the New
Parent Warrants deemed surrendered and the U.S. Holder&#146;s tax basis in such warrants. A U.S. Holder&#146;s tax basis in the New Parent Shares received would equal the sum of the U.S. Holder&#146;s initial investment in the New Parent Warrants
exercised (<I>i.e.</I>, the U.S. Holder&#146;s purchase price for the warrants (or the portion of such U.S. Holder&#146;s purchase price for EBAC Units that is allocated to the EBAC Warrants)) and the exercise price of such warrants. It is unclear
whether a U.S. Holder&#146;s holding period for the New Parent Shares would commence on the date of exercise of the New Parent Warrants or the day following the date of exercise of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative
tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise of New Parent Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Possible Constructive Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
terms of each New Parent Warrant provide for an adjustment to the number of New Parent Shares for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment that has the effect of preventing dilution
is generally not taxable. However, U.S. Holders of New Parent Warrants would be treated as receiving a constructive distribution from New Parent if, for example, the adjustment increases the warrant holders&#146; proportionate interest in New
Parent&#146;s assets or earnings and profits (<I>e.g.</I>, through an increase in the number of New Parent Shares that would be obtained upon exercise or through a decrease to the exercise price) as a result of a distribution of cash to U.S. Holders
of New Parent Shares that is taxable to such U.S. Holders as a distribution as described above under &#147;<I>&#151;Taxation of Dividends and Other Distributions on New Parent Shares</I>.&#148; Such constructive distribution would be subject to tax
as described under that section in the same manner as if the U.S. Holders of New Parent Warrants received a cash distribution from New Parent equal to the fair market value of the increase in the interest. U.S. Holders should consult their tax
advisors regarding the tax consequences in their particular circumstances, including the possibility of any constructive distributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Passive Foreign Investment Company Rules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax treatment of U.S. Holders of New Parent Shares and/or New Parent Warrants could be materially different from that described above, if New Parent is
treated as a PFIC for U.S. federal income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a foreign (<I>i.e.</I>, <FONT STYLE="white-space:nowrap">non-U.S.)</FONT> corporation
will be a PFIC for U.S. federal income tax purposes if at least 75% of its gross income in a taxable year of the foreign corporation is passive income, including its pro rata share of the gross income of any corporation in which it is considered to
own at least 25% of the shares by value (a &#147;<I>Look-Through Subsidiary</I>&#148;). Alternatively, a foreign corporation will be a PFIC if at least 50% of its assets in a taxable year of the foreign corporation, ordinarily determined for based
on fair market value and averaged quarterly over the year, including such foreign corporation&#146;s pro rata share of the assets of any Look-Through Subsidiary (and excluding the value of the shares held in such corporation), are held for the
production of, or produce, passive income. Passive income generally includes dividends (excluding any dividends received from a Look-Through Subsidiary), interest, rents and royalties (other than certain rents or royalties derived from the active
conduct of a trade or business), and gains from the disposition of passive assets. Cash and cash equivalents are generally passive assets. The value of goodwill will generally be treated as an active or passive asset based on the nature of the
income produced in the activity to which the goodwill is attributable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because New Parent&#146;s PFIC status for any taxable year is an annual determination that can be made only
after the end of such taxable year and may depend in part on the value of its unbooked goodwill (which may be determined in large part by reference to the market price of New Parent Shares from time to time, which could be volatile), there can be no
assurance that New Parent will not be a PFIC for the taxable year ending December&nbsp;31, 2022, or any future taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the PFIC status
of EBAC may affect U.S. Holders that own New Parent Shares or New Parent Warrants. If, as expected, the EBAC Mergers qualify as an F Reorganization, as discussed above, New Parent will be treated as the successor to EBAC for U.S. federal income tax
purposes, including for purposes of the PFIC rules. Because EBAC is a blank-check company with no current active business, based upon the composition of EBAC&#146;s income and assets, EBAC believes it would qualify as a PFIC for its taxable year
ending December&nbsp;31, 2022, and, if the Business Combination is not completed in 2022, would likely qualify as a PFIC for its taxable year ending December&nbsp;31, 2023. In the event that EBAC qualifies as a PFIC for its taxable year ending
December&nbsp;31, 2022, New Parent should also qualify as a PFIC for that same taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, there can be no assurance with respect
to New Parent or EBAC&#146;s PFIC status for any taxable year. Additionally, although a foreign corporation&#146;s PFIC status is determined annually, a determination that EBAC or New Parent is a PFIC for a taxable year in which a U.S. Holder holds
shares in such entity will generally continue to apply to such U.S. Holder for subsequent taxable years in which the holder continues to hold shares in such entity (including a successor entity), whether or not such entity continues to be a PFIC. As
such, if EBAC was a PFIC during the holding period of a U.S. Holder, any New Parent Shares received in exchange for EBAC Common Stock in the EBAC Mergers (or on the exercise of New Parent Warrants exchanged for EBAC Warrants) may, in the absence of
certain elections described below, be treated as stock of a PFIC, even if New Parent is not a PFIC for the taxable year ending December&nbsp;31, 2022, or future taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC or New Parent is treated as a PFIC for any taxable year during which a U.S. Holder owns or is treated as owning New Parent Securities, the U.S. Holder
generally will be subject to special rules (the &#147;<I>Default PFIC Regime</I>&#148;) unless, in the case of EBAC Common Stock and New Parent Shares, the U.S. Holder made (i)&nbsp;a timely and effective QEF Election (as defined below) for
EBAC&#146;s or New Parent&#146;s (as the case may be) first taxable year as a PFIC in which the U.S. Holder held or is treated as holding EBAC Common Stock or New Parent Shares (such taxable year as it relates to each U.S. Holder, the &#147;<I>First
PFIC Holding Year</I>&#148;), (ii)&nbsp;a QEF Election along with a purging election (as discussed below), or (iii)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election, each as
described below. The Default PFIC Regime applies with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any gain recognized by the U.S. Holder on the sale or other disposition of its New Parent Shares or New Parent
Warrants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any &#147;excess distribution&#148; made to the U.S. Holder (generally, any distributions to such U.S. Holder
during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of its New Parent Shares during the three preceding taxable years of such U.S. Holder or, if shorter,
such U.S. Holder&#146;s holding period for such New Parent Shares). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Default PFIC Regime: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Holder&#146;s gain or excess distribution will be allocated ratably over the U.S. Holder&#146;s holding
period for its New Parent Shares or New Parent Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to the U.S. Holder&#146;s taxable year in which the U.S. Holder recognized the gain
or received the excess distribution, or to the period in the U.S. Holder&#146;s holding period before the first day of the First PFIC Holding Year, will be taxed as ordinary income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to other taxable years (or portions thereof) of the U.S. Holder and included in such
U.S. Holder&#146;s holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on
the U.S. Holder in respect of the tax attributable to each such other taxable year of such U.S. Holder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ALL U.S. HOLDERS ARE URGED
TO CONSULT THEIR TAX ADVISORS REGARDING THE EFFECTS OF THE PFIC RULES ON THE EXCHANGE OR REDEMPTION OF EBAC COMMON STOCK AND EBAC WARRANTS AND ON THE OWNERSHIP OR DISPOSITION OF NEW PARENT SHARES AND NEW PARENT WARRANTS, INCLUDING THE IMPACT OF ANY
PROPOSED OR FINAL TREASURY REGULATIONS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a U.S. Holder may avoid the Default PFIC Regime with respect to its New Parent Shares (but not
New Parent Warrants) by making a timely and effective &#147;qualified electing fund&#148; election under Section&nbsp;1295 of the Code (a &#147;<I>QEF Election</I><B>&#148;</B>) with respect to such holder&#146;s First PFIC Holding Year. A U.S.
Holder that makes a QEF Election will include in income its pro rata share of New Parent&#146;s net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current basis, in each case whether or not
distributed, in the taxable year of the U.S. Holder in which or with which New Parent&#146;s taxable year ends if New Parent is treated as a PFIC for that taxable year. A U.S. Holder generally can make a separate election to defer the payment of
taxes on undistributed income inclusions under the QEF Election rules, but if deferred, any such taxes will be subject to an interest charge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S.
Holder may not make a QEF Election with respect to its New Parent Warrants. As a result, if a U.S. Holder sells or otherwise disposes of such warrants (other than upon exercise of such warrants) and EBAC or New Parent was a PFIC at any time during
the U.S. Holder&#146;s holding period of such warrants, any gain recognized will generally be subject to the special tax and interest charge rules treating the gain as an excess distribution under the Default PFIC Regime. If a U.S. Holder that
exercises such warrants properly makes a QEF Election with respect to the newly acquired New Parent Shares, the QEF Election will apply to the newly acquired New Parent Shares (though it is not clear how a previously made QEF Election that is in
effect with respect to New Parent would apply to New Parent Shares subsequently acquired on the exercise of such warrants). Notwithstanding the foregoing, the adverse tax consequences relating to PFIC shares, adjusted to take into account the
current income inclusions resulting from the QEF Election, will generally continue to apply with respect to such newly acquired New Parent Shares (which will generally be deemed to have a holding period for purposes of the PFIC rules that includes
all or a portion of the period the U.S. Holder held the warrants), unless the U.S. Holder makes a purging election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The QEF Election is made on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shareholder-by-shareholder</FONT></FONT> basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF Election by attaching a completed IRS
Form 8621 (Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including the information provided in a PFIC Annual Information Statement (as defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1295-1(g)</FONT> of the Treasury Regulations), to a timely filed U.S. federal income tax return for the taxable year to which the election relates. Retroactive QEF elections generally may be made only
by filing a protective statement with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a retroactive QEF
Election under their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the requirements of a QEF Election with respect to New Parent Shares, a U.S.
Holder must receive a PFIC Annual Information Statement from New Parent. If New Parent determines that it is a PFIC for any taxable year, New Parent will endeavor to make available to U.S. Holders a PFIC Annual Information Statement with respect to
such taxable year. However, there is no assurance that New Parent will have timely knowledge of its status as a PFIC in the future or that it will make available a PFIC Annual Information Statement. U.S. Holders are urged to consult their tax
advisors with respect to any QEF Election previously made with respect to EBAC Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder has made a QEF Election with respect to New Parent Shares, and the special tax and interest
charge rules do not apply to such shares (because the QEF Election was made in the U.S. Holder&#146;s First PFIC Holding Year or a purging election was made), any gain recognized on the sale of New Parent Shares will generally be taxable as capital
gain and no interest charge will be imposed under the PFIC rules. As discussed above, U.S. Holders that make a QEF Election with respect to a PFIC are currently taxed on their pro rata shares of such PFIC&#146;s earnings and profits, whether or not
distributed. In such case, a subsequent distribution of such earnings and profits that were previously included in income should generally not be taxable as a dividend to such U.S. Holders. The tax basis of a U.S. Holder&#146;s shares in a PFIC with
respect to which a QEF Election has been made will be increased by amounts that are included in taxable income, and decreased by amounts distributed but not taxed as dividends, under the above rules. Similar basis adjustments apply to property if by
reason of holding such property the U.S. Holder is treated under the applicable attribution rules as owning shares in a PFIC with respect to which a QEF Election has been made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, a determination that EBAC or New Parent is a PFIC for a taxable year in which a U.S. Holder holds EBAC Common Stock or New Parent Shares will
generally continue to apply to such U.S. Holder for subsequent taxable years in which the holder continues to hold such shares (including shares in a successor entity), whether or not EBAC or New Parent continues to be a PFIC. A U.S. Holder that
makes the QEF Election for the holder&#146;s First PFIC Holding Year, however, will not be subject to the PFIC Default Regime in respect to such shares. In addition, such U.S. Holder will not be subject to the qualified electing fund inclusion
regime with respect to such shares for any taxable year of New Parent that ends within or with a taxable year of the U.S. Holder and in which New Parent is not a PFIC. However, if the QEF Election is not effective for each of New Parent&#146;s
taxable years in which New Parent is a PFIC (and, if applicable, was not effective for each of EBAC&#146;s taxable years in which EBAC was a PFIC) and the U.S. Holder holds (or is deemed to hold) New Parent Shares, the Default PFIC Regime will
continue to apply to such shares unless the holder makes a purging election, and pays the tax and interest charge with respect to the gain inherent in such shares attributable to the <FONT STYLE="white-space:nowrap">pre-QEF</FONT> Election period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, if a U.S. Holder, at the close of its taxable year, owns (or is deemed to own) shares in a PFIC that are treated as marketable shares, the
U.S. Holder may make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such shares for such taxable year. If a U.S. Holder makes (or has made) a valid <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to New Parent Shares (or, if applicable, EBAC Common Stock) for such holder&#146;s First PFIC Holding Year, such holder will generally not
be subject to the Default PFIC Regime in respect of its New Parent Shares as long as such shares continue to be treated as marketable shares. Instead, the U.S. Holder will generally include as ordinary income for each taxable year in its holding
period that New Parent is treated as a PFIC the excess, if any, of the fair market value of its New Parent Shares at the end of its taxable year over the adjusted tax basis in such shares. The U.S. Holder also will be allowed to take an ordinary
loss in respect of the excess, if any, of the adjusted tax basis of its New Parent Shares over the fair market value of such shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The U.S. Holder&#146;s tax basis in its New Parent Shares will be adjusted to reflect any such income or loss amounts, and any further gain
recognized on a sale or other taxable disposition of such shares in a taxable year in which New Parent is treated as a PFIC will be treated as ordinary income. Special tax rules may also apply if a U.S. Holder makes a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for a taxable year after such holder&#146;s First PFIC Holding Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for shares that are regularly
traded on a national securities exchange that is registered with the Securities and Exchange Commission, including the Nasdaq. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in respect of EBAC Common Stock or New Parent Shares under their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares treated as stock of a PFIC under the Default PFIC Regime (including New Parent Shares received in exchange for EBAC Common Stock that were
so treated at the time of the EBAC Mergers or on the exercise of New Parent Warrants exchanged for EBAC Warrants that were so treated at the time of the EBAC Mergers) will continue to be treated as stock of a PFIC, including in taxable years in
which New Parent ceases to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be a PFIC, unless the applicable U.S. Holder makes a &#147;purging election&#148; with respect to such shares. Under one type of purging election, the U.S. Holder will be deemed to have sold such
shares at their fair market value on the last day of the last year in which EBAC or New Parent, as applicable, is treated as a PFIC, and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a
result of this election, the U.S. Holder will have additional tax basis (to the extent of any gain recognized in the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in such holder&#146;s New Parent Shares. U.S. Holders
are urged to consult their tax advisors regarding the application of the purging election rules to their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If New Parent is a
PFIC and, at any time, has a foreign (<I>i.e.</I>, <FONT STYLE="white-space:nowrap">non-U.S.)</FONT> subsidiary that is classified as a PFIC, U.S. Holders would generally be deemed to own a portion of the shares of such lower-tier PFIC, and
generally could incur liability for the deferred tax and interest charge described above if New Parent receives a distribution from, or disposes of all or part of New Parent&#146;s interest in, the lower-tier PFIC or the U.S. Holders otherwise were
deemed to have disposed of an interest in the lower-tier PFIC. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally would not technically be available with respect to such lower-tier
PFIC. U.S. Holders are urged to consult their own tax advisors regarding the tax issues raised by lower-tier PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that owns (or is deemed
to own) shares in a PFIC during any taxable year of the U.S. Holder may have to file an IRS Form 8621(whether or not a QEF Election or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market-to-market</FONT></FONT> election is
made) with such U.S. Holder&#146;s U.S. federal income tax return and provide such other information as may be required by the U.S. Treasury Department. The rules dealing with PFICs, the QEF Election, and the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders should consult their own tax advisors concerning the application of
the PFIC rules under their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE RULES DEALING WITH PFICS ARE VERY COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO
THOSE DESCRIBED ABOVE. ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION, WHETHER A QEF ELECTION, A <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MARK-TO-MARKET</FONT></FONT> ELECTION OR ANY OTHER ELECTION IS AVAILABLE AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION, AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC TREASURY REGULATIONS. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend payments with respect to New Parent Shares and proceeds from the sale, exchange, or redemption of New Parent Shares and New Parent Warrants may be
subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply, however, to a U.S. Holder that furnishes a correct taxpayer identification number and makes other required certifications,
or that is otherwise exempt from backup withholding and establishes such exempt status. U.S. Holders that are required to establish their exempt status may be required to provide such certification on IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-9.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be
credited against a U.S. Holder&#146;s U.S. federal income tax liability, and a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS
and furnishing any required information. U.S. Holders are urged to consult their own tax advisors regarding the application of backup withholding and the availability of and procedure for obtaining an exemption from backup withholding in their
particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH ABOVE IS INCLUDED FOR GENERAL INFORMATION ONLY AND MAY NOT BE APPLICABLE
DEPENDING UPON A U.S. HOLDER&#146;S PARTICULAR SITUATION. U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
ADVISORS WITH RESPECT TO THE TAX CONSEQUENCES TO THEM OF THE BUSINESS COMBINATION, THE OWNERSHIP AND DISPOSITION OF NEW PARENT SECURITIES, AND THE EXERCISE OF THEIR REDEMPTION RIGHTS, INCLUDING
THE TAX CONSEQUENCES UNDER U.S. STATE AND LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.,&nbsp;AND</FONT> OTHER TAX LAWS AND TAX TREATIES AND THE POSSIBLE EFFECTS OF CHANGES IN U.S. OR OTHER TAX LAWS. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Swiss Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of
Vischer Ltd., the following are the material Swiss tax consequences of receiving, owning and disposing of New Parent Shares and New Parent Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
summary is based upon Swiss tax laws, and the practices of the Swiss tax authorities, in effect on the date of this proxy statement/prospectus. Such laws and administrative practice are subject to change at any time, possibly with retroactive
effect. The summary does not constitute tax advice and is intended only as a general guide. It is not exhaustive and shareholders should consult their own tax advisors about the Swiss tax consequences (and tax consequences under the laws of other
relevant jurisdictions) of the acquisition, ownership and disposal of New Parent Shares and New Parent Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business Combination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss stamp issuance duty and securities transfer tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A tax ruling was obtained, confirming &#150; subject to the facts and circumstances described in the ruling &#150; that the combination of New Parent, EBAC and
Oculis should qualify as a tax neutral restructuring not subject to issuance duty or securities transfer tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The redemption of EBAC Common Stock should
not be subject to issuance duty or securities transfer tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PIPE Subscription Amount should not be subject to issuance duty. The PIPE Subscription
Amount may be subject to securities transfer tax of up to 0.3% if redeemed EBAC Common Stock are issued and a Swiss or Liechtenstein securities dealer within the meaning of the Swiss Federal Stamp Duty Act is involved in the transaction as a party
or an intermediary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange of the EBAC Warrants for New Parent Warrants should not be subject to issuance duty or securities transfer tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Withholding Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Business Combination is not subject to Swiss withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The redemption of EBAC Common Stock may be subject to Swiss withholding tax currently
levied at the rate of 35%. Such redemption of shares of EBAC Common Stock is potentially not subject to Swiss withholding tax to the extent such redemption is credited against nominal capital or reserves from capital contribution (<I>Reserve aus
Kapitaleinlage</I>) within the meaning of Swiss tax law or practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of reserve from capital contribution reserves (<I>Reserve aus
Kapitaleinlage</I>) created at the level of New Parent in connection with the Business Combination is subject to confirmation in a separate proceeding to be initiated after the completion of the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Income Taxes </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holders of EBAC Common Stock and EBAC Warrants resident outside of Switzerland and not engaged in trade or
business in Switzerland </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder who is not a resident of Switzerland for Swiss tax purposes and who, during the applicable tax
year, has not engaged in a trade or business carried on through a permanent establishment in Switzerland for tax purposes will not be subject to any Swiss federal, cantonal or communal income tax as a result of the Business Combination. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Swiss resident individual holders holding EBAC Common Stock and EBAC Warrants as private investments
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a holder who is an individual resident in Switzerland for tax purposes and who holds EBAC Common Stock and EBAC Warrants as a
private investment, the exchange of EBAC Common Stock for New Parent Shares and cash payments for fractional shares should be tax neutral for the purposes of Swiss federal, cantonal and communal income tax, as long as the sum of the New Parent share
capital and capital contribution reserves and cash payments for fractional shares from New Parent does not exceed the sum of the share capital and contribution reserves to the extent equivalent to qualifying reserve from capital contribution
(&#147;<I>Reserve aus Kapitaleinlage</I>&#148;) of EBAC and New Parent before the Business Combination. The excess is generally subject to Swiss federal, cantonal and communal income tax. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Common Stock and EBAC Warrants held as business assets </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a holder who holds EBAC Common Stock as part of a trade or business carried on in Switzerland, i.e. (i)&nbsp;corporate shareholders who are resident in
Switzerland for tax purposes, (ii)&nbsp;corporate and individual shareholders who are not resident in Switzerland, and who, in each case, hold their New Parent Shares as part of a trade or business carried on in Switzerland through a permanent
establishment with fixed place of business situated in Switzerland for tax purposes, (iii)&nbsp;individual shareholders resident in Switzerland holding their shares as part of a trade or business in Switzerland and (iv)&nbsp;Swiss resident private
individuals who, for income tax purposes, are classified as &#147;professional securities dealers&#148; (collectively, &#147;<I>Domestic Commercial Shareholders</I> &#148;), the exchange of EBAC Common Stock for New Parent Shares may be tax neutral
for the purposes of Swiss federal, cantonal and communal income tax, provided that the relevant investor applies a carryover of tax book value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other
benefits in cash or for fractional shares are included as taxable income for &#147;Domestic Commercial Shareholders&#148; in the relevant taxation period for purposes of Swiss federal, cantonal and communal individual or corporate income tax.
Participation relief (<I>Beteiligungsabzug</I>) may apply, provided the respective criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic Commercial Shareholders generally recognize
taxable gain or loss for the purposes of Swiss federal, cantonal and communal income tax to the extent that the tax book value of New Parent Warrants exceeds or is lower, respectively, than the tax book value of EBAC Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Holding New Parent Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss
Withholding Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under present Swiss tax law, dividends and similar cash or <FONT STYLE="white-space:nowrap">in-kind</FONT> distributions made by
the New Parent to a holder of New Parent Shares (including liquidation proceeds and bonus shares) are subject to Swiss federal withholding tax (the &#147;<I>Withholding Tax</I>&#148;), currently at a rate of 35% (applicable to the gross amount of
taxable distribution), unless these payments are repayments of the par value of New Parent Shares or, within the limitations accepted by the legislation in force and the respective administrative practice of the reserve from capital contribution
(<I>Reserve aus Kapitaleinlage</I>). New Parent is obliged to deduct the Withholding Tax from the gross amount of any taxable distribution and to pay the tax to the Swiss Federal Tax Administration within 30 days of the due date of such
distribution, unless a notification procedure applies (the notification procedure does not apply to portfolio holdings). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss resident individuals who hold their New Parent Shares as private assets (&#147;<I>Resident Private
Shareholders</I>&#148;) are in principle eligible for a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their income tax return. In addition Domestic Commercial Shareholders who, among
other things, are also the beneficial owners of the New Parent Shares and the dividends or the other distributions made or paid by New Parent on the New Parent Shares are in principle eligible for a full refund or credit against income tax of the
Withholding Tax if they, inter alia, duly report the underlying income in their income statements or income tax return, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders
who are not resident in Switzerland for tax purposes, and who, during the respective taxation year, have not engaged in a trade or business carried on through a permanent establishment with fixed place of business situated in Switzerland for tax
purposes, and who are not subject to corporate or individual income taxation in Switzerland for any other reason (collectively, &#147;<I><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders</I>&#148;) may be entitled to a total or
partial refund of the Withholding Tax if the country in which such recipient resides for tax purposes maintains a bilateral treaty for the avoidance of double taxation with Switzerland and further conditions of such treaty are met. <FONT
STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund) may differ from country to country.
<FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders should consult their own legal, financial or tax advisors regarding receipt, ownership, purchases, sale or other dispositions of New Parent Shares and the procedures for claiming a
refund of the Withholding Tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Federal Stamp Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent New Parent issues new shares after the completion of the Business Combination, New Parent will bear the Swiss federal issue stamp tax
(<I>Emissionsabgabe</I>) on the issuance of such New Parent Shares of 1% of the offering price, net of certain deductions. The delivery of newly issued shares against payment of the offering price is generally not subject to Swiss federal securities
turnover tax (<I>Umsatzabgabe</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent New Parent offers, after the completion of the Business Combination, existing shares currently held by
New Parent or certain existing shareholders of New Parent, the sale and delivery of any such existing shares will, subject to statutory exemptions, be subject to Swiss federal securities turnover tax (<I>Umsatzabgabe</I>) at an aggregate tax rate of
up to 0.15% of the consideration paid on such sale and will be borne (or compensated) by the current holders of such existing New Parent Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
subsequent transactions in New Parent Shares in the secondary markets are subject to Swiss securities turnover tax at an aggregate rate of 0.15% of the consideration paid for such New Parent Shares, however, only if a bank or other securities dealer
in Switzerland or Liechtenstein, as defined in the Swiss Federal Stamp Tax Act (<I>Stempelabgabengesetz</I>), is a party or an intermediary to the transaction and no exemption applies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders are not subject to any Swiss federal, cantonal or communal income tax on dividend payments
and similar distributions because of the mere holding of New Parent Shares. The same generally applies for capital gains on the sale of New Parent Shares. For Withholding Tax consequences, please see the section entitled &#147;<I>&#151;Material
Swiss Tax Considerations&#151;Business Combination&#151;Swiss Withholding Tax.</I>&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resident Private Shareholders and Domestic Commercial Shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resident Private Shareholders who receive dividends and similar cash <FONT STYLE="white-space:nowrap">or&nbsp;in-kind&nbsp;distributions</FONT> (including
liquidation proceeds as well as bonus shares or taxable repurchases of New Parent Shares as described above), which are not repayments of the par value of New Parent Shares or, within the limitations accepted by the legislation in force and the
respective administrative practice, reserve from capital contribution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(<I>&#147;Kapitaleinlagereserven&#148;</I>), are required to report such distributions in their individual income tax returns. A gain or a loss by Resident Private Shareholders realized upon the
sale or other disposition of ordinary shares to a third party will generally be <FONT STYLE="white-space:nowrap">a&nbsp;tax-free&nbsp;private</FONT> capital gain or a <FONT STYLE="white-space:nowrap">not&nbsp;tax-deductible&nbsp;capital</FONT> loss,
as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic Commercial Shareholders who receive dividends and similar cash
<FONT STYLE="white-space:nowrap">or&nbsp;in-kind&nbsp;distributions</FONT> (including liquidation proceeds as well as bonus shares) are required to recognize such payments in their income statements for the relevant tax period and are subject to
Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings accumulated (including the dividends) for such period. Domestic Commercial Shareholders who are corporate taxpayers may qualify
for participation relief on dividend distributions (<I>Beteiligungsabzug</I>), if, inter alia, New Parent Shares held have a market value of at least CHF 1&nbsp;million. For cantonal and communal income tax purposes, the regulations on participation
relief are broadly similar, depending on the canton of residency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic Commercial Shareholders are required to recognize a gain or loss realized upon
the disposal of ordinary shares in their income statement for the respective taxation period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings (including the
gain or loss realized on the sale or other disposition of ordinary shares) for such taxation period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Wealth Tax and Capital
Tax </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Shareholders holding New Parent Shares are not subject to cantonal and communal wealth or annual capital
tax because of the mere holding of New Parent Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resident Private Shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resident Private Shareholders are required to report the market value of their New Parent Shares at the end of each tax period as part of their private wealth,
which is subject to cantonal and communal wealth tax. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Domestic Commercial Shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic Commercial Shareholders are required to report their New Parent Shares as part of their business wealth or taxable capital, as defined in the
applicable cantonal and communal tax laws, which is subject to cantonal and communal wealth or annual capital tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Automatic
Exchange of Information in Tax Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2014, Switzerland signed the Multilateral Competent Authority Agreement. The
Multilateral Competent Authority Agreement is intended to ensure the uniform implementation of Automatic Exchange of Information (the &#147;<I>AEOI</I>&#148;). The Swiss Federal Act on the International Automatic Exchange of Information in Tax
Matters (the &#147;<I>AEOI Act</I>&#148;) entered into force on January&nbsp;1, 2017. The AEOI Act is the legal basis for the implementation of the AEOI standard in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AEOI is being introduced in Switzerland through bilateral agreements or multilateral agreements. The agreements have been, and will be, concluded on the
basis of guaranteed reciprocity, compliance with the principle of specialty (i.e., the information exchanged may only be used to assess and levy taxes (and for criminal tax proceedings)) and adequate data protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on such multilateral and bilateral agreements and the implementing laws of Switzerland, Switzerland collects data in respect of financial assets, which
may include New Parent Shares, held in, and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resident in an EU member state or in a treaty state since 2017, and exchanges it since 2018. Switzerland has signed and is expected to sign AEOI agreements with other countries. A list of such
agreements of Switzerland in effect or signed and becoming effective can be found on the website of the State Secretariat for International Finance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland has concluded an intergovernmental agreement with the United States to facilitate the implementation of U.S. Foreign Account Tax Compliance Act.
The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by means of group requests within the scope of administrative
assistance. Information will not be transferred automatically in the absence of consent, but instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement between the United States and
Switzerland. On September&nbsp;20, 2019, the protocol of amendment to the double taxation treaty between Switzerland and the U.S. entered into force allowing the U.S. competent authority in accordance with the information reported in aggregated form
to request all the information on U.S. accounts without a declaration of consent and on <FONT STYLE="white-space:nowrap">non-consenting</FONT> <FONT STYLE="white-space:nowrap">non-participating</FONT> financial institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;8, 2014, the Swiss Federal Council approved a mandate for negotiations with the United States on changing the current
direct-notification-based regime to a regime where the relevant information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dutch Withholding Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither EBAC nor New Parent intend
to withhold Dutch dividend withholding tax on the payment of the EBAC Share Redemption Amount. It can, however, not be excluded that the Dutch tax authorities may seek to impose Dutch dividend withholding tax in respect of any distributions made by
or on behalf of EBAC, including the payment of the EBAC Share Redemption Amount to the extent that it exceeds the aggregate recognised paid-in capital per redeemed share (please see &#147;<I>Risk Factors &#151; Risks Related to government regulation
&#151; Tax authorities may challenge EBAC&#146;s tax residency, which could adversely affect its tax burden and financial position.</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We urge
you to consult with your tax advisors with respect to the potential tax consequences of an exercise of redemption rights to you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_13"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined financial statements are provided to aid you in your analysis of the financial aspects of the
Business Combination, the consummation of the PIPE Financing and Convertible Loan Agreements, which are collectively referred to as the &#147;<I>Pro Forma Transactions</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are derived from the EBAC historical financial statements and the Oculis historical
consolidated financial statements as adjusted to give effect to the Pro Forma Transactions. The unaudited pro forma condensed combined statement of financial position gives pro forma effect to the Pro Forma Transactions as if they had been
consummated on September 30, 2022. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2022 and for the year ended December&nbsp;31, 2021 give effect to the Pro Forma Transactions as if they
had occurred on January&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been derived from and should be read in
conjunction with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of EBAC as of September&nbsp;30, 2022, for the three and
nine months ended September&nbsp;30, 2022, and for the period from January&nbsp;8, 2021 (inception) through September&nbsp;30, 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of EBAC as of December&nbsp;31, 2021 and for the period from
January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed interim consolidated financial statements of Oculis as of September 30, 2022
and December&nbsp;31, 2021, and for each of the three- and nine-month periods ended September 30, 2022 and 2021 included elsewhere in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited consolidated financial statements of Oculis as of and for the years ended
December&nbsp;31, 2021 and 2020 included elsewhere in this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections entitled &#147;EBAC Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; &#147;Oculis Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and other financial information relating to EBAC and Oculis included elsewhere in this proxy statement/prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements present two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming No Redemptions (Scenario 1)</B>: This presentation assumes that no EBAC public shareholders exercise
their right to redeem their shares of EBAC Class&nbsp;A Common Stock for their pro rata share of the Trust Account, and thus, the full amount held in the Trust Account as of the Acquisition Closing is available for the Pro Forma Transactions. This
redemption scenario also reflects the Sponsor&#146;s forfeiture of 727,096 shares of EBAC Class&nbsp;B Common Stock pursuant to the terms of the Business Combination Agreement and 74,078 shares of EBAC Class&nbsp;B Common Stock transferred to EBAC
public shareholders in connection with executing a Non-Redemption Agreement. Up to an additional 1,594,348 shares of EBAC Class&nbsp;B Common Stock are subject to forfeiture if the Sponsor fails to ensure $25.5&nbsp;million in combined cash through
(i) additional PIPE Investment Amount from specified investors and (ii) the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount) but before payment of any
transaction expenses of Oculis or EBAC as described elsewhere in the accompanying proxy statement/prospectus. As of January&nbsp;27, 2023, none of these additional shares would be forfeited in the no redemption scenario; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming Maximum Redemptions (Scenario 2): </B>This presentation assumes that 10,363,709 shares of EBAC
Class&nbsp;A Common Stock are redeemed at a per share redemption price of CHF 9.86 or $10.052, which represents the maximum amount of redemptions of CHF 102.1&nbsp;million or $104.2&nbsp;million that would allow consummation of the Pro Forma
Transactions that would still satisfy the Minimum EBAC Cash Condition in the Business Combination Agreement of CHF 98.1&nbsp;million or $100.0&nbsp;million available for use as primary capital net of any redemptions by the EBAC public shareholders
and payment of any transaction expenses. The maximum redemption scenario includes all adjustments contained in the no redemption scenario and presents additional adjustments to reflect the effect of maximum redemptions. This redemption scenario also
reflects the Sponsor&#146;s forfeiture of 727,096 shares of EBAC Class&nbsp;B Common Stock pursuant to the terms of the Business Combination Agreement and 74,078 shares of EBAC Class&nbsp;B Common Stock transferred to EBAC public shareholders in
connection with executing Non-Redemption Agreements. Up to an additional 1,594,348 shares of EBAC Class&nbsp;B Common Stock are subject to forfeiture if the Sponsor fails to obtain an additional $25.5 million in combined cash through (i) additional
PIPE Investment Amount from specified investors and (ii) the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount) but before payment of any transaction expenses
of Oculis or EBAC. 80,969 of these additional shares would be forfeited in the maximum redemption scenario as of January&nbsp;27, 2023 as described elsewhere in the accompanying proxy statement/prospectus. As of January&nbsp;27, 2023, 740,789 shares
of EBAC Class&nbsp;A Common Stock held by the EBAC public shareholders are subject to <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreements contingent upon the Acquisition Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are not necessarily indicative of what the
actual results of operations and financial position would have been had the Pro Forma Transactions taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of New Parent. The
actual level of redemptions by EBAC&#146;s public shareholders is unknowable prior to the shareholder vote with respect to the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Pro Forma Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business
Combination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Oculis entered into a definitive merger agreement with EBAC (the &#147;<I>Business Combination
Agreement</I>&#148;), a publicly traded special purpose acquisition company. Under the terms of the Business Combination Agreement, EBAC shall form (i)&nbsp;Oculis Holding AG, a stock corporation incorporated and existing under the laws of
Switzerland and that is a direct wholly owned subsidiary of EBAC (&#147;<I>New Parent</I>&#148;), (ii)&nbsp;a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 1</I>&#148;),
(iii)&nbsp;another new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 2</I>&#148;) and (iv)&nbsp;a new limited liability company incorporated and existing under the laws of
Switzerland that will be a direct wholly owned subsidiary of New Parent (&#147;<I>Merger Sub 3</I>&#148;). EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company
and remain a wholly owned subsidiary of New Parent. Oculis will merge with and into Merger Sub 3, the separate corporate existence of Oculis will cease and Merger Sub 3 will be the surviving company and remain a wholly owned subsidiary of New Parent
(together, the &#147;<I>mergers</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination and as of the Acquisition Closing Date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding share of EBAC Class&nbsp;A Common Stock (including those held by the PIPE Investors)
and share of EBAC Class&nbsp;B Common Stock will be converted into one New Parent Share, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding EBAC Public Warrant and EBAC Private Placement Warrant shall cease to be a warrant
with respect to EBAC Common Stock and shall be assumed by New Parent as warrants </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
with respect to New Parent Shares on substantially the same terms (the &#147;<I>New Parent Warrants</I>&#148;). The Company does not expect any change in classification of Public Warrants and
Private Warrants between liabilities and equity upon consummation of the Business Combination and the warrants will continue to be classified as liabilities, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding share of Oculis common stock and preferred stock will be converted into New Parent
Shares at the then effective exchange ratios determined in accordance with the Business Combination Agreement and giving effect to the accumulated preferred dividends, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent will assume the Convertible Loan Agreements (as defined below) and the Lenders (as defined below) will
exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding and unexercised options to purchase shares of Oculis common stock will be assumed by New Parent
and each option will be replaced by an option to purchase New Parent Shares (the &#147;<I>Converted Options</I>&#148;), and in the case of vested Company Options, additional Earnout Options. The Converted Options will continue to be subject to
substantially the same terms and conditions except that the number of New Parent Shares issuable and related exercise prices are adjusted by the then effective exchange ratio with all other terms remaining unchanged. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Earnout Consideration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain Oculis equityholders will
receive additional consideration in the form of an <FONT STYLE="white-space:nowrap">earn-out</FONT> of, collectively, 4,000,000 newly issued New Parent Shares and options underlying such New Parent Shares (&#147;<I>Earnout Options</I>&#148;) that
will be received pro rata in proportion to their equity interests in Oculis as of the date of entering into the Business Combination Agreement (the &#147;<I>Earnout Consideration</I>&#148;). Oculis equity holders eligible to receive the Earnout
Consideration include the holders of Oculis common stock and preferred stock, other than the holders of the Series&nbsp;C&nbsp;1(b) who have waived their right to the Earnout Consideration, and holders of vested options to purchase shares of Oculis
common stock. The Earnout Consideration will be issued to such Oculis equityholders upon the Acquisition Closing in the form of New Parent Shares or Earnout Options but shall initially be subject to forfeiture in the event of a failure to achieve
the price targets during the Earnout Period (defined below). The Earnout Consideration in the form of New Parent Shares (Earnout Shares) will consist of three tranches of New Parent Shares, as follows (in the case of each tranche, <I>minus</I> any
Earnout Options granted to replace vested options to purchase shares of Oculis common stock, on the terms and subject to the conditions in the Business Combination Agreement): (i) 1,500,000, (ii) 1,500,000 and (iii) 1,000,000, earned based on the
achievement of post-Acquisition Closing share price targets of New Parent of $15.00, $20.00 and $25.00, respectively, in each case, for any 20 trading days within any consecutive 30 trading day period commencing after the Acquisition Closing Date
and ending on or prior to the fifth anniversary of the Acquisition Closing Date (the &#147;<I>Earnout Period</I>&#148;). A given share price target described above will also be deemed to be achieved if there is a Change of Control (as defined in the
Business Combination Agreement) transaction of New Parent during the Earnout Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forfeiture provision related to the price targets above is
expected to be deemed to be a <FONT STYLE="white-space:nowrap">non-vesting</FONT> condition because there is no other service or performance vesting condition related to the Earnout Consideration. The Earnout Consideration is expected to be
accounted for as share based contingent consideration within the scope of IFRS 2, and is therefore expected to be equity classified because the Earnout Consideration ultimately settles in New Parent Shares. Any adjustment to the grant date fair
value of the IFRS 2 share listing service expense would not be subsequently adjusted regardless of whether the price target is achieved or not. The portion of the Earnout Consideration granted to the holders of vested options to purchase shares of
Oculis common stock, will be in the form of options to purchase New Parent Shares in a manner that allows for the option holder to participate in the Earnout Consideration on a pro rata basis as if they were holders of New Parent Shares. The
specific terms of the options have not yet been determined and will be assessed for any compensatory element related to a service or performance vesting condition as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PIPE Investment and Convertible Loan Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination Agreement, EBAC entered into Subscription Agreements with the PIPE Investors. Pursuant to the terms of the
Subscription Agreements, the PIPE Investors have agreed to purchase an aggregate of 7,118,891 shares of EBAC Class A Common Stock (that will become New Parent Shares) at $10.00 per share for aggregate gross proceeds of CHF 69.8&nbsp;million or
$71.2&nbsp;million (the &#147;<I>PIPE Financing</I>&#148;). In connection with the Business Combination Agreement and Subscription Agreements, Oculis entered into an interest free convertible loan agreement with the Lenders party thereto, pursuant
to which the Lenders party thereto granted to Oculis the right to receive a convertible loan with certain conversion rights that are substantially identical in principal terms and conditions as those of the PIPE Financing. Subsequent to the
execution of the Business Combination Agreement, on January 26, 2023. Oculis and an additional Lender entered into a convertible loan agreement in substantially the same form as the initial convertible loan agreement, pursuant to which, among other
things, the Lender party thereto has granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $7,000,000. The aggregate amount raised under the Convertible Loan Agreements is $19,670,000. Upon the
Acquisition Closing and assumption of the Convertible Loan Agreements by New Parent, the Lenders will exercise their conversion rights in exchange for 1,967,000 New Parent Shares at $10.00 per share, resulting in aggregate cash proceeds to New
Parent of CHF 19.3&nbsp;million or $19.7&nbsp;million, which represent the same economic conditions as the PIPE Financing. The cash payable to New Parent upon conversion of the loan is to be held in escrow for the benefit of the Lenders until the
Acquisition Closing. Together, the PIPE Financing and Convertible Loan Agreements will result in aggregate gross cash proceeds of CHF 89.1&nbsp;million or $90.9&nbsp;million to New Parent in exchange for 9,085,891 New Parent Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitalization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma
New Parent Shares expected to be issued and outstanding immediately after the Pro Forma Transactions, presented under the two scenarios listed above. Upon completion of the Pro Forma Transactions, the expected approximate ownership interests of New
Parent are set forth in the table below based on an assumed Acquisition Closing Date of March&nbsp;6, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>(Assuming&nbsp;No<BR>Redemptions<BR>for&nbsp;Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>(Assuming Maximum</B><br><B>Redemptions for Cash<BR>Such that the<BR>Minimum EBAC<BR>Cash Condition<BR>Would
Still<BR>be&nbsp;Satisfied)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Parent Class&nbsp;A common stock owned by Sponsors (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,761,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Parent Class&nbsp;A common stock owned by public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,828,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,465,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class&nbsp;A common stock in connection with closing of the PIPE
Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class&nbsp;A common stock in connection with closing of the Convertible
Loan Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class&nbsp;A common stock to Oculis stockholders in connection with
Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,033,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34,588,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">4,000,000 Earnout shares and options, 983,079 shares of vested Conversion Options, 779,831 shares of unvested
Conversion Options, 4,251,595 EBAC Public Warrants and 151,699 EBAC Private Warrants were excluded from the table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Scenario 1 and 2 reflect 727,096&nbsp;Sponsor shares forfeited and 74,078&nbsp;Sponsor shares transferred to
certain EBAC public stockholders in connection with executing Non-Redemption Agreements. Scenario 2 reflects the additional forfeiture of 80,969 Sponsor shares as described elsewhere in this proxy statement/prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent expects to issue approximately 20,276,208 New Parent Shares in the Business Combination to Oculis
Shareholders based on 3,406,771 shares of Oculis common stock, which reflects 100,000 shares of Oculis treasury stock which will be cancelled pursuant to the Business Combination Agreement, and 12,712,863 shares of Oculis preferred stock expected to
be outstanding immediately prior to the Acquisition Closing Date and the estimated exchange ratios determined in accordance with the terms of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares payable to existing Oculis stockholders, without considering the Earnout Consideration equals $208,000,000 or 20,800,000 New Parent Shares
at $10.00 per share. The exchange ratio is obtained by allocating shares for settlement of preferred dividend on Oculis Series&nbsp;B and C shares and then allocating New Parent shares remaining after settlement of preferred dividends on <FONT
STYLE="white-space:nowrap">pro-rata</FONT> basis to existing Oculis stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oculis Series&nbsp;B and C preferred stock convert based on an
exchange ratio that includes the accrued dividend of 6% compounded annually. The accrued dividend is calculated through the assumed Acquisition Closing Date of March&nbsp;6, 2023 and is converted into New Parent Shares at a price of $10.00 per
share. A total of 1,962,875 New Parent Shares are expected to be issued in settlement of the accrued dividends. For purposes of the exchange ratio calculation, the outstanding vested options to purchase Oculis shares are treated as if they were
exercised on a cashless basis. The final exchange ratios may be different from the assumed exchange ratios and will be determined at the Acquisition Closing pursuant to the Business Combination Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oculis&nbsp;shares&nbsp;outstanding</B><br><B>prior to the closing of</B><br><B>the Transactions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assumed<BR>Exchange<BR>Ratios</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;shares&nbsp;of<BR>New&nbsp;Parent&nbsp;common</B><br><B>stock&nbsp;issued&nbsp;to&nbsp;Oculis<BR>Shareholders&nbsp;upon</B><br><B>closing of
the<BR>Transactions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,406,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock after cancellation of Treasury Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,306,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,780,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,623,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,856,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,486,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,518,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B2 T1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,675,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,328,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B2 T2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">567,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B2 T3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">603,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">793,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C T1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,337,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,756,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C T2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C T3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,276,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION AS
OF SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except share and per share information) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,&nbsp;Historical<BR>as converted<BR>and translated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No Redemption<BR>for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum<BR>Redemption for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>3(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>3(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EBAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oculis</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaids and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(h)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(l)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>126,198</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>44,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>68,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>238,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(102,149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities and Equity (Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Long-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Long-term financial debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(254,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Short-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity attributable to equity holders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(h)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION AS
OF SEPTEMBER&nbsp;30, 2022 (continued) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except share and per share information) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,&nbsp;Historical<BR>as converted<BR>and translated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No Redemption for<BR>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum<BR>Redemption for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>3(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>3(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EBAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oculis</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Transaction<BR>Accounting<BR>Adjustments</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,326)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reserve for share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Actuarial loss on post employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(134,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,901)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(140,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(j)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(l)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;3(k)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 455,096 shares
issued and outstanding (excluding 12,754,784 shares subject to possible redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,188,696 shares
issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share capital of New Parent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(h)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(i)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;3(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities and equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>126,198</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>44,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>68,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>238,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(102,149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited pro forma condensed combined financial information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED
SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except share and per share amounts) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Scenario 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Scenario 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,&nbsp;Historical<BR>as&nbsp;converted&nbsp;and<BR>translated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,&nbsp;Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;No<BR>Redemptions&nbsp;for&nbsp;Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;Maximum<BR>Redemptions&nbsp;for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4(A)<BR>EBAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4(B)<BR>Oculis</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement<BR>of<BR>Operations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement<BR>of<BR>Operations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative expenses- related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income from investments held in trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income/ (loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income/ (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted, loss for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible redemption,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net income per share, Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic weighted average shares outstanding of non-redeemable Class&nbsp;A ordinary shares and Class
B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net income per share, redeemable Class&nbsp;A ordinary shares and Class B
ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Diluted weighted average shares outstanding of non-redeemable Class&nbsp;A ordinary shares and
Class B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dilutes net income per share, non-redeemable Class&nbsp;A ordinary shares and Class B ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net&nbsp;loss&nbsp;per&nbsp;share, Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,033,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,588,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(g)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited pro forma condensed combined financial information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OCULIS SA /EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS, Historical<BR>as&nbsp;converted<BR>and&nbsp;translated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS,<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No<BR>Redemptions for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum<BR>Redemptions for Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>4(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>4(D)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EBAC</B><br><B>(for&nbsp;the&nbsp;period&nbsp;from<BR>January&nbsp;8, 2021<BR>(inception) through<BR>December&nbsp;31, 2021)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oculis</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative expenses- related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income from investments held in trust</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;4(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Offering costs associated with derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income/ (loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,729</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income/ (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted, loss for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible redemption,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,199,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net income per share, Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net income per share, non-redeemable Class&nbsp;A ordinary shares and
Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Diluted weighted average shares outstanding of
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,465,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dilutes net income per share, non-redeemable Class&nbsp;A ordinary shares and Class&nbsp;B ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net&nbsp;loss&nbsp;per&nbsp;share, Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,033,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,588,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;4(g)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited pro forma condensed combined financial information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Basis of Pro Forma Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements were prepared in accordance with Article 11 of SEC Regulation
<FONT STYLE="white-space:nowrap">S-X.</FONT> The adjustments presented in the unaudited pro forma condensed combined financial statements have been identified and presented to provide relevant information necessary for an understanding of New Parent
reflecting the Pro Forma Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are derived from the EBAC historical financial
statements, and the Oculis historical consolidated financial statements as adjusted to give effect to the Pro Forma Transactions. The unaudited pro forma condensed combined statement of financial position gives pro forma effect to the Pro Forma
Transactions as if they had been consummated on September&nbsp;30, 2022. The unaudited pro forma condensed combined statement of operations for the nine months ended September&nbsp;30, 2022 and the unaudited pro forma consolidated statement of
operations for the year ended December&nbsp;31, 2021 give effect to the Pro Forma Transactions as if they had occurred on January&nbsp;1, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has made significant estimates and assumptions in its determination of the pro forma adjustments. The pro forma adjustments reflecting the Pro
Forma Transactions are based on information currently available and certain assumptions and methodologies that management believes are reasonable under the circumstances. The pro forma adjustments, which are described in the accompanying notes, are
based on preliminary estimates and may be revised as additional information becomes available and is evaluated. Therefore, the actual adjustments may materially differ from the pro forma adjustments, and it is possible the difference may be
material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Pro Forma Transactions based on information available at this time and that the pro forma
adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or
cost savings that may be associated with the Pro Forma Transactions. EBAC and Oculis have not had any historical relationship prior to the Pro Forma Transactions. Accordingly, no pro forma adjustments were required to eliminate activities between
the companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical consolidated financial statements of Oculis have been prepared in accordance with IFRS and in its presentation currency of
CHF. The historical financial statements of EBAC have been prepared in accordance with U.S.&nbsp;GAAP in its presentation currency U.S. dollars. The historical financial information of EBAC has been adjusted to give effect to the differences between
U.S.&nbsp;GAAP and IFRS for the purposes of the combined pro forma financial information, which included the only adjustment to reclassify the carrying value of EBAC&#146;s Class&nbsp;A Common Stock subject to possible redemption classified as
mezzanine equity under U.S.&nbsp;GAAP to <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities under IFRS. IFRS differs from U.S.&nbsp;GAAP in certain material respects and thus may not be comparable to financial information presented by
U.S. companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial information of EBAC has been translated into CHF for the purposes of presentation in the unaudited pro forma
condensed combined financial statements (&#147;<I>As Converted</I>&#148;) using the following exchange rates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the period end exchange rate as of September&nbsp;30, 2022 of $1.00 to CHF 0.98054 for the pro forma statement
of financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average exchange rate for the period from January&nbsp;1, 2022 through September&nbsp;30, 2022 of $1.00 to
CHF 0.95162 for the pro forma statement of operations for the nine months ended September&nbsp;30, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average exchange rate for the period from January&nbsp;8, 2021 through December&nbsp;31, 2021 of $1.00 to CHF
0.91416 for the pro forma statement of operations for the period from January&nbsp;8, 2021 through December&nbsp;31, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Accounting for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the legal form, the Business Combination will be accounted for as a capital reorganization. Under this method of accounting, EBAC will be
treated as the acquired company for financial reporting purposes, whereas Oculis will be treated as the accounting acquiror. In accordance with this accounting method, the Business Combination will be treated as the equivalent of Oculis issuing
stock for the net assets of EBAC, accompanied by a recapitalization. The net assets of Oculis will be stated at historical cost, with no goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of
Oculis. Oculis has been determined to be the accounting acquiror for purposes of the Business Combination based on an evaluation of the following facts and circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After the Acquisition Closing, persons affiliated with Oculis are expected to control a majority of the New
Parent Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis Shareholders have the largest voting interest under both redemption scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis is the largest entity based on the entity&#146;s operations and number of employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; operations prior to the Business Combination will comprise the ongoing operations of New Parent; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; existing executive officers and senior management team will comprise the executive officers and
senior management team of New Parent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination, which is not within the scope of IFRS 3 since EBAC does not meet the
definition of a business in accordance with IFRS 3, is accounted for within the scope of IFRS 2. Any excess of fair value of New Parent Shares issued over the fair value of EBAC&#146;s identifiable net assets acquired represents compensation for the
service of a stock exchange listing for its shares and is expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to Unaudited Pro Forma Condensed
Combined Statement of Financial Position </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates that could change materially as
additional information is obtained, are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma notes: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed statement of financial position as of September&nbsp;30, 2022 (after
applying an adjustment to convert to IFRS and translate into CHF as noted above). The US&nbsp;GAAP to IFRS adjustment was to reclassify the carrying value of EBAC&#146;s Class&nbsp;A Common Stock subject to possible redemption to <FONT
STYLE="white-space:nowrap">non-current</FONT> liabilities under IFRS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited consolidated statement of financial position of Oculis as of September&nbsp;30,
2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma Transaction Accounting Adjustments: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the forfeiture of the 727,096 Sponsor shares pursuant to the terms of the Business Combination
Agreement, which represents 25% of the Sponsor shares reduced by 74,078 shares of EBAC Class B Common Stock transferred to EBAC public shareholders&#146; EBAC Class A Common Stock in connection with executing Non-Redemption Agreements at the time of
announcement of the Business Combination. In Scenario 2, an additional 80,969 shares of EBAC Class B Common Stock are forfeited as the Sponsor failed to ensure $25.5&nbsp;million in combined cash through (i) additional PIPE Investment Amount from
specified investors and (ii) the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount) but before payment of any transaction expenses of Oculis or EBAC as
described elsewhere in the accompanying proxy statement/prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the exchange of EBAC Class&nbsp;A and B Common Stock and warrants for New Parent Shares and New
Parent Warrants. New Parent Shares were recorded at par value of CHF 0.01 as increase to common stock of CHF 36&nbsp;thousand and a decrease to share premium in amount of CHF 36&nbsp;thousand. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the payment of EBAC&#146;s deferred underwriting fee payable as of September&nbsp;30, 2022 of CHF
4.4&nbsp;million incurred in connection with the EBAC initial public offering, which is payable upon completion of the Pro Forma Transactions. The assumed payment of CHF 4.4&nbsp;million has been recorded as a reduction of deferred underwriting fee
payable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the release of investments from the trust account to cash and cash equivalents, assuming no EBAC
public shareholder exercise their right to have their EBAC Class&nbsp;A Common Stock redeemed for their pro rata share of the Trust Account. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the payment of EBAC&#146;s accrued expenses and other payables of CHF 1.3&nbsp;million, deferred
legal fees of CHF 0.3&nbsp;million and a reclassification of deferred transaction cost of CHF 0.1&nbsp;million that are deemed to be direct and incremental costs of the Business Combination from prepaid expenses to accumulated losses.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the reclassification of shares of EBAC Class&nbsp;A Common Stock subject to possible redemption of
CHF 125.7&nbsp;million to share capital of New Parent of CHF 128&nbsp;thousand and share premium of CHF 125.6&nbsp;million, in Scenario 1, which assumes no EBAC public shareholders exercise their redemption rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the issuance of 7,118,891 New Parent Shares related to the PIPE Financing and 1,967,000 New Parent
Shares related to the Convertible Loan Agreements at a price of CHF 9.81 or $10.00 per share, for total gross proceeds of CHF 89.1 million or $90.9&nbsp;million, and to record the fees associated with deferred underwriter compensation and the
consummation of the PIPE Financing in the amount of CHF 7.4&nbsp;million or $7.5&nbsp;million. The issuance is recorded as an increase of CHF 89.1 million to cash and cash equivalents, an increase to share capital of New Parent of CHF 91.0 thousand
and an increase to share premium in amount of CHF 89.0 million. The deferred underwriter compensation and PIPE fees are recorded as a decrease to cash and cash equivalents and a decrease to share premium. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the assumption in Scenario 2 that EBAC public shareholders exercise their redemption rights with
respect to a maximum of 10,363,709 shares of EBAC Class&nbsp;A Common Stock prior to the consummation of the Pro Forma Transactions at a redemption price of approximately CHF 9.86 or $10.052 per share, or CHF 102.1 million in cash.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the recapitalization of Oculis through the exchange of all outstanding common and preferred stock of
Oculis for the issuance of 20,276,208 New Parent Shares and the elimination of the accumulated losses of EBAC, the accounting acquiree. As a result of the recapitalization, Oculis Common Stock of CHF 0.3&nbsp;million, EBAC accumulated deficit of CHF
9.5&nbsp;million, and Oculis&#146; treasury stock of CHF 0.1&nbsp;million were derecognized. The New Parent Shares issued in exchange for the common and preferred stock of Oculis were recorded as increase to common stock of CHF 203&nbsp;thousand and
increase to share premium of CHF 115.2&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record the cost of Oculis share listing service. As described in Note 2 above, Oculis was determined to be
the accounting acquirer and EBAC is not considered to be a business under IFRS 3. Therefore, Business Combination will be accounted for as the equivalent of Oculis issuing shares at the closing of the Business Combination for the net assets of EBAC
as of the Acquisition Closing Date, accompanied by a recapitalization. This deemed issuance of shares by Oculis, in effect, was an equity-settled share-based payment transaction in accordance with IFRS 2 <I>Share-based Payment</I> (&#147;<I>IFRS
2</I>&#148;) whereby Oculis received the net assets of the EBAC together with the listing status of EBAC. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The fair value
of Oculis shares deemed to be issued in excess of the fair value of identifiable net assets of EBAC represents a service received by Oculis for the listing of New Parent Shares in accordance with IFRS 2. As shown in the table below, the cost of the
services, which is a <FONT STYLE="white-space:nowrap">non-cash</FONT> expense, is preliminarily estimated to be CHF 30.5 million in Scenario 1 and CHF 35.4&nbsp;million in Scenario 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share&nbsp;Value,&nbsp;in<BR>CHF*</B><br><B>(as&nbsp;of<BR>January&nbsp;20,&nbsp;2023)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value<BR>(in CHF<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value<BR>(in CHF<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC Sponsor Class B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC Sponsor Class A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBAC Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,251,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,251,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemptions of EBAC Class A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,363,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(96,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsors shares forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(727,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(808,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total consideration transferred</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20,074,773</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>147,148</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,630,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>49,900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less net assets of EBAC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Excess of net assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,471</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>35,372</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of September 30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct and incremental transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid assets expensed to accumulated losses in connection with Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net assets of EBAC**</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>116,677 </B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,528</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Closing price as of January&nbsp;20, 2023 for EBAC Common Stock and EBAC Public Warrants were CHF&nbsp;9.31 or
$10.13 and CHF&nbsp;0.28 or $0.305 per security, respectively. Although both public and private warrants are linked to shares of EBAC Common Stock, the warrants will remain outstanding in both, Scenario&nbsp;1 and Scenario&nbsp;2 while the EBAC
Common Stock will be redeemed. The values in the table above are preliminary and will change based on fluctuations in the share price of the EBAC Common Stock and EBAC Public Warrants through the Acquisition Closing Date. A one percent change in the
market price per ordinary share of EBAC Common Stock and per EBAC Public Warrant would result in a change to the excess of net assets of CHF&nbsp;1.5&nbsp;million and CHF 0.5&nbsp;million, and a corresponding change in the cost of the services,
assuming no redemptions and maximum redemptions, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated based on exchange rate as of September&nbsp;30, 2022 of $1.00 to CHF 0.98054. On the basis of the
foreign exchange rate of $1.00 to CHF 0.91913 as of January&nbsp;20, 2023, the net assets of EBAC as of September&nbsp;30, 2022 translated into CHF is approximately CHF&nbsp;109.2&nbsp;million and CHF 13.4&nbsp;million in Scenario&nbsp;1 and
Scenario&nbsp;2, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect preliminary estimated transaction costs expected to be incurred by Oculis of approximately
CHF&nbsp;4.9&nbsp;million for advisory, legal, research and accounting fees incurred as part of the Business Combination. As of September&nbsp;30, 2022, CHF&nbsp;1.1&nbsp;million have been recorded as expenses and accrued in accrued expenses and
other payables. The remaining transaction costs to be incurred of CHF 3.8&nbsp;million have been accrued as September&nbsp;30, 2022, of which CHF 1.3&nbsp;million represent equity issuance costs capitalized and recognized net of proceeds and CHF
2.5&nbsp;million included as an expense through accumulated loss. In Scenario&nbsp;2 capitalized equity issuance costs is CHF 1.0&nbsp;million and expenses recognized through accumulated loss is CHF 2.8&nbsp;million, the incremental change of CHF
0.3&nbsp;million was recorded as increase to share capital and decrease to accumulated loss (Note&nbsp;3e). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect preliminary estimated incremental transaction costs expected to be incurred by EBAC of approximately
CHF 3.4&nbsp;million for advisory, legal, research, accounting expenses incurred as part of the Business Combination. These incremental transaction costs are assumed to be cash settled and are recognized as an expense through accumulated losses as
of September&nbsp;30, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma notes: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed statement of operations of EBAC for the nine months ended September 30,
2022 (after translating from $ into CHF). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited consolidated statement of loss of Oculis for the nine months ended September 30,
2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the audited consolidated statement of operations of EBAC for the period from January&nbsp;8, 2021
(inception) through December&nbsp;31, 2021 (after translating from $ into CHF). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the audited consolidated statement of loss of Oculis for the year ended December&nbsp;31, 2021.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma Transaction Accounting Adjustments: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to eliminate general and administrative expenses - related party which represent
reimbursement to the Sponsor for the office space, administrative and support services provided to EBAC. The service agreement between the Sponsor and EBAC will terminate upon the closing of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to eliminate interest and dividend income earned on investments held in the trust
account. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to record the IFRS 2 Oculis share listing service cost described in Note 3j of CHF
30.5 million under the no redemption scenario and the additional charge of CHF 4.9 million for a total listing service cost of CHF 35.4 million under the maximum redemption scenario, for the year ended December&nbsp;31, 2021.&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to eliminate finance expense on accrued dividends for Oculis Series B and C preferred
shares assuming that preferred shares exchanged for the New Parent Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the estimated Oculis transaction costs of CHF 2.5&nbsp;million and CHF 2.8 million be expensed as
part of the Business Combination in Scenario 1 and 2 accordingly. The incremental change of CHF 0.3&nbsp;million was recorded in Scenario 2, as described in the Note 3(k). These costs are a nonrecurring item. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect pro forma adjustment to derecognize the currency exchange gain and loss from revaluation of the
Series C long-term liability assuming preferred shares exchanged for the New Parent Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma basic and diluted net loss per share amounts presented in the unaudited pro forma condensed
combined statements of operations are based upon the number of New Parent Shares outstanding as if the Pro Forma Transactions occurred on January&nbsp;1, 2021. The calculation of weighted-average shares outstanding for pro forma basic and diluted
net loss per share assumes that the shares issuable in connection with the Pro Forma Transactions have been outstanding for the entirety of the statements of operations periods presented. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic and diluted is calculated
as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario&nbsp;1&nbsp;(Assuming&nbsp;No<BR>Redemptions for</B><br><B>Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario&nbsp;2</B><br><B>(Assuming&nbsp;Maximum<BR>Redemptions for</B><br><B>Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average shares calculation - basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Parent Class A common stock owned by Sponsors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,761,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Parent Class A common stock owned by public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,828,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,465,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class A common stock in connection with closing of the PIPE
Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,118,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class A common stock in connection with closing of the Convertible Loan
Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Parent Class A common stock to Oculis stockholders in connection with Business
Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,276,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma weighted-average shares outstanding - basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>45,033,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>%</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>34,588,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B>%</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss for the nine months ended September 30, 2022 (in CHF thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net&nbsp;loss&nbsp;per&nbsp;share for the nine months ended September
30, 2022, Class A common stock (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss for the year ended December 31, 2021 (in CHF thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net&nbsp;loss&nbsp;per&nbsp;share for the year ended December 31,
2021, Class A common stock (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Earnout Consideration is excluded from the table above because the shares are contingently forfeitable if
the price targets are not achieved during the Earnout Period. Outstanding options and warrants are excluded because they are anti-dilutive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_14"></A>BUSINESS OF NEW PARENT BEFORE THE BUSINESS COMBINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information provided below pertains to New Parent prior to the Business Combination. As of the date of this proxy statement/prospectus, New Parent has
not conducted any material activities other than those incident to its formation and to the matters contemplated by the Business Combination Agreement, such as the making of certain required securities law filings and the preparation of this proxy
statement/prospectus. Upon the terms and subject to the conditions of the Business Combination Agreement, EBAC and Oculis will effect a transaction, the result of which is New Parent will become the ultimate parent of EBAC and Oculis. For
information about New Parent&#146;s management, stock ownership and corporate governance following the Business Combination, please see the section entitled &#147;Management of New Parent After the Business Combination.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent was incorporated as a Swiss
stock corporation on October&nbsp;31, 2022, with a share capital of CHF 100,000 divided into 10,000,000 registered shares with a nominal value of CHF 0.01 each. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed Articles of Association </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to or
simultaneously with consummation of the Business Combination and immediately after the completion of the Business Combination, New Parent&#146;s current articles of association will be amended and restated in their entirety to be in the form of the
Proposed Articles of Association as <U>Annex B</U> to this proxy statement/prospectus. New Parent&#146;s current articles of association may be amended at any time prior to or after the consummation of the Business Combination by a resolution of New
Parent&#146;s shareholders subject to the quorum required by law or the articles of association. For more information, please see the section entitled &#147;<I>Description of New Parent Securities and Proposed Articles of Association</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent is registered with the Commercial
Register of the Canton of Zug, Switzerland under the registration number <FONT STYLE="white-space:nowrap">CHE-396.695.611</FONT> and the legal name Oculis Holding AG. New Parent&#146;s legal name will remain unchanged following the consummation of
the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Official Seat </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New
Parent&#146;s official seat (Zug) is in Zug, Switzerland and its business address is Bahnhofstrasse 7, 6300&nbsp;Zug, Switzerland. It is expected that the mailing address of New Parent&#146;s principal executive office will move within two months
after the Acquisition Closing to Oculis Holding AG, EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Year </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent&#146;s financial year runs
from January&nbsp;1 up to and including December 31. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsidiaries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Business Combination Agreement, New Parent has formed each of Merger Sub 1, Merger Sub 2 and Merger Sub
3, which are direct wholly owned subsidiaries of New Parent. None of Merger Sub 1, Merger Sub 2 and Merger Sub 3 have conducted any material activities other than those incident to its formation and the pending Business Combination and only have
nominal assets consisting of cash and cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sole Shareholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is currently the sole shareholder of New Parent. In connection with the Business Combination, the EBAC Shareholders, the Oculis Shareholders and the PIPE
Investors will become shareholders of New Parent pursuant to the Acquisition Mergers and the transactions contemplated thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent&#146;s Board (<I>Verwaltungsrat</I>) is, as of the date of this proxy statement/prospectus, composed of 2 directors: Riad Sherif and
Eduardo Bravo Fernandez de Araoz. Upon completion of the Business Combination, Eduardo Bravo Fernandez de Araoz expects to resign from the New Parent Board and we expect that the New Parent Board will consist of Christina Ackermann, Lionel Carnot,
Pravin Dugel, Martijn Kleijwegt, Geraldine O&#146;Keeffe, Anthony Rosenberg and Riad Sherif. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, New Parent was not party to any material legal proceedings. In the future, New Parent may become party to
legal matters and claims arising in the ordinary course of business, the resolution of which New Parent does not anticipate would have a material adverse impact on its financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy
statement/prospectus, New Parent has leased its office at Bahnhofstrasse 7 in Zug, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, New Parent has no employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_15"></A>BUSINESS OF OCULIS AND CERTAIN INFORMATION ABOUT OCULIS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;we,&#148; the &#147;Company,&#148; &#147;us,&#148; or
&#147;our&#148; refer to Oculis SA and its subsidiaries prior to the consummation of the Business Combination, which will be the business of the post-combination company and its subsidiaries following the consummation of the Business Combination.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company, based in Switzerland, with substantial expertise in therapeutics used to treat ocular diseases, and engaged in the development of innovative drug candidates which have the potential to address many <FONT
STYLE="white-space:nowrap">eye-related</FONT> conditions. Our mission and vision is to improve the health and quality of life of patients around the world by developing medicines that save sight and improve eye care for patients. To realize this
vision, we intend to become a global leader in ocular therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our focus is on advancing therapeutic candidates intended to treat significant
ophthalmic diseases which result in vision loss, blindness or reduced quality of life, and for which prevalence is growing and there are currently inadequate, limited or no treatment options. Our clinical portfolio currently consists of three
therapeutic candidates: <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT> Our lead product candidate, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> is
currently being evaluated in two ongoing Phase 3 clinical trials: for the treatment of diabetic macular edema (&#147;<I>DME</I>&#148;), and for the treatment of inflammation and pain following cataract surgery. Our second product candidate is <FONT
STYLE="white-space:nowrap">OCS-02,</FONT> for which we anticipate initiating two Phase 2b clinical trials in the first half of 2023, evaluating: its use as a potential treatment for keratoconjunctivitis sicca, or dry eye disease
(&#147;<I>DED</I>&#148;), and its use as a potential treatment for <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis. Our third product candidate is <FONT STYLE="white-space:nowrap">OCS-05,</FONT> which is a novel
neuroprotective agent with potential application in multiple indications, including glaucoma, geographic atrophy (&#147;<I>GA</I>&#148;) , diabetic retinopathy (&#147;<I>DR</I>&#148;), and neurotrophic keratitis. We are initially evaluating <FONT
STYLE="white-space:nowrap">OCS-05</FONT> as a potential treatment for acute optic neuropathy (&#147;<I>AON</I>&#148;) for which there are no currently approved therapeutic treatments. OCS-05 was placed on clinical hold in 2016, and we in-licensed it
from Accure in 2022 with plans to clear this clinical hold (please see paragraph entitled &#147;&#151;<I>OCS-05</I> <I>was placed on a clinical hold by the FDA in 2016</I>&#148; in this section and the section entitled &#147;<I>Certain</I>
<I>Information About Oculis</I>&#148; below for further discussion on this clinical hold, the risks it poses for our business, and the steps we must take in order to clear the clinical hold). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Our Clinical Product Candidates Portfolio </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g389734g64m64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">OCS-01 is based on the OPTIREACH<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology, OCS-02
is a single chain antibody fragment (ScFv) against TNF&#225; and OCS-05 is a SGK-2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways. The Company&#146;s additional earlier stage
development candidates are discussed in the section under the header &#147;Our clinical development candidates&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilizing our internal core
competency in formulation discovery and drug development capabilities, together with extensive licensing, collaboration and acquisition activities, we have assembled a pipeline of attractive development candidates that include both late-stage
clinical candidates as well as earlier stage preclinical initiatives. Our clinical candidate portfolio includes: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead candidate is <FONT STYLE="white-space:nowrap">OCS-01,</FONT> a novel formulation (ophthalmic suspension) of dexamethasone at high concentration,
designed to enhance drug penetration into both the anterior and posterior segments of the eye with enhanced persistence following topical application. We are evaluating <FONT STYLE="white-space:nowrap">OCS-01</FONT> for use as a potential treatment
for DME and also a potential treatment for inflammation and pain following ocular surgery with further benefit in potentially treating cystoid macular edema (&#147;<I>CME</I>&#148;), a significant complication following ocular surgery. Using our
proprietary Optireach<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology, <FONT STYLE="white-space:nowrap">OCS-01</FONT> was developed to be an eye drop drug capable of treating diseases affecting the retina, which is at the back
of the eye. This approach is in contrast to currently available therapies, which require the use of more invasive treatments such as ocular implants or intravitreal injections to deliver medication to the retina. Furthermore, current treatment of
DME often involves multiple intravitreal injections. Given the burden of therapy, <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutics are not widely used for early disease intervention, despite the deterioration in visual acuity in 19%
of patients within two years. We estimate that treatment might be further complicated by a suboptimal response at 12 weeks in approximately 40% of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCS-01 is a topical dexamethasone formulation which we believe is capable of delivering therapeutic levels of drug to the retina via eye drop, a route of
administration for DME treatment that may enable earlier treatment intervention and thereby significantly increase the proportion of patients being treated as well as increase the prescribing physician base by providing a treatment option to general
ophthalmologists. We are currently not aware of the existence of any other eye drop treatment for DME which is in a similar or more advanced stage of active clinical development; however, we cannot guarantee that OCS-01 will receive regulatory
approval. Our Phase 2 clinical trial in DME met the key efficacy endpoints of central macular thickness (&#147;<I>CMT</I>&#148;) and best-corrected visual acuity (&#147;<I>BVCA</I>&#148;) with statistical significance. Our Phase 2 clinical trial in
inflammation and pain after cataract surgery met its primary endpoint with statistical significance in the <FONT STYLE="white-space:nowrap">OCS-01</FONT> once-daily cohort and key secondary efficacy endpoints. Ocular tolerability was not
significantly different between the <FONT STYLE="white-space:nowrap">OCS-01</FONT> and vehicle groups across clinical trials with the exception of change in intraocular pressure (&#147;<I>IOP</I>&#148;), consistent with known effects of topical
steroids, including dexamethasone. We have concluded an affirming <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the FDA. We have initiated Phase 3 clinical evaluations in both indications
and expect the results from the Stage One portion of our Phase 3 DME clinical trial and the Phase 3 clinical trial for the treatment of inflammation and pain related to cataract surgery to be available in
<FONT STYLE="white-space:nowrap">mid-2023.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total U.S. prevalence of DME in 2022 is estimated at 2.96 million, with the diagnosed U.S.
prevalence estimated at 1.75 million by the Decision Resources Group DME Landscape November 2020 report. The same report estimates that 875 thousand U.S. DME patients were treated with drugs in 2022, leaving 879 thousand U.S. patients diagnosed but
untreated. These 879 thousand patients are a key addressable market segment for OCS-01. Additionally, OCS-01 is also intended to address the market segment of patients with suboptimal response to anti-VEGF therapy. A study published in the American
Journal of Ophthalmology in 2016 found that nearly 40% of patients treated with anti-VEGF therapy had suboptimal responses at 12 weeks. By applying this figure to the number of treated U.S. patients, we estimate that suboptimal response occurs in
350 thousand patients. In total, we estimate that 1.2 million DME patients in the United States are addressable by OCS-01. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Informa Meddevicetracker Ophthalmic Surgical Products Market October 2017 report estimates that nearly
6.5 million ocular surgeries (which typically require inflammation and pain management post-surgery) were performed in 2019 in the United States. A study published in Investigative Ophthalmology and Visual Science, an Association for Research in
Vision and Ophthalmology journal in 2021 estimates that approximately 30% of patients who received cataract surgery from 2012 through 2019 had diabetes, a known risk factor for CME following cataract surgery. Given our observations in clinical
studies that OCS-01 treatment led to improvements in visual acuity and macular thickness in patients with DME, we believe OCS-01, if approved for inflammation and pain following ocular surgery, would mainly be used in patients with higher risk of
developing CME, a patient segment which is estimated to be approximately 2 million per year in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are also advancing the clinical development of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> a next-generation biologic treatment for both DED and <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis. Differentiating <FONT
STYLE="white-space:nowrap">OCS-02</FONT> is its use of a single chain antibody fragment formulation directed against the cytokine human tumor necrosis factor alpha (&#147;<I>TNF</I>&#945;<I></I><I></I>&#148;), to enable the topical delivery of an <FONT
STYLE="white-space:nowrap">anti-TNF&#945;</FONT> construct at increased concentrations. The anti-inflammatory and anti-necrotic properties of therapeutics inhibiting TNF&#945; activity are well established with
<FONT STYLE="white-space:nowrap">anti-TNF</FONT> pharmaceuticals already approved as systemic treatments for ocular disease. In addition, we are advancing the development of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in conjunction with the
development of a potentially novel genetic biomarker intended to identify patients who may have a greater response to <FONT STYLE="white-space:nowrap">OCS-02</FONT> therapy. Two Phase 2 clinical trials in patients with symptoms of DED were conducted
(the first with the predecessor of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and the second with <FONT STYLE="white-space:nowrap">OCS-02),</FONT> as well one Phase 2 clinical trial in acute anterior uveitis. Topical ocular administration of
OCS-02 was associated with improvements in the global ocular discomfort score versus vehicle in patients with DED, and with reaching a pre-specified responder rate in patients with non-infectious anterior uveitis, as well as being well tolerated in
all three studies. We plan to commence two Phase 2b trials for <FONT STYLE="white-space:nowrap">OCS-02</FONT> (one in DED in signs, and one in uveitis) and expect results of these trials to be available in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate the segment of DED patients in the United States addressable by OCS-02 (patients with moderate or severe DED) to be approximately 10 million
patients. This comprises an estimated 8.1 million patients with moderate DED and 1.5 million patients with severe DED (based on the rates of 42% moderate and 8% severe patients as reported in a study published in the American Journal of
Ophthalmology in 2017 of a total of approximately 19.4 million diagnosed prevalent cases of DED in the U.S. as estimated by Decision Resources Group Dry Eye Disease Landscape and Forecast, December 2020). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also estimate OCS-02 could help address a medical need in patients suffering from either chronic or recurring non-infectious anterior uveitis. This
addressable patient population is estimated to be approximately 130,000 in the United States based on a prevalence rate of non-infectious uveitis of 121 per 100,000, applied to the U.S. population and the fact that anterior uveitis is the most
prevalent form representing 81% of all cases, as found in a study published in the Journal of the American Medical Association Ophthalmology in 2016, and based on a prevalence of recurrent and chronic disease being estimated at 51%, as found in a
study published in the Journal of the American Medical Association Ophthalmology in 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-05</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third clinical candidate is <FONT STYLE="white-space:nowrap">OCS-05,</FONT> a novel serum/glucocorticoid-regulated protein kinase 2
(&#147;<I>SGK2</I>&#148;) activator peptidomimetic small molecule, in development as a potential disease modifying neuroprotective agent against neurological damage to the optic nerve. We are initially developing
<FONT STYLE="white-space:nowrap">OCS-05</FONT> as a potential therapeutic to treat AON, a rare disease with high unmet need as currently, there is no treatment which is approved by the FDA or European Commission for AON. <FONT
STYLE="white-space:nowrap">OCS-05</FONT> has been granted Orphan Drug Designation by both the FDA and the European Commission for this indication. <FONT STYLE="white-space:nowrap">OCS-05</FONT> has been studied in preclinical studies suggesting
efficacious neuroprotective and remyelinating activity, as well as in a European Phase 1 clinical trial in healthy volunteers in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which <FONT STYLE="white-space:nowrap">OCS-05</FONT> was observed to be well tolerated. We are currently conducting a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Patient</FONT></FONT> clinical trial of <FONT STYLE="white-space:nowrap">OCS-05</FONT> in AON in France to test the candidate&#146;s tolerability, and we also plan to conduct
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities for <FONT STYLE="white-space:nowrap">OCS-05</FONT> in the United States. Should the clinical results of our AON trial prove sufficiently compelling, we intend to evaluate the promise of
<FONT STYLE="white-space:nowrap">OCS-05</FONT> to treat other neuro-ophthalmic disorders such as geographic atrophy, glaucoma, diabetic retinopathy and neurotrophic keratitis. OCS-05 was placed on a clinical hold in 2016, and we in-licensed it from
Accure in 2022 with plans to clear this clinical hold (please see paragraph entitled &#147;&#151;<I>OCS-05 was placed on a clinical hold by the FDA in 2016</I>&#148; in this section and the section entitled &#147;<I>Certain Information About
Oculis</I>&#148; below for further discussion on this clinical hold, the risks it poses for our business, and the steps we must take in order to clear the clinical hold). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional development initiatives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
these five clinical development programs involving the three clinical candidates, we also are engaged in a number of earlier preclinical development initiatives, including the evaluation of <FONT STYLE="white-space:nowrap">OCS-03</FONT> as a
possible treatment for corneal neovascularization, a common disorder caused by the aberrant development of new blood vessels into the cornea and pterygium, a pink colored growth that originates in the conjunctiva. We are assessing the preclinical
candidate <FONT STYLE="white-space:nowrap">OCS-04</FONT> as a potential therapeutic to prevent rejection in patients receiving corneal transplants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Executive Management Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are led by an
experienced management team, composed of individuals who have extensive backgrounds in drug discovery and development, clinical trial design and operations, regulatory affairs, business development and commercial and general management at both large
pharmaceutical companies and emerging biopharmaceutical organizations. Collectively, our management team has a track record of advancing new drug candidates through regulatory approval and successful commercialization. The expertise of our
management team is complemented by our board of directors, which includes many accomplished industry veterans with significant capabilities in guiding the success of emerging biopharmaceutical companies such as ours. Since our inception we have
raised approximately $110 million from leading North American, European and Asian life science venture capital investors including Brunnur Ventures (Brunnur vaxtarsjodur slhf.), BVCF Management (BEYEOTECH), Novartis Bioventures Ltd., and Pivotal
Partners, among others. Please note that prospective investors should not rely on these named investors&#146; investment decisions, as each of such investor&#146;s risk tolerance and investment strategy and goal may be different those of other
prospective investors. Further, because these investors acquired their shares in rounds from financing earlier than the PIPE, during which times Oculis&#146; business activities were less advanced than at the time of the PIPE, they acquired their
shares at prices that, giving effect to their conversion to New Parent Shares, were lower than the price per share paid by PIPE Investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to become a leader in developing therapeutics to address ocular diseases characterized by significant medical needs with large
market opportunities. To accomplish this objective, we plan to focus on successful completion of our key strategic initiatives, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Executing the Phase 3 development of <FONT STYLE="white-space:nowrap">OCS-01</FONT> for DME.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on results achieved in the Phase 2 trial, we have progressed to a Phase 3 trial of <FONT STYLE="white-space:nowrap">OCS-01</FONT>
in DME which is currently ongoing. We believe the use of <FONT STYLE="white-space:nowrap">OCS-01</FONT> formulated as a <FONT STYLE="white-space:nowrap">non-invasive,</FONT> self-administered eye drop, could, if approved, promote a shift in the
current treatment paradigm to allow earlier intervention and increase both the treated patient population and the prescribing physician base. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advancing the ongoing Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">OCS-01</FONT> as a potential
therapeutic for inflammation and pain following ocular surgery with potential further differentiating benefit for patients with elevated risk of CME.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently conducting a Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> a
novel formulation of dexamethasone which incorporates our proprietary Optireach technology, to evaluate its efficacy in treating inflammation and pain following ocular surgery. <FONT STYLE="white-space:nowrap">OCS-01</FONT> is differentiated in this
indication by its potential ability to deliver therapeutic drug levels to the back of the eye. We intend to run a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial to explore further the efficacy
of <FONT STYLE="white-space:nowrap">OCS-01</FONT> in treating edema in CME. We believe this distinction of benefit in CME, if supported by this study, and if <FONT STYLE="white-space:nowrap">OCS-01</FONT> is approved, may enable us to achieve
enhanced market access. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursuing the late-stage clinical development of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> our
next-generation <FONT STYLE="white-space:nowrap">anti-TNF</FONT></I>&#945;<I></I><I> biologic.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on results achieved in three
Phase 2 clinical trials, we intend to advance <FONT STYLE="white-space:nowrap">OCS-02</FONT> into Phase 2b clinical trials to assess its clinical benefit in treating both DED and <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior
uveitis. <FONT STYLE="white-space:nowrap">OCS-02</FONT> is differentiated by its use of single-chain antibody fragment formulation technology, which enables the topical delivery of an <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> agent. We
are advancing the development of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in conjunction with further validation of a potential novel genetic biomarker intended to identify patients who may demonstrate an enhanced response to <FONT
STYLE="white-space:nowrap">OCS-02</FONT> therapy and believe this precision medicine approach may allow the candidate to deliver superior outcomes in this patient group, if approved. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Evaluating <FONT STYLE="white-space:nowrap">OCS-05</FONT> in AON and additional indications to potentially
access larger market opportunities.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The differentiated mechanism of action of <FONT STYLE="white-space:nowrap">OCS-05,</FONT>
coupled with its potential disease modifying neuroprotective properties, suggests potential benefits across many of the more pervasive neurological pathologies of the eye including geographic atrophy, diabetic retinopathy, glaucoma and neurotrophic
keratitis. We initially intend to assess the safety of <FONT STYLE="white-space:nowrap">OCS-05</FONT> as a treatment for AON and are currently evaluating <FONT STYLE="white-space:nowrap">OCS-05</FONT> in a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">First-in-Patient</FONT></FONT> study called the ACUITY (as defined below) trial. There is currently no approved therapy for treatment of AON. <FONT STYLE="white-space:nowrap">OCS-05</FONT> has been granted Orphan Drug
Designation by both the FDA and the European Commission. We believe that demonstration of therapeutic benefits in AON may provide compelling support for the exploration of <FONT STYLE="white-space:nowrap">OCS-05</FONT> in larger market
opportunities. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Leveraging our internal formulation discovery and strengthening our development pipeline through robust
licensing and acquisition activities.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to complement our ongoing development programs by accessing additional innovative
product candidates and technologies through <FONT STYLE="white-space:nowrap">in-licensing,</FONT> strategic collaborations and acquisitions. We believe that the depth of our formulation discovery and drug development expertise specific to ocular
therapeutics, coupled with the industry network of our executive management, board of directors and advisors, provide us with the differentiated set of capabilities necessary to identify and advance products candidates successfully in this
therapeutic category.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Evaluating and selectively entering into strategic collaborations to maximize the potential of our pipeline
and the scope of our product portfolio.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have retained rights globally to all of our indications, including our lead product
candidate <FONT STYLE="white-space:nowrap">OCS-01,</FONT> for the potential treatment of DME and inflammation and pain following ocular surgery; <FONT STYLE="white-space:nowrap">OCS-02</FONT> for the potential treatment of DED and <FONT
STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis; and <FONT STYLE="white-space:nowrap">OCS-05</FONT> as a neuroprotective agent. Given the potential to treat patients worldwide, we may opportunistically enter into strategic
collaborations around certain product candidates, diseases or geographic regions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diseases and disorders of the eye </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous diseases and disorders, many of which represent significant medical needs, are associated with the human eye. Ocular diseases which may result in
significant visual impairment or blindness include retinal diseases such as DME, macular degeneration (including GA), DR, and retinal vein occlusion (&#147;<I>RVO</I>&#148;); disorders caused by swelling and inflammation such as DED, corneal
keratitis and uveitis; and glaucoma, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disease states. The global market for therapeutics used to treat eye disease is estimated to have exceeded $22&nbsp;billion in 2020. We employ our substantial expertise in the development of
therapeutics, in particular pharmaceuticals used to treat ocular diseases, to potentially address many currently intractable <FONT STYLE="white-space:nowrap">eye-related</FONT> conditions. Our focus is on developing innovative drug candidates to
address significant and growing ophthalmic diseases, which result in vision loss, blindness or reduced quality of life, for which there are currently limited treatment options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our clinical development candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilizing our
internal formulation discovery and drug development capabilities, together with extensive licensing, collaboration and acquisition activities, we have assembled a pipeline of attractive development candidates that include both late-stage clinical
candidates as well as earlier stage preclinical initiatives. Our clinical portfolio is made up of <FONT STYLE="white-space:nowrap">(i)&nbsp;OCS-01,</FONT> currently in two ongoing Phase 3 clinical trials, one Phase 3 trial (in Stage One of two
stages) evaluating its use as a treatment for DME and the other Phase 3 trial assessing its utility to treat inflammation and pain following ocular surgery; <FONT STYLE="white-space:nowrap">(ii)&nbsp;OCS-02,</FONT> which we anticipate entering two
Phase 2b clinical trials, the first evaluating its use as a potential treatment for keratoconjunctivitis sicca, or DED, the second trial evaluating its potential use as a therapy for the treatment of
<FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis; and <FONT STYLE="white-space:nowrap">(iii)&nbsp;OCS-05,</FONT> a novel neuroprotective agent with potential application in multiple indications, including glaucoma, GA, and DR,
which we are initially evaluating as a potential treatment for AON. A detailed assessment of each of these clinical candidates is contained in the descriptions provided below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">OCS-01</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Key program highlights</U></I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of proprietary Optireach<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology enables
enhanced drug penetration and residence time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Topically delivered formulation design to allow <FONT STYLE="white-space:nowrap">non-invasive</FONT>
self-administration for front and back of the eye. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">May enable earlier disease intervention if approved, potentially attracting an expanded patient population and
expanded prescribing physician base. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2 trial in DME met <FONT STYLE="white-space:nowrap">pre-specified</FONT> efficacy endpoints for reduction
in CMT and improvement in BCVA, and the Phase 2 trial in ocular surgery met reduction in inflammation and pain endpoints (statistical significance on those endpoints reached in both trials). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data readouts for the Stage One portion of the Phase 3 DME clinical trial and topline data from the Phase 3
clinical trial in ocular surgery are expected in <FONT STYLE="white-space:nowrap">mid-2023.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimated 1.2&nbsp;million total addressable U.S. DME patients; estimated 2&nbsp;million total addressable U.S.
patients with inflammation and pain after ocular surgery. </P></TD></TR></TABLE></div> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead development candidate
<FONT STYLE="white-space:nowrap">OCS-01</FONT> is a 1.5% suspension of the anti-inflammatory corticosteroid dexamethasone for use as a potential treatment for DME and for inflammation and pain following ocular surgery with potential benefit for
patients at high risk for CME following ocular surgery. In contrast to currently available formulations of dexamethasone, which require the use of more invasive treatments such as an implant or intravitreal injection to deliver the medication to the
retina, differentiating <FONT STYLE="white-space:nowrap">OCS-01</FONT> is our use of the proprietary Optireach<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology, which enables the topical delivery, as an eye drop, of dexamethasone
to the back of the eye for the treatment of diseases affecting the retina. OCS-01 is a topical dexamethasone formulation which we have observed in clinical trials to be capable of delivering therapeutic levels of drug to the retina via eye drop, a
route of administration for DME treatment that may enable earlier treatment intervention and thereby significantly increase the proportion of patients being treated as well as increase the prescribing physician base by providing a treatment option
to general ophthalmologists. We are currently not aware of the existence of any other eye drop treatment for DME which is in a similar or more advanced stage of active clinical development; however, we cannot guarantee that OCS-01 will receive
regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed Phase 2 clinical trials in which we observed: In DME, a statistically significant improvement
in both BCVA and CMT, and in inflammation and pain following ocular surgery, a statistically significant increase in the proportion of subjects with absence of inflammation and pain under <FONT STYLE="white-space:nowrap">OCS-01</FONT> treatment
versus vehicle and have concluded an affirming <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the FDA. We have initiated Phase 3 clinical evaluations in both indications. We expect the
results from the Stage One portion of our Phase 3 DME clinical trial and the Phase 3 clinical trial evaluating the potential of <FONT STYLE="white-space:nowrap">OCS-01</FONT> to treat inflammation and pain related to ocular surgery to be available
in <FONT STYLE="white-space:nowrap">mid-2023.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dexamethasone is a widely studied and well characterized pharmaceutical commonly used to treat a
range of inflammatory conditions and is currently included on the World Health Organization&#146;s List of Essential Medicines. It may be administered orally, by injection, or topically. Specific to ocular disorders, dexamethasone intravitreal
implants have been approved by the FDA to treat DME, uveitis and macular edema caused by RVO. Dexamethasone is also used as an ophthalmic suspension for ocular inflammation though the required frequency of dosing in order to achieve a therapeutic
effect often limits its utility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">OCS-01</FONT> as a <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>
cyclodextrin-based formulation of dexamethasone, using the Optireach<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> delivery technology, in order to enhance its residence time at the anterior segment and its penetration into the posterior
segment of the eye following topical application. The increased drug residence time produced by the delivery vehicle, combined with enhanced drug penetration allows for increases in drug concentration of more than
<FONT STYLE="white-space:nowrap">15-fold</FONT> over conventional dexamethasone. We are currently not aware of the existence of any other topically administered formulation of dexamethasone or other active pharmaceutical ingredient in development
intended to deliver sustained therapeutic levels of drug to diseased tissue at the back of the eye. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The Optireach<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology enables the topical delivery of therapeutics to the back of the eye. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g98a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> for DME </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing <FONT STYLE="white-space:nowrap">OCS-01</FONT> as a treatment for DME, which is a complication of diabetes and is caused by the progressive
growth of new blood vessels under the retina that leak fluid and lipids, leading to swelling of the macula, which can result in significant blurring of vision and contribute to the risk of blindness from DR. DME is strongly associated with
uncontrolled blood sugar levels, high blood pressure and high cholesterol. An estimated 5.5% of diabetics worldwide are affected by the disease. It is a leading cause of blindness among the U.S. adult population. In the G7 countries (the United
States, France, Germany, Italy, Spain, UK and Japan), the market for the treatment of DME is estimated to have totaled approximately $3&nbsp;billion in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DME is estimated to impact three million people in the United States alone. Of those three million, we estimate that 1.2 million patients in the United States
are addressable by <FONT STYLE="white-space:nowrap">OCS-01.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently conducting Stage One (of two stages) of our ongoing Phase 3 DIAMOND
trial in study sites in the United States (pursuant to the protocol filed to the IND in 2021), Hungary, and Spain. The number of countries and sites for Stage Two of the study has not been determined as of December 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of current treatments for DME </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DME disease onset may initially go unnoticed and as a result an estimated 46% of patients with DME may go undiagnosed. A study by the American Academy of
Ophthalmology indicates that, among diagnosed patients, fewer than half are treated, with therapeutic intervention used most commonly in the <FONT STYLE="white-space:nowrap">one-third</FONT> of patients who have moderate to severe visual impairment.
Pharmacotherapy involves the invasive administration of a monoclonal antibody therapeutic targeting the vascular endothelial growth factor (&#147;<I>VEGF</I>&#148;) receptor to inhibit blood vessel growth. However, we estimate that approximately 40%
of patients have a suboptimal response to therapy after 12 weeks of anti-VEGF treatment, according to the results of a study published in the American Journal of Ophthalmology in 2016. Moreover, multiple intravitreal injections are required to
maintain a therapeutic effect, which necessitates an increased treatment burden on patients, their caregivers and healthcare providers. The utility of anti-VEGF therapy is further complicated by compliance issues, with patients in clinical practice
estimated to receive only around 30% of the treatments given to participants in the clinical trials which led to these therapeutics&#146; approval for this indication. Patients whose disease progresses while on anti-VEGF therapy may then receive a
steroid implant, or laser photocoagulation of the retina. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, physicians often do not treat patients who present with DME in its earlier stages of
progression (patients with recent disease onset or mild visual impairment), a category that makes up approximately 67% of diagnosed patients with symptoms. We believe this decision to observe and not intervene is often driven by the significant
burden current treatment options (laser photocoagulation, frequent intravitreal injections, intravitreal implants) place on the patient, as well as the expense and significant demands placed on healthcare resources. FDA approved therapeutics are not
widely used for early disease intervention, despite the deterioration in visual acuity of approximately five letters, the equivalent of one line, or more in 19% of this patient population within two years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-01&#146;s</FONT> innovation and differentiation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCS-01 is in development to be a topical treatment for DME, and we are currently not aware of the existence of any other eye drop treatment for DME which is in
a similar or more advanced stage of active clinical development. In addition to this potential breakthrough advancement, we believe that an eye drop therapy would allow for easy, accessible, <FONT STYLE="white-space:nowrap">low-burden</FONT>
self-administration of treatment for DME and would therefore significantly address the limitations of current, invasive therapies for DME. We expect that <FONT STYLE="white-space:nowrap">OCS-01,</FONT> if approved, could address patients who are
diagnosed with DME, with recent onset of disease or mild visual impairment and who are therefore currently observed and untreated, as well as patients who are diagnosed with DME and who have a suboptimal response to anti-VEGF intravitreal
injections. We estimate that this segment of patients in the United States alone totals 1.2 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-01</FONT>
has produced clinical trial results which support its continued development as a potential treatment for DME </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our
<FONT STYLE="white-space:nowrap">DX-211</FONT> Phase 2 clinical trial which evaluated the use of <FONT STYLE="white-space:nowrap">OCS-01</FONT> as a treatment for DME, patients who received <FONT STYLE="white-space:nowrap">OCS-01</FONT> demonstrated
a statistically significant improvement from baseline in key measurements of therapeutic efficacy. In this randomized, double blinded trial of 144 DME patients with 2:1 randomization <FONT STYLE="white-space:nowrap">(OCS-01</FONT> vs. Vehicle), 99
of the trial participants self-administered <FONT STYLE="white-space:nowrap">OCS-01</FONT> eye drops three times per day over a <FONT STYLE="white-space:nowrap">12-week</FONT> period, with 45 participants administered vehicle only. As noted in the
graphic presented below, <FONT STYLE="white-space:nowrap">OCS-01</FONT> demonstrated improvements in both CMT and BCVA, key metrics of clinical efficacy, with <FONT STYLE="white-space:nowrap">OCS-01</FONT> producing a 56.8 least squares mean
(&#147;<I>LSM</I>&#148;) change in CMT from baseline as compared to a 20.1 change for the vehicle group and a 2.6 positive change in BCVA as compared to 1.0 for the vehicle group as measured using a standard 5 letter/line Early Treatment Diabetic
Retinopathy Study (&#147;<I>ETDRS</I>&#148;) letters chart. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> generated improvements in both CMT and BCVA
measurements. </I></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g99c02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(According to Wasserstein RL, Lazar NA. The ASA&#146;s Statement on
<FONT STYLE="white-space:nowrap">p-Values:</FONT> Context, Process, and Purpose. Am Stat. 2016;70(2):129&#150;33., <FONT STYLE="white-space:nowrap">p-value</FONT> is &#147;the probability under a specified statistical model that a statistical
summary of the data (e.g., the sample mean difference between the 2 compared groups) would be equal to or more extreme than its observed value.&#148; This trial (DX211) was designed as a Phase 2 clinical study. Accordingly, the <FONT
STYLE="white-space:nowrap">pre-specified</FONT> alpha defined for the study was 0.15. The study met the above endpoints with statistical significance.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More pronounced results were achieved among patients who entered the trial with worse visual acuity at baseline. As noted in the chart presented below, among
participants whose baseline BCVA score as measured by&nbsp;an EDTRS letters test was less than or equal to 65, <FONT STYLE="white-space:nowrap">OCS-01</FONT> generated a mean improvement in BCVA of 3.8 letters and in CMT of 77.4 &micro;m in contrast
to the 0.9 letters and 23.1&micro;m improvement noted among trial participants who received vehicle. We have incorporated this appreciation of effect into our ongoing Phase 3 DIAMOND trial in which a baseline BCVA score of less than or equal to 65,
but equal or greater than 24, are the&nbsp;inclusion criteria. The trial design of DIAMOND was reviewed by the FDA as part of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the agency.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Improvements in both CMT and BCVA were greater among patients with lower baseline visual acuity . </I></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g20d04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment emergent adverse events (&#147;<I>AEs</I>&#148;) were noted in 32 of the 99 trial participants who received <FONT
STYLE="white-space:nowrap">OCS-01,</FONT> with the most prevalent AE being an increase in intraocular pressure (&#147;<I>IOP</I>&#148;), which was observed in 21 of the 99 patients in the active group. These findings of increased IOP were consistent
with our expectations given </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
glucocorticoids&#146; well-known ocular safety profiles, including the profile of an approved dexamethasone ocular implant. Patients who encountered IOP consistently noted the increase during the
beginning phase of the trial and the increase reversed after discontinuation of drug candidate dosing. No patients discontinued the trial due to IOP increase. Overall, the IOP effects observed in our trial were consistent with what is generally
expected given established ophthalmic use of dexamethasone. Other AEs observed during clinical trials included conjunctival hemorrhage and eye pain, which was not noted among patients who received <FONT STYLE="white-space:nowrap">OCS-01.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from increased IOP, eye irritation and ocular hypertension were observed in three patients each, while individual instances of cataract subcapsular,
eyelid erythema, ocular hyperaemia, and posterior capsule opacification were noted, as was a single instance of a decline in BCVA by 15 letters or more. Except for increased IOP, AEs of a similar nature and number were noted among trial participants
who received vehicle. No AE led to trial discontinuation by any patient. While <FONT STYLE="white-space:nowrap">OCS-01</FONT> may contribute to a slightly accelerated onset of cataracts, we do not believe this issue is significant given the
likelihood that the patient population expected to be treated with this drug, if approved, is more inclined to develop the condition independent of treatment with <FONT STYLE="white-space:nowrap">OCS-01.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 clinical trial results achieved with <FONT STYLE="white-space:nowrap">OCS-01</FONT> in treating DME follow outcomes achieved in two earlier small
exploratory studies of DexNP (a previous formulation of <FONT STYLE="white-space:nowrap">OCS-01).</FONT> In one of the studies, which was conducted in Japan, a <FONT STYLE="white-space:nowrap">22-patient</FONT> evaluation conducted in 2015 compared
the use of a topically delivered <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> cyclodextrin-based formulation of dexamethasone to the posterior injection of 20 mg triamcinolone acetonide. Used at the time of the trial as an <FONT
STYLE="white-space:nowrap">off-label</FONT> treatment for DME, the <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> cyclodextrin-based formulation generated significant improvements in visual acuity and decreased macular thickness, comparable to the
results achieved using triamcinolone acetonide. The results of this 2015 study confirmed similar findings achieved in another <FONT STYLE="white-space:nowrap">19-person</FONT> exploratory Japanese study conducted in 2011. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 3 trial design for <FONT STYLE="white-space:nowrap">OCS-01</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ongoing Phase 3 clinical evaluation of <FONT STYLE="white-space:nowrap">OCS-01</FONT> in DME (DIAMOND) includes two stages. In Stage One, <FONT
STYLE="white-space:nowrap">OCS-01</FONT> is compared to vehicle to evaluate the safety and efficacy of an alternate dosing regimen using a &#147;loading dose&#148; and a &#147;maintenance dose&#148; (each as defined below). The enrollment target for
Stage One is 132 patients. <FONT STYLE="white-space:nowrap">OCS-01</FONT> or vehicle is administered six times per day for six weeks (&#147;<I>loading dose</I>&#148;) and then three times per day for six weeks (&#147;<I>maintenance dose</I>&#148;).
A previous Phase 3 study of dexamethasone ocular intravitreal implants in DME patients (the &#147;<I>MEAD Study</I>&#148;) demonstrated a dose-response relationship, in which patients who received the higher dose implant showed a greater BCVA gain
compared to patients who received the lower dose implant. In an earlier Oculis study, 11 patients who received a previous formulation of <FONT STYLE="white-space:nowrap">OCS-01</FONT> (DexNP) six times per day for four weeks experienced a greater
CMT reduction than eight patients who received DexNP three times per day. In light of these findings, we believe that a &#147;loading dose&#148; may enhance the therapeutic effect of <FONT STYLE="white-space:nowrap">OCS-01.</FONT> Key inclusion
criteria of our DIAMOND study include: Diabetes mellitus 1 or 2, BCVA between 24 and 65 letters and macular thickness (Central Subfield Thickness or &#147;<I>CST</I>&#148;) of 310 &micro;m or greater. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of Stage One, we will evaluate whether to progress to Stage Two of the trial, and if so, using what dosing regimen and sample size. Currently,
we intend to conduct two, <FONT STYLE="white-space:nowrap">52-week</FONT> pivotal Phase 3 trials. We anticipate that each of these global Phase 3 trials will enroll between an estimated 350 and 450 patients. The primary endpoint of these studies
will be the mean change from baseline in BCVA at 52 weeks. Key secondary endpoints are to include the mean change in central retinal thickness, as assessed by spectral domain optical coherence tomography
(&#147;<I><FONT STYLE="white-space:nowrap">SD-OCT</FONT></I>&#148;) and the percentage of participants that exhibit ETDRS improvement of 15 letters or more from baseline. Key inclusion criteria are expected to be similar to those used in Stage One
of the trial. The Phase 3 (&#147;<I>DIAMOND</I>&#148;) clinical trial design was reviewed by the FDA during an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> has the potential to expand the number of treated patients
and prescribing physicians</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">OCS-01</FONT> was designed to address two sizeable treatment gaps pervasive among the DME
patient population in early <FONT STYLE="white-space:nowrap">on-set</FONT> and in severe segments. Furthermore, the sustained delivery of the drug to the back of the eye and <FONT STYLE="white-space:nowrap">non-invasive</FONT> self-administration
are unique differentiators to currently available treatments. Addressing the two existing treatment gaps may allow for increased early disease intervention with expanded treatment of retinal edema due to reduced treatment burden and improved access
to care. Success in demonstrating therapeutic efficacy to treat the earlier-stages of DME disease progression may promote the use of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> if approved, among those DME patients whose treatment is currently
restricted to observation. We believe that this potential expansion of the patient base to include earlier-stage DME patients may also increase the number of prescribing physicians, with general ophthalmologists, not just retina specialists, more
likely to engage in disease management. If approved, <FONT STYLE="white-space:nowrap">OCS-01</FONT> may also be used as a <FONT STYLE="white-space:nowrap">non-invasive</FONT> complement to currently approved therapeutic regimens, including anti-VEGF
medications, potentially extending or enhancing the clinical benefit of those treatments particularly among those patients with more advanced diseases whose condition have not responded adequately to the current standard of care protocol. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> for ocular surgery patients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that approximately six million cataract, glaucoma, refractive, and vitrectomy surgical procedures are performed annually in the United States.
Inflammation and pain remain an expected consequence of ocular surgery. While steroids have proven to be an effective treatment, compliance and potency are major issues with topical steroids dosed several times per day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An estimated 30% of the patients who undergo cataract surgery are at an elevated risk for CME. Clinically significant CME occurs in up to 5.8% of cataract
surgeries, and 56% of high-risk patients experience clinically significant CME following ocular surgery. Similar to DME, CME involves an accumulation of excess fluid in the macula which distorts central vision. CME is the most significant cause of
postoperative vision loss among patients who undergo ocular surgery. Although the specific causes of CME are not well understood, comorbidities including diabetes and uveitis, among other factors, are believed to be significant contributors to
disease emergence. In addition to developing <FONT STYLE="white-space:nowrap">OCS-01</FONT> to treat DME, we are also developing <FONT STYLE="white-space:nowrap">OCS-01</FONT> to treat inflammation and pain following from ocular surgery and
conducting a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study in CME to assess its potential in CME treatment. Prior to <FONT STYLE="white-space:nowrap">OCS-01&#146;s</FONT> commercial launch, if
approved, we anticipate to have completed a proof-of-concept trial of <FONT STYLE="white-space:nowrap">OCS-01</FONT> as a potential treatment for CME. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of current therapies for inflammation and pain post ocular surgery and <FONT STYLE="white-space:nowrap">OCS-01&#146;s</FONT> differentiation
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inexpensive steroids such as prednisone are currently widely prescribed after ocular surgery; but, since they are not formulated to reach the retina,
their therapeutic benefit in treating or preventing complications related to CME has not been established. Given that <FONT STYLE="white-space:nowrap">OCS-01</FONT> has demonstrated the potential to treat macular edema, as evidenced by CMT reduction
and BCVA gain in our Phase 2 DME trial, coupled with additional exploratory data that may be gained from the planned clinical evaluation of <FONT STYLE="white-space:nowrap">OCS-01</FONT> in CME, we envision
<FONT STYLE="white-space:nowrap">OCS-01</FONT> as a well-differentiated potential treatment for inflammation and pain following ocular surgery in patients at higher risk of developing CME, rather than as an alternative to prednisone in the broader
ocular surgery market. We believe that this distinction may enable <FONT STYLE="white-space:nowrap">OCS-01</FONT> to achieve enhanced pricing and market access, if approved. <FONT STYLE="white-space:nowrap">OCS-01,</FONT> if approved, may further
benefit from anticipated once daily dosing, in contrast to the multiple daily doses required of alternative treatments. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> CME trial is planned to
further evaluate the therapeutic efficacy of <FONT STYLE="white-space:nowrap">OCS-01</FONT> for this indication and we expect trial results by <FONT STYLE="white-space:nowrap">year-end</FONT> 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that <FONT STYLE="white-space:nowrap">OCS-01,</FONT> if approved, could address the segment of patients who have ocular surgery and are at higher
risk for CME. We forecast this segment to total approximately 1.9&nbsp;million patients per year in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> has produced clinical trial results which support its
continued development as a potential treatment for inflammation and pain post ocular surgery </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted the
<FONT STYLE="white-space:nowrap">DX-216</FONT> trial, which enrolled 153 patients in a vehicle-controlled, multi-center Phase 2 clinical trial in the United States, to assess the safety and efficacy of <FONT STYLE="white-space:nowrap">OCS-01,</FONT>
dosed once or twice daily, as a treatment for inflammation and pain following cataract surgery. After screening for an anterior chamber cell count of grade 2 or higher, an indication of intraocular inflammation, eligible trial participants were
randomized into one of three cohorts, an active drug cohort administered <FONT STYLE="white-space:nowrap">OCS-01</FONT> once daily, another active drug cohort administered <FONT STYLE="white-space:nowrap">OCS-01</FONT> twice daily, and a third
cohort which received vehicle beginning one day after surgery for 15 consecutive days followed by a <FONT STYLE="white-space:nowrap">one-week</FONT> observation period. The primary endpoints of the trial were the absence of anterior chamber cells at
Day 15 and the absence of pain at Day 4. The key secondary endpoints were the absence of anterior chamber cells at Day 4 and 8, and the absence of pain at Days 2, 8, and 15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial met both its primary and secondary endpoints. <FONT STYLE="white-space:nowrap">OCS-01</FONT> achieved statistical significance in both primary
endpoints for patients who received once daily dosing of <FONT STYLE="white-space:nowrap">OCS-01</FONT> versus those who received vehicle. A single daily application of <FONT STYLE="white-space:nowrap">OCS-01</FONT> was shown to reduce anterior
chamber cells at Day 15 to zero in 51% of trial participants on an intent to treat basis (p&lt;0.001), compared to 19.6% of patients in the cohort that received vehicle alone. The elimination of pain at Day 4 was observed among 72.5% of patients who
received once daily dosing of <FONT STYLE="white-space:nowrap">OCS-01</FONT> (p&lt;0.005), as compared to 45.1% in the vehicle only cohort. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">OCS-01</FONT> was also well tolerated in this trial. No serious ocular or systemic AEs were reported, and the rate of <FONT STYLE="white-space:nowrap">non-serious</FONT> AEs noted during the trial appeared to be largely
procedure related. Moreover, no patient displayed an IOP of greater than or equal to 30 mmHg at any time during the trial, nor did any participant experience a change in IOP from baseline of 10 mmHg or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The design of our Phase 3 trial follows the Phase 2 trial. Once daily administration of <FONT STYLE="white-space:nowrap">OCS-01</FONT> is compared with
vehicle over a <FONT STYLE="white-space:nowrap">15-day</FONT> period following cataract surgery and the trial involves multiple trial sites throughout the United States. The study design was reviewed with the FDA during the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting, and patient randomization for this trial began in July 2022 with trial results expected to be available in
<FONT STYLE="white-space:nowrap">mid-2023.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">OCS-02</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Key Program Highlights</U></I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Next-generation biologic in development as a potential treatment for severe DED and <FONT
STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis using single chain antibody fragment technology targeting TNF&#945;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eye drop formulation enables localized self-administration, minimizing possible complexity and side effects
associated with systemic <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results from three Phase 2 trials of <FONT STYLE="white-space:nowrap">OCS-02&#146;s</FONT> predecessor and <FONT
STYLE="white-space:nowrap">OCS-02</FONT> support moving into Phase 2b trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2b trials are planned, with results expected to be available in 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential proprietary genetic biomarker may enable precision medicine guided patient stratification in DED.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total addressable U.S. DED patient population of approximately 10&nbsp;million patients.
</P></TD></TR></TABLE></div> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also developing <FONT STYLE="white-space:nowrap">OCS-02</FONT> as a next-generation biologic treatment for both DED and as
a treatment for <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis. <FONT STYLE="white-space:nowrap">OCS-02</FONT> is differentiated by its use of a single chain antibody fragment formulation directed against the cytokine human
TNF&#945; to enable the topical delivery of an <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> construct at increased concentrations. The anti-inflammatory and anti-necrotic properties of therapeutics inhibiting TNF&#945; activity are well
established with <FONT STYLE="white-space:nowrap">anti-TNF</FONT> pharmaceuticals already approved as systemic treatments for ocular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disease. In addition, we are advancing the development of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in conjunction with the further validation of a potential genetic biomarker intended to
identify patients who may have a greater response to <FONT STYLE="white-space:nowrap">OCS-02</FONT> therapy and believe this precision medicine approach may allow the candidate to deliver superior outcomes in these patients if approved. Two Phase 2
clinical trials in patients with symptoms of DED were conducted (the first with the predecessor of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> and the second with <FONT STYLE="white-space:nowrap">OCS-02),</FONT> as well one Phase 2 clinical
trial in acute anterior uveitis. Topical ocular administration of OCS-02 was associated with improvements in the global ocular discomfort score versus vehicle in patients with DED, and with reaching a pre-specified responder rate in patients with
non-infectious anterior uveitis, as well as being well tolerated in all three studies. We plan to evaluate <FONT STYLE="white-space:nowrap">OCS-02</FONT> in two Phase 2b trials and expect results of the Phase 2b trials to be available in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TNF&#945; performs important roles in the initiation and propagation of both normal and aberrant immune responses via mechanisms ranging from the stimulation
of other cytokines to inflammatory cell recruitment to the alteration of vascular permeability. Inhibition of TNF&#945; has demonstrated significant clinical benefit in the treatment of an array of diseases arising from dysfunctional immune system
activity and anti TNF&#945; therapeutics have become among the most widely prescribed biologics. Three <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> therapeutics (etanercept, sold under the brand name Enbrel<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, infliximab, sold under the brand name Remicade<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and adalimumab, sold under the brand name Humira<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), have each been studied for use in ocular disease. While the use of antagonists to TNF&#945; have demonstrated favorable efficacy in the treatment of ocular inflammatory diseases, these drugs
require intravenous infusion or subcutaneous injection and systemic <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> therapies are associated with a range of often serious adverse effects. Ocular diseases, such as DED and <FONT
STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis, involve a local TNF&#945; driven inflammatory process which may not justify general, systemic TNF&#945;-suppressive therapy. The novel design of
<FONT STYLE="white-space:nowrap">OCS-02</FONT> embracing lower molecular weight single chain antibody fragment technology may enable it to be used in ocular disease as an eye drop for localized administration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> for the treatment of DED </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keratoconjunctivitis sicca, also referred to as DED results from inflammation related to tear gland damage. DED is a multifactorial disease of the tears and
ocular surface characterized by ocular surface inflammation and increased osmolarity of the tear film that results in ocular discomfort, visual disturbance and tear film instability. The etiology of DED can involve several deficiencies of the tear
film, including the aqueous layer, the lipid layer, mucin layer or a combination of the three layers. The disease often presents as a complication of other diseases, prominently autoimmune disorders such as rheumatoid arthritis, diabetes and
Sjogren&#146;s syndrome, which may contribute to its manifestation. As such, DED may afflict individuals with differing severity of burning sensation, a feeling of dryness, and other symptoms of ocular discomfort. In severe cases, vision may be
significantly impaired. Although the pathogenesis of DED includes a variety of causes, common consequences are a breakdown of corneal tear film with dehydration of the exposed outer corneal surfaces, ocular surface inflammation and subsequent damage
to exposed tissues. Increased concentration of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, such as TNF&#945;, in patient tears or conjunctival tissue has been demonstrated to correlate with disease severity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the U.S. DED patient population was estimated to be approximately 37.9&nbsp;million people and is expected to rise to 41.3&nbsp;million patients by
2029. The market for prescription medications to treat DED is forecasted to increase to $7.3&nbsp;billion in the G7 countries (the United States, France, Germany, Italy, Spain, UK and Japan) by 2029 from $3.9&nbsp;billion in 2019. We estimate the
segment of DED patients in the United States addressable by <FONT STYLE="white-space:nowrap">OCS-02</FONT> (patients with moderate or severe DED) to be approximately 10&nbsp;million patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of current therapies and potential for <FONT STYLE="white-space:nowrap">OCS-02</FONT> in DED </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DED patient population is significantly underpenetrated with only an estimated 9% of diagnosed patients receiving treatment. The vast majority of patients
who do receive treatment are treated with anti-inflammatory drugs, yet among treated patients only 13% achieve lasting relief. Approved topical treatments for DED include Restasis<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Cequa<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, which are both formulations of cyclosporine. These drugs act only to increase tear </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
production and are not indicated to reduce DED symptoms. Further limiting cyclosporine&#146;s therapeutic utility is a delayed onset of action necessitating a two to three month steroid bridge,
and a stinging sensation on application in some patients. Topical steroids are also often used to treat DED but are contraindicated for long-term use because of their side effects including glaucoma and cataracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02&#146;s</FONT> differentiation as a potential treatment for DED </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the central role of ocular inflammation in sustaining the pathology of DED and the utility of <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> as a
highly effective anti-inflammatory agent, we believe the localized application of <FONT STYLE="white-space:nowrap">OCS-02</FONT> as an <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> therapeutic, if approved, may provide a differentiated DED
treatment approach, which may avoid undesirable features of current therapies (such as stinging sensation, delayed onset of action, or steroid-related side effects), and which may provide benefit for many patients who do not receive lasting relief
from current therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate the segment of DED patients in the United States addressable by <FONT STYLE="white-space:nowrap">OCS-02</FONT>
(patients with moderate or severe DED) to be approximately 10&nbsp;million patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> has produced
clinical trial results which support its continued development as a potential treatment for DED </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novartis, from whom we have obtained certain
exclusive, worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OCS-02</FONT> through a December&nbsp;19, 2018 licensing agreement (please see the section entitled &#147;<I>&#151;Material Licenses,</I> <I>Partnerships and
Collaborations</I>&#148; below), conducted a randomized, multi-center, double-blinded, vehicle control Phase 2 clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial designed to assess the
safety and tolerability of <FONT STYLE="white-space:nowrap">OCS-02</FONT> and its efficacy in reducing DED symptoms. In the trial, patients were randomized on a 1:1 ratio into two cohorts. For a <FONT STYLE="white-space:nowrap">six-week</FONT>
period, the first trial cohort received a 60 mg/ml ophthalmic solution of <FONT STYLE="white-space:nowrap">OCS-02,</FONT> while the second received vehicle. Participants in both cohorts self-administered one drop to each eye three times per day. The
primary efficacy endpoint of the trial was improvement in the Global Ocular Discomfort Score as compared to vehicle. The Global ocular discomfort score is a composite of discomfort frequency and severity as assessed by a visual analog scale using an
electronic patient reported outcome. Improvement results in a reduction of the discomfort frequency or severity, or both, translating into a reduction of the resulting Global Ocular Discomfort Score as compared to baseline. A negative change from
baseline indicates improvement. The secondary efficacy endpoint was an assessment of the number of patients that achieved more than 20 points improvement in the global ocular discomfort score. The data generated in this trial, consisting of 67
participants in the active group and 64 in the control group, are presented in the charts below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> generated statistically significant improvement in ocular discomfort as compared to vehicle.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g09e05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial met both primary and secondary endpoints. As is noted in the left chart above, administration of <FONT
STYLE="white-space:nowrap">OCS-02</FONT> resulted in a statistically significant 7.9 mean point reduction in the global ocular discomfort score from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
baseline to treatment day 29 as compared to a 3.6 point mean reduction among patients that received vehicle only. In addition, as is noted in the right chart above,
<FONT STYLE="white-space:nowrap">OCS-02</FONT> generated an improvement in the global ocular discomfort score of greater than 20 points in 12 of the 67 patients, or 18% of total trial participants. A similar level of response was achieved in only
5%, or three of the 64, patients included in the vehicle control group. The results of exploratory endpoints, which included physician graded conjunctival hyperemia, corneal staining, Meibomian gland assessment and tear film osmolarity, were similar
across treatment groups. <FONT STYLE="white-space:nowrap">OCS-02</FONT> demonstrated a statistically significant improvement in the Global Ocular Discomfort Score compared to vehicle in patients with severe DED. It was well tolerated, with no
increase in IOP and minimal systemic drug exposure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proprietary genetic biomarker may enable a precision medicine approach to DED </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an exploratory pharmacogenetic analysis focused on the genes relevant to the TNF pathway and Sjogren&#146;s syndrome among those 12 patients who
displayed a greater than <FONT STYLE="white-space:nowrap">20-point</FONT> improvement in global ocular discomfort score after administration of <FONT STYLE="white-space:nowrap">OCS-02</FONT> to investigate a potential association between gene
variants and the achieved ocular discomfort score. Among the gene variants analyzed, a correlation between one variant, designated the SNP rs1800693 CC genotype (&#147;<I>CC genotype</I>&#148;), and a greater response to <FONT
STYLE="white-space:nowrap">OCS-02</FONT> was observed. Patients with this variant displayed a significant reduction in inflammatory factors, including interleukin 1 beta (IL1B), interleukin 8 (IL8) and TNF&#945;. This correlation is evidenced in the
messenger RNA (&#147;<I>mRNA</I>&#148;) expression profiles of TNF&#945; presented in the charts below which compared expression levels of patients with the various gene variants at Days 29 and 43 after dosing with either active drug candidate or
vehicle. The CC genotype is estimated to be present in 17% to 19% of the general population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>A specific gene variant may enable
biomarker based response stratification </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g02a05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that further validation of this genetic biomarker may enable us to identify a specific high response patient
population which may allow us to enrich clinical trial enrollment and enhance our ability to evaluate the efficacy of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in this indication and subpopulation. We intend to further evaluate the utility of
this biomarker during our planned Phase 2b trial of <FONT STYLE="white-space:nowrap">OCS-02.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2b trial design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the results generated by <FONT STYLE="white-space:nowrap">OCS-02</FONT> in its Phase 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials, we plan to advance <FONT STYLE="white-space:nowrap">OCS-02</FONT> into a <FONT STYLE="white-space:nowrap">10-week,</FONT> estimated 120 patient Phase 2b clinical trial to evaluate the
safety and efficacy of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in treating the signs of DED. This trial is designed to be a randomized, multi-center, double blinded, vehicle-controlled trial. Following initial screening, trial participants
will participate in a <FONT STYLE="white-space:nowrap">two-week</FONT> <FONT STYLE="white-space:nowrap">run-in</FONT> period during which time artificial tears will be administered three times daily. The patients that respond to treatment with
artificial tears will be excluded from further participation. Patients who continue with the trial will be randomized on a 1:1 basis into either the treatment cohort or the vehicle cohort and receive <FONT STYLE="white-space:nowrap">OCS-02</FONT> or
vehicle three times daily for eight weeks. The efficacy measures and endpoints of the trial include a significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improvement in signs of DED, such as total corneal fluorescein staining, the percentage of patients with a 10 mm or greater increase in Schirmer&#146;s test, as well as exploratory endpoints
evaluating symptoms of DED such as global ocular discomfort compared to vehicle. Biomarker analyses (from tear collection), as well as genotyping of subjects, are additional endpoints of the trial. We expect to commence the Phase 2b clinical trial
in the first half of 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> for the treatment of
<FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to its potential use as a therapeutic to treat DED, we are
also evaluating <FONT STYLE="white-space:nowrap">OCS-02</FONT> for use as a treatment option for patients with <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis, including patients with chronic or recurrent <FONT
STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis who would benefit from a steroid-sparing option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uveitis is a condition characterized
by the inflammation of the uveal tract but can also cause the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. Uveitis is caused by inflammatory responses inside the eye in response to an attack from the
body&#146;s own immune system, infection, or trauma and injury to the eye. Uveitis is closely associated with various systemic diseases, including autoimmune disorders, and infectious diseases. However, a significant proportion of uveitis is
idiopathic, with no identifiable cause for the disease. It primarily affects people between 20 and 60 years of age but can present at any age. If left untreated, uveitis can cause complications including macular edema, retina scarring, glaucoma,
cataracts, optic nerve damage, retinal detachment and permanent vision loss. Uveitis, which can affect one or both eyes, accounts for between 10% to 15% of all cases of blindness in the United States and is the fourth leading cause of blindness in
people aged <FONT STYLE="white-space:nowrap">20-60</FONT> years in developed countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss of vision is correlated with the severity, frequency and
duration of inflammatory episodes. Accordingly, the objective of treatment is fast and complete suppression of inflammation. Uveitis is categorized as either anterior, intermediate or posterior uveitis depending on the location of inflammation, or
as panuveitis if present in multiple locations. Anterior uveitis is the most prevalent form of the disease and is associated with visual impairment. We estimate that that approximately 51% of patients in the United States who are diagnosed with
anterior uveitis experience chronic or recurrent disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate <FONT STYLE="white-space:nowrap">OCS-02</FONT> to address a patient segment of
129,000 patients with chronic or recurrent, anterior, <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations with the standard of
care to treat anterior uveitis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The standard of care for uveitis is corticosteroids, which are administered as topical, intravitreal, periocular or
oral depending on the location and severity of the disease. Active <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis is treated with topical corticosteroids. While topical corticosteroids have demonstrated clinical efficacy, their use
is associated with a number of adverse ocular and systemic events. Topical ocular corticosteroid use is estimated to cause an increase in IOP of more than 15 mmHg among 4% and 6% of the general population and an increase of between 6 and
15&nbsp;mmHg in up to <FONT STYLE="white-space:nowrap">one-third</FONT> of users after daily application for four to six weeks. Persistent elevation in IOP may result in glaucoma, characterized by visual field loss and optic nerve damage, or the
formation of cataracts. Incidence of cataract worsening or formation is related to total topical dose and duration. Based on multi-year studies with ocular corticosteroid implants, we estimate that approximately
<FONT STYLE="white-space:nowrap">31-47%</FONT> more patients developed or experienced worsening of cataracts compared to control arms (sham implants or standard of care). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> differentiated as a steroid-sparing treatment for anterior uveitis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the limitations related to longer-term steroid use in patients with recurrent or chronic uveitis, we believe
<FONT STYLE="white-space:nowrap">OCS-02</FONT> has potential as a steroid-sparing treatment alternative. In November 2019, we commissioned a market research report which involved interviews with 14 key opinion leaders, high volume practitioners of
uveitis treatment (ophthalmologists and uveitis specialists) and payer experts. The results suggested that physicians are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likely to be receptive to prescribing a topical, <FONT STYLE="white-space:nowrap">non-steroidal</FONT> treatment after initial administration of a topical corticosteroid that may both shorten the
duration of topical steroid use and obviate the potential need to advance patients to oral steroids. If approved, <FONT STYLE="white-space:nowrap">OCS-02</FONT> may also be appropriate for patients who demonstrate an inability to tolerate steroid
treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate <FONT STYLE="white-space:nowrap">OCS-02</FONT> to address a patient segment of 129,000 patients with chronic or recurrent,
anterior, <FONT STYLE="white-space:nowrap">non-infectious</FONT> uveitis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> Phase 2 clinical trial
results support its continued development as a potential treatment for <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novartis also conducted a Phase 2 clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial to evaluate
the use of <FONT STYLE="white-space:nowrap">OCS-02</FONT> as a potential treatment for acute anterior uveitis (&#147;<I>AAU</I>&#148;). This trial was a randomized, multi-center, double blinded, active controlled evaluation to assess the safety,
tolerability and efficacy of <FONT STYLE="white-space:nowrap">OCS-02</FONT> administered for up to 21 days in resolving ocular inflammation in the anterior chamber associated with AAU. A 60 mg/ml ophthalmic solution of
<FONT STYLE="white-space:nowrap">OCS-02</FONT> was administered to trial participants in the <FONT STYLE="white-space:nowrap">OCS-02</FONT> cohort and topical dexamethasone administered to patients in the active-control cohort. Trial participants
received a maximum of eight drops daily per treated eye for the first two weeks with dosing tapered for the following <FONT STYLE="white-space:nowrap">two-week</FONT> period. Response to treatment was defined as a reduction from baseline of 2 or
more anterior chamber cell grades. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">35 patients completed the trial, with 25 patients in the <FONT STYLE="white-space:nowrap">OCS-02</FONT> cohort and 10
patients in the active control cohort. <FONT STYLE="white-space:nowrap">OCS-02</FONT> achieved the primary endpoint established for the trial, which was a responder rate in excess of 30%. Among the 25 participants that completed the trial and were
treated with <FONT STYLE="white-space:nowrap">OCS-02,</FONT> 14 patients, or 56%, demonstrated a response to <FONT STYLE="white-space:nowrap">OCS-02</FONT> treatment at Day 22, specified as the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> treatment period for the trial. In the trial, <FONT STYLE="white-space:nowrap">OCS-02</FONT> was observed to be well tolerated. No increase in IOP related to
<FONT STYLE="white-space:nowrap">OCS-02</FONT> was observed, and no systemic adverse safety signals were observed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> as a treatment for uveitis is to be advanced into a Phase 2b trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the encouraging results generated by <FONT STYLE="white-space:nowrap">OCS-02</FONT> in the Phase 2 clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial, we intend to advance this clinical candidate into a Phase 2b trial for evaluation as a therapeutic for <FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis with
potential as a steroid-sparing alternative to the currently used drugs. Trial parameters to be incorporated into this clinical evaluation are in development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">OCS-05</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Key Program Highlights</U></I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potentially unique in treatment paradigm as disease modifying, neuroprotective drug, if approved.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evidence of clinical benefit in AON may support assessment as potential therapeutic for glaucoma, geographic
atrophy and diabetic retinopathy, among other indications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advancing candidate in an ongoing Phase 2 clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial to evaluate its use as a treatment for AON based on compelling European clinical results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1 study data demonstrated <FONT STYLE="white-space:nowrap">OCS-05</FONT> was well-tolerated in 48 healthy
volunteers. </P></TD></TR></TABLE></div> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to development candidates intended to modulate inflammatory conditions associated with ocular disease
pathologies, we are also advancing <FONT STYLE="white-space:nowrap">OCS-05,</FONT> a small molecule in development as a potential disease modifying neuroprotective agent designed to address neurological damage to the optic nerve. We are initially
developing <FONT STYLE="white-space:nowrap">OCS-05</FONT> as a potential therapeutic to treat AON. <FONT STYLE="white-space:nowrap">OCS-05</FONT> has been granted Orphan Drug Designation by both the FDA and the European Commission for this
indication. <FONT STYLE="white-space:nowrap">OCS-05</FONT> has been studied in preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies suggesting neuroprotective and remyelinating activity, as well as in a European Phase 1 clinical trial (with 48 healthy volunteers) in which <FONT STYLE="white-space:nowrap">OCS-05</FONT>
was well tolerated and showed pharmacokinetics (&#147;<I>PK</I>&#148;) with good correlation with its <FONT STYLE="white-space:nowrap">pre-clinical</FONT> animal studies. We are currently studying <FONT STYLE="white-space:nowrap">OCS-05</FONT> in a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in AON. Should the clinical results of our AON trials prove sufficiently compelling, we intend to evaluate
<FONT STYLE="white-space:nowrap">OCS-05</FONT> to treat other more pervasive neurological pathologies of the eye such as geographic atrophy, neurotrophic keratitis and glaucoma. We obtained an exclusive license, worldwide to develop <FONT
STYLE="white-space:nowrap">OCS-05</FONT> through a licensing agreement we entered into with Accure Therapeutics SL (&#147;<I>Accure</I>&#148;), dated as of January&nbsp;29, 2022 (Please see the section entitled &#147;<I>&#151;Material Licenses,
Partnerships and Collaborations</I>&#148; below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">OCS-05</FONT> is a small molecule peptidomimetic that has a
differentiated mechanism of action through the activation of SGK2 which is hypothesized as part of the neurotrophic factor signaling pathways that supports neuronal cell development, survival and repair, including oligodendrocyte precursor
differentiation and myelination. Enzymes in the SGK2 family are recognized to regulate a range of fundamental cellular processes such as cellular proliferation and survival. SGK2 activation leads to an upregulation of signaling molecules forkhead
box O3 (&#147;<I>FOXO3</I>&#148;), which reduces apoptosis, the downregulation of glycogen synthase kinase 3 beta (&#147;<I>GSK3B</I>&#148;), which improves anti-oxidation, and an upregulation of <FONT STYLE="white-space:nowrap">N-myc</FONT>
downstream-regulated gene 1(&#147;<I>NDRG1</I>&#148;) involved in oligodendrocyte development and differentiation. The potential disease modulating activity of <FONT STYLE="white-space:nowrap">OCS-05</FONT> may distinguish it as a neuroprotective
SGK2 activator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OCS-05 was placed on a clinical hold by the FDA in 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accure had conducted a limited set of animal regulatory toxicology studies in 2016 and submitted them to the FDA in an IND requesting the initiation of human
testing. Upon review, the FDA found the data insufficient and asked for more animal toxicology data to be generated prior to human studies, thereby placing OCS-05 on the regulatory status of &#147;clinical hold&#148; pending the availability of the
requested data. In response, Accure chose to withdraw the IND in 2017 rather than invest in further toxicology studies to address the FDA&#146;s request. Upon our license of OCS-05 from Accure in 2022, we reactivated the IND and plan to meet with
the FDA in the first half of 2023 to agree on a comprehensive toxicology plan to satisfy the FDA&#146;s request. Other health authorities where clinical studies have been proposed, including the UK and France, have authorized us to commence clinical
studies of selected doses and reinforced safety measures as in our European Phase 1 trial in AON. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">OCS-05</FONT>
for the treatment of acute optic neuritis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AON is an inflammation of the optic nerve that can cause the death of neurons, leading to vision
impairment. A variety of infectious diseases, immune disorders, demyelinating disorders, <FONT STYLE="white-space:nowrap">non-inflammatory</FONT> systemic disease or trauma can cause AON. AON is commonly associated with multiple sclerosis
(&#147;<I>MS</I>&#148;) and shares similar physiopathology. AON is the presenting symptom of MS in <FONT STYLE="white-space:nowrap">15-20%</FONT> of patients and will impact over <FONT STYLE="white-space:nowrap">50-65%</FONT> of patients with MS at
some time during their lifetime. However, the causes of AON are not always clear, as it can also arise in patients without MS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acute inflammation of
the optic nerve causes the loss of myelin and oligodendrocytes, optic nerve conduction block and loss of vision. At the onset of AON, patients often suffer from ocular pain increasing with eye movement, associated with a variety of visual
impairments. Deterioration of visual acuity, color vision or flashes of light are common. The loss of vision ranges considerably between patients from mild blurring to loss of perception of light. The condition tends to worsen over the first several
days after the appearance of symptoms before starting to improve over the first two weeks. The recovery continues for as long as a year after onset. Even if high contrast visual acuity returns to near normal, patients often report that their vision
has not completely recovered. There remains a persistent impairment of low contrast letter acuity and clinically meaningful reduction in vision-related quality of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the inflammation recedes, remyelination often occurs but it is incomplete, the result of persistent demyelination and neuronal death. Without the myelin
sheath which normally protects the axon, neurons located in demyelinated segments become fragile and prone to death. Thinning of the retinal neural fiber layer (&#147;<I>RNFL</I>&#148;), which is made up of unmyelinated axons originating from the
retinal ganglion cell (&#147;<I>RGC</I>&#148;) bodies, indicates significant <FONT STYLE="white-space:nowrap">AON-induced</FONT> axonal loss. RNFL thinning, most pronounced three to six months after an acute AON event, along with thinning of the
ganglion cell bodies layer, correlates with diminished scores of visual acuity and visual field sensitivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No therapeutic is currently approved that preserves vision and ganglion/retinal nerve integrity after an
acute episode of AON. Medication intended to treat the inflammation and related symptoms can be administered just after AON onset and patients often receive high doses of corticosteroids for a few days to alleviate disabling vision-related symptoms
caused by the inflammation. Corticosteroids have become the current standard of care, as the therapy acts to shorten the attack and accelerate recovery of acute visual symptoms. However, vision loss persists in 10% to 20% of patients despite
administration of IOP lowering therapy. We believe a neuroprotective therapeutic, such as <FONT STYLE="white-space:nowrap">OCS-05,</FONT> if approved, could prevent long term axonal loss may promote enhanced clinical outcomes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-05</FONT> demonstrated compelling neuroprotective qualities in an animal model of AON </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a rat model of AON, animals were segregated into four groups. The first group of healthy animals represented a sham control. Three additional groups
received lysolecithin via injection into the optic nerve of study animals to induce inflammation and demyelination. Rats in group two received no treatment and served as a pathological control group. Groups three and four were administered <FONT
STYLE="white-space:nowrap">OCS-05</FONT> once daily over a <FONT STYLE="white-space:nowrap">five-day</FONT> period. Animals in group three received a 35 mg/kg dose of <FONT STYLE="white-space:nowrap">OCS-05</FONT> while animals in the fourth group
received a dose of 70 mg/kg. The animals were sacrificed on the sixth day and assessed for a decline in RGC count. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is noted in the results presented
below, both groups of animals that received <FONT STYLE="white-space:nowrap">OCS-05</FONT> generated a statistically significant reduction in RGC loss when administered following the lysolecithin challenge, with rats administered the 35 mg/kg dose
of <FONT STYLE="white-space:nowrap">OCS-05</FONT> demonstrating a 35.9% mean reduction of RGC loss. Animals in the higher dose treatment group who received a 70 mg/kg dose of <FONT STYLE="white-space:nowrap">OCS-05</FONT> displayed a more profound
benefit from <FONT STYLE="white-space:nowrap">OCS-05</FONT> dosing, with RGC loss declining 64.0%.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>RGC loss in
animals treated with <FONT STYLE="white-space:nowrap">OCS-05</FONT> was significantly reduced in an animal model of AON. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g02a09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reduction in RGC loss was also observed in a visual assessment of representative tissue samples collected from animals
in three of the four study groups, the sham control group, the pathological control group and rats treated with the higher 70 mg/kg dose of <FONT STYLE="white-space:nowrap">OCS-05.</FONT> As is depicted in the slides of the optic nerve presented
below, normal ganglion cell density was observed in the evaluation of tissue taken from a healthy animal in the sham control group. In contrast, cell counts taken from samples of rats included the lysolecithin challenge group that made up the
pathological control witnessed a prominent decrease. After completion of the <FONT STYLE="white-space:nowrap">five-day</FONT> protocol, this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decline was noted to have reversed, with rats who received the 70 mg/kg dose of <FONT STYLE="white-space:nowrap">OCS-05</FONT> observed to have retained a significantly higher number of ganglion
cells. Similar results illustrating a reduction in axonal loss and demyelination, along with improvement in clinical function, have been achieved in animal models of AON. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">OCS-05</FONT> was seen to bolster ganglion cell counts after lysolecithin challenge. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g02b09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-05</FONT> was well tolerated in a trial involving healthy volunteers. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A randomized, double-blinded, placebo controlled single-ascending dose and multiple-ascending dose trial was conducted in the United Kingdom to evaluate the
safety, tolerability and PK and pharmacodynamics of <FONT STYLE="white-space:nowrap">OCS-05</FONT> dosing through the intravenous infusion of healthy volunteers with the drug candidate. This trial was designed to include four interlocking cohorts of
eight adult subjects each to evaluate eight single ascending doses, with an additional two cohorts of eight adult subjects each included in the two multiple ascending dose trials. The single ascending dose cohorts were administered drug in doses
ranging from .05 mg/kg to 3.2 mg/kg. The two cohorts in the multiple ascending dose trial received either a 2.4 mg/kg dose or a 3.0 mg/kg dose, once daily, for five consecutive days. In this trial, it was observed that
<FONT STYLE="white-space:nowrap">OCS-05</FONT> was well tolerated with no serious AEs noted. Human PK data produced by this trial showed good correlation with data produced in animal studies of the compound. This trial was conducted under a clinical
trial protocol approved by European regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We are investigating <FONT STYLE="white-space:nowrap">OCS-05</FONT> as a treatment for AON
in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Patient</FONT></FONT> clinical trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of prior clinical and
preclinical trials of <FONT STYLE="white-space:nowrap">OCS-05</FONT> in promoting disease modifying effects, together with the safety and PK profile observed in this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial enabled us to advance the compound into a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Patient</FONT></FONT>
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial. The <B>A</B>cute Opti<B>C</B> Ne<B>U</B>r<B>IT</B>is of Dem<B>Y</B>elinating Origin (&#147;<I>ACUITY</I>&#148;) trial, a randomized,
double-blinded, placebo controlled, multiple center trial, is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Patient</FONT></FONT> trial enrolling patients diagnosed with AON within ten days of acute disease episode
onset. The objective of this study is to assess the safety and tolerability of <FONT STYLE="white-space:nowrap">OCS-05</FONT> along with initial signs of efficacy. In addition to the trial&#146;s primary safety endpoint, a key secondary endpoint
will be the effect of <FONT STYLE="white-space:nowrap">OCS-05</FONT> on retinal layer thickness and other visual parameters in the affected eye. The study is currently being conducted in France under French regulatory guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that positive outcomes in this trial could support the compound&#146;s possible use in the treatment of other ophthalmic conditions involving the
posterior segment including glaucoma, geographic atrophy, DR as well as certain diseases of the anterior segment including corneal keratitis. The novel mechanism of action of <FONT STYLE="white-space:nowrap">OCS-05</FONT> may enable it to
demonstrate benefit in treating these additional ocular conditions and may additionally allow its application in <FONT STYLE="white-space:nowrap">non-ocular</FONT> neurological disorders involving neuronal inflammation such as MS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2016, the <FONT STYLE="white-space:nowrap">OCS-05</FONT> development program was placed on clinical hold by the FDA related to the absence of no observed
adverse effects levels (&#147;<I>NOAEL</I>&#148;), in prior preclinical studies conducted by the sponsor at that time. After we licensed the asset from Accure, our strategy has included plans to complete the additional preclinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies required to establish NOAEL, in order to enable our submission of an investigational new drug (&#147;<I>IND</I>&#148;) application with the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We are investigating OCS-05&#146;s potential as a treatment for Glaucoma as well as for Neurotrophic Keratitis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical studies of OCS-05 in a model of glaucoma in Sprague rats showed results which support its potential to be developed as a treatment for glaucoma.
In these two experiments, high intraocular pressure was induced in rats by injecting hypertonic saline solution into the episcleral vein of one eye of each rat, and then the rats were treated for six weeks. In one experiment, rats in the active
group were treated with OCS-05 as an eye drop twice daily for six weeks, rats in the positive control group received nerve growth factor (&#147;<I>NGF</I>&#148;), and rats in the control group received placebo of saline 5% dimethyl sulfoxide
(&#147;<I>DMSO</I>&#148;). In the other experiment, rats in the active group were treated with OCS-05 as an intravitreal injection once every two weeks, for six weeks, and rats in the control group received placebo of saline 5% DMSO. Retinal
ganglion cells (&#147;<I>RGCs</I>&#148;) count was measured via haematoxylin and eosin stain (&#147;<I>H &amp; E</I>&#148;) histological quantification, and IOP was also measured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sprague rats displayed significant loss of RGCs one month after the induction of ocular hypertension. In animals treated with OCS-05, either as eye drops or
through intravitreal injection, there were statistically significant increases in RGCs surviving compared with those that received the placebo. In the experiment which included a positive control of NGF, OCS-05 treatment showed a similar effect to
that seen with NGF. In addition, IOP did not significantly decrease with administration of OCS-05. We believe this data suggests that OCS-05 may promote neuronal survival in this animal model of glaucoma via neuroprotection (and not by reversing the
induced ocular hypertension). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g01a67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">OCS-05 (eyedrops and intravitreal) prevents RGCs damage without reducing intraocular pressure </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the results from these preclinical studies, we plan to further study OCS-05, and if results from our ACUITY trial in AON further support OCS-05&#146;s
potential as a neuroprotective compound, we may prepare for and initiate clinical development of OCS-05 in glaucoma. Glaucoma represents a large market, and we are not currently aware of the existence of any other compound in a similar or more
advanced stage of development as a neuroprotective drug for glaucoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we also plan to further study OCS-05 for its potential to enter
clinical development as a treatment for neurotrophic keratitis (&#147;<I>NK</I>&#148;). NK is a rare eye disorder which results from damage or loss of function of nerves which innervate the cornea, which can lead to corneal perforation, corneal
scarring, corneal melting, loss of vision, or loss of the eye. In 2018, the FDA approved the NGF drug cenergermin (&#147;<I>Oxervate</I>&#148;) to treat NK. However, Oxervate may be cost prohibitive for patients and payors, as ASCRS Eyeworld
estimated in 2020 that Oxervate costs $11,000 per week for an 8-week treatment course for NK . </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that preclinical studies of OCS-05 have shown data suggesting that the OCS-05 could provide
neuroprotective benefits, we believe it may have potential to treat the nerve impairment underlying NK. If results from our ACUITY trial in AON further support OCS-05&#146;s potential as a neuroprotective compound, we may prepare for and initiate
clinical development of OCS-05 in NK. We are currently not aware of the existence any other drugs except for Oxervate which are approved or in a similar or more advanced stage of development as a treatment for NK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently conducting formulation studies to develop a topical formulation of OCS-05 which can be used in further preclinical or in clinical development
of OCS-05 in glaucoma or in NK. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Discovery Initiatives </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our five clinical development programs involving <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT>
and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> we also are engaged in a number of earlier preclinical development initiatives, including the evaluation of <FONT STYLE="white-space:nowrap">OCS-03</FONT> as a possible treatment for corneal
neovascularization, a common disorder caused by the aberrant development of new blood vessels into the cornea and pterygium, a pink colored growth that originates in the conjunctiva. We are also assessing the preclinical candidate <FONT
STYLE="white-space:nowrap">OCS-04</FONT> as a potential therapeutic to prevent rejection in patients receiving corneal transplants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Licenses,
Partnerships and Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Novartis for <FONT STYLE="white-space:nowrap">OCS-02</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a license agreement, dated as of December&nbsp;19, 2018, as amended, by and between us and Novartis (the &#147;<I>Novartis Agreement</I>&#148;), we
obtained an exclusive, royalty-bearing, sublicensable (subject to certain conditions), assignable (subject to certain conditions), worldwide license under certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and manufacturing platform
technology to develop, manufacture and commercialize pharmaceutical, therapeutic or diagnostic products containing a specified single chain antibody fragment formulation as an active ingredient in the licensed field as defined in the Novartis
Agreement. The license granted to us by Novartis includes sublicenses of rights granted to Novartis by certain third parties, and our license to such rights is expressly subject to the applicable terms and conditions of the agreements between
Novartis and such third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are deemed the owner of any inventions that are (a)&nbsp;created solely by or on behalf of us pursuant to the
Novartis Agreement and (b)&nbsp;severable from the licensed products, and grant Novartis a first right to negotiate a worldwide, royalty-bearing license under any patents directed at such inventions for purposes outside of the licensed field. We
also grant Novartis a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license back under any patents owned by us that (i)&nbsp;cover
inventions arising from the Novartis Agreement, the practice of which would infringe the patents licensed to us by Novartis, or (ii)&nbsp;otherwise incorporate Novartis&#146; proprietary information, in each case, for certain uses outside of the
licensed field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We made an initial payment to Alcon of CHF 4.7&nbsp;million ($4.7&nbsp;million at the exchange rate at the time of payment) in cash. As
of September 30, 2022, we were obligated to pay Novartis additional up to $97.0&nbsp;million (CHF 95.1&nbsp;million at the September&nbsp;30, 2022 exchange rate) in the aggregate upon the achievement of certain development, regulatory, sales and
other milestones and tiered royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to a mid-teen percentage on net sales. In consideration for the exclusive sublicense from Novartis under certain third-party intellectual
property rights, we are obligated to pay a <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty on our net sales of the licensed product, however, such payments will be deducted from royalties payable to Novartis. Our royalty payment
obligations are subject to certain reductions and expire with respect to any licensed product on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of (a)&nbsp;the expiration of
the last to expire valid claim of any licensed patent covering any such licensed product in such country; (b)&nbsp;the expiration of the period of data exclusivity in any country worldwide; or (c)&nbsp;twelve (12) years after first commercial sale
of such licensed product in such country (&#147;<I>Royalty Term</I>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Novartis Agreement, we are obligated to use diligent efforts to develop, manufacture or have
manufactured, and commercialize the licensed products in the licensed field worldwide. The Novartis Agreement will expire upon the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Royalty Term. We may
terminate the Novartis Agreement without cause at any time upon advance written notice to Novartis. Upon written notice to Novartis, we may terminate the Novartis Agreement for cause due to the following events: (a)&nbsp;an insolvency event occurs;
(b)&nbsp;Novartis materially breaches its obligations under the Novartis Agreement and fails to cure such breach within a specified period of time; or (c)&nbsp;upon advance written notice for material scientific, technical or medical reasons or in
case of a material adverse change that renders further continuation of the Novartis Agreement by us commercially unreasonable or otherwise not viable. Upon written notice to us, Novartis may terminate the Novartis Agreement for cause due to the
following events: (i)&nbsp;we fail to pay any undisputed amount due under the Novartis Agreement and we fail to remedy such failure within a specified period of time; (ii)&nbsp;an insolvency event occurs; (iii)&nbsp;we materially breach our
obligations under the Novartis Agreement and fail to cure such breach within a specified period of time; or (iv)&nbsp;following negative clinical trial results, we terminate development of the licensed product and do not pursue any further
indications in the licensed field. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Accure for <FONT STYLE="white-space:nowrap">OCS-05</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a license agreement, dated as of January&nbsp;29, 2022, by and between us and Accure (the &#147;<I>Accure Agreement</I>&#148;), we obtained an
exclusive, worldwide, sublicensable (subject to certain conditions) and transferable (subject to certain conditions) license under certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and inventory of Accure for any and all uses and
purposes, including to perform research, development, manufacturing and commercialization activities in any manner and for any purpose. The licensed patents are <FONT STYLE="white-space:nowrap">co-owned</FONT> by Accure with third parties who have
reserved the right to use the licensed patents for education and research purposes pursuant to an inter-institutional agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We made an initial
payment to Accure of CHF 1.5 million ($1.6&nbsp;million at the exchange rate at the time of payment) and another payment of CHF 0.5 million of reimbursed costs ($0.5 million at the exchange rate at the time of payment) during the nine months ended
September 30, 2022. We accrued an additional CHF 1.5 million ($1.5&nbsp;million at the September&nbsp;30, 2022 exchange rate) for liabilities owed to Accure. As of September&nbsp;30, 2022, we were obligated to pay Accure (a)&nbsp;up to
$112.1&nbsp;million (CHF 109.9&nbsp;million at the September&nbsp;30, 2022 exchange rate) in the aggregate upon the achievement of certain development, regulatory and sales milestones; (b)&nbsp;tiered royalties ranging from a <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit to a low mid-teen percentage on net sales of licensed products; and (c)&nbsp;a percentage in the high teens on sublicensing revenues received any time after 36 months from the agreement effective
date, and a higher percentage on sublicensing revenues received prior to such date, in all cases subject, in the case of this clause (c), to reduction for any amounts that were previously paid or are concurrently or later paid by us to Accure
pursuant to our milestone payment obligations. Our royalty payment obligations are subject to certain reductions and expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of (i)&nbsp;the expiration of the last valid claim of any licensed patent covering such licensed product in such country;
(ii)&nbsp;the expiration of such licensed product&#146;s Orphan Drug status, if any, in such country; or (iii)&nbsp;ten (10) years following the date of first commercial sale of such licensed product in such country (the &#147;<I>Payment
Period</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Accure Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory approval for a
licensed product in major countries of the territory as defined in the Accure Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Accure Agreement will expire on a licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of the applicable
Payment Period with respect to such licensed product in such country. We may terminate the Accure Agreement in whole or in part at any time upon advance written notice (a)&nbsp;for documented reasonable scientific, regulatory, commercial reasons
related to the licensed product without incurring any penalty or liability to Accure and (b)&nbsp;for no reason. Each party may terminate the Accure Agreement with immediate effect upon written notice to the other party (i)&nbsp;in the event such
other party commits a material breach of its obligations under the Accure Agreement and fails to cure that breach within a specified period of time or (ii)&nbsp;with certain exceptions, upon such other party&#146;s bankruptcy. Accure may terminate
the Accure Agreement with immediate effect upon written notice to us if we file any action to invalidate any of the licensed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents or fail to maintain the licensed patents in major countries of the territory as defined in the Accure Agreement, or, subject to certain exceptions, if we fail to meet certain development
obligations and are unable to agree upon modifications to the development plan with Accure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We oversee and manage third-party contract manufacturing organizations (&#147;<I>CMOs</I>&#148;), to support development and manufacture of product candidates
for our clinical trials, and, if any product candidates receive marketing approval, we expect to rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient operating and cost
infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products, if approved. Currently, we rely on
and have agreements with third-party contract manufacturers for developing and manufacturing API/drug substance for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and
<FONT STYLE="white-space:nowrap">OCS-05</FONT> and with third-party contract manufacturers to manufacture clinical trial supplies of these three clinical candidates, and we expect to enter into commercial supply agreements with such manufacturers
prior to any potential approval. We continue to develop and improve the manufacturing processes for <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05</FONT> and to address the requirements in these highly
regulated markets. Improvement of manufacturing processes may involve transferring the development and manufacturing to another CMO, taking into account technical, quality and economic aspects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05</FONT> is
manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedures and equipment employed for manufacture and analysis are consistent with standard pharmaceutical
production, and are transferable to a range of manufacturing facilities, if needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions
and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies
have formed collaborations with large, established companies to (i)&nbsp;obtain support for their research, development and commercialization of products or (ii)&nbsp;combine several treatment approaches to develop longer lasting or more efficacious
treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the
treatment of ocular conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the current standard of care treatments for patients with ocular diseases, numerous commercial and
academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Several large pharmaceutical and biopharmaceutical companies that have commercialized, or are developing treatments for ocular diseases, compete with us.
Companies that compete with us directly on the level of the development of product candidates targeting DME include Abbvie, Alimera Sciences, Bayer, Novartis, Regeneron and Roche; companies that have commercialized or are developing drug candidates
to treat inflammation and pain associated with ocular surgery include Abbvie, Alcon, Bausch&nbsp;&amp; Lomb, Kala Pharmaceuticals, Novartis and Teva Pharmaceuticals; companies that compete with us in the area of DED include Abbvie, Aldeyra, Kala
Pharmaceuticals, Novartis, Oyster Point Pharma and Sun Pharmaceuticals; and companies engaged in the commercialization or development of therapeutics to treat uveitis include Abbvie, Bausch&nbsp;&amp; Lomb and Novartis, among others. We are also
aware of an eye drop product candidate in clinical development by Ocuterra for the treatment of diabetic retinopathy, an indication related to the indication for which we are developing OCS-01. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or in combination with their respective strategic partners, have
significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval process and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology
sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient registration for clinical trials and acquiring technologies
complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunities could be reduced or eliminated if one or more of our competitors develop
and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offerings. Our competitors also may be in a position to obtain FDA or other regulatory approval for
their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience
and treatment cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions,
and improvements that are commercially important to the development of our business by obtaining, maintaining, enforcing and defending intellectual property rights, including patent rights, whether owned or licensed from third parties. We will also
seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have sought patent protection in the United States and internationally related to our novel drug targets, composition of matter, formulations and other
inventions and improvements that are central to our R&amp;D efforts. For our product candidates, our strategy is to pursue patent protection covering compositions of matter, formulations and methods of use. In addition, we seek to identify
additional means of obtaining patent protection, including specific therapeutic indications and dosing regimen-related claims, which may enhance commercial success. We also rely on trade secrets that may be important to the development of our
business. Trade secrets are difficult to protect and provide us with only limited protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, our owned and exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio included 10 issued U.S. patents, five issued European patents validated in multiple jurisdictions, and 42 issued patents in other foreign jurisdictions, as well as five pending <FONT
STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent applications, and 66 foreign pending patent applications, including four pending European patent applications, and one pending PCT application related to our different product candidates,
namely, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02,</FONT> OCS-03, <FONT STYLE="white-space:nowrap">OCS-04</FONT> and <FONT STYLE="white-space:nowrap">OCS-05.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-01</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding
our <FONT STYLE="white-space:nowrap">OCS-01</FONT> product candidate<I>, </I>as of October&nbsp;31, 2022, we owned a patent family that consisted of three issued U.S. patents and one granted European patent validated in 12 jurisdictions (Belgium,
France, Germany, Great Britain, Iceland, Ireland, Italy, the Netherlands, Poland, Spain, Switzerland, Turkey) with claims covering the composition including dexamethasone. These patents will expire in 2026, without giving effect to any potential
patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of October&nbsp;31, 2022, we owned a second patent family that consisted of one issued U.S. patent, two pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent applications, one granted European patent validated in 41
jurisdictions (Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Great Britain, Greece, Finland, France, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Luxembourg, Malta, Republic of Moldova, Monaco, Montenegro, Morocco, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden,
Switzerland, Turkey), seven issued patents in other foreign jurisdictions (India, Japan, Mexico, South Africa (two patents), Taiwan, Ukraine) and 18 pending foreign patent applications, including one pending European patent application, with claims
covering the composition of matter of <FONT STYLE="white-space:nowrap">OCS-01.</FONT> Patents (including any patents that issue from such patent applications) in this family will expire in 2037, without giving effect to any potential patent term
extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
October&nbsp;31, 2022, we also owned a patent family that consisted of one U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application and 20 additional foreign patent applications in other jurisdictions, including one European
patent application, directed to specific formulations of <FONT STYLE="white-space:nowrap">OCS-01</FONT> and methods for stabilizing the composition for use as an eye drop. Patents, if issued from patent applications in this family, will expire in
2040, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-02</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding
our <FONT STYLE="white-space:nowrap">OCS-02</FONT> product candidate, as of October&nbsp;31, 2022, we exclusively licensed from Novartis under the Novartis Agreement, in the licensed field as defined in the Novartis Agreement, one patent family that
consisted of three issued U.S. patents and two granted European patents (respectively one European patent validated in 36 jurisdictions (Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey) and
another European patent validated in six jurisdictions (France, Germany, Great Britain, Italy, Spain, Switzerland), 25 issued patents in other foreign jurisdictions (Australia (three patents), Brazil, Canada, Chile (two patents), China, India,
Hong-Kong (2 patents), Japan, Republic of Korea (two patents), Mexico (three patents), Philippines, Russia, South Africa, Taiwan (three patents), Ukraine, Uruguay) and eight patent applications pending in other foreign jurisdictions, with claims
covering composition of matter of <FONT STYLE="white-space:nowrap">OCS-02</FONT> or methods of use. Patents (including any patents that issue from such patent applications) will expire in 2031, without giving effect to any potential patent term
extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as
of October&nbsp;31, 2022, we exclusively licensed from Novartis under the Novartis Agreement, in the licensed field as defined in the Novartis Agreement, six additional patent families covering composition of matter of
<FONT STYLE="white-space:nowrap">OCS-02</FONT> or methods of use, including a biomarker for patient selection, which patents (including any patents that issue from patent applications in these families) will expire between 2023 and 2037, without
giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Under the terms of the Novartis Agreement, Novartis is responsible
for the prosecution and maintenance of these six patent families. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>OCS-03 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October 31, 2022, we also owned a pending PCT application with claims covering composition of matter of OCS-3 and its use. In order for any future patent
applications to claim the benefit of such PCT application, they must be filed not later than 12 months after the filing date of such PCT application. Patents, if issued from national phases of such PCT application, will expire in 2041, assuming
national phases filings within the 30-month entering to national phase period, and without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or
other governmental fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-04</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, we also owned a priority European patent application with claims covering composition of matter of
<FONT STYLE="white-space:nowrap">OCS-04</FONT> and manufacturing processes. In order for any future patent applications to claim the benefit of such priority application, they must be filed not later than 12 months after the filing date of such
priority application. Patents, if issued from the patent applications claiming the benefit of such priority application, if issued, will expire in 2042 or 2043, assuming a filing within the <FONT STYLE="white-space:nowrap">12-month</FONT> priority
period, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">OCS-05</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding
our <FONT STYLE="white-space:nowrap">OCS-05</FONT> product candidate<I>, </I>as of October&nbsp;31, 2022, we exclusively licensed from Accure under the Accure Agreement a patent family that consisted of three issued U.S. patents and one granted
European patent validated in 24 jurisdictions (Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Slovenia,
Spain, Sweden, Switzerland, Turkey), as well as 10 issued patents (Australia, Brazil, Canada, China, India, Israel, Japan, Republic of Korea, Mexico, Russia) in other foreign jurisdictions, with claims covering composition of matter of <FONT
STYLE="white-space:nowrap">OCS-05.</FONT> These patents (including any patents that issue from such patent applications) will expire in 2031, without giving effect to any potential patent term extensions and patent term adjustments and assuming
payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, we also exclusively licensed from
Accure under the Accure Agreement a patent family that consisted of one pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent application and 14 pending foreign patent applications, including one pending European patent
application, directed to the method of use of the composition of <FONT STYLE="white-space:nowrap">OCS-05</FONT> in combination with active compounds. Patents, if issued from such patent applications, will expire in 2040, without giving effect to any
potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, we also exclusively licensed from Accure under the Accure Agreement a patent family consisting of one pending <FONT
STYLE="white-space:nowrap">non-provisional</FONT> U.S. patent application and six pending foreign patent applications, including one pending European patent application, with claims directed to specific dosage regimen for administering the active
pharmaceutical ingredient of <FONT STYLE="white-space:nowrap">OCS-05.</FONT> Patents, if issued from such patent applications, will expire in 2040, without giving effect to any potential patent term extensions and patent term adjustments and
assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on obtaining,
maintaining, protecting and enforcing patent protection and trade secret protection of our current and future product candidates and the methods used to develop and manufacture them, as well as successfully defending any such patents against
third-party challenges, enforcing such patents against third-party infringers, and operating without infringing on, misappropriating or otherwise violating the intellectual property or proprietary rights of others. Our ability to stop third parties
from making, using, selling, offering to sell or importing our product candidates will depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot be sure that patents will
be issued with respect to any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications or with respect to any patent applications filed by us or our licensors in the future, nor can we be sure that any patents
that may be granted to us or our licensors in the future will be commercially useful in protecting our product candidates, discovery programs and processes. For this and more comprehensive risks related to our intellectual property, please see the
section entitled &#147;<I>Risk Factors&#151;Risks Related to Our Intellectual Property</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of individual patents depend upon the legal
term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing
<FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application. In the United States, a patent&#146;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Trademark Office (&#147;<I>USPTO</I>&#148;), in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. In the United States,
the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved&nbsp;drug</FONT> may also be eligible for extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review
process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the subject drug candidate is under regulatory review.
U.S. patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a
method for using it, or a method for manufacturing it may be extended. Similar provisions to extend the term of a patent that covers an approved drug are available in Europe and other foreign jurisdictions. In the future, if and when our products
receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions are available,
however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment that such extensions should be granted, and if granted, the length of such extensions. For more information
regarding the risks related to our intellectual property, see section entitled &#147;<I>Risk Factors&#151;Risks Related to Our Intellectual Property</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file <FONT STYLE="white-space:nowrap">U.S.&nbsp;non-provisional&nbsp;applications</FONT> and Patent Cooperation Treaty (&#147;<I>PCT</I>&#148;),
applications that claim the benefit of the priority date of earlier filed priority applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to
designate all of the PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues <FONT
STYLE="white-space:nowrap">a&nbsp;non-binding&nbsp;patentability</FONT> opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT
application is not issued as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of two and a half years from the first priority date of the patent
application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Office. The PCT system delays
expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all patent applications, we determine claiming strategy on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis.</FONT></FONT> Advice of counsel and our business model and needs are always considered. We seek to file patents containing claims for protection of all
useful applications of our proprietary technologies and any product candidates, as well as all new applications and/or uses we discover for existing technologies and product candidates, assuming these are strategically valuable. We continuously
reassess the number and type of patent applications in our portfolio, as well as the pending and issued patent claims to pursue maximum coverage and value for our processes and compositions, given existing patent office rules and regulations.
Further, claims may be narrowed during patent prosecution, to the extent allowed, to meet our intellectual property and business needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that
the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty <FONT STYLE="white-space:nowrap">and&nbsp;non-obviousness&nbsp;of</FONT> the invention, and
the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even
after patent issuance. Consequently, we or our licensors may not obtain or maintain adequate patent protection for any of our future product candidates or for our Optireach<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>technology platform. We cannot predict whether the owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications we are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents we own or <FONT STYLE="white-space:nowrap">in-license</FONT> will provide sufficient proprietary protection from competitors. Any patents that we own or
<FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged, circumvented or invalidated by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology
companies like ours are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misappropriating or otherwise violating the intellectual property or proprietary rights of third parties. Third-party patents could require us to alter our development or commercial strategies,
or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to intellectual property or proprietary rights required to develop or commercialize our
product candidates or future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference
or derivation proceedings in the USPTO to determine priority of invention. For more information, please see the section entitled &#147;<I>Risk Factors&#151;Risks Related to Intellectual Property</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on trademark registration, trade secrets, know how, other proprietary information and continuing technological
innovation to develop and maintain our competitive position. As of October&nbsp;31, 2022, we owned four registered U.S. trademarks, 13 registered foreign trademarks as well as five pending foreign trademark applications. We seek to protect and
maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and
trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose
our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality
agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course
of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of
employment with us or from the employee&#146;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any
such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us,
disputes may arise as to the rights in related or resulting trade <FONT STYLE="white-space:nowrap">secrets,&nbsp;know-how&nbsp;and</FONT> inventions. For more information regarding the risks related to our intellectual property, please see the
section entitled &#147;<I>Risk Factors&#151;Risks Related to Intellectual Property</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When available to expand market exclusivity, our strategy
is to obtain, or license additional intellectual property or proprietary rights related to current or contemplated development platforms, core elements of technology and/or clinical candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the
United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage,
record-keeping, promotion, advertising,&nbsp;distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug or biologic can be marketed, considerable
data must be generated, which demonstrate the product&#146;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug and Biologic Development Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
United States, the FDA regulates drugs and biologics under the federal Food, Drug, and Cosmetic Act (&#147;<I>FDCA</I>&#148;), and its implementing regulations. Biologics are additionally subject to regulations under the Public Health Service Act.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the
applicable U.S. requirements at any time during the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#146;s refusal to approve
pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product&nbsp;seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;process&nbsp;required by the FDA before a biopharmaceutical may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#146;s
good laboratory requirements and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent Institutional Review Board (&#147;<I>IRB</I>&#148;) ethics committee, either
centralized or with respect to each clinical site, before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with cGCP requirements to
establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA or Biologics License Application (&#147;<I>BLA</I>&#148;) after completion of all
pivotal trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for substantive
review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the
biopharmaceutical is produced to assess compliance with cGMP regulations to ensure that the facilities, methods and controls are adequate to preserve the biopharmaceutical&#146;s identity, strength, quality, and purity, and of selected clinical
investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA or BLA to permit commercial marketing of the product for particular
indications for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate in the United States, we
must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an IND product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s)
for&nbsp;clinical&nbsp;studies. The IND also includes results of animal and<I>&nbsp;in vitro</I><I></I>&nbsp;studies assessing the toxicology, PK, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and
controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by
the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the
FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the
supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial
conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent
form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are
being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a
data safety monitoring board, which may review data and endpoints at designated check points, make recommendations and/or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no
demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase One</I>: Phase 1 clinical trials are designed to test a new therapy in a small group of people for the first time to evaluate safety (e.g., to
determine a safe dosage range and to identify adverse effects). It can include healthy participants or patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase Two</I>: Phase 2 clinical
trials are designed to study an investigational therapy in a larger group of people to determine efficacy and to further evaluate its safety. It is conducted in participants with the condition or disease under study and will determine common
short-term adverse effects and risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase Three</I>: Phase 3 clinical trials are designed to study the efficacy of the investigational therapy in
large groups of patients by comparing the therapy to other standard or experimental therapies as well as to monitor adverse effects, and to collect information that will allow the therapy being studied to be used safely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being
exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been
associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its
charter, this group may determine whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a new biopharmaceutical, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase 2, and before an NDA or BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA
to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trial to discuss Phase 2 clinical results and present plans for the
pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop
additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP regulations. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final product. In addition, appropriate packaging must be
selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last
progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected AEs, findings from other studies suggesting a significant risk to
humans exposed to the same or similar drugs, findings from animal or<I>&nbsp;in vitro</I><I></I>&nbsp;testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared
to that listed in the protocol or investigator brochure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA or BLA Review and Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development
nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA
requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees, although a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are
assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is
cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act (PDUFA) guidelines, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA or
BLA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA or BLA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after the
application is submitted. The FDA conducts a preliminary review of all NDAs or BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA
may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for
filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it
considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities
where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP regulations and adequate to assure consistent production of the product
within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or
manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An
approval letter authorizes commercial marketing of the product with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved
in its present form. A Complete Response Letter usually describes the specific deficiencies in the application identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant
and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the application, addressing all of the deficiencies identified in the letter, or
withdraw the application. Even if such data and information are submitted, the FDA may decide that the application does not satisfy the criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for
which such product may be marketed. For example, the FDA may approve the application with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a
medicine and to enable patients to have continued access to such medicines by managing their safe use. It&nbsp;could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries, and other risk minimization tools. The FDA also may&nbsp;offer conditional&nbsp;approval&nbsp;subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved,
the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one
or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing
studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing
development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations, which impose certain procedural and documentation requirements
upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP regulations and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in
the area of production and quality control to maintain compliance with cGMP regulations and other aspects of regulatory compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on post-approval or Phase 4 clinical studies, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising, and promotion of biopharmaceutical products. A company can make only
those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may
prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that
such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> use and has enjoined companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA and other regulatory agencies have also required that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labelling. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the
same active ingredient. The FDCA permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for a new
chemical entity in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. A drug is a new chemical entity if the FDA has not previously
approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug
application (&#147;<I>ANDA</I>&#148;) or an NDA submitted under Section&nbsp;505(b)(2) (&#147;<I>505(b)(2) NDA</I>&#148;), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for
the same indication as the original innovative drug or for another indication, where the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent
invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDCA
alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical
investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six
months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake
the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;505(b)(2) NDAs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A special type of
NDA, commonly referred to as a Section&nbsp;505(b)(2) NDA, enables the applicant in certain circumstances to rely, in part, on the FDA&#146;s prior findings in approving a similar product or published literature in support of its application. A
Section&nbsp;505(b)(2) NDA may provide an alternate path to FDA approval for a new or improved formulation, a new route of administration, or a new use of a previously approved product. Section&nbsp;505(b)(2) permits the submission of an NDA where
at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section&nbsp;505(b)(2) applicant can establish that reliance
on the FDA&#146;s prior findings of safety and/or effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional
studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or some, of the indications for which the referenced product has been approved, as well as for any new indication
sought by the Section&nbsp;505(b)(2) applicant. If we choose to rely on the 505(b)(2) process to seek approval for <FONT STYLE="white-space:nowrap">OCS-01,</FONT> there can be no assurance that the FDA will agree with our use of that pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that the Section&nbsp;505(b)(2) applicant is relying on the FDA&#146;s prior findings of safety or effectiveness for an already approved
product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. Thus, approval of a Section&nbsp;505(b)(2) NDA can be stalled until
all the listed patents claiming the referenced product have expired, until any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the
Section&nbsp;505(b)(2) applicant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Approval and Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A therapeutic product may rely upon an<I>&nbsp;in vitro</I>&nbsp;companion diagnostic for use in selecting the patients that will be more likely to respond to
that therapy. If the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic
device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of<I>&nbsp;in vitro</I>&nbsp;companion diagnostics in conjunction with the review of our therapeutic
product candidate <FONT STYLE="white-space:nowrap">OCS-02</FONT> will, therefore, likely involve coordination of review by the FDA&#146;s Center for Biologics Evaluation and Research and the FDA&#146;s Center for Devices and Radiological Health.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the FDCA,<I>&nbsp;in vitro</I>&nbsp;diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA
and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing,
manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to
commercial distribution. The three primary types of FDA marketing authorization applicable to a medical device include premarket notification, also called 510(k) clearance, premarket approval (&#147;<I>PMA</I>&#148;), and <I>de novo</I>
classification requests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EU/Rest of World Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conduct of Clinical Trials in the EU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
regulations in the United States, there are a variety of regulations in other jurisdictions governing, among other things, clinical trials, commercial sales and distribution of medicinal products. Even if FDA approval of a particular product is
obtained, it must still obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have
a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the EU, the Clinical Trials Regulation (EU) No 536/2014 entered into application on January&nbsp;31, 2022. The Regulation is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the
supervision of clinical trials and increase their transparency. Specifically, the new Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure via a single entry point, the &#147;EU
portal&#148;, the Clinical Trials Information System (&#147;<I>CTIS</I>&#148;); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure
for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I is assessed by the competent authorities of a reference member state selected by the trial sponsor largely of the type of clinical
trial, risk-benefit analysis, and compliance with technical requirements. This assessment is then submitted to the competent authorities of all the concerned member states in which the trial is to be conducted for their review. Part II is assessed
separately by the competent authorities and ECs in each EU member state concerned. Individual EU Member States shall retain the power to authorize the conduct of clinical trials on their territory. The extent to which
<FONT STYLE="white-space:nowrap">on-going</FONT> clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial. If a clinical trial continues for more than three years from
January&nbsp;31, 2022, the Clinical Trials Regulation will at that time begin to apply to the clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pathways to Obtain a Marketing
Authorization in the EU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Economic Area (&#147;<I>EEA</I>&#148;), which consists of the 27 Member States of the European Union, as well
as Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after a related marketing authorization has been granted. A company may submit a marketing authorization application (&#147;<I>MAA</I>&#148;), either on the basis of
the centralized, or decentralized procedure or mutual recognition procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the EMA&#146;s Committee for Medicinal Products for Human Use
(&#147;<I>CHMP</I>&#148;). The CHMP issues an opinion concerning whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the quality, safety and efficacy of the product has been demonstrated. The opinion is considered by the European Commission which is responsible for granting a centralized marketing authorization
in the form of a binding European Commission decision. If the application is approved, the European Commission C grants a single marketing authorization that is valid throughout the EEA. The centralized procedure is mandatory for certain types of
products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated
for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in
the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">National marketing authorizations, which are issued by the competent authorities of EEA countries and only cover their respective territory, are available for
products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EEA country, this national marketing authorization can be recognized in another EEA country through the
mutual recognition procedure. The mutual recognition procedure provides for the EEA countries selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another EEA
country, referred to as the Reference Member State (&#147;<I>RMS</I>&#148;). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any EEA country. Under this procedure the applicant can
select the EEA country that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the EEA countries for which marketing authorizations are
being sought, referred to as Concerned Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 90 days of receiving the application and assessment report, each Concerned Member State must
decide whether to recognize the RMS assessment or reject it on the basis of potential serious risk to public health. If the disputed points cannot be resolved, the matter is first referred to the Heads of Medicines Agencies&#146; Coordination Group
for Mutual Recognition and Decentralized Procedures for agreement. If the Heads of Medicines Agencies&#146; Coordination Group for Mutual Recognition and Decentralized Procedures cannot reach an agreement, a referral is made to the EMA. The CHMP
will provide an opinion that will form the basis of a decision to be issued by the European Commission that is binding on all EEA countries. If the application is successful during the decentralized or mutual recognition procedure, national
marketing authorizations will be granted by the competent authorities in each of the EEA countries chosen by the applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In principle, a marketing
authorization has an initial validity of five years. The marketing authorization may be renewed after five years on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent
authority of the EEA country in which the original marketing authorization was granted. To support the application, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the eCTD (Common
Technical Document) providing up to date data concerning the quality, safety and efficacy of the product, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization
ceases to be valid. The European Commission or the competent authorities of the EEA countries may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the marketing authorization. Once
subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on
the market of the authorizing EEA country within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use in cases
where the related clinical dataset is not yet complete. A conditional marketing authorization may be granted for a medicinal product, if (i)&nbsp;the risk-benefit balance of the product is positive, (ii)&nbsp;it is likely that the applicant will be
in a position to provide the required comprehensive data after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the authorization, (iii)&nbsp;the medicinal product fulfills unmet medical needs and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the medicinal product
outweighs the risk inherent in the fact that additional data are still required. The authorization is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the
conditional marketing authorization can be converted into a traditional marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A marketing authorization may also be granted &#147;under exceptional circumstances&#148; where the applicant can show that it is unable to provide
comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications
are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional marketing
authorization, a marketing authorization granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set
that is required for the grant of a standard marketing authorization. However, unlike the conditional marketing authorization, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data.
Although the marketing authorization &#147;under exceptional circumstances&#148; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the marketing authorization is withdrawn in case the risk-benefit
ratio is no longer favorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innovative products that target an unmet medical need and are expected to be of major public health interest may be
eligible for a number of expedited development and review programs, such as the Priority Medicines (&#147;<I>PRIME</I>&#148;), scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme
aimed at enhancing the EMA&#146;s support for the development of medicinal products that target unmet medical needs. It permits increased interaction and early dialogue with companies developing promising medicinal products, to optimize their
product development plans and speed up their evaluation to help the product reach patients earlier than normal. Product developers that benefit from PRIME designation are potentially eligible for accelerated assessment of their MAA although this is
not guaranteed. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development
program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to an MAA, various other requirements apply
to the manufacturing and placing on the EU market of medicinal products. Manufacture of medicinal products in the EU requires a manufacturing authorization, and import of medicinal products into the EU requires a manufacturing authorization allowing
for import. The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance. These requirements include compliance with EU GMP standards when manufacturing medicinal products
and APIs, including the manufacture of APIs outside of the EU with the intention to import the APIs into the Union. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and
guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. Marketing authorization holders and/or manufacturing and import authorization (MIA) holders
and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the EU or EU member
states&#146; requirements applicable to the manufacturing of medicinal products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Market Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, innovative medicinal products that are subject to marketing authorization on the basis of a full dossier and do not fall within the scope of the
concept of global marketing authorization qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The concept of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
global marketing authorization prevents the same marketing authorization holder or members of the same group, or companies that have concluded tacit or explicit agreements concerning the
marketing of the same medicinal product, from obtaining separate data and market exclusivity periods for medicinal products that contain the same active substance. Data exclusivity, if granted, prevents regulatory authorities in the European Union
from referencing the innovator&#146;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application
can be submitted, and the innovator&#146;s data may be referenced. However, the generic product or biosimilar products cannot be marketed in the EU for a further two years thereafter. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT>
period may be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the
scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric
Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products must include the results of trials conducted in
the pediatric population, in compliance with a pediatric investigation plan (&#147;<I>PIP</I>&#148;), agreed with the EMA&#146;s Pediatric Committee (&#147;<I>PDCO</I>&#148;). The PIP sets out the timing and measures proposed to generate data to
support a pediatric indication of the medicinal product for which marketing authorization is being sought. The PDCO may grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data
to demonstrate the efficacy and safety of the product in adults. Furthermore, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be
ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients.
Once the marketing authorization is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six month extension to the Supplementary Protection Certificate or SPC
if any is in effect at the time of authorization or, in the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of orphan market exclusivity. For other countries outside of the European Union, such as
certain countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product approval, pricing and reimbursement vary from country to country. In all cases, the clinical trials are to be conducted in
accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan Medicinal Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulation (EC)
No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i)&nbsp;the product is intended
for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii)&nbsp;either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b)&nbsp;the product
without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii)&nbsp;there exists no satisfactory authorized method of diagnosis,
prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the
centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity for the approved therapeutic
indication, which means that the EMA cannot accept another marketing authorization application, or grant a marketing authorization, or accept an application to extend a marketing authorization for a similar product for the same indication for a
period of ten years. The period of market exclusivity is extended by two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for
orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets
the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify
maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, a marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10 year
period if: (i)&nbsp;if the applicant consents to a second original orphan medicinal product application; (ii)&nbsp;if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii)&nbsp;if the second
applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a marketing
authorization is granted in relation to a medicinal product in the EU, the holder of the marketing authorization is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of
medicinal products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United States, both marketing authorization holders and manufacturers of medicinal products are subject to
comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EEA countries. The holder of a marketing authorization must establish and maintain a pharmacovigilance system and
appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports
(&#147;<I>PSURs</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All new marketing authorization applications must include a risk management plan (&#147;<I>RMP</I>&#148;), describing the
risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing
authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, the advertising and promotion of medicinal products are subject to both EU and EEA countries laws governing promotion of medicinal products,
interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. Although general requirements for advertising and promotion of medicinal products are established under EU
directives, the details are governed by regulations in each member state and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the
product&#146;s Summary of Product Characteristics (&#147;<I>SmPC</I>&#148;), as approved by the competent authorities in connection with a marketing authorization. The SmPC is the document that provides information to physicians concerning the safe
and effective use of the product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT> and is prohibited in the EU.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicinal products is also prohibited in the EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulation of Companion Diagnostics in the EU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU,
despite the absence of a legal definition, companion diagnostics are deemed to be <I>in vitro</I> diagnostic medical devices and are governed by Directive 98/79/EC (&#147;<I>IVDD</I>&#148;). The IVDD currently regulates the placing on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the market, the <FONT STYLE="white-space:nowrap">CE-marking,</FONT> the essential requirements, the conformity assessment procedures, the registration obligations for manufacturers and devices as
well as the vigilance procedure related to such products. <I>In vitro</I> diagnostic medical devices, including companion diagnostics, must comply with the requirements provided for in the IVDD, and with further requirements implemented at national
level (as the case may be). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vitro </I>diagnostic medical devices (including companion diagnostics) are currently required to conform with the
essential requirements of the IVDD. To demonstrate compliance with the essential requirements laid down in Annex I to the IVDD, the manufacturer must conduct a conformity assessment procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For general <I>in vitro</I> diagnostic medical devices (i.e. all IVDs other than those covered by Annex II to the IVDD and IVDs for self-testing), the
conformity assessment is performed through a self-assessment of the manufacturer without the intervention of a notified body which is an independent organization designated by the competent authorities of an EU member state to assess the conformity
of devices before being placed on the market. The manufacturer must prepare an EC Declaration of Conformity confirming conformity of its products with the essential requirements laid down in the IVDD before placing the product on the EU market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By contrast, the conformity assessment of <I>in vitro</I> diagnostic medical devices for self-testing or that are listed in Annex II (i.e. essentially
moderate and high risk reagents and reagent products) to the IVDD requires the intervention of a notified body. Following successful completion of a conformity assessment procedure the notified body will issue a CE Certificate of Conformity. The
device manufacturer may, after having completed remaining related procedures and obligations, affix the CE mark to its medical device after having prepared and signed a related EC Declaration of Conformity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulation of companion diagnostics will be subject to further requirements once the <I>in vitro</I> diagnostic medical devices Regulation (No 2017/746),
(&#147;<I>IVDR</I>&#148;), becomes applicable on May&nbsp;26, 2022. The IVDR introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a
specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. If the medicinal product has, or is in the process of, been
authorized through the centralized procedure for the authorization of medicinal products, the notified body will, before it can issue a CE Certificate of Conformity, be required to seek a scientific opinion from the EMA on the suitability of the
companion diagnostic for use in relation to the medicinal product concerned. For medicinal products that have or are in the process of authorization through any other route provided in EU legislation, the notified body must seek the opinion of the
national competent authority of an EU Member State. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical manufacturers are subject to additional healthcare laws, regulation, and enforcement by the U.S. federal government and by authorities in the
states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, lease, furnishing, prescribing or
recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, (collectively, the &#147;<I>ACA</I>&#148;), among other things, amended the intent requirement of the federal Anti-Kickback Statute such that
a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate, in order to commit a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the federal False Claims Act which can be enforced by
private individuals on behalf of the government through civil whistleblower or qui tam </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
actions, and civil monetary penalty laws prohibit individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid
programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Entities can be held liable under these laws if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, or for providing medically unnecessary services or items. In addition, a
claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#147;<I>HIPAA</I>&#148;), which imposes
criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit
program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements in connection with
the delivery of or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009
(&#147;<I>HITECH</I>&#148;), and their respective implementing regulations, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as individuals and entities that
create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, known as business associates, as well as their covered subcontractors, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to &#147;payments or other transfers of value&#148;
made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals and ownership and
investment interests held by some of these healthcare professionals and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous foreign laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry,
such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance
guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug
manufacturers to file reports relating to pricing and marketing information; state and local laws which require the tracking of gifts and other remuneration and any transfer of value provided to physicians, other healthcare providers and entities;
state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These laws and regulations are subject to change, which can increase the resources needed for compliance and
delay drug approval or commercialization. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#146;s attention from the
operation of our business. Also, we may be subject to private &#147;qui tam&#148; actions brought by individual whistleblowers on behalf of the federal or state governments. Actual or alleged violation of any such laws or regulations may lead to
investigations and other claims and proceedings by regulatory authorities and in certain cases, private actors, and violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without
limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, additional reporting obligations, and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collection and use of personal health data in the EEA is governed by the General Data Protection Regulation ((EU) 2016/679), (&#147;<I>GDPR</I>&#148;),
which became effective May&nbsp;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EU
or the monitoring of the behavior of data subjects in the EU. The GDPR enhances data protection obligations for controllers and processors of personal data, including stringent requirements relating to the consent of data subjects, expanded
disclosures about how personal data is used, requirements to conduct privacy impact assessments for high-risk processing, limitations on retention of personal data and mandatory data breach notification and privacy by design requirements, and
creates direct obligations on service providers acting as data processors. The GDPR also imposes strict rules on the transfer of personal data out of the EEA to countries that do not ensure the same level of protection, such as the United States.
Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA countries may result in fines up to 20&nbsp;million Euros or 4% of a company&#146;s global annual revenues for the preceding financial year,
whichever is higher. Moreover, the GDPR grants data subjects the right to claim compensation for damages resulting from infringement of the GDPR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the United Kingdom&#146;s (the &#147;<I>UK</I>&#148;) withdrawal from the EU and the expiration of the transition period, from January&nbsp;31,
2020, companies doing business in the EU and the UK will be obliged to comply with both the GDPR and the U.K. GDPR. On June&nbsp;28, 2021, the European Commission adopted an adequacy decision permitting flows of personal data between the EU and the
UK to continue without additional requirements. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission <FONT STYLE="white-space:nowrap">re-assesses</FONT> and renews/ extends that decision and remains
under review by the European Commission during this period. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop
in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Brexit and the Regulatory Framework in
the United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK&#146;s withdrawal from the EU on January&nbsp;31, 2020, commonly referred to as Brexit, has created significant
uncertainty concerning the future relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency (MHRA) is now the UK&#146;s standalone regulator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;24, 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the
<FONT STYLE="white-space:nowrap">EU-U.K.</FONT> Trade and Cooperation Agreement. The <FONT STYLE="white-space:nowrap">EU-U.K.</FONT> Trade and Cooperation Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to
goods, including medicinal products. Although the body of the Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the <FONT STYLE="white-space:nowrap">EU-U.K.</FONT>
Trade and Cooperation Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third
country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
As part of the <FONT STYLE="white-space:nowrap">EU-U.K.</FONT> Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other party and the acceptance
of official GMP documents issued by the other party. The <FONT STYLE="white-space:nowrap">EU-U.K.</FONT> Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce
significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK has unilaterally agreed to accept EU batch testing and batch release for a period of at least two years until January&nbsp;1, 2023. However, the EU
continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and
<FONT STYLE="white-space:nowrap">re-released</FONT> when entering the EU market for commercial use. As regards marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a national marketing
authorization. Northern Ireland will, however, continue to be covered by the marketing authorizations s granted by the European Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK
regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). It is currently unclear to what extent the UK will seek to align its regulations with the EU
following entry into application of the Clinical Trials Regulation on January&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, an applicant for a centralized
procedure marketing authorization can no longer be established in the UK. Since this date, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures to obtain a
marketing authorization to market products in the UK. For an initial two year period from January&nbsp;1, 2021, MHRA is able to rely on a decision taken by the European Commission on the approval of a new centralized procedure marketing
authorization when determining an application for a Great Britain marketing authorization; or use the MHRA&#146;s decentralized or mutual recognition procedures which enable marketing authorizations approved in EEA countries to be granted in Great
Britain. This two year period was recently extended to December&nbsp;31, 2023. Post Brexit, the MHRA has been updating various aspects of the regulatory regime for medicinal products in the UK. These include: introducing the Innovative Licensing and
Access Procedure to accelerate the time to market and facilitate patient access for innovative medicinal products; and updates to the UK national approval procedure, introducing a <FONT STYLE="white-space:nowrap">150-day</FONT> objective for
assessing applications for marketing authorizations in the UK, Great Britain and Northern Ireland and a rolling review process for marketing authorization applications (rather than a consolidated full dossier submission). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan designation in Great Britain following Brexit is, unlike in the EU, not available <FONT STYLE="white-space:nowrap">pre-marketing</FONT> authorization.
Applications for orphan designation are made at the same time as an application for a marketing authorization. The criteria to be granted an orphan drug designation or essentially identical to those in the European Union but based on the prevalence
of the condition in Great Britain. It is therefore possible that conditions that were or would have been designated as orphan conditions in Great Britain prior to the end of the transition period are or would no longer be and that conditions that
were not or would not have been designated as orphan conditions in the European Union will be designated as such in Great Britain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and
Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such
as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and
reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT>
basis. One third-party payor&#146;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific
details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and
related services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products.
Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and
cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a
third-party payor not to cover a product could reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In international markets, reimbursement and
healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal
products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on
pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective
by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#146; reimbursement policies will not adversely affect the ability for manufacturers to sell products
profitably. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United
States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the ACA was signed into law, which substantially changed the
way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; it required
collection of rebates for drugs paid by Medicaid managed care organizations; imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription
drugs&#148; to specified federal government programs; it implemented a new methodology under which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or
injected; it expanded the eligibility criteria for Medicaid programs; it created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for
such research; and it established a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially
including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the
ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Since January 2017, President Trump has signed several Executive Orders and other directives designed to delay the implementation of certain provisions
of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed
comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. For example, on June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is
unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden
issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work
requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022
(&#147;<I>IRA</I>&#148;), into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025 and eliminates the &#147;donut hole&#148; under the Medicare
Part D program beginning in 2025, by significantly lowering the beneficiary maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. It is
possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges or additional health reform measures of the Biden administration will impact the ACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to
providers of up to 2% per fiscal year, effective April&nbsp;1, 2013, which, due to subsequent legislative amendments, will stay in effect until 2031 with the exception of a temporary suspension implemented under various <FONT
STYLE="white-space:nowrap">COVID-19</FONT> relief legislation from May&nbsp;1, 2020 through March&nbsp;31, 2021, unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1%
in 2022 to up to 4% in the final fiscal year of this sequester. On March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things,
further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has
resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, to review the relationship between pricing and manufacturer patient programs, and to reform
government program reimbursement methodologies for pharmaceutical products. For example, in July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple provisions aimed at
prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, the U.S. Department of Health and Human Services (&#147;<I>HHS</I>&#148;), released a Comprehensive Plan for Addressing High Drug Prices that outlines
principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things: (i)&nbsp;allows HHS to negotiate the price of certain
single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#147;maximum fair price&#148;
under the law, and (ii)&nbsp;imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the
initial years. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. It is possible that additional governmental action may be taken in response to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference to pricing systems and publication of discounts and list prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Health Technology Assessment (&#147;<I>HTA</I>&#148;) process, which is currently governed by the national laws of the individual EU Member States, is the
procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare systems of the individual country is conducted. A new regulation adopted in December 2021 the HTA Regulation, is intended to boost cooperation among EU Member States in assessing
health technologies, including new medicinal products, and to provide the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation will apply from 2025 followed by a phased
<FONT STYLE="white-space:nowrap">roll-out</FONT> ending in 2028. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, we had 32 employees. Our headcount for R&amp;D was 18, and our headcount for G&amp;A was 14. Our employees include 12 executive
leadership, administrative, and development personnel based in Switzerland; 11 executive leadership, administrative, and research personnel based in Iceland; 5 executives and administrators based in the United States; 4 management, research and
administrative personnel based in France and China. Pursuant to local laws, our employees in Iceland and France are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to
be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase
stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently lease approximately 5,500 square
feet of laboratory and office space in Iceland and Switzerland. We believe these facilities will be adequate for the foreseeable future and that suitable additional or substitute space will be available as and when needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject
to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of
outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_16"></A>OCULIS MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to the &#147;Company,&#148;
&#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer to the business of Oculis SA and its subsidiaries prior to the consummation of the Business Combination, which will be the business of Oculis and its subsidiaries following the consummation of
the Business Combination. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with
the historical consolidated financial statements as of December&nbsp;31, 2021 and for the years ended December&nbsp;31, 2021 and 2020 and the related notes thereto, the unaudited condensed interim consolidated financial statements as of
September&nbsp;30, 2022 and for the nine months ended September&nbsp;30, 2022 and 2021 and the related notes thereto, and the unaudited pro forma condensed combined financial information, included elsewhere in this proxy statement/prospectus. Some
of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements&#148; sections and elsewhere in this proxy
statement/prospectus, our actual results may differ materially from those anticipated in these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company, based in Switzerland, with substantial expertise in therapeutics used to treat ocular diseases, engaged in
the development of innovative drug candidates which embrace the potential to address many currently <FONT STYLE="white-space:nowrap">eye-related</FONT> conditions. Our focus is on advancing therapeutic candidates intended to treat significant and
growing ophthalmic diseases which result in vision loss, blindness or reduced quality of life, for which there are currently limited or no treatment options. Our clinical portfolio currently consists of
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> our lead development candidate which is currently in two ongoing Phase 3 clinical trials, one involving its use as a treatment for diabetic macular edema (&#147;<I>DME</I>&#148;), and the other
assessing its utility to treat inflammation and pain following cataract surgery. Our second clinical initiative involves <FONT STYLE="white-space:nowrap">OCS-02,</FONT> which we anticipate entering two Phase 2b clinical trials in the first half of
2023, the first for use as a potential treatment for keratoconjunctivitis sicca, or dry eye disease (&#147;<I>DED</I>&#148;), and the second trial designed to evaluate its potential as a therapy for the treatment of
<FONT STYLE="white-space:nowrap">non-infectious</FONT> anterior uveitis. Our third clinical candidate is <FONT STYLE="white-space:nowrap">OCS-05,</FONT> which is a novel neuroprotective agent with potential application in multiple indications,
including glaucoma, dry <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (&#147;<I>AMD</I>&#148;) and diabetic retinopathy (&#147;<I>DR</I>&#148;). We are initially evaluating <FONT STYLE="white-space:nowrap">OCS-05</FONT> as
a potential treatment for acute optic neuropathy, or AON, for which there is no currently approved therapeutic treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous diseases and
disorders, many of which represent significant medical needs, are associated with the human eye. The National Eye Institute, a part of the U.S. National Institutes of Health, estimates that in the United States, blindness or significant visual
impairment impacts more than four million people, including those with vision loss resulting from retinal diseases such as DME, macular degeneration, DR, and retinal vein occlusion (&#147;<I>RVO</I>&#148;); disorders caused by swelling and
inflammation such as DED, corneal keratitis and uveitis; and glaucoma, among other disease states. The global market for therapeutics used to treat eye disease is estimated to have exceeded $22&nbsp;billion in 2020, according to industry sources.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the spread of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, economic uncertainties have arisen which may negatively affect our
financial position, results of operations and cash flows. We have assessed that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has not so far had a material or direct impact on our operations or financial position. Nevertheless, in
light of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have implemented measures to protect employees and take social responsibilities while at the same time attempting to limit any negative effects on our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The duration of uncertainties and the ultimate financial effects resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic cannot be reasonably estimated at this time.
We will continue to monitor these situations closely and implement further measures if we believe they are required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Business
Environment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is extremely competitive. We are subject to risks and uncertainties common to any early-stage
biopharmaceutical company. These risks include, but are not limited to, the introduction of new products, therapies, standards of care or technological innovations, our ability to obtain, maintain, protect and enforce our licensed technology, data
and other intellectual property and proprietary rights and compliance with extensive government regulation and oversight. Please see the section entitled &#147;<I>Risk Factors</I>&#148; for more information. We are also dependent upon the services
of key personnel, including our Chief Executive Officer, executive team and other highly skilled employees. Demand for experienced personnel in the pharmaceutical and biotechnology industries is high and competition for talent is intense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions and governmental
agencies as well as public and private research institutions. Many of our competitors are working to develop or have commercialized products similar to those we are developing and have considerable experience in undertaking clinical trials and in
obtaining regulatory approval to market pharmaceutical products. Our competitors may also have significantly greater financial resources, established presence in the markets in which we hope to compete, expertise in research and development,
manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These third parties also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and registering patients for clinical trials,
entering into agreements with CMOs for the manufacture of our product candidates, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any
revenue from the sale of products since our inception and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval or
if we enter into collaboration or licensing agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or licensing agreements. However, there can be no assurance as
to when we will generate such revenue, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Grant Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income reflects reimbursement of research and development expenses and income from certain research projects managed by Icelandic governmental
institutions. We maintain a subsidiary in Iceland that provides research and development for our product candidates. Certain expenses qualify for incentives from the Icelandic government in the form of tax credits or cash reimbursements. We do not
anticipate generating significant grant income in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates and programs.
We expense research and development costs and the cost </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of acquired intangible assets used in research and development activities as incurred. Research and development expenditures are capitalized only if they meet the recognition criteria of IAS 38
(&#147;<I>Intangible Assets</I>&#148;) and are recognized over the useful economic life on a straight-line basis. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, related benefits and equity-based compensation expense, for
employees engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with the preclinical and clinical development of our product candidates and
programs, including under agreements with CROs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to CMOs that are primarily engaged to provide drug substance and product for our clinical trials,
research and development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing
registration and validation batches; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with quality and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research and development-related payments made under third-party licensing agreements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to formulation research, IP expenses, facilities, overhead, depreciation and amortization of
laboratory equipment and other expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We historically did not track our research and development costs by project category,
primarily because we use our employee and infrastructure resources across multiple research and development programs that we are advancing in parallel, and therefore do not allocate salaries, stock-based compensation, employee benefit expenses or
other indirect costs related to our research and development to specific product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product candidates in later stages of clinical development
generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase
substantially in connection with our planned clinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
clinical development of any current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development costs may vary significantly based on factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring or other studies requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up</FONT>
periods; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages or other supply interruptions in clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of product candidates we are developing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The successful development and commercialization of product candidates is highly uncertain. This is due to
the numerous risks and uncertainties associated with product development and commercialization, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of nonclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of nonclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise necessary additional funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of the development efforts of parties with whom we may enter into collaboration arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current development programs and to establish new ones; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish new licensing or collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that
are satisfactory to the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt and related terms of regulatory approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of drug substance and drug product for use in the production of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining agreements with third-party manufacturers for clinical supply for our clinical
trials and commercial manufacturing, if our product candidates are approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the
United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining third-party insurance coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition with other products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a continued acceptable safety profile of our therapies following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing
associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates or programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate and business
development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance
costs; marketing and communications expenses; and other operating costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning in 2022, we incurred increased accounting, audit, legal, regulatory,
compliance and other professional services costs as well as investor and public relations expenses associated with the Business Combination and preparing to become a public company. We anticipate that our general and administrative expenses will
increase in the future as we increase our headcount to support development of our product candidates and programs and our continued research activities as well as costs associated with being a public company such as increased costs for fees to
members of the board of directors, increased employee-related expenses, increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the
Exchange Act and Nasdaq rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Finance expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expense consists primarily of accrued interest costs associated with the preferred dividend payment of 6.00% to the holders of preferred Series B and C
shares. The preferred Series B and C shares are classified as liabilities under IAS 32 and the associated accrued dividend is recognized as interest expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exchange differences </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange
differences consists of currency exchange gains and losses that arise from transaction denominated in currencies other than Swiss Francs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of
Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial information below is presented in thousands of CHF. The totals are calculated with the original unit amounts, which could
lead to rounding differences. These differences in thousands of units are not changed in order to keep the accuracy of the original data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table summarizes our results of operations for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>In CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(896</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Nine Months Ended September 30, 2022 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant income for the
nine months ended September 30, 2022 and 2021 was CHF 0.7 million and CHF 0.6 million, respectively. The grant income is dependent upon the Icelandic government making such reimbursement available for research and development activities. While
certain of our research and development expenses have historically qualified for reimbursement and we anticipate incurring a similar level of costs in the future, there is no assurance that the Icelandic government will continue with the tax
reimbursement program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months<BR>Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were CHF 15.3 million for the nine months ended September 30, 2022 compared
to CHF 6.0 million for the nine months ended September 30, 2021. The net increase of CHF 9.3 million, or 154%, was primarily due to increased development expenses related to two ongoing Phase 3 clinical trials for OCS- 01 and other research and
development activities for our active product candidates. The two ongoing OCS-01 Phase 3 clinical trials are for DME and Post Ocular Surgery indications. We utilize external Clinical Research Organizations (&#147;<I>CROs</I>&#148;) for the execution
of these trials. Personnel costs increased by CHF 0.5 million from the prior period, which was primarily due to additional headcount for internal research and development employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses</I></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months<BR>Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses were CHF 6.6 million for the nine months ended September 30, 2022 compared to CHF 3.1
million for the nine months ended September 30, 2021. The increase of CHF 3.5 million, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or 115%, was primarily due to a CHF 1.7 million increase in personnel costs associated with additional headcount for expansion of our operations, a CHF 1.3 million increase related to other
operating expenses and a CHF 0.5 million increase related to additional external professional services both in connection with the Business Combination and preparing to become a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Finance Expenses</I></B><I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months<BR>Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense accrued on Series B and C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expenses were CHF 5.1 million for the nine months ended September 30, 2022 and CHF 3.6 million for the nine months
ended September 30, 2021. The increase of CHF 1.5 million, or 42%, was primarily due to the additional accrued interest costs associated with preferred dividends as a result of the Series C financing which was completed in April 2021 and an
extension of the Series C financing that was completed in July 2022, which raised CHF 52.5 million and CHF 2.0 million, respectively, before transaction costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Exchange Differences</I></B><I> </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months<BR>Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange difference</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange differences were a loss of CHF 3.1 million for the nine months ended September 30, 2022 compared to the loss of CHF
0.9 million for the nine months ended September 30, 2021. The loss in the nine months ended September 30, 2022 was primarily due to a loss of CHF 4.1 million caused by currency exchange rate changes between the U.S. Dollar and Swiss Franc which
impacted the long-term financial liability related to our preferred Series C shares. This loss was partially offset by gains on U.S. Dollar denominated cash balances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Grant Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income for both
the years ended December&nbsp;31, 2021 and 2020 was CHF 1.0&nbsp;million and was consistent between periods. The grant income is dependent upon the Icelandic government making such reimbursement available for research and development activities.
While certain of our research and development expenses have historically qualified for reimbursement and we anticipate incurring a similar level of costs in the future, there is no assurance that the Icelandic government will continue with the tax
reimbursement program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended<BR>December&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were CHF 9.6&nbsp;million for the year ended December&nbsp;31, 2021 compared to CHF
9.3&nbsp;million for the year ended December&nbsp;31, 2020. The net increase of CHF 0.2&nbsp;million, or 2%, was primarily due to ongoing research and development activities for our active product candidates and the additional costs associated with
more product candidates entering into and advancing through clinical trials. Personnel costs increased by CHF 0.6&nbsp;million year over year, which was primarily due to additional headcount for internal research and development employees. The
increase was partially offset by a decrease of CHF 0.4&nbsp;million related to fewer external services providers and consultants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended<BR>December&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses were CHF 4.6&nbsp;million for the year ended December&nbsp;31, 2021 compared to CHF
4.0&nbsp;million for the year ended December&nbsp;31, 2020. The increase of CHF 0.6&nbsp;million, or 16%, was primarily due to a CHF 0.6&nbsp;million increase in personnel costs associated with additional headcount for expansion of our operations in
connection with the Business Combination and preparing to become a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Finance Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended<BR>December&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense accrued on Series B and C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expenses were CHF 5.1&nbsp;million for the year ended December&nbsp;31, 2021 and CHF 2.6&nbsp;million for the year
ended December&nbsp;31, 2020. The increase of CHF 2.5&nbsp;million, or 95%, was due to the additional accrued interest costs associated with preferred dividends as a result of the preferred Series C round which was completed in April 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exchange Differences </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Year&nbsp;Ended<BR>December&nbsp;31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;2021&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;2020&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange difference</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchange differences were a loss of CHF 0.2&nbsp;million for the year ended December&nbsp;31, 2021 compared to a gain of CHF
0.2&nbsp;million for the year ended December&nbsp;31, 2020. The shift year over year was driven by changes in foreign currency exchange rates between our functional currency, CHF, and other currencies in which we transact, such as the Euro,
U.S.&nbsp;Dollar and Hong Kong Dollar. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we
have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. To date, we have funded our operations primarily with proceeds from
the sale of our preferred stock. As of September 30, 2022, we had cash and cash equivalents of CHF 28.5 million. We had accumulated losses of CHF 101.8 million and CHF 72.3 million as of September 30, 2022 and December 31, 2021, respectively.
Through September 30, 2022, we have raised CHF 103.4 million through the issuance of three series of preferred shares. Preferred Series A, B and C shares are classified as liabilities within our consolidated statement of financial position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to expand our organization through
in-licensing, strategic collaboration, and acquisition, and invest in the development of our product candidates through additional research and development activities and clinical trials. See &#147;<I>Risk Factors&#151;Risks related to development
and regulatory approval of our investigational therapies</I>.&#148; Following the completion of the Business Combination, we expect to incur additional costs associated with operating as a public company, including expenses related to legal,
accounting and financial reporting and regulatory matters, maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash and cash equivalents, CHF 28.5 million as of September 30, 2022, without taking into
consideration the net proceeds from the proposed Business Combination, PIPE Investment, and Convertible Loan Agreements, will be sufficient to fund our operations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital expenses through at least the next twelve months from the date of this proxy statement/prospectus. In addition, we believe that our cash resources, inclusive of funds available under the
Business Combination, PIPE Investment and Convertible Loan Agreements, will be sufficient to allow us to fund current planned operations beyond the next twelve months from the date of this proxy statement/prospectus without additional capital. On a
pro forma basis as of September 30, 2022, assuming the consummation of the Business Combination, the PIPE Investment and Convertible Loan Agreements, we estimate that the future company would have CHF 223.1 million in cash assuming no redemptions by
EBAC&#146;s shareholders, and CHF 121.0&nbsp;million in cash assuming maximum redemptions by EBAC&#146;s shareholders, either of which we believe will be sufficient to fund our anticipated level of operations for at least twelve months from the date
of this proxy statement/prospectus. Please see the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; for more information. We have based our estimate on assumptions that may prove to be wrong, and we
may use our available capital resources sooner than we currently expect. For example, after the closing of the Business Combination, we (in the form of New Parent) may require additional capital resources due to underestimation of the nature, timing
and costs of the efforts that will be necessary to complete the development of our product candidates. We may also need to raise additional funds more quickly if we choose to expand our development activities, our portfolio or if we consider
acquisitions or other strategic transactions, including licensing transactions. For more information regarding these risk and factors that could influence our and New Parent&#146;s future capital requirements and the timing thereof, please see the
section entitled &#147;<I>Risk Factors</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Future Funding Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the
commercialization of a product. We will not generate revenue from product sales unless and until we successfully complete clinical development and are able to obtain regulatory approval for and successfully commercialize the product candidates we
are currently developing or that we may develop. We currently do not have any product candidates approved for commercial sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates,
currently under development or that we may develop, will require significant additional research and development efforts, including extensive clinical testing and regulatory approval prior to commercialization. These efforts require significant
amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities. There can be no assurance that our research and development activities will be successfully completed, that adequate protection for
our licensed or developed technology will be obtained and maintained, that products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we obtain regulatory approval for one or more of our product candidates, we expect to incur significant expenses related to developing our
commercialization capabilities to support product sales, marketing and distribution activities, either alone or in collaboration with others. Further, following the completion of the Business Combination, as discussed further below, we expect to
incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, we can generate substantial product revenue, we may finance our operations through a combination of private or public equity
offerings, debt financings, collaborations, strategic alliances, marketing, distribution or licensing arrangements or through other sources of financing. Adequate capital may not be available to us when needed or on acceptable terms. We do not
currently have committed external sources of funds, but expect to obtain resources upon consummation of the Business Combination and PIPE Financing. To the extent that we raise additional capital through the sale of private or public equity or
convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of New Parent ordinary shares. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Debt financing would also result in fixed payment obligations. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with
third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds
through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves, obtain funds through arrangement with collaborators on terms unfavorable to us or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights
of New Parent shareholders. Please see the section entitled <I>&#147;Risk Factors&#151;Risks related to our business, financial condition, capital requirements, or financial operations&#148;</I> for additional risks associated with our substantial
capital requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the
preclinical activities, manufacturing and clinical trials of our product candidates. In addition, we have incurred additional costs associated with the Business Combination and will continue to incur additional costs associated with operating as a
public company, including significant legal, accounting, investor relations and other expenses that we did not incur or incremental to operating a private company. Our expenses will also increase as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our clinical-stage product candidates&nbsp;, including as we progress our Phase 3 clinical trials for our
most advanced programs, <FONT STYLE="white-space:nowrap">OCS-01</FONT> for DME and ocular surgery; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our preclinical stage product candidates into clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire and develop additional product candidates, including through business development
efforts to invest in <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;other</FONT> technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, medical, scientific and other technical personnel to support our
clinical operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operational, financial and management systems and increase personnel to support our operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet the requirements and demands of being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments due under the Novartis Agreement, the Accure Agreement, and any <FONT
STYLE="white-space:nowrap">future&nbsp;in-license&nbsp;or</FONT> collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of other programs to further expand
our pipeline; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertake <FONT STYLE="white-space:nowrap">any&nbsp;pre-commercialization&nbsp;activities</FONT> to establish
sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own or jointly with third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section of the proxy statement/prospectus titled &#147;<I>Risk Factors</I>&#148; for additional risks associated with our substantial capital
requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Cash flows</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>In CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">675</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2022, operating activities used CHF 18.5 million of cash, primarily consisting of our net loss of CHF 29.5 million and
partially offset by changes in net operating assets and liabilities of CHF 1.8 million and non-cash charges of CHF 9.2 million. Changes in net operating assets and liabilities were driven by a CHF 2.5 million increase in accrued expenses and other
payables primarily for one half of the upfront fee of CHF 3.0 million to Accure related to exclusive global licensing of OCS-05 and CHF 0.4 million of increased accrued costs related to the Business Combination with EBAC. Our non-cash charges
primarily consisted of CHF 5.0 million from interest expense accrued on preferred Series B and C shares and CHF 4.1 million from non-realized foreign exchange differences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2021, operating activities used CHF 10.4 million of cash, primarily consisting of our net loss of CHF
13.0 million and changes in net operating assets and liabilities of CHF 2.3 million, offset by non-cash charges of CHF 4.9 million. Changes in net operating assets and liabilities were driven by an increase of CHF 1.1 million in prepaid and other
receivables, resulting from an increase in research and development prepayments made at the start of clinical trials of CHF 1.1 million, a decrease in accrued expenses and other payables of CHF 0.5 million that was the difference between the
estimated costs to vendor and actual settlement due related to Phase 2 trials of OCS-01, and an increase of CHF 0.5 million in accrued income related to research and development tax credits provided by the Icelandic government. The increase in tax
credits was due to an increase in qualifying expenses incurred compared to the prior period and a temporary increase in the allowable limits in the program for calendar years 2020 and 2021 which increased the reimbursed amount in 2021 by CHF 0.2
million. Additionally, changes in our non-cash charges primarily consisted of CHF 3.5 million from interest expense on preferred Series B and C shares and CHF 0.5 million from non-realized foreign exchange differences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, operating activities used CHF 13.8 million of cash, primarily consisting of our net loss of CHF 18.6
million and decreases from changes in net operating assets and liabilities of CHF 0.9 million, partially offset by non-cash charges of CHF 5.6 million. Decreases in net operating assets and liabilities were driven by the timing of prepaid payments
related to contracts with third-party CROs. Our non-cash charges of CHF 5.6 million primarily consisted of CHF 5.0 million from interest expense on preferred Series B and C shares and CHF 0.9 million from compensation expense related to restricted
stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2020, operating activities used CHF 12.0 million of cash, primarily consisting of our net
loss of CHF 14.9 million and decreases from changes in net operating assets and liabilities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of CHF 0.5 million, partially offset by non-cash charges of CHF 3.3 million. Our non-cash charges of CHF 3.3 million primarily consisted of CHF 2.6 million from interest expense on preferred
Series B and C shares, and our working capital charges primarily consisted of CHF 0.6 million relating to a decrease in trade payables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2022, investing activities used CHF 1.5 million of cash as payment of one half of the upfront fee to
Accure related to exclusive global licensing of OCS-05 and an additional CHF 0.5 million of reimbursed costs in relation to the OCS-05 AON study that were capitalized as intangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2021, investing activities used a nominal amount of cash for the purchases of property, plant and
equipment of CHF 9 thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2021 and 2020, investing activities used CHF 28 thousand and CHF 19
thousand, respectively, of cash for the purchases of property, plant, and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2022, net cash provided by financing activities primarily consisted of CHF 2.0 million of proceeds from
the issuance of preferred series C shares, which are classified as liabilities within our consolidated statement of financial position, in July 2022, before transaction costs of CHF 34 thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2021, net cash provided by financing activities was CHF 51.7 million, which primarily consisted of
proceeds from issuance of preferred Series C shares, classified as liabilities of CHF 52.5 million, before transaction costs of CHF 0.8 million. In April 2021, we issued preferred Series C shares to fund research and development activities and
general working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, net cash provided by financing activities was CHF 55.2 million, which
primarily consisted of proceeds from issuance of preferred Series C shares, classified as liabilities of CHF 56.1 million, before transaction costs of CHF 0.8 million. In April and December 2021, we issued preferred Series C shares to fund research
and development activities and general working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2020, net cash provided by financing activities
was CHF 4.9 million, which primarily consisted of proceeds from issuance of preferred Series B shares of CHF 5.0 million, before transaction costs of CHF 0.1 million. In March 2020, we issued preferred Series B shares to fund research and
development activities and general working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Other Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have certain payment obligations under various license and collaboration agreements. Under these agreements, we are required to pay <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> upfront license fees, predefined development and commercial milestone payments and royalties on net sales of licensed products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Novartis for <FONT STYLE="white-space:nowrap">OCS-02</FONT>
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a license agreement, dated as of December 19, 2018, as amended, by and between us and Novartis (the &#147;<I>Novartis
Agreement</I>&#148;), we obtained an exclusive, royalty-bearing, sublicensable (subject to certain conditions), assignable (subject to certain conditions), worldwide license under certain patents, know-how and manufacturing platform technology to
develop, manufacture and commercialize pharmaceutical, therapeutic or diagnostic products containing a specified single chain antibody fragment formulation as an active ingredient in the licensed field as defined in the Novartis Agreement. The
license granted to us by Novartis includes sublicenses of rights granted to Novartis by certain third parties, and our license to such rights is expressly subject to the applicable terms and conditions of the agreements between Novartis and such
third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We originally entered into the Novartis Agreement with Alcon Research, Ltd. (&#147;<I>Alcon</I>&#148;), which subsequently assigned its
rights and obligations under the Novartis Agreement to Novartis in connection with its <FONT STYLE="white-space:nowrap">spin-off</FONT> from Novartis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are deemed the owner of any inventions that are (a) created solely by or on behalf of us pursuant to the Novartis Agreement and (b) severable from the licensed products, and grant Novartis a first right to negotiate a worldwide, royalty-bearing
license under any patents directed at such inventions for purposes outside of the licensed field. We also grant Novartis a worldwide, non-exclusive, perpetual, irrevocable, royalty-free, fully paid-up license back under any patents owned by us that
(i) cover inventions arising from the Novartis Agreement, the practice of which would infringe the patents licensed to us by Novartis, or (ii) otherwise incorporate Novartis&#146; proprietary information, in each case, for certain uses outside of
the licensed field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We made an initial payment to Alcon of CHF 4.7&nbsp;million ($4.7&nbsp;million at the exchange rate at the time of payment) in cash.
As of September&nbsp;30, 2022, we were obligated to pay Novartis additional up to $97.0&nbsp;million (CHF&nbsp;95.1&nbsp;million at the September&nbsp;30, 2022 exchange rate) in the aggregate upon the achievement of certain development, regulatory,
sales and other milestones and tiered royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to a low mid-teen percentage on net sales. In consideration for the exclusive sublicense from Novartis under certain third-party
intellectual property rights, we are obligated to pay a <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty on our net sales of the licensed product, however, such payments will be deducted from royalties payable to Novartis. Our
royalty payment obligations are subject to certain reductions and expire with respect to any licensed product on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of
(a)&nbsp;the expiration of the last to expire valid claim of any licensed patent covering any such licensed product in such country; (b)&nbsp;the expiration of the period of data exclusivity in any country worldwide; or (c)&nbsp;twelve (12) years
after first commercial sale of such licensed product in such country (&#147;<I>Royalty Term</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Novartis Agreement, we are obligated to
use diligent efforts to develop, manufacture or have manufactured, and commercialize the licensed products in the licensed field worldwide. The Novartis Agreement will expire upon the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Royalty Term. We may terminate the Novartis Agreement without cause at any time upon advance written notice to Novartis. Upon written notice to Novartis,
we may terminate the Novartis Agreement for cause due to the following events: (a)&nbsp;an insolvency event occurs; (b)&nbsp;Novartis materially breaches its obligations under the Novartis Agreement and fails to cure such breach within a specified
period of time; or (c)&nbsp;upon advance written notice for material scientific, technical or medical reasons or in case of a material adverse change that renders further continuation of the Novartis Agreement by us commercially unreasonable or
otherwise not viable. Upon written notice to us, Novartis may terminate the Novartis Agreement for cause due to the following events: (i)&nbsp;we fail to pay any undisputed amount due under the Novartis Agreement and we fail to remedy such failure
within a specified period of time; (ii)&nbsp;an insolvency event occurs; or (iii)&nbsp;we materially breach our obligations under the Novartis Agreement and fail to cure such breach within a specified period of time; or (iv)&nbsp;following negative
clinical trial results, we terminate development of the licensed product and do not pursue any further indications in the licensed field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Accure for <FONT STYLE="white-space:nowrap">OCS-05</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a license agreement, dated as of January&nbsp;29, 2022, by and between us and Accure (the &#147;<I>Accure Agreement</I>&#148;), we obtained an
exclusive, worldwide, sublicensable (subject to certain conditions) and transferable (subject to certain conditions) license under certain patents, know-how and inventory of Accure for any and all uses and purposes, including to perform research,
development, manufacturing and commercialization activities in any manner and for any purpose. The licensed patents are co-owned by Accure with third parties who have reserved the right to use the licensed patents for education and research purposes
pursuant to an inter-institutional agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We made an initial payment to Accure of CHF 1.5&nbsp;million ($1.6&nbsp;million at the exchange rate at the
time of payment) and another payment of CHF 0.5 million of reimbursed costs ($0.5 million at the exchange rate at the time of payment) during the nine months ended September 30, 2022. We accrued an additional CHF 1.5&nbsp;million ($1.5&nbsp;million
at the September&nbsp;30, 2022 exchange rate) for liabilities owed to Accure. As of September&nbsp;30, 2022, we were obligated to pay Accure (a)&nbsp;up to $112.1&nbsp;million (CHF 109.9&nbsp;million at the September&nbsp;30, 2022 exchange rate) in
the aggregate upon the achievement of certain development, regulatory and sales milestones; (b)&nbsp;tiered royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to a low mid-teen percentage on net sales of licensed
products; and (c)&nbsp;high teens on sublicensing revenues received any time after 36 months from the agreement effective date, and a higher percentage on sublicensing revenues received prior to such date, in all cases subject to reduction for any
amount that were previously paid or are concurrently or later paid by Oculis to Accure pursuant to Oculis&#146;s milestone payment obligations and such amounts received from a sublicensee will be deduced from amounts owned to Accure. Our royalty
payment obligations are subject to certain reductions and expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of (i)&nbsp;the expiration of the last valid claim of any licensed patent covering such licensed product in such country; (ii)&nbsp;the expiration of such licensed
product&#146;s Orphan Drug status, if any, in such country; or (iii)&nbsp;ten (10) years following the date of first commercial sale of such licensed product in such country (the &#147;<I>Payment Period</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Accure Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory approval for a licensed product in major
countries of the territory as defined in the Accure Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Accure Agreement will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of the applicable Payment Period with respect to
such licensed product in such country. We may terminate the Accure Agreement in whole or in part at any time upon advance written notice (a)&nbsp;for documented reasonable scientific, regulatory, commercial reasons related to the licensed product
without incurring any penalty or liability to Accure and (b)&nbsp;for no reason. Each party may terminate the Accure Agreement with immediate effect upon written notice to the other party (i)&nbsp;in the event such other party commits a material
breach of its obligations under the Accure Agreement and fails to cure that breach within a specified period of time or (ii)&nbsp;with certain exceptions, upon such other party&#146;s bankruptcy. Accure may terminate the Accure Agreement with
immediate effect upon written notice to us if we file any action to invalidate any of the licensed patents or fail to maintain the licensed patents in major countries of the territory as defined in the Accure Agreement, or, subject to certain
exceptions, if we fail to meet certain development obligations and are unable to agree upon modifications to the development plan with Accure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our preferred shares
provide preference rights to shareholders that include preferential distribution of proceeds in the case of certain liquidity events. A redemption option exists in April 2025 for a <FONT STYLE="white-space:nowrap">pre-specified</FONT> qualified
condition related to an initial public offering, with amounts equivalent to the sum of investors&#146; Series A, B and C investment, accrued dividends and applicable compounded interests at 0.00%, 6.00% and 8.00% for Series A, B and C shares,
respectively, which could lead to a potential cash-outflow. Consequently, the preferred shares are classified as long-term financial liabilities that might become due under those scenarios, which include liquidation or certain exit events. The
preferred Series B and C shares include a preferred dividend payment of 6.00%, which is also presented as long-term financial liabilities and is not cash settled but accrued until a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption event. Upon the consummation of the Business Combination, all series of preferred shares will convert to New Parent Shares under the terms of the Business Combination Agreement and the
preferred dividend associated with the preferred shares would be settled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have conducted research and development programs through collaborative
programs that include, among others, arrangements with universities, CROs and clinical research sites. As of September&nbsp;30, 2022, commitments for external research projects totaled CHF 8.6&nbsp;million, with CHF 8.3&nbsp;million due within one
year and CHF 0.3&nbsp;million due between one and five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we enter into agreements in the normal course of business with CROs for
clinical trials and with vendors for preclinical studies, manufacturing services, and other services and products for operating purposes, which are generally cancelable upon written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into two real estate lease agreements for lab and office facilities. At September&nbsp;30, 2022, these lease agreements have aggregate lease
liabilities of CHF 0.2&nbsp;million due within one year and CHF 0.7&nbsp;million due in more than one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 18 to our historical consolidated
financial statements as of December&nbsp;31, 2021 and for the years ended December&nbsp;31, 2021 and 2020 and Note 14 to our unaudited condensed interim consolidated financial statements as of September&nbsp;30, 2022 and for the nine months ended
September&nbsp;30, 2022 and 2021 included elsewhere in this proxy statement/prospectus for further details on our obligations and timing of expected future payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Policies and Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in conformity with IFRS, as issued by the IASB. In preparing our consolidated financial statements, we make
judgments, estimates and assumptions about the application of our accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Our critical accounting judgments and sources of estimation uncertainty are
described in Note 4 to our consolidated financial statements, which are included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company and Foreign Private Issuer Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. An emerging growth company may take advantage of specified reduced reporting
and other burdens that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in a registration statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirement to hold a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to the Sarbanes-Oxley Act of 2002; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirement that the PCAOB has adopted regarding a supplement to the
auditor&#146;s report providing additional information about the audit and the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these
exemptions until December&nbsp;31, 2027 or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which we have
total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; (iii)&nbsp;the date on which we are deemed to be a large accelerated filer under
the rules of the SEC; or (iv)&nbsp;December 31, 2027. We may choose to take advantage of some but not all of these exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also be considered
a &#147;foreign private issuer.&#148; Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations with respect
to a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement to comply with Regulation FD, which requires selective disclosure of material information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;containing</FONT> unaudited financial and other specified information, or current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;upon</FONT> the occurrence of specified significant
events. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a
foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive officers or directors are U.S. citizens
or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued and Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3
to of our consolidated financial statements appearing elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is
a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. After the closing of the Business Combination, as a U.S. public company, we will
be required, pursuant to Section&nbsp;404(a) of the Sarbanes-Oxley Act, to furnish a report by our management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include
disclosures of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there
is a reasonable possibility that a material misstatement of a company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation of our consolidated financial statements for the&nbsp;years ended December&nbsp;31, 2021 and 2020, we identified material
weaknesses in our internal control over financial reporting. The material weaknesses identified are related to (i)&nbsp;a lack of sufficient internal accounting personnel to support an efficient and structured financial statement close process and
allow for the appropriate monitoring of financial reporting matters; and (ii)&nbsp;the maintenance of effective controls over information technology general controls for IT accounting and financial reporting systems. Specifically, IT systems and
related operations are outsourced to third parties and therefore, we were not in a position to maintain user access controls, program change management controls, and testing and approval controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The identified control deficiencies did not result in a material misstatement to our financial statements.
However, each of these control deficiencies could result in a misstatement of our accounts or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected, and
accordingly, we determined that these control deficiencies constitute material weaknesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the section entitled &#147;<I>Risk
Factors</I>&#151;<I>Risks Related to Oculis&#146; Business Following the Proposed Transactions</I>&#151;<I>We have identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in
the future or fail to maintain effective internal control over financial reporting. If we are unable to maintain an effective system of internal controls in the future, our ability to accurately or timely report our financial condition or results of
operations may be adversely affected, which could hurt our business, lessen investor confidence and depress the market price of our securities.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To achieve compliance with Section&nbsp;404(a) when required, we will engage in a process to document and evaluate our internal controls over financial
reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over
financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial
reporting. We expect these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to a variety of risks in the ordinary course of our business, including, but not limited to, currency risk, interest rate risk, credit risk and
liquidity risk. We regularly assess each of these risks to minimize any adverse effects on our business as a result of those factors. See Note 20 to our audited consolidated financial statements, which are included elsewhere in this proxy
statement/prospectus, for further discussion of our exposure to these risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_17"></A>BUSINESS OF EBAC AND CERTAIN INFORMATION ABOUT EBAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;we&#148;, &#147;us&#148; and &#147;ours&#148; refer to European Biotech
Acquisition Corp. prior to the consummation of the Business Combination, which will be the business of New Parent and its subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is a blank check company incorporated on
January&nbsp;8, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses,
which is referred to throughout this proxy statement/prospectus as an initial business combination (the &#147;<I>initial business combination</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2021, EBAC consummated an initial public offering of 12,000,000 Units, at $10.00 per Unit, generating gross proceeds of $120.0&nbsp;million
and incurring offering costs of approximately $7.1&nbsp;million, of which $4.2&nbsp;million was for deferred underwriting commissions. EBAC granted the underwriters a <FONT STYLE="white-space:nowrap">45-day</FONT> option to purchase up to an
additional 1,800,000 Units at the initial public offering price to cover over-allotments, if any (the &#147;<I>Over-Allotment Units</I>&#148;). On April&nbsp;29, 2021, the underwriters partially exercised the over-allotment option, and the closing
of the issuance and sale of the additional 754,784 Over-Allotment Units occurred on May&nbsp;3, 2021. The issuance by EBAC of the Over-Allotment Units at a price of $10.00 per unit resulted in total gross proceeds of approximately $7.5&nbsp;million.
Substantially concurrent with the closing of its initial public offering, EBAC completed the private placement of 440,000 units (the &#147;<I>Option Units</I>&#148;) to the Sponsor at a purchase price of $10.00 per private warrant, generating gross
proceeds of $4.4&nbsp;million. Simultaneously with the issuance and sale of the Option Units, EBAC consummated the private placement with the Sponsor of 15,096 additional private placement units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately $127.5&nbsp;million of the net proceeds of the initial public offering was placed in the Trust Account. Except with respect to interest earned
on the funds in the Trust Account that may be released to EBAC to pay its taxes, the funds held in the Trust Account will not be released from the Trust Account until the earlier of: (i)&nbsp;the completion of an initial business combination and
(ii)&nbsp;the distribution of the Trust Account as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s management has broad discretion with respect to the specific application
of the net proceeds of the initial public offering and the sale of private placement units, although substantially all of the net proceeds are intended to be applied generally toward consummating an initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s units, Class&nbsp;A Common Stock and EBAC Public Warrants are each traded on the Nasdaq Capital Market under the symbols &#147;EBACU,&#148;
&#147;EBAC&#148; and &#147;EBACW,&#148; respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022 EBAC had approximately $128.3&nbsp;million held in the Trust Account, not taking into account payment of deferred underwriting
fees. As a result, EBAC offers a target business a variety of options such as creating a liquidity event for its owners, providing capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its
debt ratio. Because EBAC is able to complete the Business Combination using EBAC&#146;s cash, debt, or equity securities, or a combination of the foregoing, EBAC has the flexibility to use the most efficient combination that will allow EBAC to
tailor the consideration to be paid to the target business to fit its needs and desires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effecting the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of Public Shares and Liquidation If No Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association provide that EBAC has only 24 months (unless otherwise extended) from the closing of
its initial public offering to complete an initial business combination. If EBAC has not completed an initial business combination within the Combination Period, EBAC will: (i)&nbsp;cease all operations except for the purpose of winding up;
(ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in
the Trust Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses and any withholding taxes) divided by the number of the then issued and outstanding public shares, which redemption will completely extinguish
public shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of EBAC&#146;s
remaining shareholders and the EBAC Board, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii) to EBAC&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
law. There will be no redemption rights or liquidating distributions with respect to EBAC&#146;s warrants, which will expire worthless if EBAC fails to consummate an initial business combination within the Combination Period. EBAC&#146;s amended and
restated memorandum and articles of association provide that, if EBAC winds up for any other reason prior to the consummation of the initial business combination, EBAC will follow the foregoing procedures with respect to the liquidation of the Trust
Account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and each
member of EBAC&#146;s management team have entered into an agreement with EBAC, pursuant to which they have agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares they hold if EBAC fails
to consummate an initial business combination within the Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if EBAC fails to complete the initial
business combination within the prescribed time frame). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s Sponsor, executive officers and directors have agreed, pursuant to a written
agreement with EBAC, that they will not propose any amendment to EBAC&#146;s amended and restated memorandum and articles of association (A)&nbsp;that would modify the substance or timing of EBAC&#146;s obligation to provide holders of EBAC
Class&nbsp;A Common Stock the right to have their shares redeemed in connection with EBAC&#146;s initial business combination or to redeem 100% of EBAC&#146;s public shares if EBAC does not complete the initial business combination within the
Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of EBAC Class&nbsp;A Common Stock (including extending the deadline for completing the initial business combination), unless EBAC provides the
public shareholders with the opportunity to redeem their public shares upon approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account, including interest (<I>less</I> up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), <I>divided</I> by the number of then issued and outstanding public shares. However, EBAC may not
redeem the public shares in an amount that would cause EBAC&#146;s net tangible assets to be less than $5,000,001 (so that EBAC does not then become subject to the SEC&#146;s &#147;penny stock&#148; rules). If this optional redemption right is
exercised with respect to an excessive number of public shares such that EBAC cannot satisfy the net tangible asset requirement, EBAC would not proceed with the amendment or the related redemption of the public shares at such time. This redemption
right shall apply in the event of the approval of any such amendment, whether proposed by EBAC&#146;s Sponsor, any executive officer or director, or any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC were to expend all of the net proceeds of the initial public offering and the sale of the private placement units, other than the funds held in the
Trust Account, and without taking into account interest, if any, earned on the Trust Account, the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by shareholders upon EBAC&#146;s dissolution would be $10.00. The funds
held in the Trust Account could, however, become subject to the claims of EBAC&#146;s creditors which would have higher priority than the claims of the public shareholders. EBAC cannot assure you </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the actual <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by shareholders will not be less than $10.00. While EBAC intends to pay such amounts, if any, EBAC
cannot assure you that EBAC will have funds sufficient to pay or provide for all creditors&#146; claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although EBAC has sought to have all vendors,
service providers, prospective target businesses and other entities with which EBAC does business execute agreements with EBAC waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of
the public shareholders, there is no guarantee that any future vendors, service providers, or other entities with which EBAC does business will execute such agreements or even if they execute such agreements that they would be prevented from
bringing claims against the Trust Account including, but not limited, to fraudulent inducement, breach of fiduciary duty or responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order
to gain an advantage with respect to a claim against EBAC&#146;s assets, including the funds held in the Trust Account. If any third-party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, EBAC&#146;s
management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third-party that has not executed a waiver if management believes that such third-party&#146;s engagement would be significantly
more beneficial to us than any alternative. Examples of possible instances where EBAC may engage a third-party that refuses to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by
management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. Credit Suisse Securities (USA) LLC
(&#147;<I>Credit Suisse</I>&#148;), BofA Securities, Inc. (&#147;<I>BofA Securities</I>&#148;), Van Lanschot Kempen (USA) Inc. (formerly Kempen&nbsp;&amp; Co. USA, Inc.) (&#147;<I>Kempen</I>&#148;), SVB Securities LLC (&#147;<I>SVB
Securities</I>&#148;) and Arctica Finance hf (&#147;<I>Arctica</I>&#148;), as <FONT STYLE="white-space:nowrap">co-placement</FONT> agents, have executed an agreement with EBAC waiving such claims to the monies held in the Trust Account arising
solely out of these engagements. These waivers do not apply to rights that Credit Suisse and Kempen have under the underwriting agreement, dated March&nbsp;15, 2021, between Credit Suisse and Kempen, as representatives for the underwriters, and EBAC
relating to EBAC&#146;s initial public offering. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with EBAC
and will not seek recourse against the Trust Account for any reason. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to EBAC if and to the extent any claims by a third-party (other than Marcum
LLP, EBAC&#146;s independent registered public accounting firm) for services rendered or products sold to EBAC (other than EBAC&#146;s independent registered public accounting firm), or a prospective target business with which EBAC has discussed
entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per public share held in the Trust Account as of the date of the liquidation of the
trust account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay EBAC&#146;s tax obligations, <I>provided </I>that such liability will not apply to
any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under EBAC&#146;s indemnity of the underwriters of EBAC&#146;s initial public
offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third-party, the Sponsor will not be responsible to the extent of any liability for
such third-party claims. However, EBAC has not asked the Sponsor to reserve for such indemnification obligations, nor has EBAC independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and EBAC believes
that the Sponsor&#146;s only assets are securities of EBAC. Therefore, EBAC cannot assure you that the Sponsor would be able to satisfy those obligations. None of EBAC&#146;s officers or directors will indemnify EBAC for claims by third parties
including, without limitation, claims by vendors and prospective target businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the Trust Account are reduced below
the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the
trust assets, in each case net of the amount of interest which may be withdrawn to pay EBAC&#146;s income tax obligations, and the Sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification
obligations related to a particular claim, EBAC&#146;s independent directors would determine whether to take legal action against the Sponsor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to enforce its indemnification obligations. While EBAC currently expects that EBAC&#146;s independent directors would take legal action on EBAC&#146;s behalf against the Sponsor to enforce its
indemnification obligations to EBAC, it is possible that EBAC&#146;s independent directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, EBAC cannot assure you that due to claims of creditors
the actual value of the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price will not be less than $10.00 per public share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has sought
to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which EBAC does business
(except for the independent registered public accounts) execute agreements with EBAC waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. The Sponsor will also not be liable as to any claims under
EBAC&#146;s indemnity of the underwriters of EBAC&#146;s initial public offering against certain liabilities, including liabilities under the Securities Act. EBAC has access to up to $1,000,000 following the initial public offering and the sale of
the private placement units with which to pay any such potential claims (including costs and expenses incurred in connection with EBAC&#146;s liquidation, currently estimated to be no more than approximately $100,000). In the event that EBAC
liquidates and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received funds from EBAC&#146;s Trust Account could be liable for claims made by creditors, however such liability will not be
greater than the amount of funds from the Trust Account received by any such shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC files a bankruptcy or
<FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against EBAC that is not dismissed, the funds held in the Trust Account could be subject
to applicable bankruptcy or insolvency law, and may be included in EBAC&#146;s bankruptcy estate and subject to the claims of third parties with priority over the claims of EBAC Shareholders. To the extent any bankruptcy claims deplete the Trust
Account, EBAC cannot assure you EBAC will be able to return $10.00 per public share to the public shareholders. Additionally, if EBAC files a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition is filed against EBAC that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a
&#147;preferential transfer&#148; or a &#147;fraudulent conveyance.&#148; As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by EBAC Shareholders. Furthermore, the EBAC Board may be viewed as having
breached its fiduciary duty to EBAC&#146;s creditors and/or may have acted in bad faith, and thereby exposing itself and EBAC to claims of punitive damages, by paying public shareholders from the Trust Account prior to addressing the claims of
creditors. EBAC cannot assure you that claims will not be brought against us for these reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s public shareholders will be entitled to
receive funds from the Trust Account only (i)&nbsp;in the event of the redemption of the public shares if EBAC does not complete an initial business combination within the Combination Period, (ii)&nbsp;in connection with a shareholder vote to amend
EBAC&#146;s amended and restated memorandum and articles of association (A)&nbsp;to modify the substance or timing of EBAC&#146;s obligation to provide holders of the EBAC Class&nbsp;A Common Stock the right to have their shares redeemed in
connection with an initial business combination or to redeem 100% of the public shares if EBAC does not complete an initial business combination within the Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of
holders of the EBAC Class&nbsp;A Common Stock (including extending the deadline for completing EBAC&#146;s initial business combination), or (iii)&nbsp;if they redeem their respective shares for the right to receive an amount in cash upon the
completion of the initial business combination. Public shareholders who redeem their EBAC Class&nbsp;A Common Stock in connection with a shareholder vote described in clause (ii)&nbsp;in the preceding sentence shall not be entitled to funds from the
Trust Account upon the subsequent completion of an initial business combination or liquidation if EBAC has not consummated an initial business combination within the Combination Period with respect to such EBAC Class&nbsp;A Common Stock so redeemed.
In no other circumstances will a shareholder have any right or interest of any kind to or in the Trust Account. In the event EBAC seeks shareholder approval in connection with an initial business combination, a shareholder&#146;s voting in
connection with the initial business combination alone will not result in a shareholder&#146;s redeeming its shares to EBAC for an applicable pro rata share of the Trust Account. Such shareholder must have also exercised its redemption rights
described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These provisions of EBAC&#146;s amended and restated memorandum and articles of association, like all provisions of EBAC&#146;s amended and restated memorandum and articles of association, may be
amended with a shareholder vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC currently has two executive officers: Eduardo Bravo Fernandez de Araoz and Koen Sintnicolaas. These individuals are not obligated to devote any specific
number of hours to EBAC&#146;s matters but they intend to devote as much of their time as they deem necessary to EBAC&#146;s affairs until EBAC has completed an initial business combination. EBAC does not intend to have any full-time employees prior
to the completion of an initial business combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s officers and directors are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eduardo Bravo Fernandez de Araoz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief&nbsp;Executive&nbsp;Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koen Sintnicolaas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Wegter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volkert Doeksen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Onno van de Stolpe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mohammad Sohail Fazeli</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eduardo Bravo Fernandez de Araoz </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eduardo Bravo Fernandez de Araoz has served as EBAC&#146;s Chief Executive Officer since EBAC&#146;s inception. From July 2020 to December 2020, Mr.&nbsp;Bravo
was Interim Chief Executive Officer of OncoDNA, a cancer theranostic company. From July 2018 to February 2020, Mr.&nbsp;Bravo served Chief Executive Officer of Nordic Nanovector, a radiopharmaceutical company. Prior to joining Nordic Nanovector,
Mr.&nbsp;Bravo was CEO of TiGenix, a cell therapy company from 2011 until June 2018. Mr.&nbsp;Bravo serves on the board of Ariceum Therapeutics GmbH since November 2021 to the present. Mr.&nbsp;Bravo has a MSc in Business Administration from CUNEF
(1988)&nbsp;and an MBA from INSEAD (1991). EBAC believes that Mr.&nbsp;Bravo&#146;s experience as an executive at leading biotechnology businesses make him well qualified to serve on EBAC&#146;s management team. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Koen Sintnicolaas </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Koen Sintnicolaas has served as
EBAC&#146;s Chief Financial Officer since EBAC&#146;s inception. From July 2016 to the present, Mr.&nbsp;Sintnicolaas is the Business Controller of EQT Life Sciences (f/k/a Life Science Partners) and one of Europe&#146;s largest and most experienced
healthcare investment firms. From June 2013 to June 2016, Mr.&nbsp;Sintnicolaas served as Business Controller of Fetim Group, an international trading company. Mr.&nbsp;Sintnicolaas has a MSc in Financial Economics from the Erasmus University and a
post-graduate Business Analytics&nbsp;&amp; Data Science degree from the Vrije Universiteit. EBAC believes that Mr.&nbsp;Sintnicolaas&#146; experience as a business controller at leading investment and international trading firms make him well
qualified to serve on EBAC&#146;s management team. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Martijn Kleijwegt </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt has been a member and the Chairman of the EBAC Board since EBAC&#146;s inception. Mr.&nbsp;Kleijwegt founded LSP in 1998 and is currently a
partner at EQT Life Sciences (f/k/a Life Science Partners). Mr.&nbsp;Kleijwegt brings over 30 years of <FONT STYLE="white-space:nowrap">hands-on</FONT> finance and investment experience to EBAC. Mr.&nbsp;Kleijwegt
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently serves on the boards of Vico Therapeutics, <FONT STYLE="white-space:nowrap">A-M</FONT> Pharma and Oxthera. Mr.&nbsp;Kleijwegt has a master&#146;s degree in Economics from Amsterdam
University. EBAC believes that Mr.&nbsp;Kleijwegt&#146;s experience in healthcare investments make him well qualified to serve as a director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark
Wegter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Wegter has been a member of the EBAC Board since EBAC&#146;s inception. Mr.&nbsp;Wegter joined LSP in 1998 and is a partner at EQT
Life Sciences (f/k/a Life Science Partners). For the first ten years at LSP, Mr.&nbsp;Wegter was actively involved in raising and managing Life Sciences Partners&#146; private equity funds, taking
<FONT STYLE="white-space:nowrap">co-responsibility</FONT> for the entire investment process, from deal sourcing to actively supporting the growth and exit of a number of Life Sciences Partners&#146; portfolio companies, as <FONT
STYLE="white-space:nowrap">non-executive</FONT> director and Life Science Partners investor representative. This included both private and public companies in countries such as the Netherlands, Belgium, Germany, the UK and Switzerland. As of early
2008, Mr.&nbsp;Wegter started Life Sciences Partners&#146; public equity investment franchise, building it to become a second business line next to Life Sciences Partners&#146; existing private equity franchise. Prior to joining LSP, Mr.&nbsp;Wegter
worked as a Senior Analyst at ING Corporate and Investment Banking. Mr.&nbsp;Wegter brings 25 years of <FONT STYLE="white-space:nowrap">hands-on</FONT> finance and investment experience to EBAC. Mr.&nbsp;Wegter has a master&#146;s degree in Business
Economics from the Erasmus University of Rotterdam. EBAC believes Mr.&nbsp;Wegter&#146;s experience in healthcare investments make him well qualified to serve as a director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Volkert Doeksen </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Volkert Doeksen has been a member
of the EBAC Board since EBAC&#146;s initial public offering. Mr.&nbsp;Doeksen is a private equity investor and founder of AlpInvest Partners (originally NIB Capital), one of the largest private equity investments managers globally. AlpInvest has
committed over $70&nbsp;billion to investments since 2000. From 2000 until 2015, he served as CEO and Chairman of the Board and the investment committee of AlpInvest, which has offices in Amsterdam, Hong Kong and New York. From 2015 until 2019,
Mr.&nbsp;Doeksen was Vice Chairman of Carlyle Solutions Group and later on Senior Advisor to The Carlyle Group. Prior to founding AlpInvest, Mr.&nbsp;Doeksen was a director of Dresdner Kleinwort Benson (today &#147;<I>DKB</I>&#148;), managing over
$3&nbsp;billion of private equity investments. From 1992 to 1994, Mr.&nbsp;Doeksen served as head of the bank&#146;s Benelux region, based in the firm&#146;s London office. In 1994, he moved to New York to head up DKB&#146;s private equity
investments, including U.S. leveraged buyouts, mezzanine debt and fund of funds. Prior to DKB, Mr.&nbsp;Doeksen worked as an investment banker focusing on mergers and acquisitions for Dillon Read from 1989 through 1992. He began his career as a
financial analyst in corporate finance for Morgan Stanley International in London in 1987. Mr.&nbsp;Doeksen received his Master in Law Degree from the University of Leiden in 1987. Mr.&nbsp;Doeksen received his Master in Law Degree from the
University of Leiden in 1987. Mr.&nbsp;Doeksen also serves as a director of Athora Holdings Ltd., as director of Royal Doeksen B.V., a shipping and ferry company, as a director of Nouryon B.V. and as director of Nobian B.V. EBAC believes
Mr.&nbsp;Doeksen&#146;s extensive international experience in private equity investments and his service on the boards of directors makes him well qualified to serve as a director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Onno van de Stolpe </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Onno van de Stolpe has been a
member of the EBAC Board since EBAC&#146;s initial public offering. Mr.&nbsp;van de Stolpe founded Galapagos NV in 1999 and had served as Chief Executive Officer and member of its board of directors from 1999 to April 2022. From 1998 to 1999, he was
the managing director of Genomics at IntroGene B.V. (later Crucell N.V., which was acquired by Johnson&nbsp;&amp; Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was managing director of Molecular Probes Europe B.V. He
established this European headquarters after joining Molecular Probes, Inc. in the United States. Previously, from 1990 to 1995, Mr.&nbsp;van de Stolpe worked for The Netherlands Foreign Investment Agency in California, where he was responsible for
recruiting biotechnology and medical device companies to locate in the Netherlands. Mr.&nbsp;van de Stolpe started his career in 1987 as Manager of Business Development at MOGEN International N.V. in Leiden until 1990. He received an MSc degree from
Wageningen University in 1987. Mr.&nbsp;van de Stolpe currently also serves as a member of the Board of Directors of Leyden Laboratories B.V. and Stichting African Parks Foundation. He is nominated for Chairman of the Board of Protix B.V. EBAC
believes that Mr.&nbsp;van de Stolpe is qualified to serve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the EBAC Board because of his extensive international experience in biotechnology, private equity and mergers and acquisitions, and his service on the boards of directors of biopharmaceutical
companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mohammad Sohail Fazeli </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mohammad
Sohail Fazeli has been a member of the EBAC Board since March&nbsp;18, 2021. Mr.&nbsp;Fazeli is a Senior Pharma Analyst and Head of Research EMEA at Bloomberg Intelligence, London. From 2005 to 2010, Mr.&nbsp;Fazeli worked as Senior Biotech Analyst
and Head of Research EMEA at Piper Jaffray (currently doing business as Piper Sandler&nbsp;&amp; Co.) in London. From 2003 to 2005, Mr.&nbsp;Fazeli worked as Senior Biotech Analyst at Nomura International in London. From 2000 to 2003,
Mr.&nbsp;Fazeli worked Senior Biotech Analyst at Altium Capital (Apax) in London. From 1999 to 2000, Mr.&nbsp;Fazeli worked as Biotech Analyst Rabobank in London. Mr.&nbsp;Fazeli started his professional career as Biotech Analyst for HSBC James
Capel in London from 1998 to 1999. Mr.&nbsp;Fazeli received his Bachelor&#146;s Degree in Pharmacology from the University of Cardiff in 1985. Mr.&nbsp;Fazeli received his Ph.D. in Pharmacology from the University of London in 1989. Mr.&nbsp;Fazeli
currently also serves on the board of Arecor Limited and Exonate Limited. EBAC believes Mr.&nbsp;Fazeli&#146;s extensive experience in investment banking and his academic background and expertise in biotechnology make him well qualified to serve as
a director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Number and Terms of Office of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board is divided into three classes, with only one class of directors being appointed in each year, and with each class (except for those directors
appointed prior to EBAC&#146;s first annual general meeting) serving a three-year term. In accordance with the Nasdaq corporate governance requirements, EBAC is not required to hold an annual meeting until one year after EBAC&#146;s first fiscal
year end following EBAC&#146;s listing on the Nasdaq Capital Market. The term of office of the first class of directors, consisting of Onno van de Stolpe, will expire at EBAC&#146;s first annual general meeting. The term of office of the second
class of directors, consisting of Volkert Doeksen and Mohammad Sohail Fazeli, will expire at the second annual general meeting. The term of office of the third class of directors, consisting of Martijn Kleijwegt and Mark Wegter, will expire at the
third annual general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a
nominee chosen by holders of a majority of the founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s officers are appointed by the EBAC Board and serve at the discretion of the EBAC Board, rather than for specific terms of office. The EBAC Board
is authorized to appoint persons to the offices set forth in EBAC&#146;s amended and restated memorandum and articles of association as it deems appropriate. EBAC&#146;s amended and restated memorandum and articles of association provide that
EBAC&#146;s officers may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the EBAC Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq listing standards require
that a majority of the EBAC Board be independent. EBAC has three &#147;independent directors&#148; as defined in the Nasdaq listing standards and applicable SEC rules. The EBAC Board has determined that Volkert Doeksen, Onno van de Stolpe and
Mohammad Sohail Fazeli are &#147;independent directors&#148; as defined in the Nasdaq listing standards. EBAC&#146;s independent directors have regularly scheduled meetings at which only independent directors are present. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer and Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our
officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities were first listed on the Nasdaq Capital Market, we paid an affiliate of the Sponsor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$20,000 per month for office space, utilities, secretarial and administrative support services provided to members of our management team. As of October&nbsp;17, 2022, such arrangements has been
terminated with no further payments or other obligations owed to such affiliate. In addition, the Sponsor, and our officers and directors, or any of their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee
will review on a quarterly basis all payments that were made to the Sponsor, officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the Trust Account. Other
than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and officers for their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements,
no compensation of any kind, including finder&#146;s and consulting fees, will be paid by EBAC to the Sponsor, officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial
business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. We are not party to any agreements with our
officers and directors that provide for benefits upon termination of employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the EBAC Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board has three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Both
EBAC&#146;s audit committee and EBAC&#146;s compensation committee are composed solely of independent directors. Subject to <FONT STYLE="white-space:nowrap">phase-in</FONT> rules and a limited exception, the rules of the Nasdaq and Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to <FONT STYLE="white-space:nowrap">phase-in</FONT> rules and a limited exception,
the rules of the Nasdaq require that the compensation committee and the nominating committee of a listed company be comprised solely of independent directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Volkert Doeksen, Onno van de
Stolpe and Mohammad Sohail Fazeli serve as members of EBAC&#146;s audit committee. The EBAC Board has determined that each of Volkert Doeksen, Onno van de Stolpe and Mohammad Sohail Fazeli are independent under the Nasdaq listing standards and
applicable SEC rules. Mr.&nbsp;Fazeli serves as the Chairman of the audit committee. Under the Nasdaq listing standards and applicable SEC rules, all the directors on the audit committee must be independent. Each member of the audit committee is
financially literate and the EBAC Board has determined that Mr.&nbsp;Fazeli qualifies as an &#147;audit committee financial expert&#148; as defined in applicable SEC rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting with the independent registered public accounting firm regarding, among other issues, audits, and
adequacy of EBAC&#146;s accounting and control systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the independence of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit
and the audit partner responsible for reviewing the audit as required by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inquiring and discussing with management EBAC&#146;s compliance with applicable laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm, including the fees and terms of the services to be performed; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing or replacing the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the compensation and oversight of the work of the independent registered public accounting firm
(including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by EBAC regarding
accounting, internal accounting controls or reports which raise material issues regarding EBAC&#146;s financial statements or accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring compliance on a quarterly basis with the terms of the initial public offering and, if any
noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of the initial public offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all payments made to EBAC&#146;s existing shareholders, executive officers or directors
and their respective affiliates. Any payments made to members of EBAC&#146;s audit committee will be reviewed and approved by the EBAC Board, with the interested director or directors abstaining from such review and approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of EBAC&#146;s
nominating committee are Volkert Doeksen, Onno van de Stolpe and Mohammad Sohail Fazeli. Mr.&nbsp;Doeksen serves as chairman of the nominating committee. Under the Nasdaq listing standards, EBAC is required to have a nominating committee composed
entirely of independent directors. The EBAC Board has determined that each of Volkert Doeksen, Onno van de Stolpe and Mohammad Sohail Fazeli are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on the EBAC Board. The nominating committee considers
persons identified by its members, management, shareholders, investment bankers and others. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guidelines for Selecting Director Nominees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The guidelines for selecting nominees, which are specified in the nominating committee charter, generally provide that persons to be nominated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have demonstrated notable or significant achievements in business, education or public service;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the
EBAC Board and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving
the interests of the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominating committee will consider a number of qualifications relating to management and
leadership experience, background and integrity and professionalism in evaluating a person&#146;s candidacy for membership on the EBAC Board. The nominating committee may require certain skills or attributes, such as financial or accounting
experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among
nominees recommended by shareholders and other persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of EBAC&#146;s compensation committee are Volkert Doeksen, Onno van de Stolpe and Mohammad Sohail Fazeli. Mr.&nbsp;Doeksen serves as chairman of
the compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Nasdaq listing standards, EBAC is required to have a compensation committee composed entirely of
independent directors. The EBAC Board has determined that each of Volkert Doeksen, Onno van de Stolpe and Mohammad Sohail Fazeli are independent. EBAC adopted a compensation committee charter, which details the principal functions of the
compensation committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to EBAC&#146;s Chief
Executive Officer&#146;s compensation, evaluating EBAC&#146;s Chief Executive Officer&#146;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of EBAC&#146;s Chief Executive Officer based on
such evaluation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of all of EBAC&#146;s other Section&nbsp;16 executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing EBAC&#146;s executive compensation policies and plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing and administering EBAC&#146;s incentive compensation equity-based remuneration plans;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting management in complying with EBAC&#146;s proxy statement and annual report disclosure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements
for EBAC&#146;s executive officers and employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing a report on executive compensation to be included in EBAC&#146;s annual proxy statement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC compensation committee charter provide that the compensation committee may, in its sole discretion, retain or obtain the
advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation
consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by the Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Code of Business Conduct and Ethics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC adopted
a Code of Ethics applicable to EBAC&#146;s directors, officers and employees. A copy of the Code of Ethics will be provided without charge upon request from us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law,
directors and officers owe the following fiduciary duties: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to act in good faith in what the director or officer believes to be in the best interests of the company as
a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors should not improperly fetter the exercise of future discretion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers fairly as between different sections of shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty not to put themselves in a position in which there is a conflict between their duty to the company and their
personal interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise independent judgment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a
reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge
skill and experience of that director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As set out above, directors have a duty not to put themselves in a position of conflict and this includes a
duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders <I>provided </I>that
there is full disclosure by the directors. This can be done by way of permission granted in EBAC&#146;s amended and restated memorandum and articles of association or alternatively by shareholder approval at general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of EBAC&#146;s officers and directors presently have, and any of them in the future may have additional, fiduciary and contractual duties to other
entities, including entities that are affiliates of the Sponsor. As a result, if any of EBAC&#146;s officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current
fiduciary or contractual obligations, then, subject to their fiduciary duties under Cayman Islands law, he or she will need to honor such fiduciary or contractual obligations to present such business combination opportunity to such entity, before
EBAC can pursue such opportunity. If these other entities decide to pursue any such opportunity, EBAC may be precluded from pursuing the same. However, EBAC does not expect these duties to materially affect EBAC&#146;s ability to complete a business
combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a table summarizing the entities to which EBAC&#146;s executive officers and directors currently have fiduciary duties, contractual
obligations or other material management relationships: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Individual</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity&#146;s Business</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Affiliation</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eduardo&nbsp;Bravo&nbsp;Fernandez&nbsp;de&nbsp;Araoz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vivet Therapeutics</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sutura
Therapeutics</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Engitix Therapeutics</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ariceum
Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koen Sintnicolaas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">AM-Pharma</FONT> B.V.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vico Therapeutics B.V.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OxThera AB</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LSP Advisory B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Investment management company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Wegter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LSP Advisory B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Investment management company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volkert Doeksen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nobian B.V.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royal Doeksen B.V.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stichting DUX</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Athora Holdings Ltd.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Nouryon B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chemicals</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and ferry
services</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charity</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insurance and reinsurance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chemicals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Onno van de Stolpe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Galapagos NV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Biotechnology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Leyden Laboratories B.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Biotechnology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stichting African</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Parks
Foundation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Charity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mohammad Sohail Fazeli</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arecor Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Exonate Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potential investors should also be aware of the following other potential conflicts of interest: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC&#146;s executive officers and directors are not required to, and will not, commit their full time to
EBAC&#146;s affairs, which may result in a conflict of interest in allocating their time between EBAC&#146;s operations and EBAC&#146;s search for a business combination and their other businesses. EBAC currently does not have and does not intend to
have any full-time employees prior to the completion of a business combination. Each of EBAC&#146;s executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and EBAC executive
officers are not obligated to contribute any specific number of hours per week to EBAC affairs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC&#146;s Sponsor and each member of EBAC&#146;s management team have entered into an agreement with EBAC,
pursuant to which they have agreed to waive their redemption rights with respect to any founder shares and public shares held by them in connection with (i)&nbsp;the completion of an initial business combination and (ii)&nbsp;a shareholder vote to
approve the Existing Government Documents (a)&nbsp;that would modify the substance or timing of EBAC&#146;s obligation to provide holders of EBAC Class&nbsp;A Common Stock the right to have their shares redeemed in connection with an initial
business combination or to redeem 100% of EBAC&#146;s public shares if EBAC does not complete an initial business combination within the Combination Period or (b)&nbsp;with respect to any other provision relating to the rights of holders of EBAC
Class&nbsp;A Common Stock (including extending the deadline for completing EBAC&#146;s Business Combination). Additionally, the Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to its founder
shares if we fail to complete our initial business combination within the prescribed time frame. If we do not complete our initial business combination within the Combination Period, the private placement units and the underlying securities will
expire worthless. Except as described herein, EBAC&#146;S Sponsor, directors and executive officers have agreed not to transfer, assign or sell any of their founder shares until the earliest of (i)&nbsp;one year after the completion of an initial
business combination and (ii)&nbsp;subsequent to a business combination, (a)&nbsp;if the closing price of EBAC Class&nbsp;A Common Stock equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations,
recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after EBAC&#146;s initial business combination, or (b)&nbsp;the date on which EBAC
completes a liquidation, merger, share exchange or other similar transaction that results in all of EBAC&#146;s public shareholders having the right to exchange their ordinary shares for cash, securities or other property. With certain limited
exceptions, the private placement units, the private placement shares, the EBAC Private Placement Warrants and the EBAC Class&nbsp;A Common Stock underlying such warrants, will not be transferable until 30 days following the completion of an initial
business combination. Because each of EBAC&#146;s executive officers and director nominees will own ordinary shares or warrants directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an
appropriate business with which to effectuate EBAC&#146;s business combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will the Sponsor or any of EBAC&#146;s
existing officers or directors, or their respective affiliates be paid by us any finder&#146;s fee, consulting fee, or other compensation prior to, or for any services they render, in order to effectuate the completion of an initial business
combination. Further, as of May&nbsp;21, 2021, EBAC reimburses an affiliate of the Sponsor for office space, administrative, and support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC
cannot assure you that any of the above mentioned conflicts will be resolved in EBAC&#146;s favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and each member of EBAC&#146;s management
team have agreed to vote their founder shares and public shares in favor of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification of
Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not limit the extent to which a company&#146;s constitutive documents may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences
of committing a crime. EBAC&#146;s amended and restated memorandum and articles of association provide for indemnification of EBAC&#146;s officers and directors to the maximum extent permitted by law, including for any liability incurred in their
capacities as such, except through their own actual fraud, willful default or willful neglect. EBAC entered into agreements with EBAC&#146;s directors and officers to provide contractual indemnification in addition to the indemnification provided
for in EBAC&#146;s amended and restated memorandum and articles of association. EBAC purchased a policy of directors&#146; and officers&#146; liability insurance that insures EBAC&#146;s officers and directors against the cost of defense, settlement
or payment of a judgment in some circumstances and insures us against EBAC&#146;s obligations to indemnify EBAC&#146;s officers and directors. EBAC also entered into indemnity agreements with them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s officers and directors have agreed to waive any right, title, interest or claim of any kind in
or to any monies in the Trust Account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to EBAC and will not seek recourse against the Trust
Account for any reason whatsoever (except to the extent they are entitled to funds from the Trust Account due to their ownership of public shares). Accordingly, any indemnification provided will only be able to be satisfied by EBAC if (i)&nbsp;EBAC
has sufficient funds outside of the Trust Account or (ii)&nbsp;EBAC consummates a business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s indemnification obligations may
discourage shareholders from bringing a lawsuit against EBAC&#146;s officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against EBAC&#146;s officers
and directors, even though such an action, if successful, might otherwise benefit EBAC and EBAC Shareholders. Furthermore, a shareholder&#146;s investment may be adversely affected to the extent EBAC pays the costs of settlement and damage awards
against EBAC&#146;s officers and directors pursuant to these indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC believes that these provisions, the insurance and the
indemnity agreements are necessary to attract and retain talented and experienced officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Periodic Reporting and Audited Financial
Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC registered its units, Class&nbsp;A Common Stock, and EBAC Warrants under the Exchange Act and has reporting obligations, including
the requirement that EBAC file annual, quarterly, and current reports with the SEC. In accordance with the requirements of the Exchange Act, EBAC&#146;s annual reports contain financial statements audited and reported on by EBAC&#146;s independent
registered public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is a Cayman Islands exempted company. Exempted companies are Cayman Islands companies conducting business mainly
outside the Cayman Islands and, as such, are exempted from complying with certain provisions of the Cayman Companies Act. As an exempted company, EBAC received a tax exemption undertaking from the Cayman Islands government that, in accordance with
Section&nbsp;6 of the Tax Concessions Act (As Revised) of the Cayman Islands, for a period of 20 years from the date of the undertaking, no law which is enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains, or
appreciations will apply to EBAC or its operations and, in addition, that no tax to be levied on profits, income, gains, or appreciations or which is in the nature of estate duty or inheritance tax will be payable (i)&nbsp;on or in respect of
EBAC&#146;s shares, debentures, or other obligations or (ii)&nbsp;by way of the withholding in whole or in part of a payment of dividend or other distribution of income or capital by EBAC to EBAC Shareholders or a payment of principal or interest or
other sums due under a debenture or other obligation of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the
Securities Act, as modified by the JOBS Act. As such, EBAC is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148;
including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in EBAC&#146;s periodic reports and
proxy statements, and exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. If
some investors find EBAC&#146;s securities less attractive as a result, there may be a less active trading market for EBAC&#146;s securities and the prices of EBAC&#146;s securities may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act also provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. EBAC intends to take advantage of the benefits of this extended transition period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year
(a)&nbsp;following the fifth anniversary of the completion of the initial public offering, (b)&nbsp;in which EBAC has total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which EBAC is deemed to be a large accelerated filer,
which means the market value of shares of EBAC Class&nbsp;A Common Stock that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th and (ii)&nbsp;the date on which EBAC has issued more
than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, EBAC is a
&#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things,
providing only two years of audited financial statements. Following the Business Combination, EBAC expects that New Parent will no longer be a smaller reporting company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the knowledge of EBAC&#146;s
management, there are no material litigation, arbitration or governmental proceedings pending against EBAC or any members of EBAC&#146;s management team in their capacity as such, and EBAC and the members of EBAC&#146;s management team have not been
subject to any such proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Properties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC currently maintains its executive offices at European Biotech Acquisition Corp., EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT
STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. EBAC considers its current office space adequate for its current operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_18"></A>EBAC MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis provides information that EBAC&#146;s management believes is relevant to
an assessment and understanding of EBAC&#146;s results of operations and financial condition. This discussion and analysis should be read together with EBAC&#146;s audited and unaudited interim financial statements and related notes that are
included elsewhere in this proxy statement/prospectus. This discussion and analysis should also be read together with the section of this proxy statement/prospectus entitled &#147;Information about EBAC.&#148; In addition to historical financial
analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties and assumptions, as described under the section entitled &#147;Forward-Looking Statements.&#148; Actual
results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section entitled &#147;Risk Factors&#148; or elsewhere in this
proxy statement/prospectus. Unless the context otherwise requires, references in this section entitled &#147;EBAC&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; to the &#147;Company,&#148;
&#147;our,&#148; &#147;us&#148; or &#147;we&#148; are intended to mean the business and operations of EBAC. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a blank check company incorporated on January&nbsp;8, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a merger,
amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We intend to effectuate the Business Combination using cash derived from the proceeds of our initial public
offering and the sale of the EBAC Private Placement Units and a combination of our public shares and financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur
significant costs in the pursuit of our acquisition plans until the Business Combination occurs. We cannot assure you that our plans to complete the Business Combination will be successful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have neither engaged in any
operations (other than assessing potential business combination opportunities after our initial public offering) nor generated any revenues to date. Our entire activity to date has related to our formation, the preparation for our initial public
offering, and since the closing of our initial public offering, the search for a prospective business combination. We will not generate any operating revenues until the closing and completion of the Business Combination at the earliest. We generate <FONT
STYLE="white-space:nowrap">non-operating</FONT> income in the form of income from investments held in the Trust Account, and change in fair value of warrant liability. We incur expenses as a result of being a public company (for legal, financial
reporting, accounting and auditing compliance), as well as for due diligence expenses in our search for and completion of a business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
three months ended September 30, 2022, we had net loss of approximately $400,000, which consisted of approximately $1.0 million of general and administrative expenses partially offset by approximately $40,000 of non-operating gain from changes in
fair value of derivative warrant liabilities and approximately $576,000 in income from investments held in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the nine months ended
September 30, 2022, we had net income of approximately $1.3&nbsp;million, which consisted of approximately $2.2&nbsp;million of <FONT STYLE="white-space:nowrap">non-operating</FONT> gain from changes in fair value of derivative warrant liabilities
and approximately $761,000 in income from investments held in the Trust Account, partially offset by approximately $1.7 million of general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period from January&nbsp;8, 2021 (inception) through September 30, 2021, we had net income of approximately $1.9 million, which consisted of
approximately $2.8&nbsp;million of <FONT STYLE="white-space:nowrap">non-operating</FONT> gain from changes in fair value of derivative warrant liabilities and approximately $6,000 in income from investments held in the Trust Account, partially
offset by approximately $558,000 of general and administrative expenses and a <FONT STYLE="white-space:nowrap">non-operating</FONT> expense of approximately $315,000 related to offering costs for derivative warrant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, we had approximately $273,000 in our operating bank account and working capital deficit of approximately $968,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers
and directors may, but are not obligated to, provide us any loans (evidenced by a promissory note) for the purpose of financing costs incurred in connection with a business combination (&#147;<I>Working Capital Loans</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, there were no amounts outstanding under Working Capital Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate
of the costs of identifying a target business, undertaking <FONT STYLE="white-space:nowrap">in-depth</FONT> due diligence or negotiating a business combination is less than the actual amount necessary to do so, we may have insufficient funds
available to operate our business prior to our business combination. Moreover, we may need to obtain additional financing either to complete our business combination or because we become obligated to redeem a significant number of our public shares
upon completion of our business combination, in which case we may issue additional securities or incur debt in connection with such business combination. Moreover, the liquidity, the mandatory liquidation and subsequent dissolution that will be
required if we do not complete a business combination within the Combination Period raises substantial doubt about the our ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any long-term
debt obligations, capital lease obligations, operating lease obligations or long-term liabilities, other than a previous agreement to pay an affiliate of the Sponsor $20,000 per month for office space, administrative and support services. We began
incurring these fees on March&nbsp;18, 2021, but as of October&nbsp;17, 2022, such agreement has been terminated with no further payments or other obligations owed to such affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters of EBAC&#146;s initial public offering were paid a cash underwriting discount of $0.20 per unit, or $2.55&nbsp;million in the aggregate. In
addition, the underwriters are entitled to a deferred fee which, together with the transaction expenses of EBAC and Oculis, are estimated to amount to $7.4&nbsp;million, and will become payable to the underwriters from the amounts held in the Trust
Account upon the consummation of the Business Combination, subject to the terms of the underwriting agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, income and
expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base
our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We determined that there have been no material changes to the critical accounting policies
disclosed in our Annual Report on Form&nbsp;10-K for the period ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent
Accounting Standards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would
have a material effect on the accompanying financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in Item 303(a)(4)(ii) of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012 (the &#147;<I>JOBS Act</I>&#148;) contains provisions that, among other things, relax certain reporting
requirements for qualifying public companies. We qualify as an &#147;emerging growth company&#148; and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly
traded) companies. We are electing to delay the adoption of new or revised accounting standard; and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for <FONT
STYLE="white-space:nowrap">non-emerging</FONT> growth companies. As a result, the financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to
certain conditions set forth in the JOBS Act, if, as an &#147;emerging growth company,&#148; we choose to rely on such exemptions we may not be required to, among other things, (i)&nbsp;provide an auditor&#146;s attestation report on our system of
internal controls over financial reporting pursuant to Section&nbsp;404, (ii) provide all of the compensation disclosure that may be required of <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth public companies under the Dodd-Frank Wall
Street Reform and Consumer Protection Act, (iii)&nbsp;comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit
and the financial statements (auditor discussion and analysis) and (iv)&nbsp;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO&#146;s compensation
to median employee compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until we are no longer an &#147;emerging growth company,&#148; whichever is earlier. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Controls and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Evaluation of Disclosure
Controls and Procedures </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the supervision and with the participation of our management, including our principal executive officer and principal
financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended September&nbsp;30, 2022, as such term is defined in Rules
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer have concluded that during the
period covered by this report, our disclosure controls and procedures were effective as of September&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disclosure controls and procedures
are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules and forms, and that such information is
accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Internal Control over Financial Reporting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended September&nbsp;30, 2022 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_19"></A>MANAGEMENT OF NEW PARENT AFTER THE BUSINESS COMBINATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this section, unless otherwise stated or the context requires otherwise, the terms &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to
New Parent. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information, as of the date of this proxy statement/prospectus, concerning the persons who are
expected to be the directors, executive officers and senior management of New Parent following the Acquisition Closing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers (Senior Management)</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Riad Sherif, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sylvia Cheung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P&aacute;ll Ragnar J&oacute;hannesson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Strategy Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Management</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joanne Chang, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bastian Dehmel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Webb Ding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Manager, China</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christina Ackermann</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pravin Dugel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geraldine O&#146;Keeffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Rosenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Riad Sherif, M.D.,</I> 54, has served as the Chief Executive Officer and Director of Oculis since December 2017. Previously, from June 2016 to September
2017, Dr. Sherif served as Entrepreneur in Residence at the Novartis Venture Fund. Before that, Dr. Sherif served as the President of Europe, Middle East and Africa of Alcon, Inc. from March 2014 to May 2016. Prior to that, from January 2002 to
April 2014, Dr. Sherif held roles of increasing responsibility at Novartis AG, including as the Global Sales Head in the Transplant and Infectious Disease unit, as the Head for Latin America in transplant and infectious disease, as the President of
the Novartis Vaccines and Diagnostics Division for Latin America and where he co-founded Synergium a leading biotech company, and most recently as the President of Novartis Pharmaceuticals, Canada. Prior to Novartis, Dr. Sherif worked for several
pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif currently serves as a member of the board of directors of Revenio Group corporation. Dr. Sherif
previously served as the Vice Chairman for the Innovative Medicine Canada Association, as the Chairman of In-Vivo Montreal, and as the Chairman of the Board Ophthalmic Surgery and Vision Care of Eucomed. Dr. Sherif is a Medical Doctor by training,
and holds an MBA from IMD Business School and a Specialized Master&#146;s Degree in Medical Management from ESCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sylvia Cheung, 48</I>, has served as
the Chief Financial Officer of Oculis since September 2020. Prior to that, from&nbsp;October 2005 to August 2020, Ms. Cheung held executive positions at Anika Therapeutics, Inc., a publicly-traded joint preservation company. Most recently, from
April 2013 to August 2020, Ms. Cheung served as the Chief Financial Officer of Anika Therapeutics, Inc. Previously, from 2000 to 2005, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic
Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Before that, from 1995 to 2000, Ms. Cheung served as a Senior Associate at PricewaterhouseCoopers. Ms. Cheung holds a Bachelor of Business Administration degree in Accounting from
the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as Certified Public Accountant in Massachusetts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>P&#225;ll Ragnar J&#243;hannesson,</I> 42, has served as the Chief Strategy Officer of Oculis since
September 2020. Previously, from January 2018 to September 2020, Mr. J&#243;hannesson served as the Chief Financial Officer of Oculis. Additionally, Mr. J&#243;hannesson has served as the Managing Director of Oculis Iceland ehf. since May 2015.
Prior to that, from February 2012 to April 2015, Mr. J&#243;hannesson held a series of corporate finance positions of increasing responsibility at Straumur Investment Bank, and most recently, from September 2013 to April 2015, Mr. J&#243;hannesson
served as the Managing Director, Corporate Finance. Before that, from January 2009 to November 2011, Mr. J&#243;hannesson served as a Director, Corporate Finance at &#205;slandsbanki and its predecessor Glitnir Bank. Mr. J&#243;hannesson holds a
B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil&nbsp;in Management Science from the University of Cambridge, and was certified as securities broker in Iceland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Senior Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joanne Chang, M.D.,
Ph.D.,</I> 62, has served as the Chief Medical Officer of Oculis since September 2021. Previously, from September 2017 to August 2021, Dr. Chang served as the Worldwide Medical Affairs Head Ophthalmology of Novartis. Prior to that, from January 2014
to August 2017, Dr. Chang served as the Head, Clinical Development &amp; Medical Affairs for the U.S. and Canada of Alcon. Before that, from April 2010 to December 2013, Dr. Chang served as the Vice President, Chief Medical Officer of Novartis
Pharma China. Prior to that, from August 2008 to March 2010, Dr. Chang served as Vice President, Evidence Based Medicine of Novartis, United States. Before that, from July 2000 to July 2004, Dr. Chang served as Executive Director, US&nbsp;Health
Economics, Outcomes and Reimbursement of Bayer Pharmaceuticals. Prior to that, from June 2000 to June 2004, Dr. Chang served as Director, HEOR, Global Strategic Marketing &amp; Medical Affairs of Sanofi. Before that, from July 1999 to May 2000, Dr.
Chang served as Director, Global Health Economics of Johnson &amp; Johnson. Prior to that, from August 1995 to June 1999, Dr. Chang served as Associate Medical Director and Medical Director, Clinical Development of Abbott Laboratories. Dr. Chang
holds an M.D. from Wuhan University School of Medicine, a Ph.D. from the University of Maryland Baltimore, and was a post-doctoral fellow at Johns Hopkins University School of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bastian Dehmel, M.D.</I>, 52, has served as the Chief Development Officer of Oculis since January 2022. Previously, from October 2017 to December 2021, Dr.
Dehmel served as the Chief Medical Officer of OxThera AB. Before that, from 2006 to July 2017, Dr. Dehmel held roles of increasing responsibility at Amgen, including as Senior Medical Manager, as International Medical Director, as Clinical Research
Medical Director, and most recently, from December 2013 to July 2017, Dr. Dehmel served as Global Development Executive Medical Director of Amgen. Prior to that, from 2005 to 2006, Dr. Dehmel served as International Medical Advisor of NovoNordisk.
Before that, from 2003 to 2005, Dr. Dehmel served as Medical Advisor Diabetes of GlaxoSmithKline Germany. Dr. Dehmel holds a Doctor of Medicine (M.D.) from Free University Berlin Medical School and received his clinical training in Internal Medicine
at Charit&#233; University in Berlin, Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Webb Ding,</I> 52, has served as the General Manager, China of Oculis since February 2022. Previously,
from&nbsp;April&nbsp;2015 to February 2022, Mr. Ding served as China President of Fresenius Kabi. Prior to that, from&nbsp;June 2004 to March 2015, Mr. Ding held roles of increasing responsibility at Novartis China, including as the Head of Sales,
as Senior Vice President and General Manager North China and Business Unit Head, and most recently, from April 2012 to March 2015, Mr. Ding served as China President of Novartis Vaccines and Diagnostics. Before that, Mr. Ding held various senior
commercial roles at major pharmaceutical companies in China, including Bristol Myers Squibb and Xi&#146;an Janssen (a Johnson &amp; Johnson company). Mr. Ding holds a B.Sc. in Biochemistry from Wuhan University and an EMBA from China Europe
International Business School. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-Employee Directors </I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anthony Rosenberg,</I> 69, has served as Chairman of the board of directors of Oculis since April 2018. Since April&nbsp;2015, Mr. Rosenberg has served as
the Chief Executive Officer of TR Advisory Services GmbH. Additionally, from April 2015 to April 2020, Mr. Rosenberg served as a Managing Director of MPM Capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prior to that, from 2005 to 2012, Mr. Rosenberg held a series of business development and licensing positions of increasing seniority at Novartis, and most recently, from 2012 to 2015, Mr.
Rosenberg served as the Corporate Head of M&amp;A and Licensing at Novartis International AG. Mr. Rosenberg currently serves on the boards of directors of Argenx BV, SiO2 Materials Science, and Cullinan Oncology. Mr. Rosenberg previously served on
the boards of directors of TriNetX and Radius Health, Inc. Mr. Rosenberg holds a B.Sc. (Hons) from the University of Leicester and a M.Sc. in Physiology from the University of London. We believe that Mr. Rosenberg&#146;s experience in biotechnology
business development and licensing, in addition to his prior board experience in the life sciences industry, makes him well qualified to serve as a director and Chairman of the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Christina Ackermann,</I> 57, has served as Executive Vice President, General Counsel &amp; President Ophthalmic Pharmaceuticals at Bausch + Lomb since
January 2022. Ms. Ackermann joined Bausch Health as Executive Vice President, General Counsel, in August 2016. Prior to Bausch Health, Ms. Ackermann was part of the Novartis group of companies for 14 years, most recently serving as Senior Vice
President, General Counsel for Alcon, where she was responsible for the for the legal, intellectual property and compliance functions, in addition to Trade Compliance Function, Enterprise Risk Management, and Diversity &amp; Inclusion. Previously,
she served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics, and assumed the role of Head Legal General
Medicine in July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities, and mergers &amp; acquisitions.
Since August 2021, Ms. Ackermann has served on the board of directors of Graybug Vision, where she is Chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Ms. Ackermann holds a LL.B in law from
Queen&#146;s University in Ontario, Canada and a post graduate degree in EU competition law from King&#146;s College in London, England. We believe that Ms. Ackermann&#146;s experience in business, legal affairs, compliance, global security and
enterprise risk management makes her well qualified to serve as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lionel Carnot,</I> 55, has served as a member of the board of directors of
Oculis since from December 2017. Since March 2012, Mr. Carnot has served as the Partner of Earlybird Venture Capital. Additionally, since 2005, Mr.&nbsp;Carnot has served as the Managing Director of Bay City Capital LLC. Prior to that, from 2000 to
2005, Mr.&nbsp;Carnot served as an Associate of The Pritzker Organization, LLC. Before that, from 1999 to 2000, Mr.&nbsp;Carnot served as a Principal of Oracle Partners. Prior to that, from 1997 to 1998, Mr. Carnot served as a Senior Associate of
Booz Allen and Hamilton. Before that, from 1995 to 1997, Mr. Carnot served as a Product Manager of Eli Lilly &amp; Co. Prior to that, from 1991 to 1994, Mr. Carnot served as a Senior Consultant of Accenture. Before that, from 1989 to 1991, Mr.
Carnot served as a sales and marketing professional at Rhone-Poulenc. Mr.&nbsp;Carnot currently serves on the board of directors of iSTAR Medical, iQone Healthcare Group, and Priothera. Mr. Carnot previously served on the board of directors of
Atlantic Therapeutics, Merus, Interleukin Genetics, Madrigal Pharmaceuticals Inc., Nabsys, Bioseek, Pathway Diagnostics, and Reliant Pharmaceuticals. Mr. Carnot holds an MBA with Distinction from INSEAD and a M.Sc. in Molecular Biology from the
University of Geneva. We believe that Mr. Carnot is qualified to serve as a member of our board of directors due to his extensive experience in venture capital, business strategy and the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pravin Dugel, M.D.</I>, 59, is currently the President of Iveric Bio. He joined as Executive Vice President in April&nbsp;2020 and was promoted to
President of the Company in May 2021. Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California;
and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr.&nbsp;Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at
universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada and Australia. Dr. Dugel is internationally recognized as a major
clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been
elected and previously served as the Retina Subspecialty Day Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina
Specialists (ASRS), and the largest retina society in Europe, EURETINA. Dr. Dugel graduated from Columbia University in New York City. He then attended UCLA School of Medicine where he obtained his M.D. He completed his residency in ophthalmology at
the USC Eye Institute, Keck School of Medicine and completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident
Director. We believe that Dr. Dugel is qualified to serve as a member of our board of directors due to his extensive experience in ophthalmology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Martijn Kleijwegt,</I> 67, has been a member and the Chairman of the EBAC Board since EBAC&#146;s inception. Mr.&nbsp;Kleijwegt founded LSP in 1998 and is
currently a partner at EQT Life Sciences (f/k/a Life Science Partners). Mr.&nbsp;Kleijwegt brings over 30 years of hands-on finance and investment experience to EBAC. Mr.&nbsp;Kleijwegt currently serves on the boards of Vico Therapeutics, A-M Pharma
and Oxthera. Mr.&nbsp;Kleijwegt has a master&#146;s degree in Economics from Amsterdam University. We believe that Mr.&nbsp;Kleijwegt&#146;s experience in healthcare investments makes him well qualified to serve as a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Geraldine O&#146;Keeffe, </I>56<I></I>, joined LSP in 2008. She became a Partner of the firm in 2010. Ms.&nbsp;O&#146;Keeffe&#146;s prime focus and
responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies,
both in Europe and the US. Ms.&nbsp;O&#146;Keeffe brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product
development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Ms.&nbsp;O&#146;Keeffe has a Bachelor&#146;s degree in Biochemistry and
Microbiology from University College Cork and a Master&#146;s degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in
G&#246;ttingen, Germany. In addition, Ms.&nbsp;O&#146;Keeffe is also a graduate of The Dublin School of Business. We believe that Ms. O&#146;Keeffe is well qualified to serve as a member of our board of directors due to her extensive experience in
healthcare investments and the life sciences industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq listing standards require that a majority of the board of directors of New Parent be independent. The parties have undertaken a review of the
independence of the directors and considered whether any director has a material relationship with New Parent that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon
information requested from, and provided by, each director concerning such director&#146;s background, employment and affiliations, including family relationships, the parties have determined that Christina Ackermann, Lionel Carnot, Pravin Dugel,
Martijn Kleijwegt, Geraldine O&#146;Keeffe and Anthony Rosenberg are &#147;independent directors&#148; as defined under applicable Nasdaq rules and the independence requirements contemplated by <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT>
under the Exchange Act. In making these determinations, our board of directors considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with us and all other facts and circumstances
that our board of directors deemed relevant in determining the director&#146;s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Board
will be primarily responsible for the oversight of its risk management activities and has delegated to the audit committee the responsibility to assist the board of directors in this task. The audit committee will further monitors issues relating to
the supervision of accounting and financial reporting as well as the effectiveness of the internal control and risk management systems and of the design and implementation of the internal audit. While the New Parent Board will oversee risk
management, our management will be responsible for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. The New Parent Board will expect our management to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and to effectively implement risk management strategies adopted by the board of directors. We believe this division of responsibilities will be the most effective approach for addressing
the risks we face. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Practices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including New Parent, to comply
with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may follow home country practice in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent
that such exemptions would be contrary to U.S. federal securities laws. However, if the laws of a foreign private issuer&#146;s home country require that any such matter be approved by the board of directors or the shareholders, the audit
committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. Under Swiss law, the audit committee may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by the
shareholders at our annual general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we are a foreign private issuer, members of New Parent Board, our executive committee
and our executive officers and senior management are not subject to short-swing profit and insider trading reporting obligations under Section&nbsp;16 of the Exchange Act. They will, however, be subject to the obligations to report changes in share
ownership under Section&nbsp;13 of the Exchange Act and related SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent will have an audit committee, a nomination and governance committee and a remuneration committee. All of the board committees of New Parent will
operate pursuant to its articles of association, organizational regulations, the charter of the audit committee, the charter of the nomination and governance committee and the charter of the remuneration committee, to be adopted as applicable. The
composition and functioning of all of New Parent committees will comply with all applicable requirements of Swiss law, the Exchange Act, The Nasdaq Global Market and SEC rules and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee is expected to
consist of Lionel Carnot, Geraldine O&#146;Keeffe and Christina Ackermann. The audit committee will assist the board of directors in overseeing our accounting and financial reporting processes and the audits of our financial statements. Mr. Carnot
will serve as chairperson of the audit committee. In addition, the audit committee will be responsible for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. The New Parent Board
has determined that Mr.&nbsp;Carnot, Ms. O&#146;Keeffe and Ms. Ackermann satisfy the &#147;independence&#148; requirements set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3&nbsp;under</FONT> the Exchange Act and Mr. Carnot qualifies as
an &#147;audit committee financial expert,&#148; as such term is defined in the rules of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the members of our audit committee will qualify
as independent directors according to the rules and regulations of the SEC and Nasdaq with respect to audit committee membership. In addition, all of the audit committee members will meet the requirements for financial literacy under applicable SEC
and Nasdaq rules and at least one of the audit committee members will qualify as an &#147;audit committee financial expert,&#148; as such term is defined in Item <FONT STYLE="white-space:nowrap">407(d)&nbsp;of&nbsp;Regulation&nbsp;S-K.</FONT> The
audit committee will be governed by a charter that complies with applicable Nasdaq rules, which charter will be posted on our website prior to the listing of our common shares on Nasdaq. New Parent expects to adopt an audit committee charter, which
details the principal functions of the audit committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and discuss with management the annual and quarterly financial statements and reports, including earnings
press releases and financial information and earnings guidance given to analysts and rating agencies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose to the board to approve the quarterly and annual reports; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inform the board on its assessment of the financial statements and decide whether to recommend the statutory and
consolidated financial statements to the board for approval and presentation to the meeting of shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review in cooperation with the auditor and the management whether the accounting principles applied by the
company and any of its subsidiaries are appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and assess the qualifications, independence, performance and effectiveness of the auditor and recommend to
the board the nomination of the auditor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the scope of the prospective audit by the auditor, the estimated fees and any other matters pertaining to
such audit as the committee may deem appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve any proposal of audit and non-audit services to be provided by the auditor to the company to ensure
auditor independence; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and assess the auditor&#146;s report, management letters and take notice of all comments of the auditor on
accounting procedures and systems of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review with the auditors and management the auditor&#146;s reports to the committee/board on critical accounting
policies and practices used (and any changes thereto), on alternative treatments of financial information discussed with management and on other material written communication between the auditor and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review with the auditor any audit problems or difficulties and management&#146;s response, including any
restrictions on the scope of the auditor&#146;s activities or on access to requested information, and any significant disagreements with management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least annually monitor, review and discuss with the auditor and with management the adequacy and effectiveness
of the company&#146;s policies and procedures regarding internal controls over financial reporting and risk assessment and the company&#146;s compliance therewith; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitor compliance with respect to the Oculis Holding AG Code of Business Conduct and Ethics, as may be amended
from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">periodically review the company&#146;s policies and procedures for risk management and assess the effectiveness
thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">periodically review the company&#146;s policies and procedures designed to ensure compliance with laws,
regulations and internal rules and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by the company regarding
accounting, internal accounting controls or auditing matters, as well as the confidential, anonymous submission by officers, employees or directors of the company of concerns regarding questionable accounting or auditing matters;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitor compliance with respect to the Oculis Holding AG Related Person Transactions Policy, as may be amended
from time to time, and review, approve and/or ratify proposed transactions that have been identified as related person transactions thereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discuss with management and, if appropriate, the company&#146;s external advisors any legal matters (including
the status of pending or threatened litigation) that may have a material impact on the company&#146;s financial statements and any material reports or inquiries from regulatory or governmental agencies which could materially impact the
company&#146;s contingent liabilities and risks. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nomination and Governance Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nomination and governance committee is expected to consist of Christina Ackermann, Martijn Kleijwegt and Pravin Dugel. The nomination and governance
committee will assist our board of directors in identifying individuals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified to become our directors consistent with criteria established by us and in developing our code of business conduct and ethics. Ms. Ackermann will serve as chairperson of the nomination
and governance committee. The nomination and governance committee will be governed by a charter that will be posted on our website prior to the listing of our common shares on Nasdaq. New Parent expects to adopt a nomination and governance committee
charter, which details the principal functions of the nomination and governance committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and periodically review the qualification criteria for board candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the search for board candidates based on the qualification criteria established by the committee and any
other criteria that the committee may consider appropriate, and recommend suitable candidates to the board to be nominated for election by the shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">periodically review the policies and principles for corporate governance of the company, including the
organizational rules, and recommend changes, if any, to the board for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make recommendations to the board on board and committee compositions, including the board and committee
chairperson and the size of the board and the committees, taking into account the independence standards established by applicable laws, the company&#146;s articles of association, the organizational rules, the committee policies and corporate
governance principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting the search for candidates for the position of CEO of the company, and shall recommend suitable
candidates for evaluation and appointment by the board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify candidates for the election to the board on its own as well as by considering recommendations from
shareholders, other members of the board, officers and employees of the company, and other sources that the committee deems appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a process for and conduct an annual review of the performance of the board, its committees, and
individual board members in their role as members of the board or a committee of the board; and consider the results of the annual performance review when determining whether or not to recommend the nomination of a director for an additional term on
the board or a committee, and for developing proposals for improving corporate governance policies and effectiveness of the board and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare and review, at least annually, a succession plan for the directors of the board, the CEO, and the members
of the executive committee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the corporate governance report of the company for inclusion in the annual report for the approval of the
board and approve any other written public disclosures on corporate governance matters including, but not limited to, environmental, social and governance-related matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Remuneration Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remuneration committee is
expected to consist of Pravin Dugel, Geraldine O&#146;Keeffe and Lionel Carnot. The remuneration committee will assist the board of directors in determining compensation for our executive officers and our directors. Dr. Dugel will serve as
chairperson of the remuneration committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the first day of trading, we will be subject to the Swiss provisions regarding compensations for listed
companies under the Swiss Code of Obligations, which require Swiss corporations listed on a stock exchange to establish a remuneration committee. In accordance with the Swiss Code of Obligations, the members of our remuneration committee must be
elected by our general meeting of shareholders and the aggregate amount of compensation of each of our directors and our executive committee must also be approved by our general meeting of shareholders, in each case commencing with our first annual
general meeting of shareholders as a public company to be held in 2023. The New Parent Board will appoint the chair of the remuneration committee and will fill any vacancies on the remuneration committee until completion of the next annual general
meeting of shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the members of our remuneration committee will qualify as independent directors according to the
rules and regulations of the SEC and Nasdaq with respect to remuneration committee membership, including the heightened independence standards for members of a remuneration committee. The remuneration committee will be governed by a charter that
will be posted on our website prior to the listing of our common shares on Nasdaq. New Parent expects to adopt a remuneration committee charter, which details the principal functions of the remuneration committee, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare and recommend to the board for approval (i) a compensation policy for the board and (ii), if so requested
by the board, a compensation policy for the executive committee; and thereafter, annually review such policy or policies and recommend changes, if any, for approval by the board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may periodically review the company&#146;s compensation policies for its employees who are not members of the
executive committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and recommend to the board for approval any compensation and other payments to present and former
non-employee directors of the company to the extent not already provided for in the compensation policy for the board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose to the board the resolution to be submitted to the general meeting for the maximum total compensation of
the board and executive committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate annually the performance the CEO (as defined in the organizational rules) and submit such evaluation for
review and discussion by the board, in each case in executive session without the presence of the CEO; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and recommend for approval by the board the annual base salary, incentive compensation and equity
compensation of the CEO and, in consultation with the CEO, of the other members of the executive committee, and the overall compensation of the CEO and executive committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and approve any employment contracts, severance contracts, or other agreements that the company proposes
to enter into with any present, future or former members of the executive committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an incentive compensation plan providing for variable compensation of the members of the executive
committee based on the achievement of the company&#146;s corporate goals and the individuals&#146; performance, and approve any changes to such plan as may be proposed by the CEO from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve any incentive compensation plans providing for variable compensation of employees of the company
(excluding any member of the executive committee) and any changes thereto, as may be proposed by the CEO from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and periodically review equity compensation plans, and submit such plans and any changes to such plans to
the board for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and approve any perquisite benefits plans proposed by the CEO for the members of the executive committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the annual corporate goals proposed by the CEO, and recommend such goals as approved by the committee for
approval by the board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the level of achievement of the corporate goals as approved by the board upon completion of each
calendar year, and apply such achievement level to the determination of the variable compensation of the members of the executive committee in accordance with the applicable incentive compensation plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate its own performance on a periodic basis as part of the board performance assessment process;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervise the preparation of the annual compensation report and submit it to the board for approval; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the remuneration committee charter annually and submit any recommended changes to the board for approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer Compensation After the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Acquisition Closing, we expect New Parent&#146;s executive compensation program to reflect the compensation policies and philosophies of Oculis,
as they may be modified and updated from time to time. We also expect that decisions with respect to the compensation of our executive officers, including our executive officers, will be made by the remuneration committee of the New Parent Board.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation After the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nomination and governance committee has the primary responsibility for approving and evaluating <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation arrangements, which will be designed to provide competitive compensation necessary to attract and retain high quality <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Acquisition Closing, we expect the nomination and governance committee to establish a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation policy and to review director compensation periodically to ensure that director compensation remains competitive such that New Parent is able to recruit and retain qualified directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent will have
a code of business conduct and ethics (&#147;<I>Code of Conduct</I>&#148;), which is and will continue to be applicable to all of our employees, executive officers and directors. The Code of Conduct will be available on our website at
www.oculis.com. The audit committee of the New Parent Board will be responsible for overseeing the Code of Conduct and will be required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any
amendments to the Code of Conduct will be disclosed on our website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_20"></A>MANAGEMENT AND EXECUTIVE OFFICER AND DIRECTOR COMPENSATION OF
OCULIS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this section, unless otherwise stated or the context requires otherwise, the terms &#147;Oculis,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our&#148; and &#147;the Company&#148; refer to Oculis SA. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information, as of the date of this proxy
statement/prospectus, concerning the current directors, executive officers and senior management of Oculis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers (Senior Management)</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Riad Sherif, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sylvia Cheung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P&aacute;ll Ragnar J&oacute;hannesson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Strategy Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Management</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joanne Chang, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bastian Dehmel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Webb Ding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Manager, China</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Rosenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arni Bl&ouml;ndal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Florent Gros</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bart Dzikowski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rob Hopfner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Skinner Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Riad Sherif, M.D.,</I>&nbsp;54, has served as the Chief Executive Officer and Director of Oculis since December 2017. Previously, from June 2016 to
September 2017, Dr.&nbsp;Sherif served as Entrepreneur in Residence at the Novartis Venture Fund. Before that, Dr.&nbsp;Sherif served as the President of Europe, Middle East and Africa of Alcon, Inc. from March 2014 to May 2016. Prior to that, from
January&nbsp;2002 to April 2014, Dr.&nbsp;Sherif held roles of increasing responsibility at Novartis AG, including as the Global Sales Head in the Transplant and Infectious Disease unit, as the Head for Latin America in transplant and infectious
disease, as the President of the Novartis Vaccines and Diagnostics Division for Latin America, and most recently as the President of Novartis Pharmaceuticals, Canada. Prior to Novartis, Dr.&nbsp;Sherif worked for several pharmaceutical companies,
holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr.&nbsp;Sherif currently serves as a member of the board of directors of Revenio Group corporation. Dr.&nbsp;Sherif previously served as
the Vice Chairman for the Innovative Medicine Canada Association, as the Chairman of <FONT STYLE="white-space:nowrap">In-Vivo</FONT> Montreal, and as the Chairman of the Board Ophthalmic Surgery and Vision Care of Eucomed. Dr.&nbsp;Sherif is a
Medical Doctor by training, and holds an MBA from IMD Business School and a Specialized Master&#146;s Degree in Medical Management from ESCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sylvia
Cheung</I>, 48,&nbsp;has served as the Chief Financial Officer of Oculis since September 2020.&nbsp;Prior to that, from October 2005 to August 2020, Ms.&nbsp;Cheung held executive positions at Anika Therapeutics, Inc., a publicly-traded joint
preservation company. Most recently, from April 2013 to August 2020, Ms.&nbsp;Cheung served as the Chief Financial Officer of Anika Therapeutics, Inc. Previously, from 2000 to 2005, Ms.&nbsp;Cheung held a series of financial management positions of
increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Before that, from 1995 to 2000, Ms.&nbsp;Cheung served as a Senior Associate at PricewaterhouseCoopers. Ms.&nbsp;Cheung holds a Bachelor
of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as Certified Public Accountant in Massachusetts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>P&aacute;ll Ragnar J&oacute;hannesson</I>, 42,<I> </I>has served as the Chief Strategy Officer of Oculis
since September 2020. Previously, from January 2018 to September 2020, Mr.<I></I>&nbsp;J&oacute;hannesson served as the Chief Financial Officer of Oculis. Additionally, Mr.&nbsp;J&oacute;hannesson has served as the Managing Director of Oculis
Iceland ehf. since May 2015. Prior to that, from February 2012 to April 2015, Mr.&nbsp;J&oacute;hannesson held a series of corporate finance positions of increasing responsibility at Straumur Investment Bank, and most recently, from September 2013
to April 2015, Mr.&nbsp;J&oacute;hannesson served as the Managing Director, Corporate Finance. Before that, from January 2009 to November 2011, Mr.&nbsp;J&oacute;hannesson served as a Director, Corporate Finance at &Iacute;slandsbanki and its
predecessor Glitnir Bank. Mr.&nbsp;J&oacute;hannesson holds a B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil in Management Science from the University of Cambridge, and was certified as securities broker in Iceland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Senior Management</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joanne Chang, M.D., Ph.D.,
</I>62, has served as the Chief Medical Officer of Oculis since September 2021. Previously, from September 2017 to August 2021, Dr.&nbsp;Chang served as the Worldwide Medical Affairs Head Ophthalmology of Novartis. Prior to that, from January 2014
to August 2017, Dr.&nbsp;Chang served as the Head, Clinical Development&nbsp;&amp; Medical Affairs for the U.S. and Canada of Alcon. Before that, from April 2010 to December 2013, Dr.&nbsp;Chang served as the Vice President, Chief Medical Officer of
Novartis Pharma China. Prior to that, from August 2008 to March 2010, Dr.&nbsp;Chang served as Vice President, Evidence Based Medicine of Novartis, United States. Before that, from July 2000 to July 2004, Dr.&nbsp;Chang served as Executive Director,
US Health Economics, Outcomes and Reimbursement of Bayer Pharmaceuticals. Prior to that, from June 2000 to June 2004, Dr.&nbsp;Chang served as Director, HEOR, Global Strategic Marketing&nbsp;&amp; Medical Affairs of Sanofi. Before that, from July
1999 to May 2000, Dr.&nbsp;Chang served as Director, Global Health Economics of Johnson&nbsp;&amp; Johnson. Prior to that, from August 1995 to June 1999, Dr.&nbsp;Chang served as Associate Medical Director and Medical Director, Clinical Development
of Abbott Laboratories. Dr.&nbsp;Chang holds an M.D. from Wuhan University School of Medicine, a Ph.D. from the University of Maryland Baltimore, and was a post-doctoral fellow at Johns Hopkins University School of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bastian Dehmel, M.D.,</I> 52, has served as the Chief Development Officer of Oculis since January 2022. Previously, from October 2017 to December 2021,
Dr.&nbsp;Dehmel served as the Chief Medical Officer of OxThera AB. Before that, from 2006 to July 2017, Dr.&nbsp;Dehmel held roles of increasing responsibility at Amgen, including as Senior Medical Manager, as International Medical Director, as
Clinical Research Medical Director, and most recently, from December 2013 to July 2017, Dr.&nbsp;Dehmel served as Global Development Executive Medical Director of Amgen. Prior to that, from 2005 to 2006, Dr.&nbsp;Dehmel served as International
Medical Advisor of NovoNordisk. Before that, from 2003 to 2005, Dr.&nbsp;Dehmel served as Medical Advisor Diabetes of GlaxoSmithKline Germany. Dr.&nbsp;Dehmel holds a Doctor of Medicine (M.D.) from Free University Berlin Medical School and received
his clinical training in Internal Medicine at Charit&eacute; University in Berlin, Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Webb Ding</I>, 52, has served as the General Manager,
China of Oculis since February 2022. Previously, from April 2015 to February 2022, Mr.&nbsp;Ding served as China President of Fresenius Kabi. Prior to that, from June 2004 to March 2015, Mr.&nbsp;Ding held roles of increasing responsibility at
Novartis China, including as the Head of Sales, as Senior Vice President and General Manager North China and Business Unit Head, and most recently, from April 2012 to March 2015, Mr.&nbsp;Ding served as China President of Novartis Vaccines and
Diagnostics. Before that, Mr.&nbsp;Ding held various senior commercial roles at major pharmaceutical companies in China, including Bristol Myers Squibb and Xi&#146;an Janssen (a Johnson&nbsp;&amp; Johnson company). Mr.&nbsp;Ding holds a B.Sc. in
Biochemistry from Wuhan University and an EMBA from China Europe International Business School. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anthony Rosenberg</I>, 69, has served as Chairman of the board of directors of Oculis since April 2018. Since April 2015, Mr.&nbsp;Rosenberg has served as
the Chief Executive Officer of TR Advisory Services GmbH. Additionally, from April 2015 to April 2020, Mr.&nbsp;Rosenberg served as a Managing Director of MPM Capital. Prior to that, from 2005 to 2012, Mr.&nbsp;Rosenberg held a series of business
development and licensing positions of increasing seniority at Novartis, and most recently, from 2012 to 2015, Mr.&nbsp;Rosenberg served as the Corporate Head of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
M&amp;A and Licensing at Novartis International AG. Mr.&nbsp;Rosenberg currently serves on the boards of directors of Argenx BV, SiO2 Materials Science, and Cullinan Oncology. Mr.&nbsp;Rosenberg
previously served on the boards of directors of TriNetX and Radius Health, Inc. Mr.&nbsp;Rosenberg holds a B.Sc. (Hons) from the University of Leicester and a M.Sc. in Physiology from the University of London. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Arni Bl&ouml;ndal</I>, 53, has served as a member of the board of directors of Oculis since August 2016. Since February 2013, Mr.&nbsp;Bl&ouml;ndal has
served as the Founder and Managing Director of Brunnur Ventures. Prior to that, from November 2010 to February 2013, Mr.&nbsp;Bl&ouml;ndal served as the Founder and Managing Partner of Moneta. Before that, from April 2019 to November 2010,
Mr.&nbsp;Bl&ouml;ndal served as a Director, Corporate Finance of Askar Capital. Prior to that, from January 2006 to December 2008, Mr.&nbsp;Bl&ouml;ndal served as a Director, Corporate Finance of LBI hf. Before that, Mr.&nbsp;Bl&ouml;ndal served as
the Managing Director of Uppspretta Icelandic Capital Venture SA, an investment company managed by Kaupthing Bank, listed on the Luxembourg Stock Exchange. Prior to that, from November 1999 to January 2001, Mr.&nbsp;Bl&ouml;ndal served as the
Managing Director and board chairman of Bepaid UK, Ltd. Before that, from January 1998 to November 1999, Mr.&nbsp;Bl&ouml;ndal served as a Financial Analyst Treasury of Kaupthing Bank. Prior to that, Mr.&nbsp;Bl&ouml;ndal served as a Data Analyst of
Hagvangur. Mr.&nbsp;Bl&ouml;ndal currently serves as a member of the board of directors of Laki Power. Mr.&nbsp;Bl&ouml;ndal previously served on the boards of directors of DTE, Atmo Select and Ghostlamp. Mr.&nbsp;Bl&ouml;ndal holds a C.Sc. degree
in Engineering from the University of Iceland and a M.Sc. degree in Information Technology from the Technical University of Denmark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Florent Gros</I>,
54, has served as a member of the board of directors of Oculis since July 2022. Since 2022, Mr.&nbsp;Gros has served as Venture Partner Health Fund II of Earlybird Venture Capital. Additionally, since 2019, Mr.&nbsp;Gros has served as CEO and
Founder of Handl Therapeutics and as Managing Partner of Swissvention Partners GmbH, and since 2020, Mr.&nbsp;Gros has served as Chairman&nbsp;&amp; Founder of Amyl Therapeutics, CEO and founder of Priothera Ltd and director of public company Captor
Therapeutics. Before that, from 2000 to 2019, Mr.&nbsp;Gros held roles of increasing responsibility at Novartis, including as IP Head Biologics, Head IP Transactions, IP Site Head, and most recently, from 2007 to 2019, Mr.&nbsp;Gros served as
Managing Director of Novartis. Before that, from 1998 to 2000, Mr.&nbsp;Gros served as Head IP of Pasteur M&eacute;rieux Connaught. Prior to that, from 1993 to 1998, Mr.&nbsp;Gros served as Patent Attorney at Nestl&eacute;. Mr.&nbsp;Gros currently
serves as a member of the board of directors of Captor Therapeutics SA, Imcheck, and Amyl Therapeutics. Mr.&nbsp;Gros holds a B.Sc. in Biology from the University of Strasbourg, a M.Sc. in Biotechnology Engineering from ESBS, a CEIPI (IP Law) from
IUT Robert Schuman, a Master degree in Private Law from the University of Mulhouse, and an MBA from Kaufmann Fellowship. Additionally, Mr.&nbsp;Gros is a French and European qualified patent attorney. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bart Dzikowski</I>, 46, has served as a member of the board of directors of Oculis since May 2019. Since 2009, Mr.&nbsp;Dzikowski has been employed by
Novartis International AG, most recently as Managing Director, Head of Transactions&nbsp;&amp; Legal at the Novartis Venture Fund. Prior to that, from 2006 to 2009, Mr.&nbsp;Dzikowski served as a Vice-President at the Investment Banking Division of
Bank of America Merrill Lynch. Before that, from 2002 to 2006, Mr.&nbsp;Dzikowski served as an Associate at Allen&nbsp;&amp; Overy LLP. Mr.&nbsp;Dzikowski currently serves on the boards of directors of Enterprise Therapeutics Holdings Limited and
UZH Life Sciences Fund AG. Mr.&nbsp;Dzikowski previously served as a member of the board of directors of Enterprise Therapeutics Ltd. and Inflazome Ltd. Mr.&nbsp;Dzikowski holds a B.A. (Hons.) in History from Queen&#146;s University, a J.D. / B.C.L.
in Law from McGill University, and is a member of the New York State Bar. We believe that Mr.&nbsp;Dzikowski is qualified to serve as a member of our board of directors due to his extensive experience in law, transactions, venture capital, and the
life sciences industry. Mr.&nbsp;Dzikowski has notified us that he will resign from our Board immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rob Hopfner, Ph.D., </I>50,<I> </I>has served as a member of the board of directors of Oculis since January 2018. Since October 2017, Dr.&nbsp;Hopfner has
served as the Managing Partner of Pivotal bioVenture Partners. Prior to that, Dr.&nbsp;Hopfner held roles of increasing responsibility at Bay City Capital, and most recently, from October 2009 to September 2017, as the Managing Director and Partner.
Before that, from October 2003 to October 2006, Dr.&nbsp;Hopfner served as an Analyst/Associate of the Nutrition and Agribusiness Fund (NANAF). Dr.&nbsp;Hopfner currently serves on the boards of directors of Inozyme Pharma, Vaxcyte, RallyBio
Corporation, Evommune, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plexium. Dr.&nbsp;Hopfner previously served either as a member or observer of the boards of directors of Aciex Therapeutics, Civitas Therapeutics, Cydan, Dermira, Hyperion Therapeutics, Imara
Pharmaceuticals, NextWave Pharmaceuticals, Pharmakea Therapeutics, and Vtesse. Dr.&nbsp;Hopfner holds a B.Sc. in Pharmacy from the University of Saskatchewan, a Ph.D. in Pharmacology from the University of Saskatchewan, and an MBA from the
University of Chicago Booth School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Henry Skinner, Ph.D., </I>58,<I> </I>has served as a member of the board of directors of Oculis
since<I> </I>January 2019. Since March 2021, Dr.&nbsp;Skinner has served as the Chief Executive Officer of the AMR Action Fund. Prior to that, from October 2017 to March 2021, Dr.&nbsp;Skinner served as the Senior Vice President, Venture of Tekla
Capital Management LLC. Before that, from November 2008 to October 2017, Dr.&nbsp;Skinner served as the Deputy Head and Managing Director of the Novartis Venture Fund. Prior to that, from 2006 to 2008, Dr.&nbsp;Skinner served as the Executive
Director and Head Strategic Alliances, Therapeutics of the Novartis Institutes for BioMedical Research. Before that, from April 2005 to July 2006, Dr.&nbsp;Skinner served as the Chief Executive Officer of SelectX Pharmaceuticals, Inc. Before that,
Dr.&nbsp;Skinner served as the President and Chief Executive Officer of NeoGenesis Pharmaceuticals, Inc. Prior to that, from 1997 to 2003, Dr.&nbsp;Skinner held roles of increasing responsibility at Pfizer, including as a Director Technology
Acquisitions and Senior Director. Before that, from 1995 to 1997, Dr.&nbsp;Skinner served as a Director Business Development of Lexicon Genetics. Dr.&nbsp;Skinner holds a B.S. and a M.S. in Biology / Biotechnology from Worcester Polytechnic
Institute, a M.S. in Biochemistry and a Ph.D. in Microbiology from the University of Illinois, and a M. Jur. in Health Care Law and Policy from Texas A&amp;M University. Dr.&nbsp;Skinner was a postdoctoral fellow at Baylor College of Medicine in the
department of Human and Molecular Genetics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive officers compensation overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, our executive compensation program has reflected our innovative growth and development-oriented&nbsp;corporate culture. To date, the compensation
of our Chief Executive Officer and our other executive officers has consisted of a combination of base salary, bonuses and long-term&nbsp;incentive compensation in the form of restricted common stock awards and/or stock options. Our executive
officers who are full-time&nbsp;employees, like all other full-time&nbsp;employees, are participants in applicable retirement plans in the jurisdiction in which they reside. As we transition from a private company to a publicly traded company, we
will evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances merit. At a minimum, we expect to review executive compensation periodically with input from a third-party compensation consultant. As part
of this review process, we expect the board of directors and the remuneration committee to apply our values and philosophy, while considering the compensation levels needed to ensure our executive compensation program remains competitive with our
peers. In connection with our executive compensation program, we will also review whether we are meeting our retention objectives and the potential cost of replacing a key employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our executive officers. Base salaries are reviewed
annually, typically in connection with our annual performance review process, and adjusted from time to time to align salaries with market levels after taking into account individual responsibilities, performance and experience. In addition, our
executives are entitled to annual cash bonuses for their performance over the fiscal year, based on goals established by our board of directors. Furthermore, we have a formal process with respect to the grant of equity incentive awards to our
employees, including our executive officers. We believe that equity incentive awards provide our employees with a strong link to our long-term&nbsp;performance, create an ownership culture and help to align the interests of our employees, including
our executive officers, and our stockholders. In addition, we believe that equity incentive awards with time-based&nbsp;vesting features promote employee retention because this feature incentivizes our employees, including our executive officers, to
remain in our employment during the vesting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director compensation overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors adopted a board of directors&#146; compensation policy that is designed to enable us to attract and retain, on a long-term&nbsp;basis,
highly qualified <FONT STYLE="white-space:nowrap">non-employee&nbsp;directors.</FONT> Under the policy, each director who is not an investor director (as defined in the Oculis Shareholders Agreement, as amended from time to time) is paid annual cash
retainers, as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Cash Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strategy Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strategy Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each eligible director elected or appointed to our board of directors is eligible to participate in the Stock
Option and Incentive Plan Regulation 2018 of the Company (the &#147;<I>2018 Plan</I>&#148;), subject to its terms and conditions as approved and amended by our board of directors from time to time. Upon joining the Company, the Company issues to
eligible directors a onetime equity incentive award in the form of stock option or similar awards under the 2018 Plan or other equity incentive plans then in effect. The onetime equity incentive award for an eligible director joining the Company is
typically a number of shares of the Company equal to 0.50% of fully diluted outstanding shares of the Company for the chair of our board of directors and a number of shares of the Company equal to 0.25% of fully diluted outstanding shares of the
Company for a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eligible directors are not eligible to any benefits other than those set out in the directors
compensation policy, unless our board of directors decides otherwise. The Company reimburses all reasonable expenses in accordance with the terms and conditions of the Company&#146;s travel and expense policy then in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
year ended December&nbsp;31, 2022, the aggregate compensation paid and accrued to the members of our board of directors and our executive officers for services in all capacities was CHF 2.1 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, fees, salaries and other short-term employee benefits paid and accrued to the members of our board of directors and
our executive officers was CHF 1.8 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount contributed by us to provide post-employment benefits to executive officers amounted to a total of
CHF 0.2 million for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, 110,468 options to purchase registered ordinary
shares were granted to members of our board of directors and our executive officers for a total fair value of CHF 210 thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2022, share-based compensation expense incurred for the members of our board of directors and our executive officers accounted for CHF 144 thousand. See Note&nbsp;12 to our audited consolidated financial statements included
elsewhere in this prospectus for further details regarding the share options and restricted stock, including the exercise price and the expiration date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee benefit and equity compensation plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option and Incentive Plan Regulation 2023</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pursuant and in compliance with Section 9.07 of the Business Combination Agreement, New Parent will issue and adopt a new employee equity incentive plan
which is summarized below.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stock Option and Incentive Plan Regulation 2023 (the &#147;2023 Plan&#148;) is expected be approved by
our board of directors on or around the Acquisition Closing Date and provides for the grant of options, restricted stock awards or units or stock appreciation rights to acquire the New Parent Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2023 Plan is to attract and retain highly qualified personnel and to provide key employees with additional incentive to
increase their efforts on behalf and in the best interest of New Parent and its subsidiaries by giving them the opportunity to acquire a proprietary interest in New Parent as an incentive for them to remain in the service of New Parent. The terms of
the 2023 Plan are described in more detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Plan shall be administered by a plan administrator (one or several persons)
elected by our board of directors from time to time. The plan administrator acts within the guidelines set and approved by our board of directors or a committee thereof and is authorized to, among others, (i) determine the eligible persons who may
receive equity awards under the 2023 Plan (the &#147;Participants&#148;), (ii) determine the allocation of awards to all eligible Participants, (iii) determine the exercise price and the term of each equity award, and (iv) establish such rules and
regulations deemed to be appropriate and proper for the administration of the 2023 Plan, in each case, subject to the guidelines set and approved by our board of directors or a committee thereof. Persons eligible to participate in our 2023 Plan are
employees and consultants of New Parent or a subsidiary. The plan administrator determines within the guidelines set and approved by our board of directors or a committee which eligible persons are to receive rights to acquire options under the 2023
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan provides for up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common
shares corresponding to 16% of the New Parent Shares on a fully diluted basis at the Acquisition Closing Date. In the event Shares that otherwise would have been issuable under the 2023 Plan are withheld by New Parent in payment of the exercise
price or withholding obligations, or in the event any other outstanding award for any reason expires or is cancelled, forfeited or terminated, such New Parent Shares shall remain available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Optionee may only exercise an option to the extent that the option has become vested and has not lapsed under the 2023 Plan. Unless
otherwise determined by our board of directors at the grant date or set forth in the grant notice, options granted under the 2023 Plan typically vest as to 25% of the award at the end of the first year following the vesting start date, with the
remaining 75% of the award vesting monthly ratably over the 3 years after the first year following the vesting start date. Generally, any award not vested upon receipt of a notice of termination of the relevant legal relationship shall immediately
lapse. The 2023 Plan provides the Board with the discretion to foresee in the grant notice that either upon the occurrence of a &#147;Corporate Transaction&#148; itself (as defined in the 2023 Plan ), or an &#147;Involuntary Termination&#148; (as
defined in the 2023 Plan) following within 18 months after a Corporate Transaction, all options and restricted stock fully vest and may be immediately exercised. The 2023 Plan further permits the award of restricted stock to certain employees,
whereby at the time of cessation of service by such shareholder or New Parent (for any reason), New Parent or its assignee (to the extent permissible under applicable securities law qualification) has the right to repurchase all or part of any
restricted stock held by such shareholder. The plan administrator determines the period during which the shares issued upon exercise of options will remain restricted stock and the repurchase price which shall correspond at least to the exercise
price plus 5% per each year (or if less, the fair market value as of the date of repurchase). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has complete and
exclusive power and authority to amend or modify the 2023 Plan in any or all respects, provided that no such amendment or modification, without the consent of the concerned Optionee, adversely affect the rights and obligations of any outstanding
options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option and Incentive Plan Regulation 2018 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of our 2018 Plan, which as noted in this summary, will terminate at or prior to the Effective Time and contingent on the Acquisition
Closing, following which no further awards will be granted under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 Plan was approved and adopted by our board of directors in June
2018. Under our 2018 Plan, the maximum number of our common shares, which may be issued, is determined by our board of directors, which number is subject to adjustment in the event of a share split, share dividend, recapitalization, combination of
share, exchange of share or other similar change in our capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 Plan has been administered by a plan administrator (one or several
persons) elected by our board of directors from time to time. The plan administrator acts within the guidelines set and approved by our board of directors or a committee thereof and is authorized to, among others, (i)&nbsp;determine the eligible
persons who may receive equity awards under the 2018 Plan, (ii)&nbsp;determine the allocation of awards to all eligible optionees, including the chief executive officer and the senior management, (iii)&nbsp;determine the exercise price and the term
of each equity award, and (iv)&nbsp;establish such rules and regulations deemed to be appropriate and proper for the administration of the 2018 Plan, in each case, subject to the guidelines set and approved by our board of directors or a committee
thereof. Persons eligible to participate in our 2018 Plan are employees and consultants of the Company or a subsidiary, and members of the board of directors of the Company or a subsidiary. The plan administrator determines within the guidelines set
and approved by our board of directors or a committee which eligible persons are to receive rights to acquire options under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An optionee
may only exercise an option to the extent that the option has become vested and has not lapsed under the 2018 Plan. Unless otherwise determined by our board of directors at the grant date or set forth in the grant notice, options granted under the
2018 Plan typically vest as to 25% of the award at the end of the first year following the vesting start date, with the remaining 75% of the award vesting monthly ratably over the 36 months after the first year following the vesting start date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An optionee may only exercise any options after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period provided in the grant notice. In
addition, the 2018 Plan permits the award of restricted stock to certain employees, whereby at the time of cessation of service by such shareholder or the Company (for any reason), the Company or its assignee (to the extent permissible under
applicable securities law qualification) has the right to repurchase all or part of any restricted stock held by such shareholder. The plan administrator determines the period during which the shares issued upon exercise of options will remain
restricted stock, as well as the repurchase price. The 2018 Plan provides that upon the occurrence of a &#147;Corporate Transaction,&#148; as defined in the 2018 Plan, all options will fully vest and may be immediately exercised, except if such
options are repurchased by the Company or a third party designated by the Company for a cash consideration equivalent to the economic value applicable to such option under the 2018 Plan. At the Acquisition Closing, all outstanding options will
terminate and cease to be outstanding. The Company at the sole discretion of the plan administrator may compensate optionees for the economic value of their options terminated in connection with the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has complete and exclusive power and authority to amend or modify the 2018 Plan in any or all respects, provided that no such amendment
or modification, without the consent of the concerned optionee, adversely affect the rights and obligations of any outstanding options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No awards may be
granted under the 2018 Plan after the date that is ten years from the date our 2018 Plan was adopted by the board of directors. As of September&nbsp;30, 2022, 1,543,628 options to purchase shares of common stock were outstanding under the 2018 Plan.
The 2018 Plan will terminate at or prior to the Effective Time and contingent on the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent will establish a 2022 employee
equity incentive plan. Information about the plan will be disclosed in a subsequent filing prior to the Acquisition Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pensions and other post-employment benefit plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain post-employment benefit plans that provide our employees with an opportunity to save for retirement on a tax advantaged basis. New Parent&#146;s
Swiss entity is affiliated to a collective foundation administrating the pension plans of various unrelated employers. In addition, a customary Swiss pension plan is&nbsp;in place for eligible employees, in compliance with the requirements of
applicable laws. New Parent&#146;s Icelandic entity makes contributions to pension funds selected by our employees according to applicable laws. For New Parent&#146;s U.S. entity, we have adopted a 401(k) defined contribution plan. For New
Parent&#146;s entities in France and Hong Kong, we have adopted relevant local pension plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_21"></A>DESCRIPTION OF NEW PARENT SECURITIES AND PROPOSED ARTICLES OF
ASSOCIATION </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section of the proxy statement/prospectus includes a description of the material terms of the Proposed Articles of Association
and of applicable Swiss law. The following description is intended as a summary only and does not constitute legal advice regarding those matters and should not be regarded as such. The description is qualified in its entirety by reference to the
complete text of the Proposed Articles of Association, which are attached as <U>Annex B</U> to this proxy statement/prospectus. You are urged to read the full text of the Proposed Articles of Association. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of the material terms of the securities of New Parent following the Business Combination includes a summary of specified
provisions of the Proposed Articles of Association that will be in effect upon completion of the transactions. This description is qualified by reference to the Proposed Articles of Association as will be in effect upon completion of the
transactions, which will be substantially in the form attached to this proxy statement/prospectus as <U>Annex B</U> and which is incorporated in this proxy statement/prospectus by reference. References in this section to &#147;we,&#148;
&#147;us&#148; or &#147;New Parent&#148; refer to Oculis Holding AG and references to the &#147;Board&#148; refer to the board of directors of Oculis Holding AG. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent was incorporated as a stock
corporation (<I>Aktiengesellschaft</I>) organized under the laws of Switzerland in accordance with articles 620 et seqq. of the CO and registered with the Commercial Register of the Canton of Zug on October&nbsp;31, 2022. New Parent has its
corporate legal headquarters at Bahnhofstrasse 7, 6300 Zug, Switzerland and is expected to move its headquarters after Closing to EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne,
Switzerland. Neither the Proposed Articles of Association nor the operation of law limit the duration of New Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure of the New
Parent </B></P> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued Share Capital </I></B></P> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately
prior to the Business Combination, New Parent&#146;s share capital was CHF&nbsp;100,000 divided into 10,000,000 <FONT STYLE="white-space:nowrap">fully&nbsp;paid-in&nbsp;registered</FONT> shares with a nominal value of CHF&nbsp;0.01 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the context of the Business Combination, New Parent is expected to increase its share capital as follows: </P>
<P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An extraordinary general meeting of the shareholders of New Parent will be held on the date of the Acquisition
Closing to resolve to increase New Parent&#146;s share capital against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">contribution-in-kind</FONT></FONT> of Surviving EBAC Shares by issuing 22,001,871 New Parent Shares to the
Exchange Agent (acting in its own name, but for the account of the holders of Surviving EBAC Shares, including the PIPE Investors) and to increase New Parent&#146;s share capital against <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">contribution-in-kind</FONT></FONT> of Company Share Capital by issuing 20,348,322 New Parent Shares to Oculis Shareholders (the capital increases together the &#147;<I>New Parent Share Capital Increase</I>&#148;). In
addition, at the extraordinary general meeting of the shareholders, New Parent is expected to resolve to adopt the Proposed Articles of Association with provisions relating to conditional share capital and a capital band (<I>Kapitalband</I>)
effective as of completion of the New Parent Share Capital Increase as well as provisions related to the listing of New Parent Shares on the Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The New Parent Board will issue its board report in relation to the New Parent Share Capital Increase as
required under Swiss law and a licensed audit expert will issue its verification report as required under Swiss law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The New Parent Board will resolve the ascertainment and execution of the New Parent Share Capital Increase as
required under Swiss law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The New Parent Board will file the New Parent Share Capital Increase and the documentation required to be filed
in connection therewith for approval and registration with the Commercial Register of the Canton of Zug. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following registration of the New Parent Share Capital Increase with the Commercial Register of the Canton of
Zug, the capital increase will have been completed and the New Parent Shares referred to above will have been issued. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately
following registration of the New Parent Share Capital Increase in the Commercial Register of the Canton of Zug, New Parent&#146;s share capital will amount to CHF&nbsp;476,171.93 (assuming no redemptions by EBAC Shareholders) divided into
47,617,193 New Parent Shares, <FONT STYLE="white-space:nowrap">fully&nbsp;paid-up.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Classes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Business Combination, the Proposed Articles of Association will provide for one class of New Parent Shares with a nominal value of CHF 0.01 each.
Each New Parent Share will carry one vote in general meetings of New Parent, and the New Parent Shares will be listed on the Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Capital
Increases (General) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, New Parent may increase its share capital and issue new shares through an ordinary capital increase, an
increase by capital band (<I>Kapitalband</I>) or a conditional capital increase (<I>Bedingte Kapitalerh&ouml;hung</I>). In each case, the issue price for each share may not be less than the nominal value of the newly issued share. An ordinary
capital increase is approved at a general meeting of shareholders. The required vote is generally the approval of simple majority of the votes cast at the general meeting of shareholders. At
<FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the represented share votes and the absolute majority of the represented nominal value of the shares present in person or represented by proxy is required for capital increases
against New Parent&#146;s equity, against contributions in kind, for the purposes of acquiring assets or the granting of special benefits, or for capital increases where the <FONT STYLE="white-space:nowrap">pre-emptive/subscription</FONT> rights of
shareholders are limited or excluded. The amount by which the capital can be increased in an ordinary capital increase is unlimited, provided that sufficient contributions are made to cover the capital increase. An ordinary capital increase that has
been approved by the shareholders must be executed within six months of shareholder approval. In an ordinary capital increase, holders of New Parent Shares have <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights to obtain newly issued shares
in an amount proportional to the nominal value of the shares they already hold, unless such rights are excluded in accordance with Swiss law. For further details on these circumstances, please see the section entitled &#147;&#151;<I><FONT
STYLE="white-space:nowrap">Pre-emptive</FONT></I><I></I><I>&nbsp;Rights and Advance Subscription Rights</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shareholders of New Parent can
further authorize the New Parent Board by way of an amendment of the Proposed Articles of Association to increase or decrease the share capital within a capital band in an amount not to exceed 50% of the share capital registered in the commercial
register for a period of five years without further shareholder approval. To create a capital band, a resolution of the general meeting of shareholders passed by a supermajority of at
<FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the represented share votes and the absolute majority of the represented nominal value of the shares present in person or represented by proxy is required. Additional information
regarding capital band is set forth below in the section entitled &#147;&#151;<I>Capital band</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, conditional share capital is
used to issue new shares in the context of employee benefit and incentive plans, debt instruments with conversion rights or warrants granted to creditors or options and warrants issued to third parties. To create conditional capital, a resolution of
the general meeting of shareholders passed by a supermajority of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the represented share votes and the absolute majority of the represented nominal value of the shares present in
person or represented by proxy is required. The requirements for a conditional capital increase are set forth below in the section entitled &#147;&#151;<I>Conditional Share Capital</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital band </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles of Association, the New Parent Board is authorized to increase the share capital, at any time until 2028 at the latest, by a
maximum amount of CHF 238,085.96 (assuming no redemptions by EBAC Shareholders, such number not to exceed 50% of issued share capital) by issuing a maximum of 23,808,596 fully <FONT STYLE="white-space:nowrap">paid-up</FONT> shares with a nominal
value of CHF&nbsp;0.01 each (New Parent Shares). Such increase of the share capital (i)&nbsp;by means of an offering underwritten by a financial institution, a syndicate of financial institutions or another third party or third parties, followed by
an offer to the then-existing shareholders of the New Parent, and (ii)&nbsp;in partial amounts, are permissible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Board may determine the
time of the issuance, the issue price, the manner in which the new shares have to be paid up, the date from which the shares carry the right to dividends, the conditions for the exercise of
<FONT STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> and the allotment <FONT STYLE="white-space:nowrap">of&nbsp;pre-emptive&nbsp;rights</FONT> that have not been exercised. The New Parent Board may allow <FONT
STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> that have not been exercised to expire, or it may place such shares or <FONT STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> of which have not been exercised, at
market conditions or use them otherwise in the interest of New Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Board is authorized to withdraw or limit <FONT
STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> of the shareholders with respect to the shares to be issued under the capital band and to allot them to individual shareholders or third parties: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the issue price of the new registered shares is determined by reference to the market price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the acquisition of an enterprise, part of an enterprise or participations, or for the financing or
refinancing of any of such acquisition, or in the event of share placement for the financing or refinancing of such placement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for purposes of broadening the shareholder constituency of New Parent in certain financial or investor markets,
for purposes of the participation of strategic partners, or in connection with the listing or registration of new registered shares on domestic or foreign stock exchanges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for purposes of granting an over-allotment option (Greenshoe) or an option to subscribe additional shares to
the respective initial purchaser(s) or underwriter(s) in a placement or sale of registered shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for raising of capital (including private placements) in a fast and flexible way, which probably could not be
reached without the exclusion of the statutory <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right of the existing shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for other valid grounds in the sense of article 652b para. 2 CO; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess
of 15% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the New Parent Board, or for the defense of an actual, threatened or potential takeover bid, in
relation to which the New Parent Board, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the New Parent Board has not found the takeover bid to be
financially fair to the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorization to withdraw or limit
<FONT STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> is limited to the above listed items and exclusively linked to the particular available capital band (<I>Kapitalband</I>) set out in the Proposed Articles of Association. If
the period to increase New Parent&#146;s share capital within the capital band lapses without having been used by the New Parent Board, the authorization to withdraw or to limit
<FONT STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> lapses simultaneously with such capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conditional Share Capital
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital in Connection with Employee Benefit Plans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles of Association, the share capital of New Parent may be increased by an amount not exceeding CHF&nbsp;99,086,64 (assuming no
redemptions by EBAC Shareholders) through the issue of a maximum of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
9,908,664 fully paid up registered shares, each with a nominal value of CHF&nbsp;0.01 (New Parent Shares), in connection with the exercise of option rights or other equity-linked instruments
granted to any employee of New Parent or a subsidiary, and any consultant, members of the New Parent Board, or other person providing services to New Parent or a subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; subscription rights are excluded with regard to these shares. These new registered shares may be issued at a price below the current market
price. The New Parent Board shall determine the other conditions of issue including the issue price of the New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional Share
Capital for new Bonds and Similar Debt Instruments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles of Association, the share capital of New Parent may be increased by an
amount not exceeding CHF 50,000 through the issuance from time to time of a maximum of 5,000,000 fully paid up registered shares, each with a par value of CHF 0.01 (New Parent Shares), in connection with the exercise of convertible rights and/or
option rights or warrants, which have been granted or will be granted in connection with new bonds and similar debt instruments, including convertible loans of Oculis which are issued prior to the date of the Business Combination in accordance with
the Convertible Loan Agreements, that have been or will be issued by New Parent or its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; advance subscription rights and
subscription rights are excluded with regard to the new registered shares. These new registered shares may be issued at a price below the current market price. The New Parent Board shall determine the other conditions of issue including the issue
price of the New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital for EBAC Public Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles of Association, the share capital of New Parent may be increased by an amount not exceeding CHF 44,032.94 through the issuance,
from time to time, of a maximum of 4,403,294 fully paid up registered shares, each with a par value of CHF 0.01 (New Parent Shares), in connection with the exercise of warrants granted through the exercise of conversion and/or option rights, which
were assumed from, and allocated by, EBAC, on the basis of the Warrant Assumption Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; advance subscription rights and
subscription rights are excluded with regard to the new registered shares. These new registered shares may be issued at a price below the current market price. The New Parent Board shall determine the other conditions of issue including the issue
price of the New Parent Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participation Certificates and Profit-sharing Certificates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, New Parent has neither participation certificates (<I>Partizipationsscheine</I>) nor profit-sharing
certificates (<I>Genussscheine</I>) outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treasury Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, New Parent may hold New Parent Shares in treasury and may consider issuing additional New Parent Shares to
the Exchange Agent during the Capital Increase. Such newly issued New Parent Shares shall be transferred to New Parent for free at the Closing, becoming treasury shares. Under Swiss law, a stock company may only hold 10% of its own shares in
treasury and up to 20% under special circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-emptive&nbsp;Rights</FONT> and Advance Subscription Rights
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law provides that any share issue, whether for cash <FONT STYLE="white-space:nowrap">or&nbsp;non-cash&nbsp;consideration,</FONT> is subject to
the prior approval at a general meeting of shareholders. Shareholders are granted <FONT STYLE="white-space:nowrap">certain&nbsp;pre-emptive&nbsp;rights</FONT> (<I>Bezugsrechte</I>) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to subscribe for new issues of shares and advance subscription rights (<I>Vorwegzeichnungsrechte</I>) to subscribe for warrants, convertible bonds or similar debt instruments with option rights
in proportion to the nominal amount of shares held. Pursuant to the Proposed Articles of Association, a resolution adopted at a general meeting by a majority <FONT STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the votes represented at
the meeting is required to repeal, limit or suspend pre-emptive rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each EBAC Warrant outstanding immediately prior to the First Merger Effective Time will, at the First Merger Effective Time, be automatically converted into
Surviving EBAC Warrants and such Surviving EBAC Warrants will be deposited with the Exchange Agent in exchange for the right of each holder of EBAC Warrants to receive New Parent Warrants, on the terms, and subject to the conditions of, the Warrant
Assumption Agreement. Each such EBAC Warrant outstanding will be assumed by New Parent pursuant to the Warrant Assumption Agreement on substantially the same terms as were in effect immediately prior to the First Merger Effective Time under the
Existing Warrant Agreement. The following is a description of the New Parent Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Parent Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each whole New Parent Warrant entitles the registered holder to purchase one New Parent Share at a price of $11.50 per share, subject to adjustment as
discussed below, exercisable at any time commencing 30&nbsp;days after the completion of the Business Combination, provided that New Parent has an effective registration statement under the Securities Act covering the issuance of the New Parent
Shares issuable upon exercise of the New Parent Warrants. Pursuant to the Warrant Assumption Agreement, a warrant holder may exercise its New Parent Warrants only for a whole number of New Parent Shares. This means only a whole public warrant may be
exercised at a given time by a New Parent Warrant holder. No fractional New Parent Warrants will be issued upon separation of the units and only whole New Parent Warrants will trade. The&nbsp;New Parent Warrants will expire five years after the
completion of the Business Combination, at 5:00 p.m. Eastern Time, or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent will not be obligated to deliver
any New Parent Shares pursuant to the exercise of a&nbsp;warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the New Parent Shares issuable upon
exercise of the New Parent Warrants is then effective and a current prospectus relating thereto is current, subject to New Parent satisfying its obligations described below with respect to registration, or a valid exemption from registration is
available, including in connection with a cashless exercise permitted as a result of a notice of redemption described below under the section entitled &#147;<I>Redemption of warrants when the price per New Parent Share equals or exceeds
$10.00.</I>&#148; No New Parent Warrant will be exercisable for cash or on a cashless basis, and New Parent will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise
is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a New Parent
Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent has
agreed that as soon as practicable, but in no event later than 20 business days, after the completion of the Business Combination, New Parent will use its commercially reasonable efforts to file with the SEC a registration statement covering the
issuance, under the Securities Act, of the New Parent Shares issuable upon exercise of the New Parent Warrants, and New Parent will use its commercially reasonable efforts to cause the same to become effective within 60 business days, and to
maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the New Parent Warrants in accordance with the provisions of the Warrant Assumption Agreement. Notwithstanding the above,
if the New Parent Shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, New
Parent may, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at its option, require holders of New Parent Warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in
the event New Parent so elects, New Parent will not be required to file or maintain in effect a registration statement, but will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an
exemption is not available. In such event, each holder would pay the exercise price by surrendering the New Parent Warrants for that number of New Parent Shares equal to the lesser of (i)&nbsp;the quotient obtained by dividing (A)&nbsp;the product
of the number of New Parent Shares underlying the New Parent Warrants,<I>&nbsp;multiplied</I>&nbsp;by the excess of the &#147;fair market value&#148; (defined below)&nbsp;less the exercise price of the warrants by (B)&nbsp;the fair market value and
(ii) 0.361. The &#147;<I>fair market value</I>&#148; as used in this proxy statement/prospectus shall mean the volume weighted average price of the New Parent Shares for the 10 trading days ending on the trading day prior to the date on which the
notice of exercise is received by the warrant agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent will not redeem the New Parent Warrants as described above unless a registration
statement under the Securities Act covering the issuance of the New Parent Shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those New Parent Shares is available throughout the 30-day redemption
period. If and when the New Parent Warrants become redeemable by New Parent, New Parent may exercise its redemption right even if New Parent is unable to register or qualify the underlying securities for sale under all applicable state securities
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent has established the last of the redemption criterion discussed above to prevent a redemption call unless there is, at the time of the
call, a significant premium to the New Parent Warrant exercise price. If the foregoing conditions are satisfied and New Parent issues a notice of redemption of the New Parent Warrants, each warrant holder will be entitled to exercise his, her or its
warrants prior to the scheduled redemption date. However, the price of the New Parent Shares may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a
New Parent Warrant as described under the heading &#147;<I>&#151;Redeemable Warrants&#151;Public Shareholders&#146; Warrants</I><I></I><I>&#151;Anti-dilution</I><I></I><I> Adjustments</I>&#148;) as well as the $11.50 (for whole shares) warrant
exercise price after the redemption notice is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of New Parent Warrants when the price per New Parent Share equals or exceeds
$10.00.</I> Once the warrants become exercisable, New Parent may redeem the outstanding New Parent Warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30&nbsp;days&#146; prior written notice of redemption provided that
holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the &#147;fair market value&#148; of the New Parent Shares, except as otherwise described
below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for adjustments to the
number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;&#151;<I>Redeemable Warrants</I><I></I><I>&#151;Public Shareholders&#146;
Warrants</I><I></I><I>&#151;Anti-dilution</I><I></I><I>&nbsp;Adjustments</I>&#148;) for any 20 trading days within the <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending three trading days before we send the notice of redemption to
the warrant holders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for adjustments to the number of shares
issuable upon exercise or the exercise price of a warrant, as described under the heading &#147;&#151;<I>Redeemable Warrants</I><I></I><I>&#151;Public Shareholders&#146;
Warrants</I><I></I><I>&#151;Anti-dilution</I><I></I><I>&nbsp;Adjustments</I>&#148;) the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding New Parent Warrants, as described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period beginning on the date the notice of redemption is given, holders may elect to exercise their New Parent Warrants on a
cashless basis. The numbers in the table below represent the number of New Parent Shares that a warrant holder will receive upon such cashless exercise in connection with a redemption by New Parent pursuant to this redemption feature based on the
&#147;fair market value&#148; of the New Parent Shares on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined for these purposes based on volume weighted
average price of the New Parent Shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption is sent to the holders
of warrants, each as set forth in the table below. New Parent will provide its warrant holders with the final fair market value no later than one business day after the <FONT STYLE="white-space:nowrap">10-trading</FONT> day period described above
ends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of New Parent Warrants when the price per New Parent Share equals or exceeds $18.00.</I> Once the New Parent Warrants become
exercisable, New Parent may redeem the warrants (except as described herein with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30&nbsp;days&#146; prior written notice of redemption to each warrant holder; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of the New Parent Shares for any 20 trading days within <FONT
STYLE="white-space:nowrap">a&nbsp;30-trading&nbsp;day&nbsp;period</FONT> ending on the third trading day prior to the date on which New Parent sends the notice of redemption to the warrant holders (such price, the &#147;<I>Reference Value</I>&#148;)
equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;&#151;<I>Redeemable Warrants</I><I></I><I>&#151;Public
Shareholders&#146; Warrants</I><I></I><I>&#151;Anti-dilution</I><I></I><I>&nbsp;Adjustments</I>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This redemption feature is structured to allow for all of the outstanding New Parent Warrants to be redeemed
when the New Parent Shares are trading at or above $10.00 per share, which may be at a time when the trading price of the New Parent Shares is below the exercise price of the warrants. New Parent has established this redemption feature to provide
itself with the flexibility to redeem the New Parent Warrants without the New Parent Warrants having to reach the $18.00 per share threshold set forth above under the heading &#147;&#151;<I>Redemption of New Parent Warrants when the price per New
Parent Share equals or exceeds $18.00</I>.&#148; Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model
with a fixed volatility input as of the date of this proxy statement/prospectus. This redemption right provides New Parent with an additional mechanism by which to redeem all of the outstanding New Parent Warrants, and therefore have certainty as to
New Parent&#146;s capital structure as the warrants would no longer be outstanding and would have been exercised or redeemed. New Parent will be required to pay the applicable redemption price to warrant holders if New Parent chooses to exercise
this redemption right and it will allow New Parent to quickly proceed with a redemption of the New Parent Warrants if New Parent determines it is in its best interest to do so. As such, New Parent would redeem the New Parent Warrants in this manner
when New Parent believes it is in its best interest to update its capital structure to remove the New Parent Warrants and pay the redemption price to the warrant holders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redemption Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value of Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(period to expiration of warrants)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&#8804;<B></B><B>$10.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$11.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$12.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$13.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$14.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$15.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$16.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$17.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&#8805;<B></B><B>$18.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated above, New Parent can redeem the New Parent Warrants when the New Parent Shares are trading at a price starting at
$10.00, which is below the exercise price of $11.50, because it will provide certainty with respect to its capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for
the applicable number of shares. If New Parent chooses to redeem the New Parent Warrants when the New Parent Shares are trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer New Parent
Shares than they would have received if they had chosen to exercise their warrants for New Parent Shares if and when such New Parent Shares were trading at a price higher than the exercise price of $11.50. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional New Parent Shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, New
Parent will round down to the nearest whole number of the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New Parent Shares to be issued to the holder. If, at the time of redemption, the New Parent Warrants are exercisable for a security other than the New Parent Shares pursuant to the Warrant
Assumption Agreement (for instance, if New Parent is not the surviving company after completion of a business combination), the warrants may be exercised for such security. At such time as the New Parent Warrants become exercisable for a security
other than the New Parent Shares, New Parent (or the surviving company, as applicable) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption Procedures</I>. A holder of a New Parent Warrant may notify New Parent in writing in the event it elects to be subject to a requirement that
such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#146;s affiliates), to the warrant agent&#146;s actual knowledge, would beneficially own in
excess of 9.8% (or such other amount as a holder may specify) of the New Parent Shares issued and outstanding immediately after giving effect to such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution</I><I></I><I>&nbsp;Adjustments</I>. If the number of issued and outstanding New Parent Shares is increased by&nbsp;a capitalization or share
dividend payable in New Parent Shares, or by a split-up of New Parent Shares or other similar event, then, on the effective date of such capitalization or share dividend, split-up or similar event, the number of New Parent Shares issuable on
exercise of each New Parent Warrant will be increased in proportion to such increase in the issued and outstanding New Parent Shares. A rights offering made to all or substantially all holders of New Parent Shares entitling holders to purchase New
Parent Shares at a price less than the &#147;historical fair market value&#148; (as defined below) will be deemed a share dividend of a number of New Parent Shares equal to the product of (i) the number of New Parent Shares actually sold in such
rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for New Parent Shares) and (ii)&nbsp;one<I>&nbsp;minus</I>&nbsp;the quotient of (a)&nbsp;the price per New Parent
Share paid in such rights offering and (b)&nbsp;the historical fair market value. For these purposes, (i)&nbsp;if the rights offering is for securities convertible into or exercisable for New Parent Shares, in determining the price payable for New
Parent Shares, there will be taken into account any consideration received for such rights, as New Parent as any additional amount payable upon exercise or conversion and (ii)<I>&nbsp;&#147;historical fair market value&#148;</I><I></I>&nbsp;means
the volume weighted average price of New Parent Shares during the 10 trading day period ending on the trading day prior to the first date on which the New Parent Shares trade on the applicable exchange or in the applicable market, regular way,
without the right to receive such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of issued and outstanding New Parent Shares is decreased by a consolidation, combination, reverse
<FONT STYLE="white-space:nowrap">share&nbsp;sub-division&nbsp;or&nbsp;reclassification</FONT> of New Parent Shares or other similar event, then, on the effective date of such consolidation, combination, reverse
<FONT STYLE="white-space:nowrap">share&nbsp;sub-division,&nbsp;reclassification</FONT> or similar event, the number of New Parent Shares issuable on exercise of each warrant will be decreased in proportion to such decrease in issued and outstanding
New Parent Shares. Whenever the number of New Parent Shares purchasable upon the exercise of the New Parent Warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately
prior to such adjustment by a fraction (i)&nbsp;the numerator of which will be the number of New Parent Shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (ii)&nbsp;the denominator of which will be the
number of New Parent Shares so purchasable immediately thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if (i)&nbsp;New Parent issues additional New Parent Shares or
equity-linked&nbsp;securities for capital raising purposes in connection with the completion of the Business Combination at an issue price or effective issue price&nbsp;of less than $9.20 per ordinary share (with such issue price or effective issue
price to be determined in good faith by the New Parent Board) (the&nbsp;&#147;<I>Newly Issued Price</I>&#148;), (ii)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon,
available for the funding of the Business Combination on the date of the completion of the Business Combination (net of redemptions), and (iii)&nbsp;the volume weighted average trading price of the New Parent Shares during the 20 trading day period
starting on the trading day prior to the day on which New Parent consummate the Business Combination (such price, the &#147;<I>Market Value</I>&#148;) is below $9.20 per share, the exercise price of the New Parent Warrants will be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger prices described above under
&#147;&#151;<I>Redemption of New Parent Warrants when the price per New Parent Share equals or exceeds $18.00</I>&#148; and &#147;&#151;<I>Redemption of New Parent Warrants when the price per New Parent Share equals or exceeds $10.00</I>&#148; will
be adjusted (to&nbsp;the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described above under &#147;&#151;<I>Redemption of New Parent Warrants when
the price per New Parent Share equals or exceeds $10.00</I>&#148; will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the issued and outstanding New Parent Shares (other than those described above or that solely affects the
par value of such New Parent Shares), or in&nbsp;the case of any merger or consolidation of New Parent with or into another corporation (other than a merger or consolidation in which New Parent is continuing corporation and that does not result in
any reclassification or reorganization of New Parent&#146;s issued and outstanding New Parent Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of New Parent as an entirety or
substantially as an entirety in connection with which New Parent is dissolved, the holders of the New Parent Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants
and in lieu of the New Parent Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares, stock or other equity securities or property (including cash) receivable upon
such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the New Parent Warrants would have received if such holder had exercised their warrants immediately prior
to such event. However, if such holders are entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such merger or consolidation, then the kind and amount of securities, cash or other
assets for which each warrant will become exercisable will be deemed to be the weighted average of the kind and amount received per share by such holders in such merger or consolidation that affirmatively make such election, and if a tender,
exchange or redemption offer has been made to and accepted by such holders under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1)
under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any such affiliate or associate is
a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the issued and outstanding New Parent Shares, the holder of a warrant will be entitled to receive the highest amount of cash, securities or other
property to which such holder would actually have been entitled as a shareholder if such warrant holder had exercised the warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the New Parent Shares held by
such holder had been purchased pursuant to such tender or exchange offer, subject to adjustment (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in the Warrant
Assumption Agreement. Additionally, if less than 70% of the consideration receivable by the holders of New Parent Shares in such a transaction is payable in the form of ordinary shares in the successor entity that is listed for trading on a national
securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the New Parent Warrant properly exercises the warrant within 30
days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the Warrant Assumption Agreement based on the per share consideration<I>&nbsp;minus</I>&nbsp;the Black-Scholes&nbsp;Warrant Value (as
defined in the Warrant Assumption Agreement) of the New Parent Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Warrants will be issued in registered form under the Warrant
Assumption Agreement. The Warrant Assumption Agreement provides that&nbsp;the terms of the New Parent Warrants may be amended without the consent of any holder for the purpose of (i)&nbsp;curing any ambiguity or correcting any mistake, including to
conform the provisions of the Warrant Assumption Agreement to the description of the terms of the warrants and the Warrant Assumption Agreement set forth in this proxy statement/prospectus or defective provision or (ii)&nbsp;adding or changing any
provisions with respect to matters or questions arising under the Warrant Assumption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement as the parties to the Warrant Assumption Agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant holders do not have the rights or privileges of holders of New Parent Shares and any voting rights until they exercise their New
Parent Warrants and receive New Parent Shares. After the issuance of New Parent Shares upon exercise of the New Parent Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional New Parent Warrants will be issued upon separation of the units and only whole warrants will trade. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent has agreed that, subject to applicable law, any action, proceeding or claim against it arising out of or relating in any way to the Existing
Warrant Assumption Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and New Parent irrevocably submits to such jurisdiction, which jurisdiction
will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United
States of America are the sole and exclusive forum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends may be paid only if New Parent
has sufficient distributable profit from previous years or sufficient free reserves to allow the distribution of a dividend. Swiss law requires that New Parent retain at least 5% of its annual net profit as general reserves for so long as these
reserves amount to less than 20% of <FONT STYLE="white-space:nowrap">its&nbsp;paid-in&nbsp;nominal</FONT> share capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Profit Distribution
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, dividends are proposed by the New Parent Board and require the approval at a meeting of shareholders. New Parent&#146;s auditors
must also confirm that the dividend proposal conforms to law and the Proposed Articles of Association. Dividends that have not been collected by shareholders within five years after the due date accrue to New Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a description of certain tax considerations, including withholding taxes, in relation to dividend payments, please see the section entitled
&#147;<I>Material Tax Consideration&#151;Material Swiss Tax Considerations</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Board determines the date on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have
passed the resolution approving the payment, but shareholders may also resolve at an annual general meeting to pay dividends in quarterly or other instalments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Reduction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions out of issued
share capital (i.e., the aggregate nominal value of New Parent&#146;s issued shares) are not allowed and may be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an absolute majority of the
shares represented at a general meeting of shareholders or the introduction of a capital band (<I>Kapitalband</I>) pursuant to which the New Parent Board is empowered to make such resolution. The resolution of the shareholders must be recorded in a
public deed and a special audit report must confirm that claims of New Parent&#146;s creditors remain fully covered despite the reduction in New Parent&#146;s share capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recorded in the Commercial Register. New Parent&#146;s share capital may be reduced below CHF&nbsp;100,000 only if and to the extent that at the same time the statutory minimum share capital of
CHF&nbsp;100,000 <FONT STYLE="white-space:nowrap">is&nbsp;re-established&nbsp;by</FONT> sufficient new, <FONT STYLE="white-space:nowrap">fully&nbsp;paid-up&nbsp;capital.</FONT> Upon approval or before the general meeting of the capital reduction,
the New Parent Board must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce (&#147;<I>SOGC</I>&#148;) and notify creditors that they may request, within thirty (30)&nbsp;days of the third publication,
satisfaction of or security for their claims. The reduction of New Parent&#146;s share capital may be implemented only after expiration of this time limit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchases of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law limits the right of New
Parent to purchase and hold its own shares. New Parent may purchase its own shares only if and to the extent that: (i)&nbsp;New Parent has freely distributable reserves in the amount of the purchase price; and (ii)&nbsp;the aggregate nominal value
of all New Parent Shares held by it does not exceed 10% of its share capital (or up to 20% under certain specific circumstances). Furthermore, according to Swiss accounting rules, New Parent needs to reflect the amount of the purchase price of the
acquired New Parent Shares as a negative position through the creation of a special reserve on its balance sheet. New Parent may face negative tax consequences, if it holds more than 10% of its Shares for more than six years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares held by New Parent or its subsidiaries do not carry any voting rights at general meetings of shareholders, but are entitled to the economic
benefits, including <FONT STYLE="white-space:nowrap">dividends,&nbsp;pre-emptive&nbsp;rights</FONT> (<I>Bezugsrechte</I>) in the case of share capital increases and advance subscription rights (<I>Vorwegzeichnungsrechte</I>) and in the case of
issuance of debt instruments with option rights applicable to the New Parent Shares generally. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form and Transfer of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form of the Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares may be issued
as ordinary uncertificated securities within the meaning of article&nbsp;973c CO (<I>Wertrechte</I>) and/or global certificates. In accordance with article 973c CO, New Parent maintains a register of uncertificated securities
(<I>Wertrechtebuch</I>). New Parent may create intermediated securities (<I>Bucheffekten</I>) for New Parent Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon its registration with the share
register, a shareholder may at any time request from New Parent to issue a written confirmation of the New Parent Shares held by such shareholder. However, the shareholder has no right to request the printing and delivery of share certificates nor
the conversion of New Parent Shares issued in one form into another form. New Parent may, however, at any time print and deliver certificates for registered (single certificates or global certificates) and, with the consent of the shareholder,
delete without replacement issued share certificates, which have been returned to it. New Parent may convert New Parent Shares from one form into another form at any time and without the approval of the shareholders. New Parent shall bear the cost
associated with any such conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares in uncertificated form (<I>Wertrechte</I>) may only be transferred by way of assignment. New Parent Shares or the beneficial interest in New
Parent Shares, as applicable, credited in a securities account may only be transferred when a credit of the relevant intermediated securities to the acquirer&#146;s securities account is made in accordance with applicable rules. For certain
registration and voting right restrictions on the New Parent Shares, please see the section entitled &#147;<I>Registration and Voting Right Restrictions</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Register </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent maintains a share register
(<I>Aktienbuch</I>) (the &#147;<I>Share Register</I>&#148;) in which the owners of the New Parent Shares are registered with name, address and nationality (in case of legal entities the registered office). In relation to New Parent, only those
shareholders registered in the Share Register are recognized as shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to article&nbsp;4 of the Proposed Articles of Association, acquirers of New Parent Shares are, upon
request and presentation of evidence of the transfer, registered as shareholders with voting rights in the Share Register if they explicitly declare to hold New Parent Shares in their own name and for their own account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Board shall implement the necessary directions for maintaining the Share Register and it may issue corresponding regulations or guidelines. The
New Parent Board may delegate such tasks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the invitation to the general meeting, the New Parent Board shall announce the record date for registration
in the Share Register that is relevant with respect to the right to attend and vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent has the right to delete entries in the Share Register
retroactively as of the date of the entry if the registration has been made on the basis of false information. It may give the relevant shareholder or nominee the opportunity, in advance, to be heard. The relevant shareholder or nominee is to be
informed without delay about the deletion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Voting Right Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Articles of Association contain the following registration restrictions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Regulatory Registration and Voting Right Restrictions.</I><I></I>&nbsp;According to article 4 of the
Proposed Articles of Association, the New Parent Board may refuse the registration of an acquirer of New Parent Shares in the Share Register as a shareholder with voting rights or cancel an already occurred registration of New Parent Shares with
voting rights from the Share Register, if (a)&nbsp;the number of New Parent Shares held or acquired directly or indirectly or acting in concert with third parties or as an organized group by such acquirer exceeds 15% of the total number of voting
rights of New Parent pursuant to the entry in the commercial register, and (b) (b)&nbsp;such acquirer has not submitted prior to the acquisition of such New Parent Shares an orderly tender offer to all shareholders with a minimum price of the higher
of (i)&nbsp;the volume weighted average price of the last 60 trading days prior to the publication of the tender offer, or (ii)&nbsp;the highest price paid by such acquirer in the 12 months preceding to the publication of the tender offer.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Those associated through capital, voting power, joint management, beneficial ownership or in any other way, or joining
for the acquisition of shares shall be regarded as one acquirer for the purposes of article 4 of the Proposed Articles of Association. Acquirers who do not meet the legal or regulatory requirements according to article 4 of the Proposed Articles of
Association shall be entered in the Share Register as shareholder without voting rights for New Parent Shares exceeding the limit of 15%. In case of an already occurred registration, New Parent Shares exceeding the limit of 3% will be cancelled from
the Share Register as New Parent Shares with voting rights and instead be registered as New Parent Shares without voting rights. The New Parent Board may enact regulations governing the details of such registration restriction. Nominees do not
constitute as acquirers within the meaning of article 4 of the Proposed Articles of Association. After hearing the person concerned, New Parent may cancel the registrations in the Share Register if those registrations were based on false information
of the acquirer. In addition, according to article 4 of the Proposed Articles of Association, the New Parent Board may refuse the exercise of voting rights of a shareholder in excess of 15% of the total number of voting rights of New Parent pursuant
to the entry in the commercial register, if such shareholder does not meet the legal or regulatory requirements according to article 4 of&nbsp;the Proposed Articles of Association </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Registration and Voting Right Restrictions for New Parent Shares held through Nominees.</I>&nbsp;The
registration and voting right restrictions in connection with the regulatory registration and voting right restrictions described above are also applicable to New Parent Shares held through nominees. Accordingly, article 4 of the Proposed Articles
of Association provides that, if, any beneficial owner should as a result of such registration of a nominee being made or upheld, directly or indirectly, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
formally, constructively or beneficially own, or otherwise control or alone or together with third parties, hold a number of shares exceeding 3% of the total number of voting rights of New Parent
pursuant to the entry in the commercial register and the nominee does not, expressly declare in the registration application that it is holding the shares on its own account, and the nominee does not confirm in writing that it is willing to disclose
the names, addresses and shareholdings of the persons on whose account they hold 0.5% or more of the share capital, the New Parent Board may refuse to register (or cancel an already occurred registration of) the nominee holding New Parent Shares for
the account of such beneficial owner with respect to any New Parent Shares in excess of such restriction. The New Parent Board may make the registration with voting rights of the New Parent Shares held by a nominee subject to conditions, limitations
and reporting requirements and may impose or adjust such conditions, limitations and requirements once registered and may enter into agreements with nominees in this regard. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Further, the voting right restrictions pursuant to article 4 of the Proposed Articles of Association as set out above also apply to New Parent
Shares, which are held by a nominee for the account of a person exceeding the threshold of 15% (regulatory voting right restrictions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from the
registration and voting rights restrictions as described above, there are no restrictions on the transferability of the New Parent Shares in the Proposed Articles of Association. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meetings of Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convocation of
Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law and article&nbsp;10 of the Proposed Articles of Association, an annual general meeting of shareholders must be held each
year within six months after the end of the business year. Extraordinary meetings of shareholders may be convened when required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General meetings of
shareholders must be convened by the board of directors at least 20 days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the SOGC. Registered
shareholders may also be informed by ordinary mail or <FONT STYLE="white-space:nowrap">e-mail.</FONT> The notice of a general meeting of shareholders must state the items on the agenda, the proposals to be acted upon and, in case of elections, the
names of the nominated candidates. Except in the limited circumstances listed below, a resolution may not be passed at a general meeting without proper notice. This limitation does not apply to proposals to convene an extraordinary general meeting
of shareholders or to initiate a special investigation. No previous notification is required for proposals concerning items included in the agenda or for debates that do not result in a vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, one or several shareholders that represent at least 5% of the share capital may also request to convene a general meeting. Shareholders
representing at least 0.5% of the share capital may request items to be put on the agenda, provided the request is submitted to the New Parent Board at least 70 calendar days in advance of the relevant general meeting. Convocation requests and
requests for inclusion of agenda items need to be submitted to the New Parent Board in written form, indicating the agenda items and proposals. Swiss law and the Proposed Articles of Association do not prescribe that a particular quorum of
shareholders is required for general meetings of shareholders to be validly held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No resolutions may be passed on motions concerning agenda items which
have not been duly announced, except for motions to convene an extraordinary general meeting, to initiate a special audit or to elect auditors upon a shareholders&#146; request. No prior notice is required to submit motions relating to items already
on the agenda and to discuss matters on which no resolution is to be taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting will be chaired by the chairman of the New Parent Board,
or, in his or her absence, by another member of the New Parent Board as appointed by the New Parent Board. If no member of the New Parent Board is present, the general meeting shall appoint the chairperson of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Representation of Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each shareholder may have its shares represented in the general meeting by itself or by a third person who does not need to be a shareholder by means of
written proxy or by the independent proxy. The general meeting annually elects an independent proxy. The independent proxy&#146;s term of office begins at the day of election and ends at the end of the following annual general <FONT
STYLE="white-space:nowrap">meeting.&nbsp;Re-election&nbsp;is</FONT> possible. If New Parent does not have an independent proxy, the New Parent Board shall appoint the independent proxy for the next general meeting of shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum and Majority Requirements at General Meetings of Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except where the law or the Proposed Articles of Association provide otherwise, the general meeting passes its resolutions and performs elections with the
absolute majority of the votes cast, excluding any abstentions, blank or invalid votes. The chairperson of the general meeting determines the voting procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to article 19 of the Proposed Articles of Association, a resolution of the general meeting passed with at
<FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the votes represented at the meeting and the absolute majority of the nominal values of the New Parent Shares represented at the meeting is required for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amendment of the purpose of New Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the consolidation of shares, insofar as this does not require the consent of all shareholders concerned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the increase of the share capital against contributions in kind or by offsetting against a receivable and the
granting of special benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the limitation or withdrawal of subscription rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the introduction of conditional capital, the creation of reserve capital pursuant to article 12 of the Swiss
Banking Act or the introduction of a capital band; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of participation certificates into shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the restriction of the transferability of registered shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the creation of shares with privileged voting rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the change of currency of the share capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the introduction of the casting vote of the Chairman in the General Assembly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the introduction of a provision in the Articles of Association to hold general meetings outside of Switzerland;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the change of the registered office of New Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the introduction of an arbitration clause in the Articles of Association; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the delisting of the New Parent Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the dissolution of New Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the merger, <FONT STYLE="white-space:nowrap">de-merger</FONT> or conversion of New Parent (subject to mandatory
law); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the alleviating or withdrawal of restrictions upon the transfer of registered shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of registered shares into bearer shares and vice versa; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amendment or elimination of the provisions of articles 4, 19 and 31 of the Proposed Articles of
Association. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of the Proposed Articles of Association which require higher majorities for the passing of certain resolutions
than provided by law can only be adopted and removed with that same proposed majority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In principle, each New Parent Share entitles a holder to one vote in New Parent&#146;s general meeting, irrespective of nominal value of such share (please see
the section entitled &#147;<I>Comparison of Shareholder Rights&#151;Voting Rights</I>&#148; for details on certain exceptions under Swiss law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New
Parent Shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any nominees) who are entered in the Share Register prior to the
<FONT STYLE="white-space:nowrap">applicable&nbsp;cut-off&nbsp;date</FONT> to be determined by the New Parent Board. Those entitled to vote in the general meeting may be represented by the independent proxy holder (annually elected by the general
meeting of shareholders), by its legal representative or by another person with written authorization to act as proxy. The chairman of the general meeting has the power to decide whether to recognize a power of attorney. Only shareholders registered
in the Share Register with voting rights are entitled to vote in a New Parent shareholders&#146; meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inspection of Books and Records </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual report and the auditors&#146; report shall be made available for inspection by the shareholders at the registered office of New Parent at the latest
20 days prior to the annual general meeting. Each shareholder may demand an immediate delivery of these documents. The notice to the shareholders must refer to this right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, a shareholder may also, upon request submitted to New Parent, inspect the minutes of general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At general meetings, shareholders may further request information from the New Parent Board regarding the business and operations of New Parent and may
request information from New Parent&#146;s auditors regarding the performance and results of their examination of New Parent&#146;s financial statements. New Parent may refuse to provide certain requested information to a shareholder if, in its
opinion, the disclosure of the requested information would reveal confidential business secrets or infringe other protected interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders
representing at least 5% of the share capital or votes have the right to inspect the company&#146;s books. The board of directors must grant the inspection insofar as it is necessary for the exercise of shareholders&#146; rights and the disclosure
would not reveal confidential business secrets or infringe other protected interests. Upon inspection of the books, the shareholders may make notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Investigations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shareholders&#146;
inspection and information rights as outlined above prove to be insufficient, any shareholder may propose to the general meeting that specific facts be examined by a special commissioner in a special investigation. If the general meeting approves
the proposal, New Parent or any shareholder may, within 30&nbsp;calendar days after the general meeting, request the court at New Parent&#146;s registered office to appoint a special commissioner. If the general meeting rejects the request, one or
more shareholders representing at least 5% of the share capital or voting rights may request, within three months after the general meeting, such court to appoint a special commissioner. Such court will issue such order if the petitioners can
demonstrate that the New Parent Board, any member thereof or an officer of New Parent infringed the law or the Proposed Articles of Association and thereby damaged New Parent or the shareholders. If admitted, the costs of the investigation by such
court would generally be allocated to New Parent and only in exceptional cases to the petitioners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Official publications of New Parent shall be made in the SOGC. The New Parent Board may designate additional means of publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices to the shareholders shall be made by official publications of New Parent. Notices to shareholders may also be made by mail or email to the addresses
recorded in the Share Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Takeover Regulation and Mandatory Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law provides for certain rules and protections of shareholders of domestic listed companies. Because the New Parent Shares will be listed exclusively on
the Nasdaq Global Market, however, several of these rules do not apply to New Parent as if it were a company listed in Switzerland. In particular, the Swiss rules under the Swiss Financial Market Infrastructure Act on disclosure of shareholdings and
the tender offer rules under the Swiss Financial Market Infrastructure Act, including mandatory tender offer requirements and regulations regarding voluntary tender offers, which are typically available in relation to Swiss-listed companies, do not
apply to New Parent because it will not be listed in Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compulsory Acquisitions; Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Business combinations and other transactions that are governed by the Switzerland&#146;s Federal Act on Mergers, Demergers, Transformations and the Transfer of
Assets of October&nbsp;3, 2003, as amended (the &#147;<I>Swiss Merger Act</I>&#148;) (i.e., mergers, demergers, transformations and certain asset transfers) are binding on all shareholders. A statutory merger or demerger requires approval <FONT
STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the shares represented at a General Meeting of shareholders and the absolute majority of the nominal value of the shares represented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a transaction under the Swiss Merger Act receives all of the necessary consents, all shareholders are compelled to participate in such a transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss stock corporations may be acquired by an acquirer through the direct acquisition of the shares of the Swiss stock corporation. The Swiss Merger Act
provides for the possibility of a so-called &#147;cash-out&#148; or &#147;squeeze-out&#148; merger with the approval of holders of 90% of the issued shares. In these limited circumstances, minority shareholders of the corporation being acquired may
be compensated in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring corporation or of another corporation). For business combinations effected in the form
of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in the transaction are unreasonable, a shareholder may request a competent
court to determine a reasonable amount of compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under Swiss law, the sale of &#147;all or substantially all&#148; of its assets by
New Parent may require the approval <FONT STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the voting rights represented at a general meeting of shareholders and the absolute majority of the nominal value of the shares represented.
Whether a shareholder resolution is required depends on the particular transaction, including whether the following test is satisfied: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a core part of New Parent&#146;s business is sold without which it is economically impracticable or unreasonable
to continue to operate the remaining business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent&#146;s assets, after the divestment, are not invested in accordance with its corporate purpose as set
forth in the Proposed Articles of Association; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds of the divestment are not earmarked for reinvestment in accordance with New Parent&#146;s corporate
purpose (as set forth in the Proposed Articles of Association), but instead are intended for distribution to New Parent&#146;s shareholders or for financial investments unrelated to its corporate purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duration and Liquidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, unless the
duration of a company is limited by its articles of association, a company may be dissolved at any time by way of liquidation, or, in the case of a merger with the Swiss Merger Act (<I>Fusionsgesetz</I>), based on a resolution of a general meeting
of shareholders, which must be passed by a majority as provided by Swiss law or the relevant company&#146;s articles of association, as the case may be. The Proposed Articles of Association do not limit the duration of New Parent and provide that
the majority required for the general meeting to resolve on the liquidation of New Parent is set <FONT STYLE="white-space:nowrap">at&nbsp;two-thirds&nbsp;of</FONT> the votes represented at the general meeting and the absolute majority of the nominal
values of the shares represented at the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dissolution and liquidation by court order is also possible if, among other things, (i)&nbsp;the company
becomes bankrupt or (ii)&nbsp;shareholders holding at least 10% of the company&#146;s share capital so request for important reasons. Under Swiss law, any surplus arising out of a liquidation (after settlement of all the claims of the company&#146;s
creditors) is distributed in proportion to <FONT STYLE="white-space:nowrap">the&nbsp;paid-up&nbsp;nominal</FONT> value of shares held. This surplus is subject to Swiss federal withholding tax, except if paid out of reserves from qualifying capital
contributions (<I>Reserven aus Kapitaleinlagen</I>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_22"></A>COMPARISON OF SHAREHOLDER RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section describes the material differences between the rights of EBAC Shareholders before the consummation of the Business Combination, and the rights
of New Parent shareholders after the Business Combination. These differences in shareholder rights result from the differences between Cayman Islands and Swiss law and the respective governing documents of EBAC and New Parent. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section does not include a complete description of all differences among such rights, nor does it include a complete description of such rights.
Furthermore, the identification of some of the differences of these rights as material is not intended to indicate that other differences that may be equally important do not exist. EBAC Shareholders are urged to carefully read the relevant
provisions of the Cayman Companies Act, the Swiss Code of Obligations (Obligationenrecht) applicable to New Parent, EBAC&#146;s amended and restated memorandum and articles of association and the Proposed Articles of Association that will be in
effect as of consummation of the Business Combination (which such form is included as<U>&nbsp;Annex B</U>&nbsp;to this proxy statement/prospectus). References in this section to the Proposed Articles of Association are references thereto as they
will be in effect upon consummation of the Business Combination. However, the Proposed Articles of Association may be amended at any time prior to consummation of the Business Combination by mutual agreement of EBAC and Oculis SA or after the
consummation of the Business Combination by amendment in accordance with their terms. If the Proposed Articles of Association are amended, the below summary may cease to accurately reflect the Proposed Articles of Association as so amended. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2023, new provisions with regard to the modernization of Swiss corporate law will come into force (with certain transitional periods as
provided for therein). Most relevantly, the legislative reform addresses, among other topics, (i)&nbsp;the modernization and increased flexibility for a stock corporation&#146;s capital base, (ii)&nbsp;corporate governance and executive compensation
matters, (iii)&nbsp;the strengthening of shareholder rights and the protection of minorities, and (iv)&nbsp;financial distress/restructuring measures. The Proposed Articles of Association as described in the following overview already address the
new provisions of Swiss corporate law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Rights of EBAC Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Rights of New Parent Shareholders</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Share Capital</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC is authorized to issue up to 221,000,000 shares, consisting of (i) 200,000,000 EBAC Class&nbsp;A Common Stock, (ii) 20,000,000 EBAC Class&nbsp;B Common Stock and (iii) 1,000,000 preference shares, each with a par value of
$0.001 per share. As of the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the record date for the Extraordinary General Meeting, there were
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of EBAC Class&nbsp;A Common Stock, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of EBAC Class&nbsp;B Common Stock, and no preference
shares issued and outstanding.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share capital of New Parent as of (a)&nbsp;the date of this proxy statement/prospectus amounts to CHF 100,000 and is divided into
10,000,000 fully <FONT STYLE="white-space:nowrap">paid-in</FONT> registered shares with a nominal value of CHF 0.01 each and (b)&nbsp;the Acquisition Closing amounts to CHF&nbsp;476,171.93 (assuming no redemptions by EBAC Shareholders) and is
divided into 47,617,193 fully <FONT STYLE="white-space:nowrap">paid-in</FONT> registered shares with a nominal value of CHF 0.01 each.</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital band (Kapitalband)</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Further, the share capital of New Parent may be increased until 2028 at the latest, by a maximum amount of CHF 238,085.96 (assuming no redemptions by EBAC
Shareholders, such number not to exceed 50% of issued share capital) by issuing a maximum of 23,808,596 fully paid-up registered shares with a nominal value of CHF 0.01 each.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital</I></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the share capital of New Parent may be increased as follows:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;by an amount not exceeding
CHF&nbsp;99,086.64 through the issue of a maximum of 9,908,664 fully <FONT STYLE="white-space:nowrap">paid-up</FONT> registered shares, each with a par value of CHF&nbsp;0.01 (New Parent Shares), in connection with the exercise of option rights or
other equity-linked instruments granted to any employee of New Parent or a subsidiary, and any consultant, member of the board of directors, or other person providing services to the New Parent or a subsidiary;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;by an amount not exceeding CHF
50,000 through the issuance from time to time of a maximum of 5,000,000 fully paid up registered shares, each with a par value of CHF 0.01 (New Parent Shares), in connection with the exercise of convertible rights and/or option rights or warrants,
which have been granted or will be granted in connection with new bonds and similar debt instruments, including convertible loans of Oculis which are issued prior to the date of the Business Combination in accordance with the Convertible Loan
Agreements, that have been or will be issued by New Parent or its subsidiaries;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;by an amount not exceeding CHF 44,032.94 through the issuance from time to time of a maximum of
4,403,294 fully paid up registered shares, each with a par value of CHF 0.01 (New Parent Shares), in connection with the exercise of warrants granted through the exercise of conversion and/or option rights, which were assumed from, and allocated by,
EBAC, on the basis of the Warrant Assumption Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting Rights</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that the holders of shares of EBAC shall have one vote for every share of which he or she is the holder on each matter properly submitted to the
shareholders on which the holders are entitled to vote.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each share entitles a holder to one vote in the shareholders meeting of New Parent, irrespective of nominal value of such share. However, nominal values will be decisive, for (i)&nbsp;the election of New Parent&#146;s statutory
auditors, (ii)&nbsp;the appointment of experts to audit New Parent&#146;s business management or parts thereof, (iii)&nbsp;any resolution concerning the initiation of a special audit and (iv)&nbsp;any resolution concerning the initiation of a
liability action.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Appraisal / Dissenters&#146; Rights</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under certain circumstances, shareholders may dissent to a merger of a Cayman Islands company by following the procedure set out in the Cayman Companies Act. Where dissenter rights apply, dissenters to a merger are entitled to
receive fair market value for their shares.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If <FONT STYLE="white-space:nowrap">a&nbsp;squeeze-out&nbsp;merger</FONT> under the Swiss Merger Act occurs, a minority shareholder subject to the <FONT STYLE="white-space:nowrap">squeeze-out</FONT> merger could seek to claim,
within two months of the publication of the <FONT STYLE="white-space:nowrap">squeeze-out</FONT> merger, that the consideration offered is &#147;inadequate&#148; and petition a Swiss competent court to determine what &#147;adequate&#148;
consideration is.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Dividends</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The directors of EBAC may resolve to pay dividends and other distributions on shares in issue and authorize payment of the dividends or other distributions. Dividends may be paid out of profits, share premium or any other sources
permitted under law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend payments are subject to the approval of a meeting of shareholders. The board of directors may propose to shareholders that a
dividend or an interim dividend shall be paid but cannot itself authorize the distribution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Payments out of a Swiss stock corporation&#146;s share capital (in other words, the aggregate par value of the corporation&#146;s registered share capital) in
the form of dividends are not allowed and may be made only by way of a share capital reduction. Dividends may in general be paid only from the profits of the previous business year or brought forward from previous business years or if the
corporation has distributable reserves, each as evidenced by the corporation&#146;s audited stand-alone statutory balance sheet prepared pursuant to Swiss law, after allocations to reserves required by Swiss law and the articles of association have
been deducted and the corporation&#146;s statutory auditors have confirmed that the dividend proposal complies with Swiss law and the corporation&#146;s articles of association.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Purchase and Repurchase of Shares</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the Cayman Companies Act or applicable stock exchange or other regulatory rules, EBAC may purchase its own shares (including any redeemable shares) in such manner and on such other terms as the directors determine at the
time of such purchase.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law limits the right of a company to purchase and hold its own shares. New Parent may purchase its own shares (i.e., New Parent Shares)
only if and to the extent that: (i)&nbsp;New Parent has freely distributable reserves in the amount of the purchase price; and (ii)&nbsp;the aggregate nominal value of all New Parent Shares held by it does not exceed 10% of its share capital (or up
to 20% under certain specific circumstances). Furthermore, according to Swiss accounting rules, the New Parent needs to reflect the amount of the purchase price of the acquired New Parent Shares as a negative position through the creation of a
special reserve on its balance sheet.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New Parent Shares held by New Parent or its subsidiaries do not carry any voting rights at
general</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">meetings of shareholders, but are entitled to the economic benefits, including dividends, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights (<I>Bezugsrechte</I>) in the case of share capital increases and advance
subscription rights (<I>Vorwegzeichnungsrechte</I>) in the case of issuance of debt instruments with option rights applicable to the New Parent Shares generally.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Redemption Rights</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of an initial business combination, EBAC&#146;s amended and restated memorandum and articles of association provides
holders of EBAC Class&nbsp;A Common Stock with the opportunity to redeem their EBAC Class&nbsp;A Common Stock at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account as of two business days prior to the consummation of the initial business combination, including interest (which such interest shall be net of taxes payable) earned on the Trust Account, divided by the number of then issued EBAC Class&nbsp;A
Common Stock, provided that EBAC shall not repurchase EBAC Class&nbsp;A Common Stock in an amount that would cause EBAC&#146;s net tangible assets to be less than $5,000,001.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Swiss law does not provide for redemption rights of shareholders.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If EBAC seeks to amend any provision of its amended and restated memorandum and articles of association that would affect the substance or
timing of EBAC&#146;s obligation to redeem 100% of the holders of EBAC Class&nbsp;A Common Stock if EBAC does not consummate an initial business combination within the Combination Period, EBAC must provide the holders of EBAC Class&nbsp;A Common
Stock with the opportunity to redeem their EBAC Class&nbsp;A Common Stock in connection with such vote. EBAC will redeem the amounts owed to holders of EBAC Class&nbsp;A Common Stock and liquidate if it does not complete a business combination
within the Combination Period.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">After consummation of an initial business
combination, holders of EBAC Class&nbsp;A Common Stock are not entitled to redemption rights with respect to their EBAC Class&nbsp;A Common Stock.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Issuance of Shares</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the provisions of the Cayman Companies Act, EBAC&#146;s amended and restated memorandum and articles of association and the rules of the Nasdaq, the directors of EBAC may allot, issue, grant options over or otherwise
dispose of any unissued shares of EBAC (including fractions thereof) to such persons, at such times and on such terms and conditions as they may decide, provided that the directors may not allot, issue, grant options over or otherwise dispose of any
unissued shares of EBAC (including fractions thereof) to the extent that it may affect the ability of EBAC to carry out a Class&nbsp;B Share Conversion (as defined in EBAC&#146;s amended and restated memorandum and articles of association).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swiss law provides that the shareholders make a resolution for the creation of new share capital. An ordinary capital increase requires the
consent of more than 50% of the shareholders at a general meeting. The creation of a capital band (<I>Kapitalband</I>) or conditional share capital requires at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting rights represented
at the general meeting of shareholders and an absolute majority of the par value of shares represented at such meeting. The board of directors may issue shares out of the capital band during a period of up to five years.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shares out of conditional share capital are created and issued through the exercise of
options or of conversion rights that the board of director may grant in relation to, e.g., debt instruments or employees.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Emption&nbsp;Rights</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">None.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Swiss law provides that any share issue, whether for cash <FONT STYLE="white-space:nowrap">or&nbsp;non-cash&nbsp;consideration,</FONT> is subject to the prior approval at a general meeting of shareholders. Shareholders are granted <FONT
STYLE="white-space:nowrap">certain&nbsp;pre-emptive&nbsp;rights</FONT> (<I>Bezugsrechte</I>) to subscribe for new issues of shares and advance subscription rights (<I>Vorwegzeichnungsrechte</I>) to subscribe for warrants, convertible bonds or
similar debt instruments with option rights in proportion to the nominal amount of shares held.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Amendments to Governing Documents</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of any provision of EBAC&#146;s amended and restated memorandum and articles of association generally requires a special resolution, passed by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding EBAC shares that are entitled to vote that vote in a general meeting. The Sponsor and EBAC&#146;s officers and directors have each agreed that they will not propose any amendment to EBAC&#146;s amended and restated memorandum and
articles of association that would affect the substance or timing of EBAC&#146;s obligation to redeem 100% of its public shares if EBAC does not complete an initial business combination within the Combination Period unless EBAC provides its public
shareholders with the opportunity to redeem their shares upon approval of any such amendment. The provisions of EBAC&#146;s amended and restated memorandum and articles of association relating to the election of directors prior to an initial
business combination may only be</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The articles of association of a Swiss stock corporation may be amended with a resolution passed by a majority of the voting rights
represented at a general meeting of shareholders, unless otherwise provided in the articles of association.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A resolution of the shareholders meeting of New Parent passed with a majority of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes
represented and the absolute majority of the par value of shares represented is required for the following matters (for the complete list of matters requiring such majority, please see article 19 of the Proposed Articles of Association):</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment of the purpose
of New Parent;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the
increase of the share capital against contributions in kind or by offsetting against a receivable and the granting of special benefits;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">amended by a special resolution passed by at least 90% of the outstanding EBAC Class&nbsp;B Common Stock voted.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC may, by ordinary resolution, passed by a vote of a majority of the EBAC shares
that are entitled to vote and vote in a general meeting:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;increase its share capital;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;consolidate and divide all or
any of its share capital into shares of larger amount;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;convert all or any of its <FONT STYLE="white-space:nowrap">paid-up</FONT> shares into stock, and
reconvert that stock into <FONT STYLE="white-space:nowrap">paid-up</FONT> shares of any denomination;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;by subdivision of its existing shares or any of them divide the whole or any part of its share
capital into shares of smaller amount than is fixed by EBAC&#146;s amended and restated memorandum and articles of association or into shares without par value; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cancel any shares that have not been taken or agreed to be taken by any person and diminish the
amount of its share capital by the amount of shares so cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the
limitation or withdrawal of subscription rights;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the introduction of conditional capital, the creation of reserve capital pursuant to article 12 of
the Swiss Banking Act or the introduction of a capital band;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the restriction of the transferability of registered shares;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the creation of shares with
privileged voting rights;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the change of the registered office of New Parent;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the dissolution of New
Parent; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the merger, <FONT
STYLE="white-space:nowrap">de-merger</FONT> or conversion of New Parent (subject to mandatory law).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Number of Directors</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that, unless otherwise determined by a vote of a majority of the EBAC shares issued and outstanding, the minimum number of directors shall be one.</TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The New Parent Board shall be composed of at least three and in the maximum of nine members who shall be elected for a tenure of one year.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Nomination and Election of Directors</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that shareholders seeking to nominate candidates for election as directors of EBAC at the annual general meeting must deliver notice to the principal
executive offices of EBAC not less than 120 calendar days before the date EBAC&#146;s proxy statement is released to shareholders of EBAC in connection with the previous year&#146;s annual general meeting or, if EBAC did not hold an annual general
meeting the previous year or if the date of the current year&#146;s annual general meeting has been changed by more than 30 days from the date of the previous year&#146;s annual general meeting, then the deadline shall be set by the EBAC Board with
such deadline being a reasonable time before EBAC begins to print and send its related proxy materials.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The members of the board of directors, the chairman of the board of directors and the members of the nomination and compensation committee are each elected individually and annually by the shareholders&#146; meeting. The term of
office ends at the closing of the next ordinary shareholders&#146; <FONT STYLE="white-space:nowrap">meeting.&nbsp;Re-election&nbsp;is</FONT> possible.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of
association provides that, prior to the closing of an initial business combination, a vote of the majority of the EBAC Class&nbsp;B Common Stock outstanding will be required to appoint any person as director of EBAC. After the closing of an initial
business combination, a vote of a majority of the shares outstanding will be required to appoint any person as director of EBAC. The directors of EBAC may appoint any person to be an additional director, provided that the appointment does not cause
the number of directors to exceed any number fixed as the maximum number of directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Vacation and Removal of Directors</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association provides that the office of a director of EBAC may be vacated if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;he or she gives notice in
writing to EBAC that he or she resigns the office of director of EBAC;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;without special leave of absence from the other directors of EBAC, he or she is absent from
three&nbsp;consecutive meetings of the board of directors and that such other directors pass a resolution that he or she has by reason of such absence vacated office;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;he or she dies, becomes bankrupt or makes arrangement or composition with his or her creditors
generally;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;he or she is
found to be or becomes of unsound mind; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;all of the other directors of EBAC (being not less than two&nbsp;in number) determine that he or
she should be removed as a director of EBAC, either by a resolution passed by such other directors at a meeting of the directors duly convened and held in accordance with EBAC&#146;s amended and restated memorandum and articles of association or by
a resolution in writing signed by such other directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Parent may remove, with or without cause, any director at any time with a resolution passed by a majority of the voting rights represented at a general meeting of shareholders where a proposal for such removal was properly set
on the agenda.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that, prior to the closing of an initial business combination, a vote of the majority of the EBAC Class&nbsp;B Common Stock outstanding will be
required to remove any person as director of EBAC. After the closing of an initial business combination, a vote of a majority of the shares outstanding will be required to remove any person as director of EBAC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Filling of Board Vacancies</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that the directors may appoint any person as director of EBAC to fill a vacancy.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The New Parent Board may not increase the size of the board of directors or fill any vacancies.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Remuneration of Directors</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that the directors shall determine any amount of remuneration of the directors of EBAC, provided, that no remuneration shall be paid to any director
prior to the consummation of an initial business combination.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Swiss Code of Obligations, the general meeting of shareholders has the <FONT STYLE="white-space:nowrap">non-transferable</FONT> right, amongst others, to vote separately and bindingly on the aggregate amount of
compensation of the members of the board of directors, of the executive committee and, to the extent applicable, of any advisory boards.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Quorum and Actions the Board</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that the affirmative vote by a majority of votes at a meeting of the directors of EBAC is an act by the EBAC Board. In the case of an equality of
votes, the chairman shall have a second casting vote.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to a different approval quorum provided for in the Proposed Articles of Association, the New Parent Board shall take its resolutions with the majority of the votes cast.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Special Meetings of the Board</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that a director may, or any other officer of EBAC on the direction of a director shall, call a meeting of the directors by at least two days&#146;
notice in writing to every director. Notice may be waived.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each member of the New Parent Board may, by specifying the reasons, request the chairman of the board of directors to call a meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Director Action by Written Consent</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that a resolution in writing (in one or more counterparts) signed by all the directors of EBAC shall be valid and effectual as if it had been passed at
a meeting of the EBAC Board.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The New Parent Board shall pass its resolutions in meetings or, provided that the proposal has been submitted to all members of the New Parent Board and no member has requested oral deliberation in a meeting, in telephone or video
conferences or by circular resolution (including by email). A circular resolution requires the consent of the majority of all members of the New Parent Board.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Annual Shareholders&#146; Meetings</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association provides that all matters be determined by the vote of a majority of
the votes cast by the shareholders present in person, participating by conference telephone or represented by proxy at the annual general meeting and entitled to vote thereon, unless the matter is one upon which, by applicable law, EBAC&#146;s
amended and restated memorandum and articles of association, the Cayman Companies Act or applicable stock exchange rules, a different vote is required, in which case such provision governs and controls the decision of such matter.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The ordinary shareholders&#146; meeting of New Parent shall be held annually within six&nbsp;months after the close of the business year.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association does not require (unless required by applicable law) that EBAC hold
an annual general meeting. An annual general meeting may be called by the EBAC Board at any time.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Extraordinary General Meetings</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The amended and restated memorandum and articles of association provides that an extraordinary general meeting may be called by the EBAC Board at any time.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Extraordinary shareholders&#146; meetings of New Parent shall be called by resolution of the board of directors or the shareholders&#146; meeting or upon request of the auditors as well as in the cases provided by law.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Advance Notice Requirements for Shareholder Nominations and Other Proposals</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amended and restated memorandum and articles of association does not provide that shareholders shall have the ability to call general
meetings.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One or several shareholders of New Parent that represent at least 5% of the share capital may request to convene a shareholders&#146;
meeting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that shareholders may seek to bring business before annual general meetings. Shareholders seeking to bring business at the annual general meeting must
deliver notice to the principal executive offices of EBAC not less than 120 calendar days before the date EBAC&#146;s proxy statement is released to shareholders of EBAC in connection with the previous year&#146;s annual general meeting or, if EBAC
did not hold an annual general meeting the previous year or if the date of the current year&#146;s annual general meeting has been changed by more than 30 days from the date of the previous year&#146;s annual general meeting, then the deadline shall
be set by the EBAC Board with such deadline being a reasonable time before EBAC begins to print and send its related proxy materials.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders representing at least 0.5% of the share capital may request items to be put on the agenda, provided the request is made at least 70 calendar days in advance of the shareholders&#146; meeting concerned. Convocation
requests and&nbsp;requests&nbsp;for inclusion of agenda items need to be submitted to the board of directors in written form, indicating the agenda items and proposals.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Notice and Record Date of General Meetings</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s amended and restated memorandum and articles of association requires that notice of a general meeting be given not less than
five&nbsp;clear days before the date of the meeting. The notice must state: (i)&nbsp;the place, date and hour of the meeting and (ii)&nbsp;the general nature of the business to be conducted.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The EBAC Board may fix in advance or arrears a date as the record date for a
determination of shareholders entitled to notice of, or to vote at any general meeting of the shareholders or any adjournment thereof.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, notice convening the shareholders&#146; meeting must be given no later than 20 days before the date for which it is
scheduled in the form prescribed by the Proposed Articles of Association.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Proposed Articles of Association provide that not later than 20 days prior to the ordinary shareholders&#146; meeting, the annual report and the auditors&#146; report shall be made available for inspection at New Parent&#146;s registered office.
Shareholders shall be informed thereof in the convocation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shareholders
representing at least 5% of the share capital or votes have the right to inspect New Parent&#146;s books. The board of directors must grant the inspection insofar as it is necessary for the exercise of shareholders&#146; rights and the disclosure
would not reveal confidential business secrets or infringe other protected interests. Upon inspection of the books, the shareholders may make notes.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Quorum and Actions</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that business may only be transacted at a general meeting if a quorum is present, such quorum being one or more shareholders who together hold a
majority of the shares entitled to vote as of the record date at such meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Swiss law and the articles of association of New Parent do not provide for a quorum requirement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Shareholder Action Without Meeting</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that action of the shareholders may be taken by unanimous written consent in lieu of a meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Swiss law, shareholders may act by written consent, unless a shareholder requests oral deliberation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Indemnification of Directors and Officers</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that each director and officer of EBAC (which does not include auditors of EBAC) shall be indemnified against any liability, action, proceeding, claim,
demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions (other than such liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Proposed Articles of Association require New Parent to indemnify its directors and officers against losses and expenses, including attorney&#146;s fees, judgments, fines and settlement amounts actually and reasonably incurred in
a civil or criminal action, suit or proceeding by reason of having been the representative of or serving for New Parent. Certain limits apply, e.g., if such losses and expenses result</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(if any) that they may incur by reason of their own actual fraud, willful neglect or willful default).</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EBAC shall advance reasonable attorneys&#146; fees and other costs and expenses incurred in connection with the defense of any action, suit, proceeding or
investigation involving such person for which indemnity will or could be sought.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">from a grossly negligent breach of such director&#146;s or officer&#146;s fiduciary or other duties under Swiss law. A Swiss company may also purchase customary directors and officers liability insurance protection, with a view to
protect its directors and officers in cases where it cannot or does not indemnify them.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Dissolution/Liquidation</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that, in the event that EBAC does not consummate an initial business combination within the Combination Period, EBAC shall: (i)&nbsp;cease all
operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible, but not more than ten business days thereafter, redeem the shares issued in EBAC&#146;s initial public offering, at a
<FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be
net of taxes payable), divided by the number of then issued and outstanding shares issued in EBAC&#146;s initial public offering, which redemption will completely extinguish the rights of the holders of shares issued in such initial public offering
(including the right to receive further liquidating distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of EBAC&#146;s remaining shareholders and the EBAC Board, liquidate and
dissolve, subject, in each case, to EBAC&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A dissolution of a Swiss stock corporation requires the approval <FONT STYLE="white-space:nowrap">by&nbsp;two-thirds&nbsp;of</FONT> the
voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value of shares represented at such general meeting of shareholders. The Proposed Articles of Association may increase the voting
thresholds required for such a resolution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dissolution by law or court order is
possible if, for example, a corporation becomes bankrupt.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, any
surplus arising out of a liquidation (after the settlement of all claims of all creditors) is distributed to shareholders in proportion to the paid up par value of shares held. The Proposed Articles of Association may provide for different form of
distribution.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Rights of Inspection</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EBAC&#146;s amended and restated memorandum and articles of association provides that no shareholder who is not also a director shall have any right of inspecting any account or book or document of EBAC except as conferred by
applicable Cayman Islands law or authorized by the EBAC Board or by EBAC in general meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder may inspect New Parent&#146;s books and records if the general meeting of shareholders or the board of directors has granted
authorization.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At shareholder meetings, any shareholder is entitled to information
from the board of directors on the affairs of New Parent and from the external auditors on the methods and results of their audit, to the extent this is required for the exercise of shareholder rights and subject to New Parent&#146;s business
secrets or other interests warranting protection.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Derivative Shareholder Suits</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC&#146;s Cayman Islands counsel is not aware of any reported class action having been brought in a Cayman Islands court. Derivative
actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, the company will be the proper plaintiff in any claim based on a breach of duty owed to it, and a
claim against (for example) EBAC&#146;s officers or directors usually may not be brought by a shareholder. However, based on English authorities, which would likely be of persuasive authority and be applied by a court in the Cayman Islands,
exceptions to the foregoing principle apply in circumstances in which:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a company is acting, or proposing to act, illegally or beyond the scope of its authority;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the act complained of,
although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;those who control the company are perpetrating a &#147;fraud on the minority.&#148;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may have a direct right of action against EBAC where the individual
rights of such shareholder have been infringed or are about to be infringed.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder may bring a lawsuit for alleged violation of directors&#146; duties, either for damage caused to the shareholder itself or for
damage caused to New Parent, subject to procedural requirements.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the
bankruptcy of New Parent, actions for damages of New Parent may only be for payment to New Parent and not the shareholders themselves.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders bringing lawsuit before Swiss courts may be obliged to advance, and finally bear, court costs and compensation for the defense.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">They will generally bear the burden of proof, with
<FONT STYLE="white-space:nowrap">no&nbsp;pre-trial&nbsp;discovery</FONT> or similar procedures being available. If shareholders sue for damage caused to New Parent, any recovered damages will be paid to New Parent and not to the shareholders.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, under Swiss law, any claims by New Parent&#146;s shareholders against New
Parent must be brought exclusively in the competent courts at the registered office of the Company in Switzerland (currently Zug, expected to be Lausanne within two months after the Acquisition Closing). Class&nbsp;actions and derivative actions as
they may exist under U.S. law, are not available under Swiss law.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Anti-Takeover Provisions</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Cayman Companies Act, EBAC&#146;s amended and restated memorandum and articles of association and the rules
of the Nasdaq, the directors of EBAC may allot, issue, grant options over or otherwise dispose of any unissued shares of EBAC (including fractions thereof) to such persons, at such times and on such terms and conditions as they may decide, provided
that the directors may not allot, issue, grant options over or otherwise dispose of any unissued shares of EBAC (including fractions thereof) to the extent that it may affect the ability of EBAC to carry out a Class&nbsp;B Share Conversion (as
defined in EBAC&#146;s amended and restated memorandum and articles of association).</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The EBAC Board may so deal with the unissued shares of EBAC with or without preferred, deferred or other rights or restrictions, whether in regard to dividends
or other distributions, voting, return of capital.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Parent shareholders will not benefit from the protection afforded by certain provisions of Swiss law that are designed to protect shareholders in the event of a public takeover offer or a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-of-control&nbsp;transaction.</FONT></FONT> For example, Article&nbsp;120 of the Swiss Financial Market Infrastructure Act and its implementing provisions require investors to disclose their interest in a company if
they reach, exceed or fall below certain ownership thresholds. Similarly, the Swiss takeover regime imposes a duty on any person or group of persons who acquires more than&nbsp;one-third&nbsp;of a company&#146;s voting rights to make a mandatory
offer for all of the company&#146;s listed equity securities. In addition, the Swiss takeover regime imposes certain restrictions and obligations on bidders in a voluntary public takeover offer that are designed to protect shareholders. However,
these protections are applicable only to issuers with equity securities listed in Switzerland, and because the New</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EBAC may issue rights, options, warrants or convertible securities or
securities of similar nature conferring the right upon the holders thereof to subscribe for, purchase or receive any class of shares or other securities in EBAC at such times and on such terms and conditions as the EBAC Board may decide.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Parent Shares will be listed exclusively on the Nasdaq Global Market they will not be applicable to New Parent. Even though U.S. federal securities law will require investors to disclose their interest in New Parent if they reach,
exceed or fall below certain ownership thresholds, the U.S. takeover regime in relation to mandatory offers does not apply either because New Parent is incorporated in Switzerland. Accordingly, New Parent&#146;s ability to resist an unsolicited
takeover attempt or to protect minority shareholders in the event of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> transaction may be limited. Therefore, New Parent&#146;s shareholders may not be
protected in the same degree in a public takeover offer or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> transaction as are shareholders in a Swiss company listed in Switzerland.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_23"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the Acquisition Closing, New Parent will have up to 71,425,789 New Parent Shares authorized of which 47,617,193 New Parent Shares issued and outstanding,
based on the assumptions set out elsewhere in this proxy statement/prospectus and assuming no shares of EBAC Common Stock are redeemed in connection with the Business Combination. In addition, New Parent is expected to have 4,403,294 New Parent
Warrants issued and outstanding, with each New Parent Warrant exercisable for one New Parent Share at $11.50 per share. All of the New Parent Shares issued to the EBAC Shareholders in connection with the Business Combination will be freely
transferable by persons other than by New Parent &#147;affiliates&#148; or EBAC&#146;s &#147;affiliates&#148; without restriction or further registration under the Securities Act. Sales of substantial amounts of the New Parent Shares in the public
market could adversely affect prevailing market prices of the New Parent Shares. Prior to the Business Combination, there has been no public market for New Parent Shares. New Parent has applied for listing of the New Parent Shares and New Parent
Warrants on the Nasdaq Global Market, but New Parent cannot assure you that a regular trading market will develop in the New Parent Shares and New Parent Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up&nbsp;Periods</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Acquisition Closing Date, the Sponsor and certain shareholders of Oculis (the &#147;<I>RRA Holders</I>&#148;) and New Parent will enter into the
Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. The Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will contain certain restrictions on transfer of New Parent Shares and other
Registrable Securities (as defined therein) to be held by the RRA Holders immediately following the Acquisition Closing (the &#147;<I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities</I>&#148;). Such restrictions begin on the Acquisition
Closing Date and end (i)&nbsp;with respect to the New Parent Shares held by the Oculis Shareholders party thereto upon the Acquisition Closing, 180 days from the Acquisition Closing, and (ii)&nbsp;with respect to the New Parent Shares held by
Sponsor upon the Acquisition Closing, 270 days after the Acquisition Closing, in each case subject to earlier release if the New Parent Shares trade at or above a volume weighted average price of $15.00 for 20 trading days during any 30 trading day
period commencing at least 150 days following the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, each EBAC shareholder signatory thereto has agreed to certain restrictions on transfer of their EBAC Common Stock (to become New Parent Shares following the Acquisition Closing)
subject to such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements during the period from the date of the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements through the date that is 90 days after the Acquisition Closing
Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject <FONT
STYLE="white-space:nowrap">to&nbsp;the&nbsp;lock-up&nbsp;periods&nbsp;described</FONT> above, the RRA Holders are also entitled to registration rights pursuant to the terms of the Registration Rights and
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement.&nbsp;Pursuant to the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, New Parent will agree to, within 30 business days of the Acquisition Closing, register
for resale, by submitting to or filing with the SEC a registration statement for a shelf registration on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1&nbsp;or</FONT> a registration statement for a shelf registration on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-3,&nbsp;all</FONT> the Registrable Securities (as defined therein). The Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement also provides the RRA Holders with certain customary
demand and piggy-back registration rights with respect to their New Parent Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Subscription Agreements, New Parent has
agreed to file with the SEC, within 30&nbsp;business days after the Acquisition Closing, a registration statement covering the resale of the PIPE Shares and to use its commercially reasonable efforts to have such registration statement declared
effective as soon as practicable after the filing thereof, but no later than the earlier of (i)&nbsp;the 60th calendar day (or 90th calendar day if the SEC notifies New Parent that it will &#147;review&#148; the registration statement) following the
Acquisition Closing Date and (ii)&nbsp;the tenth (10th) Business Day after the date New Parent is notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be &#147;reviewed&#148; or will not be
subject to further review. New Parent has also agreed to use commercially reasonable efforts to keep the registration statement effective until the earliest of: (i)&nbsp;the third anniversary of the effectiveness of the registration statement,
(ii)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date when the PIPE Investor has sold all of its Registrable Securities pursuant to the registration statement or Rule 144 and (iii)&nbsp;the date all Registrable Securities held by the PIPE
Investor may be sold without restriction under Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares and New Parent Warrants received in the Business Combination by persons who become affiliates of New Parent for purposes of
Rule&nbsp;144&nbsp;under the&nbsp;Securities Act (&#147;<I>Rule 144</I>&#148;)&nbsp;may be resold by them only in transactions permitted by Rule 144 (when available, as further described below), or otherwise in accordance with the&nbsp;Securities
Act. Persons who may be deemed affiliates of New Parent generally include individuals or entities that control, are controlled by or are under common control with, New Parent, including the directors and executive officers of New Parent, as well as
its principal shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144, a person who has beneficially owned restricted New Parent Shares or New Parent Warrants for at least
six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been an affiliate of New Parent at the time of, or at any time during the three months preceding, a sale and (ii)&nbsp;New Parent is
subject to the&nbsp;Exchange Act&nbsp;periodic reporting requirements for at least three months before the sale and has filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as New
Parent was required to file reports) preceding the sale. Persons who have beneficially owned restricted New Parent Shares or New Parent Warrants for at least six months but who are affiliates of New Parent at the time of, or at any time during the
three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one percent (1%) of the total number of New Parent Shares then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of the New Parent Shares during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales by affiliates of New Parent under Rule 144 are also limited by manner of
sale provisions and notice requirements and to the availability of current public information about New Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restrictions on the Use of Rule 144
by Shell Companies or Former Shell Companies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 144 is not available for the resale of securities initially issued by shell companies (other
than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as
applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than current reports; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC
reflecting its status as an entity that is not a shell company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, although New Parent will be a new registrant, Rule 144
will not be available for the resale of New Parent Shares and New Parent Warrants until at least one year after New Parent has filed Form 10 type information with the SEC, which is expected to be filed no later than the <FONT
STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;filed</FONT> with respect to the Acquisition Closing, subject to New Parent continuing to satisfy the Exchange Act reporting requirements described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC anticipates that, following the consummation of the Business Combination, New Parent will no longer be
a shell company and, as a result, following the <FONT STYLE="white-space:nowrap">one-year</FONT> period described above, Rule 144 will become available for resale of New Parent Shares and New Parent Warrants, subject to New Parent continuing to
satisfy the Exchange Act reporting requirements above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 of the Securities Act as currently in effect, each of Oculis&#146; employees, consultants or advisors who purchases equity shares
from New Parent in connection with a compensatory stock plan or other written agreement executed prior to the completion of the Business Combination is eligible to resell those equity shares in reliance on Rule 144, but without compliance with some
of the restrictions, including the holding period, contained in Rule 144. However, the Rule 701 shares would remain subject <FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;arrangements</FONT> and would only become eligible for sale when <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;period</FONT> expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_24"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EBAC Relationships and Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18,
2021, the Sponsor paid $25,000 to cover certain offering and formation costs of EBAC in consideration for 2,875,000 Founder Shares. On March&nbsp;15, 2021, EBAC effected a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-for-5</FONT></FONT> share split, resulting in an aggregate of 3,450,000 Founder Shares issued and outstanding. The Sponsor previously transferred 50,000 Founder Shares to two of its
independent directors prior to EBAC&#146;s initial public offering and such securities would be worthless if a business combination is not consummated within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed to waive their rights to liquidating distributions from the Trust Account
with respect to any Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period and, in the event EBAC fails to complete an initial business combination within the Combination Period, the
Founder Shares would have no value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor paid an aggregate of $4.55&nbsp;million for its 455,096 Private Placement Units and such Private Placement Units (and the underlying securities)
will expire worthless if a business combination is not consummated within the Combination Period. The Private Placement Units had an estimated aggregate value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based on the
closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit on the Nasdaq Capital Market on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary
General Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the Business Combination, New Parent will enter into the Registration Rights and
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with Sponsor and certain Oculis Shareholders. Pursuant to the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, Sponsor and such Oculis Shareholders may not
transfer New Parent Shares (subject to certain exceptions) until: (i)&nbsp;with respect to the New Parent Shares held by the Oculis Shareholders party thereto upon the Acquisition Closing, 180 days from the Acquisition Closing, and (ii)&nbsp;with
respect to the New Parent Shares held by Sponsor upon the Acquisition Closing, 270 days after the Acquisition Closing, in each case subject to earlier release if the New Parent Shares trade at or above a volume weighted average price of $15.00 for
20 trading days during any 30 trading day period commencing at least 150 days following the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registration Rights and <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement provides Sponsor and the Oculis Shareholders party thereto certain customary registration rights, including demand and piggyback registration rights, subject to customary requirements and
conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC entered into an agreement, commencing on March&nbsp;18, 2021, to pay an affiliate of the Sponsor $20,000 per month for office space, secretarial and
administrative services. As of October&nbsp;17, 2022, such agreement has been terminated with no further payments or other obligations owed to such affiliate. As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, there were $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fees payable to such affiliate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor Support Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Sponsor, EBAC and Oculis entered into the Sponsor Support Agreement, pursuant to which
Sponsor agreed to, among other things, (i)&nbsp;vote to adopt and approve the Business Combination Agreement and the other documents contemplated thereby and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the transactions contemplated thereby, (ii)&nbsp;not transfer its shares of EBAC Common Stock and EBAC Warrants, in each case, until the consummation of the Acquisition Closing (subject to
certain customary exceptions), (iii) waive certain anti-dilution adjustments, and (iv)&nbsp;waive certain redemption rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oculis&#146;
Relationships and Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2019, there has not been, nor is there currently proposed, any material transaction
or series of similar material transactions to which Oculis was or is a party in which any of the members of its board of directors or executive officers, holders of more than 10% of any class of its voting securities, or any member of the immediate
family of any of the foregoing persons, had or will have a direct or indirect material interest, other than the director and executive officer compensation and indemnification arrangements described elsewhere in this proxy statement/prospectus,
including in the section entitled &#147;<I>Management of New Parent After the Business Combination</I>,&#148; and the transactions we describe below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Executive Officer Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside
from standard employment agreements, there are no transactions between the directors and executive officers of Oculis on the one hand and Oculis on the other. The remuneration of the directors and executive officers (excluding <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors), who are the key management personnel of Oculis, is described in the section entitled &#147;<I>Management of New Parent After the Business Combination</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Articles
of Association provide that we will indemnify our directors and officers to the fullest extent permitted by Swiss law, subject to certain exceptions contained in our proposed constitution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent also intends to enter into indemnification agreements with each of its directors and executive officers. The indemnification agreements will
provide the indemnitees with contractual rights to indemnification, and expense advancement and reimbursement, to the fullest extent permitted under Swiss law, subject to certain exceptions contained in those agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the Acquisition
Closing, and consistent with Swiss law and the Proposed Articles of Association, New Parent intends to adopt a policy and procedures whereby its audit committee will be responsible for reviewing and approving related party transactions. In addition,
New Parent&#146;s Code of Business Conduct and Ethics will require that all of its employees and directors inform New Parent of any material transaction or relationship that comes to their attention that could reasonably be expected to create a
conflict of interest, including any transaction that would require disclosure under Item 7 of Form <FONT STYLE="white-space:nowrap">20-F.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Business Combination Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with the Business Combination, certain agreements were entered into or will be entered into pursuant to the Business Combination Agreement. The agreements described in this section, or forms of such agreements as they will be in effect substantially
concurrently with the completion of the Business Combination, are filed as exhibits to the registration statement of which this proxy statement/prospectus forms a part, and the following descriptions are qualified by reference thereto. These
agreements include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subscription Agreements (see the section entitled &#147;<I>Certain Agreements Related to the Business
Combination</I> &#151; <I>The Subscription Agreements</I>&#148; for details); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convertible Loan Agreements (see the section entitled &#147;<I>Certain Agreements Related to the Business
Combination</I> &#151; <I>The Convertible Loan Agreements</I>&#148; for details); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis Shareholders Support Agreements (see the section entitled &#147;<I>Certain Agreements Related to the
Business Combination</I> &#151; <I>The Oculis Shareholders Support Agreements</I>&#148; for details); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sponsor Support Agreement (see the section entitled &#147;<I>Certain Agreements Related to the Business
Combination</I> &#151; <I>The Sponsor Support Agreement</I>&#148; for details); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (see the section entitled
&#147;<I>Certain Agreements Related to the Business Combination</I> &#151; <I>The Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>&#148; for details); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements (see the section entitled &#147;<I>Certain
Agreements Related to the Business Combination</I> &#151; <I>The <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements</I>&#148; for details). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_25"></A>BENEFICIAL OWNERSHIP OF NEW PARENT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Security Ownership of Certain Beneficial Owners and Management of New Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of EBAC Class&nbsp;A Common Stock as of December&nbsp;31, 2022 and New Parent
Shares immediately following consummation of the Business Combination by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by EBAC to be the beneficial owner of more than 5% of EBAC Class&nbsp;A Common Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of EBAC&#146;s current executive officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of EBAC&#146;s current executive officers and directors as a group; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person expected by New Parent to be the beneficial owner of more than 5% of the outstanding New Parent
Shares after the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is expected to become an executive officer or a director of New Parent upon consummation of the
Business Combination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of New Parent&#146;s executive officers and directors following consummation of the Business Combination as a
group. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial
ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently fully exercisable or fully exercisable within 60 days of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and restated memorandum and articles of association, each share of EBAC Class&nbsp;A Common Stock entitles the holder to one
vote per share. Pursuant to the New Parent Organization Documents, one New Parent Share will entitle the holder thereof to one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The beneficial
ownership of the EBAC Class&nbsp;A Common Stock prior to the Business Combination is based on 16,398,576 shares of EBAC Class&nbsp;A Common Stock outstanding as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of New Parent Shares post-Business Combination assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The issuance of an aggregate of 9,085,891 New Parent Shares to the PIPE Investors and Lenders under the
Convertible Loan Agreements on the Acquisition Closing Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">That 20,276,208 New Parent Shares are issued to Oculis Shareholders, not including any New Parent Shares that may
be issuable pursuant to the exercise of Rollover Options (as defined in the Business Combination Agreement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No exercise of the 4,403,294 New Parent Warrants that will remain outstanding post-Business Combination.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of New Parent Shares post-Business Combination Assuming No Redemption in the table below has been
determined based upon the following assumptions: (i)&nbsp;no public EBAC Shareholders exercise their redemption rights and (ii)&nbsp;that there will be 45,033,579 New Parent Shares outstanding. In computing the number of New Parent Shares
beneficially owned by a person and the percentage ownership person, we deemed outstanding shares subject to options held by that person that are currently fully exercisable or fully exercisable within 60 days of December&nbsp;31, 2022 to be
outstanding. We did not deem these shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
expected beneficial ownership of New Parent Shares post-Business Combination Assuming Maximum Redemption in the table below has been determined based upon the following assumptions: (i)&nbsp;that all shares of EBAC Class&nbsp;A Common Stock, other
than those committed through <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, are redeemed for an aggregate payment of approximately $120.5&nbsp;million (based on the estimated per share redemption price of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately $10.052 per share based on the fair value of marketable securities held in the Trust Account as of September&nbsp;30, 2022 of approximately $128.3 million) from the Trust Account
and (ii)&nbsp;that there will be approximately 34,588,901 New Parent Shares outstanding immediately after the Acquisition Closing. Maximum redemption assumes that the Minimum EBAC Cash Condition will still be satisfied. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Business&nbsp;Combination</FONT></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Business Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming Maximum<BR>Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of<BR>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of<BR>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of<BR>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; "></TR>
<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LSP Sponsor EBAC B.V.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,792,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,711,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>EBAC Directors and Executive Officers <FONT STYLE="white-space:nowrap">Pre-Business</FONT>
Combination<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP>:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eduardo Bravo Fernandez de Araoz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koen Sintnicolaas</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,792,618<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,711,649<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.83<BR></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;<BR></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Wegter<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,792,618<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,711,649<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.83<BR></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;<BR></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volkert Doeksen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Onno van de Stolpe</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mohammad Sohail Fazeli</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All officers and directors as a group (7 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,842,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,761,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Executive Officers of New Parent After Consummation of the Business
Combination<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Riad Sherif, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sylvia Cheung<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P&aacute;ll Ragnar
J&oacute;hannesson<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christina Ackermann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pravin Dugel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martijn Kleijwegt<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geraldine O&#146;Keeffe</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Rosenberg<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All officers and directors as a group (9 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,410,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,410,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Five Percent Holders of New Parent After Consummation of the Business
Combination:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LSP 7 Co&ouml;peratief U.A.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,023,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,023,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain funds managed by Pivotal
Partners<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,029,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,029,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brunnur vaxtarsj&oacute;&eth;ur
slhf.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,335,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,335,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BEYEOTECH<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,069,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,069,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Bioventures Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(12) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,177,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,177,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported above are held in the name of our sponsor. MRMJ Holding B.V., a Dutch limited liability
company, is the majority owner of our sponsor and as such, MRMJ Holding B.V. has voting and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
investment discretion with respect to the shares held of record by our sponsor and may be deemed to have shared beneficial ownership of the shares held by our sponsor. Ren&eacute; Kuijten,
Joachim Rothe, Martijn Kleijwegt and Mark Wegter who are directors of MRMJ Holding B.V. have voting and investment discretion with respect to the shares owned by MRMJ Holding B.V. and may be deemed to have indirect shared beneficial ownership of the
shares held by our sponsor. Mr.&nbsp;Kuijten, Mr.&nbsp;Rothe, Mr.&nbsp;Kleijwegt and Mr.&nbsp;Wegter each disclaim beneficial ownership over the founder shares except to the extent of their pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise noted, the business address of each of the entities or individuals listed is EPFL Innovation
Park Building D 1015 Lausanne, Switzerland. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interests shown consist solely of Founder Shares. In connection with the Business Combination, such shares will
automatically convert into New Parent Shares at the time of our initial business combination on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, subject to adjustment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 878,447 New Parent Shares to be issued in exchange for 768,424 ordinary shares of Oculis held prior
to the Acquisition Closing Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 66,805 New Parent Shares to be issued in exchange for 58,438 ordinary shares of Oculis held
prior to the Acquisition Closing Date and (ii) 73,212 New Parent Shares issuable upon conversion of options to be granted to replace 59,625 Oculis share options, vested and fully exercisable within 60 days of December&nbsp;31, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 249,213 New Parent Shares to be issued to replace 218,000 ordinary shares of Oculis
beneficially owned through Sj&oacute;narh&oacute;ll fj&aacute;rfestingar ehf., over which Mr.&nbsp;J&oacute;hannesson has sole voting and dispositive power, prior to the Acquisition Closing Date and (ii) 249,118 New Parent Shares issuable upon
conversion of options to be granted to replace 217,084 Oculis share options, vested and fully exercisable within 60 days of December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 96,666 New Parent Shares to be issued in exchange for 84,559 ordinary shares of Oculis held prior
to the Acquisition Closing Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,789,600 PIPE Shares and (ii) 233,405 New Parent Shares to be issued in exchange for 197,745
preferred shares of Oculis held prior to the Acquisition Closing Date. LSP 7 Management B.V. is the sole director of LSP 7 Co&ouml;peratief UA. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As
such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the securities held of record by LSP 7 Co&ouml;peratief UA. Each of Mr.&nbsp;Kleijwegt, Mr.&nbsp;Kuijten and Mr.&nbsp;Rothe disclaims
beneficial ownership of such shares. The business address of each of the entities and individuals identified in this footnote is Johannes Vermeerplein 9 1071 DV Amsterdam, Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 209,781 New Parent Shares to be issued upon conversion of the Convertible Loan Agreement held
by Pivotal bioVenture partners Fund I, L.P. (&#147;<I>Pivotal</I>&#148;), (ii) 2,169,444 New Parent Shares to be issued in exchange for 1,576,657 preferred shares of Oculis held by Pivotal prior to the Acquisition Closing Date, (iii) 57, 219 New
Parent Shares to be issued upon conversion of the Convertible Loan Agreement held by NFLS Beta Limited (&#147;<I>NFLS Beta</I>&#148;) and (iv) 592,673 New Parent Shares to be issued in exchange for 435,505 preferred shares of Oculis held by NFLS
Beta prior to the Acquisition Closing Date. The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. (&#147;<I>Pivotal GP</I>&#148;). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the
&#147;<I>Ultimate General Partner&#148;</I>). Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner, and may, along with the Ultimate General Partner be deemed to have shared voting and investment
control and power over the shares owned by Pivotal. Such persons disclaim beneficial ownership of such securities except to the extent of any pecuniary interest therein. The Ultimate General Partner is wholly owned by Pivotal Partners Ltd
(&#147;<I>Pivotal Partners</I>&#148;). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (&#147;<I>Pivotal Life Sciences</I>&#148;). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited
(&#147;<I>Nan Fung Life Sciences</I>&#148;), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (&#147;<I>NFIHL</I>&#148;). NFLS Beta is wholly owned by NFLS Platform Holdings Limited, which is wholly owned by Nan Fung Life
Sciences. Nan Fung Life Sciences is wholly owned by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Nan Fung Group Holdings Limited (&#147;<I>NFGHL</I>&#148; and together with Pivotal, Pivotal GP, Ultimate General Partner, Pivotal Partners, Pivotal Life Sciences, Nan Fung Life Sciences and
NFIHL, the &#147;<I>Pivotal Parties</I>&#148;). The members of the Executive Committee of NFGHL make voting and investment decisions with respect to shares of our common stock held by NFLS Beta. Kam Chung Leung, Frank Kai Shui Seto, Vincent Sai Sing
Cheung, Pui Kuen Cheung, Vanessa Tih Lin Cheung, Meng Gao and Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Such persons disclaim beneficial ownership of such securities except to the extent of any pecuniary interest
therein. The Pivotal Parties share voting and dispositive power over the shares held by Pivotal. The business address of Pivotal, Pivotal GP, Ultimate General Partner, Pivotal Partners and Pivotal Life Sciences is 501 Second Street, Suite 200, San
Francisco, CA 94107. The address of NFGHL is 23rd Floor, Nan Fung Tower, 88 Connaught Road Central and 173 Des Voeux Road Central, Central, Hong Kong. The address of NFIHL is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola,
VG1110, British Virgin Islands. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,335,743 New Parent Shares to be issued in exchange for 1,931,692 preferred shares of Oculis held
prior to the Acquisition Closing Date. Voting and dispositive decisions require a majority vote of the directors of Brunnur vaxtarsj&#243;&eth;ur slhf., composed of three individuals, Gu&eth;bj&#246;rg Edda Eggertsd&#243;ttir, Hj&#246;rleifur
P&#225;lsson and Gu&eth;r&#250;n Tinna &#211;lafsd&#243;ttir, and, as such, each disclaim any beneficial ownership of any such shares, except to the extent of his or her pecuniary interest therein. The business address of Brunnur
vaxtarsj&oacute;&eth;ur slhf. is Borgart&uacute;n 33, 105, 105 Reykjav&iacute;k, Iceland. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,069,297 New Parent Shares to be issued in exchange for 1,635,339 preferred shares of Oculis held
prior to the Acquisition Closing Date. Voting and dispositive decisions require a majority vote of the investment committee composed of six individuals, Zhi Yang, Robert Li, Vanessa Huang, Huacheng Wei, Maggie Chen, and Rachel Zhao, and, as such,
each disclaim any beneficial ownership of any such shares, except to the extent of his or her pecuniary interest therein. The business address of BEYEOTECH is 190 Elgin Avenue, George Town, Grand Cayman
<FONT STYLE="white-space:nowrap">KY1-9008,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 255,000 PIPE Shares owned by Novartis Bioventures Ltd., (ii) 1,521,126 New Parent Shares to be
issued in exchange for 1,102,245 preferred shares of Oculis held by Novartis Bioventures Ltd. prior to the Acquisition Closing Date and (iii) 401,702 New Parent Shares to be issued in exchange for 351,390 ordinary shares of Oculis held by Novartis
Pharma AG prior to the Acquisition Closing Date. The foregoing shares are directly owned by Novartis Bioventures Ltd. and Novartis Pharma AG, respectively. Novartis Bioventures Ltd. and Novartis Pharma AG are each wholly-owned indirect subsidiaries
of Novartis AG, which is an indirect beneficial owner of the reported securities. As the indirect parent of Novartis Bioventures, Ltd. and Novartis Pharma AG, Novartis AG shares voting and dispositive power over, and may be deemed to beneficially
own, the reported securities. The business address of Novartis Bioventures Ltd., Novartis Pharma AG and Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_26"></A>PRICE RANGE OF SECURITIES AND DIVIDENDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBAC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Price Range of EBAC Securities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC Units, each of which consists of one share of EBAC Class&nbsp;A Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one EBAC Public
Warrant, began trading on the Nasdaq Capital Market under the symbol &#147;EBACU&#148; on March&nbsp;18, 2021. On May&nbsp;4, 2021, EBAC announced that holders of its public units could elect to separately trade the EBAC Class&nbsp;A Common Stock
and EBAC Redeemable Warrants commencing on May&nbsp;6, 2021. On May&nbsp;18, 2021, the EBAC Class&nbsp;A Common Stock and EBAC Redeemable Warrants began trading on the Nasdaq Capital Market under the symbols &#147;EBAC&#148; and &#147;EBACW,&#148;
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2022, the trading date immediately before the public announcement of the Business Combination, the EBAC Units, EBAC
Class&nbsp;A Common Stock and EBAC Public Warrants closed at $9.93, $9.92 and $0.12, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has not paid any cash dividends on the EBAC Class&nbsp;A Common Stock to date and does not intend to pay cash dividends prior to the completion of the
Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oculis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Price Range
of Oculis Securities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical market price information regarding Oculis is not provided because Oculis is a privately held company and there is no
public market for Oculis&#146; securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis has not paid any cash dividends on the Oculis ordinary shares to date and does not intend to pay cash dividends prior to the completion of the Business
Combination. A contractual preferred right for an annual increase of the conversion ratio on certain Preferred Shares is reflected by a different conversion ratio for such Preferred Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_27"></A>PROPOSAL NO.&nbsp;1 &#151; THE BUSINESS COMBINATION PROPOSAL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Business Combination Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This
section of this proxy statement/prospectus describes the material provisions of the Business Combination Agreement, but does not purport to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its
entirety by reference to the complete text of the Business Combination Agreement, a copy of which is attached as <U>Annex A</U> hereto, and the summary below is included solely to provide investors with information regarding the terms of the
Business Combination Agreement. They are not intended to provide factual information about the parties or any of their respective subsidiaries or affiliates. The Business Combination Agreement was entered into by and between EBAC and Oculis on
October&nbsp;17, 2022 and contains representations and warranties by EBAC and Oculis, which were made only for purposes of that agreement and as of specific dates. The representations, warranties and covenants in the Business Combination Agreement
were made solely for the benefit of the parties to the Business Combination Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating
contractual risk between the parties to the Business Combination Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those generally
applicable to investors. Investors are not third-party beneficiaries under the Business Combination Agreement, and in reviewing the representations, warranties and covenants contained in the Business Combination Agreement or any descriptions thereof
in this summary, it is important to bear in mind that such representations, warranties and covenants or any descriptions thereof were not intended by the parties to the Business Combination Agreement to be characterizations of the actual state of
facts or condition of EBAC, Oculis or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Business Combination
Agreement, which subsequent information may or may not be fully reflected in public disclosures. You are urged to read the Business Combination Agreement in its entirety because it is the primary legal document that governs the Business Combination.
Capitalized terms used in this section but not otherwise defined herein have the meanings given to them in the Business Combination Agreement. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General Structure of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The First Merger; Conversion of EBAC Capital Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the First Merger Effective time, Merger Sub 1 will merge with and into EBAC, the separate entity existence of Merger Sub 1 will cease and EBAC will be the
surviving company and a wholly owned subsidiary of New Parent. As part of the First Merger, (i)&nbsp;each share of EBAC Common Stock (including those held by the PIPE Investors) shall be automatically converted into one class of common stock of
EBAC, as the surviving company of the First Merger, (ii)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into warrants of EBAC, as the surviving company of the First Merger and
(iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms, and subject to the
conditions set forth in the Business Combination Agreement and in the Ancillary Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Exchange Agent Contribution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time, the Exchange Agent
will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in exchange for (i)&nbsp;New Parent Shares and (ii)&nbsp;New Parent Warrants, in each case of (i)&nbsp;and (ii), to be held by the Exchange Agent solely on behalf of
the holders of Surviving EBAC Shares and Surviving EBAC Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Exchange Agent Distribution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange
Agent will (i)&nbsp;undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests
Consideration to the holders of Surviving EBAC Warrants (the &#147;<I>Exchange Agent Contribution Actions</I>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Second
Merger; Liquidation of Merger Sub 2 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution
Actions, at the Second Merger Effective Time, EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent.
Following the Acquisition Closing, Merger Sub 2 shall be liquidated, and its assets shall be distributed to New Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Oculis
Share Contribution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders executing Oculis Shareholders
Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the contribution to New Parent of all Company Share Capital held by such Oculis Shareholder free and clear of all liens (other than general
restrictions on transfer under applicable securities laws or the articles of association of Oculis) in exchange for New Parent Shares (the number of New Parent Shares so issued, the &#147;<I>Company Consideration</I>&#148;) on the terms, and subject
to the conditions set forth in the Business Combination Agreement and the Oculis Shareholders Support Agreements. All such contributing Oculis Shareholders shall have committed to undertake such steps, including the execution of a contribution
agreement, as are necessary to effect the contribution of the full legal and beneficial ownership of the applicable Company Share Capital to New Parent. Any New Parent Shares to be issued as Company Consideration to the Oculis Shareholders shall be
of the same class, with equal rights and privileges, as any New Parent Shares to be issued as part of the New Parent Interests Consideration to the EBAC Shareholders and PIPE Investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Third Merger </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 30 days
after the Acquisition Closing Date, pursuant to a merger agreement to be entered into in accordance with the Business Combination Agreement, Oculis will merge with and into Merger Sub 3, the separate corporate existence of Oculis will cease and
Merger Sub 3 will be the surviving company and remain a wholly owned subsidiary of New Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>New Parent Share Capital Increase
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent shall undertake all corporate steps required to increase its share capital to reflect the issuance of the New Parent Shares to be
transferred to EBAC Shareholders, PIPE Investors and Oculis Shareholders (the &#147;<I>New Parent Share Capital Increase</I>&#148;), as described above. Unless otherwise agreed by New Parent and the relevant recipient of the New Parent Shares, all
New Parent Shares shall be uncertificated, with record ownership reflected on the books and records of New Parent. Immediately following the New Parent Share Capital Increase, the Exchange Agent and the Oculis Shareholders shall hold all New Parent
Shares, with the exception of any New Parent Shares held by New Parent as treasury shares, and immediately thereafter, the New Parent Shares as part of the New Parent Interests Consideration shall be delivered by the Exchange Agent to the EBAC
Shareholders, including the PIPE Investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion of EBAC Capital Stock</I>. At the First Merger Effective Time, by virtue of the First Merger
and without any action on the part of any other person, holders of EBAC capital stock shall have their respective equity interests converted as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>EBAC Units</I>. Each EBAC Unit outstanding immediately prior to the First Merger Effective Time shall be
automatically detached and the holder of such unit shall be deemed to hold one share of EBAC Class&nbsp;A Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of an EBAC Warrant in accordance with the terms of the applicable EBAC Unit,
which underlying shares of EBAC Class&nbsp;A Common Stock and EBAC Warrants shall be adjusted, if applicable, in accordance with the applicable terms of the Business Combination Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>EBAC Capital Stock. </I>Immediately following the separation of each EBAC Unit in accordance with the Business
Combination Agreement and in connection with the First Merger, the shares of EBAC Common Stock will be automatically converted into the Surviving EBAC Shares, and in connection with such conversion, EBAC shall deposit, or cause to be deposited, each
Surviving EBAC Share with the Exchange Agent (solely on behalf of the EBAC Shareholders, including the PIPE Investors). As of the First Merger Effective Time, each EBAC Shareholder shall cease to have any other rights in and to EBAC and each share
of EBAC Class&nbsp;A Common Stock issued and outstanding immediately prior to the First Merger Effective Time shall automatically be cancelled and cease to exist; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exchange of EBAC Warrants</I>. Each EBAC Warrant outstanding immediately prior to the First Merger Effective
Time shall, at the First Merger Effective Time, be automatically converted into the Surviving EBAC Warrants and such Surviving EBAC Warrants shall be deposited with the Exchange Agent (solely on behalf of the holders of EBAC Warrants) in exchange
for the right of each holder of EBAC Warrants to receive New Parent Warrants pursuant to the Warrant Conversion on the terms, and subject to the conditions of, the Warrant Assumption Agreement. Each EBAC Warrant outstanding immediately prior to the
First Merger Effective Time shall, at the First Merger Effective Time, cease to be a warrant with respect to EBAC Common Stock and shall be assumed by New Parent pursuant to the Warrant Assumption Agreement on substantially the same terms as were in
effect immediately prior to the Merger Effective Time under the terms of the EBAC Warrant Agreement (including any repurchase rights and cashless exercise provisions); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>New Parent Shares Held by EBAC</I>. The New Parent Shares held by EBAC shall be cancelled for no consideration
immediately prior to the implementation of the Second Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>EBAC Treasury Stock</I>. If there are any shares of EBAC Common Stock that are owned by EBAC as treasury stock
or any EBAC Common Stock owned by any direct or indirect subsidiary of EBAC immediately prior to the First Merger Effective Time, such EBAC Common Stock (other than such shares of EBAC Class A Common Stock issued from treasury to the PIPE Investors)
shall be cancelled and shall cease to exist without any conversion thereof or payment or any other consideration; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>EBAC Redeeming Shares</I>. If there are any shares of EBAC Common Stock that are required to be redeemed
pursuant to the EBAC Share Redemption, such EBAC Common Stock shall immediately prior to the First Merger Effective Time, be repurchased by EBAC into treasury in return for which the right shall be granted to receive the applicable EBAC Share
Redemption Amount, subject to the Acquisition Closing being completed and on the terms and subject to the other conditions and limitations set forth in the Business Combination Agreement, EBAC&#146;s amended and restated memorandum and articles of
association, the Trust Agreement and this proxy statement/prospectus. The applicable EBAC Share Redemption Amount will, subject to all conditions to the Acquisition Closing being met, be paid by New Parent. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Merger Consideration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration
payable to current Oculis equityholders in connection with the Business Combination will be comprised of New Parent Shares. Each New Parent Share shall entitle the holder thereof to one vote and such holder will be entitled to receive dividends if
and when declared. The aggregate value of the consideration of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New Parent Shares payable to existing Oculis equityholders, without considering the Earnout Consideration (as defined below) equals $208,000,000 (subject to certain adjustments) (valuing each New
Parent Share at $10.00 per share). Additionally, all unexercised Oculis options will be assumed by New Parent and converted into options to purchase New Parent Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Earnout Consideration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the
consideration described above, Oculis Shareholders will also be entitled to receive at the Acquisition Closing additional consideration in the form of an earnout of, collectively, 4,000,000 Earnout Shares and Earnout Options, which will initially be
unvested and will be subject to forfeiture, on the terms and subject to the conditions set forth in the Business Combination Agreement. The Earnout Consist will consist of three tranches of Earnout Shares, as follows (in the case of each tranche,
<I>minus</I> any Earnout Options granted to replace vested options to purchase shares of Oculis common stock): (i) 1,500,000 shares, (ii) 1,500,000 shares, and (iii) 1,000,000 shares, vesting based on achievement of post-closing share price targets
of New Parent of $15.00, $20.00 and $25.00, respectively, in each case for any 20 trading days within any 30 trading day period during the Earnout Period. The achievement metrics described above are also deemed to be achieved if there is a Change of
Control (as defined in the Business Combination Agreement) (to the extent an applicable share price target has not already occurred) during the Earnout Period. The Earnout Shares shall not be entitled to vote on matters submitted to the holders of
New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New Parent Shares, if any, until such Earnout Shares vest. The Earnout Shares that have not vested by the end of the Earnout Period shall,
automatically be forfeited and cancelled for no consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor EBAC Class&nbsp;B Common Stock Forfeiture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor has agreed to forfeit 727,096 of its shares of EBAC Class&nbsp;B Common Stock for no consideration, contingent upon the consummation of the
Acquisition Closing. Furthermore, if as of the Acquisition Closing Date (i)&nbsp;the amount of cash available in the Trust Account following the Extraordinary General Meeting (after deducting the EBAC Share Redemption Amount but before payment of
any transaction expenses of Oculis and EBAC), plus (ii)&nbsp;the PIPE Investment Amount actually received by New Parent (or other financing, including through a convertible loan, in connection with the Acquisition Transactions) prior to or
substantially concurrently with the Acquisition Closing from a PIPE Investor or certain other investor that in either case has been introduced to Oculis following the date of the Business Combination Agreement by the Sponsor or its affiliates, is
less than $25,500,000, then the Sponsor will forfeit for no consideration an additional number of EBAC Class&nbsp;B Common Stock (the &#147;<I>Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Shares</I>&#148;) proportional to the available
cash relative to the $25,500,000 threshold (up to a maximum of 1,594,348 Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Shares forfeited); provided that such amount may be reduced by the number of Additional <FONT
STYLE="white-space:nowrap">At-Risk</FONT> Shares transferred by the Sponsor to EBAC Shareholders in connection with executing a <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement or similar arrangement after the date of the Business
Combination Agreement; provided further that, the number of shares transferred to any such shareholder does not exceed 10% of the number of EBAC Class&nbsp;A Common Stock owned by such shareholder as of the date of such <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement or similar arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Closing and Effective Time of the Business
Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Closings</I>. Subject to the satisfaction or waiver of all of the conditions set forth in the Business Combination Agreement, and
provided that the Business Combination Agreement has not been terminated pursuant to its terms, on the Acquisition Closing Date, the parties to the Business Combination Agreement shall cause the First Merger and Second Merger to be consummated by
filing with the Cayman Registrar of Companies certain plans of merger, duly executed and completed in accordance with the relevant provisions of the Cayman Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Acquisition Closing Date, the transferring Oculis Shareholders and New Parent shall consummate the Oculis Share Contribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Parent Share Capital Increase shall be made prior to the consummation of the Second Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the next business day (unless otherwise agreed between EBAC and Oculis) following the date which is three business days after the date on which all of the
conditions set forth in the Business Combination Agreement have been satisfied or waived, or such other time and place as EBAC and Oculis mutually agree in writing, the Acquisition Closing shall take place electronically through the exchange of
documents via email. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, the parties expect that the Business Combination will be effective during the
first half of 2023. However, there can be no assurances as to when or if the Business Combination will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is not
completed by March&nbsp;18, 2023 (the &#147;<I>Agreement End Date</I>&#148;), the Business Combination Agreement may be terminated by either EBAC or Oculis; <I>provided</I>, that if an Extension Proposal (as defined below) shall be approved at an
Extension Shareholders&#146; Meeting (as defined below), then the Agreement End Date shall be the last day of the extended time period for EBAC to consummate a business combination. A party may not terminate the Business Combination Agreement
pursuant to the provision described in this paragraph if the party seeking to terminate the Business Combination Agreement is in breach of its obligations set forth therein on the Agreement End Date. Please see the section entitled
&#147;&#151;<I>The Business Combination Agreement&#151;Termination.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Covenants and Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Oculis&#146; Conduct of Businesses Prior to the Completion of the Business Combination.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis has agreed that, from the date of the Business Combination Agreement through the earlier of the Acquisition Closing or the valid termination of the
Business Combination Agreement pursuant to its terms (the &#147;<I>Interim Period</I>&#148;), it will, and will cause its subsidiaries to, use commercially reasonable efforts to (i)&nbsp;operate its business in the ordinary course of business
consistent with past practice, and (ii)&nbsp;preserve intact the present business organization, retain the current officers, and preserve the relationships with key suppliers and customers (if applicable), in each case, except as otherwise provided
explicitly in the Business Combination Agreement or any of the Ancillary Agreements, as required by law (including any quarantine, &#147;shelter in place,&#148; &#147;stay at home,&#148; workforce reduction, social distancing, shut down, closure,
sequester or any similar law, mandate, directive, guidelines or recommendations by any governmental authority in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including the Coronavirus Aid, Relief, and Economic
Security Act (&#147;<I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</I>&#148;)), for any reasonable action or inaction, including the establishment of any policy, procedure or protocol, by Oculis and its subsidiaries that Oculis
determines in its reasonable discretion is necessary, advisable or prudent in connection with (A)&nbsp;mitigating the adverse effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or applicable <FONT STYLE="white-space:nowrap">COVID-19</FONT>
Measures, (B)&nbsp;ensuring compliance by Oculis and its subsidiaries with <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures applicable to any of them and/or (C)&nbsp;in respect of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> protecting
the health and safety of employees or other persons with whom Oculis and its subsidiaries and their personnel come into contact with during the course of business operations, with EBAC&#146;s written consent (which may not be unreasonably
conditioned, withheld, delayed or denied) or as set forth in the Oculis Disclosure Letter to the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the
general covenants above, Oculis has agreed that prior to the Acquisition Closing, subject to specified exceptions, it will not, and will cause its subsidiaries not to, without the written consent of EBAC (which may not be unreasonably conditioned,
withheld, delayed or denied): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or amend the certificate of incorporation, bylaws or other organizational documents of Oculis or any of
its subsidiaries in a manner adverse in any material respect to EBAC, New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or declare any dividend or distribution to its equityholders or make any other distributions in respect of
any Company Share Capital (as defined in the Business Combination Agreement) or the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
equity securities of Oculis or any of its subsidiaries (other than any dividends or distributions between or among Oculis and any of its subsidiaries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine, reclassify, recapitalize or otherwise amend any terms of any shares or series of Oculis and any
of its subsidiaries&#146; capital stock or equity securities, except with respect to any split, combination, reclassification or recapitalization of any shares or series of any subsidiary of Oculis&#146; capital stock or equity securities, in a
manner not adverse in any material respect to Oculis or any of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of
capital stock, membership interests or other equity securities of Oculis or any of its subsidiaries, except for (i)&nbsp;the acquisition by Oculis or any of its subsidiaries of any shares of capital stock, membership interests or other equity
securities of Oculis or its subsidiaries, or (ii)&nbsp;transactions between Oculis and any wholly owned subsidiary of Oculis or between its wholly owned subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or a
material portion of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, assign, transfer, convey, lease or otherwise dispose of any material tangible assets or properties of
Oculis or its subsidiaries, except for (i)&nbsp;dispositions of obsolete or worthless equipment, (ii)&nbsp;transactions among Oculis and its subsidiaries or among its subsidiaries, (iii)&nbsp;transactions in the ordinary course of business
consistent with past practice, or (iv)&nbsp;transactions involving assets or properties that are sold, assigned, transferred, conveyed, leased or otherwise disposed of at or above fair market value (as reasonably determined by EBAC) and that in the
aggregate generate less than 5% of the consolidated EBITDA of Oculis and its subsidiaries for the most recent four completed consecutive fiscal quarters ending prior to the consummation of such transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) issue or sell any debt securities of Oculis or any of its subsidiaries or otherwise incur or assume any
indebtedness, or (ii)&nbsp;guarantee any indebtedness of another person, in each case, except (a)&nbsp;in the ordinary course of business consistent with past practice or (b)&nbsp;for the issuance, sale, or incurrence of debt securities or
indebtedness used to refinance existing indebtedness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) fail to timely pay all material taxes that become due and payable, (ii)&nbsp;make, change or revoke any
election in respect of material taxes, (iii)&nbsp;adopt or request permission of any governmental authority to change any material method of accounting in respect of taxes, (iv)&nbsp;settle or compromise any material tax liability, (v)&nbsp;enter
into any material agreement in respect of taxes with a governmental authority, (vi)&nbsp;enter into any tax sharing agreement (other than any such agreement solely among Oculis and its subsidiaries and customary commercial contracts entered into in
the ordinary course of business not primarily related to taxes) or (vii)&nbsp;amend, modify or otherwise change in a material respect any filed tax return unless required by applicable Law, or (viii)&nbsp;consent to any extension or waiver of the
statute of limitations regarding any material amount of taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be
expected to prevent, impair or impede the Intended Tax Treatment (as defined in the Business Combination Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) issue, sell, or otherwise dispose of any existing or additional shares of Oculis share capital or securities
exercisable for or convertible into shares of Oculis share capital, other than (a)&nbsp;in respect of the PIPE Investment, including for the avoidance of doubt, the issuance of New Parent Shares, warrants or other securities pursuant to a
Subscription Agreement or an Additional Subscription Agreement (as defined in the Business Combination Agreement) or (b)&nbsp;in connection with the exercise of Oculis options outstanding on the date of the Business Combination Agreement or
(ii)&nbsp;grant any Oculis options or other equity or equity-based compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except (i)&nbsp;as required under the existing terms of any Company Benefit Plan (as defined in the Business
Combination Agreement), as in effect on the date signing of the Business Combination Agreement, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(ii)&nbsp;as required by Business Combination Agreement, (iii)&nbsp;as required by any applicable law or (iv)&nbsp;in the ordinary course of business consistent with past practice,
(a)&nbsp;adopt, enter into, terminate or materially amend or modify any material Company Benefit Plan, (b)&nbsp;increase the compensation payable to any Oculis service provider, (c)&nbsp;accelerate any payment, right to payment, vesting or benefit,
or the funding of any payment, right to payment, vesting or benefit, payable or to become payable to any service provider or (d)&nbsp;waive or release any noncompetition, <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure or other restrictive covenant obligation of any Oculis service provider; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution,
restructuring, recapitalization or other reorganization of Oculis or any of its subsidiaries (other than the Acquisition Transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate without replacement or fail to use commercially reasonable efforts to maintain any license material to
the conduct of the business of Oculis and its subsidiaries, taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, modify in any material respect or terminate (other than expiration in accordance with its terms) any
affiliate agreements, other than as required by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, assign, transfer, abandon, permit to lapse, dispose of, license, sublicense, modify, terminate, create or
incur any lien on, or otherwise fail to take any action necessary to maintain, enforce or protect, any intellectual property of Oculis, other than granting <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the ordinary course of
business consistent with past practice; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any agreement to do any action prohibited by any of the foregoing paragraphs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>EBAC&#146;s Conduct of Businesses Prior to the Completion of the Business Combination. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has agreed that from the date of the Business Combination Agreement through the earlier of the Acquisition Closing or the valid termination of the
Business Combination Agreement pursuant to its terms, subject to specified exceptions, it will not, and will cause its subsidiaries not to, without the written consent of Oculis (which may not be unreasonably conditioned, withheld, delayed or
denied): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change, modify, amend or terminate (or seek any approval from the EBAC Shareholders to) the Trust Agreement, the
Subscription Agreements, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements or the governing documents of EBAC, except as contemplated by the Transaction Proposals or Extension Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdraw any funds from the Trust Account, other than as permitted by the Trust Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as contemplated by the Transaction Proposals (including any adjustment made with respect to the New Parent
Warrants in the Warrant Conversion), (i) make or declare any dividend or distribution to the shareholders of EBAC or make any other distributions in respect of any of EBAC&#146;s capital stock, share capital or equity interests, (ii)&nbsp;split,
combine, reclassify or otherwise amend any terms of any shares or series of EBAC&#146;s capital stock or equity interests, or (iii)&nbsp;purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares
of capital stock, share capital or membership interests, warrants or other equity interests of EBAC, other than a redemption of shares of EBAC Class&nbsp;A Common Stock made as part of the EBAC Share Redemptions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, renew or amend in any material respect, any transaction or contract with an affiliate of EBAC
(including, for the avoidance of doubt, (i)&nbsp;the Sponsor and (ii)&nbsp;any person or entity in which the Sponsor has a direct or indirect legal, contractual or beneficial ownership interest of 5% or greater); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) fail to timely pay all material taxes that become due and payable, (ii)&nbsp;make, change or revoke any
election in respect of material taxes, (iii)&nbsp;adopt or request permission of any governmental authority to change any material method of accounting in respect of taxes, (iv)&nbsp;settle or compromise any material tax liability, (v)&nbsp;enter
into any material agreement in respect of taxes with a governmental authority, (vi)&nbsp;enter into any tax sharing agreement (other than customary commercial contracts entered into in the ordinary course of business not primarily related to taxes)
or (vii)&nbsp;amend, modify or otherwise </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
change in a material respect any filed tax return unless required by applicable law, or (viii)&nbsp;consent to any extension or waiver of the statute of limitations regarding any material amount
of taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be
expected to prevent, impair or impede the Intended Tax Treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue or sell any debt securities or warrants or other rights to acquire any debt securities of EBAC or otherwise
incur or assume any indebtedness, or guarantee any indebtedness of another person or entity, other than (i)&nbsp;fees and expenses incurred in support of the transactions contemplated by the Business Combination Agreement and the Ancillary
Agreements, (ii)&nbsp;any adjustment made with respect to the New Parent Warrants in the Warrant Conversion or (iii)&nbsp;in support of the ordinary course operations of EBAC (which the parties agree shall include any indebtedness in respect of any
working capital loan incurred in the ordinary course of business, on the terms and subject to the conditions set forth in the Business Combination Agreement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) issue any securities of EBAC or securities exercisable for or convertible into EBAC securities, other than
(a)&nbsp;in respect of the PIPE Investment, including for the avoidance of doubt, EBAC Class&nbsp;A Common Stock, warrants or other securities pursuant to an Additional Subscription Agreement and (b)&nbsp;to effect a transfer or agreement to
transfer (which may be effectuated as a forfeiture to EBAC and reissuance by EBAC) of EBAC Class&nbsp;A Common Stock or EBAC Class&nbsp;B Common Stock by Sponsor to an investor pursuant to a Subscription Agreement or an Additional Subscription
Agreement, in the case of an Additional Subscription Agreement, entered into with the prior written consent of Oculis, not to be unreasonably withheld, conditioned or delayed, (ii)&nbsp;grant any options, warrants or other equity-based awards with
respect to EBAC securities not outstanding on the date of the Business Combination Agreement, except as provided for in (a)&nbsp;and (b) above, or (iii)&nbsp;amend, modify or waive any of the material terms or rights set forth in any EBAC Warrant or
the EBAC Warrant Agreement, including any amendment, modification or reduction of the warrant price set forth therein except for any adjustment made with respect to the New Parent Warrants in the Warrant Conversion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or a
material portion of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution,
restructuring, recapitalization or other reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change its methods of accounting in any material respect, other than changes that are required by any securities
law or any order, directive, guideline, recommendation, statement, comment or guidance issued, passed, approved, published, promulgated or released by, the SEC, following reasonable prior consultation with Oculis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur Working Capital Loans other than the incurrence of Working Capital Loans such that the aggregate
outstanding Working Capital Loans (including those incurred prior to the date of the Business Combination Agreement) do not exceed $1,000,000 in the aggregate after such incurrence; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any agreement to do any action prohibited under the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, during the Interim Period, EBAC shall use commercially reasonable efforts to materially comply with, and continue materially performing under,
as applicable, the Trust Agreement and all other agreements or contracts to which EBAC may be a party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulatory Approvals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis and EBAC have agreed to each use commercially reasonable efforts to obtain all governmental authorizations required to be obtained in order to
consummate the Business Combination; provided that in no event shall New Parent, EBAC, Merger Sub 1, Merger Sub 2, Merger Sub 3, Oculis or its subsidiaries be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligated to bear any material expense, pay any material fee or grant any material concession in connection with obtaining any such approvals (other than any required filing fees in connection
therewith); provided, however, that each party shall bear its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in connection with the preparation of such approvals. Oculis and EBAC will
each promptly inform the other of any substantive communication between itself and any governmental authority regarding any of the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Business Combination Agreement, and their affiliates, have further agreed not to enter into any agreement with any governmental authority
not to consummate the transactions contemplated by the Business Combination Agreement, except with the prior consent of the other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, none
of the parties or their affiliates shall be obligated to (i)&nbsp;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of, any entities, assets or facilities of Oculis or any of its subsidiaries or
any entity, facility or asset of the parties to the Business Combination Agreement or any of their affiliates, (ii)&nbsp;terminate, amend or assign existing relationships and contractual rights or obligations, (iii)&nbsp;amend, assign or terminate
existing licenses or other agreements, or (iv)&nbsp;enter into new licenses or other agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting any of the foregoing, Oculis shall have
the right to direct, devise and implement the strategy with respect to obtaining governmental authorizations in accordance with the applicable provisions of the Business Combination Agreement; provided Oculis provides EBAC prompt notice of material
communications and developments with respect to such process; provided, further, that Oculis shall not be permitted to consent to any action, omission, undertaking, commitment or agreement with any governmental authority to the extent that such
action, omission, undertaking, commitment or agreement requires any action, omission, commitment, undertaking or agreement by EBAC or its affiliates without EBAC&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after the date of the Business Combination Agreement until the earlier of the Acquisition Closing or valid termination of the Business Combination
Agreement in accordance with its terms, the parties to the Business Combination Agreement shall give counsel for the other parties a reasonable opportunity to review in advance, and consider in good faith the views of the other party in connection
with any proposed material written communication to any governmental authority relating to the transactions contemplated by the Business Combination Agreement, including in respect of any tax rulings related thereto. The parties have agreed not to
participate in any substantive meeting or discussion with any governmental authority in connection with the transactions contemplated by the Business Combination Agreement, including in respect of any tax rulings related thereto, unless, to the
extent not prohibited by such governmental authority, it consults with the other parties in advance. Each of the parties shall use commercially reasonable efforts to provide (or use commercially reasonable efforts to cause its affiliates to provide)
to the other parties reasonable information or documents in such party&#146;s possession and within its control as are necessary or required for the preparation of any filings, notifications or submissions in connection with all governmental
authorizations required to be obtained in connection with the Business Combination. Notwithstanding the foregoing, any materials shared may be redacted before being provided (i)&nbsp;to remove references concerning the valuation of Oculis,
(ii)&nbsp;as necessary to comply with contractual arrangements and (iii)&nbsp;as necessary to avoid disclosure of other competitively sensitive information or to address reasonable privilege or confidentiality concerns. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Oculis, New Parent and
EBAC have agreed to, and each of them have agreed to cause its respective subsidiaries and affiliates (as applicable) and its and their officers, directors, managers, employees, consultants, counsel, accounts, agents and other representatives to,
prior to the Acquisition Closing, reasonably cooperate in a timely manner in connection with the PIPE Investment or any other financing arrangement the parties may mutually agree to seek in connection with the transactions contemplated by the
Business Combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement (it being understood and agreed that the consummation of any such financing by Oculis, New Parent and EBAC shall be subject to the parties&#146; mutual agreement), including (i)&nbsp;by
providing such information and assistance as the other party may reasonably request, (ii)&nbsp;granting such access to the other party and its representatives as may be reasonably necessary for their due diligence, (iii)&nbsp;participating in a
reasonable number of meetings, presentations, road shows, drafting sessions and due diligence sessions with respect to such financing efforts (including direct contact between senior management and other representatives of Oculis and its
subsidiaries at reasonable times and locations) and (iv)&nbsp;taking, or to causing to be taken, all actions required, necessary or advisable to consummate such financing transactions, including using commercially reasonable efforts to enforce its
rights under any Subscription Agreement or Additional Subscription Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Proxy Solicitation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC, New Parent and Oculis agreed to include provisions in this proxy statement/prospectus and to take reasonable action related thereto, with respect to
(i)&nbsp;the Business Combination Proposal, (ii)&nbsp;the Merger Proposal, (iii)&nbsp;the Adjournment Proposal and (iv)&nbsp;approval of any other proposals required by applicable securities laws or Nasdaq listing rules or reasonably agreed by EBAC
and Oculis to be necessary or appropriate in connection with the transactions contemplated by the Business Combination Agreement (the &#147;<I>Additional Proposal</I>&#148; and together with the Business Combination Proposal, the Merger Proposal and
the Adjournment Proposal, the &#147;<I>Transaction Proposals</I>&#148;). Without the prior written consent of Oculis, the Transaction Proposals shall be the only matters (other than procedural matters) which EBAC shall propose to be voted on by its
shareholders at the Extraordinary General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has agreed to use commercially reasonable efforts to, as promptly as practicable after this proxy
statement/prospectus is declared effective under the Securities Act, (i)&nbsp;duly call, give notice of, convene and hold the Extraordinary General Meeting, (ii)&nbsp;cause this proxy statement/prospectus to be disseminated to EBAC Shareholders in
compliance with applicable law and (iii)&nbsp;solicit proxies from the holders of EBAC Common Stock to vote in accordance with the recommendation of the EBAC Board with respect to each of the Transaction Proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has agreed, through the EBAC Board, to recommend to its shareholders that they approve the Transaction Proposals (the &#147;<I>EBAC Board
Recommendation</I>&#148;) and shall include the EBAC Board Recommendation in this proxy statement/prospectus. The EBAC Board shall not (and no committee or subgroup thereof shall) change, withdraw, withhold, qualify or modify, or publicly propose to
change, withdraw, withhold, qualify or modify, the EBAC Board Recommendation (together with any withdrawal, amendment, qualification or modification of its recommendation to the shareholders of EBAC described in the Business Combination Agreement, a
&#147;<I>Modification in Recommendation</I>&#148;), provided that the EBAC Board may make a Modification in Recommendation prior to receipt of the EBAC Shareholder Approval if, and only if, the EBAC Board determines in consultation with EBAC&#146;s
outside legal counsel that failure to make a Modification in Recommendation would be inconsistent with the fiduciary duties of the EBAC Board under applicable laws, provided, further, that the EBAC Board shall not be entitled to make, or agree or
resolve to make, a Modification in Recommendation unless (i)&nbsp;EBAC has provided Oculis with a written notice (a &#147;<I>Modification in Recommendation Notice</I>&#148;) advising Oculis that the EBAC Board proposes to take such action and
containing the material facts underlying the EBAC Board&#146;s determination that a Modification in Recommendation is required (in each case, it being acknowledged that such Modification in Recommendation Notice shall not itself constitute a breach
of the Business Combination Agreement), and (ii)&nbsp;at or after 5:00 p.m. on the fourth Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice (such period from the time the Modification in
Recommendation Notice is provided until 5:00 p.m. on the fourth Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice&nbsp;(the &#147;<I>Modification in Recommendation Notice Period</I>&#148;)),
the EBAC Board reaffirms in good faith (after consultation with its outside counsel) that the failure to make a EBAC Modification in Recommendation would be inconsistent with its fiduciary duties under applicable law. If requested by Oculis, EBAC
will, and will use its reasonable best efforts to cause its representatives to, during the Modification in Recommendation Notice Period, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
engage in good faith negotiations with Oculis and its representatives to make such adjustments to the terms and conditions of the Business Combination Agreement so as to obviate the need for a
Modification in Recommendation.&nbsp;EBAC&#146;s obligations under the Business Combination Agreement to call and hold the Extraordinary General Meeting with respect to all Transaction Proposals shall not be affected by any Modification in
Recommendation.&nbsp;For the avoidance of doubt, in the event of a Modification in Recommendation, EBAC shall continue to submit the Business Combination Agreement to the EBAC Shareholders for approval at the Extraordinary General Meeting unless the
Business Combination Agreement shall have been terminated in accordance with its terms prior to the Extraordinary General Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC may postpone the
Extraordinary General Meeting, or adjourn the Extraordinary General Meeting opened in accordance with its governing documents, on one or more occasions for up to 20 business days in the aggregate after the date for which the Extraordinary General
Meeting was originally scheduled upon the good faith determination by the EBAC Board that such postponement or adjournment, as the case may be, is necessary to (i)&nbsp;solicit additional proxies to obtain the approval of EBAC Shareholders,
(ii)&nbsp;obtain a quorum if one is not present at any then scheduled Extraordinary General Meeting, (iii)&nbsp;ensure that any supplement or amendment to this proxy statement/prospectus that is required by applicable law is provided to the its
shareholders with adequate time for review prior to the Extraordinary General Meeting, or (iv)&nbsp;otherwise take actions consistent with EBAC&#146;s obligations under the Business Combination Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Solicitation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the date of the
Business Combination Agreement until the Acquisition Closing Date or, if earlier, the termination of the Business Combination Agreement in accordance with its terms, Oculis and its subsidiaries shall not, and Oculis shall instruct and use its
commercially reasonable efforts to cause its representatives, not to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate any negotiations with any person with respect to, or provide any
<FONT STYLE="white-space:nowrap">non-public</FONT> information or data concerning Oculis or any of its subsidiaries to any person relating to, an Acquisition Proposal or afford to any person access to the business, properties, assets or personnel of
Oculis or any of its subsidiaries in connection with an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any acquisition agreement, merger agreement or similar definitive agreement, or any letter of intent,
memorandum of understanding or agreement in principle, or any other agreement relating to an Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any waiver, amendment or release under any confidentiality agreement or the anti-takeover laws of any state
relating to an Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise knowingly facilitate any such inquiries, proposals, discussions, or negotiations or any effort or
attempt by any person to make an Acquisition Proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, from and after the date of the Business Combination Agreement,
Oculis shall, and shall instruct its subsidiaries, officers, directors and representatives acting on its behalf or on behalf of its subsidiaries (as applicable) to, immediately cease and terminate all discussions and negotiations with any persons
that may be ongoing with respect to any Acquisition Proposal (other than the parties to the Business Combination Agreement and their respective representatives). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in the Business Combination Agreement, &#147;<I>Acquisition Proposal</I>&#148; means, with respect to Oculis and its subsidiaries, other than the
transactions contemplated by the Business Combination Agreement and other than the acquisition or disposition of equipment or other tangible personal property in the ordinary course of business, any offer or proposal relating to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any acquisition or purchase, direct or indirect, of (i) 15% or more of the consolidated assets of Oculis and its
subsidiaries or (ii) 15% or more of any class of equity or voting securities of (a)&nbsp;Oculis or (b) one or more of its subsidiaries holding assets or producing revenue constituting, individually or in the aggregate, 15% or more of the
consolidated assets or revenue of Oculis and its subsidiaries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any tender offer (including a self-tender offer) or exchange offer that, if consummated, would result in any
person or entity beneficially owning 15% or more of any class of equity or voting securities of (i)&nbsp;Oculis or (ii)&nbsp;one or more of its subsidiaries holding assets or producing revenue constituting, individually or in the aggregate, 15% or
more of the consolidated assets or revenue of Oculis and its subsidiaries; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger, consolidation, share exchange, business combination, sale of substantially all the assets,
reorganization, recapitalization, liquidation, dissolution or other similar transaction involving the sale or disposition of (i)&nbsp;Oculis or (ii)&nbsp;one or more of its subsidiaries holding assets or producing revenue constituting, individually
or in the aggregate, 15% or more of the consolidated assets or revenue of Oculis and its subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>EBAC
Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the date of the Business Combination Agreement until the Acquisition Closing Date or, if earlier, the valid termination of the
Business Combination Agreement, in accordance with the Business Combination Agreement, EBAC and its subsidiaries shall not, and EBAC shall instruct its and their representatives acting on its and their behalf, not to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any proposal or offer that constitutes a Business Combination Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate any discussions or negotiations with any person with respect to a Business Combination Proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any acquisition agreement, business combination, merger agreement or similar definitive agreement, or
any letter of intent, memorandum of understanding or agreement in principle, or any other agreement relating to a Business Combination Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise knowingly facilitate any such inquiries, proposals, discussions, or negotiations or any effort or
attempt by any Person to make a Business Combination Proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, from and after the date of the Business Combination
Agreement, EBAC shall, and shall instruct and cause its officers and directors and representatives acting on its behalf, its subsidiaries and their respective representatives (acting on their behalf) to, immediately cease and terminate all
discussions and negotiations with any persons that may be ongoing with respect to a Business Combination Proposal (other than Oculis and its representatives). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in the Business Combination Agreement, &#147;<I>Business Combination Proposal</I>&#148; means any offer, inquiry, proposal or indication of interest
(whether written or oral, binding or <FONT STYLE="white-space:nowrap">non-binding,</FONT> and other than an offer, inquiry, proposal or indication of interest with respect to the transactions contemplated by the Business Combination Agreement),
relating to a Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Directors and Officers Indemnification and Insurance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to the Business Combination Agreement have agreed that (i)&nbsp;all rights to indemnification or exculpation now existing in favor of past or
present directors, officers, members, managers and employees of EBAC, as provided in EBAC&#146;s amended and restated memorandum and articles of association or otherwise in effect as of the Acquisition Closing Date, in either case, solely with
respect to any matters occurring on or prior to the Acquisition Closing, shall survive the transactions contemplated by the Business Combination Agreement and shall continue in full force and effect from and after the Acquisition Closing for a
period of six years and (ii)&nbsp;New Parent will perform and discharge all obligations to provide such indemnity and exculpation during such <FONT STYLE="white-space:nowrap">six-year</FONT> period. To the maximum extent permitted by applicable law,
during such <FONT STYLE="white-space:nowrap">six-year</FONT> period, New Parent shall advance expenses in connection with such indemnification as provided in EBAC&#146;s amended and restated memorandum and articles of association or other applicable
agreements. The indemnification and liability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation or exculpation provisions of EBAC&#146;s amended and restated memorandum and articles of association or other applicable agreements shall not, during such <FONT
STYLE="white-space:nowrap">six-year</FONT> period, be amended, repealed or otherwise modified after the Acquisition Closing in any manner that would materially and adversely affect the rights thereunder of individuals who, as of the Acquisition
Closing or at any time prior to the Acquisition Closing, were or are directors, officers, members, managers or employees of EBAC (each, an &#147;<I>EBAC D&amp;O Person</I>&#148;) to be so indemnified, have their liability limited or be exculpated
with respect to any matters occurring on or prior to the Acquisition Closing and relating to the fact that such EBAC D&amp;O Person was a director, officer, member, manager or employee of EBAC at or prior to the Acquisition Closing, unless such
amendment, repeal or other modification is required by applicable law. However, New Parent shall not have any obligation to any EBAC D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination
shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such EBAC D&amp;O Person in the manner contemplated in the Business combination Agreement is prohibited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At or prior to the Acquisition Closing, New Parent shall purchase, and maintain in effect for a period of six years after the Acquisition Closing Date,
without lapses in coverage, a &#147;tail&#148; insurance policy(ies) providing directors&#146; and officers&#146; liability and fiduciary liability insurance coverage for the benefit of those persons who are covered by any comparable insurance
policy(ies) of EBAC as of the date of the Business Combination Agreement with respect to matters occurring on or prior to the Acquisition Closing. Such &#147;tail&#148; insurance policy(ies) shall provide coverage on terms (including with respect to
coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under EBAC&#146;s directors&#146; and officers&#146; liability and fiduciary liability insurance policy(ies)
as of the Acquisition Closing, provided that New Parent shall not be required to pay a premium for such &#147;tail&#148; insurance policy(ies) in excess of 250% of the most recent annual premium paid by EBAC prior to the date of the Business
Combination Agreement and, in such event, New Parent shall purchase the maximum coverage available for 250% of the most recent annual premium paid by EBAC prior to the date of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If New Parent or any of its respective successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity and shall
not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series of related transactions to any
person or entity, then in each such case, proper provisions shall be made so that the successors or assigns of New Parent or Oculis or any of its subsidiaries shall assume all of the obligations pertaining to the indemnification of EBAC directors
and officers set forth in the Business Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Covenants and Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains other covenants and agreements, including covenants related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis providing, subject to certain restrictions and conditions specified in the Business Combination Agreement,
to EBAC and its respective representatives, reasonable access to Oculis&#146; and its respective subsidiaries&#146; properties, books, contracts, commitments, tax returns, records and appropriate officers and employees of Oculis and its
subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis using its commercially reasonable efforts to deliver to EBAC as soon as reasonably practicable following
the date the Audited Financial Statements (as defined in the Business Combination Agreement) become stale for purpose of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Securities Act, the unaudited interim consolidated statement of
financial position as of September&nbsp;30, 2022 and the related unaudited interim statements of comprehensive income, changes in equity, and cash flows for the <FONT STYLE="white-space:nowrap">9-month</FONT> period ended September&nbsp;30, 2022 of
Oculis and its subsidiaries, together with the auditor&#146;s reports thereon; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Parent, as the sole equityholder of each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 approving and
adopting the Business Combination Agreement and the Ancillary Agreements to which New Parent is or will be a party to; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC causing New Parent to use, and New Parent using, its commercially reasonable efforts to cause New Parent
Shares issuable in accordance with the Business Combination Agreement to be approved for listing on the Nasdaq Global Market (and EBAC and Oculis shall reasonably cooperate in connection therewith); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis, New Parent and EBAC cooperating in the preparation and efforts to make effective this proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis taking all actions to cause certain agreements to be terminated or settled; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC making certain disbursements from the Trust Account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC cooperating with Oculis and using its commercially reasonable efforts to take, or cause to be taken, all
actions reasonably necessary to <FONT STYLE="white-space:nowrap">de-list</FONT> all securities of EBAC from the Nasdaq Global Market and <FONT STYLE="white-space:nowrap">de-register</FONT> such securities under the Exchange Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC keeping current and timely filing all reports required to be filed with or furnished to the SEC and
otherwise complying in all material respects with its reporting obligations under applicable laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC promptly notifying Oculis of, keeping Oculis reasonably informed with respect to the status, and providing
Oculis the opportunity to participate in, certain potential litigations related to the Business Combination Agreement, the Ancillary Agreements, and the transactions contemplated by the Business Combination Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cooperation between EBAC and Oculis in obtaining any material third-party consents and approvals required to
consummate the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis and New Parent using commercially reasonable efforts, at EBAC&#146;s request, to exempt any acquisitions
or dispositions of New Parent Shares or of EBAC Common Stock from Section&nbsp;16(a) of the Exchange Act pursuant to Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> thereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; approval and adoption of the New Parent Equity Incentive Plan (as defined in the Business
Combination Agreement), with the prior written consent of EBAC (not to be unreasonably withheld, conditioned or delayed); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC and New Parent agreeing to take all actions necessary or appropriate to cause certain appointments to the
New Parent Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis, EBAC and New Parent using commercially reasonable efforts to ensure that the intended tax treatment of
the transactions contemplated by the Business Combination Agreement is obtained; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agreements relating to the consummation of the Third Merger following the Acquisition Closing.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Representations and Warranties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains customary representations and warranties by the parties thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Representations and Warranties of Oculis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis has made representations and warranties relating to, among other things, company organization, subsidiaries, due authorization, no conflict,
governmental authorities and consents, capitalization of Oculis and its subsidiaries, financial statements, no undisclosed liabilities, legal compliance, contracts and no defaults, Oculis benefit plans, labor relations and employees, taxes,
brokers&#146; fees, insurance, permits, regulatory, real property, intellectual property, privacy and cybersecurity, environmental matters, absence of changes, anti-corruption compliance, anti-money laundering, sanctions and national security
compliance, information supplied, no outside reliance and no additional representations and warranties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Representations and Warranties of EBAC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has made representations and warranties relating to, among other things, corporate organization, due authorization, capitalization, consents and requisite
government approvals and no violations, business activities, tax matters, Investment Company Act of 1940, investigations and no other representations, no outside reliance and no additional representations or warranties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Survival of Representations and Warranties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations and warranties of the respective parties to the Business Combination Agreement generally will not survive the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conditions to the Acquisition Closing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions to the Obligations of Each Party </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the parties to the Business Combination Agreement to consummate, or cause to be consummated, the Business Combination are subject to the
satisfaction of the following conditions, any one or more of which may be waived in writing by all of such parties: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The approval of EBAC Shareholders shall have been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The registration statement of which this proxy statement/prospectus forms a part shall have become effective
under the Securities Act and no stop order suspending the effectiveness of the registration statement shall have been issued and no proceedings for that purpose shall have been initiated or threatened by the SEC and not withdrawn;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There shall not be in force any governmental order enjoining or prohibiting the consummation of any of the
Acquisition Transactions or any law that makes the consummation of any of the Acquisition Transactions illegal or otherwise prohibited; <I>provided</I> that the governmental authority issuing such governmental order has jurisdiction over the parties
to the Business Combination Agreement with respect to the transactions contemplated thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EBAC having net tangible assets of at least $5,000,001; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The New Parent Shares and New Parent Warrants to be issued in connection with the Acquisition Transactions shall
have been approved for listing on the Nasdaq Global Market; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) The amount of cash or cash equivalents available in the Trust Account following the Extraordinary General
Meeting (after deducting the EBAC Share Redemption Amount and payment of any transaction expenses of Oculis and EBAC); <I>plus </I>(ii)&nbsp;(a) the cash actually received by New Parent pursuant to the Convertible Loan Agreements from the respective
lender parties thereto and (b)&nbsp;the PIPE Investment Amount actually received by New Parent (or other financing in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing is equal to or
greater than $100&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions to the Obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and
Merger Sub 3 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to consummate, or cause to be consummated, the
transactions contemplated by the Business Combination Agreement are subject to the satisfaction of the following additional conditions, any one or more of which may be waived in writing by EBAC: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) The representations and warranties of Oculis contained in the first sentence of Section&nbsp;4.06(a) of the
Business Combination Agreement shall be true and correct in all respects as of the date of the Business Combination Agreement and as of the Acquisition Closing Date, except with respect to such
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all respects at and as of such date, except for changes after
the date of the Business Combination Agreement which are contemplated or expressly permitted by the Business Combination Agreement or the Ancillary Agreements, (ii)&nbsp;the Company Fundamental Representations (as defined in the Business Combination
Agreement) (other than the first sentence of Section&nbsp;4.06(a) of the Business Combination Agreement) shall be true and correct in all material respects, in each case as of the date of the Business Combination Agreement and the Acquisition
Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date, except for changes after the
date of the Business Combination Agreement which are contemplated or expressly permitted by the Business Combination Agreement or the Ancillary Agreements, and (iii)&nbsp;each of the representations and warranties of Oculis contained in the Business
Combination Agreement other than the Company Fundamental Representations (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect and Company Material Adverse Effect (as defined in the
Business Combination Agreement) or any similar qualification or exception) shall be true and correct as of the date of the Business Combination Agreement and as of the Acquisition Closing Date, except with respect to such representations and
warranties which speak as to an earlier date, which representations and warranties shall be true and correct at and as of such date, except for, in each case, inaccuracies or omissions that have not had, and would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each of the covenants of Oculis set forth in the Business Combination Agreement to be performed as of or prior to
the Acquisition Closing shall have been performed in all material respects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There shall not have occurred a Company Material Adverse Effect (as defined in the Business Combination
Agreement) after the date of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions to the Obligations of Oculis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of Oculis to consummate, or cause to be consummated, the Acquisition Transactions is subject to the satisfaction of the following additional
conditions, any one or more of which may be waived in writing by Oculis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the EBAC Fundamental Representations (as defined in the Business Combination Agreement) shall be true and
correct in all material respects as of the date of the Business Combination Agreement and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and
warranties shall be true and correct in all material respects at and as of such date, except for changes after the date of the Business Combination Agreement which are contemplated or expressly permitted by the Business Combination Agreement or the
Ancillary Agreements, (ii)&nbsp;and the representations and warranties set forth in the first sentence of each of Section&nbsp;5.03(a) and Section&nbsp;6.13(a) of the Business Combination Agreement shall be true and correct in all respects as of the
date of the Business Combination Agreement and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all
respects at and as of such date, except for changes after the date of the Business Combination Agreement which are contemplated or expressly permitted by the Business Combination Agreement or the Ancillary Agreements and (iii)&nbsp;the
representations and warranties of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 in Article 5 and Article 6 of the Business Combination Agreement (other than the EBAC Fundamental Representations and the representations and warranties
set forth in the first sentence of each of Section&nbsp;5.03(a) and Section&nbsp;6.13(a) of the Business Combination Agreement) (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect or any
similar qualification or exception) shall be true and correct as of the date of the Business Combination Agreement and as of the Acquisition Closing Date, except with respect to such representations and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
warranties which speak as to an earlier date, which representations and warranties shall be true and correct as of such date, except for, in each case, inaccuracies or omissions that have not
had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the transactions contemplated by the Business Combination Agreement in accordance with the terms of
the Business Combination Agreement and changes after the date of the Business Combination Agreement which are contemplated or expressly permitted by the Business Combination Agreement or the Ancillary Agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each of the covenants of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 set forth in the Business
Combination Agreement to be performed as of or prior to the Acquisition Closing shall have been performed in all material respects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There shall not have occurred a material adverse effect of EBAC after the date of the Business Combination
Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Termination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination may be terminated and the Business Combination may be abandoned at any time prior to the Acquisition Closing only as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by mutual written consent of Oculis and EBAC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if the Acquisition Closing Date has not occurred by the Agreement End Date; provided,<I>
</I>that if an Extension Proposal is approved at an Extension Shareholders&#146; Meeting, then the Agreement End Date shall be the last day of the extended time period for EBAC to consummate a business combination, provided, further, however, that a
party shall not be entitled to terminate the Business Combination Agreement pursuant to Section&nbsp;11.01(b) of the Business Combination Agreement if such party&#146;s breach of the Business Combination Agreement has prevented the consummation of
the Acquisition Closing Date at or prior to such time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if any governmental authority, shall have enacted, issued, promulgated, enforced or entered any
governmental order which has become final and nonappealable and has the effect of making consummation of any of the Acquisition Transactions illegal or otherwise preventing or prohibiting consummation of any of the Acquisition Transactions or if
there shall be adopted any law that permanently makes consummation of any of the Acquisition Transactions illegal or otherwise prohibited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis if there has been a Modification in Recommendation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Oculis or EBAC if the approval of EBAC Shareholders shall not have been obtained by reason of the failure to
obtain the required vote at the Extraordinary General Meeting duly convened therefor or at any adjournment or postponement thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by written notice to Oculis from EBAC if there is any breach of any representation, warranty, covenant or
agreement on the part of Oculis set forth in the Business Combination Agreement, such that the conditions specified in Section&nbsp;10.02(a) through Section&nbsp;10.02(d) thereunder would not be satisfied at the Acquisition Closing (a
&#147;<I>Terminating Company Breach</I>&#148;), except that, if such Terminating Company Breach is curable by Oculis prior to the end of the period ending on the date that is the earlier of (A)&nbsp;forty-five (45)&nbsp;days after receipt by Oculis
of notice from EBAC of such breach or (B)&nbsp;the Agreement End Date (the &#147;<I>Company Cure Period</I>&#148;), such termination shall not be effective, and such termination shall become effective only if the Terminating Company Breach is not
cured within the Company Cure Period, provided, however, that EBAC is not then in material breach of the Business Combination Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by written notice to EBAC from Oculis if there is any breach of any representation, warranty, covenant or
agreement on the part of EBAC set forth in the Business Combination Agreement, such that the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conditions specified in Section&nbsp;10.03(a) through Section&nbsp;10.03(c) of the Business Combination Agreement would not be satisfied at the Acquisition Closing (a &#147;<I>Terminating EBAC
Breach</I>&#148;), except that, if any such Terminating EBAC Breach is curable by EBAC prior to the end of the period ending on the date that is the earlier of (A)&nbsp;forty-five (45)&nbsp;days after receipt by EBAC of notice from EBAC of such
breach or (B)&nbsp;the Agreement End Date (the &#147;<I>EBAC Cure Period</I>&#148;), such termination shall not be effective, and such termination shall become effective only if the Terminating EBAC Breach is not cured within the EBAC Cure Period,
provided, however, that Oculis is not then in material breach of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of the termination of
the Business Combination Agreement pursuant to the foregoing paragraphs, the Business Combination Agreement shall become void and have no effect, without any liability on the part of any party thereto or its respective Affiliates, officers,
directors or shareholders, other than liability of Oculis or EBAC, as the case may be, for actual fraud or any willful and material breach (meaning an action or omission that at the time taken or made is both deliberate and known to be a material
breach) of the Business Combination Agreement occurring prior to such termination except that the provisions of this paragraph, the &#147;Miscellaneous&#148; provisions of the Business Combination Agreement and the confidentiality agreement entered
into between EBAC and Oculis shall survive any termination of the Business Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Waiver; Amendments and Extensions
of the Business Combination Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party to the Business Combination Agreement may, at any time prior to the Acquisition Closing, by action
taken by such party&#146;s board of directors, board of managers, managing member or other officers or persons thereunto duly authorized, (i)&nbsp;extend the time for the performance of the obligations or acts of the other parties to the Business
Combination Agreement, (ii)&nbsp;waive any inaccuracies in the representations and warranties (of another party thereto) that are contained in the Business Combination Agreement or (iii)&nbsp;waive compliance by the other parties thereto with any of
the agreements or conditions contained in the Business Combination Agreement, but such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party granting such extension or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing executed by the parties
thereto in the same manner as the Business Combination Agreement and which makes reference to the Business Combination Agreement, provided that certain sections may not be amended, modified or waived, as described in the Business Combination
Agreement, without the prior written consent of the Placement Agents (as defined in the Business Combination Agreement) or the Financial Advisor (as defined in the Business Combination Agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Specific Enforcement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties
to the Business Combination Agreement shall be entitled to an injunction or injunctions to prevent any breach, or threatened breach, of the Business Combination Agreement and to specific enforcement of the terms and provisions thereof, in addition
to any other remedy to which any party is entitled at law or in equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trust Account Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis has acknowledged and agreed that, prior to the Acquisition Closing and subject in all respects to the Trust Agreement, it has no right of <FONT
STYLE="white-space:nowrap">set-off</FONT> or any right, title, interest or claim of any kind (&#147;<I>Claim</I>&#148;) to, or to any monies or other assets in, the Trust Account, and has irrevocably waived any Claim to, or to any monies or other
assets in, the Trust Account that it may have now or in the future prior to the Acquisition Closing. In the event Oculis has any Claim against EBAC under the Business Combination Agreement or otherwise, Oculis shall pursue such Claim solely against
EBAC and EBAC&#146;s assets outside the Trust Account and not against the Trust Account or any monies or other assets in the Trust Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fees and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis and EBAC have agreed to each pay one half of all fees and expenses incurred in connection with the preparation and filing of the registration statement
and the receipt of Nasdaq approval in connection with the listing of New Parent Shares to be issued as part of the New Parent Interests Consideration and the New Parent Warrants (and the New Parent Shares issuable upon exercise thereof), other than
fees and expenses of advisors (which shall be borne by the party incurring such fees). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions set forth in the Business
Combination Agreement, each party thereto has agreed to be responsible for and pay its own expenses incurred in connection with the Business Combination Agreement and the transactions contemplated thereby, including all fees of its legal counsel,
financial advisers and accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Acquisition Closing does not occur, Oculis will be responsible for its own transaction expenses, and EBAC
shall be responsible for its own transaction expenses, in each case, as specified in the Business Combination Agreement. If the Acquisition Closing does occur, New Parent shall pay or cause to be paid, the transaction expenses of both Oculis and
EBAC, as specified in the Business Combination Agreement. Any payments to be made (or to cause to be made) pursuant to this paragraph shall be paid upon consummation of the transactions contemplated by the Business Combination Agreement and release
of proceeds from the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement, and all claims or causes of action based upon, arising out of, or related to the Business Combination Agreement or the
transactions contemplated thereby, will be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to principles or rules of conflict of laws to the extent such principles or rules would require or
permit the application of laws of another jurisdiction (except that Swiss Law will apply to the New Parent Share Capital Increase). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the PIPE Investment, EBAC engaged Credit Suisse, BofA Securities, Kempen, SVB Securities and Arctica, as <FONT
STYLE="white-space:nowrap">co-placement</FONT> agents in the PIPE Investment. In connection with performing their services as <FONT STYLE="white-space:nowrap">co-placement</FONT> agents, Credit Suisse, BofA Securities, Kempen, SVB Securities and
Arctica will receive fees and expense reimbursements customary for a PIPE transaction of the nature and size of the PIPE Financing (subject to the terms and conditions of their respective engagement letters with EBAC). BofA Securities was also
engaged by Oculis to act as its exclusive financial advisor in connection with the Business Combination, and will receive customary fees and expense reimbursement in connection therewith. In connection with BofA Securities&#146; engagement as a
co-placement agent in the PIPE Investment, Oculis waived, on the terms and subject to the conditions set forth in a letter agreement, dated May&nbsp;27, 2022, between Oculis and BofA Securities, any conflict arising out of the engagement of BofA
Securities by EBAC and the engagement of BofA Securities by Oculis. In connection with BofA Securities&#146; engagement as financial advisor to Oculis, EBAC waived, on the terms and subject to the conditions set forth in a letter agreement, dated
June&nbsp;3, 2022, between EBAC and BofA Securities, any conflict arising out of the engagement of BofA Securities by Oculis and the engagement of BofA Securities by EBAC. Such waivers included acknowledgment and agreement that some or all of the
members of the BofA Securities financial advisory team advising Oculis will also be members of the deal team assisting EBAC in connection with BofA Securities&#146; role as placement agent for the PIPE Financing. BofA Securities did not provide any
advisory services to EBAC and, in particular, BofA Securities did not advise on the valuation of Oculis or the terms of the Business Combination with Oculis. In addition, Credit Suisse, BofA Securities, Kempen, SVB Securities and Arctica and each of
their respective affiliates may provide investment banking and other financial services to EBAC, Oculis and each of their respective affiliates in the future, for which Credit Suisse, BofA Securities, Kempen, SVB Securities and Arctica and their
respective affiliates would expect to receive customary fees and expense reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Engagements in Connection with the Business Combination and Related
Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Credit Suisse, BofA Securities, Kempen, SVB Securities and Arctica are acting as <FONT STYLE="white-space:nowrap">co-placement</FONT>
agents to EBAC in connection with the PIPE Investment. In addition, Credit Suisse and Kempen are acting as financial advisor and capital markets advisors to EBAC in connection with the proposed Business Combination, provided that, in the case of
Kempen, it is only acting as such in connection with the European market. Credit Suisse and Kempen acted as the joint book-running managers for EBAC&#146;s initial public offering and the underwriting agreement for the offering provides for them to
receive deferred underwriting commissions payable in connection with completion of the Business Combination. Credit Suisse and Kempen performed typical and customary capital markets advisory services, including assisting in designing and executing
the market plan. Kempen did not provide financial advisory services to EBAC in connection with the Business Combination and, in particular, did not advise on the valuation of Oculis or the terms of the Business Combination with Oculis. BofA
Securities is acting as exclusive financial advisor to Oculis and SVB Securities is acting as capital markets advisor to Oculis in connection with the proposed Business Combination. In connection with all such engagements, the fees and expense
reimbursements received by Credit Suisse, BofA Securities, Kempen, SVB Securities and Arctica (or their respective affiliates) are subject to the terms and conditions of their respective engagement letters with EBAC and Oculis, as applicable. The
aggregate fees that will be payable to Credit Suisse, BofA Securities (for its engagements with both EBAC and Oculis), Kempen, SVB Securities and Arctica, including deferred underwriting commissions, are approximately $7.4&nbsp;million and are
contingent upon completion of the initial business combination. In the event that any such advisors resign or withdraw from the Business Combination, or any of the transactions contemplated thereby, and waive their fees, in whole or in part, the
amount of cash remaining on the balance sheet at the Acquisition Closing would be increased by a commensurate amount. To date, EBAC and Oculis have not received notice from any of such advisors indicating they may cease involvement in the Business
Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Agreements Related to the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Subscription Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the
execution of the Business Combination Agreement, EBAC entered into Initial Subscription Agreements with the Initial PIPE Investors, including LSP 7, certain existing Oculis Shareholders as well as certain other investors, pursuant to which the
Initial PIPE Investors have agreed to subscribe for and purchase, and EBAC has agreed to issue from treasury to such PIPE Investors, an aggregate of 6,330,391 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share, for the aggregate
purchase price of $63,303,910. Subsequent to the Initial PIPE Financing, in January 2023, EBAC entered into the Subsequent Subscription Agreements with the Subsequent PIPE Investors, pursuant to which the Subsequent PIPE Investors have agreed to
subscribe for, and EBAC has agreed to issue to the Subsequent PIPE Investors, an aggregate of 788,500 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share, for the aggregate purchase price of $7,885,000. The aggregate amount of
EBAC Class&nbsp;A Common Stock to be issued pursuant to the PIPE Financing is 7,118,891 shares for aggregate gross proceeds of $71,188,910. Pursuant to the transactions contemplated in the Business Combination Agreement, EBAC Class&nbsp;A Common
Stock will ultimately convert into New Parent Shares. The Subscription Agreements contain substantially the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the PIPE Financing
is subject to, among other customary closing conditions, the substantially concurrent consummation of the Business Combination. The Subscription Agreements provide that EBAC will cause New Parent to grant the PIPE Investors certain customary
registration rights in connection with the PIPE Financing, including demand and piggyback rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Convertible Loan Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Oculis and the Lenders party thereto entered into the a convertible loan agreement
pursuant to which, among other things, the Lenders party thereto have granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$12,670,000. Subsequent to the execution of the Business Combination Agreement, on January 26, 2023. Oculis and an additional Lender entered into a convertible loan agreement in substantially the
same form as the initial convertible loan agreement, pursuant to which, among other things, the Lender party thereto has granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $7,000,000. The
aggregate amount raised under the Convertible Loan Agreements is $19,670,000. Following the Second Merger Effective Time, it is the intention of the parties thereto that New Parent will assume the Convertible Loan Agreements, and that immediately
after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on substantially the same terms as the PIPE Investors. The Convertible Loan
Agreements provide that, upon conversion, the Lenders will be granted certain customary registration rights, substantially on the same terms as those offered pursuant to the Subscription Agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Oculis Shareholders Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Oculis, EBAC, and certain Oculis Shareholders entered into the Oculis Shareholders
Support Agreements, pursuant to which such Oculis Shareholders agreed to, among other things, (i)&nbsp;adopt the Business Combination Agreement and approve and consent to the Mergers and the consummation of the transactions contemplated therein,
(ii)&nbsp;execute and deliver the exchange notice agreeing to transfer to the Exchange Agent all Company Share Capital held by such Shareholder and (iii)&nbsp;provide a release of claims against Oculis and its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Sponsor Support Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with
the execution of the Business Combination Agreement, Sponsor, EBAC and Oculis entered into the Sponsor Support Agreement, pursuant to which Sponsor agreed to, among other things, (i)&nbsp;vote to adopt and approve the Business Combination Agreement
and the other documents contemplated thereby and the transactions contemplated thereby, (ii)&nbsp;not transfer its shares of EBAC Common Stock and EBAC Warrants, in each case, until the consummation of the Acquisition Closing (subject to certain
customary exceptions), (iii) waive certain anti-dilution adjustments, and (iv)&nbsp;waive certain redemption rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Registration Rights and <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the Business Combination, New Parent will enter into
the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with Sponsor and certain Oculis Shareholders. Pursuant to the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, Sponsor and such
Oculis Shareholders may not transfer New Parent Shares (subject to certain exceptions) until: (i)&nbsp;with respect to the New Parent Shares held by the Oculis Shareholders party thereto upon the Acquisition Closing, 180 days from the Acquisition
Closing, and (ii)&nbsp;with respect to the New Parent Shares held by Sponsor after the Acquisition Closing, 270 days after the Acquisition Closing, in each case subject to earlier release if the New Parent Shares trade at or above a volume weighted
average price of $15.00 for 20 trading days during any 30 trading day period commencing at least 150 days following the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement provides Sponsor and the Oculis Shareholders party thereto certain customary registration rights, including demand and piggyback registration rights, subject to
customary requirements and conditions, including the satisfaction of the ownership thresholds set forth in the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, EBAC, Sponsor and certain EBAC Shareholders have entered into <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, pursuant to which, among other things, such EBAC Shareholder has agreed to (i)&nbsp;vote in favor of the transactions contemplated in the Business Combination Agreement, for which the
approval of such EBAC Shareholder is required, (ii)&nbsp;not to redeem, or exercise any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right to redeem, any EBAC equity securities held by such EBAC Shareholder as of the date of the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, or acquired thereafter and
(iii)&nbsp;not to transfer any EBAC equity securities until 90 days after the Acquisition Closing. In consideration of such EBAC Shareholder&#146;s performance of its obligations under the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT>
Agreements, Sponsor has agreed to transfer to such EBAC Shareholder one New Parent Share for every ten (10)&nbsp;shares of EBAC Class&nbsp;A Common Stock held by such EBAC Shareholder. As of the record date,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of EBAC Class&nbsp;A Common Stock were subject to <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram shows the
current ownership of EBAC, New Parent and Oculis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03a30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PIPE Investors will transfer $63,303,910 to EBAC in exchange for 6,330,391 PIPE Shares; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03b30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC will undergo the First Merger, and as part of the First Merger, (i)&nbsp;each share of EBAC Common Stock (including
those held by the PIPE Investors) shall be automatically converted into the Surviving EBAC Shares (ii)&nbsp;each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into Surviving EBAC
Warrants and (iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms, and
subject to the conditions set forth in the Business Combination Agreement and in the Ancillary Agreements; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03a31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger
Effective Time, the Exchange Agent, solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants, will undertake the Exchange Agent Contribution Actions in exchange for receipt of the New Parent Interests Consideration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange
Agent will (i)&nbsp;undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests
Consideration to the holders of Surviving EBAC Warrants; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03p32a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution Actions, at
the Second Merger Effective Time, EBAC will undergo the Second Merger, pursuant to which, among other things, the separate corporate existence of EBAC will cease; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03p32b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Second Merger Effective Time but before the Oculis Share Contribution, it is the intention of the parties to the
Convertible Loan Agreements that New Parent will assume the Convertible Loan Agreements, pursuant to which the Lenders have granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $19,670,000,
and that immediately after such assumption but before the Oculis Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same terms as the PIPE Investors; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g39n95.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At approximately 10:00 a.m. Eastern Time on the Acquisition Closing Date, those Oculis Shareholders
executing Oculis Shareholders Support Agreements and the exchange notice contemplated by the Business Combination Agreement shall effect the Oculis Share Contribution; and </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g16o08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 30 days after the closing of the EBAC Mergers, Oculis will undergo the Third Merger. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g53z77.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram shows the contemplated ownership of New Parent immediately after the Acquisition
Closing Date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389734g03q73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC is a blank check company incorporated on January&nbsp;8, 2021 as a Cayman Islands exempted company and formed for the purpose of effecting a merger,
amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. In conducting a targeted search for a business combination target, as described in greater detail below,
EBAC utilized the European network and investing, life sciences and transaction experience of the Sponsor, EBAC&#146;s management and the EBAC Board. The terms of the Business Combination Agreement and the related Ancillary Agreements are the result
of extensive negotiations among representatives of EBAC and Oculis, with advice from their respective representatives and advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter
of 2021, prior to the closing of EBAC&#146;s initial public offering, EBAC issued 3,450,000 founder shares to the Sponsor in exchange for a capital contribution of $25,000, of which up to 450,000 shares were subject to forfeiture to the extent that
the underwriters&#146; over-allotment option was not exercised in full. On March&nbsp;18, 2021, EBAC completed its initial public offering of 12,000,000 units at a price of $10.00 per unit generating gross proceeds of $120,000,000 before
underwriting discounts and expenses. On May&nbsp;13, 2021, the over-allotment was partially exercised which increased the number of units to 12,754,784 and the gross proceeds to $127,547,840. Each unit consisted of one share of EBAC Class&nbsp;A
Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one EBAC Public Warrant. Each whole EBAC Public Warrant entitles the holder thereof to purchase one share of EBAC Class&nbsp;A Common Stock at an exercise price of $11.50 per
share, subject to certain adjustments. After the over-allotment exercise, there were 4,251,595 EBAC Public Warrants and 151,699 EBAC Private Placement Warrants. As the underwriters partially exercised the over-allotment option to purchase additional
units, an aggregate of 261,304 Founder Shares were forfeited, leaving an aggregate of 3,188,696 Founder Shares outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Founder Share will become worthless if EBAC does not complete a business combination within
the Combination Period as holders of Founder Shares have waived their redemption rights in return for no consideration pursuant to that certain Letter Agreement, dated March&nbsp;18, 2021, between EBAC and each of the directors and officers of EBAC
which was agreed prior to EBAC&#146;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the consummation of its initial public offering, neither EBAC, nor anyone on its
behalf, contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to any business combination transaction with EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the process that led to identifying Oculis as an attractive investment opportunity, EBAC&#146;s management team evaluated over 165 potential business
combination targets, entered into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements with eight potential business combination targets (other than Oculis), and submitted <FONT STYLE="white-space:nowrap">non-binding</FONT> indications
of interest or letters of intent with respect to six potential business combination targets (other than Oculis) (collectively, the &#147;Other Potential Targets&#148;), referred to herein as &#147;Company A&#148;, &#147;Company B&#148;,
&#147;Company C&#148;, &#147;Company D&#148;, &#147;Company E&#148;, and &#147;Company F&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the six potential business combination
targets other than Oculis, EBAC engaged in preliminary discussions with respect to a potential business combination involving each such target and, in the case of all Other Potential Targets, EBAC entered into a confidentiality agreement and engaged
in further business, operational and financial due diligence with respect to such target, which included, among other things, operational due diligence, review of financial data and discussions with management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Other Potential Targets were all companies within the biotechnology sector, including clinical-stage biotech and drug development companies and biotech
technology platform companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC approached the management of Company A in mid-March 2021 and entered into a non-disclosure agreement in mid-April
after management presentations made to EBAC. Company A then provided data room access to EBAC, and EBAC subsequently submitted a letter of intent to Company A in mid-June. Shortly thereafter, Company A ultimately decided to raise additional
financing and stay privately owned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC engaged with the management of Company B in mid-April 2021 and entered into a non-disclosure agreement almost
immediately after management presentations made to EBAC. Company B then provided data room access to EBAC. After significant internal due diligence and phone calls with key opinion leaders, EBAC submitted a letter of intent to Company B in May 2021.
Shortly thereafter, the board of Company B ultimately decided to raise additional financing and stay privately owned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management of Company C contacted
EBAC in March 2021. As EBAC was already exploring certain Other Potential Targets at that time, EBAC told Company C to remain on standby in the event other such discussions fell apart. EBAC re-engaged with management of Company C in late July 2021
after which Company C granted data room access to EBAC. EBAC sent an initial draft of a letter of intent to Company C shortly thereafter, and subsequently sent a revised draft in mid-September 2021 after most of EBAC&#146;s due diligence had been
finalized and the potential valuation had been discussed with EBAC&#146;s financial advisors. EBAC and Company C entered into an exclusivity agreement in mid-October 2021 and executed the letter of intent in November 2021. Ultimately, the financial
advisors of both EBAC and Company C recommended the parties to cancel the potential transaction due to the unfavorable market conditions in December 2021 and early January 2022. Following the recommendation, the board of Company C decided to cancel
the process and concentrate on raising additional financing as a privately-owned company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC reached out to management of Company D in August 2021.
Company D gave a management presentation to EBAC in late August 2021, and the parties entered into a non-disclosure agreement in early September 2021. Company D granted EBAC data room access. Company D was simultaneously on a dual track preparing
for an IPO, so EBAC immediately sent an initial draft of a letter of intent shortly thereafter. After significant due diligence on Company D, EBAC decided to cancel the process after a difference in valuation expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC reached out to management of Company E in mid-April 2021 and entered into a non-disclosure agreement in
mid-May. Company E granted EBAC data room access immediately thereafter. After significant internal due diligence and phone calls with key opinion leaders, EBAC submitted a letter of intent to Company E in late June 2021. In early July 2021, the
management of Company E informed EBAC that its board had decided to instead raise additional financing and remain privately owned. Management of Company E reached back out to EBAC in February 2022 to re-open discussions after the contemplated
financing round did not materialize. After completing additional due diligence on Company E EBAC decided not to pursue a potential transaction any further as EBAC was not convinced by Company E&#146;s proposed strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC reached out to management of Company F in early May 2021. After conducting initial due diligence on Company F, EBAC sent an initial draft of a letter of
intent in mid May 2021. However, EBAC decided to end the process in late May 2021 after further intensive due diligence and discussions with key opinion leaders regarding Company F&#146;s key asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compared to previous potential business combination targets, based on its preliminary due diligence, evaluation and analysis of its business, as well as the
terms of the <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent with Oculis, EBAC&#146;s directors and management believed that Oculis was a more attractive potential business combination target that could better satisfy
EBAC&#146;s key criteria for a business combination target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early February 2022, Felice <FONT STYLE="white-space:nowrap">Verduyn-van</FONT> Weegen, an
individual employed by an affiliate of the Sponsor, met with Rob Hopfner, a director of Oculis, during a board meeting for the board of an unrelated company for which they both serve as directors. The two had an informal discussion regarding the
potential fit between Oculis and EBAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2022, Felice <FONT STYLE="white-space:nowrap">Verduyn-van</FONT> Weegen reached out to Rob
Hopfner requesting an introduction to Oculis&#146; management team. On the same day, Rob Hopfner introduced Riad Sherif, the Chief Executive Officer and a director of Oculis, to Felice <FONT STYLE="white-space:nowrap">Verduyn-van</FONT> Weegen via
email. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2022, Eduardo Bravo, the Chief Executive Officer and a director of EBAC, and Felice
<FONT STYLE="white-space:nowrap">Verduyn-van</FONT> Weegen met with Riad Sherif, Sylvia Cheung, Chief Financial Officer of Oculis, and P&aacute;ll Ragnar J&oacute;hannesson, Chief Strategy Officer of Oculis, to discuss Oculis&#146; business and
assets, and the potential fit with EBAC. On February&nbsp;22, 2022, the parties executed the Confidential Disclosure Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between March&nbsp;1,
2022, and March&nbsp;9, 2022, Oculis management introduced a number of key opinion leaders in the field of ophthalmology to EBAC and the Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;9, 2022, a number of EBAC management&#146;s team members, including Eduardo Bravo, Geraldine O&#146;Keefe, Laurenz Govaerts, and Isabel Bahm had a telephonic meeting with Oculis management, including Riad Sherif, Sylvia Cheung and
P&aacute;ll Ragnar J&oacute;hannesson in which Oculis&#146; management gave a detailed presentation of <FONT STYLE="white-space:nowrap">OCS-01,</FONT> one of Oculis&#146; product candidates. On the same day, Oculis shared a payer research report for
<FONT STYLE="white-space:nowrap">OCS-01,</FONT> conducted by a third-party research company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2022, Eduardo Bravo and Riad Sherif held a
telephone call to discuss next steps and due diligence. The following day, EBAC management received access to Oculis&#146; data room, which included information regarding Oculis&#146; business, <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and clinical studies, and information regarding regulatory applications, among other things. The parties also exchanged emails regarding the potential valuation of Oculis on that same day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between March 2022 and October 2022, EBAC and its advisors conducted business, technical, financial and legal due diligence with respect to Oculis and
researched Oculis&#146; industry, product candidates and outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2022. EBAC sent a first draft of a
<FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent (the &#147;<I>Letter of Intent</I>&#148;). The Letter of Intent included a proposed <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of Oculis of $185&nbsp;million.
Furthermore, the Letter of Intent included a proposed target of $80&nbsp;million in PIPE Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;22, 2022, Eduardo Bravo introduced Riad Sherif to Credit Suisse (in its capacity as financial
advisor and capital markets advisor in connection with the European market to EBAC), who was later engaged by EBAC on June&nbsp;3, 2022 as a co-placement agent for the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the same day, EBAC&#146;s management held a telephonic meeting with Oculis&#146; management, in which Oculis&#146; management provided a detailed
presentation of <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT STYLE="white-space:nowrap">OCS-05,</FONT> two of Oculis&#146; product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2022, EBAC management visited Oculis&#146; office in Lausanne, Switzerland and met with Oculis management. The parties discussed
Oculis&#146; business, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies results, as well as Oculis&#146; intellectual property portfolio, among other things. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on April&nbsp;3, 2022, EBAC requested Oculis to provide additional information and documents in the data room, and Oculis responded to these due
diligence requests on a rolling basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2022, Oculis provided EBAC with comments to the Letter of Intent. Oculis proposed a <FONT
STYLE="white-space:nowrap">pre-money</FONT> valuation of Oculis of $233&nbsp;million, suggested that Oculis Shareholders receive 3&nbsp;million earnout shares, to be vested in equal tranches, if the average trading price for the listed company were
to close at $15.00 per share or higher for 20 out of 30 trading days, and $20.00 per share or higher for 20 out of 30 trading days, respectively. Oculis management also proposed that 550,000 of the Sponsor&#146;s Founder Shares and 50,000 of the
Sponsor&#146;s EBAC Private Warrants would be surrendered at the closing of the potential business combination and that a further 1,250,000 of the Sponsor&#146;s Founder Shares would be subject to forfeiture if certain minimum cash proceeds from
EBAC&#146;s trust account were not ultimately received by Oculis. In addition, the revised Letter of Intent also included a proposal that the Sponsor and certain of its affiliates enter into a support agreement agreeing to vote in favor of the
Business Combination and to not transfer their shares in New Parent until closing of the potential business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2022, Riad
Sherif and Sylvia Cheung visited the Sponsor&#146;s office, and held discussions with EBAC management on the transaction, including the terms of the Letter of Intent. On the same day, EBAC proposed a <FONT STYLE="white-space:nowrap">pre-money</FONT>
valuation of Oculis of $207&nbsp;million and agreed in principle to the potential forfeiture of certain Sponsor shares but proposed a different threshold for such forfeiture. On this same day, EBAC management introduced Kempen (in its capacity as
financial advisor and capital markets advisor to EBAC) to Oculis management, who was later engaged by EBAC as a co-placement agent for the PIPE Financing on June&nbsp;3, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2022, EBAC&#146;s management sent Riad Sherif and Sylvia Cheung a presentation regarding the performance of European initial public offerings
for the attention of Oculis&#146; board of directors. On April&nbsp;6, 2022, Eduardo Bravo sent Riad Sherif an Excel spreadsheet comparing the performance of recent initial public offerings with the performance of recent deSPAC transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;6, 2022, during a telephonic meeting, Oculis&#146; board of directors approved that Oculis continue negotiations with EBAC. The following day,
Eduardo Bravo sent the EBAC Board a PowerPoint presentation including information regarding Oculis&#146; business and explained the discussions held with Oculis to that point as well as the anticipated timeline for signing the Letter of Intent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2022, Sylvia Cheung shared with Eduardo Bravo Oculis&#146; capitalization table, including information regarding the valuation of Oculis at
each funding round. On the same day, Riad Sherif held a telephone call with Eduardo Bravo sharing Oculis&#146; board of directors&#146; comments to the Letter of Intent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2022, Riad Sherif introduced Eduardo Bravo by email to some of Oculis&#146; directors, including Anthony Rosenberg, the chairman of the
board of directors. The following day, Eduardo Bravo held a telephone call with Anthony Rosenberg and Lionel Carnot, a director of Oculis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between
April&nbsp;12 and April&nbsp;22, 2022, the parties exchanged several drafts of the Letter of Intent. In April 2022, Eduardo Bravo sent Riad Sherif a proposed execution version of the Letter of Intent. The final proposal included,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
among other provisions, (i)&nbsp;a <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of Oculis of $208&nbsp;million; (ii) 4&nbsp;million worth of earnout shares for Oculis Shareholders,
vesting in three tranches ((x) 1.5&nbsp;million shares upon the share price of New Parent trading at or above $15.00 per share for 20 trading days during any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period, (y) 1.5&nbsp;million upon
the share price of New Parent trading at or above $20.00 per share for 20 trading days during any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period, and (z) 1.0&nbsp;million shares upon the share price of New Parent trading at or above
$25.00 per share for 20 trading days during any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period); (iii) PIPE Financing of at least $80&nbsp;million in the aggregate; and (iv) 797,174 Sponsor shares to be forfeited if the gross proceeds
of the transaction, including EBAC&#146;s net cash in its trust account (after giving effect to redemptions in connection with the Business Combination and the payment of transaction expenses) plus the PIPE Financing is less than $100&nbsp;million.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2022, Oculis and EBAC executed the Letter of Intent. On the same date, the parties held the first telephonic meeting with the working
group, including the banks&#146; representatives and the parties&#146; legal counsels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between May and September 2022, EBAC and Oculis regularly held
telephonic meetings with Credit Suisse, Kempen, BofA Securities and SVB Securities, each in their capacity as co-placement agent for the PIPE Financing and EBAC, to plan and discuss the PIPE Financing. The parties exchanged drafts and comments to a
PowerPoint presentation for the purpose of marketing the PIPE Financing to certain potential investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;4, 2022, EBAC, Oculis,
representatives of Credit Suisse, in its capacity as a co-placement agent for the PIPE Financing and financial advisor and capital markets advisor to EBAC, Kempen, in its capacity as <FONT STYLE="white-space:nowrap">co-placement</FONT> agent for the
PIPE Financing and financial advisor and capital markets advisor in connection with the European market to EBAC, BofA Securities, in its capacity as co-placement agent for the PIPE Financing for EBAC, and SVB Securities, in its capacity as a capital
markets advisor to Oculis and co-placement agent for the PIPE Financing for EBAC, held a telephonic call to prepare a PowerPoint presentation for the purpose of marketing the PIPE Financing in upcoming investor meetings. The same parties held
regular telephonic meetings with a similar purpose until June&nbsp;6, 2022 when the PIPE investor presentation was posted to the virtual data room for PIPE Investors, including the proposed target of $60&nbsp;million in PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;23, 2022, Eduardo Bravo proposed that the exclusivity provision, initially set to expire on May&nbsp;22, 2022, be extended. On May&nbsp;23, 2022,
the parties executed an amendment to the Letter of Intent extending the exclusivity period until June&nbsp;30, 2022. The parties subsequently executed amendments to the Letter of Intent extending the exclusivity period on June&nbsp;23, July&nbsp;22,
and August&nbsp;24, 2022, extending the exclusivity period to July&nbsp;31, August&nbsp;31, and September&nbsp;30, 2022 respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between June and
August 2022, in their capacity as co-placement agents for the PIPE Financing to EBAC, Credit Suisse, Kempen, BofA Securities, SVB Securities and Arctica requested virtual data room access for certain potential PIPE Investors, with Oculis granting
such access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2022, BofA Securities entered into an engagement letter with Oculis to act as exclusive financial advisor to Oculis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;3, 2022, each of Credit Suisse, Kempen, BofA Securities and SVB Securities entered into separate engagement letters with EBAC as co-placement
agents. Arctica subsequently entered into an engagement letter with EBAC as a co-placement agent on July&nbsp;22, 2022. Credit Suisse and Kempen were also engaged as financial advisor and capital markets advisor to EBAC in connection with the
proposed Business Combination, with Kempen only engaged as such in connection with the European market. In connection with BofA Securities&#146; engagement as a co-placement agent in the PIPE Investment, Oculis waived, on the terms and subject to
the conditions set forth in a letter agreement, dated May&nbsp;27, 2022, between Oculis and BofA Securities, any conflict arising out of the engagement of BofA Securities by EBAC and the engagement of BofA Securities by Oculis. In connection with
BofA Securities&#146; engagement as financial advisor to Oculis, EBAC waived, on the terms and subject to the conditions set forth in a letter agreement, dated June&nbsp;3, 2022, between EBAC and BofA Securities, any conflict arising out of the
engagement of BofA Securities by Oculis and the engagement of BofA Securities by EBAC. Such waivers included acknowledgment and agreement that some or all of the members of the BofA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities financial advisory team advising Oculis will also be members of the deal team assisting EBAC in connection with BofA Securities&#146; role as co-placement agent for the PIPE Financing.
The co-placement agents conducted formal outreach to certain potential PIPE Investors, with PIPE Investor meetings occurring between June and August 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;20, 2022, Davis Polk circulated initial forms of the Subscription Agreements (including one form for investors participating in the PIPE
Financing without the co-placement agents, one for the investors participating in the PIPE Financing introduced by the co-placement agents). Cooley provided comments to the forms of the Subscription Agreements on June&nbsp;28, 2022. On July&nbsp;6,
2022, Davis Polk provided an updated draft of the forms of Subscription Agreements. Cooley returned comments on July&nbsp;10, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;24,
2022, Oculis introduced EBAC to Arctica to be engaged as a <FONT STYLE="white-space:nowrap">co-placement</FONT> agent for other PIPE Investors. On July&nbsp;15, 2022, Arctica entered into an engagement letter with EBAC in its capacity as a <FONT
STYLE="white-space:nowrap">co-placement</FONT> agent for the PIPE Financing and started formal outreach to other PIPE Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between July&nbsp;10,
2022, and early October 2022, Davis Polk and Cooley collected comments from the co-placement agents, the co-placement agents&#146; counsel, and certain PIPE Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2022, Davis Polk provided an initial draft of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;30, 2022, Cooley delivered a key issues list based on Davis Polk&#146;s initial draft of the Business Combination Agreement, which provided
for, among other things, the delivery of a minimum of 21.93% of the EBAC public shares entering into <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreements and removing the EBAC Board&#146;s ability to change its recommendation to the
EBAC Shareholders to vote in favor of the business combination. Davis Polk provided comments to the key issues list on September&nbsp;1, 2022, maintaining EBAC&#146;s positions set forth in the executed Letter of Intent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2022, Eduardo Bravo held a telephonic meeting with Riad Sherif, Sylvia Cheung and P&aacute;ll Ragnar J&oacute;hannesson to discuss the
timeline of the potential business combination and next steps. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2022, Cooley sent comments to the Business Combination Agreement to
Davis Polk, which included, among other things, the proposal to limit the ability of the EBAC Board to change its recommendation that EBAC Shareholders vote in favor of the business combination to the receipt of a superior business combination
proposal and providing Oculis with an opportunity to revise its offer in order to obviate the EBAC Board&#146;s recommendation change. Additionally, Cooley proposed that the Oculis business combination proposal be submitted to a vote regardless of
the recommendation of the EBAC Board. Furthermore, the markup included a proposal that the <FONT STYLE="white-space:nowrap">at-risk</FONT> shares be forfeited in two tranches, in part at the signing of the Business Combination Agreement and in part
at the Acquisition Closing. Davis Polk subsequently had a telephonic meeting with EBAC to discuss the key issues list. EBAC&#146;s and Oculis&#146; counsels had a telephone call regarding the key issues to the Business Combination Agreement on the
same day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;16, 2022, Eduardo Bravo, Koen Sintnicolaas and Laurenz Govaerts held a telephonic meeting with the EBAC Board discussing
updates to the transaction timeline and process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2022, Davis Polk provided comments to the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2022, Davis Polk provided Cooley an initial draft of the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreement. Cooley returned comments on September&nbsp;29, 2022. The parties exchanged several drafts, reflecting comments from EBAC, Oculis, and other parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;26, 2022, Cooley provided an initial draft of the Oculis Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eduardo Bravo held telephone calls with Oculis&#146; management on September&nbsp;28, October&nbsp;4 and October&nbsp;8 to discuss outstanding commercial
terms of the Business Combination Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">368 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2022, Davis Polk provided Cooley an initial draft of the form of <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2022, Cooley provided comments to Davis Polk to the key issues list.
Davis Polk had a telephone call with EBAC to discuss the key issues list. On September&nbsp;30, 2022, EBAC&#146;s and Oculis&#146; counsel had a telephonic meeting to discuss the key issues list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;3, 2022, Cooley provided comments to Davis Polk on the form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2022, Davis Polk provided comments to Cooley on the Oculis Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2022, Cooley provided Davis Polk an initial draft of the Oculis Shareholders Support Agreement. On October&nbsp;8, 2022, Cooley provided an
updated draft of the Oculis Shareholders Support Agreements as well as an initial draft of the Convertible Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2022, Davis
Polk provided Cooley an initial draft of the Sponsor Support Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2022, Davis Polk provided comments to the Business Combination
Agreement. Cooley returned comments to Davis Polk on October&nbsp;7, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;7, 2022, Davis Polk provided an initial draft of the EBAC
Disclosure Letter. Cooley returned comments to the EBAC Disclosure Letter on October&nbsp;9, 2022. On October&nbsp;16, 2022, Davis Polk provided a finalized EBAC Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;8, 2022, Cooley provided Davis Polk an updated draft of the Oculis Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2022, Davis Polk returned comments to the Convertible Loan Agreement. On the following day, Davis Polk returned comments to the Oculis
Shareholders Support Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2022, Davis Polk returned further comments to the Business Combination Agreement. Over the next
several days, the Cooley and Davis Polk tax teams reviewed the Business Combination Agreement and provided comments to the document consistent with the contemplated transaction structure of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2022, Cooley provided Davis Polk an updated draft of the Oculis Disclosure Letter. The following day, Davis Polk returned comments to the
document. On October&nbsp;15, 2022, Cooley circulated the finalized Oculis Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;13, 2022, Davis Polk circulated the
finalized form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2022, Cooley circulated the finalized form of
Registration Rights and <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2022, Vischer provided further comments to the
Business Combination Agreement. Over the next couple days, Cooley and Davis Polk exchanged comments to the Business Combination Agreement and finalized the agreement. The comments focused on finalizing the structure of the Business Combination with
the goal to obtain the intended tax treatment of the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2022, Vischer circulated the finalized versions of the Oculis
Shareholders Support Agreements and the Convertible Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2022, Davis Polk circulated the finalized forms of the
Subscription Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the morning of October&nbsp;17, 2022, Davis Polk circulated the finalized Sponsor Support Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">369 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the morning of October&nbsp;17, 2022, the EBAC Board met partly in person and partly over a telephonic
meeting in which all members of the EBAC Board were in attendance. Representatives from Credit Suisse, Davis Polk and Maples and Calder (Cayman) LLP (&#147;<I>Maples</I>&#148;) were also in attendance. During the meeting, representatives of Credit
Suisse provided an update on general market conditions for special purpose acquisition companies and reviewed the general deal framework. Following discussion, representatives of Davis Polk provided the EBAC Board with a summary of the terms and
structure of the proposed Business Combination and related Ancillary Agreements, including, among other things, the material terms and conditions of the proposed Business Combination Agreement and the post-Acquisition Closing structure of New
Parent. A representative of Maples provided the EBAC Board with an overview of the applicable laws relating to the fiduciary duties of directors of companies organized under the laws of the Cayman Islands, including in relation to the EBAC
Board&#146;s consideration of the proposed Business Combination with Oculis. The EBAC Board then engaged in discussions and deliberations with the other directors and advisors. Following these discussions and deliberations, EBAC&#146;s independent
directors held an executive session to further discuss the merits of the proposed transaction. Following discussions, the EBAC Board, having determined that entry into the Business Combination Agreement and Ancillary Agreements and the transactions
contemplated thereby were in the best interest of EBAC and its shareholders, unanimously approved the entry into the Business Combination Agreement and Ancillary Agreements and the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later that morning, EBAC and Oculis executed the Business Combination Agreement. Concurrently with the execution of the Business Combination Agreement,
(i)&nbsp;EBAC entered into Initial Subscription Agreements with the Initial PIPE Investors, (ii)&nbsp;the Sponsor and certain EBAC Shareholders entered into the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements, (iii)&nbsp;Oculis,
EBAC and the Oculis Shareholders party thereto entered into the Oculis Shareholders Support Agreements and (iv)&nbsp;EBAC, Oculis and the Sponsor entered into the Sponsor Support Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, concurrently with the execution of the Business Combination Agreement, Oculis and the Lenders entered into the Convertible Loan Agreement, pursuant
to which, the Lenders granted Oculis a convertible loan with certain conversion rights in an aggregate amount of $12,670,000. Following the Second Merger Effective Time, it is the intent of the parties thereto that New Parent will assume the
Convertible Loan Agreement, and that immediately after such assumption but before the Company Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10.00 per share, on the same economic terms as
the PIPE Investors. Prior to the Acquisition Closing Date, Oculis offered all its shareholders the opportunity to participate in the Convertible Loan Agreement on a pro rata basis by executing an Adherence Declaration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later that morning, and prior to the open of public markets in the United States, the parties issued a joint press release announcing the Business Combination
and, shortly thereafter, EBAC filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> attaching the press release, the Business Combination Agreement (including the exhibits thereto), the form of Subscription Agreement, the
Convertible Loan Agreement, the form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Oculis Shareholders Support Agreement, the Sponsor Support Agreement, the form of Registration Rights and
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and the investor presentation previously provided to certain potential PIPE Financing investors and Oculis Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Initial PIPE Financing, in January 2023, EBAC entered into the Subsequent Subscription Agreements with the Subsequent PIPE Investors,
pursuant to which the Subsequent PIPE Investors agreed to subscribe for, and EBAC agreed to issue to the Subsequent PIPE Investors, an aggregate of 788,500 shares of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share, for the aggregate
purchase price of $7,885,000. The Subsequent PIPE Financing arose due to significant demand by the Subsequent PIPE Investors. Conversations between Oculis, EBAC and the Subsequent PIPE Investors occurred in December 2022 where the topic of
increasing their PIPE subscription was discussed at the request of the Subsequent PIPE Investors. The Subsequent Subscription Agreements are in substantially the same form as the Initial Subscription Agreements. On January 26, 2023, Oculis and EBAC
agreed to accept the incremental capital. The resulting aggregate amount of shares of EBAC Class&nbsp;A Common Stock to be issued pursuant to the PIPE Financing is 7,118,891 for aggregate gross proceeds of $71,188,910. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">370 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The EBAC Board&#146;s Reasons for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business
combination, the intent to capitalize on the ability of EBAC&#146;s management team to identify a company within the life sciences industry in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;17, 2022, the EBAC Board, after consultation with its legal, financial, accounting and other advisors, (i)&nbsp;determined that it is advisable and in the best interests of EBAC Shareholders for EBAC to enter into the Business
Combination Agreement and the Ancillary Agreements, (ii)&nbsp;approved the execution and delivery of the Business Combination Agreement and the Ancillary Agreements and (iii)&nbsp;recommended the adoption and approval of the Business Combination
Agreement and the Ancillary Agreements, and each of the proposals presented in this proxy statement/prospectus, by EBAC Shareholders. In evaluating the Business Combination and making these determinations and this recommendation, the EBAC Board
consulted with EBAC senior management and considered a wide variety of factors, including the reasons for the Business Combination and the risks related thereto, in each case, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the complexity of those factors, the EBAC Board did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative
weights to the specific factors it considered in reaching the directors&#146; respective decisions. Individual members of the EBAC Board may have given different weight to different factors. This explanation of the reasons for the EBAC Board&#146;s
approval of the Business Combination, and all other information presented in this section, is not intended to be exhaustive but includes material factors considered by the EBAC Board and is forward-looking in nature and, therefore, should be read in
light of the factors discussed under the section entitled &#147;<I>Cautionary Note Regarding Forward-Looking Statements</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board and
management of EBAC considered the general criteria and guidelines that EBAC believed would be important in evaluating prospective target businesses as described in the prospectus for EBAC&#146;s initial public offering. The EBAC Board also
considered that EBAC could enter into a business combination with a target business that does not meet those criteria and guidelines. In the prospectus for its initial public offering, EBAC stated that it intended to focus primarily on acquiring a
company or companies exhibiting some of the following criteria and guidelines: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has a strong management team with scientific accomplishments and commercial expertise and with the capacity to
lead a company listed in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has a European life sciences footprint that would provide access to the European biotech ecosystem;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the ability to achieve clinical POC (e.g., Phase 2 data) or product approval for
<FONT STYLE="white-space:nowrap">post-POC</FONT> assets within three years of investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">operates therapeutic drug candidates in clinical development and also addresses attractive underserved markets.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the Business Combination, the EBAC Board determined that the Business Combination was an attractive business opportunity
and met the criteria and guidelines above (although not weighted or in any order of significance). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the EBAC Board considered the following
factors (although not weighted or in any order of significance) in deciding to approve the proposed Business Combination: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Experienced management team and New Parent Board. </I></B>The EBAC Board believes that Oculis&#146; management
team has extensive experience in the biopharma industry in general and the ophthalmology market in particular. The EBAC Board is confident in the management team&#146;s deep industry knowledge and strategic vision and believes that the EBAC and
Oculis teams (together with the new incoming directors of the New Parent Board who have extensive executive experience working in the biopharma industry) will form a collaborative and effective long-term partnership that is positioned to create and
enhance shareholder value going forward. For additional information regarding Oculis&#146; executive officers, please see the section entitled &#147;<I>Management of New Parent After the Business Combination</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">371 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Advanced and diversified pipeline. </I></B>The EBAC Board
considered that the current pipeline of Oculis provides multiple product candidates that may be developed in several indications where the existing unmet medical need could provide significant market opportunities and long-term shareholder value.
For additional information regarding Oculis&#146; pipeline, please see the section entitled<B><I> </I></B>&#147;<I>Business of Oculis and Certain Information about Oculis.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Upcoming milestones. </I></B>The EBAC Board considered that with the funds that Oculis is expected to receive
with the proposed transaction, it may be able to reach significant clinical and regulatory milestones for all three of its product candidates, <FONT STYLE="white-space:nowrap">OCS-01,</FONT> <FONT STYLE="white-space:nowrap">OCS-02</FONT> and <FONT
STYLE="white-space:nowrap">OCS-05,</FONT> in a total of five different indications. These milestones could provide opportunity for potential uplifts in valuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Benefit for Oculis of being U.S. listed</I></B>. As a result of the proposed transaction, Oculis will become a
public company listed on the Nasdaq Global Market (via New Parent). By having access to the largest biotech capital market, Oculis will be better positioned to have the capacity to raise additional funds in the future if and when needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Investment by Third Parties</I></B><B>. </B>The EBAC Board considered that certain sophisticated investors
(i)&nbsp;subscribed for the PIPE Financing in the aggregate amount of approximately $71.2&nbsp;million and (ii)&nbsp;agreed to grant Oculis a right to receive a convertible loan with certain conversion rights in the aggregate amount of approximately
$19.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Terms of the Business Combination Agreement and the Ancillary Agreements</I></B><B>.
</B>The EBAC Board considered the terms and conditions of the Business Combination Agreement and the Ancillary Agreements, including the transactions contemplated thereby, each party&#146;s representations, warranties and covenants, the conditions
to each party&#146;s obligation to close and the termination provisions, as well as EBAC&#146;s and Oculis&#146; strong commitment to complete the Business Combination. The EBAC Board determined that such terms and conditions are reasonable and were
the product of extensive <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between EBAC and Oculis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<B><I>Continued Ownership of Oculis Shareholders</I></B><B>.</B> The EBAC Board considered that the Oculis Shareholders would be receiving a significant amount of New Parent Shares in the proposed Business Combination. Oculis Shareholders have
demonstrated confidence in the long-term prospects of New Parent by agreeing not to transfer their New Parent Shares for 180 days following the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The Role of the Independent Directors</I></B><B>.</B> In connection with the Business Combination, EBAC&#146;s
Independent Directors evaluated the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements, and unanimously approved, as members of the EBAC Board, the Business Combination Agreement, the
Ancillary Agreements, and the transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Other Alternatives</I></B><B>. </B>The
EBAC Board believed, after a thorough review of other business combination opportunities reasonably available to or explored by EBAC, that the proposed Business Combination represented the optimal potential business combination for EBAC and its
shareholders based upon the process utilized to evaluate and assess other potential acquisition targets, and the EBAC Board&#146;s belief that such processes had not presented a better alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board also identified and considered a variety of uncertainties and risks and other potentially negative factors concerning the Business Combination,
including, but not limited to, the following (although not weighted or in any order of significance): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Macroeconomic Risk</I></B>: macroeconomic uncertainty and the effects it could have on New Parent in the
future; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Uncertainty of Benefits</I></B>: the risk that the potential benefits of the Business Combination
may not be fully achieved, or may not be achieved within the expected timeframe; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">372 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Redemption Risk</I></B>:<B></B>&nbsp;the risk that some of
EBAC Shareholders decide to exercise their redemption rights, thereby depleting the amount of cash available in the Trust Account to meet the Minimum EBAC Cash Condition and adequately support New Parent&#146;s development plans following completion
of the Business Combination; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Liquidation of EBAC</I></B>:<B></B>&nbsp;the risks and costs to EBAC if the
Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in EBAC being unable to effectuate a business combination within the Combination
Period, and force EBAC to liquidate in accordance with its amended and restated memorandum and articles of association; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Exclusivity</I></B>: that the Business Combination Agreement includes an exclusivity provision that prohibits
EBAC from, among other things, initiating discussions in connection with other business combination proposals, restricting EBAC&#146;s ability, as long as the Business Combination Agreement is in effect, to consider other potential business
combinations prior to the termination of the Business Combination Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Diversion of Management;
Risk of Management Departures</I></B>: the potential for diversion of management and employee attention during the period prior to the completion of the Business Combination, and the potential negative effects on Oculis&#146; business as a result
thereof, and the risk that key employees of Oculis may not remain with Oculis following the closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Shareholder Vote</I></B>:<B></B>&nbsp;the risk that EBAC Shareholders may fail to provide the respective votes
necessary to effectuate the Business Combination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT STYLE="white-space:nowrap">Non-Survival</FONT></I></B>: that the remedies for breach of representations,
warranties or covenants will not survive the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Closing Conditions</I></B>: that completion of the
Business Combination is conditioned on the satisfaction of certain closing conditions that are not within EBAC&#146;s control, including (i)&nbsp;approval by EBAC Shareholders, (ii)&nbsp;approval by the Nasdaq of the initial listing application made
for the New Parent Shares and New Parent Warrants to be issued in connection with the Business Combination and (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock, or if EBAC does not obtain all or a portion of the
PIPE Financing, such that the Minimum EBAC Cash Condition would not be satisfied, and the risk that the Business Combination may not be consummated in a timely manner or at all; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Public Company Readiness</I></B>: the challenges associated with preparing New Parent, a foreign, private
entity, for the applicable disclosure and listing requirements to which New Parent will be subject to as a publicly traded company on the Nasdaq Global Market, including the time and attention of management and employees that will be diverted from
operating matters to achieve and maintain such requirements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>EBAC Shareholders Receiving a Minority
Position in New Parent</I></B>:<B></B>&nbsp;the risks associated with EBAC Shareholders holding a minority position in New Parent following the Acquisition Closing and the transactions contemplated thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></B>:<B></B>&nbsp;the risk of uncertainties regarding the
potential impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related economic disruption on Oculis&#146; business due to, among other things, difficulty in recruiting patients for clinical trials, on manufacturing of
products or due to government-mandated shutdowns; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Litigation</I></B>:<B></B>&nbsp;the possibility of
litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Fees and Expenses</I></B>:<B></B>&nbsp;the significant fees and expenses associated with completing the
Business Combination; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conflicts of Interest</I></B>; the potential conflicts of interest described in
the section entitled &#147;<I>Certain EBAC Relationships and Related Party Transactions</I>&#148;; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">373 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Other Risks</I></B>: various other risks associated with
the Business Combination, the business of EBAC and the business of Oculis, as described further under the section entitled &#147;<I>Risk Factors</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to considering the factors described above, the EBAC Board also considered that certain of the officers and directors of EBAC may have interests
in the Business Combination as individuals that are in addition to, and that may be different from, the interests of EBAC Shareholders, including as a result of the corporate opportunities waiver included in EBAC&#146;s amended and restated
memorandum and articles of association. The executive officers and directors of EBAC have established reputations in the biopharma industry and might have had many opportunities available to them, which would not have needed to be disclosed to the
Board in connection with its consideration of the potential Business Combination. These potential conflicts are more thoroughly described in more detail under the section entitled &#147;<I>Certain Relationships and Related Person
Transactions</I>,&#148; EBAC&#146;s independent directors reviewed and considered these interests during the negotiation of the Business Combination and in evaluating and approving, as members of the EBAC Board, the Business Combination Agreement
and the transactions contemplated therein, including the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board concluded, based on its review of the foregoing
considerations as a whole, that the potential benefits that it expected EBAC and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly,
the EBAC Board unanimously determined that the Business Combination Agreement and the Business Combination were advisable, fair to, and in the best interests of EBAC and its shareholders. The EBAC Board realized that there can be no assurance about
future results, including results considered or expected, as disclosed in the foregoing reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Satisfaction of 80% Test </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is a requirement under EBAC&#146;s amended and restated memorandum and articles of association and the Nasdaq listing requirements that the business or
assets acquired in EBAC&#146;s Business Combination have a fair market value equal to at least 80% of the balance of the funds in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust
Account) at the time of the execution of a definitive agreement for such Business Combination. As of October&nbsp;17, 2022, the date of the execution of the Business Combination Agreement, the fair value of marketable securities held in the Trust
Account was approximately $123.9&nbsp;million (excluding deferred underwriting commissions and taxes payable on the income earned on the Trust Account) and 80% thereof represents approximately $99.1&nbsp;million. In reaching its conclusion that the
Business Combination meets the 80% asset test, the EBAC Board reviewed the <FONT STYLE="white-space:nowrap">pre-transaction</FONT> enterprise valuation of Oculis of approximately $208.0&nbsp;million. In determining whether the equity value described
above represents the fair market value of Oculis, the EBAC Board considered all of the factors described in this section and the $208.0&nbsp;million Oculis enterprise value was determined as a result of
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations. As a result, the EBAC Board concluded that the fair market value of the equity acquired was significantly in excess of 80% of the assets held in the Trust Account (excluding the
deferred underwriting commissions and taxes payable on the income earned on the Trust Account). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Certain Persons in the Business
Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the EBAC Board&#146;s recommendation that EBAC Shareholders vote in favor of the approval of the Business Combination
Proposal and the Merger Proposal, EBAC Shareholders should be aware that aside from their interests as shareholders, the EBAC Initial Shareholders and EBAC&#146;s other current officers and directors have interests in the Business Combination that
are different from, or in addition to, those of other EBAC Shareholders generally. For example, such interests may incentivize the Sponsor to complete the Business Combination with Oculis, or an alternative initial business combination with a less
favorable company or on terms less favorable to EBAC Shareholders, rather than to liquidate, in which case the Sponsor would lose its entire investment. The EBAC Board was aware of and considered these interests, among other matters, in evaluating
and negotiating the Business Combination, and in recommending to EBAC Shareholders that they approve the Business Combination Proposal and the Merger Proposal. EBAC Shareholders should take these interests into account in deciding whether to approve
the Business Combination Proposal and the Merger Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">374 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interests include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed not to redeem any EBAC
Common Stock held by them in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $25,000 for the Founder Shares. The Founder Shares had an estimated aggregate
market value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based upon the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per public share on the Nasdaq Capital Market on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor transferred Founder Shares to two independent directors prior to EBAC&#146;s initial
public offering and such securities would be worthless if a business combination is not consummated within the Combination Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EBAC Initial Shareholders and the other officers and directors of EBAC have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to any Founder Shares held by them if EBAC fails to complete an initial business combination within the Combination Period and, in the event EBAC fails to complete an initial business
combination within the Combination Period, the Founder Shares would have no value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be entered into by
the Sponsor, the EBAC Initial Shareholders and the other officers and directors of EBAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of $4.55&nbsp;million for its 455,096 Private Placement Units and that such
Private Placement Units (and the underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The Private Placement Units had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit on the Nasdaq Capital Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor paid an aggregate of 4,550,960 for its 455,096 Private Placement Units and that such EBAC Private
Placement Units (and underlying securities) will expire worthless if a business combination is not consummated within the Combination Period. The EBAC Private Placement Warrants had an estimated aggregate value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; based on the closing price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant on the Nasdaq Capital Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other
shareholders experience a negative rate of return in the post-business combination company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fact that the Sponsor will own 2,842,618 New Parent Shares, which collectively will represent approximately
6.3% of outstanding New Parent Shares and have a value of approximately $28,426,180 based on an implied value of $10.00 per New Parent Share and assuming that the maximum number of EBAC Class&nbsp;A Common Stock are redeemed while still satisfying
the Minimum EBAC Cash Condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right of EBAC Initial Shareholders and the other directors and officers of EBAC to receive New Parent
Shares, subject to certain <FONT STYLE="white-space:nowrap">lock-up</FONT> periods (it being understood that no contractual selling restrictions apply to any shares issued in connection with the PIPE Financing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the anticipated designation by EBAC of Martijn Kleijwegt and Geraldine O&#146;Keefe as directors of New Parent
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued indemnification of EBAC&#146;s existing directors and officers and the continuation of
EBAC&#146;s directors&#146; and officers&#146; liability insurance after the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LSP 7, an affiliate of the Sponsor, previously invested $2,104,007 into Oculis on July&nbsp;22, 2022 prior to
the execution of the Business Combination Agreement. In connection with the Oculis Share Contribution, LSP 7 will receive 233,405 New Parent Shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">375 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an affiliate of the Sponsor has also entered into a Subscription Agreement in connection with the PIPE
Financing, pursuant to which such affiliate has agreed to subscribe for and purchase, and EBAC has agreed to issue from treasury to such affiliate, a certain number of EBAC Class&nbsp;A Common Stock at a price of $10.00 per share for an aggregate
purchase price of $37.896&nbsp;million. Certain of EBAC&#146;s directors also hold a personal financial interest in such affiliate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor and EBAC&#146;s officers and directors will lose their entire investment in EBAC and will not be
reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated within the Combination Period if an initial business combination is not
consummated within the Combination Period. If the Business Combination is consummated within the Combination Period, pursuant to the Business Combination Agreement, the reimbursement of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the Sponsor and its affiliates and EBAC&#146;s officers and directors in connection with activities on EBAC&#146;s behalf. The
aggregate value of all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for which the Sponsor and EBAC&#146;s officers and directors are entitled to reimbursement as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Extraordinary General Meeting, is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Trust Account is liquidated, including in the event EBAC is unable to complete an initial business
combination within the Combination Period, the Sponsor has agreed to indemnify EBAC to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on
the liquidation date, by the claims of prospective target businesses with which EBAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to EBAC, but only if such a vendor or target business
has not executed a waiver of any and all rights to seek access to the Trust Account; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the consummation of the transactions contemplated hereby, each of the Founder Shares held by
the Sponsor and by certain other directors of EBAC will ultimately be exchanged and converted into a number of New Parent Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interests may influence EBAC&#146;s directors in making their recommendation that EBAC Shareholders vote in favor of the approval
of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to EBAC&#146;s amended and restated memorandum and articles of association, holders of EBAC public shares may elect to have their shares redeemed for
the right to receive an amount in cash at the applicable redemption price per share calculated in accordance with EBAC&#146;s amended and restated memorandum and articles of association. As of September&nbsp;30, 2022, this per share redemption price
would have amounted to approximately $10.00 per share. If a holder of EBAC public shares exercises its redemption rights, then such holder will, subject to the Acquisition Closing being completed, be exchanging its EBAC Class&nbsp;A Common Stock for
the right to receive an amount in cash and will not own shares of New Parent following the closing of the transactions contemplated by the Business Combination Agreement, including the Business Combination. Such a holder will be entitled to receive
the right for an amount in cash for its public shares subject to the Acquisition Closing being completed and only if it properly demands redemption and delivers its shares (either physically or electronically) to the Transfer Agent in accordance
with the procedures described herein. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to the Transfer Agent in order to validly
redeem its shares. Notwithstanding the foregoing, a holder of the public shares, together with any affiliate of his, her, it or any other person with whom he, she or it is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of
the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the outstanding EBAC Class&nbsp;A Common Stock. Accordingly, all public shares in excess of the 15% threshold beneficially owned by a public
shareholder or group will not be redeemed for cash. The EBAC Initial Shareholders and certain other officers and directors of EBAC have agreed, for no consideration in return, to waive their redemption rights with respect to any Founder Shares and
other EBAC Common Stock they may hold in connection with the consummation of the Business Combination, and the Founder Shares and such other EBAC Common Stock will be excluded from the pro rata calculation used to determine the <FONT
STYLE="white-space:nowrap">per-share</FONT> redemption price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">376 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC has no specified maximum redemption threshold under its amended and restated memorandum and articles of
association, other than the aforementioned 15% threshold. Each redemption of EBAC Class&nbsp;A Common Stock by EBAC&#146;s public shareholders will reduce the amount in the Trust Account, which held marketable securities with a fair value of
approximately $128.3&nbsp;million as of September&nbsp;30, 2022. The conditions to the Acquisition Closing are for the sole benefit of the parties thereto and may be waived by such parties. If, as a result of redemptions of EBAC Class&nbsp;A Common
Stock by EBAC&#146;s public shareholders, the Minimum EBAC Cash Condition is not met or is not waived by the parties to the Business Combination Agreement, then either of the parties thereto may elect not to consummate the Business Combination. In
addition, in no event will EBAC redeem its EBAC Class&nbsp;A Common Stock in an amount that would cause its net tangible assets to be less than $5,000,001, as provided in EBAC&#146;s amended and restated memorandum and articles of association. Under
these circumstances, EBAC Shareholders may exercise their redemption rights with respect to a maximum of 10,363,709 shares of redeemable EBAC Class&nbsp;A Common Stock upon consummation of the Business Combination at a redemption price of
approximately $10.052 per share. The estimated per share redemption value of $10.052 was calculated by dividing the Trust Account balance of approximately $128.3&nbsp;million as of September&nbsp;30, 2022, by 12,754,784 shares of EBAC Class&nbsp;A
Common Stock outstanding and subject to redemption. Please see the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information&#151;Redemption Scenarios</I>.&#148; EBAC Shareholders who wish to redeem their public shares
for cash must refer to and follow the procedures set forth in the section entitled &#147;<I>Extraordinary General Meeting of EBAC&#151;Redemption Rights</I>&#148; in order to properly redeem their public shares. Holders of EBAC Public Warrants will
not have redemption rights with respect to such warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination and the transactions contemplated by the Business Combination Agreement are not subject to any regulatory requirement or approval,
except for (i)&nbsp;filings with the Cayman Registrar of Companies, the Commercial Register of the Canton of Zug, Switzerland and the Commercial Register of the Canton of Vaud, Switzerland to effect the Mergers and New Parent Share Capital Increase
and (ii)&nbsp;filings required with the SEC pursuant to the reporting requirements applicable to EBAC, and the requirements of the Securities Act and the Exchange Act, including the requirement to file the registration statement of which this proxy
statement/prospectus forms a part and to disseminate this proxy statement/prospectus to EBAC shareholders. EBAC must comply with applicable United States federal and state securities laws in connection with the PIPE Financing, and with the Nasdaq
continued listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses of Funds for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the sources and uses for funding the Business Combination. All of the sources and uses below are for illustrative purposes only.
Where actual amounts are not known or knowable, the figures below represent EBAC&#146;s good faith estimate of such amounts. The maximum redemption scenario represents the maximum amount of shares of EBAC Class&nbsp;A Common Stock that can be
redeemed such that the Minimum EBAC Cash Condition can still be satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Redemption
Scenario<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing<SUP STYLE="font-size:75%; vertical-align:top">(3)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Expenses<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">377 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that none of EBAC&#146;s outstanding public shares are redeemed in connection with the Business
Combination. Excludes interest earned in the Trust Account; the actual amount of cash in the Trust Account is subject to change depending on actual interest earned. Approximately $7.4&nbsp;million in
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements has been committed from existing EBAC investors as of the announcement of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approximately $19.7&nbsp;million of the PIPE Financing is in the form of convertible loan agreements at zero
percent interest and convertible at the Acquisition Closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Company Equity Value under the terms of the Business Combination Agreement, with a <FONT
STYLE="white-space:nowrap">pro-forma</FONT> number of approximately 20.3&nbsp;million New Parent Shares to be issued to Oculis Shareholders as rollover equity. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Parent Shares issued to Oculis Shareholders and PIPE Investors are at a deemed value of $10.00 per share.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximum Redemption Scenario<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing<SUP STYLE="font-size:75%; vertical-align:top">(3)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Expenses<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that EBAC&#146;s public shareholders exercise redemption rights with respect to 10,363,709 of
EBAC&#146;s public shares, which represents redemptions of approximately 81% of EBAC&#146;s public shares and which is the maximum number of redemptions which may occur such that the Minimum EBAC Cash Condition would still be satisfied at a
redemption price of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and excluding EBAC public shares subject to Non-Redemption Agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approximately $19.7&nbsp;million of the PIPE Financing is in the form of convertible loan agreements at zero
percent interest and convertible at the Acquisition Closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Company Equity Value under the terms of the Business Combination Agreement, with a <FONT
STYLE="white-space:nowrap">pro-forma</FONT> number of approximately 20.3&nbsp;million New Parent Shares to be issued to Oculis Shareholders as rollover equity. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Parent Shares issued to Oculis Shareholders and PIPE Investors are at a deemed value of $10.00 per share.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Information Relating to New Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent Shares and New Parent Warrants currently are not traded on any stock exchange. New Parent has applied to list the New Parent Shares and New Parent
Warrants on the Nasdaq Global Market under the symbols &#147;OCS&#148; and &#147;OCSAW,&#148; respectively, upon the closing of the transactions contemplated by the Business Combination Agreement, including the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">378 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delisting EBAC Common Stock and Deregistration of EBAC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC and Oculis anticipate that, following consummation of the transactions contemplated by the Business Combination Agreement, including the Business
Combination, the EBAC Class&nbsp;A Common Stock, EBAC Public Units and the EBAC Public Warrants will be delisted from the Nasdaq Capital Market, and EBAC will be deregistered under the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Shareholder Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until consummation of
the transactions contemplated by the Business Combination Agreement, including the Business Combination, Cayman Islands law and EBAC&#146;s amended and restated memorandum and articles of association will continue to govern the rights of EBAC
Shareholders. After consummation of the transactions contemplated by the Business Combination Agreement, including the Business Combination, Swiss law and the Proposed Articles of Association will govern the rights of New Parent shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are certain differences in the rights of EBAC Shareholders prior to the Business Combination and the rights of New Parent shareholders after the
Business Combination. Please see the section entitled &#147;<I>Comparison of Shareholder Rights</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Tax Consequences of the Business
Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the section entitled &#147;<I>Material Tax Considerations</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment of the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Business Combination will be accounted for as a capital reorganization. Under this method of accounting, EBAC will be treated as the acquired company for financial reporting purposes, whereas Oculis will be treated as the accounting acquiror. In
accordance with this accounting method, the Business Combination will be treated as the equivalent of Oculis issuing stock for the net assets of EBAC, accompanied by a recapitalization. The net assets of Oculis will be stated at historical cost,
with no goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of Oculis. Oculis has been determined to be the accounting acquiror for purposes of the Business Combination based on an evaluation
of the following facts and circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After the Acquisition Closing, persons affiliated with Oculis are expected to control a majority of the New
Parent Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis Shareholders have the largest voting interest under both redemption scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis is the largest entity based on the entity&#146;s operations and number of employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; operations prior to the Business Combination will comprise the ongoing operations of New Parent; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oculis&#146; existing executive officers and senior management team will comprise the executive officers and
senior management team of New Parent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination, which is not within the scope of IFRS 3 since EBAC does not meet the
definition of a business in accordance with IFRS 3, is accounted for within the scope of IFRS 2. Any excess of fair value of New Parent Shares issued over the fair value of EBAC&#146;s identifiable net assets acquired represents compensation for the
service of a stock exchange listing for its shares and is expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the holders of EBAC Warrants have appraisal rights in connection the Business Combination under the Cayman Companies Act. EBAC Shareholders may be
entitled to give notice to EBAC prior to the meeting that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">379 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they wish to dissent to the Business Combination and to receive payment of fair market value for his, her or its EBAC Common Stock if they follow the procedures set forth in the Cayman Companies
Act, noting that any such dissention rights may be limited pursuant to Section&nbsp;239 of the Cayman Companies Act which, states that no such dissention rights shall be available in respect of shares of any class for which an open market exists on
a recognized stock exchange at the expiry date of the period allowed for written notice of an election to dissent provided that the merger consideration constitutes inter alia shares of any company which at the effective date of the merger are
listed on a national securities exchange. It is the view of the EBAC Board that such fair market value would equal the amount which EBAC Shareholders would obtain if they exercise their redemption rights as described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to Oculis Shareholders in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences if the Adjournment Proposal is Not Approved </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Proposal and the Merger Proposal are not approved by EBAC Shareholders, then EBAC will not meet the conditions to closing of the
Business Combination and EBAC will not consummate the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned on the approval of the Business Combination Proposal and the Merger Proposal at the Extraordinary General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Business Combination Proposal and the Merger Proposal (and consequently, the Business Combination Agreement and the transactions contemplated thereby,
including the Business Combination) will be adopted and approved, subject to the next sentence, only if EBAC Shareholders approve an ordinary resolution which requires the affirmative vote of the holders of at least a majority of the outstanding
EBAC Common Stock that are entitled to vote and are voted at the Extraordinary General Meeting vote &#147;FOR&#148; the Business Combination Proposal, the Merger Proposal and the Adjournment Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, the Sponsor and each member of EBAC&#146;s management team have agreed to vote any EBAC Common Stock
(including Founder Shares and any other public shares of EBAC as of the record date) owned by them in favor of the Business Combination and the transactions contemplated thereby (including by voting in favor of the Business Combination Proposal, the
Merger Proposal, the Adjournment Proposal and for any other proposal presented to EBAC Shareholders in this proxy statement/prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> and abstentions will have no effect on the outcome of the vote on the Business Combination Proposal and the Merger Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the EBAC Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EBAC Board has
determined that the business combination agreement is advisable, fair to and in the best interests of EBAC and its shareholders and recommends that the shareholders vote or instruct that their vote be cast &#147;FOR&#148; the approval of the
Business Combination Proposal, the Merger Proposal and the Adjournment Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE EBAC BOARD RECOMMENDS THAT EBAC&#146;S SHAREHOLDERS VOTE
&#147;FOR&#148; THE BUSINESS COMBINATION PROPOSAL, THE MERGER PROPOSAL AND THE ADJOURNMENT PROPOSAL. WHEN YOU CONSIDER THE RECOMMENDATION OF THE EBAC BOARD, YOU SHOULD KEEP IN MIND THAT EBAC&#146;S DIRECTORS AND EXECUTIVE OFFICERS HAVE INTERESTS IN
THE TRANSACTION THAT MAY CONFLICT WITH YOUR INTERESTS AS A SHAREHOLDER, WHICH ARE DESCRIBED ELSEWHERE IN THIS PROXY STATEMENT/PROSPECTUS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">380 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_28"></A>PROPOSAL NO.&nbsp;2 &#151; THE MERGER PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Proposal, if approved, will approve
and authorize the Plan of Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Plan of Merger is attached to this proxy statement/prospectus as <U>Annex C</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Merger Proposal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Companies Act
required that the entry into the Plan of Merger be authorized by special resolution of the shareholders of EBAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of the Merger Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the ordinary shares who, being present in person or represented by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting. Abstentions and
broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purpose of establishing a quorum, will not count as votes cast at the Extraordinary General Meeting, and otherwise will have no effect on a particular
proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution to be Voted Upon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text
of the resolution to be proposed is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, as a special resolution, that the Plan of Merger be authorized, approved and
confirmed in all respects, that European Biotech Acquisition Corp. be and is hereby authorized to enter into the Plan of Merger, and that the merger of Merger Sub 1 with and into EBAC, the separate entity existence of Merger Sub 1 will cease, and
EBAC will be the surviving company and a wholly owned subsidiary of Oculis Holding AG, be authorized, approved and confirmed in all respects.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the EBAC Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE EBAC BOARD
UNANIMOUSLY RECOMMENDS THAT EBAC SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE MERGER PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existence of financial and personal
interests of one or more of EBAC&#146;s directors may result in a conflict of interest on the part of such director(s) between what he, she, or they may believe is in the best interests of EBAC and EBAC Shareholders and what he, she, or they may
believe is best for himself, herself, or themselves in determining to recommend that shareholders vote for the proposals. In addition, EBAC&#146;s officers have interests in the Business Combination that may conflict with your interests as a
shareholder. Please see the sections&nbsp;entitled &#147;<I>Business Combination Proposal&#151;Interests of Certain Persons in the Business Combination</I>&#148; and &#147;<I>Risk Factors&#151;Risks Related to EBAC and the Business
Combination&#151;Since the Sponsor and EBAC&#146;s directors and executive officers have interests that are different from, or in addition to (and which may conflict with), the interests of EBAC Shareholders, a conflict of interest may have existed
in determining whether the Business Combination with Oculis is appropriate as EBAC&#146;s initial business combination. Such interests include that the Sponsor, as well as EBAC&#146;s executive officers and directors, will lose their entire
investment in EBAC if the Business Combination is not completed</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">381 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_29"></A>PROPOSAL NO.&nbsp;3 &#151; THE ADJOURNMENT PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal allows the EBAC Board to submit a proposal to approve, by ordinary resolution, the adjournment of the Extraordinary General Meeting
to a later date or dates (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to EBAC Shareholders, (ii)&nbsp;in order to solicit additional proxies from EBAC Shareholders in favor of the Business
Combination Proposal and the Merger Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement or (iii)&nbsp;if EBAC Shareholders redeem an amount of EBAC Class&nbsp;A Common Stock such
that the Minimum EBAC Cash Condition would not be satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences if the Adjournment Proposal is Not Approved </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved by EBAC Shareholders, the EBAC Board may not be able to adjourn the Extraordinary General Meeting to a later date
in the event that, based on the tabulated votes, there are not sufficient votes at the time of the Extraordinary General Meeting to approve the Transaction Proposals or EBAC Shareholders have elected to redeem an amount of public shares such that
the Minimum EBAC Cash Condition to the obligation to closing of the Business Combination would not be satisfied </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required For Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of
the ordinary shares who, being present in person or represented by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT>
while considered present for the purposes of establishing a quorum, will not count as votes cast at the Extraordinary General Meeting, and otherwise will have no effect on the proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the EBAC Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE EBAC BOARD
UNANIMOUSLY RECOMMENDS THAT EBAC SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE ADJOURNMENT PROPOSAL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existence of financial and personal
interests of one or more of EBAC&#146;s directors may result in a conflict of interest on the part of such director(s) between what he, she, or they may believe is in the best interests of EBAC and EBAC shareholders and what he, she, or they may
believe is best for himself, herself, or themselves in determining to recommend that shareholders vote for the proposals. In addition, EBAC&#146;s officers have interests in the Business Combination that may conflict with your interests as a
shareholder. Please see the sections&nbsp;entitled &#147;<I>Business Combination Proposal&#151;Interests of Certain Persons in the Business Combination</I>&#148; and &#147;<I>Risk Factors&#151;Risks Related to EBAC and the Business
Combination&#151;Since the Sponsor and EBAC&#146;s directors and executive officers have interests that are different from, or in addition to (and which may conflict with), the interests of EBAC Shareholders, a conflict of interest may have existed
in determining whether the Business Combination with Oculis is appropriate as EBAC&#146;s initial business combination. Such interests include that the Sponsor, as well as EBAC&#146;s executive Officers and directors, will lose their entire
investment in EBAC if the Business Combination is not completed</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">382 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_30"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of New Parent Shares and New Parent Warrants has been passed on by VISCHER AG. Davis Polk&nbsp;&amp; Wardwell LLP has opined upon the material
U.S. federal income tax consequences of the Business Combination to U.S. shareholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_31"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of EBAC as of December&nbsp;31, 2021 and for the period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021 included
in this proxy statement/prospectus have been audited by Marcum LLP (PCAOB ID: 688), an independent registered public accounting firm, as stated in their report, which includes an explanatory paragraph as to EBAC&#146;s ability to continue as a going
concern, appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Oculis SA as of December&nbsp;31, 2021 and 2020 and for the years then ended included in this Prospectus have been so
included in reliance on the report of PricewaterhouseCoopers SA, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. PricewaterhouseCoopers SA is a member of EXPERTsuisse
&#150; Swiss Expert Association for Audit, Tax and Fiduciary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">383 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_32"></A>SHAREHOLDER COMMUNICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders and interested parties may communicate with the EBAC Board, any committee chairperson or the
<FONT STYLE="white-space:nowrap">non-management</FONT> directors as a group by writing to the EBAC Board or committee chairperson at European Biotech Acquisition Corp., EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT
STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. Following the Business Combination, such communications should be sent to Oculis Holding AG, Bahnhofstrasse 7, <FONT STYLE="white-space:nowrap">CH-6300</FONT> Zug, Switzerland or, once
the move contemplated within two months after the Acquisition Closing has taken place, to Oculis Holding AG, EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland. Each
communication will be forwarded, depending on the subject matter, to the EBAC Board (or, if after the Business Combination, the New Parent Board), the appropriate committee chairperson or all <FONT STYLE="white-space:nowrap">non-management</FONT>
directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">384 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_33"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent is organized under the laws of Switzerland and its registered office and domicile is located in Zug, Switzerland. Moreover, a number of New
Parent&#146;s directors and executive officers are not residents of the United States, and a substantial portion of the assets of such persons are located outside the U.S. As a result, it may not be possible for investors to effect service of
process within the United States upon New Parent or upon such persons or to enforce against them judgments obtained in United States courts, including judgments in actions predicated upon the civil liability provisions of U.S. federal securities
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent has been advised by its Swiss counsel, VISCHER AG, that there is doubt as to the enforceability in Switzerland of original actions, or
in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S.
federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International Law of December&nbsp;18, 1987, as amended (the &#147;<I>PILA</I>&#148;). The PILA provides that the
application of provisions <FONT STYLE="white-space:nowrap">of&nbsp;non-Swiss&nbsp;law</FONT> by the courts in Switzerland shall be precluded if the result would be incompatible with Swiss public policy (<I>ordre public</I>). Also, mandatory
provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have appointed Corporation Service Company, located
at 19 West 44th Street, Suite 200, New York, New&nbsp;York 10036 as our agent to receive service of process with respect to any action brought against us in the United States District Court for the Southern District of New York under the federal
securities laws of the United States or of any state in the United States or any action brought against us in the Supreme Court of the State of New York in the County of New York under the securities laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland and the United States do not, as of the date of this proxy statement/prospectus, have a treaty providing for reciprocal recognition of and
enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle that a
judgment rendered by <FONT STYLE="white-space:nowrap">a&nbsp;non-Swiss&nbsp;court</FONT> may be enforced in Switzerland only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-Swiss</FONT> court had jurisdiction pursuant to the PILA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the judgment of <FONT STYLE="white-space:nowrap">such&nbsp;non-Swiss&nbsp;court</FONT> has become final <FONT
STYLE="white-space:nowrap">and&nbsp;non-appealable;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the counterparty has been properly served with process according to the law of the state of his/her/its domicile
or ordinary residence (if in Switzerland, through judicial aid granted by the Swiss authorities) or the counterparty has unconditionally joined the proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recognition of the foreign judgment is not manifestly contrary to the public policy or the law in
Switzerland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceedings leading to the judgment have respected the principles of a fair trial (as understood in
Switzerland) and, in particular, that the counterparty has been granted the right to be heard and the possibility to properly defend his/her/its case; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no action between the same parties and on the same subject matter has been commenced or decided first in a Swiss
court and no judgment between the same parties and on the same subject matter has been first rendered by a foreign court, which judgment may be recognized in Switzerland. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">385 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_34"></A>HOUSEHOLDING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless EBAC has received contrary instructions, it may send a single copy of this proxy statement/prospectus to any household at which two or more
shareholders reside if EBAC believes the shareholders are members of the same family. This process, known as &#147;householding,&#148; reduces the volume of duplicate information received at any one household and helps to reduce expenses. A number
of brokers with account holders who are EBAC Shareholders will be &#147;householding&#148; this proxy statement/prospectus. EBAC Shareholders who participate in &#147;householding&#148; will continue to receive separate proxy cards. If shareholders
prefer to receive multiple sets of disclosure documents at the same address, such shareholder should follow the instructions described below. Similarly, if an address is shared with another shareholder and together both of the shareholders would
like to receive only a single set of disclosure documents, the shareholders should follow these instructions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shares are registered in the name of
the shareholder, the shareholder should contact EBAC at its offices at European Biotech Acquisition Corp., EPFL Innovation Park, Bat D 3e Route J-D. Colladon, <FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland or by telephone at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+41-77-976-21-09,</FONT></FONT></FONT></FONT> to inform EBAC of his or her request; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a bank, broker or other nominee holds the shares, the shareholder should contact the bank, broker or other nominee directly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">386 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_35"></A>TRANSFER AGENT AND REGISTRAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent for EBAC and New Parent securities is Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_36"></A>FUTURE SHAREHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Proposed Articles of Association, the New Parent Board is required to convene an extraordinary general meeting of shareholders if one or
several shareholders that represent at least 5% of the share capital request such extraordinary general meeting of shareholders in writing. Shareholders representing at least 0.5% of the share capital may request items to be put on the agenda,
provided the request is made at least 45&nbsp;calendar days in advance of the extraordinary general meeting concerned. Convocation requests and requests for inclusion of agenda items need to be submitted to the New Parent Board in written form,
indicating the agenda items and proposals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">387 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc389734_37"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EBAC files annual, quarterly and current reports, proxy statements and other information with the SEC required by the Exchange Act. EBAC&#146;s public filings
are also available to the public from the SEC&#146;s website at: <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy
statement/prospectus or EBAC&#146;s other filings with the SEC (excluding exhibits), or if you have questions about the Business Combination or the proposals to be presented at the Extraordinary General Meeting, you should contact EBAC at the
following address and telephone number: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">European Biotech Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EPFL Innovation Park, Bat D </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3e
Route J-D. Colladon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">CH-1015</FONT> Lausanne, Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+41-77-976-21-09
</FONT></FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also obtain additional copies of this proxy statement/prospectus by requesting them in writing or by telephone from
EBAC&#146;s proxy solicitation agent at the following address and telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D.F. King &amp; Co., Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 Wall Street, 22nd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Individuals call toll-free: (877) 732-3619 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and Brokerage firms, please call collect: (212) 269-5550 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will not be charged for any of the documents you request. If your shares are held in a stock brokerage account or by a bank or other nominee, you should
contact your broker, bank or other nominee for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an EBAC shareholder and would like to request documents, please do so
by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, or five business days prior to the Extraordinary General Meeting, in order to receive them before the Extraordinary General Meeting. If you
request any documents from EBAC, such documents will be mailed to you by first class mail, or another equally prompt means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy
statement/prospectus is part of a registration statement and constitutes a prospectus of New Parent in addition to being a proxy statement of EBAC for the Extraordinary General Meeting. As allowed by SEC rules, this proxy statement/prospectus does
not contain all of the information you can find in the registration statement or the exhibits to the registration statement. Information and statements contained in this proxy statement/prospectus are qualified in all respects by reference to the
copy of the relevant contract or other document included as an Annex to this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information contained in this proxy
statement/prospectus relating to EBAC has been supplied by EBAC, and all such information relating to Oculis and New Parent has been supplied by Oculis. Information provided by either EBAC or Oculis does not constitute any representation, estimate
or projection of any other party. This document is a proxy statement of EBAC for the Extraordinary General Meeting. EBAC has not authorized anyone to give any information or make any representation about the Business Combination, the transactions
contemplated thereby or the parties thereto, including EBAC, that is different from, or in addition to, that contained in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. The
information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus, unless the information specifically indicates that another date applies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">388 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc389734_38"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EUROPEAN BIOTECH ACQUISITION CORP.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_12">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_13">Balance Sheet as of December 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_14">Statement of Operations for the period from January 8, 2021 (Inception) through
 December&nbsp;31,&nbsp;2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_15">Statement of Changes in Shareholders&#146; Deficit for the period&nbsp;
from January 8, 2021 (Inception) through December 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_16">Statement of Cash Flows for the period from January 8, 2021 (Inception) through
 December&nbsp;31,&nbsp;2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_17">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_18">Condensed Balance Sheets as of September 30, 2022 (Unaudited) and December 31,
2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_19">Condensed Statements of Operations for the three months ended September 30, 2022
 and 2021, the nine months ended September 30, 2022, and the period from January 8, 2021 (Inception) through September&nbsp;30, 2021 (Unaudited) </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_20">Condensed Statements of Changes in Shareholders&#146; Deficit for the three months
 and nine months ended September 30, 2022, the three months ended September 30, 2021, and the period from January 8, 2021 (Inception) through September 30, 2021 (Unaudited) </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_21">Condensed Statements of Cash Flows for the nine months ended September 30, 2022
 and the period from January 8, 2021 (Inception) through September 30, 2021 (Unaudited) </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_22">Notes to Unaudited Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OCULIS SA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_22a">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_24">Consolidated Statements of Loss for the years ended December 31, 2021 and December
 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_25">Consolidated Statements of Comprehensive Loss for the years ended December 31,
2021 and December&nbsp;31,&nbsp;2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_26">Consolidated Statements of Financial Position as of December 31, 2021 and December
 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_27">Consolidated Statements of Changes in Equity for the years ended December 31,
 2021 and December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_28">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and
 December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_29">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_30">Interim Condensed Consolidated Statements of Loss for the three months and nine
 months ended September 30, 2022 and September 30, 2021 (Unaudited) </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_31">Interim Condensed Consolidated Statements of Comprehensive Loss for the three months
 and nine&nbsp;months ended September 30, 2022 and September 30, 2021 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_32">Interim Condensed Consolidated Statements of Financial Position as of September
 30, 2022 and December&nbsp;31, 2021 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_33">Interim Condensed Consolidated Statements of Changes in Equity for the nine months
 ended September&nbsp;30, 2022 and September 30, 2021 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_34">Interim Condensed Consolidated Statements of Cash Flows for the nine months ended
 September 30, 2022 and September 30, 2021</A> (Unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin389734_35">Notes to Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_1"></A><A NAME="fin389734_12"></A>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Biotech Acquisition Corp. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of European Biotech Acquisition Corp. (the &#147;Company&#148;) as of December&nbsp;31,
2021, the related statements of operations, changes in shareholders&#146; deficit and cash flows for the period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021, and the related notes (collectively referred to as the
&#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2021, and the results of its operations and its cash flows for the
period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Explanatory Paragraph - Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company&#146;s business plan is dependent on the completion of a business
combination and the Company currently has a mandatory liquidation date of March&nbsp;18, 2023. These conditions raise substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans in regard to these
matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum LLP</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum LLP</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New
York, NY </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 31, 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_2"></A><A NAME="fin389734_13"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">868,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">916,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,556,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>128,472,759</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Class&nbsp;A Ordinary Shares Subject to Possible Redemption and Shareholders&#146;
Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,641,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,464,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,611,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A ordinary shares subject to possible redemption, $0.0001 par value; 12,754,784
shares at $10.00 per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 455,096 shares
issued and outstanding (excluding 12,754,784 shares subject to possible redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,188,696 shares
issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,686,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,686,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Class&nbsp;A Ordinary Shares Subject to Possible Redemption and
Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,472,759</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_3"></A><A NAME="fin389734_14"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF OPERATIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Period&nbsp;from<BR>January&nbsp;8,<BR>2021<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">912,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses&nbsp;-&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,099,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,884,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs associated with derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(314,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,478,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible
redemption, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,199,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, Class&nbsp;A ordinary shares subject to possible
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic weighted average shares outstanding of
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic net income per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A
ordinary shares and Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted weighted average shares outstanding of
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,465,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_4"></A><A NAME="fin389734_15"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF CHANGES IN SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM JANUARY&nbsp;8, 2021 (INCEPTION) THROUGH DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>New Parent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Additional</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shareholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;- January&nbsp;8, 2021 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Class&nbsp;B ordinary shares to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of units in private placement, less allocation to derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,210,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,210,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of units in private placement, less allocation to derivative warrant liabilities
(over-allotment)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(261,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,380,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,165,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,546,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,478,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,478,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;- December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,686,801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,686,436</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_5"></A><A NAME="fin389734_16"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM JANUARY&nbsp;8, 2021 (INCEPTION) THROUGH DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,478,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs associated with derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,884,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in the Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses paid by Sponsor in exchange for issuance of Class&nbsp;B
ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">376,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(688,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,547,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,547,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from private placement, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,550,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of note payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,956,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,104,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">868,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>868,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid by Sponsor under promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,464,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,546,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_6"></A><A NAME="fin389734_17"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 -
Description of Organization, and Business Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Biotech Acquisition Corp. (the &#147;Company&#148;) was incorporated as a Cayman Islands
exempted company on January&nbsp;8, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#147;Business
Combination&#148;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had not commenced any operations. All activity for the period from January&nbsp;8, 2021 (inception) through
December&nbsp;31, 2021 relates to the Company&#146;s formation and the initial public offering (the &#147;Initial Public Offering&#148;) described below and, subsequent to the Initial Public Offering, identifying a target company for a Business
Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of
interest and other income on investments of the proceeds derived from the Initial Public Offering, along with gains and losses from the change in fair value of warrant liabilities. The Company has selected December&nbsp;31 as its fiscal year end.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is LSP Sponsor EBAC B.V., a Dutch limited liability company (the &#147;Sponsor&#148;). The registration statement for the
Company&#146;s Initial Public Offering was declared effective on March&nbsp;15, 2021. On March&nbsp;18, 2021, the Company consummated its Initial Public Offering of 12,000,000 units (the &#147;Units&#148; and, with respect to the Class&nbsp;A
ordinary shares included in the Units being offered, the &#147;Public Shares&#148;), at $10.00 per Unit, which generated gross proceeds of $120.0&nbsp;million, and incurring offering costs of approximately $7.1&nbsp;million, of which
$4.2&nbsp;million was for deferred underwriting commissions (see Note 3). The Company granted the underwriter a <FONT STYLE="white-space:nowrap">45-day</FONT> option to purchase up to an additional 1,800,000 Units at the Initial Public Offering
price to cover over-allotments, if any&nbsp;(the &#147;Over-Allotment Units&#148;). On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in total gross proceeds of approximately $7.5&nbsp;million, and the allotment option
for the remaining 1,045,216 Over-Allotment Units expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the
private placement (&#147;Private Placement&#148;) of 440,000 units (each, a &#147;Private Placement Unit&#148; and collectively, the &#147;Private Placement Units&#148;), at a price of $10.00 per Private Placement Unit with the Sponsor, generating
gross proceeds of $4.4&nbsp;million (see Note 4). If the over-allotment option would have been exercised in full, the Sponsor would have purchased an additional 36,000 Private Placement Units. On May&nbsp;3, 2021, simultaneously with the issuance
and sale of the Over-Allotment Units, the Company consummated the private placement with the Sponsor of 15,096 units (the &#147;Additional Private Placement Units&#148;), generating total proceeds of $150,960. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, approximately $120.0&nbsp;million ($10.00 per Unit) of the net proceeds of the
Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (&#147;Trust Account&#148;), located in the United States with Continental acting as trustee, and will be invested only in United States
&#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), having a maturity of 185 days or less or in money market funds meeting certain
conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i)&nbsp;the
completion of a Business Combination and (ii)&nbsp;the distribution of the Trust Account as described below. In addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover
for the over-allotment option, if exercised. The over-allotment option was not exercised, so the excess funds&nbsp;were returned to such related parties. Upon partial exercise of the over-allotment, on May&nbsp;4, 2021, the Company returned excess
cash of $209,040 to the related parties, and placed the net proceeds of $7.4&nbsp;million in the Trust Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net
proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company
will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the
deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business
Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment
company under the Investment Company Act.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders (the &#147;Public Shareholders&#148;) of its Public Shares with the
opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&nbsp;in connection with a shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer.
The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares
for a pro rata portion of the amount then in the Trust Account ($10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes). The <FONT
STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note
5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Public Shares were classified as temporary equity in accordance with the Financial Accounting Standards Board&#146;s (&#147;FASB&#148;)
Accounting Standards Codification (&#147;ASC&#148;) Topic 480,&nbsp;&#147;Distinguishing Liabilities from Equity&#148; (&#147;ASC 480&#148;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets
of at least $5,000,001 upon such consummation of a Business Combination and, only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business
Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which
the Company will adopt upon the consummation of the Initial Public Offering (the &#147;Amended and Restated Memorandum and Articles of Association&#148;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange
Commission (&#147;SEC&#148;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for
business or reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public
Shares irrespective of whether they vote for or against the proposed transaction or vote at all. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their
Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider
trading policy which will require insiders to: (i)&nbsp;refrain from purchasing shares during certain blackout periods and when they are in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT> information and (ii)&nbsp;to
clear all trades with the Company&#146;s legal counsel prior to execution. In addition, the initial shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the &#147;Private Placement
Shares&#148;) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not
conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such
shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Exchange Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Class&nbsp;A ordinary shares sold in the Initial Public Offering,
without the prior consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, officers and directors (the &#147;initial shareholders&#148;) agreed not to propose
an amendment to the Amended and Restated Memorandum and Articles of Association (a)&nbsp;that would modify the substance or timing of the Company&#146;s obligation to provide holders of its Public Shares the right to have their shares redeemed in
connection with a Business Combination or to redeem 100% of the Company&#146;s Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the Initial Public Offering, or March&nbsp;18, 2023 (the
&#147;Combination Period&#148;) or with respect to any other provision relating to the rights of Public Shareholders (including extending the deadline for completing the initial Business Combination), unless the Company provides the Public
Shareholders with the opportunity to redeem their Class&nbsp;A ordinary shares in conjunction with any such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed a
Business Combination within the Combination Period, the Company will (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public
Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released
to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then issued and outstanding Public Shares, which redemption will completely extinguish Public
Shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders
and the board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There
will be no redemption rights or liquidating distributions with respect to the Company&#146;s warrants, which will expire worthless if the Company fails to consummate a Business Combination within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company
fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account
with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account
in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the
Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party for
services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per
Public Share and (ii)&nbsp;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability
will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company&#146;s indemnity of the underwriters
of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a
third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by
endeavoring to have all vendors, service providers (excluding the Company&#146;s independent registered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of
any kind in or to monies held in the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had approximately $868,000 in their operating bank account and working capital of approximately $411,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has determined that the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business
combination before March&nbsp;18, 2023 raises substantial doubt about the Company&#146;s ability to continue as a going concern. Although Management expects that it will complete a business combination on or prior to March&nbsp;18, 2023, it is
uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after March&nbsp;18, 2023. The financial statements do not include any adjustment that
might be necessary if the Company is unable to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the industry and has concluded that while it is
reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these
financial statements. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 - Basis
of Presentation and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America
(&#147;GAAP&#148;) for financial information and pursuant to the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act, and it may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation
requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the
JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition
period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s financial statements with another public company that is
neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements
in conformity with GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which
management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all
short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December&nbsp;31, 2021, the Company did not have any cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that
potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and cash held in Trust
Account. As of December&nbsp;31, 2021, the Company has not experienced losses on these accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investments Held in Trust Account </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of investments is comprised of investments in money market funds that invest in U.S. government securities and generally have a
readily determinable fair value, or a combination thereof. When the Company&#146;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#146;s
investments held in the Trust Account are comprised of mutual funds, the investments are recognized at fair value. Trading securities and investments in mutual funds are presented on the balance sheet at fair value at the end of each reporting
period. Gains and losses resulting from the change in fair value of these securities are included in income from investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the
Trust Account are determined using available market information. Through December&nbsp;31, 2021, no&nbsp;amounts have been withdrawn from the Trust Account to pay taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial Instruments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the
Company&#146;s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, &#147;Fair Value Measurements&#148; equal or approximate the carrying amounts represented in the balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs
used in measuring fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices for identical instruments in active markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity
to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the
fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative warrant liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not use
derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC 480 and FASB&nbsp;ASC <FONT STYLE="white-space:nowrap">815-40,</FONT> &#147;Derivatives&nbsp;and Hedging-Contracts in Entity&#146;s Own Stock&#148;&nbsp;(&#147;ASC <FONT
STYLE="white-space:nowrap">815-40&#148;).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity,&nbsp;is <FONT STYLE="white-space:nowrap">re-assessed</FONT> at&nbsp;the end of each reporting period. The 4,251,595 warrants issued in connection with the Initial Public Offering (the &#147;Public Warrants&#148;) and the
151,699 Private Placement Warrants are recognized as derivative liabilities in accordance with&nbsp;ASC <FONT STYLE="white-space:nowrap">815-40.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period.
The liabilities are subject&nbsp;to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at&nbsp;each balance sheet date until exercised, and any change in fair value is recognized in the Company&#146;s statement of operations. The fair value of
the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model (see Note 8). For periods subsequent to the detachment of the Public Warrants
from the Units, on May&nbsp;13, 2021, the fair value of the Public Warrants is based on the observable listed price for such warrants. Since the Private Placement Warrants have substantially the same terms as the Public Warrants, the Company
determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offering Costs Associated with the
Initial Public Offering </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering
that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering
costs associated with derivative warrant liabilities were expensed as incurred and presented as <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses in the statement of operations. Offering costs associated with the Class&nbsp;A common
stock issued were charged against the carrying value of the shares of Class&nbsp;A ordinary shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as
<FONT STYLE="white-space:nowrap">non-current</FONT> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Ordinary Shares Subject to Possible Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class&nbsp;A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class&nbsp;A ordinary
shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class&nbsp;A ordinary shares (including Class&nbsp;A ordinary shares that features redemption rights that
are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary equity. At all other times, Class&nbsp;A ordinary shares is
classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events.
Accordingly, 12,754,784 shares of Class&nbsp;A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders&#146; equity (deficit) section of the Company&#146;s balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering, the Company elected to immediately recognize the remeasurement from initial book value to redemption amount.
The change in the carrying value of redeemable shares of Class&nbsp;A ordinary shares resulted in charges against additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital (to the extent available) and accumulated deficit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the asset and liability
method of accounting for income taxes under FASB ASC Topic 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established,
when necessary, to reduce deferred tax assets to the amount expected to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 prescribes a recognition threshold and a measurement
attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by
taxing authorities. There were no unrecognized tax benefits as of December&nbsp;31, 2021. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s only major tax jurisdiction. The Company recognizes accrued interest and
penalties related to unrecognized tax benefits as income tax expense. As of December&nbsp;31, 2021, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of
any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are
not levied on the Company. Consequently, income taxes are not reflected in the Company&#146;s financial statements. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next
twelve months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Income Per Ordinary Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share.&#148; The Company has two classes of shares, which are referred to as Class&nbsp;A ordinary shares subject to possible redemption <FONT
STYLE="white-space:nowrap">and&nbsp;non-redeemable&nbsp;Class</FONT> A ordinary shares and Class&nbsp;B ordinary shares. Income and losses are shared pro rata between the two classes of shares based on weighted average shares for the period. Net
income (loss) per common share is calculated by dividing the net income (loss) by the weighted average shares of ordinary shares outstanding for the respective period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted net income (loss) does not consider the effect of the warrants underlying the
Units sold in the Initial Public Offering (including the consummation of the Over-allotment) and the private placement warrants to purchase an aggregate of 4,403,294 Class&nbsp;A ordinary shares in the calculation of diluted income (loss) per share,
because their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net income (loss) per share is the same as basic net income (loss) per share, related to the public warrants and private placement
warrants,&nbsp;for the period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021. Remeasurement associated with the redeemable Class&nbsp;A ordinary shares is excluded from earnings per share as the redemption value approximates
fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has considered the effect of Class&nbsp;B ordinary shares that were excluded from weighted average number as they were contingent
on the exercise of over-allotment option by the underwriters. Since the contingency was satisfied, the Company included these shares in the weighted average number as of the beginning of the period to determine the dilutive impact of these shares,
resulting in a greater number of Class&nbsp;B ordinary shares being included in weighted average shares for the diluted calculation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below
presents a reconciliation of the numerator and denominator used to compute basic and diluted net income per share for each class of ordinary shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period&nbsp;from&nbsp;January&nbsp;8,&nbsp;2021<BR>(inception)&nbsp;through&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A non-<BR>redeemable</B><br><B>and<BR>Class B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per ordinary share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,108,197</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;370,475</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,199,476</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,409,725</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period from January&nbsp;8, 2021<BR>(inception) through December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A non-<BR>redeemable<BR>and<BR>Class B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per ordinary share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,103,709</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;374,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,199,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,465,069</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Standards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT><I> Debt-Debt with
Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging-Contracts in Entity&#146;s Own Equity (Subtopic</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;815-40):</FONT> Accounting for
Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies accounting for convertible instruments by removing major separation models
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the
diluted earnings per share calculation in certain areas. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> on January&nbsp;8, 2021 using the modified retroactive method for transition. Adoption of the ASU did not impact
the Company&#146;s financial position, results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management does not believe that any other recently
issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3
- Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2021, the Company consummated its Initial Public Offering of 12,000,000 Units, at $10.00 per Unit,
generating gross proceeds of $120.0&nbsp;million, and incurring offering costs of approximately $7.1&nbsp;million, of which $4.2&nbsp;million was for deferred underwriting commissions. The Company granted the underwriter a <FONT
STYLE="white-space:nowrap">45-day&nbsp;option</FONT> to purchase up to an additional 1,800,000 Units at the Initial Public Offering price to cover over-allotments. On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in
total gross proceeds of approximately $7.5&nbsp;million, and the allotment option for the remaining 1,045,216&nbsp;Over-Allotment units expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
Unit consists of one Class&nbsp;A ordinary share, and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (each, a &#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A
ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). On April&nbsp;29, 2021, the Underwriters partially exercised the Over-allotment Option to purchase an additional 754,784 units (the &#147;Option Units&#148;). Each
Option Unit consists of one Class&nbsp;A Ordinary Share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one Warrant. On May&nbsp;3, 2021, the Company completed the sale of the Option Units to Underwriters for net proceeds of $7,396,883 in
the aggregate after deducting the underwriter discount (the &#147;Option Unit Proceeds&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 - Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Founder Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2021, the Sponsor paid
$25,000 to cover certain expenses of the Company in consideration of 2,875,000 Class&nbsp;B ordinary shares, par value $0.0001, (the &#147;Founder Shares&#148;). On March&nbsp;15, 2021, the Company effected a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">6-for-5</FONT></FONT> share split, resulting in an aggregate of 3,450,000 Class&nbsp;B ordinary shares outstanding. Prior to the Initial Public Offering, the Sponsor transferred 25,000 Founder Shares to two of the
Company&#146;s independent directors. These 50,000 shares are not subject to forfeiture in the event the underwriters&#146; over-allotment option is not exercised. The Sponsor agreed to forfeit up to 450,000 Founder Shares to the extent that the
over-allotment option was not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#146;s issued and outstanding ordinary shares (excluding the Private Placement Shares and assuming the initial
shareholders do not purchase any Units in the Initial Public Offering) after the Initial Public Offering. On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in the forfeiture of 261,304 Class&nbsp;B ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale or transfers of the Founder Shares to members of the Company&#146;s board of directors, as described above, is within the scope of FASB ASC Topic
718, &#147;Compensation-Stock Compensation&#148; (&#147;ASC 718&#148;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Founder Shares were effectively sold or
transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under the applicable
accounting literature in this circumstance. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant date fair value per share (unless
subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of December&nbsp;31, 2021, the Company determined that a Business Combination is not considered probable until the business combination is
completed, and therefore, no stock-based compensation expense has been recognized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their
Founder Shares until the earlier to occur of: (A)&nbsp;one year after the completion of the initial Business Combination and (B)&nbsp;subsequent to the initial Business Combination, (x)&nbsp;if the closing price of Class&nbsp;A ordinary shares
equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period
commencing at least 150 days after the initial Business Combination, or (y)&nbsp;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the
right to exchange their ordinary shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 440,000 Private Placement Units, at a price of
$10.00 per Private Placement Unit with the Sponsor,&nbsp;which generated gross proceeds of $4.4&nbsp;million. If the over-allotment option is exercised in full, the Sponsor will purchase an additional 36,000 Private Placement Units. Simultaneously
with the closing of the Over-Allotment on May&nbsp;3, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 15,096 Private Placement Units at $10.00 per additional
Private Placement Unit (the &#147;Additional Private Placement Units&#148;), generating additional gross proceeds of approximately $151,000. The Private Placement Units (including the Private Placement Shares, the Private Placement Warrants (as
defined below) and Class&nbsp;A ordinary shares issuable upon exercise of such warrants) will not be transferable or salable until 30 days after the completion of the initial Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Private Placement Unit consists of one <FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of a private placement warrant. Each whole private placement warrant underlying the Private Placement Units (the &#147;Private Placement Warrants&#148;) is exercisable for one whole Class&nbsp;A ordinary
share at a price of $11.50 per share. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the
Combination Period, the Private Placement Units and the underlying securities will expire worthless. The Private Placement Warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> (except as described in Note 6 below under
&#147;Redemption of warrants for Class&nbsp;A ordinary shares when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148;) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private
Placement Units until 30 days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Due to Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover for expenses related to the Initial Public Offering
pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon the completion of the Initial Public Offering. The Company borrowed approximately $38,000 under the
Note. The Company repaid the Note in full on March&nbsp;22, 2021. Subsequent to the repayment, the facility was no longer available to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover for the over-allotment option, if exercised. If the over-allotment option was not exercised, the excess funds
would have been returned to such related parties. Upon partial exercise of the over-allotment, on May&nbsp;4, 2021, the Company returned excess cash of $209,040 to the related parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s
officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the
Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay
the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon
consummation of a Business Combination, without interest, or, at the lenders&#146; discretion, up to $1.5&nbsp;million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per
warrant. The warrants would be identical to the Private Placement Warrants. As of December&nbsp;31, 2021, the Company had no outstanding borrowings under the Working Capital Loans.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administrative Support Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on the date
that the securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination or the Company&#146;s liquidation, the Company agreed to reimburse the Sponsor for office space, administrative and support
services provided to the Company in the amount of $20,000 per month. During the period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021, the Company incurred approximately $188,000 of such fees, which are recognized in general
and administrative expenses-related party, in the accompanying statement of operations. As of December&nbsp;31, 2021, there was no amount such fees in accounts payable on the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor, officers and directors, or their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on the Company&#146;s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The
Company&#146;s audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made
using funds held outside the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 - Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Founder Shares,
Private Placement Units, Private Placement Warrants, Class&nbsp;A ordinary shares underlying the Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class&nbsp;A ordinary shares issuable
upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective
date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registered such securities. In addition, the holders have certain &#147;piggy-back&#148;
registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration and shareholder rights agreement provide that the Company will not permit any registration
statement filed under the Securities Act to become effective until termination of the applicable lockup period. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Underwriting Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to
an underwriting discount of $0.20 per Unit, or $2.6&nbsp;million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $4.5&nbsp;million in the aggregate will be payable to the underwriters for
deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting
agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2021, the underwriters partially exercised their over-allotment option. As a result, the
underwriters were entitled to an underwriting discount of approximately $151,000, which was paid upon closing of the over-allotment. In addition, $264,000 will be payable to the underwriters for deferred underwriting commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 - Class&nbsp;A Ordinary Shares Subject to Possible Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s control and subject
to the occurrence of future events. The Company is authorized to issue 200,000,000 Class&nbsp;A ordinary shares with a par value of $0.0001 per share. Holder of the Company&#146;s Class&nbsp;A ordinary shares are entitled to one vote for each share.
As of December&nbsp;31, 2021, there were 12,754,784 Class&nbsp;A ordinary shares were subject to possible redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A ordinary shares
subject to possible redemption reflected on the balance sheet is reconciled on the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Public Warrants at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,331,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs allocated to Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,214,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,546,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 - Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to
issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of December&nbsp;31, 2021,
there were no preference shares issued or outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 200,000,000 Class&nbsp;A ordinary shares with a par value of $0.0001 per share. As of December&nbsp;31, 2021, there were
13,209,880 Class&nbsp;A ordinary shares issued and outstanding, of which 12,754,784 shares were subject to possible redemption and are classified as temporary equity (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Ordinary Shares- </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is
authorized to issue 20,000,000 Class&nbsp;B ordinary shares with a par value of $0.0001 per share. As of December&nbsp;31, 2021, the Company had 3,188,696 Class&nbsp;B ordinary shares issued and outstanding (See Note 4). Ordinary shareholders of
record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&nbsp;A ordinary shares and holders of Class&nbsp;B ordinary shares will vote together as a single class on
all matters submitted to a vote of the shareholders except as required by law. The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares at the time of the initial Business Combination or earlier at the option of
the holders thereof at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as converted basis, 20% of the sum of (i)&nbsp;the total number of ordinary shares
issued and outstanding (excluding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&nbsp;the total number of Class&nbsp;A ordinary shares issued or deemed
issued or issuable upon conversion or exercise of any equity-linked securities (as defined herein) or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding
any Class&nbsp;A ordinary shares or equity-linked securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement
Warrants issued to the Company&#146;s Sponsor, its affiliates or any member of the Company&#146;s management team upon conversion of Working Capital Loans. In no event will the Class&nbsp;B ordinary shares convert into Class&nbsp;A ordinary shares
at a rate of less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 - Derivative Warrant
Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had 4,251,595 Public Warrants and the 151,699 Private Placement Warrants outstanding. Public
Warrants may only be exercised for a whole number of shares. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The
Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement
covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business
Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if
the Class&nbsp;A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the
Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event the&nbsp;Company so elect, the
Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of
the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a
&#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but the Company will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is
not available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant has an exercise price of $11.50, subject to adjustments as described herein, and will expire five years after the completion
of a Business Combination or earlier upon redemption or liquidation. In addition, if (x)&nbsp;the Company issues additional Class&nbsp;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the
initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of
any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds
from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions),
and (z)&nbsp;the volume weighted average trading price of Class&nbsp;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the
&#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger
price described under &#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $18.00&#148; and &#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148; will be
adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price under &#147;Redemption of warrants when the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148; will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except as described below.&nbsp;The Private
Placement Warrants (including the Class&nbsp;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except
pursuant to limited exceptions to the officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants) and they will not be redeemable by the Company (except as described under
&#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148;) so long as they are held by the Sponsor or its permitted transferees&nbsp;(except as otherwise set forth herein). The Sponsor, or its
permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be
redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants
when the price per Class&nbsp;A ordinary share equals or exceeds $18.00. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding
warrants (except with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sales price (the &#147;closing price&#148;) of the Class&nbsp;A ordinary
shares equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on
the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will
not redeem the warrants as described above unless an effective registration statement under the Securities Act covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is effective and a current prospectus relating to those
Class&nbsp;A ordinary shares is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when
the price per Class&nbsp;A ordinary share equals or exceeds $10.00. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding
warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30 days&#146; prior written notice of redemption <I>provided</I> that
holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#147;fair market value&#148; of Class&nbsp;A
ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of Class&nbsp;A ordinary shares equals or exceeds $10.00 per Public Share (as
adjusted) for any 20 trading days within the <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the closing price of the Class&nbsp;A ordinary shares for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement
Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;fair market value&#148; of Class&nbsp;A ordinary shares for the above purpose shall mean the
volume weighted average price of Class&nbsp;A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection
with this redemption feature for more than 0.361 Class&nbsp;A ordinary shares per warrant (subject to adjustment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed the
initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution
from the Company&#146;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 - Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
presents information about the Company&#146;s liabilities that are measured at fair value on a recurring basis as of December&nbsp;31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine
such fair value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Description</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices in<BR>Active<BR>Markets&nbsp;(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account&nbsp;-&nbsp;U.S. Treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,556,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&nbsp;-&nbsp;Public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,550,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&nbsp;-&nbsp;Private placement warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the
Public Warrants was transferred from a Level&nbsp;3 measurement to a Level&nbsp;1 measurement in May 2021, when the Public Warrants were separately listed and traded in an active market. The estimated fair value of the Private Placement Warrants was
transferred from a Level&nbsp;3 measurement to a Level&nbsp;2 measurement in May 2021, as the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the
same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 assets include investments in mutual funds that invest solely in U.S. government securities. The Company uses inputs such as actual trade data,
quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides
quantitative information regarding Level&nbsp;3 fair value measurements inputs at their measurement dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>May&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilized a Monte-Carlo simulation to estimate the fair value of the Public and Private Placement Warrants at the
issuance dates, and as of March&nbsp;31, 2021. For the period from January&nbsp;8, 2021 (inception) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through December&nbsp;31, 2021, the Company recognized a gain resulting from changes in the fair value of derivative warrant liabilities of approximately $2.9&nbsp;million, which is presented in
the accompanying statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative warrant liabilities, measured using Level&nbsp;3 inputs, for the
period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities as of January&nbsp;8, 2021 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Public and Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,229,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Public Warrants - over-allotment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Private Placement Warrants - over-allotment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of Public Warrants to Level&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,691,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of Private Placement Warrants to Level&nbsp;2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(171,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(663,470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10 - Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events and transactions that occurred up to the date the financial statements were issued. Based upon this review, the
Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_7"></A><A NAME="fin389734_18"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">868,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">916,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,317,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,556,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,701,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,472,759</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Class&nbsp;A Ordinary Shares Subject to Possible Redemption and Shareholders&#146;
Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,139,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,352,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,641,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,464,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,464,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,528,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,611,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, $0.0001 par value; 12,754,784 shares
at $10.052 and $10.000 per share as of September&nbsp;30, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,217,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as
of September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 455,096 shares
issued and outstanding (excluding 12,754,784 shares subject to possible redemption) as of September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,188,696 shares
issued and outstanding as of September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,044,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,686,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,044,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,686,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Class&nbsp;A Ordinary Shares Subject to Possible Redemption and
Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,701,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,472,759</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_8"></A><A NAME="fin389734_19"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Three Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Nine</B><br><B>Months<BR>Ended</B><br><B>September&nbsp;30,</B><br><B>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For
The<BR>Period</B><br><B>From<BR>January&nbsp;8,</B><br><B>2021<BR>(Inception)</B><br><B>Through</B><br><B>September&nbsp;30,</B><br><B>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,470,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,015,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(253,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,650,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(557,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,453,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,201,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs associated with derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(314,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,201,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,311,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,929,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible
redemption, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,679,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income (loss) per share, Class&nbsp;A ordinary shares subject to possible
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, basic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,458,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,536,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_9"></A><A NAME="fin389734_20"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2022 (UNAUDITED) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Additional</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shareholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,686,801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,686,436</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,510,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,510,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;March 31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,175,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,175,536</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Subsequent remeasurement of Class&nbsp;A ordinary shares subject to possible redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(93,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(93,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;June 30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,068,755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,068,390</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Subsequent remeasurement of Class&nbsp;A ordinary shares subject to possible redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(575,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(575,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;September 30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,044,512</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,044,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE MONTHS ENDED SEPTEMBER&nbsp;30, 2021 AND FOR THE PERIOD FROM </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JANUARY&nbsp;8, 2021 (INCEPTION) THROUGH SEPTEMBER&nbsp;30, 2021 (UNAUDITED) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Additional</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shareholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;January 8, 2021 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Class&nbsp;B ordinary shares to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Sale of units in private placement, less allocation to derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,210,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,210,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,235,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,619,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,855,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;March 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>440,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,364,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,364,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Forfeiture of Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(261,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Sale of units in private placement, less allocation to derivative warrant liabilities, gross
(over-allotment)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption amount
(over-allotment)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(545,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(690,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">473,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">473,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;June 30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,437,108</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,436,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,201,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,201,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance&#151;September 30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>455,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,188,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,235,714</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,235,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_10"></A><A NAME="fin389734_21"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Nine</B><br><B>Months</B><br><B>Ended</B><br><B>September&nbsp;30,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Period</B><br><B>From January&nbsp;8,</B><br><B>2021 (Inception)</B><br><B>Through</B><br><B>September&nbsp;30,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,311,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,929,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs associated with derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,201,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,796,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in the Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(760,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses paid by Sponsor in exchange for issuance of Class&nbsp;B
ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">692,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(595,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(480,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,547,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,547,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from private placement, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,550,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of note payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,956,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,104,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(595,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,076,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">868,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>272,629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,076,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid by Sponsor under promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,464,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">669,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,546,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_22"></A><A NAME="fin389734_11"></A>EUROPEAN BIOTECH ACQUISITION CORP.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 -
Description of Organization, and Business Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Biotech Acquisition Corp. (the &#147;Company&#148;) was incorporated as a Cayman Islands
exempted company on January&nbsp;8, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#147;Business
Combination&#148;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had not commenced any operations. All activity for the period from January&nbsp;8, 2021 (inception) through
September&nbsp;30, 2022 relates to the Company&#146;s formation and the initial public offering (the &#147;Initial Public Offering&#148;) described below and, subsequent to the Initial Public Offering, identifying a target company for a Business
Combination (see note 10). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income
in the form of income from investments of the proceeds derived from the Initial Public Offering, along with gains and losses from the change in fair value of warrant liabilities. The Company has selected December&nbsp;31 as its fiscal year end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is LSP Sponsor EBAC B.V., a Dutch limited liability company (the &#147;Sponsor&#148;). The registration statement for the
Company&#146;s Initial Public Offering was declared effective on March&nbsp;15, 2021. On March&nbsp;18, 2021, the Company consummated its Initial Public Offering of 12,000,000 units (the &#147;Units&#148; and, with respect to the Class&nbsp;A
ordinary shares included in the Units being offered, the &#147;Public Shares&#148;), at $10.00 per Unit, which generated gross proceeds of $120.0&nbsp;million, and incurring offering costs of approximately $7.1&nbsp;million, of which
$4.5&nbsp;million was for deferred underwriting commissions (see Note 3). The Company granted the underwriter a <FONT STYLE="white-space:nowrap">45-day</FONT> option to purchase up to an additional 1,800,000 Units at the Initial Public Offering
price to cover over-allotments, if any (the &#147;Over-Allotment Units&#148;). On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in total gross proceeds of approximately $7.5&nbsp;million, and the allotment option for
the remaining 1,045,216 Over-Allotment Units expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private
placement (&#147;Private Placement&#148;) of 440,000 units (each, a &#147;Private Placement Unit&#148; and collectively, the &#147;Private Placement Units&#148;), at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross
proceeds of $4.4&nbsp;million (see Note 4). If the over-allotment option would have been exercised in full, the Sponsor would have purchased an additional 36,000 Private Placement Warrants. On May&nbsp;3, 2021, simultaneously with the issuance and
sale of the Over-Allotment Units, the Company consummated the private placement with the Sponsor of 15,096 units (the &#147;Additional Private Placement Units&#148;), generating total proceeds of $150,960. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, approximately $120.0&nbsp;million ($10.00 per Unit) of the net proceeds of the
Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (&#147;Trust Account&#148;), located in the United States with Continental Stock Transfer&nbsp;&amp; Trust Company acting as trustee, and
will be invested only in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), having a maturity of 185 days or less or
in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company,
until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the Trust Account as described below. In addition, the Sponsor and certain investors have advanced an aggregate amount of approximately
$360,000 into the Trust Account to cover for the over-allotment option, if exercised. The over-allotment option was not exercised, so the excess funds were returned to such related parties. Upon partial exercise of the over-allotment, on May&nbsp;4,
2021, the Company returned excess cash of $209,040 to the related parties, and placed the net proceeds of $7.4&nbsp;million in the Trust Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net
proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company
will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the
deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business
Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment
company under the Investment Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders (the &#147;Public Shareholders&#148;) of its Public Shares with the
opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&nbsp;in connection with a shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer.
The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares
for a pro rata portion of the amount then in the Trust Account ($10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes). The <FONT
STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note
5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Public Shares were classified as temporary equity in accordance with the Financial Accounting Standards Board&#146;s (&#147;FASB&#148;)
Accounting Standards Codification (&#147;ASC&#148;) Topic 480, &#147;Distinguishing Liabilities from Equity&#148; (&#147;ASC 480&#148;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at
least $5,000,001 upon such consummation of a Business Combination and, only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business
Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which
the Company will adopt upon the consummation of the Initial Public Offering (the &#147;Amended and Restated Memorandum and Articles of Association&#148;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange
Commission (&#147;SEC&#148;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for
business or reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public
Shares irrespective of whether they vote for or against the proposed transaction or vote at all. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their
Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider
trading policy which will require insiders to: (i)&nbsp;refrain from purchasing shares during certain blackout periods and when they are in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT> information and (ii)&nbsp;to
clear all trades with the Company&#146;s legal counsel prior to execution. In addition, the initial shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the &#147;Private Placement
Shares&#148;) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the
tender offer rules, the Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a
&#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Class&nbsp;A
ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, officers and directors (the
&#147;initial shareholders&#148;) agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a)&nbsp;that would modify the substance or timing of the Company&#146;s obligation to provide holders of its
Public Shares the right to have their shares redeemed in connection with a Business Combination or to redeem 100% of the Company&#146;s Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the
Initial Public Offering, or March&nbsp;18, 2023 (the &#147;Combination Period&#148;) or with respect to any other provision relating to the rights of Public Shareholders (including extending the deadline for completing the initial Business
Combination), unless the Company provides the Public Shareholders with the opportunity to redeem their Class&nbsp;A ordinary shares in conjunction with any such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&nbsp;cease all operations except for the purpose
of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the
number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as
reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to the Company&#146;s obligations under
Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#146;s warrants, which will expire worthless if the
Company fails to consummate a Business Combination within the Combination Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed to waive their liquidation rights with
respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public
Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their
rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the other
funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust
Account assets) will be only $10.00 per share initially held in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to protect the amounts held in the Trust Account, the Sponsor
agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement,
reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii)&nbsp;the actual amount per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This
liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company&#146;s indemnity of the
underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Moreover, in the event that an executed waiver is deemed to be
unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to
claims of creditors by endeavoring to have all vendors, service providers (excluding the Company&#146;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute
agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Going
Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had approximately $273,000 in their operating bank account and working capital deficit of
approximately $968,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s liquidity needs through the consummation of the Initial Public Offering were satisfied through a payment of
$25,000 from the Sponsor to purchase Founders Shares, and the loan proceeds from the Sponsor of $300,000 under the Note (Note 4). We repaid the Note in full on March&nbsp;22, 2021. Subsequent to the consummation of the Initial Public Offering, our
liquidity needs have been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a
Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us Working Capital Loans (as defined in Note 4). As of September&nbsp;30, 2022 and December&nbsp;31,
2021, there were no&nbsp;amounts outstanding under Working Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not believe the current cash on hand will be sufficient to
cover obligations that come due within one year of release. Management has determined that the liquidity and, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before
March&nbsp;18, 2023, raises substantial doubt about the Company&#146;s ability to continue as a going concern. Although Management expects that it will be able to raise additional capital to support its planned activities and complete the proposed
business combination on or prior to March&nbsp;18, 2023, it is uncertain whether it will be able to do so (see note 10). No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after
March&nbsp;18, 2023. The condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to
evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results
of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from
the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a
result of this action, various nations, including the United States, have instituted economic sanctions against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific
impact on the Company&#146;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 - Basis of Presentation and Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited
condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) for interim financial information and with the instructions to Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and Article 8 of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by
GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair presentation of the balances and results for the periods presented.
Operating results for the three and nine months ended September&nbsp;30, 2022 are not necessarily indicative of the results that may be expected through December&nbsp;31, 2022, or for any future interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as filed with the SEC on March&nbsp;31, 2022, which contains the audited financial statements and notes thereto. The accompanying financial information as of
December&nbsp;31, 2021, is derived from the audited financial statements presented in that Form <FONT STYLE="white-space:nowrap">10-K.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging
Growth Company </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS
Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further,
Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration
statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to
opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out
of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at
the time private companies adopt the new or revised standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s condensed financial statements with another
public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires the Company&#146;s management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that
the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future
confirming events. Accordingly, the actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of
September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company did not have any cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at
times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000, and cash held in Trust Account. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company has not experienced losses on these accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investments Held in Trust Account </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
portfolio of investments, as of September&nbsp;30, 2022 and December&nbsp;31, 2021 is comprised of investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value. When the
Company&#146;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#146;s investments held in the Trust Account are comprised of mutual funds, the
investments are recognized at fair value. Trading securities and investments in mutual funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of
these securities are included in income from investments held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market
information. Through September&nbsp;30, 2022, no amounts have been withdrawn from the Trust Account to pay taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial Instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, &#147;Fair Value
Measurement&#148; equal or approximate the carrying amounts represented in the condensed balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices for identical instruments in active markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the
fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative warrant liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not use
derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC <FONT STYLE="white-space:nowrap">815-40,</FONT> &#147;Derivatives and Hedging-Contracts in Entity&#146;s Own Stock&#148; (&#147;ASC
<FONT STYLE="white-space:nowrap">815-40&#148;).</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is <FONT STYLE="white-space:nowrap">re-assessed</FONT> at the end of each reporting period. The 4,251,595 warrants issued in connection with the Initial Public Offering (the &#147;Public Warrants&#148;) and the 151,699
Private Placement Warrants are recognized as derivative liabilities in accordance with ASC <FONT STYLE="white-space:nowrap">815-40.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly,
the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at each balance
sheet date until exercised, and any change in fair value is recognized in the Company&#146;s condensed statements of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were
initially measured at fair value using a Monte Carlo simulation model (see Note 9). For periods subsequent to the detachment of the Public Warrants from the Units, on May&nbsp;13, 2021, the fair value of the Public Warrants is based on the
observable listed price for such warrants. Since the Private Placement Warrants have substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each
Public Warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offering Costs Associated with the Initial Public Offering </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the
Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative
warrant liabilities were expensed as incurred and presented as <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses in the condensed statements of operations. Offering costs associated with the Class&nbsp;A common stock issued were charged
against the carrying value of the shares of Class&nbsp;A ordinary shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Ordinary Shares Subject to Possible Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class&nbsp;A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class&nbsp;A ordinary
shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class&nbsp;A ordinary shares (including Class&nbsp;A ordinary shares that features redemption rights
that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary equity. At all other times, Class&nbsp;A ordinary shares are
classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events.
Accordingly, 12,754,784 shares of Class&nbsp;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#146; equity section of the Company&#146;s condensed balance sheets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to initially recognize changes in redemption value immediately as they occur and subsequently adjust (for interest income and
dissolution expenses) the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital (if available) and accumulated deficit. The change in the carrying value of redeemable shares of Class&nbsp;A ordinary shares resulted in charges against additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital (to the extent available) and accumulated deficit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;).
Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or
expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September&nbsp;30, 2022 and
2021. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts
were accrued for the payment of interest and penalties as of September&nbsp;30, 2022 and December&nbsp;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation
from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no taxation imposed
on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company&#146;s condensed financial statements. The
Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Income Per Ordinary Share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share.&#148; The Company has two classes of shares,
which are referred to as Class&nbsp;A ordinary shares subject to possible redemption and <FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares. Income and losses are shared pro rata
between the two classes of shares based on weighted average shares for the period. Net income per common share is calculated by dividing the net income by the weighted average number of ordinary shares outstanding for the respective period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the
consummation of the Over-allotment) and the private placement warrants to purchase an aggregate of 4,403,294 Class&nbsp;A ordinary shares in the calculation of diluted income per share, because their inclusion would be anti-dilutive under the
treasury stock method. As a result, diluted net income per share is the same as basic net income per share, related to the public warrants and private placement warrants, for the three months ended September&nbsp;30, 2022 and 2021, for the nine
months ended September&nbsp;30, 2022 and for the period from January&nbsp;8, 2021 (inception) through September&nbsp;30, 2021. Remeasurement associated with the redeemable Class&nbsp;A ordinary shares is excluded from earnings per share as the
redemption value approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has considered the effect of Class&nbsp;B ordinary shares that were excluded from the weighted
average number until the contingency was resolved, as they were contingent on the exercise of over-allotment option by the underwriters. Since the contingency was satisfied, the Company included these shares in the weighted average number as of the
beginning of the period to determine the dilutive impact of these shares, resulting in a greater number of Class&nbsp;B ordinary shares being included in weighted average shares for the diluted calculation for the applicable periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted
net income per share for each class of ordinary shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Three Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A <FONT STYLE="white-space:nowrap">non-</FONT></B><br><B>redeemable</B><br><B>and Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Class&nbsp;A&nbsp;non-</FONT></B><br><B>redeemable</B><br><B>and Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per ordinary share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss), basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(311,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss), diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(311,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Nine Months Ended</B><br><B>September&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;The&nbsp;Period&nbsp;From&nbsp;January&nbsp;8,</B><br><B>2021 (Inception) Through</B><br><B>September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A non-</B><br><B>redeemable</B><br><B>and Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Class&nbsp;A&nbsp;non-</FONT></B><br><B>redeemable</B><br><B>and Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per ordinary share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Numerator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,020,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,430</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,421,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">508,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,020,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,413,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">516,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Denominator:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,679,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,458,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,679,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,536,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Standards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material
effect on the accompanying condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 - Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2021, the Company consummated its Initial Public Offering of 12,000,000 Units, at $10.00 per Unit, generating gross proceeds of
$120.0&nbsp;million, and incurring offering costs of approximately $7.1&nbsp;million, of which $4.5&nbsp;million was for deferred underwriting commissions. The Company granted the underwriter a <FONT STYLE="white-space:nowrap">45-day</FONT> option
to purchase up to an additional 1,800,000 Units at the Initial Public Offering price to cover over-allotments. On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in total gross proceeds of approximately $7.5&nbsp;million,
and the allotment option for the remaining 1,045,216 Over-Allotment units expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Unit consists of one Class&nbsp;A ordinary share, and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (each, a &#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of $11.50 per share, subject to
adjustment (see Note 8). On April&nbsp;29, 2021, the Underwriters partially exercised the Over-allotment Option to purchase an additional 754,784 units (the &#147;Option Units&#148;). Each Option Unit consists of one Class&nbsp;A Ordinary Share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one Warrant. On May&nbsp;3, 2021, the Company completed the sale of the Option Units to the Underwriters for net proceeds of $7,396,883 in the aggregate after deducting the underwriter discount (the
&#147;Option Unit Proceeds&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 - Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Founder Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2021, the Sponsor paid
$25,000 to cover certain expenses of the Company in consideration of 2,875,000 Class&nbsp;B ordinary shares, par value $0.0001, (the &#147;Founder Shares&#148;). On March&nbsp;15, 2021, the Company effected a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">6-for-5</FONT></FONT> share split, resulting in an aggregate of 3,450,000 Class&nbsp;B ordinary shares outstanding. Prior to the Initial Public Offering, the Sponsor transferred 25,000 Founder Shares to two of the
Company&#146;s independent directors. These 50,000 shares are not subject to forfeiture in the event the underwriters&#146; over-allotment option is not exercised. The Sponsor agreed to forfeit up to 450,000 Founder Shares to the extent that the
over-allotment option was not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#146;s issued and outstanding ordinary shares (excluding the Private Placement Shares and assuming the initial
shareholders do not purchase any Units in the Initial Public Offering) after the Initial Public Offering. On May&nbsp;3, 2021, the Company issued 754,784 Over-Allotment Units resulting in the forfeiture of 261,304 Class&nbsp;B ordinary shares during
the three months ended June&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale or transfers of the Founder Shares to members of the Company&#146;s board of directors, as described
above, is within the scope of FASB ASC Topic 718, &#147;Compensation-Stock Compensation&#148; (&#147;ASC 718&#148;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The
Founder Shares were effectively sold or transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable
of occurrence under the applicable accounting literature in this circumstance. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant
date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of September&nbsp;30, 2022, the Company determined that a Business Combination is not considered probable until
the business combination is completed, and therefore, no stock-based compensation expense has been recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed, subject
to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A)&nbsp;one year after the completion of the initial Business Combination and (B)&nbsp;subsequent to the initial Business Combination,
(x)&nbsp;if the closing price of Class&nbsp;A ordinary shares equals or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after the initial Business Combination, or (y)&nbsp;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that
results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement
Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 440,000 Private Placement
Units, at a price of $10.00 per Private Placement Unit with the Sponsor, which generated gross proceeds of $4.4&nbsp;million. If the over-allotment option is exercised in full, the Sponsor will purchase an additional 36,000 Private Placement
Warrants. Simultaneously with the closing of the Over-Allotment on May&nbsp;3, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 15,096 Private Placement Units at
$10.00 per additional Private Placement Unit (the &#147;Additional Private Placement Units&#148;), generating additional gross proceeds of approximately $151,000. The Private Placement Units (including the Private Placement Shares, the Private
Placement Warrants (as defined below) and Class&nbsp;A ordinary shares issuable upon exercise of such warrants) will not be transferable or salable until 30 days after the completion of the initial Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Private Placement Unit consists of one <FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of a private placement warrant. Each whole private placement warrant underlying the Private Placement Units (the &#147;Private Placement Warrants&#148;) is exercisable for one whole Class&nbsp;A ordinary
share at a price of $11.50 per share. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the
Combination Period, the Private Placement Units and the underlying securities will expire worthless. The Private Placement Warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> (except as described in Note 6 below under
&#147;Redemption of warrants for Class&nbsp;A ordinary shares when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148;) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private
Placement Units until 30 days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Due to Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover for expenses related to the Initial Public Offering
pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon the completion of the Initial Public Offering. The Company borrowed approximately $38,000 under the
Note. The Company repaid the Note in full on March&nbsp;22, 2021. Subsequent to the repayment, the facility was no longer available to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover for the over-allotment option, if exercised. If the over-allotment option was not exercised, the excess funds
would have been returned to such related parties. Upon partial exercise of the over-allotment, on May&nbsp;4, 2021, the Company returned excess cash of $209,040 to the related parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s
officers and directors may, but are not obligated to, loan the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust
Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside
the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and
no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lenders&#146; discretion, up to $1.5&nbsp;million of such Working
Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the
Company had no outstanding borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administrative Support Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on the date that the securities were first listed on the Nasdaq, the Company agreed to reimburse affiliates of the Sponsor for office space,
administrative and support services provided to the Company in the amount of $20,000 per month. Such agreement terminated as of October&nbsp;17, 2022. During the three months ended September&nbsp;30, 2022 and 2021, the Company incurred approximately
$60,000 of such fees, which are recognized in general and administrative expenses-related party, in the accompanying condensed statements of operations. During the nine months ended September&nbsp;30, 2022 and the period from January&nbsp;8, 2021
(inception) through September&nbsp;30, 2021, the Company incurred approximately $180,000 and $140,000 of such fees, which are recognized in general and administrative expenses-related party, in the accompanying condensed statements of operations,
respectively. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, there was $186,000 and $0 of such fees in accounts payable on the condensed balance sheets, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor, officers and directors, or their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on the Company&#146;s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The
Company&#146;s audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made
using funds held outside the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 - Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Founder Shares,
Private Placement Units, Private Placement Warrants, Class&nbsp;A ordinary shares underlying the Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class&nbsp;A ordinary shares issuable
upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective
date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registered such securities. In addition, the holders have certain &#147;piggy-back&#148;
registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration and shareholder rights agreement provide that the Company will not permit any registration
statement filed under the Securities Act to become effective until termination of the applicable lockup period. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Underwriting Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $2.6&nbsp;million in the aggregate, paid upon the closing of the Initial
Public Offering. In addition, $0.35 per unit, or $4.5&nbsp;million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the
Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;3,
2021, the underwriters partially exercised their over-allotment option. As a result, the underwriters were entitled to an additional underwriting discount of approximately $151,000, which was paid upon closing of the over-allotment. In addition,
$264,000 will be payable to the underwriters for deferred underwriting commissions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 - Class&nbsp;A Ordinary Shares Subject to Possible
Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s
control and subject to the occurrence of future events. The Company is authorized to issue 200,000,000 Class&nbsp;A ordinary shares with a par value of $0.0001 per share. Holder of the Company&#146;s Class&nbsp;A ordinary shares are entitled to one
vote for each share. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, there were 12,754,784 Class&nbsp;A ordinary shares subject to possible redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A ordinary shares subject to possible redemption (including the over-allotment) reflected on the condensed balance sheets is reconciled on the
following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross proceeds from Initial Public Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Public Warrants at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,331,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs allocated to Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,214,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,546,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,547,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsequent remeasurement of Class&nbsp;A ordinary shares subject to possible redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,641,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsequent remeasurement of Class&nbsp;A ordinary shares subject to possible redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,217,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 - Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preference Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to
issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of September&nbsp;30, 2022
and December&nbsp;31, 2021, there were no preference shares issued or outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 200,000,000 Class&nbsp;A ordinary shares with a par value of $0.0001 per share. As of September&nbsp;30, 2022 and
December&nbsp;31, 2021, there were 13,209,880 Class&nbsp;A ordinary shares issued and outstanding, of which 12,754,784 shares were subject to possible redemption and are classified as temporary equity (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is
authorized to issue 20,000,000 Class&nbsp;B ordinary shares with a par value of $0.0001 per share. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company had 3,188,696 Class&nbsp;B ordinary shares issued and outstanding (See Note 4).
Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class&nbsp;A ordinary shares and holders of Class&nbsp;B ordinary shares will vote
together as a single class on all matters submitted to a vote of the shareholders except as required by law. The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares at the time of the initial Business
Combination or earlier at the option of the holders thereof at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as converted basis, 20% of the sum of
(i)&nbsp;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&nbsp;the total number of Class&nbsp;A
ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities (as defined herein) or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the
initial Business Combination, excluding any Class&nbsp;A ordinary shares or equity-linked securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business
Combination and any Private Placement Warrants issued to the Company&#146;s Sponsor, its affiliates or any member of the Company&#146;s management team upon conversion of Working Capital Loans. In no event will the Class&nbsp;B ordinary shares
convert into Class&nbsp;A ordinary shares at a rate of less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one.</FONT></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 - Derivative Warrant Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company had 4,251,595 Public Warrants and the 151,699 Private Placement Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. The Public Warrants will become
exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The Company agreed that as soon as practicable, but in no event later than 20 business days
after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants, and the
Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current
prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement; provided that if the Class&nbsp;A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a
&#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with
Section&nbsp;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&nbsp;A ordinary shares
issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the
Company will have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but the Company will use its best efforts
to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant has an exercise price of
$11.50, subject to adjustments as described herein, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x)&nbsp;the Company issues additional Class&nbsp;A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective
issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as
applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial
Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of Class&nbsp;A ordinary shares during the 20 trading day period starting on the
trading day prior to the day on which the Company consummates the initial Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal
to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described under &#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $18.00&#148; and
&#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per
share redemption trigger price under &#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148; will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued
Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except as described below. The
Private Placement Warrants (including the Class&nbsp;A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination
(except pursuant to limited exceptions to the officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants) and they will not be redeemable by the Company (except as described under
&#147;Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $10.00&#148;) so long as they are held by the Sponsor or its permitted transferees (except as otherwise set forth herein). The Sponsor, or its permitted
transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable
by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when the price per Class&nbsp;A ordinary share equals or exceeds $18.00. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except with respect to the Private Placement Warrants): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sales price (the &#147;closing price&#148;) of the Class&nbsp;A ordinary
shares equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on
the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will
not redeem the warrants as described above unless an effective registration statement under the Securities Act covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is effective and a current prospectus relating to those
Class&nbsp;A ordinary shares is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when
the price per Class&nbsp;A ordinary share equals or exceeds $10.00. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding
warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30 days&#146; prior written notice of redemption <I>provided</I> that
holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#147;fair market value&#148; of Class&nbsp;A
ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of Class&nbsp;A ordinary shares equals or exceeds $10.00 per Public Share (as
adjusted) for any 20 trading days within the <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the closing price of the Class&nbsp;A ordinary shares for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement
Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
&#147;fair market value&#148; of Class&nbsp;A ordinary shares for the above purpose shall mean the volume weighted average price of Class&nbsp;A ordinary shares during the 10 trading days immediately following the date on which the notice of
redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 Class&nbsp;A ordinary shares per warrant (subject to adjustment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed the initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust
Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#146;s assets held outside of the Trust Account with the respect to such warrants. Accordingly,
the warrants may expire worthless. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 - Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis as of
September&nbsp;30, 2022 and December&nbsp;31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>September&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Description</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices</B><br><B>in Active</B><br><B>Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account&#151;Money Market Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,317,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;Public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">425,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;Private placement warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Description</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices</B><br><B>in Active</B><br><B>Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account&#151;Money Market Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,556,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;Public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,550,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;Private placement warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the
Public Warrants was transferred from a Level&nbsp;3 measurement to a Level&nbsp;1 measurement in May 2021, when the Public Warrants were separately listed and traded in an active market and subsequently transferred to a Level&nbsp;2 in September
2022 due to low trading volume. The estimated fair value of the Private Placement Warrants was transferred from a Level&nbsp;3 measurement to a Level&nbsp;2 measurement in May 2021, as the transfer of Private Placement Warrants to anyone who is not
a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, so the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 assets include investments in money market funds that invest solely in U.S. government securities. The Company uses inputs such as
actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides quantitative information regarding Level&nbsp;3 fair value measurements inputs
at the initial measurement dates for the Public Warrants and Private Placement Warrants: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>May&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilized a Monte-Carlo simulation to estimate the fair value of the Public and Private Placement Warrants at the
issuance dates, and as of March&nbsp;31, 2021. For the three months ended September&nbsp;30, 2022 and 2021, the Company recognized a gain/(loss) resulting from changes in the fair value of derivative warrant liabilities of approximately
$0.04&nbsp;million and $1.5&nbsp;million, respectively, which is presented in the accompanying condensed statements of operations. For the nine months ended September&nbsp;30, 2022 and for the period from January&nbsp;8, 2021 (inception) through
September&nbsp;30, 2021, the Company recognized a gain/(loss) resulting from changes in the fair value of derivative warrant liabilities of approximately $2.2&nbsp;million and $2.8&nbsp;million, respectively, which is presented in the accompanying
condensed statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative warrant liabilities (prior to the over-allotment), measured using
Level&nbsp;3 inputs, for the period from January&nbsp;8, 2021 (inception) through June&nbsp;30, 2021 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at January&nbsp;8, 2021 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Public and Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,229,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(663,470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,565,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Public Warrants&#151;over-allotment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Private Placement Warrants&#151;over-allotment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of Public Warrants to Level&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,691,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of Private Placement Warrants to Level&nbsp;2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(171,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10 - Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events and transactions that occurred up to the date the financial statements were issued. Based upon this review, except
for as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proposed Business Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17,
2022, the Company (&#147;EBAC&#148;), entered into a Business Combination Agreement (as it may be amended and/or restated from time to time, the &#147;Business Combination Agreement&#148;) with Oculis SA, a public
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited liability company (<I>soci&eacute;t&eacute; anonyme</I>) incorporated and existing under the laws of Switzerland (&#147;Oculis&#148;). Capitalized terms used in this Quarterly Report on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> but not otherwise defined herein have the meanings given to them in the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the Business Combination Agreement and in accordance with applicable law, as soon as practicable following the
date of the Business Combination Agreement, EBAC will form, or cause to be formed, (a)&nbsp;Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and that will be a direct wholly owned
subsidiary of EBAC (&#147;New Parent&#148;), (b) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (&#147;Merger Sub 1&#148;), (c) another new Cayman Islands exempted company that will be a direct
wholly owned subsidiary of New Parent (&#147;Merger Sub 2&#148;) and (d)&nbsp;a new limited liability company (Gesellschaft mit beschr&auml;nkter Haftung) incorporated and existing under the laws of Switzerland that will be a direct wholly owned
subsidiary of New Parent (&#147;Merger Sub 3&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Business Combination Agreement, among other
things, (i)&nbsp;Merger Sub 1 will merge with and into EBAC, with EBAC surviving such merger as a wholly owned subsidiary of New Parent (the &#147;First Merger&#148;), (ii) as a result of the First Merger, (a)&nbsp;each issued and outstanding share
of EBAC Common Stock will automatically convert into one class of ordinary shares of the surviving company in the First Merger (&#147;Surviving EBAC Shares&#148;), (b) each issued and outstanding warrant issued by EBAC to purchase Class&nbsp;A
Common Stock of EBAC will be automatically converted into warrants of the surviving company in the First Merger (&#147;Surviving EBAC Warrants&#148;), and (c)&nbsp;EBAC will deposit or cause to be deposited with the Exchange Agent the Surviving EBAC
Shares and Surviving EBAC Warrants, (iii)&nbsp;following the First Merger Effective Time but prior to the Second Merger Effective Time, the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in
exchange for New Parent Class&nbsp;A ordinary shares, nominal value CHF 0.01 per share (the &#147;New Parent Shares&#148;) and a right to acquire New Parent Shares (each, a &#147;New Parent Warrant&#148;), with both New Parent Shares and New Parent
Warrants to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the &#147;New Parent Interests Consideration&#148;), (iv) prior to the Second Merger Effective Time, the Exchange Agent
will undertake to (a)&nbsp;distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (b)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests Consideration
to the holders of Surviving EBAC Warrants, (v)&nbsp;after the First Merger Effective Time and following the completion of the Exchange Agent Contribution Actions, EBAC will merge with and into Merger Sub 2, with Merger Sub 2 as the surviving company
and remaining a wholly owned subsidiary of New Parent, (vi)&nbsp;consenting Oculis shareholders executing the Company Shareholders Support Agreements will contribute their shares of Oculis to New Parent in exchange for New Parent Shares and
(vii)&nbsp;approximately 30 days after the Acquisition Closing Date, Oculis will merge with and into Merger Sub 3, with Merger Sub 3 as the surviving company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information regarding the Business Combination Agreement, see the Company&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;17, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent initially filed a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> with
the SEC on November&nbsp;7, 2022, in connection with the registration under the Securities Act of the shares of the New Parent&#146;s ordinary shares and warrants to be issued in connection with the transactions contemplated in the Business
Combination Agreement. However, there is no assurance as to when or if this Registration Statement will be declared effective by the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11 - Subsequent Events (Subsequent to the Filing of Form 10-Q for the Quarterly Period Ended
September 30, 2022) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the filing of Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30,
2022, the Company identified an immaterial error in the reported weighted average shares outstanding and the allocation of net income (loss) for each class of share in the unaudited condensed financial statements included in the September&nbsp;30,
2022 quarterly report in the Company&#146;s Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;14, 2022. The Company incorrectly included 455,096 and 347,500 <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares in the weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible redemption for the periods discussed below. This error impacted the weighted average shares outstanding presented in the
statements of operations for the three months ended September&nbsp;30, 2021, the nine months ended September&nbsp;30, 2022 and for the period from January&nbsp;8, 2021 (inception) through September&nbsp;30, 2021, and the net income (loss) per
ordinary share disclosure in Note 2 of the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for these periods. The error also impacted the income (loss) allocable to each class of equity presented in the disclosure for these periods, but it did not
impact the reported income (loss) per share amounts for any of the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also identified certain typographical errors in
previously reported (1)&nbsp;Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, basic, and the corresponding diluted weighted average shares
amounts for the period from January&nbsp;8, 2021 (inception) through September&nbsp;30, 2021, and (2)&nbsp;Allocation of net income (loss), basic, Class&nbsp;A <FONT STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares,
and the corresponding diluted allocation of net income (loss) amounts for the nine months ended September&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited
condensed financial statements for the periods described above have been revised to correct these immaterial errors. The impact of these revisions is presented below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Three Months Ended<BR>September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), basic, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 967,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 934,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), diluted, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 967,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 934,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), basic, Class&nbsp;A
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 233,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 33,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 266,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), diluted, Class&nbsp;A
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 233,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 33,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 266,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible redemption,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,209,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(455,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Diluted net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN BIOTECH ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Nine Months Ended</B><br><B>September&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period From January&nbsp;8,&nbsp;2021<BR>(inception) through&nbsp;September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), basic, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,156,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(136,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,020,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,472,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (51,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,421,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), diluted, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,156,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(136,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,020,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,464,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (50,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,413,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), basic, Class&nbsp;A
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,550</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 288,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 291,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 456,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 51,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 508,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net income (loss), diluted, Class&nbsp;A
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,550</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 288,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 291,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 465,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 50,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 516,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares subject to possible redemption,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,209,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(455,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,754,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,027,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(347,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,679,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,111,301</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,652,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,458,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average shares outstanding of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,643,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,188,696</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,652,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,536,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Diluted net income (loss) per share, <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Typographical errors being corrected in relation to the weighted average shares outstanding of <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, basic, and the corresponding diluted amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Typographical errors being corrected in relation to the allocation of net income (loss), basic, Class&nbsp;A <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> and Class&nbsp;B ordinary shares, and the corresponding diluted allocation of net income (loss) amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_22a"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To<B> </B>the<B> </B>Board of Directors and Shareholders of Oculis SA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated statements of financial position of Oculis SA and its subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2021 and 2020, and the related consolidated statements of loss, comprehensive loss, changes in
equity and cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company as of December&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with the International Financial Reporting Standards as issued by the
International Accounting Standards Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated<B> </B>financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated<B> </B>financial statements in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated<B> </B>financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated<B> </B>financial statements. Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated<B> </B>financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers SA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lausanne, Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;7, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_2aa"></A><A NAME="fin389734_24"></A>Consolidated Statements of Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6.&nbsp;(A),&nbsp;10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>993</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (B)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (B)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,329</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,232</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,336</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (C)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before tax for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(18,524</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(18,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(14,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted, loss for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_3aa"></A><A NAME="fin389734_25"></A>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Items that will not be reclassified to profit or loss</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains / (losses) of defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Items that may be reclassified subsequently to profit or loss</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2.&nbsp;(D)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive profit/(loss) for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_4aa"></A><A NAME="fin389734_26"></A>Consolidated Statements of Financial Position </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6.&nbsp;(D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaids and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>58,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,383</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity attributable to equity holders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial loss on post employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(60,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,654</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term financial debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit pension liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6.&nbsp;(D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>118,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>60,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>58,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,383</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_5aa"></A><A NAME="fin389734_27"></A>Consolidated Statements of Changes in Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attributable to equity holders of the parent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reserve&nbsp;for<BR><FONT STYLE="white-space:nowrap">share-based</FONT><BR>payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cumulative<BR>translation<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actuarial<BR>(loss) / gain<BR>on post-<BR>employment<BR>benefit<BR>obligations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(981</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29,163</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial loss on post-employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT> other comprehensive loss for the
period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(115</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(115</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share base payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,728</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,654</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,728</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,654</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gain on post-employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total&nbsp;other</FONT> comprehensive profit (/loss)
for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share base payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,434</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,967</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(72,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_6aa"></A><A NAME="fin389734_28"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,524</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Net financial result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Depreciation of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6.&nbsp;(B),&nbsp;7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (B), 9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Recognized expense for stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6.&nbsp;(B),&nbsp;12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Payroll expenses related to restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12, 15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Interest expense on Series B&nbsp;&amp; C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6. (C), 14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Interests on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- <FONT STYLE="white-space:nowrap">Non-realized</FONT> foreign exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- De/(In)crease in prepaid and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- De/(In)crease in accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Changes in receivables/payables from/to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- (De)/Increase in trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- (De)/Increase in accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,825</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for purchase of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash from/(used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">14, 15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred shares, classified as liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payment of lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash from/(used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>55,194</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(De)/Increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>41,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange difference</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash and cash equivalents variation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>41,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_7aa"></A><A NAME="fin389734_29"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. CORPORATE INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis SA (&#147;Oculis&#148;,
the &#147;Group&#148;, or the &#147;Company&#148;) is a limited company (soci&eacute;t&eacute; anonyme) with registered office at EPFL Innovation Park, c/o B&acirc;timent D, 1015 Lausanne, Ecublens, Switzerland and its shares are not publicly
traded. It was established on December 11, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company controls four wholly owned subsidiaries: Oculis ehf (&#147;Oculis Iceland&#148;), which was
incorporated in Reykjavik, Iceland on October 28, 2003, Oculis France SARL (&#147;Oculis France&#148;) which was incorporated in Paris, France on March 27, 2020, Oculis US Inc. (&#147;Oculis US&#148;) which was incorporated in Delaware, USA, on May
26, 2020, and Oculis HK, Limited (&#147;Oculis HK&#148;) which was incorporated in Hong Kong, China on June 1, 2021. The Company and its subsidiaries form the Oculis Group (the &#147;Group&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Group is the research, study, development, sale and marketing of biopharmaceutical products and substances as well as the purchase, sale
and exploitation of intellectual property rights, such as patents and licenses within the field of biopharmaceutical products. More precisely, Oculis is a global biopharmaceutical company driven to save sight and improve eye care with breakthrough
innovations to deliver life-changing treatments for patients worldwide. The Company&#146;s highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Oculis as of and for the year ended December 31, 2021 were authorized for issue by the Company&#146;s Board of
Directors on November 7, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. BASIS OF PREPARATION AND CHANGES TO THE GROUP&#146;S ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Going concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s accounts are prepared
on a going concern basis. To date, the Group has financed its cash requirements primarily from share issuances, as well as government research and development grants. The Board of Directors believes that the Group has the ability to meet its
financial obligations for at least the next 12 months. In April and December 2021, the Company completed a Series C equity financing (see Note 14) for CHF 56.1&nbsp;million ($60.6 million) to operate its business and execute its strategic plan and
meet its financial obligations for at least the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical stage company and is exposed to all the risks inherent to
establishing a business. Inherent to the Company&#146;s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company&#146;s success may depend in part upon its ability
to (i)&nbsp;establish and maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in the biotech and pharmaceutical industry, (iii)&nbsp;successfully move its product candidates through clinical
development, and (iv)&nbsp;attract and retain key personnel. The Company&#146;s success is subject to its ability to being able to raise capital to support its operations. To date, the Company has financed its cash requirements primarily through
share issuances and grant income. Shareholders should note that the long-term viability of the Company is dependent on its ability to raise additional capital to finance its future operations. The Company will continue to evaluate additional funding
through public or private financings, debt financing or collaboration agreements. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. If the Company is unable to raise additional capital when
required or on acceptable terms, it may have to (i)&nbsp;significantly delay, scale back or discontinue the development of one or more product candidates; (ii)&nbsp;seek collaborators for product candidates at an earlier stage than otherwise would
be desirable and on terms that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">less favorable than might otherwise be available; or
(iii)&nbsp;relinquish or otherwise dispose of rights to product candidates that the Company would otherwise seek to develop itself, on unfavorable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the first half of 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has negatively impacted the economies of most countries around the
world. The Group&#146;s operations, similar to those of other life sciences companies, have been impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. With regards to the Group&#146;s clinical programs, certain of its clinical
trials and outsourced development work experienced delays as a result of the pandemic. Since the onset of the pandemic, the Company has kept in close contact with its external vendors and continues to partner closely with principal investigators and
clinical sites and assesses the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its clinical trials. Further, the Group has modified its business practices and continues to adapt to the changing environment, including
moderating employee travel, developing social distancing plans for its employees and restricting physical participation in meetings, events and conferences. As the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to evolve, the
Group believes the extent of the impact to its operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration of the pandemic, the pandemic&#146;s impact on the global economies and
the timing, scope and effectiveness of national, regional and local governmental responses to the pandemic. Those primary drivers are beyond the Group&#146;s knowledge and control and cannot be reasonably predicted. However, on the basis of the risk
mitigation measures undertaken, the Group has concluded that there is no material uncertainty that may cast a significant doubt upon the Group&#146;s ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Statement of compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial
statements of Oculis SA are prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board (&#147;IASB&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Basis of measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policies set out below are
consistently applied to all the years presented. The consolidated financial statements have been prepared under the historical cost convention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial information is presented in thousands of CHF. The totals are calculated with the original unit amounts, which could lead to rounding differences. These differences in thousands of units are not changed in order to keep the accuracy of the
original data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Functional currency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of the Group are expressed in Swiss Francs (&#147;CHF&#148;), which is the Company&#146;s functional and the&nbsp;Group&#146;s&nbsp;presentation currency. The functional currency of the Company and Oculis Iceland is
CHF. The functional currency for Oculis France is EUR, for Oculis US is USD, and for Oculis Hong Kong is HKD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities of foreign
operations are translated into CHF at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at average exchange rates. The exchange differences arising on translation for consolidation are
recognized in other comprehensive income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation of these financial statements are set out below. The policies set out below are consistently
applied to all the years presented, unless otherwise stated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Current vs.
<FONT STYLE="white-space:nowrap">non-current</FONT> classification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents assets and liabilities in the balance sheet based on current
and <FONT STYLE="white-space:nowrap">non-current</FONT> classification. The Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be
<FONT STYLE="white-space:nowrap">non-current.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Foreign currency transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into the functional currency Swiss Francs (CHF) using prevailing exchange rates at the dates of the transactions.
Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of loss in the period in which
they arise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Group accounting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to 2020, the
Company had only one subsidiary, Oculis ehf, Iceland. During the first half of 2020, Oculis established two new and fully owned subsidiaries. Oculis France was established on March 27, 2020 and Oculis US on May 26, 2020. Oculis Hong Kong was
established on June 1, 2021. The Company&#146;s consolidated financial statements present the aggregate of the five Group entities, after elimination of intra-group transactions, balances, investments and capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Segment reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is managed and
operated as one business. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business and accordingly, has one reporting segment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has locations in five countries: Switzerland, Iceland, France, USA and Hong Kong. An analysis of
<FONT STYLE="white-space:nowrap">non-current</FONT> assets by geographic region is presented in Note 5, &#147;Segment Information&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(E) Leases
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All leases are accounted for by recognizing a <FONT STYLE="white-space:nowrap">right-of-use</FONT> asset and a lease liability except for leases of
low value assets and leases with a duration of 12 months or less. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities are measured at the present value of the expected contractual
payments due to the lessor over the lease term, with the discount rate determined by reference to the rate inherent in the lease unless this is not readily determinable, in which case the Group&#146;s incremental borrowing rate on commencement of
the lease is used. Variable lease payments are only included in the measurement of the lease liability if they depend on an index or rate and remain unchanged throughout the lease term. Other variable lease payments are expensed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On initial recognition, the carrying value of the lease liability also includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amounts expected to be payable under any residual value guarantee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price of any purchase option granted in favor of the group if it is reasonably certain to assess
that option. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets are initially measured at the amount of the lease liability, reduced for any lease incentives
received, and increased for lease payments made at or before commencement of the lease and initial direct costs incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the initial measurement, lease
liabilities increase as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are
depreciated on a straight-line basis over the remaining expected term of the lease or over the remaining economic life of the asset if, rarely, this is judged to be shorter than the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Group revises its estimate of the term of any lease, it adjusts the carrying amount of the lease liability to reflect the expected payments over the
revised term, which are discounted using a revised discount rate. The carrying value of lease liabilities is similarly revised if the variable future lease payments dependent on a rate or index revised. In both cases, an equivalent adjustment is
made to the carrying value of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset, with the revised carrying amount being amortized over the remaining lease term. If the carrying amount of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset is adjusted to zero, any further reduction is recognized in profit or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(F) Grant income recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income is recognized
where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with, and in the year when the related expenses are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(G) Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taxes reported in the consolidated income
statements include current and deferred taxes on profit. Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxation is the tax attributable to the temporary differences that appear when taxation authorities recognize and measure assets and liabilities with
rules that differ from those of the consolidated accounts. Deferred income tax is calculated using the liability method, and determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are
expected to apply when the related deferred income tax asset is realized, or the deferred income tax liability is settled. Any changes of the tax rates are recognized in the income statement unless related to items directly recognized in equity or
other comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities are recognized on all taxable temporary differences. Deferred income tax assets are recognized only to
the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized. Deferred income tax assets from tax credit carry forwards are recognized to the extent that
the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable. Deferred income tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different
taxable entities where there is an intention to settle the balances on a net basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(H) Earnings / (loss) per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents basic earnings / (loss) per share for each period in the financial statements. The earnings (loss) per share is calculated by dividing the
earnings / (loss) of the period by the weighted average number of shares outstanding during the period. Diluted earnings per share, applicable in case of positive result, reflect the potential dilution that could occur if dilutive securities such as
preferred shares or share options were vested or exercised into common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(I) Preferred shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judgment was required in determining the classification of the preferred shares issued by the Company as either equity or liabilities. The preferred
shareholders hold certain preference rights that include preferential distribution of proceeds in the case of liquidity events as defined in the shareholder agreements. Under IAS 32 the Company classifies the Preferred Shares as liabilities. This
applies to Series A, B and C shares as per Note 14. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(J) Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All property, plant and equipment are shown at cost, less subsequent depreciation and impairment. Cost includes expenditure that is directly attributable to
the acquisition of the items. Subsequent costs are included in the asset&#146;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group
and the cost of the item can be measured reliably. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation is calculated on a straight-line basis over the useful life, according to the following
schedule: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Category</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Useful&nbsp;life&nbsp;in&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5&nbsp;-&nbsp;7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory fixtures and fittings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office - IT tools</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2&nbsp;-&nbsp;3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets&#146; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. An
asset&#146;s carrying amount is impaired immediately to its recoverable amount if the asset&#146;s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposal or retirement of tangible fixed assets are determined
by comparing the proceeds received with the carrying amounts and are included in the consolidated income statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(K) Intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a) Research and development costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenditure
is recognized in expense in the year in which it is incurred. Internal development expenditure is capitalized only if it meets the recognition criteria of IAS 38 &#147;Intangible Assets&#148;. Where regulatory and other uncertainties are such that
the criteria are not met, which is almost invariably the case prior to approval of the drug by the relevant regulatory authority, the expenditure is recognized in the income statement. Where, however, recognition criteria are met, internal
development expenditure is capitalized and amortized on a straight-line basis over its useful economic life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licenses acquired are capitalized as intangible assets at historical cost and amortized over their useful lives, which are determined on a basis of the
expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received. These licenses are tested for impairment in
the last quarter of each financial period, or when there is any indication for impairment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortisation of capitalised licenses is to be charged to
research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c) Impairment of licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment of capitalized licenses is charged to research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(L) Impairment of <FONT STYLE="white-space:nowrap">non-financial</FONT> assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset
may not be recoverable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss is recognized for the amount by which the asset&#146;s carrying amount exceeds its recoverable amount. The
recoverable amount is the higher of an asset&#146;s fair value less costs of disposal and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">value-in-use.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are
largely independent of the cash flows of other assets (&#147;cash-generating units&#148;). Impairment losses are recognized in the income statement. Prior impairments of <FONT STYLE="white-space:nowrap">non-financial</FONT> assets are reviewed for
possible reversal of the impairment at each reporting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(M) Financial instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal financial instruments used by the Group are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other receivables </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash and short-term deposits </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Long-term financial debt </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trade and other payables </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial instruments are carried at amortized cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due
to their short-term nature, the carrying value of cash and cash equivalents, prepaids and other receivables, and trade and other payables approximates their fair value. For details of the fair value hierarchy, valuation techniques, and significant
unobservable inputs related to determining the fair value of long-term financial debt, refer to Note&nbsp;20. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a) Other receivables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amount of other receivables is reduced through the use of an allowance account, and the amount of the loss is recognized in the income statement.
Subsequent recoveries of amounts previously written off are credited to the income statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Cash and cash equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash in hand and highly liquid investments with original maturities of three month or less. This position is readily
convertible to known amounts of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c) Long-term financial debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term financial debt exclusively results from the issuance of preferred shares that qualify as financial liabilities under IAS 32. Long-term financial debt
is carried at amortized cost, plus the accrued interest/preferred dividend payments that are due by the Group under certain conditions. Refer to Note&nbsp;14 for further information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Trade and other payables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and other payables are amounts due to third parties in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(N) Employee benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a) Pension obligations
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group operates a defined benefit pension plan for its Swiss-based employees, which is held in multi-employer fund. The pension plan is funded by
payments from employees and from the Company. The Company&#146;s contributions to the defined contribution plans are charged to the income statement in the year to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The liability / asset recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at
the balance sheet date less the fair value of plan assets, together with adjustments for unrecognized past-service costs. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality
corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive
income in the period in which they arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Past-service costs are recognized immediately in income, unless the changes to the pension plan are conditional
on the employees remaining in service for a specified period of time (the vesting period). In this case, the past-service costs are amortized on a straight-line basis over the vesting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Employee Participation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group operates an
equity-settled, share-based compensation plan, under which the entity receives services from employees as consideration for equity instruments (e.g. options) of the Group. The fair value of the employee services received in exchange for the grant of
the options is recognized as an expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-market</FONT> vesting conditions are included in assumptions about the
number of options that are expected to vest. The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each reporting period, the entity revises
its estimates of the number of options that are expected to vest based on the <FONT STYLE="white-space:nowrap">non-marketing</FONT> vesting conditions. It recognizes the impact of the revision to original estimates, if any, in the income statement,
with a corresponding adjustment to equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the options are exercised, the Company issues new shares. The proceeds received net of any directly
attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(O) Standard and
Interpretations in issue not yet adopted </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The International Accounting Standards Board (IASB) issued a number of standards, amendments to standards,
and interpretations, which will be effective in the future. There are no standards, amendments or interpretations that are not yet effective and that would be expected to have a material impact on the Group in the current reporting periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s principal accounting policies are set out in Note 3 of the Group&#146;s consolidated financial statements and conform to
International Financial Reporting Standards (IFRS). Significant judgments and estimates are used in the preparation of the consolidated financial statements which, to the extent that actual outcomes and results may differ from these assumptions and
estimates, could affect the accounting in the areas described in this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Impairment of licenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group assesses whether there are any indicators of impairment for all licenses at each reporting date, which refers exclusively to a license of a specific
product candidate: <FONT STYLE="white-space:nowrap">OCS-02.</FONT> Given the stage Oculis&#146; development activities and the importance of <FONT STYLE="white-space:nowrap">OCS-02</FONT> in Oculis&#146; portfolio, the impairment test is performed
first on the basis of a fair value model for the entire Company using a market approach, and second on the basis of the continued development feasibility of the relevant product candidate. Refer to Note 8. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Deferred income taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets are
recognized for all unused tax losses only to the extent that it is probable that taxable profits will be available against which the losses can be utilized. Judgment is required from management to determine the amount of tax asset that can be
recognized, based on forecasts and tax planning strategies. Given the uncertainty in the realization of future taxable profits, no tax asset on unused tax losses has been recognized as of December 31, 2021 and 2020. Refer to Note 6. (D). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Pension benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The present value of the pension
obligations depends on several factors that are determined on an actuarial basis using a number of assumptions. The assumptions used in determining the net cost (income) for pensions include the discount rate. Any changes in these assumptions will
impact the carrying amount of pension obligations. The independent actuary of the Group uses statistical based assumptions covering future withdrawals of participants from the plan and estimates on life expectancy. The actuarial assumptions used may
differ materially from actual results due to changes in market and economic conditions, higher or lower withdrawal rates or longer or shorter life spans of participants. These differences could have a significant impact on the amount of pension
income or expenses recognized in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determines the appropriate discount rate at the end of each year. This is the interest rate
used to determine the present value of estimated future cash outflows expected to be required to settle the pension obligations. In determining the appropriate discount rate, the Group considers the interest rates of high-quality corporate bonds
that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating the terms of the related pension liability. Other key assumptions for pension obligations are based in part on current market
conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Share-based compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period
is determined by reference to the fair value of the instruments granted, excluding the impact of any <FONT STYLE="white-space:nowrap">non-market</FONT> vesting conditions, if applicable. <FONT STYLE="white-space:nowrap">Non-market</FONT> vesting
conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">balance sheet date, the Company revises its
estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the income statement, and a corresponding adjustment to equity over the
remaining vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted are valued using the Black-Scholes option pricing model (see Note 12). This valuation model as well as
parameters used such as expected volatility and expected term of the stock options are partially based on management&#146;s estimates. The Company estimates the fair value of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock awards
(restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. The Company classifies its share-based payments as equity-classified awards as they are settled in shares of the
common stock. The Company measures equity-classified awards at their grant date fair value and does not subsequently remeasure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant-date
amortized over the vesting period of the award using the graded method. The Company reclassifies a portion of vested awards to share premium as the awards vest. The proceeds received net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium when the options are exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. SEGMENT INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below provides <FONT STYLE="white-space:nowrap">non-current</FONT> assets, excluding financial and deferred income tax assets, by geographic area:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Iceland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Others</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,805</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,163</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. INCOME AND EXPENSES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) GRANT INCOME </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income reflects research and
development expenses reimbursements and certain research projects managed by Icelandic governmental institutions. Refer to Note 10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) OPERATING EXPENSES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Research&nbsp;and&nbsp;Development<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>General&nbsp;and&nbsp;Administrative<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Operating&nbsp;Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Personnel expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,568</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,329</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to help companies during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Swiss authorities
reimbursed part of the salaries and social charges for employees that could not work full time due to <FONT STYLE="white-space:nowrap">COVID-19</FONT> impact. The related reimbursements received amounted to CHF 20&nbsp;thousand and CHF
41&nbsp;thousand for 2021 and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) FINANCE EXPENSE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense accrued on Series B and C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,628</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expense primarily represents interest related to the preferred dividend owed to the preferred Series&nbsp;B and
C&nbsp;shares (refer to Note 14). Preferred Series&nbsp;B and C shares qualify as liabilities under IAS 32 and the related accrued dividend as interest expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) INCOME TAX AND DEFERRED TAX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total tax expense reported in the income statement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s expected tax expense for each year is based on the applicable tax rate in each individual jurisdiction, which
ranged between 13.6% and 28.0% for both 2021 and 2020 in the tax jurisdictions in which the Group operates. The weighted average tax rate applicable to the profits of the consolidated entities was 13.6% for both
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2021 and 2020. The tax on the Group&#146;s profit /
loss before tax differs from the statutory amount that would arise using the weighted average applicable tax rate as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Group&#146;s average expected tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes at weighted average income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of unrecorded tax losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of non-deductible expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total tax expense reported in the income statement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of&nbsp;December&nbsp;31, 2021 and 2020, the Group has tax losses which arose mainly in Switzerland that are available for
offset against future taxable profits of the company until expiration. Deferred tax assets have not been recognized in respect of these losses in Switzerland as it is not probable that future taxable profit will be available against which the unused
tax losses can be utilized. This does not affect the management assumption on the going concern hypothesis of the Group. Below is the maturity of the Group reportable losses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>41,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group did not recognize the following temporary differences: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax losses in Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The balance sheet contains the following</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deferred tax liability recorded in 2021 relates
to temporary differences on the valuation of property, plant and equipment in Iceland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. PROPERTY, PLANT AND EQUIPMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;equipment</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;fixtures</FONT><BR>and fittings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Office<BR>equipment<BR>&amp; IT tools</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>532</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>78</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>555</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>851</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;equipments</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;fixtures</FONT><BR>and fittings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Office<BR>equipment<BR>&amp; IT tools</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(174</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>(228)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense - note 6. (B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>(104)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(246</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>(332)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense - note 6. (B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(305</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>(420)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying amount:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>135</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>431</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. INTANGIBLE ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets as of December&nbsp;31, 2021 and 2020 of CHF 8,724&nbsp;thousand refer exclusively to a license purchased under a license agreement dated
December&nbsp;19, 2018 with Novartis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This licensed asset is a novel topical <FONT STYLE="white-space:nowrap">anti-TNF</FONT> alpha antibody for
ophthalmic indications. The compound, renamed as <FONT STYLE="white-space:nowrap">OCS-02,</FONT> is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Three clinical trials were conducted by
Novartis Institute of Biomedical Research, including two Phase II controlled studies under IND. The Phase II studies demonstrated positive results and showed a promising profile for treating inflammatory conditions of the anterior segment of the
eye, including Dry Eye Disease and Uveitis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Carrying amount and amortization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amount of this license is CHF 8,724&nbsp;thousand as of December&nbsp;31, 2021 and 2020. The cost of the license was obtained using the discounted
cash flow (DCF) model, with Oculis recognizing CHF 4,025&nbsp;thousand as the license was partially acquired in a share-based compensation transaction completed in 2019 which increased the amount of share premium for the corresponding value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The product candidate related to the capitalized
intangible assets is not yet available for use. The amortization of the license will be accounted for when the market approval is obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Annual
impairment testing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis performs an assessment of its licenses in the context of its annual impairment test. Given the stage Oculis&#146;
development activities and the importance of the relevant product candidate, <FONT STYLE="white-space:nowrap">OCS-02,</FONT> in Oculis&#146; portfolio, the impairment test is performed first on the basis of a fair value model for the entire Company
using a market approach and second on the basis of the continued development feasibility of <FONT STYLE="white-space:nowrap">OCS-02.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis
performs its annual impairment tests on its entire portfolio of research and development assets, by deriving the fair value from an observable valuation for the entire Company (enterprise value) based on the latest rounds of external financing. The
enterprise value of Oculis, i.e. the Company&#146;s total value, is derived from the latest issuance of preference shares. The preference shares qualify as financial liability instruments under IAS 32 and are classified as long-term liabilities (see
Note 14). The fair value of the asset portfolio is derived by deducting the carrying value of tangible assets, which consist primarily of cash and cash equivalents, from the Company valuation. In 2021 and 2020 this resulted in a derived fair value
of Oculis&#146; portfolio of research and development assets that was multiple times the carrying value of its intangible assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">OCS-02,</FONT> is additionally tested for impairment by assessing its probability of success. Assessments includes reviews of the following indicators, and if the candidate fails any of those indicators the entire balance
is written off: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Importance allocated to the candidate within Oculis&#146; development portfolio, including future contractual
commitments and internal budgets approved by the Board of Directors for ongoing and future development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consideration of the progress of technical development and clinical trials, including obtaining technical
development reports, efficacy and safety readout data, and discussions with regulatory authorities for new trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consideration of market potentials supported where available by external market studies, and assessments of
competitor products and product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021 and 2020, review of all these indicators for
<FONT STYLE="white-space:nowrap">OCS-02</FONT> was positive. No impairment losses were recognized in 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">RIGHT-OF-USE</FONT></FONT> ASSETS AND LEASE LIABILITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2019,
the Company recognized CHF 1,083&nbsp;thousand of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> of leased assets and lease liabilities. The entire amount is related to facility leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of CHF
147&nbsp;thousand and CHF 124&nbsp;thousand in 2021 and 2020, respectively. Movements of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use&nbsp;assets</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition/remeasurement/renewal of lease period Oculis SA office lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation charge for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no variable lease payments which are not included in the measurement of lease obligations. Expected extension
options have been included in the measurement of lease liabilities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease&nbsp;liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition/remeasurement/renewal of lease period Oculis SA office lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease payments for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the lease obligations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PREPAIDS AND OTHER RECEIVABLES, AND ACCRUED INCOME </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid and other receivables: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>944</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in prepaid expenses was primarily related to R&amp;D prepayments for the start of clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued income: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iceland offers incentives for research and development in the form of tax credits for innovation companies as outlined in Act No 152/2009. The aid is granted
as a reimbursement of companies&acute; paid income tax or paid out in cash when the tax credit is higher than the calculated income tax. The tax credit is subject to companies having a research project approved as eligible for tax credit by the
Icelandic Centre for Research (Rann&iacute;s). These grants are claimed together with annual tax filings in ISK and reimbursed in the fourth quarter of the following year, which implies a revaluation based on ISK/CHF closing rate at each reporting
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;11, 2020, the Icelandic Parliament passed a legislation changing certain provisions of Act No 152/2009 on tax credits for innovation
companies. The changes involve temporary provisions which may affect Oculis potential grant income for costs incurred in 2020 and 2021. The changes involve (i)&nbsp;the increase of possible tax credit for SMEs from 20% to 35%; (ii) an increase in
the overall cap on eligible costs from ISK 900&nbsp;million to ISK 1,100&nbsp;million; and (iii)&nbsp;the introduction of a new annual cap on outsourced expenses at ISK 200&nbsp;million, which was previously only subject to the overall cap on
eligible expenses. The new legislation had a positive impact of CHF 326&nbsp;thousand in 2021, and no material impact in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to the 2020
reimbursement, Oculis ehf received CHF 998&nbsp;thousand in 2021 for its 2020 accrued income estimated at CHF 993&nbsp;thousand. The difference between the actual reimbursement amount and the accrued income was due to foreign exchange fluctuations
of ISK and CHF on December&nbsp;31, 2020, and the payment date in November 2021. The Group accrued an income to be received of CHF 760&nbsp;thousand for 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. PENSIONS AND OTHER POST-EMPLOYMENT BENEFIT PLANS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s Swiss pension plan is classified as a defined benefit plan under IFRS. Employees of the Icelandic, French and American subsidiaries are covered by local post-retirement defined contribution plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Iceland pension </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pension costs are charged to the
income statement when incurred. CHF 117&nbsp;thousand and CHF 127&nbsp;thousand were recorded related to Iceland pension expenses in 2021 and 2020, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) French retirement plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pension costs are charged to
the income statement when incurred. In 2021, pension costs amounted to CHF 47 thousand and CHF 20&nbsp;thousand in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) U.S. retirement plan
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. entity adopted a 401(k) defined contribution plan effective December&nbsp;1, 2020. There were no employer contributions made and plan
administration cost was immaterial in 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subsidiary in Hong Kong has not employed any personnel in 2021. Consequently, there was no pension plan in place and no pension related costs have
occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(E) Switzerland pension plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s Swiss entity is affiliated to a collective foundation administrating the pension plans of various unrelated employers that qualifies as defined benefit plan under IAS 19. For employees in Switzerland, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pension fund provides post-employment, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">death-in-service</FONT></FONT> and disability benefits in accordance with the Swiss Federal Law on Occupational Retirement, Survivor&#146;s and Disability Pension Plans which is specifying
the minimum benefits that are to be provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pension plan of the Company&#146;s Swiss entity is fully segregated from the ones of other
participating employers. The collective foundation has reinsured all risks with an insurance company. The most senior governing body of the collective foundation is the Board of Trustees. All governing and administration bodies have an obligation to
act in the interests of the plan beneficiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The retirement benefits are based on the accumulated retirement capital, which is made of the yearly
contributions towards the old age risk by both employer and employee and the interest thereon until retirement. The employee contributions are determined based on the insured salary, depending on the age, staff level and saving amount of the
beneficiary. The interest rate is determined annually by the governing body of the collective plan in accordance with the legal framework, which defines the minimum interest rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an employee leaves the pension plan before reaching retirement age, the law provides for the transfer of the vested benefits to a new pension plan. These
vested benefits comprise the employee and the employer contributions plus interest, the money originally brought into the pension plan by the beneficiary and an additional legally stipulated amount. On reaching retirement age, the plan beneficiary
may decide whether to withdraw the benefits in the form of an annuity or (entirely or partly) as a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment. The annuity is calculated by multiplying the balance of the retirement capital with the
applicable conversion rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All actuarial risks of the plan, e.g. old age, invalidity and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">death-in-service</FONT></FONT> or investment, are fully covered by insurance. However, the collective foundation is able to withdraw from the contract with the Company at any time, in
which case the Company would be required to join another pension plan. In addition, the risk premiums may be adjusted by the insurance company periodically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Swiss pension plan is fully reinsured with Swiss Life (&#147;Swiss Life Business Protect&#148;), therefore the plan assets are 100% covered
by an insurance contract. The insurance company bearing the investment risk is also making these investments on behalf of the collective foundation. As a result, the assets of the plan consist of a receivable from the insurance police. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss Law.
The insurance policy has been treated as a qualifying insurance policy and therefore the pension assets are presented as one asset and are not desegregated and presented in classes that distinguish the nature and risks of those assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the components of net benefit expense recognized in the income statement, amounts recognized in the balance sheet and other
comprehensive loss. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Actuarial gains / (losses) recognized in other comprehensive loss:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF Thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(115</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Net benefit expense (recognized in personnel costs):</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost on benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of plan changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administration cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net benefit expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Benefit asset / (liability)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net benefit liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of plan changes relates mainly to the changes of applicable rates for converting mandatory savings when employees
do retire (see also below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the present value of the defined benefit obligation are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation as of January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions paid by participants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees&#146; contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid from plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of plan changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains / (losses) on obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Defined benefit obligation as of December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,666</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the fair value of plan assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets as of January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions by employer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions by employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid from plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions paid by participants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains / (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of plan assets as of December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,821</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,159</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group expects to contribute CHF
205&nbsp;thousand to its defined benefit pension plan in 2022. The average duration of the plan was 16.6 years and 18.1 years as of December&nbsp;31, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal assumptions used in determining pension benefit obligations for the Group&#146;s plan are shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Future salary increases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Future pensions increases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">M65/W64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">M65/W64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demographic assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">BVG&nbsp;2020&nbsp;GT</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">BVG&nbsp;2015&nbsp;GT</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, the guaranteed interest to be credited to employees&#146; savings was 1.0% (same as in 2020) for mandatory retirement
savings, and 0.125% (same as in 2020) for supplementary retirement savings. The applicable rate for converting mandatory savings at age 65 for male and 64 for female employees retiring in 2021 was 6.8% and will be reduced to 6.5% for 2022 and 6.2%
for 2023 and subsequent years. The rate for converting supplementary savings to an annuity decreases from 4.95% in 2021 to 4.712% in 2022 and to 4.4855% starting in 2023 for male employees, and decreases from 4.9954% in 2021 to 4.7626% in 2022 and
to 4.5411% starting in 2023 for female employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Sensitivity analysis </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quantitative sensitivity analysis for significant assumption as of December&nbsp;31, 2021 and 2020 is as shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Discount rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Future salary<BR>increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Mortality<BR>assumptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assumptions as of December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-0.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+1&nbsp;year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-1&nbsp;year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potential defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,922</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease / (increase) from actual defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assumptions as of December 31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-0.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>+1 year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>-1 year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Potential defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease / (increase) from actual defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analysis above is subject to limitations and has been determined based on a method that extrapolates the
impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. SHARE
BASED PAYMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;19, 2018, the Board of Directors approved a revised stock option and incentive plan (the &#147;Plan&#148;). The Plan allows
for the grant of equity incentives, including share-based options and restricted stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share-Based Option Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share-based option granted under the Plan entitles the grantee to acquire from the Company common shares with payment in cash of the exercise price. For
each grant of share-based options, the Company offers options, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with the issuance of a grant notice, which details
the terms of the option, including exercise price, vesting conditions and expiration date. The terms of each grant are set by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table summarizes share-based option awards granted in 2021 and 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting over 4 years from grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">406,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>298,972</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>406,141</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total expense recognized in the income statement for share options granted amounts to CHF 328&nbsp;thousand for each of
the year 2021 and 2020. The reserve for share option increased from CHF 1,640&nbsp;thousand to CHF 1,967 thousand as of December&nbsp;31, 2021. The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing
model used in determining the fair value of these awards: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF&nbsp;2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF&nbsp;2.11&nbsp;to&nbsp;2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price (option-pricing model)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF 2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">CHF 1.92 to 2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-0.94% to 0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5&nbsp;-&nbsp;5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90.8&nbsp;-&nbsp;101</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number and weighted average exercise prices of share-based options under the Plan are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price (CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Range of<BR>Expiration&nbsp;Dates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">608,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2026-2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">406,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2027-2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>976,220</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2.24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2026-2028</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2026-2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2026-2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2027-2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,127,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2.34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">2026-2030</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">664,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2026-2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each restricted stock granted under the Plan is immediately exercisable with the Company holding a call option to repurchase shares diminishing ratably on
monthly basis over three years from grant, considered as &#147;vesting period&#148; of the restricted stock. For each grant of restricted stock, the Company issues a grant notice, which details the terms of the grant, including exercise price,
vesting conditions and expiration date. The terms of each grant are set by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number and weighted average exercise prices of
restricted stock under the Plan are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Restricted&nbsp;Stocks</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price (CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and exercised as of&nbsp;January 1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted and exercised during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Issued and exercised as of December 31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>652,110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.81</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not subject to repurchase as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and exercised as of January 1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">652,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted and exercised during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Issued and exercised as of&nbsp;December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,038,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.98</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not subject to repurchase as of December 31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">621,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock is granted and expensed at fair value. The payroll expense related to restricted stock, including the total
expense and the part contributable towards restricted stock issuance, is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payroll expense related to restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense contributable towards restricted stock issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of restricted stock issued and respective contribution towards purchase and issuance of restricted stock is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of restricted stock issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense contributable towards restricted stock issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee contributions for restricted stock issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CASH AND CASH EQUIVALENTS, AND FINANCIAL ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist primarily of cash balances held at banks and in the following currencies: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By currency</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss Franc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iceland Krona</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Euro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US&nbsp;Dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash and cash equivalent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash earned interest at floating rates based on
daily bank deposit rates. Interest rate on the short-term deposits was between (0.8)% and 0.32% in 2021 and between (0.50)% and 0.50% in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has two deposits in escrow accounts, presented as <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets on the balance sheet, totalling CHF 52&nbsp;thousand for the lease of the Company&#146;s premises as of December&nbsp;31,
2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. LONG-TERM FINANCIAL LIABILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2021, the Company had 6,815,305 preferred shares outstanding for CHF 682&nbsp;thousand. These shares are divided into 1,623,793
registered &#147;A Series&#148; shares of CHF 0.10 each and 5,191,512 registered &#147;B Series&#148; of CHF 0.10 each. The &#147;A Series&#148; and &#147;B Series&#148; shares have a liquidation preference corresponding to their respective initial
purchase price. Furthermore, the &#147;B Series&#148; shares include a preferred dividend payment of 6.00% (as a compounded interest). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;9,
2021, the Company completed the issuance of 5,337,777 new &#147;C Series&#148; shares raising cash proceeds of $56.8&nbsp;million (CHF 52.5 million). In addition, an extension to C Series of 362,036 shares was issued on December&nbsp;14, 2021
raising cash proceeds of $3.8&nbsp;million (CHF 3.51 million). Consequently, the total Series C gross proceeds raised in 2021 amount to $60.6&nbsp;million (CHF 56.1 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;C Series&#148; shares have a liquidation preference corresponding to their respective initial purchase price and include a preferred dividend
payment of 6.00% (as a compounded interest). The Shareholders&#146; Agreement contains a redemption option upon certain events with amounts equivalent to the sum of investors&#146; Series C investment and applicable interests at 0.00%, 6.00% and
8.00% for Series A, B and C shares, respectively. The Company considered the expected future cash outflows and concluded that the probability of the certain events of occurring to be remote. Refer to Note 18 for discussion on the redemption feature.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judgment was required in determining the classification of the preferred shares issued by the Company as either equity or liabilities. The preferred
shareholders hold certain preference rights that include preferential distribution of proceeds in case of liquidity events as defined in the shareholder agreements. Consequently, under IAS 32 the Company classifies the preferred shares as long-term
financial liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The B Series and C Series shares include a preferred dividend payment of 6.00%, and the corresponding deemed interest expense of
CHF 10,643&nbsp;thousand was accrued as of December&nbsp;31, 2021. The nominal amounts (for &#147;A, B and C Series&#148;) and the accrued preferred dividend resulted in a long-term debt of CHF 113,502&nbsp;thousand on December&nbsp;31, 2021. The
movement of the long-term financial liability is illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,267</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,799</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>53,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,799</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>53,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>48,569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56,754</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>113,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. SHARE CAPITAL, SHARE PREMIUM AND TREASURY
SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Share capital and premium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
January&nbsp;1, 2021, the Company had 2,967,155 shares outstanding for CHF 297&nbsp;thousand. These shares are divided into 2,315,045 common shares of CHF 0.10 each and 652,110 shares for restricted stock of CHF 0.10 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2021, an additional 386,116 shares for restricted stock of CHF 0.10 each have been granted. However, these shares were not registered
yet in the commercial register at the balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 14, due to the characteristics of the instruments issued, the A Series, B
Series and C Series preference shares qualify as financial liability instruments under IAS 32, presented under long-term financial liabilities and are consequently not included in the equity and related premium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activities for share capital and share premium accounts in 2021 and 2020 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><I>Number of shares </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><I>In CHF thousands </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common<BR>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Restricted&nbsp;stock<BR>awards</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share&nbsp;capital</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share&nbsp;premium</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;January&nbsp;1, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>571,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>289</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,315,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>652,110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of&nbsp;December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,038,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,434</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Conditional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditional share capital as of&nbsp;December&nbsp;31, 2021 amounted to a maximum of CHF 185&nbsp;thousand split into 1,849,784 common shares with a par
value of CHF 0.10 each, in connection with the potential future exercise of options granted to employees and advisors. 386,116 shares of restricted stock were granted 2021, which had not yet been registered in the commercial register at the balance
sheet date. Respectively as of December&nbsp;31, 2020 of CHF 92&nbsp;thousand split into 921,289 common shares with a par value of CHF 0.10 each. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C)
Treasury shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017 related to the initial corporate consolidation, the Group acquired 100,000 treasury shares which are held at a cost
of CHF 1.00 each. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. TRADE PAYABLES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>In CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade payables are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and are normally settled on <FONT
STYLE="white-space:nowrap">60-day</FONT> terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. ACCRUED EXPENSES AND OTHER PAYABLES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll related accrual</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued R&amp;D expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued G&amp;A expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019, Oculis entered into clinical research management agreements with a vendor for its
<FONT STYLE="white-space:nowrap">DX-216</FONT> and <FONT STYLE="white-space:nowrap">DX-217</FONT> <FONT STYLE="white-space:nowrap">OCS-01</FONT> Phase 2 studies. As of December 31, 2020, the accrued expenses for these studies reflected best
estimates based on completion status and contractual commitments. During the third quarter of 2021, a reduction of the accrued expenses (in the income statement under Research and development expenses) for this contract of CHF 500&nbsp;thousand was
recorded based on final amounts due and agreement between the Company and the service provider. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitments related to Novartis license agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2018, Oculis SA entered into an agreement with Novartis, under which Oculis licensed a novel topical <FONT STYLE="white-space:nowrap">anti-TNF</FONT> alpha antibody, now renamed as <FONT STYLE="white-space:nowrap">OCS-02,</FONT> for
ophthalmic indications (see Note 8). As consideration for the licenses, Oculis SA is obligated to pay, <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> license fees, predefined development and
commercial milestone payments and royalties on net sales of licensed products. Royalties ranges from high one digit to low teens, based on sales thresholds. As of December 31, 2019, Oculis SA has paid in full the contractual <FONT
STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fee of CHF 4,699&nbsp;thousand. Oculis SA has not reached any milestones or royalties thresholds according to the agreement. If all predefined
milestones will be reached, Oculis SA will be obligated to pay additional CHF 88.5&nbsp;million ($97 million). Oculis SA assumes to reach the first milestone payment of CHF 4.5&nbsp;million ($5 million) in 2023. Royalties are based on net sales of
licensed products, depending on the sales volumes reached. Oculis SA estimates that sale of licensed products will not begin until 2024 or later. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group conducts
product research and development programs through collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. Oculis has contractual arrangements with these
organizations. As of December&nbsp;31, 2021, commitments for external research projects total CHF 14,408&nbsp;thousand as detailed in the schedule below. The increase compared to December&nbsp;31, 2020 was due to advancements in clinical and
technical developments, more specifically for <FONT STYLE="white-space:nowrap">OCS-01</FONT> phase III clinical trials and <FONT STYLE="white-space:nowrap">OCS-02</FONT> CMC activities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Between one and five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,408</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares redemption option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per the Series C Shareholders&#146; Agreement, a redemption option exists in April 2025 for a <FONT STYLE="white-space:nowrap">pre-specified</FONT> qualified
condition related to an initial public offering, with amounts equivalent to the sum of investors&#146; Series A, B and C investment, accrued dividends and applicable compounded interests at 0.00%, 6.00% and 8.00% for Series A, B and C shares,
respectively, which could lead to a potential cash-outflow. As of December 31, 2021, the sum of amounts due related to the aforementioned redemption option was approximately CHF 119&nbsp;million, reflecting investment amounts, cumulative accrued
dividend and compounded interest for Series A, B and C shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. RELATED PARTY DISCLOSURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management, including the Board of Directors and the Executive Management compensation were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and other short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll expenses related to restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,537</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term employee benefits comprise of salaries, bonuses, social security and expense allowances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The receivable of CHF 29&nbsp;thousand as of December&nbsp;31, 2020 from related parties was reimbursed in 2021. In addition, the Group contributes to post
retirement plans in all Oculis entities, including a defined benefit plan in Switzerland for the benefit of its key management personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.
FINANCIAL INSTRUMENTS / RISK MANAGEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Categories of financial instruments: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated in Note 2, all financial assets and liabilities are shown at amortized cost. The following table shows the carrying amounts of financial assets
and liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands </I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Financial assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets - <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables (without prepaids)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>47,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,136</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Financial liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term financial debt related to preferred shares and accrued dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>118,141</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>58,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is the net debt table of liabilities from
financing activities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Leasing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net debt as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(46,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(47,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cashflows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest calculated on Series B shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oculis SA office lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest calculated on leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net debt as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(53,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(54,811</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cashflows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest calculated on Series B&nbsp;&amp; C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oculis SA office lease addition/remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest calculated on leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net debt as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(113,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(114,273</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair values </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to their
short-term nature, the carrying value of cash and cash equivalents, trade and other receivables and trade and other payables approximates their fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For long-term financial debt, resulting from the issuance of preferred shares as commented in Note 14, the fair value can be determined from the similar or
identical instruments issued by the Company during 2021. This level 2 value resulted in a fair value of CHF 107,187&nbsp;thousand compared to a book value of CHF 113,502&nbsp;thousand. In 2020, these shares had a book value of CHF
53,978&nbsp;thousand while the fair value was CHF 50,799&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk assessment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2018, the Company implemented an Internal Control System (ICS), which includes a risk assessment. The ultimate responsibility of the risk management is
of the Board of Directors and a yearly review takes place during one of the Board of Directors meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company&#146;s income
or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign currency risks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019 and 2020, the Group had
all of its grant income and a significant part of its expenses, assets and liabilities denominated in Islandic Krona (ISK). Starting in 2020, Oculis is also present in the U.S. and France </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with local currencies in US&nbsp;dollars and Euros.
In 2021, Oculis also reports figures in HKD from its subsidiary in Hong Kong. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table demonstrates the sensitivity of reasonably possible
changes in ISK, EUR, USD and HKD exchange rate on the Group net result or on equity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Change in rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact&nbsp;on&nbsp;profit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact&nbsp;on&nbsp;equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact&nbsp;on&nbsp;profit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact&nbsp;on&nbsp;equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+5% ISK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>-5% ISK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+5% EUR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>-5% EUR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+5% USD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>-5% USD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+5% HKD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>-5% HKD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest rate risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s long-term financial liabilities, which result from the issuance of preferred shares as indicated in Note 14, bear a deemed interest resulting from the preferred dividend, due under certain circumstances, at a fixed rate of 6.00% per
year. The other financial instruments of the Group are not bearing interest and are therefore not subject to interest rate risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hedging activities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no hedging activities within the Group. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Credit risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, there is no
material credit risk in the Group. The maximum exposure is the carrying amount of cash and other receivables. There is no concentration of credit risk within the Group. Furthermore, there is no significant credit risk on cash and cash equivalents.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk that the
Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. Liquidity management is performed by Group finance based on cash flow forecasts
which are prepared on a rolling basis and focuses mainly on ensuring that the Group has sufficient cash to meet its operational needs. The Group&#146;s liquidity needs have been historically satisfied by issuing preferred shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s financial instruments,
except long-term financial liabilities and the long-term portion of the lease liabilities are due within one year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>in CHF thousands</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>one year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Over&nbsp;one<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>one year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Over&nbsp;one<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term financial debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>113,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,148</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,329</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,817</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term financial liabilities result from the issuance of preferred shares as indicated in Note 14. They might become due in
the case of certain liquidation or exit events within the next year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its incorporation, the Group has primarily funded its operations through capital increases, and at the current development stage, the Group frequently
raises new funds to finance its projects. Refer to Notes 14 and 15 for further details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. LOSS PER SHARE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year attributable to Oculis Shareholders - in CHF thousands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss for the period attributable to equity holders - in CHF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute loss per share basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,777,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,579,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Company has a loss for all periods presented, basic net loss per share is the same as diluted net loss per share. We
have excluded from our calculation of diluted loss per share all potentially dilutive securities, including (i)&nbsp;share options and (ii)&nbsp;restricted stock awards subject to repurchase, as the inclusion of these awards would have been
anti-dilutive. All preferred shares in Note 14 are also potentially dilutive securities which have not been included in the diluted per share calculations because they would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the years Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,127,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,544,468</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,155,828</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with Accure Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;29, 2022, the Company entered into a License Agreement with Accure for the exclusive global licensing of its <FONT STYLE="white-space:nowrap">ACT-01</FONT> technology. The License Agreement contains an upfront payment of CHF
3&nbsp;million, certain milestone payments for achievements of specified development events, sales-based milestone payments and sales-based royalty payments. The Company intends to advance the development of
<FONT STYLE="white-space:nowrap">ACT-01</FONT> with the focus on multiple ophthalmology neuroprotective applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research agreement with the
Rennes University and CNRS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, the Company entered into a collaboration research agreement with the Rennes University and CNRS
in France. This agreement is for the research of Antisense Oligonucleotide (&#147;ASO&#148;) to modulate gene expressions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extension round to the
Series C equity financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2022, the Company completed the closing of an extension round to the Series C equity financing of
approximately CHF 2.0&nbsp;million ($2.1 million) with an issuance of 197,745 preferred shares (&#147;Series C1b Shares&#148;) at a per share purchase price of CHF 10.27 ($10.64) and a nominal per share value of CHF 0.50. The Series C1b shareholders
have the same rights and preferences as the Series C shareholders. Same as Series A, B and C preferred shares, the Series C1b preferred shares qualify as financial liability instruments under IAS 32 and will be presented on the balance sheet as
long-term financial debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Oculis SA entered into a Business Combination Agreement (&#147;BCA&#148;) with European Biotech Acquisition Corp., a NASDAQ listed
blank check company incorporated in Cayman Islands as an exempted company (&#147;EBAC&#148;). Under the BCA and in accordance with applicable law, EBAC will be transferred into Oculis Holding AG, a public liability company incorporated and existing
under the laws of Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the merger, the Company&#146;s then outstanding common and preferred shares will automatically convert
into common shares of New Parent at the then-effective exchange ratio. In addition, existing equityholders of Oculis will also be entitled to receive additional consideration in the form of an aggregate of 4,000,000 newly issued restricted shares of
New Parent (the &#147;Earnout Shares&#148;), subject to predefined price targets of New Parent shares. The aggregate value of the consideration of the shares of New Parent payable to existing Oculis equityholders, without considering any Earnout
Shares, equals $208.0&nbsp;million (CHF 207.9 million) (at a deemed value of $10.00 (CHF 9.99) per share. In connection with and contingent upon the close of the merger, EBAC has received PIPE and private investment commitments of $78.0&nbsp;million
(CHF 78.0 million). Private investments include $2.1&nbsp;million (CHF 2.0 million) related to the July 2022 Series C1b financing extension (this amount is not contingent upon the close of the merger), and $12.67&nbsp;million (CHF 12.66 million) is
in the legal form of Convertible Loan Agreements (the &#147;CLAs&#148;). The CLAs are intended to provide the same economic terms as the other PIPE investors. The CLAs convert automatically into common shares of New Parent at $10.00 (CHF 9.99) per
share upon the close of the merger and entitled to Earnout Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no further material subsequent events to report and no events out of the
ordinary course of business with the exception of the above-mentioned events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_30"></A><A NAME="fin389734_150"></A>Interim Condensed Consolidated Statements of Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(A),&nbsp;9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>698</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>573</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(B)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(B)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,924</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(21,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,904</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(21,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(8,551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(C)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(C)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.&nbsp;(D)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,082</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(8,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before tax for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,986</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(29,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) / credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(29,515</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted, loss for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the interim condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_31"></A><A NAME="fin389734_151"></A>Interim Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(29,515</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Items that will not be reclassified to profit or loss</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains / (losses) of defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.&nbsp;(F)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Items that may be reclassified subsequently to profit or loss</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive profit/(loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,959</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(28,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,995</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the interim condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_152"></A><A NAME="fin389734_32"></A>Interim Condensed Consolidated Statements of Financial Position </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaids and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity attributable to equity holders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12.&nbsp;(A)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12.&nbsp;(A)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial loss on post employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.&nbsp;(F)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12.&nbsp;(C)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(88,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term financial debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit pension liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.&nbsp;(F)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>133,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the interim condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_33"></A><A NAME="fin389734_153"></A>Interim Condensed Consolidated Statements of Changes in Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="32" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Attributable to equity holders of the parent</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Note</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share&nbsp;capital</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>premium</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Reserve&nbsp;for<BR><FONT STYLE="white-space:nowrap">share-based</FONT><BR>payment</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Treasury<BR>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Cumulative<BR>translation<BR>adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Actuarial&nbsp;loss&nbsp;/<BR>(gain)&nbsp;on&nbsp;post-<BR>employment<BR>benefit<BR>obligations</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>losses</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January 1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,097</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(53,728</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,654</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive profit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT> other comprehensive profit for the
period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,995</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,825</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(265</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,097</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(66,732</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(56,463</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,434</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,967</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(72,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(60,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive profit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gain on post-employment benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.&nbsp;(F)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2.&nbsp;(D)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT> other comprehensive profit for the
period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(29,515</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(28,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(267</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(101,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(88,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the interim condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin389734_154"></A><A NAME="fin389734_34"></A>Interim Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Net financial result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Depreciation of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Recognized expense for stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Interest expense on Series B&nbsp;&amp; C preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Interests on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- <FONT STYLE="white-space:nowrap">Non-realized</FONT> foreign exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">5.&nbsp;(D)&nbsp;/&nbsp;11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- De/(In)crease in prepaid and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Increase in accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Decrease in trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- (De)/Increase in accrued expenses and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for purchase of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for purchase of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred shares, classified as liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payment of lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(De)/Increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,227</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange difference</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash and cash equivalents variation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,227</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental <FONT STYLE="white-space:nowrap">Non-Cash</FONT> Investing
Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital expenditures recorded in other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes form an integral part of the interim condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin389734_155"></A><A NAME="fin389734_35"></A>NOTES TO THE INTERIM CONSOLIDATED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CORPORATE INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis SA (&#147;Oculis&#148;, the &#147;Group&#148;, or the &#147;Company&#148;) is a limited company (soci&eacute;t&eacute; anonyme) with registered office
at EPFL Innovation Park, c/o B&acirc;timent D, 1015 Lausanne, Ecublens, Switzerland and its shares are not publicly traded. It was established on December&nbsp;11, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company controls four wholly owned subsidiaries: Oculis ehf (&#147;Oculis Iceland&#148;), which was incorporated in Reykjavik, Iceland on October&nbsp;28,
2003, Oculis France SARL (&#147;Oculis France&#148;) which was incorporated in Paris, France on March&nbsp;27, 2020, Oculis US Inc. (&#147;Oculis US&#148;) which was incorporated in Delaware, USA, on May&nbsp;26, 2020, and Oculis HK, Limited
(&#147;Oculis HK&#148;) which was incorporated in Hong Kong, China on June&nbsp;1, 2021. The Company and its subsidiaries form the Oculis Group (the &#147;Group&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Company is the research, study, development, manufacture, promotion, sale and marketing of pharmaceutical products and substances as well
as the purchase, sale and exploitation of intellectual property rights, such as patents and licenses, in this field. More precisely, Oculis is a global biopharmaceutical company developing treatments to save sight and improve eye care with
breakthrough innovations. The Company&#146;s differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed consolidated financial statements of Oculis as of and for the three and nine months ended September&nbsp;30, 2022, were
approved and authorized for issue by the Company&#146;s Board of Directors on December&nbsp;12, 2022. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BASIS OF PREPARATION AND CHANGES TO THE GROUP&#146;S ACCOUNTING POLICIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(A)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Going concern </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s accounts are prepared on a going concern basis. To date, the Group has financed its cash requirements primarily from share issuances, as well
as government research and development grants. The Board of Directors believes that the Group has the ability to meet its financial obligations for at least the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#146;s business are
various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company&#146;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent position and
protection, (ii)&nbsp;enter into collaborations with partners in the biotech and pharmaceutical industry, (iii)&nbsp;successfully move its product candidates through clinical development, and (iv)&nbsp;attract and retain key personnel. The
Company&#146;s success is subject to its ability to being able to raise capital to support its operations. To date, the Company has financed its cash requirements primarily through share issuances and grant income. Shareholders should note that the
long-term viability of the Company is dependent on its ability to raise additional capital to finance its future operations. The Company will continue to evaluate additional funding through public or private financings, debt financing or
collaboration agreements. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to
(i)&nbsp;significantly delay, scale back or discontinue the development of one or more product candidates; (ii)&nbsp;seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less
favourable than might otherwise be available; or (iii)&nbsp;relinquish or otherwise dispose of rights to product candidates that the Company would otherwise seek to develop itself, on unfavourable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the first half of 2020, the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has negatively impacted the economies of most countries around the world. While <FONT STYLE="white-space:nowrap">COVID-19</FONT> has showed signs of easing, the uncertainty associated with
coronavirus may continue to affect companies and businesses worldwide. On the basis of the risk mitigation measures undertaken and the experiences gained since the onset of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the Group has concluded
that there is no material uncertainty that may cast a significant doubt upon the Group&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conflict
between Russia and Ukraine has caused major macroeconomic disruptions that have impacted the global trade and economies. As such increasing inflation around the globe has forced national banks to increase their interest rates, consequently impacting
interest yields around the globe. The Group has assessed the impact of these measures and concluded that this impacted primarily the estimates in relation to the pension plan obligations, as noted below under 3 (F). As of today, no further material
impact has been identified on the Group&#146;s business nor its ability to continue as a going concern. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(B)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Statement of compliance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interim condensed consolidated financial statements as of and for the three and nine months ended September&nbsp;30, 2022, have been prepared in
accordance with International Accounting Standard 34 (IAS 34), Interim Financial Reporting, and such financial information should be read in conjunction with the audited consolidated financial statements for the year ended December&nbsp;31, 2021.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(C)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Basis of measurement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policies set out below are consistently applied to all period presented. The interim condensed consolidated financial statements have been prepared under
the historical cost convention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial information is presented in thousands of Swiss Francs (&#147;CHF&#148;). The totals are calculated with the
original unit amounts, which could lead to rounding differences. These differences in thousands of units are not changed in order to keep the accuracy of the original data. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(D)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Functional currency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements of the Group are expressed in CHF, which is the Company&#146;s functional and the Group&#146;s
presentation currency. The functional currency of the Company and Oculis Iceland is CHF. The functional currency for Oculis France is EUR, for Oculis US is USD, and for Oculis Hong Kong is HKD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities of foreign operations are translated into CHF at the rate of exchange prevailing at the reporting date and their statements of profit
or loss are translated at average exchange rates. The exchange differences arising on translation for consolidation are recognized in other comprehensive income. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies applied by the Company in these unaudited condensed consolidated interim financial statements are the same as those applied by the
company in its audited consolidated financial statements as of and for the year ended December&nbsp;31, 2021 and have been applied consistently to all periods presented in these unaudited condensed consolidated interim financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(A)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Current vs. <FONT STYLE="white-space:nowrap">non-current</FONT> classification </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents assets and liabilities in the balance sheet based on <FONT STYLE="white-space:nowrap">current/non-current</FONT> classification. The
Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be <FONT STYLE="white-space:nowrap">non-current.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(B)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Foreign currency transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into the functional currency Swiss Francs (CHF) using prevailing exchange rates at the dates of the transactions.
Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of loss in the period in which
they arise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(C)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Group accounting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis SA has four wholly owned subsidiaries, including Oculis Iceland, Oculis France, Oculis US and Oculis Hong Kong. The Company&#146;s interim condensed
consolidated financial statements present the aggregate of the five Group entities, after elimination of intra-group transactions, balances, investments and capital. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(D)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Segment reporting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is managed and operated as one business. A single management team that reports to the Chief Executive Officer comprehensively manages the entire
business and accordingly, has one reporting segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has locations in five countries: Switzerland, Iceland, France, USA and Hong Kong. An
analysis of <FONT STYLE="white-space:nowrap">non-current</FONT> assets by geographic region is presented in Note 4, &#147;Segment Information&#148;. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(E)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant income recognition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income is recognised where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with, and in the
year when the related expenses are incurred. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(F)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Critical judgments and accounting estimates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s interim condensed consolidated financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions
that affect the amounts reported in these accounts interim condensed financial statements and accompanying notes and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses.
Revisions to accounting estimates are recognized in the period in which the estimates are revised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The areas where Oculis makes judgments, estimates and
assumptions are related to (i)&nbsp;impairment of intangible assets, (ii)&nbsp;deferred income taxes, (iii)&nbsp;pension benefits and (iv)&nbsp;share based compensation. Actual results may differ from these estimates. Estimates and underlying
assumptions are reviewed on an ongoing basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In regard to the underlying estimates for the calculation of the defined benefit pension liabilities the
Company updated the discount rate assumption to 2.25% (2.05&nbsp;% on June&nbsp;30, 2022, 0.35% on December&nbsp;31, 2021) during the third quarter of 2022. The change of estimate was due to major changes in the Swiss interest environment driven by
increasing inflation. This resulted in a decrease of defined benefit pension liabilities of CHF 1,774&nbsp;thousand, which was partially offset by impact from the asset ceiling implied by IFRIC 14. The net result is a reduction of defined benefit
pension liabilities of CHF 845&nbsp;thousand from December&nbsp;31, 2021. Other assumptions for defined benefit pension liabilities remain unchanged. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(G)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounting policies, new standards, interpretations, and amendments adopted by the Group
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on
January&nbsp;1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not
relevant, are not listed here. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEGMENT INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below provides <FONT STYLE="white-space:nowrap">non-current</FONT> assets, excluding financial assets, by geographic area: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>in CHF thousands</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Iceland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Others</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September<BR>30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December<BR>31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September<BR>30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December<BR>31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September<BR>30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December<BR>31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September<BR>30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December<BR>31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,244</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,805</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,137</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INCOME AND EXPENSES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(A)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT INCOME </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant income reflects research and development expenses reimbursements and certain research projects managed by Icelandic governmental institutions. Refer to
Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government grants correspond to tax reimbursements on research and development expenses and as subsidies on specific research projects by
Icelandic governmental institutions. Icelandic government grant income for the three-month and nine-month periods ended September&nbsp;30, 2022, were CHF 202&nbsp;thousand and CHF 698&nbsp;thousand, respectively, compared to CHF 20&nbsp;thousand and
CHF 573&nbsp;thousand for the same periods in 2021. Refer also to Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oculis has a funding agreement with the Icelandic Technology Development Fund
which is currently ongoing. This agreement was signed in March 2021 for an amount of up to ISK 30.0&nbsp;million (CHF 224 thousand) upon reaching specified contractual commitments. As of September&nbsp;30, 2022, Oculis received ISK 27.0&nbsp;million
(CHF 200 thousand) in compensation for services rendered in accordance with the second funding agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(B)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPERATING EXPENSES</B><I> </I><B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Research&nbsp;and&nbsp;Development<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>General&nbsp;and&nbsp;Administrative<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Operating&nbsp;Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2022&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2022&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Personnel expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,778</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,483</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,924</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Research&nbsp;and&nbsp;Development<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>General&nbsp;and&nbsp;Administrative</B><br><B>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Operating&nbsp;Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Personnel expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External service providers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of PPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(15,335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,084</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(21,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9,124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In General&nbsp;&amp; Administrative (G&amp;A) other operating expenses, for the three and nine-month periods ending
September&nbsp;30, 2022, CHF 549&nbsp;thousand and CHF 1,175&nbsp;thousand were related to a potential financing transaction. Please refer to Note 17 for disclosures on the Business Combination Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(C)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FINANCE INCOME AND EXPENSE </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total finance income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>61</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>70</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense accrued on Series B and C preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interests on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total finance expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,834</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expenses represent mainly interests related to the preferred dividend owed to the preferred Series B and C shares
(refer to Note 11). Preferred Series B and C shares qualify as liabilities under IAS 32 and the related accrued dividend as interest expense. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(D)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CURRENCY EXCHANGE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three-month and nine-month periods ended September&nbsp;30, 2022, the Company recognised currency exchange losses of CHF 1,302&nbsp;thousand and CHF
3,134&nbsp;thousand, respectively, compared to a loss of CHF 545&nbsp;thousand and CHF 852&nbsp;thousand for the same periods in 2021. For the three-month and nine-month period ended September&nbsp;30, 2022, the loss from revaluation of the Series C
long-term liability (see Note 11) was CHF 1,561&nbsp;thousand and CHF 4,138&nbsp;thousand, while for the 2021 period the loss was CHF 582&nbsp;thousand and CHF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">485&nbsp;thousand. This main driver of the period
over period currency exchange loss was partially offset by a net gain from revaluation of USD cash balances of approximately CHF 337&nbsp;thousand for the three-month period and CHF 979&nbsp;thousand for the nine-month period in 2022, in comparison
to prior year periods. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROPERTY, PLANT AND EQUIPMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lab&nbsp;-&nbsp;equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;fixtures&nbsp;and</FONT><BR>fittings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Office&nbsp;equipment<BR>&amp; IT tools</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>544</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>555</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>851</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>591</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>902</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;equipments</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Lab&nbsp;-&nbsp;fixtures</FONT> and<BR>fittings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Office equipment<BR>&amp; IT tools</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(246</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(41</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(332</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(65</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(305</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(354</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>(518)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying amount:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>139</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>436</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>431</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>237</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>113</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>383</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTANGIBLE ASSETS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets as of December&nbsp;31, 2021, of CHF 8,724&nbsp;thousand refer exclusively to a license purchased under a license agreement dated
December&nbsp;19, 2018, with Novartis. As of September&nbsp;30, 2022, the total intangible assets balance was CHF 12,206&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase was
related to the License Agreement with Accure Therapeutics for the exclusive global licensing of its <FONT STYLE="white-space:nowrap">OCS-05</FONT> (formerly <FONT STYLE="white-space:nowrap">ACT-01)</FONT> technology, entered into on January&nbsp;29,
2022. This License Agreement contains an upfront payment of CHF 3,000&nbsp;thousand, a reimbursement of development related cost up to CHF 500&nbsp;thousand, certain milestone payments for achievements of specified development events, sales-based
milestone payments and sales-based royalty payments. The Company intends to advance the development of <FONT STYLE="white-space:nowrap">OCS-05</FONT> with the focus on multiple ophthalmology neuroprotective applications. As of September&nbsp;30,
2022, CHF 3,000&nbsp;thousand upfront payment (of which 50% was paid as of September&nbsp;30, 2022) and CHF 482&nbsp;thousand reimbursed costs in relation to the <FONT STYLE="white-space:nowrap">OCS-05</FONT> AON study were capitalized as intangible
assets in accordance with IAS 38. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">RIGHT-OF-USE</FONT></FONT> ASSETS AND
LEASE LIABILITIES </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use&nbsp;assets</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation charge for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>796</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>852</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no variable lease payments which are not included in the measurement of lease obligations. Expected extension
options have been included in the measurement of lease liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the lease obligations: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>(696</B></TD>
<TD NOWRAP VALIGN="top"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="top"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease&nbsp;liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indexation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease payments for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(778</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PREPAIDS AND OTHER RECEIVABLES, AND ACCRUED INCOME </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid and other receivables: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>680</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>944</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued income: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iceland offers
incentives for research and development in the form of tax credits for innovation companies as outlined in Act No 152/2009. The aid is granted as a reimbursement of companies&acute; paid income tax or paid out in cash when the tax credit is higher
than the calculated income tax. The tax credit is subject to companies having a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">research project approved as eligible for tax credit
by the Icelandic Centre for Research (Rann&iacute;s). These grants are claimed together with annual tax filings in ISK and reimbursed in the fourth quarter of the following year, which implies a revaluation based on ISK/CHF closing rate at each
reporting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;11, 2020, the Icelandic Parliament passed a legislation changing certain provisions of Act No 152/2009 on tax credits for
innovation companies. The changes involve temporary provisions which may affect Oculis potential grant income for costs incurred in 2020 and 2021. The changes involve (i)&nbsp;the increase of possible tax credit for SMEs from 20% to 35%; (ii) an
increase in the overall cap on eligible costs from ISK 900&nbsp;million to ISK 1,100&nbsp;million; and (iii)&nbsp;the introduction of a new annual cap on outsourced expenses at ISK 200&nbsp;million, which was previously only subject to the overall
cap on eligible expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three-month and nine-month periods ended September&nbsp;30, 2022, the Company recognized CHF 202&nbsp;thousand and CHF
698&nbsp;thousand, respectively, related to the above-mentioned Rann&iacute;s program. Accrued income as of September&nbsp;30, 2022, and December&nbsp;31, 2021, were CHF 1,434&nbsp;thousand and CHF 760&nbsp;thousand, respectively, related to the
Rann&iacute;s program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to the 2020 reimbursement, Oculis Iceland received CHF 998&nbsp;thousand in 2021 for its 2020 accrued income estimated
at CHF 993&nbsp;thousand. The difference between the actual reimbursement amount and the accrued income was due to foreign exchange fluctuations of ISK and CHF on December&nbsp;31, 2020, and the payment date in November 2021. In relation to the 2021
reimbursement, Oculis Iceland has an accrued income of CHF 736&nbsp;thousand on September&nbsp;30, 2022, revalued at the exchange rate on that date, which will be paid out in Q4 2022. The difference with the total accrued income balance of CHF
1,434&nbsp;thousand corresponds to the accrued income for the first nine months of 2022. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CASH AND CASH EQUIVALENTS, AND FINANCIAL ASSETS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist primarily of cash balances held at banks and in the currencies: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>28,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>46,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>by currency</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss Franc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iceland Krona</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Euro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US&nbsp;Dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>28,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>46,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has two deposits in escrow accounts, presented as <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets on the balance sheet, totalling CHF 52&nbsp;thousand for the lease of the Company&#146;s premises as of September&nbsp;30, 2022, and December&nbsp;31, 2021. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LONG-TERM FINANCIAL LIABILITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had 12,712,863 preferred shares for an amount of CHF 1,350&nbsp;thousand. These shares are divided into 1,623,793
registered &#147;A Series&#148; shares of CHF 0.10 each, 5,191,512 registered &#147;B </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series&#148; of CHF 0.10 each, 5,699,813 registered
&#147;C1a Series&#148; shares (denominated in USD) of CHF 0.10 each and 197,745 registered &#147;C1b Series&#148; shares (denominated in USD) of CHF 0.50 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2022, the Company completed the closing of an extension round to the Series C equity financing of approximately CHF 2.0&nbsp;million ($2.1
million) with an issuance of 197,745 shares of preferred shares (&#147;Series C1b Shares&#148; at a per share purchase price of CHF 10.27 ($10.64) and a nominal per share value of CHF 0.50. The Series C1b shareholders have the same rights and
preferences as the Series C shareholders. Same as Series A, B and C preferred shares, the Series C1b preferred shares qualify as financial liability instruments under IAS 32 and are presented on the Balance Sheet as long-term financial debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All preferred shares have a liquidation preference corresponding to their respective initial purchase price. Furthermore, the &#147;B Series&#148; and &#147;C
Series&#148; shares include a preferred dividend payment of 6.00% (as a compounded interest). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shareholders&#146; Agreement contains a redemption
option upon certain events with amounts equivalent to the sum of investors&#146; Series C investment and applicable interests at 0.00%, 6.00% and 8.00% for Series A, B and C shares, respectively. The Company considered the expected future cash
outflows and concluded that the probability of the certain events of occurring to be remote. Refer to Note 14 for discussion on the redemption feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judgement was required in determining the classification of the preferred shares issued by the Company as either equity or liabilities. The preferred
shareholders hold certain preference rights that include preferential distribution of proceeds in case of liquidity events as defined in the shareholder agreements. Consequently, under IAS 32 the Company classifies the preferred shares as long-term
financial liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The B Series and C Series shares include a preferred dividend payment of 6.00%, and the corresponding deemed interest expense of
CHF 15,679&nbsp;thousand was accrued as of September&nbsp;30, 2022. The nominal amounts (for &#147;A, B and C Series&#148;) and the accrued preferred dividend resulted in a long-term debt of CHF 124,652&nbsp;thousand on September&nbsp;30, 2022. The
movement of the long-term financial liability is illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,799</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>53,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,863</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,703</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>109,745</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,754</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>113,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FX revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65,716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>124,652</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE CAPITAL, SHARE PREMIUM AND TREASURY SHARES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(A)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share capital and premium </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had 3,406,771 shares for CHF 341&nbsp;thousand. These shares are divided into 2,368,545 common shares of CHF 0.10
each, of which 4,000 had not yet been registered in the commercial register at the balance sheet date, and 1,038,226 shares for restricted stock of CHF 0.10 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 11, due to the characteristics of the instruments issued, the A Series, B Series and C Series preferred shares qualify as financial
liability instruments under IAS 32. As a result, they are presented as long-term financial liabilities and are consequently not included in the equity and related premium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activities for share capital and share premium accounts in 2022 and 2021 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><I>number of shares</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><I>in&nbsp;CHF&nbsp;thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted&nbsp;stock<BR>awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>652,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>652,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,315,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,038,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,434</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,368,545</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,038,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(B)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditional Capital </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditional share capital at September&nbsp;30, 2022, amounted to a maximum of CHF 144&nbsp;thousand split into 1,443,829 common shares with a par value of
CHF 0.10 each, in connection with the potential future exercise of options granted to employees and advisors (respectively as of December&nbsp;31, 2021, to a maximum of CHF 185&nbsp;thousand split into 1,849,784 common shares with a par value of CHF
0.10 each). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(C)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Treasury shares</B><I> </I><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017 related to the initial corporate consolidation, the Group acquired 100,000 treasury shares which are held at a cost of CHF 1.00 each. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ACCRUED EXPENSES AND OTHER PAYABLES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll related accrual</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued R&amp;D expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued G&amp;A expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred consideration Accure license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,137</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in the accrued Research&nbsp;&amp; Development (R&amp;D) expense compared to the previous <FONT
STYLE="white-space:nowrap">year-end</FONT> was mainly related to the Company&#146;s ongoing clinical studies. The increase in the Accrued G&amp;A expense was primarily due to accrued cost in relation to a potential financing transaction. The
deferred consideration is linked </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to License Agreement with Accure Therapeutics for
the exclusive global licensing of its <FONT STYLE="white-space:nowrap">OCS-05</FONT> (formerly <FONT STYLE="white-space:nowrap">ACT-01)</FONT> technology, entered into on January&nbsp;29, 2022 (see note 7). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMITMENTS AND CONTINGENCIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitments related to Novartis license agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2018, Oculis SA entered into an agreement with Novartis, under which Oculis licensed a novel topical <FONT STYLE="white-space:nowrap">anti-TNF</FONT> alpha antibody, now renamed as <FONT STYLE="white-space:nowrap">OCS-02,</FONT> for
ophthalmic indications (see Note 7). As consideration for the licenses, Oculis SA is obligated to pay <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> license fees, predefined development and
commercial milestone payments and royalties on net sales of licensed products. Royalties ranges from high one digit to low teens, based on sales thresholds. As of December&nbsp;31, 2019, Oculis SA has paid in full the contractual <FONT
STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fee of CHF 4,699&nbsp;thousand. Oculis SA has not reached any milestones or royalties thresholds according to the agreement. If all predefined
milestones will be reached, Oculis SA will be obligated to pay additional CHF 95.1&nbsp;million ($97.0 million). Oculis SA assumes to reach the first milestone payment of CHF 4.9&nbsp;million ($5.0 million) in 2023. Royalties are based on net sales
of licensed products, depending on the sales volumes reached. Oculis SA estimates that sale of licensed products will not begin until 2024 or later. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitments related to Accure license agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;29, 2022, the Company entered into a License Agreement with Accure Therapeutics for the exclusive global licensing of its <FONT STYLE="white-space:nowrap">OCS-05</FONT> technology. Under this agreement, Oculis licensed a novel
neuroprotective drug candidate, now renamed as <FONT STYLE="white-space:nowrap">OCS-05,</FONT> for ophthalmic and other indications (see Note 7). As consideration for the licenses, Oculis SA is obligated to pay
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> license fees, predefined development and commercial milestone payments and royalties on net sales of licensed products. Royalties ranges from
one digit to low teens, based on sales thresholds. As of September&nbsp;30, 2022, Oculis SA has paid the first contractual <FONT STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fee of CHF
1,500&nbsp;thousand, reimbursed costs in the amount of CHF 482&nbsp;thousand and accrued CHF 1,500&nbsp;thousand for further liabilities owed. Oculis SA has not reached any milestones or royalties thresholds according to the agreement. If all
predefined milestones will be reached, Oculis SA will be obligated to pay additional CHF 109.9&nbsp;million ($112.1 million). In case of a commercialization, sublicense revenues will be subject to further royalty payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitments related to Rennes University Collaboration Research agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, the Company entered into a collaboration research agreement with the Rennes University and CNRS in France. This agreement is for the
research of Antisense Oligonucleotide (ASO) to modulate gene expressions. As consideration for the licenses, Oculis SA is obligated to pay <FONT STYLE="white-space:nowrap">non-refundable</FONT> cost contribution, predefined development and
commercial milestone payments and royalties on net sales of licensed products. Royalties are in low one digit range, based on sales thresholds. As of September&nbsp;30, 2022, Oculis SA has paid the first contractual
<FONT STYLE="white-space:nowrap">non-refundable</FONT> cost contribution of CHF 27&nbsp;thousand (EUR 27 thousand). Oculis SA has not reached any milestones or royalties thresholds according to the agreement. If all predefined milestones will be
reached, Oculis SA will be obligated to pay additional CHF 6.7&nbsp;million (EUR 7.0 million). In case of a commercialization, sublicense revenues will be subject to further royalty payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group conducts
product research and development programs through collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. Oculis has contractual arrangements with these
organizations. As of September&nbsp;30, 2022, commitments for external research projects total CHF 8,564&nbsp;thousand (CHF 14,408&nbsp;thousand, as of December&nbsp;31, 2021) as detailed in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">schedule below. The decrease compared to
December&nbsp;31, 2021, was due to advancements in clinical and technical developments, primarily for <FONT STYLE="white-space:nowrap">OCS-01</FONT> phase III clinical trials and <FONT STYLE="white-space:nowrap">OCS-02</FONT> CMC activities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Between one and five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,408</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares redemption option </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per the Series C Shareholders&#146; Agreement, a redemption option exists in April 2025 for a <FONT STYLE="white-space:nowrap">pre-specified</FONT> qualified
condition related to an initial public offering, with amounts equivalent to the sum of investors&#146; Series A, B and C investment, accrued dividends and applicable compounded interests at 0.00%, 6.00% and 8.00% for Series A, B and C shares,
respectively, which could lead to a potential cash-outflow. As of September&nbsp;30, 2022, the sum of amounts due related to the aforementioned redemption option was approximately CHF 137&nbsp;million, reflecting investment amounts, cumulative
accrued dividend and compounded interest for Series A, B and C preferred shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RELATED PARTY DISCLOSURES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management, including the Board of Directors and the Executive Management compensation were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and other short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>736</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>in CHF thousands </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and other short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,174</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,736</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LOSS PER SHARE </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months<BR>Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months<BR>Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) for the period attributable to Oculis shareholders&#151;in CHF thousands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss for the period attributable to equity holders&#151;in CHF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute loss per share basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,028,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,806,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,963,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,763,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g389734g00s02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Company has a loss for all periods
presented, basic net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all potentially dilutive securities, including (i)&nbsp;share options and (ii)&nbsp;restricted stock
awards subject to repurchase, as the inclusion of these awards would have been anti-dilutive. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBSEQUENT EVENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Oculis SA entered into a Business Combination Agreement (&#147;BCA&#148;) with European Biotech Acquisition Corp., a NASDAQ listed
blank check company incorporated in Cayman Islands as an exempted company (&#147;EBAC&#148;). Under the BCA and in accordance with applicable law, EBAC will be transferred into Oculis Holding AG, a public liability company incorporated and existing
under the laws of Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the merger, the Company&#146;s then outstanding common and preferred shares will automatically convert
into common shares of Oculis Holding AG at the then-effective exchange ratio. In addition, existing equityholders of Oculis will also be entitled to receive additional consideration in the form of an aggregate of 4,000,000 newly issued restricted
shares of Oculis Holding AG (the &#147;Earnout Shares&#148;), subject to predefined price targets of Oculis Holding AG shares. The aggregate value of the consideration of the shares of Oculis Holding AG payable to existing Oculis equityholders,
without considering any Earnout Shares, equals $208.0&nbsp;million (CHF 207.9 million) (at a deemed value of $10.00 (CHF 9.99) per share. In connection with and contingent upon the close of the merger, EBAC has received PIPE and private investment
commitments of $78.0&nbsp;million (CHF 78.0 million). Private investments include $2.1&nbsp;million (CHF 2.0 million) related to the July 2022 Series C1b financing extension (this amount is not contingent upon the close of the merger), and
$12.67&nbsp;million (CHF 12.66 million) is in the legal form of Convertible Loan Agreements (the &#147;CLAs). The CLA&#146;s are intended to provide the same economic terms as the other PIPE investors. The CLAs convert automatically into common
shares of Oculis Holding AG at $10.00 (CHF 9.99) per share upon the close of the merger and entitled to Earnout Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no further material
subsequent events to report and no events out of the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii389734_100bb"></A><A NAME="toc389734_39"></A>Annex A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Execution Version </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and among </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN
BIOTECH ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OCULIS SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated as of
October&nbsp;17, 2022 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">P<SMALL>AGE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_1">Section&nbsp;1.01. <I>Definitions</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_2">Section&nbsp;1.02. <I>Construction</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_3">Section&nbsp;1.03. <I>Knowledge</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>THE</SMALL> M<SMALL>ERGERS</SMALL>; S<SMALL>HARE</SMALL> C<SMALL>ONTRIBUTION</SMALL>;
C<SMALL>LOSING</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_4">Section&nbsp;
2.01.&#8201;<I>The Mergers; Exchange Agent Contribution; Contribution of Company Common Shares to New Parent</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_5">Section&nbsp;
2.02. <I>Effective Times</I>; <I>Sponsor Forfeitur</I>e; <I>Closings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_6">Section&nbsp;2.03. <I>Closing Deliverables</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">E<SMALL>FFECTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> M<SMALL>ERGER</SMALL> <SMALL>ON</SMALL>
EBAC S<SMALL>ECURITIES</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_7">Section&nbsp;3.01. <I>Conversion of Securities</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_8">Section&nbsp;3.02. <I>Equitable Adjustments</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_9">Section&nbsp;3.03. <I>Delivery of Shares</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_10">Section&nbsp;3.04. <I>Withholding</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_11">Section&nbsp;3.05. <I>Earn Out Shares</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_12">Section&nbsp;3.06. <I>Treatment of Company Options</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 4</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_13">Section&nbsp;4.01. <I>Company Organization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_14">Section&nbsp;4.02. <I>Subsidiaries</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_15">Section&nbsp;4.03. <I>Due Authorization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_16">Section&nbsp;4.04. <I>No Conflict</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_17">Section&nbsp;4.05. <I>Governmental Authorities;
Consents</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_18">Section&nbsp;4.06. <I>Capitalization of the Company</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_19">Section&nbsp;4.07. <I>Capitalization of Subsidiaries</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_20">Section&nbsp;4.08. <I>Financial Statements</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_21">Section&nbsp;4.09. <I>Undisclosed Liabilities</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_22">Section&nbsp;4.10. <I>Litigation and Proceedings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_23">Section&nbsp;4.11. <I>Legal Compliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_24">Section&nbsp;4.12. <I>Contracts; No Defaults</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_25">Section&nbsp;4.13. <I>Company Benefit Plans</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_26">Section&nbsp;4.14. <I>Labor Relations; Employees</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_27">Section&nbsp;4.15. <I>Taxes</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_28">Section&nbsp;4.16. <I>Brokers&#146; Fees</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_29">Section&nbsp;4.17. <I>Insurance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_30">Section&nbsp;4.18. <I>Permits</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_31">Section&nbsp;4.19. <I>Regulatory Compliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_32">Section&nbsp;4.20. <I>Real Property</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_33">Section&nbsp;4.21. <I>Intellectual Property</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_34">Section&nbsp;4.22. <I>Privacy and Cybersecurity</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_35">Section&nbsp;4.23. <I>Environmental Matters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_36">Section&nbsp;4.24. <I>Absence of Changes</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_37">Section&nbsp;4.25. <I>Anti-Corruption Compliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_38">Section&nbsp;
4.26. <I>Anti-Money Laundering, Sanctions and National Security Compliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_39">Section&nbsp;4.27. <I>Information Supplied</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_40">Section&nbsp;4.28. <I>No Outside Reliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_41">Section&nbsp;4.29. <I>No Additional Representation or
Warranties</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 5</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> R<SMALL>ELATING</SMALL>
<SMALL>TO</SMALL> N<SMALL>EW</SMALL> P<SMALL>ARENT</SMALL>, M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 1, M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 2 <SMALL>AND</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 3</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL>
</SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_42">Section&nbsp;5.01. <I>Corporate Organization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_43">Section&nbsp;5.02. <I>Due Authorization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_44">Section&nbsp;5.03. <I>Capitalization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_45">Section&nbsp;
5.04. <I>Consents and Requisite Governmental Approvals; No Violations</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_46">Section&nbsp;5.05. <I>Business Activities</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_47">Section&nbsp;5.06. <I>Brokers&#146; Fees</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_48">Section&nbsp;5.07. <I>Tax Matters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_49">Section&nbsp;5.08. <I>Investment Company Act</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_50">Section&nbsp;5.09. <I>Investigation; No Other
Representations</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_51">Section&nbsp;5.10. <I>No Outside Reliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_52">Section&nbsp;5.11. <I>No Additional Representation or
Warranties</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 6</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL>
EBAC</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_53">Section&nbsp;6.01. <I>Company Organization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_54">Section&nbsp;6.02. [<I>Intentionally Omitted</I>]</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_55">Section&nbsp;6.03. <I>Due Authorization</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_56">Section&nbsp;6.04. <I>No Conflict</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_57">Section&nbsp;6.05. <I>Governmental Authorities;
Consents</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_58">Section&nbsp;6.06. <I>Litigation and Proceedings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_59">Section&nbsp;6.07. <I>SEC Filings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_60">Section&nbsp;
6.08. <I>Internal Controls; Listing; Financial Statements</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_61">Section&nbsp;6.09. <I>Trust Account</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_62">Section&nbsp;6.10. <I>Investment Company Act; JOBS
Act</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_63">Section&nbsp;6.11. <I>Absence of Changes</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_64">Section&nbsp;6.12. <I>No Undisclosed Liabilities</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_65">Section&nbsp;6.13. <I>Capitalization of EBAC</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_66">Section&nbsp;6.14. <I>Brokers&#146; Fee</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_67">Section&nbsp;6.15. <I>Indebtedness</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_68">Section&nbsp;6.16. <I>Taxes</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_69">Section&nbsp;6.17. <I>Business Activities</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_70">Section&nbsp;6.18. <I>Stock Market Quotation</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_71">Section&nbsp;6.19. <I>Investigation; No Other
Representations</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_72">Section&nbsp;6.20. <I>No Outside Reliance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_73">Section&nbsp;6.21. <I>No Additional Representation or
Warranties</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 7</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_74">Section&nbsp;7.01. <I>Conduct of Business</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_75">Section&nbsp;7.02. <I>Inspection</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_76">Section&nbsp;
7.03. <I>Preparation and Delivery of Additional Company Financial Statements</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_77">Section&nbsp;7.04. <I>Affiliate Agreements</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_78">Section&nbsp;7.05. <I>Acquisition Proposals</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_79">Section&nbsp;7.06. <I>Subsidiary Member Approval</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_80">Section&nbsp;7.07. <I>Stock Exchange Listing of New Parent
Shares</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_81">Section&nbsp;7.08. <I>EBAC D&amp;O Indemnification and
Insurance</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_82">Section&nbsp;7.09. <I>Agent Deliverables</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 8</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> EBAC</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_83">Section&nbsp;
8.01. <I>Trust Account Proceeds and Related Available Equity</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_84">Section&nbsp;
8.02. <I><FONT STYLE="white-space:nowrap">De-Listing</FONT></I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_85">Section&nbsp;8.03. <I>No Solicitation by EBAC</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_86">Section&nbsp;8.04. <I>EBAC Conduct of Business</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_87">Section&nbsp;8.05. <I>EBAC Public Filings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_88">Section&nbsp;8.06. <I>Shareholder Litigation</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_89">Section&nbsp;8.07. <I>New Parent Corporate Documents</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_90">Section&nbsp;8.08. <I>Corporate Formation</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_91">Section&nbsp;8.09. <I>Agent Deliverables</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_92">Section&nbsp;
8.10. <I>Extension of Time to Consummate a Business Combination</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 9</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">J<SMALL>OINT</SMALL> C<SMALL>OVENANTS</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_93">Section&nbsp;9.01. <I>Efforts to Consummate</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_94">Section&nbsp;
9.02.&#8201;<I>Preparation of Proxy Statement/Registration Statement; Shareholders&#146; Meeting and Approvals</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_95">Section&nbsp;9.03. <I>Support of Transaction</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_96">Section&nbsp;9.04. <I>Cooperation; Consultation</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_97">Section&nbsp;9.05. <I>Additional Equity Financing</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_98">Section&nbsp;9.06. <I>Section</I><I></I><I>&nbsp;16
Matters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_99">Section&nbsp;9.07. <I>Employee Matters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_100">Section&nbsp;9.08. <I>Director and Officer
Appointments</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_101">Section&nbsp;9.09. <I>Tax Matters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_102">Section&nbsp;9.10. <I>Third Merger</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_103">Section&nbsp;9.11. <I>Engagement Letters; Subscription
Agreements</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_104">Section&nbsp;9.12. <I>Agent Deliverables</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 10</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONDITIONS</SMALL> <SMALL>TO</SMALL> O<SMALL>BLIGATIONS</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_105">Section&nbsp;10.01. <I>Conditions to Obligations of the
Parties</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-6.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_106">Section&nbsp;
10.02.&#8201;<I>Conditions to Obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_107">Section&nbsp;
10.03. <I>Conditions to the Obligations of the Company</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 11</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>ERMINATION</SMALL>/E<SMALL>FFECTIVENESS</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_108">Section&nbsp;11.01. <I>Termination</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_109">Section&nbsp;11.02. <I>Effect of Termination</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>RTICLE</SMALL> 12</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><SMALL></SMALL>&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_110">Section&nbsp;12.01. <I>Trust Account Waiver</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_111">Section&nbsp;12.02. <I>Waiver</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_112">Section&nbsp;12.03. <I>Notices</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_113">Section&nbsp;12.04. <I>Assignment</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_114">Section&nbsp;12.05. <I>Rights of Third Parties</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_115">Section&nbsp;12.06. <I>Expenses</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_116">Section&nbsp;12.07. <I>Governing Law</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_117">Section&nbsp;12.08. <I>Headings; Counterparts</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_118">Section&nbsp;12.09. <I>Company and EBAC Disclosure
Letters</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_119">Section&nbsp;12.10. <I>Entire Agreement</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_120">Section&nbsp;12.11. <I>Amendments</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_121">Section&nbsp;12.12. <I>Publicity</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_122">Section&nbsp;12.13. <I>Severability</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_123">Section&nbsp;12.14. <I>Jurisdiction; Waiver of Jury
Trial</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_124">Section&nbsp;12.15. <I>Enforcement</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_125">Section&nbsp;
12.16. <I><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_126">Section&nbsp;
12.17. <I><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations, Warranties and Covenants</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#anxa389734_127">Section&nbsp;12.18. <I>Conflicts and Privilege</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Registration Rights Agreement</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Business Combination Agreement, dated as of October&nbsp;17, 2022 (this &#147;<B>Agreement</B>&#148;), is made and entered into by and
among European Biotech Acquisition Corp., a Cayman Islands exempted company (&#147;<B>EBAC</B>&#148;) and Oculis SA, a public limited liability company (<I>soci&eacute;t&eacute; anonyme</I>) incorporated and existing under the laws of Switzerland
(the &#147;<B>Company</B>&#148;) that is wholly and directly owned by the Company Shareholders (as defined below). EBAC and the Company are collectively referred to herein as the &#147;<B>Parties</B>&#148; and each individually referred to herein as
a &#147;<B>Party</B>.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, (a)&nbsp;EBAC is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities and (b)&nbsp;New Parent (as defined below) will be a newly formed entity, wholly owned by EBAC, and
formed for the purpose of this Agreement and the transactions contemplated hereby (the &#147;<B>Transactions</B>&#148;) and the other documents and the transactions contemplated thereby, including to act as the publicly traded holding company for
the Company and its businesses after the Acquisition Closing (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as soon as practicable following the
execution of this Agreement, (a)&nbsp;EBAC shall form or cause to be formed (i)&nbsp;Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and that will be a direct wholly owned subsidiary of
EBAC (&#147;<B>New Parent</B>&#148;), (ii) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (&#147;<B>Merger Sub</B>&nbsp;<B>1</B>&#148;), (iii) another new Cayman Islands exempted company that will
be a direct wholly owned subsidiary of New Parent (&#147;<B>Merger Sub 2</B>&#148;) and (iv)&nbsp;a new limited liability company (<I>Gesellschaft mit beschr&auml;nkter Haftung</I>) incorporated and existing under the laws of Switzerland that will
be a direct wholly owned subsidiary of New Parent (&#147;<B>Merger Sub 3</B>&#148;) and (b)&nbsp;EBAC shall cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to become a party hereto as a &#147;Party&#148; and &#147;EBAC Party&#148; by
executing a joinder agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the execution and delivery of this Agreement, in connection with
the Transactions, EBAC and certain investors (the &#147;<B>PIPE Investors</B>&#148;) have entered into subscription agreements, dated on or around the date hereof (as amended or modified from time to time, the &#147;<B>Subscription
Agreements</B>&#148;), pursuant to which the PIPE Investors who are parties thereto have committed, on the terms and subject to the conditions of the Subscription Agreements, to subscribe for and purchase a number of shares of EBAC Class&nbsp;A
Common Stock (the &#147;<B>PIPE Shares</B>&#148;) equal to 6,330,391 before the First Merger Effective Time (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as a condition and inducement to the Company&#146;s willingness to enter into this Agreement, simultaneously with the
execution and delivery of this Agreement, the Sponsor and certain of its Affiliates (as applicable) have executed and delivered to the Company a Sponsor Support Agreement, dated as of the date hereof (the &#147;<B>Sponsor Support
Agreement</B>&#148;), pursuant to which the Sponsor and certain of its Affiliates (as applicable) have agreed to, among other things, on the terms, and subject to the conditions, set forth therein (i)&nbsp;vote to adopt and approve this Agreement
and the other documents contemplated hereby and the transactions contemplated hereby and thereby, (ii)&nbsp;lock up their (a)&nbsp;shares of EBAC Common Stock and (b)&nbsp;EBAC Warrants, in each case, until the consummation of the Acquisition
Closing, (iii)&nbsp;waive certain anti-dilution adjustments and (iv)&nbsp;waive certain redemption rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, subject to the
terms and conditions hereof and as an inducement to EBAC&#146;s and the Company&#146;s willingness to enter into this Agreement, certain EBAC Shareholders have entered into <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreements with EBAC
and New Parent in the form attached as <U>Exhibit A</U> hereto (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements</B>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as a condition and inducement to EBAC&#146;s willingness to enter into this
Agreement, simultaneously with the execution and delivery of this Agreement, certain of the Company Shareholders have executed and delivered to EBAC a Company Shareholder support agreement, dated as of the date hereof (collectively, the
&#147;<B>Company Shareholders Support Agreement</B>&#148;), pursuant to which such Company Shareholder has agreed to, among other things, on the terms, and subject to the conditions, set forth therein (i)&nbsp;adopt this Agreement and approve and
consent to the Mergers and the consummation of the Transactions, (ii)&nbsp;execute and deliver the exchange notice contemplated by Section&nbsp;2.01, (iii) vote in favor of the Third Merger and the transactions contemplated thereby pursuant to
Section&nbsp;9.10 and (iv)&nbsp;provide a release of claims against the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, subject to the
terms and conditions hereof, on the day before the Acquisition Closing Date (as defined below) and at the First Merger Effective Time, Merger Sub 1 will merge with and into EBAC, the separate corporate existence of Merger Sub 1 will cease and EBAC
will be the surviving company and wholly owned subsidiary of New Parent (the &#147;<B>First Merger</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as part of
the First Merger, (i)&nbsp;each share of EBAC Common Stock (including those held by the PIPE Investors) shall be automatically converted into one class of common stock of EBAC, as the surviving company of the First Merger (the &#147;<B>Surviving
EBAC Shares</B>&#148;), (ii) each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into warrants of EBAC, as the surviving company of the First Merger (&#147;<B>Surviving EBAC
Warrants</B>&#148;) and (iii)&nbsp;EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the
terms, and subject to the conditions set forth herein and in the Ancillary Agreements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, on the day before the Acquisition
Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time (as defined below), the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent (the
&#147;<B>Exchange Agent Contribution</B>&#148;) in exchange for (i)&nbsp;New Parent Class&nbsp;A Shares, nominal value CHF 0.01 per share (the &#147;<B>New Parent Shares</B>&#148;) and (ii)&nbsp;a right to acquire New Parent Shares (each, a
&#147;<B>New Parent Warrant</B>&#148;), in each case of (i)&nbsp;and (ii), to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the &#147;<B>New Parent Interests
Consideration</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing
Date and prior to the Second Merger Effective Time, the Exchange Agent will (i)&nbsp;undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares on the terms as further
specified in Section&nbsp;3.03(b) and (ii)&nbsp;distribute the New Parent Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants (the &#147;<B>Exchange Agent Contribution Actions</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution Actions, at the
Second Merger Effective Time, EBAC will merge with and into Merger Sub&nbsp;2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent (the &#147;<B>Second
Merger</B>&#148; and, together with the First Merger, the &#147;<B>EBAC Mergers</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, at approximately 10:00am ET
on the Acquisition Closing Date, those Company Shareholders executing Company Shareholders Support Agreements and the exchange notice contemplated by Section&nbsp;2.01 shall effect the Company Share Contribution (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, approximately thirty (30)&nbsp;days after the Acquisition Closing Date, pursuant to a merger agreement to be entered into in
accordance with Section&nbsp;9.10, the Company will merge with and into Merger Sub&nbsp;3, the separate corporate existence of the Company will cease and Merger Sub 3 will be the surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company and remain a wholly owned subsidiary of New Parent (the &#147;<B>Third Merger</B>&#148; and together with the EBAC Mergers, the &#147;<B>Mergers</B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties intend that, for U.S. federal income Tax purposes (i)&nbsp;the EBAC Mergers, taken together, will qualify as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(F) of the Internal Revenue Code of 1986 (the &#147;<B>Code</B>&#148;) and the applicable Treasury Regulations, (ii)&nbsp;the Company Share Contribution and the Third Merger,
taken together, will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code and the applicable Treasury Regulations, (iii)&nbsp;with respect to each of the EBAC Mergers, the Company Share Contribution, and the
Third Merger, this Agreement will constitute a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a)</FONT> and for
purposes of Sections 354, 361, and 368 of the Code and the applicable Treasury Regulations, and (iv)&nbsp;with respect to the Convertible Loans, (A)&nbsp;the Convertible Loans will be treated as issued solely by New Parent after the Second Merger
Effective Time but before the Company Share Contribution on the Acquisition Closing Date and not at any other time or by any other Person or entity (including, for the avoindance of doubt, the Company), (B) the Convertible Loans will not be treated
as issued until the receipt by New Parent of cash to fund the Convertible Loans from the respective lender parties thereto, (C)&nbsp;until such time as cash to fund the Convertible Loans has been paid to New Parent, the &#147;Escrow Agent&#148; (as
defined in the Convertible Loan Agreement) will hold any such cash on behalf of the Lenders that funded such payment, and such Lenders will be treated as the owners of such cash unless and until such cash is delivered to New Parent pursuant to the
Convertible Loan Agreement (together, the &#147;<B>Intended Tax Treatment</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Board of Directors of the
Company has (a)&nbsp;determined that it is advisable for and in the best interests of the Company and its shareholders to enter into this Agreement and the other documents to which the Company is a party contemplated hereby and (b)&nbsp;approved the
execution and delivery of this Agreement and the other documents to which the Company is a party contemplated hereby and the transactions contemplated hereby and thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the EBAC Board has (a)&nbsp;determined that it is advisable and in the best interests of the EBAC Parties and their
shareholders for the EBAC Parties to enter into this Agreement and the other documents to which the EBAC Parties are a party contemplated hereby and consummate the transactions contemplated hereby and thereby, (b)&nbsp;approved the execution,
delivery and performance of this Agreement and the other documents to which the EBAC Parties are a party contemplated hereby and the transactions contemplated hereby and thereby, and (c)&nbsp;recommended the approval and adoption of this Agreement
and the other documents to which the EBAC Parties are a party contemplated hereby and the transactions contemplated hereby and thereby by the EBAC Shareholders and sole shareholder of the other EBAC Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in furtherance of the Transactions and in accordance with the terms hereof, EBAC shall provide an opportunity to its
shareholders to have their outstanding shares of EBAC Common Stock redeemed on the terms and subject to the conditions set forth in this Agreement and EBAC&#146;s Governing Documents (as defined below) in connection with the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, at the Acquisition Closing, New Parent, the EBAC Class&nbsp;B Holders and certain of their respective Affiliates shall enter
into a Registration Rights Agreement (the &#147;<B>Registration Rights Agreement</B>&#148;) in substantially the form attached hereto as <U>Exhibit B</U> (with such changes as may be mutually agreed in writing by EBAC and the Company), which shall
be effective as of the Acquisition Closing; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth in this Agreement, the receipt and sufficiency of which are hereby acknowledged and, intending to be legally bound hereby, the Parties agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_1"></A>Section&nbsp;1.01. <I>Definitions</I>. As used herein, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition Closing</B>&#148; has the meaning specified in Section&nbsp;2.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition Closing Date</B>&#148; has the meaning specified in Section&nbsp;2.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition Proposal</B>&#148; means, with respect to the Company and its Subsidiaries, other than the Transactions and other than
the acquisition or disposition of equipment or other tangible personal property in the ordinary course of business, any offer or proposal relating to: (a)&nbsp;any acquisition or purchase, direct or indirect, of (i)&nbsp;fifteen percent (15%) or
more of the consolidated assets of the Company and its Subsidiaries or (ii)&nbsp;fifteen percent (15%) or more of any class of equity or voting securities of (x)&nbsp;the Company or (y)&nbsp;one (1) or more Subsidiaries of the Company holding assets
or producing revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries; (b)&nbsp;any tender offer (including a self-tender offer) or exchange offer
that, if consummated, would result in any Person beneficially owning fifteen percent (15%) or more of any class of equity or voting securities of (i)&nbsp;the Company or (ii)&nbsp;one or more Subsidiaries of the Company holding assets or producing
revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries; or (c)&nbsp;a merger, consolidation, share exchange, business combination, sale of
substantially all the assets, reorganization, recapitalization, liquidation, dissolution or other similar transaction involving the sale or disposition of (i)&nbsp;the Company or (ii)&nbsp;one or more Subsidiaries of the Company holding assets or
producing revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition Transactions</B>&#148; means the transactions contemplated by the EBAC Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Action</B>&#148; means any claim, action, suit, audit, examination, assessment, arbitration, mediation, inquiry, proceeding or
investigation by or before any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor
Shares</B>&#148; means 1,594,348 shares of EBAC Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional
<FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Forfeit Amount</B>&#148; means a number equal to (x)&nbsp;the Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares <I>minus </I>(y)&nbsp;the product of (i)&nbsp;the
Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares and (ii)&nbsp;a fraction, the numerator of which is equal to the Closing Trust Proceeds and the denominator of which is equal 25,500,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Proposal</B>&#148; has the meaning specified in Section&nbsp;9.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Sponsor Incentive Shares</B>&#148; has the meaning specified in Section&nbsp;2.02(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Subscription Agreement</B>&#148; means a subscription agreement in respect of the purchase or sale of EBAC Class&nbsp;A
Common Stock, New Parent Shares, warrants or other securities in compliance with the exceptions set forth in Sections 7.01(k), 8.04(a)(vii) and 8.04(a)(viii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Adjournment Proposal</B>&#148; has the meaning specified in Section&nbsp;9.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any specified Person, any Person that, directly or indirectly, controls, is controlled by,
or is under common control with, such specified Person, whether through one or more intermediaries or otherwise. The term &#147;<B>Control</B>&#148; (including the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common
control with&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate Agreements</B>&#148; has the meaning specified in
Section&nbsp;4.12(a)(vii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliated Group</B>&#148; means a group of Persons that elects, is required to, or otherwise files a
Tax Return or pays a Tax as an affiliated, consolidated, combined, unitary or other group recognized by Law in respect of Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agent</B>&#148; means any Placement Agent or Financial Advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agent Deliverables</B>&#148; means the documents deliverable pursuant to Sections 7.09 and 8.09. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning specified in the Preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement End Date</B>&#148; has the meaning specified in Section&nbsp;11.01(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ancillary Agreements</B>&#148; has the meaning specified in Section&nbsp;12.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Bribery Laws</B>&#148; means all applicable anti-corruption and bribery Laws (including, as applicable, the United Kingdom
Bribery Act 2010, the U.S. Foreign Corrupt Practices Act, as amended, national laws governing bribery of private and public employees, and any rules or regulations promulgated thereunder or other Laws of other countries implementing the OECD
Convention on Combating Bribery of Foreign Officials). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Money Laundering Laws</B>&#148; means all applicable Laws concerning
or relating to the prevention of money laundering or countering the financing of terrorism, including applicable Laws governing customer due diligence, licensing and registration, financial recordkeeping, and suspicious activity reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares</B>&#148; means 797,174 shares of EBAC Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Audited Financial Statements</B>&#148; has the meaning specified in Section&nbsp;4.08(a)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Combination</B>&#148; has the meaning set forth in Article 1.1 of EBAC&#146;s Governing Documents as in effect on the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Combination Proposal</B>&#148; means any offer, inquiry, proposal or indication of interest (whether written or
oral, binding or <FONT STYLE="white-space:nowrap">non-binding,</FONT> and other than an offer, inquiry, proposal or indication of interest with respect to the Transactions), relating to a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day other than a Saturday, Sunday or any other day on which commercial banks in either New York, New
York, or Lausanne, Switzerland or the Governmental Authorities in the Cayman Islands (for so long as EBAC remains domiciled in Cayman Islands) are authorized or required by Law to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CARES Act</B>&#148; means the Coronavirus Aid, Relief, and Economic Security Act (Pub. L.
<FONT STYLE="white-space:nowrap">116-136),</FONT> together with all rules and regulations and guidance issued by any Governmental Authority with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Companies Act</B>&#148; means the Companies Act (as revised) of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Plan of Merger</B>&#148; has the meaning specified in Section&nbsp;2.02(b)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Control</B>&#148; means any transaction or series of transactions (a)&nbsp;following which a Person or &#147;group&#148;
(within the meaning of Section&nbsp;13(d) of the Exchange Act), other than the Company and its Subsidiaries, has direct or indirect beneficial ownership of securities (or rights convertible or exchangeable into securities) representing fifty percent
(50%) or more of the voting power of or economic rights or interests in New Parent and its Subsidiaries that, in the aggregate, constitute at least 50% of the consolidated assets of New Parent (excluding any &#147;holding company&#148;
reorganizations or similar reorganizations that do not affect the ultimate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beneficial ownership of New Parent), (b) constituting a merger, consolidation, reorganization or other business combination, however effected, following which the voting securities of New Parent
immediately prior to such merger, consolidation, reorganization or other business combination do not continue to represent or are not converted into fifty percent (50%) or more of the combined voting power of the then outstanding voting securities
of the Person resulting from such combination or, if the surviving company is a Subsidiary, the ultimate parent thereof, or (c)&nbsp;the result of which is a sale of all or substantially all of the assets of New Parent to any Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Claim</B>&#148; has the meaning specified in Section&nbsp;12.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Trust Proceeds</B>&#148; has the meaning specified in Section&nbsp;2.02(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collaboration Partners</B>&#148; means the Company&#146;s or its Subsidiaries&#146; research, development, collaboration or similar
commercialization partners with respect to Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collective Bargaining Agreement</B>&#148; means any collective bargaining
agreement or any similar labor-related agreement or arrangement with any labor or trade union, employee representative body, works council or labor organization, in each case to which the Company or its Subsidiaries is party or by which it is bound.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commercial Register Zug</B>&#148; has the meaning specified in Section&nbsp;2.02(b)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; has the meaning specified in the Preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Benefit Plan</B>&#148; has the meaning specified in Section&nbsp;4.13(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Common Shares</B>&#148; has the meaning specified in Section&nbsp;4.06(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Consideration</B>&#148; has the meaning specified in Section&nbsp;2.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Cure Period</B>&#148; has the meaning specified in Section&nbsp;11.01(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Disclosure Letter</B>&#148; has the meaning specified in the introduction to Article 4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Plan</B>&#148; means the Company&#146;s Stock Option and Incentive Plan Regulation 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Value</B>&#148; means an amount equal to (i) $208,000,000 <I>plus </I>(ii)&nbsp;the Equity Investment Amount<I>, minus
</I>(iii)&nbsp;the aggregate value of the vested Company Options in accordance with Section&nbsp;3.06(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Fundamental
Representations</B>&#148; means the representations and warranties made pursuant to the first and second sentences of Section&nbsp;4.01 (Company Organization), Section&nbsp;4.03 (Due Authorization), Section&nbsp;4.06(a) and (c) (Capitalization of
the Company), Section&nbsp;4.07(b) (Capitalization of Subsidiaries) and Section&nbsp;4.16 (Brokers&#146; Fees). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Group</B>&#148; has the meaning specified in Section&nbsp;12.18(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IP</B>&#148; means the Company Owned IP and the
Company Licensed IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IT Systems</B>&#148; means any and all computers, hardware, software, firmware, middleware,
systems, workstations, servers, routers, hubs, switches, networks, platforms, peripherals, data communication lines, and other information technology equipment and related systems and services, and all associated documentation, in each case, that
are owned or controlled by (or purported to be owned or controlled by), or licensed or leased to (or purported to be licensed or leased to), the Company or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Licensed IP</B>&#148; means any and all Intellectual Property owned by a
third party and licensed or sublicensed (or purported to be licensed or sublicensed) to the Company or any of its Subsidiaries or for which the Company or any of its Subsidiaries has obtained (or purported to have obtained) a covenant not to be
sued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Material Adverse Effect</B>&#148; means any event, state of facts, development, circumstance, occurrence or effect
(collectively, &#147;<B>Events</B>&#148;) that (a)&nbsp;has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, results of operations or financial condition of the
Company and its Subsidiaries, taken as a whole or (b)&nbsp;does or would reasonably be expected to, individually or in the aggregate, prevent the ability of the Company to consummate the Transactions; <I>provided</I>, <I>however</I>, that in no
event would any of the following, alone or in combination, be deemed to constitute, or be taken into account in determining whether there has been or will be, a &#147;Company Material Adverse Effect&#148;: (i) any change in applicable Laws or IFRS
or any interpretation thereof following the date of this Agreement, (ii)&nbsp;any change in interest rates or economic, political, business or financial market conditions generally, (iii)&nbsp;the taking of any action required by this Agreement,
(iv)&nbsp;any natural disaster (including hurricanes, storms, tornados, flooding, earthquakes, volcanic eruptions or similar occurrences) or change in climate, (v)&nbsp;any epidemic, pandemic or disease outbreak (including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic), or any Law or mandate, directive, pronouncement or guideline issued by a Governmental Authority, the Centers for Disease Control and Prevention, the World Health Organization or industry group
providing for business closures, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;sheltering-in-place,&#148;</FONT></FONT> curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease
outbreak (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or any change in such Law or directive, pronouncement or guideline or interpretation thereof after the date hereof or any material worsening of such conditions after
the date hereof, (vi)&nbsp;any acts of terrorism or war, the outbreak or escalation of hostilities, geopolitical conditions, local, national or international political conditions, (vii)&nbsp;any failure of the Company to meet any projections or
forecasts (provided that this clause (vii)&nbsp;shall not prevent a determination that any Event not otherwise excluded from this definition of Company Material Adverse Effect underlying such failure to meet projections or forecasts has resulted in
a Company Material Adverse Effect), (viii) any Events generally applicable to the industries or markets in which the Company and its Subsidiaries operate (including increases in the cost of products, supplies, materials or other goods purchased from
third-party suppliers), (ix) the announcement of this Agreement and consummation of the Transactions, including any termination of, reduction in or similar adverse impact (but in each case only to the extent attributable to such announcement or
consummation) on relationships, contractual or otherwise, with any landlords, customers, suppliers, distributors, partners or employees of the Company and its Subsidiaries (it being understood that this clause (ix)&nbsp;shall be disregarded for
purposes of the representation and warranty set forth in Section&nbsp;4.04 and the condition to Acquisition Closing with respect thereto), (x) any matter set forth on the Company Disclosure Letter that would not reasonably be expected to have a
material adverse effect on the business, assets, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole, or (xi)&nbsp;any action taken by, or at the written request of, EBAC; <I>provided</I>,
<I>further</I>, that any Event referred to in clauses (i), (ii), (iv), (v), (vi) or (viii)&nbsp;above may be taken into account in determining if a Company Material Adverse Effect has occurred to the extent it has a disproportionate and adverse
effect on the business, assets, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole, relative to similarly situated companies in the industry in which the Company and its Subsidiaries conduct their
respective operations, but only to the extent of the incremental disproportionate effect on the Company and its Subsidiaries, taken as a whole, relative to similarly situated companies in the industry in which the Company and its Subsidiaries
conduct their respective operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Options</B>&#148; means each outstanding and unexercised option to purchase Company
Common Shares, whether issued pursuant to the Company Equity Plan or otherwise, whether then vested or fully exercisable, granted prior to the Acquisition Closing Date to any current or former Service Provider of the Company (each such Service
Provider, a &#147;<B>Company Optionholder</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Owned IP</B>&#148; means any and all Intellectual Property owned
or purported to be owned by the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Preferred Shares</B>&#148; has the meaning specified
in Section&nbsp;4.06(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Registered Intellectual Property</B>&#148; has the meaning specified in
Section&nbsp;4.21(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Share Capital</B>&#148; has the meaning specified in Section&nbsp;4.06(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Share Contribution</B>&#148; has the meaning specified in Section&nbsp;2.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders</B>&#148; means, collectively, the holders of shares of Company Share Capital as of any applicable determination
time prior to the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders Support Agreement</B>&#148; has the meaning specified in the
Recitals hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Transaction Expenses</B>&#148; means the following <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses paid or payable by the Company or any of its Subsidiaries (whether or not billed or accrued for) as a result of or in connection with the negotiation, documentation and
consummation of the transactions contemplated hereby: (a)&nbsp;all fees, costs, expenses, brokerage fees, commissions, finders&#146; fees and disbursements of the Company&#146;s financial advisors, investment banks, data room administrators,
attorneys, accountants, and other advisors and service providers; (b)&nbsp;the filing fees incurred in connection with making any filings under Section&nbsp;9.01; (c) the fees and expenses in connection with preparing and filing the Registration
Statement, the Proxy Statement or the Proxy Statement/Registration Statement under Section&nbsp;9.02 and obtaining approval of the Stock Exchange under Section&nbsp;7.07; (d)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> payments, transaction bonuses, retention payments, severance or similar compensatory payments payable by the Company or any of its Subsidiaries to any
current or former Service Provider as a result of the transactions contemplated hereby (and not tied to any subsequent event or condition, such as a termination of employment), including the employer portion of any employment or payroll Taxes
arising therefrom; (e)&nbsp;amounts owing or that may become owed, payable or otherwise due, directly or indirectly, by the Company or any of its Subsidiaries to any Affiliate of the Company or any of its Subsidiaries in connection with the
consummation of the transactions contemplated hereby, including fees, costs and expenses related to the termination of any Affiliate Agreement; and (f)&nbsp;any other fees and expenses as a result of or in connection with the negotiation,
documentation and consummation of the transactions contemplated hereby, in each case of clauses (a)&nbsp;through (f), solely to the extent such fees and expenses are incurred and unpaid as of the Acquisition Closing. Company Transaction Expenses
shall not include any fees or expenses of the Company&#146;s equityholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidentiality Agreement</B>&#148; has the meaning
specified in Section&nbsp;12.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contracts</B>&#148; means any written contracts, agreements, subcontracts, leases, and purchase
orders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Control</B>&#148; has the meaning specified in the definition of &#147;Affiliate.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible Loan</B>&#148; or &#147;<B>Convertible Loans</B>&#148; means the &#147;Loan&#148; or &#147;Loans&#148; as defined in the
Convertible Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible Loan Agreement</B>&#148; means the Convertible Loan Agreement, dated as of
October&nbsp;17, 2022, by and among the Company, Vischer, Earlybird Growth GmbH, Pivotal bioVenture Partners Fund I L.P., NFLS Beta Limited, and any other &#147;Adhering Shareholders&#148; (as defined in the Convertible Loan Agreement), including
any successor or replacement agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cooley</B>&#148; has the meaning specified in Section&nbsp;12.18(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cooley Privileged Communications</B>&#148; has the meaning specified in Section&nbsp;12.18(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">COVID-19</FONT></B>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions or mutations thereof or related or associate epidemics, pandemic or disease outbreaks.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</B>&#148; means any
quarantine, &#147;shelter in place,&#148; &#147;stay at home,&#148; workforce reduction, social distancing, shut down, closure, sequester or any similar Law, mandate, directive, guidelines or recommendations by any Governmental Authority in
connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including the CARES Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT
STYLE="white-space:nowrap">COVID-19</FONT> Reasonable Response</B>&#148; means any reasonable action or inaction, including the establishment of any policy, procedure or protocol, by the Company and its Subsidiaries that the Company determines in
its reasonable discretion is necessary, advisable or prudent in connection with (i)&nbsp;mitigating the adverse effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or applicable <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures,
(ii)&nbsp;ensuring compliance by the Company and its Subsidiaries with <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures applicable to any of them and/or (iii)&nbsp;in respect of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> protecting
the health and safety of employees or other persons with whom the Company and its Subsidiaries and their personnel come into contact with during the course of business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Davis Polk</B>&#148; has the meaning specified in Section&nbsp;12.18(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Davis Polk Privileged Communications</B>&#148; has the meaning specified in Section&nbsp;12.18(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosure Letter</B>&#148; means, as applicable, the Company Disclosure Letter or the EBAC Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dollars</B>&#148; or &#147;<B>$</B>&#148; means lawful money of the United States; provided that any amount of currency that is
calculated in accordance herewith or for purposes hereof that is not in U.S. dollars will be converted into U.S. dollars calculated using the spot currency exchange rate applicable to obligations payable in any foreign currency published by
Bloomberg L.P. five (5)&nbsp;Business Days prior to the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Earnout Achievement Date</B>&#148; means each of the First
Earnout Achievement Date, Second Earnout Achievement Date, and Third Earnout Achievement Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Earnout Options</B>&#148; has the
meaning specified in <U>Section</U><U></U><U>&nbsp;3.06</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Earnout Shares</B>&#148; means 4,000,000 New Parent Shares
authorized for issuance by New Parent on the terms, and subject to the conditions set forth in Section&nbsp;3.05. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC</B>&#148;
has the meaning specified in the Preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Articles</B>&#148; means the amended and restated memorandum and articles
of association of EBAC, dated as of March&nbsp;18, 2021, as in effect on the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Board</B>&#148; means
the Board of Directors of EBAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Board Recommendation</B>&#148; has the meaning specified in Section&nbsp;9.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Class</B><B></B><B>&nbsp;A Common Stock</B>&#148; means Class&nbsp;A ordinary shares, par value $0.0001 per share, of EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Class</B><B></B><B>&nbsp;B Common Stock</B>&#148; means Class&nbsp;B ordinary shares, par value $0.0001 per share, of EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Class</B><B></B><B>&nbsp;B Holders</B>&#148; means holders of shares of EBAC Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Common Stock</B>&#148; means EBAC Class&nbsp;A Common Stock and EBAC Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Cure Period</B>&#148; has the meaning specified in Section&nbsp;11.01(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC D&amp;O Persons</B>&#148; has the meaning specified in Section&nbsp;7.08(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Disclosure Letter</B>&#148; has the meaning specified in the introduction to
Article 6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Financial Statements</B>&#148; means (i)&nbsp;the audited balance sheet as of December&nbsp;31, 2021, and the
related audited statements of operations, changes in shareholder&#146;s equity and cash flows of EBAC for the period ended December&nbsp;31, 2021, together with the auditor&#146;s reports thereon, and (ii)&nbsp;the unaudited balance sheet as of
June&nbsp;30, 2022, and the related unaudited statements of operations, changes in shareholder&#146;s deficit and cash flows of EBAC for the six months ended June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Fundamental Representations</B>&#148; means the representations and warranties set forth in Section&nbsp;6.01 (Company
Organization), Section&nbsp;6.03 (Due Authorization), Section&nbsp;6.13(b) and (c) (Capitalization) and Section&nbsp;6.14 (Brokers&#146; Fees). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Group</B>&#148; has the meaning specified in Section&nbsp;12.18(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Mergers</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Parties</B>&#148; means, collectively, EBAC and, upon execution of a joinder to this Agreement pursuant to Section&nbsp;8.08(d),
New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Private Placement Warrant</B>&#148; means a warrant to purchase
one (1)&nbsp;share of EBAC Class&nbsp;A Common Stock at an exercise price of eleven Dollars fifty cents ($11.50) issued to the Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Public Warrant</B>&#148; means a warrant to purchase one (1)&nbsp;share of EBAC Class&nbsp;A Common Stock at an exercise price
of eleven Dollars fifty cents ($11.50) that was included in the units sold as part of EBAC&#146;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC
SEC Filings</B>&#148; has the meaning specified in Section&nbsp;6.06. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Securities</B>&#148; has the meaning specified in
Section&nbsp;6.12(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Share Redemption</B>&#148; means the election of an eligible (as determined in accordance with
EBAC&#146;s Governing Documents) holder of shares of EBAC Class&nbsp;A Common Stock to redeem all or a portion of the shares of EBAC Class&nbsp;A Common Stock held by such holder at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable
in cash, equal to a pro rata share of the aggregate amount on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) (as determined in accordance with EBAC&#146;s Governing Documents) in connection with
the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Share Redemption Amount</B>&#148; means the aggregate amount payable with respect to all EBAC Share
Redemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Shareholder Approval</B>&#148; means the approval of those Transaction Proposals identified in clauses
(i)&nbsp;through (iii) of Section&nbsp;9.02(c) by an affirmative vote of the applicable majority of the outstanding EBAC Common Stock entitled to vote, who attend and vote thereupon (as determined in accordance with EBAC&#146;s Governing Documents),
in each case, at an EBAC Shareholders&#146; Meeting duly called by the EBAC Board and held for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC
Shareholders</B>&#148; means the shareholders of EBAC as of any applicable determination time prior to the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Shareholders&#146; Meeting</B>&#148; has the meaning specified in Section&nbsp;9.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Transaction Expenses</B>&#148; means the following
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses paid or payable by EBAC or its Affiliates (whether or not billed or accrued for)&nbsp;(A) to the extent directly arising out of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negotiation, documentation and consummation of the transactions contemplated hereby or EBAC&#146;s initial public offering: (a)&nbsp;all fees, costs, expenses, brokerage fees, commissions,
finders&#146; fees and disbursements (&#147;<B>Expenses</B>&#148;) of EBAC&#146;s financial advisors, investment banks, data room administrators, attorneys, accountants, auditors and other advisors and service providers (&#147;<B>Advisors</B>&#148;)
(including any deferred underwriting commissions and placement fees incurred in connection with the PIPE Investment); (b) the filing fees incurred by EBAC in connection with making any filings under Section&nbsp;9.01; (c) the fees and expenses
incurred in connection with preparing and filing the Registration Statement, the Proxy Statement or the Proxy Statement/Registration Statement under Section&nbsp;9.02; (d) repayment of any Working Capital Loans; and (e)&nbsp;any other fees and
expenses to third-party advisors or third-party service providers as a result of or in connection with the negotiation, documentation and consummation of the transactions contemplated hereby, (B)&nbsp;to the extent arising out of the customary
operations of EBAC (as a special purpose acquisition company, including expenses related to exploration of initial business combination opportunities) and related activities, including Expenses of Advisors; and (C)&nbsp;to the extent arising out of
the customary operations of EBAC (as a special purpose acquisition company) and related activities, including Expenses of Advisors, in each case of clauses (A)&nbsp;through (C), solely to the extent such fees and expenses are incurred and unpaid as
of the Acquisition Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Unit</B>&#148; means the units issued in EBAC&#146;s initial public offering consisting of one
share of EBAC Class&nbsp;A Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of an EBAC Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Warrant
Agreement</B>&#148; means the Warrant Agreement, dated as of March&nbsp;15, 2021, between EBAC and Continental Stock Transfer&nbsp;&amp; Trust Company, as warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>EBAC Warrants</B>&#148; means the EBAC Public Warrants and the EBAC Private Placement Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Investment Agreement</B>&#148; means the Investment Agreement Extension, dated as of June&nbsp;30, 2022, between the Company
and LSP 7 Co&ouml;peratief U.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Investment Amount</B>&#148; means the aggregate proceeds received by the Company pursuant
to the Equity Investment Agreement, as adjusted in accordance with Schedule 2.01 of the Company Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Enforceability Exceptions</B>&#148; has the meaning specified in Section&nbsp;4.03(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; means any and all applicable Laws relating to Hazardous Materials, pollution, or the protection or
management of the environment or natural resources, or protection of human health (with respect to exposure to Hazardous Materials). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Securities</B>&#148; means any share, share capital, capital stock, partnership, membership, joint venture or similar interest
in any Person (including any stock appreciation, phantom stock, profit participation or similar rights) and any option, warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent</B>&#148; has the meaning specified in Section&nbsp;3.04(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent Agreement</B>&#148; has the meaning specified in Section&nbsp;3.04(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent Contribution</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent Contribution Actions</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Fund</B>&#148; has the meaning specified in Section&nbsp;3.04(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Extension Proposal</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.23(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Extension Proxy Statement</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.23(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Extension Shareholders&#146; Meeting</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.23(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDCA</B>&#148; means the United States Federal Food, Drug and Cosmetic Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Advisor</B>&#148; means BofA Securities, Inc. in its capacity as financial advisor to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Advisor Engagement Letters</B>&#148; means, (i)&nbsp;that certain letter agreement dated as of May&nbsp;27, 2022, by and
between the Company and BofA Securities, Inc.; and (ii)&nbsp;that certain letter agreement dated as of October&nbsp;16, 2022, by and between the Company and BofA Securities, Inc </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Statements</B>&#148; has the meaning specified in Section&nbsp;4.08(a)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>First Earnout Achievement Date</B>&#148; has the meaning set forth in Section&nbsp;3.05(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>First Merger</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>First Merger Effective Time</B>&#148; means the time at which the First Merger becomes effective pursuant to the filing and
registration of the Plan of Merger with the Cayman Registrar of Companies or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Food and Drug Law</B>&#148; has the meaning specified in Section&nbsp;4.19(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the United States as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governing Documents</B>&#148; means the legal document(s) by which any Person (other than an individual) establishes its legal
existence or which govern its internal affairs. For example, the &#147;Governing Documents&#148; of a corporation are its certificate of incorporation and bylaws, the &#147;Governing Documents&#148; of a limited partnership are its limited
partnership agreement and certificate of limited partnership, the &#147;Governing Documents&#148; of a limited liability company are its operating agreement and certificate of formation and the &#147;Governing Documents&#148; of an exempted company
are its memorandum and articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Government Funded IP</B>&#148; has the meaning specified in
Section&nbsp;4.21(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any federal, state, provincial, municipal, local or foreign
government, governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court or tribunal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authorization</B>&#148; has the meaning specified in Section&nbsp;4.05. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Order</B>&#148; means any order, judgment, injunction, decree, writ, stipulation, determination or award, in each case,
entered by or with any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Materials</B>&#148; means any (a)&nbsp;pollutant, contaminant,
chemical, (b)&nbsp;industrial, solid, liquid or gaseous toxic or hazardous substance, material or waste, (c)&nbsp;petroleum or any fraction or product thereof, (d)&nbsp;asbestos or asbestos-containing material, (e)&nbsp;polychlorinated biphenyl,
(f)&nbsp;chlorofluorocarbons, (g) <FONT STYLE="white-space:nowrap">per-</FONT> and polyfluoroalkyl substances (including PFAs, PFOA, PFOS, Gen X, and PFBs) and (h)&nbsp;other substance, material or waste, in each case of (a) - (h), which are
regulated under any Environmental Law because of its dangerous or deleterious properties or characteristics or as to which liability may be imposed pursuant to Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IFRS</B>&#148; means international financial reporting standards, consistently
applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indebtedness</B>&#148; means, with respect to any Person, without duplication, any obligations, contingent or
otherwise, in respect of (a)&nbsp;the principal of and premium (if any) in respect of all indebtedness for borrowed money, including accrued interest and any per diem interest accruals, (b)&nbsp;amounts drawn (including any accrued and unpaid
interest) on letters of credit, bank guarantees, bankers&#146; acceptances and other similar instruments (solely to the extent such amounts have actually been drawn), (c) the principal of and premium (if any) in respect of obligations evidenced by
bonds, debentures, notes and similar instruments, (d)&nbsp;the marked to market value of interest rate protection agreements and currency obligation swaps, hedges or similar arrangements (without duplication of other indebtedness supported or
guaranteed thereby), (e) the principal component of all obligations to pay the deferred and unpaid purchase price of property and equipment which have been delivered, including &#147;earn outs&#148; and &#147;seller notes,&#148; except in connection
with the purchase of any business, any post-Acquisition Closing payment adjustments to which the Company may become entitled to the extent such payment is determined by a final Closing balance sheet or such payment depends on the performance of such
business after the Acquisition Closing, (f)&nbsp;breakage costs, prepayment or early termination premiums, penalties, or other fees or expenses payable as a result of the consummation of the Transactions in respect of any of the items in the
foregoing clauses (a)&nbsp;through (e), and (g)&nbsp;all Indebtedness of another Person referred to in clauses (a)&nbsp;through (f) above guaranteed directly or indirectly, jointly or severally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property</B>&#148; means any and all intellectual property or proprietary rights throughout the world, including any and
all United States and foreign: (i)&nbsp;patents, patent applications, invention disclosures, and all provisionals, non-provisionals, continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, reissues, renewals, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> substitutions, and extensions thereof;
(ii)&nbsp;trademarks, logos, service marks, trade dress, trade names, service names, slogans, internet domain names, and other similar designations of source or origin, together with all goodwill symbolized by or associated with any of the
foregoing; (iii)&nbsp;copyrights and rights in copyrightable subject matter, including such corresponding rights in software and other works of authorship; (iv)&nbsp;rights in algorithms, databases, compilations and data; (v)&nbsp;trade secrets and
all rights to other confidential and proprietary information, <FONT STYLE="white-space:nowrap">know-how,</FONT> proprietary processes, inventions (whether or not patentable or reduced to practice), discoveries, specifications, improvements, methods,
formulae, models, and methodologies (&#147;<B>Trade Secrets</B>&#148;); (vi) rights of publicity and privacy, (vii)&nbsp;moral rights and rights of attribution and integrity; (viii)&nbsp;social media addresses and accounts and usernames, account
names and identifiers; and (ix)&nbsp;all applications and registrations, and any renewals, extensions and reversions, of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intended Tax Treatment</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Period</B>&#148; has the meaning specified in Section&nbsp;7.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investment Company Act</B>&#148; means the Investment Company Act of 1940. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IRS</B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>JOBS Act</B>&#148; has the meaning specified in Section&nbsp;6.07(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Knowledge</B>&#148; or &#147;<B>to the knowledge</B>&#148; has the meaning specified in Section&nbsp;1.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Labor Organization</B>&#148; has the meaning specified in Section&nbsp;4.14(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any statute, law, ordinance, rule, regulation or Governmental Order, in each case, of any Governmental Authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Leased Real Property</B>&#148; means all real property leased, licensed, subleased or otherwise used or occupied by the Company
or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Legal Proceedings</B>&#148; has the meaning specified in Section&nbsp;4.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Transmittal</B>&#148; has the meaning specified in Section&nbsp;3.04(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licenses</B>&#148; means any approvals, authorizations, consents, licenses, registrations, permits or certificates of a Governmental
Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; means all liens, mortgages, deeds of trust, pledges, hypothecations, encumbrances, licenses, security
interests, options, restrictions, claims or other liens of any kind whether consensual, statutory or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Local
Counsels</B>&#148; has the meaning specified in Section&nbsp;12.18(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Contracts</B>&#148; has the meaning specified in
Section&nbsp;4.12(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Permits</B>&#148; has the meaning specified in Section&nbsp;4.18. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Mergers</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Modification in Recommendation</B>&#148; has the meaning specified in Section&nbsp;9.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Modification in Recommendation Notice</B>&#148; has the meaning specified in Section&nbsp;9.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Modification in Recommendation Notice Period</B>&#148; has the meaning specified in Section&nbsp;9.02(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Board of Directors</B>&#148; has the meaning specified in Section&nbsp;9.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Class</B><B></B><B>&nbsp;A Shares</B>&#148; means Class&nbsp;A ordinary shares, nominal value CHF 0.01 per share of New
Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Equity Incentive Plan</B>&#148; has the meaning specified in Section&nbsp;9.07. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Interests Consideration</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Organizational Documents</B>&#148; has the meaning specified in Section&nbsp;2.02(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Share Capital Increase</B>&#148; has the meaning specified in Section&nbsp;2.02(b)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Shares</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent <FONT STYLE="white-space:nowrap">Squeeze-Out</FONT> Shares</B>&#148; means, if applicable, a number of common shares of
CHF 0.01 nominal value of New Parent to be issued in the Third Merger to Company Shareholders that do not exchange Company Share Capital for New Parent Shares pursuant to the Company Share Contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Parent Warrant</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Option Exchange Ratio</B>&#148; shall have the meaning as set forth in Schedule 2.01 of the Company Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Owned Real Property</B>&#148; means all real property owned in fee simple by the Company or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; have the meaning specified in the
Preamble hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Liens</B>&#148; means (i)&nbsp;mechanic&#146;s, materialmen&#146;s and similar Liens arising in the
ordinary course of business with respect to any amounts (A)&nbsp;not yet due and payable or which are being contested in good faith through appropriate proceedings and (B)&nbsp;for which adequate accruals or reserves have been established in
accordance with IFRS or GAAP, as applicable, (ii)&nbsp;Liens for Taxes (A)&nbsp;not yet due and payable or which are being contested in good faith through appropriate proceedings and (B)&nbsp;for which adequate accruals or reserves have been
established in accordance with IFRS or GAAP, as applicable, (iii)&nbsp;defects or imperfections of title, easements, encroachments, covenants, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> conditions,
matters that would be apparent from a physical inspection or current, accurate survey of such real property, restrictions and other similar charges or encumbrances that do not, individually or in the aggregate, materially impair the value or
materially interfere with the present use of the Realty, (iv)&nbsp;with respect to any Leased Real Property, (A)&nbsp;the interests and rights of the respective lessors with respect thereto, including any Lien on the lessor&#146;s interest therein
and statutory landlord liens securing payments not yet due and (B)&nbsp;any Liens encumbering the underlying fee title of the real property of which the Leased Real Property is a part, (v)&nbsp;zoning, building, entitlement and other land use and
environmental regulations promulgated by any Governmental Authority that do not, individually or in the aggregate, materially interfere with the current use of, or materially impair the value of, the Realty,
<FONT STYLE="white-space:nowrap">(vi)&nbsp;non-exclusive</FONT> licenses of Intellectual Property entered into in the ordinary course of business consistent with past practice, (vii)&nbsp;ordinary course purchase money Liens and Liens securing
rental payments under operating or capital lease arrangements for amounts not yet due or payable, (viii)&nbsp;reversionary rights in favor of landlords under any real property leases with respect to any of the buildings or other improvements owned
by the Company or any of its Subsidiaries and (ix)&nbsp;other Liens that do not materially and adversely affect (x)&nbsp;the value, use or operation of the asset subject thereto or (y)&nbsp;the operation of the businesses of the Company or any of
its Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means any individual, firm, corporation, partnership, limited liability
company, incorporated or unincorporated association, joint venture, joint stock company, Governmental Authority or instrumentality or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Investment</B>&#148; means the purchase of any PIPE Shares pursuant to the Subscription Agreements and the purchase of any EBAC
Class&nbsp;A Common Stock, warrants or other securities pursuant to any Additional Subscription Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Investment
Amount</B>&#148; means the aggregate proceeds actually received by EBAC prior to or substantially concurrently with the Acquisition Closing for the shares in the PIPE Investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Investors</B>&#148; has the meaning specified in the Recitals hereto and shall include, for the avoidance of doubt, investors
that are party to any Additional Subscription Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Placement Agents</B>&#148; means Credit Suisse Securities (USA)
LLC, Kempen&nbsp;&amp; Co. USA, Inc., BofA Securities, Inc., SVB Securities LLC and Arctica Finance hf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Placement Agent
Engagement Letters</B>&#148; means, collectively, (1)&nbsp;that certain letter agreement dated as of June&nbsp;3, 2022, by and between EBAC and Credit Suisse Securities (USA) LLC, (2)&nbsp;that certain letter agreement dated as of June&nbsp;3, 2022,
by and among, among others, EBAC and Kempen&nbsp;&amp; Co. USA, Inc., (3) that certain letter agreement dated as of June&nbsp;3, 2022, by and between EBAC and BofA Securities, Inc., (4) that certain consent letter dated as of June&nbsp;3, 2022, by
and between EBAC and BofA Securities, Inc., (5) that certain letter agreement dated as of June&nbsp;3, 2022, by and between EBAC and SVB Securities LLC and (6)&nbsp;that certain letter agreement dated as of July&nbsp;15, 2022, by and between EBAC
and Arctica Finance hf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Shares</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy and Cybersecurity Requirements</B>&#148; has the meaning specified in Section&nbsp;4.22(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Products</B>&#148; means any products or services under development, developed,
manufactured, performed, <FONT STYLE="white-space:nowrap">out-licensed,</FONT> sold, distributed other otherwise made available by or on behalf of the Company or any of the Company&#146;s Subsidiaries, from which the Company or any of the
Company&#146;s Subsidiaries has derived previously, is currently deriving or is scheduled or intends to derive, revenue from the sale or provision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prospectus</B>&#148; has the meaning specified in Section&nbsp;12.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Proxy Statement</B>&#148; means the proxy statement filed by EBAC as part of the Registration Statement with respect to the EBAC
Shareholders&#146; Meeting for the purpose of soliciting proxies from EBAC Shareholders to approve the Transaction Proposals (which shall also provide the EBAC Shareholders with the opportunity to redeem their shares of EBAC Common Stock in
conjunction with a stockholder vote on the Transactions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Q2 2022 Financial Statements</B>&#148; has the meaning specified in
Section&nbsp;4.08(a)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Q3 2022 Financial Statements</B>&#148; has the meaning specified in Section&nbsp;7.03(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Realty</B>&#148; means, collectively, the Owned Real Property and the Leased Real Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; has the meaning specified in Section&nbsp;9.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctioned Country</B>&#148; means at any time, a country or territory which is itself the subject or target of any country-wide or
territory-wide Sanctions Laws (at the time of this Agreement, the Crimea region, Cuba, Iran, Russia, North Korea and Syria). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctioned Person</B>&#148; means (i)&nbsp;any Person identified in any sanctions-related list of designated Persons maintained by
(a)&nbsp;the United States (including the Department of the Treasury&#146;s Office of Foreign Assets Control or the United States Department of State); (b) the United Kingdom; (c)&nbsp;any committee of the United Nations Security Council;
(d)&nbsp;the European Union or any European Union member state; or (e)&nbsp;any other jurisdiction where the Company or any of its Subsidiaries operates; (ii)&nbsp;any Person located, organized, or resident in a Sanctioned Country; (iii)&nbsp;a
Governmental Authority or government instrumentality of any Sanctioned Country or Venezuela; and (iv)&nbsp;any Person directly or indirectly owned fifty percent (50%) or more, or controlled by, or acting for the benefit or on behalf of, a Person or
Persons described in clauses (i)&nbsp;or (ii), either individually or in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctions Laws</B>&#148; means any
trade, economic or financial sanctions Laws administered, enacted or enforced from time to time by (i)&nbsp;the United States (including the Department of the Treasury&#146;s Office of Foreign Assets Control or the United States Department of
State)&nbsp;(ii) the European Union or any European Union member state, (iii)&nbsp;the United Nations, (iv)&nbsp;the United Kingdom or (v)&nbsp;any other jurisdiction where the Company or any of its Subsidiaries operates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sarbanes-Oxley Act</B>&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Earnout Achievement Date</B>&#148; has the meaning set forth in Section&nbsp;3.05(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Merger</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Merger Effective Time</B>&#148; means the time at which the Second Merger becomes effective pursuant to the filing and
registration of the Plan of Merger with the Cayman Registrar of Companies or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Service Provider</B>&#148; means, as of any relevant time, any director, officer, employee, independent contractor or consultant of
the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor</B>&#148; means LSP Sponsor EBAC B.V. a Dutch limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Incentive Shares</B>&#148; has the meaning specified in Section&nbsp;2.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Nominee</B>&#148; has the meaning specified in Section&nbsp;9.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Support Agreement</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Staleness Date</B>&#148; has the meaning specified in Section&nbsp;7.03(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Stock Exchange</B>&#148; means the Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subscription Agreements</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means, with respect to a Person, a corporation or other entity of which (i)&nbsp;more than fifty percent (50%)
of the voting power of the equity securities or equity interests is owned, directly or indirectly, by such Person or (ii)&nbsp;such Person otherwise directs the management policies or corporate direction whether by equity ownership, contract or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Surviving EBAC Shares</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Surviving EBAC Warrants</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Swiss Code of Obligations</B>&#148; means the Swiss Federal Act on the Amendment of the Swiss Civil Code of 30&nbsp;March 1911. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Grant</B>&#148; means any Tax exemption, Tax holiday, reduced Tax rate or other Tax benefit granted by a Governmental Authority
with respect to the Company or any of its Subsidiaries that is not generally available without specific application therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Return</B>&#148; means any return, declaration, report, statement, information statement or other document filed or required to
be filed with any Governmental Authority with respect to Taxes, including any claims for refunds of Taxes, any information returns and any schedules, attachments, amendments or supplements of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Sharing Agreement</B>&#148; means any agreement or arrangement (including any provision of a Contract) pursuant to which a Person
is or may be obligated to indemnify another Person for, or otherwise pay, any Tax of or imposed on any Person, or indemnify, or pay over to, another Person any amount determined by reference to actual or deemed Tax benefits, Tax assets, or Tax
savings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Taxes</B>&#148; means any and all U.S. federal, state, and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxes, including all income, gross receipts, license, payroll, recapture, net worth, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, ad valorem, value added, ad valorem,
inventory, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum,
estimated, and other taxes and all governmental charges, duties, fees, levies, and other similar charges in the nature of a tax, including any interest, penalty, or addition thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Terminating Company Breach</B>&#148; has the meaning specified in
Section&nbsp;11.01(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Terminating EBAC Breach</B>&#148; has the meaning specified in Section&nbsp;11.01(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Earnout Achievement Date</B>&#148; has the meaning set forth in Section&nbsp;3.05(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Merger</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Merger Effective Time</B>&#148; means the time at which the Third Merger becomes effective pursuant to the filing and
registration of the Plan of Merger in accordance with the provisions of the Swiss Code of Obligations or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trade Secrets</B>&#148; has the meaning specified in the definition of &#147;<B>Intellectual Property</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any day on which New Parent Shares are actually traded on the principal securities exchange or securities
market on which New Parent Shares are then traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Expenses</B>&#148; means the EBAC Transaction Expenses and the
Company Transaction Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Proposals</B>&#148; has the meaning specified in Section&nbsp;9.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transactions</B>&#148; has the meaning specified in the Recitals hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Tax</B>&#148; means any direct or indirect transfer (including real estate transfer), sales, value added, use, stamp,
documentary, registration, conveyance, recording, or other similar Taxes payable as a result of the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Treasury Regulations</B>&#148; means the regulations promulgated under the Code by the United States Department of the Treasury
(whether in final, proposed or temporary form). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Account</B>&#148; has the meaning specified in Section&nbsp;12.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Agreement</B>&#148; has the meaning specified in Section&nbsp;6.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trustee</B>&#148; has the meaning specified in Section&nbsp;6.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Vischer</B>&#148; has the meaning specified in Section&nbsp;12.18(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>VWAP</B>&#148; means, for any security as of any day or <FONT STYLE="white-space:nowrap">multi-day</FONT> period, the dollar
volume-weighted average price for such security on the principal securities exchange or securities market on which such security is then traded during the period beginning at 9:30:01 a.m., New York time on such day or the first day of such <FONT
STYLE="white-space:nowrap">multi-day</FONT> period (as applicable), and ending at 4:00:00 p.m., New York time on such day or the last day of such <FONT STYLE="white-space:nowrap">multi-day</FONT> period (as applicable), as reported by Bloomberg
through its &#147;HP&#148; function (set to weighted average) or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time on such day or the first day of
such <FONT STYLE="white-space:nowrap">multi-day</FONT> period (as applicable), and ending at 4:00:00 p.m., New York time on such day or the last day of such <FONT STYLE="white-space:nowrap">multi-day</FONT> period (as applicable), as reported by
Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as
reported by OTC Markets Group Inc. during such day or <FONT STYLE="white-space:nowrap">multi-day</FONT> period (as applicable). If the VWAP cannot be calculated for such security for such day or <FONT STYLE="white-space:nowrap">multi-day</FONT>
period (as applicable) on any of the foregoing bases, the VWAP of such security shall be the fair market value per share at the end of such day or <FONT STYLE="white-space:nowrap">multi-day</FONT> period (as applicable) as reasonably determined by
the Board of Directors of New Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant Assumption Agreement</B>&#148; means a Warrant Assignment and Assumption
Agreement to be entered into among EBAC, New Parent and the Exchange Agent, in a form to be agreed upon among EBAC, New Parent, the Exchange Agent and the Company, to be effective upon the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant Conversion</B>&#148; means the right of the EBAC Shareholders to receive a New Parent Warrant in exchange for EBAC Warrants
to be transferred immediately to holders of EBAC Warrants pursuant to the Warrant Assumption Agreement, to be effective upon the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Working Capital Loans</B>&#148; means any loan made to EBAC by any of the Sponsor, an Affiliate of the Sponsor, or any of EBAC&#146;s
officers or directors, and evidenced by a promissory note, for the purpose of financing costs incurred in connection with a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_2"></A>Section&nbsp;1.02. <I>Construction.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless the context of this Agreement otherwise requires, (i)&nbsp;words of any gender include each other gender; (ii)&nbsp;words using the
singular or plural number also include the plural or singular number, respectively; (iii)&nbsp;the terms &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;hereto&#148; and derivative or similar words refer to this entire Agreement;
(iv)&nbsp;the terms &#147;Article&#148; or &#147;Section&#148; refer to the specified Article or Section of this Agreement; (v)&nbsp;the word &#147;including&#148; shall mean &#147;including, without limitation&#148;; and (vi)&nbsp;the word
&#147;or&#148; shall be disjunctive but not exclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless the context of this Agreement otherwise requires, references to
statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All accounting terms used herein and not expressly defined herein shall have the meanings given to them under IFRS or GAAP, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The term &#147;actual fraud&#148; means, with respect to a party to this Agreement, any actual and intentional fraud with respect to
the making of the representations and warranties pursuant to Article 4, Article 5 or Article 6 (as applicable); <I>provided</I> that such actual and intentional fraud of such Person shall only be deemed to exist if any of the individuals included on
Section&nbsp;1.03 of the Company Disclosure Letter (in the case of the Company) or Section&nbsp;1.03 of the EBAC Disclosure Letter (in the case of EBAC) had knowledge that a representation or warranty made by such Person pursuant to, in the case of
the Company, Article 4 and Article 5 as qualified by the Company Disclosure Letter, or, in the case of EBAC, Article 6 as qualified by the EBAC Disclosure Letter, were false when made, with the intention that any of the other Parties to this
Agreement rely thereon to its detriment, and such other Party actually did rely thereon to its detriment and incurred a loss as a result of such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as otherwise specifically provided herein, to the extent this Agreement refers to information or documents having been &#147;made
available&#148; (or words of similar import) by or on behalf of one or more Parties to another Party hereto, such obligation shall be deemed satisfied if (i)&nbsp;such one or more Parties hereto or a Person acting on its behalf made such information
or document available (or delivered or provided such information or document) in the electronic data rooms hosted by Intralinks, Inc. and labeled &#147;Oculis&#148; prior to 6:00 p.m. Eastern time on the date that is one Business Day prior to the
date of this Agreement or (ii)&nbsp;such information or document is publicly available prior to 6:00 p.m. Eastern time on the date that is one Business Day prior to the date of this Agreement in the Electronic Data Gathering, Analysis and Retrieval
(EDGAR) database of the SEC and not subject to any redactions or omissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_3"></A>Section&nbsp;1.03.
<I>Knowledge</I>. As used herein, (i)&nbsp;the word &#147;knowledge&#148; or the phrase &#147;to the knowledge&#148; of the Company shall mean the knowledge of the individuals identified on Section&nbsp;1.03 of the Company Disclosure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Letter, and (ii)&nbsp;the word &#147;knowledge&#148; or the phrase &#147;to the knowledge&#148; of EBAC shall mean the knowledge of the individuals identified on Section&nbsp;1.03 of the EBAC
Disclosure Letter. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>THE</SMALL> M<SMALL>ERGERS</SMALL>; S<SMALL>HARE</SMALL> C<SMALL>ONTRIBUTION</SMALL>; C<SMALL>LOSING</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_4"></A>Section&nbsp;2.01. <I>The Mergers; Exchange Agent Contribution; Contribution of Company Common Shares to New
Parent</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>The EBAC Mergers and Exchange Agent Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date
and at the First Merger Effective Time, Merger Sub 1 shall be merged with and into EBAC in the First Merger. Following the First Merger, the separate corporate existence of Merger Sub 1 shall cease and EBAC shall continue as the surviving company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Upon the terms and subject to the conditions set forth in this Agreement, as part of the First Merger, EBAC shall
deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date
and following the First Merger Effective Time but prior to the Second Merger Effective Time the Exchange Agent shall effect the Exchange Agent Contribution, and immediately thereafter shall perform the Exchange Agent Contribution Actions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date
and at the Second Merger Effective Time, which shall be approximately 30&nbsp;minutes after the First Merger Effective Time, EBAC shall be merged with and into Merger Sub 2 in the Second Merger. Following the Second Merger, the separate corporate
existence of EBAC shall cease and Merger Sub 2 shall continue as the surviving company. Following the consummation of the EBAC Mergers, all New Parent Shares shall be of the same class of shares and consist only of New Parent Class&nbsp;A Shares.
Following the Acquisition Closing, Merger Sub 2 shall be liquidated, and its assets shall be distributed in the framework of the liquidation procedure to New Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Share Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As soon as reasonably practicable following the date hereof, the Company shall cause the Company Shareholders to sign an
exchange notice, pursuant to which such Company Shareholders agree, subject to the substantially concurrent satisfaction or waiver of all of the conditions set forth in Article 10 of this Agreement, to transfer, assign and surrender to the Exchange
Agent all Company Share Capital held by such Company Shareholder free and clear of all Liens (other than general restrictions on transfer under applicable securities Laws or the articles of association of the Company), in exchange for New Parent
Shares on the terms, and subject to the conditions set forth in this Agreement, including the Company Share Contribution ratios set forth in Schedule 2.01 of the Company Disclosure Letter. All such transferring Company Shareholders authorize the
Exchange Agent as its lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to do any and all things and to take any and all actions reasonably necessary to effect the exchange of Company Share
Capital into New Parent Shares. All such transferring Company Shareholders shall undertake all such further steps, including executing an ad hoc contribution agreement, as are necessary to effect the contribution of the full legal and beneficial
ownership of the applicable Company Share Capital to New Parent (and, in exchange, New Parent shall issue New Parent Shares to Company Shareholders, the &#147;<B>Company Share Contribution</B>&#148;) (the number of New Parent Shares so issued, the
&#147;<B>Company Consideration</B>&#148;). The aggregate value of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Company Consideration shall be deemed to be equal to the Company Equity Value, and shall be subscribed for by the Company Shareholders at a value of $10.00 per New Parent Share. For the avoidance
of doubt, any New Parent Shares to be issued as Company Consideration to the Company Shareholders shall be of the same class, with equal rights and privileges, as any New Parent Shares to be issued as part of the New Parent Interests Consideration
to the EBAC Shareholders and PIPE Investors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) At approximately 10:00 am ET on the Acquisition Closing Date, such
transferring Company Shareholders and New Parent shall consummate the Company Share Contribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>The Third Merger</U>. Upon the
terms and subject to the conditions set forth in this Agreement and as an integrated part of the Transactions, approximately thirty (30)&nbsp;days after the Acquisition Closing Date and at the Third Merger Effective Time, the Company shall be merged
with and into Merger Sub 3 in the Third Merger. Following the Third Merger, the separate corporate existence of the Company shall cease, and Merger Sub 3 shall continue as the surviving company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_5"></A>Section&nbsp;2.02. <I>Effective Times</I>; <I>Sponsor Forfeitur</I>e; <I>Closings</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>First Merger and Second Merger</U>. Subject to the satisfaction or waiver of all of the conditions set forth in Article 10 of this
Agreement, and provided this Agreement has not theretofore been terminated pursuant to its terms, on the Acquisition Closing Date, the Parties shall cause the First Merger and Second Merger to be consummated by filing with the Cayman Registrar of
Companies a Plan of Merger (the &#147;<B>Cayman Plan of Merger</B>&#148;), duly executed and completed in accordance with the relevant provisions of the Cayman Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>First Merger Capital Increase by New Parent</U>. New Parent shall undertake all corporate steps required to increase its share capital
to reflect the issuance of the New Parent Shares to be transferred to (i)&nbsp;the Exchange Agent (held solely on behalf of the holders of Surviving EBAC Shares, including the PIPE Investors) in connection with the distribution of New Parent Shares
as part of the New Parents Interests Consideration to such holders following the Exchange Agent Contribution in accordance with the Exchange Agent Contribution Actions performed prior to the consummation of the transactions contemplated by the
Second Merger and (ii)&nbsp;the Company Shareholders in connection with the Company Share Contribution (together, clauses (i)&nbsp;and (ii), the &#147;<B>New Parent Share Capital Increase</B>&#148;) and to register on the Acquisition Closing Date in
one single application the New Parent Share Capital Increase in the Commercial Register of the Canton of Zug, Switzerland (&#147;<B>Commercial Register Zug</B>&#148;), which registration shall be made using the express procedure allowing for <FONT
STYLE="white-space:nowrap">same-day</FONT> registration (<I>Hyperexpressverfahren</I>). Upon registration of the New Parent Share Capital Increase in the Commercial Register Zug pursuant to this Section&nbsp;2.02(b), New Parent shall issue to
(x)&nbsp;the Exchange Agent, New Parent Shares to be distributed to holders of Surviving EBAC Shares following the consummation of the Exchange Agent Contribution and in accordance with the Exchange Agent Contribution Actions performed prior to the
consummation of the transactions contemplated by the Second Merger and (y)&nbsp;to the Company Shareholders, the New Parent Shares constituting the Company Consideration for the Company Share Contribution on the terms, and subject to the conditions
of, this Agreement and the Ancillary Agreements. Unless otherwise agreed by New Parent and the relevant recipient of the New Parent Shares, all New Parent Shares shall be uncertificated, with record ownership reflected on the books and records of
New Parent. Immediately following the New Parent Share Capital Increase, the Exchange Agent and the Company Shareholders shall hold all New Parent Shares, with the exception of any New Parent Shares held by New Parent as treasury shares, and
immediately thereafter, the New Parent Shares as part of the New Parent Interests Consideration shall be delivered by the Exchange Agent to the EBAC Shareholders, including the PIPE Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Sponsor Forfeiture Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) All of the <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares are hereby forfeited for no consideration,
contingent upon the consummation of the Acquisition Closing; <I>provided</I>, that the number of <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
forfeited pursuant to this <U>Section</U><U></U><U>&nbsp;2.02(c)(i)</U> is reduced by the number of <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares that the Sponsor or its
affiliates has agreed to transfer to any EBAC Shareholder in connection with such EBAC Shareholder&#146;s execution of a <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement (the &#147;<B>Sponsor Incentive Shares</B>&#148;);
<I>provided</I>, <I>further</I>, that the number of Sponsor Incentive Shares granted to any EBAC Shareholder does not exceed ten percent (10%) of the number of shares of EBAC Class&nbsp;A Common Stock owned or controlled by such EBAC Shareholder as
of the date of the appliable <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding
anything to the contrary herein, if, as of the Acquisition Closing Date, (A)&nbsp;the amount of cash or cash equivalents available in the Trust Account following the EBAC Shareholders&#146; Meeting (after deducting the amount required to satisfy the
EBAC Share Redemption Amount but before payment of any Company Transaction Expenses or EBAC Transaction Expenses); <I>plus </I>(B)&nbsp;the PIPE Investment Amount actually received by New Parent (or other financing, including through a convertible
loan, in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing from a PIPE Investor or other investor that in either case has been introduced to the Company following the date hereof by the
Sponsor or its affiliates as set forth on Section&nbsp;2.02(c)(i) of the EBAC Disclosure Letter (which, subject to the Company&#146;s prior approval (not to be unreasonably withheld, conditioned or delayed), schedule EBAC may update from time to
time after the date hereof) (collectively, the &#147;<B>Closing Trust Proceeds</B>&#148;) is less than $25,500,000, then a number of Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares equal to the Additional <FONT
STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Forfeit Amount shall be forfeited for no consideration concurrently with the consummation of the Company Share Contribution; <I>provided</I>, that the number of Additional <FONT
STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares forfeited pursuant to this <U>Section</U><U></U><U>&nbsp;2.02(c)(ii)</U> shall be reduced by the number of Additional <FONT STYLE="white-space:nowrap">At-Risk</FONT> Sponsor Shares to be
transferred by the Sponsor or its affiliates (such transfer as reasonably evidenced to the Company) to any EBAC Shareholder in connection with a <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement or similar arrangement executed after
the date of this Agreement (the &#147;<B>Additional Sponsor Incentive Shares</B>&#148;); <I>provided</I>, <I>further</I>, that the number of Additional Sponsor Incentive Shares that may be granted to any EBAC Shareholder shall not exceed ten percent
(10%) of the number of shares of EBAC Class&nbsp;A Common Stock owned or controlled by such EBAC Shareholder as of the date of such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Closings</U>. On the next Business Day (unless otherwise agreed between EBAC and the Company) following the date which is three
(3)&nbsp;Business Days after the date on which all conditions set forth in Article 10 shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Acquisition Closing (as defined below), but subject
to the satisfaction or waiver thereof) or such other time and place as EBAC and the Company may mutually agree in writing, the closing of the First Merger, Second Merger and Company Share Contribution (collectively, the &#147;<B>Acquisition
Closing</B>&#148;) shall take place electronically through the exchange of documents via email. The date on which the Acquisition Closing is completed is referred to herein as the &#147;<B>Acquisition Closing Date</B>.&#148; The New Parent Share
Capital Increase shall be made contemporaneously with the filing of the Cayman Plan of Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Effects of the EBAC Mergers and New
Parent Capital Increase</U>. The EBAC Mergers shall have the effects set forth in this Agreement and the Cayman Companies Act, and the New Parent Share Capital Increase shall have the effect set forth in the Swiss Code of Obligations. Without
limiting the generality of the foregoing and subject thereto, by virtue of the (i)&nbsp;First Merger and without further act or deed, at the First Merger Effective Time, all of the property, rights, privileges, powers and franchises of Merger Sub 1
shall vest in EBAC, as the surviving company of the First Merger, and all of the debts, liabilities and duties of Merger Sub 1 shall become the debts, liabilities and duties of EBAC and (ii)&nbsp;Second Merger and without further act or deed, at the
Second Merger Effective Time, all of the property, rights, privileges, powers and franchises of EBAC shall vest in Merger Sub 2, as the surviving company of the First Merger, and all of the debts, liabilities and duties of EBAC shall become the
debts, liabilities and duties of Merger Sub 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Articles of Association of New Parent</U>. In connection with the Acquisition
Transactions, on the Acquisition Closing Date, New Parent will take all requisite action to adopt the articles of association (the &#147;<B>New</B> <B>Parent Organizational Documents</B>&#148;) amended in accordance with their terms and Swiss Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Directors and Officers of the Surviving Company</U>. Persons constituting the directors and officers of Merger Sub 2 prior to the
Second Merger Effective Time shall continue to be the directors and officers of Merger Sub 2 following the consummation of the EBAC Mergers until the earlier of their resignation or removal or until their respective successors are duly appointed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_6"></A>Section&nbsp;2.03. <I>Closing Deliverables.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Acquisition Closing, the Company will deliver or cause to be delivered: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to EBAC, a certificate signed by an executive officer of the Company, dated as of the Acquisition Closing Date, certifying
that, to the knowledge and belief of such officer, the conditions specified in Section&nbsp;10.02(a), Section&nbsp;10.02(b) and Section&nbsp;10.02(c) have been fulfilled; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to EBAC, the Registration Rights Agreement, duly executed by certain Affiliates of the Company party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Acquisition Closing, EBAC will deliver or cause to be delivered: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to the Company, a certificate signed by an officer of EBAC, dated as of the Acquisition Closing Date, certifying that, to
the knowledge and belief of such officer, the conditions specified in Section&nbsp;10.03(a) through Section&nbsp;10.03(d) have been fulfilled; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to the Company, the Registration Rights Agreement, duly executed by the EBAC Class&nbsp;B Holders and New Parent; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to the Company, the written resignations of all of the directors and officers of EBAC and New Parent, effective as of the
Second Merger Effective Time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E<SMALL>FFECTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> M<SMALL>ERGER</SMALL> <SMALL>ON</SMALL> EBAC S<SMALL>ECURITIES</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_7"></A>Section&nbsp;3.01. <I>Conversion of Securities.</I> Treatment of Securities of EBAC in the First Merger. At the
First Merger Effective Time, by virtue of the Merger and without any action on the part of EBAC, Merger Sub 1, New Parent or the holder of any shares of capital stock of any of the foregoing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>EBAC Units</I>. Each EBAC Unit outstanding immediately prior to the First Merger Effective Time shall be automatically detached and the
holder thereof shall be deemed to hold one share of EBAC Class&nbsp;A Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of an EBAC Warrant in accordance with the terms of the applicable EBAC Unit, which underlying shares of EBAC
Class&nbsp;A Common Stock and EBAC Warrants shall be adjusted in accordance with the applicable terms of this Section&nbsp;3.01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<I>EBAC Capital Stock</I>. Immediately following the separation of each EBAC Unit in accordance with Section&nbsp;3.01 and in connection with the First Merger, the shares of EBAC Common Stock shall be automatically converted into the Surviving EBAC
Shares, and in connection therewith, EBAC shall deposit, or cause to be deposited, each Surviving EBAC Share with the Exchange Agent (solely on behalf of the EBAC Shareholders, including the PIPE Investors). As of the First Merger Effective Time,
each EBAC Shareholder shall cease to have any other rights in and to EBAC and each share of EBAC Class&nbsp;A Common Stock issued and outstanding immediately prior to the First Merger Effective Time shall automatically be cancelled and cease to
exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Exchange of EBAC Warrants</I>. Each EBAC Warrant outstanding immediately prior to the First Merger Effective Time shall, at
the First Merger Effective Time, be automatically converted into the Surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EBAC Warrants and such Surviving EBAC Warrants shall be deposited with the Exchange Agent (solely on behalf of the holders of EBAC Warrants) in exchange for the right of each holder of EBAC
Warrants to receive New Parent Warrants pursuant to the Warrant Conversion on the terms, and subject to the conditions of, the Warrant Assumption Agreement. Each EBAC Warrant outstanding immediately prior to the First Merger Effective Time shall, at
the First Merger Effective Time, cease to be a warrant with respect to EBAC Common Stock and shall be assumed by New Parent pursuant to the Warrant Assumption Agreement on substantially the same terms as were in effect immediately prior to the
Merger Effective Time under the terms of the EBAC Warrant Agreement (including any repurchase rights and cashless exercise provisions). EBAC and New Parent shall take all lawful action to effect the aforesaid provisions of this Section&nbsp;3.01,
including entering into the Warrant Assumption Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>New Parent Shares Held by EBAC</I>. The New Parent Shares held by EBAC
shall be cancelled for no consideration immediately prior to the implementation of the Second Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>EBAC Treasury Stock</I>.
Notwithstanding clause (a)&nbsp;above or any other provision of this Agreement to the contrary, if there are any shares of EBAC Common Stock that are owned by EBAC as treasury stock or any EBAC Common Stock owned by any direct or indirect Subsidiary
of EBAC immediately prior to the First Merger Effective Time, such EBAC Common Stock shall be cancelled and shall cease to exist without any conversion thereof or payment or other consideration therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>EBAC Redeeming Shares</I>. Notwithstanding clause (a)&nbsp;above or any other provision of this Agreement to the contrary, if there are
any shares of EBAC Common Stock that are required to be redeemed pursuant to the EBAC Share Redemption, such EBAC Common Stock shall not be exchanged pursuant to clause (a)&nbsp;above but shall, immediately prior to the First Merger Effective Time,
be cancelled and shall cease to exist and shall thereafter be redeemed for the consideration, and on the terms and subject to the conditions and limitations, set forth in this Agreement, EBAC&#146;s Governing Documents, the Trust Agreement and the
Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_8"></A>Section&nbsp;3.02. <I>Equitable Adjustments</I>. If, between the date of this Agreement and
the First Merger Effective Time, the outstanding shares of any class or series of Company Share Capital or EBAC Common Stock shall have been changed into a different number of shares or a different class, by reason of any stock dividend,
subdivision, reclassification, recapitalization, split, combination or exchange of shares, or any similar event shall have occurred, then, without duplication, any number, value (including dollar value) or amount contained herein which is based upon
the number of shares of any class or series of Company Share Capital or EBAC Common Stock will be appropriately adjusted to provide to the holders of Company Share Capital and the holders of EBAC Common Stock the same economic effect as contemplated
by this Agreement; <I>provided</I>, <I>however</I>, that this Section&nbsp;3.02 shall not be construed (i)&nbsp;to permit any party to take any action with respect to its respective securities that is prohibited by the terms and conditions of this
Agreement or would reasonably be expected to prevent, impair or impede the Intended Tax Treatment or (ii)&nbsp;to apply to any adjustment made with respect to the New Parent Warrants in the Warrant Conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_9"></A>Section&nbsp;3.03. <I>Delivery of Shares.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to the First Merger Effective Time, New Parent, the Company and EBAC shall, with the Company&#146;s prior consent, (i)&nbsp;appoint
a Person authorized to act as exchange agent in connection with the Transactions, which Person shall be selected by New Parent, the Company and EBAC (the &#147;<B>Exchange Agent</B>&#148;) and shall act on behalf of the Company and the Company
Shareholders and on behalf of EBAC and holders of the Surviving EBAC Shares and Surviving EBAC Warrants, as the case may be, and (ii)&nbsp;enter into an exchange agent agreement with the Exchange Agent reasonably acceptable to New Parent, the
Company and EBAC for the purpose of, among other things, (A)&nbsp;contributing the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in exchange for New Parent Shares and New Parent Warrants, (B)&nbsp;effecting the distribution of such
New Parent Shares and New Parent Warrants to the holders of Surviving EBAC Shares (including the PIPE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investors) and Surviving EBAC Warrants, (C) exchanging the Company Share Capital for New Parent Shares and (D)&nbsp;effecting the distribution of such New Parent Shares to the Company
Shareholders, all in accordance with this Agreement (the &#147;<B>Exchange Agent Agreement</B>&#148;). New Parent Shares deposited with the Exchange Agent shall be referred to as the &#147;<B>Exchange Fund</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As soon as reasonably practicable after the registration of the New Parent Share Capital Increase with the Commercial Register Zug, the
Exchange Agent shall mail or otherwise deliver to (i)&nbsp;each holder of record of EBAC Common Stock who has the right to receive the New Parent Shares delivered by the Exchange Agent as part of the New Parent Interests Consideration hereunder and
(ii)&nbsp;each Company Shareholder who has the right to receive the New Parent Shares delivered by the Exchange Agent as part of the Company Consideration hereunder, a letter of transmittal in customary form to be approved by New Parent, the Company
and EBAC (such approval not to be unreasonably withheld, conditioned, or delayed) prior to the Acquisition Closing (the &#147;<B>Letter of Transmittal</B>&#148;), which shall be in such form and have such other customary provisions as New Parent,
the Company and EBAC may reasonably specify. In the event a holder of EBAC Common Stock or a Company Shareholder does not deliver to the Exchange Agent a duly executed and completed Letter of Transmittal, where applicable, such Person shall not be
entitled to receive such uncertificated New Parent Shares as part of the New Parent Interests Consideration unless and until such Person delivers a duly executed and completed Letter of Transmittal, as applicable, to the Exchange Agent. Each
uncertificated share of EBAC Common Stock (and each resulting Surviving EBAC Share) or uncertificated share of Company Share Capital represents only the right to receive, upon compliance with these requirements, the New Parent Shares as part of the
New Parent Interests Consideration or as part of the Company Consideration in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If applicable, upon
receipt of a Letter of Transmittal duly, completely and validly executed in accordance with the instructions thereto, and such other documents as may reasonably be required by New Parent, the holder of such EBAC Common Stock (and resulting Surviving
EBAC Shares) or the Company Shareholder shall be entitled to receive, pursuant to the terms of this Agreement, in exchange therefor the New Parent Shares as part of the New Parent Interests Consideration or as part of the Company Consideration in
book-entry form. Until surrendered as contemplated by this Section&nbsp;3.03(c), each EBAC Common Stock (and resulting Surviving EBAC Shares) or share of Company Share Capital shall be deemed to represent only the right to receive upon such
surrender the New Parent Shares as part of the New Parent Interests Consideration or as part of the Company Consideration which the holders of Surviving EBAC Shares or the Company Shareholder were entitled to receive in respect of such shares
pursuant to the terms of this Article 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Immediately after registration of the New Parent Share Capital Increase with the Commercial
Register Zug, without any action of the EBAC Shareholders and the Company Shareholder, (x)&nbsp;New Parent, the Company and EBAC shall cause the Exchange Agent to deliver to the Depository Trust Company book-entry shares representing the New Parent
Shares to be issued as part of the New Parent Interests Consideration and as part of the Company Consideration and (y)&nbsp;all Surviving EBAC Warrants held by New Parent will be cancelled for no consideration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All New Parent Shares distributed by the Exchange Agent upon the surrender of EBAC Common Stock or shares of Company Share Capital in
accordance with the terms of this Article 3 shall be deemed to have been exchanged and paid in full satisfaction of all rights pertaining to the securities represented by such EBAC Common Stock (and resulting Surviving EBAC Shares) or shares of
Company Share Capital, as applicable, and there shall be no further registration of transfers on the stock transfer books of EBAC of the shares of EBAC Common Stock or the Company of the shares of Company Share Capital that were issued and
outstanding immediately prior to the First Merger Effective Time. From and after the First Merger Effective Time, holders of EBAC Common Stock shall cease to have any rights as shareholders of EBAC, except as provided in this Agreement or by
applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any portion of the Exchange Fund payable to EBAC Shareholders as part of the New Parent Interests Consideration that
remains unclaimed by the holders of EBAC Common Stock who were entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive a portion of the Exchange Fund in accordance with Section&nbsp;2.02 and this Section&nbsp;3.03 twelve (12)&nbsp;months after the Acquisition Closing Date shall be returned to New Parent
for no consideration and any such holder of EBAC Common Stock who has not received its portion of the Exchange Fund in accordance with Section&nbsp;2.02 and this Section&nbsp;3.03 prior to that time, shall thereafter look only to New Parent (subject
to abandoned property, escheat or other similar Laws), as general creditors thereof, for the delivery of the New Parent Shares to which they are entitled, subject to New Parent receiving a Letter of Transmittal duly, completely and validly executed
in accordance with the instructions thereto, and such other documents as may reasonably be required by New Parent. Notwithstanding the foregoing, New Parent shall not be liable to any holder or former holder of EBAC Common Stock for any amounts paid
to any Governmental Authority pursuant to applicable abandoned property, escheat or similar Laws. Any New Parent Shares remaining unclaimed by holders of EBAC Common Stock twenty-four (24)&nbsp;months after the Acquisition Closing Date shall become,
to the extent permitted by applicable Law, the property of New Parent free and clear of any claims or interest of any Person previously entitled thereto and New Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_10"></A>Section&nbsp;3.04. <I>Withholding</I>. Notwithstanding any other provision to this Agreement, each of the Parties,
their respective Affiliates, and the Exchange Agent, as applicable, shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld from the making
of such payments under applicable Law. In the event that any Person reasonably determines in good faith that any payment hereunder in subject to deduction or withholding (other than compensatory payments to employees of the Company or any of its
Subsidiaries), such Person shall use commercially reasonable efforts to (a)&nbsp;notify the Company as soon as is reasonably practicable after such determination and (b)&nbsp;cooperate with the Company and its shareholders to reduce or eliminate any
applicable deduction or withholding. To the extent that any amounts are so deducted and withheld, such deducted and withheld amounts shall be (i)&nbsp;timely remitted to the appropriate Governmental Authority and (ii)&nbsp;treated for all purposes
of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_11"></A>Section&nbsp;3.05. <I>Earn Out Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to and conditioned upon the occurrence of the Acquisition Closing, New Parent shall issue the Earnout Shares to the Company
Shareholders in accordance with the Company Share Contribution ratios set forth in Schedule 2.01 of the Company Disclosure Letter,which shall initially be unvested and shall be subject to the following transfer restrictions, vesting and forfeiture
provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If, at any time during the five (5)&nbsp;years following the Acquisition Closing Date (the
&#147;<B>Vesting Period</B>&#148;), the VWAP of New Parent Shares is greater than or equal to $15.00 for any twenty (20)&nbsp;Trading Days within a period of thirty (30)&nbsp;consecutive Trading Days (the date when the foregoing is first satisfied,
the &#147;<B>First Earnout Achievement Date</B>&#148;), then 1,500,000 Earnout Shares; <I>minus</I> any Earnout Options granted in replacement of vested Company Options pursuant to Section&nbsp;3.06, shall automatically become vested, shall no
longer be subject to forfeiture the transfer restrictions provided for in Section&nbsp;3.05(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If, at any time
during the Vesting Period, the VWAP of New Parent Shares is greater than or equal to $20.00 for any twenty (20)&nbsp;Trading Days within a period of thirty (30)&nbsp;consecutive Trading Days (the date when the foregoing is first satisfied, the
&#147;<B>Second Earnout Achievement Date</B>&#148;), then an additional 1,500,000 Earnout Shares; <I>minus</I> any Earnout Options granted in replacement of vested Company Options pursuant to Section&nbsp;3.06, shall automatically become vested,
shall no longer be subject to forfeiture the transfer restrictions provided for in Section&nbsp;3.05(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If, at any
time during the Vesting Period, the VWAP of New Parent Shares is greater than or equal to $25.00 for any twenty (20)&nbsp;Trading Days within a period of thirty (30)&nbsp;consecutive Trading Days (the date when the foregoing is first satisfied, the
&#147;<B>Third Earnout Achievement Date</B>&#148;), then the remaining 1,000,000 Earnout Shares; <I>minus</I> any Earnout Options granted in replacement of vested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Company Options pursuant to Section&nbsp;3.06, shall automatically become vested, shall no longer be subject to forfeiture the transfer restrictions provided for in Section&nbsp;3.05(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For the avoidance of doubt, the Earnout Shares shall be entitled to vesting described in Section&nbsp;3.05(a)(i), Section&nbsp;3.05(a)(ii)
and Section&nbsp;3.05(a)(iii), respectively, only upon the occurrence of the respective Earnout Achievement Date; <I>provided</I>, <I>however</I>, that each such date shall only occur once, if at all, and in no event shall such Company Shareholders
be collectively entitled to receive more than an aggregate of 4,000,000 shares of New Parent Shares as Earnout Shares; <I>minus</I> any Earnout Options granted in replacement of vested Company Options pursuant to Section&nbsp;3.06. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Earnout Shares that do not vest in accordance with Section&nbsp;3.05(i), Section&nbsp;3.05(ii) and Section&nbsp;3.05(iii) during the
Vesting Period shall automatically be forfeited by the Company Shareholders back to New Parent for no consideration and without any encumbrance, third party right, further right, obligation or liability of any kind or nature on the part of New
Parent or any of the Company Shareholders. New Parent shall pay any stamp, transfer, documentary or similar taxes imposed upon the forfeiture of any Earnout Shares. Similarly, any Earnout Options that do not vest in accordance with
Section&nbsp;3.05(i), Section&nbsp;3.05(ii) and Section&nbsp;3.05(iii) during the Vesting Period shall automatically expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For the
avoidance of doubt, it is understood and agreed that the Earnout Shares shall not be entitled to vote on matters submitted to the holders of New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New
Parent Shares, if any, until such Earnout Shares vest pursuant to Section&nbsp;3.05(a)(i), Section&nbsp;3.05(a)(ii), Section&nbsp;3.05(a)(iii) or Section&nbsp;3.05(e) and may not be offered, sold, transferred, redeemed, assigned, pledged,
hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) by such Person or be subject to execution, attachment or similar process without the consent of New Parent, and shall bear a customary legend with respect
to such transfer restrictions. Any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of such Earnout Shares shall be null and void; <I>provided</I>, that, notwithstanding the foregoing, transfers, assignments
and sales by the holders of the Earnout Shares are permitted (i)&nbsp;in the case of a holder who is an individual, by bona fide gift to a member of such holder&#146;s immediate family or to a trust created and controlled by such holder, the
beneficiary of which is a member of one of the individual&#146;s immediate family, an Affiliate of such person or to a charitable organization; (ii)&nbsp;in the case of a holder who is an individual, by virtue of laws of descent and distribution
upon death of the individual; (iii)&nbsp;in the case of a holder who is an individual, pursuant to a qualified domestic relations order; (iv)&nbsp;to New Parent for a price not exceeding the nominal value of such Earnout Shares; and (v)&nbsp;in the
event of completion of a liquidation, merger, share exchange or other similar transaction which results in all of New Parent shareholders having the right to exchange their New Parent Shares for cash, securities or other property subsequent to the
completion of the Transactions; <I>provided</I>, <I>however</I>, that in the case of clauses (i)&nbsp;through (iii) these permitted transferees must enter into a written agreement agreeing to be bound by the restrictions herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event that there is a Change of Control during the Vesting Period, to the extent an applicable Earnout Achievement Date has not
already occurred, each respective Earnout Achievement Date shall be deemed to occur on the day prior to the closing of such Change of Control, and (A)&nbsp;all Earnout Shares shall automatically become vested on the date prior to the closing of such
Change of Control (to the extent such Earnout Shares has not previously been issued) and (B)&nbsp;thereafter, the obligations in this Section&nbsp;3.05 shall terminate and no longer apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The New Parent Shares price targets set forth in this Section&nbsp;3.05 shall be equitably adjusted for stock splits, reverse stock
splits, stock dividends, reorganizations, recapitalizations, reclassifications, combinations, exchanges of shares or other like changes or transactions with respect to the New Parent Shares occurring on or after the Acquisition Closing (other than
the Transactions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_12"></A>Section&nbsp;3.06. <I>Treatment of Company Options</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Acquisition Closing, all of the Company Options outstanding and unexercised immediately prior to the Acquisition Closing,
automatically and without any action on the part of any Company Optionholder or beneficiary thereof, will be assumed by New Parent and each such Company Option shall be replaced by a stock option (each, a &#147;<B>Converted Option</B>&#148;) to
purchase New Parent Shares and the option to acquire Earnout Shares (each, an &#147;<B>Earnout Option</B>&#148;) at the same proportion as a holder of Company Common Shares receives New Parent Shares and Earnout Shares pursuant to Schedule 2.01 of
the Company Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each such Converted Option as so assumed and replaced shall continue to have and be subject to
substantially the same terms and conditions (other than the vesting and transfer restrictions applicable to each Earnout Option) as were applicable to such Company Option immediately before the Acquisition Closing (including vesting (if applicable),
expiration date and exercise provisions), except that, as of the Acquisition Closing, each such Converted Option as so assumed and replaced shall be exercisable for that number of New Parent Shares and Earnout Shares determined by multiplying the
number of Company Common Shares subject to such Company Option immediately prior to the Acquisition Closing by the Option Exchange Ratio, which product shall be mathemathically rounded to the nearest whole number of shares at a per share exercise
price determined by dividing the per share exercise price of such Company Option immediately prior to the Acquisition Closing by the Option Exchange Ratio, which quotient shall be mathematically rounded to the nearest whole cent; <I>provided</I>,
that the exercise price and the number of New Parent Shares purchasable under each Converted Option shall, in the case of any Company Option to which Section&nbsp;409A of the Code applies, be determined in a manner consistent with the requirements
of Section&nbsp;409A of the Code and the applicable regulations promulgated thereunder; <I>provided</I>, further, that in the case of any Company Option to which Section&nbsp;422 of the Code applies, the exercise price and the number of New Parent
Shares purchasable under such Converted Option shall be determined in accordance with the foregoing in a manner that satisfies the requirements of Section&nbsp;424(a) of the Code; <I>provided</I>, that the exercise price shall not be lower than CHF
0.01. As of the Acquisition Closing, all Company Options shall no longer be outstanding and each holder of Converted Options shall cease to have any rights with respect to such Company Options, except as set forth in this Section&nbsp;3.06. For any
unvested Company Option, the Company may replace any Earnout Option with another option of economically similar value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Solely for
purposes of determining the Company Equity Value (as defined herein), all Company Options that are vested and not exercised at the Acquisition Closing Date shall be treated as if they had been exercised on a cashless basis. The value of the total
number of Company Common Shares resulting from such deemed cashless exercise, as determined in accordance with Section&nbsp;2.01 of the Disclosure Letter, shall be deducted from determining the Company Equity Value in accordance with the definition
thereof for purposes of calculating the number of New Parent Shares to be issued to the Company Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding
anything to the contrary herein, absent the exercise of a vested Company Option, no New Parent Share shall be issued to Company Optionholders and all vested Company Options shall be replaced by vested New Parent Options and Earnout Options which
reflect economically the terms of replaced vested Company Options as outlined in this Section&nbsp;3.05. For the avoidance of doubt, this Section&nbsp;3.05 shall not create any rights to any Company Optionholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the disclosure letter delivered to EBAC by the Company on the date of this Agreement (the &#147;<B>Company Disclosure
Letter</B>&#148;) (each section of which, subject to Section&nbsp;12.09, qualifies the correspondingly numbered and lettered representations in this Article 4), the Company represents and warrants to EBAC as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_13"></A>Section&nbsp;4.01. <I>Company Organization</I>. The Company has
been duly incorporated and is validly existing as a public limited liability company (<I>soci&eacute;t&eacute; anonyme</I>) incorporated and existing under the laws of Switzerland and has all power and authority necessary to own, lease or operate
all of its properties and assets and to conduct its business as it is now being conducted. The Governing Documents of the Company as previously made available by or on behalf of the Company to EBAC, are true, correct and complete. The Company is
lawfully licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to
be so licensed or qualified or in good standing, as applicable, except where the failure to be so licensed or qualified or in good standing has not been, and would not reasonably be expected to be, material to the business of the Company and its
Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_14"></A>Section&nbsp;4.02. <I>Subsidiaries</I>. A complete list of each Subsidiary of
the Company and its jurisdiction of incorporation, formation or organization, as applicable, is set forth on Section&nbsp;4.02 of the Company Disclosure Letter. All Subsidiaries of the Company have been duly formed or organized and are validly
existing under the Laws of their jurisdiction of incorporation or organization and have the requisite power and authority to own, lease or operate all of their respective properties and assets and to conduct their respective businesses as they are
now being conducted. True, correct and complete copies of the Governing Documents of the Subsidiaries of the Company, in each case, as amended to the date of this Agreement, have been previously made available to EBAC by or on behalf of the Company.
Each Subsidiary of the Company is duly licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its
activities is such as to require it to be so licensed or qualified or in good standing, as applicable, except where the failure to be so licensed or qualified or in good standing has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_15"></A>Section&nbsp;4.03. <I>Due
Authorization.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company has all requisite company or corporate power, as applicable, and authority to execute and deliver this
Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. The execution and delivery of this
Agreement and the other documents to which the Company is a party contemplated hereby and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized and approved by the Board of Directors of the
Company, and no other company or corporate proceeding on the part of the Company is necessary to authorize this Agreement and the other documents to which the Company is a party contemplated hereby. This Agreement has been, and on or prior to the
Acquisition Closing, the other documents to which the Company is a party contemplated hereby will be, duly and validly executed and delivered by the Company and this Agreement constitutes, and on or prior to the Acquisition Closing, the other
documents to which the Company is a party contemplated hereby will constitute, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors&#146; rights generally and subject, as to enforceability, to general principles of equity (the &#147;<B>Enforceability Exceptions</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the date of this Agreement, the Board of Directors of the Company has duly adopted resolutions (i)&nbsp;determining that
this Agreement and the other documents to which the Company is a party contemplated hereby and the transactions contemplated hereby and thereby are advisable and fair to, and in the best interests of, the Company and its shareholders, as applicable,
(ii)&nbsp;approving the transfer of the Company Common Shares to New Parent, and (iii)&nbsp;authorizing and approving the execution, delivery and performance by the Company of this Agreement, the Transactions and the other documents to which the
Company is a party contemplated hereby and the transactions contemplated hereby and thereby. No other corporate action is required on the part of the Company or any of its shareholders to enter into this Agreement or the other documents to which the
Company is a party contemplated hereby or to approve the transactions contemplated hereby and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereby. The Governing Documents of the Company have been duly and validly approved in accordance with applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_16"></A>Section&nbsp;4.04. <I>No Conflict</I>. Subject to the receipt of the Governmental Authorizations set forth in
Section&nbsp;4.05 of the Company Disclosure Letter and except as set forth on Section&nbsp;4.04 of the Company Disclosure Letter, the execution and delivery by the Company of, and the performance by the Company of its obligations under, this
Agreement and the other documents to which the Company is a party contemplated hereby and the consummation of the Transactions and thereby do not and will not (a)&nbsp;violate or conflict with any provision of, or result in the breach of, or default
under, the Governing Documents of the Company or any of its Subsidiaries, (b)&nbsp;violate or conflict with any provision of, or result in the breach of, or default under, any Law, License or Governmental Order applicable to the Company or any of
its Subsidiaries, (c)&nbsp;violate or conflict with any provision of, or result in the breach of, result in the loss of any right or benefit, or cause acceleration, or constitute (with or without due notice or lapse of time or both) a default (or
give rise to any right of termination, cancellation or acceleration) under any Material Contract to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries may be bound, or terminate or result in
the termination of any such foregoing Contract or (d)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any of the properties or assets of the Company or any of its Subsidiaries, except, in the case of clauses
(b)&nbsp;through (d), to the extent that the occurrence of the foregoing which (i)&nbsp;has not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of the Company to enter
into and perform its obligations under this Agreement or (ii)&nbsp;would not be, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_17"></A>Section&nbsp;4.05. <I>Governmental Authorities; Consents</I>. No action by, notice, consent, approval, waiver or
authorization of, or designation, declaration or filing with, any Governmental Authority is required on the part of the Company or its Subsidiaries with respect to the Company&#146;s execution, delivery and performance of this Agreement and the
other Ancillary Agreements to which the Company is a party and the consummation of the transactions contemplated hereby and thereby (each, a &#147;<B>Governmental Authorization</B>&#148;), except for (i)&nbsp;the filings and approvals set forth in
Section&nbsp;4.05 of the Company Disclosure Letter, (ii)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of
the Exchange Act as may be required in connection with this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby, (iii)&nbsp;such filings with and approvals of the Stock Exchange to permit New Parent Shares to be
issued in accordance with this Agreement to be listed on the Stock Exchange, (iv)&nbsp;filing of the Cayman Plan of Merger and, if applicable, the plan of merger under the applicable law of the Swiss Code of Obligations, as appropriate,
(v)&nbsp;such filings with the relevant Swiss commercial register as per Section&nbsp;2.02(b), Section&nbsp;8.07 or Section&nbsp;9.10 or (vi)&nbsp;any actions, notices, consents, approvals, waiver or authorizations, designations, declarations or
filings, the absence of which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement is not, and would not reasonably be
expected to be, material to the business of the Company and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_18"></A>Section&nbsp;4.06. <I>Capitalization of the Company.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The issued share capital of the Company consists of CHF 1,690,661.40, divided into (i) 3,402,771 registered shares with a nominal value of
CHF 0.10 each (the &#147;<B>Company Common Shares</B>&#148;), (ii) 1,623,793 registered Series A preferred shares (the &#147;<B>Series A Preferred Shares</B>&#148;) with a nominal value of CHF 0.10 each, (iii) 2,486,188 registered Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred shares (the &#147;<B>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares</B>&#148;) with a nominal value of CHF 0.10 each, (iv) 2,705,324 registered Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares (the &#147;<B>Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares</B>&#148;) with a nominal value of CHF 0.10 each, (v) 5,699,813 registered Series
<FONT STYLE="white-space:nowrap">C-1(a)</FONT> preferred shares (the &#147;<B><FONT STYLE="white-space:nowrap">Series&nbsp;C-1(a)</FONT> Preferred Shares</B>&#148;) with a nominal value of CHF 0.10 each and (vi) 197,745 registered Series <FONT
STYLE="white-space:nowrap">C-1(b)</FONT> preferred shares (the &#147;S<B>eries <FONT STYLE="white-space:nowrap">C-1(b)</FONT> Preferred Shares&#148;</B>) with a nominal value of CHF 0.50 each (collectively, the Series A Preferred Shares, the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, the Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, the Series <FONT STYLE="white-space:nowrap">C-1(a)</FONT> Preferred Shares and the Series
<FONT STYLE="white-space:nowrap">C-1(b)</FONT> Preferred Shares, the &#147;<B>Company Preferred Shares</B>&#148; and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
together with the Company Common Shares, &#147;<B>Company Share Capital</B>&#148;), and there are no other authorized Equity Securities of the Company that are issued and outstanding. All of the
issued and outstanding shares of Company Share Capital (i)&nbsp;have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> (ii)&nbsp;have been offered, sold and issued in compliance
with applicable Law and all requirements set forth in (1)&nbsp;the Governing Documents of the Company and (2)&nbsp;any other applicable Contracts governing the issuance of such securities; (iii)&nbsp;are not subject to, nor have they been issued in
violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, the Governing Documents of the Company or any Contract to which the Company
is a party or otherwise bound (other than the Company&#146;s shareholders&#146; agreement dated April&nbsp;1, 2021 (and any prior version thereof)); (iv) are fully vested and nonforfeitable; and (v)&nbsp;are free and clear of any Liens (other than
restrictions under applicable securities Laws or the articles of association of the Company or the Company&#146;s shareholders&#146; agreement dated April&nbsp;1, 2021 (and any prior version thereof). As of the date of this Agreement, 1,543,829
(including conditional capital of 1,443,829 and 100,000 treasury shares) are reserved for future common share issuance pursuant to the Company Equity Plan, of which 1,538,297 Company Common Shares are subject to outstanding Company Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise set forth on Section&nbsp;4.02 of the Company Disclosure Letter, neither the Company nor any of its Subsidiaries owns
or holds (of record, beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person or the right to acquire any such Equity Security, and, without limiting the foregoing, none of the Company or any of its
Subsidiaries are a partner or member of any partnership, limited liability company or joint venture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as otherwise set forth on
Section&nbsp;4.06(c) of the Company Disclosure Letter, the Company has not granted any outstanding subscriptions, options, stock appreciation rights, warrants, rights or other securities (including debt securities) convertible into or exchangeable
or exercisable for shares of Company Share Capital, any other commitments, calls, conversion rights, rights of exchange or privilege (whether <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> contractual or by matter of Law), plans or other
agreements of any character providing for the issuance of additional Equity Securities, the sale of Equity Securities, or for the repurchase or redemption of Equity Securities of the Company or the value of which is determined by reference to shares
of Company Share Capital or other Equity Securities of the Company, and there are no voting trusts, proxies or agreements of any kind which may obligate the Company to issue, purchase, register for sale, redeem or otherwise acquire any shares of
Company Share Capital or other Equity Securities of the Company or vote any Equity Securities of the Company in any manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
Section&nbsp;4.06(d) of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding, if applicable: (i)&nbsp;the name of the Company Optionholder and whether such Company Optionholder is a
current or former employee of the Company or any of its Subsidiaries; (ii)&nbsp;the number of shares of the Company Common Shares outstanding with respect to such Company Option; (iii)&nbsp;the exercise price of such Company Option; (iv)&nbsp;the
date on which such Company Option was granted; and (v)&nbsp;the date on which such Company Option expires. The Company has made available to EBAC an accurate and complete copy of the Company Equity Plan and all forms of award agreements evidencing
all outstanding Company Option. No Company Option was granted with an exercise price per share less than the fair market value of the underlying Company Common Shares as of the date such Company Option was granted, as determined in accordance with
Section&nbsp;409A of the Code. All Company Common Shares subject to issuance as aforesaid, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be duly authorized, validly issued, fully
paid and nonassessable. All Company Options may, by their respective terms, be treated as set forth in Section&nbsp;3.07 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_19"></A>Section&nbsp;4.07. <I>Capitalization of Subsidiaries.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of capital stock or Equity Securities of each Subsidiary of the Company (i)&nbsp;have been duly authorized and
validly issued and are, to the extent applicable, fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (1)&nbsp;the Governing Documents of
each such Subsidiary of the Company, and (2)any other applicable Contracts governing the issuance of such securities; (iii)&nbsp;are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal,
preemptive right, subscription right or any similar right under any provision of any applicable Law, the Governing Documents of each such Subsidiary or any Contract to which each such Subsidiary is a party or otherwise bound; and (iv)&nbsp;are free
and clear of any Liens (other than restrictions under applicable securities Laws). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company owns of record and beneficially all
the issued and outstanding shares of capital stock or Equity Securities of such Subsidiaries of the Company free and clear of any Liens other than Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth on Section&nbsp;4.07(c) of the Company Disclosure Letter, there are no outstanding subscriptions, options, warrants,
rights or other securities (including debt securities) exercisable or exchangeable for any capital stock of such Subsidiaries of the Company, any other commitments, calls, conversion rights, rights of exchange or privilege (whether <FONT
STYLE="white-space:nowrap">pre-emptive,</FONT> contractual or by matter of Law), plans or other agreements of any character providing for the issuance of additional shares, the sale of treasury shares or other Equity Securities, or for the
repurchase or redemption of shares or other Equity Securities of such Subsidiaries or the value of which is determined by reference to shares or other Equity Securities of the Company Subsidiaries, and there are no voting trusts, proxies or
agreements of any kind which may obligate any Subsidiary of the Company to issue, purchase, register for sale, redeem or otherwise acquire any of its Equity Securities or vote its Equity Securities in any manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_20"></A>Section&nbsp;4.08. <I>Financial Statements.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Attached as Section&nbsp;4.08(a) of the Company Disclosure Letter are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) true and complete copies of the audited consolidated statement of financial position as of December&nbsp;31, 2021 and
December&nbsp;31, 2020, and the related audited statements of comprehensive income, changes in equity and cash flows for the years ended December&nbsp;31, 2021, and December&nbsp;31, 2020, of the Company and its Subsidiaries, together with the
auditor&#146;s reports thereon (the &#147;<B>Audited Financial Statements</B>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) true and complete copies of
the unaudited interim consolidated statement of financial position as of June&nbsp;30, 2022, and the related unaudited interim statements of comprehensive income, changes in equity, and cash flows for the
<FONT STYLE="white-space:nowrap">6-month</FONT> period ended June&nbsp;30, 2022 of the Company and its Subsidiaries (the &#147;<B>Q2 2022 Financial Statements</B>&#148; and, together with the Audited Financial Statements, and Q3 2022 Financial
Statements (if delivered pursuant to Section&nbsp;7.03) the &#147;<B>Financial Statements</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth on
Section&nbsp;4.08(b) of the Company Disclosure Letter, the Financial Statements (i)&nbsp;fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries, as at the respective dates
thereof, and the consolidated results of their operations, their consolidated comprehensive incomes or losses, their consolidated changes in shareholders&#146; equity and their consolidated cash flows for the respective periods then ended (except
for, in the case of the Q2 2022 Financial Statements and Q3 2022 Financial Statements (if delivered), any normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and any absence of footnotes), and (ii)&nbsp;were prepared in conformity
with IFRS applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto and, in the case of the Q2 2022 Financial Statements and Q3 2022 Financial Statements (if delivered), the absence of footnotes or
the inclusion of limited footnotes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company (including, to the knowledge of the Company, any employee thereof) nor any
independent auditor of the Company has identified or been made aware of (i)&nbsp;any significant deficiency or material weakness in the system of internal accounting controls utilized by the Company, (ii)&nbsp;any fraud, whether or not material,
that involves the Company&#146;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&nbsp;any written claim or allegation regarding any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_21"></A>Section&nbsp;4.09. <I>Undisclosed Liabilities</I>. Except as set
forth on Section&nbsp;4.09 of the Company Disclosure Letter, as of the date of this Agreement, there is no other liability, debt (including Indebtedness) or obligation of, or claim or judgment against, the Company or any of the Company&#146;s
Subsidiaries (whether direct or indirect, absolute or contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due) of the type required to be set forth on a balance sheet in accordance with IFRS, except
for liabilities, debts, obligations, claims or judgments (a)&nbsp;reflected or reserved for on the Financial Statements or disclosed in the notes thereto, (b)&nbsp;that have arisen since the date of the most recent balance sheet included in the
Financial Statements in the ordinary course of business, consistent with past practice, of the Company and its Subsidiaries (none of which results from, arises out of or was caused by any tortious conduct, breach of Contract, or infringement or
violation of applicable Law), (c) that will be discharged or paid off prior to or at the Acquisition Closing or (d)&nbsp;which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to
enter into and perform its obligations under this Agreement or would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole. This <U>Section</U><U></U><U>&nbsp;4.09</U> shall not apply to Tax
matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_22"></A>Section&nbsp;4.10. <I>Litigation and Proceedings</I>. Except as set forth on Section&nbsp;4.10 of
the Company Disclosure Letter or which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or has not had, and would not
reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, (a)&nbsp;there are no pending or, to the knowledge of the Company, threatened, lawsuits, actions, suits, judgments, claims, proceedings or
any other Actions (including any investigations or inquiries initiated, pending or threatened by any Governmental Authority), or other proceedings at law or in equity (collectively, &#147;<B>Legal</B> <B>Proceedings</B>&#148;), against the Company
or any of the Company&#146;s Subsidiaries or their respective properties or assets; and (b)&nbsp;there is no outstanding Governmental Order imposed upon the Company or any of the Company&#146;s Subsidiaries; nor are any properties or assets of the
Company or any of its Subsidiaries&#146; respective businesses bound or subject to any Governmental Order. This <U>Section</U><U></U><U>&nbsp;4.10</U> shall not apply to Tax matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_23"></A>Section&nbsp;4.11. <I>Legal Compliance.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except where the failure to be, or to have been, in compliance with such Laws has not had, and would not reasonably be expected to have, a
material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a
whole, each of the Company, its Subsidiaries and, to the knowledge of the Company, Collaboration Partners, is, and for the prior three (3)&nbsp;years has been, in compliance with all applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except where the failure to maintain such program has not had, and would not reasonably be expected to have, a material adverse effect on
the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, the Company and its
Subsidiaries maintain a program of policies, procedures and internal controls reasonably designed and implemented to (i)&nbsp;prevent the use of the products and services of the Company and its Subsidiaries in a manner that violates applicable Law
(including money laundering or fraud), and (ii)&nbsp;otherwise provide reasonable assurance that violation of applicable Law by any of the Company&#146;s or its Subsidiaries&#146; directors, officers, employees or its or their respective agents,
representatives or other Persons, acting on behalf of the Company or any of the Company&#146;s Subsidiaries, will be prevented, detected and deterred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the past three (3)&nbsp;years, neither the Company nor any of its Subsidiaries or any of the officers or directors of its Subsidiaries
acting in such capacity, or to the knowledge of the Company, Collaboration Partners, has received any written notice of, or been charged with, the violation of any Laws, except where such violation has not had, and would not reasonably be expected
to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries,
taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This <U>Section</U><U></U><U>&nbsp;4.11</U> shall not apply to Tax matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_24"></A>Section&nbsp;4.12. <I>Contracts; No Defaults.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) True, correct and complete copies of the Contracts listed described in clauses (i)&nbsp;through (xi) below to which, as of the date of
this Agreement, the Company or any Subsidiary of the Company is a party or by which they are bound, other than a Company Benefit Plan, (the &#147;<B>Material Contracts</B>&#148;) have previously been delivered to or made available to EBAC or its
agents or representatives, together with all amendments thereto. Section&nbsp;4.12(a) of the Company Disclosure Letter contains a listing of all Material Contracts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Contract, excluding leases, subleases or other occupancy agreements related to real property, pursuant to which
Company or any of the Company&#146;s Subsidiaries is obligated to pay, or entitled to receive, payments in excess of $500,000 in the twelve (12)&nbsp;month period following the date hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each note, debenture, other evidence of Indebtedness, guarantee, loan, credit or financing agreement or instrument or
other Contract for money borrowed by the Company or any of the Company&#146;s Subsidiaries, including any agreement or commitment for future loans, credit or financing, in each case, in excess of $50,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Each Contract for the acquisition of any Person or any business unit thereof or the disposition of any material assets of
the Company or any of its Subsidiaries in the last three (3)&nbsp;years, in each case, involving payments in excess of $50,000 other than Contracts (A)&nbsp;in which the applicable acquisition or disposition has been consummated and there are no
material obligations ongoing or (B)&nbsp;between the Company and its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Each lease, rental or occupancy
agreement, installment and conditional sale agreement, and other Contract that provides for the ownership of, leasing of, title to, use of, or any leasehold or other interest in any real or personal property that involves aggregate payments in
excess of $50,000 in any calendar year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Each Contract that is material to the Company and its Subsidiaries, taken as a
whole, involving the formation of a (A)&nbsp;joint venture, (B)&nbsp;partnership, or (C)&nbsp;limited liability company, in each case providing for the sharing of revenues, profits, losses or costs (excluding, in the case of clauses (B)&nbsp;and
(C), any Subsidiary of the Company); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Contracts (other than employment agreements, employee confidentiality and
invention assignment agreements, equity or incentive equity documents and Governing Documents) that are material to the Company and its Subsidiaries, taken as a whole, between the Company and any Subsidiary of the Company, on the one hand, and
Affiliates of the Company or any of the Company&#146;s Subsidiaries (other than the Company or any of the Company&#146;s Subsidiaries), the officers and managers (or equivalents) of the Company or any of the Company&#146;s Subsidiaries, the members
or shareholders of the Company or any of the Company&#146;s Subsidiaries, any employee of the Company or any of the Company&#146;s Subsidiaries or a member of the immediate family of the foregoing Persons, on the other hand (collectively, the
&#147;<B>Affiliate Agreements</B>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Each employment Contract with each executive officer of the Company or any
of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Material Contracts containing covenants of the Company or any of the Company&#146;s
Subsidiaries (or, after the Acquisition Closing, that would reasonably be expected to bind, in any material respect, the operations of New Parent or any of its Affiliates)&nbsp;(A) prohibiting or limiting the right of the Company or any of the
Company&#146;s Subsidiaries to engage in or compete with any Person in any line of business in any material respect, (B)&nbsp;prohibiting or restricting the Company&#146;s and the Company&#146;s Subsidiaries&#146; ability to conduct their business
with any Person in any geographic area in any material respect, (C)&nbsp;prohibiting the Company or any of the Company&#146;s Subsidiaries from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
soliciting any strategic partner or (D)&nbsp;granting exclusive or preferential rights or &#147;most favored nations&#148; status to any person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) Any Collective Bargaining Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Contracts with any Governmental Authority; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Each Contract involving any resolution or settlement of any actual or threatened Action under which the Company or any of
its Subsidiaries has any ongoing <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations (other than customary confidentiality or similar provisions) or monetary obligations in excess of $50,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) Each Contract pursuant to which the Company or any of its Subsidiaries licenses or sublicenses from or to any third party
(or receives from or grants to any third party a covenant not to sue with respect to) any Intellectual Property that is material to the business of the Company and its Subsidiaries taken as a whole, other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software licenses that are commercially available on reasonable terms to the public generally; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) Each Contract requiring capital expenditures by the Company or any of the Company&#146;s Subsidiaries after the date of
this Agreement in an amount in excess of $50,000 in any calendar year; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) Contracts granting to any Person (other
than the Company or its Subsidiaries) a right of first refusal, first offer or similar preferential right to purchase or acquire Equity Securities in the Company or any of the Company&#146;s Subsidiaries that are material to the Company and its
Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except for any Contract that will terminate upon the expiration of the stated term thereof prior to
the Acquisition Closing Date, all of the Material Contracts listed pursuant to Section&nbsp;4.12(a) in the Company Disclosure Letter are (i)&nbsp;in full force and effect and (ii)&nbsp;represent the legal, valid and binding obligations of the
Company or the Subsidiary of the Company party thereto and, to the knowledge of the Company, represent the legal, valid and binding obligations of the counterparties thereto. Except where such breach, receipt of claim or notice or occurrence of an
event has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material
to the business of the Company and its Subsidiaries, taken as a whole, (1)&nbsp;neither the Company, the Subsidiaries of the Company, nor, to the knowledge of the Company, any other party thereto is in breach of or default under any such Contract,
(2)&nbsp;during the last twelve (12)&nbsp;months, neither the Company nor any of the Subsidiaries of the Company has received any written claim or written notice of termination or breach of or default under any such Contract, and (3)&nbsp;to the
knowledge of the Company, no event has occurred which individually or together with other events, would reasonably be expected to result in a breach of or a default under any such Contract by the Company or any Subsidiary of the Company or, to the
knowledge of the Company, any other party thereto (in each case, with or without notice or lapse of time or both). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_25">
</A>Section&nbsp;4.13. <I>Company Benefit Plans.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.13(a) of the Company Disclosure Letter sets forth a complete
list, as of the date hereof, of each Company Benefit Plan. For purposes of this Agreement, a &#147;<B>Company Benefit Plan</B>&#148; means any plan, policy, program or agreement (including any &#147;employee benefit plan&#148; as defined in
Section&nbsp;3(3) of the U.S. Employee Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), whether or not subject to ERISA, and all other employment, bonus, incentive or deferred compensation, Service Provider loan, note
or pledge agreements, equity or equity-based compensation, severance, retention, retirement, change in control or similar plan, policy, program or agreement) providing compensation or other benefits to any current or former Service Provider, which
are maintained, sponsored or contributed to by the Company or any of its Subsidiaries, or to which the Company or any of the its Subsidiaries is a party or has any liability, and in each case whether or not (i)&nbsp;in writing or (ii)&nbsp;funded,
but excluding in each case any statutory plan, program or arrangement that is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintained by any Governmental Authority. The Company has made available to EBAC true, complete and correct copies of such Company Benefit Plan (or, if not written a written summary of its
material terms). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth on Section&nbsp;4.13(b) of the Company Disclosure Letter or which has not had, and would not
reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company
and its Subsidiaries, taken as a whole, (i)&nbsp;each Company Benefit Plan has been operated and administered in compliance with its terms and all applicable Laws; and (ii)&nbsp;in all material respects, all contributions required to be made with
respect to any Company Benefit Plan on or before the date hereof have been made and all obligations in respect of each Company Benefit Plan as of the date hereof have been accrued and reflected in the Company&#146;s financial statements to the
extent required by IFRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had, and would not reasonably be expected to have, a material adverse effect on the
ability of the Company to enter into and perform its obligations under this Agreement is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, no employee has previously
transferred to the Company or any of its subsidiaries pursuant to the United Kingdom Transfer of Undertakings (Protection of Employment) Regulations 1981 or 2006 (as amended), and there are no such employees who prior to such transfer participated
in a defined benefit pension scheme that made provision for benefits other than related to old age, invalidity or on death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) With
respect to each Company Benefit Plan, no material actions, suits or claims (other than routine claims for benefits in the ordinary course) are pending or, to the knowledge of the Company, threatened, and to the knowledge of the Company, no facts or
circumstances exist that would reasonably be expected to give rise to any such actions, suits or claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth on
Section&nbsp;4.13(e) of the Company Disclosure Letter, the consummation of the Transactions will not, either alone or in combination with another event (such as termination following the consummation of the Transactions), (i) entitle any current or
former Service Provider to any severance pay or any other compensation or benefits payable or to be provided by the Company or any Subsidiary of the Company, (ii)&nbsp;accelerate the time of payment, funding or vesting, or increase the amount of
compensation or benefits due any such Service Provider or (iii)&nbsp;result in the forgiveness of any Indebtedness of any Service Provider. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries has incurred any current or projected liability in respect of post-employment or
post-retirement health, medical or life insurance benefits for current or former or retired Service Providers, except as required by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each Company Benefit Plan that constitutes a &#147;nonqualified deferred compensation plan&#148; (as defined in Section&nbsp;409A(d)(1) of
the Code) has been documented and operated in compliance with Section&nbsp;409A of the Code. There is no agreement, plan, or arrangement, or other contract by which the Company or any of its Subsidiaries is bound to compensate any Service Provider
for any Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_26"></A>Section&nbsp;4.14. <I>Labor Relations; Employees.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) Neither the Company nor any of its Subsidiaries is a party to or bound by any Collective Bargaining Agreement with any labor or
trade union, works council, employee representative body or labor organization or association (collectively, a &#147;<B>Labor Organization</B>&#148;), (ii) no such Collective Bargaining Agreement is being negotiated by the Company or any of its
Subsidiaries, (iii)&nbsp;no employees of the Company or any of its Subsidiaries are represented by any Labor Organization with respect to their employment with the Company or its Subsidiaries and (iv)&nbsp;no Labor Organization has, to the knowledge
of the Company, requested or made a pending demand for recognition or certification or sought to organize or represent any of the employees of the Company or any of its Subsidiaries with respect to their employment with the Company or its
Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the past three (3)&nbsp;years, there has been no actual or, to the knowledge of the
Company, threatened material unfair labor practice charge, grievance, arbitration, strike, slowdown, work stoppage, lockout, picketing, hand billing, or similar labor dispute against or affecting the Company or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The execution of this Agreement and the consummation of the Transactions will not result in any breach or other violation of any
Collective Bargaining Agreement and will not require the approval of any Labor Organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each of the Company and its
Subsidiaries are, and have been for the past three (3)&nbsp;years, in compliance in all material respects with all applicable Laws respecting labor and employment, including, but not limited to, all Laws respecting terms and conditions of
employment, health and safety, wages and hours, holiday pay and the calculation of holiday pay, working time, employee classification (with respect to exempt vs. <FONT STYLE="white-space:nowrap">non-exempt</FONT> status and employee vs. independent
contractor and worker status), child labor, immigration, employment discrimination, disability rights or benefits, equal opportunity and equal pay, workers&#146; compensation, labor relations, employee leave issues and unemployment insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth on Section&nbsp;4.14(e) of the Company Disclosure Letter or would not reasonably be expected to be, individually or in
the aggregate, material to the Company and its Subsidiaries, taken as a whole, in the past three (3)&nbsp;years, the Company and its Subsidiaries have not received (i)&nbsp;notice of any unfair labor practice charge or complaint pending or
threatened before any Governmental Authority against them, (ii)&nbsp;notice of any complaints, grievances or arbitrations arising out of any Collective Bargaining Agreement or any other complaints, grievances or arbitration procedures against them,
(iii)&nbsp;notice of any charge or complaint with respect to or relating to them pending before the Equal Employment Opportunity Commission or any other Governmental Authority responsible for the prevention of unlawful employment practices,
(iv)&nbsp;notice of the intent of any Governmental Authority responsible for the enforcement of labor, employment, wages and hours of work, child labor, immigration, or occupational safety and health Laws to conduct an investigation with respect to
or relating to them or notice that such investigation is in progress, or (v)&nbsp;notice of any complaint, lawsuit or other proceeding pending or threatened in any forum by or on behalf of any present or former employee of such entities, any
applicant for employment or classes of the foregoing alleging breach of any express or implied Contract of employment, any applicable Law governing employment or the termination thereof or other discriminatory, wrongful or tortious conduct in
connection with the employment relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of the Company, no current Service Provider is in violation of any term
of any employment agreement, restrictive covenant, nondisclosure obligation or fiduciary duty (i)&nbsp;to the Company or any of its Subsidiaries or (ii)&nbsp;to a former employer or engager of any such individual relating to (A)&nbsp;the right of
any such individual to work for or provide services to the Company or any of its Subsidiaries or (B)&nbsp;the knowledge or use of trade secrets or proprietary information, except as has not had, and would not reasonably be expected to have, a
material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a
whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its Subsidiaries is party to a material settlement agreement with a current or former officer
Service Provider that involves allegations relating to sexual harassment, sexual misconduct or any form of illegal discrimination by an officer of the Company or any of its Subsidiaries. To the knowledge of the Company, in the last three
(3)&nbsp;years, no material allegations of sexual harassment, sexual misconduct or any form of illegal discrimination have been made against any employee of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In the past three (3)&nbsp;years, the Company and the its Subsidiaries are and have been in compliance in all material respects with all
notice and other requirements under all applicable Laws relating to layoffs and individual and collective dismissals. The Company and its Subsidiaries have not engaged in broad-based layoffs, furloughs, employment terminations (other than for cause)
or effected any broad-based salary or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation or benefits reductions, in each case, whether temporary or permanent, since January&nbsp;1, 2021, through the date hereof. The Company, taken as a whole with its Subsidiaries, has
sufficient employees to operate the business of the Company and its Subsidiaries as currently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_27"></A>Section&nbsp;4.15. <I>Taxes</I>. Except as disclosed on Schedule 4.15 of the Company Disclosure Letter: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All income and other material Tax Returns required to be filed by or with respect to the Company or any of its Subsidiaries have been
timely filed (taking into account any applicable extensions), all such Tax Returns (taking into account all amendments thereto) are true, complete and accurate in all material respects and all material amounts of Taxes of the Company or any of its
Subsidiaries that are due and payable (whether or not shown on any Tax Return) have been fully and timely paid, other than Taxes being contested in good faith and for which adequate reserves have been established in accordance with IFRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of its Subsidiaries have withheld from amounts owing to any employee, creditor or other Person all material Taxes
required by Law to be withheld, paid over to the proper Governmental Authority in a timely manner all such withheld amounts required to have been so paid over and complied in all material respects with all applicable withholding and related
reporting requirements with respect to such Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company nor any of its Subsidiaries has any liability for unpaid Taxes
which has not been accrued for or reserved on the Financial Statements, other than any liability for unpaid Taxes that has been incurred since the end of the most recent fiscal year in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no Liens for any material Taxes (other than Permitted Liens) upon the property or assets of the Company or any of its
Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No claim, assessment, deficiency or proposed adjustment for any material amount of Tax has been asserted or assessed by
any Governmental Authority against the Company or any of its Subsidiaries that remains unpaid except for claims, assessments, deficiencies or proposed adjustments being contested in good faith and for which adequate reserves have been established in
accordance with IFRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There are no ongoing or pending Legal Proceedings with respect to any Taxes of the Company or any of its
Subsidiaries and neither the Company nor any of its Subsidiaries has received written notice from any Governmental Authority that any such Legal Proceeding is contemplated or pending. There are no waivers, extensions or requests for any waivers or
extensions of any statute of limitations currently in effect with respect to any material Taxes of the Company or any of its Subsidiaries (other than pursuant to an extension of time to file a Tax Return of not more than seven months obtained in the
ordinary course of business). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its Subsidiaries has made a request for an advance Tax ruling, a request
for administrative Tax relief, a request for technical Tax advice, a request for a change of any method of accounting or any similar request with respect to Taxes that is in progress or pending with any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any of its Subsidiaries is a party to any Tax Sharing Agreement other than (i)&nbsp;any such agreement solely
among the Company and its Subsidiaries and (ii)&nbsp;customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries has ever been a member of an Affiliated Group (other than an Affiliated Group the common
parent of which is the Company or any of its Subsidiaries and which consists only of the Company and its Subsidiaries). Neither the Company nor any of its Subsidiaries is liable for Taxes of any other Person (other than the Company and its
Subsidiaries) under Treasury Regulation Section&nbsp;1.1502-6 or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law or as a transferee or successor or by Contract (other than (i)&nbsp;any such agreement
solely among the Company and its Subsidiaries and (ii)&nbsp;customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No written claim has been made by any Governmental Authority in a jurisdiction where the
Company or any of its Subsidiaries does not pay a particular type of Tax or file a particular type of Tax Return that it is or may be required to pay such type of Tax or file such type of Tax Return in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To the Company&#146;s Knowledge, neither the Company nor any of its Subsidiaries has, or has ever had, a permanent establishment in any
country other than the country of its organization, or is, or has ever been, subject to income Tax in a jurisdiction outside the country of its organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its Subsidiaries has constituted either a &#147;distributing corporation&#148; or a &#147;controlled
corporation&#148; in a distribution of stock qualifying for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code in the prior two (2)&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Neither the Company nor any of its Subsidiaries has participated in a &#147;listed transaction&#148; within the meaning of Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Neither the Company nor any of its Subsidiaries will
be required to include any material amount in taxable income or exclude any material item of deduction or loss from taxable income for any taxable period ending after the Acquisition Closing Date as a result of any (i)&nbsp;installment sale or open
transaction disposition made prior to the Acquisition Closing outside the ordinary course of business, (ii)&nbsp;prepaid amount received or deferred revenue recognized prior to the Acquisition Closing outside the ordinary course of business,
(iii)&nbsp;change in method of accounting for a taxable period ending on or prior to the Acquisition Closing Date, (iv) &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state,
local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law) executed on or prior to the Acquisition Closing Date or (v)&nbsp;binding agreement with respect to Taxes with a Governmental Authority executed prior to the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Neither the Company nor any of its Subsidiaries has any obligation to make any payment described in Section&nbsp;965(h) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) To the Company&#146;s Knowledge, the Company and its Subsidiaries have complied in all material respects with the conditions stipulated in
each Tax Grant that the Company and its Subsidiaries have utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) The Company reasonably believes it was not a &#147;passive
foreign investment company&#148; within the meaning of Section&nbsp;1297 of the Code for its taxable year ended December&nbsp;31, 2021, and reasonably does not expect to be a &#147;passive foreign investment company&#148; within the meaning of
Section&nbsp;1297 of the Code for its taxable year ending December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) Neither the Company nor any of its Subsidiaries has
taken any action or agreed to take any action not contemplated by the Transactions, and to the knowledge of the Company there are no facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended Tax Treatment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) The Company has not and will not exercise any rights to cause funding to occur under the Convertible Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_28"></A>Section&nbsp;4.16. <I>Brokers&#146; Fees</I>. No broker, finder, investment banker or other Person (except the
Person(s) set forth on Section&nbsp;4.16 of the Company Disclosure Letter) is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon arrangements made by the Company, any of the
Company&#146;s Subsidiaries&#146; or any of their Affiliates for which EBAC, the Company or any of the Company&#146;s Subsidiaries has any obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_29"></A>Section&nbsp;4.17. <I>Insurance</I>. Except as has not had, and would not reasonably be expected to have, a
material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taken as a whole: (i)&nbsp;all the material policies or binders of property, fire and casualty, product liability, workers&#146; compensation, and other forms of insurance (other than any such
policies relating to a Company Benefit Plan) held by, or for the benefit of, the Company or any of its Subsidiaries as of the date of this Agreement are in full force and effect and (ii)&nbsp;there is no existing default or event that, with notice
or lapse of time or both, would constitute a default by any insured thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_30"></A>Section&nbsp;4.18.
<I>Permits</I>. Each of the Company and its Subsidiaries holds all permits (the &#147;<B>Material Permits</B>&#148;) that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted, except as
has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the
business of the Company and its Subsidiaries, taken as a whole. Except as is not and would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole, (i)&nbsp;each Material Permit is in full force and effect in
accordance with its terms and (ii)&nbsp;no written notice of revocation, cancellation or termination of any Material Permit has been received by the Company and its Subsidiaries. The Company is, and since January&nbsp;1, 2019, has been, in
compliance with the terms of all the Material Permits except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole. To the Company&#146;s knowledge, no
event, circumstance, or state of facts has occurred which (with or without due notice or lapse of time or both) would reasonably be expected to result in the failure of the Company or any of its Subsidiaries to be in compliance in all material
respects with the terms of the Material Permits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_31"></A>Section&nbsp;4.19. <I>Regulatory Compliance.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Company and each Subsidiary of the Company is, and for the past three (3)&nbsp;years has been, in material compliance with the
FDCA, the Federal Trade Commission Act, and the Fair Packaging and Labeling Act (collectively &#147;<B>Food and Drug Law</B>&#148;). Neither the Company nor any Subsidiary of the Company has received any claim (and, to the Company&#146;s knowledge,
no claim has been filed, commenced or threatened against the Company or any Subsidiary of the Company) alleging a material violation under any Food and Drug Law that has not been duly cured, and there are no pending or, to the Company&#146;s
knowledge, threatened legal proceedings, investigations, subpoenas, or civil investigative demands by any Governmental Authority, or other entity or individual, with respect to any alleged violation by the Company or any Subsidiary of the Company of
any Food and Drug Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Products are not adulterated or misbranded within the meaning of the FDCA. All of the claims the Company
and any Subsidiary of the Company makes or has made for its Products are and have been adequately supported and are otherwise compliant with Food and Drug Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since the date of the most recent balance sheet included in the Financial Statements, neither the Company nor any Subsidiary of the
Company has received any warning letter, notice of violation, seizure, recall request, injunction, regulatory enforcement action, or criminal action issued, initiated, threatened in writing, or to the Company&#146;s knowledge, otherwise threatened,
by the FDA. Neither the Company nor any Subsidiary of the Company has made an untrue statement of material fact or fraudulent statement to the FDA or any other similar Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_32"></A>Section&nbsp;4.20. <I>Real Property</I>. Except as had not had, and would not reasonably be expected to have, a
Company Material Adverse Effect, the Company and its Subsidiaries have title, in fee or valid leasehold, easement or other rights, in each case, free and clear of all Liens other than Permitted Liens, to the land, buildings, structures and other
improvements thereon and fixtures thereto necessary to permit the Company and its Subsidiaries to conduct their business as currently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_33"></A>Section&nbsp;4.21. <I>Intellectual Property</I>. Except as has not had, and would not reasonably be expected to
have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement and except as is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;4.21(a) of the Company Disclosure Letter lists, in a true and complete manner, each item of Intellectual Property that is
registered or <FONT STYLE="white-space:nowrap">applied-for</FONT> with a Governmental Authority or other applicable registrar and, as of the date hereof, is owned by, or exclusively licensed to, the Company or any of its Subsidiaries, whether
applied for or registered in the United States or internationally (&#147;<B>Company Registered Intellectual Property</B>&#148;), in each case listing, as applicable, (i)&nbsp;the owner, (ii)&nbsp;the jurisdiction where the application/registration
is located (or, for domain names, the applicable registrar), (iii) the title, (iv)&nbsp;the application or registration number, (v)&nbsp;the filing date or issuance/registration/grant date, and (vi)&nbsp;for each item of Company Registered
Intellectual Property that is exclusively licensed to the Company or any of its Subsidiaries, the applicable agreement pursuant to which such item of Company Registered Intellectual Property is so licensed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company or one of its Subsidiaries is the sole and exclusive owner, and with respect to Company Registered Intellectual Property,
record owner, of all of Company Owned IP, and the Company and its Subsidiaries hold their respective rights under all Company Licensed IP, in each case, free and clear of all Liens (other than Permitted Liens). All Company Registered Intellectual
Property (i)&nbsp;has been duly maintained (including the timely payment of registration, maintenance and renewal fees and timely filing of statements of use), (ii) is subsisting, in full force and effect and not expired, abandoned or cancelled,
(iii)&nbsp;to the knowledge of the Company, is valid and enforceable, and (iv)&nbsp;has not been adjudged invalid or unenforceable, in whole or in part. With respect to each item of Company Registered Intellectual Property that is held by the
Company or any of its Subsidiaries or any of their respective licensors by assignment, such assignment has been duly recorded with the applicable Government Authority from which such Company Registered Intellectual Property was issued or granted or
before which such Company Registered Intellectual Property is pending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company and its Subsidiaries and, to the knowledge of the
Company, the Company&#146;s and its Subsidiaries&#146; licensors, have complied with all necessary and applicable Laws regarding the duty of disclosure, candor and good faith in connection with each issued patent or pending patent application
included in the Company Registered Intellectual Property. To the knowledge of the Company, there is no relevant prior art revealed, disclosed or discovered after the issuance of any patent included in the Company IP that was not cited during the
prosecution of such patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company and each of its Subsidiaries owns, or has a valid and enforceable written license to use, all
Intellectual Property used or held for use in, or otherwise necessary for, the continued conduct of the business of the Company and its Subsidiaries as currently conducted and in substantially the same manner as such business has been conducted
during the twelve (12)&nbsp;months prior to the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company nor any of its Subsidiaries have infringed,
misappropriated or otherwise violated, or are infringing upon, misappropriating or otherwise violating, any Intellectual Property of any Person. There is no Action pending, or, to the knowledge of the Company, threatened (including by way of a cease
and desist letter or offer or invitation to take a license), (i) alleging the Company&#146;s or any of its Subsidiaries&#146; infringement, misappropriation or other violation of any Intellectual Property of any Person, or (ii)&nbsp;challenging the
scope, use, registrability, validity, or enforceability of, or the Company&#146;s or any of its Subsidiaries&#146; right, title or interest in, to, or under, any Company IP, and there has not been any such Action brought or threatened in writing.
Neither the Company nor any of its Subsidiaries is a party to or bound by any decree, judgment, order, or arbitral award that requires the Company or any of its Subsidiaries to grant to any Person any license, covenant not to sue, immunity or other
right with respect to any Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of the Company, no Person is infringing, misappropriating or
otherwise violating, or has infringed, misappropriated or otherwise violated, any Company Owned IP or any of the Company&#146;s or any of its Subsidiaries&#146; rights under any Company Licensed IP. Neither the Company nor any of its Subsidiaries
has commenced or threatened any Action with respect to any such infringement, misappropriation or other violation against any Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Section&nbsp;4.21(g) of the Company Disclosure Letter contains a true and complete list
of any and all Company IP that was created, developed or reduced to practice, or is being created, developed or reduced to practice, (i)&nbsp;pursuant to, or in connection with, any Contract with any Governmental Authority or Governmental
Authority-affiliated entity, or university, college or other educational institution, or (ii)&nbsp;using any funding or facilities of any Governmental Authority or Governmental Authority-affiliated entity, or university, college or other educational
institution (collectively, &#147;<B>Government Funded IP</B>&#148;). The Company and its Subsidiaries and, to the knowledge of the Company, the Company&#146;s and its Subsidiaries&#146; licensors, have taken any and all actions necessary to obtain,
secure, maintain, enforce and protect the Company&#146;s or its applicable Subsidiary&#146;s, or such licensors&#146;, as applicable, right, title and interest in, to and under all Government Funded IP, and the Company and its Subsidiaries and, to
the knowledge of the Company, the Company&#146;s and its Subsidiaries&#146; licensors, have complied with any and all any Intellectual Property disclosure and/or licensing obligations under any applicable Contract referenced in clause
(i)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company and each of its Subsidiaries has taken reasonable steps, in accordance with normal industry practice, to
maintain, defend and enforce all Company Owned IP and their respective rights in all Company Licensed IP, including reasonable actions to maintain and protect the confidentiality of any Trade Secrets included in the Company IP, and no such Trade
Secrets have been disclosed other than pursuant to written and enforceable confidentiality agreements, which have not been breached or otherwise violated. Each current and former employee, consultant and contractor of the Company and its
Subsidiaries, and each other Person currently or formerly engaged in the development or creation of any Company IP, has executed a written agreement whereby such employee, consultant, contractor or other Person presently assigns to the Company or
one of its Subsidiaries or their respective licensors all right, title and interest in and to any and all Intellectual Property developed or created by such employee, consultant, contractor or other Person during the term of employment or engagement
with the Company or its Subsidiaries or licensors, as applicable, and, to the knowledge of the Company, no such agreement has been breached or otherwise violated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The execution and delivery of this Agreement and the consummation of the Transactions will not alter, encumber, impair or extinguish any
Company IP. There exist no restrictions on the disclosure, use, licensing or transfer of any of the Company IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_34"></A>Section&nbsp;4.22. <I>Privacy and Cybersecurity</I>. Except as has not had, and would not reasonably be expected
to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and except as is not, and would not reasonably be expected to be, material to the business of the Company and its
Subsidiaries, taken as a whole: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries are presently in compliance with, and have at all times been in
compliance with, all applicable (i)&nbsp;Laws, (ii) internal and posted or publicly facing rules, policies, and procedures, (iii)&nbsp;contractual obligations and (iv)&nbsp;industry standards, in each case, relating to the collection, storage, use,
privacy, security or other processing of the Company IT Systems or Personal Data (the foregoing clauses (i)&nbsp;through (iv), &#147;<B>Privacy and Cybersecurity Requirements</B>&#148;). There currently are not, and historically have not been, any
Actions pending or, to the knowledge of the Company, threatened, against the Company or any of its Subsidiaries alleging any breach or violation of any Privacy and Cybersecurity Requirement, and, to the knowledge of the Company, there exists no
reasonable basis for any such Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company IT Systems are fully functional and operate and perform in all respects in
accordance with their documentation and functional specifications and otherwise in the manner as is necessary for the business of each of the Company and each of its Subsidiaries as currently conducted, and do not contain any faults, viruses, bugs,
worms, defects, similar corruptants or hardware components designed to permit unauthorized access to or to disable or otherwise harm any computer systems or software. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There have been no breaches (including any ransomware attack), violations, outages or unlawful, accidental, unauthorized uses,
interruptions, exfiltrations, destructions, losses, disclosures, thefts, corruptions, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compromises, disablements, modifications or transmissions of or accesses to any Company IT Systems or to any Personal Data otherwise in the possession, custody or control of the Company or any of
its Subsidiaries or held or processed by any vendor, processor or other Person for or on behalf of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries has notified or been required to notify any Governmental
Authority or any other Person of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company IT Systems are adequate for and meet the needs of the business and
operations of the Company and each of its Subsidiaries as currently conducted. The Company and each of its Subsidiaries have established and maintain, and use reasonable efforts to ensure that all Persons operating any Company IT Systems or
otherwise processing Personal Data on behalf of the Company or any of its Subsidiaries have established and maintain, commercially reasonable and legally compliant policies, safeguards and procedures to maintain and protect the Company&#146;s and
its Subsidiaries&#146; Trade Secrets and other confidential information and the operation, integrity, redundancy, continuity and security of the Company IT Systems (including any and all information and data (including Personal Data) stored thereon
or transmitted thereby), including the implementation, maintenance, monitoring and periodic testing of (i)&nbsp;data <FONT STYLE="white-space:nowrap">back-up,</FONT> (ii)&nbsp;disaster avoidance, disaster recovery and business continuity plans,
policies and procedures and (iii)&nbsp;encryption, redaction and other reasonable and appropriate organizational, administrative, technical and physical safeguards. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the
Company, any such Person, has received any written notice or complaint from any other Person with respect to any of the foregoing, nor, to the knowledge of the Company, has any such notice or complaint been threatened in writing against the Company
or any of its Subsidiaries or any such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The consummation of the Transactions shall not breach or otherwise cause any violation
of any Privacy and Cybersecurity Requirements or result in the Company or any of its Subsidiaries being prohibited from receiving or using any Personal Data in the manner currently received or used by the Company or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_35"></A>Section&nbsp;4.23. <I>Environmental Matters</I>. Except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries are and, except for
matters which have been fully resolved, have been in compliance with all Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There has been no release of any
Hazardous Materials by the Company or its Subsidiaries in quantities or concentrations that require remediation by the Company or its Subsidiaries under Environmental Laws (i)&nbsp;at, in, on or under any Realty or in connection with the
Company&#146;s and its Subsidiaries&#146; operations <FONT STYLE="white-space:nowrap">off-site</FONT> of the Realty or (ii)&nbsp;to the knowledge of the Company, at, in, on or under any former Realty during the time that the Company owned or leased
such property or at any other location where Hazardous Materials generated by the Company or any of the Company&#146;s Subsidiaries have been transported to, sent, placed or disposed of. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company nor its Subsidiaries are subject to any current Governmental Order relating to any
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with Environmental Laws by the Company or its Subsidiaries or the investigation, sampling, monitoring, treatment, remediation, removal or cleanup of Hazardous Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Legal Proceeding is pending or, to the knowledge of the Company, threatened with respect to the Company&#146;s and its
Subsidiaries&#146; compliance with or liability under Environmental Laws, and there are no facts or circumstances which could reasonably be expected to form the basis of such a Legal Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_36"></A>Section&nbsp;4.24. <I>Absence of Changes</I>. From the date of the most recent balance sheet included in the
Financial Statements to the date of this Agreement, there has not been any Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_37"></A>Section&nbsp;4.25. <I>Anti-Corruption Compliance.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For the past four (4)&nbsp;years, neither the Company nor any of its Subsidiaries, nor any director, officer, or, to the knowledge of the
Company, employee or agent, in each case acting on behalf of the Company or any of the Company&#146;s Subsidiaries, has offered or given anything of value to: (i)&nbsp;any official or employee of a Governmental Authority, any political party or
official thereof, or any candidate for political office, (ii)&nbsp;any other Person, in any such case while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to any official or
employee of a Governmental Authority or candidate for political office, or (iii)&nbsp;any director, officer, employee, or agent of a commercial enterprise, in each case, in material violation of applicable Anti-Bribery Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the knowledge of the Company, there are no pending or threatened, material claims, complaints, charges, investigations, voluntary
disclosures or Legal Proceedings against the Company or any of the Company&#146;s Subsidiaries related to any Anti-Bribery Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_38">
</A>Section&nbsp;4.26. <I>Anti-Money Laundering, Sanctions and National Security Compliance.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries
are, and have been for the past four (4)&nbsp;years, in compliance with all Anti-Money Laundering Laws and Sanctions Laws in all material respects. To the knowledge of the Company, there are no pending or threatened claims, complaints, charges,
investigations, voluntary disclosures or Legal Proceedings against the Company or any of the Company&#146;s Subsidiaries related to any Anti-Money Laundering Laws or Sanctions Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its Subsidiaries nor any of their respective directors or officers, employees, agents, representatives or
other Persons acting on behalf of the Company or any of the Company&#146;s Subsidiaries, (i)&nbsp;is a Sanctioned Person, or (ii)&nbsp;has during the past four (4)&nbsp;years been a Sanctioned Person with whom the Company or any Subsidiary was
prohibited from dealing pursuant to applicable Sanctions Laws. Neither the Company nor any of its Subsidiaries nor any of their respective directors or officers, or, to the knowledge of the Company, employees, agents, representatives (in each case
acting in their capacity as such) or other Persons acting on behalf of the Company or any of the Company&#146;s Subsidiaries, has transacted material business in the past four (4)&nbsp;years directly or knowingly indirectly with any Sanctioned
Person or Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_39"></A>Section&nbsp;4.27. <I>Information Supplied</I>. None of the information
supplied or to be supplied by the Company or any of the Company&#146;s Subsidiaries specifically in writing for inclusion in the Registration Statement will, at the date on which the Proxy Statement/Registration Statement is first mailed to the EBAC
Shareholders or at the time of the EBAC Shareholders&#146; Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they are made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_40"></A>Section&nbsp;4.28. <I>No Outside Reliance</I>.
Notwithstanding the delivery or disclosure (except in Article 6 and the EBAC Disclosure Letter) to the Company or any of their respective representatives of any documentation or other information (including any financial projections or other
supplemental details), the Company and its directors, managers, officers, employees, equityholders, partners, members or representatives, acknowledge and agree that the Company has made its own investigation of EBAC and that none of EBAC nor any of
its Affiliates, agents or representatives is making any representation or warranty whatsoever, express or implied, beyond those expressly given by EBAC in <B></B>Article 6, including any implied warranty or representation as to condition,
merchantability, suitability or fitness for a particular purpose or trade as to any of the assets of EBAC, the prospects (financial or otherwise) or the viability or likelihood of success of the business of EBAC as conducted after the Acquisition
Closing, as contained in any materials provided by EBAC or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise, and no statement contained in any of such
materials made or made in any such presentation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business and affairs of EBAC shall be deemed a representation or warranty hereunder or otherwise or deemed to be relied upon by the Company in executing, delivery or performing this Agreement or
the Transactions. Except as otherwise expressly set forth in this Agreement, the Company understands and agrees that any assets, properties and business of EBAC are furnished &#147;<B>as is</B>,&#148; &#147;<B>where is</B>&#148; and subject to and
except as otherwise provided in the representations and warranties contained in Article 6, with all faults and without any other representation or warranty of any nature whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_41"></A>Section&nbsp;4.29. <I>No Additional Representation or Warranties</I>. Except as provided in this Article 4,
neither the Company nor any of its Affiliates, nor any of their respective directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to EBAC or
their Affiliates and no such party shall be liable in respect of the accuracy or completeness of any other information provided to EBAC or their Affiliates. Except for the representations and warranties expressly set forth in this Article 4, it is
understood that any cost estimates, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations, including any offering memorandum or similar materials made available by or on behalf
of the Company are not and shall not be deemed to be or to include representations or warranties of the Company or any of its Subsidiaries or any other person, and are not and shall not be deemed to be relied upon by EBAC in executing, delivering or
performing this Agreement or the Transactions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> N<SMALL>EW</SMALL>
P<SMALL>ARENT</SMALL>, M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 1, M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 2 <SMALL>AND</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> 3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the disclosure letter delivered to the Company by EBAC on the date of this Agreement (each section of which, subject to
Section&nbsp;12.09, qualifies the correspondingly numbered and lettered representations in this Article 5), each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 hereby represents and warrants to the Company (each upon execution of a
joinder agreement) as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_42"></A>Section&nbsp;5.01. <I>Corporate Organization</I>. At the time of formation,
each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will be a corporation, exempted company, limited liability company or other applicable business entity duly organized, incorporated or formed, as applicable, validly existing and in
good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation, incorporation or
organization (as applicable) and has the requisite company or corporate power, as applicable, and authority to own, lease or operate all of its properties and assets and to conduct its business as it is now being conducted. The Governing Documents
of each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, as amended to the date of this Agreement and as previously made available to the Company, are true, correct and complete. New Parent is duly licensed or qualified and in good
standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified or in good
standing, as applicable, except where the failure to be so licensed or qualified or in good standing is not and would not reasonably be expected to be material to its business and the business of EBAC and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_43"></A>Section&nbsp;5.02. <I>Due Authorization.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will have, the requisite company or corporate power, as applicable, and authority
to execute and deliver this Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. Subject to
the receipt of the approvals and consents to be obtained by New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 pursuant to Section&nbsp;7.06, the execution and delivery of this Agreement and other documents to which either of New Parent, Merger
Sub 1, Merger Sub 2 and Merger Sub 3 is a party contemplated hereby and the consummation of the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby and thereby have been duly and validly authorized and approved by all necessary corporate (or other similar) action on the part of each of New Parent, Merger Sub 1, Merger Sub
2 and Merger Sub 3 and no other company or corporate proceeding on the part of each of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, is necessary to authorize this Agreement and the other documents to which any of New
Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 is a party contemplated hereby. This Agreement has been, and on or prior to the Acquisition Closing, the other documents to any of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case
may be, is a party contemplated hereby will constitute a legal, valid and binding obligation of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, enforceable against New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3,
as the case may be, in accordance with its terms, subject to the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Acquisition Closing
Date, the Board of Directors of New Parent shall duly adopt resolutions (i)&nbsp;determining that this Agreement and the other documents to which New Parent is a party contemplated hereby and the transactions contemplated hereby and hereby are
advisable and fair to, and in the best interests of, New Parent and its stockholders and (ii)&nbsp;authorizing and approving the execution, delivery and performance by New Parent of this Agreement and the other documents to which it is a party
contemplated hereby and the transactions contemplated hereby and thereby. No other corporate action is required on the part of New Parent or any of its stockholders to enter into this Agreement or the other documents to which New Parent is a party
contemplated hereby or to approve the transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_44"></A>Section&nbsp;5.03.
<I>Capitalization.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the Acquisition Closing Date, immediately prior to the Acquisition Closing, the issued share capital of New
Parent consists of CHF 100,000 divided into 10,000,000 registered shares (Namenaktien/actions nominatives) with a nominal value of CHF 0.01, which shall be duly authorized and validly issued. Except as set forth in the first sentence of this
Section&nbsp;5.03(a), immediately prior to the issuance of New Parent Shares in accordance with this Agreement, there shall be no other New Parent Shares or other Equity Securities of New Parent authorized, reserved, issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(i) As of the date of formation of New Parent, the sole stockholder of New Parent will be EBAC and (ii)&nbsp;upon consummation of the
transactions set forth in <U>Section</U><U></U><U>&nbsp;8.08</U>, the sole stockholder of each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 will be New Parent. As of the date its formation, New Parent will have no Subsidiaries and will not own,
directly or indirectly, any Equity Securities in any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Immediately prior to the issuance of New Parent Shares in accordance
with this Agreement, there shall be (i)&nbsp;no subscriptions, calls, options, warrants, rights or other securities convertible into or exchangeable or exercisable for New Parent Shares or any other Contracts to which New Parent is a party or by
which New Parent is bound obligating New Parent to issue or sell any shares of capital stock of, other Equity Securities in or debt securities of, New Parent, (ii)&nbsp;no equity equivalents, stock appreciation rights, phantom stock ownership
interests or similar rights in New Parent and (iii)&nbsp;no voting trusts, proxies or other Contracts with respect to the voting or transfer of New Parent Shares, in each case except as expressly provided for in this Agreement or the Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_45"></A>Section&nbsp;5.04. <I>Consents and Requisite Governmental Approvals; No Violations.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Authority is required on the part
of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 and, upon executing a joinder in accordance with <U>Section</U><U></U><U>&nbsp;8.08(d)</U> hereto, New Parent&#146;s, Merger Sub 1&#146;s, Merger Sub 2&#146;s or Merger Sub 3&#146;s
execution, delivery or performance of its obligations under this Agreement or the other Ancillary Agreements to which it is or will be party or the consummation of the transactions contemplated hereby or by the Ancillary Agreements, except for
(i)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Exchange Act as may be required in connection with this Agreement, the Ancillary Agreements or the transactions contemplated by hereby or thereby, (ii)&nbsp;such filings with and approvals of
the Stock Exchange to permit New Parent Shares to be issued in accordance with this Agreement to be listed on the Stock Exchange, (iii)&nbsp;filing of the Cayman Plan of Merger and, if applicable, the plan of merger under the applicable law of the
Swiss Code of Obligations, (iv)&nbsp;the approvals and consents to be obtained by New Parent pursuant to <U>Section</U><U></U><U>&nbsp;7.06</U> and Merger Sub 1, Merger Sub 2 and Merger Sub 3 pursuant to <U>Section</U><U></U><U>&nbsp;8.08(e)</U>, or
(v)&nbsp;any consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not reasonably be expected to be, individually or in the aggregate, material to EBAC and its Subsidiaries, taken as a whole.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery by New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 of this Agreement and other documents to which
each will be a party as contemplated hereby and the consummation of the transactions contemplated hereby and thereby will not (i)&nbsp;violate or conflict with any provision of, or result in the breach of, or default under, the Governing Documents
of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, (ii) violate or conflict with any provision of, or result in the breach of, or default under, any Law, License or Governmental Order applicable to New Parent, Merger Sub 1, Merger Sub 2 or
Merger Sub 3 or (iii)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any of the properties or assets of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, except, in the case of clauses (i)&nbsp;through (iii), to the
extent that the occurrence of the foregoing would not reasonably be expected to be material to the business of EBAC and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_46"></A>Section&nbsp;5.05. <I>Business Activities</I>. Each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3
will be organized or formed solely for the purpose of entering into this Agreement, the Ancillary Agreements and consummating the transactions contemplated hereby and thereby and will not have engaged in any activities or business, other than those
incident or related to or incurred in connection with its organization or formation, as applicable, or the negotiation, preparation or execution of this Agreement or any Ancillary Agreements, as applicable, the performance of its covenants or
agreements in this Agreement or any Ancillary Agreements or the consummation of the transactions contemplated hereby or thereby. At all times prior to the Acquisition Closing Date, none of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 shall
have, except as expressly contemplated by the Transaction Agreements and the Transactions, any assets, properties, liabilities or obligations of any kind other than those incident to its formation and this Agreement, and will not conduct any
business or operations except as expressly contemplated by the Transaction Agreements and the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_47"></A>Section&nbsp;5.06. <I>Brokers&#146; Fees</I>. No broker, finder, investment banker or other Person is entitled to
any brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon arrangements made by or on behalf of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 or any of their Affiliates for which New Parent,
Merger Sub 1, Merger Sub 2 or Merger Sub 3 have any obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_48"></A>Section&nbsp;5.07. <I>Tax Matters.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For U.S. federal income Tax purposes, each of New Parent, Merger Sub 1 and Merger Sub 3 will be treated as an association taxable as a
corporation since the date of its formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the Acquisition Closing, Merger Sub 2 will have timely filed an initial entity
classification election on a valid IRS Form 8832 to be treated as an entity disregarded as separate from New Parent for U.S. federal income Tax purposes effective as of the day of its formation and will not subsequently change such classification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of immediately prior to the First Merger Effective Time, the Second Merger Effective Time and the Third Merger Effective Time,
respectively, Merger Sub 1, Merger Sub 2 and Merger Sub 3 shall be direct wholly owned Subsidiaries of New Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) None of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 has taken or agreed to
take any action not contemplated by the Transactions, and to the knowledge of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 there are no facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended
Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_49"></A>Section&nbsp;5.08. <I>Investment Company Act</I>. New Parent is not an &#147;investment
company&#148; or a Person directly or indirectly &#147;controlled&#148; by or acting on behalf of a person subject to registration and regulation as an &#147;investment company,&#148; in each case, within the meaning of the Investment Company Act of
1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_50"></A>Section&nbsp;5.09. <I>Investigation; No Other Representations.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, on its own behalf and on behalf of its representatives, acknowledges,
represents, warrants and agrees that (i)&nbsp;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company
and (ii)&nbsp;it has been furnished with or given access to such documents and information about the Company and its businesses and operations as it and its representatives have deemed necessary to enable it to make an informed decision with respect
to the execution, delivery and performance of this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In entering into this Agreement and the other Ancillary Agreements to which it is a party, New Parent, Merger Sub 1, Merger Sub 2 and
Merger Sub 3 will have relied solely on its own investigation and analysis and the representations and warranties expressly set forth in Article 4 and in the Ancillary Agreements to which it is a party and no other representations or warranties of
EBAC or any other Person, either express or implied, and each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that, except for the
representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements to which it is a party, neither the Company nor any other Person makes or has made any representation or warranty, either express or implied, in
connection with or related to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_51">
</A>Section&nbsp;5.10. <I>No Outside Reliance</I>. Notwithstanding anything contained in this Article 5 or any other provision hereof, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, and their directors, managers, officers, employees,
equityholders, partners, members or representatives, acknowledge and agree that they and their Affiliates have made their own investigation of the Company and that none of the Company nor any of its Affiliates, agents or representatives is making
any representation or warranty whatsoever, express or implied, beyond those expressly given by the Company in Article 4, including any implied warranty or representation as to condition, merchantability, suitability or fitness for a particular
purpose or trade as to any of the assets of the Company, the prospects (financial or otherwise) or the viability of likelihood of success of the business of the Company as conducted after the Acquisition Closing, as contained in any materials
provided by the Company or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise. Except as otherwise expressly set forth in this Agreement, New Parent,
Merger Sub 1, Merger Sub 2 and Merger Sub 3 each understands and agrees that any assets, properties and business of the Company furnished &#147;as is,&#148; &#147;where is&#148; and subject to and except as otherwise provided in the representations
and warranties contained in Article 4, with all faults and without any other representation or warranty of any nature whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_52">
</A>Section&nbsp;5.11. <I>No Additional Representation or Warranties</I>. Except as provided in this Article 5, neither New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 nor any of its and their Affiliates, nor any of their respective
directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to the Company or their Affiliates and no such party shall be liable in respect of the
accuracy or completeness of any other information provided to the Company or their Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> EBAC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in (a)&nbsp;any EBAC SEC Filings filed or submitted on or prior to the date hereof (excluding (i)&nbsp;any disclosures in
any risk factors section that do not constitute statements of fact, disclosures in any forward-looking statements disclaimer and other disclosures that are generally cautionary, predictive or forward-looking in nature and (ii)&nbsp;any exhibits or
other documents appended thereto) (it being acknowledged that nothing disclosed in such EBAC SEC Filings will be deemed to modify or qualify the representations and warranties set forth in Section&nbsp;6.08, Section&nbsp;6.12 and Section&nbsp;6.15),
or (b)&nbsp;in the disclosure letter delivered by EBAC to the Company on the date of this Agreement (the &#147;<B>EBAC Disclosure Letter</B>&#148;) (each section of which, subject to Section&nbsp;12.09, qualifies the correspondingly numbered and
lettered representations in this Article 6), EBAC represents and warrants to the Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_53"></A>Section&nbsp;6.01. <I>Company Organization</I>. EBAC has been duly formed or organized and is validly existing
under the Laws of its jurisdiction of incorporation or organization, and has the requisite company or corporate power, as applicable, and authority to own, lease or operate all of its properties and assets and to conduct its business as it is now
being conducted. The Governing Documents of EBAC, as amended to the date of this Agreement and as previously made available by or on behalf of EBAC to the Company, are true, correct and complete. EBAC is duly licensed or qualified and in good
standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified, except where
the failure to be so licensed or qualified or in good standing is not and would not reasonably be expected to be material to the business of the EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_54"></A>Section&nbsp;6.02. [<I>Intentionally Omitted</I>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_55"></A>Section&nbsp;6.03. <I>Due Authorization.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Other than the EBAC Shareholder Approval, EBAC has all requisite company or corporate power, as applicable, and authority to execute and
deliver this Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. The execution and delivery
of this Agreement and the other documents to which EBAC is a party contemplated hereby and the consummation of the transactions contemplated hereby and thereby have been (A)&nbsp;duly and validly authorized and approved by the EBAC Board and
(B)&nbsp;determined by the EBAC Board as advisable to and in the best interests of EBAC and the EBAC Shareholders, and recommended for approval by the EBAC Shareholders. No other company or corporate proceeding on the part of EBAC is necessary to
authorize this Agreement and the other documents to which EBAC is a party contemplated hereby (other than the EBAC Shareholder Approval). This Agreement has been, and at or prior to the Acquisition Closing, the other documents to which EBAC is a
party contemplated hereby will be, duly and validly executed and delivered by EBAC and this Agreement constitutes, and on or prior to the Acquisition Closing, the other documents to which EBAC is a party contemplated hereby will constitute, assuming
the due authorization, execution and delivery by the other parties hereto, a legal, valid and binding obligation of EBAC, enforceable against EBAC in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Assuming that a quorum (as determined pursuant to EBAC&#146;s Governing Documents) is present, each of those Transaction Proposals
identified in clauses (i), (ii) and (iii)&nbsp;of Section&nbsp;9.02(c), in each case, shall require approval by an affirmative vote of the holders of at least a majority of the outstanding EBAC Common Stock entitled to vote, who attend and vote
thereupon (as determined in accordance with EBAC&#146;s Governing Documents) at a shareholders&#146; meeting duly called by the EBAC Board and held for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The foregoing votes are the only votes of any of EBAC&#146;s share capital necessary in connection with entry into this Agreement by EBAC
and the consummation of the Transactions, including the Acquisition Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) At a meeting duly called and held, the EBAC Board has unanimously approved the
Transactions as a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_56"></A>Section&nbsp;6.04. <I>No Conflict</I>. Subject to the EBAC
Shareholder Approval and the receipt of the Governmental Authorizations set forth in Section&nbsp;6.04, the execution and delivery of this Agreement by EBAC and the other documents to which EBAC is a party contemplated hereby by EBAC and the
consummation of the transactions contemplated hereby and thereby do not and will not (a)&nbsp;violate or conflict with any provision of, or result in the breach of or default under the Governing Documents of EBAC, (b)&nbsp;violate or conflict with
any provision of, or result in the breach of, or default under any applicable Law or Governmental Order applicable to EBAC, (c)&nbsp;violate or conflict with any provision of, or result in the breach of, result in the loss of any right or benefit,
or cause acceleration, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration) under any Contract to which EBAC is a party or by which EBAC may be bound,
or terminate or result in the termination of any such foregoing Contract or (d)&nbsp;result in the creation of any Lien upon any of the properties or assets of EBAC, except, in the case of clauses (b)&nbsp;through (d), to the extent that the
occurrence of the foregoing would not (i)&nbsp;have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to enter into and perform its obligations under this Agreement or
(ii)&nbsp;be, and would not be reasonably expected to be, material to EBAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_57"></A>Section&nbsp;6.05.
<I>Governmental Authorities; Consents</I>. Assuming the truth and completeness of the representations and warranties of the Company contained in this Agreement, no Governmental Authorization is required on the part of EBAC with respect to
EBAC&#146;s execution, delivery and performance of this Agreement and the other Ancillary Agreements to which EBAC is a party and the consummation of the transactions contemplated hereby and thereby, except for the filing of the plan of merger under
the Cayman Companies Act and Swiss Code of Obligations (if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_58"></A>Section&nbsp;6.06. <I>Litigation and
Proceedings</I>. There are no pending or, to the knowledge of EBAC, threatened Legal Proceedings against EBAC or its properties or assets, or, to the knowledge of EBAC, any of their respective directors, managers, officers or employees (in their
capacity as such). There are no investigations or other inquiries pending or, to the knowledge of EBAC, threatened by any Governmental Authority, against EBAC or its properties or assets, or, to the knowledge of EBAC, any of its directors, managers,
officers or employees (in their capacity as such). There is no outstanding Governmental Order imposed upon EBAC, nor are any assets of EBAC&#146;s business bound or subject to any Governmental Order the violation of which would have, or would
reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. As of the date hereof, EBAC is in compliance with all applicable Laws, except as would not have, or
would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. For the past three (3)&nbsp;years, EBAC has not received any written notice of or been
charged with the violation of any Laws, except where such violation would not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. This
<U>Section</U><U></U><U>&nbsp;6.06</U> shall not apply to Tax matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_59"></A>Section&nbsp;6.07. <I>SEC Filings</I>.
EBAC has timely filed or furnished all statements, prospectuses, registration statements, forms, reports and documents required to be filed by it with the SEC since August&nbsp;15, 2022, pursuant to the Exchange Act or the Securities Act
(collectively, as they have been amended since the time of their filing through the date hereof, the &#147;<B>EBAC SEC Filings</B>&#148;). Each of the EBAC SEC Filings, as of the respective date of its filing (or if amended or superseded by a filing
prior to the date of this Agreement or the Acquisition Closing Date, then on the date of such amendment or superseding filing), complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act, the
Sarbanes-Oxley Act and any rules and regulations promulgated thereunder applicable to the EBAC SEC Filings. As of the respective date of its filing (or if amended or superseded by a filing prior to the date of this Agreement or the Acquisition
Closing Date, then on the date of such amendment or superseding filing), the EBAC SEC Filings did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements made therein, in light of the circumstances under which they were made, not misleading. As of the date hereof, there are no outstanding or unresolved comments in comment letters
received from the SEC with respect to the EBAC SEC Filings. To the knowledge of EBAC, none of the EBAC SEC Filings filed on or prior to the date hereof is subject to ongoing SEC review or investigation as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_60"></A>Section&nbsp;6.08. <I>Internal Controls; Listing; Financial Statements.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as not required in reliance on exemptions from various reporting requirements by virtue of EBAC&#146;s status as an
&#147;<B>emerging growth company</B>&#148; within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (&#147;<B>JOBS Act</B>&#148;), EBAC has established and maintains disclosure controls and procedures
(as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act). Such disclosure controls and procedures are designed to ensure that material information relating to EBAC, including its consolidated Subsidiaries, if any,
is made known to EBAC&#146;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared. To
EBAC&#146;s knowledge, such disclosure controls and procedures are effective in timely alerting EBAC&#146;s principal executive officer and principal financial officer to material information required to be included in EBAC&#146;s periodic reports
required under the Exchange Act. EBAC has established and maintained a system of internal controls over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act) sufficient to provide reasonable
assurance regarding the reliability of EBAC&#146;s financial reporting and the preparation of EBAC Financial Statements for external purposes in accordance with GAAP, except as would not have, or would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each director and
executive officer of EBAC has filed with the SEC on a timely basis all statements required by Section&nbsp;16(a) of the Exchange Act and the rules and regulations promulgated thereunder. EBAC has not taken any action prohibited by Section&nbsp;402
of the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EBAC has complied in all material respects with the applicable listing and corporate governance rules and
regulations of the Nasdaq. The EBAC Class&nbsp;A Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and is listed for trading on the Nasdaq. There is no Legal Proceeding pending or, to the knowledge of EBAC, threatened
against EBAC by the Nasdaq or the SEC with respect to any intention by such entity to deregister the EBAC Class&nbsp;A Common Stock or prohibit or terminate the listing of EBAC Class&nbsp;A Common Stock on the Nasdaq. EBAC has taken no action that
would reasonably be likely to result in the termination of the registration of the EBAC Class&nbsp;A Common Stock under the Exchange Act. EBAC has not received any written or, to the knowledge of EBAC, oral deficiency notice from the Nasdaq relating
to the continued listing requirements of the EBAC Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as disclosed in the EBAC SEC Filings, the EBAC
Financial Statements (i)&nbsp;in all material respects fairly present the financial position of EBAC, as at the respective dates thereof, and the results of operations and consolidated cash flows for the respective periods then ended, (ii)&nbsp;were
prepared in all material respects in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated therein or in the notes thereto), and (iii)&nbsp;comply in all material respects with the applicable
accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof. The books and records of EBAC have been, and are being, maintained in accordance with GAAP
and any other applicable legal and accounting requirements in all material respects. Since the consummation of the initial public offering of EBAC&#146;s securities, EBAC has timely filed all certifications and statements required by (i)&nbsp;Rule <FONT
STYLE="white-space:nowrap">13a-14</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14</FONT> under the Exchange Act or (ii) 18 U.S.C. Section&nbsp;1350 (Section 906 of the Sarbanes-Oxley Act) with respect to any EBAC SEC Filing. Each such
certification is correct and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no outstanding loans or other extensions of credit made by
EBAC to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> under the Exchange Act) or director of EBAC. EBAC has not taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither EBAC (including any employee thereof) nor EBAC&#146;s independent auditors has
identified or been made aware of (i)&nbsp;any fraud, whether or not material, that involves EBAC&#146;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by EBAC or
(ii)&nbsp;any claim or allegation regarding any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_61"></A>Section&nbsp;6.09. <I>Trust Account</I>. As
of the date of this Agreement, EBAC has at least $127,741,378 in the Trust Account (including, if applicable, an aggregate of approximately $4,944,024 of deferred underwriting commissions and other fees being held in the Trust Account), such monies
invested in United States government securities or money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act pursuant to the Investment Management Trust
Agreement, dated as of March&nbsp;15, 2021, between EBAC and Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee (the &#147;<B>Trustee</B>&#148;) (the &#147;<B>Trust Agreement</B>&#148;). The Trust Agreement is in full force and effect
and is a legal, valid and binding obligation of EBAC, enforceable in accordance with its terms. The Trust Agreement has not been terminated, repudiated, rescinded, amended, supplemented or modified, in any respect by EBAC or the Trustee, and no such
termination, repudiation, rescission, amendment, supplement or modification is contemplated by EBAC. There are no separate Contracts, side letters or other arrangements or understandings (whether written or unwritten, express or implied) that would
cause the description of the Trust Agreement in the EBAC SEC Filings to be inaccurate or that would entitle any Person (other than shareholders of EBAC holding EBAC Common Stock sold in EBAC&#146;s initial public offering who shall have elected to
redeem their shares of EBAC Common Stock pursuant to EBAC&#146;s Governing Documents and the underwriters of EBAC&#146;s initial public offering with respect to deferred underwriting commissions) to any portion of the proceeds in the Trust Account.
Prior to the Acquisition Closing, none of the funds held in the Trust Account may be released other than to pay Taxes and payments with respect to all EBAC Share Redemptions. There are no material claims or material proceedings pending or, to the
knowledge of EBAC, threatened with respect to the Trust Account. EBAC has performed all material obligations required to be performed by it to date under, and is not in default, breach or delinquent in performance or any other respect (claimed or
actual) in connection with, the Trust Agreement, and no event has occurred which, with due notice or lapse of time or both, would constitute such a default or breach thereunder. As of the First Merger Effective Time, the obligations of EBAC to
dissolve or liquidate pursuant to EBAC&#146;s Governing Documents shall terminate, and as of the First Merger Effective Time, EBAC shall have no obligation whatsoever pursuant to EBAC&#146;s Governing Documents to dissolve and liquidate the assets
of EBAC by reason of the consummation of the Transactions. To EBAC&#146;s knowledge, as of the date hereof, following the First Merger Effective Time, no EBAC Shareholder shall be entitled to receive any amount from the Trust Account except to the
extent such EBAC Shareholder is exercising an EBAC Share Redemption. As of the date hereof, assuming the conditions set forth in Section&nbsp;10.01 and Section&nbsp;10.02 are satisfied, EBAC does not have any reason to believe that any of the
conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be available to EBAC on the Acquisition Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_62"></A>Section&nbsp;6.10. <I>Investment Company Act; JOBS Act</I>. EBAC is not an &#147;investment company&#148; or a
Person directly or indirectly &#147;controlled&#148; by or acting on behalf of an &#147;investment company,&#148; in each case within the meaning of the Investment Company Act. EBAC constitutes an &#147;emerging growth company&#148; within the
meaning of the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_63"></A>Section&nbsp;6.11. <I>Absence of Changes</I>. Since March&nbsp;31, 2022, (a) there
has not been any event or occurrence that has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions and (b)&nbsp;EBAC has, in all material
respects, conducted its business and operated its properties in the ordinary course of business consistent with past practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_64">
</A>Section&nbsp;6.12. <I>No Undisclosed Liabilities</I>. Except for any fees and expenses payable by EBAC as a result of or in connection with the consummation of the Transactions, as of the date of this Agreement, there is no liability, debt or
obligation of or claim or judgment against EBAC (whether direct or indirect, absolute or contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due), except for liabilities and obligations
(a)&nbsp;reflected or reserved for on the financial statements or disclosed in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notes thereto included in EBAC SEC Filings, (b)&nbsp;that have arisen since the date of the most recent balance sheet included in the EBAC SEC Filings in the ordinary course of business of EBAC,
or (c)&nbsp;which would not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. This <U>Section</U><U></U><U>&nbsp;6.12</U> shall not
apply to Tax matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_65"></A>Section&nbsp;6.13. <I>Capitalization of EBAC.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As of the date of this Agreement, the authorized share capital of EBAC is consists of (i) 200,000,000 shares of EBAC Class&nbsp;A Common
Stock, of which 13,209,880 shares are issued and outstanding (including those underlying the EBAC Units), (ii) 20,000,000 shares of EBAC Class&nbsp;B Common Stock, of which 3,188,696 shares are issued and outstanding, and (iii) 1,000,000 preferred
shares, par value $0.0001 per share, of which no shares are issued and outstanding (the foregoing clauses (i), (ii) and (iii)&nbsp;collectively, the &#147;<B>EBAC Securities</B>&#148;). The foregoing represents all of the issued and outstanding EBAC
Securities as of the date of this Agreement. All issued and outstanding EBAC Securities (i)&nbsp;have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> (ii)&nbsp;have been offered,
sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (A)&nbsp;EBAC&#146;s Governing Documents, and (B)&nbsp;any other applicable Contracts governing the issuance of such
securities; and (iii)&nbsp;are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law,
EBAC&#146;s Governing Documents or any Contract to which EBAC is a party or otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement,
4,251,595 EBAC Public Warrants (including those underlying the EBAC Units) and 151,699 EBAC Private Placement Warrants are issued and outstanding. All outstanding EBAC Warrants (i)&nbsp;have been duly authorized and validly issued and constitute
valid and binding obligations of EBAC, enforceable against EBAC in accordance with their terms, subject to the Enforceability Exception; (ii)&nbsp;have been offered, sold and issued in compliance with applicable Law, including federal and state
securities Laws, and all requirements set forth in (1)&nbsp;EBAC&#146;s Governing Documents and (2)&nbsp;any other applicable Contracts governing the issuance of such securities; and (iii)&nbsp;are not subject to, nor have they been issued in
violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, EBAC&#146;s Governing Documents or any Contract to which EBAC is a party or
otherwise bound. Except for the Subscription Agreements, any Additional Subscription Agreements, EBAC&#146;s Governing Documents and this Agreement, there are no outstanding Contracts of EBAC to repurchase, redeem or otherwise acquire any EBAC
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Other than in connection with the PIPE Investment or the Transactions, and except as set forth in this Section&nbsp;6.13
as contemplated by this Agreement or the other documents contemplated hereby, or with the written consent of the Company, EBAC has not granted any outstanding options, stock appreciation rights, warrants, phantom stock, stock-based performance unit,
profit participation, restricted stock, restricted stock unit, rights or other securities convertible into or exchangeable or exercisable for EBAC Securities, or any other commitments or agreements providing for the issuance of additional shares,
the sale of treasury shares, for the repurchase or redemption of any EBAC Securities or the value of which is determined by reference to the EBAC Securities, and there are no Contracts of any kind which may obligate EBAC to issue, purchase, redeem
or otherwise acquire any of its EBAC Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_66"></A>Section&nbsp;6.14. <I>Brokers&#146; Fee</I>. No broker,
finder, investment banker or other Person (except the Person(s) set forth on Section&nbsp;6.13 of the EBAC Disclosure Letter) is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon
arrangements made by EBAC or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_67"></A>Section&nbsp;6.15. <I>Indebtedness</I>. EBAC does not
have any Indebtedness other than Working Capital Loans. As of the date hereof, the balance of the Working Capital Loans is $0.00. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_68"></A>Section&nbsp;6.16. <I>Taxes.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All income and other material Tax Returns required to be filed by or with respect to EBAC have been timely filed (taking into account any
applicable extensions), all such Tax Returns (taking into account all amendments thereto) are true, complete and accurate in all material respects and all material amounts of Taxes of EBAC that are due and payable (whether or not shown on any Tax
Return) have been fully and timely paid, other than Taxes being contested in good faith and for which adequate reserves have been established in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) EBAC has withheld from amounts owing to any employee, creditor or other Person all material Taxes required by Law to be withheld, paid
over to the proper Governmental Authority in a timely manner all such withheld amounts required to have been so paid over and complied in all material respects with all applicable withholding and related reporting requirements with respect to such
Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EBAC does not have any liability for unpaid Taxes which has not been accrued for or reserved on the EBAC Financial Statements,
other than any liability for unpaid Taxes that has been incurred since the end of the most recent fiscal year in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no Liens for any material Taxes (other than Permitted Liens) upon the property or assets of EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No claim, assessment, deficiency or proposed adjustment for any material amount of Tax has been asserted or assessed by any Governmental
Authority against EBAC that remains unpaid except for claims, assessments, deficiencies or proposed adjustments being contested in good faith and for which adequate reserves have been established in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There are no ongoing or pending Legal Proceedings with respect to any material Taxes of EBAC and EBAC has not received written notice from
any Governmental Authority that any such Legal Proceeding is contemplated or pending. There are no waivers, extensions or requests for any waivers or extensions of any statute of limitations currently in effect with respect to any material Taxes of
EBAC (other than pursuant to an extension of time to file a Tax Return of not more than seven months obtained in the ordinary course of business). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) EBAC has not made a request for an advance Tax ruling, a request for administrative Tax relief, a request for technical Tax advice, a
request for a change of any method of accounting or any similar request with respect to Taxes that is in progress or pending with any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) EBAC is not a party to any Tax Sharing Agreement other than customary commercial Contracts entered into in the ordinary course of business
not primarily related to Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) EBAC has never been a member of an Affiliated Group and is not liable for Taxes of any other Person
(other than EBAC) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law or as a transferee or successor or by
Contract (other than customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
No written claim has been made by any Governmental Authority in a jurisdiction where the EBAC does not pay a particular type of Tax or file a particular type of Tax Return that it is or may be required to pay such type of Tax or file such type of
Tax Return in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To EBAC&#146;s Knowledge, EBAC does not have, nor has ever had, a permanent establishment in any
country other than the country of its organization and is not, nor has ever been, subject to income Tax in a jurisdiction outside the country of its organization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) EBAC has not constituted either a &#147;distributing corporation&#148; or a
&#147;controlled corporation&#148; in a distribution of stock qualifying for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code in the prior two (2)&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) EBAC has not participated in a &#147;listed transaction&#148; within the meaning of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) EBAC will not be required to include any material amount in
taxable income or exclude any material item of deduction or loss from taxable income for any taxable period ending after the Acquisition Closing Date as a result of any (i)&nbsp;installment sale or open transaction disposition made prior to the
Acquisition Closing outside the ordinary course of business, (ii)&nbsp;prepaid amount received or deferred revenue recognized prior to the Acquisition Closing outside the ordinary course of business, (iii)&nbsp;change in method of accounting for a
taxable period ending on or prior to the Acquisition Closing Date, (iv) &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law) executed on or prior to the Acquisition Closing Date or (v)&nbsp;binding agreement with respect to Taxes with a Governmental Authority executed prior to the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) EBAC has not taken any action or agreed to take any action not contemplated by the Transactions, and to the knowledge of EBAC there are no
facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_69">
</A>Section&nbsp;6.17. <I>Business Activities.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since formation, EBAC has not conducted any business activities other than
activities related to EBAC&#146;s initial public offering or directed toward the accomplishment of a Business Combination. Except as set forth in EBAC&#146;s Governing Documents or as otherwise contemplated by this Agreement or the Ancillary
Agreements and the transactions contemplated hereby and thereby, there is no agreement, commitment, or Governmental Order binding upon EBAC or to which EBAC is a party which has or would reasonably be expected to have the effect of prohibiting or
materially impairing any business practice of EBAC or any acquisition of property by EBAC or the conduct of business by EBAC or as currently conducted or as contemplated to be conducted as of the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except for the transactions contemplated by this Agreement and the Ancillary Agreements, EBAC does not own or have a right to acquire,
directly or indirectly, any interest or investment (whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity. Except for this Agreement and the Ancillary Agreements and the transactions contemplated
hereby and thereby, EBAC has no material interests, rights, obligations or liabilities with respect to, and is not party to, bound by or has its assets or property subject to, in each case whether directly or indirectly, any Contract or transaction
which is, or would reasonably be interpreted as constituting, a Business Combination (other than confidentiality agreements, term sheets, letters of intent or other customary agreements entered into in connection with review of potential initial
business combinations conducted by EBAC, in each case which were entered into prior to the date hereof and which do not contain binding terms with respect to liabilities or obligations to effect a Business Combination). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the date hereof and except for this Agreement, the Ancillary Agreements and the other documents and transactions contemplated hereby
and thereby (including with respect to expenses and fees incurred in connection therewith), EBAC is not a party to any Contract with any other Person that would require payments by EBAC or any of its Subsidiaries after the date hereof in excess of
$500,000 in the aggregate with respect to any individual Contract, other than Working Capital Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_70"></A>Section&nbsp;6.18. <I>Stock Market Quotation</I>. As of the date hereof, the shares of EBAC Class&nbsp;A Common
Stock are registered pursuant to Section&nbsp;12(b) of the Exchange Act and is listed for trading on the Nasdaq under the symbol &#147;EBAC.&#148; As of the date hereof, the EBAC Warrants are registered pursuant to Section&nbsp;12(b) of the Exchange
Act and are listed for trading on the Nasdaq under the symbol &#147;EBACW.&#148; EBAC is in compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the rules of the Nasdaq and there is no Action or proceeding pending or, to the knowledge of EBAC, threatened against EBAC by the Nasdaq or the SEC with respect to any intention by such
entity to deregister the shares of EBAC Class&nbsp;A Common Stock or EBAC Warrants or terminate the listing of shares of EBAC Class&nbsp;A Common Stock or EBAC Warrants on the Nasdaq. Neither EBAC nor its Affiliates has taken any action in an
attempt to terminate the registration of the shares of EBAC Class&nbsp;A Common Stock or EBAC Warrants under the Exchange Act except as contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_71"></A>Section&nbsp;6.19. <I>Investigation; No Other Representations.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) EBAC, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that (i)&nbsp;it has conducted
its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company and its Subsidiaries and (ii)&nbsp;it has been furnished with or
given access to such documents and information about Company, its Subsidiaries and their respective businesses and operations as they and their respective representatives have deemed necessary to enable it to make an informed decision with respect
to the execution, delivery and performance of this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In entering into this Agreement and the other Ancillary Agreements to which it is a party, EBAC has relied solely on its own investigation
and analysis and the representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements to which it is a party and no other representations or warranties of the Company, its Subsidiaries or any other Person, either
express or implied, and EBAC, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements
to which it is a party, neither EBAC nor any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Agreements or the transactions contemplated hereby
or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_72"></A>Section&nbsp;6.20. <I>No Outside Reliance</I>. Notwithstanding the delivery or disclosure (except
in Article 4 or the Company Disclosure Letter) to EBAC or any of its respective representatives of any documentation or other information (including any financial projections or other supplemental details), EBAC and its directors, managers,
officers, employees, equityholders, partners, members or representatives, acknowledge and agree that EBAC has made its own investigation of the Company and that neither the Company nor any of its Affiliates, agents or representatives is making any
representation or warranty whatsoever, express or implied, beyond those expressly given by the Company in Article 4, including any implied warranty or representation as to condition, merchantability, suitability or fitness for a particular purpose
or trade as to any of the assets of the Company or its Subsidiaries, the prospects (financial or otherwise) or the viability or likelihood of success of the business of the Company as conducted after the Acquisition Closing, as contained in any
materials provided by Company or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise, and no statement contained in any of such materials made or made in
any such presentation of the business and affairs of the Company shall be deemed a representation or warranty hereunder or otherwise or deemed to be relied upon by EBAC in executing, delivery or performing this Agreement or the Transactions. Except
as otherwise expressly set forth in this Agreement, EBAC understands and agrees that any assets, properties and business of the Company and its Subsidiaries are furnished &#147;as is,&#148; &#147;where is&#148; and subject to and except as otherwise
provided in the representations and warranties contained in Article 4, with all faults and without any other representation or warranty of any nature whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_73"></A>Section&nbsp;6.21. <I>No Additional Representation or Warranties</I>. Except as provided in this Article 6,
neither EBAC nor its Affiliates, nor any of its directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to the Company or its Affiliates and no
such party shall be liable in respect of the accuracy or completeness of any other information provided to the Company or its Affiliates. Except for the representations and warranties expressly set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth in this Article 6, it is understood that any cost estimates, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations,
including any offering memorandum or similar materials made available by or on behalf of the EBAC are not and shall not be deemed to be or to include representations or warranties of EBAC or any other person, and are not and shall not be deemed to
be relied upon by the Company in executing, delivering or performing this Agreement or the Transactions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_74"></A>Section&nbsp;7.01. <I>Conduct of Business</I>. From the date of this Agreement through the earlier of the
Acquisition Closing or valid termination of this Agreement pursuant to Article 11 (the &#147;<B>Interim Period</B>&#148;), the Company shall, and shall cause its Subsidiaries to, except as explicitly contemplated by this Agreement or the Ancillary
Agreements, as required by Law (including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures), for any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Reasonable Response, as consented to by EBAC in writing (which consent shall not be
unreasonably conditioned, withheld, delayed or denied) or as set forth on Section&nbsp;7.01 of the Company Disclosure Letter, use commercially reasonable efforts to (x)&nbsp;operate the business of the Company in the ordinary course of business
consistent with past practice and (y)&nbsp;preserve intact the Company&#146;s present business organization, retain the Company&#146;s current officers, and preserve the Company&#146;s relationships with its key suppliers and customers (if
applicable). Without limiting the generality of the foregoing, except as explicitly contemplated by this Agreement or the Ancillary Agreements, as required by Law (including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures), for any <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Reasonable Response, as consented to by EBAC in writing (which consent shall not be unreasonably conditioned, withheld, delayed or denied) or as set forth on Section&nbsp;7.01 of the Company Disclosure
Letter, the Company shall not, and the Company shall cause its Subsidiaries not to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) change or amend the Governing Documents of the
Company or any Subsidiary of the Company, in each case, in a manner adverse in any material respect to EBAC, New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) make or declare any dividend or distribution to the equityholders of Company or make any other distributions in respect of any shares of
the Company Share Capital or the Equity Securities of the Company or any Subsidiary of the Company (other than any dividends or distributions between or among the Company and any of its Subsidiaries); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) split, combine, reclassify, recapitalize or otherwise amend any terms of any shares or series of the Company or any Subsidiary of the
Company&#146;s capital stock or Equity Securities, except with respect to any split, combination, reclassification or recapitalization of any shares or series of any Subsidiary of the Company&#146;s capital stock or Equity Securities, in a manner
not adverse in any material respect to the Company or any Subsidiary of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) purchase, repurchase, redeem or otherwise
acquire any issued and outstanding share capital, outstanding shares of capital stock, membership interests or other Equity Securities of the Company or any Subsidiary of the Company, except for (i)&nbsp;the acquisition by the Company or any of its
Subsidiaries of any shares of capital stock, membership interests or other Equity Securities of the Company or its Subsidiaries, or (ii)&nbsp;transactions between the Company and any wholly owned Subsidiary of the Company or between wholly owned
Subsidiaries of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or
a material portion of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) sell, assign, transfer, convey, lease or otherwise dispose of any material tangible
assets or properties of the Company or its Subsidiaries, except for (i)&nbsp;dispositions of obsolete or worthless equipment, (ii)&nbsp;transactions among the Company and its Subsidiaries or among its Subsidiaries, (iii)&nbsp;transactions in the
ordinary course of business consistent with past practice or (iv)&nbsp;transactions involving assets or properties that are sold, assigned, transferred, conveyed, leased or otherwise disposed of at or above fair market value (as reasonably
determined by EBAC) and that in the aggregate generate less than 5% of the consolidated EBITDA of the Company and its Subsidiaries for the most recent four completed consecutive fiscal quarters ending prior to the consummation of such transaction;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;(i) issue or sell any debt securities of the Company or any Subsidiary of the Company or otherwise incur or assume any
Indebtedness, or (ii)&nbsp;guarantee any Indebtedness of another Person, in each case, except (x)&nbsp;in the ordinary course of business consistent with past practice or (y)&nbsp;for the issuance, sale, or incurrence of debt securities or
Indebtedness used to refinance existing Indebtedness; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;(i) fail to timely pay all material Taxes that become due and payable,
(ii)&nbsp;make, change or revoke any election in respect of material Taxes, (iii)&nbsp;adopt or request permission of any Governmental Authority to change any material method of accounting in respect of Taxes, (iv)&nbsp;settle or compromise any
material Tax liability, (v)&nbsp;enter into any material agreement in respect of Taxes with a Governmental Authority, (vi)&nbsp;enter into any Tax Sharing Agreement (other than any such agreement solely among the Company and its Subsidiaries and
customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes) or (vii)&nbsp;amend, modify or otherwise change in a material respect any filed Tax Return unless required by applicable Law, or
(viii)&nbsp;consent to any extension or waiver of the statute of limitations regarding any material amount of Taxes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) take any action,
or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent, impair or impede the Intended Tax Treatment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;(i) issue, sell, or otherwise dispose of any existing or additional shares of Company Share Capital or securities exercisable for or
convertible into shares of Company Share Capital, other than (1)&nbsp;in respect of the PIPE Investment, including for the avoidance of doubt, the issuance of New Parent Shares, warrants or other securities pursuant to a Subscription Agreement or an
Additional Subscription Agreement or (2)&nbsp;in connection with the exercise of Company Options outstanding on the date of this Agreement or (ii)&nbsp;grant any Company Options or other equity or equity-based compensation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Except (w)&nbsp;as required under the existing terms of any Company Benefit Plan, as in effect on the date of this Agreement, (x)&nbsp;as
required by this Agreement, (y)&nbsp;as required by any applicable Law or (z)&nbsp;in the ordinary course of business consistent with past practice, (i)&nbsp;adopt, enter into, terminate or materially amend or modify any material Company Benefit
Plan, (ii)&nbsp;increase the compensation payable to any Service Provider, (iii)&nbsp;accelerate any payment, right to payment, vesting or benefit, or the funding of any payment, right to payment, vesting or benefit, payable or to become payable to
any Service Provider or (iv)&nbsp;waive or release any noncompetition, <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure or other restrictive covenant obligation of any Service
Provider; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization of the Company or any Subsidiary of the Company (other than the Acquisition Transactions); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)
terminate without replacement or fail to use commercially reasonable efforts to maintain any License material to the conduct of the business of the Company and its Subsidiaries, taken as a whole; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) enter into, modify in any material respect or terminate (other than expiration in accordance with its terms) any Affiliate Agreements,
other than as required by Law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) sell, assign, transfer, abandon, permit to lapse, dispose of, license, sublicense,
modify, terminate, create or incur any Lien on, or otherwise fail to take any action necessary to maintain, enforce or protect, any Company IP, other than granting <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses in the ordinary course
of business consistent with past practice; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) enter into any agreement to do any action prohibited under this Section&nbsp;7.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_75"></A>Section&nbsp;7.02. <I>Inspection</I>. Subject to confidentiality obligations (whether contractual, imposed by
applicable Law or otherwise) that may be applicable to information furnished to the Company or any of the Company&#146;s Subsidiaries by third parties that may be in the Company&#146;s or any of its Subsidiaries&#146; possession from time to time,
and except for any information that is subject to attorney-client privilege (<I>provided</I> that, to the extent possible, the parties shall cooperate in good faith to permit disclosure of such information in a manner that preserves such privilege
or compliance with such confidentiality obligation), and to the extent permitted by applicable Law, the Company shall, and shall cause its Subsidiaries to, afford to EBAC and its accountants, counsel and other representatives reasonable access
during the Interim Period (for purposes of consummating the Transactions), during normal business hours and with reasonable advance notice, in such manner as to not materially interfere with the ordinary course of business of the Company and its
Subsidiaries, to all of their respective properties, books, Contracts, commitments, Tax Returns, records and appropriate officers and employees of the Company and its Subsidiaries; <I>provided</I> that such access shall not include any unreasonably
invasive or intrusive investigations or other testing, sampling or analysis of any properties, facilities or equipment of the Company or its Subsidiaries without the prior written consent of the Company. All information obtained by EBAC or its
representatives pursuant to this Section&nbsp;7.02 shall be subject to the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_76"></A>Section&nbsp;7.03. <I>Preparation and Delivery of Additional Company Financial Statements.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the First Merger Effective Time has not occurred prior to the date the Audited Financial Statements become stale for purposes of
Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Securities Act (the &#147;<B>Staleness Date</B>&#148;), the Company shall use its commercially reasonable efforts to deliver to EBAC, as soon as reasonably practicable following the
Staleness Date, the unaudited interim consolidated statement of financial position as of September&nbsp;30, 2022 and the related unaudited interim statements of comprehensive income, changes in equity, and cash flows for the <FONT
STYLE="white-space:nowrap">9-month</FONT> period ended September&nbsp;30, 2022 of the Company and its Subsidiaries (the &#147;<B>Q3 2022 Financial Statements</B>&#148;), together with the auditor&#146;s reports thereon, which comply in all material
respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act applicable to a registrant; <I>provided</I> that upon delivery of such Q3 2022 Financial Statements, the
representations and warranties set forth in Section&nbsp;4.08 shall be deemed to apply to the Q3 2022 Financial Statements with the same force and effect as if made as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall use its commercially reasonable efforts to cause its independent auditors to provide any necessary consents to the
inclusion of the financial statements set forth in Section&nbsp;4.08 and this Section&nbsp;7.03 in EBAC&#146;s filings with the SEC in accordance with the applicable requirements of federal securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_77"></A>Section&nbsp;7.04. <I>Affiliate Agreements</I>. At or prior to the Acquisition Closing, the Company shall
terminate or settle, or cause to be terminated or settled, without further liability to EBAC or any of its Affiliates, the Company or any of the Company&#146;s Subsidiaries, all Affiliate Agreements of the Company (other than any such agreements set
forth in Section&nbsp;7.04 of the Company Disclosure Letter) and provide EBAC with evidence of such termination or settlement reasonably satisfactory to EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_78"></A>Section&nbsp;7.05. <I>Acquisition Proposals</I>. From the date hereof until the Acquisition Closing Date or, if
earlier, the termination of this Agreement in accordance with Article 11, the Company and its Subsidiaries shall not, and the Company shall instruct and use its commercially reasonable efforts to cause its representatives, not to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;initiate any negotiations with any Person with respect to, or provide any <FONT STYLE="white-space:nowrap">non-public</FONT> information or data concerning the Company or any of the
Company&#146;s Subsidiaries to any Person relating to, an Acquisition Proposal or afford to any Person access to the business, properties, assets or personnel of the Company or any of the Company&#146;s Subsidiaries in connection with an Acquisition
Proposal, (b)&nbsp;enter into any acquisition agreement, merger agreement or similar definitive agreement, or any letter of intent, memorandum of understanding or agreement in principle, or any other agreement relating to an Acquisition Proposal,
(c)&nbsp;grant any waiver, amendment or release under any confidentiality agreement or the anti-takeover laws of any state relating to an Acquisition Proposal, or (d)&nbsp;otherwise knowingly facilitate any such inquiries, proposals, discussions, or
negotiations or any effort or attempt by any Person to make an Acquisition Proposal. From and after the date hereof, the Company shall, and shall instruct its Subsidiaries, officers and directors and representatives acting on its behalf or on behalf
of its Subsidiaries (as applicable) to, immediately cease and terminate all discussions and negotiations with any Persons that may be ongoing with respect to any Acquisition Proposal (other than the Parties and their respective representatives).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_79"></A>Section&nbsp;7.06. <I>Subsidiary Member Approval</I>. As promptly as reasonably practicable following the
consummation of the transactions contemplated by <U>Section</U><U></U><U>&nbsp;8.08</U>, New Parent, as the sole shareholder of each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 will approve and adopt this Agreement, the Ancillary Agreements to
which New Parent is or will be a party and the transactions contemplated hereby and thereby (including the Acquisition Transactions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_80">
</A>Section&nbsp;7.07. <I>Stock Exchange Listing of New Parent Shares</I>. EBAC shall cause New Parent to, and New Parent shall, use its commercially reasonable efforts to cause New Parent Shares issuable in accordance with this Agreement to be
approved for listing on the Stock Exchange (and EBAC and the Company shall reasonably cooperate in connection therewith), subject to official notice of issuance, as promptly as practicable after the date of this Agreement, and in any event prior to
the Acquisition Closing Date and to cause New Parent to satisfy any applicable initial and continuing listing requirements of the Stock Exchange, subject to any available exemptions or <FONT STYLE="white-space:nowrap">phase-in</FONT> periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_81"></A>Section&nbsp;7.08. <I>EBAC D&amp;O Indemnification and Insurance.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that (i)&nbsp;all rights to indemnification or exculpation now existing in favor of past or present directors, officers,
members, managers and employees of EBAC, as provided in an EBAC&#146;s Governing Documents or otherwise in effect as of the date of the Acquisition Closing, in either case, solely with respect to any matters occurring on or prior to the Acquisition
Closing, shall survive the Transactions and shall continue in full force and effect from and after the Acquisition Closing for a period of six years and (ii)&nbsp;New Parent will perform and discharge all obligations to provide such indemnity and
exculpation during such <FONT STYLE="white-space:nowrap">six-year</FONT> period. To the maximum extent permitted by applicable Law, during such <FONT STYLE="white-space:nowrap">six-year</FONT> period, New Parent shall advance expenses in connection
with such indemnification as provided in EBAC&#146;s Governing Documents or other applicable agreements. The indemnification and liability limitation or exculpation provisions of EBAC&#146;s Governing Documents or other applicable agreements shall
not, during such <FONT STYLE="white-space:nowrap">six-year</FONT> period, be amended, repealed or otherwise modified after the Acquisition Closing in any manner that would materially and adversely affect the rights thereunder of individuals who, as
of the Acquisition Closing or at any time prior to the Acquisition Closing, were or are directors, officers, members, managers or employees of EBAC (the &#147;<B>EBAC</B> <B>D&amp;O Persons</B>&#148;) to be so indemnified, have their liability
limited or be exculpated with respect to any matters occurring on or prior to Acquisition Closing and relating to the fact that such EBAC D&amp;O Person was a director, officer, member, manager or employee of EBAC at or prior to the Acquisition
Closing, unless such amendment, repeal or other modification is required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) New Parent shall not have any obligation
under this Section&nbsp;7.08 to any EBAC D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the
indemnification of such EBAC D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) New Parent shall purchase, at or prior to the Acquisition Closing, and maintain in
effect for a period of six (6)&nbsp;years after the Acquisition Closing Date, without lapses in coverage, a &#147;tail&#148; insurance policy(ies) providing directors&#146; and officers&#146; liability and fiduciary liability insurance coverage for
the benefit of those Persons who are covered by any comparable insurance policy(ies) of EBAC as of the date hereof with respect to matters occurring on or prior to the Acquisition Closing. Such &#147;tail&#148; insurance policy(ies) shall provide
coverage on terms (including with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under EBAC&#146;s directors&#146; and officers&#146; liability
and fiduciary liability insurance policy(ies) as of the Acquisition Closing; <I>provided</I> that New Parent shall not be required to pay a premium for such &#147;tail&#148; insurance policy(ies) in excess of 250% of the most recent annual premium
paid by EBAC prior to the date of this Agreement and, in such event, New Parent shall purchase the maximum coverage available for 250% of the most recent annual premium paid by EBAC prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If New Parent or any of its respective successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation
or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series of related
transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of New Parent or the Company or any of its Subsidiaries shall assume all of the obligations set forth in this Section&nbsp;7.08.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The EBAC D&amp;O Persons entitled to the indemnification, liability limitation, exculpation and insurance set forth in this
Section&nbsp;7.08 are intended to be third-party beneficiaries of this Section&nbsp;7.08. This Section&nbsp;7.08 shall survive the consummation of the Transactions and shall be binding on all successors and assigns of New Parent, the Company and the
Company&#146;s Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_82"></A>Section&nbsp;7.09. <I>Agent Deliverables. </I>The Company shall: (a)&nbsp;cause
its chief executive officer or the president of the Company and the chief financial or chief accounting officer of the Company to deliver to the Placement Agents and the Financial Advisor a certificate on behalf of the Company certifying that
(I)&nbsp;the representations and warranties of the Company contained in this Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case, such
representations and warranties shall be true and correct in all respects) as of the date when made and as of the date of such certificate, as though made on and as of such date, except for such representations and warranties that speak as of a
specific date, except to the extent otherwise disclosed in the Proxy Statement/Registration Statement and (II)&nbsp;the Registration Statement and any amendments thereto conformed in all material respects to the requirements of the Securities Act
and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, (b)&nbsp;use reasonable best efforts to cause its independent
auditors to deliver to the PIPE Placement Agents and Financial Advisor a comfort letter in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, and (c)&nbsp;use reasonable best efforts to
cause its counsel to deliver a customary negative assurance letter in respect of the Proxy Statement/Registration Statement in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, in each
case in form and substance reasonably satisfactory to the Placement Agents and Financial Advisor, with each of the deliverables set forth in clauses (a), (b) and (c)&nbsp;to be provided: (1)&nbsp;on the date of the effectiveness of the Registration
Statement and (2)&nbsp;on the date of the EBAC Shareholders&#146; Meeting, each dated the date of delivery. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> EBAC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_83"></A>Section&nbsp;8.01. <I>Trust Account Proceeds and Related Available Equity.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) EBAC shall take all necessary and appropriate actions to release and make available all of the remaining funds from the Trust Account,
after payments for any deferred underwriting commissions and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EBAC Share Redemptions, including (1)&nbsp;providing notice to the Trustee of the anticipated Acquisition Closing Date for the purpose of unwinding any
<FONT STYLE="white-space:nowrap">non-cash</FONT> assets in the Trust Account, sufficiently in advance of the Acquisition Closing Date and in accordance with the terms of the Trust Agreement, (2)&nbsp;upon satisfaction or waiver of the conditions set
forth in Article 10, (i) in accordance with and pursuant to the Trust Agreement, at the Acquisition Closing, EBAC (A)&nbsp;shall cause any documents, opinions and notices required to be delivered to the Trustee pursuant to the Trust Agreement to be
so delivered and (B)&nbsp;shall use its commercially reasonable efforts to cause the Trustee to, and the Trustee shall thereupon be obligated to (I)&nbsp;pay as and when due all amounts payable to EBAC Shareholders pursuant to the EBAC Share
Redemptions (II)&nbsp;pay any deferred underwriting commissions, and (III)&nbsp;pay all remaining amounts then available in the Trust Account to New Parent for immediate use, subject to this Agreement and the Trust Agreement, and
(ii)&nbsp;thereafter, the Trust Account shall terminate, except as otherwise provided therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_84"></A>Section&nbsp;8.02. <I><FONT STYLE="white-space:nowrap">De-Listing</FONT></I>. Prior to the Acquisition Closing,
EBAC shall cooperate with the Company and, with respect to EBAC, shall use its commercially reasonable efforts to take, or cause to be taken, all actions reasonably necessary to <FONT STYLE="white-space:nowrap">de-list</FONT> all securities of EBAC
from the Stock Exchange and <FONT STYLE="white-space:nowrap">de-register</FONT> such securities under the Exchange Act as soon as practicable following the First Merger Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_85"></A>Section&nbsp;8.03. <I>No Solicitation by EBAC</I>. From the date hereof until the Acquisition Closing Date or, if
earlier, the termination of this Agreement in accordance with Article 11, EBAC shall not, and shall cause its Subsidiaries not to, and EBAC shall instruct its and their representatives acting on its and their behalf, not to, (a)&nbsp;make any
proposal or offer that constitutes a Business Combination Proposal, (b)&nbsp;initiate any discussions or negotiations with any Person with respect to a Business Combination Proposal, (c)&nbsp;enter into any acquisition agreement, business
combination, merger agreement or similar definitive agreement, or any letter of intent, memorandum of understanding or agreement in principle, or any other agreement relating to a Business Combination Proposal or (d)&nbsp;otherwise knowingly
facilitate any such inquiries, proposals, discussions, or negotiations or any effort or attempt by any Person to make a Business Combination Proposal, in each case, other than to or with the Company and its respective representatives. From and after
the date hereof, EBAC shall, and shall instruct and cause its officers and directors and representatives acting on its behalf, its Subsidiaries and their respective representatives (acting on their behalf) to, immediately cease and terminate all
discussions and negotiations with any Persons that may be ongoing with respect to a Business Combination Proposal (other than the Company and its representatives). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_86"></A>Section&nbsp;8.04. <I>EBAC Conduct of Business.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the Interim Period, EBAC shall, except as explicitly contemplated by this Agreement (including as contemplated by any of the
Subscription Agreements, any of the Additional Subscription Agreements or in connection with the PIPE Investment) or the Ancillary Agreements, as required by Law or as consented to by the Company in writing (which consent shall not be unreasonably
conditioned, withheld, delayed or denied), operate its business in the ordinary course and consistent with past practice. Without limiting the generality of the foregoing, except as explicitly contemplated by this Agreement (including as
contemplated by any of the Subscription Agreements, any of the Additional Subscription Agreements or in connection with the PIPE Investment) or the Ancillary Agreements, as required by Law or as consented to by the Company in writing (which consent,
except with respect to clause (xii), shall not be unreasonably conditioned, withheld, delayed or denied), EBAC shall not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) change, modify, amend or terminate (or seek any approval from the EBAC Shareholders to) the Trust Agreement, the
Subscription Agreements, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreements or the Governing Documents of EBAC, except as contemplated by the Transaction Proposals or Extension Proposal; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) withdraw any funds from the Trust Account, other than as permitted by the Trust Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) except as contemplated by the Transaction Proposals (including any adjustment made with respect to the New Parent
Warrants in the Warrant Conversion), (A) make or declare any dividend or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
distribution to the shareholders of EBAC or make any other distributions in respect of any of EBAC&#146;s capital stock, share capital or equity interests, (B)&nbsp;split, combine, reclassify or
otherwise amend any terms of any shares or series of EBAC&#146;s capital stock or equity interests, or (C)&nbsp;purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, share
capital or membership interests, warrants or other equity interests of EBAC, other than a redemption of shares of EBAC Class&nbsp;A Common Stock made as part of the EBAC Share Redemptions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) enter into, renew or amend in any material respect, any transaction or Contract with an Affiliate of EBAC (including, for
the avoidance of doubt, (x)&nbsp;the Sponsor and (y)&nbsp;any Person in which the Sponsor has a direct or indirect legal, contractual or beneficial ownership interest of five percent (5%) or greater); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;(i) fail to timely pay all material Taxes that become due and payable, (ii)&nbsp;make, change or revoke any election
in respect of material Taxes, (iii)&nbsp;adopt or request permission of any Governmental Authority to change any material method of accounting in respect of Taxes, (iv)&nbsp;settle or compromise any material Tax liability, (v)&nbsp;enter into any
material agreement in respect of Taxes with a Governmental Authority, (vi)&nbsp;enter into any Tax Sharing Agreement (other than customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes) or
(vii)&nbsp;amend, modify or otherwise change in a material respect any filed Tax Return unless required by applicable Law, or (viii)&nbsp;consent to any extension or waiver of the statute of limitations regarding any material amount of Taxes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to
prevent, impair or impede the Intended Tax Treatment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) issue or sell any debt securities or warrants or other rights
to acquire any debt securities of EBAC or otherwise incur or assume any Indebtedness, or guarantee any Indebtedness of another Person, other than (x)&nbsp;fees and expenses incurred in support of the transactions contemplated by this Agreement and
the Ancillary Agreements, (y)&nbsp;any adjustment made with respect to the New Parent Warrants in the Warrant Conversion or (z)&nbsp;in support of the ordinary course operations of EBAC (which the parties agree shall include any Indebtedness in
respect of any Working Capital Loan incurred in the ordinary course of business, subject to Section&nbsp;8.04(a)(xii) below); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;(A) issue any EBAC Securities or securities exercisable for or convertible into EBAC Securities, other than
(x)&nbsp;in respect of the PIPE Investment, including for the avoidance of doubt, EBAC Class&nbsp;A Common Stock, warrants or other securities pursuant to an Additional Subscription Agreement, and (y)&nbsp;to effect a transfer or agreement to
transfer (which may be effectuated as a forfeiture to EBAC and reissuance by EBAC) of EBAC Class&nbsp;A Common Stock or EBAC Class&nbsp;B Common Stock by Sponsor to an investor pursuant to a Subscription Agreement or an Additional Subscription
Agreement, in the case of an Additional Subscription Agreement, entered into with the prior written consent of the Company, not to be unreasonably withheld, conditioned or delayed, (B)&nbsp;grant any options, warrants or other equity-based awards
with respect to EBAC Securities not outstanding on the date hereof, except as provided for in clause (x) and (y)&nbsp;above, or (C)&nbsp;amend, modify or waive any of the material terms or rights set forth in any EBAC Warrant or the EBAC Warrant
Agreement, including any amendment, modification or reduction of the warrant price set forth therein except for any adjustment made with respect to the New Parent Warrants in the Warrant Conversion; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or a material portion
of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution, restructuring,
recapitalization or other reorganization; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) change EBAC&#146;s methods of accounting in any material respect, other
than changes that are required by any securities Law or any order, directive, guideline, recommendation, statement, comment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
or guidance issued, passed, approved, published, promulgated or released by, the SEC, following reasonable prior consultation with the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) incur Working Capital Loans other than the incurrence of Working Capital Loans such that the aggregate outstanding
Working Capital Loans (including those incurred prior to the date of this Agreement) do not exceed $1,000,000 in the aggregate after such incurrence; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) enter into any agreement to do any action prohibited under this Section&nbsp;8.04. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) During the Interim Period, EBAC shall use commercially reasonably efforts to materially comply with, and continue materially performing
under, as applicable, the Trust Agreement and all other agreements or Contracts to which EBAC may be a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_87"></A>Section&nbsp;8.05. <I>EBAC Public Filings</I>. From the date hereof through the First Merger Effective Time, EBAC
will keep current and timely file all reports required to be filed or furnished with the SEC (including any amendment or restatement of any report previously filed or furnished to the extent necessary to respond to comments or other guidance,
whether formal or informal from the SEC) and otherwise comply in all material respects with its reporting obligations under applicable Laws. Any report filed by EBAC with the SEC after the date hereof shall be considered an EBAC SEC Filing for the
purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_88"></A>Section&nbsp;8.06. <I>Shareholder Litigation</I>. In the event that any
litigation related to this Agreement, any Ancillary Agreement or the transactions contemplated hereby or thereby is brought, or, to the knowledge of EBAC, threatened in writing, against EBAC or the EBAC Board by any of the EBAC Shareholders prior to
the Acquisition Closing, EBAC shall promptly notify the Company of any such litigation and keep the Company reasonably informed with respect to the status thereof. EBAC shall provide the Company the opportunity to participate in (subject to a
customary joint defense agreement), but not control, the defense of any such litigation, shall give due consideration to the Company&#146;s advice with respect to such litigation and shall not settle any such litigation without the prior written
consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_89"></A>Section&nbsp;8.07. <I>New Parent Corporate Documents</I>. As soon as reasonably practical after the date hereof,
EBAC shall cause all Swiss corporate documents of New Parent to be submitted for formal positive <FONT STYLE="white-space:nowrap">pre-clearance</FONT> <I>(Vorpr&uuml;fung / examen pr&eacute;liminaire</I>) from the commercial register of the Canton
of Zug. EBAC and New Parent shall use their commercially reasonable efforts to procure that the relevant corporate documents will be <FONT STYLE="white-space:nowrap">pre-registered</FONT> (<I>vorerfasst / pr&eacute;-enregistr&eacute;s</I>) by the
commercial register of the Canton of Zug in the expedited <FONT STYLE="white-space:nowrap">pre-registration</FONT> procedure (<I>Vorerfassungsverfahren / proc&eacute;dure de pr&eacute;-enregistrement</I>) when submitted to the commercial register of
the Canton of Zug on the Acquisition Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_90"></A>Section&nbsp;8.08. <I>Corporate Formation</I>. The
following shall occur as soon as practicable following the execution of this Agreement as set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) EBAC shall form New Parent
as a public limited liability company (<I>soci&eacute;t&eacute; anonyme</I>) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of EBAC; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) New Parent shall form Merger Sub 1 as a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) New Parent shall form Merger Sub 2 as a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New
Parent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) New Parent shall form Merger Sub 3 as a new public limited liability company (<I>soci&eacute;t&eacute; anonyme</I>)
incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Following the formation of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3,
EBAC, in the case of New Parent, and New Parent, in the case of Merger Sub 1, Merger Sub 2 and Merger Sub 3, shall cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, as applicable, to become a party to this Agreement by executing a
joinder agreement, in form and substance reasonably satisfactory to each of New Parent and the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) New Parent shall cause
each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 to approve and adopt resolutions similar in substance to those resolutions of New Parent contemplated by <U>Section</U><U></U><U>&nbsp;5.02(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_91"></A>Section&nbsp;8.09. <I>Agent Deliverables. </I>EBAC shall: (a)&nbsp;cause its chief executive officer or the
president of EBAC and the chief financial or chief accounting officer of EBAC to deliver to the Placement Agents and Financial Advisor a certificate certifying that (I)&nbsp;the representations and warranties of EBAC contained in this Agreement are
true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case, such representations and warranties shall be true and correct in all respects) as of the date when made
and as of the date of such certificate, as though made on and as of such date, except for such representations and warranties that speak as of a specific date, except to the extent otherwise disclosed in the Proxy Statement/Registration Statement
and (II)&nbsp;the Registration Statement and any amendments thereto conformed in all material respects to the requirements of the Securities Act and did not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading, (b)&nbsp;use reasonable best efforts to cause its independent auditors to deliver to the PIPE Placement Agents and Financial Advisor a comfort letter in a form that is
generally provided to underwriters in connection with underwritten public offerings of securities, (c)&nbsp;use reasonable best efforts to cause its counsel to deliver a customary negative assurance letter in respect of the Proxy
Statement/Registration Statement in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, in each case in form and substance reasonably satisfactory to the Placement Agents and Financial
Advisor, and (d)&nbsp;use reasonable best efforts to obtain from counsel to the Placement Agents delivery of a customary negative assurance letter in respect of the Proxy Statement/Registration Statement, in each case in form and substance
satisfactory to the Placement Agents and Financial Advisor, with each of the deliverables set forth in clauses (a), (b) and (c)&nbsp;to be provided: (1)&nbsp;on the date of the effectiveness of the Registration Statement and (2)&nbsp;on the date of
the EBAC Shareholders&#146; Meeting, each dated the date of delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_92"></A>Section&nbsp;8.10. <I>Extension of Time
to Consummate a Business Combination.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If EBAC and the Company determine in good faith by December&nbsp;15, 2022 that it is
probable the Acquisition Closing will not occur prior to the Agreement End Date, EBAC and the Company shall cooperate to prepare and, not later than fifteen (15)&nbsp;Business Days after the date of such mutual determination (or such other date as
the parties may agree in writing), shall file with the SEC a mutually acceptable proxy statement (such proxy statement, together with any amendments or supplements thereto, the &#147;<U>Extension Proxy Statement</U>&#148;) to amend the EBAC
Articles, on terms and conditions agreed by the parties, to (i)&nbsp;extend the period of time EBAC is afforded under the EBAC Articles and the Prospectus to consummate an initial business combination for an additional three months, from
March&nbsp;18, 2023 to June&nbsp;18, 2023 (or such earlier date as the parties may agree in writing) (the &#147;<U>Initial Extension Date</U>&#148;) and (ii)&nbsp;provide that EBAC may extend the Initial Extension Date one time by an additional
three months (for a total of up to 30 months to complete an initial business combination) if the Sponsor provides five (5)&nbsp;days&#146; advance notice prior to the applicable deadline (the &#147;<U>Extension Proposal</U>&#148;). EBAC shall
cooperate and provide the Company (and its counsel) with a reasonable opportunity to review and comment on the Extension Proxy Statement, and any amendment or supplement thereto, and any responses to comments from the SEC or its staff or the
provision of additional information in connection therewith, prior to filing or delivery of the same with or to the SEC. The EBAC Parties, with the assistance of the Company, will promptly respond to any SEC comments on the Extension Proxy Statement
and will use all commercially reasonable efforts to cause the Extension Proxy Statement to be cleared by the SEC as promptly as practicable after such filing. The EBAC Parties will advise the Company reasonably promptly after: (A)&nbsp;the time when
the Extension Proxy Statement has been filed; (B)&nbsp;in the event the Extension Proxy Statement is not reviewed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SEC, the expiration of the waiting period in Rule <FONT STYLE="white-space:nowrap">14a-6(a)</FONT> under the Exchange Act; (C)&nbsp;in the event the preliminary Extension Proxy Statement is
reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC; (D)&nbsp;the filing of any supplement or amendment to the Extension Proxy Statement; (E)&nbsp;any request by the SEC for amendment of the
Extension Proxy Statement; (F)&nbsp;any comments from the SEC relating to the Extension Proxy Statement and responses thereto (and shall provide the Company with a copy or, in the case of oral communications, summary of such comments); (G) requests
by the SEC for additional information (and shall provide the Company with a copy or, in the case of oral communications, summary of such request); and (H)&nbsp;any other communication, whether written or oral, from the SEC (and shall provide the
Company with a copy or, in the case of oral communications, summary of such communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each party shall promptly correct any
information provided by it for use in the Extension Proxy Statement if and to the extent that such information is determined to have become false or misleading in any material respect or as otherwise required by applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As promptly as practicable after the Extension Proxy Statement is cleared by the SEC, EBAC shall distribute the Extension Proxy Statement
to the EBAC Shareholders and (x)&nbsp;shall duly call and give notice of special meeting of the EBAC Shareholders (the &#147;<U>Extension Shareholders&#146; Meeting</U>&#148;) in accordance with the EBAC Articles and the Cayman Companies Act for a
date no later than forty-five (45)&nbsp;days after such notice, subject to EBAC&#146;s right to adjourn the Extension Shareholders&#146; Meeting as provided in this Agreement, (y)&nbsp;subject to the other provisions of this Agreement, shall solicit
proxies from the EBAC Shareholders to vote in favor of the Extension Proposal, and shall duly convene and hold the Extension Shareholders&#146; Meeting, and (z)&nbsp;shall provide its shareholders with the opportunity to elect to convert their EBAC
Common Stock into a pro rata portion of the Trust Account in connection with the extension as provided for in the EBAC Articles. EBAC may only adjourn the Extension Shareholders&#146; Meeting (i)&nbsp;to solicit additional proxies for the purpose of
obtaining approval of the Extension Proposal or to take steps to reduce the number of shares of EBAC Common Stock issued in the IPO as to which the holders thereof elect to convert such shares into a pro rata portion of the Trust Account in
connection with the extension as provided for in the EBAC Articles, (ii)&nbsp;if a quorum is not present at the Extension Shareholders&#146; Meeting, (iii)&nbsp;to amend the Extension Proposal, subject to the Company&#146;s consent, not to be
unreasonably withheld, conditioned or delayed, or (iv)&nbsp;to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure that EBAC has determined in good faith after consultation with outside legal counsel
is required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by the EBAC Shareholders prior to the Extension Shareholders&#146; Meeting; provided that the Extension Shareholders&#146; Meeting is
reconvened as promptly as practical thereafter. EBAC agrees that if the approval of the Extension Proposal shall not have been obtained at any such Extension Shareholders&#146; Meeting, then EBAC shall continue until the Agreement End Date to take
all such necessary actions and hold additional Extension Shareholders&#146; Meetings in order to obtain the approval of the Extension Proposal by the Agreement End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The EBAC Parties shall comply with all applicable provisions of and rules under the Exchange Act and all applicable provisions of the
Cayman Companies Act in the preparation, filing and distribution of the Extension Proxy Statement, the solicitation of proxies thereunder, and the calling and holding of the Extension Shareholders&#146; Meeting. Without limiting the foregoing, EBAC
Parties and the Company shall each ensure that the Extension Proxy Statement does not, as of the date on which it is first distributed to EBAC Shareholders and the holders of the Company Securities, and as of the date of the Extension
Shareholders&#146; Meeting, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made in light of the circumstances under which they were made, not misleading (provided that no
party shall be responsible for the accuracy or completeness of any information relating to another party or any other information furnished by another party for inclusion in the Extension Proxy Statement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) EBAC, acting through the EBAC Board, shall include in the Extension Proxy Statement the EBAC Board&#146;s recommendation that EBAC
Shareholders vote in favor of the Extension Proposal, and shall otherwise use reasonable best efforts to obtain approval thereof. Neither the EBAC Board nor any committee or agent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representative thereof shall withdraw (or modify in a manner adverse to the Company), or propose to withdraw (or modify in a manner adverse to the Company) the EBAC Board&#146;s recommendation
that the EBAC Shareholders vote in favor of the adoption of the Extension Proposal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J<SMALL>OINT</SMALL> C<SMALL>OVENANTS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_93"></A>Section&nbsp;9.01. <I>Efforts to Consummate.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions herein provided, each of EBAC, New Parent, Merger Sub 1, Merger Sub 2, Merger Sub 3 and the Company
shall, and the Company shall cause its Subsidiaries to: (i)&nbsp;use commercially reasonable efforts to assemble, prepare and file any information (and, as needed, to supplement such information) as may be reasonably necessary to obtain as promptly
as practicable all Governmental Authorizations required to be obtained in connection with the Transactions, (ii)&nbsp;use commercially reasonable efforts to take, or cause to be taken, and to do, or cause to be done, all things reasonably necessary
or advisable to consummate and make effective as promptly as practicable the Transactions, including using commercially reasonable efforts to obtain all material Governmental Authorizations that any of EBAC, the Company, or their respective
Affiliates are required to obtain in order to consummate the Transactions; <I>provided</I> that in no event shall New Parent, EBAC, the Merger Sub 1, Merger Sub 2, Merger Sub 3, the Company or its Subsidiaries be obligated to bear any material
expense, pay any material fee or grant any material concession in connection with obtaining any such approvals (other than any required filing fees in connection therewith); <I>provided</I>, <I>however</I>, that each Party shall bear its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in connection with the preparation of any such approvals, and (iii)&nbsp;take such other action as may reasonably be necessary or as any other
Party may reasonably request to satisfy the conditions of the other Parties set forth in Article 10 or otherwise to comply with this Agreement. The Parties shall promptly inform the other of any substantive communication between any itself, and any
Governmental Authority regarding any of the Transactions. Without limiting the foregoing, each Party and their respective Affiliates shall not enter into any agreement with any Governmental Authority not to consummate the Transactions, except with
the prior consent of the other Parties. Nothing in this Section&nbsp;9.01 obligates any Party or any of its Affiliates to agree to (i)&nbsp;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of,
any entities, assets or facilities of the Company or any of its Subsidiaries or any entity, facility or asset of such Party or any of its Affiliates, (ii)&nbsp;terminate, amend or assign existing relationships and contractual rights or obligations,
(iii)&nbsp;amend, assign or terminate existing licenses or other agreements, or (iv)&nbsp;enter into new licenses or other agreements. Without limiting in any respect the Parties&#146; obligations under this Section&nbsp;9.01, the Company shall have
the right to direct, devise and implement the strategy with respect to obtaining Governmental Authorizations in accordance with this Section&nbsp;9.01; <I>provided</I> EBAC is provided prompt notice by the Company of material communications and
developments with respect to such process; <I>provided</I>, <I>further</I>, that the Company shall not be permitted to consent to any action, omission, undertaking, commitment or agreement with any Governmental Authority to the extent that such
action, omission, undertaking, commitment or agreement requires any action, omission, commitment, undertaking or agreement by EBAC or its Affiliates without the prior written consent of EBAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date of this Agreement until the earlier of the Acquisition Closing or termination of this Agreement in accordance with
its terms, the Parties shall give counsel for the other Parties a reasonable opportunity to review in advance, and consider in good faith the views of the other in connection with, any proposed material written communication to any Governmental
Authority relating to the Transactions, including in respect of any Tax rulings related thereto. Each of the Parties agrees not to participate in any substantive meeting or discussion, either in person, videoconference, or by telephone with any
Governmental Authority in connection with the Transactions, including in respect of any Tax rulings related thereto, unless, to the extent not prohibited by such Governmental Authority, it consults with the other Parties, in advance. Each of the
Parties shall use commercially reasonable efforts to provide (or use commercially reasonable efforts to cause its Affiliates provide) to the other Parties reasonable information or documents in such Party&#146;s possession and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within its control as are necessary or required for the preparation of any filings, notifications or submissions in connection with all Governmental Authorizations required to be obtained in
connection with the Transactions. Notwithstanding the foregoing, any materials shared may be redacted before being provided to the other Parties (i)&nbsp;to remove references concerning the valuation of the Company, (ii)&nbsp;as necessary to comply
with contractual arrangements and (iii)&nbsp;as necessary to avoid disclosure of other competitively sensitive information or to address reasonable privilege or confidentiality concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_94"></A>Section&nbsp;9.02. <I>Preparation of Proxy Statement/Registration Statement; Shareholders&#146; Meeting and
Approvals.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable following the execution and delivery of this Agreement, the Company, New Parent and EBAC
shall prepare, with the assistance of the Company, and cause to be filed with the SEC by New Parent a registration statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (as amended or supplemented from time to time, and including the Proxy
Statement contained therein, the &#147;<B>Registration Statement</B>&#148;) in connection with the registration under the Securities Act of the New Parent Shares to be issued under this Agreement as part of the New Parent Interests Consideration and
Company Consideration and the New Parent Warrants (and the New Parent Shares issuable upon exercise thereof). Each of EBAC and the Company shall use its commercially reasonable efforts to cause the Registration Statement to comply with the rules and
regulations promulgated by the SEC, to have the Registration Statement declared effective under the Securities Act as promptly as practicable after such filing and to keep the Registration Statement effective as long as is necessary to consummate
the Acquisition Transactions. Each of EBAC and the Company shall furnish all information concerning it as may reasonably be requested by the other party in connection with such actions and the preparation of the Registration Statement. Promptly
after the Registration Statement is declared effective under the Securities Act, EBAC will cause the Proxy Statement to be mailed to shareholders of EBAC. The Company and EBAC shall each pay one half of all fees and expenses incurred in connection
with the preparation and filing of the Registration Statement and the receipt of stock exchange approval in connection with the listing of New Parent Shares to be issued as part of the New Parent Interests Consideration and the New Parent Warrants
(and the New Parent Shares issuable upon exercise thereof), other than fees and expenses of advisors (which shall be borne by the party incurring such fees). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of EBAC, New Parent and the Company shall cooperate and mutually agree upon (such agreement not to be unreasonably withheld,
conditioned or delayed) any response to comments of the SEC or its staff with respect to the Registration Statement and any amendment to the Registration Statement filed in response thereto. If EBAC, New Parent or the Company becomes aware that any
information contained in the Registration Statement shall have become false or misleading in any material respect or that the Registration Statement is required to be amended in order to comply with applicable Law, then (i)&nbsp;such party shall
promptly inform the other parties and (ii)&nbsp;EBAC and New Parent, on the one hand, and the Company, on the other hand, shall reasonably cooperate and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed) an
amendment or supplement to the Registration Statement. EBAC, New Parent and the Company shall use commercially reasonable efforts to cause the Registration Statement as so amended or supplemented, to be filed with the SEC and to be disseminated to
the holders of shares of EBAC Common Stock pursuant to applicable Law and subject to the terms and conditions of this Agreement and EBAC&#146;s Governing Documents. Each of the Company, New Parent and EBAC shall provide the other parties with copies
of any written comments, and shall inform such other parties of any oral comments, that New Parent receives from the SEC or its staff with respect to the Registration Statement promptly after the receipt of such comments and shall give the other
Parties a reasonable opportunity to review and comment on any proposed written or oral responses to such comments prior to responding to the SEC or its staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EBAC, New Parent and the Company agree to include provisions in the Proxy Statement and to take reasonable action related thereto, with
respect to (i)&nbsp;approval of the Transactions, including the Business Combination (as defined in EBAC&#146;s Governing Documents) and the adoption and approval of this Agreement (the &#147;<B>Transaction Proposal</B>&#148;), (ii) adjournment of
the special meeting (the &#147;<B>EBAC Shareholders&#146; Meeting</B>&#148;), if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the foregoing proposals (the &#147;<B>Adjournment Proposal</B>&#148;) and (iii)&nbsp;approval of any other proposals required by applicable securities Laws or Nasdaq listing rules or
reasonably agreed by EBAC and the Company to be necessary or appropriate in connection with the Transactions (the &#147;<B>Additional Proposal</B>&#148; and together with the Transaction Proposal and the Adjournment Proposal, the
&#147;<B>Transaction Proposals</B>&#148;). Without the prior written consent of the Company, the Transaction Proposals shall be the only matters (other than procedural matters) which EBAC shall propose to be voted on by the EBAC Shareholders at the
EBAC Shareholders&#146; Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EBAC shall use commercially reasonable efforts to, as promptly as practicable after the Registration
Statement is declared effective under the Securities Act, (i)&nbsp;duly call, give notice of, convene and hold the EBAC Shareholders&#146; Meeting, (ii)&nbsp;cause the Proxy Statement to be disseminated to EBAC Shareholders in compliance with
applicable Law and (iii)&nbsp;solicit proxies from the holders of EBAC Common Stock to vote in accordance with the recommendation of the EBAC Board with respect to each of the Transaction Proposals. EBAC shall, through the EBAC Board, recommend to
its shareholders that they approve the Transaction Proposals (the &#147;<B>EBAC Board Recommendation</B>&#148;) and shall include the EBAC Board Recommendation in the Proxy Statement. The EBAC Board shall not (and no committee or subgroup thereof
shall) change, withdraw, withhold, qualify or modify, or publicly propose to change, withdraw, withhold, qualify or modify, the EBAC Board Recommendation (together with any withdrawal, amendment, qualification or modification of its recommendation
to the shareholders of EBAC described in the Recitals hereto, a &#147;<B>Modification in Recommendation</B>&#148;); <I>provided</I> that the EBAC Board may make a Modification in Recommendation prior to receipt of the EBAC Shareholder Approval if,
and only if, the EBAC Board determines in consultation with EBAC&#146;s outside legal counsel that failure to make a Modification in Recommendation would be inconsistent with the fiduciary duties of the EBAC Board under applicable Laws;
<I>provided</I>, <I>further</I>, that the EBAC Board shall not be entitled to make, or agree or resolve to make, a Modification in Recommendation unless (x)&nbsp;EBAC has provided the Company with a written notice (a &#147;<B>Modification in
</B><B>Recommendation Notice</B>&#148;) advising the Company that the EBAC Board proposes to take such action and containing the material facts underlying the EBAC Board&#146;s determination that a Modification in Recommendation is required
hereunder (in each case, it being acknowledged that such Modification in Recommendation Notice shall not itself constitute a breach of this Agreement), and (y)&nbsp;at or after 5:00 p.m. on the fourth
(4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice (such period from the time the Modification in Recommendation Notice is provided
until 5:00 p.m. on the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice (the &#147;<B>Modification in Recommendation Notice
Period</B>&#148;)), the EBAC Board reaffirms in good faith (after consultation with its outside counsel) that the failure to make a EBAC Modification in Recommendation would be inconsistent with its fiduciary duties under applicable Law. If
requested by the Company, EBAC will and will use its reasonable best efforts to cause its Representatives to, during the Modification in Recommendation Notice Period, engage in good faith negotiations with the Company and its Representatives to make
such adjustments in the terms and conditions of this Agreement so as to obviate the need for a Modification in Recommendation. EBAC&#146;s obligations under Section&nbsp;9.02(c) to call and hold the EBAC Shareholders&#146; Meeting with respect to
all Transaction Proposals shall not be affected by any Modification in Recommendation. For the avoidance of doubt, in the event of a Modification in Recommendation, EBAC shall continue to submit this Agreement to the EBAC Shareholders for approval
at the EBAC Shareholders&#146; Meeting unless this Agreement shall have been terminated in accordance with its terms prior to the EBAC Shareholders&#146; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) EBAC may postpone the EBAC Shareholders&#146; Meeting, or adjourn the EBAC Shareholders&#146; Meeting opened in accordance with
EBAC&#146;s Governing Documents, on one or more occasions for up to twenty (20)&nbsp;Business Days in the aggregate after the date for which the EBAC Shareholders&#146; Meeting was originally scheduled upon the good faith determination by the EBAC
Board that such postponement or adjournment, as the case may be, is necessary to (i)&nbsp;solicit additional proxies to obtain the EBAC Shareholder Approval, (ii)&nbsp;obtain a quorum if one is not present at any then scheduled EBAC
Shareholders&#146; Meeting, (iii)&nbsp;ensure that any supplement or amendment to the Proxy Statement that is required by applicable Law is provided to the EBAC Shareholders with adequate time for review prior to the EBAC Shareholders&#146; Meeting,
or (iv)&nbsp;otherwise take actions consistent with EBAC&#146;s obligations under Section&nbsp;9.03. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_95"></A>Section&nbsp;9.03. <I>Support of Transaction</I>. Without
limiting any covenant contained in Article 7, or Article 8, EBAC and the Company shall each, and each shall cause its respective Subsidiaries to (a)&nbsp;use commercially reasonable efforts to obtain as soon as practicable all material consents and
approvals of third parties (including any Governmental Authority) that any of EBAC, or the Company or their respective Affiliates are required to obtain in order to consummate the Acquisition Transactions, and (b)&nbsp;take such other action as soon
as practicable as may be reasonably necessary or as another party hereto may reasonably request to satisfy the conditions to the obligations of the other parties set forth in Article 10 or otherwise to comply with this Agreement and to consummate
the Transactions as soon as practicable and in accordance with all applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_96"></A>Section&nbsp;9.04.
<I>Cooperation; Consultation.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to Acquisition Closing, each of the Company, New Parent and EBAC shall, and each of them
shall cause its respective Subsidiaries and Affiliates (as applicable) and its and their officers, directors, managers, employees, consultants, counsel, accounts, agents and other representatives to, reasonably cooperate in a timely manner in
connection with the PIPE Investment or any other financing arrangement the parties may mutually agree to seek in connection with the Transactions (it being understood and agreed that the consummation of any such financing by the Company, New Parent
or EBAC shall be subject to the parties&#146; mutual agreement), including (i)&nbsp;by providing such information and assistance as the other party may reasonably request (including the Company and EBAC providing such financial statements and other
financial data relating to the Company or EBAC and their Subsidiaries, as applicable, and as would be required (x)&nbsp;if New Parent were filing a general form for registration of securities under Form 10 following the consummation of the
Transactions, (y)&nbsp;for a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> for the resale of the securities issued in the PIPE Investment following the Acquisition Closing), (ii) granting such access to the other party
and its representatives as may be reasonably necessary for their due diligence, and (iii)&nbsp;participating in a reasonable number of meetings, presentations, road shows, drafting sessions and due diligence sessions with respect to such financing
efforts (including direct contact between senior management and other representatives of the Company and its Subsidiaries at reasonable times and locations) and (iv)&nbsp;taking, or to causing to be taken, all actions required, necessary or
advisable to consummate such financing transactions, including using commercially reasonable efforts to enforce its rights under any Subscription Agreement or Additional Subscription Agreement. All such cooperation, assistance and access shall be
granted during normal business hours and shall be granted under conditions that shall not unreasonably interfere with the business and operations of the Company, EBAC, or their respective auditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From the date of the announcement of this Agreement or the date of the Transactions (pursuant to any applicable public communication made
in compliance with Section&nbsp;12.12), until the Acquisition Closing Date, EBAC and the Company shall use their commercially reasonable efforts to, and shall instruct their respective financial advisors to, keep each other and each other&#146;s
financial advisors reasonably informed with respect to the PIPE Investment and the rotation of the EBAC Common Stock during such period, including by (i)&nbsp;providing regular updates and (ii)&nbsp;consulting and cooperating with, and considering
in good faith any feedback from, each other and each other&#146;s financial advisors with respect to such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_97">
</A>Section&nbsp;9.05. <I>Additional Equity Financing</I>. For the avoidance of doubt, during the Interim Period and subject to Sections 7.01(j) and 8.04(a)(viii), EBAC and the Company and/or New Parent may execute Additional Subscription Agreements
with investors with the prior written consent of the other Parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_98"></A>Section&nbsp;9.06.
<I>Section</I><I></I><I>&nbsp;16 Matters</I>. Prior to the First Merger Effective Time, upon request of EBAC, each of the Company and New Parent shall use commercially reasonable efforts to take all such steps (to the extent permitted under
applicable Law) to cause any acquisitions or dispositions of the New Parent Shares or of EBAC Common Stock (including, in each case, securities deliverable upon exercise, vesting or settlement of any derivative securities) resulting from the
Transactions by each individual who is or may become subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act in connection with the Transactions to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_99"></A>Section&nbsp;9.07. <I>Employee Matters</I>. Prior to the
Acquisition Closing and with the prior written consent of EBAC (not to be unreasonably withheld, conditioned or delayed), the Company shall approve and adopt an incentive award plan (the &#147;<B>New Parent Equity Incentive Plan</B>&#148;), which
shall provide for an aggregate share reserve thereunder equal to sixteen percent (16%) of the New Parent Shares on a fully diluted basis plus (inclusive of the Converted Options). Within two (2)&nbsp;Business Days following the expiration of the
sixty (60)&nbsp;day period following the date New Parent has filed a current Form 10 information with the SEC reflecting its status as an entity that is not a shell company, New Parent shall use its commercially reasonable efforts to file an
effective registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or other applicable form, including Form <FONT STYLE="white-space:nowrap">F-3)</FONT> with respect to the New Parent Shares issuable under the New Parent Equity
Incentive Plan, and New Parent shall use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards
granted pursuant to the New Parent Equity Incentive Plan remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_100"></A>Section&nbsp;9.08. <I>Director
and Officer Appointments</I>. Except as otherwise agreed in writing by the Company and EBAC prior to the Acquisition Closing, and conditioned upon the occurrence of the Acquisition Closing, subject to any limitation imposed under applicable Laws and
Nasdaq listing requirements, EBAC and the Company shall take all actions necessary or appropriate to cause the individuals set forth on Section&nbsp;9.08 of the Company Disclosure Letter to be elected as members of the Board of Directors of New
Parent (the &#147;<B>New Parent Board of Directors</B>&#148;) and/or officers of New Parent, as indicated thereon, in each case effective as of the Acquisition Closing. Such New Parent Board of Directors will, at the Acquisition Closing, include:
(i)&nbsp;two (2) individuals designated as the Sponsor director nominees (individually, the &#147;<B>Sponsor Nominee</B>&#148;) and (ii)&nbsp;up to five (5)&nbsp;individuals designated by the Company, one of whom shall be the chief executive of the
Company and at least three of whom, who in each case will be subject to the prior approval of the Sponsor (not to be unreasonably withheld) shall qualify as &#147;independent&#148; under applicable SEC and Nasdaq listing rules. If any of the
individuals set forth on Section&nbsp;9.08 of the Company Disclosure Letter is prohibited by applicable Law from acting as a director or officer of New Parent or does not meet any regulatory fit and proper requirements or the Company (acting
reasonably) determines that any such individual is in breach of any applicable Laws (including Anti-Bribery Laws and Sanctions Laws but excluding any other minor offenses that do not have an effect on the reputation or fit and proper status of such
individual), a replacement individual shall be selected by the Company, or in the case of the Sponsor Nominee by the Sponsor, to act as a member of the New Parent Board of Directors and/or officer of New Parent, as applicable. On the Acquisition
Closing Date, New Parent shall enter into customary indemnification agreements reasonably satisfactory to the Sponsor with the Sponsor Nominees, which indemnification agreements shall continue to be effective following the Acquisition Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_101"></A>Section&nbsp;9.09. <I>Tax Matters.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties intend that the EBAC Mergers, taken together, the Company Share Contribution and the Third Merger, taken together, and the
Convertible Loans qualify for the Intended Tax Treatment. This Agreement is intended to constitute and hereby is adopted as a &#147;plan of reorganization&#148; with respect to each of the EBAC Mergers, the Company Share Contribution, and the Third
Merger within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a)</FONT> and for purposes of Sections 354, 361, and 368 of the Code and the applicable
Treasury Regulations. The Parties (i)&nbsp;shall use commercially reasonable efforts to cause the Transactions to qualify for the Intended Tax Treatment, (ii)&nbsp;shall not take any action that could reasonably be expected to prevent, impair, or
impede the Intended Tax Treatment, and (iii)&nbsp;shall not take any position for Tax purposes inconsistent with the Intended Tax Treatment unless otherwise required by a &#147;determination&#148; within the meaning of Section&nbsp;1313 of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Transfer Taxes shall be borne and paid by New Parent. Unless otherwise required by applicable Law, New Parent shall timely file
any Tax Return or other document with respect to Transfer Taxes (and the other Parties shall reasonably cooperate with respect thereto as necessary). The Parties shall reasonably cooperate to reduce or eliminate the amount of any Transfer Taxes.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Parties shall use commercially reasonable efforts to cooperate fully, as and to the
extent reasonably requested by the other Party or its counsel, in connection with filing relevant Tax Returns, conducting and defending relevant Legal Proceedings with respect to Taxes, and documenting and supporting the Intended Tax Treatment,
including by providing customary representation letters. Such cooperation shall include the reasonable provision of records and information that are reasonably relevant to any such matters and within such Party&#146;s possession or obtainable by
such Party without material cost or expense, and the use of commercially reasonable efforts to make employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EBAC shall (i)&nbsp;cause Merger Sub 2 to timely file an initial entity classification election on a valid IRS Form 8832 to be treated for
U.S. federal income Tax purposes as an entity disregarded as separate from New Parent, effective as of the date of its formation (and shall not thereafter change such classification), (ii) take no action that would result in New Parent, Merger Sub
1, or Merger Sub 3 being treated as anything other than an association taxable as a corporation for U.S. federal income Tax purposes, and (iii)&nbsp;take no action that would result in Merger Sub 1, Merger Sub 2, or Merger Sub 3 being other than a
wholly owned direct Subsidiary of New Parent as of immediately prior to the First Merger Effective Time, the Second Merger Effective Time, and the Third Merger Effective Time, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event that EBAC is treated as a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297 of the Code,
New Parent shall make available to the <FONT STYLE="white-space:nowrap">pre-closing</FONT> EBAC shareholders information that is reasonably required to make a timely and valid &#147;Qualifying Electing Fund&#148; election under Section&nbsp;1295 of
the Code and the Treasury Regulations promulgated thereunder with respect to EBAC for the taxable year that includes the Acquisition Closing Date and the immediately preceding taxable year (including through provision of a PFIC Annual Information
Statement described in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1295-1(g)),</FONT> including, at New Parent&#146;s election, by making such information publicly available on New Parent&#146;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each of the Parties shall promptly notify the other Parties in writing if, before the Acquisition Closing, it determines that it is not
reasonable for the Transactions to qualify for the Intended Tax Treatment. Following such notice, the notifying Party may propose amendments to the terms of this Agreement (including, without limitation, having Merger Sub 3 timely file an entity
classification election on a valid IRS Form 8832 to be treated as an entity disregarded as separate from New Parent for U.S. federal income Tax purposes, effective prior to the Acquisition Closing) that such Party reasonably believes could
facilitate such qualification without an adverse effect on any other Party. In that case, each other Party shall consider in good faith the proposed amendments and, if it determines in good faith that such amendments would not have an adverse effect
on such Party, the Parties shall use commercially reasonable efforts to effect such amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Company shall not call, request,
receive, or otherwise take possession in cash of any amounts pursuant to the Convertible Loan Agreement. In the event that cash to fund the Convertible Loans is funded by the lender parties thereto prior to the assumption of the Company&#146;s
rights and obligations under the Convertible Loan Agreement by New Parent, such cash shall only be funded to the &#147;Escrow Agent&#148; (as defined in the Convertible Loan Agreement), which the Escrow Agent shall hold on behalf of the Lenders that
funded such cash, and such Lenders shall be treated as the owners of such cash for U.S. federal income Tax purposes unless and until such cash is distributed to New Parent pursuant to the Convertible Loan Agreement. No person other than the Escrow
Agent shall be entitled to receive any cash funded pursuant to the Convertible Loan Agreement until after the Second Merger Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company, EBAC, and New Parent will use commercially reasonable efforts to ensure that the intended Tax treatment set forth in clause
(iv)&nbsp;of the definition of Intended Tax Treatment is obtained. In furtherance of the foregoing, following the Second Merger Effective Time but prior to the Company Share Contribution, the Company shall agree with New Parent for the assumption by
New Parent of all rights and obligations of the Company under the Convertible Loan Agreement pursuant to documentation and/or instruments reasonably satisfactory to New Parent and the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_102"></A>Section&nbsp;9.10. <I>Third Merger.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the Acquisition Closing Date, and after the Company Share Contribution, the New Parent Board of Directors shall hold a meeting to
implement the issuance of the New Parent <FONT STYLE="white-space:nowrap">Squeeze-Out</FONT> Shares, if any, and take any other actions required in order to effect the Third Merger. The New Parent Board of Directors shall execute the application to
the commercial register for an expedited <FONT STYLE="white-space:nowrap">pre-registration</FONT> procedure (<I>Vorerfassungsverfahren / proc&eacute;dure de pr&eacute;-enregistrement</I>), and any other actions that may be required in connection
with such meeting of the New Parent Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Immediately after conducting such meeting of the New Parent Board of
Directors, but in any event not later than 11:00 a.m. Swiss time on the Acquisition Closing Date, the New Parent Board of Directors shall file the application for registration in the expedited <FONT STYLE="white-space:nowrap">pre-registration</FONT>
procedure (<I>Vorerfassungsverfahren / proc&eacute;dure de pr&eacute;-enregistrement</I>) of the matters covered in such meeting with the commercial register of the Canton of Zug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On or prior to the Acquisition Closing Date, New Parent, the Company, and Merger Sub 3 shall prepare a merger agreement, on mutually
agreeable terms, to effect the Third Merger. New Parent, the Company and Merger Sub 3 shall also adopt a merger report in accordance with the Swiss Code of Obligations in connection with the Third Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No less than three (3)&nbsp;and no more than five (5)&nbsp;Business Days following the Acquisition Closing Date, the Company shall invite
all Company Shareholders that did not execute a Company Shareholders Support Agreement and the exchange notice contemplated by Section&nbsp;2.01 to effect the Company Share Contribution to an Extraordinary Shareholders&#146; Meeting
(&#147;<B>Company EGM</B>&#148;) with the resolutions required for the Third Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company and Merger Sub 3 shall each hold the
Company EGM and the Merger Sub 3 extraordinary shareholders&#146; meeting, respectively, on or about <FONT STYLE="white-space:nowrap">thirty-two</FONT> (32)&nbsp;calendar days after the Acquisition Closing Date before a Swiss notary public, to
approve the Third Merger. The Company shall file the application for registration with the commercial register of the Canton of Vaud. Upon registration of the Third Merger, and with no further action required on the part of any Person, (i)&nbsp;New
Parent shall issue to the Company Shareholders that did not execute a Company Shareholders Support Agreement or the exchange notice contemplated by Section&nbsp;2.01 an amount of New Parent <FONT STYLE="white-space:nowrap">Squeeze-Out</FONT> Shares,
using the applicable ratios set forth in Schedule 2.01 of the Company Disclosure Letter and (ii)&nbsp;following such payment, each interest of Company Share Capital held by such Company Shareholders shall be cancelled and cease to exist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The New Parent Board of Directors shall file the transfer of New Parent&#146;s registered seat to Lausanne with the commercial register of
the Canton of Vaud on or about forty-five (45)&nbsp;calendar days after the Acquisition Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_103"></A>Section&nbsp;9.11. <I>Engagement Letters; Subscription Agreements. </I>As of the Acquisition Closing, New Parent
will assume all of the obligations of EBAC under the PIPE Placement Agent Engagement Letters and the Subscription Agreements, and of the Company under the Financial Advisor Engagement Letters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_104"></A>Section&nbsp;9.12. <I>Agent Deliverables.</I> EBAC and the Company shall not allow any of the following events to
occur without delivering the Agent Deliverables to the Agents, in form agreed to (but unexecuted) by the Agents at least two (2)&nbsp;Business Days prior to the date of the following events, in each case, dated as of the respective dates of the
following events: (i)&nbsp;the Registration Statement to be declared effective or (ii)&nbsp;the EBAC Shareholders&#146; Meeting to take place (with any such failure of delivery, a &#147;Delivery Default&#148;), in each case, unless the Agents, after
being notified by EBAC and the Company in writing in reasonable detail of an expected Delivery Default, have had a reasonable period of time but no less than three (3)&nbsp;Business Days (the &#147;Resignation Period&#148;) prior to the occurrence
of the relevant event to take any action the Agents deem appropriate, including without limitation, to elect to (A)&nbsp;resign from their respective roles, (B)&nbsp;disclose such resignation publicly, and/or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(C)&nbsp;disclose such resignation to the SEC or otherwise (in each case above at their sole and absolute discretion) as is deemed necessary by the Agents. Notwithstanding the foregoing, nothing
in this Agreement shall limit the right of any Agent to take any action it deems appropriate, including without limitation, to resign from any or all of its capacities at any time and for any reason, in its sole and absolute discretion. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONDITIONS</SMALL> <SMALL>TO</SMALL> O<SMALL>BLIGATIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_105"></A>Section&nbsp;10.01. <I>Conditions to Obligations of the Parties</I>. The obligations of the Parties to
consummate, or cause to be consummated, the Transactions is subject to the satisfaction of the following conditions, any one or more of which may be waived in writing by all of such parties: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The EBAC Shareholder Approval shall have been obtained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Registration Statement shall have become effective under the Securities Act and no stop order suspending the effectiveness of the
Registration Statement shall have been issued and no proceedings for that purpose shall have been initiated or threatened by the SEC and not withdrawn; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There shall not be in force any Governmental Order enjoining or prohibiting the consummation of either or both of the Acquisition
Transactions or any Law that makes the consummation of either or both of the Acquisition Transactions illegal or otherwise prohibited; <I>provided</I> that the Governmental Authority issuing such Governmental Order has jurisdiction over the parties
hereto with respect to the Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EBAC having net tangible assets of at least $5,000,001; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The New Parent Shares and New Parent Warrants to be issued in connection with the Acquisition Transactions shall have been approved for
listing on the Stock Exchange; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;(i) The amount of cash or cash equivalents available in the Trust Account following the EBAC
Shareholders&#146; Meeting (after deducting the amount required to satisfy the EBAC Share Redemption Amount and payment of any Company Transaction Expenses or EBAC Transaction Expenses); <I>plus</I> (ii)&nbsp;(A) the cash actually received by New
Parent pursuant to the Convertible Loan Agreement from the respective lender parties thereto and (B)&nbsp;the PIPE Investment Amount actually received by New Parent (or other financing in connection with the Acquisition Transactions) prior to or
substantially concurrently with the Acquisition Closing is equal to or greater than $100&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_106"></A>Section&nbsp;10.02. <I>Conditions to Obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub
3</I>. The obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to consummate, or cause to be consummated, the Acquisition Transactions are subject to the satisfaction of the following additional conditions, any one or more
of which may be waived in writing by EBAC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) The representations and warranties of the Company contained in the first sentence
of Section&nbsp;4.06(a) shall be true and correct in all respects as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and
warranties shall be true and correct in all respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements, (ii)&nbsp;the Company
Fundamental Representations (other than the first sentence of Section&nbsp;4.06(a)) shall be true and correct in all material respects, in each case as of the as of the date hereof and Acquisition Closing Date, except with respect to such
representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date, except for changes after the date of this Agreement which are
contemplated or expressly permitted by this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement or the Ancillary Agreements, and (iii)&nbsp;each of the representations and warranties of the Company contained in this Agreement other than the Company Fundamental Representations
(disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect and Company Material Adverse Effect or any similar qualification or exception) shall be true and correct as of the date hereof and as
of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct at and as of such date, except for, in each case,
inaccuracies or omissions that have not had, and would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the covenants of the Company set forth in this Agreement to be performed as of or prior to the Acquisition Closing shall have been
performed in all material respects; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There shall not have occurred a Company Material Adverse Effect after the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_107"></A>Section&nbsp;10.03. <I>Conditions to the Obligations of the Company</I>. The obligation of the
Company to consummate, or cause to be consummated, the Acquisition Transactions is subject to the satisfaction of the following additional conditions, any one or more of which may be waived in writing by the Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) the EBAC Fundamental Representations shall be true and correct in all material respects as of the date of this Agreement and as
of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date, except for
changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements, (ii)&nbsp;the representations and warranties set forth in the first sentence of each of the first sentence of each
of Section&nbsp;5.03(a) and Section&nbsp;6.13(a) shall be true and correct in all respects as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date,
which representations and warranties shall be true and correct in all respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements
and (iii)&nbsp;the representations and warranties of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 in <B></B>Article 5 and Article 6 (other than the EBAC Fundamental Representations and the representations and warranties set forth in
the first sentence of the first sentence of each of Section&nbsp;5.03(a) and Section&nbsp;6.13(a)) (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect or any similar qualification or
exception) shall be true and correct as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and
correct as of such date, except for, in each case, inaccuracies or omissions that have not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the
Transactions in accordance with the terms of this Agreement and changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the covenants of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 set forth in this Agreement to be performed as of
or prior to the Acquisition Closing shall have been performed in all material respects; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There shall not have occurred a material
adverse effect of the EBAC after the date of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 11 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>ERMINATION</SMALL>/E<SMALL>FFECTIVENESS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_108"></A>Section&nbsp;11.01. <I>Termination</I>. This Agreement may be terminated and the Transactions abandoned: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of the Company and EBAC; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by the Company or EBAC if the Acquisition Closing Date has not occurred by
March&nbsp;18, 2023 (the &#147;<B>Agreement End Date</B>&#148;); <I>provided, </I>that if an Extension Proposal shall be approved at an Extension Shareholders&#146; Meeting, then the Agreement End Date shall be the last day of the extended time
period for EBAC to consummate a business combination; <I>provided</I>, <I>further, however</I>, that a party shall not be entitled to terminate this Agreement pursuant to this Section&nbsp;11.01(b) if such party&#146;s breach of this Agreement has
prevented the consummation of the Acquisition Closing Date at or prior to such time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by the Company or EBAC if any Governmental
Authority, shall have enacted, issued, promulgated, enforced or entered any Governmental Order which has become final and nonappealable and has the effect of making consummation of either or both of the Acquisition Transactions illegal or otherwise
preventing or prohibiting consummation of either or both of the Acquisition Transactions or if there shall be adopted any Law that permanently makes consummation of either or both of the Acquisition Transactions illegal or otherwise prohibited; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by the Company if there has been a Modification in Recommendation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by the Company or EBAC if the EBAC Shareholder Approval shall not have been obtained by reason of the failure to obtain the required vote
at the EBAC Shareholders&#146; Meeting duly convened therefor or at any adjournment or postponement thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by written notice to the
Company from EBAC if (i)&nbsp;there is any breach of any representation, warranty, covenant or agreement on the part of the Company set forth in this Agreement, such that the conditions specified in Section&nbsp;10.02(a) through
Section&nbsp;10.02(d) would not be satisfied at the Acquisition Closing (a &#147;<B>Terminating Company Breach</B>&#148;), except that, if such Terminating Company Breach is curable by the Company prior to the end of the period ending on the date
that is the earlier of (A)&nbsp;forty-five (45)&nbsp;days after receipt by the Company of notice from EBAC of such breach or (B)&nbsp;the Agreement End Date (the &#147;<B>Company Cure Period</B>&#148;), such termination shall not be effective, and
such termination shall become effective only if the Terminating Company Breach is not cured within the Company Cure Period; <I>provided</I>, <I>however</I>, that EBAC is not then in material breach of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by written notice to EBAC from the Company if there is any breach of any representation, warranty, covenant or agreement on the part of
EBAC set forth in this Agreement, such that the conditions specified in Section&nbsp;10.03(a) through Section&nbsp;10.03(c) would not be satisfied at the Acquisition Closing (a &#147;<B>Terminating EBAC Breach</B>&#148;), except that, if any such
Terminating EBAC Breach is curable by EBAC prior to the end of the period ending on the date that is the earlier of (A)&nbsp;forty-five (45)&nbsp;days after receipt by EBAC of notice from the Company of such breach or (B)&nbsp;the Agreement End Date
(the &#147;<B>EBAC Cure Period</B>&#148;), such termination shall not be effective, and such termination shall become effective only if the Terminating EBAC Breach is not cured within the EBAC Cure Period <I>provided</I>, <I>however</I>, that the
Company is not then in material breach of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_109"></A>Section&nbsp;11.02. <I>Effect of Termination</I>.
In the event of the termination of this Agreement pursuant to Section&nbsp;11.01, this Agreement shall forthwith become void and have no effect, without any liability on the part of any party hereto or its respective Affiliates, officers, directors
or shareholders, other than liability of the Company or EBAC, as the case may be, for actual fraud or any willful and material breach (meaning an action or omission that at the time taken or made is both deliberate and known to be a material breach)
of this Agreement occurring prior to such termination except that the provisions of this Section&nbsp;11.02 and Article 12 and the Confidentiality Agreement shall survive any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 12 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_110">
</A>Section&nbsp;12.01. <I>Trust Account Waiver</I>. The Company understands and acknowledges that EBAC is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization
or similar business combination with one or more businesses. The Company further acknowledges that, as described in the final prospectus relating to EBAC&#146;s initial public offering filed with the SEC on March&nbsp;18, 2021 (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-23220)</FONT> (the &#147;<B>Prospectus</B>&#148;), substantially all of EBAC&#146;s assets consist of the cash proceeds of such initial public offering and private placement of securities, and substantially
all of those proceeds have been deposited into a trust account (the &#147;<B>Trust Account</B>&#148;) for the benefit of EBAC and EBAC&#146;s public shareholders. As further described in the Prospectus, the funds held from time to time in the Trust
Account may only be released upon certain conditions. The Company acknowledges and agrees that, prior to the Acquisition Closing and subject in all respects to the Trust Agreement, it has no right of <FONT STYLE="white-space:nowrap">set-off</FONT>
or any right, title, interest or claim of any kind (&#147;<B>Claim</B>&#148;) to, or to any monies or other assets in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies or other assets in, the Trust Account that it may
have now or in the future prior to Acquisition Closing. In the event the Company has any Claim against EBAC under this Agreement or otherwise, the Company shall pursue such Claim solely against EBAC and EBAC&#146;s assets outside the Trust Account
and not against the Trust Account or any monies or other assets in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_111"></A>Section&nbsp;12.02.
<I>Waiver</I>. Any Party to this Agreement may, at any time prior to the Acquisition Closing, by action taken by its Board of Directors, Board of Managers, Managing Member or other officers or Persons thereunto duly authorized, (a)&nbsp;extend the
time for the performance of the obligations or acts of the other parties hereto, (b)&nbsp;waive any inaccuracies in the representations and warranties (of another party hereto) that are contained in this Agreement or (c)&nbsp;waive compliance by the
other parties hereto with any of the agreements or conditions contained in this Agreement, but such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party granting such extension or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_112"></A>Section&nbsp;12.03. <I>Notices</I>. All notices and other communications among the parties shall be in writing
and shall be deemed to have been duly given (i)&nbsp;when delivered in person, (ii)&nbsp;when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid,(iii) when
delivered by FedEx or other nationally recognized overnight delivery service, or (iv)&nbsp;when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding any automated reply, such as an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-office</FONT></FONT> notification), addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to
EBAC prior to the Acquisition Closing, or to Merger Sub 2 after the Second Merger Effective Time, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">European Biotech Acquisition Corp.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">EPFL Innovation Park Building </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1015 Lausanne </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Eduardo Bravo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: eduardo.bravo@eqtpartners.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with copies to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michael Davis </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derek Dostal
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;michael.davis@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
derek.dostal@davispolk.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company prior to the Acquisition Closing, or to New Parent after the
Acquisition Closing, to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Oculis SA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">EPFL Innovation Park Building D </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1015 Lausanne </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Switzerland </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Riad Sherif </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;riad.sherif@oculis.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with copies to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley (UK) LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">22 Bishopsgate
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London EC2N 4BQ, UK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michal Berkner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Divakar Gupta
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ryan Sansom
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mberkner@cooley.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
dgupta@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
rsansom@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside
counsel shall not constitute notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_113"></A>Section&nbsp;12.04. <I>Assignment</I>. No party hereto shall assign
this Agreement or any part hereof without the prior written consent of the other parties and any such transfer without prior written consent shall be void. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of
the parties hereto and their respective permitted successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_114"></A>Section&nbsp;12.05. <I>Rights of
Third Parties</I>. This Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns and, except as provided in Section&nbsp;7.08, the last two sentences of this Section&nbsp;12.05,
Section&nbsp;12.16 and Section&nbsp;12.17, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. Legal
counsel identified in Section&nbsp;12.18 shall be express third-party beneficiaries of Section&nbsp;12.18. The PIPE Placement Agents and the Financial Advisor shall be express third-party beneficiaries of the provisos to Section&nbsp;12.11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_115"></A>Section&nbsp;12.06. <I>Expenses</I>. Except as otherwise set forth in this Agreement, each party hereto shall be
responsible for and pay its own expenses incurred in connection with this Agreement and the Transactions, including all fees of its legal counsel, financial advisers and accountants. If the Acquisition Closing shall not occur, the Company shall be
responsible for the Company Transaction Expenses, and EBAC shall be responsible for the EBAC Transaction Expenses. If the Acquisition Closing shall occur, New Parent shall (x)&nbsp;pay or cause to be paid, the Company Transaction Expenses, and
(y)&nbsp;pay or cause to be paid, the EBAC Transaction Expenses. For the avoidance of doubt, any payments to be made (or to cause to be made) by New Parent pursuant to this Section&nbsp;12.06 shall be paid upon consummation of the Acquisition
Transactions and release of proceeds from the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_116"></A>Section&nbsp;12.07. <I>Governing Law</I>. This
Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the Transactions, shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to
principles or rules of conflict of Laws to the extent such principles or rules would require or permit the application of Laws of another jurisdiction (except that Swiss Law shall apply to the New Parent Share Capital Increase). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_117"></A>Section&nbsp;12.08. <I>Headings; Counterparts</I>. The headings
in this Agreement are for convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be delivered by email (including by .pdf, .tif, .gif, .jpeg or similar formatted attachment thereto) by any Party and such
signature will be deemed binding for all purposes hereof without delivery of an original signature being thereafter required. This Agreement shall become effective when each Party hereto shall have received one or more counterparts hereof signed by
each of the other Parties hereto and unless and until such receipt, this Agreement shall have no effect and no Party hereto shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other
communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_118"></A>Section&nbsp;12.09. <I>Company and EBAC Disclosure Letters</I>. The Company Disclosure
Letter and the EBAC Disclosure Letter (as the EBAC Disclosure Letter may be supplemented from time to time after the date hereof in accordance with Section&nbsp;2.02(c)(ii)) (including, in each case, any section thereof) referenced herein are a part
of this Agreement as if fully set forth herein. All references herein to the Company Disclosure Letter and/or the EBAC Disclosure Letter (including, in each case, any section thereof) shall be deemed references to such parts of this Agreement,
unless the context shall otherwise require. Any disclosure made by a party in the applicable Disclosure Letter, or any section thereof, with reference to any section of this Agreement or section of the applicable Disclosure Letter shall be deemed to
be a disclosure with respect to such other applicable sections of this Agreement or sections of applicable Disclosure Letter if it is reasonably apparent on the face of such disclosure that such disclosure is responsive to such other section of this
Agreement or section of the applicable Disclosure Letter. Certain information set forth in the Disclosure Letters is included solely for informational purposes and may not be required to be disclosed pursuant to this Agreement. The disclosure of any
information shall not be deemed to constitute an acknowledgment that such information is required to be disclosed in connection with the representations and warranties made in this Agreement, nor shall such information be deemed to establish a
standard of materiality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_119"></A>Section&nbsp;12.10. <I>Entire Agreement</I>. (a)&nbsp;This Agreement (together with
the Company Disclosure Letter and the EBAC Disclosure Letter), (b) the Sponsor Support Agreement, (c)&nbsp;the Confidentiality Agreement, dated as of February&nbsp;22, 2022, by and between EBAC and the Company (the &#147;<B>Confidentiality
Agreement</B>&#148;), (d) the Company Shareholders Support Agreement and (e)&nbsp;when entered into at the Acquisition Closing, (i)&nbsp;the Registration Rights Agreement and (ii)&nbsp;the Warrant Assumption Agreement (the foregoing clauses
(b)&nbsp;through (e), collectively, the &#147;<B>Ancillary Agreements</B>&#148;) constitute the entire agreement among the parties to this Agreement relating to the Transactions and supersede any other agreements, whether written or oral, that may
have been made or entered into by or among any of the parties hereto or any of their respective Subsidiaries relating to the Transactions. No representations, warranties, covenants, understandings, agreements, oral or otherwise, relating to the
Transactions exist between such parties except as expressly set forth in this Agreement and the Ancillary Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_120">
</A>Section&nbsp;12.11. <I>Amendments</I>. This Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing executed by the Parties hereto in the same manner as this Agreement and which makes reference to
this Agreement, provided that Section&nbsp;7.09, Section&nbsp;8.09, Section&nbsp;9.11, Section&nbsp;9.12, the last sentence of Section&nbsp;12.05 and Section&nbsp;12.11 of this Agreement may not be amended, modified or waived without the prior
written consent of the Placement Agents; provided further that Section&nbsp;7.09, Section&nbsp;8.09, Section&nbsp;9.12, the last sentence of Section&nbsp;12.05 and Section&nbsp;12.11 of this Agreement may not be amended, modified or waived without
the prior written consent of the Financial Advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_121"></A>Section&nbsp;12.12. <I>Publicity.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All press releases or other public communications relating to the Transactions, and the method of the release for publication thereof,
shall prior to the Acquisition Closing be subject to the prior mutual approval of EBAC and the Company, which approval shall not be unreasonably withheld by any party; <I>provided</I> that no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party shall be required to obtain consent pursuant to this Section&nbsp;12.12(a) to the extent any proposed release or statement is substantially equivalent to the information that has previously
been made public without breach of the obligation under this Section&nbsp;12.12(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The restriction in Section&nbsp;12.12(a) shall
not apply to the extent the public announcement is required by applicable securities Law, any Governmental Authority or stock exchange rule; <I>provided</I>, <I>however</I>, that in such an event, the party making the announcement shall use its
commercially reasonable efforts to consult with the other party in advance as to its form, content and timing. Disclosures resulting from the parties&#146; efforts to obtain approval or early termination under any regulatory approvals needed in
connection with this Agreement, and to make any relating filing shall be deemed not to violate this Section&nbsp;
12.12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_122"></A>Section&nbsp;12.13. <I>Severability</I>. If any provision of this Agreement is held invalid or
unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. The parties further agree that if any provision contained herein is, to any extent, held invalid or unenforceable in
any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by Law and, to the extent necessary, shall amend or
otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_123"></A>Section&nbsp;12.14. <I>Jurisdiction; Waiver of Jury Trial.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any proceeding or Action based upon, arising out of or related to this Agreement or the Transactions must be brought in the Court of
Chancery of the State of Delaware (or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware), or, if it has or can acquire jurisdiction, in the United States District Court for the District
of Delaware, and each of the parties irrevocably (i)&nbsp;submits to the exclusive jurisdiction of each such court in any such proceeding or Action, (ii)&nbsp;waives any objection it may now or hereafter have to personal jurisdiction, venue or to
convenience of forum, (iii)&nbsp;agrees that all claims in respect of the proceeding or Action shall be heard and determined only in any such court, and (iv)&nbsp;agrees not to bring any proceeding or Action arising out of or relating to this
Agreement or the Transactions in any other court. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by Law or to commence Legal Proceedings or otherwise proceed against any other party
in any other jurisdiction, in each case, to enforce judgments obtained in any Action, suit or proceeding brought pursuant to this Section&nbsp;12.14. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY BE BASED ON, ARISE UNDER OR RELATE TO THIS AGREEMENT AND THE
TRANSACTIONS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY, UNCONDITIONALLY AND VOLUNTARILY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR
PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_124"></A>Section&nbsp;12.15. <I>Enforcement</I>. The parties hereto agree that irreparable damage could occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent any breach, or
threatened breach, of this Agreement and to specific enforcement of the terms and provisions of this Agreement, in addition to any other remedy to which any party is entitled at law or in equity. In the event that any Action shall be brought in
equity to enforce the provisions of this Agreement, no party shall allege, and each party hereby waives the defense, that there is an adequate remedy at law, and each party agrees to waive any requirement for the securing or posting of any bond in
connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_125"></A>Section&nbsp;12.16.
<I><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></I>. Except in the case of claims against a Person in respect of such Person&#146;s actual fraud: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Solely with respect to the Company and EBAC, this Agreement may only be enforced against, and any claim or cause of action based upon,
arising out of, or related to this Agreement or the Transactions may only be brought against, the Company and EBAC as named parties hereto; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) except to the extent a party hereto (and then only to the extent of the specific obligations undertaken by such party hereto), (i) no
past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney, advisor or representative or Affiliate of the Company or EBAC and (ii)&nbsp;no past, present or future director, officer,
employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney, advisor or representative or Affiliate of any of the foregoing shall have any liability (whether in Contract, tort, equity or otherwise) for any one or more of the
representations, warranties, covenants, agreements or other obligations or liabilities of any one or more of the Company or EBAC under this Agreement for any claim based on, arising out of, or related to this Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_126"></A>Section&nbsp;12.17. <I><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations, Warranties and
Covenants</I>. Except (x)&nbsp;as expressly otherwise contemplated by Section&nbsp;11.02, none of the representations, warranties, covenants, obligations or other agreements in this Agreement or in any certificate, statement or instrument delivered
pursuant to this Agreement, including any rights arising out of any breach of such representations, warranties, covenants, obligations, agreements and other provisions, shall survive the Acquisition Closing and shall terminate and expire upon the
occurrence of the First Merger Effective Time (and there shall be no liability after the Acquisition Closing in respect thereof), except for (a)&nbsp;those covenants and agreements contained herein that by their terms expressly apply in whole or in
part after the Acquisition Closing and then only with respect to any breaches occurring after the Acquisition Closing and (b)&nbsp;this Article 12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="anxa389734_127"></A>Section&nbsp;12.18. <I>Conflicts and Privilege.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Parties to this Agreement, on its own behalf and on behalf of its successors and assigns, hereby agree that, in the event a
dispute with respect to this Agreement or the Transactions arises after the Acquisition Closing between or among (i)&nbsp;the Sponsor, the shareholders or holders of other equity interests of EBAC, New Parent, Merger Sub 1, Merger Sub 2, Merger Sub
3 or the Sponsor, or any of their respective directors, members, partners, officers, employees or Affiliates (collectively, the &#147;<B>EBAC Group</B>&#148;), on the one hand, and (ii)&nbsp;the Company or the shareholders or holders of other equity
interests of the Company, or any of their respective directors, members, partners, officers, employees or Affiliates (collectively, the &#147;<B>Company Group</B>&#148;), on the other hand, Davis Polk&nbsp;&amp; Wardwell LLP (&#147;<B>Davis
Polk</B>&#148;), and Maples Group (collectively, the &#147;<B>Local Counsels</B>&#148;) may represent the Sponsor or any other member of the EBAC Group in such dispute even though the interests of such Persons may be directly adverse to New Parent,
Merger Sub 2 or Merger Sub 3, and even though such counsel may have represented EBAC, New Parent, Merger Sub 2 or Merger Sub 3 in a matter substantially related to such dispute, or may be handling ongoing matters for the Company or the Sponsor. The
Parties, on behalf of their respective successors and assigns, further agree that, as to all communications prior to the Acquisition Closing (made in connection with the negotiation, preparation, execution, delivery and performance under, or any
dispute or Action arising out of or relating to, this Agreement, any Ancillary Agreements or the transactions contemplated hereby or thereby) between or among EBAC, the Sponsor or any other member of the EBAC Group, on the one hand, and Davis Polk
and/or Local Counsels, on the other hand, shall be deemed subject to attorney client privilege (the &#147;<B>Davis Polk Privileged Communications</B>&#148;), and the attorney/client privilege and the expectation of client confidence shall survive
the Transactions and belong to the members of the EBAC Group after the Acquisition Closing, and shall not pass to or be claimed or controlled by the Company. Any privileged communications or information shared by the Company prior to the Acquisition
Closing with EBAC or the Sponsor under a common interest agreement shall remain the privileged communications or information of the Company. The Parties, together with any of their respective Affiliates, Subsidiaries, successors or assigns, agree
that the EBAC Group may restrict access to the Davis Polk Privileged </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Communications, whether located in the records or email server of any Party or its respective Subsidiaries, in any Action against or involving any of the Parties after the Acquisition Closing,
and the Parties agree not to assert that any privilege has been waived as to the Davis Polk Privileged Communications, by virtue of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the Parties to this Agreement, on its own behalf and on behalf of its respective directors, managers, members, partners, officers,
Affiliates, successors and assigns, hereby agree that, in the event a dispute with respect to this Agreement or the Transactions arises after the Acquisition Closing between or among (i)&nbsp;the members of the Company Group, on the one hand, and
(ii)&nbsp;Company or any member of the EBAC Group, on the other hand, any legal counsel, including Cooley (UK) LLP (&#147;<B>Cooley</B>&#148;) and Vischer AG (&#147;<B>Vischer</B>&#148;) that represented the Company prior to the Acquisition Closing
may represent any member of the Company Group in such dispute even though the interests of such Persons may be directly adverse to the Company, and even though such counsel may have represented the Company in a matter substantially related to such
dispute, or may be handling ongoing matters for the Company, further agree that, as to all communications prior to the Acquisition Closing (made in connection with the negotiation, preparation, execution, delivery and performance under, or any
dispute or Action arising out of or relating to, this Agreement, any Ancillary Agreements or the transactions contemplated hereby or thereby) between or among Company or any member of the Company Group, on the one hand, and Cooley or Vischer, on the
other hand, shall be deemed subject to attorney client privilege (the &#147;<B>Cooley Privileged Communications</B>&#148;), and the attorney/client privilege and the expectation of client confidence shall survive the Transactions and belong to the
members of the Company Group after the Acquisition Closing, and shall not pass to or be claimed or controlled by New Parent. Any privileged communications or information shared by EBAC or the Sponsor prior to the Acquisition Closing with the Company
or Company Group under a common interest agreement shall remain the privileged communications or information of the EBAC Group. The Parties, together with any of their respective Affiliates, Subsidiaries, successors or assigns, agree that the
Company Group may restrict access to the Cooley Privileged Communications, whether located in the records or email server of any Party or its respective Subsidiaries, in any Action against or involving any of the Parties after the Acquisition
Closing, and the Parties agree not to assert that any privilege has been waived as to the Cooley Privileged Communications, by virtue of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B> the parties have hereunto caused this Agreement to be duly
executed as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OCULIS SA</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EUROPEAN BIOTECH ACQUISITION CORP.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Business Combination Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii389734_100aaa"></A><A NAME="toc389734_40"></A>Annex B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Oculis Holding AG</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Oculis
Holding SA)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Oculis Holding Ltd)</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with registered office in</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zug</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Translation; in case of controversy the German text shall prevail)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATUTEN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>der</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Oculis Holding AG</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Oculis
Holding SA)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Oculis Holding Ltd)</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>mit Sitz in</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zug</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>I.&#8195;&#8201;&#8202;CORPORATE NAME, REGISTERED OFFICE, DURATION AND PURPOSE OF THE
COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>I.&#8195;&#8201;&#8202;FIRMA, SITZ, DAUER UND ZWECK DER GESELLSCHAFT</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;1&#8195;&#8194;&#8201;Corporate Name, Registered Office and Duration</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;1&#8195;&#8194;&#8202;Firma, Sitz und Dauer</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the name</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Oculis Holding AG</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Oculis Holding
SA)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Oculis Holding Ltd)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a company limited by shares which is subject to the provisions of articles 620 et seq. of the Swiss Code of Obligations (CO) exists with registered office in
Zug (Switzerland) (the &#147;Company&#148;). The duration of the Company is unlimited.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unter der Firma</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Oculis Holding AG</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Oculis Holding
SA)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Oculis Holding Ltd)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">besteht eine Aktiengesellschaft gem&auml;ss Artikeln 620 ff. OR mit Sitz in Zug (Schweiz) (die &#147;Gesellschaft&#148;). Die Dauer der Gesellschaft ist
unbeschr&auml;nkt.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;2&#8195;&#8194;&#8201;Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;2&#8195;&#8194;&#8202;Zweck</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The purpose of the Company is to acquire, hold, manage and sell interests in companies of all kinds in Switzerland and abroad, in particular in the areas of research and development in the field of pharmaceutical products, including
biological and biotechnological products, as well as the production and commercialisation of such products.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft bezweckt den Erwerb, das Halten, die Verwaltung und die Ver&auml;usserung von Beteiligungen an Gesellschaften aller Art in der Schweiz und im Ausland, insbesondere in den Bereichen Forschung und Entwicklung auf dem
Gebiet von pharmazeutischen Produkten, einschliesslich <FONT STYLE="white-space:nowrap">bio-logischen</FONT> und biotechnologischen Produkten, sowie die Herstellung und Kommerzialisierung derartiger Produkte.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company may purchase, hold and sell patents, copyrights, trademarks and other intellectual property rights as well as licenses of any kind.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann Patente, Urheber-rechte, Marken und andere Immaterialg&uuml;terrechte sowie Lizenzen jeder Art erwerben, halten und ver&auml;ussern.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company may engage in and carry out any and all commercial, financial or other activity, which is directly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann alle kommerziellen, finanziellen und anderen T&auml;tigkeiten aus&uuml;ben, welche</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">or indirectly related to the purpose of the Company. The Company may purchase, hold and sell shares or interests in other companies in Switzerland or abroad. It may establish and maintain branches and subsidiaries in Switzerland and
abroad.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">mit dem Zweck der Gesellschaft direkt oder indirekt im Zusammenhang stehen. Die Gesellschaft kann Beteiligungen an anderen Unternehmen im <FONT STYLE="white-space:nowrap">In-und</FONT> Ausland erwerben, halten und ver&auml;ussern.
Sie kann Zweigniederlassungen und Tochtergesellschaften im <FONT STYLE="white-space:nowrap">In-und</FONT> Ausland errichten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company may purchase, hold and sell real estate and carry out other investments.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann Grundst&uuml;cke erwerben, verwalten und ver&auml;ussern sowie Verm&ouml;gensanlagen anderer Art t&auml;tige.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>II.&#8194;&#8201;&#8201;SHARE CAPITAL, SHARES AND SHARE REGISTER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>II.&#8194;&#8201;&#8201;AKTIENKAPITAL, AKTIEN UND AKTIENBUCH</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;3&#8195;&#8194;&#8201;Share Capital and Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;3&#8195;&#8194;&#8202;Aktienkapital und Aktien</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The share capital of the Company is CHF&nbsp;476&#146;171.93<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> and is fully <FONT STYLE="white-space:nowrap">paid-in.</FONT> It is divided into 47&#146;617&#146;193<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> registered shares with a nominal value of CHF 0.01 each.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Aktienkapital der Gesellschaft betr&auml;gt CHF&nbsp;476&#146;171.93 und ist voll liberiert. Es ist in 47&#146;617&#146;193 Namenaktien mit einem Nennwert von je CHF&nbsp;0.01 eingeteilt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;3a&#8195;&#8201;Capital Band</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;3a&#8195;&#8202;Kapitalband</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors is authorized to increase the share capital at any time until [DATE], at any time and as often as desired within the upper limit of
CHF&nbsp;238&#146;085.96<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>, corresponding to 23&#146;808&#146;596<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> registered shares with a par value of CHF 0.01 each. A reduction of the share
capital is excluded.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat ist erm&auml;chtigt, jederzeit bis zum [DATE], das Aktienkapital jederzeit und beliebig oft innerhalb der oberen Grenze von CHF&nbsp;238&#146;085.96, entsprechend 23&#146;808&#146;596 Namenaktien mit einem
Nennwert von je CHF&nbsp;0.01 zu erh&ouml;hen. Eine Kapitalherabsetzung wird ausgeschlossen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The increase shall be effected by issuing a maximum of 23&#146;808&#146;596<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> fully paid registered shares with a par value of CHF&nbsp;0.01 each. An increase of the share capital
(i)&nbsp;by subscription of shares based on an offer signed by a financial institution, an association, another third party or third parties, followed by an offer to the then existing shareholders of the Company as well as (ii)&nbsp;in partial
amounts is permitted.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Erh&ouml;hung hat Ausgabe von h&ouml;chstens 23&#146;808&#146;596 vollst&auml;ndig zu liberierende Namenaktien mit einem Nennwert von je CHF&nbsp;0.01 zu erfolgen. Eine Erh&ouml;hung des Aktienkapitals (i)&nbsp;durch die
Zeichnung von Aktien aufgrund eines von einem Finanzinstitut, eines Verbandes, einer anderen Drittpartei oder Drittparteien unterzeichneten Angebots, gefolgt von einem Angebot gegen&uuml;ber den zu diesem Zeitpunkt bestehenden Aktion&auml;ren der
Gesellschaft sowie (ii)&nbsp;in Teilbetr&auml;gen ist zul&auml;ssig.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall determine the time of the issuance, the issue price, the manner in which the new registered shares have to be paid up, the date from which the registered shares carry the right to dividends, the
conditions for the exercise of the preemptive rights and the allotment of preemptive rights that have not</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat soll den Ausgabezeitpunkt, den Bezugspreis, die Art und Weise der Liberierung, das Datum, ab welchem die Aktien zum Bezug einer Dividende berechtigen, die Bedingungen zur Aus&uuml;bung der Bezugsrechte sowie die
Zuteilung nicht ausge&uuml;bter Bezugsrechte festlegen. Der</TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum amount assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum number assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum amount assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum number assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum number assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">been exercised. The Board of Directors may allow the preemptive rights that have not been exercised to expire, or it may place with third
parties such rights or registered shares, the preemptive rights of which have not been exercised, at market conditions or use them otherwise in the interest of the Company.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors is authorized to withdraw or limit the preemptive rights of the shareholders and to allot them to third parties:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;if the issue price of the new
registered shares is determined by reference to the market price; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;for the acquisition of an enterprise, part of an enterprise or participations, or for the financing or
refinancing of any of such acquisition, or in the event of share placement for the financing or refinancing of such placement; or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Verwaltungsrat kann bestimmen, dass nicht ausge&uuml;bte Bezugsrechte verfallen oder er kann Drittparteien solche Rechte oder Aktien,
f&uuml;r welche die Bezugsrechte nicht ausge&uuml;bt wurden, zu Marktbedingungen zuteilen oder sie sonst im Interesse der Gesellschaft verwenden.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Der Verwaltungsrat ist erm&auml;chtigt, das Bezugsrecht der Aktion&auml;re auszuschliessen oder Dritten zuzuteilen:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;falls der Ausgabepreis der neuen
Aktien anhand des Marktwertes festgelegt wird; oder</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;f&uuml;r die &Uuml;bernahme eines Unternehmens, den Teil eines Unternehmens oder Beteiligungen oder
f&uuml;r die Finanzierung oder Refinanzierung solcher Erwerbe, oder im Falle einer Aktienplatzierung f&uuml;r die Finanzierung oder Refinanzierung solcher Platzierungen; oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;for purposes of broadening the shareholder constituency of the Company in certain
financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing or registration of new registered shares on domestic or foreign stock exchanges; or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;zum Zweck der Erweiterung der Aktion&auml;rskreises der Gesellschaft in bestimmten
finanziellen oder Investorenm&auml;rkten, f&uuml;r die Zwecke der Beteiligung von strategischen Partnern, oder im Zusammenhang mit der Auflistung oder Meldung neuer Namenaktien an inl&auml;ndischen oder ausl&auml;ndischen B&ouml;rsen;
oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;for purposes of granting an over-allotment option (<I>Greenshoe</I>) or an option
to subscribe additional shares to the respective initial purchaser(s) or underwriter(s) in a placement or sale of registered shares; or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;zum Zweck der Gew&auml;hrung einer Mehrzuteilungsoption (<I>Greenshoe</I>) oder
eine Option zur Zeichnung von zus&auml;tzlichen Aktien an die betreffenden Erstk&auml;ufer oder Fest&uuml;bernehmer im Rahmen einer Aktienplatzierung oder eines Aktienverkaufs; oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;for raising of capital (including private placements) in a fast and flexible way,
which probably could not be reached without the exclusion of the statutory <FONT STYLE="white-space:nowrap">pre-emptive</FONT> right of the existing shareholders;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;um Kapital (inklusive durch private Vermittlung) in schneller und flexibler Weise
zu beschaffen, welches wahrscheinlich ohne den Ausschluss der gesetzlichen Vorkaufsrechte der existierenden Aktion&auml;re nicht erhoben werden k&ouml;nnte; oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;for other valid grounds in the sense of article 652b para. 2 CO;
or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;aus anderen, gem&auml;ss Artikel 652 Abs. 2 OR zul&auml;ssigen
Gr&uuml;nden; oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;following a shareholder or a group of shareholders acting in concert having
accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the Board of Directors, or for the defense of an actual,
threatened or potential takeover bid, in relation to which the Board of Directors, upon consultation with an independent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;einem Aktion&auml;r oder einer Gruppe von Aktion&auml;ren folgend, die gemeinsam
mehr als 15% des im Handelsregister eingetragenen Aktienkapitals halten und den &uuml;brigen Aktion&auml;ren auf Empfehlung des Verwaltungsrats hin kein &Uuml;bernahmeangebot unterbreitet haben, oder im Rahmen der Abwehr eines tats&auml;chlichen,
drohenden oder etwaigen &Uuml;bernahmeversuchs, f&uuml;r den der</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the Board of
Directors has not found the takeover bid to be financially fair to the shareholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">Verwaltungsrat, nach Konsultation eines unabh&auml;ngigen Finanzberaters, keine Zustimmungsempfehlung abgegeben hat, da
das &Uuml;bernahmeangebot vom Verwaltungsrat den Aktion&auml;ren gegen&uuml;ber als finanziell zu wenig angemessen betrachtet wird.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The acquisition of registered shares out of authorized capital increase of share capital for general purposes and any transfers of registered shares shall be subject to the restrictions specified in article 4 of the articles of
association.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Erwerb von Namenaktien aufgrund einer genehmigten Aktienkapitalerh&ouml;hung f&uuml;r allgemeine Zwecke sowie jeder Transfer von Namenaktien unterliegen den Einschr&auml;nkungen in Artikel 4 dieser Statuten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;3b&#8195;&#8201;Conditional Share Capital for Bonds and Similar Debt
Instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;3b&#8195;&#8202;Bedingtes Aktienkapital f&uuml;r Anleihensobligationen oder
&auml;hnliche Instrumente</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The share capital of the Company may be increased by the maximum amount of CHF&nbsp;50&#146;000.00 by issuing up to 5&#146;000&#146;000 fully <FONT STYLE="white-space:nowrap">paid-up</FONT> registered shares with a nominal value of
CHF&nbsp;0.01 each, through the exercise of conversion and/or option rights or warrants or granted in connection with bonds or similar instruments, assumed, issued or to be issued by the Company or by its subsidiaries, including convertible debt
instruments.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Aktienkapital der Gesellschaft wird im Maximalbetrag von CHF&nbsp;50&#146;000.00 erh&ouml;ht durch Ausgabe von h&ouml;chstens 5&#146;000&#146;000 vollst&auml;ndig zu liberierenden Namenaktien mit einem Nennwert von je CHF 0.01
durch Aus&uuml;bung von Wandlungs-und/oder Optionsrechten, welche im Zusammenhang mit von der Gesellschaft oder ihren Tochtergesellschaften &uuml;bernommenen oder emittierten Anleihensobligationen oder &auml;hnlichen Instrumenten einger&auml;umt
wurden oder werden, einschliesslich Wandelanleihen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders&#146; subscription rights for these shares are excluded. Shareholders&#146; advance subscription rights with regard to the new bonds or similar instruments may be restricted or excluded by decision of the Board of
Directors in order to finance or <FONT STYLE="white-space:nowrap">re-finance</FONT> the acquisition of companies, parts of companies or holdings, or new investments planned by the Company, or in order to issue convertible bonds or similar
instruments on the international capital markets or through private placement. If advance subscription rights are excluded, then (1)&nbsp;the instruments are to be placed at market conditions, (2)&nbsp;the exercise period is not to exceed ten years
from the date of issue of option rights and twenty years for conversion rights and (3)&nbsp;the conversion or exercise price for the new shares is to be set at least in line with the market conditions prevailing at the date on which the instruments
are issued.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Bezugsrecht der Aktion&auml;re ist f&uuml;r diese Aktien ausgeschlossen. Das Vorwegzeichnungsrecht der Aktion&auml;re in Bezug auf neue Anleihensobligationen oder &auml;hnliche Instrumente kann durch Beschluss des
Verwaltungsrates zu folgenden Zwecken eingeschr&auml;nkt oder ausgeschlossen werden: Finanzierung und Refinanzierung des Erwerbs von Unternehmen, Unternehmensteilen, Beteiligungen, oder von der Gesellschaft geplanten neuen Investitionen, oder
f&uuml;r die Ausgabe von Anleihensobligationen oder &auml;hnlichen Instrumenten auf internationalen Kapitalm&auml;rkten oder mittels Privatplatzierungen. Falls Vorwegzeichnungsrechte ausgeschlossen werden, m&uuml;ssen (1)&nbsp;die Instrumente zu
Marktkonditionen platziert werden, (2)&nbsp;der Aus&uuml;bungszeitraum darf zehn Jahre seit dem Ausgabedatum der Optionsrechte und 20 Jahre seit dem Ausgabedatum der Wandlungsrechte nicht &uuml;berschreiten und (3)&nbsp;der Wandlungs-oder
Aus&uuml;bungspreis f&uuml;r die neuen Aktien muss mindestens gem&auml;ss den Marktbedingungen am Ausgabedatum der Instrumente festgelegt werden.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The acquisition of registered shares through the exercise of conversion rights or warrants and any transfers of registered shares shall be subject to the restrictions specified in article 4 of the articles of Association.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Erwerb von Namenaktien durch Aus&uuml;bung von Wandelrechten oder Warrants sowie s&auml;mtliche weiteren &Uuml;bertragungen von Namenaktien unterliegen den &Uuml;bertragungsbeschr&auml;nkungen gem&auml;ss Artikel 4 der
Statuten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;3c&#8195;&#8201;&#8202;Conditional Share Capital for Employee Benefit
Plans</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;3c&#8195;&#8201;Bedingtes Aktienkapital f&uuml;r
Mitarbeiterbeteiligungspl&auml;ne</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The share capital of the Company shall be increased by an amount not exceeding CHF&nbsp;99&#146;086.64<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> through the issue of a maximum of 9&#146;908&#146;664<SUP
STYLE="font-size:75%; vertical-align:top">7</SUP> registered shares, payable in full, each with a nominal value of CHF 0.01, in connection with the exercise of option rights or other equity-linked instruments granted to any employee of the Company
or a subsidiary, and any consultant, members of the Board of Directors, or other person providing services to the Company or a subsidiary.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Aktienkapital kann durch die Ausgabe von h&ouml;chstens 9&#146;908&#146;664 voll zu liberierenden Namenaktien im Nennwert von je CHF&nbsp;0.01 um h&ouml;chstens CHF 99&#146;086.64 durch Aus&uuml;bung von Optionsrechten oder
anderen eigenkapitalbasierten Instrumenten erh&ouml;ht werden, welche Mitarbeitenden der Gesellschaft oder ihrer Tochtergesellschaften, Personen in vergleichbaren Positionen, Beratern, Verwaltungsratsmitgliedern oder anderen Personen, welche
Dienstleistungen zu Gunsten der Gesellschaft erbringen, gew&auml;hrt wurden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders&#146; subscription rights shall be excluded with regard to these shares. These new registered shares may be issued at a price below the current market price. The Board of Directors shall specify the precise conditions
of issue including the issue price of the shares.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Bezugsrecht der Aktion&auml;re ist f&uuml;r diese Aktien ausgeschlossen. Diese neuen Namenaktien k&ouml;nnen zu einem Preis unter dem aktuellen Marktpreis ausgegeben werden. Der Verwaltungsrat legt die genauen Bedingungen
f&uuml;r die Ausgabe, einschliesslich des Ausgabepreises der Aktien fest.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The acquisition of registered shares in connection with employee participation and any further transfers of registered shares shall be subject to the restrictions specified in article 4 of the articles of association.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Erwerb von Namenaktien im Zusammenhang der Mitarbeiterbeteiligung sowie s&auml;mtliche weiteren &Uuml;bertragungen von Namenaktien unterliegen den &Uuml;bertragungsbeschr&auml;nkungen gem&auml;ss Artikel 4 der
Statuten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;3d&#8195;&#8201;Conditional Share Capital for EBAC-Warrants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;3d&#8195;&#8202;Bedingtes Aktienkapital f&uuml;r EBAC-Warrants</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The share capital shall be increased by an amount not exceeding CHF&nbsp;44&#146;032.94 through the issue of a maximum of 4&#146;403&#146;294 registered shares, payable in full, each with a nominal value of CHF&nbsp;0.01. The
increase of the share capital shall occur in connection with the share capital increase of [DATE] through the exercise of conversion and/or option rights, which were assumed from, and allocated by, European Biotech Acquisition Corp. with registered
seat in George Town, Cayman Islands and business address at EPFL Innovation Park Building D, 1015 Lausanne, Switzerland (EBAC), on the basis of a Warrant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Aktienkapital kann durch die Ausgabe von h&ouml;chstens 4&#146;403&#146;294 voll zu liberierenden Namenaktien im Nennwert von je CHF&nbsp;0.01 um h&ouml;chstens CHF&nbsp;44&#146;032.94 erh&ouml;ht werden. Die Erh&ouml;hung des
Aktienkapitals erfolgt im Zusammenhang mit der Kapitalerh&ouml;hung vom [DATUM] durch die Aus&uuml;bung von Wandlungs- und/oder Optionsrechten, welche von European Biotech Acquisition Corp. mit Sitz in George Town, Cayman Islands und
Gesch&auml;ftsadresse an der EPFL Innovation Park Building D, 1015 Lausanne, Schweiz (EBAC), auf der Grundlage eines Warrant</TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum amount assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maximum number assuming no redemptions by EBAC Shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Assumption Agreement between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, with registered seat in [PLACE] as Warrant Agent.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Assumption Agreements zwischen der Gesellschaft und Continental Stock Transfer&nbsp;&amp; Trust Company, mit Sitz in [ORT] als Warrant Agent, &uuml;bernommenen und einger&auml;umt wurden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Only the bearers of such conversion and/or option rights shall be entitled to obtain such new registered shares. The terms and conditions of the exercise and/or conversion rights, such as the exercise and/or conversion price and
period, the time of entitlement to dividends and the type of contributions shall be defined by the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zum Bezug der neuen Namenaktien sind die Inhaber von Wandlungs- und/oder Optionsrechten berechtigt. Die Bezugsbedingungen, wie Aus&uuml;bungs- und/oder Konvertierungspreis und -frist, Zeitpunkt der Dividendenberechtigung und Art der
Einlagen, werden durch den Verwaltungsrat festgelegt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The shareholders&#146; subscription rights are excluded for these shares. The shareholders&#146; advance subscription rights regarding these Warrants are excluded to abide by the obligations stemming from the Business Combination
Agreement dated 17&nbsp;October 2022 between EBAC and Oculis SA with registered seat in Ecublens (VD), Switzerland, and assumed by the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Bezugsrecht der Aktion&auml;re ist f&uuml;r diese Aktien ausgeschlossen. Das Vorwegzeichnungsrecht der Aktion&auml;re in Bezug auf diese Warrants ist ausgeschlossen, um die im Business Combination Agreement vom 17.&nbsp;Oktober
2022 zwischen EBAC und Oculis SA mit Sitz in Ecublens (VD), Schweiz, eingegangenen und von der Gesellschaft &uuml;bernommenen Verpflichtungen zu erf&uuml;llen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The acquisition of registered shares through the exercise of conversion and/or option rights and the further transfer of registered shares shall be subject to the restrictions specified in article&nbsp;4 of the articles of
association.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Erwerb von Namenaktien durch die Aus&uuml;bung von Wandlungs- und/oder Optionsrechten sowie s&auml;mtliche weiteren &Uuml;bertragungen von Namenaktien unterliegen den &Uuml;bertragungsbeschr&auml;nkungen gem&auml;ss Artikel 4
der Statuten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;4&#8195;&#8194;&#8201;Share Register</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;4&#8195;&#8194;&#8202;Aktienbuch</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company shall maintain a share register in which it shall register the name, first name and place of residence (in case of legal persons the place of incorporation) of the owners of its registered shares. Natural and legal
persons as well as legal representatives of minors etc. entitled by law to the voting rights of a share which they do not own will be noted in the share register upon request.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft f&uuml;hrt ein Aktienbuch, worin die Eigent&uuml;mer und Nutzniesser von Namenaktien mit Namen, Vornamen und Wohnort (bei juristischen Personen Sitz) eingetragen werden. Nat&uuml;rliche und juristische Personen
sowie gesetzliche Vertreter von Minderj&auml;hrigen usw., welchen kraft Gesetzes Stimmrechte eines Anteils zukommen, den sie nicht besitzen, werden auf Anfrage im Aktienregister angemerkt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Upon request, acquirers of shares will be registered in the share register without limitation as shareholders if they expressly certify that they acquired the shares in their own name and for their own account.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Erwerber von Aktien werden auf Gesuch hin ohne Begrenzung als Aktion&auml;re mit Stimmrecht im Aktienregister eingetragen, falls sie ausdr&uuml;cklich erkl&auml;ren, die Aktien im eigenen Namen und auf eigene Rechnung erworben zu
haben.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Persons who do not expressly declare in the registration application that they are holding the shares on their own account (thereafter: nominees) shall forthwith be entered on the share register as shareholders with voting rights up
to a maximum of 3% of the share capital. Beyond that limit, registered shares of nominees shall only be</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Personen, die im Eintragungsgesuch nicht ausdr&uuml;cklich erkl&auml;ren, die Aktien f&uuml;r eigene Rechnung zu halten (nachstehend: Nominees) werden ohne weiteres bis maximal 3% des jeweils ausstehenden Aktienkapitals mit
Stimmrecht im Aktienbuch eingetragen. &Uuml;ber diese Limite hinaus</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">entered as voting if the nominees in question confirm in writing that they are willing to disclose the names, addresses and shareholdings of the persons on whose account they hold 0.5% or more of the share capital. The Board of
Directors concludes agreements with nominees that among other things govern the representation of shareholders and the voting rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">werden Namenaktien von Nominees nur dann mit Stimmrecht eingetragen, wenn sich der betreffende Nominee schriftlich bereit erkl&auml;rt, gegebenenfalls die Namen, Adressen und Aktienbest&auml;nde derjenigen Person offenzulegen,
f&uuml;r deren Rechnung er 0.5% oder mehr des jeweils ausstehenden Aktienkapitals h&auml;lt. Der Verwaltungsrat schliesst mit Nominees Vereinbarungen ab, die unter anderem die Vertretung der Aktion&auml;re und der Stimmrechte regeln.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">After hearing the registered shareholder or nominee, the Board of Directors may remove entries in the share register with retroactive effect as per the date of entry, if such entry was based on false information. The party affected
must be informed of such removal immediately.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nach Anh&ouml;rung des eingetragenen Aktion&auml;rs oder Nominees, kann der Verwaltungsrat die Eintragungen im Aktienregister r&uuml;ckwirkend nach dem Datum der Eintragung entfernen, wenn ein solcher Eintrag aufgrund falscher
Angaben erfolgte. Der Betroffene muss &uuml;ber eine solche Entfernung sofort informiert werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No individual or legal entity may, directly or indirectly, formally, constructively or beneficially own (as defined in the next paragraph below) or otherwise control voting rights (&#147;Controlled Shares&#148;) with respect to 15%
or more of the registered share capital recorded in the Commercial Register except if such individual or legal entity has submitted prior to the acquisition of such Controlled Shares an orderly tender offer to all shareholders with a minimum price
of the higher of (i)&nbsp;the volume weighted average price of the last 60 trading days prior to the publication of the tender offer or (ii)&nbsp;the highest price paid by such individual or legal entity in the 12 months preceding to the publication
of the tender offer. Those associated through capital, voting power, joint management or in any other way, or joining for the acquisition of shares, shall be regarded as one person. The registered shares exceeding the limit of 15% and not benefiting
from the exemption regarding a tender offer shall be entered in the share register as shares without voting rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Weder eine Einzelperson, noch eine juristische Person kann, direkt oder indirekt, formell, konstruktiv oder vorteilhaft (wie im n&auml;chsten Abschnitt unten definiert) oder sonst wie das Stimmrecht (&#147;Kontrollierte
Aktien&#148;) hinsichtlich 15% oder mehr des im Handelsregister registrierten Aktienkapitals innehaben oder kontrollieren. Eine Ausnahme besteht dann, wenn diese Einzelperson oder juristische Person vor der &Uuml;bernahme solcher Kontrollierter
Aktien allen Aktion&auml;ren eine ordentliche Offerte mit einem Minimalpreis stellt, wovon der h&ouml;here Preis, der entweder (i)&nbsp;dem gewichteten Durchschnittskurs der letzten 60 Handelstage vor der Ver&ouml;ffentlichung der
&Uuml;bernahmeofferte oder (ii)&nbsp;dem h&ouml;chsten bezahlten Preis durch diese Einzelperson oder juristische Person w&auml;hrend der 12 Monate vor der Ver&ouml;ffentlichung der &Uuml;bernahmeofferte entspricht, der relevante Preis darstellt. Die
durch Kapital, Stimmrecht, gemeinsame F&uuml;hrung oder in anderer Weise oder durch Beitritt zur &Uuml;bernahme der Aktien verbundenen Personen, sind als eine Person zu betrachten. Die Namenaktien, welche die Limite von 15% &uuml;bersteigen und
nicht von der Ausnahme mit Bezug auf die &Uuml;bernahmeofferte profitieren, sollen im Aktienbuch als Aktien ohne Stimmrecht verzeichnet werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For the purposes of this article 4, &#147;Controlled Shares&#148; in reference to any individual or entity means:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Im Rahmen dieses Artikel 4 bedeuten &#147;Kontrollierte Aktien&#148; in Bezug auf jegliche Einzelperson oder juristische Person:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;all shares of the Company directly, indirectly or constructively owned by
such individual or entity; provided that</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;alle Aktien der Gesellschaft, die direkt, indirekt oder konstruktiv von
einer solchen Einzelperson oder juristischen Person gehalten werden; vorausgesetzt dass</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;shares owned, directly or indirectly, by or for a partnership, or trust or estate will
be considered as being owned proportionately by its partners, or beneficiaries; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;Aktien, die direkt oder indirekt durch oder f&uuml;r eine Personengesellschaft oder
einen Trust oder eine Verm&ouml;gensmasse gehalten werden, proportional auf die Partner oder Beg&uuml;nstigten aufgeteilt werden; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;shares owned, directly or indirectly, by or for a corporation will be considered
as being owned proportionately by any shareholder owning 50% or more of the outstanding voting shares of such corporation; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;Aktien, die direkt oder indirekt durch oder f&uuml;r eine Gesellschaft gehalten
werden, proportional auf jeden Aktion&auml;r, der 50% oder mehr der ausgegebenen Stimmrechtsaktien besitzt, aufgeteilt werden; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;shares subject to options, warrants or other similar rights shall be deemed to
be owned; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;Aktien, die in Abh&auml;ngigkeit zu Optionen, Bezugsrechten oder anderen
&auml;hnlichen Rechten stehen, als Eigentum gelten; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;all shares of the Company directly, indirectly or beneficially owned by
such individual or entity; provided that</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;alle Aktien der Gesellschaft, die direkt, indirekt oder vorteilhaft durch
eine solche Einzelperson oder eine juristische Person gehalten werden, vorausgesetzt dass</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;a beneficial owner of a security includes any person who, directly or indirectly,
through any contract, arrangement, understanding, relationship, or otherwise alone or together with other such persons has or shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;ein beg&uuml;nstigter Eigent&uuml;mer eines Wertpapiers jede Person umfasst, die direkt
oder indirekt, durch jede Art von Vertrag, Vereinbarung, Einvernehmen, Bindung oder anderweitig allein oder mit anderen Personen gemeinsam hat oder teilt:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(1)&#8194;&#8201;&#8202;voting power which includes the power to vote, or to direct the voting of,
such security; and/or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(1)&#8194;&#8201;&#8202;das Stimmrecht, welches das Recht zur Stimmabgabe, oder zur Leitung der
Stimme eines solchen Wertpapiers umfasst; und/oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(2)&#8194;&#8201;&#8202;investment power which includes the power to dispose, or to direct the
disposition of, such security.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(2)&#8194;&#8201;&#8202;das Investitionsrecht, welches die Verf&uuml;gungsmacht oder ein Recht zur
Bestimmung &uuml;ber die Verf&uuml;gung eines solchen Wertpapiers umfasst.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;Any person who, directly or indirectly, creates or uses a trust, proxy, power of
attorney, pooling arrangement or any other contract, arrangement, or device with the purpose or effect of divesting such person of beneficial ownership of shares of the Company or preventing the vesting of such beneficial ownership as part of a plan
or scheme to evade the provisions of these articles of association shall be deemed to be the beneficial owner of such shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;Jede Person, die, direkt oder indirekt, einen Trust, Stellvertretung, Vollmacht,
Pooling-Vertrag oder jede andere Form von Vertrag, mit dem Zweck oder Ziel schafft oder benutzt, um eine Person von ihren wirtschaftlichen Beg&uuml;nstigungen aus dem Eigentum an den Aktien der Gesellschaft zu entheben oder zur Verhinderung der
Aus&uuml;bung eines solchen beg&uuml;nstigenden Eigentums als Teil eines Plans oder Vorhabens zur Umgehung der Regelungen in diesen Statuten, soll als beg&uuml;nstigter Eigent&uuml;mer solcher Aktien gesehen werden.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;A person shall be deemed to be the beneficial owner of shares if that person
has the right to acquire beneficial ownership of such shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;Eine Person soll als beg&uuml;nstigter Eigent&uuml;mer von Aktien eingestuft
werden, wenn diese Person das Recht hat, ein</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">within 60 days, including but not limited to any right acquired: (A)&nbsp;through the exercise of any option, warrant
or right; (B)&nbsp;through the conversion of a security; (C)&nbsp;pursuant to the power to revoke a trust, discretionary account, or similar arrangement; or (D)&nbsp;pursuant to the automatic termination of a trust, discretionary account or similar
arrangement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">beg&uuml;nstigendes Eigentum an solchen Aktien innerhalb von 60 Tagen zu erwerben, inklusive, aber nicht
beschr&auml;nkt auf jegliches erworbenes Recht: (A)&nbsp;durch die Aus&uuml;bung jeglicher Option, jedes Bezugsrechts oder sonstigen Rechts; (B)&nbsp;durch die Umwandlung eines Wertpapiers; (C)&nbsp;aufgrund der Befugnis, einen Trust, ein
Verm&ouml;gensverwaltungskonto oder &auml;hnliche Verh&auml;ltnisse zu widerrufen oder (D)&nbsp;in Zusammenhang mit der automatischen Aufl&ouml;sung eines Trusts, Verm&ouml;gensverwaltungskontos oder eines &auml;hnlichen
Verh&auml;ltnisses.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The limit of 15% of the registered share capital also applies to the subscription for, or acquisition of, registered shares by exercising option or convertible rights arising from registered or bearer securities or any other
securities issued by the Company or third parties, as well as by means of exercising purchased preemptive rights arising from either registered or bearer shares. The registered shares exceeding the limit of 15% shall be entered in the share register
as shares without voting rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Grenze von 15% des eingetragenen Aktienkapitals gilt auch f&uuml;r zur Zeichnung von, oder Akquisition von Namenaktien durch Aus&uuml;bung einer Option oder umwandelbaren Rechte, welche aus Namen- oder Inhaberaktien hervor gehen
oder jeder anderen von der Gesellschaft oder Dritten ausgegebenen Sicherheit, sowie durch die Aus&uuml;bung von erworbenen Vorkaufsrechten, welche entweder aus Namen- oder Inhaberaktien hervorgehen. Die Namenaktien, welche die Grenze von 15%
&uuml;bersteigen, sind im Aktienbuch als Aktien ohne Stimmrecht einzutragen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors may in special cases approve exceptions to the above regulations. The Board of Directors is in addition authorized, after due consultation with the person concerned, to delete with retroactive effect entries
in the share register which were effected on the basis of false information.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat kann in besonderen F&auml;llen Ausnahmen zu den oben genannten Regelungen genehmigen. Der Verwaltungsrat ist zus&auml;tzlich berechtigt, nach angemessener Anh&ouml;rung der betreffenden Person, Eintr&auml;ge ins
Aktienbuch, welche aufgrund falscher Informationen erfolgten, r&uuml;ckwirkend zu l&ouml;schen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;5&#8195;&#8194;&#8201;Reporting Obligation of the Shareholder and Register of
Beneficial Owners</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;5&#8195;&#8194;&#8202;Meldepflicht des Aktion&auml;rs und Verzeichnis der
wirtschaftlich berechtigten Personen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Any person who, alone or in concert with third parties, acquires shares in the Company and thereby reaches or exceeds the threshold of 25% of the share capital or voting rights must notify the Company within one month of the first
name, last name and address of the natural person on whose behalf he is ultimately acting (beneficial owner).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wer allein oder in gemeinsamer Absprache mit Dritten Aktien der Gesellschaft erwirbt und dadurch den Grenzwert von 25% des Aktienkapitals oder der Stimmrechte erreicht oder &uuml;berschreitet, muss der Gesellschaft innert
Monatsfrist den <FONT STYLE="white-space:nowrap">Vor-</FONT> und den Nach-namen und die Adresse der nat&uuml;rlichen Person melden, f&uuml;r die er letztendlich handelt (wirtschaftlich berechtigte Person).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The shareholder must notify the company within three months of any change in the first or last name or address of the beneficial owner.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Aktion&auml;r muss der Gesellschaft innert drei Monaten jede &Auml;nderung des <FONT STYLE="white-space:nowrap">Vor-</FONT> oder des Nachnamens oder der Adresse der wirtschaftlich berechtigten Person
melden.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall keep a register of the beneficial owners reported to the Company. This register contains the first and last name as well as the address of the beneficial owners. The register must be kept in such a way
that it can be accessed in Switzerland at any time.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat f&uuml;hrt ein Verzeichnis &uuml;ber die der Gesellschaft gemeldeten wirtschaftlich berechtigten Personen. Dieses Verzeichnis enth&auml;lt den <FONT STYLE="white-space:nowrap">Vor-</FONT> und den Nachnamen sowie
die Adresse der wirtschaftlich berechtigten Personen. Das Verzeichnis muss so gef&uuml;hrt werden, dass in der Schweiz jederzeit darauf zugegriffen werden kann.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">As long as the shareholder has not fulfilled his reporting obligations, the membership rights associated with the shares whose acquisition must be reported shall be suspended. The property rights attached to such shares may only be
exercised by the shareholder once he has complied with his notification obligations. If the shareholder fails to comply with his reporting obligations within one month after the acquisition of the shares, the property rights shall be forfeited. If
the shareholder makes the notification at a later date, he may assert the property rights accruing as of that date. The Board of Directors shall ensure that no shareholders exercise their rights in breach of the reporting obligations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Solange der Aktion&auml;r seinen Meldepflichten nicht nachgekommen ist, ruhen die Mitgliedschaftsrechte, die mit den Aktien verbunden sind, deren Erwerb gemeldet werden muss. Die Verm&ouml;gensrechte, die mit solchen Aktien
verbunden sind, kann der Aktion&auml;r erst geltend machen, wenn er seinen Meldepflichten nachgekommen ist. Kommt der Aktion&auml;r seinen Meldepflichten nicht innert eines Monats nach dem Erwerb der Aktien nach, so sind die Verm&ouml;gensrechte
verwirkt. Holt er die Meldung zu einem sp&auml;teren Zeitpunkt nach, so kann er die ab diesem Zeitpunkt entstehenden Verm&ouml;gensrechte geltend machen. Der Verwaltungsrat stellt sicher, dass keine Aktion&auml;re unter Verletzung der
Melde-pflichten ihre Rechte aus&uuml;ben.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;6&#8195;&#8194;&#8201;Share Certificates and Intermediated Securities</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;6&#8195;&#8194;&#8202;Aktienzertifikate und Bucheffekten</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company may issue its shares in any legally permissible form, namely in the form of individual certificates, global certificates, simple uncertificated securities pursuant to article 973c CO or registered uncertificated
securities pursuant to article 973d CO and have them managed as intermediated securities.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann ihre Aktien in jeder gesetzlich zul&auml;ssigen Form, namentlich in Form von Einzelurkunden, Globalurkunden, einfachen Wertrechten nach Artikel 973c OR oder Registerwert-rechten nach Artikel 973d OR ausgeben
und als Bucheffekten f&uuml;hren lassen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Within the legal framework, the Company is free to convert its shares issued in one of these forms into another form at any time and without the consent of the shareholders, and to withdraw shares held as intermediated securities
from the custody system. It shall bear the costs thereof.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Gesellschaft steht es im Rahmen der gesetzlichen Vorgaben frei, ihre in einer dieser Formen ausgegebenen Aktien jederzeit und ohne Zustimmung der Aktion&auml;re in eine andere Form umzuwandeln sowie als Bucheffekten
gef&uuml;hrte Aktien aus dem Verwahrungssystem zur&uuml;ckzuziehen. Sie tr&auml;gt daf&uuml;r die Kosten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The shareholder shall not be entitled to the certification of membership rights in the form of physical securities or to the conversion of shares issued in a certain form into another form. However, the shareholder may at any time
request the Company to issue a written confirmation of the shares held by him in accordance with the share register.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Aktion&auml;r hat keinen Anspruch auf wertpapierm&auml;ssige Verbriefung der Mitgliedschaftsrechte oder auf Umwandlung von in bestimmter Form ausgegebenen Aktien in eine andere Form. Der Aktion&auml;r kann jedoch von der
Gesellschaft jederzeit die Ausstellung einer schriftlichen Bescheinigung &uuml;ber die von ihm gem&auml;ss Aktienbuch gehaltenen Aktien verlangen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The transfer of simple uncertificated securities pursuant to article 973c CO and registered uncertificated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die &Uuml;bertragung von einfachen Wertrechten nach Artikel 973c OR und Registerwertrechten nach</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">securities pursuant to article 973d CO as well as the provision of security for such uncertificated securities shall be governed by the provisions of the CO.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Artikel 973d OR sowie die Bestellung von Sicherheiten an diesen Wert-rechten richten sich nach den Bestimmungen des OR.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The transfer of intermediated securities and the provision of security for such intermediated securities shall be governed by the provisions of the Swiss Intermediated Securities Act.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die &Uuml;bertragung von Bucheffekten und die Bestellung von Sicherheiten an diesen Bucheffekten richten sich nach den Bestimmungen des Bucheffektengesetzes.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;7&#8195;&#8194;&#8201;Exercise of Shareholders Rights</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The shares are indivisible and the Company recognizes only one single representative per
share.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;7&#8195;&#8194;&#8202;Aus&uuml;bung von Aktion&auml;rsrechten</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Die Aktien sind unteilbar und die Gesellschaft anerkennt nur einen einzigen Vertreter
pro Aktie.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The right to vote and the other rights pertaining to a registered share may only be exercised by a shareholder or a nominee who is registered with the right to vote in the share register and by persons who are entitled by law to the
voting rights of a share.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Stimmrecht und die anderen zu einer Namenaktien geh&ouml;renden Rechte d&uuml;rfen nur von einem Aktion&auml;r, einem Nutzniesser oder Nominee, dessen Stimmrecht im Aktienregister eingetragen ist und von Personen, welchen kraft
Gesetzes die Stimmrechte einer Aktie zustehen, ausge&uuml;bt werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>III.&#8194;CORPORATE STRUCTURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>III.&#8194;ORGANISATION DER GESELLSCHAFT</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;8&#8195;&#8194;&#8201;Corporate Bodies</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate bodies are:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">A.&#8195;the General Meeting;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">B.&#8195;the Board of Directors;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">C.&#8195;the Auditors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;8&#8195;&#8194;&#8202;Gliederung</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Die Gesellschaftsorgane sind:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">A.&#8195;die Generalversammlung;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">B.&#8195;der Verwaltungsrat;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">C.&#8195;die Revisionsstelle.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>IV.&#8194;&#8202;GENERAL MEETING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>IV.&#8194;&#8202;GENERALVERSAMMLUNG</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;9&#8195;&#8194;&#8201;Powers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;9&#8195;&#8194;&#8202;Befugnisse</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The General Meeting is the supreme body of the Company. It has the following non delegable powers:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oberstes Organ der Gesellschaft ist die Generalversammlung. Ihr stehen folgende un&uuml;bertragbare Befugnisse zu:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;to adopt and amend the articles of association (articles 651a, 652g, 653g und 653i
CO remain reserved);</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Festsetzung und &Auml;nderung der Statuten (Artikel&nbsp;651a, 652g, 653g und 653i
OR bleiben vorbehalten);</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;to elect and remove the members of the Board of Directors, the Chairman of the
Board of Directors, the members of the Compensation Committee, the Auditors and the Independent Proxy;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Wahl und Abberufung der Mitglieder des Verwaltungsrats, des Pr&auml;sidenten des
Verwaltungsrats, der Mitglieder des Verg&uuml;tungsausschusses, der Revisionsstelle und des unabh&auml;ngigen Stimmrechtsvertreters;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;to approve the management report and the annual accounts and to determine the
allocation of profits, in particular with regard to dividends and bonus payments;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Genehmigung des Lageberichts und der Jahresrechnung sowie Beschlussfassung
&uuml;ber die Verwendung des Bilanzgewinnes, insbesondere die Festsetzung der Dividende und der Tantieme;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;to determine the interim dividend and the approval of the required interim
financial statements;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;Festsetzung der Zwischendividende und Genehmigung des daf&uuml;r erforderlichen
Zwischenabschlusses;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;to make a resolution on the repayment of the statutory capital reserve;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Beschlussfassung &uuml;ber die R&uuml;ckzahlung der gesetzlichen
Kapitalreserve;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;to discharge the members of the Board of Directors and of the Executive
Committee;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Entlastung der Mitglieder des Verwaltungsrates und der
Gesch&auml;ftsleitung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;delisting of the Company&#146;s equity securities;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;Dekotierung der Beteiligungspapiere der Gesellschaft;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">h)&#8195;&#8202;to approve the total compensation paid to the Board of Directors and the Executive
Committee as per article 34 and article 35 below;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">h)&#8195;&#8202;Genehmigung der Gesamtverg&uuml;tungen des Verwaltungsrats und der
Gesch&auml;ftsleitung nach Massgabe von Artikel 34 und Artikel 35 hiernach;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">i)&#8195;&#8201;&#8202;to pass resolutions concerning all matters which are reserved to the
authority of the General Meeting by law or by the articles of association.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">i)&#8195;&#8201;&#8202;Beschlussfassung &uuml;ber die Gegenst&auml;nde, die der Generalversammlung
durch das Gesetz oder die Statuten vorbehalten sind.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;10&#8195;&#8201;Ordinary General Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;10&#8195;&#8202;Ordentliche Generalversammlung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Ordinary General Meeting shall be held annualy within six months after the end of the business year at such time and at such location, which may be within or outside Switzerland, as determined by the Board of Directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die ordentliche Generalversammlung findet j&auml;hrlich innerhalb von sechs Monaten nach Abschluss des Gesch&auml;ftsjahres statt, zum Zeitpunkt und an einem Ort, der innerhalb oder ausserhalb der Schweiz sein kann, gem&auml;ss
Festlegung durch den Verwaltungsrat.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;11&#8195;&#8201;Extraordinary General Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;11&#8195;&#8202;Ausserordentliche Generalversammlung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Extraordinary General Meetings may be called by resolution of the General Meeting, the Auditors or the Board of Directors, or by shareholders with voting powers, provided they represent at least 10% of the share capital and who
submit (a)(1) a request signed by such shareholder(s) that specifies the item(s) to be included on the agenda, (2)&nbsp;the respective proposals of the shareholders and (3)&nbsp;evidence of the required shareholdings recorded in the share register
and (b)&nbsp;such other information as would be required to be included in a proxy statement pursuant to the rules of the country where the Company&#146;s shares are primarily listed.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ausserordentliche Generalversammlungen k&ouml;nnen einberufen werden durch Beschluss der ordentlichen Generalversammlung, durch die Revisionsstelle oder den Verwaltungsrat oder durch stimmberechtigte Aktion&auml;re, sofern sie
mindestens 10% des Aktienkapitals erreichen und die Folgendes einreichen: (a)(1) einen unterschriebenen Antrag dieser Aktion&auml;re, welcher die Traktanden angibt, die auf die Traktandenliste gesetzt werden, (2)&nbsp;die entsprechenden Antr&auml;ge
der Aktion&auml;re und (3)&nbsp;den Nachweis der erforderlichen Beteiligung dieser Aktion&auml;re aufgrund des Aktienregisters und (b)&nbsp;alle anderen Informationen, die f&uuml;r eine Vollmacht nach den Regeln des Landes, in welchem die Aktien des
Unternehmens haupts&auml;chlich eingetragen sind, erforderlich w&auml;ren.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;12&#8195;&#8201;Notice and Agenda of Shareholders&#146; Meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;12&#8195;&#8202;Mitteilung und Traktanden der Generalversammlung</B></P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of a General Meeting of Shareholders shall be given by the Board of Directors or, if necessary, by the Auditor, not later than 20&nbsp;calendar days prior to the date of the General Meeting of Shareholders. Notice of the
General Meeting of Shareholders shall be given by way</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Mitteilung einer Generalversammlung erfolgt durch den Verwaltungsrat oder gegebenenfalls durch die Revisionsstelle, sp&auml;testens 20 Kalendertage vor dem Datum der Generalversammlung. Die Mitteilung der Generalversammlung
erfolgt durch eine</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">of a <FONT STYLE="white-space:nowrap">one-time</FONT> announcement in the official means of publication of the Company pursuant to article 48 of these articles of association. The notice period shall be deemed to have been observed
if notice of the General Meeting of Shareholders is published in such official means of publication, it being understood that the date of publication shall not be computed in the notice period. Shareholders of record may in addition be informed of
the General Meeting of Shareholders by ordinary mail or <FONT STYLE="white-space:nowrap">e-mail.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">einmalige Bekanntmachung in den amtlichen Publikationsmitteln der Gesellschaft gem&auml;ss Artikel 48 dieser Statuten. Die Frist gilt als eingehalten, wenn Ank&uuml;ndigung der Generalversammlung im offiziellen Publikationsmittel
ver&ouml;ffentlicht wurde, wobei das Datum der Ver&ouml;ffentlichung nicht in die Mitteilungsfrist eingerechnet werden darf. Eingetragene Aktion&auml;re k&ouml;nnen zus&auml;tzlich per Post oder <FONT STYLE="white-space:nowrap">E-Mail</FONT>
&uuml;ber die Generalversammlung informiert werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The convocation of an extraordinary general meeting may also be requested in writing, indicating the agenda items and the proposals and, in case of elections, the names of the nominated candidates, by one or more shareholders
together representing at least 5% of the share capital or the voting rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Einberufung einer ausserordentlichen Generalversammlung kann auch von einem oder mehreren Aktion&auml;ren, die zusammen mindestens 5% des Aktienkapitals oder der Stimmen vertreten, schriftlich unter Angabe des
Verhandlungsgegenstandes und des Antrages, bei Wahlen der Namen der vorgeschlagenen Kandidaten, verlangt werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall state the matters on the agenda.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat setzt die Verhandlungsgegenst&auml;nde auf die Traktandenliste.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The notice of a General Meeting of Shareholders shall specify the items on the agenda and the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting of Shareholders be held or an item be
included on the agenda, and, in the event of elections, the name(s) of the candidate(s) that has or have been put on the ballot for election.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Mitteilung der Genrealversammlung hat die Traktanden und die Antr&auml;ge des Verwaltungsrates und der Aktion&auml;re, welche beantragt haben, dass eine Generalversammlung abgehalten werden oder ein Traktandum auf die
Traktandenliste gesetzt werden soll zu enthalten sowie, im Falle von Wahlen, die Namen der Kandidaten, welche auf den Wahlzettel gesetzt wurden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders, together representing more than 0.5% of the share capital or the voting rights, may demand that an item be placed on the agenda. Such request must be made in writing at least 70 days prior to the meeting by indicating
the agenda items and the proposals.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aktion&auml;re, die zusammen mindestens &uuml;ber 0.5% des Aktienkapitals oder der Stimmen vertreten, k&ouml;nnen die Traktandierung eines Verhandlungsgegenstandes verlangen. Dies hat mindestens 70 Tage vor der Versammlung
schriftlich unter Angabe der Verhandlungsgegenst&auml;nde und Antr&auml;ge zu erfolgen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each request for inclusion of an item on the agenda must include (i)&nbsp;a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting; (ii)&nbsp;the name
and address, as they appear on the Company&#146;s register of shareholders, of the shareholder proposing such business; (iii)&nbsp;the number of shares of the Company which are beneficially owned by such shareholder; (iv)&nbsp;the dates upon which
the shareholder acquired such shares; (v)&nbsp;documentary support for any claim of beneficial ownership; (vi)&nbsp;any material interest of such shareholder in such business; and (vii)&nbsp;a statement in support of the matter and, for proposals
sought to be included in the Company&#146;s proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeder Antrag auf Aufnahme eines Traktandums hat zu enthalten: (i)&nbsp;eine kurze Zusammenfassung des Gesch&auml;fts, welches der Generalversammlung vorgelegt werden soll, sowie eine Begr&uuml;ndung, weshalb an der Versammlung
dar&uuml;ber entschieden werden soll; (ii)&nbsp;den Namen und die Adresse des Gesuchstellenden Aktion&auml;rs, wie sie im Aktienbuch der Gesellschaft eingetragen sind; (iii)&nbsp;die Anzahl Aktien der Gesellschaft, die in der wirtschaftlichen
Berechtigung des Aktion&auml;rs stehen; (iv)&nbsp;die Daten, an denen der Aktion&auml;r seine Aktien erworben hat; (v)&nbsp;erforderliche Nachweise bei allf&auml;lligen Anspr&uuml;chen von wirtschaftlicher Berechtigung; (vi)&nbsp;jegliches
materielle Interesse des Aktion&auml;rs im</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">statement, any other information required by Securities and Exchange Commission Rule <FONT STYLE="white-space:nowrap">&#147;14a-8&#148;.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zusammenhang mit diesem Gesch&auml;ft; und (vii)&nbsp;eine Stellungnahme zum fraglichen Punkt und, f&uuml;r Antr&auml;ge, welche der Aktion&auml;rsinformation durch die Gesellschaft beigef&uuml;gt werden sollen, jede andere
Information, welche die Securities and Exchange Commission Rule <FONT STYLE="white-space:nowrap">&#147;14a-8&#148;</FONT> verlangt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">In addition, if the shareholder intends to solicit proxies from the shareholders of the Company, such shareholder shall notify the Company of this intent in accordance with Securities and Exchange Commission Rule <FONT
STYLE="white-space:nowrap">&#147;14a-4&#148;</FONT> and/or Rule <FONT STYLE="white-space:nowrap">&#147;14a-8&#148;.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">F&uuml;r den Fall, dass ein Aktion&auml;r gedenkt, die Stimmrechtsvertretung von anderen Aktion&auml;ren der Gesellschaft zu erlangen, hat dieser Aktion&auml;r die Gesellschaft &uuml;ber diese Absicht gem&auml;ss der Securities and
Exchange Commission Rule <FONT STYLE="white-space:nowrap">&#147;14a-4&#148;</FONT> und/oder Rule <FONT STYLE="white-space:nowrap">&#147;14a-8&#148;</FONT> zu informieren.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No resolution may be passed at a General Meeting of Shareholders concerning an item in relation to which due notice was not given. Proposals made during a General Meeting of Shareholders to (i)&nbsp;convene a extraordinary General
Meeting or (ii)&nbsp;initiate a special investigation in accordance with article 697a of the Swiss Code of Obligations are not subject to the due notice requirement set forth herein.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An der Generalversammlung darf kein Beschluss &uuml;ber ein Traktandum getroffen werden, &uuml;ber den nicht mit entsprechender Vorlaufzeit informiert worden ist. Antr&auml;ge, die w&auml;hrend der Generalversammlung gestellt
werden, f&uuml;hren zu (i)&nbsp;einer ausserordentlichen Generalversammlung oder (ii)&nbsp;einer speziellen Untersuchung gem&auml;ss Artikel 697a OR und unterliegen nicht der hierin geforderten Voraussetzung der rechtzeitigen Information.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No advance notice is required to propose motions on duly notified agenda items and to debate items without passing resolutions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zur Stellung von Antr&auml;gen im Rahmen der Verhandlungsgegenst&auml;nde und zu <FONT STYLE="white-space:nowrap">Ver-handlungen</FONT> ohne Beschlussfassung bedarf es keiner vorherigen Ank&uuml;ndigung.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;13&#8195;&#8201;Documentation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;13&#8195;&#8202;Unterlagen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The annual business report, the compensation report and the Auditor&#146;s report must be submitted for examination by the shareholders at the registered office of the Company at least 20 days prior to the date of the Ordinary
General Meeting. Each shareholder may request that a copy of this documentation be sent to him promptly. Such reference shall be included in the invitation to the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sp&auml;testens zwanzig Tage vor der ordentlichen Generalversammlung sind der Gesch&auml;ftsbericht, der Verg&uuml;tungsbericht und der Revisionsbericht am Sitz der Gesellschaft zur Einsicht der Aktion&auml;re aufzulegen. Jeder
Aktion&auml;r kann verlangen, dass ihm unverz&uuml;glich eine Kopie dieser Unterlagen zugestellt wird. In der Einberufung zur Generalversammlung ist hierauf hinzuweisen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;14&#8195;&#8201;Form of the General Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;14&#8195;&#8202;Form der Generalversammlung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors determines the location of the General Meeting. It may be abroad.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat bestimmt den Ort der Generalversammlung. Er kann im Ausland liegen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors may provide that shareholders who are not present at the venue of the General Meeting may exercise their rights electronically (hybrid General Meeting).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat kann vorsehen, dass Aktion&auml;re, die nicht am Ort der Generalversammlung anwesend sind, ihre Rechte auf elektronischem Weg aus&uuml;ben k&ouml;nnen (hybride Generalversammlung).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A General Meeting may be held by electronic means without a meeting place (Virtual General Meeting).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eine Generalversammlung kann mit elektronischen Mitteln ohne Tagungsort durchgef&uuml;hrt werden (virtuelle Generalversammlung).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors regulates the use of electronic means. It shall ensure that:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat regelt die Verwendung elektronischer Mittel. Er stellt sicher, dass:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;the identity of the participants is established; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;die Identit&auml;t der Teilnehmer feststeht;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;the votes at the General Meeting are transmitted directly; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;die Voten in der Generalversammlung unmittelbar &uuml;bertragen
werden;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;each participant can submit motions and take part in the discussion; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;jeder Teilnehmer Antr&auml;ge stellen und sich an der Diskussion beteiligen kann;
und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;the voting results cannot be falsified.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;das Abstimmungsergebnis nicht verf&auml;lscht werden kann.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If technical problems occur during a Virtual General Meeting so that the General Meeting cannot be held properly, it must be repeated. Resolutions passed by the General Meeting before the occurrence of the technical problems shall
remain valid.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treten w&auml;hrend einer Generalversammlung mit elektronischen Mitteln technische Probleme auf, sodass die Generalversammlung nicht ordnungsgem&auml;ss durchgef&uuml;hrt werden kann, so muss sie wiederholt werden. Beschl&uuml;sse,
welche die Generalversammlung vor dem Auftreten der technischen Probleme gefasst hat, bleiben g&uuml;ltig.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;15&#8195;&#8201;Meeting of All Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;15&#8195;&#8202;Universalversammlung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders or their proxies representing all shares issued may hold a General Meeting without observing the formalities required for calling a meeting, unless objection is raised. At such a meeting, discussions may be held and
resolutions passed on all matters within the scope of the powers of a General Meeting for so long as the shareholders or proxies representing all shares issued are present.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Eigent&uuml;mer oder Vertreter s&auml;mtlicher Aktien k&ouml;nnen, falls kein Widerspruch erhoben wird, eine Generalversammlung ohne Einhaltung der f&uuml;r die Einberufung vorgeschriebenen Formvorschriften abhalten
(Universalversammlung). Solange die Eigent&uuml;mer oder Vertreter s&auml;mtlicher Aktien anwesend sind, kann in dieser Versammlung &uuml;ber alle in den Gesch&auml;ftskreis der Generalversammlung fallenden Gegenst&auml;nde verhandelt und
g&uuml;ltig Beschluss gefasst werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;16&#8195;&#8201;Chairman, Secretary, Scrutineers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;16&#8195;&#8202;Vorsitz, Protokollf&uuml;hrer,
Stimmenz&auml;hler</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Chairman of the Board of Directors shall preside over the General Meeting. In his absence, a member of the Board of Directors or another Chairman of the Meeting designated by the General Meeting shall preside.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den Vorsitz der Generalversammlung f&uuml;hrt der Pr&auml;sident, bei dessen Verhinderung ein anderes Mitglied des Verwaltungsrates oder ein anderer von der Generalversammlung gew&auml;hlter Tagespr&auml;sident.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Chairman of the Meeting shall designate a Secretary and the scrutineers who need not be shareholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Vorsitzende bezeichnet den Protokollf&uuml;hrer und die Stimmenz&auml;hler, die nicht Aktion&auml;re zu sein brauchen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Chairman shall have all powers and authority necessary to ensure the orderly conduct of the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Vorsitzende hat s&auml;mtliche Leitungsbefugnisse, die f&uuml;r die ordnungsgem&auml;sse Durchf&uuml;hrung der Generalversammlung n&ouml;tig sind.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;17&#8195;&#8201;Minutes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;17&#8195;&#8202;Protokoll</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors is responsible for the keeping of the minutes of the Meeting, which shall state the number, kind, nominal value of shares represented by the shareholders, by the corporate bodies and by the independent proxy
and gives information on resolutions passed, elections, requests for information and information as well as declarations given by the shareholders. The minutes shall be signed by the Chairman and the Secretary.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat sorgt f&uuml;r die F&uuml;hrung des Protokolls &uuml;ber die Generalversammlung, welches Anzahl, Art, Nennwert und Kategorie der von den Aktion&auml;ren, von den Organen und von unabh&auml;ngigen
Stimmrechtsvertretern vertretene Aktien festh&auml;lt und Aufschluss &uuml;ber Beschl&uuml;sse, Wahlergebnisse, Begehren um Auskunft und die darauf erteilten Ausk&uuml;nfte sowie die von den Aktion&auml;ren zu Protokoll gegebenen Erkl&auml;rungen
gibt. Das Protokoll wird vom Vorsitzenden und vom Protokollf&uuml;hrer unterzeichnet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The shareholders are entitled to inspect the minutes.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Aktion&auml;re sind berechtigt, das Protokoll einzusehen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;18&#8195;&#8201;Right to Vote</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;18&#8195;&#8202;Stimmrecht</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each share entitles to one vote.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jede Aktie berechtigt zu einer Stimme.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each shareholder may be represented at a General Meeting by any person who is so authorized by a written proxy. A proxy need not be a shareholder.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeder Aktion&auml;r kann sich in der Generalversammlung aufgrund einer schriftlichen Vollmacht durch eine andere handlungsf&auml;hige Person vertreten lassen, die nicht Aktion&auml;r zu sein braucht.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each shareholder may be represented by the Independent Proxy. The requirements regarding proxies and instructions are determined by the Board of Directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeder Aktion&auml;r kann sich vom unabh&auml;ngigen Stimmrechtsvertreter vertreten lassen. Die Anforderungen an Vollmachten und Weisungen werden vom Verwaltungsrat festgelegt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;19&#8195;&#8201;Resolutions and Elections</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;19&#8195;&#8202;Beschlussfassung und Wahlen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All voting and elections are held openly or electronically. A written voting or election shall be held if instructed so by the Chairman or if decided by the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Abstimmungen und Wahlen erfolgen offen oder elektronisch. Eine schriftliche Abstimmung oder Wahl wird durchgef&uuml;hrt, wenn dies vom Vorsitzenden angeordnet oder von der Generalversammlung beschlossen wird.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The General Meeting shall pass its resolutions and carry out its elections with the simple majority of the votes cast regardless of abstentions and empty or invalid votes, unless law or articles of association state otherwise. In
the event of tie votes, the request shall be refused. The Chairman shall not have a casting vote.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Generalversammlung fasst ihre Beschl&uuml;sse und vollzieht ihre Wahlen, soweit das Gesetz oder die Statuten es nicht anders bestimmen, mit der einfachen Mehrheit der abgegebenen Aktienstimmen ohne Ber&uuml;cksichtigung von
Stimmenthaltungen oder leer eingelegten oder ung&uuml;ltigen Stimmen. Bei Stimmengleichheit gilt ein Antrag als abgelehnt. Dem Vorsitzenden steht kein Stichentscheid zu.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A resolution of the General Meeting passed by at least two thirds of the represented share votes and the absolute majority of the represented shares par value is required for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ein Beschluss der Generalversammlung, durch mindestens zwei Drittel der vertretenen Aktienstimmen und die absolute Mehrheit der vertretenen Aktiennennwerte, ist erforderlich f&uuml;r:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;The cases listed in article 704 para. 1 CO:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;die F&auml;lle gem&auml;ss Artikel 704 Abs. 1 OR:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">i.&#8195;&#8201;&#8201;the amendment of the purpose of the Company;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">i.&#8195;&#8201;&#8201;die &Auml;nderung des Gesellschaftszweckes;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">ii.&#8195;&#8202;the consolidation of shares, insofar as this does not require the consent of all
shareholders concerned;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">ii.&#8195;&#8202;die Zusammenlegung von Aktien, soweit daf&uuml;r nicht die Zustimmung aller
betroffenen Aktion&auml;re erforderlich ist;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">iii.&#8194;&#8201;&#8201;the increase of the share capital against contributions in kind or by
offsetting against a receivable and the granting of special benefits;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">iii.&#8194;&#8201;&#8201;die Kapitalerh&ouml;hung aus Eigenkapital, gegen Sacheinlagen oder durch
Verrechnung mit einer Forderung und die Gew&auml;hrung von besonderen Vorteilen;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">iv.&#8194;&#8201;&#8201;the limitation or withdrawal of subscription rights;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">iv.&#8194;&#8201;&#8201;die Einschr&auml;nkung oder Aufhebung des Bezugsrechts;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">v.&#8195;&#8201;the introduction of conditional capital, the creation of reserve capital pursuant
to article 12 of the Swiss Banking Act or the introduction of a capital band;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">v.&#8195;&#8201;die Einf&uuml;hrung eines bedingten Kapitals, die Schaffung von Vorratskapital
gem&auml;ss Artikel 12 des Bankengesetzes oder die Einf&uuml;hrung eines Kapitalbands;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">vi.&#8194;&#8201;&#8201;the conversion of participation certificates into shares;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">vi.&#8194;&#8201;&#8201;die Umwandlung von Partizipationsscheinen in Aktien;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">vii.&#8194;&#8202;the restriction of the transferability of registered shares;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">vii.&#8194;&#8202;die Beschr&auml;nkung der &Uuml;bertragbarkeit von Namenaktien;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">viii.&#8201;&#8201;the creation of shares with privileged voting rights;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">viii.&#8201;&#8201;die Einf&uuml;hrung von Stimmrechtsaktien;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">ix.&#8194;&#8201;&#8201;the change of currency of the share capital;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">ix.&#8194;&#8201;&#8201;der Wechsel der W&auml;hrung des Aktienkapitals;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">x.&#8195;&#8201;the introduction of the casting vote of the chairman in the general
assembly;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">x.&#8195;&#8201;die Einf&uuml;hrung des Stichentscheids des Vorsitzenden in der
Generalversammlung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xi.&#8194;&#8201;&#8201;the introduction of a provision in the articles of association to hold
General Meetings abroad;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xi.&#8194;&#8201;&#8201;eine Statutenbestimmung zur Durchf&uuml;hrung der Generalversammlung im
Ausland;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xii.&#8194;&#8202;the change of the registered office of the Company;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xii.&#8194;&#8202;die Verletzung des Sitzes der Gesellschaft;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xiii.&#8201;&#8201;the introduction of an arbitration clause in the articles of
association;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xiii.&#8201;&#8201;die Einf&uuml;hrung einer statutarischen Schiedsklausel;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xiv.&#8201;&#8201;the delisting of the shares; or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xiv.&#8201;&#8201;die Dekotierung der Beteiligungspapiere; oder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xv.&#8194;&#8201;the dissolution of the Company.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">xv.&#8194;&#8201;die Aufl&ouml;sung der Gesellschaft.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;the merger, <FONT STYLE="white-space:nowrap">de-merger</FONT> or conversion of the
Company (subject to mandatory law);</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;die Fusion, Spaltung oder Umwandlung der Gesellschaft (vorbehalten zwingender
gesetzlicher Bestimmungen);</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;the alleviating or withdrawal of restrictions upon the transfer of registered
shares;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;die Erleichterung oder den Entzug der Beschr&auml;nkungen betreffend die
&Uuml;bertragung von Namenaktien;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;the conversion of registered shares into bearer shares and vice versa;
and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;die Umwandlung von Namenaktien in Inhaberaktien und umgekehrt; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;the amendment or elimination of the provisions of articles 4 and 31 of the
articles of association as well as those contained in this article 19.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;die &Auml;nderung oder Aufhebung der Bestimmungen der Artikel 4 und 31 der
Statuten sowie dieses Artikels 19.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;20&#8195;&#8201;Votes on Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;20&#8195;&#8202;Abstimmung &uuml;ber Verg&uuml;tungen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each year, the General Meeting approves in one or separate resolutions the total maximum amounts pursuant to articles 34 and 35 of the articles of association for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Generalversammlung genehmigt j&auml;hrlich in einem oder mehreren Beschl&uuml;ssen die maximalen Verg&uuml;tungen gem&auml;ss Artikel 34 und 35 der Statuten betreffend:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;the <FONT STYLE="white-space:nowrap">non-performance-related</FONT> compensation
of the Board of Directors for the next term of office;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;die nicht-erfolgsabh&auml;ngige Verg&uuml;tung des Verwaltungsrates f&uuml;r die
Zeitperiode bis zur n&auml;chsten Generalversammlung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;a possible additional compensation of the Board of Directors for the preceding
business year;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;eine allf&auml;llige zus&auml;tzliche Verg&uuml;tung f&uuml;r den Verwaltungsrat
f&uuml;r das abgeschlossene Gesch&auml;ftsjahr;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;the <FONT STYLE="white-space:nowrap">non-performance-related</FONT> compensation
of the Executive Committee for the following business year;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;die nicht-erfolgsabh&auml;ngige Verg&uuml;tung der Gesch&auml;ftsleitung f&uuml;r
das folgende Gesch&auml;ftsjahr;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;the variable compensation for the Executive Committee for the following business
year; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;die variable Verg&uuml;tung der Gesch&auml;ftsleitung f&uuml;r das folgende
Gesch&auml;ftsjahr; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;the grant of options, shares or other equity-linked instruments in the Company to
the Board of Directors and the Executive Committee.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;die Gew&auml;hrung von Optionen, Aktien oder anderen eigenkapitalbasierten
Instrumenten der Gesellschaft an den Verwaltungsrat oder die Gesch&auml;ftsleitung.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The respective total compensation amounts include all social security and occupational pension contributions for the benefit of the members of the Board of Directors, the Executive Committee and the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die entsprechenden Gesamtverg&uuml;tungen umfassen s&auml;mtliche Beitr&auml;ge zugunsten des Verwaltungsrats und der Gesch&auml;ftsleitung an die Sozialversicherung und die Berufliche Vorsorge.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If the General Meeting refuses to approve a respective motion by the Board of Directors, the Board of Directors may either submit a new motion at the same meeting or determine a maximum total remuneration or several maximum partial
remunerations, subject to the relevant principles of the compensation, or submit a new motion to the next General Meeting for approval. The Company may pay remunerations within the framework of the maximum total or partial remuneration and subject
to the approval by the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lehnt die Generalversammlung einen entsprechenden Antrag des Verwaltungsrats ab, kann der Verwaltungsrat entweder an der gleichen Versammlung einen neuen Antrag stellen, eine ausserordentliche Generalversammlung einberufen oder
einen maximalen Gesamtbetrag oder mehrere maximale Teilbetr&auml;ge unter Ber&uuml;cksichtigung der relevanten Grunds&auml;tze festsetzen und der n&auml;chsten Generalversammlung zur Genehmigung vorlegen. Die Gesellschaft kann im Rahmen des
maximalen Gesamt- oder Teilbetrages und unter Vorbehalt der Genehmigung durch die Generalversammlung Verg&uuml;tungen ausrichten.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;21&#8195;&#8201;Independent Proxy</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;21&#8195;&#8202;Unabh&auml;ngiger Stimmrechtsvertreter</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Independent Proxy shall be elected by the Ordinary General Meeting for a term of one year until the end of the next Ordinary General Meeting. <FONT STYLE="white-space:nowrap">Re-election</FONT> is permitted. The Independent
Proxy informs the Company about number, type, par value and category of the represented shares. The Chairman of the Board discloses the information to the General Meeting. The other duties of the Independent Proxy are determined by the applicable
statutory provisions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Unabh&auml;ngige Stimmrechtsvertreter wird von der ordentlichen Generalversammlung f&uuml;r eine Amtsdauer von einem Jahr bis zum Ende der n&auml;chsten ordentlichen Generalversammlung gew&auml;hlt. Wiederwahl ist m&ouml;glich.
Der unabh&auml;ngige Stimmrechtsvertreter informiert die Gesellschaft &uuml;ber Anzahl, Art, Nennwert und Kategorie der vertretenen Aktien. Der Pr&auml;sident des Verwaltungsrats gibt diese Informationen der Generalversammlung bekannt. Die Pflichten
des Unabh&auml;ngigen Stimmrechtsvertreters ergeben sich aus den anwendbaren gesetzlichen Bestimmungen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>V.&#8195;BOARD OF DIRECTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>V.&#8195;VERWALTUNGSRAT</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;22&#8195;&#8201;Number of Members, Term of Office</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;22&#8195;&#8202;Anzahl der Mitglieder, Amtsdauer</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall consist of at least 3 and not more than 9 members. The chairman and the members of the Board of Directors are individually elected by the General Meeting for a term of one year until the end of the next
Ordinary General Meeting, provided that he/she does not resign or is not replaced during his term.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat besteht aus mindestens 3 und h&ouml;chstens 9 Mitgliedern. Der Pr&auml;sident sowie die Mitglieder des Verwaltungsrates werden jeweils f&uuml;r die Dauer von einem Jahr bis zum Ende der n&auml;chsten ordentlichen
Generalversammlung einzeln gew&auml;hlt. Vorbehalten bleiben vorheriger R&uuml;cktritt oder Abberufung.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The members of the Board of Directors may be <FONT STYLE="white-space:nowrap">re-elected</FONT> without limitation. The maximum age limit of members of the Board shall be 75 years. When a member of the Board of Directors reaches
this age limit during his term of office, such term shall automatically extend to the next ordinary shareholders&#146; meeting. The shareholders&#146; meeting may resolve to grant an exception to the age limit.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Mitglieder des Verwaltungsrates sind jederzeit wieder w&auml;hlbar. Die oberste Altersgrenze von Mitgliedern des Verwaltungsrats betr&auml;gt 75 Jahre. Wenn ein Mitglied des Verwaltungsrats diese Altersgrenze w&auml;hrend seiner
Amtszeit erreicht, wird diese automatisch zur n&auml;chsten ordentlichen Generalversammlung verl&auml;ngert. Die Generalversammlung kann eine Ausnahme von der Altersgrenze beschliessen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If the office of the Chairman becomes vacant, the board of directors shall appoint a new Chairman, from among its members for the remaining term of office.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wird das Amt des Pr&auml;sidenten vakant, ernennt der Verwaltungsrat f&uuml;r die verbleibende Amtsdauer aus seiner Mitte einen neuen Pr&auml;sidenten des Verwaltungsrates f&uuml;r die verbleibende Amtszeit.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;23&#8195;&#8201;Constitution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;23&#8195;&#8202;Konstituierung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the powers of the General Meeting, the Board of Directors determines its own organization. It appoints a Secretary who needs not be a member of the Board of Directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat konstituiert sich vorbeh&auml;ltlich der Befugnisse der Generalversammlung selbst. Er bezeichnet insbesondere einen Sekret&auml;r, der nicht Mitglied des Verwaltungsrates sein muss.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;24&#8195;&#8201;Function, Organization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;24&#8195;&#8202;Funktion, Organisation</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">It is the Board of Director&#146;s duty to lead the Company and to supervise the management. The Board of Director represents the Company and may take decisions to all</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dem Verwaltungsrat obliegt die oberste Leitung der Gesellschaft und die &Uuml;berwachung der Gesch&auml;ftsf&uuml;hrung. Er vertritt die Gesellschaft nach</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">affairs which are not assigned to any other body of the Company by law, the articles of association or Regulations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">aussen und besorgt alle Angelegenheiten, die nicht nach Gesetz, Statuten oder Reglement einem anderen Organ der Gesellschaft &uuml;bertragen sind.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall adopt the organizational regulations and the corresponding contractual relationships.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat erl&auml;sst das Organisationsreglement und ordnet die entsprechenden Vertragsverh&auml;ltnisse.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;25&#8195;&#8201;Powers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;25&#8195;&#8202;Aufgaben</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors has the following <FONT STYLE="white-space:nowrap">non-delegable</FONT> and inalienable duties:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat hat folgende un&uuml;bertragbare und unentziehbare Aufgaben:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;the overall management of the company and the issuing of all necessary
directives;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Oberleitung der Gesellschaft und Erteilung der n&ouml;tigen
Weisungen;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;the determination of the company&#146;s organisation;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Organisation des Rechnungswesens, der Finanzkontrolle sowie der Finanzplanung zur
F&uuml;hrung der Gesellschaft;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;the organisation of the accounting, financial control and financial planning
systems as required for management of the company;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Festlegung der Organisation der Gesellschaft;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;the appointment and dismissal of the persons entrusted with the management and
representation of the Company and grant of signatures;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;Ernennung und Abberufung der mit der Gesch&auml;ftsf&uuml;hrung und der Vertretung
betrauten Personen und Regelung der Zeichnungsberechtigung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;the overall supervision of the persons entrusted with managing the company, in
particular with regard to compliance with the law, articles of association, operational regulations and directives;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Oberaufsicht &uuml;ber die mit der Gesch&auml;ftsf&uuml;hrung betrauten Personen,
namentlich im Hinblick auf die Befolgung der Gesetze, Statuten, Reglemente und Weisungen;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;the compilation of the annual report, preparation for the general meeting
and implementation of its resolutions;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Erstellung des Gesch&auml;ftsberichtes sowie Vorbereitung der
Generalversammlung und Ausf&uuml;hrung ihrer Beschl&uuml;sse;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;the preparation of the compensation report and to request approval by the General
Meeting regarding compensation of the Board of Directors and the Executive Committee; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g)&#8195;&#8202;Erstellung des Verg&uuml;tungsberichts sowie Antragsstellung betreffend die
Genehmigung der Verg&uuml;tungen des Verwaltungsrats und der Gesch&auml;ftsleitung an die Generalversammlung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">h)&#8195;&#8202;the notification of the court if liabilities exceed assets.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">h)&#8195;&#8202;Benachrichtigung des Richters im Falle der &Uuml;berschuldung.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors may assign responsibility for preparing and implementing its resolutions or monitoring transactions to committees or individual members. It must ensure appropriate reporting to its members.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat kann die Vorbereitung und die Ausf&uuml;hrung seiner Beschl&uuml;sse oder die &Uuml;berwachung von Gesch&auml;ften Aussch&uuml;ssen oder einzelnen Mitgliedern zuweisen. Er hat f&uuml;r eine angemessene
Berichterstattung an seine Mitglieder zu sorgen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;26&#8195;&#8201;Representation of the Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;26&#8195;&#8202;Vertretung der Gesellschaft</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall assign the persons with signatory power for the Company and the kind of signatory power.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat bestimmt die f&uuml;r die Gesellschaft zeichnungsberechtigten Personen und die Art ihrer Zeichnung.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;27&#8195;&#8201;Delegation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;27&#8195;&#8202;Delegation</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Moreover, the Board of Directors is authorized to delegate, in part or entirely, the management and the representation of the Company, within the limits of the law, to one or more individual directors (Delegates) or to third parties
by pursuant to organizational regulations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat kann die Gesch&auml;ftsf&uuml;hrung und alle Aufgaben und Befugnisse, die ihm nicht durch das Gesetz oder die Statuten zwingend zugewiesen sind, nach Massgabe des Organisationsreglements ganz oder zum Teil an
einzelne oder mehrere Mitglieder oder Dritte &uuml;bertragen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;28&#8195;&#8201;Meetings, Resolutions and Minutes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;28&#8195;&#8202;Sitzungen, Beschlussfassung und Protokoll</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The organization of the meetings, the presence quorum and the passing of resolutions of the Board of Directors is determined by the organizational regulations. No presence quorum is required for the approval of a capital
increase.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sitzungsordnung, Beschlussf&auml;higkeit und Beschlussfassung des Verwaltungsrats richten sich nach dem Organisationsreglement. F&uuml;r den Feststellungsbeschluss einer Kapitalerh&ouml;hung ist kein Pr&auml;senzquorum
erforderlich.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Resolutions may be passed via telephone or videoconference. Resolutions may also be passed by way of circulation, provided that no member requests oral deliberation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beschlussfassung via Telefon-oder Videokonferenz ist zul&auml;ssig. Beschl&uuml;sse k&ouml;nnen auch auf dem Zirkularweg gefasst werden, sofern nicht ein Mitglied die Durchf&uuml;hrung einer Sitzung verlangt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Minutes are kept of the Board&#146;s discussions and resolutions and signed by the chairman and the minute-taker.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&Uuml;ber Verhandlungen und Beschl&uuml;sse des Verwaltungsrats wird ein Protokoll erstellt, welches vom Vorsitzenden und vom Sekret&auml;r des Verwaltungsrates zu unterzeichnen ist.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;29&#8195;&#8201;Disclosure and Right of Inspection</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;29&#8195;&#8202;Recht auf Auskunft und Einsicht</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Any member of the Board of Directors may request information on any company business.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jedes Mitglied des Verwaltungsrates kann Auskunft &uuml;ber alle Angelegenheiten der Gesellschaft verlangen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Outside meetings, any member may request information from the persons entrusted with managing the company&#146;s business concerning the Company&#146;s business performance and, with the Chairman&#146;s authorization, specific
transactions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ausserhalb der Sitzungen kann jedes Mitglied von den mit der Gesch&auml;ftsf&uuml;hrung betrauten Personen Auskunft &uuml;ber den Gesch&auml;ftsgang und, mit Erm&auml;chtigung des Pr&auml;sidenten, auch &uuml;ber einzelne
Gesch&auml;fte verlangen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Where required for the performance of his duties, any member may request the Chairman to have books of account and documents made available to him for inspection.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Soweit es f&uuml;r die Erf&uuml;llung einer Aufgabe erforderlich ist, kann jedes Mitglied dem Pr&auml;sidenten beantragen, dass ihm B&uuml;cher und Akten vorgelegt werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If the Chairman refuses a request for information, a request to be heard or an application to inspect documents, the Board of Directors rules on the matter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Weist der Pr&auml;sident ein Gesuch auf Auskunft, Anh&ouml;rung oder Einsicht ab, so entscheidet der Verwaltungsrat.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;30&#8195;&#8201;Compensation Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;30&#8195;&#8202;Verg&uuml;tungsausschuss</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Compensation Committee shall comprise at least 2 members. The members of the Compensation Committee shall be individually elected by the Ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verg&uuml;tungsausschuss umfasst mindestens 2 Mitglieder. Die Mitglieder des Verg&uuml;tungsausschusses werden j&auml;hrlich von der</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Meeting from among the members of the Board of Directors for a term of one year until the next Ordinary General Meeting. <FONT STYLE="white-space:nowrap">Re-election</FONT> is permitted. The Compensation Committee has the
following duties:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ordentlichen Generalversammlung aus den Mitgliedern des Verwaltungsrats f&uuml;r die Dauer von einem Jahr bis zur n&auml;chsten ordentlichen Generalversammlung einzeln gew&auml;hlt. Wiederwahl ist zul&auml;ssig. Der
Verg&uuml;tungsausschuss hat folgende Aufgaben:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;to draw up principles for compensation of members of the Board of Directors and
the Executive Committee and to submit them to the Board of Directors for approval;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Ausarbeiten der Grunds&auml;tze betreffend Verg&uuml;tung an den Verwaltungsrat
und an die Gesch&auml;ftsleitung und Vorlegen derselben zur Genehmigung durch den Verwaltungsrat;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;to propose to the Board of Directors the resolution to be submitted to the
Ordinary General Meeting for the maximum total compensation of the Board of Directors and Executive Committee;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Antragstellung an den Verwaltungsrat zur Unterbreitung an die Generalversammlung
betreffend Gesamtverg&uuml;tung des Verwaltungsrats und der Gesch&auml;ftsleitung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;subject to and within the bounds of the maximum compensation approved by the
Ordinary General Meeting, to request approval by the Board of Directors of the individual remuneration packages to be paid to members of the Board of Directors and members of the Executive Committee;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Antragstellung an den Verwaltungsrat betreffend individuelle Verg&uuml;tung der
Verwaltungsratsmitglieder und der Mitglieder der Gesch&auml;ftsleitung unter Vorbehalt und im Rahmen der H&ouml;he der Gesamtverg&uuml;tung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;to request approval by the Board of Directors regarding the determination of the
compensation-related targets for the Executive Committee;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;Antragstellung an den Verwaltungsrat hinsichtlich der f&uuml;r die
Gesch&auml;ftsleitung verg&uuml;tungsrelevanten Ziele;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;to request approval by the Board of Directors regarding the adjustments to the
articles of association relating to remuneration; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Antragstellung an den Verwaltungsrat betreffend Anpassung der Statuten
hinsichtlich des Verg&uuml;tungssystems; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;to prepare the Compensation Report and submit it to the Board of
Directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Entwurf des Verg&uuml;tungsberichts und Unterbreitung des
Verg&uuml;tungsberichts an den Verwaltungsrat.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall set out any further duties and responsibilities vested on the Compensation Committee in the Company&#146;s organizational regulations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat kann weitere Aufgaben und Zust&auml;ndigkeiten des Verg&uuml;tungsausschusses im Organisationsreglement vorsehen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;31&#8195;&#8201;Indemnification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;31&#8195;&#8202;Schadloshaltung.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To the extent not included in insurance <FONT STYLE="white-space:nowrap">cover-age</FONT> or paid by third parties, the Company shall indemnify and hold harmless, to the extent permitted by law, the existing and former members of
the board of directors, the executive committee, and their heirs, executors and administrators, out of the assets of the Company from and against all threatened, pending or completed actions, suits or proceedings &#150; whether civil, criminal,
administrative or investigative &#150; and all costs, charges, losses, <FONT STYLE="white-space:nowrap">dam-ages,</FONT> and expenses which they or any of them, their heirs, executors or administrators, shall or may incur or sustain by or by reason
of any actual or alleged actions, consents or omissions in or about the execution of their <FONT STYLE="white-space:nowrap">du-ty,</FONT> or alleged duty, or by reason of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Soweit nicht durch Versicherungen gedeckt oder von Dritten bezahlt, h&auml;lt die Gesellschaft soweit gesetzlich zul&auml;ssig, die gegenw&auml;rtigen und bisherigen Mitglieder des Verwaltungsrates und der Gesch&auml;ftsleitung
sowie deren Erben, Testamentsvollstrecker und Verwalter aus dem Verm&ouml;gen der Gesellschaft von allen angedrohten, h&auml;ngigen, und abgeschlossenen Klagen, Prozessen oder Verfahren &#150; ob zivil-, straf-, verwaltungs- oder
untersuchungsrechtlich &#150; schadlos, sowie von allen Kosten, Geb&uuml;hren, Verlusten, Sch&auml;den und Ausgaben, die ihnen oder einem/einer von ihnen, ihren Erben, Testamentsvollstreckern oder Verwaltern durch oder aufgrund von
tats&auml;chlichen</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">the fact that he/she is or was a member of the board of <FONT STYLE="white-space:nowrap">di-rectors</FONT> or executive committee of the Company or the board of directors (or equivalent corporate body) or the management of one of
its subsidiaries, or, while serving as a member of the board of directors or executive committee of the Company, is or was serving at the <FONT STYLE="white-space:nowrap">re-quest</FONT> of the Company as a director, member of the executive
committee, employee or agent of another corporation, partnership, joint venture, trust or other enterprise; provided, however, that this indemnity shall not extend to any matter in which any of said persons is found, in a final judgment or decree of
a court or governmental or administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the board of directors or executive
committee.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">oder vermeintlichen Handlungen, Zustimmungen oder Unterlassungen im Zusammenhang mit der Aus&uuml;bung ihrer Pflicht oder vermeintlichen Pflicht oder aufgrund der Tatsache, dass er/sie ein Mitglied des Verwaltungsrates oder der
Gesch&auml;ftsleitung der Gesellschaft oder des Verwaltungsrates (oder eines gleichwertigen Gesellschaftsorgans) oder der Gesch&auml;ftsleitung einer ihrer Konzerngesellschaften ist oder war, oder dass er/sie w&auml;hrend seiner/ihrer T&auml;tigkeit
als Mitglied des Verwaltungsrates oder der Gesch&auml;ftsleitung der Gesellschaft, auf Ersuchen der Gesellschaft, als Mitglied des Verwaltungsrates oder der Gesch&auml;ftsleitung, Angestellter oder Beauftragter einer anderen Kapitalgesellschaft,
Personengesellschaft, eines Joint Ventures, eines Trusts oder eines anderen Unternehmens t&auml;tig ist oder war, entstanden sind, entstehen oder entstehen k&ouml;nnten, jedoch unter der Voraussetzung, dass sich diese Schadloshaltung nicht auf eine
Angelegenheit erstreckt, in der eine der genannten Personen gem&auml;ss einem rechtskr&auml;ftigen Urteil oder Beschluss eines Gerichts oder einer zust&auml;ndigen Regierungs- oder Verwaltungsbeh&ouml;rde, gegen den kein Rechtsmittel eingelegt
werden kann, eine vors&auml;tzliche oder grobfahrl&auml;ssige Verletzung ihrer gesetzlichen Pflichten als Mitglied des Verwaltungsrates oder der Gesch&auml;ftsleitung begangen hat.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Without limiting the foregoing paragraph of this article&nbsp;31, the Company shall advance costs and expenses indemnifiable thereunder to the existing and former members of the board of directors and executive committee to the <FONT
STYLE="white-space:nowrap">ex-tent</FONT> not included in insurance coverage or advanced by third parties. The Company may however recover such advanced costs if any of said persons is found, in a final judgment or decree of a court or governmental
or administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the board of directors or executive committee.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ohne den vorstehenden Absatz dieses Artikels 31 einzuschr&auml;nken, hat die Gesellschaft den gegenw&auml;rtigen und ehemaligen Mitgliedern des Verwaltungsrates und der Gesch&auml;ftsleitung die Kosten und Auslagen zu erstatten, die
nach diesem Artikel erstattungsf&auml;hig sind, soweit sie nicht durch Versicherungen gedeckt sind oder von Dritten vorab erstattet werden. Die Gesellschaft kann jedoch diese vorausbezahlten Konten zur&uuml;ckfordern, wenn eine der genannten
Personen in einem rechtskr&auml;ftigen Urteil oder Beschluss eines Gerichts oder einer <FONT STYLE="white-space:nowrap">zu-st&auml;ndigen</FONT> Regierungs- oder Verwaltungsbeh&ouml;rde, gegen das kein Rechtsmittel eingelegt werden kann, wegen
vors&auml;tzlicher oder grob-fahrl&auml;ssiger Verletzung ihrer gesetzlichen Pflichten als Mitglied des Verwaltungsrates oder der Gesch&auml;ftsleitung verurteilt wird.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>VI.&#8194;&#8202;AUDITORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>VI.&#8194;&#8202;REVISIONSSTELLE</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;32&#8195;&#8201;Election, Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;32&#8195;&#8202;Wahl, Amtsdauer</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The General Meeting shall elect one or more accountants as its Auditors in terms of articles 727 et</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Generalversammlung w&auml;hlt jedes Jahr eine oder mehrere nat&uuml;rliche oder juristische Personen als</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">seq. CO every year with the rights and duties determined by law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Revisionsstelle im Sinne von Artikeln 727 ff. OR mit den im Gesetz festgehaltenen Rechten und Pflichten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The General Meeting may appoint Special Auditors for a term of up to three years who provide the attestations required for capital increases.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Generalversammlung kann f&uuml;r die Dauer von bis zu drei Jahren Sonderrevisoren bestimmen, welche die bei Kapitalerh&ouml;hungen erforderlichen Bescheinigungen erbringen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;33&#8195;&#8201;Duties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;33&#8195;&#8202;Aufgaben</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Auditors shall perform their duties to audit and report whether the accounting, the annual accounts and the proposal regarding allocation of profits is in accordance with law and the articles of association.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Revisionsstelle pr&uuml;ft, ob die Buchf&uuml;hrung und die Jahresrechnung sowie der Antrag &uuml;ber die Verwendung des Bilanzgewinns Gesetz und Statuten entsprechen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>VII.&#8201;COMPENSATION AND RELATED PROVISIONS </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>VII.&#8201;VERG&Uuml;TUNGEN UND VERWANDTE BESTIMMUNGEN</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;34&#8195;&#8201;Principles of the Compensation of the Board of
Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;34&#8195;&#8202;Grunds&auml;tze der Verg&uuml;tung f&uuml;r die Mitglieder des
Verwaltungsrats</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The compensation payable to the members of the Board of Directors comprises, subject to and within the bounds of the approval by the General Meeting of the total compensation, the following elements:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Verg&uuml;tung f&uuml;r die Mitglieder des Verwaltungsrats umfasst, unter Vorbehalt der Genehmigung durch die Generalversammlung und im Rahmen der durch diese genehmigten Gesamtverg&uuml;tung, folgende Elemente:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;a fixed basic remuneration;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;ein fixes Grundhonorar;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;a fixed committee fee for work in a committee of the Board of Directors;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;eine fixe Entsch&auml;digung f&uuml;r T&auml;tigkeiten als Mitglied eines
Ausschusses des Verwaltungsrats;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;a lump sum compensation for expenses;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;eine pauschale Spesenentsch&auml;digung;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;a number of options or shares in the Company, as further outlined in
article&nbsp;43 of the articles of association.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;eine Anzahl von Optionen oder Aktien der Gesellschaft, gem&auml;ss Artikel 43 der
Statuten.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The compensation is paid in cash and in form of options or shares in the Company. The board of directors or, to the extent delegated to it, the Compensation Committee shall determine grant, exercise and forfeiture conditions. In
particular, they may provide for continuation, acceleration or removal of vesting, exercise and forfeiture conditions, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of <FONT
STYLE="white-space:nowrap">pre-determined</FONT> events such as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> or termination of an employment or mandate agreement. The Company may procure the
required shares through purchases in the market, from treasury shares or by using contingent or authorized share capital.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Verg&uuml;tung kann bar und in Form von Optionen und Aktien der Gesellschaft bezahlt werden. Der Verwaltungsrat oder, soweit an ihn delegiert, der Verg&uuml;tungsausschuss legen Zuteilungs-, Aus&uuml;bungs- und
Verfallsbedingungen fest. Sie k&ouml;nnen insbesondere vorsehen, dass aufgrund des Eintritts im Voraus bestimmter Ereignisse, wie eines Kontrollwechsels oder der Beendigung des <FONT STYLE="white-space:nowrap">Arbeits-oder</FONT>
Mandatsverh&auml;ltnisses, Vesting-, Aus&uuml;bungs-und Verfallsbedingungen weitergelten, verk&uuml;rzt oder aufgehoben werden, Verg&uuml;tungen unter der Annahme der Erreichung von Zielwerten ausgerichtet werden oder Verg&uuml;tungen verfallen. Die
Gesellschaft kann die erforderlichen Aktien auf dem Markt erwerben, aus Best&auml;nden eigener Aktien entnehmen oder unter Verwendung von bedingtem oder genehmigtem Kapital bereitstellen.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the approval by the General Meeting, the members of the Board of Directors may receive remuneration in cash at customary conditions for advisory services rendered outside their capacity as Board member for the benefit of
the Company or companies under its control. The General Meeting may approve an additional bonus for the members of the Board of Directors in exceptional cases.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vorbeh&auml;ltlich der Genehmigung durch die Generalversammlung, kann den Mitgliedern des Verwaltungsrats eine Entsch&auml;digung in bar zu markt&uuml;blichen Konditionen f&uuml;r Beratungst&auml;tigkeiten, welche diese ausserhalb
ihrer Funktion als Verwaltungsratsmitglied und zu Gunsten der Gesellschaft oder von ihr kontrollierter Gesellschaften erbringen, ausbezahlt werden. Die Generalversammlung kann in Ausnahmef&auml;llen einen zus&auml;tzlichen Bonus zu Gunsten der
Verwaltungsratsmitglieder genehmigen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The compensation may also be paid for activities in companies that are directly or indirectly controlled by the Company and may be paid by the Company or by a company controlled by it.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Verg&uuml;tung kann auch ausgerichtet werden f&uuml;r T&auml;tigkeiten in Unternehmen, die durch die Gesellschaft direkt oder indirekt kontrolliert werden und kann durch die Gesellschaft oder durch von ihr kontrollierte
Unternehmen ausgerichtet werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;35&#8195;&#8201;Principles of the Compensation of the Executive
Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;35&#8195;&#8202;Grunds&auml;tze der Verg&uuml;tung f&uuml;r die Mitglieder der
Gesch&auml;ftsleitung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The compensation payable to the members of the Executive Committee is subject to the approval by the General Meeting and comprises the following elements:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Verg&uuml;tung f&uuml;r die Mitglieder der Gesch&auml;ftsleitung ist von der Generalversammlung zu genehmigen und umfasst folgende Elemente:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;a fixed remuneration payable in cash;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;eine fixe Verg&uuml;tung in bar;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;a performance-related remuneration payable in cash (variable);</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;eine erfolgsabh&auml;ngige Verg&uuml;tung in bar (variabel);</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;a number of options, shares or equity-lined instruments in the Company (variable),
as further outlined in article&nbsp;43 of the articles of association.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;eine Anzahl Optionen, Aktien oder anderen eigenkapitalbasierten Instrumenten der
Gesellschaft (variabel), gem&auml;ss Artikel 43 der Statuten.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The performance-related remuneration depends on the Company&#146;s business success and the individual performance of the member of the Executive Committee based on the achievement of
<FONT STYLE="white-space:nowrap">pre-determined</FONT> targets during a business year. The Board of Directors determines annually at the beginning of each relevant business year the decisive targets and their weighting upon proposal by the
Compensation Committee. The amount of the performance-related remuneration in cash for each member of the Compensation Committee is determined by the Board of Directors and may not exceed 100% of the respective individual fixed remuneration for the
same year.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die erfolgsabh&auml;ngige Verg&uuml;tung richtet sich nach dem Gesch&auml;ftserfolg und der individuellen Leistung gemessen nach dem Erreichen bestimmter vordefinierter Ziele &uuml;ber ein Gesch&auml;ftsjahr. Der Verwaltungsrat
definiert j&auml;hrlich am Anfang jeder Leistungsperiode auf Antrag des Verg&uuml;tungsausschusses hin die relevanten Ziele und deren Gewichtung. Die H&ouml;he der erfolgsabh&auml;ngigen Verg&uuml;tung in bar f&uuml;r das jeweilige
Gesch&auml;ftsleitungsmitglied wird vom Verwaltungsrat festgelegt und darf 100% der im entsprechenden Gesch&auml;ftsjahr relevanten individuellen, fixen Verg&uuml;tung nicht &uuml;berschreiten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The compensation may also be paid for activities in companies that are directly or indirectly controlled by the Company and may be paid by the Company or by a company controlled by it.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Verg&uuml;tung kann auch ausgerichtet werden f&uuml;r T&auml;tigkeiten in Unternehmen, die durch die Gesellschaft direkt oder indirekt kontrolliert werden und kann durch die Gesellschaft oder durch von ihr kontrollierte
Unternehmen ausgerichtet werden.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;36&#8195;&#8201;Compensation for new Members of the Executive
Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;36&#8195;&#8202;Verg&uuml;tungen f&uuml;r neue Mitglieder der
Gesch&auml;ftsleitung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If new members of the Executive Committee are appointed and take up their position in the Company after the General Meeting has approved the maximum total compensation for members of the Executive Committee for the year in question,
the new members may be paid an additional amount for the period until the next Ordinary Meeting of Shareholder. The additional amount payable to all new members of the Executive Committee may not exceed 50% of the respective total compensation
already approved by the General Meeting. The additional compensation may only be paid if the total compensation amount that has been approved by the General Meeting for the compensation of the members of the Executive Committee is insufficient to
compensate the newly appointed members. The General Meeting is not required to vote on this additional amount.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sofern neue Mitglieder der Gesch&auml;ftsleitung ernannt werden und ihre Stelle antreten, nachdem die Generalversammlung die Gesamtverg&uuml;tung f&uuml;r die Gesch&auml;ftsleitungsmitglieder im entsprechenden Jahr genehmigt hat,
darf diesen neuen Mitglieder ein zus&auml;tzlicher Betrag f&uuml;r die Dauer bis zur n&auml;chsten ordentlichen Generalversammlung verg&uuml;tet werden. Dieser Zusatzbetrag an alle neuen Mitglieder der Gesch&auml;ftsleitung darf 50% der von der
Generalversammlung f&uuml;r das betreffende Jahr bereits genehmigten Gesamtverg&uuml;tung nicht &uuml;bersteigen. Der Zusatzbetrag darf nur ausgerichtet werden, sofern und soweit die von der Generalversammlung beschlossenen
Verg&uuml;tungsbetr&auml;ge an die Gesch&auml;ftsleitungsmitglieder bis zur n&auml;chsten ordentlichen Generalversammlung f&uuml;r die Verg&uuml;tung der neuen Mitglieder nicht ausreicht. &Uuml;ber den verwendeten Zusatzbetrag stimmt die
Generalversammlung nicht ab.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">This additional overall compensation is understood to include any settlements for any disadvantage suffered as a result of the change of job.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mit diesem Zusatzbetrag sind allf&auml;llige durch ein Gesch&auml;ftsleitungsmitglied erlittene Nachteile aufgrund Stellenwechsel abgegolten.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;37&#8195;&#8201;Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;37&#8195;&#8202;Spesen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expenses which are not covered by the lump sum compensation pursuant to the Company&#146;s expense regulations shall be reimbursed following presentation of the supporting receipts. This additional remuneration is not subject to a
separate vote by the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Spesen, welche nicht durch die pauschale Spesenentsch&auml;digung gem&auml;ss Spesenreglement abgedeckt sind, werden nach Vorlage der entsprechenden Belege r&uuml;ckverg&uuml;tet. Diese R&uuml;ckverg&uuml;tung ist von der
Generalversammlung nicht zu genehmigen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;38&#8195;&#8201;Compensation Agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;38&#8195;&#8202;Vertr&auml;ge &uuml;ber die Verg&uuml;tung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreements on compensation with members of the Board of Directors may not exceed the term of maximal one year.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vertr&auml;ge, die den Verg&uuml;tungen f&uuml;r die Mitglieder des Verwaltungsrats zugrunde liegen, sind auf maximal ein Jahr befristet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Employment agreements of the members of the Executive Committee are principally concluded for an indefinite period of time whereas a notice period may not exceed twelve months. If an employment agreement is concluded for a fixed
term such term may not exceed one year.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Arbeitsvertr&auml;ge der Gesch&auml;ftsleitungsmitglieder sind grunds&auml;tzlich unbefristet, wobei die K&uuml;ndigungsfrist maximal zw&ouml;lf Monate betragen darf. Wird ein befristeter Vertrag abgeschlossen, so darf dieser
die Dauer von ein Jahr nicht &uuml;berschreiten.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;39&#8195;&#8201;Mandates of a Member of the Board of Directors outside the
Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;39&#8195;&#8202;Mandate eines Verwaltungsratsmitglieds ausserhalb der
Gesellschaft</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A member of the Board of Directors may cumulatively assume not more than the following number of mandates in the board of directors, the superior management or an administrative body of a legal entity which is obliged to be
registered in the Swiss commercial register or an equivalent foreign register:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ein Mitglied des Verwaltungsrats darf kumulativ maximal folgende Mandate in einem obersten Leitungs- oder Verwaltungsorgan von Rechtseinheiten, die verpflichtet sind, sich ins Handelsregister oder in ein entsprechendes
ausl&auml;ndisches Register eintragen zu lassen, &uuml;bernehmen:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;7 mandates for publicly traded companies pursuant to article&nbsp;727 para. 1
number 1 CO; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;7 Mandate f&uuml;r Publikumsgesellschaften gem&auml;ss Artikel 727 Abs. 1 Ziff. 1
OR; und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;8 mandates for companies pursuant to article&nbsp;727 para. 1 number 2 CO;
and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;8 Mandate f&uuml;r Gesellschaften gem&auml;ss Artikel 727 Abs. 1 Ziff. 2 OR;
und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;5 mandates for companies which do not fulfil the criteria under a) and b)
hereunder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;5 Mandate f&uuml;r Rechtseinheiten, welche die Kriterien gem&auml;ss lit. a) und
b) hiervor nicht erf&uuml;llen.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mandates held in several legal entities each operating under the same management or same beneficial owner (group) are deemed to be a single mandate.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mandate von verschiedenen Rechtseinheiten, welche aber derselben F&uuml;hrung oder derselben wirtschaftlichen Eigent&uuml;merin unterstehen (Konzern), gelten als ein Mandat, d&uuml;rfen aber insgesamt vierzig nicht
&uuml;bersteigen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If a legal entity fulfills several of the above mentioned criteria, it can be freely counted towards any category. The following mandates are excepted from this restrictions:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Erf&uuml;llt eine Rechtseinheit mehrere der vorgenannten Kriterien, kann sie beliebig jeder auf sie zutreffenden Kategorie zugerechnet werden. Folgende Mandate sind von diesen Beschr&auml;nkungen ausgenommen:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;mandates in legal entities which are controlled by the Company or which control
the Company;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Mandate in Rechtseinheiten, welche von der Gesellschaft kontrolliert werden oder
welche die Gesellschaft kontrollieren;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;honorary mandates in charitable legal entities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Ehrenamtliche Mandate in gemeinn&uuml;tzigen Rechtseinheiten.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;40&#8195;&#8201;Mandates of a Member of the Executive Committee outside the
Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;40&#8195;&#8202;Mandate eines Gesch&auml;ftsleitungsmitglieds ausserhalb der
Gesellschaft</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Each member of the Executive Committee may, with approval of the Board of Directors, cumulatively assume not more than the following number of mandates in the board of directors, the superior management or an administrative body of
a legal entity which is obliged to be registered in the Swiss commercial register or an equivalent foreign register:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jedes Mitglied der Gesch&auml;ftsleitung darf mit Genehmigung des Verwaltungsrats kumulativ maximal folgende Mandate in einem obersten Leitungs- oder Verwaltungsorgan von Rechtseinheiten, die verpflichtet sind, sich ins
Handelsregister oder in ein entsprechendes ausl&auml;ndisches Register eintragen zu lassen, &uuml;bernehmen:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;2 mandates for publicly traded companies pursuant to article&nbsp;727 para. 1
number 1 CO; and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;2 Mandate f&uuml;r Publikumsgesellschaften gem&auml;ss Artikel 727 Abs. 1 Ziff. 1
OR; und</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;3 mandates for companies pursuant to article&nbsp;727 para. 1 number 2 CO;
and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;3 Mandate f&uuml;r Gesellschaften gem&auml;ss Artikel&nbsp;727 Abs. 1 Ziff. 2 OR;
und</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;5 mandates for companies which do not fulfil the criteria under litera a) and b)
hereunder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;5 Mandate f&uuml;r Rechtseinheiten, welche die Kriterien gem&auml;ss lit. a) und
b) hiervor nicht erf&uuml;llen.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mandates held in several legal entities each operating under the same management or same beneficial owner (group) are deemed to be a single mandate.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mandate von verschiedenen Rechtseinheiten, welche aber derselben F&uuml;hrung oder derselben wirtschaftlichen Eigent&uuml;merin unterstehen (Konzern), gelten als ein Mandat.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If a legal entity fulfills several of the above mentioned criteria, it can be freely counted towards any category. The following mandates are excepted from this restrictions:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Erf&uuml;llt eine Rechtseinheit mehrere der vorgenannten Kriterien, kann sie beliebig jeder auf sie zutreffenden Kategorie zugerechnet werden. Folgende Mandate sind von diesen Beschr&auml;nkungen ausgenommen:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;mandates in legal entities which are controlled by the Company or which control
the Company;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Mandate in Rechtseinheiten, welche von der Gesellschaft kontrolliert werden oder
welche die Gesellschaft kontrollieren;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;honorary mandates in charitable legal entities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Ehrenamtliche Mandate in gemeinn&uuml;tzigen Rechtseinheiten.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;41&#8195;&#8201;Loans and Credits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;41&#8195;&#8202;Darlehen und Kredite</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The members of the Board of Directors and the Executive Committee may not be granted any loans, credits or securities. Excepted from the above are advances in the maximum amount of CHF 500&#146;000 per person for attorneys&#146;
fees, court and other similar costs required for the defense of third-party liability claims permitted by article&nbsp;31.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Den Mitgliedern des Verwaltungsrats und der Gesch&auml;ftsleitung d&uuml;rfen keine Darlehen, Kredite oder Sicherheiten gew&auml;hrt werden. Ausnahme davon bilden Vorschusszahlungen &uuml;ber einen Betrag von maximal CHF
500&#146;000 pro Person f&uuml;r Anwalts-, Gerichts- und &auml;hnliche Kosten zur Abwehr von Verantwortlichkeitsanspr&uuml;chen, sofern zul&auml;ssig nach Artikel&nbsp;31.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;42&#8195;&#8201;Pension Funds</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;42&#8195;&#8202;Pensionskasse</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company shall remunerate members of the Board of Directors only in respect of the employer&#146;s mandatory contributions to social insurance. Above and beyond this, the Company shall not make any contributions to pension funds
or other such pension plans. In exceptional cases, contributions such as these may be made subject to a request by the Compensation Committee and the approval of the General Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft leistet f&uuml;r die Mitglieder des Verwaltungsrats die gesetzlichen Arbeitgebersozialversicherungsbeitr&auml;ge. Abgesehen davon richtet die Gesellschaft keine Beitr&auml;ge an die Pensionskasse oder andere
Vorsorgeeinrichtungen f&uuml;r die Mitglieder des Verwaltungsrats aus. Solche Beitr&auml;ge k&ouml;nnen ausnahmsweise auf Antrag des Verg&uuml;tungsausschusses und nach Genehmigung der Generalversammlung ausgerichtet werden.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Executive Committee participate in the Company&#146;s pension plans (the Company&#146;s pension fund and the management pension plan). The pension plans conform to the legal requirements (BVG). For members of the
Executive Committee, the insured income is defined as the fixed remuneration plus 50% of the target</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Mitglieder der Gesch&auml;ftsleitung partizipieren am Pensionsplan der Gesellschaft (Pensionskasse sowie Management Pensionsplan). Der Pensionsplan hat den gesetzlichen Bestimmungen (BVG) zu entsprechen. Das versicherte
Einkommen der Mitglieder der Gesch&auml;ftsleitung entspricht jeweils</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">performance-related remuneration, up to the legal maximum. Equity-linked income components are not included.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">dem Betrag der fixen Verg&uuml;tung zuz&uuml;glich 50% der erfolgsabh&auml;ngigen Verg&uuml;tung bis zum gesetzlichen Maximum. Aktienbezogene Verg&uuml;tungen werden nicht ber&uuml;cksichtigt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Within the overall compensation approved by the General Meeting, the Company may make additional payments into the Company&#146;s pension funds for the benefit of members of the Executive Committee in order to cover any disadvantage
suffered as a result of the change of jobs or to purchase additional pension entitlements. In this context the Company may conclude life insurance policies on behalf of members of the Executive Committee and pay the insurance premiums either fully
or in part.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann zugunsten der Gesch&auml;ftsleitungsmitglieder und im Rahmen der von der Generalversammlung genehmigten Gesamtverg&uuml;tungen zus&auml;tzliche Eink&auml;ufe in die Pensionskasse t&auml;tigen, um Nachteile
aufgrund von Stellenwechsel auszugleichen oder zugunsten zus&auml;tzlicher Rentenanspr&uuml;che. In diesem Zusammenhang kann die Gesellschaft Lebensversicherungen zugunsten der Mitglieder der Gesch&auml;ftsleitung abschliessen und die
Versicherungspr&auml;mien vollumf&auml;nglich oder teilweise zahlen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Upon retirement, the Company may also grant members of the Executive Committee a bridging pension to cover the period between early retirement at 62 and the ordinary age of retirement, if such bridging pension does not exceed 100%
of the total annual compensation of the respective member last paid.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann ihren Gesch&auml;ftsleitungsmitgliedern eine &Uuml;berbr&uuml;ckungsrente zusichern, um die Zeitdauer zwischen einer Fr&uuml;hpensionierung ab dem 62. Altersjahr und dem ordentlichen Pensionsalter abzudecken,
soweit eine solche &Uuml;berbr&uuml;ckungsrente 100% der letztmalig an dieses Mitglied bezahlte Jahresverg&uuml;tung nicht &uuml;bersteigt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;43&#8195;&#8201;Option and Share Plans</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;43&#8195;&#8202;Options-und Aktienpl&auml;ne</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Company&#146;s Option Plan, the Board of Directors, upon proposal of the Compensation Committee, allocates the participating members of the Executive Committee and the Board of Directors a fixed number of options, shares
or other equity-linked instruments with a vesting for a period to be determined by the Board of Directors (the vesting period). At the end of the vesting period, participants in the Option Plan are entitled to exercise the options granted against
payment of the strike price. These options to acquire shares in the Company or allocated shares or other equity-linked instruments are subject to the basic principles set out in the following:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gem&auml;ss dem Optionsplan der Gesellschaft, teilt der Verwaltungsrat auf Antrag des Verg&uuml;tungsausschusses den Mitgliedern der Gesch&auml;ftsleitung und des Verwaltungsrats eine bestimmte Anzahl Optionen, Aktien oder anderen
eigenkapitalbasierten Instrumenten zu, welche einer durch den Verwaltungsrat festzulegenden Sperrfrist unterliegen. Am Optionsplan partizipierende Mitglieder sind nach Ablauf der Sperrfrist berechtigt, die gew&auml;hrten Optionen gegen Bezahlung des
Aus&uuml;bungspreises auszu&uuml;ben. Die Optionen, welche zum Erwerb von Aktien an der Gesellschaft berechtigen, bzw. zugeteilten Aktien oder anderen eigenkapitalbasierten Instrumenten unterliegen den folgenden Grunds&auml;tzen:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;it is the sole discretion of the Board of Directors to decide whether to allocate
options or shares and to whom;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a)&#8195;&#8201;Es liegt im freien Ermessen des Verwaltungsrats, ob und wem Optionen und Aktien
zugeteilt werden;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;each year, the Board of Directors, upon proposal of the Compensation Committee,
stipulates the number of options and shares to be allocated, the date of allocation and the strike price;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b)&#8195;&#8202;Der Verwaltungsrat bestimmt j&auml;hrlich auf Antrag des
Verg&uuml;tungsausschusses Anzahl und Datum der Zuteilung sowie Aus&uuml;bungspreis der Optionen und Aktien;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;each option incorporates a
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> and contingent right to acquire a certain number of Company&#146;s shares;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c)&#8195;&#8201;Jede Option begr&uuml;ndet ein un&uuml;bertragbares, bedingtes Bezugsrecht eine
bestimmte Anzahl Aktien der Gesellschaft zu erwerben;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;in the case of a change of control (as defined in the Option Plan) or delisting of
the Company&#146;s shares, the vesting period shall end (accelerated vesting) and the participant shall be entitled to exercise the options on a pro rata basis on the day the transaction that led to the change of control or delisting was executed.
It is at the sole discretion of the Board of Directors to decide upon proposal of the Compensation Committee whether the financial objectives have been met;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d)&#8195;&#8202;Im Falle eines Kontrollwechsels (gem&auml;ss Definition im Optionsplan) oder der
Dekotierung der Aktien der Gesellschaft endet die Sperrfrist vorzeitig und das teilnehmende Gesch&auml;ftsleitungsmitglied ist berechtigt, seine Optionen <FONT STYLE="white-space:nowrap">pro-rata</FONT> basierend auf dem Stichtag der Transaktion,
welche zum Kontrollwechsel gef&uuml;hrt hat, oder der Dekotierung der Aktien auszu&uuml;ben. Der Verwaltungsrat entscheidet nach freiem Ermessen und auf Antrag des Verg&uuml;tungsausschusses, ob die finanzwirtschaftlichen Ziele in diesem
Zusammenhang gegeben sind;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;the individual members of the Executive Committee or the Board of Directors
participating in the Option Plan are responsible for paying any taxes or social security contributions and for declaring income correctly to the authorities;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e)&#8195;&#8201;Das jeweilige Mitglied der Gesch&auml;ftsleitung oder des Verwaltungsrats, welches
am Optionsplan teilnimmt, ist selber daf&uuml;r verantwortlich, dass jegliche damit zusammenh&auml;ngenden Steuern oder Sozialabgaben bezahlt und Einkommen der zust&auml;ndigen Beh&ouml;rden korrekt gemeldet werden.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;it is at the sole discretion of the Board of Directors to decide whether to
supplement the Option Plan within the bounds of the principles set out above or to discontinue it.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f)&#8195;&#8201;&#8202;Der Verwaltungsrat entscheidet nach freiem Ermessen &uuml;ber
Erg&auml;nzungen des Optionsplans im Rahmen der obgenannten Grunds&auml;tze oder &uuml;ber dessen Beendigung.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Company may periodically offer shares in the Company to important and long-term employees for a price being at maximum 10% below the average volume-weighted price of the last 30 trading days at the stock exchange. Members of the
Board of Directors and the Executive Committee may be included in this programme. The shares acquired thereby shall be blocked for a period of at least 3 years.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft kann periodisch Aktien der Gesellschaft zu einem Preis, der maximal 10% unter dem &uuml;ber 30 B&ouml;rsentage volumengewichteten durchschnittlichen Kurs an der B&ouml;rse liegt, an wichtige und langj&auml;hrige
Mitarbeiter abgeben. Die Mitglieder des Verwaltungsrats und der Gesch&auml;ftsleitung k&ouml;nnen in dieses Programm eingeschlossen werden. Die so erworbenen Aktien sind f&uuml;r mindestens 3 Jahre gesperrt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman"><B>VIII.&#8194;&#8201;&#8202;FISCAL YEAR, ACCOUNTING PRINCIPLES, ALLOCATION OF
PROFITS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman"><B>VIII.&#8194;&#8201;&#8202;GESCH&Auml;FTSJAHR, RECHNUNGSLEGUNG,
GEWINNVERTEILUNG</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;44&#8195;&#8201;Fiscal Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;44&#8195;&#8202;Gesch&auml;ftsjahr</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Board of Directors shall determine the start and the end of the Company&#146;s business year.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Der Verwaltungsrat bestimmt, wann das Gesch&auml;ftsjahr beginnt und wann es endet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;45&#8195;&#8201;Accounting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;45&#8195;&#8202;Rechnungslegung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The annual accounts consist of the profit and loss statement, the balance sheet, the cash flow statement, the annex and the management report, and shall be</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Jahresrechnung besteht aus der Erfolgsrechnung, der Bilanz, der Geldflussrechnung, dem Anhang und dem Lagebericht und ist gem&auml;ss den Vorschriften des</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">drawn up pursuant to the provisions of the Swiss Code of Obligations, particularly of articles&nbsp;958 et seq. CO, and the generally accepted commercial principles and customary rules in that business area.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Schweizerischen Obligationenrechts, insbesondere Artikeln 958 ff. OR, sowie nach den allgemein anerkannten kaufm&auml;nnischen und branchen&uuml;blichen Grunds&auml;tzen zu erstellen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If required by law, the consolidated financial statements shall be drawn in accordance with the provisions of article&nbsp;962 CO.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Konzernrechnung wird, sofern gesetzlich vorgeschrieben, gem&auml;ss den Bestimmungen von Artikeln&nbsp;962 OR erstellt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;46&#8195;&#8201;Allocation of Profits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;46&#8195;&#8202;Gewinnverteilung</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the legal provisions regarding distribution of profits, the profit as shown on the balance sheet shall be allocated by the General Meeting at its discretion after receipt of the proposals of the Board of Directors and the
Auditors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Generalversammlung beschliesst nach Entgegennahme der Antr&auml;ge des Verwaltungsrates und des Berichtes der Revisionsstelle unter Vorbehalt der gesetzlichen Bestimmungen &uuml;ber die Verwendung des Bilanzgewinnes und setzt
die Dividende und den Zeitpunkt ihrer Auszahlung fest.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">In addition to the legal reserves, the General Meeting may create supplemental reserves.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zus&auml;tzlich zu den gesetzlichen Reserven kann die Generalversammlung zus&auml;tzliche Reserven bereitstellen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dividends not claimed within five years after the due date shall remain with the Company and be allocated to the general reserves.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividenden, die nicht innerhalb von f&uuml;nf Jahren nach dem F&auml;lligkeitstag beansprucht werden, verbleiben bei der Gesellschaft und werden den allgemeinen R&uuml;cklagen zugef&uuml;hrt.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>IX.&#8194;&#8202;DISSOLUTION AND LIQUIDATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>IX.&#8194;&#8202;AUFL&Ouml;SUNG UND LIQUIDATION</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;47&#8195;&#8201;Dissolution and Liquidation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;47&#8195;&#8202;Aufl&ouml;sung und Liquidation</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The dissolution and liquidation of the Company shall take place in accordance with the provisions of the Swiss Code of Obligations.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">F&uuml;r die Aufl&ouml;sung und Liquidation der Gesellschaft gelten die Bestimmungen des Schweizerischen Obligationenrechts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>X.&#8195;NOTICES AND PUBLICATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>X.&#8195;MITTEILUNGEN UND BEKANNTMACHUNGEN</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;48&#8195;&#8201;Notices and Publications</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;48&#8195;&#8202;Mitteilungen und Bekanntmachungen</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Swiss Official Gazette of Commerce (SOGC) is the official publication medium.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Das Schweizerische Handelsamtsblatt (SHAB) ist das offizielle Publikationsmedium.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder communications and notices the shareholders shall be made by publication in the Swiss Official Gazette of Commerce or sent by mail or <FONT STYLE="white-space:nowrap">e-mail</FONT> to the addresses registered in the
share register.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mitteilungen und Bekanntmachungen an die Aktion&auml;re erfolgen durch Publikation im Schweizerischen Handelsamtsblatt oder durch Brief oder <FONT STYLE="white-space:nowrap">E-Mail</FONT> an die im Aktienbuch verzeichneten
Adressen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless the law provides otherwise, notices shall be given to creditors by publication in the Swiss Official</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bekanntmachungen an die Gl&auml;ubiger erfolgen in den vom Gesetz vorgeschriebenen F&auml;llen durch</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gazette of Commerce. The Board of Directors may assign further means of communication.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ver&ouml;ffentlichung im Schweizerischen Handelsamtsblatt, dem Publikationsorgan der Gesellschaft. Der Verwaltungsrat kann weitere Publikationsmittel bezeichnen.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>XI.&#8194;&#8202;QUALIFIED FACTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>XI.&#8194;&#8202;QUALIFIZIERTE TATBEST&Auml;NDE</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Article&nbsp;49&#8195;&#8201;Contribution in Kind</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-5.50em; font-size:10pt; font-family:Times New Roman"><B>Artikel&nbsp;49&#8195;&#8202;Sacheinlage</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">In connection with the capital increase of [Date], and in accordance with the contribution in kind agreement as of [Date] (the Contribution in Kind Agreement), the Company acquires [22&#146;001&#146;871] ordinary shares of Oculis
Merger Sub II Ltd. with registered seat in George Town, Cayman Islands, from [Name] (Contributor), acting in its own name but on behalf of the shareholders Oculis Merger Sub II Ltd. The shares of Oculis Merger Sub II Ltd are acquired for a total
value of CHF [Amount]. Based on the Contribution in Kind Agreement and as consideration, the Company issues to the Contributor, acting in its own name but for the account of the holders of ordinary shares of Oculis Merger Sub II Ltd, a total of
[Number] fully paid Shares with a with a par value of CHF 0.01 each and an aggregate par value of CHF [Amount]. The difference between the aggregate par value of the issued shares and the total value of CHF [Amount] is allocated to the statutory
capital contribution reserves of the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft &uuml;bernimmt bei der Kapitalerh&ouml;hung vom [Datum] gem&auml;ss Sacheinlagevertrag vom [Datum] (Sacheinlagevertrag) [22&#146;001&#146;871<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>] Aktien (ordinary
shares) der Oculis Merger Sub II Ltd. mit Sitz in George Town, Cayman Islands, von [Name] (Einlegerin), handelnd im eigenen Namen aber auf Rechnung der Aktion&auml;re der Oculis Merger Sub II Ltd. Die Aktien der Oculis Merger Sub II Ltd werden zu
einem &Uuml;bernahmewert von insgesamt CHF [Betrag] &uuml;bernommen. Im Einklang mit dem Sacheinlagevertrag weist die Gesellschaft als Gegenleistung der Einlegerin, handelnd im eigenen Namen aber auf Rechnung der er Inhaber der Aktien Oculis Merger
Sub II Ltd, insgesamt [Anzahl] voll einbezahlte Aktien mit einem Nennwert von je CHF 0.01 und gesamthaft CHF [Betrag] zu. Die Gesellschaft weist die Differenz zwischen dem totalen Nennwert der ausgegebenen Aktien und dem &Uuml;bernahmewert der
Sacheinlage im Gesamtbetrag von CHF [Betrag] den gesetzlichen Kapitaleinlagereserven der Gesellschaft zu.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">In connection with the capital increase of [Date], and in accordance with the contribution in kind agreement as of [Date] (the Contribution in Kind Agreement), the Company acquires 20&#146;348&#146;322 shares of Oculis SA with
registered seat in Ecublens (VD), Switzerland, from [Name] (Contributor), acting in its own name but on behalf of the shareholders Oculis SA. The shares of Oculis SA are acquired for a total value of CHF [Amount]. Based on the Contribution in Kind
Agreement and as consideration, the Company issues to the Contributor, acting in its own name but for the account of the holders of ordinary shares of Oculis SA, a total of [Number] fully paid Shares with a with a par value of CHF 0.01 each and an
aggregate par value of CHF [Amount]. The difference between the aggregate par value of the issued shares and the total value of CHF [Amount] is allocated to the statutory capital contribution reserves of the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Die Gesellschaft &uuml;bernimmt bei der Kapitalerh&ouml;hung vom [Datum] gem&auml;ss Sacheinlagevertrag vom [Datum] (Sacheinlagevertrag) 20&#146;348&#146;322 Aktien der Oculis SA mit Sitz in Ecublens (VD), Schweiz, von [Name]
(Einlegerin), handelnd im eigenen Namen aber auf Rechnung der Aktion&auml;re der Oculis SA. Die Aktien der Oculis SA werden zu einem &Uuml;bernahmewert von insgesamt CHF [Betrag] &uuml;bernommen. Im Einklang mit dem Sacheinlagevertrag weist die
Gesellschaft als Gegenleistung der Einlegerin, handelnd im eigenen Namen aber auf Rechnung der Aktion&auml;re der Oculis SA, insgesamt [Anzahl] voll einbezahlte Aktien mit einem Nennwert von je CHF 0.01 und gesamthaft CHF [Betrag] zu. Die
Gesellschaft weist die Differenz zwischen dem totalen Nennwert der ausgegebenen Aktien und dem &Uuml;bernahmewert der Sacheinlage im Gesamtbetrag von CHF [Betrag] den gesetzlichen Kapitaleinlagereserven der Gesellschaft zu.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[PLACE]/[DATE]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[ORT]/[DATUM]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Maximum number assuming no redemptions by EBAC&#146;s shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc389734_41"></A>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Companies Act (As Revised) of the Cayman Islands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plan of Merger </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This plan of merger (the
&#147;<B>Plan of Merger</B>&#148;) is made on [<B><I>insert date</I></B>] between European Biotech Acquisition Corp. (the &#147;<B>Surviving Company</B>&#148;) and Oculis Merger Sub I Company<B> </B>(the &#147;<B>Merging Company</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whereas the Merging Company is a Cayman Islands exempted company and is entering into this Plan of Merger pursuant to the provisions of Part XVI of the
Companies Act (As Revised) (the &#147;<B>Statute</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whereas the Surviving Company is a Cayman Islands exempted company and is entering into this
Plan of Merger pursuant to the provisions of Part XVI of the Statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whereas the directors of the Merging Company and the directors of the Surviving
Company deem it desirable and in the commercial interests of the Merging Company and the Surviving Company, respectively, that the Merging Company be merged with and into the Surviving Company and that the undertaking, property and liabilities of
the Merging Company vest in the Surviving Company (the &#147;<B>Merger</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms not otherwise defined in this Plan of Merger shall have the
meanings given to them under the Business Combination Agreement dated October&nbsp;17, 2022 and made between, amongst others, the Surviving Company and the Merging Company (as it may be amended, modified or supplemented, the &#147;<B>Business
Combination Agreement</B>&#148;) a copy of which is annexed at Annexure 1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now therefore this Plan of Merger provides as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The constituent companies (as defined in the Statute) to this Merger are the Surviving Company and the Merging
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The surviving company (as defined in the Statute) is the Surviving Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registered office of the Surviving Company is c/o Maples Corporate Services Limited of PO Box&nbsp;309,
Ugland House, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands and the registered office of the Merging Company is c/o&nbsp;Maples Corporate Services Limited of PO Box 309, Ugland House, Grand Cayman, <FONT
STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately prior to the Effective Date (as defined below), the share capital of the Surviving Company will be
US$22,100 divided into 200,000,000 Class&nbsp;A ordinary shares of a par value of US$0.0001 each, 20,000,000 Class&nbsp;B ordinary shares of a par value of US$0.0001 each and 1,000,000 preference shares of a par value of US$0.0001 each and the
Surviving Company will have [<B><I>insert number</I></B>] Class&nbsp;A ordinary shares and [<B><I>insert number</I></B>] Class&nbsp;B ordinary shares in issue. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately prior to the Effective Date (as defined below), the share capital of the Merging Company will be
US$50,000 divided into 50,000 ordinary shares of a par value of US$1.00 each and the Merging Company will have one ordinary share in issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date on which it is intended that the Merger is to take effect is the date that this Plan of Merger is
registered by the Registrar in accordance with section 233(13) of the Statute (the &#147;<B>Effective Date</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of the Merger, including the manner and basis of converting shares in each constituent
company into shares in the Surviving Company, are set out in the Business Combination Agreement in the form annexed at Annexure 1 hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights and restrictions attaching to the shares in the Surviving Company are set out in the Amended and
Restated Memorandum and Articles of Association of the Surviving Company in the form annexed at Annexure 2 hereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Amended and Restated Memorandum and Articles of Association of the Surviving Company immediately prior to
the Merger shall be its memorandum and articles of association after the Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no amounts or benefits which are or shall be paid or payable to any director of either constituent
company or the Surviving Company consequent upon the Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Merging Company has granted no fixed or floating security interests that are outstanding as at the date of
this Plan of Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Surviving Company has granted no fixed or floating security interests that are outstanding as at the date
of this Plan of Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The names and addresses of each director of the surviving company (as defined in the Statute) are:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<B><I>Insert name of Director</I></B>] of [<B><I>Insert personal/business address of Director</I></B>];
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<B><I>Insert name of Director</I></B>] of [<B><I>Insert personal/business address of Director</I></B>]; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<B><I>repeat for all</I></B> <B><I>Directors of the surviving company (i.e. the merged entity)</I></B>].
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Merger has been approved by the board of directors of each of the Surviving Company and the
Merging Company pursuant to section 233(3) of the Statute. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Merger has been authorised by the shareholders of each of the Surviving Company and the Merging
Company pursuant to section 233(6) of the Statute by way of resolutions passed at an extraordinary general meeting of the Surviving Company and Merging Company, as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any time prior to the Effective Date, this Plan of Merger may be: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminated by the board of directors of either the Surviving Company or the Merging Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amended by the board of directors of both the Surviving Company and the Merging Company to:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">change the Effective Date provided that such changed date shall not be a date later than the ninetieth day
after the date of registration of this Plan of Merger with the Registrar of Companies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effect any other changes to this Plan of Merger which the directors of both the Surviving Company and the
Merging Company deem advisable, provided that such changes do not materially adversely affect any rights of the shareholders of the Surviving Company or the Merging Company, as determined by the directors of both the Surviving Company and the
Merging Company, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Merger may be executed in counterparts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Merger shall be governed by and construed in accordance with the laws of the Cayman Islands.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page to follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In witness whereof</B> the parties hereto have caused this Plan of Merger to be executed on the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIGNED </B>by
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Duly authorised for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and on behalf of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>European Biotech Acquisition Corp.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIGNED </B>by
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Duly authorised for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and on behalf of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Oculis Merger Sub I Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annexure 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Business Combination Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annexure 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated Memorandum and Articles of Association of the Surviving Company </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;20. Indemnification of directors and officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive committee in relation to potential personal liability
is not effective to the extent the director or member of the executive committee intentionally or grossly negligently violated his or her corporate duties towards the corporation. Furthermore, the general meeting of shareholders may discharge the
directors and members of the executive committee from liability for their conduct to the extent the respective facts are known to shareholders. Such discharge is effective only with respect to claims of the company and of those shareholders who
approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition,
indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Articles
of Association provide for indemnification of the existing and former members of the board of directors or the executive committee against liabilities arising in connection with the performance of their duties in such capacity. In addition, under
general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the employer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of the members of our board of directors and executive officers, the form of which has been
filed as an exhibit to this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;21. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1&#134;+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000119312522278594/d389734df4.htm#toc389734_39">Business Combination Agreement, dated as of October&nbsp;
17, 2022, by and among EBAC and Oculis (included as Annex A to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#toc389734_41">Form of Plan of Merger, by and between EBAC and Merger Sub 1 (included as Annex C) to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex0301.htm">Amended and Restated Memorandum and Articles of Association of EBAC (incorporated by reference to the corresponding exhibit to EBAC&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000119312522278594/d389734df4.htm#toc389734_40">Articles of Association of New Parent (included as Annex&nbsp;B to the proxy statement/prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321003562/dp147296_ex0401.htm">Specimen Unit Certificate (incorporated by reference to the corresponding exhibit to EBAC&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (No. <FONT STYLE="white-space:nowrap">333-253220)</FONT> filed with the SEC on March&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321003562/dp147296_ex0402.htm">Specimen Class&nbsp;
A Ordinary Share Certificate (incorporated by reference to the corresponding exhibit to EBAC&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (No. <FONT STYLE="white-space:nowrap">333-253220)</FONT> filed with the SEC
 on March&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321003562/dp147296_ex0403.htm">Specimen Warrant Certificate (incorporated by reference to the corresponding exhibit to EBAC&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (No. <FONT STYLE="white-space:nowrap">333-253220)</FONT> filed with the SEC on March&nbsp;4, 2021. </A></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex0401.htm">Warrant Agreement, dated March&nbsp;15, 2021, between EBAC and Continental Stock Transfer&nbsp;
&amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex1003.htm">Registration Rights and Shareholder Agreement, dated March&nbsp;
15, 2021, between EBAC and certain security holders (incorporated by reference to Exhibit 10.3 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex1001.htm">A Letter Agreement, dated March&nbsp;
15, 2021, among EBAC and its officers, certain of its directors and the Sponsor (incorporated by reference to Exhibit 10.1 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex47.htm">Form of Warrant Assignment and Assumption Agreement, by and among EBAC, New Parent and the Exchange Agent. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex51.htm">Opinion of VISCHER AG, Swiss counsel to Oculis, as to the validity of the New Parent Shares and New Parent Warrants being registered.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex81.htm">Opinion of Davis Polk&nbsp;&amp; Wardwell LLP regarding certain tax matters. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex82.htm">Opinion of VISCHER AG regarding certain Swiss tax matters. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex1002.htm">Investment Management Trust Agreement, dated March&nbsp;15, 2021, between EBAC and Continental Stock Transfer&nbsp;
&amp; Trust Company, as trustee (incorporated by reference to Exhibit 10.2 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1004.htm">Oculis Shareholder Support Agreement, dated as of October&nbsp;
17, 2022, by and among Oculis, EBAC the other parties thereto (incorporated by reference to Exhibit 10.4 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1005.htm">Sponsor Support Agreement, dated as of October&nbsp;
17, 2022, by and among the Sponsor, EBAC and Oculis (incorporated by reference to Exhibit 10.5 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1001.htm">Form of PIPE Subscription Agreement by and among EBAC and certain investors party thereto (incorporated by reference to Exhibit 10.1 to EBAC&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1002.htm">Form of Convertible Loan Agreement by and among Oculis SA and certain shareholders party thereto (incorporated by reference to Exhibit&nbsp;10.2
 to EBAC&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the SEC on October&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1003.htm">Form of Shareholder <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, by and among Sponsor and certain investors party thereto
 (incorporated by reference to Exhibit 10.3 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010322017851/dp182518_ex1006.htm">Form of Amended and Restated Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, dated as of October&nbsp;
17, 2022, by and among New Parent and the other signatories to be a party thereto (incorporated by reference to Exhibit 10.6 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;
17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8+&#134;&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312522302894/d389734dex108.htm">License Agreement by and among Alcon Research, LTD., and Oculis, dated December&nbsp;19, 2018. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9+&#134;&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312522302894/d389734dex109.htm">Amendment to License Agreement by and among Alcon Research, LTD. and Oculis, dated September&nbsp;11, 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex1010.htm">Form of New Parent Director and Officer Indemnification Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11+&#134;&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312522302894/d389734dex1011.htm">Letter Agreement by and among Novartis Technology LLC and Oculis, dated October&nbsp;12, 2021. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12+&#134;&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312522302894/d389734dex1012.htm">License Agreement by and among Accure Therapeutics SL and Oculis, dated January&nbsp;29, 2022.
</A></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex1013.htm">Form of Stock Option and Incentive Plan Regulation 2023 of Oculis Holding AG. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321004216/dp148015_ex1004.htm">Administrative Services Agreement, dated March&nbsp;
15, 2021, between EBAC and the Sponsor (incorporated by reference to Exhibit 10.4 to EBAC&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;18, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1841258/000095010321003562/dp147296_ex1004.htm">Form of EBAC Indemnity Agreement (incorporated by reference to Exhibit 10.4 to EBAC&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> filed with the SEC on March&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex211.htm">List of subsidiaries of New Parent. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d389734dex231.htm">Consent of PricewaterhouseCoopers SA, independent registered public accounting firm for Oculis.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d389734dex232.htm">Consent of Marcum LLP, independent registered public accounting firm for EBAC.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex51.htm">Consent of VISCHER AG (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex81.htm">Consent of Davis Polk&nbsp;&amp; Wardwell LLP (included in Exhibit 8.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dex82.htm">Consent of VISCHER AG (included in Exhibit 8.2). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex991.htm">Form of Proxy Card for EBAC Extraordinary General Meeting. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex992.htm">Consent of Christina Ackermann to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex993.htm">Consent of Lionel Carnot to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex994.htm">Consent of Pravin Dugel, M.D. to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex995.htm">Consent of Martijn Kleijwegt to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.6+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex996.htm">Consent of Geraldine O&#146;Keeffe to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1953530/000119312523003678/d389734dex997.htm">Consent of Anthony Rosenberg to be named as a director. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d389734dex998.htm">Representation under Item 8.A.4 of Form 20-F.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001953530/000119312523017735/d389734dexfilingfees.htm">Filing Fee Table </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Filed herewith</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certain schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The Registrant agrees to furnish supplemental copies of all omitted exhibits and
schedules to the Securities and Exchange Commission upon its request.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Previously filed.</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;22. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant, hereby undertakes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the
&#147;<I>Securities Act</I>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;<I>Calculation of Registration
Fee</I>&#148; table in the effective registration statement; and </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial<I>&nbsp;bona</I><I></I><I>&nbsp;fide</I>&nbsp;offering thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed
pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, will be deemed to be part of and included in the
registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in
the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in
the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is
a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable
registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That every prospectus: (i)&nbsp;that is filed pursuant to the immediately preceding paragraph, or
(ii)&nbsp;that purports to meet the requirements of Section&nbsp;10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be
used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment will be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time will be deemed to be the initial<I>&nbsp;bona fide</I>&nbsp;offering thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to: (i)&nbsp;respond to requests for information that is incorporated by reference into the prospectus pursuant
to Item&nbsp;4, 10(b), 11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means and (ii)&nbsp;to arrange or provide for a facility in the
United States for the purpose of responding to such requests. The undertaking in clause (i)&nbsp;above includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to
the request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and
the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ii389734_101abc"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Amendment No. 4 to the Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-4</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in Zug, Switzerland on February&nbsp;1, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>OCULIS HOLDING AG</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eduardo Bravo Fernandez de Araoz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Eduardo Bravo Fernandez de Araoz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Principal Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following
persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eduardo&nbsp;Bravo&nbsp;Fernandez&nbsp;de Araoz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>February&nbsp;1,&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eduardo Bravo Fernandez de Araoz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Principal Executive Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Riad Sherif</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>February&nbsp;1,&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Riad Sherif</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Principal Financial and Accounting Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned has signed this registration statement, solely in the capacity as the
duly authorized representative of the Registrant, in Boston, Massachusetts, on February&nbsp;1, 2023. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sylvia Cheung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sylvia Cheung</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d389734dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form F-4<B> </B>of Oculis Holding AG<B> </B>of our report dated November 7, 2022 relating to
the consolidated financial statements of Oculis SA, which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148;<B> </B>in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers SA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lausanne, Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;1, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d389734dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of Oculis Holding AG on Form <FONT STYLE="white-space:nowrap">F-4,</FONT> Amendment No.&nbsp;4
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268201)</FONT> of our report dated March&nbsp;31, 2022, which includes an explanatory paragraph as to the ability of European Biotech Acquisition Corp. to continue as a going concern, with respect
to our audit of the financial statements of European Biotech Acquisition Corp. as of December&nbsp;31, 2021 and for the period from January&nbsp;8, 2021 (inception) through December&nbsp;31, 2021, which report appears in the Prospectus, which is
part of this Registration Statement. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum
<SMALL>LLP</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;1, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>4
<FILENAME>d389734dex998.htm
<DESCRIPTION>EX-99.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.8 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;1, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of the Chief Accountant
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street NE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, DC 20549 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Oculis Holding AG Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> <FONT
STYLE="white-space:nowrap">(333-268201)</FONT> </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Request for Waiver of Requirements of Form <FONT STYLE="white-space:nowrap">20-F,</FONT> Item 8.A.4
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned, Oculis Holding AG (&#147;<U>New Parent</U>&#148;) and Oculis SA (&#147;<U>Oculis</U>&#148;), each a stock corporation (<I>Aktiengesellschaft</I>) incorporated and existing under the laws of Switzerland, are submitting this letter in
connection with New Parent&#146;s filing of its registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-4</FONT> on November 7, 2022 (the &#147;<U>Registration Statement</U>&#148;), as amended to date, including New Parent&#146;s
filing on the date hereof of Amendment No.&nbsp;4 thereto (&#147;<U>Amendment No.</U><U></U><U>&nbsp;4</U>&#148;) in connection with the proposed business combination among European Biotech Acquisition Corp., a Cayman Islands exempted company, New
Parent and Oculis. We hereby respectfully request that the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) waive the requirement of Item&nbsp;8.A.4 of <FONT STYLE="white-space:nowrap">Form&nbsp;20-F,</FONT> which states that
in the case of a company&#146;s initial public offering the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-4</FONT> must contain audited financial statements of a date not older than 12 months from the date of the offering
unless a waiver is obtained. See also Division of Corporation Finance, Financial Reporting Manual, Sections&nbsp;1140.5 and 6220.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of
initial filing of the Registration Statement on November&nbsp;7, 2022, the Registration Statement satisfied Item 8.A.4 of Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is applicable to the Registration Statement pursuant to Item 14(h) of
Form <FONT STYLE="white-space:nowrap">F-4,</FONT> because it contained Oculis&#146; audited financial statements for the years ended December&nbsp;31, 2021 and 2020 prepared in accordance with International Financial Reporting Standards
(&#147;<U>IFRS</U>&#148;) as issued by the International Accounting Standards Board (&#147;<U>IASB</U>&#148;). However, because Oculis&#146; audited financial statements for the year ended December&nbsp;31, 2022 will not be available until
approximately March&nbsp;30, 2023, Amendment No.&nbsp;4 contains only audited financial statements for the years ended December&nbsp;31, 2021 and 2020 and unaudited financial statements for the nine months ended September&nbsp;30, 2022 and 2021, in
each case prepared in accordance with IFRS as issued by the IASB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Parent and Oculis are submitting this waiver request pursuant to Instruction 2 to
Item 8.A.4 of Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which provides that the Commission will waive the <FONT STYLE="white-space:nowrap">12-month</FONT> age of financial statements requirement &#147;if the company is able to represent
that it is not required to comply with the <FONT STYLE="white-space:nowrap">12-month</FONT> requirement in any other jurisdiction outside the United States and that complying with the <FONT STYLE="white-space:nowrap">12-month</FONT> requirement is
impracticable or involves undue hardship.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See also the Commission&#146;s November&nbsp;1, 2004 release entitled International Reporting and
Disclosure Issues in the Division of Corporation Finance (available on the Commission&#146;s website at http://www.sec.gov/divisions/corpfin/internatl/cfirdissues1104.htm) in Section&nbsp;III.B.c, in which the Commission notes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>the instruction indicates that the staff will waive the <FONT STYLE="white-space:nowrap">12-month</FONT> requirement where it is not
applicable in the registrant&#146;s other filing jurisdictions and is impracticable or involves undue hardship. As a result, we expect that the vast majority of IPOs will be subject only to the <FONT STYLE="white-space:nowrap">15-month</FONT> rule.
The only times that we anticipate audited financial statements will be filed under the <FONT STYLE="white-space:nowrap">12-month</FONT> rule are when the registrant must comply with the rule in another jurisdiction, or when those audited financial
statements are otherwise readily available.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this request, New Parent and Oculis represent to the Commission that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;Oculis is not currently a public reporting company in any other jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Oculis is not required by any jurisdiction outside the United States to prepare,
and has not prepared, financial statements audited under any generally accepted auditing standards for any interim period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Compliance with Item 8.A.4 is impracticable and involves undue hardship for Oculis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;Oculis does not anticipate that its audited financial statements for the year ended December&nbsp;31, 2022 will be available until
March 2023. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;In no event will Oculis seek effectiveness of the Registration Statement if its audited financial statements are
older than 15 months at the time of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed this letter as an exhibit to Amendment No.&nbsp;4 pursuant to Instruction 2 to Item 8.A.4
of Form <FONT STYLE="white-space:nowrap">20-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please do not hesitate to contact Oculis&#146; Chief Financial Officer, Sylvia Cheung, at
sylvia.cheung@oculis.com if you have any questions regarding the foregoing or if we can provide any additional information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Riad Sherif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Riad Sherif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Director, Principal Financial and Accounting Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Oculis Holding AG</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sylvia Cheung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sylvia Cheung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oculis SA</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g389734g00s02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g00s02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1#64&AO=&]S:&]P(#,N,  X0DE-! 0
M    $+J^0H(X0DE-! 0      "$< @   @  ' )0  M$87)I;R!"96QL;QP"
M!0 %24Y$15@ .$))300E       0S<0A%J5TUCJK0+"F]_<S#3A"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!PP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@             _
M@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #00    8              $D
M  $>    !@!G #  , !S #  ,@    $                          0
M           !'@   $D                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   $D     4F=H=&QO;F<   $>    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !)
M     %)G:'1L;VYG   !'@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%! 6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0'_P  1"  : &8# 1$  A$! Q$!_\0 '0   @(#  ,
M    "0H&" $%!P,$"__$ #80  $$ @$# @0#! L       0" P4& 0<("1$2
M !0*$Q4A%B2U%Q@Y<S@Z475V=WBQM+:W_\0 '0$  @(" P$
M!@<#!00( 0() /_$ $(1  (" 0,# 00%" 4-      $" P0%!A$2 !,A!Q0B
M,4$((S91<14R,S5U@;*S%C0W<H4D0F%B<W21H;&TP<3A_]H # ,!  (1 Q$
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>JU>#&PF""&$R#E(8HDC,C D N44%R!X!;<@=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g389734g01a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g01a67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2EV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *5J^$%ACA"24T$)0      $                      X0DE-!#H
M   .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
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MUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M    !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8V
MMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M   $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F
M1456YT1B-2;'0               !";&0@56YT1B-2;'0
M!2<VQT56YT1B-0>&Q =JX4@         IV96-T;W)$871A8F]O; $     4&
M=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M       %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M          $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='
M1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296
M-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M      $ %JX4@  0 ! 6KA2  !  $X0DE-!"8       X             /X
M   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M )           ! #A"24TG$       "@ !          $X0DE- _4      $
M@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M    8       $ -0    $ +0    8       $X0DE- _@      '   /____
M________________________\#Z     #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z   .$))300(       0     0   D    )      #
MA"24T$'@      !      X0DE-!!H      S4    &              /F
M (W          !                          $             "-P
M/F                      $                         $     $
M    !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M   %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M/F     %)G:'1L;VYG   (W     9S;&EC97-6;$QS     4]B:F,    !
M     %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&
M]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T
M=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M@       P    "/_         X0DE-!!$       $! #A"24T$%       !
M    4X0DE-! P     'V     !    H    $8   '@  "#0   'T0 &  !_]
MC_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@
M "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M
M8  0    #3+4A0("
M                   !%C<')T   !4    #-D97-C   !A    &QW='!T
M !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%
ME:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (
M9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M    QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M   $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D
M="($E%0S8Q.38V+3(N,0
M                          6%E:(        /-1  $    !%LQ865H@
M                   %A96B        !OH@  ./4   .06%E:(        &
M*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+F
MEE8RYC:
M        !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&
M-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M          9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6
M]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M           '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5
MA96B       $P)5@!0    5Q_G;65A<P         !
M       H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %
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M!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM?S'CBXOSQ<7M?7Q:=T?;31\PUW;U==P?"E3SS;M%=5<+V7*.*!Y4L?GA/M
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M))!$G1(M+WZ1XDL>QP/FL3P#;D\#G47^KZO^;_XS]3M>V7:]N2+\#3L;/D3
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M3<2MR+N4N3<#QRF_U59A<+^7&NH<LNRVMTDBU&3RZ79X2WVCLFQ2N"IJM"K
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M(^2XUYQW5#LN3:;AXC.9C2#:_;[2OW]0V.PY%@+T3(@J2CEE>253>1/YO*H
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MKG<:46>R_-7,>*QS;O+8:\M=54C5LU!+?:BR-SF<K[>\6&:P05])EE6B9(V
MG*U;1Q1L"(WD9C$W4?%>K(;.ZV,<9Q'487"6C9&JU>0$Q TJR2.I#2+& )%*
M+YC'&OD1L@[C+RK8$T/UW;U\1Q$N=[QG@>^/+\I+V.]LW%_.6XYJY;+VW*.M
MY%I.Z'-ZWN[I^WG6E<VS7=)%<8233V6'K,9O>+:4@%Q<7$+\?;F@'K=["2Z
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M/Q/.E%TTT=--::XSN?T7V7^4%%37OV'<@Z*D^V*L*S^Q]!6>[]FWM7\[!/\
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M5F[:)D%KG])4@7E'9P1S1D1PV%3:#E &Q,(AAG9&2/*QLT4<K41[&N2" >"
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MU[HY$:Y4\.5CT155KO#37UTTT=--'331TTT=--'331TTU'ONI[?QNZ/@;?\
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MZ::.FFCIIHZ::0O*/(V7X>XSY%Y;VY!0>+XMPNNY&UY8(<UB:+E\1G[#37Y
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MJZ7G!%:YS7(O9MWFHK7,E)A>UR+P!Y:YDP1L4B.\*R0(UC_#A"$B?SF\._\
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M(Z2P.?6/M*YS3ZYIJ0.-"<A0R2P*DG5[&U[&V3I>W&<9LZ7_ +2$@.O=2;$
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MV-AR'8DR 7#L\BXRRQ3\A^ /-SB+ #F]U  3GR*$(,44MH?P8?\ ;!J%?/\
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M'337YY>L_LA\O*G_ '\N=/[OG[X-M^"HOX^4^GZ?*(OGU-:L7S=XLY\2;O\
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M4Q'IXH@<2X_17/&9M7'",W4.EE]Z.KDA5&IZT+,K0T8XD\:)[3U_;_=I6_\
M9V^R[TJY,QW%O1&*]%CXG'D5[$B=,CHTCU3EE22)(7P^VCO?:;5^S[GVM6?-
MM-3V[1^\3B+O4PFPY!X<BV(U-A>1;#BW1B;?-NS-L+JZW)XW;3,'%^</@.K9
M<]O,X4+9B%RC3R$3P-=[@TB=--2JZ::A_P#$*^G8)WQ+_P#0_P"Y?^3_ 'E]
MK^GU-_\ .;_X2?CU*]Q]H_?J&['[#^[7E(\(Y$_-1S7(W\&M<UR/9#]$1(2&
M.8Z,N-K&-9/$Z$H:.* L<VO&UGKW\"2.#>X!^T@WOVY_?T GGO\ M^7;\/GZ
M<=C;A%]7E55%1455\JCD<BL=(]7*LI#7M<A);WJ]Q,<C##'RO+BM+0S>O]O'
MY[F_R'Q];Q;MS?\ -^?]7;N .+#E]/E57TN;ZG*YRHU6JWWY%<Y\CX'-<CAR
M)'OD)@>CH39I2X7P6]E2/MO\_N^/I^SO]FIOW[>MA^;G]]K_ !U<9\%1$36]
MX7A$1?';\U?#$:OF.OY8B1'>((7*Z-L;8O2]7/A;&T;V*ML+:2KZ%XF_RBG_
M %6*_P!O4E_/V:[3LO\ BC?]._\ V8_G_#[/4WV===UR^CIIKR/=K3D_:Q=N
MB^4:U.!N)'*OEC8T1..Z:=[G*V2.!&*BG2RO>Z.%6RVA!$\L9FAO;[Y,WO\
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M=T2:P6MEY>T.4Q;B3LZ,>K1CKV ITP\)54-):""$AX)1=@H56+QRJ59B@<6
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MJRHLE#;D30W5U9"2:+3QX'#-V>O>.NMV_P"1F4=KKNZ=GJE1)!(4J+!3T_*
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MC$W+&==QJ68-ETZAA/$4MTS+G-64_KR.Q/-PI.WM&@L0!T6VRD56 !>G5X)
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M:_/*UOE.1.7U\_[^7.G_ #?ZL&V5?TM_4B^47_<KX>BM]8_S=XL%_$>\7O\
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MIIHZ::\5?Q3?]L-[G_\ CGB7]'G\>W7AM/U*B_1?'U1WXHGA47VIO"_I'O\
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MLJY45SY$57.5SWN;)/[DKGRR&6,SY;$OH7B;_**?]5B_[R;7:ME_Q,_],_\
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M+BBA"Q4*,% 8+Y0BVC105+>1%)+,6+<6H!YBQ9B6 !+'(FU^2S7=C8V\S$
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M1BME/=186!^8[:VO5-6T=--'3356NBS/?C5:3O<'QT>RO\]R0V@B[=KRUUF
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M-[^C(606!)9UM;WA=;XRVM;!2P-[D"6,K:WJ'Q8WXQ5KW'E.WX!;0IQ3GES
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M26Y%VQJIJ24EP6>.F,;7#8ZRF2'-CTO(TN=KV;'VF!RHMPH-+'+#BA""23,
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M:>K+T&+CV>J!CW&BI21:ZIM$!&CQ)D45*2-58Y8!*>GHXF;@!II!MY6-T$8
M:>((R],15E+2,)'L&,E0[, 1<M/4U<B+=B4C4UV3QDL+I#(,&ZADGN+RYQB;
MM8N.@]UFBMO/6@VX^;@LQY;$FNLQKHRO)%:QRQ%-,"SF@,'C'EDEE$I+8ID:
MP5Y4D1?-<KR%RN1S;!:9FO\ )5K*4D]K3Q']8:A@5MD",@I%_4.U0BG_ /<]
M)4J/G#(/U=.+TU&CIIJE7FCL;XATN]Y$L-;W4<0XRNUG)/-E]G:^QPN8%Y%7
ME/9Y'.<P;?!<O;VSY1&9S+Q-D\#@I-78\*2Y#%%0<1UX46@UDE!DZRT&Q1E8
M(E/43Z@R5$;N 8A'#OD.[S/.M_K!%5PK2M*'C$<+/$PS.0SL7E<CIM9Q%&X4
M?69R;7-M4(B?$]/JP5/65"CF298I 2JXGMS';CQ3RQW!<#<DX?O'[8XN3:?C
M"WTT%3VS\;9C,7.OQ3]KS8UF]XPR1/.O)F'IZ$+4\HZ$&QU&YXWYMMQMA5:8
MB@UN4.UFR +R(A665USXA57'!:/J02(C7*E8X[50FBQ1)&Z@26>>GE6(86<M
M%&IM8S.Z$WP<K+"9!8,"\A%+T9"7:,!,HX8IHNIK$Y,^%2"3+N=7>]TL-!)H
M.4LGM:G?Z+CQ]/MJFY+T'.\[[C3:W$\J\:TFSY5DV/<E:C<47\^8IL#CA*G,
M9"QX>WP$Q8YDP@1R1-:Y%5%($7A#C55DT<<*-F$FF:OE@J)&ZHJ(NFG11@S-
M:5C(DH[7I7C+MYF%J:CA=Y& 5FBCCH(Y8XT:(Q29OU63%%N$V.]Q''E;#<[W
M79O&5!),P0]GJ+JOH@)RQZJRO"!8B[(@:"2>&EIK>VEB:]7QUU8>8YJ#B3R,
M@D @$@%L[ GD].-YI"/B$BCDE<_JQH[FRJ2*A6:^()MC>P)MFZQKV_M2.B+\
M795%R0"J8Y(Y8V2Q/9+%*QLD<D;FOCDC>U',>Q[55KV/:J.:YJJUS514547J
MQ!!(((()!!%B".""#R"#W&J@@@$$$$7!'((/8@^H.OOJ-3HZ::.FFCIIHZ::
M.FFCIIHZ::.FFCIIHZ::.FFCH>QMR?0=KZ:I'X^XI^*EB;>WUX^GBT,H%!K\
M_59CD7D&EN+#D"(JOW=KF;_72E6NXRO'VPK]L=GHVS<=P.QMCG(JTEN-QM7+
M8<89NJ!EC*L;EJ.FC) !=9X(]Y;J*7+?6R2R;:LV;O&^<HRP@A:+(Y0MY> *
MR60<&Q@EDVP%#8K]6D:5QCQ5)%QC; O)(LJYQU9\8(F+ VNOT_%59+7D5D&U
MRK*/CLY+^NK]6X@DLNZKIXT N;_)B!U]LW.J-5@&6-T32"#3+4.J,J8B:(/S
M"7INL5N+)EM25)C'O\))N\R97)D@I5L$=DDQ'F$E;B;Z_$&Q';='IRY!Q)R3
M:8F"V&,U2Q.2AXW1VO\ V2YW)Y3<4F"9QZO-J_+/*_(1U:WB)MYFUHO"%JNO
M6KDPOY9?>3[J?EXG*GY*MX[]/'BW,B8H\[QY@6O4=7[/:8^CCCS;V+J]/U]L
MQZ]J?5WQ^MPO[L/2^WV:7JEKCN*WI9_J^QY=(&HOIJZ#&?%HFN>-C-5RAG(4
MFAS%+O'9^GXBCI:D/2%]G5YR+?341M<3):VV+8_O&R7'Q567)[T51QZ;<U%N
MRX)+/1W$["3F$(EC?EF1*MVX%BC22RTD0X*"&"1B1(09)DP*KA<$23W'^@S1
M+!>YLRJD<CR<AQ+,H3ZO((\W;OEN_$ON(BVW<L?FHN-:+"\[9BKJ<M<U<()&
MCU>T[?K3('04%%,V"UR@-+C-Y#@KG6P2<CT8UCHP]3*/^404,LPW$ ZO^,,*
M?.WN I">N%Y(%ZF241V]ZF6FZA,RR62E,V$7,0D<H6 S*=281Y&P)/L_L_4!
MX%0:@Q@1&/5CG4ZIHZ::.FFF![GJ'F#2\+Z6GX+M):KD&>WPQ#'!W0^9M[7&
MU^]S-CR;F,YJ"A3!\OJM;QL+K,SEM)(P7[$T%M76,=O0RCLO:VCACA:Y D0N
M ;%E!Y'#QDJ#9G021-*@:)986<2I>,J"V5N4<*3R Q4@'W7 /HK%)!&Q$ABE
M"F-ZM:3"?%]QN:JDQ'Y"Q:S7;A#=;)MN1DVU!ELJ!QY@,K20(%OM!R9K(_<L
M(M=I+:&BY%TE@'KJH*(NPW]'=%VCY<OY@H%C%4..00*@[70QP(IP0E!N$=00
M6559#)+*H>07F\96*]PRR0(U@03!^DJR2=W&3#/V%X+ ,S!RL<;A8M/&98?%
M;LP;NP3/Y+-/-H:\B@S]+8\06MQ3NGY]MEUX%A8WDLM&7R&%V[_DLWBN2*8C
MC9VU7:MY(+-1F7FE/ED^'"EY"O:ZQF>H, %[W<1^SK4Y&W1#F M4=Z"UA<"^
M*@DDV+=" 2DV ./5ZY@Q ;JE!,!!V3QM=\9 ,"2]9H>%;J[CQ:?,8*H Q=/G
M2]O#@*.OF2CU]T+870-87N[35WX,]W6G,A9G,D"8$VIGOQ+V3[S CR%GY4\J
MI_294QAK7PZ>U"-9.6%14B5@5RBL<+)AD/*"0_?)?T=99"G'U@?<A*T=@C0P
M-$I5L)+&.V]W.#N#^._VR,=-'S>RFFAY!_)]:QU7-:069\(942TKG4Z$F4T=
M:78MJDBK664Q; AQ1FQ#19'PNN'_ !4.=KV$W23KA<O-@)NH$O<XVY/?6%,K
M-GQ];-A>U^CUGZ&6/&?1Z>=N,\K<:>[JFKZ.FFCIIHZ::BKW;<3\@\N8S#UF
M"@IM!%F>20M7M.--)R5MN(,[RSDHL;ML\S'W'(G'V?U>EH!ZC6:+*\D"QQ9N
MX NK+! T-D..)9OL0J,I+QL "%SN"S)9FC94D!4$L8V/"FP%S(I$L<9%U8!9
M%/!8( 0H8^66-V7DC$.BLI(O>^# QNX,  >Q7NP'XYV^)UVWKN2MYH.)\!E@
M>X-O=+S?A-PR3-Y#A2FT'&\.)*XRY$PK*&TT. W.@BY(U VV.NB->\G:<=7Q
M.AVS+6SW*E026#0F26RJU6R5$4K3R16:.!F5&4T\1>( =))$CGE* RYY8A4(
MGQB!+"E66&>-(8Y04DG"-(EIY DEP96C9XHE*G,[/>^&QS_:?5&\V<=QQ<*U
MV> MP\[I^8\]=9PVKW/#^FLM-8;<^QU07<+=6.$X]WG#HPNAX[X=H:RFYCTU
MXE0>((/F5K,K.Q*L58TKPB5+H5=J:GC91&YFRZTZ3$U<KR5$4;12*DE0LLDR
M-D12"EQ[4)@CV<&,35+*&=!"1TTEA;H1JD4DD3(&AB,8BF/V-<)\D]O7;GE>
M*N5+Z#0Z;/W.OF'*;K9N0#A<_::6RLL_777($^!XLDVUV)6DPML=$_CO*2DR
MO08D2R*$GO[?,S*5C %BJN&LH5>9I70*H9K81/'&S @2.CR*D:N(UQ $-(;^
M5F4H";D 11HY)LM\Y5DD46\B.L9+%"S2[ZIJVCIIHZ::.FFCIIHZ::.FFCII
MHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIJ.?=3AM;R'
MQ*+G<97.N;4;F+MNUME3-+""6XQO'W<7Q7O>0:OW[$D0)Z'83-:,=1""&,L4
M>M=X>XI(WU(.<)M<)40N1VMBXPD+#S**>3"I. +MT<%!+VU8$!9@?UJ>H0?$
MEX77 #L3("8AE91G=B "14O8?#/[R+_/GBP\W9'BS1VI?--D)887FGG^_IN.
M#M_5Z" &#C&HL*/*E5=#L8;BHRNZJ[6U.M<Y!E'\D9S2W^XV%@/2U1"A@N1)
M'#'3B2%A9:@1R;E)44KN+M'35+UT.+*K24\5#2Q8S/$DZY7E#F8XA6DDE*.+
M%H2R4"0U(6RJ]3 *25F4XQ32U4SDQQ.U.<#5\!_%QXLX_P!ME.#=5E+:CSNF
MKRL/EX>3K)Y'Y-<B<@YK5W^&PEQIZ4&\DPO!^5EO^/*:XTFEQ>VO:)QECEJR
MD.J\Y7FPQE*,"7=AC"C_ %:.RI1[6.N0+HEYZ>M5 >H6DJ"TZ/$"9(!B#QL%
M508S+(GG:,2M5[D3#<G-B8):-G*X ",+"Z/Q').J[7^\O<TL._DY=T';]RQH
M2>/J/61KK,YL-9/QWQ1D,A19C.7VNILG=9S0SV&T,YUY)-)!JZ@<FQY2@C(K
M@$A.JX,S*HJ R&].U7/+-'Y@3"VX44:K"3YDRVBB<1Y-E%55COP;E**X,!5E
M/66&!(I#8@,*.KDD+C@$C<JJ+)@@ZE/1HI#+976G;#VK\[<-]Q(V[Y)U(7(4
M5S@N9)-OR,(5#$3HM)J*;LBR&&KKL*06I-L;T6#M^Y0T1UM#3150;-- P>=I
MUW9"PXH%9(@CVS$,(E9>$GG:HKIY)$4=EA:>3RL$ ]KM&"$8+,S*[%E)(-0[
M1!KEH:=*:FIQ&Q)L6FZ4)R4L3[)]81=,K/.LFL>F?[@>+I>:^$^3^*![5E&9
MN\;<T%=<30R$BUUH2,YU66>)%)%*;616,8KK0%DL;CJ_YD1)&+-ZDJP-XV6V
M44T$Z \*ST\\<Z*Q )"LT85B 3B38$ZL"/.K7QDBFA8BV02>)X6*WXR57)6_
M&0%^-0_N_AK8#7;ZWY'VO-'-6FT-[RE#R'9?-+Q(+'+F(=3E]?'PDTVOXH#M
MXN)1;;"8AM:"+8"ZVIAH32*K6@VVTWUGJ"(J=,"[=,2@E@%,K25-!5K+*$L#
M)'/ME&8R+ 11+3$-3I'&DM([=3LO4"@ >81**>MI7CC+7.$D.X50?($F20SJ
M5F9V:/\ =?!SR!7SF<JN>^6H>/R^*A<*?5V+N/WWFC/RE%@\1Q>!H;6HXYJ)
MQL?Q_@^,<-3!OQY&5VUT?3SVVBU5P=9G$2U*$QSK?)Y(G568"S32P;K3S3R@
M#$L4W.3!$40K;F(XKJ>H#) Y!58INH54D6C6HVVHCAC))8*)-O4L[,TISL)!
MSKJP'P<>/+7A,[CKN(VDFOO[^VY M[-F RO&N9Q%$5M<+W'\<0%93-1\9UN?
MK[BIINXZWT\%K69//B1[O%8*X$I!AZ2Q'OKNJ.P<@EPSMD3R"]3/4J%O<CI&
MIFC5K@E990%CC=(HJQN4XQ1E!CLK*",8X:6%E/ !644<+.I![ %G<-(\G^./
MA[\=</\ *6!W?'6@N:VER7).MY+)RQD-+%70%70O=:RFRV7#S])1#4N6J">[
M_?-C#G4U(:C(X6K'B6:"ULC+(2I<]PRS'XD22Q;33^O'36#:ULMB1+(7!LJ!
M(<YJHM8JL,?' Z<51N55?U/4:;<&!8$ Q+B1=G+V#=1J-'3355/)WPLL3S;J
M#[_D/ECDJM@$W7<Y;9\#%V&>B%(QO=5@.0\CR%5VD.EREZ14Z.%.4[NF'N*"
MQ:/89/&8$.Q$?-7Q1U>-$PB$8/FZ=5$6]ZPJ*^MK48!N,HS5J"I!21H(>HKK
M&HUF,QZA< 6SI),>US3044)5K>\K^QW!&+()IL"K.[,C]C\)P0B**_Q7/>U@
MY"?R!E^5#[;1TF)6B(Y39W'F<X[+DJ"LK,FZ84Q];JMO09C!I+)BHIGYJ6V@
MGG#LK0[("5=66P FIY;-YL<)]MFJ".Q9I?T9 4#'%"TJ^XZ"'&QR4JPO>&6+
MCRY?T:MIX ;"RB-:V1795NX6-B.H',J'XL^$4=@^>;/3V?)@-MQ/%Q508P6U
M?79V3F3:7U*SM6(!38'A\=44-5C:"][8@M#2YH78Z>IBM=CHY*6FR4%I9#%X
M#3J\#4[,P3H-3( 2<HVI#3I+,?+G-"^+Q%UDQ6*"-&C2+!LZ5+1S),JJSBI2
MK8L+!9%J))7BC N5AF25TD"LER[LZ2,^06V3^#MPQQ.&*=Q%>MHM!1TYC*L&
M;*9:FS.DN1\ 1D*%FV9G:>$TRH@LS[W1%I!',3'8[#7F"L4F[.<5>9#*DJAL
M3(*WMP%-8F^QW %K=&+?&ABM:T5%2QBRJ0,=/*('A;$-T?9A<\LRT[;4YN3R
M3(^UB1[GF2IG<^8@ZM5XXQ\?'G'F#P$-B7<18;&9?'Q6QZJIUI'F:,&E98FJ
MKGJI9S0D)(57N59I7KZG?BNS/)UIII;8]6623'CRYN6MP .+VX 'R&M:&/I1
M117+=.-(\CW;!0MS\S:YTL^L6LFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCII
MHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCII
MHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFFJMN7<]3V9U437W,DX!,HLL
MD$(+H721.]+EC60^-ZL5?WJNC:OC\43JA<"_?@VTUKOOPS'\67W\Q7?TETS'
MS_/WZ:/OOS'\6WW\Q7_TETS'P/X?QTT???F/XMOOYBO_ *2Z9CX'\/XZ:/OO
MS'\6WW\Q7_TETS'P/X?QTT???F/XMOOYBO\ Z2Z9CX'\/XZ:/OOS'\6WW\Q7
M_P!)=,Q\#^'\=-'WWYC^+;[^8K_Z2Z9CX'\/XZ:/OOS'\67W\Q7_ -)=,Q\_
MS]^FEO+M*V+))L7#'+7+'%)\NC!_G?3,>RO:GH4A(/*3/1[OZH\>VBJBJ[PQ
M9R%LN;?CWMII$??AF/XMOOYBO_I+J,Q\#^'\=-'WWYC^+;[^8K_Z2Z9CX'\/
MXZ:/OOS'\6WW\Q7_ -)=,Q\#^'\=-'WWYC^+;[^8K_Z2Z9CX'\/XZ:/OPS'\
M67W\Q7_TETS'S_/WZ:/OPS'\67W\Q7_TETS'P/X?QTT???F/XMOOYBO_ *2Z
M9CX'\/XZ:/OOS'\6WW\Q7_TETS'P/X?QTUMZ'E>@T%L'3A@V\1)KY&1R$PA-
M@:L<,DZ^XZ(Z5Z(K(G(GIC<OJ5OE$1?*2&!(%CS]GI]^FNW1\HT69MB:<T&V
MF)&; ]\@L0;X7(1!&0ST+*;#(JHR1$=YC3\Y%1/*>%46 -B#^%OWZ:T?WWYC
M^++[^8K_ .DNHS'P/X?QTT???F/XMOOYBO\ Z2Z9CX'\/XZ:/OOS'\6WW\Q7
M_P!)=,Q\#^'\=-'WWYC^+;[^8K_Z2Z9CX'\/XZ:/OOS'\6WW\Q7_ -)=,Q\#
M^'\=-'WWYC^+;[^8K_Z2Z9CX'\/XZ:/OOS'\6WW\Q7_TETS'P/X?QTT???F/
MXMOOYBO_ *2Z9CX'\/XZ:6])M*V^H+'1"#'1!UJFI-"0P=I+U!$C,E]IL9$L
M2HZ.5K8_7,SR]%1WI;X<M@P()%^/VZ:1'WWYC^+;[^8K_P"DNJYCX'\/XZ:/
MOOS'\6WW\Q7_ -)=,Q\#^'\=-'WX9C^++[^8K_Z2Z9CX'\/XZ:/OOS'\6WW\
MQ7_TETS'P/X?QTT???F/XMOOYBO_ *2Z9CX'\/XZ:/OOS'\6WW\Q7_TETS'P
M/X?QTT???F/XMOOYBO\ Z2Z9CX'\/XZ:/OOS'\6WW\Q7_P!)=,Q\#^'\=-=L
M'-6:(GA@977B/FECA:KH*_THZ1Z,17*EBJHB*OU\(JHGGPBK].F8^?Y^_33P
M]7TT=--'331TTT=--'336GT%V-G:@RY,BGF&"2%98QFQNG=[Y$(S?;;+)#&J
MH^9JN]4C?S4<J>5\(L$V%]--C]]^8_BV^_F*_P#I+JN8^!_#^.FC[[\Q_%M]
M_,5_])=,Q\#^'\=-'WWYC^+;[^8K_P"DNF8^!_#^.FC[[\Q_%M]_,5_])=,Q
M\#^'\=-'WWYC^+;[^8K_ .DNF8^!_#^.FC[[\Q_%M]_,5_\ 273,? _A_'31
M]]^8_BV^_F*_^DNF8^!_#^.FC[[\Q_%M]_,5_P#273,? _A_'36RI^7,_=68
M-4,!<QD'D,&BDGA";"Q[_P %D6,^1Z-3]*M8Y?U(O0.";<\_9_'37;>\KT.?
MMC*<L&WE)"?&R60:$)T#EDACG:L;I3HI%1&2M1?5&W\Y%1/*>%62X!MS^?OT
MUJ/OOS'\6WW\Q7_TEU&8^!_#^.FC[\,Q_%M]_,5_])=,Q\#^'\=-'WWYC^+;
M[^8K_P"DNF8^!_#^.FC[[\Q_%M]_,5_])=,Q\#^'\=-'WWYC^+;[^8K_ .DN
MF8^!_#^.FC[[\Q_%M]_,5_\ 273,? _A_'31]]^8_BV^_F*_^DNF8^!_#^.F
MC[[\Q_%M]_,5_P#273,? _A_'32SH-Q5Z*HM+D,8^$:I]_YB,F,=L\GL"H6_
MV6Q$S1KYC7TM]<D?E_T7PW\[J0P()YXTTC/OOS'\6WW\Q7_TEU&8^!_#^.FC
M[\,Q_%E]_,5_])=,Q\#^'\=-'WWYC^+;[^8K_P"DNF8^!_#^.FC[[\Q_%M]_
M,5_])=,Q\#^'\=-'WWYC^+;[^8K_ .DNF8^!_#^.FC[[\Q_%M]_,5_\ 273,
M? _A_'31]^&8_BV^_F*_^DNF8^!_#^.FC[[\Q_%M]_,5_P#273,? _A_'31]
M]^8_BV^_F*_^DNF8^!_#^.FGE:J.:CD_!R(J>?Q\*GGZ]7TUSTTU"+=?PQTG
M_&YG_P#=7K W<_:?WZ:2G4::KXYARO<H?S';F\;D\E"T-E=98>.SBT8X>7S^
M8CJLREG84E;)R7-FKD1MZ ;\_FK+B6DY"DL3+NR=R598!X>//@ W47L#549<
M\7$(KZ$SD!@X(]D2HR5>FACZB/%)(ZM-<E<3P"?9Z@*.0.J::K$88J4*GK/$
M0QS;+ILC(%)BZDT7?,3M(,XN<EK<LVSI,T5ND%XY)]W/?>#@1+#>C4ZSND'U
M9.$FY#,(CE^<SL)@ #F<?5:QU/Y6VCNP)D 2],CV4W(J>A1LT2W+?5]:2L4Y
M9M]3$1* &ZLOTU(P)D'7F3FXO#G7")VL%\V$=$W&(^MD#+<_4KVAN.Z^/BJ>
M76UQ4FX?J,&XXK,4F%?I <M<<48F\VZ92AM;V'(GDYWE^PU.1$CO[*0J+&UY
M!K)M);A@6-R/+J  %SG4F][A:9W@8@LME>K,<+C)2( Q+HUZ@+1@-YBQ,<9
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MCO+DD<GUZJ;60#N(H0W_ #Q$@DN?4YAKGU-SZZE[=28K[AGG,?PZ9F<QV!Y
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M$H$]U>H+D$%EZ]0(VL;."T1A;&4NZBRL<Q<39_1_^O\ _3X__1U3U_A_=?\
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MD6)"1M;MZ.P6,\=[/QZV/&O5MN\);GNE FXT\M&L,C2(J2RS+*3$Y1KJE.Z
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M*'UM_H?7;6\IA5H0*0]5)5I<3JM";-:^$TM!(HWR3-G&0>6,C[/ECG"$C]6
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M-)S0=T,',FBXT2KS6LER1X=^>?IPJ<^EH::6KL"_EJZSIA9+,S[2M!0;00B
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MJCCJJC"I>&%DIY76&8/ H&XWVIO;9FWR_'/*@QPI-QK'RD;XVIO F7==;5%
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MGJ,FQ@A&M9*+W84,2NF4=)'3#MEY&CI*=%5A.TP(#')BXX-B"K&X[7%^W'P
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M+*QTHP5;$=:M)(G *$]"5$=896I ZWMSEN%KVP0L.!8>B<68T:1&3!@Q#,&
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M$>7F&QV%3+75TR.,A(&&5DSU<]2D4<DC%854KU6R8=0$,.  64H#P"@L;DW
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M=6C$TH<(L1UPP0[[-D];+-\\I'51-&S"GL<C8&P#<W%[=@00/CW];<Z5TJ,
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M7I[GT:T9MR5 Y8W!4\<<M9@,0;D$ VL>_;QN6 *#YCV[$W!)'H.#<\WY%KW
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M/-'(P<>5BI8D&^!-[6#YW %];3+1.LZI4+&[XE5;($@J;=SY2Q!'-KW) L"
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M48#SL%" KS9>]AQ8GD>I&LTLJJUG(RQ!6X /K?'BW8W^/%K \'YN$NF%O<5
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MGPQE5RO]KUHP9A(\3_'YRRL<B>I/2QS;B.&165 $.&(255)R%B50D68GA.;
M<C6.:%&R$D2XJRHI:Q\Q(-UM>Z^IX-CVOWUZD\7R+<\=?!ZXPW5?G(=A<UM"
M.Y@)8[)QH"9N2KP=]X5$@Y2+#22.^U97-2!JH+^Z$C1.DD;YWN%'3UN^5--5
MR)!"S O(;8)TZ=&7X#N!QVOQR.=?'0V*FW_^4=NNT35(HJ>:ID=G5^GDL6QT
MTK4ZN2I4U&)B!Y*E[@$@:I/R)?,?(UM9W0.BM[[:38XN[RU0S3UF>B<ZWMX:
MB0J$8F>OI_9HZYQ)\%+"Z-DKHX)6-?"&L,NPU/1T21M!3I.(D*JQ.0FRY#@,
M2J@+8<?+D<:^S]]C\/>&J&BB2FCIMO:IB2H84IK"P2$LRM*5=HWD94M(UQ<L
M 1(RL'@H^4>6N&8LYF:V//[Z:JNY\9R=<%FR71YO()"5]S+3OMJN:2WBKL0
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MVTX/&>/H,[;A0U)8J*C+)[XSRF-)?\Q(+"]B,?\ N,_%R2S+)+AR(E$BV(+
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MJ6RXVHYKNQUV?H/LNN&GUCM!FK/.2RU+:EWR(=L%>FV]A4""!E@3^PMPV M
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M&>&15D5$]F=O.9XWCD>9\RJL <7X&:EK8HTPDM&XLZY26R1HQ+"_:Q$RMY5
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M@WY&3'BYUU6N^DJLVF@W\[1M[K5RTQFI3U)G:&C+].GJ8@K8B-6,K/&P#.$
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M-HC*6EDSQHEC!\FZ<>DRJH<LI0+(<]02@6%J<-(^8TE)/+8)WO3J@V9"9<F
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M50M96(R! /;5;^HR'9PZ[!T-#RF+>ESV=KAQ0M12U.6S5!?T%=7Z0D5F=HA
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M).CTW)X8E?$3%\@58C ^T;&L8@("49R26(D I,PCGPT]?6QH<X!7E0Q R>E
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M>'IY2K#H0A*B^;2K>5I2&3SL(G:0@N$C!M>SLRC+(2K-P%+$KZ FP'RN0 +
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MS6QO=(GGC&X^C_<>YGI\;!/+6M<C?K]53SX5.K1;V(E"B!L2#F,QYN+  XW
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MO35,4\*O4*\2I&!=.GTQRQR(-[ F]N]X\,_8\G=O%-I5&^(M#7@;,VCM]A3
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M<!&JEEILR, 0UW-V8LN-@-5'BBG1EZ-)41(H%@M1&3P_4(LT)0!F)# )[N(
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L57TH[QY7QYZ^<ZB7KSS36QZTLDN-[VZCL]KV%[7M>P^S7*@6 'P '[-?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g389734g02a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g02a05.jpg
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M$X0?$&'#F"(/\'MA*Q.*"<KF1GF3>[*(K"'$Q2T8C\WC=FG6A&W!M>W!+'7
MM]38;BDQ!:2'8SY=,?<1"A#:OR-,)J_;=M$JZY;@NMVGVUX,G<6XRH+RLJ"5
MT8KE=L/-L@BBMG0*&84ZC$35.B>*-JZ4M2-2],S>><>SLJ=T$R(2R+S+B (=
MF 3@(GM/.%6]ZY$V8+RIIMX3R&'_ "7I[RKS9RDSI)37)QQ,D$$' _8))M\3
M1/#0).-^/FB- TLDO$_F-!5?*5KVO"*4(B(TX,NVQ'[I\S$$C$,+,L\=#KDI
MND=0\L])]Y*^W4['R<,<J57($->Q"5NT@OJ?[@:2VX.4A9A3\%6851N.56EM
M":-;:*3/ZYRBBA._2-%%XR_/+G#H=&4S:4_P^&/SSY-B8PZS$^>$QS6R'=EM
M0,W6L$18"]S.[/;1F)/"]WR][3K>(J%_D_MZ(M%[KESB?%Y1AX9T7H>UH$02
M$N4ZT8S\FCP+T,%B#'0'S$JSJ%(8Q,*-"6:[R UF:$Z0LY<J3*7Y[,;D8"0&
MK%RLQO1J'=R$3@:A4I-0IC5APSCC$Q0A" 46E+DH]JNY7:_>G*:SN[:D51:.
M[M-UTZW'U4H;YM6\F4 C<AE<X=T<4DZ5CEZHYHF.44E;<X 0%PC/KBG LZ2D
M8(2C7%F]P<&1_E:&F?<=O7LNVOSDUB=^VRAZJ"Y(>\[?K_A-VW[<.W.T\O<4
M>9554RF]V3JTX+)&N05U)GX>&!V:9(P,M@QX+BA6X<6Q2J:,#<XY#9;@C7EK
MI&(@ CH0!!_I[=%36].3RWAV6FY#%+)*6;K2^0>0T/F[L+K-ZG5-\K<')#4*
M&5,L5;Y/*$*:;N!BB"21<X!>$K''UQ3@TE)W-0-6X%M94/ ^8!(#OTD=!)Y]
M>1Z2KT[U^3O>)K4NQ1@VOLB%D9=DV^VF=W"6CU*]D8$$A@D3G\AEDKK2'G ,
M11!F>X^EEBY'7:-T<D$82MB 4?5/Z<"DIW"4:Z.*?\S2WZGKB<^?LN9R7VUS
M<CMVL/>C/+^@$(8';=[N%G>Y]4_1N=I),X1]+,7LQN@-&+FM"U)D^7&KXTW.
MKQ)I2E='9@=UT[:6V..#F8S/ZX91SIX8Z- ^N)/TQ6IZ:\EYOED.W[=3 D-+
MI RBY.6G4;_8BB4V9599 :,<'$]VRE=5H)D:F1SE'A$2B4L!9BA")4Y)1)7I
M2E+7*4A9EXD<\*?!RZP1(QY8]CV4I;A>3MWH3TWEUR(I2V%X.476;5T.WU4H
ML>JD"5,EI8ET03%VG^%,V"LC:144:2KCQ"!&^.*\!Q1+@C:#<*,)R@>!\O\
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MM/7L4 8&Y"G03]+8:.OIC6SZ_/,JCK+#7*9%*F&.QU(ZHR88XKR2%93C _,
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MCM:W4'V'6.5*TC<+#Y*S%&Y99:$=@06V3%,D6MTC<"R&J-N#([N[:.9C2-I
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MEW+E\";79?9<Y.G+ZQ)FYA>I0W.&68P;JULJEW7%H2T[JLR8,G+.G4.P"-<
MT@S/$#I^ZH;MJY-K>G4+9R%A,HIHM0=R=KOO66;@BF6QJL5Y.3[@'TTV"9@0
ME<U0%R092,05C^!8-D]W@%ZE-EP48R5@J7M/S(!_/PQ@,(,F<?:56B+\A_O'
M.K"_[498,STQOI@6_65[V=GL^'.:Z?H](XQ*E\<,74O82MG?'<*99CW'E\3%
M/;2NBB9U+]UEOA;/*):$XLOF"0#);P!CAA.$XC'RZCT7HCKZ'7!>4S> [M=J
MB:/Q2W]HD)J.Z6-5,ZOG=;CG#9(+%<I[%42)LFCA*7B#/B.:%E1MZ4,1#CC
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M1:']<A<=;GJC_)36/[/87_+;;K0[F?,^ZWMY#R'LL,W0 D(]M]\8B++*I#+
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MY@L4DON(8*Q827I-(VZ'R]BDDM,8Y;"F1XA#Z3DK'W'/EO/^JM];SXRL\72
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M .*L'_\ 1W/^]C._<K6G6VPJWD]F,E<X@S?&'N!%06>256VS&-IUT5C-AO\
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MH9/A-C3M<.+:GH$>!-9-Q[+=MW6%SW6*P6*QNJ -J.LMEH6=SV@R&O-&FPN
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M=/EUXRUN*?YD]H(BVFL3*';Y8]V*B #BD:9XV4VN3[6Y,3*<S(^8K1,TJ-$
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M25F2R-V3GQI,>S)7,*7&7$!):]62,)D>1,%8$P7S9$EA=$25NL,;N[OE^RN
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MB^SK-0[:IA$+=7$*4\A&E.C,X>I,[,3>X9=G!N.<E.(PC7JV?#DB Z%+U(W
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M>PM90J51:+?5;5BSV=[V,L['GB)K5F$M%)M6I3X[K=96N8WYS'<;B):YI:R
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M\_96I:6EM86MM9&9$G;6AG0I&QL;TA>"DJ%O0D 3)$B<L/S )3D%%E%AQ]
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M)N=EVU11)DEU5J-2KGI(3+(CI\5<!-[6V8<X_(D)R5Y8Y,N9 KG)$0L()!C
M@<_XN6'/S5BJ!WIU/N2L*RZXK9NE)[O3\HL."60M7G00:2'SRL92U0Z20V2-
M3'.7R7QQW6/#@O,B"F0QAJ8IVRQF1R*'/#VQ(TKBN+$B([B=??Z3BK>:*)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M#^N0N.MSU1_DIK']GL+_EMMUH=S/F
M?=;V\AY#V4A:BJ:(FB)HB:(FB)HB:(FB)HB:(O@T C"C"P&F$#&6, 3BL%9-
M)$(.0A-+P<6<3DPO.<#!@THTK(L8P86,'.')%K$C_)3TJP;8]W6U'%N[@76O
M-Z%EV/;%JO3F[5!B:LTLMI8U+9^*".+73+8Q-+:^B9TA(43[')+EK)R=[G.;
MSAX. 67$9!PEH 'T$#12@OV$0O%ZU5N,BEP77 ;2KR@FS;#*'J+KJUR3<M*L
MS\1*VN-V*WO=9O"!N=T,E*4N:.7UDFKV3H N[NC;7-"G-08;BG$8X<(F?(Q&
M!YZR%2K_ .X;VV*XM*XG(+YW1RM%,:$N+;L].4AD=1*Y(LA=QW@T[A'5X<Y*
MGII*^2.;L]D,R)R1RZ5+GUX=$@,-4A4.K04G;R7HLN,\X;@01$X$=ICZ<E,4
MBY(:F)?);+F<IOC<P]RRV[@VE7C-7L]VHU*8KG>S-E R50- B04,E;6UE<22
M4BF8M)"/);@H1)B6,V.M^5"%1(Y]S/MLH'$<@.1'7D>?5?V%<D33=7W,+<)5
MUZ[D(+<2VV]Q=I/TT;G6F'!1(4.Z.0,TLM*LW)H>J3<([F!!E+$BD$0]6T8E
M\7<A*#4TL4!$F EJ%Y(@P1 CM @'GSC#'#LOR'R/&WE0^X?%MJ[B%^1[JMP.
M[Y8VJY'58D+A9FY6O\UG8K,L/*IXEYS"BXJ:M(CZ%.[)Y$@6N"E>LD[FH+1"
M2$XCV& 'T!!]P"5-"/DZ:9.V!G\G-,Y99UBT>;6*2I4[])W2)([$;(LR!;\0
M\38Z12&1N,DN<*-9F58Q+%,35X5+VHE9)"G\]4XB6DXCQ<6$S/:>NO\ HH/>
M>2'K:0SV36H];F]TRZQIQ<6V*[IN_B<J)+;)7+=I\%<:_K1$]PP%$8AKK'#&
MAR]Y/#*\,;FF-D[4P25%[$[M05)Y.(Q$" "(QY$SG//DNDK#DT(Y63YL_HDB
M(+Y;M\V,S]\W$TC>4UL=B6VLHL.=J[Q,EM3/<1B]=1%.7%FI^G\&FK4]X<%I
M;^"-80/Q@%34B3N+[U5+IXCU=@1&',&?/#+#G*M[4FR"J:CW#2O="W.<BD%P
MS*O'&L9#)W=!!VM:_P 8<9LDG 1R]9#8=%U\\?V54V,\<C4HFRM^D+/#VE,S
M8<E1ZIV<7$L9,1TF?3]U<O11-$31$T1-$31$T1-$31$T1-$31$T1-$31%&]-
M_DAJK]F\&_EAKU7<SYGW4;R'D/921J*IHB:(FB)HB:(FB)HB:(FB)HB_F<<^
M,XQG.,YQG&,XYN?'/_OCGQG'/CZ<<^,X_/C./FT1:T(]R6].QZF]\M'@MZ_G
M2*<H'8%IV;=KBYNE08D3+++F0I6J?JJY5-E,MC8Q)75I1)FU,B?FB5$-9)7K
MV_"=>,:P19<1EIZM  ^AD+,W'D]X)BR]O=R0^XKOKNT]O]$F;9 3B*+JQ&ZV
MG19JAC<LPBRD4@J][CV1$/T>02! _P %9(0^-KL:M4(%J?(T>$)3B,$803/D
M>W5525<AMMV=@2HF17IN=DY$P@.ZZMG@;[)*G6O"J.;N7]!)YN<X2L5/!ELB
M?XP^-C<NATBE;X_NY!3<V,;TJ>8H@(CV"RXSA@W M/(\V\NO+/S*R]TY&JCG
M]/:7Q'?NY]Z=+B7;/'.;/9[Q129::MV/F*CZ7$TD(Z#(;FQ.8H5B,EB7V)06
M[ )3)D&6A,6(HPG&9D #]6?^;F,25WL?Y(RFX/=BC<97%Y[C8%=2V_=P%]JY
MRTN5+.1QRC<XW1)NMFMC&&0TF[1=972S$(CKC&4SNR.DKBSRC&Y-TKR:H/ 8
M4XS$0"( C'IR//GFOW'R0] G2<V3J[6W#K35.\V7;YEC8KD=7'-ZVWYM6Q%3
M/C,J5<(0OYD#,A1'L)#;A[#)@+#3G0V6GN&0'@*\9&7Z>&>TS[X_T4N0WDZ:
M8C>PMQY.R0RJS;)HE?73Q5A;G,G6)IY\U0]P!D+0E:G>'PV*L9*V)F@2KF!Q
M5QM:H,<TA:U\R\B-4@.*<1XN+ &9^OU5?W3D=JN?)%(9L\;F]U*V<3&9;1)K
M,'[+I1)2&4N&RMJ?V>GVR01$JA\1!^C@T\E<ULICD@97=D?GQ.QOJI!ES8T1
M^"O&<A'YH&,#BP/6?+%=?">3-CD!<MK6WLB)N4ZVX;5;I?\ =_7-VSNQH^.U
M6VXI=+[MD4DJ11#HI7$53KH,-ZL2-R5.[*W180^HB7IE?R"#F"-X<2A<3)P!
M(#3AT$9SECZ=K@5QL?JBN-S4BW;)G.1/]S22$3ZN7*1NB"#MBMRAT^L9CL<3
M1*'&(PZ-O,ZQ"#XQ'XC6J^;.3^Z1&#MXV,M<N-6*5XBG$8CI(,=P(WF.9./2
M+EZ*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M#^N0N.MSU1_DIK']GL+_EM
MMUH=S/F?=;V\AY#V4A:BJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBC>F_P D-5?LW@W\
ML->J[F?,^ZC>0\A[*2-15-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:']<A<=9I$MS=X-
M<5C+8AFWJ$+='V9"C(^&XB;ZE*D;DR=.5ZPY@,.,]626 'IFF#,'S>D,8A9R
M+./"T]/4[K+B<.OH-ED'RJ;ZZ=_9>&>7=.!N7J=TXW9^@V3Y5-]=._LO#/+N
MG W+U.Z<;L_0;)\JF^NG?V7AGEW3@;EZG=.-V?H-D^53?73O[+PSR[IP-R]3
MNG&[/T&R?*IOKIW]EX9Y=TX&Y>IW3C=GZ#9/E4WUT[^R\,\NZ<#<O4[IQNS]
M!LGRJ;ZZ=_9>&>7=.!N7J=TXW9^@V3Y5-]=._LO#/+NG W+U.Z<;L_0;)\JF
M^NG?V7AGEW3@;EZG=.-V?H-D^53?73O[+PSR[IP-R]3NG&[/T&R?*IOKIW]E
MX9Y=TX&Y>IW3C=GZ#9/E4WUT[^R\,\NZ<#<O4[IQNS]!LGRJ;ZZ=_9>&>7=.
M!N7J=TXW9^@V3Y5-]=._LO#/+NG W+U.Z<;L_0;)\JF^NG?V7AGEW3@;EZG=
M.-V?H-D^53?73O[+PSR[IP-R]3NG&[/T&R?*IOKIW]EX9Y=TX&Y>IW3C=GZ#
M9/E4WUT[^R\,\NZ<#<O4[IQNS]!LGRJ;ZZ=_9>&>7=.!N7J=TXW9^@V3Y5-]
M=._LO#/+NG W+U.Z<;L_0;)\JF^NG?V7AGEW3@;EZG=.-V?H-D^53?73O[+P
MSR[IP-R]3NG&[/T&R?*IOKIW]EX9Y=TX&Y>IW3C=GZ#9/E4WUT[^R\,\NZ<#
M<O4[IQNS]!LGRJ;ZZ=_9>&>7=.!N7J=TXW9^@V3Y5-]=._LO#/+NG W+U.Z<
M;L_0;)\JF^NG?V7AGEW3@;EZG=.-V?H-D^53?73O[+PSR[IP-R]3NG&[/T&R
M?*IOKIW]EX9Y=TX&Y>IW3C=GZ#9/E4WUT[^R\,\NZ<#<O4[IQNS]!LGRJ;ZZ
M=_9>&>7=.!N7J=TXW9^@V3Y5-]=._LO#/+NG W+U.Z<;L_0;)\JF^NG?V7AG
MEW3@;EZG=.-V?H-D^53?73O[+PSR[IP-R]3NG&[/T&R?*IOKIW]EX9Y=TX&Y
M>IW3C=GZ#9/E4WUT[^R\,\NZ<#<O4[IQNS]!LGRJ;ZZ=_9>&>7=.!N7J=TXW
M9^@V700S<Q=K5#XHUH)KZA"VQIB0(B/AN)&^I2(VM*G3%>M.83#C/5DE@!ZP
MTPPT?-Z1@Q#SD67"T]/4[IQ.'7T&RR7Y4]\=._LQ#?+VG W+U.Z<;L_0;)\J
M>^.G?V8AOE[3@;EZG=.-V?H-D^5/?'3O[,0WR]IP-R]3NG&[/T&R?*GOCIW]
MF(;Y>TX&Y>IW3C=GZ#9/E3WQT[^S$-\O:<#<O4[IQNS]!LGRI[XZ=_9B&^7M
M.!N7J=TXW9^@V3Y4]\=._LQ#?+VG W+U.Z<;L_0;)\J>^.G?V8AOE[3@;EZG
M=.-V?H-D^5/?'3O[,0WR]IP-R]3NG&[/T&R?*GOCIW]F(;Y>TX&Y>IW3C=GZ
M#9/E3WQT[^S$-\O:<#<O4[IQNS]!LGRI[XZ=_9B&^7M.!N7J=TXW9^@V3Y4]
M\=._LQ#?+VG W+U.Z<;L_0;)\J>^.G?V8AOE[3@;EZG=.-V?H-D^5/?'3O[,
M0WR]IP-R]3NG&[/T&R?*GOCIW]F(;Y>TX&Y>IW3C=GZ#9/E3WQT[^S$-\O:<
M#<O4[IQNS]!LGRI[XZ=_9B&^7M.!N7J=TXW9^@V3Y4]\=._LQ#?+VG W+U.Z
M<;L_0;)\J>^.G?V8AOE[3@;EZG=.-V?H-D^5/?'3O[,0WR]IP-R]3NG&[/T&
MR?*GOCIW]F(;Y>TX&Y>IW3C=GZ#9/E3WQT[^S$-\O:<#<O4[IQNS]!LGRI[X
MZ=_9B&^7M.!N7J=TXW9^@V3Y4]\=._LQ#?+VG W+U.Z<;L_0;)\J>^.G?V8A
MOE[3@;EZG=.-V?H-D^5/?'3O[,0WR]IP-R]3NG&[/T&R?*GOCIW]F(;Y>TX&
MY>IW3C=GZ#9/E3WQT[^S$-\O:<#<O4[IQNS]!LGRI[XZ=_9B&^7M.!N7J=TX
MW9^@V3Y4]\=._LQ#?+VG W+U.Z<;L_0;)\J>^.G?V8AOE[3@;EZG=.-V?H-D
M^5/?'3O[,0WR]IP-R]3NG&[/T&R?*GOCIW]F(;Y>TX&Y>IW3C=GZ#9/E3WQT
M[^S$-\O:<#<O4[IQNS]!LGRI[XZ=_9B&^7M.!N7J=TXW9^@V3Y4]\=._LQ#?
=+VG W+U.Z<;L_0;*BOQ]+/K;_P#HMOW/62Q7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g389734g02a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g02a09.jpg
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M P$1  (1 0,1 ?_$ !X  0 !! ,! 0             (!@<)"@$"!0,$_\0
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MSCRD\IY56GHOQW\3:_\ FY#]W7E[(5OY5-],J\>UK .Y%#]0U/1?COXFU_\
M-R'[NG9"M_*IOIE/:U@'<BA^H:GHOQW\3:_^;D/W=.R%;^53?3*>UK .Y%#]
M0U/1?COXFU_\W(?NZ=D*W\JF^F4]K6 =R*'ZAJ>B_'?Q-K_YN0_=T[(5OY5-
M],I[6L [D4/U#4]%^._B;7_S<A^[IV0K?RJ;Z93VM8!W(H?J&IZ+\=_$VO\
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M=K'Z6<7_ -I-/;"WNQ#_ &R'TT]P';3\SNV7Z#;0?X:GIKV%_CMVL?I9Q?\
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M]NVV?];MI_[_ ,5_BT]!6$?Q.8K_ $>U'^J-.M:;\G@^IC]%/;MMG_6[:?\
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MB)HB:(HX[Q?XHNZ?_9QSA_\ &5GUY*_X#6_-*G]B];"ZD?\ O6ZF/_4+8O\
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M)HB:(HX[Q?XHNZ?_ &<<X?\ QE9]>2O^ UOS2I_8O6PNI'_O6ZF/_4+8O_\
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M))*I3=UIE7MLY!5BWS$$^L<'&+LFT=)MTX:%"/)<_9X.;U^TJ0FBA8VNQ_\
MO:.T#\EW]);!HBR2Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HBA+D#[X)MD_V9]UO_'.V75LF^^]#\RK_ -K1+<V _P"X7JE?]2.I9_V/
MJEJ;6KFM,IHB:(H2YLVXY!W&R%CH>77N*9'"2>0,6Y!QI+0<#/Q^8J,M0IR
ML4Y""[>NI*"7=6MS#O(4MQB'L$]BJ[.S#-6"E?$($:6VIHY:QSXZ@T[J82T\
MT!:QXJ(C$YCWMN26DR%I;PC2TM8YS2QP-AN;8SJAX#U/:?#\<V3AVII]LW8#
MM/@&T=+6UU!/LCC;,=HJ_#Z&LX&"*FKHXL+BK(:PX15PUT-5B%#23-KJ7@WF
M7\3/;5DRS9$@,K92?8)6R9B2SY+G,-9&Q_CJ<@+(\CKK2;?2(:O9+3?6!VH^
M@8=I:_A2:B(F7.G8Y:%@'1'40>/?&FH;13/F9/4&E,].^9]/-#"]CR)8I(@V
M<%YNUHDS.:UUGN:PW;8YOM-U1MF\-V?K]EMF(-MX]FMJ\,V;HMK]G<=V@H:_
M#H:C!<:PC&JO$-G'0X?"V&NJYL*ZVHJNJI&NPZEK:^)T56)X!14SE+97*;G:
M?BVL[FW&*9R8@HVMHY@R#1Z,FPO.3FD'-M[0KCFO3\BDG(XVQQ*6./C)"SIQ
M;R5D+,DW<-8YK3 >++#\Y\-=6QP,K3 ]S6L%1-%%:6<-<'F%CR 8(7/ +\I<
M7BX:(B;JY[,=62FZFN+[38EU-H]J**CKJG$7[)8#C>..J,$V:EK:*3#&;0XA
M04[C3[1[14N'5%33X8^IAI8,-?(R6HDQC@6,60E%%%NBDW;I)H(()D1111(5
M-)%%(H$3223( $333(4I"$* %*4 *4   #5W  %@+ : #<!S+03WOD>Y[W.>
M][G/>][BY[WN)+G.<22YSB27.)))))-U]-%2FB)HB:(FB)HB\.SU^.MM;L-5
MERJFB;-!RU?DRH*=RN:.FF#B->E15Z3=TJ+9RJ":G2;H/TFZ1XXU2]@D8^-U
M\KVN8ZVALX$&QY#8KVX;7U&%8C08I2%@JL-K:6OIC(W.P5%'/'40E[+C,P21
MM+FW&87%Q>ZQ38U[+A*'7QZSOF5I]&+Q)M[+M]J<WB:7F:#>)IFSSF3,D+=9
M"?;<.*K)1814%%# Q+F;;.7JLS)A,MTSM&1;##@8:81+.^U/1BDC=3N=%(X-
MJNN&REXUC<,K&EC2X$EQS#0+J/:/V33ZQFT$V![+T#ZK:O;\[?8K1;54M)CV
M"44TVQ+MD*S!J>@EO'B=-4]=UU5U]5Q44D<+*.FZTD<V68USM_V19LVQRF6)
M+&.?1G5,O;GZQDNRJY9-:<B.E\+1K5RVL=>,N_E&QS9ALQ7*2<KD4YU DV43
M#,W:)!CVCEM]:3#*FB=4.@JLW7%:R9_7'"3'K8 A[-7#_:'BP,U^,&M!'%!%
MDV]ZM&QO5*I=E:?:3804+=DNIGB>S>&MV5&&;/1,VRJ98Y<.Q ,@I96C9'#3
M&]U+L\&@T\U5631/(J)8Y/TX([/%AAS(N!II2TLI&C;69#<_(X8C&S9TG.NE
M=S,^V?N4K8=8 8H$H%=-+UE@>.4>FLZL@WGG 5XS$T0ZFEP@4TU,[.#%1&M-
M.VQSGKUX<>$)T' MSL;8N+\P<<ELI^>W'5_GVOV>VYHVX9-3XWU3Z?J9T^V-
M5))$:*-O4VH):>)V%AAX>1V/8@*3$J@5#81AC*=]#'V0$XJXLF>KTN;DT11Q
MWB_Q1=T_^SCG#_XRL^O)7_ :WYI4_L7K874C_P!ZW4Q_ZA;%_P#])AJN!A/[
MC.(_R8T+_A6)U]:?X/!\C%^HU6+;/\,-K/\ Y+CO_=*I7.U]EC2:(FB*,^YS
M[6JY\N*_L"^KY@?OL_R;?UEKCJD_>[#OGK_V#U=K%GW.J;\@L?U>K?B'PZJ^
M6?YUE6S'X/X1\RA\Q5?:\:OJ:(L6>Z#M.X#9[N]Q'@3.>*75=P'EV-J3)#=N
MUN2CJFXZR-?Y"[Q5$I&6:JYIC%M36%M?X\M"<3<"7F6CTF[)21EF$9&,9IY$
ME4&W!(.HY+:GGMSV&I4K:]N:K<; VF?SG(8TPLTB\O7G%=3.\R@681N8TPCY
MV:0:*3M2HBZ,RZAHF:L+^L132Q!"P,1(2SB;<L&+]PT*+<VMA<Z;N?Q'2ZIG
M>1NZB=K>S3*F\:J5Z&S;6L<T.-R-%P\->FT##7JLR+Z(21?0%XCH"[,#MW<7
M+%E8AZWB9!A*D*@F1TW;N@?)$ N0-US;PG172BMR&%W,G3*I-Y,Q]6LBW2(I
M,@PQW)W2"3M*;[($0_F*I"?!R[EJ]4D[$VAK">L-#LV[VSH5R>=0K-TE#R?A
M"BQYEU'<_MS#X8XSEBLPP#HC&6*G>*\H=L]5N),=-V9$TWYCNG3O(9_1^R;L
MRN%GMZ37I[0BUC;.(U(ECS>N_P VJNC4;C4[]7V-KH]D@[=6),[Y*.L%;E&<
MS#/E(N1=Q$DFUD6"R[1=1A*L'L:\(FJ8S9\T<M5@(N@H0I%4FB)HBQ^]H=M\
MJN7L12&1K?EO<_C:*V_TK)V01A]M.?)_;^[NAT(!C*G;7*RP)!%PPC&]:63C
MG$F88N")+R\JZ16*0.@I:==+:Z:@'R&X^WRK&=V1MGV\R6X%DRQUN:S)G[,4
MEMSS*_RG4Y#?/9]\.&L-(UG/^/*E$MFUUF*W!Q*<_DEBWBK'09J+2AWT_6(F
MZK2->1C4Z\_<%4X. U%M1;B!I-P>8#P@Z[MVJV,]%0FB)HB:(FB+&UV/_P![
M1V@?DN_I+8-$6271$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$4#MP\=F:L;G<"YLQI@JTYQKU2Q%GB@6>-J-QQ=5)2'E+]9,+R]?<J!DNZ
MTYN]:+MZ--D5&-5>*(*$1!<J0*IB>U5;:AE=25,--)4LCIZJ)[8Y(6.:Z5],
MYA^[21@@B)U[$VTYUO'J?U&Q^)=37;K8S:/;C"]BJ_%=K-A<>PRHQ;"-IL4I
MJRFP'#MLZ2OB:=F\&Q>2&5DF.419UPV)KVE^0NRNMZ_K*;E_YO;.GZ8-J']^
M6J^O:SN35?7T/\2O+[G/4X_/[L1^B752_P DIZRFY?\ F]LZ?I@VH?WY:=>U
MG<FJ^OH?XE/<YZG'Y_=B/T2ZJ7^24]93<O\ S>V=/TP;4/[\M.O:SN35?7T/
M\2GN<]3C\_NQ'Z)=5+_)*>LIN7_F]LZ?I@VH?WY:=>UG<FJ^OH?XE/<YZG'Y
M_=B/T2ZJ7^24]93<O_-[9T_3!M0_ORTZ]K.Y-5]?0_Q*>YSU./S^[$?HEU4O
M\DIZRFY?^;VSI^F#:A_?EIU[6=R:KZ^A_B4]SGJ<?G]V(_1+JI?Y)3UE-R_\
MWMG3],&U#^_+3KVL[DU7U]#_ !*>YSU./S^[$?HEU4O\DIZRFY?^;VSI^F#:
MA_?EIU[6=R:KZ^A_B4]SGJ<?G]V(_1+JI?Y)3UE-R_\ -[9T_3!M0_ORTZ]K
M.Y-5]?0_Q*>YSU./S^[$?HEU4O\ )*>LIN7_ )O;.GZ8-J']^6G7M9W)JOKZ
M'^)3W.>IQ^?W8C]$NJE_DE/64W+_ ,WMG3],&U#^_+3KVL[DU7U]#_$I[G/4
MX_/[L1^B752_R2GK*;E_YO;.GZ8-J']^6G7M9W)JOKZ'^)3W.>IQ^?W8C]$N
MJE_DE/64W+_S>V=/TP;4/[\M.O:SN35?7T/\2GN<]3C\_NQ'Z)=5+_)*>LIN
M7_F]LZ?I@VH?WY:=>UG<FJ^OH?XE/<YZG'Y_=B/T2ZJ7^24]93<O_-[9T_3!
MM0_ORTZ]K.Y-5]?0_P 2GN<]3C\_NQ'Z)=5+_)*>LIN7_F]LZ?I@VH?WY:=>
MUG<FJ^OH?XE/<YZG'Y_=B/T2ZJ7^24]93<O_ #>V=/TP;4/[\M.O:SN35?7T
M/\2GN<]3C\_NQ'Z)=5+_ "2GK*;E_P";VSI^F#:A_?EIU[6=R:KZ^A_B4]SG
MJ<?G]V(_1+JI?Y)3UE-R_P#-[9T_3!M0_ORTZ]K.Y-5]?0_Q*>YSU./S^[$?
MHEU4O\DJUF=,K[I\JX2S%B^)V!YHC97)&+,@T*,D9'+^U<8]A(7"I2]>9/7P
M-LW+.19M7,BFNZ!NBJN*"9^Z3.ITE'X5-16ST]1"W"JD.F@EB:3/16!DC<P$
MVJ2; FYL";+)]B=E>ICLQMGLCM+5=7?8ZHI=GMI\!QRIIZ?9+JG]<3T^$XK2
M5\T,'";%LCX:6.G<R+A'M9G<W.YK;D3RQ;#25=QECJOS+;P<O!42HPTJT[U!
M?PLE&5^/9/FW?ME5FRW<.D%4N];K*H*=/6DJHF8IQND+2R&)CA9S8HVN%P;%
MK0"+BX-B-X)',M&[35E-B.TFT.(4<G#4E=CF+5E++D?'PM-4U]1/!)P<K62,
MSQ/:[)(QCVWRO:UP(%=Z^JL::(FB*,^YS[6JY\N*_L"^KY@?OL_R;?UEKCJD
M_>[#OGK_ -@]7:Q9]SJF_(+']7JWXA\.JOEG^=95LQ^#^$?,H?,57VO&KZFB
M*$6;MJ41N;M&X;'>><?TBX;:,YX"Q7B]V4UJE#7I&RT&VY?LJDJWKIZ6G&0"
MT8XR3$RM/ML;=W<S$V&LD?!$("=NJD4@VM8D$$GS<M^C=;PK&_B'LLMQN#4=
MA=@'+<-GBT;&[KOBB 97ZQ34&?+.+=RM-FZ%BJP2$X,%8BQF0,>5YE28NP1K
MQ@]8+0CJWMXBP.%VL:C/%47 YK"V;+NY"-X[Q.O1HKE2?9GYB@.Q%6[,JH7V
MDW',:F$!QN6]W*7LE?H!9Z=O8W2<%.28UBTV5.KUHD@_A*H0:R+U[%Q4.BZ9
MPW?K R)F&?-:PS9K#?OOX^=6;M_9+Y]M5CRY%CD"D,:MG_<OL(W)6.\)V2Q.
M;KBLVU*H0,/>Z'5&IJHT+9%GTI4(5#$UC-(5MLPA9N5/8(J(<UE@TMI X6&A
MN&N;T<:^OE-^\+='F1G9'9A!A<\?R4L+';Q>34N\CA*!W)7\LEM^S\TODUDR
MT98V29:>8V&Z85BX^U-*E8H#'%I5M5=G[8YG&]A<,V$9#6E=9"[HUY[#4;A<
M;B;$ZV!Z5F/V;XSS%AW;7C'&^?L@H95RY6V=B);[^D1L+FQJ2EQL,W#.)I\T
MA:ZE/VAI79*(C;;;#PD<YN-G9R]J>M_&3"YSE2X@DD:#F];J3>BA-$6&WM;]
MS&:-KK?!]XI.4+SB?$3^K;JH7+EDI.#)+.+M.V2.#GD9M\?)14?BR_M(V9J6
M5I)E?(U"VV;&M"L,55;'%VN>E4/"PK@JV 'FWC>;:7UY1WM->91:[(*]5-]N
M4OM5H^[_ "AGN-F,-W&YV.D6KLY:=L;KS>?8W[%L<UO3B?JV,L9J9$LY$)V2
MB4F+]"?4CF4O)/1<QAG'1)E+]P.4#6UP_-X-YLMC?1?--$31$T1-$6-KL?\
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M5&G=+N8C-KF.'F07>),WYP=M6TI)!C[;_2&EXOBL%7V?PC9+$=G+SM6@&,)
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M2;(X!38CA$M754+*B7&\%H'F>B##4WIZZOIYVQQ<(T&9T;8G$D->XM=:T?\
MTB/ G #ZHF\;CI$W/1M<\B@(!U&_[3?L@(B %ZN.H1 "@(B'/B.W&S8);U[(
M2)&P@"CJSFF<"[@F6AX\C&M)E:V_! .,F7*ZV8?_ .0^KR0#[4J( L=)<[3[
M- "-I X1U\5XK'$@,)MPEQD#LS;A_P (CP( "([0]XP=)0,;DFUSD.K[$HAZ
MS?V8\<@0.3"'(\< (@&W&S9+0*Y[L[WL9:DJB'<&+R/:>!L8H] ^8?<VDM;F
MS.:#!]B'U>@"3LC1@-8U[K[3;-@MSDAC7#LI<2/MQ([9W"Y#;-<1;J!_PC:
M<6N49VC89N AZ0B9T6%L,!D_ 5DM<@8J_2P+)TR1O55B(D[AKPL]*SO<YX!P
M(M4Q?$ '0P-N=FB 17/RF-\N8TE6&MB9<&5Q,(RQN((C>ZPE(/!YK&TGV(75
M[!(]J-'</;'8;3;-$F5UK1- Q4YI ""]K;E@[?+<7N,'^$1X$$0 -HF\4>1$
M ]C:YP/'/4(#ZS? D+P/4?GH  YYX\]#MSLT XFME;EC;(X&CK 6B1P;&US3
M#F$LI+>#A(X5^9H:PES00]B%U>B0!LE1$N<YC;;3[,G,6-+I"#V5L61@'A)
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M3O&+%V8W6BWZRE/8K"<PKKJ 5!!8'(M#D7W=/,;^O?TY.=%T'H.0W/AU$E$
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MA>U[V)O]@]>13IT4)HB:(FB)HB:(M!S?AQZ_V^ /9\]P"@FYY\RAC'&? J&
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M9JJA)RM5GQ,O'.&S])FJ!2V]P0";$;A?E^WRK6OV=8_)N S?MMK.!+IL0R/
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MG\U?UI]-$31$T1:#N_#^/[O?X$.0W G, <<@4WHPQJ!3F_"HI[RHI^8!R8W
M 8PCH_;\7V@=Q7'/10L%WV=+& YTD,1N!34PXLE=47#Y1P4.8Y(S%^O7L+C_
M .B<&HLS:C'7'BW:QQ=2M9)(#[_,;%E+#JUA$LF49I!)%[_U#D.!Z0\^3%,8
M0ZBE_ HY/Y=9_L4B\ 'F! )A.A:;Y'![ XYADB?%%VCI !]PPJ!V;@:< .K)
M<Q<'-=,V3K/5I&KFEKW 927/9)( 7-8[7A<0E%A+,26TT=@TM(C<QQY\![A
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M"D?>J\Y?-J[WSVXT+)%<N%LND#3:Y$SUK?K0$?7XQHE-.'LG85? *H,FY2P
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MY6(AWUGK\54BNU;!:J\R=%(!)L/7I_>HN[&]^N5=T=[GZ1F/;-3]OLF>EO\
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M2J\;D+WK];P;<BG3UMW,'U'BU\'+WT4L!'[,YC@(<)NE%'27!> ]E"5E4"B
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M6F%P.<Y[J&C<7,[(R.>_$ZM]5,99A&V:39,UEZYK31$T1-$6@YOPX#?]O?Y
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M$3/^%#>\CK%QWO$-:6N:QK9F2-DDIF0TDG#U<51.#PN%X;4%A%1CU8"'8[M
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M-$XB2I;?[DZ3MHZ?*TPQV:X!^=C/S']GG^%/4_MVHV?Q9HR>\-RXE""R _\
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M(F;ERQ9.C!UMHIL8.9R=,7OG:P&00 [DR395ZV\5^;0>O,BB-N!,0VX?LY#
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M)D<0&YK1_2B:V-VF4@\)! \\4-MF-;6.L"S.P')F:,V78"?QO-Q ^_G;?2P
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M#%A\)#>#A!#JIX87 VC<SD1#S$1YX]HPF#RZA\BJ*%]PCQR""''!0Y$P  G
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M/"JITV 2E9%JX8?"#UO,E'/?S=[Q_;N6-XA"F!!-)%,2J(O(5FVB'9D$5&"
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M0%%--(2"(N(INWB'/*P%$05?52JR"BGLK+"4'.2,CN%1,DF56/CUTE3,WU<
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MH/UZ]A=_N3I]6@-VHQYYXF9K#FI V6:_OS[\6EI@2,^:1S1J)8O<?^AB])@
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MXW-R^FI7NT=*1=V(XBXAL3;QQDC,:?K0D:DD7($A+VV&4:,GJ&"Y;&+@45$
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MV5SY6EL9C;VE34MWQT<?:T-"./4/L][>#X1\,C2PL0071M:PYGYW6+X('?\
M$J7[ZJJ/%@;=C3GR-EY_]@ 0, E "CTE,4O/4 '_ )#<G ]XH(\J'Z@ PAU&
M))-M29&D/;(7/8'OCDDL(Y)& $S8E/<-I*0 BD80Y^60,9- %[:-(+2T-:[*
MQS&=NQKB1P5#%8FIJ";U#P6MS,+G1N?+CD.! !]K@"B4O'UQ0 #DJ)1'A)+C
MJ4-Q[)A$I3+6( :X$%T361N:^1DCVDNIZ=Y.22MD%S65KCP-+%G^Z!@+XH)O
M<W:;M#RZ1I8PL:;-FE;8N92QG2FI0.$J) V["XM9+P(\<B(B' @<1$ ,)1,
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M'OV;)T79HU%TR>2I'"<I86ZI]Q)^FRR"3E1!Q-'*H[!N)FR HMUG*2Y+(?\
MP<C<**2R*?:/U1LBI'-H=(C79HB@+*'2<I.GL9'JDW&@NS0G%$A">715*_E
M54,N\[X$E4BBWKSZ6U7*W^#D[A''B2+=HW33MW:T>#EGZEC,C):+BT>Z85L6
MI-Q)425A _"YH-,I&3E4O2[(NW,= Y+;NCO>OB5\MN?8E;O-L>98[.]![1+&
M$O?HV+N40DXN.R1>48+L[N6-2DBND(S=!".E08-8EFSA$0>D:QS<JH%;JJKJ
MJG*5DC]"G:F_Z_.UO_=^VC_G0T1/0IVIO^OSM;_W?MH_YT-$3T*=J;_K\[6_
M]W[:/^=#1$]"G:F_Z_.UO_=^VC_G0T10*R#V06^#(V6,B9BE>T?Q;%V?)UCB
M+;8V,+L; E?2L<%C:AXIBY:+CY;<Y+N&KEI5,=0 (=\^=)H2BDE)-TTE7*96
M]MK,*I*Z5DU0)"^-F1H;(6M NYP=EM8N!<ZQY+\X!&;[,]4':+9*@K,-P9]'
M'3U]2RHJC/2-FFD 8R.2F$Q<U[*6H;'$*F)A'#"-K7.R%[7TF3L5-ZJ9$RI=
MIA04A;Q[E@T43V/, 59J/C+&DY5LH;<:8Q)N3!8R3V7,)WBB(&234236=%7\
M?M<PS3BS: @?=G7!=?,X$B^=U[%QN;7 (!-\F/5NV[<7E\^%O$M3%43M=AD.
M2=M.V-M)1RM#@#A])P8=3T30V!CR'N:YT<)C'[%/>B<BZ9>TKQXBFLS:1A2-
M]CC!$&L0W5077BF9B;C0.U92BJ!3S )'*XDC&$SAP8R;<49]KF&:\287:&Z3
M.%FW!+1S!UAFMJ[E*-ZM^WH<QYJL.>]D\U6YTF&P/,U;+')''63AQ(EGI&2%
MM$7@QTH:!%& Z42=U>Q6WI+=Z"O:4XY42<.FBSIN.Q>,!NY:1Z1TX^%60+N+
M*F, S.<JZ4.0I&1UTP%PFNFHNFM!V<PPWNR74MN.%=8AM\K"+6R F^0:7W@W
M-X9U;=O(\A95T#7Q0S1PR]81F6*:I>UU37LD<\N[)3M:8WUSBZ=L;B(W,<V-
MS.Y>Q:WK@LDX4[2['KA5.25F%#.=C4<L#N3$Q3,W;P#;C.')X@"%+#IJ *,<
M)2+() X2263GVNX;<')-H[-K,XW=R$W&N7\6^@WC54NZM>W1C=&VIPZ-AI64
M31%AT3.!I0")X8"'?<A6DEU<YEI*J[F2/,3WQN^*78J;UT$T2I=IG0RK-T'Q
M4'8['8T[M.1D4S).Y_O5-Q1N\GU$SF(225*=1NF/<-R)-_K6H&SF&@ !LV@-
MCPQOF=H7WMVY_I<@T%AHJW]6[;F1TA?-A19++3ND@[&1-@=34KVO@P[(UXRX
M:US0YU*PM;*\<)*Y\MGJY.$.RAWT8$RZPS33^T5P_)6N*Q?<,1Q;&Q[&'+FN
ML*I>K1CJX6-1&,B-T\(LI-/)K%]86&5=/7"IR#)=^1=9X"R/OHL-IL/X3K8/
M:)1&'!SR\ 19\MK[B>$<7'4N-B3HL0VJVWQ[;+K-V.RTT\M%+6RQ30TL<$KW
M5PI&RB5[.WCC914\=-" V*FC:61,:UQ"FQZ%.U-_U^=K?^[]M'_.AKWK$4]"
MG:F_Z_.UO_=^VC_G0T1/0IVIO^OSM;_W?MH_YT-$3T*=J;_K\[6_]W[:/^=#
M1%BARSV ^Y[,F6LE9FM':+4%C;,JVL;E:&T%LL,UA"30P<-7Q/&,W^YB3=-&
M_@()B((JOW72X[Y0AR@KT%QO%-E,(QBI?5UK)W3R11P.='.^,<#$XN$0 '%8
M]QO*!;A"&YR0QF7>W4^]D9U3.IEL]'LQLK5X1#A45;5X@R.MPB"MEZ[K P2R
MF:1P<XM#&\$""(N-EMF=>@O^CA;A/YR&J\@40 ?4S;<@)A#J, ^L5]F;C@3^
M\0\N?(./ =@MGB23%4D.D8]X-2XM>(P[@HG#+8P19KLA%F @7!UOFW_^S.K>
M  ,1V>&5CF-ML_37:7EI?(T\)<2ORV=)V]B0"-+!_P '"W"" A_C(:J')0+Y
M;,VP<%#WE#_M%>0&]Y^/,P\\CP(@(;!;/YFN,=6XMD?+QJIQS2NT;*_B\9\0
MTA+KB*]V .#2!]F9U;B".R&SH!8V,!NSU,,L8O>-GW3BMD)O*!K)N<2"X%_T
M<+<)Y_\ >057@1 1#U,FO @7CI(/&XGS(' <%YXY\_> "$>T'9\  ,JP6L>Q
MKNNG9FNDN))02TVFD#BUTO;9>(+-)!D^S-ZMQ))K]G.,]KG#VNTN4AEC'&1P
MEN"81<1BS2[C.N0"'_1PMPGD(]I#51$!$WGLR:CR80X P\[BO,2A]ASY%_ '
MF/([ [.D.:(:IH+&Q#+5/;DC#@YS&$"[!*0>&(.:2Y+G7-Q(]F=U;[@G$=G2
M0]TA)V>I3FD(<&O>.$LXQAWW($966%FVN"#_  </<(''':0U8!#JX'U,VW5U
M&'DQ^?6*YZQ]W5[P#C@0X#@=@=G79KPU-GEF9O7+LKF1BS("W+;K=NAX$ ,<
M19P<-% ]F;U;Q:V([/7:'97>U^F+@]YNZ6YDN9CJ.%-W $Y2#8B3VTKL=-YN
MS*^V_(^)NT-Q)(V*[4^,H\N%UV/OI>/2A(J:7GFW@6L3NH@#(O#/W"@K.5EG
M '1Z4P3((=6K[A."4&"LJ&T391UU*)IGS2F5[G@%K1F(%FL:<K6C0#I))T_U
M2^JWMCU6:S"J[;">@FFP:DFHJ 8?01T$;()Y6S2YXXW.#WOD8'%YUY-U@)^^
MA3M3?]?G:W_N_;1_SH:NZUDJMH>)>T:B;I5I/(N]/;I<Z(PG(YU;JE7=DMBI
M4[8Z^BY3/*0\1;G&["UH5N0?M04;M9E:M3J;!4Y7!XMZ!!0.13WT1-$31%&?
M<Y]K5<^7%?V!?5\P/WV?Y-OZRUQU2?O=AWSU_P"P>KM8L^YU3?D%C^KU;\0^
M'57RS_.LJV8_!_"/F4/F*K[7C5]31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T16PS7EZE[?\/Y/SCD9T]94+$=$M.1;@YC61Y&13KU1AW<W*_![!,R9
MGCX[1FHFT;BJB15P=,BJZ"8G5(4@$D ;R;#OE19M7:'8<H3W$9[[6;S4Z=F[
M(5=Q[0<L.Y3$,IB&14LN,<@Y79W ^1*[E:8@345E6\96II+SK)9\O&3"#(CB
M.")DF,PN0 F_0+GQVMW[D*6R66,6+O:W&(9+Q^M(W&*9SM0CTKE75'MJA)&.
M?R\?,5MH22%><BGT3%2DHSD(Q-TT<QT:_>H+';,W"J918\W1X>94HRW)[=9)
MPBTCL^X5?NG,E7(9NV993HSIPO,7$[M.HQ2**$ZHHK)6E1@^)7&)"F=3AV3L
ML8DZ,V6 A38\Q_TW^)7"L%WI=2=PC"U6^KUE]9GR477&5@GXF%=V"36>,(]&
M.A&\D[;+2KY9_*1C%)HP(X<*/)%@V(F*SQN10H5.N,SX>9MY9V[ROC5JT@9M
MI69QTXO570;PMDD'[R+85^665E"IQTV]DX]_'-(IX9%^Y?L7C1%N=PV63(4V
M/,5;Q;=YMC2N%$HQ,Z8P>3^2Z%?,H4OX.N<!(Q$SC[&;]A%W2VI6!F_6@TH:
M&D9#P9W2T@0KE6-L/A 7)6; >-)8\QWV\/-W]%7,?G7",NFR5BLQXJDTI*<)
M6(Y2/R%47J;^R*(0;I.O,CMI=4KJ<4;6:MN"1* J/S(6"#6*W%.68&<%%CS>
MN[SZ*E]OFXJE;D83),Y28FUPJ.*\YY>V^6=G;F4.R>FO6%+>]I-O<Q@0<[8&
M;NO.)A@N>$D%'C9X]9="[J-8*&% 'KXE)%K=(OXU?S10FB+RIV5^ X.9F_ /
M97X'BI"4^"XP6!9&1^#VBSOP$>:4?1D85Z\[GP[49&2CV(+J)B[?-&_>+ID6
M.O;3VJFV/<U)8]BHAKD'%:^5=O1]SU!<YD8TBN14[B=#* 8>>R"DS6[[<(F#
MFF=[<1<6,#8WD._?DF8U:&))\O",RJ+2+\MC8VOOWVW<W,KF9][0S:WM[KMP
MFI^_L;S+4[;U9]TJM(QC)5FS6V?PI4Y!A'2%MK)'EAA:])I/57CE>!15L+,9
M]G!6-U$G=IP;\4B@ FUN4@>$[@I24+)=!R?6_JLH5OK=K@DG"["0?U^?AIQO
M#2[)%%:4@9ES#OW[2.G8;OTTIB*<."NXY8>ARF3DHB4+S$<U8;<14=.M\M8R
M7A)>9-7(F91OE65BI2PE217-!1T@25,T>S)4'#=8T6V65? DNBH*'0J03$L>
M;=O7CR^XK $"M:&LQF[$L>]I,5;YRX1SC(E2+*5F'Q^T3?7J1G(L)89"-:4Y
MFLBYLZKILD6#270-)>&!9+K*;'F.MK:;[[O'R+R*-NDV[9%KN.;+5\SXW<,\
MLURHVF@1[^XP$38K#%7IBZD*N#6M2<@UG"R$HE'RB*44HP+(E?0\PP.V*\BG
MZ+<H(MH53-SW?8:J-NV\U)E++7\-RN59C#=&L^-Y"IVRJ0UTA<:6;+"R%PDV
M]G;N(YFZJ54DU6BL0QGG(.UHXCMHT:OT'@E-C8GF /@) N/"0I0Z*$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$01  $1'@ \Q$?< ?Z1T16<INX3!^0YN,KE
M(RI2+/,3S&P2M8:1$\R=%N,34I)&&MLO1W15 9W>(J<RY;0]IE:DXF8^N2SE
MM&S3EB]<(H')8\W-Y=WCY%YZ&YK;VY?M(Y+,F/ 4D9JW5R(=K6:-;PT[8<>Q
MT]+Y"@J[8'"R4%8IC'T;5K*]OL9"2+][2T("8-9D8L8YV"138\QW7\!M8]XW
M'C"JZCY;QMDEY+1M'N$189.!C*W-S,6T461E(V#N2<HO3YUU&O$6SY*#MK:%
ME7E7F!;_  ;86+!P^B'3QH3OA*+'F5-/=Q^ HUODMY(9CQRQ9X;AIJQY3>/+
M;#MF=$K]:>2\99)NQNEG1&["*KLO7YZ#GY Z@M8:?@YB!DE6LQ%OF2!38Z:'
M7=IO[W.J@Q'F7%&?*+%Y.PGD2GY4QU-N))K#W>B3K"RU>4<0T@XB99&/FHM9
MPQ=GCI1H[CGH(+'\.];.&JO2LBH0I""#8@@\QT*N5HH31$T1-$31$T11GW.?
M:U7/EQ7]@7U?,#]]G^3;^LM<=4G[W8=\]?\ L'J[6+/N=4WY!8_J]6_$/AU5
M\L_SK*MF/P?PCYE#YBJ^UXU?4T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$5N,O56R7C&MOJ-2D*M&SUABABVR]YK"=UICAJY<($E8NV5%5RS)9*Y-Q
M'CH:9AO&L3/X]^X;IOF2ARNDB+#[$=CQ%TJRU:4Q#+4?$&.:_N^KVZQAMTB1
MMEKQ)3)"(V]Y%PI/0V/C3!XXT [OL_D9WD6;7CJY$5Z&&NUZJPM9$C=6PF*O
M.3>^I+<MSOW@W//:UAR\M]+*A<6=CWF_&[W:@@KN$Q;*UW:])[,)5JSC\43%
M:G+DXVL0V9:S-$L,_%VH'$_]6$5E-%Q5U[>E9O1NG&O:]5V[-C-V22L1"X'-
MIO+COW9K<EK:6Y+'GW!4E'=B#D".QC%T%/-V.1?1NW7&&#"SY*#-HG4?XXW_
M #C>Z>U%0+-&621G6ZP8^4BP=G68OB?5:,D^((0!2%P.\<_+SMMS>'UNLGF9
MMGTWDK=IC_<:VG\>SU2984=X-R)A_+-%<WBN.(]GE^EYRIV2:&*4S&MH?(-8
MO5'AE@-*L'C)V:.K,VV<QLQ4(LZQ4@BQ%ND$>*QZ/+XRL>*78J6=I2JI4$,]
MQS\N/,?;6L/UY>8K4FY;6^E[:MYMGW>#;<AM"R8%>7^Z'FF./!(U.XC*]S;+
MB5[,C;0JD(56?6]OZ6E_Z3<NA(N+;^G0<BK^G=E%DVE3!IF,S30E3/\ '_:3
M8[E6#NC6 [9*(WZ9ABLSP[B'5;V9J+5WCB7CAKTAXENY;3T<(RC5M'.E_@]N
M49K\G]#_ /#2WFY;WZ.E>9:^QF;SF*<=X]K^2JS1I-'8A ;&LMSU5I81)9TL
M1:]OTZ[W#51NQ<-ET\IR41@9E75VMB=/CJ(.:6NM:U6V-&L99RD/.O+QLP!Y
M]=_+;77G\*R-;.MMDYMEK6<H.=M49;%LN;K=Q&X]FYC&#U@6$89UOSR]HU1X
M+YRZ4D7U:5D5XM:93%LE+D02?@PCSK':)!IY?*;JDF]N2P \2EYHH31%XMD9
M/I*NS\=&&:$DG\+*,H\[\5BL2OG3%=!H9X9N11P#4JZB8N!0(=8$0/W93'Z0
M$BP]8H[*J1PQL=PCMPH\]@EIG7%-DPJI9-PSS"4>]F<ATO$&;D,N-(07:SSZ
ML:A,]/B6]6L4;9Y&4HD^=2ST]["3R[65B2K+KN)-[&YL#N)%AW^G<K#L>Q<R
MQ&89F\2M]Q%!<_55L6S[LKGII[CBTJ*I-,L;B;CF^NWN*(>^++%7A&]O&*F(
M:26?>,/$%0:29 DS2D:3/J#;<X.W\UM-W0IL4'L]IF#PQVA.&I[)K2)8;YY6
MXO6,Y08=W'/L4-[EMMH6WMR#!!V]12F7L:6BHVMLX1/#INC21H95% K(LB[*
M,VK3;M>?6YS%VN[GW>56$R9V4-TRQC^$CIK(F(*AD*5VO9[VKY3E<=XMDH"H
MVIOGBC81Q])Y_)"J6)P^D<QP4%@NMM4TY5ZFVEJ\>!IJMB8,*-&RDN4YK<A-
MG BYON)-MVXWUZ=>A4__ (GRW?5[/V0,VP!XN;S7O.R<9T_JTK)VX\)NIV<5
M?:5$PDK*GEFB4O+TOZF@R)+RJ@-FUG?/5(-!C"BG\.*%&;=IN '1VQ=N[YL.
M8*K8;LF9*Q- C<QY!Q_8$S]ES1NSK93M6H#IO8Z5/45W?#Q.=J(ZLTM-C#V%
MFQNR)631!PS>MIN!1FVTLT1?EAXQR^+[?7P)FU!MN=FMR:VT\@7WH'9772I9
MSQ!G5]F"NKR5"SCA;*5@IT=7I=*L.H;".R)ULQC8^M=]) I'6&W-Y.0R).2S
MQLLWCVS*L8]20E48(]R?DS:$6T(([UW!U_);RK--HJ4T1-$31%&S>39,RT[:
M9N5MFW:*6F\[5O!N3YO$44UCB3+YYD&-ITN[JY(V%5272FY4DJDV5BH15!=*
M8D4VL8HBJ1T9,Q2+7%]UQ?O7U6$IWE[<%5S=F7(;++I<\UY%ROL<W)7?<17)
M^XV#(S*Z3=<VVP=IQED?+#*=EI5*KWU7=$K'4:,F%48.7DW<[8L8#_F6%")K
MY56%G9A;46W::Z]_3]ZNAB6P5#)/9EX;R7(;TKSB3=/*;8+@_P EY7D<J6A[
M.5G/-TQ'9*1E6>S;CP9L"LXO N5[8\DV23^'@%<-R%0K\%4WE79)H0CXCA9Y
M%K@.T%MXO<"^_4>$JZNR_<AG^!?Y@IV8=J&1;-F*F9-PQBJ_.=K>7*_E[;4Z
MB[)17]IB\XX[].&2*)*XXK2L3(,W.5,>1#NRW-F]D*I:U*S)RMNEGJI00-+$
M6L2+WOIR&P(WWL>;>1:RQ7XOW";P;31+G7,E[@*[AF9R;M):AF.Z[A\J9.QO
MC;'&[.:[33/F.8ZC.+O0YN'N>(+%;<15R\8M@QHLS5)"'@Z/0R-5&\72X--
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MV_E4Q-NFV.Q82S+,VIG!XZJ>+#[4MN^!*?2J;:KK8'=/D,-Y#W#V]S#-S6Z
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KH#,UP02;FX"Q;:K:JEQ^EIH(*6H@=!4&9SIC&6N:8W,L,CB;W(.HM9?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g389734g02b09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g02b09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %6"^5'(X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $8 4 !' "  4 !R &D ;@!T &4 <@ @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q @\*/8         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          2I   /<     8 9P P #( 8@ P #D    !
M          $             #W    2I                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   2I     %)G:'1L;VYG   /<     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   $J0    !29VAT;&]N9P  #W     #=7)L5$585     $
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M!!$       $! #A"24T$%       !     0X0DE-! P     "PP    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4Z&QP1<U0E)RD[*SM.$E8G-T@X22\4."TQDV1525&$1C9':%HJ3$_\0 ' $
M 04! 0$               ,$!08' @$(_\0 3Q$  0,"! ,%!08% 04%!@8#
M 0(#$00A  42,1-!408B87&!%#*1H? '%2.QP=$S0E+A\8(6)#1BLB5#4W*2
M%U24HL+B1&-SD]+3-56#_]H # ,!  (1 Q$ /P#]Z>09 JD5%2F*F3Z2EXDE
MXM<G2+8]S;G-S=3ZMMO?OV,&&[]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7
M/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]
M/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#
M!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\
M&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^
MS\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K
M5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1
M]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\
ML1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZ
MY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/
MIZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P
M8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?
M@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:O
MV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M
M:OV?@P8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P8VF,QE2$E;=6URA122J:H=P
M ?+T8^Y0X] )V&.2H#?&7Z5S?E;/Y?3E?LV_]7'NE73YC]\&M/\ :/H?/!]*
MYORMG[<?V;@TJZ?E@UIZ_(X/I7-^5L_;E?LWY_\ GVX-"NGS'[X-:?H?7E_:
M^/OTKF_*V/MROV;@T*Z?,?OCS6GQP?2N;\K8^W*_9N#0KI\Q^^#6GQ^&/GTK
MF_*V?MQ_9N#2KI\Q^^/=:>OR.#Z5S?E;/VX_LW!H5T^8_?!K3U^1Q]^E<WY6
MQ]N5^S<&E73\L>:T^/PP?2J;\K8^W*[?_P"MP:5'E\QY]?'!K3XX/I7-^5L?
MD].5^S;?U\&A73YC]\&M/CY_5_ECY]*YORMG[<?V;@TJZ?,?OCW6GK\CC[]*
MYORMC[<K]F_MX-*NGS'+UQYK3X_#&-S+Y;2%.+JV>5(W.TTD^8'EZ-]?'A21
M<C;'H4"8'U:<:?T]<^6(^UJ_9^/,=8/IZY\L1]K5^S\&#!]/7/EB/M:OV?@P
M8/IZY\L1]K5^S\&##BQ_(%7:I2514QO1DLD$/%WGZI<'O;;Y>7I_7OO[MNY@
MPW<]_E*S_0E_[4?@P8C[@P8.#!@X,&#@P8R):=4 I+3B@?(I0H@_D(&QX,>2
M.H^./O0?_H7?]6O]7!@D=1\1@Z#_ /0N_P"K7^K@P2.H^(P=!_\ H7?]6O\
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MV4ZFT8%29^0^(_!'L=PS%)L?#XE8Q<W<6-06\BPHD@2008MTF>M_U^$8"1!
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MIR?4/,-:(^F5CD+^1.XP,4I=8\VLLC1EK56[?V>(5U;@DFH8>=GY8_[I(CF
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MFDJ "#L02W!GE&^+!2]D.UE=_P %V7[15G=U_P"ZY+F51W(G5^%3+[L G5M
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M2ODF]A 1)\HO.$UY9F38*EY?7(2#!4JD?2D$>); ^>-&;K-I!71&Y]AJKIO
M@NQ43FILW.,9BQ'(3N_3F-R'[-#*XKFQY)"5EI>QY5G;CM&6YBXOAMY?7..
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M%(40A1(2I)/90W31E&;.DI;RO,G5)N4MT%6HC>) :)%P=[2/"RIR[, )-#6
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M,D#<N1\B2.Y&WXVC[]CWV[;_ )?T]-_Q4>OZ87I_X@\]_C;U^HQ4NO6 T%*
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M)3-784<VM6OG3$L'W)4AI]]C= 6%)2"4 VUJFI4I5E36A&9U;A<=6G4M3"E
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MZ"1\>F/FO&0JW0$GV021N3]>Q[?OV^'F <_-7YGZ_08,:<O=IOJ[@I1[/ES
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MZ%*5$%3M36:S>80A%6LV2#!5IW!(WQ8J7)&GW4)IE(K-8&I$ ! OWBH!/,1
M),\HQ*V#_A ?')%>529UJIEXN/5K;ZI*ZK$6X3;J)"T.%*X^/;ESR0XVHH2
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M ),DWV!@3>YWV,03X6WV<N)03< F;R)(\!/+ZZ8405!LN)!)<<[G?S]PW(^
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M'SEIEQP)W"@I2DE*-TJ/EN =HU+D#2VH%(,J3M!5!) VZ7,0+SB:::2D#A*
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M*20H2G'0/2&3Z%,A*:F0H2CR<[KX4A]P.'E+3+@2KI[  ^SR[G;<[>SQE69
MJ2X2%J -@+I  W4-SO<P.9 !QO\ 7(2IE"2E2@0%0"+&)$[#?UZ;R+BU2Y-[
M<U*9MK*BUD.0CII;;4EDJ2E7405)2I3K;X5[3CFZSL.5P;;<0#A"&^ZA)61N
M=^778VMOMMOBGA*6$UBDH"UJ28!/,D1:T*'A $S!QV4Q&2U,QFD>9>#S:J^.
MD+[\RNDV$#E/P/;?<$[]S]67UR%4;[Y !+KKBSJFQ6M1M!'(GTOSD?*_:-ER
MFSFJ96C2E]]]W:""XXI?=@1 F!,[>>' 4^RK8'8 GMY?';R]W]?D/CQ'+<5<
M:1< V!YGS\O*<5Z/>$$P3?P!,?*_4VL,>$(Y@=P?S?7L?S?5\02.WGPDKJ ;
MDR(%H'K!W,[_ *@%MB?3R/I^H)%M\; !"RLE1]D=OAY=AY;;;;]R>/"?")N;
M$>4#X_':TXZ(O)G8&V_+;8 B^Y)CQOC.G<C?8@D$CL>VQ)[]^^Y^(/N/GQY!
M&X(MTGI]>&TX+]"+6M,7F\G>9BW0S.#N-NW8@]MAVVWV_C'\_F-^_'GU?Y_7
M/'EYN-P;&\&_]1\S<B;XRJ2""#OMY'8]_P"L?W?FX<8;\0]!SZ\[=<31HZ@(
M7D &_=%6>_\ Y[ZAQVV2=4B(,#RZX=4JBKB3_P O_P!7[8B'Q9<PEX*4C?:-
MDGQ\^I2;>1'?SVX6!B1:_P"G^;\NN)-@QKVBTSX3]3(CKBHS">5*U$ +*7%K
M/F1OMVYE=R-]NVY &_O V[2J3&PC<;?,FWD-O 664M1* F#J5>09@[D1SMSW
MF;WPIL[/=-*4J"$$*6H>2E;=AWW\CY_4/COQXM92D%(-U)3>-B0.9O8SON+C
M?'-0$^Y/O1S$_5S?Y'$?:Q6=G3X#<RZ7\78*0TPQR=E!;[G3)3[U+]O8!/Y"
MG;MQ-]G6$/5ZPN2AHZSL;P;*FQ'E$'<[8LO82E9J\]99?(#33R5$]T@V) 7,
MB+W@ _GBBE,[;ZBUS^(,9-8U,Z9#E0D2G&5O]%+@3Z=&<;W05-OA"T !84E'
M=( "5<:.'&Z-T5!82ZE "RF0 HIG000(,6Y#?:9C8LYH4TM$Y4):IRI"Y2D%
M.DP%:%0%7CG!CD1-L2K>8!+PZ!B<.H=A6<BMB1(EM926D)?E,M-O*8F/[J(6
M4O$M(2K<\O+L.9(5PT16BK#SCB5MI=E26T@A*%'3K2D"5 ;'?8SUQ"Y+5%XE
M;Y#"Q)3I*@D*$>ZE14D B]A!&P,B5)^'+CLQP_,,IN''5T0E*4!MU6[CC6RB
MH+7SD,J4L'90.VW;A%*D*)(3IUF^YD;3\ 2-B9Z[2RW"%*+8DJ42><WB;6 B
MXC87YX:]64NL!<E[TAQQOKK:2-_1W%/);;0M*M]U(0>5PI )&^PX6<3!L( ,
M3S(WL?'ET'.198.N2.[ ! @R 0!-HYGE.]N1&-:]MVJ=D.<C$$)E="5(>W1&
M2XYLVRVA0.Q0X'N0E02>?;;W[C;>M425&)2!=4;DF1R(!\!)Y6<M-N.R;D*3
M*4CH")/*XB3N!ZC#3RW*7<7EQHL&L@OT&2M/1KWH(2JPB%V&6C)BM%OIRU..
M*[LK#A<"00 1S</:2G-0%J*U!=/I4U,PM6N="B#*82)! L9O<#$14J;0A)>6
ML/K<+2$VT!H"09-P02JYM -I$X@/PX9"RO4:NP1&09B<#EO6=TOJQ6(+LRQB
M LM4EJ(:G76:IQU2UMH3T4RGD("NVR>+-GK"A0*K>#2^V(##6D+4I(;5<NHU
M&5+@7$F!((B<5*NIU/(=;0E)(6L!1,%204E0 A))F-@50/.*_:AV%!.U-SEH
M1)E;C8RYZP<I9,%ZROY-C%M4Q6):GUI4IE4LN*6B$^M:4L!06!S#B<I4OIH*
M18*5OJI0VEU*PVRE*V]92I/,)"8*P)U;3<X6H IM*&3 =1IB3IE&DDIO<F8$
M@QZR1T D89,.$(DTU@MR):4LZQ?GY1&$2_:L'D(CH:4TH(0Q!0TTVPQ#1RI*
M-P5\4-^I0FJ0EYN"AQ*-%.HK9+<S.J2=1*B5*,FX-IO*Y*Z7G*QH=U3:3 23
M<)DJOM[LWCRN,<H\GR"LA+QF#"AS*V31WEC697:N18*I4QN:6934^#(A-]>-
M.:HR['KH[00IMZ..9YQY]23JE'3O+;?6I2'$NL-N4S94H)04 IT+2LA*D%[2
M7";0HD  3BMU:F4UCBE2"IP \,F-R%743SN"+01YF5]'<Y4_.U3=P;U]?:A3
MG&111I4V*PFUI)E8]32\DMX'(Y'<35"*9#DAPNKCJD.JFQU<^PC<WH]"<L]N
MX3-&@$.EM"U%MY+B70PA<R"YJ"0+).GN*M9-I04V> H*3J5(<DD$G81$ S()
MV D';#1=A8E"KZ[3S$;VV_PA:D7M=-N4Y#55E/BJI+>\2950KEQ*+.##ERW)
M3L:RBMICOJ4V6V]_:#E*ZIU;F8U+#7L% RM#(IW%NU(2>\AQ304IM:TITA25
M0I($*N!*I2VF&%A*G1JTR3$<R2(!/03,V$S9*1A5QBEE<Z=:PYE8XEIK!;<N
M5,U-O(S&RN%B2U"A,1G65O(#D)Z.\IYUQ<9+$8^0?W*NQ6T]6PW7Y-3M5V8+
M46M;C:*9IA0"E+U>Z#J"@F!)*@03 (QXHN\9I51-,B A*400X!_-("H2L02+
M1,\I%U\4Q[3VD@USND>165AC^0E9>CR+:3*J;2#-BL;N&$0&FY$5P*+: IHL
M!2FE*5S<PH.85->Z\XG-&&T5#)TDAH)<0M*C;4()!  DZIW$7Q>,L92IM+B'
M'$A")9]P%("M1MIDR!(/B3;;$XXIB<F#9-)>?=B;%AR-90B6@A(V<Z$IE!4X
MXDHY^=P+44I0D^0/$(^\V42E"5*N"% DF;2DV'.P(O?GA\X]4.M%*WUJ0"4E
MHA.DQ(U D3)^)F-MY(P:7;Q]9].&529-HVO.:1+SR7%K::8=GLH2L[HV2D]U
M]B-@=M^W=E5I0K+:T@)0?9'R 0)D-FP^KD;[8C,V2U]S9B>&&B**I T#WB&7
M"5*W!.R>7(^7</C*L?/>#@P8.#!@X,&(8U5&\ND[D?B)@[?6Y'_5QPH24^?Z
MC_/IA%T3I/0_F4_#TQ$Y62I2"!L!Y^\D>6_N\]M^WQXY)-Q:!!]+1X=#TGX8
M1N24';PL8@=-OJ(L,>B=N7??F*05=]AS=QY#\WD?+MY]^./H[?*UL><),1?Y
M?43>#(PB9&ZEBCM'5K80AN%)4I<I7+&0A+2R5R2-N5A*?:</^9S'W\)U0"VB
MVI00AM!5K5[HTI)EP_T 3KL(3)Z87:84_49:TE#ZE.5C"$HID@U"U*=0@(8!
MLI]1,- VUZ>F*&8'8Q8>GM#$<8PAJ.N--0B?IGUF,*;7-LIK[/T?1+_A*8\@
MKZDE2O:5.5*6G9)3Q9/L\;">Q^3:3D1ENH<2GLXAQ.2*2JL?5JH0Y"P@SJ=U
MB#4%X@:2)^ONUU/4.]L,\>4OMRM8J:="D_:0ZP]VU!8H:-E2,^<I?P%5#?#T
MT_#]VA32)/>!&&EFL!]_$<ACQVK"R'H4EQL54IF);/+,9Q08K[!126)RU;)B
MO*6$MN%*S_%XLF?H4[D>;MM,9A4NNY;6-)I<HJ!1YF^I;*T!O+ZI12FFJUS#
M#Y4D-N%*M0B</>S#R6.TF1.551EM$TUFE"LU.<TJJ[*6$IJ$$NYE1)"C54+8
M&JI92"IUK6@ ZL%$:>34T$&6F6RMFC@( L'TRK.*ZF(VEP3WP5)D34J!$ET$
M]5X+7Y*/#G*VWF,KRULM532FZ&B;4W7N^T5B"BF:26ZNH$A^J04Z:A\$AUX+
M6"9&.<V5.;9T\T_2/)>S3,'$N9>R:3+G4KJW5)<H*:$FFHEA6NE8(!99+;<=
MV,,?7O&,5G8>[&EM0IE>(OK".\_NZZAYEK^5/*M 8)4% J0$[))\N)_*'ZAN
MM;4VI27-7#*18%)($"Q*N5KB1SC$4R^M-*^7!H,Z3 .VJPOU$=9\P<<@\@Q>
M(QC4F?"CO&5.OTK#K5BMN.G&V4E#\J.'G%M+2Q(4E#I25K3S<IY3W&RTM0M3
M[3;BAI131I4T"KV@^ZA6D!4D D3 -R/'/*I: MX@ :G'-YN"LSXW $Q ,FT1
MB3?#YBJ(&?1YS]+9*KFH_K2'+$DRV9D!*D)$B-,"-F6^OLATI<!0!V(W!$)V
MIJU+RXM!YLNE9:6@I"%)7?NJ1-S%TV-[03O8>RK#)J5K)2A"4I5JL85!)3!F
M1 D#<[W@#"/XD=0:S4W5MN10UV/VU*S'8Q.2E*'$75I8-E3J\=KC+_@Z)4.2
M@*BS&RT'5(_&E0Y5"2[+Y<<KR8<9VI:?6HU2 HI+3:"F \L([Q2I.Z2#";B]
MA5<_JZJJS1QM+3:4MEQ0C5<!0$DZHDI@D<A;$"9P]<4SU=7Y%7IM8T&#$MZE
MVQE"QO84=@F$B)/LZJ*[$;F0YX:BN1B\M3;/*%A922;'0HIZ@.KIW%-+6I;;
MJ6T:&%*(U:D(=(44+1*@J!J,E, 0(*HJ7FRE!;9 *@%#OS$W([V\;&X(VG'B
MMEX[&N*FW=G)>BOE07#;*KN8NT4HMSFG52FV(\*GHI<A+Z'TM *"G6]E;@<>
MN(J%,NM!!"DW"B>"CA@2@@(E:WGTITJ2285'N\@.(4"$)03>.A^<F;>L6M9&
MLY[/TBE-3*1:/5<F-):>F1HS\NZ6ZI45<J+!D.N,0X;SABO(:@-]0,[/+2GL
M X:;6*=LH>D/(4"$K4E#0'?TJ6@:EJ2G4F7#&JP.\ME!+Y<U@(X2M*=)%^=Q
M>9YFUB8 $$RWI)CI:OD29<I<FR?3N\X&FGXB7)4I:@(\\IZA>0TE#+L9M(;2
ME"1MVWXK':.KFG+2$A+4]T20N$I$ZFP8B25!9!,[>&B]C*-)5[3WAH*4A-M,
M*$F><B(W L9L,=9-.:YYC'&PX_LXHN;K4V3RA6^ZP$;%1[\VQ\SO[O+(:I>M
MY?=$  6(OX$';] .9WO.9:4/H4!,Z9!(@$F(-A!O\>1Q=OPV54%F5;RV9:7Y
M:6FVEI;2IM7*M6_.ML^TD[@@'R(W!!/%5S]Q::%7=($R)-O(<R ()Z?/&6?:
M74+72,TQ2$(6"J9,@@@  S$=)%CSWQ;=Y"0CF/,KEW.P4=E$ ^SN"-]QN=O+
M?O[NU*0]J(F!;D9,'K<W$">?/&+<9SC);T)""8)OJ$P!S Y\_*V&ST1*GJ2O
MKM I[IW"4^R.P  V[[;=O/S\^'/&"4B(-YWZ\[7GU&V)2K<32,(4R.(H@$\0
M6!)O $>G..F%B+":CA0"EKW)[K5OL._;X=_<//N=SV/"!J75:AH2 FX@D&^X
M/A]=!AD*XK;U+2A).P3(OU@J\Y'/P.$6ZAJ<3&CQP0X\^ 5 [*"5'ORGR]_P
M._U[\+T;BEJU*2!!M$QMSO\ +#^A?1H6L %24R+<^G7J;'X86X[3%;#4T.8A
MH$ $@E>P 5Y>\D?#M[]N_"=0X7'2D@ $FXW&\&]K?&>@ &&CS_M#A0H!(.Y2
M3;P$S\8(,WQAA3VI8<Z;;@+"^1P.)*-EG?M[B>Q\P-C^3CI20A*8)LD18'I'
M+PWL)C";U,TVG4EQ1,3!BYZ6$^>+68@D)QJH WV$7W^?=UP^[M[_ ,_#)1E1
M,1?;""/='K^9PY..<=8.#!@X,&$/)/\ $LW_ ,M_Q;'";ON'S'3XW!V^.$:C
M^"O_ $_]2<18GLI)^"@?J_?\FW#50.E5OY2(Y]9MOO\ &Y V$4OW%<QI)\;"
M?B?+?X8\V15Z)* !]J.\D';L%%MP)).W8>\;>?N\N[MIU++M%*2HV  CPOU^
MHOB0R549C0N$0"4PGU!L8Z"UL<!+3Q&4OABU[M)^3X=;WLN]L;*"V*-Z.AXQ
M[*0XN.^&G5MF6XXI2/Q+04ZD \W??C>,O[/5/:/+5>R5#+;=.VEQ8?F 4IE2
M9N$BT2>Z?(X^I^T=71N=F<JI:VJ]G<K$M-L$LK< 2D!"=2FP8L-N0\,."]S'
M7>]U'L)CU%25&DBJJ-,@%V,\]>O3;%P.+JY,=*E):>C[*](>=0AMHI1S^RZG
MAJ*;)&LN0%.NKS3BK0M(4D,I;;D)6%1=*D@:0E1-XM$E;+6GVGFV*0J=ID--
M:7KZ%*2A(<*0I(@ W$*)F1 N2U\NNEL2H$B+75TTEER/*IK!CI*?G<Z@X^\I
M'.XEH-\FX2$I5R@ 'MLE3M)4A84MQN%!27D$&$1( %@5$\YMN3UNE+QX4WKW
M*>^@>Z!$)$V,7 W\9.&/E=MCPQV?7OT]7+ANQ'9-A$;G-M-5: C=\2I<]M!@
MQPH(25D<JFU+0E2"L*#RB:J?:6UH>=0H+"6UZ3+A)[I"4*(6J+Q.J8,&+^UI
M3[,][0EM4(*076[.*@@  $23)OX7%L4CU%5E<O!\!PO'-%J.@RNZ?OW,=F8C
M4F5,R7"IL9*S(BR_X5'D].2P'$RTRB.19"0@'EXU3+/94UM57U6=O5%+3MTY
M>;JW=#;-8@P$N-@I(&DQITW@SM? Z[645E!2T(3[6^IM;J A*D-J)GAJ@:%D
M$>$^,S7&)%E.K<QYQ9H8[L5%5ELR(V[,O"S'4HHA=) Z2 7VTI<820"-T;H\
M^+/4AN$UJ :E047J1M<(II4+NRJ28"B03Y[VQ7<KKWDN.935D4J$$H+R0?:(
M!4$RN(3/6.?*QQ:BRANV>C;E/1EV?%E4S3'3;8<JY,AZ*M8"9+3^[\9726E2
MU-I&RDH._;<9S3O!CM.*FJTM14$W4'4H"R+I*++ ,P";BV]L;_FE&:[L"*&D
M!=>33J>UF0%I2W.E( G40G?E.P-\<^Y]EB>*+A(31VN4W4(V$6TQJR;C1*N$
M7'6T].8\QS6,N.TT2_&(6U^+0%.[I6>-?6G,*@*+3K;=.YPBV^RK4M:" 2L<
M2$)-X5"5\X (!Q\J(=RMA#A>HW7:]"EMK8U)3PW LB5DI)(C:T$$DCF']38/
MDVHU=-L:B'I_CL0J?4E,I^LQ;'E1/268L=]$8OQ4RY3*RE#KTE2UOG9;BB$=
MF3]=192H4Z36/.*(6HH:74N\9225ZU!,@* !A.D@"Q$X>T^75V8)%>Z&:9I*
ME--)<$#A A:5E*8*A*U JL"0;[#&AZ)(H)4+I9!47TBH:+#K50EF2U!GL+;;
MF,2?1@S52(<B1U&X0D%2>DI*@XM>QX[2MNI:6'Z9UA+D$%R4EP*20DHG4XE:
M$@%8 L1%A?#QMNLIW4_=M6V\^>X\4)*>$$W!)7W2"HF!R@W.+(XK5RJN16VF
M6ZDV<."FQ9AU6.XY;QI[#<BQB&6JOE50=C)KDR4NM&0RI&PZ:RGF"=A2LV>;
MJ$.,4&3-J<X2ENU;["FW"EI6DNMNZ5%>C2=*@>8D XU'LBW54;J'LT[0:D+6
MG53+= 8U&0@*1<K*5$%&F(6$D['%P-*;NLJ+%ER:IU+33B4J<<;$EL<BR.5*
M4A:T%0V]H @'?N>,VS%E:TJ"0"LWT A*KB\F8\-_G?&XU2"\TE2%I*"W*5B0
M%6!M'7X7ZXNG*LF8E;6V=8MK:0D/NN?C$/*9))2&'4CV%\H*=BGL/J\JWH)4
M4KD%((BVXY*!Y SM/+TJS2%*=J&E!1*IB(@':5 G<^?K&.I'AROUWFG<-:PX
MCT.0Y'2TX>=:6RVTMI17OOL1SGR&_GWXSSM4R4.-+3_,LS @[VVY"?&+&U@/
MGW[2J1+&=L1"9;&M8%BH3(Y7F]]_7%A.3V=@=^<=O[/Z^_GV[C?W[P#J9(5,
M=Q-AX)'.?#&;]V5 &;F]H(!-P9\]^1$V!QY2RX-P4_#_ "D[]@!Y]OA_RW'#
M;4#(@R"23&\_XD=9MCD[#8@^(G8"-AM$3MUOC*67.78C8;C8[@GRV^KW>0V]
MW % F!>//Z^&/3,3!B009G\_"(D>>,Q22GEV[[ ;';S'N^'?CHJM\YW^ASCS
MCICD&2 >H-[DD<KG8_K-A;&+H.]QMV/UIV_,-^VWY>Y[D]MCQK3U^1QU!N(,
M'EW8]!-OC<WFT'X3LL((\_?^4'ZCV[?$?F/#K"'#,$S8>']_KX8FG1X[KR'Z
MO5H_KF_ D;>_M\>%&_YO,?5L.:80%W_I_7$3>*S^=X/V_P#W;(_]Y2_N?R>1
MXZ*@F)F^)!I03J)VL/C/[?/%-[>SCU<"5,>7R,-'G>4E(7^)0VE:TD>_F!2G
MM_G=O+AY2TSE2LI;T@Z2KOJT@@$6V)\Q&TXE:*F75E2D:80DK.HZ9 (%K&]Y
MB9B_+"[4RF9M?%EQ5!;$EE,E)'8\KJ0I/L[>??8_#X\<U;184&G"@K40$Z#J
M ,C<[@=; V)M;$;6(4FJ0"1I3(,&9,&-@/JY&((\3D;*IFEM@WA]I'I[ENQJ
MI+$V4VIQE+;,I+KJ3RA127&T<G, >4;^SW)%J[$^SL9A4&L;+K2@04((FZ3!
MO',F;GKRQ9^Q;2SF=41_3$#WB3.WQ(\_"^*P6,SU;JEIO+K9=3)EV>)Q(N1U
M,&;%8=<LVV'%2Y0CMDOJD/@=5E]#?42EMQ+@Y$CB[-H*Z"O4II20W4*53N05
M LDC2DJ(@;P4R1.F#C14.5);J::O6H-)</ ,*,@20%:B /W-_"9):H5(X\XB
MRDS$6I<F3FYJ_2%(5N/X/$0LA2$QN4H;  25E9/?RB@XMY*):#9"4A 387%R
MN!$F1RY"(QU24FMLN *2$ $P((GK<VC]^=V_8NQTM]=MQ:G3&'5CA*RVIA3J
M$MON!92EMQP+)YPH$+2-B>XXZ&J8($ V((WO(&Y(M'D3XXFZ=.N$JVD *,28
M%P.9CQL;\['25&>CH6X0TJ.X8P;]$5T]F=G"&5 %:G'.H4+=]HJ(WYMAOMT5
M3%R#I)[W4<R;1;8Q?:,+@(#A3!D%8,[3:X/B)CQ/7&2S8K_54B3/<B+CL2XK
M:T2&RI/.HCHMAL I>4EU/,DJ&R04A1/'C>I2TI3)4I*MC\3U%MR-^4'":GW&
MW%(0% )3/=WC3)O(M<R+\[Q?$*3\\P"[<K\B7C&3Y@[@N85\2+ K'O5::ZQ#
M#C:[*R'-T)=7U5) :7NI2A[0  XG6*.M92XREYACVNF42ISO\1LJ!*$6)0X$
M@G;D!:<5W-''RI)1I3+:B=9T@@D['O$D#ESC##:TFOGJG4K-\4R&EJ,NIM2Y
ML=44.*C1[JJ?99M8<1#D=Q0B2$)?"(B@A4?\4\%<J2I0E3F5,7Z&BJ:>I=I7
M:!!UE (:=1W%+N(6E1,*V4=MQB!-:\T&6UI05+4\I"@20"= ,V'("!>8)@DX
MIQC3L7/<RM9-[>1\-R'UJ[8P[5A6T-#M>\[.FBR2ZZW&6\X^D--S@XKJ*9W4
ME7.GBU5(50TC:&6354RF^&I"@-4. )040F0 ));V[UB(.%TIUK0Y=3C<+4C^
MH#NI%YD0;VVY6QTKKLC?U(@TMKJ'.A8_0,T4IN9<T]H%UUE CQI"6''E$LML
M2)#BUR&E("U((1ND@]LVJ&11/+9H$+J'"\%!IY&E;;A(40D=\E*8@I/QOB<H
M6$4U'6U0M4E2 TT.]/$6EM>HD" $+5  N;$\L4/U+Q[13*9E=B^B]NQ7Y- R
MIZ!D=QFLANGLILKK/N1+23:WH7THT5_<UXKX0,EPI2ISI)"3?\LJ<VID*J,X
M96NG6P%T[=(DO-I1I * VSI!*A_$UJ.@"8),XKK[#ZBXH!G5[P&J+$S TI)D
M#D;"Y)(,X@,U$>GO;RDQ'*9C.JL7((V*TTG&)C*,5L(EM($27,;FLQNJU(]*
M<ZEH&4,0I#*G@V-TDJGE/*<98J*NF2K+"RJH=34()JT+:!4E!0504E$!J2I2
M51)$X9TR05*83"7B%*7/N#G$WY>!(5S.'(O&LHRANTQ>[IL?G7& \\2_U.L+
ME-]"H&K$N\U0[*:?KQ!=C24]*(>1PLEYPI2D!1+,U-/1<.J9>J U7PIC+&V2
MPMXMQ#FDAP*2H'OFP5I DF"'S:!6:$:2UIW6!IF))4DD22 08)'+;;%EM/L>
MU?@PL.I,"T]QIK';F(D97+N[:IR_#K]3[+J)MHL*+EK5J=6P2S%AK6RM<M:G
M2>4\5RMJ,L(J7ZVM?54-K(ITT[+E%4,:5 H;C4IMT)"M*EJ[W<$ 20%$,K<?
M2B4D-D@$]Y12DR"D]V"J+V4!MB3L,QU_'9LV/9T=9CRTRI(3%HFW8N.%]YP=
M>97H<!4RP\VTUSLH2&FW5..-C90VKM=4(J"E:'EO@I3WW2"^$@60L@7(O>\B
M$GPO5"@H;0 % I;2D@BPL3IF0#!O/2QN!B=H<N[A+COHL(TM[F$6,AEI"D(4
MDCHAU:FP2 EQ20KV?<-]N(@I;7J!2I($E0)()G>!.\CKUWVPH_P]&D)B.\I0
M4=CN!RFUQUD8E?1R?<.:O87$M(<=R/Z\@[K::0E]M[TR.MMSF3[(0A:!O[P2
M>WGPQS!M'W?5J0HR&7!!,@C0J0 ;B08N1//E$)GZFQDM;PY)52/25$P$\%8,
M".DD;=)G;M!QE^, P<&#!P8,'!@Q"^JRDB33<RDC\1-VWW[_ (R./<-^W[^_
MA-8,CR_7X\Q]3AK4*"2B1R5^GEMB)QLK<@C8;'S]Q\MO<?S<)D1]=;X12XG4
M!)B3;TW^?3],>D[<W?;8=_W_ '_YGK^?[86UIZ_GAF:AV$6LPK*K"7,B5L:O
MH+B7)GSV%2H,)B- D/NRYD9'.N3'C-MK>D,(2I;S2%MI!) +?,'44]/6/./-
M,-L4=2\Z^\@N,L-M,K<<>=;2"IQIM"2MQ !4I*5) DXL79^C=S7/NS.7T5)5
M5]57YYE5%34-&^FEK*RHJJUAEFDI*E2@FGJ:AQ:66'U*"6G5H<4H!-J'1%E6
M'XXEN116<*32UEGZSQZI52T,EB2GTMF75512V8++[#Z'FHZD)4.8J4 5;<7G
ML0V$=E\C7QZ&H#M"T^W49;3>Q4-2U4S4-/4M(0DT[+C;B5)04@]XDR3CZHS<
MJ:[09ZPNDSB@=ILWKJ1V@S_-/OO.Z1ZE=-,]2YEFP6X*ZJIW6ELN/!2TDH"0
MJ$C#+U1MXZL.NZZ+7+N(;D=N(*M%BFE,]M\(;?859JW$!Q86>F_WY3LE/M*&
MSOM13./]G,Y93EGWRY44+K'W6,U3DJJT/*2V:=&:N+0FB4M*R0]J20H!*2%J
M2<3'8I7#[6Y!4NYK]Q&EKDU2<X.4+SU- NG0MU%0<H;2I=>E"FTZF D@I)6O
MNH4,9XL2NATU9(B,RX:V(4:.VUS%WE0AE#:6%2' .NML (4\0"Z1U#Y]IJA:
M+5+24@:#+=/3,,)94Z7BT&FDH#9>5*G2@)">*J5+@J49.(C,7U/5U<^X\*E=
M55U+Y>2T&$O+>><<4\&$D!@.E2G$LIE+84$ 6Q!/B#LLYJ<==3B&-)R9;Z6:
MZ<Q*=0PTW734E#Q0US@K5R%1/+W*00/:(XL_9YNB=K4JJZ@TZ$$K0I*=1*T&
MP)CPM/.QL<1>8I0G+EMK7H<=A2(CO$&1J-X $'8"\6F3RWS*UNK*+#PE:ZF9
M#QN9-:H(U72R*A;7IQ0_9TDQ]?3-CS2 !U%E:4J25)VW'&P4#=.A2JT!Q*JA
M"2^MQU#LZ>ZT\E(GAVE1  L=CC+JUM]N1'>61J,Z@8)O.V_3<1;K/GA]U!S5
M6:T.#2:V#"Q"NH)U:Y1E#$L,/36BTVW*=;6)D9EJ4M+JD)4D%03LKOOQ6NT]
M!0BA>KDNK=K%U"7$NRI 4A!!E C0I12#$7W,6Q8.SREHJ%@I6D.-M]^2(6"J
M1>4D%,;W)ZD88V5T4[#\^?J+^:UCS-9$NK],ZI@1EO9$TSZ0E+-3CCBG9;KB
M%+#?IK+[<A0"UGLDCB6RVH:KLM0ZP@OJ<6RR4/+4 P>[WG7Q" "!.@I4D6&\
M8K>?!VBS-T'OAS5&E6N!,@*,)&QV MM>;P%CEB8=,W8U%I;6<>EG@VL2)/;J
M(<")(L1.@NS(MRE E6%J[U&'VX[JT^D-(2%$$*-B> XRFG&FFU.IAI2D%QQ:
M@WI7I4T92AM)"AJ&Q)C?$,614=]:@FY5"MX'*+$<HD7,&,(D<XR53)%I57S+
M%U-E.,7L2Q;F64:&M;YF1Y$6.IU##KLE262B&TILH2DJV5N>%UBJA(:<866D
M)"F%H4AM2A!04J5!4 !,J(,[6(&/4%I!T]XD "(FTR(,VY[&V_E]=5"E+CJA
MNI0_#E1FVAD[;D5II+D0-]%Z4E"GI$B9&"2I(<1TECVMB./96A)"TDA:%DFF
M5J)TKF4@F$I;5,6O(Y7PDA(4Z_IF%.\A<B1UZ"0)'@3TM7HOCK*W'78E3&KO
MX0$H%58KG0G$)*3Z0VMP_BUE942A.YW&VY/?C/.TE4I2TH6\IR$FSC00M))(
MTD)W@6G;&V=E*5+.7%8 '\,FU_<5$6CU]-KXZC8K!DQ*.$TK<N=#G4\$K2O8
M=ASE6R KMV .QW.VW;C-'2"ZM7(E0 ,>/ZB1)-I'CAY6O-K7N24J1:T6@G:;
M$8NOX=JI$*/<6[[#C)DNLPVI#BD'GY$J<*E!H$(02DA/-NH[$$=QQ5>T3H-,
MFGU#4LDI%XGG)/I>#R.XQD_VCOH4FE1,D)58 B-C%_.XZQM8XM&DI.VQYC[]
MCN#OWW[_ /(^_BB(:>203$<P#\N6T\YQD;D(.E8[UH@3U.\B/SGI@6EKNXM"
M-VTJ]K8[A)!))/Y.VX VVX62%ZH.P@3/AM>U_E8G'@<+B@A1F=ND3Z1'7^Y"
M49K"0\Z\I+307RMDD[KV3L/9(';M[P/UO>& F+2NPN")'7XSMUZ0':,O6^-*
M-,;)E40?J/0^.$F/(]:R67XSBUML.'F4-BA&Q_B]S]7YC[_BLV$4R5!R9([N
MGO#XR/7?#DTOL+#O$("B@Z=)F\^,6B^W@=R YU)0HGF;W"BH@J![C<>[?\YW
M_-N?-F4E;H6-IY[_ *R<0R"HN:A[I)(^6_/TVGGSQX4D!"B$<HV._L@=^VV^
MQ\QY=_(';ZN.W5@#8[ &W2TB\&\1R('KCI2U*)FPDV\/7;^PQ9K$?_NW3_\
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MI2& =E.#D/$1G=?EU3DX=I33*=6\CCI:2"0XXD%1"'?Q0!$%Q*E))-P+XDJ
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M>]+<'SNNTRRB\D1\DD-LMQW?5R8]3+DEEIIH/F,D-1 ^KVD,MH#*2L-HY4H
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M!@1:-(\3U7:40V.7F YE=U;$DE1/Y.,J"-"%)G5I6[?<3K5:>@C;<7@X^5W
MD.+2D:0DJ2!:Q3(,CT(@7YVQM[#8$>_?WC\Q_)^7A ;J]-I\?JWYX3/3D"8\
MOJ_J,?..O3Z^ORP01O;Z/[8..DB5)'B,>8^[?7[M_P"SMY^[^[RX<Z$B>\/'
M83YWQT1$][F0>MIW'C^N-?8%1/;??S)V'F=Q^3Z]QV^L@<<8;0>A^!Q-.CW\
M:_\ /^+6_D\YOE_7QTU_/>;CG,"_P\O"V']/&DP(,)FT2;_4XB'Q8'>5@J/<
MMC(=_P @=I#^D^[\_#E&_E]?M\\/6UZ$K']6GY:OW^N=08[A5;)1S$I5'6H
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MA+1FK90I3C (<4\E 2H%Q*VE+0D!)*R.4]AQRE1;<<4)2DDG2# U$0!/K%Q
M^6&U0LM.)>1*0XHD"38SI@GY3?RL(II-B64/5NPRI_*[B?5BPK*RIQJ*TN-&
MK7K:+Z&FPEQE*;#+3+\18;W0M2G'>8[#8\6ZG?9<RYNC33-)>TN.+?605+2V
MK5PT*$E1(4-0D2 -P"<1]=2/-MJJBD-HTJ"UJT]]0)64H)-SI4DD].@Q%>28
M;K7ZTF6\-JTP[&<HL;/&(3\V\;EB-:275*<BJF/!?07:;EMM;0+:6W%QRZ"D
M\3C-1DX:;87PZFHIDMOK2ELHU-@6(2""H-Q,$R8"HYXKK=2E#JG%.(<D=Q,
M2-H W5 ,\X@*Z8;&GN)+QJ_G0LSJ*2K+[BJ*%;6&SK]--BO,RF9E;6D.Q9"Y
MX*"].6I2%M+4/95L"KF-8:AA"J-UQTH3QG&TQI=0H04N+.E20@B @ 1!L9,.
MJ9ID*"G%.0MU*QPY[Q.HP2F\1)@$?&(LKJXQI[A4C'L62].M9EK52);,&%"K
M&JM%E(2),>?'L+=#%)#DH>8>4W'DLR$NF4?Q?LM\5W*45M4'ZS2VWP7$I*RM
M9=X9.A2%(:)>4DA4*4F"D(%P)PO65AT^SZG0TLQ+A7?APH CS2(N+I!'/%+\
M>;ZF?V]I+Q[,Y^+UC5MZ8Q5.J?18M19S< 2+Y^*N/6-QJ-=A(9DPHL5M<@*8
MDMI*4)(NCYBB9;;>I45+BFM)=$%LK05PTE04X5/: 0M9A)!3O.(1*BI"RX4E
M($@$6)@DP(DR!:\@ ]+8Z<WVF-!;9MIMJ#C"<=RRSEXDYC#R9LV3+JST6TJL
M:FXC-J:>8AN/LH:9<<;>7**H[JUMJV4=+.:/MT684-0'Z5M%3[4"AM*7 %&$
M.-E04E:PDR;C3"M\-PCV5"GD$K2M2243(25V.E23)(DP!TN+6<59@.I<EF@M
MZ[$,Z59S%-C$+;$I1JEO6R8CZ&Y\W')+TB-1JKH\5V,_'66!)C/QWE.!U25%
MF[79:E3S3U50\-,^T-U+8< ;*@2A%0D)4\5E04%"2"E0 *08D$\4:DTY<(&Z
M2[((B8!U"9$1O?N\XQ/6FC>M5=92\6U.MKF(IAVJD)II;L"W>DRI#86\6I4<
MF5 =:6A*78JIDEMP*<YBD@)-:SHY*I"'\N;;45A8XJ XV E)M*5=U84"=*M*
M2+ 3?%DR%56ZKB.$ #4G6>Z0$7(4(N-,C41BZ>&0[^"U+@2VW97I"VY!LW8"
M%.,H<Y4NQBOVTH"04(0OF!0L A2=B>*>ZI"H4B$V*0V%;Q[JHL2=Y'2W2)7,
MA2G2XI:=3=E#4()!LKEO>=YMS.%')JMBO8?9-SM/C-I6W"G)_&/B4I!Z2'5/
MK*T)1[.Z=T\W<CCEI941+<I5NI&PCF;#GUVCX(4SZGE)6A +1[JE)Y:1!)Z7
M'U).$?0),5>M6$K?9Y7A>P^GR;.-)6)L<'E))*3S*WW ">WGV[&:!1RVK .S
M*YY'W#)Y;^?ICWM&L(R:O$@E5)403,QPECEXQ,WL-S$]WN,FQ\Z8.#!@X,&#
M@P8AC57^<TW_ &$S_>1^$G#<> GZ^&$UM\2+[3SC>/V^IQ%&QWVVV/Y?/Z_/
M^SMPG(.U]]O#Z]>6..!S_7R\/$8^A!(WWV^'Z_/CW![.;D&8$[C]O\<\5[\1
M<R3"TXM)T:PR^M<BS:9_KX+6MW&3.(3;P4.18%<X"F2B0A9;F@>VW!,EX;J;
M"3"YXZMG*:EYE_.&%M.42^)D-*FLS5215TX4U34R@H/<5)*'DP5(94ZM(U)
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M">8#MS;A1M50A(J24\9! ;(2H7G>UB "#S@^(N[6Z'E&*5):4DHL(@R+[ &
M#S.UB;8YF:UP,4PC56QHT.TDZK$=V)*MXD%V0EAZ2RI<:!%5'ZY7*BN+2TZ4
MA0YFED$[<;)V<56UN3)J5*?2ZDA:&BX$E24'ON*U:0$$ %-Q.H>$XCVI?HF\
MW3E[-,&E/=U2B)(4N0DR +FQ CTZ-;$](\FPJ_P)-3E2J[/[^"[>5DAN6N(F
MM:L ]ZDFRKJ>ZQZA2XQS-J6M 3%W22$#L'SN?4U929@ARB+N74[O">!&M3BD
M*!?0EI.KCPH@A(5! M$8A:CLLIBK8J%5Q;K"#PY2HD@] 23 [HM8G83;%J],
M,4TXR;32R?Q?*;M[4[&(K]+F53:REJKS96$B1UI%==2&VF\@CK+2GFU,+=Y%
M+4OG*=DB@Y\JMI,V2Y4T[*,LJWD5%)PT ++:$H4@+:25%DC4D*D"(@7$XUSL
MEG]75Y:WE+2 ^_24SM,YF"94I"2R4*U6.F)]Z0"+ @[\R\SP23CV<2<6L:^S
MC6$Z<NR5/KO1;)<MN65,)GK <1 AU\=LEZ0S*<:<"0M?MD';9,LSAJJRP5;
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MP"D^Q_% "1Y</FBXBQ1.XY!5CL2 1:?&;;[XDLNI:NC0EL:E).I?>][OF8)
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MPH3Z$+<>2?:3)E.*]&=4%#E1MPS50&5EYYM32.&"D)-.\ALME*0M:2=(N!I
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M(4WPD!9@$JX8TJ "1L,954TM2U7-T3V7Y?2LO,)J2MEQY]R%K6W*5+E0*N#
M2!ID3>3&M6::7&1T=SFB<<R6!78EA4W(WY690ULKMKR"_&@1JNFCU[\>;(,I
MZ<P&I0C.*<;0XZZH-H6KA)S.V6RRP>$I^IJ@RTBG5"V&R%K*WPL.)3&@C2#>
M0$R8PN,E*N*4+?+5,T72BH:;2EQ>E7=;*%%2E0FY4% \B2<(V%8R,MFMPL@:
M;K OE*:&I44R[-$*&I*8,=]M?/+L4.N*D*@J*GBI:&P>8[<2&9U:Z.G#C(#B
MRD@ON&4-%Q7OK! TM$2D+$)@:CL<,>SE,WF&8+9<"V&TN#4A"E G1R2H0)!
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M\L@R(W_.\XS_ % )0HF-0)Y_6QYCF1?'S?;S/;?8[;>?YS_5^HGA):=0L+_
MFW41CS6GK\C^V/@4"=N^_N\MOSG?]?'"4$$'IU)//S./=8,7%STC\A_;X8]?
MU>7[_JX6Q[C"D['<_OW'U_#CV/KIY_ VWQSJ3U_/Z^'Y8FO2%25*OMO,"NW\
MOC-V\B?AQTW,KM D1>3SWZ<K0,.:<@ZXBVF3SY[^FV(8\6RBF1@FWO;OTG\A
M>H]^'C7NN?Z>4_U?4\L2E-[KODGYZOKQQ13+JK5J0]!.G>68#C\ ,.&P9R["
MKS*)4F2MWF;?AOU6;XPTQ&#94A3;L64[S\NTA*-TE B%&^UH]=\,G%DJ((@
M[#UF/"#^EIM337K$/%W89!@[>G&<X>-58ZW95-DE!IEF%)A-11(F14VT?4J7
M9:KV%!94,M/32Q2FBM;Z8Z.>G1&4RN2 .);.I0) MM-U" 8M,3R(OSMCA*VT
M27$E2(5W1WB5%/=&FW/G;?>V)VU3J'[5-+])G*.S?K:F-$S ,11'JYSCR65V
MRHL27(ERHL1'+(D16WY+SK#)0E;BU))XT#L\X44@CB!965M2"DZA[L1<@J('
M6<:]V06^UE$MEUL5!(:@%.B;)4#(WVB0+XJOI\;-\6+U7;P?HG7SI[-- BO
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M1TH E(=:D-A04IH#B[4[+J:IZH"5H *4![VA3JG2ZYI>=:"P VC3H22YI*5
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M"3:WC/6V&HAC2ZSO(5*&JGZ5PIJK.$AY#0G"S:C!274>R4K="5AS96ZEJ'.
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M4Y554]*I3[J2H.D)@MO^VR=5?CUM)AQFI*VB73U"$) 0RI!YP0 -MM]T@[$
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MANFIDA"= A;Q;@A>H"0K20E25*[R+QN<=U;]+4K<JG%ERM42I:FR&Z8$>X$
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M!2G2H $ F"0$BPDR%$DVOB>/![%CG,'[-+J'E2["K88+83R(0S+8+K>Z1L'
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MYJG['Y2*SM#44-#V7HJBEI,^RY&7"BJ<R<=J<P3E 0VVNKR9]\)>H:YPN*J
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M'W4XV94TKA$D1%EI(\+P-R1OXC%YUAPM)#:PTM2$$J"><=T@@%*M@>Q\^_\
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MA>M)0@N)4JQ*('>$$F";FUYQLGV;53E315'MKSC+C@*F$+;<5-])"2E)"0%
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M22XDU9?9(K$YXXRI#&E=(E:5]TI6IMRQ<!N)$GK2'&A)4Q'91W6E!:6DI'M
M<R0/(=N^W?C7:5"6Y!0+&)453?O$@J)/*?/I,8FLAR]ZF3QUR0I2IUFT%1V&
MPWVMTZ'%0=.4EX91#0G'@ZC,;;G&-Q5M+942P4IODO!)^D*@2JQ4U^+4HM<B
MB02*_P!DU(0.U#25]F#PNUF<I4UV:;<;#7%+#J1GJ7!W^TBTKUYHXC\):E-:
M"8,[+VZ2I9[(5!1VJ <[&Y(H.]JG6WN*$>T-J5V=4TI0'9A*AIRI#FEY*>-Q
M$I!3A^9C2BSQVVIY*E+@RXJXLHM/.!USTAM2"URI.R' .;;V@0>^Y XME*^6
M'VW4P%H6E29 @%*IYS8[7!L?'%)6V'XDR8,<@(@[IBT@'<2+3?'))^#IKBF7
MNQ[ZI<9Q7#L@1+Q^#1V@$_)6VEE4YG(&%.+=F1!RN=5*D*!W 3W.XV%@YA5T
M32F')J*EF'E.MZ6Z92A"."I,)2HZK2(D D2+9WFVENI==<[SQ"TJ*E+"0(Y)
M"@#:X!$ ]ZYB5;)-8K_4"GJZN?642,/J+B:C3F'C*&X-@EM]T+E5B8:@'W9"
M0ILA1!!4LG<;=QO)F:!YYU+KWM;S*59BJI[[<@0ES5<)0>?EM)@IT54ESA):
M0J6U  DJ@$%0U2"#S.Y(-HY8LYJ9Z\J-)J)^PP]N=09$TP<FQ_(I$IF5!HZ]
MMGTAI;L58D-V"]R\P6$.%;FP4DD'>HY0AM[.G@W5E+S.HT[].E!2MY14$F%"
M"@3!DCNXLF:5C--DQ#BOQ4K6I*D[%2PDG<F4V(-YY P2<<^79&/9UF=W'QBH
ML*2SK9<%-3C---DPI3]-45CRG+F3<7SBX=FA#6PD(Z#;[+J0HI!=01I[9=HZ
M=MNI=;>2I"E./O-A2$N/+3I:;;82E2;]V0M0!L8*<90^[QB7FYU;J,$2%= 0
M1$B^F8-C<70&+RNF19D7(J9N25"C9:BU3L5W(I\AB4EQJTRC(9#;#-BTRE*E
M!A@.)!0&T%7*.'*Z53:TN4SNG^,I2W H,H3I(+=.P"HH-XE4'<[Q@:JE$A*T
MG<"2(!O!L--Q,_U"^\P,,FNJ8V.*=KKR5$?R:[E&LK;Q@*7"=@H5%GO04.-$
M\\WG0EAV0M$=J,0M.^_'*'7E5,.,I6FG92'7&"(6%=Y"5D$0$05$)DE6]A.)
M)32"V0E))BP!5-I-IGH=AY6P]<-JW*JYJ899R;'+":T%3)4%;=A5Y,AF.@\D
MGH*6W71V-^5 2 'U>?*=CQ$YM4\9A]6JFJ&D*5H0L%"Z>3NG4 7%*MXIW\[+
MV<HTI=:=@%P)222H@S-C>0;@^-A-IQU$T5D-HC*$QGG0(J&0ZT4M/;(_B+)5
ML4E!\_\ *5N=N,DS0PY8P9) ,D#:?.WPOXXT6KIE%"5!1N9,C5>-HB.?(0(&
MQOBZ_A]C=7.WI<5UQR(U"D=52R#SE2N4#<;@J&^_GOV/EOQ5,^)3ERR(!U-B
M.DK2#'F+7F)M.^*+VWJ"WD;C"DZ7%+9(.Q #J";<I .U^O7%[FAN@*4.7=""
M001R[#8@_#8  ^7U\4&!.KGU-_B.>/GESO.+U2;VY3Y1O:.4;6ZXYB%.(6$K
M4VKE/2*0=@L))!(V([ '<'<$'RX+VY]>7PORZ=.O-=H-*,*3\2>=K0;_ )^&
MV,#!3*BL^D("BWYK!WYE#V2I7EL#MW&VVWD#VV  "5#<\_0#],.TJ+<ALZ4\
MA$B^_O ^/Z82IME'0M3$AE28R5!+CB4%24#?<#Z]R-]P0>VW;L.%F .+/-5C
M-Y ,\S:#T_3#JD*EO %0[Q3-AL";&W3\_/"=6-M2GA,@RT/H2ZM#K(]@-H)[
M*[DDJ]_;8_E'#NJ2$) 38$&0)O\ $R /EOR&%,V0IE!2@@!:3(A)G81*A(WM
M!ZCJ</ E1.YVW('D2=^VWE[CMV/Q]_$?]?MBLM**ED*-K #EO?;G\QCTG_*_
MT3^4?5^^_!A8B"1T)'SQ9?%_\05G_=S_ +QS]_U>7""MSYG\\*I]T?7/"]QY
MCK!P8,'!@PAY)_B6;_Y;_BV.$WOX:O3\QAO5?\.Y_H_ZTXC9D$).^_G[_=]7
MQ^OX=^WOX9XACY]>5H\?K;Q$C*A1Y0=QN2=_R#R_M/Z/R[A(O>P^O#],>XUY
M("FE!7*0YNT0H @A9Y-B% @;\WF1W/O^/KB'$LTJD+G_ 'D&$W@*<!,B9%K;
M@>>.Z!U0S&A(DI34)DP2  L;G:QW]?''YT?$W49[>YCE.,U%'%OZR19J$R@M
M]T4]D8]T\R6Y3758;6[R.-%A:5M+:YU+2X-@4_0V0.9<VRVY6/+9_#(#K2=3
MJ0ID&P*5=W?4GO3($<L?9O"=5E%(]E_"54:3JXFG2E)3)A1"A!2#(VFQZX5]
M!Z_4*??Y179K5M8A$I8$.#CE3'@QWJJJAU\9*&ZZ.\\Z^[TT",VMOF>6MU2R
MHN'8 H9U]VMML+H'55*G%+4^ZI2DN+6M4ZRB$B>\0;"(L!A^E]\T;**D-*=6
MHJ4&EZB9,*U:1!().^P&QOA_YHZ85N'E&#,4Y7,@Q8ZDSULNRI"5>D2%NN++
M*^RN>.SRM-A>_*>VT6Q^(C^9/XA.HR@0D&4I 'S-S'69D*1D%M8 4DPHZC*0
M8CNI@7F]Y!L;6Q43Q0P;2VP:C$&AL[NRARY4AE^HFAINOAMDKDAZ*RI+(:42
MVXEQ0YVTM$%2D^5R['/M,9H\'7VF65A*5!Y 7K63"0E1O(N(F"3L-L5_M?EZ
MG\G<+25%Q+1(0$D+*A[I) W%Y%O#KAM:$3_#;!P/5*1K7BM-GN79U-J(#%38
M9!,BEVVHJM,K'(=ID<*4RYCS3M@TVVI]I3B3TPVZD-C8S><T^=N9C1HRIQVD
MHF$..NK13@E32UE+SB&""7M*((%H!D [XR^M9XV7,.)=;14H("G]25:ER$I;
MU:C*P G2F=0,D DXKMJCG669YJAGDRWTXQW#,EBT\&#=X9C[,^M>H*> VRQ#
M=5:32VFT4E(:6N<$)3-Y^IN=TGBR4%'EM#EU$FGS%^I"GM:*FH*%I>=<*R4A
MI(EL$ZTI3NF"F$WPRRYW-ZAVH9JF$+H6VE*ULC6X)DA2U)@:)! !@ =#,S+I
M_49-D.C=K*Q'&'<G-.W(JHM=&>CKD2'7F5N*:0E];/ILAB0H+'*XX5@H1L0!
MS5/-O9F>T;)KZKV?BK2XI:TJ 'NB2!.D*2#$Z0-S VU;),T<1V0J:2B;0%+I
MR IOOE6DK E21 F8,\YO[T42RK ,LPNUI(F?X[/T[FYJ84%3ES(15SZQN1+<
MC)N9F.U:D3XD&*TR$1WY?HD"6\=E$^THZS29I2U=*LY:XFM:I05@-(4ZE:PB
M>"FI6E;963=125%((3(D8^:JS+BK,5JS!Q3=0ZL0A).H)4I02-*9B#()DI)(
MORPM3</TOH,(@SZ+(IUED%A*D0%6EVIUA$*9CUBM]ZP8JZV4M3=%*1RM-2''
M=USUI;4M2"3PU8K,WJ:YQM^G0FG;0A90T KB(>1I2VIQQ*4EY!N4!(AL$Q,8
MEJBCRFBHTK2XLU![I)DK3I$ZEH!24PH[ )!) N9PS:=_ ?6DZ1:MY-(R-<1I
MO%9F/VB+EM<VR:4V^[<NVCY8J7H#J>9B&RI00TZ%.+3R[EX^G-(2AGV5-*AP
M^T(?2IK\-!22$);1W]5Y)"ICNF5%(9TWW,E"UO*?-2XD\-Y 4Z4%2=B#W4'5
M:)[J3-B",:<FR<HZST"-$B8PJYO9$6TMO7JY%Z\^RXAV*FS9A+1$B0GY!#X6
MP%J5LXDKV)X7]G2\Z7GE+?#; 4ALL!MA(4"%%I:P"MR(3"C8Q:=F[5>XS3I:
M9"&DJJD@$.I><6KB"$K:026TKMJ)$ $W.POQIWG^H-_AUSBV4M0G<)5$@7FG
MDK&J>**YQ<!TU]R;.P@L-JZC[K3CKCE@M^9UMBI9:4GC)<[RZB8KDU5,I7M'
M$4S5H?=5QDAQ <;(0LD=TF$AL!.DCG./H3L355@#*76F$!2@ I*S*TJ"9@$Q
M90)3H$:3!BV)ITQD26K5A$9M"@M:&Y#;:P%J9WW6 2@[$ '<CV@ =MB.]5KP
M"VJ2; E)(L%7CQCI&QZS.--KD(+1*B!W1N1$_&#<?'YVGER:Z'(KGE,-1VQ(
M24O)?6A;:@0=EI"D]16X)4%\P.VQ V/$"CB*#@E2C&T3(ZWL!<?'QO754REE
M)%]Y&D01)&X%A&WK<\^VFDEHS>:=XE/;=ZJ7*B,A2P1M^)2&P?>.X'Z0=SV(
M&79TUPJYTJ$:U&3'($'RYS\<?+G;NB]D[25"])"7%*)400F0K^HB"+VO-_/$
MD]@=OA[O+R_?O_;Q#\I%QUW&W7KO;EXXI3W\0'D4V/7;'W?^_P"'O_-_[>[;
M@PG@[?O^Y]_Z?JX,&#_-.Y[$GW=OR?I/U']/!CV#T/P.)JT?_C7PW) 16>>W
MF?32?( _IW^K;CMO=<]1X<L.Z3_O/]/_ -7U]#$2>*S^=X/_ -WR+_>4O"N'
M*]OG^GZXJ8T=E#ZSMM^GO\.W_L?CYNM"?ZU1/2W3"8-],3J[N^UB9^K^(OAG
M:FNI&(3H;NR46"FX:E+4$MJ;=<!7OV)V(;*=^VW-O[MC.]GFRY7%T3I8"Q82
M5:DE,CI&H'GTGGBV=@S_ -M-OMN!*Z-3CJ4E,I<*$'NDR-),;PHB=CBD#NJ5
M;A.4T2J9I=1B6+N/-Y,(;2)(OI$D=%OJA*2MA+#SBG&W5.[<JDK Y5 <:(B@
M%6TXRYWWWF]-.I1 +42=0D7,"(WF1<XV+.\HK*_)ZMY]_4[7.*>:203[*!>W
M>'$-K?PR2""+ &6\@OZZ]1'O*J:PTS;1F9T);B$+4ZB4@EM9("BAQMM2DG?<
M$$@;$<- RI@EI:5$M$I6-O<L;<P8'PYX;Y TXS2IIWI7PN[KDI!@S[LF+BPD
MQXX8<WE=E^BJ+:)9;9"76EEKF"D]0J6A/LE?* D $[I5V4DGEX50($R2D$R"
M)VM YD;B>7.PQ8 YH1KTR),W._(3!@6G;I;GA5S;()T'"$+8JW+.97=01H06
M$&2XI#+94VXVA2PH.*"4C?F4 KW;[]TC*%U8"G VA1&I4$P 3N">DF;<L0I"
MD&H6  'DD3JC2%*)Z0;;@QTZ$4?@0K!C+7YN6T.1Y-CN0(R.([645K&9LJ7J
M+CS7JQ$"*%HEOL/++0+O1=+2D*<0%L;KO&M!IDHIG&*9]K@J2MUM1;> "DAT
MK-T)(@D1&J;WQ5G])-G65)005J@DI4DV%](CE-P#/7&&\I:S*\C?N!CF5UN$
MEFSB2:&?&;E&LFU4&O80W1+D.JF=62_T75[%M)#;R'#LE*..V5KI6"T*BF=K
M90H/MDIXB%K6?Q@)3"4R)FYA0B\)!UU24(6$!I"TAL1IDK))4JY@$R0)O(,@
MX0]:83-%JJ:7&,6BU=@[AM'%H4IK&IT^)9S:UOJV]DVM3K,9:6D/5[WI'4[M
MI<[$\*Y,HOY8'ZBH6M'M+KCZ5.%"2E*S##9!E1DA8T1O&.GE*T$K;"0A5CJL
MI! -NZ([RK 2!!O<XU--+URWRZ3CV1U+TJ5<6#.-O*KUHEP8KM2(SRU6JXA6
MVTN9(85T$M\K+.Q2M*N7A/-F.%3)?I7 @,H+\N'2XI+I4!P]0!4$I,DDR;0<
M2^4K:"8?5J0H!:&R(F-7\QVTE8.T\I!Q+?B4H+C'ZJGR.=10KC#Z^2%V4*TF
M2*VGC1&H2VV(=T(<AA\,2Y 1!"6FWA*?6VH-@J/+%]F5MOU#K2'EMU+B(;4V
MVEQU2BL$J9*@1*4RLR00 1.V'.:U;9IRT" HPA*0J3!"B2DE(!&UK1L3BEUY
MF\/),[1F%!#GZ>4K-?*]1+K4&SL9D]^JK*]-;!%@Q*D4D.2\H152TMH:CQF3
M+::2ZIQ2[VS1KIJ)5*^MNO=+B>,%GA(0@.K<XBRV4I>6D#4$$DE2M))  Q2P
M4N+:;*>\WK)43(4 %&X@$6Y$J!F]KAP5>L4^@PVODS\MAO5S]];R\OT_CHQZ
M)>7E/+*(L19O(3$9QT(39-A33S*)27EMO))4E2@W7E**BJ6A%,L.!AI-)7'C
MJ99=3*E0RHJ GAJ@@D1(Y@84=?CAK3(0A2=0$JE(5)202  8Y"^YVPP\;?A6
MD^;'QO#*S,*N5Z5(K:FGO95-E^-SWEI>=<E6CTE=I(:>BQEU5DZVM<1YPNAM
MA'M.![5(<:;0:FL<I'4!*''76$O4M2@) &EM*0VE04L.-@@* (E1MCIF' M;
M:1"N\23I3$;3I(&\@^0)(,8<.$7&GF/6AMH.B<RWR*OL%UK.-Y#GT.9'6]8S
M&6%MN0)L9F7.DE/1>*FRM#:'D*4KF"N9M7-9C4,\(YRVTRM 6:AJ@6(#:"4G
M6VLI0F9$2)(,;C"C IVUD+9T'?4E1), WF(&YO;8WY&[6G5_H3GE1;7&':9T
M^FV:T,IJIRBLB-0_265S&D0VE*F1N9#L-]?I+3"FG6W0^V5+3L>U'S=K/*%3
M3-;F3V84KR>(PX2M+92%:B0VHRE21H*ID00/$S^0--./+[C:@"M224S)$F"-
M0,R/$3XB,6UJX$.K@R8[DURQ<:86?X1Z1+'04IM[JH9]*$8+0D%+8;2%=B2I
M>_>IJ6I:DF-()Y0#(!!!,3<Q,^%AMB5J%%QP+0PAHDB=!" "+6&DGJ8)Y^>$
M2^;AQTPA,L'&S)EQT>C,+;+)47-E!;9!+328ZNHR@*5L[ND$[[A1O42=*!W0
M8*IO8Q!YF;&T$7Z##FE4M7'2$@DMGOF9 BT1N21!D[=<= ],84>O:Q:/%/.R
M)=44'<'L7F#ON!L=]]P-SL?/N.,XSEUPU[Q78*V\ D08YWCP\)WQA_:);CF:
M/:S&A2D@7Y*F\_"W(;QBZW$5B#P<&#!P8,'!@Q#&JQVD4Y^$>:?_ /-CA)>X
M\OU.&=4)*3T!^9 Q$Z>Z2?+L.WY3QR!)C;#="=C(\O3\_J<>DJY1MMOWW\_^
M7"H3 (G??X>?SPL%0(B9WOCG_K-J,_B^KSL9RWR'T6P9QJ@:J9E*(^*PY-I,
MF.NW%??E)<F6@:0(LR&E71CM!I2DE;@*778QAZK[59TS[;F)9H,DIG#0N4(1
ME:G5U#BO::?,#"G:PH'"=IP5);;"%:03./H;L;E;(^SG):X93V>%74=I,Y=.
M<T^<*?[3.TE)1TS0RO,,D!X=#E:'5>TT5:4J=JGE.H!TH@^_5DB%/GN1D^E.
M.QVUQICR$KY@OE<=((.P2>8\B@$]MNW;?C1U$*@*, *N-B-P!S-K S,@&\8M
MS=0'*=LD! )4%- ^[!(O82%$20?*YQ &*7*7<JU"I4.5TYQ-VW(<@55:J#,K
M%2XZ70Y:2 VVW93'>53RI*%*44CD<5OL!6^S;[2LX[64*<QRNJ<H<TIWGJ*@
MRTT#^6BNHTOMMYF_I",QJZI*34&K25*T%*'#J2!C1NUU$XWV:["YHJAS6B:K
M<FJJ=JNS+-4YE3YF<NJRRLY73AU;F5T5(I89%&M*$:Y6VDI)47;<PIV/5=C=
M-6!M"S%E26:=Z*0LR4,J6VLD$J<', E.Z222-OCQ<FPEU]IM20VE2T@N39()
MO(Y1SN)&YC&?HJ-3+R=,*2DG6#:#-@9M/3YSCC];T,_.SDF6YA$E8A&FY.F'
M4(K8++]XIZ3,Z+Y$<++[4)E*E/2>JD*Z7^3N"1LS#S>7MTU-1K16*12ZWN(L
MH9A*"4W/=*SLB#=72P.>U/\ O-8XTHA,:N\HZA()\$@S:+[^(PPVLDEX1E::
M:H.-62<2O52L<N<KJDMM>M$J::E+ZK3K13&D!IMP!_G 7N #OQ(NTJ:Z@-4]
M[0V:EC14,4SI)+7>*;*294)*1 ]TSMLTHG0UF",O3J5Q#I+B3! 5?24=[4;D
M&%2<=1-6;$YSH=&M[JO#N845?7Y!%N,=K)EQ&;M4*CN!=?7,26FY+4ELO)"5
MAQI([*2OE XRS)B*/.U(95%,\M;"FWW$M*+9*D@+<*24J20DF #,1BSYI1#V
M0MJ?U(E0"%)A<!,P1*C(5 @'<Q:<43AV^GEG?LIRN &L2J,?E0\LQZHL9%9F
M=_/R&2W-7(A05MEZ/;RWUAMZO@OA*8R%( &VPT%Y%>W2K]G4I54ZZ'*9Y38<
MIVFV$J1H*TFZ$@#2XH E1!YDBAZ$,:A(W*4@BUA($@[&%7W)G<3A5\1V":&V
MF?U#V*9+>^M;-&*LIPBEH$&VPJH9QQMZMJI\)QUEOU@^\$+DR$!YT.%:GBM1
MW5YV>K<[9H7E53#): ?7[0^[I;?<+H#JTK2%$I3>$]P1W1L,,];;ZDI.EA25
MA0).K4 J3([I$^9$2 " "*VR@;J;28YZXAVC$9;]6O%LC!@Y@ZM3ZU3)!?:;
M6/3I:$M-5\1EWV4)20=U$B=!+:'JCA+:4H)<%0QWZ2R82F"1+:3)6HIN9@\L
M2C1#:RDJ"@8O &^_7X ".L&,2GBV3UE.XSC$09EAED]9-R)=9=QD7,!^)&:,
M:)4MV*$<T-XA)DNI#G8'IK'/N>(+,J9UYE54H4E6@-$)6TKA.)4I4J=4B3K'
M\J;3S&V+-D#H=S#AV@  * B)(D[@&)  G:]^72/2B7&F07%"-UE-M(4ZYR]-
M)V2=VU)!WY@=CV['?R\^,LS))2J^Q)@3)LJ ;BXZSY;8T1Y1XB&TN$A$"XN9
M.]B8M8G<D1;<75\-DI:LHM(+33(CM5RW@64E"DK<7NE"E$DD]AN=AWW[;;\5
M;/4:LN5*E ZTB#<66#/T>8WYY]]H30^[2Y<$%%B1?2I/2(D$]>L8NVTS9=="
MS+0(H'ML[!*^8DG;F[[]N7OMMY]AMN<\+WXFC3\[GX?WQ\_M0Z'7YTZ"1'(R
M!>9!'P'7KA24GV0.;L5#OMY#OO[_ "(W'Y]Q]:V.6TE)B=@3!'/X^-^A]<):
MFI'XWD<0R"O=IM1.ZDC^-[@?,';S!W\QP"YB8^A\KB3RG#MI>M8;BUN\#(\!
M'RW^.-.).CRVWTOMMK*)+C3B5 =U->R#N=M@KVMCL=OS\.$I+12JQGTCU]1(
M_:[UYIRF]G<:7Q.(I04D#3I  W,JF9\(W\O,1MJN3S-1R$OO[J*%#V H]MTC
M?OW\O?OY#CM][B)]W3%A>?&#:UO"T>6$:TO5"FP3 F"3>-S;K._.8PX L [C
M<CFV&^P/P^LCSWV[_J9DQ'B0/+Z^CB'2GAND3JA1Y1M,_4]8&,@\U_D/_+]_
MT<>X5)DD]3.+*XO_ (@K/^P5_O7.$%;GS.%T[#R^OAMA?X\Q[@X,&#@P80\D
M_P 2S/\ RW_%L<)O?PU>GYC#>J_X=S_1_P!:<1PVKF3OMMMV\]_(#ZAPS/A_
MC]\0U_3PW]1&W/?ECWPWQY,1,\S/0;[7-MMO+'A2=R#N1R[*[>8Y3S _I ]W
MU^[AVW9MOQ=MMS('Y_X..Z-?"6TH[&HY_P#ZD3N.OY8XQ^*++!IUK1,L%*9-
M89EG/M&U);2Y90&(D>6_%9*DK2'42$-!K^*I3BU[D#??:<GIS5T"6DH/&"6V
MT*_H6I:DI)VL0#UL+#'V-V69%;DC3JGR@!D)2!<)4)3J,$0" 22=M_.#<<UX
MQ755Z3-BJFQ'G)):N*)R(AA$)&QCP7&'VUK<=4[NGTAP;)]H)* 4!1E*[)JK
M+4(2XD%)1J:=2L*U@=Y<R![NX23Y3) >T*6PZ\W3N)=]G4D%9,F5:B01M&E)
M@$<O/#\OJOILQV$5S=;&>A(FLRR6D]5UE[HK<=6G=U3+C3>S#9V43S;@;<W$
M2TH225%Q05H*9-@1-@8O._R//$TV^HF4K*U P4WL-[6@&3)M ,=1B+;K%)][
M!R"HB3?5"/53L!FTV#S:&Y@6IY\LJ.X0MIP)6&UJ6"%)*N'[%6U2.L/K;XQ#
MR7"T+*)00 F>H(M( VV!G#EQM>8,EB=*G@I&KFV=, SX&XD=8Y''+O*=/[33
M.>U3-M1[6+"R;TUR[15R9<-VY7^/K4.5KC2@^T.LHN(>0$/#F0GF"AQM]!FU
M-FX=J25,+-"4!GBI2H,A,.D.R"DF.[$J'2Q&/G;.,HK,LIJ*D;<XR:G-V%;2
M2I3J=-A(NKS@P1MB8?$IGFJ4[/45NN&/4,75VA89HY.7XM$1"Q[)\>F,1)-)
M!DPF#RRY4-MY2G''4I#!4J.$)2TD\179_+LJ<I%/90^^O*%*+Z:6I7JJ*9]L
MK#KB5*N@*@"!=5C[QL-UV9Y/1HHP6_:ZXEO2D%3,$E)UDD*!@C4+ 7()!QNZ
M,RDVFB^;8[!<NW+NDS"2^F^DVT*.RJ/815QU4M9"@R!-:@LOL+E+EAOV D)
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M(:.JW6A;P#3+B^NM2B$MDIVXU!5=G-+3Y2ZE-+4&H2U3<!+396IH"T%>I/$
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MH5\M^PB1YLY";*4X1*GURVTA9@PR^L)3Z0TR&4)+@90%E24*43S2O9#-UU=
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M,G?^S^S8?O\ EX\PM@.WN[?'N=O[-_[?JX!;:WE;\L>R3N2?7$U:/_QK\?\
M5K3^8F;M_9QVV22N;^[N9Y=/KY8<T:I+HCW2D?\ 5^T^N(D\5G\[P?\ [OD7
M^\I>%<.U[#S_ $.*GLJ))&PVV']6_P 3WX\F(\3'R..&P2^S')9G_P!*OVQ1
M'Q=T\B_RO3*G35S+&/):O%<\(+W;D,H8=#1<0"M*Y"4\K?+L=T+\P>VF]CU)
MI<IJ'RM"3Q "%09UJ*;"P[NYGP/B=I^S)QIVAS-M*TMN)J.+)($AH%Q1N8GN
MVFQL+B<1ECF!X/:5=MB>8OKQU,NF](JF)3KL*9)<B24]%R,U)/5DK:EA+:M@
M>I[6P/,%<3@>JVG4U-*GC*0Z"L@!20"F2%$"$RF;&+7WQ<\ZS9:D4SL!Y+SH
MIWUC22V@B)D3!CTYG$M>@PL:A,,PI@G)@-LJ2'F!U4!3+:0-]MDJ64<Z&]O:
M()![=F*UN/+47$Z"HF8(@D$_'<B=XVY2A2\-U X*92J4F3(CS&]NL;1C%&DI
ML-UJ:92 \3(+8VYCT 2KF2D[+!=!0@;$'L%<![MA,;#>P)CK?:2>8O&'):X9
MYP1W1MSVO> !!,;WZ17W5ZGQQF+82K_)Y[D?)X+>,U>-O1WW8[LY:"IN<ZEM
MU+O1B/*9>60L<Y;"%@A929_)EOEQ"&6$33*-2X\"D*"! TW!$J *8BQ,@VQ$
M9B\>&E8D*"SK6%"X)TP!',3U@7Q"%5J)F^FSF-Y3.E8['K\<BLXV8J?3(;18
ML[:/ZR58XNQNMU^=4QGGXMLE*@P0E#K@4>3BR+HJ;,45%)3APU%0?:$J6E+D
M%MLZ0A[4F$H<4$K;!$F#!@G%*KFUI<4^20PV=*5D SI,3JYB^F.I]<.#5?'Z
M^-F4V!IOD<AG =1ZNBM[Z<MU+;E!#DK?><CNV<@%U%&^\DF1#=<!</(@DH3R
ME/+GUBF0NOITFLR];S=.@ 0^L:4@AL;O)$0H"$[Q)G"J4JJ4(E1.K4'3?W4A
M(04B=](%X(N3UB"J&=E]#:P(\:_F"KH;A^OIYF#4:I]U,9]-,AUQXQVDM1H+
MH7'>:<FK!>9<*&4.(*MY2J32OLK<6RE+M0REQY%6]H:0K2$ (U'4M8(4DI0!
M!WTX>4RD\0,MH2XVVH)U.& 82(),F#WE"WG.+KZ_,9 [IRWG64NHETS4>'"5
M&6PS/DI0$,L1E(K0XVPHJD!M;O.L)8<*N8@(4DT?(TH5F;=)2REU2EJU%2D)
MB97+D%0$$CJ1IC><6%ZJI6**I0M &A"24@$ K5Q ),$G3< :;SN),\RX$6K5
M'L;'+Y-Y&L)<9V\QFWE5\R',BSXG55ZK'396;&JGM+<F*9@6C$=M4=#,8$\Z
M#J2UN:VVZ1+*D-D,5#2%I6A:%Z1Q+J[CB" @*<;*B%%2K0<4H:4ME:QJ#CDM
MCHF%6$W%N1 D7QEQ^7<75LTF[R'U1%F26F<LR'+8BK:J<4AMM,&<@.0 N [)
MVBPBS%4EQEY7IBB7&"05"&6FE<%CBN)&JEIZ51;<@E7$199UA/?7*@0H2C8D
MXX2MP'W4H9$RL) (L=(N8@J@7YFW0[++\"KQQR7$R+ ;0U68(DRR[66#>5R8
M[4,"7(?M+MA<QBKD#G$0MM2S*4\KF<!=5OPI"G'PA=+7-\6D*4Z7$*ITG5"$
MI;:(07$?S E,1&F ,=A92L*2^A8$*TJ *29]TD$>1Y7M()B\^E6-9I-E/Z[N
M:8:;MZ;WF)KL3 JXT"9DT5^LF.2(R6H\>&))FRDM%T%)"F"TVEP<R2#2<SJ:
M5$9&,PS+[Q;J8#BR4TY2M(2J5+)3"9 N"%:B1$@8>!QN$+/"T@=Z! *HC<J@
M@7()GIS,/BMT6T[J;^MUHDY#9R$W$RER&H9R2EB.Y-6*@R5R+.KEN/(;DK8G
M!:6N=]"9$8--D.@$#B/J<YS T[F4I9;0IE+C+A9<7P' H0AQ("BG4D ^Z0"2
M3>+OJ.A-;+B"$!PZ5*"H3$0#> ";B;<YF,*-/II2,T>5B)4I>E*NEVN/,/6C
M4R97JO)WILAYU#ZN?T%H.HCI8<4ZEA">5H ]^(]_,'WWJ=2UP REIXI;*$K#
M3>D"PC48*I$%0WY8MC39H&6D)40A16'"$D)6$ I$$1))E0B)G<W!?..XS:8Q
M7B1<IJPJ8E:I*8$EYUQN/#= 6V@)!;"U!;3H0@@) .X*206CKJ'50V7"$QIU
M) NJTGP$$$QS\H\75(J72T@J[AA.I*0"2!%CR&T6%^1-W?ALEJQU&IH;;'\'
M::4ZA:G%N+DM!_F4XX'-MCLKW=T]@!L  UJCPZ%]R;@*,  00CP\A)V^>&>:
MI+&7NJ495I62+"#I-I!F.7/?J;]&\?&UU1)  ";.N"0/+;TEC;;N?+?;MY[?
M'?C)7'"Z4J.\+\#,GF?2^V/G]0_&JU<UN@GXQBW''N.<'!@P<&#!P8,0)K(2
M)U  2 8MAN/C^-B\)+Y;\_KZ\,(/[)ZR?TG],1)$63V[>_W'^W?CC#5?N>']
MQ^V-[@PACFSKQ0P)WB-HKNPJ[J2UCV'O6L&:_/0O'X5HW+F-LMLU798M76Y"
MG'I*1R.LB.VH;LIVG>RZ7J7/JIYBDSGV;,,A53/UZ<Q0.S[:V\T0ZBD^[">(
M,V=3+GMR$E/LB. HRH8^M_L\;2K[*4T!S#LZW4,]LC5)RW[K6GM34,.Y,EMR
ML7G0!;.1M+2&6\M5"DUI=J$'38Q9H[J6C4Z1=N,Q(Q&,3[6LM8:-VGVW@MQ;
M+[B5I5W>;"2C8#=25';8@<:IG.6JH/9@HF*AIEYM5B"%) (F8.DR#&WIAU0/
M)2A\K)U+=>2DFX*6W5(($>"?4V@ 7WJM3L'4.VBJF7[C2Z2OFQHIB(30-%<M
MQ"_19X2E3MFL[>D15<P3'0'.^_%';?>':VOIE5&?+95D=&\BG=H@GLW3J35/
M-+72UX25.9J](-12E7<IT(<TC5.+R]3T[W8;+:Q%)V=;>1VAS"G>J6:Y2^T[
MZ#2-N(;K,NG2UE#0'^[U21WZA:F[1B0+60LMRU=$R'3#4N1L5I#0:0H!SE.P
M4$[[J', KRW'%D:2"I,F!J $?E];7Q3W%:4*1L#MXDP8^-ABD-=U<GH-6=*K
MR.AC'X5'8W\K5VOEPX?)(:D"7'QN_B,(#-G7.*"&%PG^=U2N5/,3WXT) 2RK
M+J]HJ+BW&VDY<H+,@ )+K2B92H@J.H=V"01MC-,\;4Y5MN#4)61PY(@WN >1
MB=M.W6\):03LJS+*Z![*[.RL<8QV"F'7B%5,1L;Z%>A0@->A)"4[)2G9.Y61
MS[E78D2?:!5'0TKR:5M#=34+"G"MTKJ 7#*R%D\SRL#$7G$YV8RVJK%.N%L*
MTNJ(!,JT!1B#:;1Y$V%[V7UC7,GU&"XK:,5J<8MK617R7U1J-V3)B>AOR_5,
M619.LS(3U@4LL,KKW4/(=<0$*2-QQ7.SJ4I<K7TJ4IU#86D:G=()6E!<4E 4
MA00"5$.""G><)]L6V5ITK1I4AM*2F#%E*DE.TDVD_IBC^9V<V?+EQKF5?XIC
M6.Q8\ZEQ!NQB3H+LC'Y'112OU<F1(NY%H_$*FY(6MQ#02IR.>10Y=&HVT--!
M3:&*A]]90[4Z%)<2'DE1>0XA(92@+$ICO$F%;8SUU06M#+.D*"9*@()2D@'I
M-U#D-ASF8PF8[=1D2*J??1XS3L>NL)$*ID(HF,1BWSB;*N8,1]L.2,A])2B+
M)AON%:]P5[(.Y>IJ6EJ2XVPI1"G&TN. O*J54X+:SJ!(2P$DJ2L#3:W3$@AD
M-M*4X.]H7?IW29,S86(V'6!;#05.QR@:OXEU67&26%@PS9RW[R9$A7%'4,O-
M-2H_K2(Y(6\[8/(2ZBM0T5%I?2= W!X?AFI>4RIIYNG;0HH0EI"E,NNE)TD-
ME*=*6P2"XJ\W!A,"+%2PDF(W.Z00"0"0( Z$\^?*,3CAYCSKEA3.07%45L(G
M0Z*2[M(FQE(:::@(<C1Q':K(*"A[T-XMN[CG<"U'O6,W2INF6%4[3NE1;6^D
M=U"I)+AU*)+KAD:A(Z$ '%W[).!=8TI*04E(DQL"=X)CE%I%]IQTHT@9E,0G
MGRIKO%=;VYD*4I00 5 A/9/D4@#L0?/C*J\I*X$[@DD0+FP@[].EP3'/2:\I
M+I%S*DP1('G>/'KTCK<SPJ+4;O*D*2>9*6RXHDGVR=Q^8IVV&P'D0.*EVH_X
M!L__ )@GY?J?CC,OM-MEU.1>'$P(Y:DWB>4?KMB\B?XI^._;R[;@#OO^7;;8
M\9^+@8P5S>_0'F>9/*^!PD-E7*%'EWV.P'D?CVX<8Z'\9(\0?41&$N$TVZI;
MZFDAU!(!!VWV)V!(]D#M[@/>>_?A1,1RF9\KQ)OR!M,1<^.'M4ATI!23I($1
M,6'+GOXCTQC?Z?IA6Z^5K4@);8(]E'?N4J'GO[QN>WG]7I,D;6-^?,?"_P#>
M]L=M\1IH:COMYB][\N?AXX0;F-#1)AO/QPMUMU*4OH*QTU.*&P YB"%#8'F"
MN_D1PZ3_  U?^7;?8W^?+Q-L2=,Z33O@G=/0]1;KO/PYSAY\VR0/R=]O/?;8
M_KW_ +>(YXWCZL(^O2,5Y?\ &5_YE?KO];1C(05)VVVW';\G;?R\A\//\VW'
MHV$=+?0_3'6+,8BHJQNI4?,QB3_KG>$5>\?/Z_OXX63[H^N>''QYCK!P8,'!
M@PA9,":2: =CO%._Y)D<_P!W"3W\,^GYCP_;]"WJO^'<_P!'_6G$<-J*D;GM
MMVW/U =_U_V_%D4"]K^!^@/TQ#0!?]YYDV^?^,9.$<>'S,"9F3O^<#J#RZ$8
M\+_Y_G&P'N[^_?WGW\2-*D%I6]RKG_>P\@#TBTB$A$E-M1*CYGP,XYX?A#8%
MM7Z>5.:XWSHOJV0_2)<94I!3 MVSZ8A:QL$I6E&R% D\X3M[0'%\[ N4[CSM
M&]=IMSBP5&-0)6GGU(MMN((.-\^QVN<4FORX.)"%PM:'$H<!4+ITAQ*@DB1=
M/GO?'-;PY>&K)J7+VM4-3IL6%CKT%Z7CZ7K'JR+VP6REQ<:<YZ0AR(B)'=4Z
MZXX5*/*D(;.RB-.S[M!3OT R^@:*W4* ?*40EE$D!282=6I21TOYXNQ0EC,*
MAI%04.NK2"(!2D F"E*@0+D !$"%8M1<V-*]1SI%5'F28<::(;3M?,7+"RM*
MU)+TB1OS1FG=^@D**?;(2-P=JFG45)"]*5:=2@L:8-@=CN1 )YQM?$[3TM4S
M4-H<<2>*0K6I"0"D39( L3N2!/C>1 ZZ"CL8<UR9%=D7@=D/Q)"972>0A"DC
MI.-M@LJ"B@D[I7N""2?(/>(X-!"M+9 "DQ /,$&RN=B(W@ XM35?4T50&F7$
M);"4C\1I#J0;S(="M7+>WA$1"NJ.E6E:-+<VF6:7,,RX)C7;>1U-9 R*7?L0
M'6A+HY#,UM2@^YU4*::9Z0;* XI1V(-F[/YYF:<RI&$CVNF!+*:=UQ=.ADN
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MD6DDCL#ON+IV48"J"I"YTK=$E)O G8;3/,CGO;&Q?9YES+V75R5JA+BP%'J
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MK(U"P0!:P_I%[R#$@6Q.WA>Q.QR;!Y\K''[I^MKKR6_!K<@1TY+#8(6E@N!
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MD DD1&K8B-QMSD\ML+% T@I))(!BT7]?E.(PUHPVIS/ ;FINVT/UZD-2U)4
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M^[$F+E.RXC^8YN_&E/S=_29$AA[(EMNR'-S^/6DNI)W0M)[\.!VU[2!25#,
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MC^N.4L)&ZB;SS'ZG'A6DRSY7Z4^?_P"&$CN"/(S_ *]^W'"DZUE:B9,;2-A
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M-3TWW'G!13!"FVPU0(;XP !<*4UVDQ<I"D&YDQ,#*:G-GJBOK*L*<2FH6M2
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M1[/4E1"@"4LI D$2-+NXGF#U,Q!A*W[0.SU53N->P9L5*0M*5.(HX25 B?\
MBE'G<09^6-^O\ &MD2#$CN_A&_&&X^S'CM.K$[1E;)=988:4XT']'EO)"EM*
M4.=U;IW"G'%JYN:CK3J=<6#99) -CZP"-N0/7PQB5>S[35..L0AI9)"7)"M[
M2$R.LPH1)C"%,_!GYI8(L$3?'?XII"+=FRC6R'(F@2T6D6WBF':QYZ5:(_PI
MNTBJ6Q9)?+B9C?3#P6$;*\T=-O/_ .WI\/'#3V)SDIL?^KF9/+IM\^N-BF_!
MKYKC4&OK,9\=WBEQRNJ8\>+5P:*#X>ZB) 8BL-QH[<6/6Z%16HZ6H[3;*$LI
M0D(0!R]SQYH-[CZ]/7G>,'L+G]2/_F__ (]/VPJ6WX/S6B?6S(4?\([XQ8[L
MEE32'S,T;;#15MLHJA:20Y1 V[I9EQUJ'8.IWWX0]G<_K3\#^V%/97/ZD?%7
MPV'QQU9T8HI./U\JOE3UV;T:OI8B[!\DRISD)A]AR;,V0A'I4M:3(?+8""\X
MYRA*=APX;24B%$$]1/4]?/#AAI385J(,Q$3RF=P.H^&)CDP8<PH,J+'DEOF"
M"^RVZ4!6W,$\Z3R\W*-]O/8;^7"F%\:WJ6H^5P/LC'W.#!@]2U'RN!]D8^YP
M8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^
MYP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D
M8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!
M]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'R
MN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U
M'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]
M2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!
M@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.
M#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'
MW.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/L
MC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P
M/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^
M5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6
MH^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'
MJ6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8
M,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^Y
MP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8
M^YP8,'J6H^5P/LC'W.#!@]2U'RN!]D8^YP8,'J6H^5P/LC'W.#!@]2U'RN!]
MD8^YP8,'J6H^5P/LC'W.#!C9C08<,K,6+'C%SE"RPRVT5A._*%<B1S<O,=M_
(+<[>?!@Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g389734g03a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03a30.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ ]0'[ P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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M.S^/@R>+L-8JSL[,^FV2*0=.9!/&_?131N[,8%Z3B8N49@95@(Y2J B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B BP=\K]G6*]
M[:M$*_<N$J_2)N2K<%#8.8K5 T6X.P?R9DL9P15Y*.D%5\NCERIAF9JU*;LD
M"]/J;L?8*GB>'J-J( *YE*L-VW9T9Y":<&EB@8O",4$9"'+9]O-:21VW&^GC
MOLF<17\UQ/D:D\AA1P]N?'TJFKM$#UC>&:RXMHQ2V9 *3F$SDT3QQ,^P&5L8
MSI:[0$530%BQ"1MOC\LLNL6RNI5XZV'/898IHV.OV4KHI.[K=X/EU76K<R1C
MHE[NNXZ#X5RD=.QN4NE38Z;F\OM?=*XP[-_-<J5RD\;OO'8W+N2&Q,Q/O$.I
MQW,\C1OM3KY6#D\SMI0&@Y<S9R1#(4<@TC#RSYCO+0B!Q=P;8<G7NVN,DN=K
MLI15HS\4NJ\S/,1;A=^TE32*\>S;VN3LJYTD#Q[9>0615FGQ$CNWBCMRFBT.
M]=.WN7;QW!AP]+ ,DO28[LK5K !#)!R FE/'P408B:8PA AJQ$31Q#&#G(T0
M1Q<N..?/B:&R<4;U9*,3VZTASQ6'L'!%'D[&1-P H8SG,2N3B+RS/)((1/-)
M+-S99?RR;)8=24C(4LF=N[1+EL]C[&Z9),U%DYYJ_CBY;5>K+R5;?LYYQWB)
M>1C%=)T=T1*15CW3ELXYHX276">R\#'&3[XIJ4<I2B+U#BG???OC!=AEJCLL
M1SR@4;1N4(S1@8,AQ!!MLUZ8V7"4/.YH+\D(Q$8W8YJ[<O&XT[&/FANR;ZLM
M>$QE*1AG*O))%)&%JG,6:R3=B[IW%2<DG<LX:]OWDB+M^L=T[*BKV*!N[Y<J
MJY;IG(91%#*:2BSA0AEU)W'U.@TJM+F<UJL,=<)-FQRCB%@C<AW&V_8([R9V
M$CW$(@+L X[DKG;'(7+_ "N25RQ+9./?S&&6<WDE82V ^SF$7+%V<A#:)&9,
MYET O%8H"*]?A)LZQ0&T(_7F'+AU5KH24PK&'.91".EH^)=RJ$NS3SG/8*JI
M1QV+["74(X;JIK."J'8MLIZP[*."IW,%-F>6$=_&/ XSLS"4U>:Q'7.O*^G?
MB)3-+%NU<#%Q!V:4V+;W8@XBOT>(H,%S#EQN6:SNKD[D%>U!5ELA:A']X1#
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M4HI2 I(2.)]A%$8.[,W7JS.TPN3;$L;<]I@'3=)O*-E9UM6(S"CAZ4L=/04
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M[,V_K]%]@N*\-;B"8V-L;)-1CAW:\L[D86'L/%KU;@A.NTSMUNQ0,^NQM,D
MTJM^H"("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("+'URCXF2-XEGVQ]:D04L3Q,BEBJZJJ34LRL@D5(LG$.%C)MDI-1%-,CQDY
M.B@^,3O22Y'IE4WNX. ^R%#BJ\6%S;D-*-W:E>$2D>L)DY/!9 =3*!B)WCD
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M)MT<9&[2"49N0ANY#QDVX9WD\Y8'\)];.XZ$]NHGU9("("("+U8!\OUOA 1
M1 1 1 1 1 1 1 1 1 1:+?N@C\(1(?0WK/\ VGA[9[ WT@Q_;?)??@6KN+O1
M=_>T'_NL(8W.L85X?'?6TYN*-FJ](W.RQ\E+M'%2T/%XNC:)9S6X(-@C;8""
MCX>5D$U[!EXK'P.NV4174"/XBU;4H]A.X1CXIRV>8EG\C!B)(;$=.L<4)C;S
MDO0RE.'$SF56>>26*-VK[&DGR$DUAW"6KB[L#"4DHD$E2@.RQ@\IL1,\=4>:
MPL5@&:0!82)G/5Q"%A!G<3GB/J879^\@.,.SK K#8<7*YH/T:YK;8JQDJW99
M%NTBMLN-0Q-4F:K)^-6[>=<L%MJPT=<UTSQ"M8<0$@P[625-%INZ-CB7&UVF
MTJ5'C*QD<>S%8KQD<N+'+2VH;47*(H1D;&324Q=I6LC.$FD;<UP[A1G-QW2R
ML^R&;79(3,-AZX@49;F8G'I#-*^H['!VU+4=9%E=!;*4J<0G-WO,I7-24F\/
MZ<FG!3,*U*]4UGR9WV>01FXJ9;KOYV$L^K;@=M(O#.ETI*9B&CWM(1)W$M8^
M/.XYK4SPT>78RMVC';?GQ3$X-DN&\%L*&6(AC@FK9.INC!A%XX9C#2=PE*L5
M.;E#NEW!7BF>-F @;7D7K6[>)ZN8R02:.^O?&(OWFHMU<9QDLC6/M[9_LZ<6
M:1:5IL,98JMF0E3V-!IIKDCLSJ0\>C<D6>4;#,Z$DH"V,K TBKO7)W)X:=B(
MR<C)^%;U9>)*Y25"#&P"<KUH):]G9%T<BR_#V-\^,JCEK7ASD<]62 Y:5B'2
M:"62"2"8NK4#89&*<W9FD,3CU+F,U:Y/H+-+H[&50A-C891-G Q$A-F^C?BE
M=7U\8-(G:IJJZO&89*.?M5+$JU68D=:<AGK.:F%["=\WL#?.V(A_'5MZNZ*^
M129-FS]EF>@$%^'XHIA1D.7&=*"ESGDC)J[&)N.7FC.&$:[ 4!=JY8Y+ "+@
M[F1 ;06"9VOE*9F&QRWEV[79S+J9ZPD)$YN3&SV!<0=WUT9F<=P*BZ=H[N>Q
M5*W(7*QVJ,9<?K[NVGUZ*7D*S-7*3CJW-/5Z2@S;OYA9H1S*0DI)6(L*Z6D[
M!38-_EDM#S$@DI$7ES-N>/:Q'4KU9),]1PURQ,P68:D4EB$!ND91Q,;C'/%'
M7YXC%!<GCWC-"#M-3CJ[9G I3E%J<UJ,!<HRE(1-WBTW.[:D)$>QW(XQ?3:3
M][3\5JF1V+28:SQ[]_K2'EZ_LZ.4KQWUBFX"4>:-ICK<TLJH69EL/*[#V.L2
MB4=K*.<KV5O8-@Q%G0*^A6I'#YI7DRD>/NS5C ,C-%/C9&G8*\$\09NX&'B%
MGABV6):]F(I,E(+5BKT):S[)B<0+H%8IXA-B* 2"8=CN9 ;U8WLN[[BU 3 F
M&!G<V.839G%M7:KMC\<Y>F06U9-/>5@FG]'L&V(&4:R,#*0T799;45FUGKR^
M%S-'N$H<AY%?9$4A5?&,9E:Q1T:JQE"0#UW%1KNUQW$,5R?&1OA8(0NU\7/$
M4<\4TM:+*ULED*/G+5(M6B''RE:Y<FVO)*TD3SQA+*%2:F<8V":V9O$=@2W"
M0B95CAAE[[F%]%SF:/<.IB+B6QW$7L1&;*)7I->#R^\0X>?DVZ<_42$'SMX_
M^GCB[^D67_'IEN?$>A6.]Y5OP(*\88BI% 1 1 1 1 1 1 1 1 1 1 1 1 1
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M<)%&VO82S-Y62JUHGK?=;'1Y.,K=JAJXA3V\C<K:Y9NX2!AK;!0S\T1'6QE
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M:]2I<7*IH"("+U8!\OUOA 1 1 1 1 1 1 1 1 1 1 1:+?N@C\(1(?0WK/\
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M>A6.]Y5OP(*\88BI% 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M9&*KEZ]7RS[;+<JKUX<B93.E\J4"JUCYK'!$8S&,DHF F$D@"(#(0$S@YL(
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M5OP(*\88BI% 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M$OQB7Y2>8:\&_P#-E>/6Q>_:P>;CV0_;*EXJH^23N5PWK$OQB7Y2>8:\&_\
M-E>/6Q>_:P>;CV0_;*EXJH^23N5PWK$OQB7Y2HFU> U\'?%3NM&#+6UU(VLM
MV?PDL4^T[NH9:/0US?[&FFF<\KDR!\2M?C%LJIY*?*:2B.<]FLH7-[5[-7'\
ML&2D/(TW*M2CFB=L92;20LC0KN[LT7?-RK$C:/U:NQ>%F5,^%\.)0LT,NAR.
M)>?R];-#*?\ "ZN^ 7__ #TU6WF&O!O_ #97CUL7OVL++S<>R'[94O%5'R2J
M=RN&]8E^,2_*3S#7@W_FRO'K8O?M8/-Q[(?ME2\54?))W*X;UB7XQ+\I/,->
M#?\ FRO'K8O?M8/-Q[(?ME2\54?))W*X;UB7XQ+\I/,->#?^;*\>MB]^U@\W
M'LA^V5+Q51\DG<KAO6)?C$ORD\PUX-_YLKQZV+W[6#S<>R'[94O%5'R2=RN&
M]8E^,2_*65;6.N:MJ#75&U71VCAA3==56"IE69.WKB1=-("N1S>*BF[A^[.H
MZ>K(LVJ)%'+A0ZRQBY44,8YLYSJ_)9"UELA=RETQDN9"U/<M& #&)SV)"EE(
M8P9A!G,G=A%F$6ZF;13T$,=>&*")G:.&,(HV=W)V !819W?K=V9FZWZW]-5T
M+)54!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%:?
MROX5:!YJ5^I5G?U=F;%$4F8?3M?1A[/-5E1M(R+(D>Z567A7355T0[8A2%27
M,=,AL=<N,&STC*>%N,L]P=/;LX*Q#7ENPA!8*:M#98HXS>0&$9A)A=B=W=Q9
MG?P/U*POXVIDPCCM@1C$3F#"9!H3MM=W<79WZO2?J5C_ )AKP;_S97CUL7OV
ML,T\W'LA^V5+Q51\DHON5PWK$OQB7Y2>8:\&_P#-E>/6Q>_:P>;CV0_;*EXJ
MH^23N5PWK$OQB7Y2>8:\&_\ -E>/6Q>_:P>;CV0_;*EXJH^23N5PWK$OQB7Y
M2>8:\&_\V5X];%[]K!YN/9#]LJ7BJCY).Y7#>L2_&)?E)YAKP;_S97CUL7OV
ML'FX]D/VRI>*J/DD[E<-ZQ+\8E^4GF&O!O\ S97CUL7OVL'FX]D/VRI>*J/D
MD[E<-ZQ+\8E^4GF&O!O_ #97CUL7OVL'FX]D/VRI>*J/DD[E<-ZQ+\8E^4GF
M&O!O_-E>/6Q>_:P>;CV0_;*EXJH^23N5PWK$OQB7Y2>8:\&_\V5X];%[]K!Y
MN/9#]LJ7BJCY).Y7#>L2_&)?E)YAKP;_ ,V5X];%[]K!YN/9#]LJ7BJCY).Y
M7#>L2_&)?E)YAKP;_P V5X];%[]K!YN/9#]LJ7BJCY).Y7#>L2_&)?E+,@-1
M+(T!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%&=\_I3I7Z3)7]CFV1)4?W+F?M
M;%^6,4J,OT=?[,7XO.I,$:JR B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B BC.^?TITK])DK^QS;(DJ/[ES/VMB_+&*5
M&7Z.O]F+\7G4F"-59 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M:-KHKG4Z/M6TZVU+=-;;2E;1*R,<MJJ/=Q36K1:]8+-U+9-8+J"^S<3(>_\
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M$!$!$!$!%%>POZ7:*^E27_8CN,2F/_<F<^U</Y:PZH3?ME7[.7XM84J"+5=
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M)W_(<C!E>2^D_A;[:\4_Z.'U'P>B5_WO0^_<5W0Q12" B B B B B B B B
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MY7WB^P/RGKY^S33H\:?JA/IVH?T:H_E++K9O!WH5+[]F_ UUGV&BEE: B B
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g389734g03a31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03a31.jpg
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MTM,(&#,T-C="<G22EK.UT2128K&RP25#6)>AUO F5V-VP_$G9'=X@K;A_]H
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MK:5:_P F];UO+A (V(!'K$;C\1RT"0=P2#ZX.Q_&,N ?;[8)4E0JSV(8I/\
M>J'FB4)2?_Z[C26]Z_\ 3>8<VFZ=8\+%"E.#X$358)=QZWEQMF=!JNIU3O6U
M&_7(\Q@N6(2-O-XQR+YLF:!WWQ%45$!]70+/MF8TT_%189,2SMO,NPX1!M#B
M3K95QE3@\D/EI:7MB0F).BR$:0A]EQ4:FX1X,U8S(-(HAHF99#3CDH%6626%
MBIJFNK@30S1EASH9(I$.Y1@)9#QMQYHP@D.MZB4E17C%Z2+40Z-%#.H87%LL
MA:"Q!*%8I)TIHI!LKHQG^D^/^WP%LQ[[4 ]@B:VE#A  Z\#*(1^+UGG(LE9
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M^"K!;M(A*]]L3,SQ]4C;G@KHB&./Z7K%W<,R1<FO7.Q9PO*N (:$F1I/WLE
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M*6V[)/EHRX\N=%WO2E( #9&D2)[KR//34YQML6W_  EJDO.-ZBNPSB;C_1M
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M&#%:C$5;U_%I4N$6%Z3Y?QJU#5Y__EUDJK=L=A0!;T*&0^EJUYX1^".6O/\
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M:H@9H@QO2FRQ-#IPJV[KRWMYB<8=FO0W-[UY[]RW&1K\B$)3_!R$ZIQ?Q)K
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M3G6^U?1ZLBQMININS5ZED;=U"A+E2&W&I)L$\RI.JOY.W.&Y21L3C1]B.OR
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MX)^Q'AKX$TWXMCU6U3VQO>^I_P!/'W__ (Z/GC>)[Z=.E_VEQ\PG!/V(\-?
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MMC>]]3_IX^__ /'1\\;Q/?3ITO\ M+CYA."?L1X:^!--^+8]5M4]L;WOJ?\
M3STIL_.K.T8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9KI](%UBW<^D^&.
MHUUT>V'ZWVQZH7!$R"F5(=#P*58K#'0/?4M&X,C1$=&4M]*7-J9TMKU=:7O>
ML0:K;T[B#A:O6,8CU759*-L.@<F T;,^T9W'(_/$GE#?PW&WCG;NRG@30.+>
M#^VW6]82V][@/L_K<1Z U>R8(DU*7B;1]*=K<85A9A[I=G B8J!(5??=0,AW
M.QYQG-6-'K74.=UN[&*Q1RD:]L]H\4%B!QA_#I+-ECT:U>*>SWD(5E=!.N.#
M;$(,\<<4.KE& C5G=[L8"$T,9*U5#PS4QI+$LC)&P?KVF4+!Y8C>VT@;J-X,
M&A\%C4<WE+L-UW'P^)W\?1Z_^J-_#[?AX^&_B/$^,B#;1XM9TZRD']7F&-"&
M:P^+#NTBEQ'#-)(>*[K]7NQ#2WZK(DSK16?"XQS>[5X$.F19A*P(@;<$G9TT
MU79EP-<)8[ORJR;+TT',AN3)(?%-RRU>DZJ""2!NK,64AOYO<.Y]T+N-O-YS
ML/1Z?MBR#'1?&8JU= JE-(23?0J=4J1=*+1BU2J<&J7.JVSN'BMJT"?TNP;
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M:%:VE25)WO2DJ3O6MI4G>MZWK>M;UO6];UYY)//YLP/-Y\_.,8QC/5@S\O\
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M0Q-@BK8IT99H;$4"1H0H>%M(.?XISU8;</E)-1BEA\>/X;)P&VR)HIRN38A
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MDRU763&'[D_2*_,PHG]*6F?V1R,?-[QE]@E3^U=;Y,SM7SNOV+__ &F.(_\
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M)"P@=UV +>9%;P)L:Z>'_K//1\LM;ZQ&%C8;]ABO36[14"L=<BK%*<(-LQ'
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MDF@%F)%D%4QM8D@+2K55C9*13MT?]'GZ=DZ?<'@8@#S,FQEA#;H_38E3)S!
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MQC&,8QC&,8QC(;XJ!KH 3?6:W:6;6P2[+UD\5DLQ-P]!K$:NA0@>JSB=OO\
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M;^)?_?[GOV2YU7]L%QO]9<.>\;_RKD?^8[2O9;OY6'XOC][G^!/]-_$O_O\
M<]^R7'[8+C?ZRX<]XW_E7'S':5[+=_*P_%\?O<_P)_IOXE_]_N>_9+C]L%QO
M]9<.>\;_ ,JX^8[2O9;OY6'XOC][G^!/]-_$O_O]SW[)<?M@N-_K+ASWC?\
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M*RI#P_+H-1]#JV0U>N3>K:>88KK!95:=7*V)P1(TR9LL@V,8R(^D?X9>'_\
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M^KND>V%?^L?\L?A3_1Y?.TY+_.L[ZNQ\['C_ .Q75?R2?K,>KND>V%?^L?\
M+(TO?I.? (2M/%YD'Q4<KDQ0'2RI8R^T4F[0.&O<=ZP":F2-['ZVEE9@T*'I
MWK2M^\3F$^7DK:M;*CV;\=1U=91^&-45K&FQ10J8DWDD75]*G*+]$\XAAED]
M'DHV6)=;TEI*Q%^N0D[,QYCX*:UA 3X>;F91]LC)+_"G^CR^=IR7^=9WU=FM
M^=CQ_P#8KJOY)/UF7_5W2/;"O_6/^6/PI_H\OG:<E_G6=]78^=CQ_P#8KJOY
M)/UF/5W2/;"O_6/^6/PI_H\OG:<E_G6=]78^=CQ_]BNJ_DD_68]7=(]L*_\
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M1%!9F( !) RXS*BLSL%5069F(554#<EB=@ !XDD[ >?-35D].5Z-ZN&R(/\
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M)/UF/5W2/;"O_6/^6/PI_H\OG:<E_G6=]78^=CQ_]BNJ_DD_68]7=(]L*_\
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MF&@"L%K(DX\.91[G6@4BR'R#ZE-PA(=B9 %MRICR4.;;U--%@X$>A*%+F&3
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M**CQQA8'O)/859NO3F9YEKP[])D1DAA:*.-AR<W,T8^F5N9@A)!.["*KA?\
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M+,CUE/DE0>9ME!VR[)WC#EMW'I9N%31DH;>.B1+E&8CN;K$6$P)YUV#F\9F
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M>F<0+79FTK3HZ%2.-$>109##!8LOS!2T<L<421SJL%N2^'#\L10F*>)!S\X
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CC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g389734g03b30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03b30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X<]/:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P,V(S,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S S8C,P+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P,RU.;W8M,C R,B Q.3HU,SHS-R8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P,RU.;W8M,C R,B Q,#HR,SHS-R8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[
M)B-X03OB@*(@,2!R87-T97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E
M;&]W(#(V-2XF(WA!.R8C>$$[XH"B(#(V-2!#35E+(&)L86-K(&-H87)A8W1E
M<G,@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @(%1I;65S+5)O;6%N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L
M;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @
M("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!I=&5M<R!H879E(&)E96X@9FQA9V=E9"!F;W(@0U,Z)B-X03LF(WA!
M.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R97,F(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<P,V(S,"YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,#,M3F]V+3(P,C(@,C Z,#4Z-3,F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,#,M3F]V+3(P,C(@,3 Z,S4Z-3,F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($9L;W<@0VAA<G0F(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I;65S+5)O;6%N
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @
M(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @
M(" @(" @9S S8C,P+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E
M;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,RU.;W8M,C R,B R
M,#HT-3HP,"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,RU.;W8M,C R
M,B Q,3HQ-3HP,"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X
M03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@
M='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E
M9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A
M;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97,M4F]M86XF(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(R+3$Q+3 S5#(P.C0U.C T*S U.C,P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,BTQ,2TP,U0R
M,#HT-3HP-"LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#(R+3$Q+3 S5#(P.C0U.C T*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @
M(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=)
M;6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ
M,C0\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%<T%!
M1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"3$%!
M04%!14$F(WA!.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O
M8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!
M.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF
M2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9B\X04%%46=!9D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!
M04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%1
M14)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G
M44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7
M>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/
M>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!
M.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(
M,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU
M2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!
M:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC
M=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I
M9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E
M6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R
M<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1E509C8F(WA!
M.VA:,D9U8FDV:T5C63)(8VLK04AC-5!(:DUZ46$X;5=-0F-I>&U4>C-,8UA#
M,BMM,F9.-41X:DUZ059*.6AS4"M#>D]':$%&>4QR>C(F(WA!.VE:1V]2*V%$
M;#@P96)J>4ET46=88VQ)6$LP<%=T4U<R<'983$)P8U!F.7)59%AN-W9S5DQF
M>DPU=DTV46UZ1%-33GA66DEM:G%E=$LF(WA!.VMO0C!W4S R1W)V-U=59%9N
M=75(-T5482MF55=5=S9J84Y!-FMQ-TEA.%-.:E9';U)4-3584%%B6$4R,E$W
M4T8Q355Y:3%U<F4V9U<F(WA!.V4S:T5K5&EQ=75936]M2F\X,UEW;4I#>'E6
M8VEY9&EQ1S%$56)05#=C,T8Q245J1W<W:VYW03=N2C0X8W!M9S$U8W-90S5-
M5G90>D,F(WA!.U!):7IT4&@W4$UD>B]S5B\U<7I943=0+T%*>&1B4'10*V%0
M;6PW*V4Y8V)P-DMF-G%(*TI/6$11-"].;U!A3U1Y8FHX*V$R<$A*65HF(WA!
M.T(S<7!(-FU'039#2&UK9&\U4$I.3$@X=UE(64QE,GAI0C9Y4FYK4'!5,% T
M-5)0<S@O=VQY369A45 Q0VU65SEZ0F-W2E!!-&MI:T8F(WA!.U5D96AZ06Q%
M>$Y&,E5:0U%S8VQ427-N67$W1EA9<3=&6%EQ;S-T,T9:,FMT,4Q5>'=Q5UE$
M<6%D:&MO44UI04]R1$I-4FE:2&\X.#$F(WA!.TAZ:').,C5%8W!T668R56DR
M4#!V.7).>FHP8TDX>%ID1FPQ,E-823!02E$P-F94<F=/;7)32#1M1DIY,')3
M2W9&<3AA8VPK,$8K,'8F(WA!.V9*6DEY2#!F;UDT<%%L=&M0>#-236QH-5EI
M="]71C@W4TUR96I%1%@T;%EG37A#8VQ"1D11<CDK44=42U163FAX-%%,-'9X
M.&MS='0F(WA!.UDQ4S%)348Q2V=(-U!);&8K0D\R6'EW=VQZ06-A1V5C95),
M379+,VUU9E5*+W%6-&\Y8W%7:FQ5541C9'E'2&HX<S%U<3!O9T]+4$HF(WA!
M.S(R:C%H;65'6$YL1UE$<UA9<3=&6%EQ-T9867%X+WIH;V0Q<61R0SEQ955T
M=5=0<$4P-4)Q9$LY>'AZ33!E8U%*=G$T3W4P.'-K4G<F(WA!.SAW=T(T<C)Y
M;D%D6DQA9&5L86]W-V)D33)W35I$=D1P0TI14%5&3V]B=7=M=#1Z3G$Y>F(S
M1$E23V=$;4]V16]O54E&-DMO1&5.978F(WA!.UA-67=K1'1%14]:1V-33C5Y
M0C9O5R]V0VA%,7)Q<S@X9V1L05EY0F=U+WAC>G@V:C)Y>DA#.6I%1#5.5UA*
M5SA::R].03(Y<&8S.'@F(WA!.SE'3U,T;%DQ9&=#>'%E-TXO6$Q:5&I!8C=.
M35E3;61H6F5J958Y26XP=E1F4FY91U=2>DDV:F-,54%5<CE'85A66FAK;%ED
M.7!-0G@F(WA!.W=O.# S>DAC<#)+<V0X-#9&96%L0D1,82]&2F(X<7=K,#5"
M<6)I=3%D<WI.2&YJ06M(<31'=3 X<V=":C!9<F$V-7)':G<O56A%274F(WA!
M.TQ-,T=66$1C;4%&96\V52M78D-70T=1.%9U=&AQ36U)8TY5<&YZ1F1.37-S
M:T5%=$EK9TUC:7-Y1DEZ5595=%1R:"],:7%"4$\P9FTF(WA!.W!86D%/,4Y$
M6&TK1W1H6DAI4V%I14M454U#1'A),BM,<#=$1#1(.4M8>E(K6B]O>"M3,"]8
M=%AA3TLR<UEW>49T-V%0:#EQ;7IT,&\F(WA!.TMB5G@Y3U!C>2M:4C9S=3!9
M:C1";C-L;E-:=$PP<U<X-T)P6&-Y3T%A:&%G1&E0=7I5-FY+2GIS3S<P;44T
M-%5E86$U:G53-T9867$F(WA!.S=&6%EQ-T96:S!-53A4=WEQ2&IK0E8Q4%%G
M-TA$16M'=VE545)2675V:S9A=S%"8C-4-5!64D]624AB,#(S0D9"249B>#A"
M.#AZ>G(F(WA!.T)/4$1*,7<P2FA,:6AV-69T57IB,S!!5#%F3'%816E+<6U1
M=DA*>6]I<E4O0U0K>%A$>%)03$I8>EDX36AZ>#,X:TY!.38T94I.1$PF(WA!
M.U1X96Y$3DQY6&QY4D5B-'5316)I:F(W9E!*;F@O;C=-4G@O-FYV.$%J>5)C
M=6DS*V]7>G=N4UE,1U-10W1Y>F]Z5D1":3-W;UAQ9'@F(WA!.SEO9&-G33!9
M1RM)>3AV=U=C<T5P:75!4C@O=T5Z,$1Y=F%A4U1,>DTY,'<T;55I9T%054M.
M.&]Z-F\U3G518VI485-/3&9M539Z1F,F(WA!.W0R2W5X5C)+=7A6,DMU>%9B
M2D9&2W9#5D9D5"MY=T)(,TA#0U)Y45%$>E-B6#E',&QD1S%#6DQ/1DI5='!M
M4C%25DE925-#0T%.-C4F(WA!.V9I>E0T9TQ03G!/;G@O>E(X:V1(;V5J4FUQ
M5TU!4&HV86LO:4UG8SAZ,4M2<#A9+VA(>5)I26E+1E)1<6IO;T9"*T=6:S(R
M9U4S9U,F(WA!.S=&56UT0C5K:C@P6'DS0D4R9WI1<$I:=5)':&=M6&ER4D%+
M4SAG9C1N3$XP-D1+63AF:4<O;W!Z<VYG2%1X-&1S=TIV;C9H,SEW<FPF(WA!
M.U$Y-DUF5EE3>&IT16$X;%5K37-.0VEK9%$X:$E24T\V,35E,D4U4C S+TAE
M,$14;FY,,&IZ+U9Z+U(U<$0U;S%7-71T375*<%EF,&HF(WA!.TIB,&%44TQ!
M:W1X<4LK<%!X6F@X4'A$84]U-"M,2V-U85529#=J<$@Y2B]S8S=2-E-'5UEI
M86I'6#A5*UAW:CEN.%AW5&$P,&948FTF(WA!.S%H;G5T2V=T<FE203!K2$9'
M2T4W.%-Y9T%K9#AZ;V%J2E<U22M,<4TR;'=I4D%!:T(Q<7)2165I84Y'87!9
M=T$K4'!Q5"M)>5)Z>E F(WA!.U5T63 K369W:C5)>$521D-O;U92,%5#9T=6
M171W1DXT<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T950G!V*SEU<F8X>%,O.5%S
M1U=4-40F(WA!.S-F<$M%9FQA6%EQ-T9867$W1EA9<3=&6%EQ.'0X,2]N>G!V
M;#=Z1&4V3$QP33%X2EI/16%:6E553E91,G=)4#@R8E!$,F%C:T)+*V(F(WA!
M.U1,34%A4VXO04M'6C!J+W%X,T@O04-/5"]M;DQ0-4EL+T]$2#AW3S5$-FHO
M04TU2#949#9F9%=G,%<T43-%36M18WEO86,Q2S%P5#,F(WA!.WE53WEP06<X
M4R]M0C-):B]!2T=:,&HO<7@S2"]!0T]4+VUN22]W06M3+VY"9GI!-VYF.$%1
M>D]K9CE73S0O-4A*+WI4:B]*178U=U@F(WA!.SAW3S50+TDS-3$V9C5S.'=2
M-DY"<&LQ<DI*1SAG;6525T$Y359P44%D8V\Q2%HU>%$T:6):=WI#4G!L1VME
M8TE.8F4K:C!Q,V0O<4TF(WA!.WAH:VYU1#9-4D%'>F<O1356="M.1C=D<S!S
M3E1X,W=J:S=F561M;D%);DEF<D8P3GHW=3<W5E5T.61.3U0V<E@Y;5 Y>EEJ
M<#%A<F4F(WA!.V]0-6A74V@W1$@V=C98,E(O8CER1W5$+T%'=C=:+W,O,E!V
M4R]6=DU7:F%B9%%A9'%L-#5N8WA**VIR0TYX2$5K<#1)6E=4-'%$=S4F(WA!
M.T1K;W%%,D]1>5I9>$E%:CA"*U!X,T]2<#E(;'EX33AC9'0O5DUI>E<U<3EV
M<TY(*TIL34U%3453>%%2<D9%=C)9,$%64E4Q,D$R>DTF(WA!.T%!1D(Q37!'
M4G-M>79W<UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ=S<X>'9Z2G102D56:$IC
M5U5L-$PU<$954G5Q8V930VLQ<40Q-34F(WA!.VPV6%-(3F1'<6$X;5%265(O
M=T)$3392+S%9-VHO:V-N+TY/6FXX:U,O;D)R+TU$=60O,$UZ<$@O0499-VHO
M:V-N+TY/4#AK4R]N0F8F(WA!.WI!-VM082\X-4@V5$)095-(4F)H=G)5=VQ!
M.590:'!&2$94<"]W058Q>5(W2VM14%9Y6#AW3S5%9CE$3392+S%9-VHO04I(
M2B]W03 F(WA!.S5(*U-*9GIG=C5G9'IV.$%O6FY34"MR2&-F.$%)-5 K86-F
M-4EL+T]#+VU",U!A33%$:T]X5C)+=7A6,DMU>%8X:B]M+W=$*U1*,3,F(WA!
M.R]J378O2G!--FY1+S--6$%Z9E574398<G0W<6YL=7AT<&8X041C,#=W<' P
M35=P,6$T=&]L<&)1>E)T2DLO0U)Y2%HV2T]+;W)(6FLF(WA!.T=55'AI37EF
M6#,W8VHQ+T@Y<EE$64A*2%A6;&)-671/:V)Y6EI0170P8FU1.%-X;&PK14IY
M4'!Y25DO<DY%4G9S1DMK;FIT05-04#DF(WA!.S9E6#0K>C=5,% V2T9L,74W
M:&=K<U1C95=0,%%D55<T93%H3$]I;61N=$=A3T0Q3TAP27-:9&Q6=6I!,6]C
M:TU92G5P.%A$*S-N,W(F(WA!.WAF,6%63E!V-7I02'%&;$@U5% Q5S%U>71R
M8U%+<WI)1EIP4DML<S@V+UE5<DA76&IW<#!,57=3:4MO*TIU4BM.-BM/>6<Y
M,T-L=C4F(WA!.T-%3BM:3G5106]-1G=E27)19D(P1F$U6C)L+V-N-$U-2#%0
M<%)T3&AM8W9E=3$S=5-S56Q04U56,D%J2'=M;FDQ5#<U>3-H02]6=CDF(WA!
M.S-Y9&]--6E+:#9F=BMF-G%#5&5B4$Q/<V$U9%=Y,BMP0WAS26MB,4%I<UIF
M54HT,4)5<'E6;S):4VIN:E=H2W0P>7)09VQ-:6I18S<F(WA!.W,O6%ES15IC
M54]/6BM69F].,&)'+T]I3V%.,%!Y:F]U:D-&<F5.<')Q0T57-C-K-V,U4V=*
M-S!#<6%(:CA+:C11<3E&54-E3%1W:'DF(WA!.S5T1W$W4GDU-S1J55-B;V-V
M>#=Z>DI036Q/8W9C1C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8T:B]Z:S4O
M=DHU92\T>5A8-F]S,U F(WA!.UI(3UAW8V)58V<X26AH;&UL5T]*1VMD=6E)
M0WI'9W%A064R8F]M;D9!6B]D84HK5W8Q=%EN;75B3V5*-69R54I7-E99;S%N
M<D4P<V(F(WA!.S(X,&@U44U!,4=(>#EU2C5:9VI*;7)O9FPS92]V*WAV-%E7
M:#<S5"]!375%,4M76%1R;')Y>$,S5'EO5G5Z2$-N1T57>"]U;W!#9E8F(WA!
M.VMD5S5.>$Y",'%+>6I,3E<T;S=D,VYF5D91=$E0365N84U,.6XX='E46'5L
M2D9%2&UA2U)74U9565-E<'E&0C9H:&5684=N12M)248F(WA!.RM+57$Y93!V
M>"]9=VM"93-*2DUU65!U:D],9&TW1EA9<3=&6%EQ-T98>5 K8B\X035-;EAF
M*TUY+W=$2G!--FY1+S--6$%Z9E55+S F(WA!.V968F8Y039F2F,S3VM00S92
M>'DV8F963$MK1'AO6DDQ1'E297-F5')Y;6<V1FA6:S)Y:6-$>$=H3#-J.&-V
M8U<P2%EC;%=057)!47@F(WA!.S)C<TAL2#8R.&1V8S(X>3(V=$94,4=M94LU
M;CE74# S06DT=6EX=%5%3'1805E(;BLX<F9R.7=R.4M,2#E&6#!Y=C%E1TY,
M-WEM>50F(WA!.U)+2E9V-5 W<C9V9&U55WDP;69L1$DX9S).059(5#114THX
M*U=4-&4W;GDU<"\P<44X=V%H0EEP94I(+T%)6G5)0C9R47@V5W!,<E8F(WA!
M.TE&<EAN27%C>$-Q;6I.>35U=&1Y5FQI:5I6.69X*U T*U-K,3-)6#AG9CA!
M>5DY<B]W07<Y>"]X1$ID<"]W0GEF94='1#9N,49N3G4F(WA!.V$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAI4"]/5&XK.&YL-R]J2F1F<6EZ
M8SEK8S5F0GAT4GE$>$143E-L,"LT33 F(WA!.V%,2GE89WE0>6]254U.,4MS
M4&E59$--,T4T8U%C84UQ6F1A9FY$-7!T,&II.4LQ;'0T5VQE1T)L;5)595IX
M27IQ,%5S8CAG46%(;"LF(WA!.S!E*UES=$1!.2\T*T1B-'A6:BMD4&UD<FAP
M;71,33AO-$DO5'!C:&$R,')42DEA5&=S+W%337I--4Y4,7=F:TE6>E R9&9G
M=FIL0V$F(WA!.S,K83)U-G992EEZ5V1P1$)'2%=)42]74&A6-%I)3TMR2DY)
M;T-P33%.=753>#9+351D;C=09C-)3UEL:&5::E4K-DTT=#)B<U9D:7(F(WA!
M.W-69&ER<U99='$S-5AE43E7,4-F5612,&Q,:3EU0T=M;4UK>6QI04(P5G=/
M9SA->5EA>DQ%541S=T]/2C9)5"]!2E5Z*U=F+T%&630F(WA!.R]W1&MB8V8Y
M5DUN*V9Z9GIV=5(T564U0C9Z*U5(-6-7*VM8,7A$;W-A>7<R.'-K8F5R3V%-
M<45G,$UL3W53>#8W35I!8UA8>54T;SDF(WA!.WE-+S55>BM79B]6:FHO-4<S
M2"]65$DO;C@S.#<W;#A+4&,W+T%*57HK5V8O0499-"]W1&MB8V8Y5DUF>BMB
M*V0Y>2M&2'541%$O>30F(WA!.SAL849Q0S9J<$]M2F$S:4MY3$U*2E=)5FA2
M:%(S66(O04-Y=DIQ.&MX56I94TE!8VU36FIS,UEQ-T9867$W1EA9<3=&6%EQ
M-T9867$F(WA!.S=&6%EQ-T9867%K,VU0>60U8CAY3$%M=#)3,VDR<%EW0FYK
M5&E8<'DK=WDY94DV-61I>GIX+U-A=&I+25!.2E K5DTO;&XO,5DT+RLF(WA!
M.U)T>"\Q57DW."]M+VYF8W@X2U!C-R]L5% U6B\Y5T]0+VMB8V8Y5DUF>BMB
M*V0Y>2M&2'5D+WEP;CAS+RMR2$@O=T%J8FHO<7!J*V8F(WA!.WIF>G9U6'=O
M.7IV*U9-+VQN+S%9-"\X06MB8V8Y5DUF>BMB*V0Y>2M&2'5D+W=!<5HO3% O
M<7AX+W=$23(T+S9Q62]N.#,X-S=L.$LF(WA!.U!C>E1-3G-D:7)S5F1I<G-6
M9&EQ0FTQ,U$T2E=H;3%',FEL43!E3C5O,5E(=TE*<4UM36-J>4)287HO16YL
M,R]!2W5L<"]Y4&DO-7$F(WA!.W<K1E!U4'E7=V=D9#AW-D$K:#9I:6%N84TW
M5S!W5E)01U-367E!04$R5'@T<#A1,E!.4U%J=CA!16YL,R]Q-E=N+TDK3"]M
M<DEE1E F(WA!.W50>5=W-R]%;FPS+T%+=6QP+WE0:2\U<7@X2V9C9FMT:%9T
M=%HP:39L14YR9E<X.'!"26II;%(R;T]U>6MN06-C:'I"5S!::T5U>%8F(WA!
M.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5CAG9FUJ+S5-4%@O*UEU5$\F(WA!.W(P9CDQ2#-/
M0FPK;W-E9E1T45-Z4SEE,FQ7>FM)161Y>4U);4Q&,5=J:V-457=U0G8K>3-G
M8W8T:&18=7=O=4=N86=B139G3&%5,D,F(WA!.WEE:3$R16(P4DQ13G=-;$]0
M2VA"<%=U4$5,<3DQ;S@Q04MX0DE"255666IS2S S*VLU2D-*=61+,5,Q:4TQ
M>EIZ=U%I47=M4U-.,%@F(WA!.S%&3$)K<7=!-4%O=TDY:C1:151I95)345=E
M9FM$+S5-93$O-6@W:B]!26AM1#)N+T%(2CDT8F-(,5!Q3$]B8S$R2W5X5C)+
M=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=FM$.#!F+TIH-B]W1#AX8VUD6&\O-W%0=6,F(WA!
M.T1,.5)45'E4-7IU=$\X=C9P1$XU9VXP=S)T=#9E:C)D=7%$,4IM85=B-&HV
M37 T*W!S>#5+9'=/6$5B5F%J04I40C1B<S<O:3)52C F(WA!.T1U;39A-6]C
M:EA,="M957E36%5S:W0S2DQP0E!Q;31T,6=C.$8U,4MP.$AX34]/+T%B,4Y8
M:'DR+V0X=C988V(O2#)S=4EF>G9S5CDF(WA!.U$X-E%A=G W>#,O-6=&,FEL
M.5-/0S0P9%=357AL2C1J>%--<6<Y4TY624Q.6&9B:CEO4C U9V1S9BMY57IV
M.$%I*WAI6&YF6&YU4TPF(WA!.T\Q,71T67-(-&-R:5-*235*9G$T6EDU2D1W
M4UAD<%I$>&M*87172DIA=5I7;G@Q=5DX2B]7=WE3-VIA8V9K1"]!3U1(=&8X
M06U(=5 F(WA!.RM)6E0R;B]C;C-H3T0V;C%&;DYU83=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F(WA!
M.S=&6%EQ-T98:&YN2#AH9DTR=65A3E0Q93)V-TM/0SEN86%/3U%Y.'='-TY3
M36HX8S-71'1+14E#2D(R8V%E06LR:S,O045,6#5U+S8F(WA!.W57;B]!4$)4
M9CE5.'0O;&)(,T9J*UA097!8;B]!1&IR-7)T3$]E-FLQ1W=-9'9'.')H5$Y5
M:$9,1VQ9>'9T:&HR<D%M<4LO;'HS<78F(WA!.R]1=&9M-R]Q-6%F+T%-1DXO
M=T)5.$@X<EDK-'(K6%!E-R]O5W9Z9"\Q8W10+W=#0VTO-G T+WET:C=I=C5C
M.3=++WEZ+TIF>D(U53@F(WA!.S%W-GAE,W1P4$)(1DQ'631425AR271".7!&
M2#0U:F%V6'=Y=S110S)9.$II8F5W-7%7.3)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8F(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2V]854Y11FU)
M04E*3&E3-&LY2TM+3&='3$)':T\X:E)R5&I'92M3:D<Q55 P<&9F.$$F(WA!
M.U9N=2\K1'10*WEJ2F-!+VY$-V8Q270S-E5V=BMR4&0O.$AA9CEL1U!!4#5W
M*S,Y4S(W.4M8,R]6;G4O*T1T4"MY:DAG2#@T9F(K<&(F(WA!.V0K;$PW+W%Z
M,V8X07=D<"\R55DX02]N1#=F,4QB=C!P9F8X059N=2\K1'10*WEJ2&=(.#1F
M8BMP8E%/=F%N971O96]Q9$IU,4)T6F<F(WA!.U=,5W1"*S=/-7!/5&LX54)X
M1&-C+U X055P2T\O4VPY+W="5V4W+S1/,"\W2TUH=T0K8U!T+U5T=2]3;#DO
M,5HW=CA!-$\P+S=+364F(WA!.T%F>F@Y=C9L=#,V579V.$%Q>C-F+T(R;B]:
M4FIW1"MC4'0O571U+U-L.2\Q6C=V+T%)3S O=T-Y:DAG2#@T9F(K<&)D*VQ,
M-R]Q>C,F(WA!.V8O0C)N+UI2:G=$*V-0="]5='4O4VPY+S%:-W8O9S=4+W-O
M>#1"+T](,B]Q5S-287<W6'-.<%!96$9Q,#1C>'E3;4%Q94%Q4BLV;&LF(WA!
M.V)P-UEN2'1925!Z+T%&3&%9-5=L,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W-2+S57,RM82"]6.70O=68O;6XF(WA!.TUR.&IM+VUL
M:#1K93DS+TLR+WDT+W=#<C=B+V,O=T1Z5&HK4GIF>E-V:5(W,$9Q2#5Q9FPY
M3&0V639A,T%Y=UA,4U-N-"]H53(P>58F(WA!.RMZ+TTT1U1J;SAO0CE05#E)
M4C1K93E'+SAR8B]!0S0O-G9T=CEZ+S@P-40X:FTO;6Q0:5(W,V8X<F(O3&HO
M<2LR+S-0+W=!,#0O:V,F(WA!.S,X,'(T:V4Y3TY!.#$K6&9-0WI.;S$Y2&5R
M8FQ23UDK6'=L-CAA.&=/=D4U5FQW>G@O54M:0U%02DIF368U<RM2+TPR<'9P
M;6\S>D,F(WA!.SEI04US555B>6-/47%!>%5%5G!V5$QS5VEY6DDX44=Z0U=7
M24Y&3% K5CDO;'0O>3)Z9CE).'8Y37,O:S-.,V9A:G@T;U16+WIZ+TPF(WA!
M.W4U,'$Y=&]R>5EY>G=3>'AG,CAO2$HP2VIE;FEC;D1S-TM*03$Y<41M:6DO
M*U8Y+VQT+WDR>F8Y23AV.4UH+TIU8G4K,5!J>&0O>78F(WA!.W8X='8K5S)B
M+W!(;"]P:B]!0V)M-W9T6'@T<#$U5R]-,WED-6]V2'-T2G93.31I1U0P2DDS
M:5IK1WA+.&=!,4LY=#AP>F%42FI&>4<F(WA!.WI+3U%3-4UJ=G(R,7-B2S1V
M8G0O4W1B5TXU<#530U%S8V%L;6%G<61G3S)9.%EM4D%(37-Y85EJ+W=!<FTO
M3% O<2M2+W=$27$T+S8F(WA!.W U;"]K33,X,S=M=GA9.3=V*U9Z9FQN+T%.
M6'E0+VM68V8X05902#AH;2]M+V-V:7@W,$)E9FTW*UA-;7%A9D]M<WAM2T@Q
M=E9B,' F(WA!.SEU84%,+W5V>'EC9$1M-%-/1F9&:C-O+R]L8S,U6B\Y6'E0
M+T%*1EA(+U90269K33,X,S=L.%=093<O;&,S-5HO=T16.&HO-4982"\F(WA!
M.T%&5'@O25IV-78S3#1S93EK4&PW>DYO6&U+>64Y,&$V1C5A>'E'1C565C%!
M:U9667)2=W V3TUX.'5'5TTQ25578UI!.&MZ>71,<U8F(WA!.V1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7(T6'IT2%=-;CAU9FPU-6<X=S97,F\V8V)9
M=W!*4$55;6U71FDY=D5K<$$Y5&EV>$PF(WA!.TIT=C)02V<S>D=Y-G%'3U9'
M,F-C6FM,1&$O;&XU,DYI8B\X05(V<F%!2696931T;'(V:U-Z3%%.24-F,V-G
M8G!T,S9(2#@S:G5R,SDF(WA!.WA4-%5L8R]L6#5S8E1H<4U%8TYX8695-#<U
M,U-52U974E,O<'-S9VIB;7%)>$\S2&%G671T:V9Z;4\V4$\V6'=P36$Q2%1B
M;E0U66\F(WA!.W)G04Y.0D1C<%-T1$AC4G)+;C)G=C=,-6MW;4IC;4)&4&-0
M*V-9+SDU4$U0+T=3,2]63&UM-U@U>"M,:S9F:UAM=C5V+W=$:WED9"\F(WA!
M.S1Z3"]!36UK>EEA2"LU:3 U=G%+5BM59DHK<BMA.5)L,"]3:D8Y66AI13=#
M6GEG2T=73T4P3D0P36]B-4$P<6%!,C4X.&-1=51'140F(WA!.TDP17A8.'%F
M4%0S3GAB>#)#3S%S6D9M8UA.<45(;VE.;BM.<%%V=VED4'8Y:E-V.#=I<3<U
M*U(O2%)L-%5N5VXU6"MB8G(P;&AH:F$F(WA!.UHU2D5K:#E11F]L:#1C-4A9
M5E1I4%5!*T9I83=5<4M9>3%M34PT36MP,69Y='%U:U=Z5%AY<D=5=7!,2U--
M8VU+>E%G1FAZ0RMK,S(F(WA!.W8R6$]7=WI2:V%(9&)'54-/8DPO04UG9B]*
M:C)V+TU08V8X045->$\P+S=K*SA.;40V;C!,-3@O-5%B>D8O,GI,>B]Q2&9.
M1'!V-S(F(WA!.U Y669E-6,O<$PT,'IR;EA-,'1V>6DX-EAL<&(S3FA$8C-F
M,6U+0S1I:%-E3DI05'5);&Q6:4I41T)4;48S3S4K>E5B-6AN6%EW4T0F(WA!
M.UER>6)F0FQ316(X<R]..$Q74#%U,6IT671194992G!*-%=!1G=W5TXS4TIP
M2E%V>%8K>%=L9'1J:R]Z94TS4G5V,$DX2U-P<4@U6"LF(WA!.V$Y4%='5S=J
M:%,Q;G5X6G@S26LU25=:>6EY8U9":S1-56(Y;FM+9D5O,G%)-GE%=5A/<E4T
M<$U8=7)E4S)U6G)A46=Y474P8FQ4558F(WA!.U$P3D0Y1UI)3FDR<VEN,%HO
M=T$T,B\X04M$6#,O8E1L+W=#;V5$3V8W5R]V4B]6+U-833 O=T),,69.63-U
M>%8R2W5X5C)+=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R2W9H+U1P-V5#.6EL
M=5EV5VA1,5I+03EJ43A4<S-%-SA4<V5M9&Q)16I:,7-4=7EI1'I4-4EK;&MM
M,4QY=4PF(WA!.VAG>G1&2$AC1S-1;WI)5F@O=T)(4T%,=RM-:5)G-T5(:6$W
M375-8T]4<% W4#$S.'1M9DA(<49M;V5A=DM6>' P;'!B*UA*8F1L:T0F(WA!
M.S9E>#%'96%/,T@W<WE!47E)>4YZ2T]46"MF,D='3TA)1%IL-R]4>E5Z2&0Y
M<71.-70X:'I,3TI02G$X<$=:;U=J=G!)=E-,>&A7;TDF(WA!.S1L-69V4&I!
M3W<K>6]!=T1";$@X9C)*-#0Y>5AA-7)V;&TO=$A45#E#6%1,:7%"2%=9>6IG
M:V%)2VMQ;30T3U1T.&9/<F)Q2WIX-#4F(WA!.WA/.'(O2#0K5$=59U)Y97-F
M.#1X+W=#.&YM2"]!27E7=C9P8S%N82]/4'AB.5!Y3'IB.#-V+TIK-C588V5U
M=B]!0V%43FAO9C=M3%0F(WA!.VTK;W%F*TIF2C@Y-$)E95@V,D%98U5G:U-&
M,5@Q;&1I4%122%ET17!3:GEK0W9*855P:#A,24)T3&8X04@T-4HT-#EY=79N
M1'E1:V8F(WA!.W!X*U5N:&AL.4@V-6)X87)D<D9.-E)9<T=5:&I2:7=)<51X
M<'0S>5!G6E U+W=$<U%V2$AU*S%$4BMA9DM8,5(T8FIY=6LP<C)O=#$F(WA!
M.VY&>C943$EK55-2>D%24DE/4W9%-W0S9FY2:6%:231C;#=4-CDS=C@O=T%5
M:FIJ,T]V=DUN:W%E,&%#,#AR:7=K2')'2S0K=%!C35 F(WA!.U5754MP1'%T
M47)02%%K,4A$8C=2>&II>4$R6C,X4'@K0W9(2'54=CAG9CA!>5DY<B]W07<Y
M>"]X1$ME,"]W0S50=D1,0CE4-D8X*V8F(WA!.SAO3C5I+S=:;#4O,41V;6@P
M,SDW2"MS4'9C=68P;#AA6C%Z<FU5>&5:+TLV5VQT87IE5S1B=%EO>4I:1VQA
M1C)L355A8RMC258V2S8F(WA!.T9G1UEG.&IT,'!J2$1/>5)+;7IJ:C-)-U5F
M3S-K>3EN4S1L.&\K<&,K<D<X<S@R<%A-:G9(1R]*;W%C5E%":TA#=DA99FA#
M3VYY058F(WA!.W@O-T5*3U-*-DE7-CAZ95-*2DHU3&9Y;CE8955/15DS>GE"
M0SA$>%9#1TY5,FMD6E)T<U9O2T1P25EC;E=F,F5F-$-/3U!C>')56G(F(WA!
M.V%A+W5:<E=,,&)A4U8S9V@O:U)M2E9F;T=:15%10F9.9V5B-DHO-7AT+S51
M82LO-V%C=B]!1D1W6F]/,78W,&8Q9C!L>3E0.4PQ9DXF(WA!.UDS=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=FDW+T%*,4@O=%EF.&MC-B]W1&5E
M5'(O044K8G8K9%(O=T,Q:"]Y4G@O964F(WA!.U,K;GID+WIQ4"]A=R]W0U-/
M4#=Z>5@P*V)V.$%N568K,6@O>5)X+V5E4RMN>F0O>G%0.$$R<U K4T]0-WIY
M6# K8C(W+VY(4#E%+U8F(WA!.V1D+U(S,6EN3S(Y5#9X=SA*2V-E1V%B=%AI
M=4XK8FLT2V\P.#,O3S,Y12\X<D0Q4#9L-G9R,6HK=65P5&@V=G!,6# O,G%5
M<#$W,3<F(WA!.UIS3WHK3'=H8E)M<FE91FUC,4]X5C)+=7A6-FXO=T$T-R]O
M:B]'<B]!1FHQ9C!J.5=K*V\P<#963G95-69T8W5.861V<'!M<S=5-'8F(WA!
M.T0R-5AU,S9E<F4Y*V1V4B]W6G(O04LS3#!F,&1D*W)W<'DT*V<O3&I8871/
M;6%45"]W0C5'=C5W*SEY<#AI*U-0*V12+W=#,6@O>5(F(WA!.WIQ9C-N:S10
M<#@S9C@V:B]!3G)$+VMJ:BLX.&PY4&TW+VY59BLQ:"]Y4G@O9653*VYZ9"]Z
M<5 O04=S4"M33U W>GE8,"MB=BMD4B\F(WA!.S=72"]!0U)X+V5E4RMN>F91
M9CA!>FHU*VIV.$%";#<K:B]7.4@Y27DX=E@T.'58;U%6<'<R<%-M84QT4R]%
M1B]Z9C!L>7-&5G,Y3WHF(WA!.U=T>G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<B\O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z
M5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z
M-S0S.$4Q-$$X035"140Q,3DV,4%%,$0P-#=".# X-$4\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-S0S
M.$4Q-$$X035"140Q,3DV,4%%,$0P-#=".# X-$4\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU
M1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^
M9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-S,S.$4Q-$$X035"
M140Q,3DV,4%%,$0P-#=".# X-$4\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-S,S.$4Q-$$X035"
M140Q,3DV,4%%,$0P-#=".# X-$4\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ
M1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"1D$S,S8P035#-4)%1#$Q.38Q
M044P1# T-T(X,#@T13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TP,U0Q.#HR.#HP-BLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-S0S.$4Q-$$X035"140Q,3DV,4%%,$0P-#=".# X-$4\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C(M,3$M,#-4,C Z-#4Z,#0K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O
M;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL
M=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T
M87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B
M"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS
M.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N
M=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!4
M4&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z
M36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W1$:6TZ=SXU,2XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @
M(#QS=$1I;3IH/C@T+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&EC87,\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G
M.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @
M(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y4:6UE<RU2;VUA;CPO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I;65S/"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M
M86X\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R
M<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET
M93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9I;&5.86UE/E1)4E]?7U\N4$9".R!425)?7U]?+E!&33PO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT
M<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @
M(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$
M969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU9
M2R!2960\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!996QL;W<\+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D--64L@1W)E96X\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!#>6%N/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+
M($)L=64\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!-86=E;G1A/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$U($T],3 P(%D].3 @2STQ,#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,30N.3DY.3DX/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N
M,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].3 @63TX-2!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3@P(%D].34@2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C@P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TU,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TS-2!9/3@U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS-2XP,# P,#0\+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STU($T],"!9/3DP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^-2XP,# P,#$\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(P
M($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C$Y+CDY.3DY.#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]
M,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9
M/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ
M,# @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STY,"!-/3,P(%D]
M.34@2STS,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.3 N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,S N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXS,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3<U
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX,"!-/3$P(%D]-#4@2STP
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C0U+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW,"!-/3$U(%D],"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$T+CDY.3DY.#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TU,"!9/3 @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DU(%D]-2!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY-2XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C4N,# P,# Q/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3$P,"!-/3$P,"!9/3(U($L],C4\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXR-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3<U($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/34P($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3,U($T],3 P(%D],S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# T/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,S4N,# P,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STQ,"!-/3$P,"!9/34P($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,3 N,# P,# R/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TY-2!9/3(P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$Y+CDY.3DY.#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STR-2!-/3(U(%D]-# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XR-2XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C,Y+CDY.3DY-CPO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STT,"!-/30U(%D]-3 @2STU/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XT-2XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C4N,# P,# Q/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU
M,"!-/34P(%D]-C @2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV
M,"XP,# P,#0\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34U
M($T]-C @63TV-2!+/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXU-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8U
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C,Y+CDY.3DY-CPO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C4@
M33TT,"!9/38U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,SDN.3DY.3DV/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],S @33TU
M,"!9/3<U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C,P+C P,# P,CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS-2!-/38P
M(%D].# @2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,S4N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-C4@
M63TY,"!+/3,U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS
M.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XV-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C,U+C P,# P-#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @33TW,"!9
M/3$P,"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS
M.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]-S @
M63TX,"!+/3<P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@P+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C<P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F]U<$YA;64^1W)A>7,\+WAM<$<Z9W)O=7!.86UE/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y
M<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @
M(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L],3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/3DP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C@Y+CDY.30P-3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L].# \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-SDN.3DX
M-SDU/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STW,#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXV.2XY.3DW,#(\+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/38P/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4Y+CDY.3$P-#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3 @63TP($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3 @2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXS.2XY.3DT,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D]
M,"!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C(Y+CDY.#@P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],C \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3DN
M.3DY-S Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ,#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXY+CDY.3$P,SPO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXT+CDY.#@P,SPO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X
M;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^0G)I9VAT<SPO>&UP
M1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP
M93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STP($T],3 P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TW-2!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S4N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3 @33TQ,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STX-2!-/3$P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3$P,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/38P
M($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^-C N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,S Y.3PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# S,#DY/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E
M(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" #U ?L# 1$  A$! Q$!_\0 'P !  $$ P$! 0            <&" D*! 4+
M P(!_\0 5A    8" 0 #"0@,# 4"!P    (#! 4& 0<($1(3"105&!DA6)?5
M"A87&C%7=]8B.#E!87B6I[:WU^<C,C8W45)39VB5L;4D-':BLR9Q,T)B<G6!
MDO_$ !T! 0 !! ,!               % P0&!P$"" G_Q !?$0 !! $" @,&
M"P\3 P0" P "  $#! 41$@83!Q0A%18B,4'3%R,U45-55I.4E=(D,C0V5&%D
M<7-T=:6TU.4(&#-"4F5F=H&1HZ2QLK.UU>/DDJ'"-T-B<B5$@Z+!_]H # ,!
M  (1 Q$ /P#?X!$!$!$!$!$!$!$!$!$!$!$!$!$!%_,YP7&3&SC!<8SG.<YQ
MC&,8QTYSG.?-C&,>?.<^;& \?B1W9F=W?1F[7=_$S>NZB^Q;MU%5#J)3VQJB
MR<)=.%62<TS?2"><?>4CH]1T^)T]&<8ZS?'6SC.,=.<9P)ZGPOQ%D&8JF%R,
MH%HXRO6DBA)G\HS3-'$_\AOIY5CE_B_A?&.0W<]BX9 =V*%K<4TXNW8[%! 4
MLS/JSMVQ^-G911(\S^/K$QBHVR0E<E\V?!U9L'5Z<?+@IW\>P(;_ .XIC$S\
MN#9QYQD$/1GQA*S.6/AKL_BYUZGK_*T,TKM]IV9V\K,L9GZ6N!X7=@R<]EV]
M@Q][1_M%-!"+_;9]/6=4Z?G5HXIN@N+DIC^L2OH8+_[]"DH0W_;T_@%XW13Q
M4_C[FM]9[A?_ .0.W_=6#],W!S/HS98OKM1#3_\ M9%_^RYK7G!H9P;&%I*R
ML<9^4SJMNCE+^'.&*CPWF_\ I+G/]&!2DZ+>+09W&"E+IY([L;._UFYHQ-_.
M[-]=5HNF'@N1]#GR$'UY:$CM_0E,_P#V5?PO*304\8A&>RH5L<_1CHFD)2OE
M+G/FZ#K3C"/;XZ,_*;M<D^_@V<><1%K@/BZHSO+A+1LW;\RE!<=V^L-2:8W^
MUMU^LINITC\$W79HN(*D;OV:6PLT69_KG=@@!OM[MOUU-,1/0=@:X>P,S%3;
M+/1T.XB19R37/3CIQT.&2RR6>G&,YQT'\^,>88S9J6J<G*MUK%67M]+LPR02
M=GC\"41+L\O8LNJW:=Z/G4K=:Y"^FDM6>*Q&^O:WAPF8]K=K=O:NU%NKE 1
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M$A?^[1L21NWK:0S//6;3ZT+:^)W[&TRC&]*_&F/<6/(19*(?_:R-6*5G^W-
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MM8H=VRA) ^SM>&7][EBCG"1_ *T,A-/(*(55\(5R+CY)!99U%N$GCW"HX,G
M->.(+1/4L,461&E9CEM0M@\RPO=I3 3=<&R=:.U8$7ANSS0$(!.!11Y[+8Q-
M@K,L\E0!N52&;%%?J30TYWXBP3R=0O5S$FI'4&W+3JD7/H5X+ $<E8QEEI,E
M0UTS:+NG,K#R!F2,XL@@E<HSKR?8PEK>Q)'!$ED71559>(A(T[5FS;&ZLGC"
M3M\5ZQ>ED'R6:ED  KV86E*H)D6-GT@WVL?%8<'(2!Q&O9M3M)+(;,]?PHHN
M7+$\8.*P,4)R26JLQ0C<, '+5M;+!3R<M89&$PD8BM5:E<HXHHW=K#;)9FFA
MF;F1['7\2TFFY#P[UO+52&RFJXM;#!93ONXZR?JMLLDW?A*!EX=%.T=^$<KL
M'2L<D9)-GV+-Y(R-.:7,6)*QDUF(Z^0M:B&/FUK\O&YR$3:4H^1;KV2>CRG
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MC>W4T;Q$]BMS8@9V[6&0@/3QBSL[-$6<9QG.,XZ,X\V<9^7&?Z,C(EBWB\:
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MDDDA.<DAF[D9F9.Y$9$[D1$[N3N[N[NZ^HY71 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 11GNK^9S;/T9WS]%I426&]6,5^$J/Y5$J-
MCZ'G^XR_W"4F"-59 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1:7_=T.17(+
M67.Q_6-;;UW)KZM%U-KM^6O4?9UVJ<&5\[Q-]]O2Q,#.,&&';KLD^^'.&^%E
MNS)VAS=0O1["Z$^'\#DN"([.1PF(OV7RN0![%W&TK4[@')V \L\,DFT=7VCN
MT'5]&;5:WXIN6X,HX06K,(=7A?9%/+&.K[]7V@3-J^C:OIJZPY>.9S ]*WDG
MZ]-H?6D;<[T.$_<OP[\28W\V6.=TLC]7W?A4_G%7<GO_ )^PU?96F4Y#<I&4
M!(P;&S,));>>R<).Z[)2F81C.H)XMQG!XEQ-%/#DD,(]ZXE2*1QU2O$SHELH
M\#P+-.=6+ <,G/'.=8XQPN.U"Q'%SS@)^J;6E&%VF>/7=RG:1F<'9WK%:RX@
MTA7+S 0#(Q=;F[0(MHFS<W7:Y>#KIINU'QL[*A/',Y@>E;R3]>FT/K2+WO0X
M3]R_#OQ)C?S94>Z61^K[OPJ?SB>.9S ]*WDGZ]-H?6D.]#A/W+\._$F-_-D[
MI9'ZON_"I_.+X+\PN6[DS<SGE)R,<&:+E=-3+[NV8J9LZ*FHD5RWRI9S917*
MDLJF59/JJ8354)@V"G-C/8>$N%1W,/#/#XL0[2VX7&MN%W9W$M*W:+NS/H^K
M:LSZ:LRX?(Y!]-;]U]'U;6U/V/Z[>F=C]KJM*IR1YX7G,R6H\CN44_FNQB4U
M.X8;QV8?P5$KRT; HR3[)[83"#)6<F8>&3<'Z$C2LO%Q^#9=R+-%:SM</<#T
MN2]OA[AF!K$CPP<S"XUN;*,4DY1A\RON-H(9IG%NUHHI9--D9NU6.[E9=_+N
MWCY8[STM3^".YAW/Z9V-N(1U_=$+>-V9^!.\H^<=775:V3DERF@7K>5F8-W'
MR^Z=JQTDQF:\Y39SD5(1KNSI/H^0BGBI6KYH];H+MW.#H')A1)0I.\'#/!5D
M6*OP[PS.!10SA)#A\7)$<-@7."6.4*SQR1R@SD!@1"0Z$SZ.SOP=[*1]AW;X
M/N(78K-@28@?0A<7-G9Q?L=G9G9^Q=(?F1S$3ZG7Y5<EB=H3"A.OO':)>NF;
M.<%.3IM&.L3.<9Q@V.DN<XSC&?-D5VX0X2?Q<,<./H^CZ87&=C^M]#>-=.Z6
M2;QW[O;VM\U3]K>O^R+M#<K>;9(!&TFY,\H"UQQ,.8!":SNW:6(]6;9LFLBZ
MBTW.;1U#/6[%\S=K(8SDZ:#E!0V,84+TTFX7X->=ZS<-\-=8&(9RA[C8SF-"
M9G&,KCU;5@(P,&+Q.0NWD7;K^4V<SKM[8Y.#'UJ?:YLS$XZ\SQLSL[MY&=O7
M74>.9S ]*WDGZ]-H?6D5>]#A/W+\._$F-_-EU[I9'ZON_"I_.+?ZX>7>VJ\
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MTWQYEDV\A0T(I!:-B9]1.W9CEC)M)*)MJ*Y?$< \,=N>S,_&V6#QX+@Z;J.
MKRMV/'DN,LA3F.Z4$H[9ZO#6$O8^_ 3E1XNK&XRMWE;T738F:8VZS.)O:-^C
MU,KL;QLMZWL,K#NC$RFHXJ,*W91M*U\==+.$71=>U:K$?)E+F0P[5ZRIJD&+
MK1RC8G*6];!]1M72&:2,M-'>O$(A6IZMV$U."!C_ &^Y^U1^4Z0L[=H6,)B8
MZ'"/#=D>78X>X5@EQM.]"Q,0Q9J_+/:SW$PQFW,A?B;+Y@JY.[5G@#0&^=^W
MQ1:.\E*^5Z>?N49BN(N*W$M)A\6.D;E-Q->J$=9I>(B)=C5WMGDIIIFO1<IT
M6&RLD)1W58.?Q%/TT>+>6JU2DA8N=9CY#/!&,A;#LRQPU@GDCCD" YSE'DQR
M>G3BTA5XIN6;-VX<Z.^(>((*F2> <;@K7=22/*W9Z-=[57!4+N3S=K$TKMVE
M8R]?$5:$[9.Y4UQF*GDJ0YC(8U[E<I*/I6W]@S6S6M;L>NWD/!62'CGL>FQL
M=+G)*AKXKSQ])--B,(N95?,7C>V0=MI3J5KB]NJBDLRK;-O(L';V0RK;5LC<
MEO#!-2*.*>,##9-6E.H_)(S&Z$<KF)-8BL57D@>Q7>08!8P,SUF\]P3PU0X3
MFRN+XH@O9'%WK5>P5C%YW'U>(H^Z<%>K/PQ9N40KV()<-D,-GX:>4CPF9"E8
MRL\M6S!!68+FA.+5" B B B B B B B B B B B B B B B B B B B B BU
MX_=#&VMJ:FT]QVD-5[,V#K-_+[*MC.5?:_N=CIKR39H5=NN@UD'-<DHU9ZV1
M6SE9)!R=5)-7.5"$P?.<C?W0%BL7E<MQ!'D\;0R018ZH<07Z=>X$1E9(2*,;
M$<C 1-V.0LSNW8[Z+$>+[$]>M4*">: BG-B>&0XG)FCU9G<"%W;7MT?LU6J=
MXYG,#TK>2?KTVA]:1Z@[T.$_<OP[\28W\V6!=TLC]7W?A4_G$\<SF!Z5O)/U
MZ;0^M(=Z'"?N7X=^),;^;)W2R/U?=^%3^<3QS.8'I6\D_7IM#ZTAWH<)^Y?A
MWXDQOYLG=+(_5]WX5/YQ/',Y@>E;R3]>FT/K2'>APG[E^'?B3&_FR=TLC]7W
M?A4_G%QW?,'EM(-'3!_RCY%O6+UNLT>LG>[=EN6CMHY3,BX:NFZUF.BX;N$3
MG2615(=-5,YDU"F*;.,]@X2X5C,3#AGA\# A,###8X3 Q=G$A)JS.)"[,XDS
ML[.S.SZKA\CD'9V>]<=G9V=GM3NSL_8[.SGH[.W8[/XUR/',Y@>E;R3]>FT/
MK2.O>APG[E^'?B3&_FRY[I9'ZON_"I_.)XYG,#TK>2?KTVA]:0[T.$_<OP[\
M28W\V3NED?J^[\*G\XGCF<P/2MY)^O3:'UI#O0X3]R_#OQ)C?S9.Z61^K[OP
MJ?SB>.9S ]*WDGZ]-H?6D.]#A/W+\._$F-_-D[I9'ZON_"I_.)XYG,#TK>2?
MKTVA]:0[T.$_<OP[\28W\V3NED?J^[\*G\XGCF<P/2MY)^O3:'UI#O0X3]R_
M#OQ)C?S9.Z61^K[OPJ?SB],T?.%;K0$0$0$0$0$0$0$0$0$0$0$6BW[H(^Z$
M2'T-ZS_TGA[9Z!OI!C_"^2_M@6KN+O5=_O:#_P UA#&YUC"OYK.]*DK Z>FG
M]+M=@K>AJEKFIW-%MKNB+LW+O&S[=9G*LCL)PX>3[:$F(.T6"%B:D_(UC)Z:
MCF+IZHW23,BWP:SA+;3Y:$+E6O8S=K(VJ;ED+S$(=S:E86CH"(0%-%-6KS2V
M@<Y((9#$&)WW/+QVX]E<WBD,*D4,<C-#"[.7/D-W*9W<]A 9B,;LS$;,[N/D
MX,OR<UJK"05=AZ;,-6K2O3\%*3)H:K,YT\HXXZ:9U!5[NU<M7*J[B;K]ZUK:
M-D$CW;Y/J*WZ3*PG&=A*I8U.\7#>1::>Q-;A,BL03Q0\ZT<+1CQ!F,M:I$)B
MPC#8I9&MCGD '[*,3G =?2LW4KT&T0&,F9@,"+9&Q[GI5ZT<K.SN[D$T,D^U
MW;ME+0F/PU,#ODGJ96'K\L37,3.P\YJVUMKI4J]#TUL[U?:5-SVM2#W8W743
M2POM&,B)N#=14,DRCX [6UNXQO-1[-B5I'Q(<.Y1IK$3Y"6"6')U2J6IYK9A
ME*S8:JTV&(=7VXR2:&9I9G.2PQU1D>"0Y'.2Z>]7VB7)$Q*"3F1B,3/!(]@W
M"SKV:SL)AH+,(:2$#$+-H-#Q7(S6S>LN):1U]8)F;G):YY2LF:=K9BR<V5"I
M[-@EY=M#0.8J/B,N6VWZ-8IAJXCI>182]31)FXV9JZAB4Z]EX?R166BBOP0P
MPPU-:_7,C(85BM8V=HBFG:625A+$WH(B&2*(XK3NU.J03/;I#<AV;GA,G(Y=
M#:* 6WM',+DPAM8/HF(RU8B8HV]-/4>50+?>M5K&T.1\H]KLE!FVA1(K7Q&:
MU-HUQ3@[1#;$U)=+-,3]1L#_ !4IY.1EM93*2K-4[E%P]GTY54^5&ATG%\6$
MM6<;P]&%B.;N9>EON;7+M-YJLV/RM.M#!;@CZW \<62A=C9A<0@>)F9B9QH]
M;C"Q=(@(.?$,.G*BDVF,U>20CC(FC+<4!ZL[NSD>Y]='UE#'(RI;0M=PEZUI
MJQGLLO?=B[9>3*.8>SRE9@IO9>M+T^2L-BL'52D*\^CJO9(.VR]D-'1L:2YX
M;D,\@<RD#.1O>_;QM6I%8S%?D14<?BPA)IJT5F>#&Y&B#UZ]?5X[ 26:T]2*
MLTDLG4]7V3\N>"NUV.>20@K2.9S36')MDA )SP3/O,^QP<8S"0CT$>;IVAN
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MG>%M(7FE>)O6B<R>-NWM[ T\:H,7RHH"+U8!\OUOA 1 1 1 1 1 1 1 1 1
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MWD:O&\,$9 QNS.?.L1SVR=V9V.R0NVK.[V,QB7+8>UPC82/3:YEN,F?;VZ;
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M$OPB7Y2>0:[F_P#-E>/6Q>_:P>CCTA^V5+XJH^:3O5PWL$OPB7Y2S(#42R-
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M(?:/<-?Q4^/'ZHJ>/G/QQ].G%_\ &CB#_-K:W3BO4O&_>%/\GC5U@Q=7Z B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M>B;Q_P#594?98=_G&GNJSWQG;\ZG<C%^U]3WB/Y*>(#P@]$WC_ZK*C[+#O\
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M>B;Q_P#594?98=_G&GNJSWQG;\ZG<C%^U]3WB/Y*>(#P@]$WC_ZK*C[+#O\
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M(#=F;;\T!8=GC/L9QT+;MTC"EW"D5:T<BG&O=F0M'UG-I;-K-%H%^8WR1>;
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M/G,0,JLPJ-FI=882LC+:\YQL_$ V9)K%:SU>]<JR78[430/!&^+PL%IX-1.
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M0GT[4/XM4?\ ,LNMF\'>I4OW[-_@UUGV&BEE: B B B B B B B B B B B
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MX_5%3Q\Y^./ITXO_ (T<0?YM;6Z<5ZEXW[PI_D\:NL&+J_6L1[I@_FTXH_\
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*"("("("("+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g389734g03p32a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03p32a.jpg
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MDI:VM]'4(S,Y87)VM35"<72RM+@GH2@V4F)U@;'_Q  > 0$  @(# 0$!
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MZR-CP(M=4B!X^0>-:%JP#]DI*G)^0#TRDYGECE6;<7J;Y$O)N][5I3!5GFO
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M0\DQ,;,*[[9PL["/);2AZ2;.#(KP J#@5,.M!)$D%O,QQK&EE L.C'#)"O\
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MT:<JE9H:;R1S2SV(R.Z*2=XHA'$P62.-&,@!E"KV 9U%G>.;&2C(Z9 *BY<
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MT/,Z'QFV45L'SUOP_"2K+"06^#N>_O=2!V\=O)[N?0X/HLU?F1+V6^T0&/\
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MYUV0F6!B=[VIZ. *#B^]O6FP6T)0A.WT--K=8/UG4CC?C@S,#).W/OYFD+2
M'Y55E3["@9ZKZ']D?L[]G* ])],4*%SL*2;:97O[B56'#JVTNM/<2.0^KUX)
M8:O/UL"@ #)K+/.Q\8QC&,A8,Q7'^1+37Q8OP;=&4NA3$Y-^1#;W(5R=G.2
MJM%^LD.;D"_4\G7;B7Y$IEL..]>;(!<=?DY%+,5)8#>L0K'Q9CJTY9I>Q1WP
M337TKQ^(#WMX4D%INQ@%3QNY"3(X%]8H[2/IC4;*:YWZ6WONHZ.OH>8G;RVT
MU^OZ6L;BYY1D%:'SU39Z.'S$3M/9^#_#L(D=2L9)IDK*'&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9TY^GB_V
M;O*?_.G$W]X$)G;GL/\ _F)K/YGM?\!-FN]5?N+8_E*_]\F>"O/<F=4XQC.>
MA*W+6!F>)CF$J#K$([8IXUU?AC1D4F1C85@@ESL5O7G9V:AH0)*4JV])RP+&
M^XAU3J,$UB* P+(3WV9Q7@0#EI)3'),54>@^)!#-,Y)'$<3MZD 'FB,_>1[D
M0NY/N5>0H)]_O=E0?99E'RYDO+T+J3X5GGN+X,F:D[)4;3):>KE+A9R?G>/+
ME,D5^I+E8-1M89E:Q(75XNJQ<#=*0ZV!>]M5W4#8)I0,2IC78KW3NY@79S+#
M'7M58RMBY-#!!?IPK8MB*?LLF*S'2"VI9Z=T%Z/=9\>O#XDW=.:&]5;P%+,\
M<C?$B5G>&1NR,LI*=T9EYC5)8CVS<)V.W"G/S7K7U5I#CKS79.Y.&P-5>B-&
M-U4K<A'TCC9KC>WQ4W)3,A64Q,H/77(_C@RL2[LS*6F!75Z@H3U4&'3W"4]3
MICODI6(J86>T)>PVD[)+NQ.QJ2PQ0I9,T36!)L4LQ"&*M.+5L-XK/<"DDV'"
MRHTO*1E/1#W+%!X,BLS%.U@A$)C8LTB%(^.T"/F-ES/4VD#4(?7[XF/"B(*6
M5&&<<;T.U!UL.^5*ORKX[]:[JHR)'L'(D*!(/I4,P0586D/><%?V/(6'IPOX
MZ6*)DDEGA$J;'XQGLO1MSQ*PL\B65H-?,\:D,RK7)7L=>[@7OGXI2;XJHW:8
M3Z*GC1HW!3ZU>^9 3Z EQ[QZ<ZY7NJ6G":MB@+L/9;Y>KYZR *JTJ3R;&W*'
MBJ6[8[,8/+5U=AK9TV!S16FP++$%#ER9,WIKS39C8FE818Z9MOY7OI-7HTJ)
MCD6S$NMDIS2W!7K*T5@5[*0R:>R7K3*R1+"3V%"^<BE^(>)VRAY9INY3&QG6
M54B\1R&3O0LMI.'4@DM[P0,B2 NH4II^$)KUWCXOF.*J<*^@NBG!1%J@*<'5
MY&L+ 2S7NX]&UN)*J<JR9 ,[<8B3HDQ2W1I(=1,HOH%(F6Q2DEU$EN8%+L;R
MU9[;VH[/B=T_Q9;$JVXBLY]94E0<-&W;C N,"O9*%LB-6YA(5UC"&/CA/<BF
M-@4'(4J?<PY@'(7&=IXSES8BQL"KV#8[;4UR48\X7$O6"CS3D%9HQ@M;+&]E
MQA>A2'1G6FB/5LI#R6VM!RH3KTZALJVRA2:NS#OKU;0CD 240781/6E9 S?$
MD3N4,"5\2*:/GOB<+AGKR5V*N >'DC[E)*EXF[)%!('JIXY! ]&5O<P)K_)^
M8<8QC&,^K!GY?YWQC&,8QC&,8QC&,8QC&,8QD+Y)EJW <=WZ=N49ZZJ$+2[3
M+6N&\D+)>MJW&P9YD[&>KC7&0S_/Q;)0ODBWFA2O%\ AQ#3BU:B7Y((:-R:U
M'XM6*I8DLQ=BR>)!'"[31]CD*_?&&7L8A6YX8@$G+[I6EM=EU/TYKM%;\AN[
M^^T]+3WO'FJ^2VMK85X-?;\U71YZWEK<D,WCP(\T/9XD:,ZJ#-,EY0YQLS,1
M%=B)6P6"4CH.!@HTZ8FYJ7-&C8F'B(P5TV2E)21,=9# CH\-AXLTTIYH849E
MU]]UMIM:M9(89;$L4$$4D\\\B0PPPHTDLTLC!(XHHT#/))([!$1%+.Q"J"2!
MGQF5%9W8*J@LS,0JJJCDLQ/   !))(  Y.8T?5U=$GRPNESY_N*?QLS8_H)Z
MS^]'J?\ $&U_1,A?">M^Z-'YW7_.8^KJZ)/EA=+GS_<4_C9CZ">L_O1ZG_$&
MU_1,?">M^Z-'YW7_ #F/JZNB3Y872Y\_W%/XV8^@GK/[T>I_Q!M?T3'PGK?N
MC1^=U_SF/JZNB3Y872Y\_P!Q3^-F/H)ZS^]'J?\ $&U_1,?">M^Z-'YW7_.8
M^KJZ)/EA=+GS_<4_C9CZ">L_O1ZG_$&U_1,?">M^Z-'YW7_.92_*/6KT<2-X
MZ;S(_JQZ:CA(+FB=E9LD3G/C D>'BWNGCGJ#:D91YFT+; !=FIF(B&RRE-,+
MDY2.!2YLHT9IRXUG1W5T=+J)).E>I$>?3P10J^CV:M-*.H-%.8X@:H,CB&&:
M4HH+".*1R.U&(C3[+7&6F1?I$+9=F(M0$*IIVU[F(?A1W,J\G@=S*O/) -T?
M5U=$GRPNESY_N*?QLRG^@GK/[T>I_P 0;7]$R3\)ZW[HT?G=?\YCZNKHD^6%
MTN?/]Q3^-F/H)ZS^]'J?\0;7]$Q\)ZW[HT?G=?\ .8^KJZ)/EA=+GS_<4_C9
MCZ">L_O1ZG_$&U_1,?">M^Z-'YW7_.8^KJZ)/EA=+GS_ '%/XV8^@GK/[T>I
M_P 0;7]$Q\)ZW[HT?G=?\YCZNKHD^6%TN?/]Q3^-F/H)ZS^]'J?\0;7]$Q\)
MZW[HT?G=?\YEO\:\S\/\S!2<GQ!RKQORK'0I3(,Q(<<7>LW<*)-(9V0.')%5
MF3DV 2GV-;>9'*<:=<:UMQ"%(UWLJ=CI]MIWCCVVKV.KDF4O#'L:-FD\J*>U
MGC6S%$SJK?%+*" ?0GG)$-FO9#&O/#.%(#&&5)0I/J Q1F )'J >.<LK*[,V
M0H"6K;W(MI@A8SPK?&TJ@RTY,^2%;\_6YJ=Y)#JD9ZQ0[LTKU1*0%R*\D0RV
M*!Z[\<-UUV2.0S$22 WK$*Q\6HZE.2:7L4=\$LU]:T?>#W-X<D-INQ@%3Q>5
M),C@7UBEM8^F-/L9K??I+6^ZCI:^CX\S>6VM#7]*S[BWY5D$$/G:FRT4/CQN
MTUGR'ASHB5:Y>:Y+RAQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&=.?IXO]F[RG_SIQ-_>!"9VY[#_ /YB:S^9
M[7_ 39KO57[BV/Y2O_?)G@KSW)G5.,8R?4F]D5".OL/H-DV-Y J8M8E4.MH<
M6RF*N53OT20RAW2F7$^OZ9%"R+#R%))ABY,=OPB71R&8-RDMN2C-W%)*%IK,
M1!(!,M2U1E4D>H^H7)6C(([9EB8\J&4YHI3&LJ< K-&$8?\ VR1RJ1__ +QJ
M&'RJ6'H>"+M1U@\I D55ROBUZ %I-6M-0JH+.K).I@X>P6,&Z0PT?)6ZQV&=
M8%XWNT-7KCQC&:E=Q-2LL %+M EF&SCLM3'I/62+:\=K$[W;56W:<^7@\>:O
M7>G,TD=2O7@9MC2FL4]E)X7BVJT[PEU1(1%*^$IP4**B"..2., R-V*[K(O:
MTCNP$,J)) O=VQN@8*26YV!'51<BP+=%%5#CUR,N,MR')F@#QEBC!8T;D.OU
M*M/P,(Q$V@!B.@JO&T>M)JHJ&EEBJ!4U*G2XC[@V\B],TUDJ3+;OB6I#0B1S
M+7D:1J$]NPL\S2UI&DGLR7;'FF)",'!B2)U#9\.PD(D4Q0]LK3,5"NH E6-.
MQ0LBA4C6*,( .1V_&+<G-_/]6URL,=9XM^DT.+"L2HQL,> *Y-AFJM%Q-:D*
M2)7(!H3DE*':OJD&"51=?L29Z-7&PX)2F/7)MBE)W'7Z5J5Y*TJW;TKUQ(7:
M==;,;4LME+K6;!;7<BUYU'M"Q7,$@DE=>?!2O%!];8RNKJ8HE#E> AG7L"H8
MPB@3\&/PN(^Q^]>%!X[R[/ST%UKWV#M)5O\ I?<5R4L_R[?.;!E'@7KPXN[<
MAWCB"]S:HQ8=^$)'C!S>&*[#1XKA#Q'N>FK4!)F2;LD(5'8)^C:,U9*GG]I'
M$NIHZ9A')2YDIZ^EMJ,/B!Z+JTK)N+$TC=H7S$-62)(A$R2<DVDJR&3P:[,;
M,UH<B7XLL\M>5^WB8<+S61%'J0C."26Y'&;ZPKJ] '54VA<8G5Z2KM2K!\:^
M'>$;(C:/4>%JG6MZ-8OC4@*4#](/CZ?>("*&4;,LS+!>G:]+.P+>0=)4UG2T
ME[9)/'8MV4D5Z1[9+MO<V[/*-1,;*_P[?@"NK!(6A*<3Q"<_/A*4H8VA@:-D
MC0J1+ZK%'6C3U\7D$"I"W(()8-SRK=HJWE/F27Y19;9/C(^+01R'RERQ+-1Z
M24BNWCEXZO/6E48T84<6% "QU/J\7$QQ<A)EMKCSI$B0<<E-BAV>LU$6L),<
MDDG;K]9JHC(5++2U*6!5$A141YWDMVI99%CC4^(D:Q@1!GCV++3CU4+S-/8;
MCG@RV"AD[02Q" 1QJH))]"2?C<"F\M\C8QC&,9]6#/R_SOC&,8QC&,8QC&,8
MQC&,8QC(7R3*5F#X[OTU=([UO3H>EVF4MD3Y1B0]:5F/@SRYV.\@2XT,=YV+
M9*&\H0ZTP3XO@NN(;6I6HM^2O#1N2VD\6K%5L268^T/XE=(7:9.QB%?OC#+V
ML0&YX) .7W2U/:[#J?IRAH;7DMY>WVHIZ:[X\E;RFUL["O#KK7F8E>6OY>X\
M,OCQ(TD79XB*S* 9IDK*',<>L7]J+U3_ ,W'G#^[*SYL/2/_ &KZ8_\ $.E_
M]RK9#V/[GWOYG:_N'SYEN?H_G2>6UQ7PY9>7FN0G:T;%CJXVI0]]FQ31;.>>
M="$7BF<?^'!1U6KED.D)!F<O<&\^,L<9#<6D\W3ZO)J:75;3;UM2: LI*WPC
M<:C R-62-)UI7+_,\EFQ72.-H*,X5@S$R^&G [P1(@K26/&\,K]1B\9@0Y)7
MQ8XN$"(Y9NZ5?3@?%Y//IQFH9P/RRU-/0L50[=9U^>\C'&U^IVI\>;VNRSU.
M'(BA3X..F5LE6FKV*OM-F101K<U"2L04(-)1Y@C)-WJS")Y;U2L.SOD2>W55
MH?UM!;9962>2$,M:S7G)25T,,T4JNT<B.WTT[ <HL4DGKPK)'(0_U1H@5[E5
MO61'3AE!#*RD!@0-FUPAS&^^L4?BZ^E%-D&B.C"U6:*(9?CPK!(F)?9'#<<9
M2S'U*V'>*ZE#3@=6LA+2ULP4JL3F=SJ54,VSH*I5'#-:A52LCP1IVLS@,3):
MJQ\ E@]JLI :Q"'^"I9)[1!*3R1P$8D%0Y/(X]/2.0^O'(C<CD*W'X?X3Y@&
M*/!(XPO;)L7(!1<B(NK3"20CI%3*(]HAG8GB-H-62*D0A2=#$;+$TT\KS0_B
M%W.I94==E1*21O+&XM0E7CCY,C*W?P>P*W<O/<O8_('8W'SRMD$J8)@P8*1X
M;<@M]:"./3GY#[CZ>OKFTD>(N4XB"E;/*<=W2/K<&^Z-+SY=;EF(:.>8-A(U
M[14DX*D-M#4A9JV$MW;WA)*L$&QM>G98!)'./:ZR6>*M%L*<EB90T4"68FFD
M!2:0=L0?O),=:PX';R4KSMQQ%(5^-6L*K.T,JHA(=RC!5(*J>6XX]&=!SSQR
MZ#WLO-KKZ4>1_I<5CE >0KIM=M58K%LCV0Q[HY(:C[5RC,<0 QK6W*<U%3-J
M'N$(=LBG5B5GK01 MO6&)B9.* EB8^K'5&O^$+.M:.PEBK9LU9&=J8C\2KK(
MML\AXN&6&JU29.VW9B@K+.17EEBEDB621\'S^ DX9"CQQR  2E@)+#5E7]B[
M6D$B'F.-G<IRZJRAB("!P/RW+RKL5#T6QR"D'R\>@[<1(QD>XN%U9EF/K?G!
M8M8+"D4VV>6U*,@D$$5J> ;8W)0\D&+.DWFJBB$LUZO'S'%(4\6.20";RW8H
M$#2B1OUY4[O":156S!(6\.:-VQ"G99NU8G/QF7GM*K\7O)/+!> 1%)QW $E&
M '<I XD/A_E61U$* XZN9J;!I7J-8M=E'T2SB5PS>AH];8RDEG.N6.MH' 9V
MLTE=DKJ1QW=ST3HS*^VUD9F#["FAK\>.'L1*8@1,>Z0%@50"O8+.>$7R]CN8
M>!+V<16L'MXAD/?];PA/=ZJ.!P/4\NG ]Y[TX'QEYW?)O#MYXG>@U6J+=U$6
M>&K\W6[,&)*:KDZQ/TNH7S0<7)2,='>:DH:#O-<U/!H9[\<4>SK>W12 RR>&
MMV]':";RLH\6M-/#8K.\7F(&@N6Z):6..23LCEGI6/ <GB18R1PRNJ_9ZTM<
MKXB_%=49) &[&[XHYN%+*O+*DJ=PX]"1[P035N6>1\]@GT-/^PCU,_RJ4_\
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M!=.LCOO*VVPZM+JD.:1M"L4XF,$PK-&M@Q.(&E!,:RE2(VD"@DHK<%E'JP!
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MPH8CIYG:361Q1I%2;@UDC[5XYFTT>J76%&KEGAAI2##DX&9%C%.$BBL2E6E
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MY+];2KO"W4:)51#9Z2GI:[PM2Z=H$T8OE4XL.U-4Z* C.;A8Y<D[+UX4^Y$
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ML(ZS5K(C['K>,L\=J182[16&Y%FDU>2-HRGAV4N"984\J&X2BF%4PN2XDC+
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M8>/ZE')'X8BE$_BM-6@@4/U.QL;>GJ;>PWM59NMM+TQ)LSIX6K6J&T]IN_\
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M)'&4LIQEI<2_96E3M6V@FLI5@DL/!76-YY$A4R,(DEDB1Y JDJA=2Q':O+$
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M:G.P/BUE1RL%6Y,;9Y[8:]J3Q D,I78R?,/!<%#SS!G(7&[<571RVK!$A3\
M?N,'U8D5 X<^#CB"2&D:M1:*T8PX'K2)U_<40E)JE,YPDV>HABF#7:(C@5A-
M&DT+^&OC^6</$C,P'F&\!@5_9CX9'?R,D5.B/:%L+NND@Z9ZI:YM)86UEV?6
M[*N+<OP8=W7DK;"U%%&[? T)VL$B3\G71^<B)K@29-X<^E&'^5@#:L7)PX'D
MMC0Y$2^?%1FWDI\IX(2UD @;(80GP.ZT/MYE.NYWV]=DN)ZCOVPM7:2-.WB)
MHR\<?/UO"$LB=P]WHO(]W(S7[M??05_&V,&WAJ7K'F!+=BN1U[EOL)\?OG41
MV+'A2,?$Y>7L<GN[6/,IR1E1C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE <O\
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M8^*L#@:68R4.K8\#JS[1ZVM;4Y,H#.#M:FM\K;L6A.3YKO:6O&KQUC,\G>;
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M8RA^7]Z3R!TM;5O2=:YWL/;O>]:UK_\ #)U&:]N]^SX?9EYJ?VAU/_N.O_\
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M@+S^:A>)XXH8^\6'AE@1*AJV#(J@]@,$A7DF1)8NY0_B JQC9@$\-@P)8@%
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M<++NZ=B*-.Z1PTZUXI+2I%+R6I82$]EH"%O#=U0S!>)(;$H=E** >*DB,3P
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M5VMGY*IMXMCYN:"Q2CBDA;8AX:=JBXDEDKFJT<@GMKT=8O+LS,X*GN/QQ/'
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M.CR.BQ!G(<W5966&1*CQ45M[&K9DLO462=J.LN7CY1UO""'X]>).^V5CD6<
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L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g389734g03p32b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03p32b.jpg
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M 1$  A$! Q$!_\0 'P !  $#!0$!              <%!@@#! D*"P$"_\0
M71   00" 0(!!0D("1$&!@, ! (#!08  0<($1()$Q0A6!46&3%!5Y?6V H7
M&%&5EIC3&B(R.#EWDK?7(R0S-C="87%S=7:!L[6VQ=4E-5-XL<$T8G*1H;A2
MP_#_Q  = 0$  04! 0$             !0(#! 8'" $)_\0 8Q$  @(! P(!
M! H($ L&! 4% 0(#!  %$1(&$R$'%"(Q%19!45155F&4U!<C,G&3E=/6"!@D
M,S0U='6!D9*6L[31TC8W0G*CI;&RM<'54E-B<X.%0T1VH24FHK;P8\+#X?'_
MV@ , P$  A$#$0 _ ._QC&;*2DHZ' *E)8\.,C065D&R$@2R&$(PC7=;Q))"
MVV66D_*MQ:4Z[ZUW[[UEV&":S+'!7BDGGE8)%#"C22R.?4J1H"S,?<"@G+-B
MQ!4AELVIHJ]>%#)-//(D442#UO)(Y5$4>Z6(&8.<D]>-!KCI$=0(<R]'M;4W
MN4>=7"5U#FM^'Q,//,/2<CIM6M^+38(8SR?"H<]:%:7KJ>B^2?5[JI-J]F+2
MHFV/FZJ+5TCU[.JNL$.XVVWEE=3N'A4C8\;Z@\M6AZ>TE?0ZLVM3J2OG+,:=
M ,/#='='L3A3ON%ABC<#>.<J0V8=VGK3YXLKBVXZ:C*F,ZKPI$K,*+YW:=[[
M(1HZ7U+R*7/B[K&)'VI??PI2G>D:Z/0\F72=$!IJL^H.HW,EZR_$$>L]JMYM
M"5^:1'V'ND^)Y3J7E>ZUU%BM>W6TN-CL(M/J1<B#ZAWK0M3AO5XQR1DGU  [
M9"$WRMRK-.NIG>0KR8OQ;2X,999K33>_E1H/9:&&=?C0AE&M?BS:*N@:!653
M4T?2HAL"'BHU>3>\3*(R[??+$_/FG7.INIKC,+VNZS*=R&CFU"X$7WU[/=")
M_FA /FRQ23SC%;46:64K>][VHDEY]6][^/>]NK5O>]_+WR52**, 1QQQ@>H(
MBH!]X*!D+)//*299I92?69)'<G[Y8G-)HA\=7B8?>95K??2FG%MJ[_C[H4G?
M?*F56&S*K#WF (_B(.4I))&=XW=#Z]T9E._O[J1EVQ7(7(4.XW[B7>XQCFE)
MTUJ,LDT&KQ;WV2E*13&^_BWOMX=:WXN_;MOOVR/L:/H]D'SK2]-G78EN_2JR
M#;W23)$=O5Z_<VR3JZ[KM1E\SUG5J[;CB*VH7(B3Z@ (YEW]P ;>/JVR8ZYU
M;\_59U+>[J_-L,J\+@%HC@9?QJ1OP[0\8\.W,)WK>MZ7IN1:5O??Q=U:UO6M
M7?)YTC?4GV,2J[#=9J$TM?8'Q!6-7:L=_<W@8;>KPS;:'E1ZXTU@IU=[B*=F
MAU&O#9W(.Q#2M&MH>\0LZGW_ !S*WC_R@@!+K 7)E-5'>/:4N3M2=<*%0I7;
M6UO04B[LMEA&_P!NM8\L>_X=[TV*XI.M+T'5_)!*BO+H>I";;<K4U%1&Y \0
M%MP+VV<CP >O$NX'*0 DKTS0_+G!(R0]1:2:^Y :[I;M+$-_#=Z4[=U$'K9H
M[,[D>"Q$CQSZIUYJ/($,U/TV?C[!%.[TC9 +N]N#N^'2MC'"NI;+ +2G:5+$
M-8'(2E25*:TE2=[Y)J6E:CH]EJ>I5)J=A?'A*O@Z[D<XI%+1S1D@@21.Z$@@
M-N"!V[2=9TO7*BWM)O07JS>'<A;=HVVW[<T3!98)0-B8IDCD ()78@FZ\C\D
M\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QF._+'4_P 5\2./QLK*.SUF
M9UO2JS7$M''CN=O4B4)6ZT!%;UO:=K9+)T=II6G6@7T]N^Y=/]"Z_P!0A)X*
MZU*+;$7KI:*%U]^! K36-QOLT:&'D.+2H<T/J?RC=-=+L]>S::[J* [Z=0"S
M3HWN"Q(66"MX[;K+()N)Y+"XS ^Y]?7)<NXZS3(&OT\)6U::()0Y8YE.OB2K
M9!>A8G7?7[;;:H9WPJ[)TZM.M[5U?3?))H=<*VI6[FI2C[I$*TJQ]6XX1]RQ
MX'P!%I=Q_D@^KBNK>6_J&TS)I-&CI4)WXR2AK]L>\><HBJCP\2IJ/L?#D0/'
M'.>ZA>;K(I:I3D^WZ2YO?C9BY5V &7K?QI4) ZC1MH_^3;7@U\B<W.IT?TO2
M $&A:<2NVS3UUMN-O=$EOOOO\_+?Y\T*[UWUCJ!8V>H]4 ;[I*UEJ,9^8QTA
M7CV_\/';YLC4ZQV&34I4E/34@I7?Q*.E#BU*[]^_BV^^YO??OOOWWZ^^_P >
M3<5*G  (*E:$#U"*"*,#;U;!$&:[-J%^P2;%VW.3XDS69I23[Y+NQ.4?Q*\7
MC\2O%W[^+OOQ=_Q]^_?O_KS)V&VVPV][W/XLQ=SOON=_7ON=]_?W]>5D&RV.
M,5I4;8)N/4G>MI4#*GB*3O7Q;UL=]O>MZ^3MOU9BRTJ4XVGJ59@? B6O%("/
M>V=&S+AU'4*Q!KW[D!'B##:GB((]1!1U(V^;)-@>HGG&MJ0J,Y/MJTM]O S+
MR2K",G2?B3H:P)DQ](^3P::\/;U=LA+?1O2UT$3Z%IP+>MJ\ IN?G,E,P/O\
M_+?Y\V*EU[UEIY4U^H]48+ZEM6#?C ][MWA83;YN.V9'4OK\Y%B5LL7:N0%M
M"UM.G2@-.UV9WK?J4O;C.C(IS:?W:6D10NE[[IV\C2M*1I>I^2/1K 9M,NV]
M.E.Y6.7C=K#WAQ<Q6%W]18V)-AX\21L=_P!(\N&O5BB:OI]'5(@0&D@Y4+9'
MNGDG>K,1ZPHK1[^HL-]QGGQ/U+<6<O*: @Y=R(LCB.^ZO84- 2KJDI\2_<]:
M7G@99*>RU:0 4\4AE&WB!1T^K7)NH.B->Z=#36JXL4E/[/IEIJZ@G8=X%5EK
MGQ WFC6,L>*2.<[7TQY0NF^JBL%.TU74"-SIMX+!98@;GL$.\-D#8G:"1Y H
MY21QC)_S4<WC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*9,
MS417HPN9G9,&'B0&MOFR,D4R&&,UK>M>-XA]:&T=U;TA&MJ\2UJ2A&E+4E.[
M]:M8N3QUJD$MFQ,W&*&"-I)7;U[*B L=AN3X;  D[ $YCV[=6A7EMW;$-2K
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M+W_.EA:#CV)=N:V/M)/+CP#[>GQV(.QR08UKCF;5%V,G4?"/Q93 4C%OGPC
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MY%'ZEC[T%_\ :DYX_(/3/]G;'LK0^3.B?2.H_P X,>;3?#[?\BC]2Q]Z"_\
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ML<R'U/$ZR(?O,A(/\>=@TW5M+UFJMW1]2T_5:;_<6]-N5[U5_ 'T;%626)O
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MEI)+\K>@W9IXPY0H?,M&K_)'&=EC[93+.'HR(F8Y2_ YI*U-$"E#O(:+CY(
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M]_IJ#2!%%&CQV=:J#[9+''#=_=EZ;J;6=S:BKK/$(@PB-O(1$P<<2?M<I<@
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MC&,8QC&,8QC&,8QC&,8QC&,8QG2I^Z0?WZ_%'_E=J'\ZW,N>Q_T//^!FJ?\
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M?YWC&,8QC&,8QC&,8QC&,8QC&,8QC&,9PA?=!'\'P?\ QR\9_P#/\[1Y!?\
M#U/WGU+_ &U\UGJW]IW_ '1!_M;.BYGMC.6XQC&,8QC&,8QC&,8QC&,8QC)C
MZ=OWP/!7\<?&/_&T)D1U!^T.M_O1J7]2FS)I?LRI^Z8/Z5,]/W/S6SM^,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8SJ+>7WZ:>HOF7J\XSLW$/ G,W*=< Z<:M!G3_'?&-TND*'-#\E\L
MGD1!4I7(62!'E& 9*.-> =?04T*>&0MI+13"U^KO(5U'T]H_26I5M6UW1]+L
M2=16ITKZAJ=*E,\+:;I,:S)%9FC=HFDBD02!2A>-U!W5@.?]64KEF_ ]:I9G
M1::*S0PR2*&[TYXED4@-L0=B=]B#ZB,X-_P#>N#V.NJ/Z N5/JKG:?;ST5\K
M^F/Q]I?UK-7]B=4^+KWT6?\ N8_ -ZX/8ZZH_H"Y4^JN/;ST5\K^F/Q]I?UK
M'L3JGQ=>^BS_ -S'X!O7!['75'] 7*GU5Q[>>BOE?TQ^/M+^M8]B=4^+KWT6
M?^YC\ WK@]CKJC^@+E3ZJX]O/17ROZ8_'VE_6L>Q.J?%U[Z+/_<Q^ ;UP>QU
MU1_0%RI]5<>WGHKY7],?C[2_K6/8G5/BZ]]%G_N8_ -ZX/8ZZH_H"Y4^JN/;
MST5\K^F/Q]I?UK'L3JGQ=>^BS_W,?@&]<'L==4?T!<J?57'MYZ*^5_3'X^TO
MZUCV)U3XNO?19_[F/P#>N#V.NJ/Z N5/JKCV\]%?*_IC\?:7]:Q[$ZI\77OH
ML_\ <Q^ ;UP>QUU1_0%RI]5<>WGHKY7],?C[2_K6/8G5/BZ]]%G_ +F/P#>N
M#V.NJ/Z N5/JKCV\]%?*_IC\?:7]:Q[$ZI\77OHL_P#<Q^ ;UP>QUU1_0%RI
M]5<>WGHKY7],?C[2_K6/8G5/BZ]]%G_N9Z6.?G1G:,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QG"%]T$?P?!_\<O&?_/\[1Y!?\/4_>?4O]M?-9ZM_:=_W1!_M;.B
MYGMC.6Y>W&E?A[;R)1*K8"I(&#L]PK==ECH=H5^5  FY<.,*.CQC5M"%F!-%
M**8#)?&9+<:2,X6(EW9+6'J-B6II]ZU L;S5JEBQ$DQ98GDAA>14D9 71'*A
M6=59D!+!'(XF[ BR30QN6"R2HC%0"P#L%) .P) .X!(!VVW'K&3%AZ/Y<,.%
M/KUNJYU5L!,Y-P/+=BL %4XPG^-_=+CV J=G;.DF-OP,J9:+R_5+= 2Q2R*7
M9:].1,TL=R)DWA=<K]6PN\T<]2RENNL$,^E5X'M:E!J/:U">U6*1G:>):U%;
M52Q$H6Y6L030AA-$&SGTU@%*21E&+LEAY%C@>#>%(Y.1'HLSS&.16/VIT=6\
M0=HRN'39R%2*.QR++$5]^J%"1IC$C&ER9*7&IFO<?V2'3I3D.PRER4&Y!&CP
MTK>3I4W4[_$NJ:*J$FE,E4ZBH7+K:?$LZVE:1&CD6)2##8OUYO5,Q(B:@TC[
M _:+="4;I;C.6)*,T47>8IV]E.X+G[I(G4?<#Q82A1[G..5208SDG2_3%4T\
M?4F<BN06(Z[6_C6L<CQ]:GBHXY$P":UR&5=&QP:^T39J\%3HV@ZEFYB8ARHN
M;3,HBVBPC@FE2<;#U):-^Y#+0,E*IJ-G3Y+,"R(871M/2F6><K6L/<EO=HPP
MS++ 83*5=';M7VH)V8G68"22".=8W*GDI[QEV";R*(EB#<F0J_+B""OC;DIT
M@<D0+BF)^S<9P!##LR-()G+:Y$AQ)43R+>.*619*;.BF*\P]-7GCBZ1,1M$N
MZUMB$<EY)R-ARP#RK\75FGS@-7K:E.K+"T9AJK*\J2Z?2U0M'"DIL,(:6HTY
M9=X@>4XAC$DRNBT'39U\&D@0[L&#R%0I$TM<!F*A 6EAE1?2/W!8[(0QV4YT
MJ7:MTBPWR8LU+:B("DMW/;0A5@,,,VZ1T]J:KZ$:KK+;,N[#=3'&DVAU;JHA
M+)4D 1)L24::,Q<AZGIV+L%&*M<,T]TT]W6!%39=?WL$^<,3")NG-2@( $Q9
M8Y%B:.1&;X^GRQQ/,TD7%(^YL"Y)\:?H?<#9BMV!@?N?$@D%6 N/B3I M/,-
M2X_FH*:;BYB[\O\ '7'KPDQ&$M0D)3^4[AOC:M\E%SC;BF]Q,5R(*]7+2 IA
MHF.3/4DP=93=BTD;&U7JRKI%K4(9X3+%2TG4+X:&13--;TRG[)6--2 C?O3:
M>ZV:L@)63L748*:_I5U]-DL1PNC<6EL0PD,I")%/)V$G+[_<K,"CKMN.<1&_
M([1+=J! 1]*3>:D'<T5]OD6?X\3)VQ^K-;E"8:)CY9HGW#CC$S]=EG134D2<
M$8'+1<0A\,8:X31:R6QY:G>GDN&E:>F9SI]>_P!NJ+)[2S2R1%>](G8L1*R<
M8IT>&64AV:G"G$MCRPHL7>C$O'OO#O(8QR*J&WX \T8[[E"K*H('<8GPA?)?
M,7)CZ=OWP/!7\<?&/_&T)D1U!^T.M_O1J7]2FS)I?LRI^Z8/Z5,]/W/S6SM^
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8SA"^Z"/X/@_^.7C/_G^=H\@O^'J?O/J7^VOFL]6_M._[H@_V
MMG1<SVQG+<J4-,RU=E8Z=@9(Z&FH@QB0BI:-)>"D8T\5Q+PIH)@ZVWQ2QGDI
M='(86AYEU"7&EI6E*M6YH8IXI()XTFAE1HY8I55XY(W!#(Z,"K(P)#*P(()!
M!&5([(RNC%74[JRG9E(]1!'B"/6"/$'Q'CF4W"=(Z@+!J)B^/^0K15B;72K_
M &NKU.O3MCU8[I5AK'$PMJ:J%4@7-/V4V=M%0T[JOQ:7I>47QA+S*0'"*M#>
MFZSK-W0H#++?H5K2U;E&M9MV(*QK4[3UY9JQMVIQQK)!5MD=^7:&(:G%$9 M
MJ;AGU8K;\5BF>,RQ321QHS]R5 ZJ_;C3Q<M)%N$7=CV'<+NB\K&G./\ G%=?
M5$^F6&S<< %!CPI;4V9JH' 1-QY1@J_+QT5-D $@1J+1OE1<;[IQ,85$ES%F
M=,%CB)HW16;#?T83B4K!6U"17,R-"GG:224],GGADEA617D-7V+$G;ED65(:
MRHTBPIQM/#;*<=VDA! 0\_095DG5&"L0P4/W]N2@J6?D%).7L[QYU0 SM+=A
M)VV&3*T3'#7'K@]T:B;*F/9KM5?F*'!Q!\X).QT&1#\O0HS40V.S'2HUG(]$
M9?9*)WO"&H=-/#<$T%5(?M.L:@&I&6L9&L6EBO3RI \$DRS:3,QF+-)$]9>;
M*R+M=,-]7C".[-Z5:':4!]N$9>%49PX0K80<=@K!_ $$YJJ"ZSI$0B]%S?+W
MN=8*I+ZD;>?<I,<0ZF2%MKMLEFI*7)F6TKAY&Y\GU>X>B%.^"2F[W$6@1D@J
MPC2!02=(1NM%(=)[D%J+MU(Z<3.EN.K8J1&*%(21-'3TRS4YH-XH:,U9V5:[
M1K](U,@RL]C9XV#2-*0#$TB.V[%ON#+-')\[2JXW+@G=W*C]5T?8;QQNW9K[
M=8JO6*U\:29$799ARN3;4,$-$2Z&090P-]5=.A>$8<5#D@ .&0'QI 1;FM$5
M6-#!HJ7NEY*]'436H4Y;%>KJ,2RUH18@:9VEB)>)'46$FUJ9B(Y&=7U&Q*/1
MM2NZ6+4.<T(>654=X7*NW!@H ;P8C9"M90-P 1 B_P#PP!18GC_GZ.CN69^;
MM\[Q\/3>.:Y%VQ^5GY5I^T<?C\B<1<?QE?C=0CISUEJ%?/N%"G!E"Z,K+<5!
MQKL.^0>+!BNWI;^AR2:5!#4@OFYJ-B2JL4$16K?;3]6OR3R=X(M:W/'4O0L&
M,=DRSR"8*CSN*5AMJMAWE>$1PHLA9SO)")H(0JA23)'&TD3 C= %7B2P09$G
M*$]RMNPSU'Y3LEGE)NHVVQ"3L5.SI4ND:Y"E>X]CD2%K*)'/G"GHQL20GU.$
MFR; 0FGCB1V!_#*Z;!I?8@NZ96K10VZM=X)8(%A+4V3O5XU 16CA59"Z0;*D
M;.Q"*S-OCV'L<VAL.[-'(X968MM)OQ=CXD,QV\7\2P \2-LB_)+,?)CZ=OWP
M/!7\<?&/_&T)D1U!^T.M_O1J7]2FS)I?LRI^Z8/Z5,]/W/S6SM^,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8SA"^Z"/X/@_\ CEXS_P"?YVCR"_X>I^\^I?[:^:SU;^T[_NB#_:V=%S/;
M&<MQC&2K'\MSH415XHF-A9C5/A#:O ORPBW7 *V7=U\DLQX3XCH4C%FQUX+F
M)D*<B)&/F/,S\S#$EDPY?H2(Q]+@>6S*LDT)MSI9G6)@!)86D-.:1U=7CE22
MDD,+PRQR0[P0S*BS+S.0MAPL:E4;MJ8T+#?9#+WN((V8%92S*ZLK;,RDE3ME
MTRG4_P WS49R!$2=T=*!Y2GK[9KTA45"MKG9CDR7K\]<"'7&8]M8K)\M7 C1
M 0=C P[QDVN('!5.2NRL6+IK18)*$L5,(^F04:U$B68B"'38;$%10#(>;1Q6
M71WDY/,J0B9G$$7"MKUIEF1I-UL/*\HXKZ33NCR'U> +(" /!>3\0"[$U!SJ
MEY1?22@K58)20BV-(6J :8, 9O-)HO'5M:BY8,@68C4SM,X[KL >H.09<<CE
MS0NEI'GY=HNV.F=-4J5-E2IJD_;RR.:-R]J%0RQ.K0R=BYJ%BQ&'C($HA<@M
M!$4K.H3G?<1^/<_R-B.['%#)Q8$,.<<*(VS>*\@?!V!H4YU!WRQ1\Y'28M0V
MW9:#7^-)\@"I0\0=+52IRE(E*R*67$LA/>DPKG'%*&&,:4T\\+":T=LLB2F"
M)#(AT*C7DADC:WO6OV-2@62U-*D5JU%=BLLBRLXX3#4;C,AW >;T."QPK'0]
MR9PX81D21)"^T:J6CC:)D!*['=>S& 00=E\22S$WN[UC<SO;GU+>J&E6>9L5
M@G'&JA$#O2$O:%V9<J<^0.VT0HE6KE9F!W]N[>8"DV8U+FXV%KPD3@CI'1P(
M %M;5H:]> &U*P2*J*PB0!B5X_J.LS#;BSQF0CN33M+=]D[)Y_K7VQG=]HU!
M+/SY$D;'?[8X'O!@OJ1 M&F^J/DVTPLA6K/NO2D'+5R.I,BTBOQ8DKNC1T]1
M+0FI@3GHSY\?&N6+CFM3:7FU.'"22)1\(D=N;EF3+T/3.FUIH[-;SB*>*Q)=
MC)GD>+SZ2"]6-J2$L$DD%?4;,/'P1HS&KJQAB*4M?GD4I)P9&01, BANT'AD
M[:OL2J\X(WW\2&Y$$!V!A:Z6V9OUPM-YL;S3\_<;%,VB:>8:TP.Y*3LB1)G;
M''TI21Q_22G-#CI5M+#.D-)WX4:R8IU8:-2K2K@K!4KPUH0QY,(H(UBCY-X<
MFXJ.3>MCN3Z\Q)9&FDDE<[O([.Q'@.3$L=A[@W/@/<'AELYDY1DQ].W[X'@K
M^./C'_C:$R(Z@_:'6_WHU+^I39DTOV94_=,']*F>G[GYK9V_&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M9PA?=!'\'P?_ !R\9_\ /\[1Y!?\/4_>?4O]M?-9ZM_:=_W1!_M;.BYGMC.6
MXQC&,8QC&,8QC&,8QC&,8QC)CZ=OWP/!7\<?&/\ QM"9$=0?M#K?[T:E_4IL
MR:7[,J?NF#^E3/3]S\UL[?C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,H-CJU8N$;N'MU<@;3$;?:)W%6
M.(CYN-V2QXO,$;!DQRA=OL^-?FG=M><;\2O K7BWWOU[5FG)WJEB>K-Q*]VO
M-)!)Q;;DO.)E;B=AN-]CL-QE#QI(O&1$D7??BZAEW'J.S C<>_E@_@_\#_,G
MQ']&]-_Z-F?[/Z[\=:M^,;GY;+7FE3X-7_ Q_P!W'X/_  /\R?$?T;TW_HV/
M9_7?CK5OQC<_+8\TJ?!J_P"!C_NX_!_X'^9/B/Z-Z;_T;'L_KOQUJWXQN?EL
M>:5/@U?\#'_=Q^#_ ,#_ #)\1_1O3?\ HV/9_7?CK5OQC<_+8\TJ?!J_X&/^
M[C\'_@?YD^(_HWIO_1L>S^N_'6K?C&Y^6QYI4^#5_P #'_=R$.*."^$2;YU-
M,D<.<5D,Q_-\ ( T]Q[4G6PA%]-W3Z>L41MR(4D8=9QIIJF6=(;46641M.WB
M'5KFM5US6EH]-LNL:HIDT6=Y"NH6P7<=1:_&&<B;=F"(B!FW(1%7?90!C05:
MIEN@UH"!90#>&/P'F=0[#T? ;DG8>Z2?6<F_\'_@?YD^(_HWIO\ T;(7V?UW
MXZU;\8W/RV9/FE3X-7_ Q_W<?@_\#_,GQ']&]-_Z-CV?UWXZU;\8W/RV/-*G
MP:O^!C_NX_!_X'^9/B/Z-Z;_ -&Q[/Z[\=:M^,;GY;'FE3X-7_ Q_P!W'X/_
M  /\R?$?T;TW_HV/9_7?CK5OQC<_+8\TJ?!J_P"!C_NYKC<$<'A$CF!\-<4B
M%B/M$BE#<>5%@D8EAQ+K! [[4.AUE]EU"7&G6U)<;<2E:%:5K6]4MKFMNK(^
ML:HZ.I5T;4+;*RL"&5E,Q#*P)!!!!!((VSZ*M4$$5H 0001#&""/$$$+N"#Z
MCDJY%Y?QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&01Q#_ '0>J7^/>O?_ *Q].>3F
MK?L#IC]X['_[EZAS%K_KU[]U)_4J>3OD'F5C&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,A'ENS\AQ=@XJJ7'4K
M3(&1OMFL$9)3-UI\Y=@@XV"I%AL_@!AH*^<>/Z-*,BA1_2GYMYAD9;^O0775
MMN-36E5M/EKZI;U"*Y/'0K5Y8X:=N&D[R3W:];=YIZ.H+P5)6;BL(9F"^F "
M#C6'F5X(X6C0RNZEI(VE "1N_@JRPG<E0-RVP&_AFU][W4[\[W _Z.7(/VI\
MJ\XZ:^*=<_G#0_-C/G"[\(J_0Y?KV/>]U._.]P/^CER#]J?'G'37Q3KG\X:'
MYL8X7?A%7Z'+]>Q[WNIWYWN!_P!'+D'[4^/..FOBG7/YPT/S8QPN_"*OT.7Z
M]CWO=3OSO<#_ *.7(/VI\><=-?%.N?SAH?FQCA=^$5?H<OU['O>ZG?G>X'_1
MRY!^U/CSCIKXIUS^<-#\V,<+OPBK]#E^O8][W4[\[W _Z.7(/VI\><=-?%.N
M?SAH?FQCA=^$5?H<OU['O>ZG?G>X'_1RY!^U/CSCIKXIUS^<-#\V,<+OPBK]
M#E^O8][W4[\[W _Z.7(/VI\><=-?%.N?SAH?FQCA=^$5?H<OU['O>ZG?G>X'
M_1RY!^U/CSCIKXIUS^<-#\V,<+OPBK]#E^O8][W4[\[W _Z.7(/VI\><=-?%
M.N?SAH?FQCA=^$5?H<OU['O>ZG?G>X'_ $<N0?M3X\XZ:^*=<_G#0_-C'"[\
M(J_0Y?KV/>]U._.]P/\ HY<@_:GQYQTU\4ZY_.&A^;&.%WX15^AR_7LA/BJ!
MZCU7OJ72)RMPBP^WS; HDW2.GZ]E,F';Z<>G]QL@!AKJ8#7'")C5QXBPR")1
MY9PID@D]M@]B,CIK5)^GA1Z<YZ7K3*=%G,077J*E$]L.O K(QZ<<2.9!(X=5
MB 1DC[9:-I9,:!+G=N[3U@?.4Y;U)2"?,ZGB!YZ-AQV&Q+'<$[[$*)L][W4[
M\[W _P"CER#]J?(7SCIKXIUS^<-#\V,R>%WX15^AR_7L>][J=^=[@?\ 1RY!
M^U/CSCIKXIUS^<-#\V,<+OPBK]#E^O8][W4[\[W _P"CER#]J?'G'37Q3KG\
MX:'YL8X7?A%7Z'+]>Q[WNIWYWN!_T<N0?M3X\XZ:^*=<_G#0_-C'"[\(J_0Y
M?KV/>]U._.]P/^CER#]J?'G'37Q3KG\X:'YL8X7?A%7Z'+]>Q[WNIWYWN!_T
M<N0?M3X\XZ:^*=<_G#0_-C'"[\(J_0Y?KV/>]U._.]P/^CER#]J?'G'37Q3K
MG\X:'YL8X7?A%7Z'+]>Q[WNIWYWN!_T<N0?M3X\XZ:^*=<_G#0_-C'"[\(J_
M0Y?KV/>]U._.]P/^CER#]J?'G'37Q3KG\X:'YL8X7?A%7Z'+]>Q[WNIWYWN!
M_P!'+D'[4^/..FOBG7/YPT/S8QPN_"*OT.7Z]CWO=3OSO<#_ *.7(/VI\><=
M-?%.N?SAH?FQCA=^$5?H<OU['O>ZG?G>X'_1RY!^U/CSCIKXIUS^<-#\V,<+
MOPBK]#E^O8][W4[\[W _Z.7(/VI\><=-?%.N?SAH?FQCA=^$5?H<OU[+AX4M
MUDN_'H<Y;E0CMC8LW(=8E"*Y&'PL(:[1^1+526I "(DYNR'1K<B-7V3G B)Z
M64,^0ZTDUYM*%9CZS4KTK[PU!,*[5J%F);$L<TR"[I]6X8Y)8H:R2&-IV0.L
M$095!* DY76D>6%7DXE^<J,44JI,<KQ[A69RNX0'8NVQ/KR5\B\OXQC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC()Y,_NM=.'^F5__ )I+IDYIO[5=1?N.A_Q:
MEF+-^R*?_F3?U>3)VR#S*QC&,8QC&,8QC&,8QC&,8QC&,8QC&01Q#_=!ZI?X
M]Z]_^L?3GDYJW[ Z8_>.Q_\ N7J',6O^O7OW4G]2IY.^0>96,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&01TW_W,7_XT^?OY^N2\F^H?VR7][-"_P"!Z=F+3_6/
M_6M?UF;)WR$S*QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S!WX2[H!]KO@G\_(C];FZ_8XZ[^
M2>M_0I?[,B_9O2?C"K^%7'PEW0#[7?!/Y^1'ZW'V..N_DGK?T*7^S'LWI/QA
M5_"KCX2[H!]KO@G\_(C];C[''7?R3UOZ%+_9CV;TGXPJ_A5Q\)=T ^UWP3^?
MD1^MQ]CCKOY)ZW]"E_LQ[-Z3\85?PJX^$NZ ?:[X)_/R(_6X^QQUW\D];^A2
M_P!F/9O2?C"K^%7(=O\ Y13H7D>2^!Y0'JKX3*CJ_:KJ7-F,W>*6/%C'<9VN
M+#?,<T[V9;)D2Q0VE*]2R'VV]>M6LEZ'D^ZVCTW7(GZ7UE9+%6FD*-3D#2LF
MI5975!MXE8T9R/<52?<S'EUG2C/587ZQ"/*6(D&R@PNH)][<D ?.<F+X2[H!
M]KO@G\_(C];D1]CCKOY)ZW]"E_LS(]F])^,*OX5<?"7= /M=\$_GY$?K<?8X
MZ[^2>M_0I?[,>S>D_&%7\*N/A+N@'VN^"?S\B/UN/L<==_)/6_H4O]F/9O2?
MC"K^%7'PEW0#[7?!/Y^1'ZW'V..N_DGK?T*7^S'LWI/QA5_"KCX2[H!]KO@G
M\_(C];C[''7?R3UOZ%+_ &8]F])^,*OX5<RIXVY,X_YAID/R+Q;;X&^46P;D
M-0EKK)[,G"2FXJ4-A9+01S&U-/>A2T<='D>'>_-E"/M*_;(WFKZCIM_2+DVG
MZG4GHWJ_;[]6S&8IHN[$DT?-&\1SBD21??5U(\#F?#/%8B6:"198GWX2(>2M
MQ8JVQ]W9E(/S@Y?&]ZUK>][UK6M;WO>]]M:UKU[WO>_5K6M>O>]_%F%EW.(C
MF;RX?D_>&KC(T=?(%IY.F(4QZ/FC.):FNT5N..'6IM\9JU2,A UZ=VTM.T.D
M5>2G0VW=+8<)20VZTCJVC^1CKS6*D=U=/K:=#,@DA75+0JV)$8;JQK(DUB'<
M'<+9CA<C9@I4@F#L]1Z35D:)[!=U)#=E&E52/<+*.)/WB=O=R*F_NA7R?Z]Z
MTIGG5GXO6YQM&*UKOOY?,W!WXOCWV[_X.^_5DH?()UX/4-%/WM1?_G5&8_MK
MT;_O9OP$G]F;Y'W05Y/=7;Q'<SM=^W?Q\8[5V[_'W\S/._%\>^W?O_>]]^K*
M3Y!NOO<CT<_,-2 _WH5'_P!\J'5.C'_X\@^_#)_9_P#[S>M_= /D[E]O'8N6
MF>_;U.<5RZNWK^7S);NO5\>^V]_X.^_5E!\A'E 'JK:4?O:I!_S48]M.C?")
M/P,G]W-ZUY?CR<R^WCNO)K'Q?V7B6UJ[=]_+YAE[XOCWV[^KXN^_5EL^0KRA
M#U4M./WM5J?\V'K_ /\ NV??;1HWPE_P,O\ =R-^.?+B>3V@+=SK+2W(-\$!
MO7*L/:JZYKB>]$*)AA.$>'*0^^^V+$OK%=18*;.CZ'>2EU3##)24[9)94J1U
M'R+]?3U-#BBT^D[T=+FJV![*45"S/K6L7552TRAP:]R!N2[@,Q7?DK 6H>H]
M(22TS6B!+.KH>U*=U%:O$2=DW'IQN-CX[#?U$9,+?EY?)JK_ '?+=T9^+OYS
MAGE17;O^/S-5=[]OE[=]^OU=]]]:B#Y#_*,/5I-0_>U?2_\ G:&W\.9'MFT7
MX7_H9OR>;UOR[GDS%]O'S?:&>_;^R<)\TJ[?X_,T-[XOE[=_C]7?U]J3Y$?*
M./5HM8_>UG1O^=X9]'4FC'?]6 ;>_%-^3S>-^72\F(O]UU!3;/Q?V3@WGU7;
MO^/;/&3NO5\OK[?B[[RV?(GY21ZM B/WM:T+_GJ0SZ.I-%^&J/OQ3_DLWC?E
MR/)?N=N_4B>UW[?V3@SJ)UV[_C\'$R_B^/?_ +[]64GR+>4H;?\ Y=0_>UK0
M/#[^^J#/HZCT4[_JY/X8YQ__ (LRHZ=NOKH^ZKY,F"X#YVJ=XL@HSQJZF0+8
M:;<7@!M:V5(!5"^0M8LTC'!Z4CTV0CXHD(/;C6B7VMNMZ5K'4'0W5O2T:SZ[
MHEJE79@@M!H+=0.WW,;VZ4UFM'(_^1&\JN^QXJ=CMFU=2HWB15M13,-]U4D/
ML/6>#A7V'O[;?/F7^:GF=C&,@CF7J?Z>NGA^OB\X\Q4'BLBU,R)%;9NM@#A'
M)IF(6$W*.QR2EIV2@!<B"@G:.^FE%L:5^[UDYH_36O\ 4"V&T32+VIK5,:V&
MIP/,(6F#F(2%1Z)<1N5!]?$^]F)9O4Z906K,4!D#%!*X7D%VY;;^O;D-_OC(
M4^$NZ ?:[X)_/R(_6Y,_8XZ[^2>M_0I?[,QO9O2?C"K^%7'PEW0#[7?!/Y^1
M'ZW'V..N_DGK?T*7^S'LWI/QA5_"KCX2[H!]KO@G\_(C];C[''7?R3UOZ%+_
M &8]F])^,*OX5<?"7= /M=\$_GY$?K<?8XZ[^2>M_0I?[,>S>D_&%7\*N/A+
MN@'VN^"?S\B/UN/L<==_)/6_H4O]F/9O2?C"K^%7(<X'\HIT+U_CYZ.F^JOA
M.+/WR+S3):$,N\4R_L"<YFOTW$%Z0IW6_,2,1( R(CGQ/"%,NI[I7K)?6_)]
MUM/?$D/2^LRI['Z/'R2G(R]R'2*,,J;@?=1RQO&X]QE8'Q&8]76-+2'BU^LI
M[M@[&5?4UB5E/WBI!'O@C)C^$NZ ?:[X)_/R(_6Y$?8XZ[^2>M_0I?[,R/9O
M2?C"K^%7'PEW0#[7?!/Y^1'ZW'V..N_DGK?T*7^S'LWI/QA5_"KCX2[H!]KO
M@G\_(C];C[''7?R3UOZ%+_9CV;TGXPJ_A5Q\)=T ^UWP3^?D1^MQ]CCKOY)Z
MW]"E_LQ[-Z3\85?PJY?O&?6[TC<S7*,X\XJZB>*;_>)IJ0>B:M5[9'RDU(-1
M4>3*R3@H0[BG74!1H91I&TZ[-CL.N*]2=Y@ZET7U7H].34-4Z?U2A2A,:RVK
M-5XH8S+(L489V&P+R.J+[[,![N78-3T^S(L->Y!-*P)6-) S$*"S; >\ 2?F
M&92YK&9^,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8SRG\_4#.#Y./$?!D_R_"7R9@"#'7*'JH;*A(BNR]EGI?5
MRL"*T![DQT2A2G5"R+PZC=$.,)2,[MQE3KB/,JA=5UN#29J,,ZH!>\[XSRV(
MJ\$/F=<V7[TDI\ T88)Q#>D-CL#N,NM4:RDS*6^U=K=%1I';NOP4*JD>(;;?
M?;P]WW,VB. >4SE[>@*K(6"&?=2J*G0DMC 2T<0)R#)1\NPB1=$+%"/B>*^0
MI)'N@.(\,S4IMHUH8D!YE-9UW3(QM/:CKS*")8'):2*17H1R1,8PZN\<NIT(
MSVV=6:U"4+*X.?/,[!W*1ET_R778!E(F96 8@@,L$S>D 1VV# $$9^1^GWF(
MIXAABCGKV$VM^1>V=#-AQ(J:V9<V3YH]R20#"QI],C9*Y1$E*D!@350C9&T1
M!)L$"7(,FU[2$"LUV,<R%C7A*7E<V4IE(8Q&7FDCN2Q4YHXE=X;<D=:54G=8
MS\%.R20(B2/7XKLNZ&4%CRV0-$K2*S$!HU9U)121^I'IXYMAQI$R6XVLL:)$
M2IT-*%'BM"#QQD:S9GSGC7GWD-C13#-,MJ]SKRD0CFJY,^:D%[CR=-H]?T:5
MHTBU&O(\T231)&Q=I$D:LJ*BJI9I6:Y5'8 ,X\XAWC'<7<U.TH8M ZA6*L6
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MO68*MIH^2U)Y4CLF)V53BK3L."1'X!"[$LBA5$33@MNPX\XD>2,-L9$5F3D
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M!')258!@&4D;,"8BR5S'ST!/(B?P8W3;_E.8?Y]^3<\'^6;_ !D]1_\ M'_
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M*9\U#225FE[G<6R:\=BVB&+@U>I9?N Q<3DQU)9:[V(^+".5(FC&_<^V;!7
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MR)(?3)))C&!ZM*_"-UQA?$+<B/ C\5:7HFXM#%DR'%MM#L8DBU(QM/!)\W,
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MLL+4-RZLNELZ,ZJJK*2RK$X#1,U(E1MX!O1N\20=@ZHI3[6\4!\JS_!<EQ[
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MOOZ+HG_]NGC/GM;T7X$OX6;\IFR7Y"#R:"OW/#%M:_PHYJY@W^/Y';HYK_\
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MS;;S(_J8E/UP]W'O/)]^'OL]^ET]'[=O>?[H17O/_P"[/<[OZ#[B^Z??Q_\
M:?\ WQ_WG_5O_A_ZVQYLWG/G/G5KC\&YQ^;?K?;^X[7<]?VS]=_7/'[GT<>S
M<7L)[#>P6A=SX[\VM^S?[+\Z_9'GWFOW/ZD_87[$]#]=^W814"46Y=KW<[FL
M=>MZU4%GQ6ZBCO'Z [H!U"ID];TO7NAKO+J_[0WMW?=GL/H*S"R;'G5HJ?\
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BC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g389734g03q73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g03q73.jpg
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M 0$! 0$! 0$!_\  $0@!40(2 P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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MA(4FHK;A)63Q_]H # ,!  (1 Q$ /P#W\ B B B B B B B B B B B B B
MB B B B BA%V@O+1QPPXZO\ <#"(CY26=W.FT.)<3C63?5FNNK=)Y;.;99V,
M*NTF)&%KD6VD9)2)C'L>]FGJ+&&0D8\\AAZANG 7"H\8<01XDY9(H@IW+THP
M'%'9L#4CW#5K23"<,<UB4HXVED"0(0<YBCD:/849EK_BVF]AA%R>6*(7-B<
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MJYF]-'+D<9BS">#'PSC;IV"&O.%DGCCM1^S6Q.P1!+([WLK7&ADL5:B JV/
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MD=097ECB<W B%A-F,R-V+:^CZ$3Z/HSZ='U[U*L:NL] 1 1 1 1 1 1 1 1
M1 1 1.F/W 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14Z1F(B'2\:6E(Z+1Z9SXLB^;,DN
MF/CSXCE5(G3'Y\]?1^<7H:UBR6VO!-.7[F&(Y2_F 2?^I8]BU5JCOM6:]8/W
M=B:.$?Z4A"W]:Q[(;PTW&&R1YM&A)J%Z]Y)*TPSI8N<?F,BU=KJES_%DF,Y_
M,)B'A;B6?1XL#EW9^XBH68Q?S]"DC$7_ )U!S\8<*5]6EXCP@NW>(Y*I(;?C
M".4R;^96VMR<T(AGH?9U>-G'[SY>XQ_[D&2A<_HR,X>!N+3;5L%<;]]R@?\
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MAJS8V5]?9*,YL.OFU@L<^!A]L8PCU;7JSZ.V]8KPM<8XYQ&>W7RL(Z-R\C7
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MUYFGG7T5X"FL]GXC<MW8^=C6BUUV=I8+G/V>;=RGK\SSZ<KS:+9&.*+OR B
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M%VZL3.[.W5G7SE+%)#(<,T9Q2Q$0212@4<D9B^A 8&S$!"[.Q"3,[.VCMJN
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MV)Y9NOM^R&77X5-UL?0IMI4I5*K,VC-6K0P-I[6D0#T5:&,LM 1 1 1 1 1
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M2X3O19:T%N];XECMSBX-).%.?&#6$WV::0M-*P:,W0WUUZ*)K\ \'%D<A$6
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MX.\:KFP;'_FQGO?GZC39>+.)IF=CS^7T?O8+]F)G^!VBD!M/@[O@4W#P9PE
M[/'PWA-6[G/&U97;X6>6(W9_A;JK]BZW78/&"PL#"PY<8Z8Q%Q;&/QC'3ITQ
MAH@CCIT]'3XN@B+%VY:?6U;LV7UUUL3RS/K[>LAEU4W6Q]"FVE2E4JLS:,U:
MM# VGM:1 /15H8RRT!$!$!$!$!$!$!$!$!$!$!%!GLV?R+=.?^MLS];U^&[>
M$7]F68_^/_NJBHK"?>RM^.Q^<S*<PTE2J B B B B B B B B B B B B B
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MH4&VUZLUG;<;*EGLR]XHL95JVO$)L<M(V18;%HM_S(RRCEVW=9;G+1R0Z2+
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M%F9Y2@*;-9B7+21UXW".MS*=*H-492VG88>R%.\Q10;I+$FD(=2/$N6FLM5
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M["9>$(YQ&M4['8F\>V:-Y^72>V)^'</9DGEGJD9V;%&W8?M=T1FM8T8@I6I
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M("("("("("("("("("("("("("("("("("("("("("("("("*#6E?RZ^<_\
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M>U^N;'\/-_:$L^/_ $<?[P?^EE7187M 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1:W^2_:Q\'.*MI?4'8FV33VPXE4R$S1=;04G>IJ!<DZ>*QL3Z+
M3+6*[*H]Y/*L'.6"/G$TU4EC1O@'PJ.A<.>"WC7BBL%['8KDX^5MT-W(3Q4H
M9Q?N.N$K]HL1/H^DT$$D+NSCS-W115S-8V@3QV+(M*W?$#%(;?OF%G87^ G9
M^O<HI?C"O9__ +SO7YMHSZ8#:/4$X\_W+\XG]56!Y5X;\+-\1)_X3\85[/\
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MSO7YMHSZ8#6_4$X\_P!R_.)_55G>5>&_"S?$2?\ A/QA7L__ -YWK\VT9],
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MT)F?1V?N=E/ 82")@0F!,SB0NQ"3/W.SMJSM\+.KE&.O2 B B B B B B B
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M8E:J0SRV;,UIXI2WU8"!K+01[I(&"691\6ML7C..,6A&:9YH8(HG=F!M(Y2
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MZ==EN.G'[=SZX6JT0;RFP\GM/D[2./MFBI.MHTF$?,X"*87@]M;/U;1EZR-
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M8L_MFO&#^4-H_J0V6.9>&/\ U;\2_O,7_?>-4[PU]^Z/X['YK.OT&!\&+K:
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MY7^,/M1M;ZH _P H?@_T3Q+\EQ?VNGD9DO=%'XRQ]63\6[YG?*_QA]J-K?5
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M[)I.W:7"[#UU.I66FV+$AF'FD6<BP3>>:I5]"2&/(Y9FPD6YVLK&OF:A'3-
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MIAK4,R;=PB^>JGL;I2:J9IR-G;<K/V&N9L,_7*S*PU.=(5UL57=WT;VO\?\
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M6Z49"$9Y<U5.GP:.PMW=6]OS? ^K]=7=E:C6N;W8[ L.VJUQ_P"6B#>R\9N
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M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HD\^?R(.7?\
M5OW-^K^>!5'O;\;?\UK;[ /\DR?_ )S17^#8!>C[V_%_W=;V@7A 1 1 1 1
M1 1 1 1 1:A.+O[;GVF']"W"_P#_ ,W<"KYF_&__ "%;>P5$!$!$!%JT[:O]
MK Y<?S 8?YJ@ 7H/NF_+_P G6QO7G_<"C?S/K/\ @K(%Y5X B B B B B@UV
MF?[7US%_J_;'_P ONA0NY_Q/_P E4>]OQM_S4.NPE_(W=?SX7_R_!BJ%WO\
KC?\ YK=4"H@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g389734g09e05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g09e05.jpg
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M ?_$ !\  0$  @(# 0$!           (!PD&"@0%"P," ?_$ %40  $#! $
M @X$" D*!P #  4#! 8  0('" DX$1(4%1@96'B7I[:WUM<35W>'%A<A-SEV
MEK(*(C%55IBUU=@:(R5!4W64E=/4)C(U-E&SN"1AD?_$ !T! 0 " @,! 0
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M!0"@% * @CC+QAXU27CQI.0R/CSHT^?-ZQAA4T<-:F@)4P7)O@3)R^)%";X
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M%[$"&M29! @AM2:INF9!SJ+7FJ-?I/V*N.3-Z."Z^C3D0Z05%2!JYDK(P0>
MNSHV/K3\])2%"!0"@% 3'%.N9OOS8^(_O5YLT)Z2=E?R:4Y0@4 H!0"@% *
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M% * 4 H!0"@)QV9U@^,OWS^Q+"K*EZ'73[%Y]QCMRVP8:^^>!1E'56F1"@%
M* 4 H">N)?5@T!]D4"]G!]6%VZ)W#YY4>=<4.%MK=A[4T'!HRA:KR^)(YO'
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M2&"%Q2XMF(7]99_UTE'4 H!0"@)CBG7,WWYL?$?WJ\V:$]).ROY-*<H0* 4
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MO:YU?LF.$)-<E9Y)LI+%F&!9PT'.@*%XXF)=O07L(G8T_CI_T[I;%"!0"@%
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MRH\ZXH<+;6[#VIH.#1E"U7E\15ST=$T=()-&44'2]B9EPD$9%WF6XH=+;L3
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M72T?ET]&G+/1GL:43/2;(J$"@% * F&/]<_;?FP\=O>MRAH"GJ 4 H!0"@%
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M<$ [ERW410*,$##$H(6>CU<\';5$H,(CE%T<,'S%VVR5;J#B1=IR'2B&\O\
M=;.4[8FVVG3OC;QT<MBLW#ZT#O1:&.S^3R5Q[)'64!U^-5:YJ8Y.<E"3!^^L
MJIEC@[Q0M@C@)7L9=W^N9<%"!0"@% * 4 H!0"@% * PU/>.?'O:AS"3[/T1
MIK8\D38MQ>$AGNKX1,#F QHHNLU'8%I"#(O\6+95TY5;M+.+-T5'"^::>.2R
ME\K&EO%VH8N445TN-'"KE>L-+75-/$KW(B.?RN&5C-4Y&M1799JB(BKH0H;E
MA;#%YJ$J[OARPW6K2-L*55RM%OKJA(6*YS(DFJJ>61(V.>]S6([4M5[E1$5R
MY\*\"GAMY)7&7T#:L^%*[.N3$6_]Z\*5WMSH:P<"=16$O^W+/Q,>!3PV\DKC
M+Z!M6?"E-<F(M_[UX4KO;C6#@3J*PE_VY9^)CP*>&WDE<9?0-JSX4IKDQ%O_
M 'KPI7>W&L' G45A+_MRS\3'@4\-O)*XR^@;5GPI37)B+?\ O7A2N]N-8.!.
MHK"7_;EGXF/ IX;>25QE] VK/A2FN3$6_P#>O"E=[<:P<"=16$O^W+/Q,S9"
M-?P/6<?0B>MX3$=?19JNZ=-8U"(V&BD?;.GJMUWKE ,!9,!R*[M?+)9TLFVQ
M4<*Y745RSSO?*JVIJZJME6HK*FHJYW(UKIJF:2>5S6IDU%DE<]ZHU$1&HKLD
M30F2&06^V6VTTS:*U6^BME&QSWLI+?2045,Q\CM5(]L%-'%$USW*KGN1B*YR
MYN55.75USNB@% * 4 H!0"@% * 4!..S.L'QE^^?V)8594O0ZZ?8O/N,=N6V
M##7WSP*,HZJTR(4 H!0"@% 3UQ+ZL&@/LB@7LX/JPNW1.X?/*CSKBAPMM;L/
M:F@X-&4+5>7Q(?+?DIHGC_'HMGM@SK5U)2<JC9*!0.<[5UAK)R4+##K+%K+T
MG6S)3&QN(B%D5FA5T8PQ(Y"2:8M9JUN3[AS3$HBKL?DJ_DBF0.,D[B>SM- )
M]"0\/!1Z4R'9)1%C I[$=G154HILZ8I2(L-G$$>D8H:6/R-(L>*V$O%L19@D
M_#O.T(CW:6 *F2Y+UMG-.EU]/8ZQGRA H!0"@)CBG7,WWYL?$?WJ\V:$]).R
MOY-*<H0* 4 H!0"@% * 4 H!0"@-)W3]_H_2/VPZU_>.UG_(UVSQ?,JS^5AX
M1\(OY.).W=K_ +@Z.%;$F@PH!0"@% * ^D%T?G47X?\ FVZ9]@05:IXFVQ7W
MMM<.%2GT\Y'&T#!7T7L?HZG*^JC,T% :]>E5ZA.^/NO]\VNZR+">V"@^U<"J
M3 >2AM&OGW9Z8MYGGAMU0>*GFW:-]V$7KH7KHS=NV=?PJ4O,(;4L+_1VR>C*
M4I&JPR(AK1&_]G;:W%)(3.X*C&HZ 'STH,;O=&\G(JNU*Q"=@(R$59;6VQK*
M%ZBFN+D62?D+9P0B\?D+9MBH))<"R*/<1*HF7^J?DF:I^M@N6A H!0"@)AC_
M %S]M^;#QV]ZW*&@*>H!0"@/&>9NTFJRC%NB[=XXVN@V<.LF2*N?;6M?%1U@
MV>9(VMC?++MK-E;WO:V/:V[/;6 XUWQFW]%@/[7NOA2IT;J]Q/61IW$[J^H=
M\9M_18#^U[KX4IHW5[B>L:=Q.ZOJ'?&;?T6 _M>Z^%*:-U>XGK&G<3NKZAWQ
MFW]%@/[7NOA2FC=7N)ZQIW$[J^H=\9M_18#^U[KX4IHW5[B>L:=Q.ZOJ'?&;
M?T6 _M>Z^%*:-U>XGK&G<3NKZAWQFW]%@/[7NOA2FC=7N)ZQIW$[J^H=\9M_
M18#^U[KX4IHW5[B>L:=Q.ZOJ'?&;?T6 _M>Z^%*:-U>XGK&G<3NKZAWQFW]%
M@/[7NOA2FC=7N)ZQIW$[J^HY*SS=*-D<WS=%J[RP[*[=NYR>(I9]F_\ $3<Y
MMVF2V/8[%^WNV1OV;WMVGY.S>"3R: 4 H!0"@% * 4 H!0"@% * 4!..S.L'
MQE^^?V)8594O0ZZ?8O/N,=N6V##7WSP*,HZJTR(4 H!0"@% 3UQ+ZL&@/LB@
M7LX/JPNW1.X?/*CSKBAPMM;L/:F@X-&4+5>7Q(?+@)L4K$QKR +D@A$&8#/F
M!Z.[8D>L"#IT[</ Y<1+B(/CQR!18Z_&1PD_EKPR\CCA%$V$'-G5P;')P;Q$
MIE^O]T_77.<<6!IL5HV)-Y&4$'#;@G.BK\R"VTXWD)+*&]@RHRD2:;/<036-
MY%9\V?HNET&T"C#"/N55HT.'Y, [=TX!?UTOZJ4)0@4 H!0$QQ3KF;[\V/B/
M[U>;-">DG97\FE.4(.%S^> ];QIS*I%B^R%M7#1LK8<W3<NOI'J^+='M4E%V
M^-\?I,K=O>ZMKXX]F]K7_DH# 7AF:@_V$O\ ^2L_[VH!X9FH/]A+_P#DK/\
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MHU"6Q1YV^>6'=",5A\9"X?0XI)]R!VM[IW6NJJH!R&@% * 4 H!0"@% * 4
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MV!M,N%$D.-G'J2NA ^1;)DLJD+<1G(#QHPF*P*6'MR!8BY;-DE':]\Q&>?\
MLB?D7[0$X[,ZP?&7[Y_8EA5E2]#KI]B\^XQVY;8,-??/ HRCJK3(A0"@% *
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M(<4DRA4F)')5S395=*;.>YUW+NZ<D_H;H*'$4 H!0$PQ_KG[;\V'CM[UN4-
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MQ[&/8ME?\OY*#1NKW$]9%G@V\R?J.A'IO#_"=!HW5[B>L>#;S)^HZ$>F\/\
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M?5@T!]D4"]G!]6%VZ)W#YY4>=<4.%MK=A[4T'!HRA:KR^% * 4 H!0"@% *
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M80VI87^CMD]&4I2-5AD0H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * G'9G6#XR_?/[$L*LJ7H==/L7GW&.W+;!AK[Y
MX%&4=5:9$* 4 H!0"@)ZXE]6#0'V10+V<'U87;HG</GE1YUQ0X6VMV'M30<&
MC*%JO+X4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MIK.PYO=XW7\:'/7Q_O\ ^2K+[N'C=.D,\H/U4:0^6M-9V'-[O&Z_C0YZ^/\
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IMUQNWQBCJ.4\NA^(VV+5\IJ(IX_\R"CBE;J98F._9>W/4ZEV;55%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g389734g16o08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g16o08.jpg
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M 0$! ?_  !$( +,"& ,!$0 "$0$#$0'_Q  ?  $  0,% 0$
M!P4&" $#! D*"P+_Q !5$   !@(  @,(#08, P@#   ! @,$!08 !P@1$A,4
M%1<8(2(QE]4)"A8:05976'B5EK?6&3(W.%'4(R0S0E15=Z2FMM/7.6%Q-$-2
M8G:!H;@E-43_Q  = 0$  00# 0              !0,$!@<! @@)_\0 6A$
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MD/#,Q1N3Z@5/G[V2U \8'$!6UNJ<6Q.;30.)%&%EA(UV('3,('(LY0;,9<#
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MN\3#EXTW#2*,;GS*IR\8[3U'L2;2RJ2[B[#K48 FM HMV@/M7972M&WWTDL
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M<:Z8/.>:=EG1)# \4<_"9S^I$WB_71")F9[*91N9:,7.HE2',W'*(Q"R1!,
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MA#%42,=,Y3$.4P"4Q@Y#Y^>7Z.LBAU)*GGCD%3Y$@@A@""""."!D=)&\3E'
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M'U<D<\B_^I;I36^?4/7M%Y![F37=&:FYU5L()1_!FMWINF>F)8?5S9U?4FU
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M=QNVKJ'L^U6MMWUJQG_Q;<E:&1*L*^MYK#1Q(H+.ZJ"187?I7FO(UYJO:=X
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M+N+UK;R+P3!&/0*9/K*NL;R6G /D"MF$$<]R>? S5KU:K]2BV\)6(6-@8EL
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MK/7?)KO_ "0?3X]\D<(?R*\2'U1K'_<S'^SOU7]V>GOG=E_[=CZL]=\FN_\
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M;<7TFK']UFI<\=_JA_WWZC^K=?\ U3:YLKHS]S;'].D_R];.[:7/OF6E)!E
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M:&Q'%=C[>6D:KLUH2J<J8B<;9WD)6W3]A7GJBC5\1)M-/4&\:JJ+)WU17(J
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M#IXN9%'H()F*BDFF11I5==5AI4HO!JUU[(8@[N$3N+=H:1G<@$GCN8\#@#R
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M&,8QC&,8QC&,8QF-'&E^IUQ9?1HWO]UMJS(^COWW=+?UCT?^IU<LME^YU_\
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MO@%_JS?OHZK_ ..\?K!==_;Z/\83?H6/JKTWQLWS$GY,>^&^ 7^K-^^CJO\
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M%EW#A8QUEUUE#&4665.=550QE%#F.8QA^C055 55554!550%554<*JJ  JJ
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MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QF$7LE7_#\XR_HX;9_R?*9F?L=?O\
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M<JG$3JKN7"JBRRAA$QU#F,81$1R[CCCACCBB18XHD6.-% "I&BA410/(*J@
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M6)K=RU*\UBS/(TLTTKGEWD=B69B?A/D. .  ,V@B)$BQQJJ(BA451PJJ/(
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/C&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g389734g20d04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g20d04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X<E":'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P," W.2XQ
M8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C
M.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CYG,C!D,#0\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @
M(&<R,&0P-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$96QT828C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#,M3F]V+3(P,C(@,3DZ-3<Z
M,C0F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#,M3F]V+3(P,C(@,3 Z
M,C<Z,C0F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,C8N-2XQ)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03OB@*(@,S$R(&)L86-K('1E
M>'0@8VAA<F%C=&5R<R!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[
M5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE
M;G0Z)B-X03L@(" @(" @(" @5&EM97,M4F]M86XF(WA!.R @(" @(" @("!4
M:6UE<RU";VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C
M>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z
M(" @(" @(" @(" @(" @9S(P9# T+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,RU.
M;W8M,C R,B R,#HQ-CHS,R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P
M,RU.;W8M,C R,B Q,#HT-CHS,R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-BXU+C$F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ
M*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U
M<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ
M*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<RU2;VUA;B8C>$$[
M(" @(" @(" @(%1I;65S+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,C(M,3$M,#-4,C Z,38Z-#0K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3$Q+3 S5#(P.C$V.C0T*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E
M/C(P,C(M,3$M,#-4,C Z,38Z-#0K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R(#(V
M+C4@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z
M5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^
M"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XX.#PO>&UP1TEM
M9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*
M4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV
M9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[
M05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"
M055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$
M07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W
M8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!
M04519T%7045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%
M04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!
M04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'
M06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[
M571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P
M=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L
M85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP
M<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%
M1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA
M4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z
M=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7
M<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[
M*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!
M44%#15%-4D%$.$$Y531Q-T9867%X2'HO=T1L:F]8;B8C>$$[:C9P*VQB<3ET
M:%IX6$U#0WEL5TAM;#))>$E*3U-0>7 V2VM$-U!I1&ER161:="]+6&M8>DI:
M4RM94$]0;6(P3'%Z;%9)8G4X938P.28C>$$[=VE25V)E<6E2=$M*4S%W<V=B
M66-Q;6\V65%A67IJ>$%J=E,W569Z1B]*94ME>6MM,5,X87<Q5G!K4RM7,S17
M<V-K8T-6-7A'2DA"2R8C>$$[>F]69%EI3UAC54Y,4FYK2%AY-TMX>4IS;C=+
M-59Y<6M&-7<Q-SAV8G)Z:'!T,4)R=FUE,'5D5G-O8G)46G1+;&AT3%)B4S1M
M:G16:"8C>$$[075L:F5'37E766MD5T%4-U1%-S55-TE#:'-Q*U4W:E)O.55H
M1C<U=C@Q:$Y54RMT.4IS3E)N-50Q=$E*175:955$>DQ-96,W*VAX428C>$$[
M5F5-8V58145Q;V5+1'ES,VU+>3AT465D9E!5.3-F36YP>FDO6#!G2C1N6E=A
M4C!6=4MQ=%1X0F]X,S-";T9T3&)N571-;3 R,3%'>28C>$$[.#AE8CEB,%(Y
M4W5B2EI.2352,U13>E=T=$I"2$DX.'-D1FIJ4FXU96E!5TPW2C-65$\Q="]W
M07-R+UA,+U(Y33@U96%0<D]T6$8S9B8C>$$[6$EH=5=T26UM<S1Z2F-7-$US
M54YE8U5G3E151E5(>&EM-G%E*UAV2R]L6#AX3D=N=4QB>D8U:V%Z4U)!,%4R
M<%)S2WEM2%5O:C954B8C>$$[;6I":3E54G)Y05I+1F5Q<5%Q.40X;V55<EAY
M=G P*VXR=#=D,VM%.3%.94MB,3!K84YR:'5B>'@X16I#>#@V<T)4<7@S>%90
M359D:28C>$$[<G-69&ER<U992G)(-5!A1'%N;3$O3DQA<'$Q;G%4,TU.,7AS
M-V]14D(T8F-7=D965D]116M3.%A03&M2=%AJ=&EQ3#!4.'193DUS3"8C>$$[
M>7EU4$U/=#9Z1F501$IY,5<W5S9E17=%:V5I>E)J:'HU9D8T,$=3:$QH3G1/
M;W=J3$AH2UE3*U-D2F15<$I.2$MG;THT>6EY9%%14R8C>$$[,T0T:4]0,FIV
M=6%K,7E9>D9X<&1N67HQ25!F=&8S9FEY;%!M1#AR3&)79&5/=68T:C$S5'(R
M;D)265AA46]S6E=%3D5G351L63)A,B8C>$$[5C)51VA9<V4K5D]E16]8>4<S
M;&@W:E5.5#@V*UER,U1P1BMR5VM-=# W=D<X.%5S4F53569U>5$P,TI(6E56
M0W%62C1J1E=),F)E5"8C>$$[26)N6$E,:GHU-3%T-V)Y*S=1-FIF,U8Y>6A%
M<W,W865&47!'.'!+>3=R.$%!,EDY3FQ60T4K5S5H0D1C9FUF-6UJ=$EI6C)6
M178T-R8C>$$[:W@S.&--9&]J,UA#5TIV5#E&:5-%*S!Z;C1+3FA61%0S9C5:
M>39.96$S6BMA=DYI,D]O87)Q0S-K5G9F45=::VYH:$TX<75K+V]6:B8C>$$[
M:V=I6#!U4C5B:$1X63AC0W95<%!Y<S K.$U%,#-M3%AR:4]/4F)I3THY45HT
M5TLS4S-K5EDK4'!K4G-V1D146F4Y47!#<5@R,S5&-B8C>$$[4&$V6%DV9F%E
M6E!-1G-D3V4W83%V24PR3TLT5DPT>$Y.1C9I46HY,EI)03E+9F%*3RM+=3%4
M.&ID3S%+*W1.47503F9M55@Y:C8O,28C>$$[4S97+U0Q279R3$9P4%19=VXP
M-F<X9F=P.$E!4%1&559R2#5--D1R175J5#9J<75Q6$YZ;V=U0F(S17,P36MK
M=C%M47E-3&AP25<Y4B8C>$$[5DHT<6XR3U!W;%-T4FEQ27-V>6HX=6%D<59R
M9C988S-E;E-7.31L*SA6<5E)-'!P16@Y1&A);F]K0TUQ.'A+2G@K2U=1:G%V
M1E9M*R8C>$$[2W!486%T<60Q87<S35=M2# U,%=22WI)1'AC0FA8-SAM66=D
M5T%K4TQP5BMV87@O,6)0*U,V9C!W54\Y3FYU9#EE,6HO<3)F.&PP+R8C>$$[
M<&I1-S%S.7IV<C)S9CE7>B]K=6XY36%(971N=60Y93%J+W$R9CAL,"]P:E$W
M,7,Y>G9R,G-F.$%6<R\U3' O5$=H,W):-VYF6'19+R8C>$$[-G1N+T%#6%0K
M;4Y$=E=Z,TQ:8FY5-5DS:6PP;U-24T%Q-DY.1U9:4TM%145B9S0P3SEB4&,Q
M0E!Q3453=W=A4W-52T-I4G!,1W%G928C>$$[04%&0FI1-S%S.7DO-CER2"]6
M<R\U3' O5$=H,W):-VYF6'19+W=#<EHO>5A4*VU.1'97>C-/*W9A>"\Q8E X
M06MU;CE-84AE=&YU9"8C>$$[.64Q:B]Q,F8X;# O<&I1-S%S.7IV<C)S9CE7
M>B]K=6XY36%(971N=60Y93%J+W$R9CAL,"]P:E$W,7,Y>4HP*SA&-5IX6$E1
M>"MO0R8C>$$[4VA)2D)"24EQ4&QG26]P0G-):D%L3&TQ3SEA-G598F%X37DR
M>FE.<$1+<599>'!*<T0W4T1*8TDW,DA%8C5.+UAD6"]!3W)B+W=!;"8C>$$[
M,"]P:E$W,#)E-3,Q,U8O*W)B+WE85"MM3D1V5WHS3RMU-G8O04Y7,R]K=6XY
M36%(971N=60Y9#%F+W$R+W=$2F10-EDP3SEB4&-O,R8C>$$[3%AL,4=)-W)2
M;S4T=U%W4U=32G='2%$P64AF1V@S<EHW;&(V-W$O+T%&8F8K4S9F,'AO9#8R
M934S,3-6+W=$<3(O.$%*9% V63!/.28C>$$[8E!C-S8W<2\O5G0O-4QP+U1'
M:#-R6C=N9EAD6"]W0W)B+WE85"MM3D1V5WHS3RMU-G8X03E7,R]!2DQP+U1'
M:#-R6C=N9EAD6"\V="8C>$$[=B]*9% V63!/.6)08S<V-W$O.$$Q8F8K4S9F
M,'AO9#8R934S,3-6+RMR8B]!36PP+W!J43<Q<SEY;&1A='%D<F%Z6$UU;6XP
M-$5A4B8C>$$[-E1)5'A11FI4-W-):40Q45I%0S96=DPO05!X=V1.+S5H65 K
M5&$T2F-Y;4@P:$@U1FMW>3(O3'@T=E!-;FUG,VQU1F%C>DQA>%=H:B8C>$$[
M:T%-1%%K1V8Q;35->&9K-V-0:6]Q-T)2:7)-;$I*665";U!U0GA63&1:,&%B
M56YG079:<E<R4EI5=5E94U8Y6EI60S!,06=R>#-O8R8C>$$[;$=104]Z5&MX
M4VQ+2D5I04]N97A-+VMV-5I%=&Y.2&0S8U4Q:&-P95=S<7):.#!M:FMA5F5*
M83)01TU-,SDP=$DK+T=U*U)B:U5F>28C>$$[<C!T2#%U4S$Q2RMG:S$R84]E
M-$EE3#DP.&1Z.5HU46Q9,6-'<$DK2FTK+T954R\U95)3-EED4&XQ-U=,:$,Q
M:2]R5%A-8VML9%!O528C>$$[4'AX1F8S<DM';2M(-'IV:7%9*U5V2VQL-5DP
M*U14-TM2,W13-DY%<VQ+;W%1>'=Q=G<P2%-+=7=(6$953C5I.&UT<C$K-UAE
M<%A#828C>$$[5$QA1S)L,'E06F96-4TV6%--4V5-<V)&5U$X9&EO3U1%:'<Q
M5R]E,4A'95!I=F%U6#95;&HO2GI364PR3S9S.64Q>7I71EI9;TQA1R8C>$$[
M.%524E%V>D5555EA3FU23&1:0W-)52]#4$=P<D)T4DU0-5A7;'9O.7!P5G1R
M=7)X>#)D=S%X1&1F5U%B:4Y72VM1>%!W0WAX<4EW9R8C>$$[54Q49WIR*S%8
M1E52<E U8U=/<C9*63949#9V<5I7=VMK:U<X13!B6%5V<6-Q<DQ+.%1K<4]D
M2T-M=T%.4FER261(,#%.3C R0WA2>B8C>$$[27-)241%54<U3%558CA61F%+
M=EE51TMO>D95=3AV9CAC93,O04YN+T%-5&)*5#5S66-K>'E,2D%A8B]V6G%V
M+T%$1DPO=T)1<T=3;"8C>$$[>41'4$TO:F]J.&EY44]U=V%P8V%*<45':WIR
M839P3&)42EE836=Q:V,W25)%-T-J8DLY1#!0>7A69'!59#="<&1J0F5L1W9%
M:&IJ=28C>$$[5VIA4C Y4EDO:C1V35=L66-H<UA*63DY.%92;4MO6%4R,49B
M0UIT3E-/4RM!2&]P3EAG5%56-55+;G W-4M.6'9Y87-X;G=(9W)I-B8C>$$[
M6'E9='%7;F9M9E!D>5,R97 R='9A>49#='5#:4]G*W)C5U9893%U855U9FDK
M3&YY6%EC2V9%1%1/3C!,-7%D:G S-7-P9#)"=DY4<R8C>$$[2F)A1TLR4R]#
M;6I44T-D5W5:5D%T5C0Q:$QO:6AQ8DQU3GIG6DDW4F@K6F$V:U)Q=C9,9E-2
M2DI2:TUW=7EV<"]",$AP065T5VYF,"8C>$$[-E8K3W5+<4AL;7@O375$5EDU
M9DU/;U=T>EIV15),0F)+=G!Q-G1)95-%>%)3,5E.1T%#>D-I=#-)<7%N6&U3
M8GI.1F)7>#AV=U<X.28C>$$[=V)H1G5L=6EW55=X1&,R5&EY9D=$>'!K.%EJ
M+T%"3E=9-4M(0EA092LW.6)%-S-3=GIV9U=34%1D83!M.%1N>FAL=C1N:6TT
M.&YJ-"8C>$$[35E)=E1P-DEJ;'%%<C9X668S64-M1&%M1G)"*V)!;3%:<BLT
M,&\R<VM98E,T-TU3;65/44UO6F55>7)(5# Q2DA0;"LX4%5*=&EQ2B8C>$$[
M=%4O33)447115%5(,&U(5VUG46%A.6LQ=TE28V-4-FAL33AC<#1C<6-A2513
M=4MQ9&A$-7AI.',V=W9M964S=4QR-G9.=V4R1DDO<R8C>$$[3U1W*T=-.$]*
M541K3UA,;#%&1&MO8W=W;CE*63DU5C@T86AD+VU*8F58<F9526XP;7HP4T8U
M-T@P,D5G=7%)4S-Q1U!E:7-U,T]N,"8C>$$[-UEY-6Q99E-(<#)26G!&<4@K
M2U X5F%98E-V-D(T<TPX1#!A8W5%;3<X+S-V,G94-&5N+T%*6$QB1E4U5FE(
M:V]P4'AD4E0K565*>"8C>$$[5F1Z8BM2=BM&+W)I<51A+S5U,')1;FA3+U=6
M5$]'369"43)Y,')89C-Y>4=)>35/2'%T9FIW5G@Y57$O-5=R-5<O-650*U)9
M+W=#828C>$$[<W,O3%1C5"M83E S;C5*=F](;7I3.64Y9CE(<DLS,6)H-G9.
M478R*UA';2\K4V-R>5EJ2&TU96PQ,E!09D(P+U-X1"]!2E@Y-4,O-28C>$$[
M9E X06M34"MA.'8O04-74F\O;&9",VXU3R\U6#DU0R\U9E K4DDO-7)X+TI:
M1B]L9D(S;C50431B:C%9:VQ21S132T=7=DAO4E5D."8C>$$[>$,W34PK8F9Y
M3B]W=CEC5EA!,4A3;G-C5F1I<G-64S=Y.2]X>#=F+T%'9B]!0DYS;%!M>&AY
M5$A)<VM"<'8X079:<78O355V+U5,0B8C>$$[:W!C9WAJ>E T-DU*:D8V9GIZ
M8WIZ<TEH;S4K<C)Y1S5-6FHY569%,59&=GHU.'1G,6%5=TUM96%N3F-W-F)D
M>E=O5G)Q3T=2-$$V>28C>$$[3W!K5E-6-4I%1VM95C9H05=08F9!<6AO;#%F
M,V5I-EAD86I#3&952C1)<$QY04MY0DIN:3532T9C;&QO>$EO,B]J:7%967$W
M1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T950G(O=T1X=W12+S5H6G8K5&):
M2TA-35HO4U=#95(U+T]!.#508E-Z=$XU6"MO4GE28S)T1'=U9E%T<28C>$$[
M>$MI>5!C:%969S-X2V\K3'!U1TQ,;551*VM04UAD555U-4-Q;TI::6%!0613
M5&M78D=B1#AW9$IV9&1':E)7,7HV<E1'1DQO:49R9"8C>$$[=UE$8U)3;S93
M<U=J;6I5.$-&-V9%0G165FMQ9F%F.$$Q=CA!:E59<75X5C5J*V-8*SE/;"]W
M0W!,*W1C>G1(,658.6]U8U!J*V@U,R8C>$$[;5DX,#E*+TIV+W!B+W=$4G0O
M>DYZ0S%N4C9F,F,O>6XK8B]V;GIB;3-D1S=&6#)N<#,O2%!T9BM-368O04)%
M6GIK=6(V1$AK:4U#6"8C>$$[67$W1EA9<6PS;#<O04DT.78O<R\K2G1K<#@R
M34]3635&:V=.3B\S<S%8+VU+6"]Q1F=Y575167@U;CAD1T)43F\R;2]N5%!Q
M3B],4"8C>$$[2$ED2BM,56)Q849,2TM.<$9544M$0W!5,5AL=DY8-'5M0FLY
M16958D).4&)55W5)+W%#>$<T83=$07AE:48U;51M3G502&5U0EA7="8C>$$[
M-6)8=')A6&QS+W%7,7EQ>E%354DU2DEN2E119T560C<T<6E-5F1I<4$Q+U=R
M8E$Y179T6'5595<S<TE8;FQI:31E;WEO2VQ51'-I;"8C>$$[:C)(3&,T<6A0
M3"]M>E1.9'4Y5G1B2EI1*VM8071B;'!!;U9N2T(V>#A766M$;%$Q03-"2&)&
M539X5C)+=7A6,DMU>%8R2V]$6"\X028C>$$[:FAA:B]W07=S,R]*='-L1&U'
M32]P3'EF5V1+=3=Y+VPP-GEU<D]3-C%$>39N,5!1>39T8TYC=7%G6%EJ;45C
M4R]W0GHX4D5N26A+-R8C>$$[,'AL>DM)9E-(<&YK9E0Y5C W>6AP1FAQ>7%U
M;S)T=$A&8W%J8S%$24MF82M86#E:-C5&;6EB8GDQ-6-T8C%R*S$P<7IG=FYL
M:W5(=28C>$$[;W)E2DI43DU+4WE&,55.>F-F86%T5#-X5DU%*S O.$%R9CA!
M1V]X5F1I<GI(.#1V.39D3"]W0E-8.6$U;F%0<3AV-U)C-&9(.41Z=B8C>$$[
M37@U<#94*U1F+U,S+W=#:F(O;6)M1G)/:C O<S4O;% X,R]F2V9M+WE*-4<P
M4%1L=4Q$>6ED5W4S9%97,&A..&%O6%988FY"2&-H4R8C>$$[=E!L4F=+:71$
M=&Q8-6Y*,W4V+VLO0B]-0W1O;C5F.$%K2%5R:6%'6'EO.6M)<F4R;35Z1S=1
M33@O<65P14,O<&=T15DO:31K.5%D<28C>$$[:D@X>FLW,2]K+T(O340P5T].
M230Q:E%54D%&565!1W=Z2&-X9&ER<U9D:7)S5E,W>3DO>'@W9B]!1V8O04).
M<VQ0;7AH>51(27-K0B8C>$$[<'8X079:<78O355V+U5,0FMP8V=X:GI0-#90
M3"].,&UI2C5K.#)01BMK3EAV,3!E9&(K>G5,;$QF4S!H0WAT-E!Q<GAK43!C
M=E-V:B8C>$$[-&I!>5IV-5-S.4XQ;CAU9$MT2G)33TQ4-S-4;U5E>70U;FMJ
M4TYO=T1':WET>DE(4V]B07%F5V1J839F6C)D:&%)63=7,%))3&1#>B8C>$$[
M3U9J:FHT24-Z;&UA9TA5;75+;W)&6%EQ.'!V4'I7.'A1,V,X2S(Y;U9I:UI&
M2E-7=$999U8O95IN>#!S4T]R>658=#=.1UI!161J-28C>$$[+W)5=BM6=65:
M4#A!;&US+RM!;"\V<31F>6MF3G(O,%%:*S9(>5 V,V]N;%!6-VY74$PY<G%.
M>7%*4% V;DY9=U%G-%--9V]'3$AO=B8C>$$[:FU(;&=)>4E$,&UG,45S,D=-
M-6-Z9DPS:TIV;&)M3WA6,DMU>%8R2V]$6"]!4&IH86HO>D-Z9CAM,GE53UE9
M>BMK=D,O3FQP2'%0;28C>$$[1CE1:&%:4#!:-5AA2#8P.&0Q1D1&3$9%1VY-
M8S!F=W4V5SDS54)63S4V,5@T5UA-;V@Y265W9FPU5U1Y1&]*1G=::3EH05)C
M:&UC="8C>$$[>6I"1&-P4GE0*WE'4EIP5'!F-6(S,7 U>&9Z2F0V,&116G)G
M>G!(3F)H6E98-G(Y5D5A>7!)15=O;WHX66=';TYH,7A6;39F868X028C>$$[
M,78X06I567%U>%8U:BMC6"LY3VPO=T-P3"MT8WIT2#%E6#EO=6-0:BMH-3-M
M63@P.4HO2G8O<&(O=T12="]Z3GI#,6Y2-F8R8R]Y;B8C>$$[*V(O=FYP3UE4
M,'IS5F1I<G-69&ER<U9D:7%895AV.$%J:C(O*WHO-&TR4VYZ67<U2FIK5U-!
M,#,O97I69BM9<&8K;U=$2E,U0FI(;28C>$$[9G@P95IE9')4>E!"<4]V5'<V
M1&%M=VQA3UI.6'9$<'),3%(W5E)#>3-,2U524W-H0F1T>65G3DU$2FYV;&%'
M-F)Y4G P36MC560P,28C>$$[:6EM3S):25EG-U(O-W)E,C5O9W(P84]T3V]W
M2VI.07-R*W@P4%1,3%5*+W)..6)1>'A81GAY95%Y3VMF1758:RM.:3%+;&HQ
M3RM+<"8C>$$[;FER<U9F3S)P+SA!2%-U+RM-,&XO16IM-&AY1#5X<5 W>5@Y
M62]E:'-K,'9B=GDT+W=#54TP-R]!2C=F.&XU33%E;RMS=F1D:F8T<B8C>$$[
M1#0O-V]S:WEL,F)S5F1I<G-69&EQ03$O+VIH86HO>D-Z9CA!2G1S;$1M1TTO
M<$QY6%0W5S4Q=GIH8RM83"M--EIB86QO.$A#*W1P5R8C>$$[5S=N=&]O-$MI
M:W%01#928FMP-'(S<%4O14%Y-6Q%4'!$,6Y23DEI,%A1-U!38E(S;6ES245T
M-$AM241-23$T<GI+2T(R,V]U4EIS628C>$$[.'5Z+T%*;U1E6C5',3(P4S P
M9U,S2W%K371T3D%945=%1$$X5751>$%J27(Q+V5&9W9W2W%R3E4K,"\K="]X
M<4U66%EQ.'@O3TPO928C>$$[;E,O.5-8.6$U;F%0<3AV-U)C-&9(.41Z=DUX
M-7 V5"M49CA!,'0O*VIB+VUB;49R3VHP+W,U+VQ0.#,O04AZ,&Y-2C9:,DMU
M>%8R2R8C>$$[=7A6,DMU>%9,=DPS+TA(="]W1%HO=T1%,GE5*V)'2$I-8VEY
M44=M+S<R87(O=T%X4R\X055,0FMP8V=X:GI0-#902&9Z6'-D475F>B8C>$$[
M26ET<D,S*W,S3GIP.75W:V-#-5-*26)O>70V;'!(8C-%:%0Y,D)Y2W1U,D)K
M.5$P0DY1,'9Y2%II-%=.8BLP,#A.271V8E-L4%532R8C>$$[=G=7<V%24VYF
M+V1A;T=044-U0E5D;T8Y95@K:#9893,P4FAV8FE#2U,V:$U5:TA#5F\V>4PV
M53,W>$M.6#17,T=+<&YI<G-69D\R<"8C>$$[+W=$2%-U+RM-,&XO04))-75)
M8V<K8V%J*SAL+U=0,V]B2DY,,C<X=5 K54TP-R]N="]Y9FMZ5C9J-GDY,3).
M+VES4&HO=6EY5$M86B8C>$$[=7A6,DMU>%8R2V]$6"\X06IH86HO=T%W<S,O
M2G1S;$1M1TTO<$QZ,WEX-6QA5#@P3%!Y+T9,2&-W>&58;V)Q569!>E<X<F-&
M.5!M4"8C>$$[:EAK=$<Y3G9(:T)V:DQM55$K:U!52&15574U0W%O2EII84%!
M9%-4:U=B179,=C5N*U<O34=S5&%:<'%Z>4Y$8WHR6G5Q4D="<$QC128C>$$[
M,5)K:UES<V=2>6IC9C)45VQ6<7%Y>%!T4"]R9CAA:D96,DMS02]-+U%T6#%/
M-# Y<D,Q931%4U-#46]"<U-6<%@W<WDY3FM%8G-V4"8C>$$[.70V5$IL365!
M6%8O;UE0+T%)2C@Q+SA!5G-M*S1F,7I+.&5(939,*U,Y4B]-3%!0>74P5%9T
M3"]!16XK:TQ6-V(Q=E$Y3&Y4-'50<28C>$$[8W%F3&M->$Y435-Q;F9D:#98
M2FDT*TU69&9P6C-M2S<Y,DMU>%8R2W5X5C)+=7A63'9,,R](2'0O=T1:+W=$
M13)Y52MB1TA*36-I>28C>$$[44=M+S<R87(O=T%X4R\X055,0FMP8V=X:GI0
M-#9-4G0Y3'5(+T]#6%5R=6%Z.5-05#)H=$QD4D-,:C9U5U%Q.51).#50<4=1
M3BLW5B8C>$$[2U5O5'9G6DTW;&Q32THU6')W:E5S,4%73D%+;6=&4V9O=TMO
M,C$S8C-L=&$S;',O<5<Q>7%Z45-!16-K:U1K<E5.1'5$:7%)>%8R2R8C>$$[
M=FYB52]W1&IP6&8O04)M:R]W0TI(3GA$:TAZ:E5F,VMV-G@K.41:2G!E,V9L
M>"]Y:&UN9C@Y=BM4.&UA=E5F5UAU=7AV.%9H.&8X028C>$$[9$9'*V%.8G9D
M1S U8G5Z,'EB5EI$36MB5SEU2$QH1W)6-DEK<D=L2T0T859)-496<7=P9&UR
M-D)Q3B]Q3VUI-G8Y4&943&MY>GAM,"8C>$$[:UE/=U-'9#1O-4]10S=3;V=K
M1S-F=C%X5DU-5F1I<G-644=V+W=$2$,Q2"]!2FA:=BM48EI+2$U-6B]356XX
M<RM5=$-H=4Q0>DUK528C>$$[:#%M9E0T3&%3-&%E9#$Y2# P4$)9;6-X24MR
M6#161RM-=5I72#!H:RM26DE',S!,4DQA-V$Y=#E0=&]B>#)K9')M3T=.2E,P
M-4)L628C>$$[=4%'<DE56&MA-S!&8U92:69A9B]!1G8K3E)I<3=&6%EQ=W$X
M.&AE64I'=F)I>C@P6%9N93-W65-/1&1445)C,FED+U%T-6)P,&DS:"8C>$$[
M4$AJ.6M/-$<S2&EQ>EA&6%EQ-T9867$W1EA9<3=&6%EQ;#-L-R]J:C(O.$%S
M+SA!:6):2V9.:D1K;4]26DE$5&8Y-TY6+S5I;"\V:"8C>$$[64UL3&M'365:
M+TA2:4YT;S-M1U0X-')J5V)J4UE%,&%,5&9Q='1Q-5-)5'9*>E8O5$1#-&MK
M-"]%,C5I6'<Y>D9K>G5A2DIO;FEE=B8C>$$[0U)3<E5*53!954Y'56=J-6I&
M55!:,DYR<#EN6C)&;VAJ=&)216=T,$Q--5=/3U!G9TQ/5UIQ0613831Q:7-6
M9&ER-3(Q4#A!-#96,R8C>$$[+W=!6G!0.$%I4GIC435".#0Q2#DU3"MS9G91
M,E-A6'!K5V\S=6TO:WA.9C)-<&=U-V5#6C1:5D%*5G9R3$-U-$EZ0FQ%2$Y2
M97DP328C>$$[>DA10U$U9U,K.'9'9BM6="]M3"]!3EAU8B]G278K84TR2#58
M2#-/;R]L5%5F>G9S2#9N9CAR8B]!1$8O-G9C,R]!4F8X,%DO;&-F8R8C>$$[
M=CAQ86HK9#EG+U4K<')'4C5,2S-K8S%D-#!::C1K<4-C,&@U=EEJ:W)9175X
M5D%A+W=$.&-,568K65=B+VLR,E-H>D1'9C!L0C9.<28C>$$[:T5':U=-13!.
M,&MS5G9%:VDO5DQR6FQ106IA4'AW>4<W1T5Q02]55C)P6#EV95=C;'9',3-!
M6$9#=W-:,T1$=6IQ.$IQ:F1'<%$P-B8C>$$[161C2$-Y-'@K05=%95=0261R
M;VUT5T]Q4&9Z,U5L;T%(+S-&6%5C:VA&=3A*4'%%=E%S6DXY:CA#>' K>GE,
M4E)X:CA!=E%"<E9K0R8C>$$[5#9D,75A;B]!15,V.$MF-S9X-%4X62]!3&8V
M8G,O.$%F9#$O,&@S6"]63$AH6&I(-$)D*VTW4"]!2#-D9CE)9#$O,5-X-%8T
M>"M!6"8C>$$[9G!U>B]W0CDS6"]32&1F.55S949E369G1C,V8G,O.$%F9#$O
M,&@S6"]63$AH6&I(-$)D*VTW4"]!2#-D9CE)9#$O,5-X-%8T>"M!6"8C>$$[
M9G!U>B]W0CDS6"]32&1F.55S949E369G1C,V8G,O.$%F9#$O,&@S6"]63$AH
M6&I(-$)D*VTW4"]!2#-D9CE)9#$O,5-X-%8T>"M!6"8C>$$[9G!U>B]W0CDS
M6"]32&1F.55S949E369G1C,V8G,O.$%F9#$O,&@S6"]63$AH6&I(-$)D*VTW
M4"]!2#-D9CE)9#$O,5-X-%8T>"M!6"8C>$$[84-K:6%28G)):E)T4FE59%-R
M0W)%:7%T46HV8UIC,6AY4BM26DI41&5X,FPO<5-Z4EA(-WDT5C0R4S-N:U9L
M*W)X3%5-:4UV5E-/=28C>$$[5$ES0G)";VQ8+U16;B]V=38O-E),<B]Q;F<T
M4WDT>"M!549R9'A:87!O,3EP<"MT4D,Y=#5B9C%0<58P,T@Q54M62RMM=DML
M96QD."8C>$$[945R>&HX07%7:$YA851O.7)P=TYZ2V)92#1X63-32CA263A5
M:C1.=U)E5D58:V%!05DX2E)X:CA!<&@K;5E0-6)J+W!#=78K84UE128C>$$[
M<#1X*T%89G!M1"M7-"\V47)R+VUJ2&A+.%DO04Q"8FHX=CA!47 U-4IM=3E1
M1%-U>FM#>&YO0WAR+W9V36]A:5%(4C!5*WA-57!%."8C>$$[570O3#EI>B]!
M2E9Z;T@O3%IQ2"]!16=Z+W=$5E!$*UIL-4U0-4)W+WIP+TPY:65484QP:VYK
M-EAY=5IR=U=S<V)X;30K<%A0<4%0228C>$$[6D-F-W5N5354>&YJ-'1V;3=0
M2'!947=E1%IR9G S+T)G9CA!>6]R>78O,61.5"\V44IV*W%E6E@U,F9C4&TT
M4#AJ674K6#0K1'8X028C>$$[;%)8;&8O<39A;B\P9U1F.54X9GIS*S1F3F8U
M1WAD.'9X.$AR34=Q5S!-16-)1GE21V]113)6,55H4E0K5$U%>$QU:$EF9T95
M+U1-2"8C>$$[.'1X+S!H6%@O3D=$:$ME369G1F-U=%=T4&E3-4HY<D\V2"]-
M<S0X2EAJ2#1"46US87!"4'!&.4)&1&1.3$QB>7!'=C%3-3-::TE!,R8C>$$[
M:CAC;$=/-%EZ;%E04#5&+R\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z.68P.68U,S,M.6,Y-"UD-31E+3DX-C0M,F0R83=F,#4S
M,#0P/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.CEF,#EF-3,S+3EC.30M9#4T92TY.#8T+3)D,F$W9C U
M,S T,#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S
M,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#
M;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M=75I9#HU.&9B96$X.2TR.34Q+31E,#4M.#0U8BUD,#0S-S(S,F$P,&,\+W-T
M4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$
M/GAM<"YD:60Z-F-A-CAE8F,M8SEF8BUE9C1B+6)C.#8M864Q9C!D9&0V,&5A
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z9C9D-#0T96$M9C4S-RUB930W+3AA9&,M,F4W,#5B,#<Q9#$R/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(R+3$Q+3 S5#$X.C4R.C,Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B R-BXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.68P
M.68U,S,M.6,Y-"UD-31E+3DX-C0M,F0R83=F,#4S,#0P/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q
M+3 S5#(P.C$V.C0T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R
M-BXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^
M061O8F4@26QL=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO
M>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB
M;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM
M<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXU
M,2XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C@T+C P
M,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&EC87,\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU2
M;VUA;CPO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/E1)4E]?7U\N4$9".R!425)?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU";VQD/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM
M97,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/C P,2XP
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y424)?7U]?+E!&0CL@
M5$E"7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M
M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @
M(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^5VAI=&4\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0TU92R!2960\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!996QL
M;W<\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@1W)E96X\+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0TU92R!#>6%N/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#35E+($)L=64\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!-86=E
M;G1A/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$U($T],3 P(%D].3 @2STQ
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,34N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].3 @63TX-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3@P(%D].34@2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C@P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TU,"!9/3$P,"!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TS-2!9/3@U($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS-2XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STU($T],"!9/3DP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3(P($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C(P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/34P($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ
M,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U
M($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T]
M,3 @63TQ,# @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STY,"!-
M/3,P(%D].34@2STS,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^.3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,S N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXS,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T]
M,"!9/3<U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX,"!-/3$P(%D]
M-#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C0U+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW,"!-/3$U(%D],"!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<P+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TU,"!9/3 @2STP/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DU(%D]-2!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C4N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3$P,"!9/3(U($L],C4\+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXR-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],3 P(%D],"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3,U($T],3 P(%D],S4@2STQ,#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,S4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STQ,"!-/3$P,"!9/34P($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TY-2!9/3(P($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY-2XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C(P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STR-2!-/3(U(%D]-# @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XR-2XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C0P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STT,"!-/30U(%D]-3 @2STU/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XT-2XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STU,"!-/34P(%D]-C @2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXV,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/34U($T]-C @63TV-2!+/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXU-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C8U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C0P+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],C4@33TT,"!9/38U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,S @33TU,"!9/3<U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C,P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M-S4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS
M-2!-/38P(%D].# @2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P
M($T]-C4@63TY,"!+/3,U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XV-2XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C,U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @
M33TW,"!9/3$P,"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P
M($T]-S @63TX,"!+/3<P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C<P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<$YA;64^1W)A>7,\+WAM<$<Z9W)O=7!.86UE
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG
M<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*
M(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L],3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP
M(%D],"!+/3DP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C@Y+CDY.30P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]
M.# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M-SDN.3DX.# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STW,#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXV.2XY.3DW
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/38P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4Y+CDY.3$P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXS.2XY.3DT,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @
M33TP(%D],"!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C(Y+CDY.#@P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP
M($L],C \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,3DN.3DY-S P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXY+CDY
M.3$P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXT+CDY.#@P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @
M(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^0G)I9VAT
M<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STP($T],3 P(%D],3 P($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TW-2!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S4N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TQ,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STX-2!-/3$P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3$P,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/38P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^-C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,S$P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# S,3 P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L
M;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,38N,#<\
M+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,\"80,!$0 "$0$#$0'_Q  ?
M  $  @$% 0$!            !P@%! 8)"@L" P'_Q !5$  ! P0!  $/!@D)
M!0<%   % P0&  $"!P@)$1(3%!48&3=7=7>7MM77%CA8E)6U(3(T-5-VL[33
M%R(Q-E5XEK?6"B.2T=(:)#E!4<;C)E)4D:/_Q  = 0$  00# 0
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MS*W&#[E%$$VJA*[)M=_FU17P<HMLWET^V,D$G*23A-')2Z::Z>"N.-E,,<K
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M/'"0YFV9)+NUL<,572R;9-+!5PKBFGBHOG;)7/'#"V65[8X]0#(4 H!0"@%
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M _#Y#0GJ=;\CXMUMNR=2WR?$]2W94,6JOX.U.I_O&V.+=3_[T,<4LNJG:V-
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MQBT!T5/MLX0,6X*99H/2,9UC*TVVO-;O,F+AYUY#70, J3=N.S&VI)5)LX;
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MGVHUR+$;H83Q47T<=_EQ%\M\9^H23W)34Q/LVOO#<^U&N18C=#">*B^CCO\
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M1FQ@-!Z]Q;.'N3-HL3=-4W+K%FU=.\FZ.6:MFS9PO?#L2*F>(@U3.0@")<P
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MDD=:"'\@CS0HQ<G 3&0=T.X#TR)17S?C&ASN05[D.'K=!$EW,(=I9K]I.>Q
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M)XS*01;D(W"MOY=QNZG[9D=@$N'LFY1'$ !;QQ<*F."Z[TX<J[^2F/NDT::
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M-60U]( 13CEQM)0YT\?B#0S*/DXHZ)LB $JU>)A[M4V2@E>ZO9WM^JU.0BA
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M24;=7,%6O^*43$B7K=\7ETJ$"@% * Q8S\8GYT<?LF] 92@% * 4 H!0"@%
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MXMBR(GG3)K@R9N33YL@FY*.&C---HV6?*KJ(-4\&Z66"6&.%@,S0"@% * 4
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MS%;=;2+9?96T/JB,.F76R)XTB@% * 4!W5M=>+Z"?J;&/N1C6M$;UY%\)?\
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MKKQ?03]38Q]R,:UHC>O(OA+_ )5L]I[.;7I#Q-*^8N#>5<8O(H!0"@% * 4
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M'I+SS(?8F35C=K]KDS[6XYTX.X_D_P#\X;$\-F'J69':_KH,]710"@% * 4
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M2J"S2!P_.2OA[5N/>DGA@M9/)LS$A&3=EGBY)D7C9OBX7:-L+J+.,,*:=O\
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M3(JJJ$LN7+"HTRY=,M)@:9=L(J8KE1$5+KC4U2?44 H!0"@% * 4 H!0"@%
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M)Y.GVVR" Q%\IF\:J+2)X;)R18L)M'!*K5$2F#'?D1/R_2A:VA H!0"@% *
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M8Y7QOU<;Y8VO?&_X/PXWO:_4O^"WX;=3^BU ?5 8L9^,3\Z./V3>@,I0"@%
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ME,S% * X[>8KN8R/1\,6GVOPD6-!.<O 4G&$!$GM/%U(W&N;_'<_))CVW:,
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MVSO/&W4M>_79X(98X_\ EUU[=6]K=6]A!K* 4 H!0"@% * 4 H!0"@% * 4
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M-TCSS)/O=@\-_P!&A]($CZGMU_#VFH"U>;&?+I?TH:_.A9ND>>9)][L'AO\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g389734g39n95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g39n95.jpg
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M4U9A<7=XDY68MM/8%SE"<I34U20S-W6!D9*Q*$.U8O_$ !T! 0 !!0$! 0
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MAI1]O96\40B7L)*_)"#DJ22"22,BI4@COR;-5<;"4N9+9FF,S>0!7^4TA #
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M,Z&SV\22Q*8E=4>0/"N][WO>][WO>][WO>]]][WOW[WO>_?O>]^_>]_+FV
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MPM-'%),RIV]\*N62/Y:IV]Y!HJ;S6]%I=V,U:;W.[+";:5 "18 =(["P/-%
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MT Q55<_C9B?PY;JNH[G1:O%OE&VZW\O9,AX$_=_:(;2C7\6D]OM?)DT=%]*
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M,F0,]1<VG[6TQ3>M[[]];UVUK?*7LEZ=@ -NSL;SC]D#+'6A/XDAC\J\_/\
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M*##3H:NYX).UDD)GVWOL"(M=Y9);$->JB]LT1KNT<H[@[13;=KZVF.HU[["
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MYB:CIQ)]E'F*_P# <U,8UT#VA] VO9M=K]0].37&I3VKB0V&KP2KI// D=:
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M4:U:4QM0VC-&9(8D<H616*D]I*J2.0.-GZ2LV9MG(DMB>5?<Y3VR2R.O(E@
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MY!8>GHQ!()'J>3R?7!NW&[RUNRQDB2"3F>4]\,;*T<+\O\J)&562-N45E4J
M0.-A5?@]]U)AXMMSMOPO(C0?-;5YVR4K1M8ZT^)!._64^)*D^L?LNT[7O>]^
M>&+X^.,'Z0B\CUYY^'T^OX_7+@V-\>ANVV3]TC6K'8P\8B*L!(#P81XCP0?%
M\@$+P,MZF<=5&ATNLT"OQ(Z:S4(B.@X,,YMH]UB/B8M$& D@DAM3QI34.VB.
M=D"U/'F#Z7Z\22Z\^X[9K4JU2K!3AC @K1I%$K@.0D<8B3N9@2[",!"[$NP_
M9,Q))R>]ZHW?4>^VW4FRNRMMMW>M;'83UV>NDEJ[<;863'%&P2O"]YVM)6A"
M5H)"!7BB1(T2YE0T.M*TJBHU27!6 7$J!%VE80J]N#!KUMK>E"CN;VM@=7=I
ME>]J;0E6][R_XXSSS&GJH0_(7U13RJGT_8J?4+\ ?@,Q(O75*D7+0*S26%(L
M2@K8F';-.I#^DTJ@+)*/EN!PS$9N;BXS8CX&XX'8).W%$A;$'V(0IU7C=4^/
MMOR7=NK^N<VXA6UJ^N5WW[\>-.TIV)V-SW+VCM//QY7C@\_/R/7*1;M":.P+
M-@6(@HBG$T@FC"#M01R]W>@1?10K */0<#-UH(-AY\E@09D@K3>B2&F&FWB-
M,I\#6GW4(2X[II'UK>G%*\"?K4]M>[/0J@E@J@MQW$  GCX<D#D\?-S\,H>>
M>2..*2:5XHBQBC>1VCC+GN<QHQ*H7;U;M [CZGDYQDPL.C4BE$3&I3,*4N72
MD 5.I1:T;;6N1UIK6CE+;WMM2B?-VI&]IWO:=]L\\48[^(T'D),GR%^R$C@E
M_3Y9(]#W<^GIETWKS&J3<M$T0%I$V)B:BJW<JU27YKA6 8"+L 8<CU]<U>R8
MK3Z"M1D?HEO;*D$>I#>>A0S:F1]H>\OS$[894IIG>E:VTVI3:/"G>];>./D-
MV)W#C@]J\CM' X/'/H/0?0/09Y[Y;\9B]ZL^)A(&B\\OC82N))04[NTB210\
M@(^6X#-R0#FMZ-CB=M;(CPG]L,/BL;>%8=VR*4VAHD9K:VU>6P0TVAM]E'9M
MYM"$.)4E.M:]*(>.44]H*CE0>%8 ,HY'H&  ('H0 #\,ICM68@XBL3QB22.:
M01S2('EA9GAE?M8=TD3LSQNW+1LS,I!).;?L>(\;#GLN.\P5(J1E^HC>,=(6
MWE!)85Y7B92(HA]0NF]IT/M][;6D;<7XO/%'R#XTY7M[3V+RO;SV\'CT[>YN
MWCX<GCCDY7[[<[9%][M=LQF,J^\2]LIL!!8,@[^',XCC$Q;DRB- _<$7C\;A
MHAI+"6HJ-:2,X2Z,EL$5"1W3=J48XQI+6M-.%J6K9*V])4_M2MN[7M6^X1Q@
M "- %+%0%4 %OV1'IZ%N3W<?'GUPUZZYD+W+3F98DE+6)6,J0 "!9"7)=80J
MB)6Y$8 "!>!GZY#Q+H3$<[%QSD>+IO0P#@(RPA]-(4VUI@536V&M-H4I#>FV
MT^!"E)3VUO>L&.,J$,:%%X[4*J57@<#A>.!P"0.!\#A;UU)Y+27+2V9>[RV%
ML2K/+WD,_DF#B1^Y@&;N8]Q )Y(&?K,3%#^J>KQD>QZALC8/DA#->I;+UM)6
MQ/ VGU?9.M[T1MGP>=K>].>+6\".,=O"(.SGLX51V]W[+MX'R>[Y^..?GSR2
MY<E\WEM69/>/&+'DGE?SB$\PB;N<^7Q'UC[^[L/['C./\':_X--^PH?R](TW
MI'LP+P:;2VPRE&D^1X=(2T*,UI/;PZ;'81K7A:;TGSPP\<>*/CCCCL7CC@#C
MCCX<*H_$ /@!EWZI[+N+?5"]W%BQ;WN?N+%I'+$^3DL7FE<GXEI9&)Y=B:Q\
MGR9<R#C&,8QC&,8QGAY_5#_V?$+_ #?>._[S<@Y]H^P#^\:?_'^P_P!5U^<Q
MZP_;5/X'#_.3YT2YV_-5QC&9&V#I?Y&@GN0XEAZ$L-OXB+KX7)]'KZILNR4T
MF>DAX!Q!B28,.)DM5RUFQU0M#D)*R3<98) 5#"CHO;THSK\'4NOG%"5A-7J;
M5)WUEV?PK6N+!&TX*=LSRQ^\54DMUA/%$9*\;ENR7MB::]"9/,O*/)6*">).
M\O&7(7UY0(P1R(Y"K$*Q'!*_*RD5'IOY<M=VIM)=JLE5W[K8JE709VSQTL+7
MH_X:6Z/H\'.298$?)%(KS]CE  =2H0)S+JBQ-BZ(]=#T_=M]0ZJK2N71:CLK
M2KVK$D%:2)[$GN=22[/#$CR1J;"UXW?Q.Z, K=W;V/VTQT;,DL<1C:/R21QA
MW5@@\LBQ*Q(!/878#N (]1Q\1S8\_P :6ZOQH\T7#2?L9Z!KT^J4>AYB+%:%
ML@<:8$E.YH"-=,0G4M&HW(1S9D20F0C2PCR@9./))FP;&I/(T*31^83SP>,2
MPRL6KO(C\^&24(3XI#XY"DJF.1'C5XY%6T\$J*'*MV%$?N*LH D ('R@O/'<
M 2O*GD$$AAS<U_X2LO&].I%RL,G#;#Y"@Z_9*L&&S8G%2T)/QIA[AT9-$0 U
M4F=5HH3X.W(6$L,B=5K6[\'I45@X<M+$:AN:VQMW:E>.;OH3SUK3N:X$,T$B
MQB.6%9VM0FRK>\4VFKQQVJH]XB<HR%JYJKP10RNR\3(CQ@!^65@22K%!&_81
MV2A'8QR'L8 @Y0K5Q9:Z?2N/;]+- JKW)+,][%=$+T^4!(5U^/7(0D^)X$.1
M4PN"GJG;PQ7/,294[E6)AAU3<CMMF_5V=6W<OT8B_O&N,'F#IVK)'8601S0/
MR1+")X+51W'!2W3LPLH,?+4R5Y(HH9F [)PW80>2"A'*N/W+%620#YXY$8'U
M($<9D,L8QC._/]3F?9U7S^;)??RC\09PO^R#_O(H_P#B2C_L[;9M?1W[:R_P
M*;^>KY[;<^,\Z;C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,L#DG<3\'XO4U8Y*K!JO_ !7IB3B]%;)*ED\FU)<#7'E!M/.(
MC;A.(CJE+[<2D545-F-F.LBK==1#O>/PQ^69ZZ^^:_AX^[N:3WZN883V@D)9
MF"5Y.1V^.5@Q )(V3I7WWZIVS0U=7;SCIOK#R5+AA\45(]);M=CM$$[QJ;6C
MUYM;JB$)F%S7P- DDRHC=:OIQO\ 5E=0?_F/#GY;N.\[![%?_N1H/^[V_P#L
M789SOJC]I+?_ &JW^LQ9X",^[,Y/E?B;/-0<=/1462P,)9A8\.7VJ.C"3'!X
MN6#G D!210;\E$*;E(\(IQV(+ >)]7;9*<>'UMK=B6M#-)!+*K,]9I'B^R2*
M@:6)X'+QJZQS Q2.H$R.%[BRA6]<K61T5U4@"0*&^2I)"L''#$%EX8 \J03Q
MP>1Z9E)8+OU:6&-%O%KF/6RJO<YFR1MPLC?&HW(PMTI850OMF'B+#*LL<CGF
M5M,C5;=:*M&F%CQ\S*NS,W$-S<G+OD:S!2Z5KRO2JP]BVJ<->6I7.Q;7O3N/
M;HUFFKQ,VN1+!CLU*UF1$:2&(0PRF&*)5GO+L742R-R8Y&<2/X!,)8A'*X5V
M F)3F.1T!/#,69>YF)B(#F/EV6Y&I/).KF@GD#C'3%@I=BL2ZLG4*NCR$K?X
MWR465E$'*%1\IZZ_ 0I[$@3*'+CJS"QY[[L1#JRTFHU46ON:[W,K0V7=!<KU
MQ:/F%V.*A)R:S&>)9(NQ9YHVC6)!)9FD11+,(PLV'FBF\O,T'#QN_C^3XBTJ
M_LQV,0W)12&+-PBAB57*E4N>N:N(=24'790.LN%6!=H. D^/Z0<8/-FJA3MD
ML(L56.+BV'5PD"8S&A;$C4+CP2&0TJ;0O+=K1Z?;>.:Q$UD+7]U22._=1&A0
M3)VL:]I$E8":=#(_?)Q)(I?U(RJ.W:K]R(P3E_(P:&(D.>T\COC)4'M0]HX7
MT!XRJUKECGFR G UXZ&.11:)RBX66NG\9L3,5QW>1[4-R3#MS<C ,SAM=.1R
M1;"FJJ,<6/#ESQLO6XJ/-%;,$M6=7HZ[I)829#>O:P*HM[)H9=A2:JVMF,,<
M[0)80ZZHAM,B-*D"0V)9$<H]26+<@8(5;Q0S]Q,<'>L$HD$Z][('*'S2'Q@G
MM+ED4$ BV)_G[EFT3\!9Y^P 24]59>8GX&1>IU*0Y&RD^0@V0*0TQ7&AW4>T
M$ZE(X8EEX2'E5N2L.P#(/.DKDU]%JZL$]6"O)'!9AA@GC%NX1)% I2-26L%@
M?']CD92'FB BE9XU"BA[EB1D=W#-&S.A,47R6<\L1PG'[+Y2@CA6^4H#>N7D
MJ_\ 437^+*O&%%L%\6$TR1=@XR3@:!:0"*4;RA+Z>*EP3XN6E' (SE4&93#G
M6-O;]6G9DE,$_%(NFM3<3W#03[.U*J,FS%R(3RQSWJSK<361=JQ.DL40DDU;
MPF9*YXM00J9UE-/[#<\UQ*\:D@US$2JLL,@,1G8DL"&;A; ;M+^L;N0I7R_+
M@NWV^Q7RQ25LM<CN5GY90VSCMBA!)<2$&/'!M-!QPX@ @X@ @H@PP@K [ [#
M33324IUK,U4J5Z->.K5C\4$7=V)W.Y'>[2.2\C/([.[L[,[,S,Q)))R))(\S
MM)(W<[<<G@#X */10        !EMY(RC/J2UQW3/&4$]MMEW35$BW=M$->>.
MYINOL+VV^SW3YS*^WA=:[Z\Q&U([Z[]\_,78GML7CP#Q-:/!'(/#N>"!\0?G
M'SC._:Y/)8H)W.G?-53OB?QR)W2(.Z-^#V.O/*/P>U@#P>,Y''$[)VCCRAV6
M;$9 F;%3*O.RX(S+HPX4G+08,@>(..0X\^PR.60ZRTR\\ZZTVA*''%K2I6X%
M*5YZ=2>50DLU:"61%!55>2)'=5!)("LQ !)( X))]<R_5&OJ:CJ;J+5:^:2S
M0UF]V^OI6)7266>I2V%BM6FDDC2..226&)'=XT1'9BR(JD 7GDG,%GG%]+3U
M^=;W"4U(<8\?\73O _&4JZ]&Q?/B%"V*7OK2FU^)%5L<9ZW7^/GW6=/*W%O.
M.\@CM-,2;!4!X_*5QCV@]6]4:N5Z-.C+J:,A*1[8=LTEP<'GW>=.Z&F2.3XR
M3<4!9 T//&?J1_87_P!C;_8_^T"A6ZLZEZOUWM%ZLIHEJW[-R)M72Z<<,O#;
MG5V_!L^I8TD[%%R-4Z:E=Y*DD6R[>\=OEEY4YFX]Z=.&;7Q/P7.=2USF:_Q\
M'.5@3D.OT22$C#Z*Y)2%P-L-N9,%DE-RH@$>0%K6Y HB;2=YNVQ2/%T6:_LZ
M>FUEC7ZJ7=V98::RP+<AJ.J/5+O9::P&5^)%1"O[-C+W\\*>?B34]']"=3>U
M#KK3=9^T/7^RC14=EU-/K]O/TQL^HJDUNMU"E2MHX-9I'@EJAZ<]FU%8)%:&
M/7FOV=TT7;L]/7._4MRC<I2 YFZ,[!TZUD.LF2X%TEN8Z'R&/*SK$K#!#5=$
M-5PACQ7C(\^3EDR;RU!LHA7!'$;>-'VGS3[7=W[,D.RZ:FTT"P-(EF395+BR
M2B2-5@$4"*ZED=Y/(3V@1%2.6&7/:9[.O91TCHJ>RZ$]NVL]I^VGVT%&SH:7
M0W4?3$M/724[\\NW:_M[$M::."S6J4C4C43NU])E;QP2 UCJ+YIZA.*I.L"<
M*=)DYU( 3 $B3/2D1RO2^.45<L4@=H(!\6U!E/2BI%EUXA#X>T-CZ&4V[K:G
M$;RYN=GN*#P+K.GY=TDB.TLD>PK4A RE0J%;"L9.\$L"O 7MX/Q&0?9?T'[,
M^L:FWGZ]]L^O]EEBC8JQ:ZI=Z-WW5+;>&:*5Y[,<VFGB2H*LB1Q-'."TIE#(
M>$;*YTZ<L<W<JQMH+YKZ:9CIN.ASHX>!C)?DFI\C+M(A;!+IIS!-5%%:BTQK
MS+ ZV#$K<)V4EQK>DMKUN[IMAM+Z3ML]))I6C9%A22[7NFPK!B[!JZJ(_&0H
M(;DMW<CX',?[4.C?9_T=;U$/0/M6H^U.O>KVI=C;I=*[KI9=/-#)$E>O)%N9
M97N&TCR2K) 0L0A*N"77(MYNZB>JWCSD.5JW%?0I9><J6$)%/Q_(T;SEQU2!
M)8@V/'*D!$5VPQY$H(J)-=>CENO.J06L?9+.DM.)UJ!M-SU!3N204.E)]I65
M8REU-K3JK(616=1#,C2+XV)0DGABO</0YM_0'LP]C?4_3%/;]8?V0^J]GN^G
MFN1V>E[?L]ZHZ@FIQ069(:T[;3668Z<PN0*EI4C0-")!%(2ZDYD/PC=^1>0^
M/(RT\J\0G\&7,PR58/XZDK=!W@N+&"/?&CS%V*NLCQ92941MJ00RRUIP5#^A
MWM[=0K>\SJ[5VY3CGOZY]599I ])[$5IHU5RJ,9H0L;>10'  Y7GM/J#G,>O
M^G^E^F.I[FHZ.ZVK>T+1004Y*W5%72;#I^&Y+/6CFLP+K-F\ER$TYW>LSNY6
M9HS)'PC 9B'=.JGK5@+C;(&K^C>MUVK4)99V(KMS&ZC>*X4>W04;*%!Q%G8A
MI",</B69^/9'E6HPY:S $%I%)6IYI>]Z[9WW4\-FQ%!T78M013RQPV1NJ$0L
M1)(RQSB)XR\8F0"0(Q+(&[6)(.=LT/L>]@FST6EV.W_LIM+H-ML-3KKNTT,O
MLNZQORZ38VZ<,]W427JUM:UV36V9):;VZZK!9:$S1*(W4#.*O6"TRG'4':IF
MD$UVZR-*C+!*\;O3<?(EP5I+@F)$ZD.V,5M,4<3%RSCL"N;&:3'DNL;/9;T,
MM*<VB&:>2G%8EJM#:>JDTE(RH[13M$'>J9E'C=HY"8C*H[&([P.TY\_;/6:B
MGU1L=/0Z@BVFAJ[^WK*75,="S5@V.H@V,E6OU FKF8W*\5RDJ;%:$KFS"D@K
MR,95)S :,ZN.N<R2CQ#_ $8MRBP2CA!S9-?4QQ&4B.$?(;:).4,S%)=)2(RI
M9"F&E:<>TWMM&]*5K>:DG4/53.BOT-916959SO-<P120"W:(^3VCD\#U/' S
MZ/M^Q7^QZ@JV9JW]EKHK=B&O-+!47V3]:PM:FCC9XJZRO<*1&=PL0D<%4+=S
M @',ZN6;5=*3QY9[3QWQP7RY=(@09^"XY!L<54B[00[(!BOB,V*;:>BXQ0P3
MY,CMTQI:'4!J&1K3KS>];5L+%JK3GGITFV-F-5,5))HZ[3DNJE1-*#''VJ6?
ME@00O:/4C/GCHS3Z'?\ 4^IU'4_5,/16AO32Q['JBQJ[FZAU$25IYHYY-7KW
M2Y;$L\<54) ZLAG$K'LC89B5Q/U+]7UUY#K%6Y#]'[:>)*9,&$,3W(I_/W&E
ML$JXS0!9+)CU=A(YF4E$D%L#Q^F0W4.-K+20K>VF5ZWK^OW?45JY!!<Z0GU]
M:1B);K[>E86!0C,&,,48DD[F"IPI!'=W'T!SM'6?LH]B.@Z8VVWZ8_LE=/UK
MO:,$4FNZ7K^S;JS2S;>5[,$,D$>SOVI*=0Q022V2\Z,K+ 8Q\MU(R ZA>2>7
M.+J=%3W#/ 4IU%64VRBQ$A3(F^UKCPB)@GHN7,(L[DS:!R0"V1) &-BE1C*$
MF.KF&RD+TR&_I67W%W8T*T<NMU$FYG:=8WK1VX*9CB,<C-.99U9&"NB1]@'<
M3(&YX4\\U]F?2O175V]N:[KOVD5/9AJ8-3-=K;Z[TYM>IXKFQCN48(M0M'42
MQ689)ZUFW<%N1C BT6A93)/&1&G3USOU+<HW*4@.9NC.P=.M9#K)DN!=);F.
MA\ACRLZQ*PP0U71#5<(8\5XR//DY9,F\M0;*(5P1Q&WC1]IA:?:[N_9DAV73
M4VF@6!I$LR;*I<62421JL B@174LCO)Y">T"(J1RPS;/:9[.O91TCHJ>RZ$]
MNVL]I^VGVT%&SH:70W4?3$M/724[\\NW:_M[$M::."S6J4C4C43NU])E;QP2
M UCJ+YIZA.*I.L"<*=)DYU( 3 $B3/2D1RO2^.45<L4@=H(!\6U!E/2BI%EU
MXA#X>T-CZ&4V[K:G$;RYN=GN*#P+K.GY=TDB.TLD>PK4A RE0J%;"L9.\$L"
MO 7MX/Q&0?9?T'[,^L:FWGZ]]L^O]EEBC8JQ:ZI=Z-WW5+;>&:*5Y[,<VFGB
M2H*LB1Q-'."TIE#(>$;*YTZ<L<W<JQMH+YKZ:9CIN.ASHX>!C)?DFI\C+M(A
M;!+IIS!-5%%:BTQKS+ ZV#$K<)V4EQK>DMKUN[IMAM+Z3ML]))I6C9%A22[7
MNFPK!B[!JZJ(_&0H(;DMW<CX',?[4.C?9_T=;U$/0/M6H^U.O>KVI=C;I=*[
MKI9=/-#)$E>O)%N997N&TCR2K) 0L0A*N"77(MYNZB>JWCSD.5JW%?0I9><J
M6$)%/Q_(T;SEQU2!)8@V/'*D!$5VPQY$H(J)-=>CENO.J06L?9+.DM.)UJ!M
M-SU!3N204.E)]I658REU-K3JK(616=1#,C2+XV)0DGABO</0YM_0'LP]C?4_
M3%/;]8?V0^J]GN^GFN1V>E[?L]ZHZ@FIQ069(:T[;3668Z<PN0*EI4C0-")!
M%(2ZDYD/PC=^1>0^/(RT\J\0G\&7,PR58/XZDK=!W@N+&"/?&CS%V*NLCQ92
M941MJ00RRUIP5#^AWM[=0K>\SJ[5VY3CGOZY]599I ])[$5IHU5RJ,9H0L;>
M10'  Y7GM/J#G,>O^G^E^F.I[FHZ.ZVK>T+1004Y*W5%72;#I^&Y+/6CFLP+
MK-F\ER$TYW>LSNY69HS)'PC 9B'=.JGK5@+C;(&K^C>MUVK4)99V(KMS&ZC>
M*X4>W04;*%!Q%G8AI",</B69^/9'E6HPY:S $%I%)6IYI>]Z[9WW4\-FQ%!T
M78M013RQPV1NJ$0L1)(RQSB)XR\8F0"0(Q+(&[6)(.=LT/L>]@FST6EV.W_L
MIM+H-ML-3KKNTT,OLNZQORZ38VZ<,]W427JUM:UV36V9):;VZZK!9:$S1*(W
M4#.*O6"TRG'4':IFD$UVZR-*C+!*\;O3<?(EP5I+@F)$ZD.V,5M,4<3%RSCL
M"N;&:3'DNL;/9;T,M*<VB&:>2G%8EJM#:>JDTE(RH[13M$'>J9E'C=HY"8C*
MH[&([P.TY\_;/6:BGU1L=/0Z@BVFAJ[^WK*75,="S5@V.H@V,E6OU FKF8W*
M\5RDJ;%:$KFS"D@KR,95)S :,ZN.N<R2CQ#_ $8MRBP2CA!S9-?4QQ&4B.$?
M(;:).4,S%)=)2(RI9"F&E:<>TWMM&]*5K>:DG4/53.BOT-916959SO-<P120
M"W:(^3VCD\#U/' SZ/M^Q7^QZ@JV9JW]EKHK=B&O-+!47V3]:PM:FCC9XJZR
MO<*1&=PL0D<%4+=S @',ZN6;5=*3QY9[3QWQP7RY=(@09^"XY!L<54B[00[(
M!BOB,V*;:>BXQ0P3Y,CMTQI:'4!J&1K3KS>];5L+%JK3GGITFV-F-5,5))HZ
M[3DNJE1-*#''VJ6?E@00O:/4C/GCHS3Z'?\ 4^IU'4_5,/16AO32Q['JBQJ[
MFZAU$25IYHYY-7KW2Y;$L\<54) ZLAG$K'LC89B5Q/U+]7UUY#K%6Y#]'[:>
M)*9,&$,3W(I_/W&EL$JXS0!9+)CU=A(YF4E$D%L#Q^F0W4.-K+20K>VF5ZWK
M^OW?45JY!!<Z0GU]:1B);K[>E86!0C,&,,48DD[F"IPI!'=W'T!SM'6?LH]B
M.@Z8VVWZ8_LE=/UKO:,$4FNZ7K^S;JS2S;>5[,$,D$>SOVI*=0Q022V2\Z,K
M+ 8Q\MU(R ZA>2>7.+J=%3W#/ 4IU%64VRBQ$A3(F^UKCPB)@GHN7,(L[DS:
M!R0"V1) &-BE1C*$F.KF&RD+TR&_I67W%W8T*T<NMU$FYG:=8WK1VX*9CB,<
MC-.99U9&"NB1]@'<3(&YX4\\U]F?2O175V]N:[KOVD5/9AJ8-3-=K;Z[TYM>
MIXKFQCN48(M0M'42Q689)ZUFW<%N1C BT6A93)/&1&G3USOU+<HW*4@.9NC.
MP=.M9#K)DN!=);F.A\ACRLZQ*PP0U71#5<(8\5XR//DY9,F\M0;*(5P1Q&WC
M1]IA:?:[N_9DAV734VF@6!I$LR;*I<62421JL B@174LCO)Y">T"(J1RPS;/
M:9[.O91TCHJ>RZ$]NVL]I^VGVT%&SH:70W4?3$M/724[\\NW:_M[$M::."S6
MJ4C4C43NU])E;QP2 ^3W]4/_ &?$+_-]X[_O-R#GWI[ /[QI_P#'^P_U77Y\
M@=8?MJG\#A_G)\Z)<[?FJYR10C#EN-A"DEN-#D%NMBL.OK;%%:4^42XEI*U(
M8'90MU]Y6M-M-I4M:DIUO>4LZ( 794!95!9@H+,0JJ"2.68D!0/4D@ $YZ 3
M\ 3P"3P"?0?$^GS#YSF8<OU#=0''%IL\Y;Z#'5RV<L-:;Y6(N%.LT6;S)#"(
MD8&T0UO#DI01KV79I-1[EX^!XU8.,M0?KJS@9J+96+J<6@T6PK58:EZ2Q5U9
MYU:U+E>5-1,QCGK35'CC<^6M&(Q2][:S&E5^P1R0RD-D7N7(7D:2$1R6/2P9
M(I%-E1RLBR!F X=B3+XQ&3(.>0RCBDU'JAY+X_AZG(UWC^BQ\)7[8.74)!V&
MN+P CM(Y&I/,C-0%+>M^VI*/@;4)79$]<@L^TO1]A4U,SY>CX]X>Y;Z:UU^6
MU'8OW9)K%1DMQB:H)&6[K[FH:VR"IW1/8K-8CC$8CJB2OS# GC=3Y'?GA6-H
MX8E1).8SVRE08IHK/C!,IY"2"-FYY<AOENW(RQ)KJ*O$W29'C]T"MB5N6JM,
MJ1PHXLP0AP2@;B]5B7;%E9R2C!K1'#QK\>Q9!H]J6'BYZS181(H%@DAWYT/3
M]*&Y'?#V&L16KEI'9H5(>]Y?>8BT4,<C5I&D61JS2&)I8*TKJTE>-EM/=E>(
MPD($:.*,CACZ0]OC8!G*B10"!(%[@KNH(#$9O2?*MV$XM@Z+)\?P,?QI8#1[
M7%#$QMS#B+-9ZK2)[BAJ]0[KMF0$S- .2Q\K8"JBF*B+-=XV.<O$?8!8$&&$
M\CU=-MG->COSR;&!&JRLLE-YJU:U=@VAHS 5BYA<11Q5UM^66M2DD%*2NT[S
M,:>45TB:%%@<^105D"R21Q-7$J\OP&7N+,8^U7E ,H<(%%2:YQY*Y'#=XJ<J
M$9R%'6[D&K3E)X_V->9M58GH^&F*77ZAQ;&QUJU+14,?%SP4-NM!N'*EMUZG
M,N;?<@(]*;9TNNU[C:"U)0DJ4+4-R_W4819@DFAN6+>SDDJ^*6:.6!YO>7""
M+WBXP[1/)E0MSS#P>-9EDFC>*$B5_&X5HDC@42%E5E<+V GN*1_.@S'4L,L!
MW3!HI ;ZF1B4LE,N,.J',':+$?2AU*5;9*%>9)&=UK;;X[K3S2E-N)5O/JZ.
M"497 9E)5@P#(Q1U)!([D=2K#XJP*D @C(1!!X((/H>""#P?4'U^D?#.-E6>
M9WY_J<S[.J^?S9+[^4?B#.%_V0?]Y%'_ ,24?]G;;-KZ._;67^!3?SU?/;;G
MQGG3<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QEHWU,QJH3I%=KL9;;%&AZFZ]6Y?8K8<Q/P3[,S"AI).>&# /7)@"JB)0HD
M8>*EDA23I+"!=O(CV_+[M,T,*6)D7RPP2=H66:(B6).YRJHYD1?'(S*L<G:Y
M8!>1FNG31^K>NBV>TMZ766IS0V>UI"9YZ.MV,;T;\YBKI+/9K+4L3"[4ABED
MN4S/52*1I@C=8GIQO]65U!_^8\.?ENX[SKGL5_\ N1H/^[V_^Q=AFB]4?M);
M_P"U6_UF+/ 1GW9G)\U(7MM:%ZTE6T*2O25ITM"MIWK>M+3OW*3OMV4G?NWK
MOK?NW@^H(^GZ/CC,S9GJL&<WSJP!6I>0C^;K=>[\Y"RME'=J52M]QD!)RNVV
M$KI-:,DXCD;C,]R5CXR^52UUHNS1>HN/F T0+<U!3VGQ=+L/J&7LQ1R:6I1H
MB:*LRVK=2I&\%BI-86RD4NNV*"*22C:JV4K2^22%S.89Z^3>^/[J"HS+:DEF
M*L_,<<DI#HZH4++-7/<JRQR(9!P&^1W(]:LW6Y)VV02?*<>ABK)JG-%8F40M
MG, U*IYBX\Y$@2'E)*BI(<<.N<E\T<R<GQT;H9WQL7*.HK!D?"U*$,19K=&1
M58S'%L'8+;T]J$S5D<Q'4;#7SJO*2QLSV-;I]1K)).X>M.2\R236YDRJ3:-(
MW+0@<QVHV"R$=WO,,R$^JD )-9LS@<>OD6($+&IRL?'@"<D9TXSCJU'(N5M5
M9[J.9RNP:B4:;JH]9BHJ'1)<<'CP(]6*-M5QK*E#RC*;N52)VRB6='&\("5:
M^LQQ'"B;"JGNE45J;)JC&8B;36999C'L$:=K*I5J6/E1-[DMV"L]8[&9UK^J
MH)<F!R)9.^0&P#R/&L:JG="0@C/DEC]&'E:-G$GA4&W3NLT^4C'H26KMPF(D
MN&Y'CI,62Y+'2B9D[R]&)CK+*"Q-#B8EV<KT<+*A.&C1@A$F]8),L1Z#204*
M7?3I".*4316*D,J3:Z2)H]<Q,,=$2F2O$TMZ6406)6B<1M(ZQK7C1A-VJZ4'
M:,RE621@4F5@TXX9I>T!V"PJI9%5AR%!)=B.WD@WU(]>L<\B1&C^)9CV?+1]
MMCI>-L'*29\.?'GZ7S?3HAJT(1Q]%.61J"1RU!23RI-UTV7)X\C%.'!%GLR$
M-#CZ'D7QM)M8O)%)4DBDKZSW=X&KW-+;E-8^_P HKF<ZJ=!XP$A&PEX1TC,<
MUUMNI[@*S<,LBL'G[P_?%:B42?85+A/>%;Y7J3"OR@2"L:\D=4L+?A+*H.H3
MT*X=QK;^-XB/G[BU=]-C7KG<KFDTYTY-8JR1PZRDLV!@X] C[GK6X:6T\WL
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MA,^+R0P !VQ Q6O$I2O+'':;:1XE*5X4:[JWOOO*XXTB1(HU"1QHL:*/@J(
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M5FO'Y9:<Y:38;$3"6M6A1RTIAF\RR3I*.V9'812*T;P]C02%O52%$L;GM65
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M@V&H1J4E2I$E$L%9(7V8R/(7#TYMY9&#V=!'4>N4,:]3]/K;,LG[)O/%NT6
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M"CL&E< @E4#,!Z\94L;N&9$=E0 NRJ6" _ L0"%!X/!/ ],H67LHQC&?2GZ
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MD<?M"HJ[!6FUVUCB!/!>05'F*K])\<4C\?0AS7^IU+::UP.>UH6/X )4Y/\
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+8QC&,8QC&,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g389734g53z77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g53z77.jpg
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M&1HB-SA!47:UMM0C,C,T-3E"4]<V4F%B<G5X@;*TMQ<D<9&"DJ'_Q  = 0$
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MY+>%[@8UH[>F2'<@U;#RQ\WNM%;[1ZW_ '8WB]P%<S/3/+!QA1*BW+3U:(;
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M0ZJJJIRIII)IE$ZBBBAQ I"$* F.<P@4I0$1$  1SZJLS!5!9F(554$LS$[
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MP882?$%(ZG18*?$*\TH/MDC-1:IY8N+KC.M,TM(CW*A:U99YP-_!Y;O74N/
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MV9%NHF"/7@<JS=54CA%0QFKM-%)5(BKA5D^20(HHR=%1Y1:G1FDZ4-E)7W4
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MB2/UPDCCQJS-\U]C&,F^MF4;(W^GL)E%!Q$/+!&MY5)UR!N:.5<$(]%8PJ)
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M((/@01L0?SC,$OM6_D]?5*T_] K?OF9O^$WC[Y5:M^O7T,J_4/2/Q?6_5_\
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M8[K7#'ZN>B/9#K_P]CSGXE^4.N?:U_[QCL-+XG5^KQ>ACNM<,?JYZ(]D.O\
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M*#!$0H[%3;8 IW#F9FV'=N2?$G+L[K7#'ZN>B/9#K_P]E-YS\2_*'7/M:_\
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MG$_8[O\ _P *L?@;\I/R:;[5T/\ [GCSAT;X_%]&7]GC[=IY,/UG$_8[O_\
MPJQ^!ORD_)IOM70_^YX\X=&^/Q?1E_9X^W:>3#]9Q/V.[_\ \*L?@;\I/R:;
M[5T/_N>/.'1OC\7T9?V>;U7O++>30LTNSA8_BFKS-V^5*BBYLM%VS381$QA
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MZUH,B1G2KP=DCH\1K(ZIT.9DC:6)78 A3)&&(+KO&>[3[9 >UUMA6M@GKQ;
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MM9U&6MSPD'9Y2HQ]C;+QD2_:LB'N?7%QA;N2T+$%<1H^GO-8TLS0=HDFL5=
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MU3>N7#I+8Y*M8=BZNM.N;\K9$DDKL@S:S:KZNU=>TP%=7C85)E80!*'C&KJ
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MDTD\3;\K"73KM6!V"^N9([-B(NH'K49IO&$9)KO&JV%?UK21H$8;;CDGBD<
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M/9]]]U;W/R9UV^Z!K3X<O/TG >&<] >=FH_ TOU<_P!YS#_4Z#WTOTD]#'=
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0+]7/]YQZG0>^E^DGH9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g389734g64m64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g64m64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2"B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ((:^@R8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'K(+1         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "Y@
M"H\          0                         !              J/   "
MY@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MY@    !29VAT;&]N9P  "H\    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   N8     4F=H=&QO;F<
M  J/     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   '.$))300,     !:+     0   *     L   !X   4H   !9O !@  ?_8
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB
M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G
M)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ I@)> P$1  (1 0,1 ?_$ !X  0  !P$! 0
M       !! 4&!P@) PH"_\0 <Q    4# 0$("@H("Q,("P$  @,$!08  0<(
M$0D2%!@96);6$Q47(3%7EYG5UQ9!45598974V/ B-#96=8&4M2,E-3A4<9&A
ML;33)"8G*#(S-SE&1V9G=X:WP='A\4))979XA(?&14AC9(68HZ:GL[;%_\0
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MFGNA2AER+G7&$/C!(,/O/L(D$ZD>!'V-R)6%GF%T+A$XV]O*&/262ITK.O/
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MQO%TARJJ<')2X,T<&^C;T"Y]ODV@<0S,JS!I%D"[M&O3VYRK;"1PC$@E8NT
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MIC*I3&*8Q3&*8Q3&*8Q3&4@S]7DGX(</XXV?[J8RKTQBF,4QBF,4QEGN&/(
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M:6K<NQ3&*8Q3&*8Q3&*8Q3&:9R#<_M*DIFF5,A2"#3!SEV:%T==L@N9V<<]
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MT.+5)+-&62>6)Z<5UWTKO22-IT=#/)=WY:[W:AU$SE5CW4^\D,D?>IMAAQD
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M@;?*6. N#U:Q+2UZ2[&EN>M7TYM2H5M0GL4Z*O8HF3O.PH,DS+?IW(*MA;=
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MJ6@]TZMJM%I'A[XJ</*ZK+&0'BD4ZZ'BD7<,4D56*,C@%'5CD+D/4_.7.\D
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MIV3P]KE;3:?3+>=2F35'EOVN]=)U!)(8A1A9+$DNE4I(I>JUB$R11B_7C2M
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M5-,JL"ACH+,JR&Q80GOFVZ)((V[VB6.(S-8Z7=V?$'C3QYTSCOI&N;SW7?\
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M4V 4=L=^%&>N0HU1A-K[T9R8H=^^"U7B1Q&T08B-W21DW\UGC6148C\JK+(
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M>Z!4K25*_#^K1PR&P3_<M'F0VX$JVC#9>!K-<V*T:P2]"6/GB!1MU9@:M)\
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M$L7/$6!&+M9+Q/YFZ,8UD*9W%@ASJY1I4]#C[J[Q9I=G)*Q.3@VJ%3=PD)Q
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M_-K>XR'*@:]^<M-_R&*=7J>)G"_H>M\Z?WN/*1QQZQ7?FUO<8Y4#7OSEYO\
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M4-G+)63%6-!($XS!V2D"5&%/!%K!3W O+N2JYCB'A8Z;'WW1,LU10!.C[/+
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M3&7RP1YJC#<%J9BE)*(!IIX0*W)S=3K&'7M<R]U;LL7++AO<-MZ7<^Y8/ 6
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MWCREKZJ:!]"/=XY1U-S6\&?)1?HVGBD?36I_2'[>/*6/530/H1[O/$C=%TQ
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M#21[$3JS,&())6=Q\NP(!SK-.X&TZEP]<X;FL6;=*[;%N:0\D$P935945D#
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=,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g389734g98a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g98a02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1G04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &;2^98 X0DE-! 0      % < 5H  QLE1QP"   "   < E  "&-G,#(R
M.#<T' (% "]-:6-R;W-O9G0@5V]R9" M(%9I<VEO;B M($-O;G-O;&ED871E
M9"!&+30N1$]#6#A"24T$)0      $ J_76MX'>P1MFOQ9#/NXITX0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 8L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ "4S,P  0 " )3,S  !  (X0DE-!"8       X
M/X   #A"24T#\@      "@  ________   X0DE-! T       0   !:.$))
M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!$0      !     "   "0
M D      .$))300>       $     #A"24T$&@     #00    8
M     .(   (S    !@!G #D . !A #  ,@    $
M     0             ",P   .(                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   #B     %)G:'1L;VYG   ",P    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$%
M    !     ,X0DE-! P     #Q,    !    GP   $    '@  !X    #O<
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M+FW'%Z"&>DPP_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"
M10(0  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                     0  ]M8  0    #3+4%$0D4
M                                              ID97-C    _
M '1C<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !
ML   H@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R
M  6W*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T
M960@*%-73U I('8R
M
M '1E>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@
M6%E:(        +5:  "\9P  DC!M9G0R      0#"0   0
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M[W;P5?$S\@_RZO/#])SU<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\
M  'H Z<%+ :$![\(YPH$"Q8,' T>#AP/&1 7$102$!,+% 04_!7S%N87V!C,
M&=8:WAOA'.$=WQ[;']8@T2'+(L0COB2X);,FKB>J**8IHBJ@*YXLG2V:+I4O
MD3"-,8DRAC.#-($U?S9_-W\X@#F".G\[?CQ\/7P^?#]]0']!@D*%0XE$C462
M1IA'FDB;29U*GTNC3*9-JDZO3[10NE' 4L=3SE355==6V5?;6-Y9X%KC6^=<
MZEWM7O%?]6#X8?QC &0#90%E_V;\9_IH^&GU:O-K\&SN;>MNZ&_E<.%QWG+:
M<]9TS77#=KEWKWBE>9MZD'N%?'I];WYD?UB 38%!@C6#*80<A1"%_H;MA]N(
MRHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ FVV<6IU(
MGC:?): 4H02A]:+FH]BDRJ6]IK&GIJB;J9&JAZM_K'>M;ZYGKV"P6K%4LD^S
M3+1)M4:V1;=$N$6Y1KI(NTJ\3KU2OE>_7<!CP6K"<L-[Q(3%BL:0QY;(G<FE
MRJW+MLR_S<C.TL_<T.;1\=+[U ;5$M8>URK8-]E$VE';7MQKW7G>AM^4X)SA
MHN*HXZWDLN6VYKKGO>C Z</JU.OE[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN
M^6_Z;/MD_%;]1/XO_Q?__P   @4#V 5H!L8(!@DR"E(+90QR#7@.>@]Z$'H1
M>1)U$W 4:!5>%E(711@W&2D:-!L]'$ =/QXZ'S0@+"$C(ADC#R0$)/DE[B;C
M)]@HS"G!*K8KJRR?+9,NAR]\,' Q9#)9,TTT034V-BLW(3@6.0LZ #KV.^T\
MXSW;/M,_RT#$0;U"MT.R1*Q%ID:A1YQ(ETF42I!+CDR+38I.B4^(4(A1B5*(
M4XA4B%6(5HE7BEB+68U:CUN17)-=EEZ87YM@G6&?8J!CH62C9:1FIF>G:*AI
MJ6JJ:ZILJVVK;JMOJW"I<:ARI7.C=*!UG7:9=Y5XD7F,>H=[@GQ\?79^;W]I
M@&&!6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5
MB9: EWB8<)EJFF.;7IQ9G56>4I]0H$^A3Z)0HU*D5:59IE^G9JANJ7BJ@JN.
MK)RMJZZ[K\RPW['SLPFT(+4XME&W;+B'N:2ZPKOAO0&^(;]#P&7!A\*JP\[$
M\<85QSG(7LF"RJ;+RLSMSA#/,M!4T732E-.RU,_5Z]<&V![9-MI,VV'<=-V'
MWIC?I^"SX;[BQ^/-Y-'ETN;0Y\SHQ.FZZJSKF^R'[6_N6.]<\%OQ5O),\SWT
M*O42]?;VUO>S^(WY8OHO^O3[L?QF_1']L_Y-_N'_<?__   !V0.-!0D&5 =_
M")8)H0JD"Y\,DPV"#G /7Q!,$3<2(1,)$_ 4UA6[%I\7@QB!&7T:=!MF'%4=
M01XL'Q<@ "#J(=,BO2.F)) E>B9D)TXH.2DE*A J_2OJ+-<MQ"ZQ+YXPC#%Y
M,F<S531$-3(V(C<1. $X\3GB.M,[Q#RU/:8^F#^*0'U!;T)B0U5$244\1C!'
M(T@720M)_TKS2^A,W$W03L5/N5"M4:%2E5.(5'I5;59?5U%80UDU6B9;&%P)
M7/I=ZU[<7\Q@O6&L8IMCB61X969F5&=":#!I'FH+:OAKY6S2;;YNJF^6<()Q
M;')6<T!T*742=?MVY'?->+9YGGJ&>VY\5GT^?B5_#7_T@-N!PH*H@XV$<H57
MACN'((@%B.J)SXJSBYB,?8UBCD>/+9 2D/B1WI+$DZJ4D95XEF"71Y@OF1B:
M 9KJF]2<OYVJGI:?@Z!QH5^B3Z,_I#"E(J85IPBG_:CSJ>JJXJO;K-6MT*[+
MK\>PQ+'"LL&SP;3"M<6VR+?-N-.YV[KCN^V\^+X$OQ' (,$PPD##4L1FQ7K&
MC\>FR+[)ULKQS S-*LY'SV/0@-&?TK_3X-4#UB?73-ASV9O:Q-OOW1K>1M]S
MX*'AS^,"Y$WEF>;GZ#;IANK8["OM@.[7\#'QD/+O]$WUJO<$^%KYJ_KV_#K]
M>_Z[____ (  @ #EM'_-?U3,/W^E?L.RC'^4?FF8?W^>?DQ]XW_!?F-B07_^
M?I)$88!_?P4?9('^@!S\N'YTBWGD#WY7B;+*VWY/B!2Q/GY<AK27+WZ"A9M\
MDWZ^A+I@Z7\/@_1# '^6@W@=HH#D@]_ZHWTEEPCB2'T<E#')6'TED7JOSGU+
MCQZ5UGV&C0U[3GW7BSQ?M'XWB8E!RW[ B"T<!'_/B!'XOWP7HK#@@GP7GLG'
MLGPKFQ2N17Q;EZ.4<WRKE*9Z#GT,D>9>E7UWCT] MGW_C2T:C'[$B\GW"7M'
MKG7>VGM$J7K&&WM=I,2LTGN6H&:3$'OJG%IXVGQ;F+M=B'S/E4T_N7U2DHL9
M/'W&CO#UA7JJNEW=67J?M$C$IWJSKHNK?'KPJ3V1XGM,I$YWLGO G[I<BWP]
MFX\^TWR\F'88%WS;D$GT.'HOQG+<#7H;OSO#8GHGN'.J37IDLC:0WWK)K'%V
MTGM$IQ!;KGO HC ^#'P[GP\7''P'CZ#S'7G1TLC:\7FTRF'"27FXPHVI/WGP
MNV&/YWI9M,YV!GK=KL9;!GM>J8<]8WO0I-,627M2CQ'R*GF,WX39_7EFU=/!
M57E@S.ZH5GF4Q.*/$WG^O9)U2WJ&MP=::7L,L=P\VGMZJ245GGK(CIWM[8D3
M?BO6?H@ ?;&^S8<%?5>FM88P?3..&H6$?4ATT(3\?8Q::X2;?>@]CH2??HL8
MBX9Z@ 'KR8>NB0C5 (:CAWV]C86YAB&E?H3XA0.,T(1DA"IS?8/T@XA9#X.H
M@P<\.8.X@N 6^85WA /I^X9PD_C34X5WD76\$(2<CQFD%(/UC1.+B8-UBU9R
M58,7B=57_X+8B'P[+(+KAY05B(1[AZCH4H5SGOC1LH2#FX&Z?X.RF#NBH8,.
ME3J*.(*@DJ%Q*8)0D$-6]X(;CAPZ-((NC)84.(.)BLGFR(2JJAC0,H.[I:VY
M!H+QH8*A/X)5G:2([H'CFA)P"X&CEN=6 H%UD_\Y4X&&D@P3%8*:C.?E8X0,
MM6+.UH,=L .WM8)2JNJ@!8&YIBZ'U8%.H<9N_8$)G;Q5'X#CFC,XB8#SF#@2
M'X&\C$'D+X.+P-K-K(*<NH*VDH'.M'J>]($VKM^&Z(#3J;!N,8"3I.U47(!E
MH-@WW8!TGE@15($#B[?C*8,DS)7,KX(VQ3NUF(%EOD.> X#*M\N&"8!IL=UM
M=X SK(U3QH (J%8W38 *HUP0KH!LBT?B3H+0V+O+VH'FT$ZTQ($3R&&=-8!T
MP12%3H 2NGILU7_?M,U3/'^ZL$@VT7^\I1 0*G_TBN[=/))A?)C':Y!Z?$.Q
M5HZR?!":QXT:?!&#EXNW?$EKGHJ"?+%2=8F(?3(VCHDG?@$1,HO6?][;1I$M
MALO&!8]"A82P*HV#A&^9LHO\@Y""@XJM@O)JC(F-@HA17HBC@D U>HA)@F 0
M!(J8@X;9LY  D23$G8XBCNVN_8QCC-^8@(KQBR:!58FSB;)I:HBFB'Q02H?+
MAW8T=H=YAP4.^HE6AKO81X\(FY+#+HTRF'NM@8N&E9>7'HH3DOV %XCHD+YH
M4X?FCKQ/6X<3C/\SG8;"C!T.%(@HB836Z8Y*IA7!T8QXHB:L)(K4GG.5THEH
MFPI^YH@RE^IG2X<^E2U.?89ODLPRV88<D<$-3H<EB/_5IXVQL,? FXOBK "J
M]HH^IW>4M(C6HT%]XH>DGUQF6(:GF]I-M87=F/DR+(6*E_(,J(9+B(_4D(TS
MNZ6_DHMGM@6I\HG"L*:3OHA;JZ1]"H<PIPAEGH8VHN=-#(5?GZ\QG84+G3\,
M'H67B#'3HXS+QL>^LXL#P$FI%HE>NA22YX?TM$E\0H;,KP1D]H7<JG=,AX4%
MIV4Q)(2BH3H+KH4$A^;2X(QRTE>]^XJPRO&H78D-P^&2,8>CO5-[G89ZMWQD
M:86+LL=,#82]KF<PMX1<H/ +582.AZG,^YOR>UNXDYE'>R&C]I:X>PF.WI1@
M>R9Y%9)%>WAB:9!E>_E*<H[:?),O8XXU?7X*?I ??\#+.IKBA/VW9I@C@^>C
M 969@OR-^I--@DMX*Y%#@=AA?(]U@9I)?HWW@8$N>8U7@>,)SXZ;@PC)TYG?
MCJVV')<EC,*AY928BOB,X9);B8EW(9!>B%1@@XZ>AUY(F(TJAJ MIXR,AIT)
M-8U'A>C(J)CGF(ZTXY8]E<Z@IY.]DS2+NY%RD.UV X^&CO]??XW2C5)'L8QF
MB_LLWHO,B\T(KXP?A=_'?)@LHH:SQI6$GOJ?>Y,+FZR*A)#2F*IT[([9E?1>
MCXTQDZ!&[HO%D<0L.XLGD;X(/(LAA9'&7Y>;K*6RLI3UJ%F>;))^I$J)A)!*
MH(UT 8Y3G2-=N(R=FB=&08LTE_<KKHJ4ESL'VXI,A5#%9I<FMNRQR92 L=Z=
MB9((K0Z(JH_5J)IS0(WEI(]=$XPPH1-%L8JTGM,K.HH2F\@'BXF;A1K$DI;#
MP7BQ!Y0>NZ6<R9&GMA:'[H]RL.YRCXV%K%5<?8O:J)E%/HI<ID$JV8FHG/D'
M2HD+A.[#XI9NS'FP9Y/*Q=B<*)%6OX6'3H\CN;-Q_HTVM*I< XN-L1-$U8H:
MK$(J?(EIG+H'%HB9A,N]/Z70>GJJ'*)H>DV6T9\<>D6#%)P(>G)NG9DX>M19
M+):R>V1"4Y2B? HG\Y/S?/T$JI-_?Z:[LZ3B@Y2I*J%:@IR6%9X*@=""8)K]
M@3YMVY@Z@.M88Y7"@,Y!@I.\@-LG-),+@74$:)(#@IJZB*/KC,*H%Z!HBP&5
M))T5B6Z!:YH7B"EL\9==AR=7BI3OAF9 O)+NA>@FCI(XAEL$+Y"T@M2Y?*,;
ME?6F_9^CDWJ3_YQ9D3F 7YE.CS-K]9:=C9%6K90TC#%  I(TBSDE^9%WB]D#
M_8^2@K*XEJ)5GVBF"I[IG#.2_INJF3]_5IBFEHMK!)78E"Y5V9-\DC\_4I%^
MD.PE;I"_D58#TXZ9@I:WHZ'(J0*E-9Y5I162+IL1H6M^@I@1GAEJ.956FR)5
M(I+KF*P^PY#LES\E 9 GE@L#KXW(@GVVRZ%7LKVD;9WAKAZ1;)J=J<9]RI>@
MI=%IEI3KHE)4EI* GX,^3Y!LGE0DK(^@F,P#D8T:@FFV#Z#^O+:CQIV"MV&0
MRIH]LEQ]+)<_K<QI 92.J>!4%Y(MIPT][Y 2I,,D98\PF)L#>8R-@EFU<:"O
MQRRC/)TMP1>009GJNU]\I9;PMC]HB)1 LA)3LY'@KT<]FX_2J:@D'X[TF&P#
M98P=@DRN'J_^>>2<*:O>>;:*$*?>>;)WBJ07>>9D1Z"8>E!/^9US>N8Z'YKV
M>XT@*9J8?'$  )73?\JLSJ\H@H.;:*KD@9F)?J;:@.!V^Z,3@&-CJ)^;@"9/
M4YQ_@",Y=)H%@$P?H9F6@1<  )2.@ "KWZX]BRZ:BJG^B8V(O:7MB!IV,:(P
MAOMBY)Z\AB!.GYNFA8XXU9DLA4L?+IBKAD8  )-P@ "K$JUJD^>9JJDWD9J'
MS*4PCX1U4*%HC;UB$IW\C%%-Z)KHBS@X09AJBJ(>RI?7B[,  ))X@ "J0:S*
MG+28VJB8F<*&\Z24EQ=T=:#/E,!A39U+DK!-0IH]D2@WOY>XD&L>=9<4D&$
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M>72.U;6K>3I]T;#\>3)L9*R+>6=:.*AD>=1&[Z2N>FHQZZ'F>P<7\*)R>[X
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MHNZ+V;'1GY)Z^JT/G(]IBZB/F?A7>:1:E]9$?:"2EG O^)V>EJ07)YUGCZ@
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M@.:!MK[S?_AQPKF0?TIA2K1M?N)0#:^>?L0]K:M??N4I7:AF?S(/A:G#@$0
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MJ)1__+LJI-!P%K6JH8=?HK!OGM].B:N3G0<\?:<ZG*PHN*/@FFX03J0&BP8
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MA\5U;\A\AD%F0\*%A/I6F;R]A"%&/[=+@YXTOK*1@X$A"Z^5@_@(YJ\H@_X
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MK:9U1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\
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MSH9.F9Z.@85=EL)XA(28E!YAPH0(D=%)P(.3C] NKX-^CO$)TH/AAJ3*]H@
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MCX8\@Q6ZI)#/NP&H-HZ]M@"4^8S*L0^!!(L.K%YL>8F4J#!7*(A7I-= G8=
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MMFJ;4)@-L>.)2)51K75VA9+.J59C()"3I<M.YHZGHTHY68T H5L@#(R0E:L
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MCB^18Z/VC(. ?:" BOYNVYU$B;)<59I9B*M(RY?%A^$SH971AW@:$Y8:B#@
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MN]Z.?:%4MR%]A)W0LHMKUYJ#KGI9D)>&JX-&;)3OJ4(QSI+8H:P8]Y*UD.$
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ME)*$5*T$DG!T6:C<D(ACLJ3ICM]22J% C80_R)X?C*$K@9O;C*@2&YSNBN(
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M<U%YX;KU<ZUJV;9#="M;)['*=,Q*BJV>=8<XDZH4=D8D4J@K=K<*6*H'=Q<
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MFE-X4+9GE]9I-;&(E9Q9=:S?D[U(^:B,DE4W7:33D<8CPZ)KD>@+=**4A[\
M (3"@ "&A[K>HE]X";7:GV1H];#OG*Y9.:P^FFM(PJ?LF-LW.:0LF*HCNJ&8
MEJ,+G*&4A]D  (2:@ "&3;IBJI5WU;5:IQYHQK!KH_99#ZNSH65(FJ=>G^4W
M%*.FGPHCJJ#\F!T+P*"TA_(  (1[@ "&#;H1LSYWP+3XKSEHMZ_SJX-8]:LC
MJ*A(B*:]ISDW$Z+]I \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUMF<6V<S=?
M6,!_<YI0<[N"="= GK;?=,LO1;,A=60;!K'X=6L#;[!-=XD  (,D@ ![:,I
M>HAMJ\3">A%?7K]K>=E0<+I)>=I F;6'>@TO4K&H>E8;1[ Q>E\$"ZXO?$8
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MGW5M1[_JG+->][I@FD=0"K4,F&9 6[ EEUTO>:P EWD<2ZFCDR$&.Z;.A#<
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M[G^(=O90,7_/> @TFH!9>0</6('R>3S4C'U1?'_ LGUS?'JKSGV7?'R5_GW
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M>">7TI<]>("&UY4.>-UTY),->4=AZY$[><5-T(^L>E X&8Z5>LP>!H\U>PL
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MIBZ34I*>HQF"2I!ZG_IP:(Z!G/Q=R8S#FE-*-HM&F#\U)8H6EY0;T8HLDL\
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M?\&)ZI]]?UYZ"IR6?PUI'YGM?N!71I=Z?M!$.Y5F?MDO8I0'?N@55)5X?P@
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MJY>&G9N]J$YVDIC2I/EEMI8.H==4'I.5GU%!AY&"GA M6(_IF^ 4.9"$C:P
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MAF=\SZ@ZA7=MPZ2KA*)=ZZ%-@_E-$9Y#@X$[ )NT@S8FX)HU@RT-/YNU@Q$
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ML()ZO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<
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MC#API+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$
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M;-YEI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L
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MD6AE2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5
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MC]N8F(3@CHJ'@X07C2)U8H-GB[9B;X+6BF1.:X)UB4HXX8(RB&X?,H)FB'L
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M:4Z/U),F:R-_[I%Y;-1NS) #;FI<C8ZP;_9)#XV=<70SUHT0<K(9AXZB<O8
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MEE&+/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4
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M<6."2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(
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MF_=^FI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL
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M>&AU/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<
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MH--RPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8
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M?EUHZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\
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MI1=GM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP
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M@W]=-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@
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M@VB-CGZ+#VJ#C+MUUVQNBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6,
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MJCF8<W-BIQ:'*W/HHZQT_W1RH#EB#G48G1-.*W7'FG@X_78LF1 ?[W5ZE/0
MQWZP@(:H7')$M%B7\'+BL(J&CW-;K&)T6G/7J#AA<W1VI(%-I74BH; X?'6#
MGX8?=W2HE48 M'[1@'FB?X7%9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+
M\8/R;JPV@80@<$@<985A<.8  (!,=KJAF(.X;8.2IX-%;PF"@(+H<&UQ-8*?
M<;Y>PX)K<P1+%X):=#LUP()]=3@;R(-O=68  (  >KF@BX'9=M619H&(=XN!
M78$[>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (  ?CJ?9H 9
M@"60,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<
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MKY^,.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<
M (  @ "4T8\,8Y*&\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI
M;T<3R(R;;Q0  (  >D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"
MD8B3<S\MWXA]=!X38HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD
M=W!4?8>?>!I!UX<3>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T
M\H?!?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,
MALR##X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8
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M8Q5Z:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70
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MC,AV<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0
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M:GMMH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(
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MD==J@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL
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M<+-A.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#
M (  @ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR
M>/4  )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0F
MG9MP?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+
MA5 VV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2
MWY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/
MEA!?5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@
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M==A5);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8
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MF:!4NZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @
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M:(V56G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$
M (  =P6C-G(7<E"4 G,?<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'=S8W$7>%
M=^T=G7>2> <  (  >QBAQ&_U>_>2C7$7?$^"6'(??(QQ&7,>?+E>N'0E?.E+
M/'4>?1@V-775?38<\W5W?0,  (  ?J*@;&XFA9R1.&]:A3N!"'!UA+=OU'&#
MA!]=M'*4@Y!*57.?@Q<U?'1-@JT<:G.%@F\  (  @ "?4&ROCU:0(&WOCCY_
M^&\3C/=NS7 LBYU<O7%%BE5)C7),B38TVW+RB&,;[W'+B$L  (  @ ">;6N
MF1.//&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@
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M<+Z( 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4
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MGLR#-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X
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M=^AZ^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET
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MH[%W='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H
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M?@5N>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\
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M7+)E\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\
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M@UIB?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<
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M8R=9IJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP
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MA[]7&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@
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M:&A-2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT
M (  @ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<
M<OP  (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6
M":)==RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W
M?3\FDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9
MN:-U@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2
MBT-,$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@
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M@7V28& 9@5V"+6)\@29P_F2X@.)>Z&;A@*1+EVC4@'<VZ&H#@$L>:VAT@!T
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M6/>,U7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH
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MB)*&3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,
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M8;J $':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8
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MCKIZ=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW
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M:5US.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L
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MD_!NSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L
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M;]]FH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT
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MF$MC:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P
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M=4Q:EHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4
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M5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D
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M><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @
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M6RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@
M (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>
M:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.
MQJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,
M<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O X
MY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3
M?55#?YV#?:(XJYO/?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @
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MA4Y>PUBIA*E+V%N)A!XWF%T-@[,@ 5OT@Z #<'HP@BN?=D=QD8J0>$O3D V
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M<2:)[EHB<E]ZKET#<X=J>%^V=)U9"&)%=:=&=61Q=J0R866%=W8:*V4[=[8
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MH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&E8TOR5P3E/L865YFD'8
M (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4$' C87A!K'&89( M=7*E
M9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA8HED VMO93=3&6TG9\!
MV&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B" W61R:$ERCV:,:E=BZ&B!
M;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (  >K.,MU[H;VY_4V%H<-=P
M_F.K<B5AH67&<UA0_F?#='@_&VEC=8 K<6GK=D42DFQ'=@P  (  ?D>+15P,
M>+A]\EZU>6EOK6$@>?Q@8&-9>G50$&5L>N8^1V<7>U$JT&=H>YT2-&IZ>V\
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M4T!X:G*65O-JI7.S6GA;I7387<E+7G7W8.<YEW<.8[LEF7?Y9=<+NGK$9@(
M (  =<*#QVW27 YW-V\P7P-I@7"$8<Y:I7'-9'-*@G,&9NTXX70B:20E"W3(
M:K8+C7?W:JH  (  >>&"<&I=9-UUTFP!9Q=H6&V#:3)9C6[N:RE)F'! ;/\X
M(W%>;IXD@G&\;[(+976";XH  (  ?8"!#F<S;;!T<&D,;S=G &JV<*%8E6Q
M<?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (  @ !_NF1R=H!S2&9S=V-E
MW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+"G&;>F4  (  @ !^H&(=
M?UER-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI??Y@B]VG*?Z,*WW 8?\<
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M6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'9^H<B'L%:/$$FWXI:;(
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MA/EFH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU@Y<:F&V(@]X$FG@X@H,
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M8B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*:V<2E'^):S\  (  ;WH
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MB9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @
M (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_
MBO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>
M"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$
M8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(
MUX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H
M9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L
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MC6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @
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M;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8
M (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895
M>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81
MJ(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P
M@:<AFX41@:81+X48@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 Z
MN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q
M3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H
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M;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @
M (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R
M?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(
M4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z)9#.A/0O\9 RA+,DF8]9
MA&472H\%A(<(A8Q9@U@  ()Q@    (  @    (  @ ">^U/53=6/R%<(4AV
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M84F" E1M8]=SF5>Y9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH
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MD/][LD3*CZUMXDDPCDI? 4TFC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L
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M:6EV%U=Y:T)HE5IT;0M:%%TP;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\
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MEF=Q2$I3E/)D'TX1DS95\U%;D7I&NE0+D!<V,55/CU$CWU50CV0,X6H\B+4
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M<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[==8=N&+[=CT&YW15=X0
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M3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#7MD6G7@P8!8 IW[F8EH
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M=H!>R&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0
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M5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@
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M>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @
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M6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0
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M?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @
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M7T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL
M (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (
M<'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+
M$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%
M=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] R
MO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;
M@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @
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M8IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @
M (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (
M>3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"
MEH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27
M=Z@.HX1)=Y(";H,">BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G
M"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @    (  @    (  @    /__
M  #__P  __\  &UF=#(     ! ,)   !                     0
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MYN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK^O;\.OU[_KO___\ @ "
M .9/?\Y_6,V9?ZA^S;3:?YE^>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D
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MBQQ_Q*]<K5*"9I[4J-F!@HX&I(2 T'S^H%" 6FN_G#* (EI]F ^ '4F-D\J
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M@@1^=>#A@HZ"J<Q<@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z
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MBBUWW9=?B/YX?(*IA^9Y0VW1AMYZ-%D8A=Y[1D1[A/%\H3!:A!I^:]%UBY2
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M1+A>A?*M)Z3'A,ZG_Y#)@]JBWWRR@Q>=RFBD@G.8H%39@=V3/4%7@7*-?BZ
M@1:')\J@AL>\#[><A8JV :0 A&.OU9 $@VJIH7O\@JJC=V@+@A2=,E1I@8>6
MI4$+@1Z/IRY6@,Z(&LH*AG7%S;<#A3R^P*-9A!"W?8]9@Q*P)7MB@E&HU&>-
M@<"A:%0&@3^9L$#%@.&1B"XT@)6(Y,.[E?AUWK'*D[)V<I]OD9!W$(R4CY%W
MR7E<C:EXJF7^B\MYN%++B>MZZC_$B U\:RUIAB1^8,)\E,%_-+#0DH-^V)Z$
MD&U^DXNVCGI^<GB%C*)^>64UBME^I5(4B0]^YS\[AT=_6RTKA72 #,%9DZ*(
M?Z^BD6^'0)U[CUJ&$HJOC7>%&W>6B["$1&1EB?R#BE%HB$:"US[!AI2"-BST
MA->!G<!%DI.1V*Y\D&R/NIQ+CF6-JHFGC'V+QW:>BLR*#6.1B2F(8E#"AX>&
MKSY0A>^$\BS%A$N#$+\GD;Z;)JUTCYB8,9L\C9>548B+B\"2B76HB@Z/UV+%
MB("--5 IANV*=CWMA62'D"R<@]*$8KXGD1ND<ZQVCOB@JYI"C/B<Z(>ABR69
M-737B7B5BV(2A^>1W$^FAF*.#CV9A.N)_BQY@VN%CKU.D)BMKJNECGBI#9ES
MC':D8(;:BJ2?MG0HB/Z;$F&%AW.66$\YA>F1;#U5A(*,-2Q<@Q6&DKR?D#&V
MV:KZCA.Q5YC#C!"KM88MBCFF!W.(B):@6F#_AQ>:E$[;A924CCT;A"R.+BQ%
M@LZ'<+P9C]^_]ZIRC<:YAI@NB\"RVX66B>6L%W,!B$&E4V"3AL:>=$Z&A4^7
M53SA@_./WRPR@I6()[4.GSUU,J1CG"AUSI-BF3=V>H'QEF5W17 LDZ-X.EY&
MD.%Y7DR=CA%ZJ#LVBRQ\1"JMB!Y^5+0'GBE]_*.CFQ1]MY*NF"=]CH%$E5M]
MBF]^DJ1]LEVCC_)^ 4P*C3)^:CK4BF!_"RJ=AV5_[K,=G1>&O**MF@V%H)'1
MER"$H(!DE&*#T6ZRD;F#*5SSCQF"GTM^C&F"'SI]B:F!NRJ/AL&!:[(IG"F/
M8J&JF26-?Y#"ED&+O'][DWZ*%&W=D.2(G%Q%CE&'+4K]B[&%O#HQB02$2BJ#
MAC&"R+%,FTN8'Z#%F%&5=(_7E7:2XGZ/DKN08FT7D!2-^UN@C92+I4J%BP.)
M.#GLB&R&LBIYA;2$ [!TFJN@VJ &E["=98\=E-*9^GW.DAF6H6QBCX"34EL*
MC/R/_TH;BG>,D3FPA^^(\BIPA4J%&*^[FBZI>9]1ES6E.HYIE%6@\WTED9V<
MLFO.CPF8=5J3C(F4)DG%B?V/K#F"AX2*^2IIA/*&"*\AF<ZQ_IZ]EM2LZXW4
MD_*GOGR3D3:BB&M(CJ2=5%HCC"Z8!TEZB:62ASE;ARN,Q"ICA*J&TJZJF8&Z
M=IY&EHBT@8U4DZ.N67P2D..H'&K7CE"AX5G+B]V;CDDVB6&5"CDPAO*.22I>
MA'"'>*<!J+ITP9=^I-QU6X>XH1YV#'>;G75VXF<YF<YWYE;$EAEY'$:ADD5Z
M>#;@CD1\*B@OB?Y^2*8RI\1]"I;SH^!\SX<VH!U\MW<:G'-\R6:UF-%]"U9)
ME2=]>$8WD5Y^ 3:HC6U^R"A+B3A_T:5_IK^%/98SHN2$.H:-GQZ#6'9JFWR"
MK&84E^."*E7!E$>!RD71D(R!>C9XC*N!3"ADB(J!.Z3&I<^-6Y5FH?R+GH6Q
MGCZ* '6JFIF(CF5GEPZ'1E4WDWV&$$5QC]"$VS9,B_^#KRAZA_*"A:0$I1&5
M:I2FH3^2^(3NG860I73GF>..<63(EDJ,2E2YDLB*.T4=CR6(&#8HBV2%ZBB-
MAW"#JZ-CI&.=CY0'H)B:8(1/G-Z70W1.F3R4.60\E::1-U1*DAF..$34CH.+
M)S8(BMF']2B<AP&$K*+/H^6EEI.*H!>AI(/4G%:=M'//F*^9SF/&E2*5\E/M
MD9^2"427C@*. #7OBF>)SRBIAJ:%B:).HXBM>I,1G[>HP(-=F_*C]7-=F$:?
M*V-?E+J:9U.8D4&5D$1@C:>0EC7;B@N+;BBTAEN&0J'HHS^U2)*NGVJON(+V
MFZ&I_W+XE_*D/F,)E&6>AU-7D.Z8OT0SC5^2US7$B<^,RBB\AA^&V9FLLFQT
M:8L\K<=T^GR=J3IUK6V^I+-VC%ZPH!IWG4^BFV!XXD#^EG9Z3S+<D41\%"7V
MB[=^/)D:L8M\/(KEK-Q\ 7Q*J$)[]&UIH[%\&%Y6GQ=\<D]1FF-\^T"_E8!]
MHS+1D%M^C"8\BN-_MIBAL(F#ZHI=J^*"]GO2IT*"*FSHHK2!G5WAGB"!/D[S
MF7>!!D""E)^ XC+'CXJ YR9ZBBF!$)@BKY:+>XG)JO2)VWLNIEJ(8FQ9H<>'
M&UUBG3^& TZ2F*&% 4!'D]2$!C*_CM*#'R:OB8B"1Y>8KLZ3 XD\JB^0NGJ<
MI9>.EVO'H0:,EESMG'6*L4XZE^2(X4 3DR&'!S*XCBZ%+R;<B/Z#6Y<0KC6:
MAHB^J9.7D'HCI/>4M&M5H&61]%R'F]2/0DWPES6,D3_JDGV)V#*SC9Z'$"<"
MB(J$2Y:KK:6A\(A:J0:>17G"I&J:J&KYG]B7'5PXFTJ3F4VXEJZ0"S_-D>:,
M:C*PC1R(NB<AB"J%%Y9'K4:I-X@:J*"DS'F&H_6@66JUGU&;\5OUFL*7F4U^
MECJ3.#^KD8..P3*OC+N*,B<[A]R%PI7TK/RP88?0J$VK*7D]HYREU&IQGO6@
MAEN_FF6;44U:E=Z6%#^8D320QS*OC'F+;"=/AYV&3(T1O%)T''^BMN-TH'(6
ML81U461DK!=V-U:<IG]W5$CKH*YXJSN\FIAZ*B\PE"-\ B0!C4E^,(R_NWA[
M@G]]M@%[0G'PL(U[.V0YJPU[;U9MI6Q[WTC&GYU\A3NKF8M]3"]2DR-^5R1N
MC&1_GHR$NFZ"LG\NM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR 33N8F)6
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MA$-^LK=ZC?F"RZ<$C&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2 ODW,A="
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MA@I^T)+[F3J"%X7$EJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V D3\-BF&
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MG41YJV&HF=UZ,E17EF9ZV4<7DMY[HCI@CSA\@"Y<BWI]AR/&AZA^K(<6HL2
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MCX=CA=&-6GF@A-Z+[&M)@_:*5ES/@RF(O$Y:@GR'*4!'@>J%CC*Y@7F#U":
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M:!AW;(I%:IMX-G>/;3!Y$&2Q;^9Y_%(1<L1Z]S_,=>=\$2Z!>65]4[UI8+"
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MEJ]ZS$V-D\M[4$-VD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM:
M2V$]F$R 4E=8E9* .DU DK* %$,VC\1__#EHC--__# \B>N ""?>AQ: &R#M
MA'" ,&IMF>F&I&#SEV:&+%<7E*J%=$T!D<F$GD+YCN6#TSE&C .#&3!'B2&"
M;B?^AFN!OR$E@^F!%6HGF2J,OV"REJR+PU;6D_"*:4S&D0V(WT+'CBV'7CD5
MBUV%ZS WB(2$CB@>A=V#*R%2@WR!U&GOF**2LF"GEB*125;+DUF/.TRRD&",
MW$+%C76*F3DJBJV(<S!0A_2&9R@VA6^$6B%V@R6"<&*LJ\I>&EE]J'-@UU W
MI.-CO4;1H/%FT#UIG*5J&30XF!UMG2NUDW=Q32/ZCL=U11V5BE1Y56(5JI!D
MP5DOIR)FX5 $HV=I,$:]GUQKKSUQFPIN8C1?EHYQ2RO\D?MT6B1HC6AWHQXM
MB19Z^&&]J-YK)%C4I71LO$_%H<!N>$:+G;AP:CU=F7=RAS1ME1-TU2PQD)QW
M0"3%C"QYV1ZPB )\<V%PIQIQ5EA]H[QR<T]IH!5SJ493G"-U"3T[E_IVDC1M
MD[5X/2Q7CU]Z 241BQ5[YA\@AQ5]Q6$CI9)W>%@XHD%X(4\IGJ)XTT83FKEY
ME#TEEJ5Z?C1LDGU[ABQVCD=\G251BB-]RA]_ADM^[V#=I%U]DE@*H0Y]RD\&
MG7%][47TF8U^$#T-E81^2C1UD6E^I"R5C5%_#B6(B5)_@A_/A:-_\&"CHV:#
M>E?JH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!B2RTC'Z!126YB**!!B 0
MA1B RF!VHJB)*E?8GT^(@$[EFZB'>$76E\2&2CSND\R%+S1HC]>$*BR\B]N#
M/B7@B!&"5R!$A*B!?V!9HAB.I%?3GJ^-AT[BFO^+X473EQ>* #SSDR&(-#1Y
MCS>&@RS*BU"$[27UAY^#:2!NA$Z"$;=98K=:Z:;W95Y>6)8K9_9AN83.:HUE
M#7+^;3IH9V$ < UKVT]&<PUO>3W<=EMS:"UQ>@IWX[5R7VIE5*5^8F1GN93@
M94-J%X.L:!YL=7'[:Q%NVV ?;BUQ6TZ,<7AS^SU==1-VX"U&>0YZ++.I7(%O
MI*/.7[EQ 9-Q8M5R7()69>MSQ7#3:1MU/%\K;'IVR$W2< IX;#SG<^UZ0"TA
M>"M\5;'D6>EYQJ(9759Z*Y'-8*%ZE8#Y8^M[!V^B9UI[C5XV:O9\(TT>;L9\
MQ3QY<NE]@BT =V-^6[!!5ZN#Q*"76T6#1)!@7KR"P7^?8B^"0&Z49<R!R5U6
M::2!9$Q];:V _CP9<@B G2SD=K2 -Z[E5=.-J9];68^,2(\]72:*UGZ38+Z)
M76VA9(&'Z%R<:'^&>TOT;+V%"SO%<4F#ARS,=A^!XZW.5$^79IY=6">5'XY3
M6]22MWV[7X>00VS=8VV-TUO[9Y"+7TN&:_&(VCN$<*B&-"RY=:*#6ZS[4R&@
MYYV<5PN=LHV:6L::3WT-7HB6VVP\8H>3;5MM9LV/]DL>:U",8SM,<".(FRRI
M=3N$GJQS4DFJ#)T85CREV(T36?BA<WR(7;^= 6O%8<N8F%L-9B:4(DK*:L./
MACL/;[6*K2R<=.B%K*K<:@Q:K)OZ:_U>-8QV;?%AGGP\;^YD\VN$<@1H4%JA
M=#]KRTH+=J1O=#G2>5-S=2JN?%IX *E:9O!DDYK=:31G'(MW:V1IDWM;;9EL
M FJ\;^AN>EGZ<F1Q#DF,=0]SQCF%> IVQRJ?>UIZ,*?,9"5N5IE!9J9OZXH-
M:0UQ=7H*:WIR_VF?;@9TEUD2<,)V1$C><ZYX##D?=NEZ!2J1>G9\/Z8W8:AW
M[9>Q9%EXH8B-9NYY27C2:8IY[6B.;%%ZGU@Z;TA[84A%<G%\,CC(=>E]'RJ%
M>:Q^*:2_7X&!:9938EJ!1X<_91F!#W>59]V RV>>:L^ CE=T;?Z 8$>[<5Z
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M15+(>L=\ND83>ZY].SGM?*U]R"YC?=U^9B0\?RI_#H(5=KR"GG;8=W&"D6L
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M@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=?X^ 'F'[?W" (5:^?TV
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M4)QXFW$:5>!Y;6)M6V9Z2U-]83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ
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M%6-*>X=5+EEM?&)98$\I?45=KT2D?BUB)3HP?RUFU3!5@$IKOB<X@9IQ#A^
M@P1VLFMH=Q]856)$>#Q;Y5B5>5Y?@TZ$>H)C-40O>[-G"3GN?01K#S!*?G)O
M1R=H@!)SUA_L@;]XHFI <Z=?H&$M=1]BEU>[=HMEF$W&=_1HJ$.E>7!KUCF:
M>Q)O+S P?-!RLB>*?KEV>R!)@*%Z:VDH<'IFWV =<CUI.%:[<^UKETT-=9YN
M!$,1=VAPB3D]>5=S,3 ->V%U^B>A?8UX^""9?ZI\"F@D;:1N"U\S;ZEOQE7D
M<9EQ@DQ&<XQS0T*D=95U&#CS=\YW#B_V>AMY&2>Z?(9[2"#>?M=]?&<[:RIU
M)EY?;6UV1%4M;YEW5$NW<<1X84(U= =Y?3C-=G)ZN2_R>/I\!B?4>Z!]9B$7
M?B5^P69\:0=\$5W#:X=\F%2K;>=\^$M&<$%]2T'.<K5]L#B$=51^+B_D> 5^
MOB?G>MY_3R%&?9)_UV7D9SV"N5TY:>Z"K%0O;'R"7$K>;OZ!\D%V<9R!G#@Z
M=&J!7"_ =T*!+B?U>C^ ^R%L?1J P65R9<N)'%S0:*2(@U/+:UB'@$J';?N&
M4T$X<+>%.S@7<Z6$.R^I=J6#3"?Q><B"7R&+?+J!@&*$@MQ0X5GT@O%4]U$4
M@R!9*D?3@TM=@SY;@VYB#34#@YMFUBQ-@]MKV"1BA$-Q-1W5A,1VQV%#?VI7
MMUD#?]U;3U!'@$I>^T<V@*IBQ#WT@0AFMC35@7MJWRQ;@@)O."2J@K%SWAY2
M@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V ?M!K0S28?XQNR2Q:@%QR
M=B3B@4]V81Z^@DEZ6U]4>0YE7E<B>A=GV4ZE>P-J7T7P>^1L^CT'?,YOLC14
M?=)RD2Q.?NEUCR4-@!QXNQ\<@4E[YUYP=D]L'U9.=YAN!DWC>,%O\T5&>=QQ
MZCRE>P9T #07?$YV-BQ"?:-X@24P?Q%ZZA]K@&Y]1UVE<^1RRU67=6QT(4U'
M=LYU;D3">"%VP3Q!>7YX*#/Z>O1YKBQ%?(%[1B53?BA\Z1^M?[=^>EST<<EY
M1%3R<X]Z"$RW=2AZLD1.=JM[63OJ>#5\%#/0>=A\YBQ=>X5]RB5Y?5]^KQ_C
M?Q]_@%QF< )_C%2(<@=_QTQG<]%_QD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L&
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M?_V  U+@=W&"'DO,>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R ^"DG?6.
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M@,2 5   __\  /__  #__P  ;69T,0     #!"$   $
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MFY[9_Z0X*O^A14#_HDE3_*='8?*M1G#ILD9_X+='C-F[3I?3OU>?T,5CI,7
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MI;& P9^NA,:8JX3*D*B$SHBFAM&"I(S3@*22TX"DDM. I)+3@*22TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3_Z4W*O^A
M1$'_I451_JQ"7_6T/VSMO#YXY\= @>#61H?)S5&:N,)@JJRZ;;6EM7B\H+&
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MB;"'PX:OB,2"KHK%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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MILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;-_Z,V(O^?0S?_I4-&_ZQ
M4O^T/EWYO3]F[LA#;>/636_5W4Z!Q--9D;7)9I^IP7&KH+MYLYFV@+J4LH7
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MP+QYK\&T>;#!L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M;F!7]W%A5O9T857V=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2
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M8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\.
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M)?^33"__E5$Z_Y171/^274[_CF58_(AK8?>"=&GR?']P[G>(=NMSD7SH;YF
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MJ-"48:C0E&&HT)1AJ-"48:C0E&&HT)1AJ-"4_X8A!O^7* K_IBP-_[$H#O+
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MAZ-OVH>C;]J'_W$@!/]V+ K_AC(1_Y(Z&/^90B#_G$<G_YY,+_B>4CCPG5A
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M?M./B'[4CH=^U8V'?M6-AW[5C8=^U8V'?M6-AW[5C8=^U8V'?M6-_W0?!/^
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M\5_D5O)?Y%;R7^16\E_D5O)?Y%;R7^16\E_D5O)?_V E!/];, ;_8CD-_VQ
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M6;B'=V&R@G]HK7Z&;JEZCG.D=Y9XH'6>>YUSJ'Z:<K. EW' @99RTX&3<]^
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MFXM^;I:(AG.1A8YXC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX"
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M/C3_OCXS_\H_,__*/S/_RC\S_\H_,__*/S/_RC\S_\H_N+(  *J]  "=R@
MD=@" (C[#0%__QD"=O\D!F[_+0QF_S427_\\%UC_0QM3_TD>3O]/(4K_521&
M_ULF0_]@)T#_9BD^_VLJ._]R*SG_>2TV_X$N-/^*+S'_E# P_YPQ+O^E,BW_
MKS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS,L_[<SJ[@  )[%  "0T@  @^
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M+PCXGC8+[:([#N2E0!+:I$8<SIY1*L676C>]D6)"M8QJ3*^'<E2I@GE;I'^
M8)]\B&6;>9!JEW>8;9-UH7"0<ZQSC7.X=(MSR76*=.)TB73H<XAUZ7*'=>IQ
MAW7J<(=UZG"'=>IPAW7J<(=UZG"'=>IP_V4? _]T&@+_@QX"_Y F!/^:+0;T
MH30)Z:8W"^"J/0[4IT0;R:%/*<";6#:XE6!"L)!H2ZF+;U.CAW9:GH-^8)F
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M1.B?0D+IK$-!Z;I$0.K-1$#JY$1 Z/5$0.?X0T#G^$- Y_A#0.?X0T#G^$-
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MFR\T_Z8P,_^R,3+_OC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\
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M9'"!\V1P@?-D<('S9'"!\V1P@?-D_VL4 ?][$@'_BA( _Y82 .VB$ #>K0X
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MKD!$U+]!0]780$33[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@
M ,.E  "UK@  J;@  )[# @"4S08 BMD* (3C& %]Y"8#=>0R"&[C/ ]GXT45
M8>--&USC52!7XUTD5.-D)U#B:RI-XG,M2N-\,$CCAC)%XY T0^.<-4'DJ39
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M)3#_OR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@
MALT  'G:  !P\@@ :/\1 &'_&@%:_R,#5/\K!$__,P9*_SL(1O]""T/_20U
M_T\./?]5$#K_6Q$X_V$3-?]H%#/_;Q4P_W@6+O^"%RS_C1DJ_YD:*?^D&BC_
MKQLG_[H<)O_''";_QQPF_\<<)O_''";_QQPF_\<<H;0  )._  "&R@  >-8
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M)?5>;2OR6W@P[UB"-.Q6BS?J5)0YZ%.;.^91HSWE4:H^XU"R/^%/NT#@3\=
MWD_80=E/Z$'43_1#T$[^1<Y._T;(4/]&PE'_1\!1_T? 4?]'P%'_1\!1_T?
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M5WQR_5=\<OU7?'+]5WQR_5=\<OU7_V(4 ?]Q$0'_?1$ _X@2 /*2$@#CFA(
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MJDY/J+I/3JC/3TZGZ4]-IO=/3:7_3TZD_T].I/]/3J3_3TZD_T].I/]/^G\
M -B.  #)FP$ OJ4" +2M 0"KM0  H;\$ )O!% "4P24"C, S"(2_/A%\O4@9
M=;Q0(6^Z6"=JN5\M9;AE,F"W;#9<MG0Z6+5\/E6TA4%1M)!$3K.<1DRSJ4A*
ML[E(2;3.2$FSZ4A(L?9)2+#_2DBP_TI(L/]*2+#_2DBP_TI(L/]*XH8  ,Z4
M  #"H0  MJD  *NQ  "AN@$ F,,% )#)$ "*R2 !@\DO!7O(.PUTQT44;L9.
M&VC%5B%CQ%TG7L-D*UK":R]6P7(S4\%[-D_ A#E,P(\\2L";/D? J#]&P+A
M1<#-0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "X
MI0  K:X  **V  "8OP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'0
M4QI<SUL?6,]B(U3.:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_-
M-4'.Z#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@
MH[,  )B\  "-Q@, @L\' 'C9"P!SWA@ ;MXF FC>,P5BWCX*7=Y(#UG>4!15
MWE@74=Y@&T[>9QY+W6\@2-YX(T;>@25#WHPG0=Z8*3_>IBH^W[4J/>#(*CW?
MXRH\W?$K.]S[+3K<_2XZW/TN.MS]+CK<_2XZW/TNP)\  +&G  "DL   F+H
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M$B+_T!(B_] 2(O_0$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP
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M71'_06D6_SYV&?\\@1S_.HP>_SF6(/\XGB'_-Z4C_S>K(_\VLB3_-KDE_S;
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M' 'R?R(!YX$I MZ",P33?T ,RWI,%<1V5AZ^<6 EN6YH++1K<3*Q:'DVK6:
M.JIDB#VG8H] I6"70Z)?H$6?7JE'G5ZT29M=PDJ97=9*EU[L2I9?^DF57_])
MDV#_2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M
M@QT XH<C =:'+@/,@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)H
MA#Z?9HQ!G&641)ECG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_
M28MD_TF+9/])BV3_28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ<
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MD+A,5Y#,3%>0YTM7C_=*5X[_2EB._TE8CO])6([_25B._TE8CO])_W$! ."
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M0TRCY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@
MMY\  *VF  "CK0  F;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUF
MM%HB8K-A)EZR:"M:L6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>N
MXSQ&K?,]1JO^/D6K_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0
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M(C?4_R,WU/\C-]3_(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@
M<,X# &76!P!=XPX 6N,; %;C)P%2Y#("3N0\!$KD1 9'Y4T(1>55"D+E7 Q
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M!1'_O 41_[P%C+@  'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL
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M.:%4_SBA5/\XH53_.*%4_SBA5/\X_T\4 ?]9$ #_8Q( _VH4 /]O&0#R<A\
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MB&#_/8A@_SV(8/\]_U</ /]B# #_; P ^'0, .EZ# #>?@P TH$5 ,B!)P'
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M0G1NKD1R;KU%<&[117!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</]
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M0UJ$XT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P
MPHP  +F3  "PF   IYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYU
MEETC<)1C*&R2:BQHD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+
MX4!4BO,_58K^/U6)_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$
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M,T.F_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K
MB+(  'RY @!VNA$ <KLA &Z[+@)HNSH&9+I#"E^Z3 Y;N5,25[A:%E2X81E1
MMVD<3K=Q'TNV>B)(MH0E1;:0)T.UG2E!M:PJ0+:^*C^VV"H_M.XJ/K/Z+#VR
M_RT]L?\M/;'_+3VQ_RT]L?\MQXD  +F5  "LG0  H:0  ):K  "*L@  ?[@
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M$"S?_1 LW_T0J*   )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8
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M.F=OXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=
MR'P  +^! 0"WA0$ KX<' *B)%0"AB24!FX@S!)2&/@F.A$</B8%0%81_5QI_
M?EX>>WQE(GAZ;"9T>7,J<7A[+6YWA#!K=HXS:'69-F9TI3AD<[,Y8G/$.F)S
MX#IB<_,X8W/_-V-S_S9C<_\V8W/_-F-S_S9C<_\V_V$  .!M  #/=P  Q'\
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M-%*%_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0
MEYD  (^;"P"*G1@ A)TG 7Z<- 1YFSX(<YI'#6^93Q)JF%879I==&V.58QY?
ME&HB7)-R)5F2>RA5D84K4I&0+E"0G3!.D*LQ3)"\,DR0TS),C^TR3([Z,DR-
M_S%,C/\Q3(S_,4R,_S%,C/\QW'$  ,A^  "[B   L9$  *:6  "<F@  D)\
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M(SJL_R,ZK/\CP(8  +.2  "GF0  G)\  )"F  "$K   >;$  &VW  !AO 4
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M@0(@ZI$#'^NA QWKL@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0
M (VL  !_M0  <KT  &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1,
M*/(< ";R)  D\RL (O0R "'T.0 ?]4$ '?5) !OV40 9]UH!%_=E 17X<@$4
M^8$!$_F2 1+ZH@(1^K,"$/O& A#[W0(0^^D"$/OI A#[Z0(0^^D"CZL  (&T
M  !SO0  9L8  %G-  !+TP  0-D  #7>   LXP  )O$  "3^"@ A_Q  '_\6
M !S_'  9_R( %_\H !7_+@ 3_S4 $O\\ !#_0P ._TP #?]6  O_8@ )_V\
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M+W1>X2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P
MRVT  ,-Q 0"[<P( M7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2$(QL612)
M:F 8A6EG&X)H;AY_9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O;V+$+VYB
MWB]N8_(N;F/^+6YC_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3:0  R'
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M+5]O_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@
MH8(  )F##@"4A!T CH0K 8B#-@2#@D (?H!)#'E_41!U?5@4<GQ?&&Y[91MK
M>FP>:'ET(F5X?25B=X<G8':2*EUUGBQ;=:LN6G2[+UEUT2]9=.PN673Z+5IT
M_RQ:=/\K6G3_*UIT_RM:=/\KYF$  -%M  ##=@  N7T  *^#  "FA@  G(8
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M3X#_*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0"
ME!( >Y4A '>5+0%RE3@$;91"!VF32@MEDE$.8I%8$EZ07Q5;CV886(YM&U6.
M=AY2C8 A3XR+(TV+F"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_
M)TF'_R=)A_\GT6\  ,%[  "UA   JXP  *"0  "5E   B9<  'Z:  !WFPX
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MC@XTMYT/,[>M#S*WP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX
M *65  ":FP  CJ(  (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL
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M 1;FK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0
M;KD  &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9
M[1\ %^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OU
MG  *]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(
M %7)  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!<
M#OP=  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0
M_YL  /^K  #_NP  _\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1
M   ZU@  +]T  "7A   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4
M  /_&   _QX  /\C  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4
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M_ST- /]"" #_2 H _TL, /I,#P#L3!0 X4H= -9*+ #.2SL!R4I( L1(4P3
M1UT'O$9F";I$;@NW0W8-M4-]#K-"A!"Q08L1L$&2$JY FA.L0*(4JD"K%:E
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M(85.XB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6
MT5T  ,E@ @##8 0 O5X- +5@&@"N82H J6 W J1>0P2?74T(FUM5"YA970Z5
M6&01DE=K$X]6<A:-57D8BU2!&HA3B1R&4Y(>A%*<'X)2IR& 4K0B?U+$(WU2
MWB-\4_$B?%/^(7M4_R%[5/\@>U3_('M4_R![5/\@_TH  .E4  #:7   S&$
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M)&I?_R-J7_\B:E__(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N  "O;P
MIVX! *!O$ ":<!\ E' L 8]O. .*;4(&AFQ+"8)J4@Q^:5D/>VA@$G=F9A1U
M9FX7<F5U&G!D?AUM8X@?:V.2(FEBGB1G8JLE96*Z)F1BSR9D8NHF96+Z)&5C
M_R-E8_\B96/_(F5C_R)E8_\BZU4  -A@  #(:   O&X  +-Q  "K<P  HG$
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M(E=O_R)7;_\BWU\  ,II  "\<@  LG@  *E]  "??P  DGX  (I_!P"$@!,
M@($A 'N!+@%W@#D#<H!"!6Y_2@AK?E$+:'U8#F1\7Q%B>V847WIM%UQY=1E9
M>'\<5WB*'E1WEB%2=J0B47:S(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T
M_R%1=/\AV&,  ,5M  "X=@  KGT  *6"  ":@P  C8,  (2$ P!]A1  >88>
M '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:
M47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+
M>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.
M)P!JCC(!9HT\ V.-1 5@C$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%
M&DJ&DAQ(AJ =1H:O'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>
MRFT  +IX  "O@0  I8<  )J+  "/C0  @8X  '21  !NDPH :905 &:5(@!C
ME2X!8)4X ER50019E$D&5I10"%235PI1DUX,3I)F#TR2;A%)D7@41I"#%D20
MD!A"CYX90(^M&C^/P!H_C]P:/XWQ&C^,_1L_B_\;/XO_&S^+_QL_B_\;PG,
M +5^  "JAP  GXP  )20  "(DP  >Y4  &R9  !EFP0 8)P0 %V='0!;GBD
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M""VRN DLLM (++#L"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F
MB9T  'VC  !QJ   9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 T
MO3( ,[T[ #*]1  QODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_
MM ,CO\L#([[H R.\]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4
M '.K  !GL   6[4  $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2<
M)<DP "3*.0 CRD( (LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8
MSL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS
M  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB
M !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@
M#.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0
MP0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH
M(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\
M  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0
M-\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&
M]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #W
MMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<
M "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0
M /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0
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M#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10
MX4@  -E(!0#31@D S$42 ,1'(@"]2#$ N$@_ ;-'2@*P1E0$K$5=!:I$9 >G
M0VP(I4)S"J-">@NA08$,H$&(#9Y D ^<0)@0FD"A$9A K!*70+@2E4#($Y-
MX1.10?,4D$'_%(]!_Q2.0O\3CD+_$XY"_Q..0O\3_SP  /E$  #D2@  V$X
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M&79/_QEV3_\8=D__%W9/_Q=V3_\7^$8  .)0  #05P  Q%P  +M>  "T70
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M&F%>_QIA7O\:Y%(  ,]<  # 9   MFD  *QL  "C;   F6D  ))J"P",:A8
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MD!A/<IX937&M&DQQOQM+<=D;3''P&DQP_1I-</\936__&4UO_QE-;_\9SF
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M$CN*N!(ZBL\2.XCK$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P
MF8<  (R(  !_B0  <XP  &60  !<DP  5Y4, %26%@!2EB( 4)<M $V7-@!+
MES\!29=' D>73@-%EE4$0Y9=!4&6908^E6\(/)5Z"3J5APLXE94,-I2E#364
MM@XTE,P--)/I#322^ XTD/\/-)#_#S20_P\TD/\/M7@  *J"  ">B   DXT
M (:.  !YD   ;9,  &&7  !5FP  39X& $F?$ !'GQL 1J F $2@, !#H3H
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M 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP
M5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9
MQ#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&
M[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@
M $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H
M#-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !
MU>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#
M   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH
M  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4
M .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?
MT   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J
M)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(
M  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W
M#N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2  #T&
M]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_
ML   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H
M /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +,
M]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M
M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$
M;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X
M .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\
M_QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]
M"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)
MP #F"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7
M /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\
M\!!W .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>
M#\P VA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B
M#P#_(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R
M .(6>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D
MS!C> ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_
M* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4 U1YM -(?
M=0#0'WT SA^# ,P?B@'+'Y !R1^7 <@?G@'&'Z4!Q2"M <,@MP'!(,0!P"'6
M ;PBZ@*Y(O@#MB+_ [4C_P.T(_\$LR/_!+,C_P2S(_\$_RD+ /\J!0#_+@@
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M#8D\_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@(
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M$6M._Q%K3O\1Z$8  --0  #$5@  N5H  +!<  "F6@  GU8  )A6#0"25QD
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MD1)979X46%VL%5==O1967=465EWN%5==_!177?\35UW_$E==_Q)77?\2UE,
M ,1<  "W8P  K&@  *!H  "59P  BF,  (-E @!]9@\ >&8: '1G)P!Q9S(
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M$DALN!-';,T31VSJ$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@
MH7(  )-R  "'<0  >G$  '%R  !K= < 9G41 &-V'0!@=R@ 7G<S %MX/ %9
M=T,"5G=+ U1W4@12=ED%4'9@!TYU: A+=7$*271\#$=TB Y%<Y8/0W.E$$)S
MMA%!<\L10G+H$4)R^!%"<?\00W#_$$-P_Q!#</\0P6,  +-L  "H<P  FW8
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M!R^,] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP
M98H  %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ V
MFDH -9I2 3.:6@$QFF0!+YIO BV:>P(LFHH#*IJ: RF:K 0HFL $)YG> R>7
M\@0GEOT%)Y7_!2>5_P4GE?\%J7X  )Z%  "2B0  A(H  ':,  !JCP  7I,
M %27  !)FP  0)\  #>B!  RHPX ,:,7 #"D(0 NI"H +:0R "RE.@ KI4,
M*J5+ "FE5  HI5X )J5I "6E=@$CI84!(J66 2"FJ $?I;L!'J77 1ZD[P$>
MHOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF   5YT  $VA
M  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >L#H ';%"
M !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.QZP 3K_D
M$Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [
ML   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^
M00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ
M  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN
M)[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "
MRD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,
M\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0
M !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30
M -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@
MWN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2
M   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q
M  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8
M=*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L   />
MX0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W
M+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ?
M /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '<
M_P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q
M ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1
M&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![
M /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8
MYP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_
M#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\
M?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1
M -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\
M_Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D
M!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(
MY0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1
M /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P
MU0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@#
M$?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=
M$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5]
M ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!
ML1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L
M'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$ NA]X +D?
M?@"W'X4 MA^, +0?DP"S'YH!L2"C ; @K &N(+<!K"'& :LAW0&G(N\"I2+]
M J,C_P*B(_\"HB/_ J$C_P*A(_\"_R4  /\H  #R*@  Y2L  -\H!0#<(0L
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M"'H\_PAZ//\([C<  -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!$0"=0AX
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MD0MD3)T,8DVK#6%-NPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@3?\+W$<
M ,=0  "Y5@  KED  *)8  "85@  D%$  (E2!@"#4Q$ ?U,= 'M4*0!X5#0
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M#E)9M@Y16<H/45GG#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P
MHV$  )9@  "+7P  @5L  'E=  !S7@P ;UX5 &M?( !H7RL 9F U &-@/0%A
M7T4!7U], EU?4P-;7UH$65YA!5=>:0957G((4UY]"5%=B0M0798,3EVD#4U=
MM Y,7<@.3%WF#DU=]PU-7/\,35S_#$Y<_PQ.7/\,R50  +E<  "M8P  GV,
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M"CUM] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0
M;&X  &%P  !;<@  5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A! $AX20%&
M>% !1'=7 D)W7P- =V@#/G=S!#QV?P8Z=HT'.7:<"#=UK0@W=< (-G7>"#=T
M\@@W<_X(-W+_"#=R_P@W<O\(M68  *EO  ":<0  BW$  'YQ  !S<@  :',
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M B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@
M.I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?
MGU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;
M_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z
M "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT
M$JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -
MJ/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N
M   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/
M  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?<
MCY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3
MNP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$
M4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@
M 'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0
M!L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41
MU%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF
M  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "T    -0
M  #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,
M .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5
MM@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0   .$   #C
M    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#
M  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D
M_P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z
M (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L
MY@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8
M /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0
M\ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#?
M /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\
M'@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"%
M .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T
MT #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_
M B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D
MA@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W
M ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX
M]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)
M!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,
M_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA
M -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H,
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M 9 C_P&0(_\!_R(  .LI  #=+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@
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MDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD
M ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#<
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M"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@
MHU$  )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H
M3$8 9DQ- 61,4P%B3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'5TRC"%9,
ML@A53,8)54SB"55,]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O50  H%0
M )-3  ")40  @4T  'I.  !U3PP <$\5 &U0( !J4"H 9U S &50/ !C4$,
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M"$=8\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@
M<E@  &M9  !E6@, 8%L. %U<%P!:7"$ 6%TK %9=- !47CP 4UY$ %%>2P%0
M7E(!3EY9 DQ>80)+76H#25UT!$==@ 5%78T&1%V<!T-=K ="7;X(0EW:"$)<
M\0="7/X'0UO_!D-;_P9#6_\&O54  *]=  "?7P  D%X  (->  !X70  ;5P
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M!#%L_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0
M1G,  $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE- #5Y50 S
M>5X ,7EH 3!Y= $N>8,"+7F2 BMXHP(J>+4"*GC, BIWZ@(J=OD#*G7_ RIT
M_P,J=/\#JFH  )IM  ");   ?&T  '!M  !F;@  6W$  %!U  !(>   07L
M #I^!0 V?PX -( 6 #.!(  R@2@ ,($P "^".  N@D  +8)( "R"4  K@EH
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M9  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T
M (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0
M%Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )
MI&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"
M  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L
M  RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$
M +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !J
MC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y
M P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE
M  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@
M59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(   #$
MQ00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/
M:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX
M $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0    T0
M -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7
MY&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\
M   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?    WP   .$
M  #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\
M /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_
M "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4
MC@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#]
M .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L
M_P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J
M (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8
M_P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R
M /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L
MW "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#(
M /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P
M.0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ",
M ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\
MN@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#<
M #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X
MC@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_
M *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S<
MR 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P
M!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-
M_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\
M +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT
MI ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4
M%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P5
M0 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1
M )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\
M]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">
M'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0 C""- (H@
MEP")(:( AR&N (8BO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D_P%_)/\!["4
M -LM  #),0  O#$  +$N  "K*0  IR0% *,C$0">)!T FB4J )8F-0"3)C\
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M FDULP-H-<8#9S;B V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@
MID$  )L_  "3/   C3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S
M.4D <3E0 ' Y5P!N.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(Z
ML0-A.L,#8#O@!%\[\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40
M )5#  "-0   AST  (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48
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M!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@
M>$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$ %=)2@!6
M25$ 54I9 51*80%22FD!44IT D]*?P-.2HP#34J;!$Q+J@1+2[P$2DO3!4I+
M[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P  D4\  (5.  ![30  <TD
M &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!633H 5$U! %-.2 !23D\
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M SU6_P,]5O\#ME,  *57  "45P  A58  'E6  !O5@  954  %Q6  !76
M4ED' $Y:$ !,6A@ 2ELA $A<*@!'7#( 15PZ $1=00!#74@ 0EU0 $!=6  _
M76$!/5UK 3Q==@(Z780".5V3 CA=HP,W7;4#-EW+ S9<Z ,W7/D#-UO_ SA;
M_P,X6O\#LE<  *!:  "/60  @5D  '59  !K60  8%H  %9;  !170  3%X"
M $A@#0!%8!0 1&$> $)B)@! 8BX /V(V #YC/@ ]8T4 /&-- #MC50 Y8UX
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M;0 G<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64
M (YD  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H
M*WD1 "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ?
M?'8 '7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI
M  !Y:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,-
M ""$$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$
M%(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T
M;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/
M#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z
M  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P
M8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +
MG X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<
MA   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X
M %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP
M *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@
MJ8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.
M   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,
M  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((
M +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   W
MH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@   +\&  #
M"P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*
M  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL
M)+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P   #- P
MS@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@
MD0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\
M !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=    WP
M .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@
M])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\
M10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3
M .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\
MX0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[
M $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ .,
ME0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_
M -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $<
M[0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1
M )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,(
M_P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+
M -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ),
MP0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T
M /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H
M3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5
M +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\
M_P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y
M %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4
MF@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH
M /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH
MJ@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8
M"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87
M  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP],
M )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\
MBQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*
M)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(6
M3@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG
M 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+
ML"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%
M'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0B
ML@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#
M )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL
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M 5DU[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@
M?3<  '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@
M-E, 7C=: %TW8@!<-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"4SK/ E,Z
MZP)3.OL!4SK_ 5,Y_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^/0  >#H
M ',X  !N.0@ :CD1 &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[2@!:.U
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M D5%_P)%1?\!ND8  *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1
M6D4+ %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'
M2&$ 1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(
M_P) 2/\!MDD  *)*  "12@  @TH  '=*  !N20  944  %Y'  !92   54D(
M %%*$ !/2A@ 3$HA $I+*0!)2S$ 1TLX $9,/P!%3$8 1$Q. $--5@!"35\
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M;P T5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(
M )52  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A
M.UH7 #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N
M77H +%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5
M  !_50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3
M #)B'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8
M)F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z
M60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II
M%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR"
M !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7
M:5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @
M<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1U
MD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$
M %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1,
M%7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +
M?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H
M  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4
M  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98
M (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&
M=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4
M%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A
M  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@
M-8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@
MH!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "B
MK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I
M "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L#0  K1$
M *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP
MLK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC
M   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"   N@P  +L0
M  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L
M ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -
MM@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+
M#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN
M  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@
M ,4   #)    S0   -    #2    T@   -4   #6    V0   -L   #>!0
MX H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #P
MJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6
M /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L
MZ "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#>
M /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /
M6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"=
M -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\
M_P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@
M %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,<
MH0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P
M /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %<
MRP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W
M *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\
M  #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9
M +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$
MIP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J
M    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P
M60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G
M )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0
MRPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P">
M %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"
ML0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(
M +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50
MD0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L "
M#<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89
M  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5
M (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X
M=!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6
M'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H7
M5@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0
M &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0
MB"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O
M'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & D
MZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@
M 'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50
M925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8
M*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J
M  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7
M %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_<
M4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K
M+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P
M6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_
M $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@(
M83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.
M-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X
M_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+
M %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X
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M;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(
M )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q(
M1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W
M1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%
M  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8
M #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'<
M,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^
M2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.
M'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$
M "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P
M;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P
M52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17
MD@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X
M %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T
M)UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <
M7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2
M  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@
M !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X
M$V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/
M5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M
M(0 4;2D %&TP !-M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM
M  MMP@ +;.  #&OS  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7
M05\  #EC   Q9@  *FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -
M=R, #'<J  MW,P *=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !V
MNP !==4  73K  )T]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<
M #-K   K;@  )'(  !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T
M 8$D  "!+0  @C8  ()   ""3   @ED  ()H  "">0  @HT  (&@  " M
M@,L  '_G  !^\@  ?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT
M   E>   'GP  !>    1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?
M  "-)@  C2\  (XY  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,
M (S?  "+[@  B_8 ;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >
MA   %H@  !",   ,CP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":
M'P  FR8  )LP  "<.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0
M  ":YP  FO$ :FT  %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0
M$)4   J9   $G    *    "B    HP$  *,&  "D"P  I0X  *82  "G%P
MJ!X  *HF  "K,0  JSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "K
MV0  JN@ 9'4  %=Y  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,
M  &G    J@   *X   "P    L    +$   "R P  M @  +4-  "V$   MQ4
M +D=  "[)@  O#,  +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@
MO=< 7'\  %"%  !$BP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V
M    N0   +T   "_    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3
M  #+'   SB8  - U  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0
M58P  $F3   ]F@  ,*(  "6H   :K@  $;0   FY    O0   ,$   #$
MR    ,L   #-    S0   ,\   #0    T@   -0   #8    V@8  -T,  #@
M$0  XQH  .8G  #G.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P -
M /\ "P#_  L _P 0 /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &(
M\P!I /$ ;P#P '4 [@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A
M *\ WP"[ -T RP#; .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\
M! #_  0 _P - /\ %0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D
M .0 :@#B '  X !U -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H
MS0"U ,L Q #) -T R #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_
M    _P * /@ $0#Q !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -(
M90#0 &H S@!P ,P =0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P
M +L O0"Z -  N #K +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]
M\P % .D #@#A !8 VP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#
M &4 O@!J +P ;P"[ '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T
MMP"K ,@ J0#C *@ ]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0
M -< "@#- !$ QP < ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\
MKP!D *T :0"L &\ J@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"=
M ,$ FP#: )H [P"9 /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8
M! "]  T MP 5 +, ( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!?
M *  9 "> &D G0!N )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L
MC0#/ (P Z0"+ /@ C #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q
M  @ JP 0 *< &0"D "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ),
M7@"2 &0 D !I (\ ;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#*
M (  Y0"  /4 ?P#_ '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"
MH (, )P $P"8 !T E0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"&
M E\ A -D (,#:P"! W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(
MXP!U"?0 = K_ ',*_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$
M ),(#0".!Q4 BPD@ (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H
M>@Q@ '@,9P!W#&X =0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J
M$/< :1#_ &D0_P!I$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1
M!P"%#A  @0\: 'X0) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%<
M &X28@!M$FH :Q)S &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8
M8!?_ & 7_P!@%_\ QR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z
M%0T =Q45 '06'P!Q%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &48
M7@!C&68 8AEO & 9>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_
M %@>_P!8'O\ OR<  *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D
M;AP1 &L<&@!I'2, 9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;
M'V( 62!K %@@=@!6(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D
M_P!1(_\ N2L  *,L  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$.
M &,B%@!A(A\ 7R,G %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\
M4B5H %$F<P!/)G\ 3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+
M*?\ LRX  )XO  ".,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG
M$P!:)QL 6"@D %8H*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE
M $HK< !)*WP 2"R+ $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\
MKC$  )HR  "),P  ?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4
M+!@ 4BP@ % L* !.+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P
M;0!#,'H 0C&) $$QF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,
M )8U  "&-0  >38  &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4
M3#$= $HQ)0!(,2P 1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^
M-7@ /36' #PVE@ [-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W
M  "".   =3@  &LX  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4:
M $4U(@!#-2D 034O $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78
M.#F% #<ZE0 W.J4 -CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^
M.@  <CL  &@[  !?.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y
M'P ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV#
M #,^DP R/J0 ,3ZV #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/
M;CT  &0]  !</0  53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y
M/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"
MD0 M0J( +$*U "M"RP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\
M &%   !9/P  4C\  $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$
M,D,H #%$+P P1#8 +T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G
M1Z$ )D>S "9'R0 F1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"
M  !50@  3D(  $5"   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE
M "M)+  J23, *4HZ "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\
M(4RQ "!,QP @2^8 (4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !2
M10  2D8  $%'   \2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/
M*  D3S  (U W ")0/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O
M !E1Q0 94>0 &E#V !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2
M1TD  #Y+   Y3   ,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =
M5BP '%8S !M7.P :5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7
MP@ 25^$ $U;T !15_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T
M #Q/   U40  +U0  "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B<
M%%XN !->-P 27D  $5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,
M7MH #5WP  U<_  .7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4
M   P5P  *EH  "1=   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I
M  UG,@ ,9SL "V=%  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\
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M  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,
M 'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y
M8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#
M$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0
M  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0
M*7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)  "/#0
MD!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5
MG0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\
M !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=!P  G@L
M )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE
MI:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2
M   +EP  !)P   "@    HP   *8   "H    J0   *H   "L    K00  *X)
M  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T
M +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #
MIP   *L   "N    L@   +8   "X    N    +H   "[    O0   +X   #
M!0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD
M  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@
M +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X   #0
MT@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #G
MI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!-
M /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$
MX0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#*
M /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@
M4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3
M ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\
M_P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1
M %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L
ME@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P
M /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T
MO !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J
M )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<
M  #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !-
M *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4
MF0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3
M    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P
M3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP":
M (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0
MM    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "-
M $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T
MHP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L
M )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@
M@ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P
M *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0
M  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05(
M '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P
M9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!
M%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-
M2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"]
M %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P
M=!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@
M$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6
MT@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X
M &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$<
M5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)
M'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A
M  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU*
M $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D
M0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9
M(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C
M30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY
M #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@
M428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _
M*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L
M_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H
M $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%
M.2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T
M+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N
M" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7
M #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\
ME3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \
M,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV
M8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0
M '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL
M-#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H
M.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX
M  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP.
M "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@
M(4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I
M.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="
M$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T
M !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@
M6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @
M210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+
M@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(
M $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$
M%U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -
M49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%
M  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3
M !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P
M!5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!
M20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@
M%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:
M  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@
M-5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P
M:!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !H
MJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<
M "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q$   <10
M '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP
M<KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7   *F   ")D
M   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5
M  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(
M '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4
M<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+
M%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!
M  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0
M"(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,  ":#P
MFQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">
MRP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0
M  "8    G    )\   "A    H@   *0   "E    IP   *@$  "J"0  K T
M *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP
ML<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H
M    K    *\   "Q    L0   +,   "U    M@   +@   "Z    O 8  +X,
M  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P
M1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,   "W
MO    +\   #!    P@   ,0   #%    QP   ,D   #+    S0   ,\#  #2
M"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P "
M /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %<
M[0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6
M *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\
M  #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9
M -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *
MP@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^
M    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4
M60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E
M *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N
MX@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P
M %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\
MK "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP
M ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %,
MGP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@".
M +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'    N@   +
M  "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2
M (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\
M?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";
M  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- ((
M4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z
M '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".
MB@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U
M %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8
MRP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<!
M 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T
M:0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;
M!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,
M! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=.
M %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0
M40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G
M#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.
M40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W
M $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $
M7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,
M$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7
M_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518&
M %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%(
M0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \
M'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;
M# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8
M #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\
MEB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$
M'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C
M7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28
M '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T
M/202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O
M*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ
M  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0
M #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&<
M*2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J
M+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M
M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S
M ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,
M7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I
M,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV
M@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630
M % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4
M(C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7
M.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV
M  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8
M !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\
M$4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#
M.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$
M&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?
M  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /
M.CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /
M2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+
MK@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\
M #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L
M"%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0
M4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%
M   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=
M  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H
M %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B
M3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810  &$9  !B
M(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/
M  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3   <5P
M%EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P
M;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !K
MY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   68   $&0
M  QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P
M 'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP
M=^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S
M    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<
M  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@
M4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!
MA0   (@   "*    C    (T   "/    D 0  )((  "3#   E1   )<5  "9
M'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP
M $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1    E0
M )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.  "J%
MK1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK
M   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A    I0   *@
M  "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\#0  OQ,
M ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G
M@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@   +D   "[
M    O    +X   #     P@   ,0   #&    R    ,L   #.!0  T0T  -84
M  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_
M_P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D
M &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H
MNP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ %
M /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X
MS !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W
M ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4
M"P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!>
M +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X
MI0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$
M  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8
M7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#,
M )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L
MJP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5
M %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4
MX@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ .
M )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8
MA !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V
M .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  ( BP + (@
M$ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5
M '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@
M:0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P & 'L #0!Y
M !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H
M5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T
M %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \
M;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!>
M %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0
M^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0
M &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0
M4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*
M!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&
M$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9
M $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\
MFA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1
M#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/
M80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@
M ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!
M2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y
M%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=
M  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143
M #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68
M,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J
M(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9
M%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ
M "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)
M7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q
M'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C
M?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<
M % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A<
M*B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?
M)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ
M  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<:
M "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T
M&2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#
M+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L
M'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#">
M !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@
M.RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9
M,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! U
ML  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#
M #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\
M$C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *
M.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R
M   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC
M  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP
M!#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I
M-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$
M)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31
M  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P
M(#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P
M2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*
MZ0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,
M !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8
M %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP
M4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-
M   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ
M  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?,
M5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *
M60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G
M+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8
M $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@   "8P
M &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@
M=#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*
M   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K    ;P   '(
M  !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D
M (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U
M4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0   ($   "#
M    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L
M  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70
M)&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$   "3
ME    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I
M,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7
M !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D    I0
M *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@
MOC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(
M   %CP   )8   "<    H@   *<   "L    L    +,   "V    MP   +D
M  "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P
M -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_
M !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P
M: #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L
M +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !(
MZ  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#"
M &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X
M^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6
M ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &(
MK@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"<
M /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +(
M&@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@
M )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T
MC #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 . )\ %0"=
M !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H
M8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_
M 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T $0"+ !@
MB0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y
M &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X
M_P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ;
M 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L
M:P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A
M /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P
M'0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!=
M %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\
MJ $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@
M !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %,
M80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D
M (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D
M5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!)
M &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/
M  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$;
M $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60
M/P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N
M%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4(
M'0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO
M #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P
M7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]
M#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0
M?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L
M %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L
M-1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H
M%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>
M  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0=
M "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H
M(1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$
M(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8
M(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z;
M !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@
M.R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A
M'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8B
MK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20
M #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$
M&R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1
M)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E
M   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E
M !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT
M#2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K
M)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M
M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0
M  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@
M)"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,
M,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,S
MYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT
M !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P
M!#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@
M-_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS
M   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ
M   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?(
M6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2
M.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&
M-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530
M $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_   /00
M#$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@
M33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X
M   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +20  !TL
M  ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@
M %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [
M.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40   %0   !7
M    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^
M  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P
M,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X   !A
M8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N
M10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<
M "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M    ;P
M '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0
M?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5
M   46P  #F    =E    :@   &X   !R    =@   'D   !\    ?@   '\
M  "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0
M )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .
M:   !VX   !T    >0   'X   ""    A@   (D   ",    C@   )    "2
M    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-
M  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P
M 'X   "$    B@   (\   "4    F    )L   ">    GP   *(   "D
MI@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z
M6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F     B    (\
M  "6    FP   *$   "F    J@   *X   "P    L0   +0   "V    N
M +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@
MT&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /<
M)0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M
M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\
ML0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #>
M "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D
M;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_
M )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0
MO@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D
M &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )
M_P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G
M *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8
MD !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"!
M /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D DP A )(
M* "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G
M 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\
MRP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_
M "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X
M:0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N
M *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0
M;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@
M &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4
M  "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E
M &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@
M4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![
M P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8
M)0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O
M $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@
M9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+
M "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X
M>  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX
M %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$
M0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U
M (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1
M  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B
M #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X,
M+0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&
M%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #()
M)  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5
M "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@
M/18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K
M#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0
MJ0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@
M #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0
M)! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7
M%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:
M   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G
M !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H
M$A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K
M&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9
M+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0
M  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0
M)1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2
M'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@
MY0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\
M " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\
M#B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '
M(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA
M   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T
M  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_
M7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8
M)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M
M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0
M $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0
M$2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@
M,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI
M   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S
M  TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X
M #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \
M+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW
M @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&
M  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P
M,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^
M000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(
M3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$
M "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&    2 (
M $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@
M45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U
M   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/    40   %,"
M  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0
M %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   <
M/P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7    %T   !?
M    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?
M  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$   620
M$$T   I1   $50   %H   !=    8    &,   !F    :    &H   !K
M;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X
M;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED
M  )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![    ?0
M '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P
MBGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M
M    <@   '<   ![    ?P   (,   "&    B    (H   "-    CP   )$
M  "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'
M )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<   !]
M@P   (@   "-    D0   )4   "8    F@   )P   "?    H0   *,   "F
M    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^
M  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/    E@
M )L   "@    I    *@   "K    K    *\   "R    M    +8   "Y
MO    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+
MC0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S
M .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4
MPP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P";
M /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P
M-@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V
M *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\
M\P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O
M #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H
M> "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP
M -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #
MF  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "%
M 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,
M  "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P
M (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ',
M<P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";
M    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ',
M, !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X
M &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*
M?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C
M "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4
M@0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0
M &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H
M5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!)
M (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X
M  !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J
M $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4
M/@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0
M!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$
M*@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3
M #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P
M1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W
M "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P
MH@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T
M #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "<
M+P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E
M +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/
M   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I
M "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![
M'0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N
M$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)
M+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S%
M !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3   J$@
M*!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;
M#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /
MY  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,
M "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3
M%!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -
M$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5
M   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V
M  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X
M7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9
M%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9
M/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@
M $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $
M%1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &
M'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<
M  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL"
M !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D
M "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^
M(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@
M!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)
M   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@
M,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *
M)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M
M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0
M "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4
M BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4
M,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F
M   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'
M   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP
M #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B
M)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(  #L%   \
M"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J
M  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P
M&2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"  !%!0
M1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+
M>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30
M ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !. 0  3P0
M %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P
M58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q
M   '1    $<   !*    30   %    !3    50   %<   !9    6@   %P#
M  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4
M &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8   9*
M3P   %,   !6    60   %P   !?    80   &0   !E    9P   &D   !L
M 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5
M  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7    7
M &    !D    :    &L   !N    <0   ',   !U    =P   'H   !\
M?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#
MI0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F    :P   &\
M  !T    >0   'T   "     @P   (4   "'    B@   (P   "/    D@
M )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0
MF:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0   ((   "&
M    BP   (\   "3    E0   )<   ":    G0   *    "C    I@   *H
M  "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0
M(E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4   ":
MGP   *,   "F    J    *L   "N    L    +,   "V    N@   +T   #"
M    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _
M /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X
MV0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y
M (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P
M  #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^
M +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4
MH@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9
M    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0
M/0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+
M (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[
MK@   *4   "?    G  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P",
M #P BP!! (D 1@"( $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H
MD@!X *, =P"Y '8 X !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0
M (\   ")    A0 $ (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8
M>0 [ '< 0 !V $0 =0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H
M )L 9P"O &8 S !E /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T
M  !W    <P   '  " !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T
M &< .0!F #X 90!# &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ),
M6 "F %< OP!7 .H 5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H
M    9    &$ ! !@  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D
M,P!8 #@ 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "?
M $L M0!* -P 2@#Z $H _P!* /\ D@   (    !R    9P   %\   !:
M5P   %4  0!3  < 4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!,
M #, 2P X $H /0!) $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $
MK@!  ,L /P#R $  _P!  /\ A0   '0   !G    70   %4   !/    3
M $H   !(  0 1P * $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T
M00 S #\ .  ^ #X /0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V
M ,  -@#H #8 _@ V /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$
M   _  $ /@ ' #T "P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N
M #8 ,P U #H - !! #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@
M+0#= "T ^  N /\ <P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W
M P  -@ $ #4 "  T  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X
M+P M #8 +  ] "L 10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/
M "4 \  F /\ ;08  %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"
M+@8" "X#!@ M  H +  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E
M #( )  Y ", 0@ B $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X
MZ0 ? /H : D  %D,  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L
M "<)!  F!@@ )@0+ "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X
M'@$V !T!/P < 4D &P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8
M /0 8PP  %4.  !)#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(,
M P @"P8 ( D) !\'#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S
M !<&/  6!D8 %@92 !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\
M7PX  %$/  !&$   /!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <
M#04 &@T' !H+"@ 9"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*
M.@ 2"T4 $0M1 ! ,7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \
M $X1  !#$@  .A,  #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0
M%@X' !4."0 4#0L $PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -
M#D8 #0Y1  P/7@ +#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2
M  ! $P  -Q0  # 4   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q '
M !(0"0 1#PH $ X,  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$
M"1%-  @26@ '$FH !A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^
M%0  -18  "T6   G%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1
M"0 /$0H #1$+  P2#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*
M  ,56  "%6<  15Z   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P
M,A<  "L7   E%P  (18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .
M$PD #!0*  H5#0 (%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   9
M50  &60  !EW   9C   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D
M "D9   C&0  'Q@  !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@
M"A<*  <9#  $&@X  AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@
M'6(  !UU   =B@  '*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;
M   A&@  '1D  !D9   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)
M  ,="P  'PT  " 0   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\
M ")R   AB   (9\  ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @
M'   '!L  !@:   6&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B
M"@  ) P  "8.   F$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N
M   FA0  )IT  "6T   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0
M&QP  !@;   4'   $1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"
M*@L  "L-   M$   +14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M
M@0  +)H  "NR   JT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX
M !8>   2'P  #R$   TB   *)   !B8   (H    *P(  "T$   O!@  , D
M #(,   T#@  -1(  #48   U(   -2H  #4V   U0P  -5,  #1F   T?
M,Y8  #*O   QS0  ,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C
M   0)0  #2<   DI   %*P   2X    P    ,@   #0!   V!   . 8  #H)
M   \#0  /A   #X4   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$
M #JK   YR0  ..T -R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -
M*P  "2X   4P    ,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$
M"@  1@T  $D1  !)%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E
M  !"PP  0>@ -"H  "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P
M S8    Y    /    #X   !!    0P   $8   !(    2@   $P#  !.!@
M4 H  %,.  !4$P  5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-
MN0  3.  ,"T  "LL   F*P  'RP  !@N   2,@  #34   @Y   "/0   $
M  !#    1@   $D   !,    3@   %$   !3    50   %<   !9 0  7 8
M %\*  !B#@  8Q4  &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L
M6<\ +S   "HO   B,   &C,  !,W   ..P  "#\   %$    2    $P   !/
M    4@   %4   !8    6P   %T   !@    8@   &0   !F    :0   &T%
M  !P"P  =!   '08  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L
M+C,  "4U   =.   %#P   Y!   '1P   $P   !1    50   %D   !=
M80   &4   !H    :P   &T   !O    <@   '0   !W    >@   'X   ""
M!   A@L  (H1  ")'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H
M " ]   60@  #T@   A.    5    %H   !@    9    &D   !N    <@
M '8   !Z    ?0   (    ""    A0   (@   "+    C@   )(   "6
MFP,  * ,  "B$P  H"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(
M   13@  "54   !<    8P   &H   !Q    =@   'L   "     A@   (H
M  ".    D0   ),   "6    F0   )P   "@    HP   *<   "K    L
M +8$  "\#0  NA<  +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +
M7    60   !L    =    'P   "#    B0   (\   "4    F@   )\   "B
M    I    *<   "J    K@   +$   "T    N    +P   #!    QP   ,T
M  #4!0  V!   -4>  #3,0  T$@  ,U?  #+=@  R(X
M      $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T
M-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN
M;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:G
MJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@
MXN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____________________________
M_________________________P                     ! P0%!@@)"@L-
M#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&
M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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MZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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M@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MA)72L8*9T[&!GM2N@*+4K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
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MA:J(RH.JB<N!JHO+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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MF7:VPIM_N<"<A[V]FHG NY:*P[F2B\:WCHW)MHJ/S+2'DLZSA);0LH&:T;*
MG]*N?Z/2JG^ESZ9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^G
MS:9_I\VF?Z?-IG^GS?^S%@G_LR >_[ M.O^K.EGLI4=ZUIQ9FL:8;;+$FG2V
MPIQ]N;^=A;V]G(C!NYB)Q;B4BLBVD(O+M(R.SK.(D=&QA973L(.:U+""H-6J
M@:+3IH&ET*.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!
MI\VC@:?-HX&GS?^S%0C_M" >_[$M.O^L.5GKI49[UIQ8F\:9:[+$G'*VPIU[
MN;^?@[Z\GHC"NIJ(QK>6B<JUDHK-LXZ,T+&*C].OAY36KH6:V*N#G]>F@Z+4
MHH.DT)^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?
M@Z;-GX.FS?^T%0C_M!\>_[$L.O^L.5GKID5[U9U8F\>::;+$G7"VPI]YNK^@
M@KZ\GXC"N9R(Q[:8B,NTE(G/L9"+TZ^,CM:MB9/9K(>;VZ:&GMFBA:'5GH6D
MT9R%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.
MG(6FSO^T% C_M!\=_[$L.O^M.%GKID5[U9U7G,>;9[+$GFZVPJ!WNK^A@+Z[
MH8C#N)Z'R+6:A\VREXC1L).*U:V/C=FKC)/=J(J;WJ*(GMF>B*'5FX>DT9F'
MILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>F
MSO^T% C_M1X=_[(K.O^M.%KKID1[U9U7G,><9;+$GVRUPJ%UNKZB?K^[HX?$
MN*"'R;2=A\ZQF8C3KI:)V*N3C-RHD)+AHXZ:WYZ,GMJ:BZ'5EXJDT9:)ILZ6
MB:;.EHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSO^T
M% C_M1X=_[(J.O^M-UKKIT-\U9Y5G<>=8[+$H&JUPJ-SNKZD?+^[I(7$MZ*'
MRK.?A]"PG8?5K)J)VZF8C."EEY/FGI2:WYF1G=J6CZ#6E(VCTI.,I<^3C*7/
MDXRESY.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<^3C*7/DXRES_^U$PC_
MM1X=_[,J.O^N-EKKIT-\U9]3G<>>8++%HFBUPJ5PNKZF>K^[IH/%MZ6'R[.B
MA]&OH(?7JIZ)W*2;B^"=F8[CFIN9X)66G-N3DZ#7D9&CTY"/I<^0CZ7/D(^E
MSY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ES_^U$PC_MAT=
M_[,I.O^N-EKKJ$)\U:!1G<>?7K'%I&2UPJ=MN;ZI=[^[J8'$MJB(R[&EA]&K
MHH?7I9^(VYZ=B-V7FXO@DIN3WY*<G-R/F)_7CI6BTXV3I-"-DZ30C9.DT(V3
MI-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT/^U$PC_MAT=_[0I
M.O^O-5KJJ$%\U:).G,>A6K'%IF"TPJIIN;^M<[Z[KGW$M*J'RZVEAM&GHH;5
MH*"&V)F?AMN2G8G=C9V.W8R>F-N,GI_8BYJBU(J7I-&*EZ31BI>DT8J7I-&*
MEZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT?^V$@C_MQP=_[0H.?^P
M-%KJJ4!]U:1)G,BD5;#&JENSPZ]CM\"S;+VVKGS%L*F'S*FFAM"CI(74G**$
MUI6AA=B/GX?:BI^+VX>?DMJ(H9S7B)^AU(><I-&'G*31AYRDT8><I-&'G*31
MAYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRDT?^V$@C_MQL=_[4G.?^P,UKJ
MJCY]UJA$F\FH3Z_'L%.RQ;A9M;FS;;^QK7W&K*J&RZ6GA<^?IH31F*2$TY*C
MA-6,HH;7B*&*UX6ACM>#HI;6A*2?U(2BH]&$HJ/1A**CT82BH]&$HJ/1A**C
MT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT?^W$0?_N!H<_[8E.?^Q,5KJJSQ^
MUZP[F<JM1*W)N46NO;A9N+*R;\"LKG[&J*N%RJ&IA,V;IX//E::#T(^EA-**
MI(;3AJ.(U(.CC-2!HY'4@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"F
MH=& IJ'1@*:AT8"FH=& IJ'1@*:AT?^X$ ?_N1D<_[<D.?^S+UKIK3E^V;0O
MELRX,JG"O4"PL[9=NJRQ<<&GKG[%I*R%R)VK@\J7J8/,DJB$SHVGA,^)IX;0
MA::(T(*FB]& IH[1?J:4T'VGFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]
MIYK/?:>:SWVGFL]]IYK/?:>:S_^Y#P?_NA<<_[DB.?^U+5KLLS!ZW< ?D,G#
M(:BUNDBTJ[5BO*:R<\"CKW[#H*Z$QIFL@\B4JX3)CZJ$RHNJA<N(J8;,A:F(
MS8*HBLV J(W.?JB1S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-
M?*F6S7RIELU\J9;-?*F6S?R[#@?\O!4;_KL?./^W*5KPO21TW],.AKG!*JJJ
MN4^VI+5EO*"R=+^>L7_"FZ^$PY:NA,61K83&C:V%QXJLALB'K(?)A:N(R8*K
MBLJ JXS*?JN/RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2
MRGRKDLI\JY+*?*N2RO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:X
MG;5HNYNS=;Z9LG_ F+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!
MK8O&?ZV.QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVM
MD,=]K9#'?:V0Q]_ " 7UP@\9]L(6-N[(%5#-W QFM=H/B*+)-J":OE:PE[=J
MN96U=KR4M'Z^E+.$OY"RA<"-L8;!BK&&P8BQA\*&L(C"A+")PH.PBL.!L(O#
M@*^-PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^
MKX_#?J^/P]G"!P7DQPL8[\@0--':"T6ZZ0YHIMX8@IC1-Y61R%.AC\)EJ8Z^
M<JZ-O'NRC+J!M8FX@K>'N(2XA;>%N8.VAKJ"MH>Z@;6(NX"UB;M^M8J\?;2,
MO'RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]
M?+2-O=3$!P36RPD5T]0+)[WB#$FI]!1EF>8E>([<.8:(U$^0AL]@EX3,;9R#
MR76@?\=XHGW&>Z1ZQ7VF><2 IW?#@:AVPH.I=<*$JG3!AJMSP8>K<L")K'&_
MBZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+
MK<_&!P+0S0D2P-D)+*SW#TB;^AY<C^\Q:X;G0G: XE!^?MU?A7O9:8IWU6Z/
M=--SDG'1=Y1PT'J6;L]]EVW.?YELS8&9:\V#FFK,A9MIS(><:,N)G6?*C)UG
MRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G<K(
M" '"T@<3KN8)+9W_%4&1_RA0A_HY7('S2&9\[51N=^A>=7'D97IMX6M^:M]P
M@6C>=81FW'B%9=M[AV/:?HABVH&)8=F#BF#9A8I@V(>+7MB*C%[6C8U>UHV-
M7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C<3*!P.Q
MV@05G_\-*)+_'3>)_RY#@O\]3GS]2U=W^%9?;_-=96CP8FID[6EN8>MO<5_I
M<W-=Z'=U7.=[=EOF?G=:YH!X6>6#>5CEA7I8Y(AZ5^2+>U;CCGQ6XXY\5N..
M?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?/^J' 7_JB<7
M_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_
MAY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V
M+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]
MOH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B
M1$KZG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26
MO[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZ
MG5)EZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"
MF<"]@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)E
MZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]
M@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=?
M?MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!
MO7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"N'FOPO^J&P7_JB<7_Z<U+_^C1$KZG5%EZ9=>?MN4
M;93/DG>FQ9*!M,23B+;#DHVXP8^/NL"+D;R_B).^OH66O[V"F,&\@)O"O'Z>
MPKQ]H<.[>Z3$NWJIQ+IYK<2U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#
MM7FNP[5YKL.U>:[#M7FNP_^K&P7_JR87_Z@T+_^D0TKYGE!EZ9A=?]J5:97-
ME'2HQ91^M,25AK;"E8RYP9&.N[^-D+V^B9*_O8:4P;R#E\.[@9K$NGZ=Q;I]
MH<:Z>Z7&N7JJQK5ZK,:Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JM
MQ+%ZK<2Q>JW$L7JMQ/^K&@7_JR47_ZDT+_^D0DKYGT]FZ)E<@-J69I;,E7&I
MQ95\M,26@[?"EXNZP).,O+Z/CK^]BY#!O(>3P[J$EL6Y@9G&N7^=Q[A]H<BX
M?*;)M7JJR;![J\>L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[
MK<6L>ZW%K'NMQ?^L&07_K"06_ZDS+_^E04KYGT]FZ)E;@=F88Y;,EF^JQ99Y
MM,.7@;?!F(FZOY6+O;Z1C<"\C8_"NHB2Q;F%E<>X@IC)MW^=RK9]HLNV?*C+
ML'NIRJQ\JLBH?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H
M?:S%J'VLQ?^L&07_K"06_ZHR+_^E04OYH$YGYYI9@=F989?+EVVKQ9=WM,.9
M?[?!FH>[OY>*OKV3C,&[CH[$N8J0Q[B&D\FV@IC+M7^=S;1^H\ZQ?*;.K'VH
MRZA]JLFE?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&
MI7ZLQO^L&07_K2,6_ZHR+_^F0$OXH$UGYYQ7@=F:7I?+F&JLQ9ETM,.:?;?!
MFX6[OIF)O[R5BL*ZD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_
MJ<FA@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"L
MQO^M& 7_K2,6_ZLQ+_^F/TOXH$UGYYU5@=F<7)?*F6BLQ9IRM,.<>KC G(.[
MOIR)O[N7B<.YDXO'MXZ-R[2)D,ZRA);1L8&=TZR HM.G@*70I("GS:"!J<J>
M@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQO^M
M& 7_K2(6_ZLQ+_^G/TOXH4QGYYY3@=F=69?*FV6LQ9QOM,.=>+C GH&\O9Z(
MP+N:B,2XE8G)M9"+S;*+C]&PAI75KH2>UZ>"H=2C@J31GX*GS9R#J<J:@ZO'
MFH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQ_^M%P7_
MKB(6_ZLP+_^G/DOXH4MHYY]1@=F?5I?*G&*LQ9ULM,.?=;C H'Z\O:"'P;J=
MB,:WF(C+LY.)S[".C=2MB939J(:=VJ*%H=6>A:31FX6FSIF%J<J7A:O'EX6K
MQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQ_^N%P3_KB(6
M_ZPP+_^G/DOXHDMHZ*%/@=F@4Y?*GE^LQI]IM,.A<KC HGR\O:*$P;F@A\>U
MG(?-LI>(TJZ3B]BJCI/?HHN<W)R)H-:9B*/2EXBFSI6(J<J4B*O'E(BKQY2(
MJ\>4B*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BKQ_^N%P3_KB$6_ZPO
M+_^H/4OXHDIHZ*)-@-FB4)?+H%RLQJ%EL\.D;K? I7B\O*6"PKBDA\BTH(?.
ML)V(U:N9BMVEEY/FFY&;W9:/H->4C:/3DHRFSY&+J,N0BJO(D(JKR)"*J\B0
MBJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR/^N%@3_KR$6_ZTO+_^H
M/$OWHDEHZ*1*@-FD39;+HEBKQJ1AL\2G:K? J72\O*E^PKBHA\BSIH?/K**'
MUZ2=B=V:FHWAE9J;WI&5G]B/DZ+3CI"ET(Z/J,R-CJK)C8ZJR8V.JLF-CJK)
MC8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR?^O%@3_KR$6_ZTN+_^I/$OW
MHTEIZ*9(?]JG2)7,I5.JQZA<LL2L9+;!KFZ[O:]XP+:LA,FNIX?0IJ.&U9V@
MAMF3G8G=C9V4W8V=G]B+F:'4BY:DT(J3I\V*D:G)BI&IR8J1J<F*D:G)BI&I
MR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR?^O%03_L" 6_ZXN+_^I.TOWI$=I
MZ:A$?MNK0Y3-J4RIR*U4L,:S7+/"MV:YM[!WPK"KA,FIIX;/H:2$TY>BA-:.
MH(?9B)^/VH>AFMB'H*'4AYNDT8>8ILZ'E:G*AY6IRH>5J<J'E:G*AY6IRH>5
MJ<J'E:G*AY6IRH>5J<J'E:G*AY6IRO^P%03_L" 5_ZXM+_^J.DOXID1HZJM
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MV(]\F-".A*3*CHRMQHV0M,2*D[?#AI6XPH28N<&!F[K!?YV[P'V@O,![I+S
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ME(R_O(Z.P[F(DL>W@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV
ML;^=@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"QO_^F& +_IR8/_Z0U
M)?^@0S[_G5!5]Y]1:.N@4WO@H%>-U)Y?GLJ;:ZS%FW6TPYM^N,";A[R]EXK
MNI&,Q;>*D,JTA)?/LH"CTJA_I<^C@*C+H("KQYV!K<6;@:_"F8*QOYF"L;^9
M@K&_F8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&_F8*QO_^F& +_IR4/_Z4T)?^A
M0S[_GDY5^*%.:.RB4'K@HU*,U:%;G<N>9JS&G7&TPYYZN,">A+R\FXC"N96*
MQ[6-C<ZPAI;4J8*@UJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+#
MEH2PP):$L,"6A+# EH2PP):$L,"6A+# EH2PP/^F& +_IR4/_Z4T)?^A0C[_
MGTQ5^*),9^RE37GAIDZ+U:16G,RA8:K&H6RSPZ)VM\"B@+V\H(?#MYJ(RK*3
MBM*LBY3;H(>?V)J&I-&7AJ?,E8:JR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>P
MP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP/^G& +_J"0/_Z8S)?^B0C[_H$I4
M^:1*9NVG2GCBJ4N*UJA1FLVF6ZG'I66RQ*=PML"G>KR\IH/#MJ*'RZ^=B-:E
MEY7FEX^>VI.-H]*1BZ?-D(NJR9"*K,:/BJ[#CXFPP8^)L,&/B;#!CXFPP8^)
ML,&/B;#!CXFPP8^)L,&/B;#!CXFPP?^G& +_J"0/_Z8S)?^B03[_HDA4^:9'
M9NZJ1W?CK4>(V:U+F,^L5*;(K%ZOQJ]HL\*Q<[F^LGW LJJ'RZ6BAM64G(O>
MCYJ=VHV5HM.,DJ;.BY"IRHN.J\>+C:W$C(ROP8R,K\&,C*_!C(ROP8R,K\&,
MC*_!C(ROP8R,K\&,C*_!C(ROP?^H& +_J20/_Z<R)?^C03[_I$93^JE$9.^M
M0W7DL4*%V[1$E-*U2J'+MU.KRKY?K;VW;KBRL'S"J:J&RYREA-*-H(?8AJ"7
MV8>>HM.'F*7/AY6HRX>3JLB(D:W%B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"
MB)"OPHB0K\*(D*_"B)"OPO^H& +_J2,/_Z<R)?^C0#[_ID-2^ZM!8_"Q/W/G
MMSV"WKX[C];$/YK,Q4JFO+Q=LK&U;[NJL'W#HZN$R9:G@\Z*I(;3@:.0U8&E
MG]*"H:7/@IRHS(.9JLF$EJS&A92NPX64KL.%E*[#A92NPX64KL.%E*[#A92N
MPX64KL.%E*[#A92NP_^I& +_JB,/_Z@Q)?^D/S[_J$!1_*\\8?.V.7#JOS=]
MX\HUA]31-Y6^PDNIL+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]
MJ*3.?J2HRW^?JLF FZO&@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8
MK<2!F*W$@9BMQ/^J%P+_JB(/_Z@P)?^E/C[_JSM/_[0W7?:],VKKRC%UW-HI
M@L3..)FRP4^KI[ACMZ&T<[R>L7_!F*^$Q(^LA,B'JH?*@*F,S'RID\QZJIS+
M>:NFRGJGJLA\HJO'?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]
MGJW$?9ZMQ/^J%@+_JR$._ZDN)?^G/#[_L#9,_+HP6>_(+&+>V2=MR]PFAK;,
M/)NHP52KG[EFMINU=+R9LG^_E;"$PHVOA<2&K8?&@:R+R'VLD,A[K)C(>:V?
MQW>MI\=WJJS&>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$
M>:6MQ/^K%0+_K" ._ZLM)/^K-CO_MB](\\0H4>#6)E;,Y")QN]HHB*K,09N?
MPU>IF;QILI:W=KF4M("]D;*%P(NQAL&&L(C#@:^+Q'ZNC\5[KI3%>J^:Q'BO
MH,1UKZ?$=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VN
MP_^L% +_K1\._ZPK)/^P+S?ZOR5!Y-$@1<[D'5N]Z2)TK=HLB9_.19F7QEJD
MD\!JK9&[=K.0N'^WC;:$NXFTAKV%LHB_@K&+P7^QCL%\L9+">K&6P7FQF\%X
MLJ' =+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP?^N
M$@'_KQT-_ZXH)/^X)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5J
MI8O!=JJ)OGVOA;R LH*Z@[1^N8:V?+B)MWFWC+AWMX^Y=K:3NG6VE[ITMIVZ
M<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN?^P$ '_
ML1H-_[$E(_/$%R?4WQ KP>\72+#W(&"AZBMSE=\Y@HW73(V(T5V5ALQJFX3)
M=*" QGFD?<1]IGK"@*EWP8.J=<"&K'._BJUQOXVN;[Z0KVZ^E*]LOIFO:[Z@
MKVN^H*]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@K_^S#@'_M!8,
M_+P7&M;6"Q;#[1 PLOP92J+Y)5Z6[3-NC.5!>H7>3X.!V5Z*?]5JCWK2<)-V
MSW67<\YYF7',?9MORX"=;<J$GFO)AY]IR8J@:,B.H6?'DJ)EQY:B9,><HV3'
MG*-DQYRC9,><HV3'G*-DQYRC9,><HV3'G*-DQYRC9,><H_2V"@'_N!(+U<P*
M"\3;"AFR_!$SH_\=2);\+%B,\SMEA.Q);W[G579ZXV!\==]G@7'=;81MVW*'
M:MEVB6C8>HMFUWV-9-:!CF/5A(]AU(B08-.+D5_3CY)>TI227-*9DUS2F9-<
MTIF37-*9DUS2F9-<TIF37-*9DUS2F9-<TIF37-*9D]R[! #8PP<$Q-$(![/H
M"ARC_Q0QEO\D0XS_-%"$^T):??9/8GCQ6FAQ[E]M:^MD<6?I:71DYVYV8N9S
M>&#E=WE?Y'I[7>-^?%SB@7U;XH5^6N&(?UG@BX!7X)" 5M^5@5;?E8%6WY6!
M5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@=2]!0#$R < M-D%"J/^#1R6
M_QHLB_\K.H/_.D1\_TA-=?]24V[]5UAG^EU<8_=B7V#V9V)=]&MD6_-O95GR
M<V=7\7=H5O%Z:57P?6I4[X!K4^^$:U+NAVQ0[HMM3^V0;D_MD&Y/[9!N3^V0
M;D_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;L; !0"TT 0!H^,""I;_$!B+_R D
M@O\P+WK_/S=R_T@^:O].0V3_5$A>_UE,6_]?3UC_9%)5_VE44_]M55+^<5=0
M_7183_QX64[[>UI-^W];3/J#7$OYAEU)^8M>2/B07TCXD%](^)!?2/B07TCX
MD%](^)!?2/B07TCXD%](^)!?2/B07[7' @"DV@ !EO\&!XK_%!&!_R0:>?\S
M(G#_.RIH_T(Q8?]*-ES_43M7_U<_4_]=0E#_8D1._V=&3/]L2$K_<$E)_W1*
M2/]W2T;_>TQ%_W]-1/^#3D/_ATY"_XM/0?^14$'_D5!!_Y%00?^14$'_D5!!
M_Y%00?^14$'_D5!!_Y%00?^14/^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,
M:V/RBG)QZHA\?>.&A(?>@HJ/VG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72F
MJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"J
MQ'' JL1QP*K$<<"JQ'' JO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/R
MBG)QZHA\?>.&A(?>@HJ/VG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,UR
MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MO?^>$ '_HR4)_Z(T'/^E.2W_KC4X_[@S0O3#,TKGT#A.V=XY6LOF/6Z^X$*
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MG*/.=:.GS'*KJLMPM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'?
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MO+![E;RP>Y6\L/^3#@'_EA\%_YDS%/^E,!S_KS C_;HO*?#&,BWCU#LLUN!
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M>/\>#&[_)A)E_R\97?\W'E?_/R)2_T8F3?],*$K_4BM&_U@M1/]=+D+_82]
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MR9V4?,F=E'S)G91\R9V4?,F=E'S)G?^!$0'_@!L#_X(N#O^1-A;_G#P@_Z%
M*O^E1#3_J$H_^JE02?*J5E+JJEU<XJEF9M>B;W++F7B!P9"!C;B(BI>O@96@
MJ'RBIJ-ZLJF>>L&IF7S!J)9]PZ:4?L2DDG[%HY%^QZ&0?LB?D'[)GI!^R9Z0
M?LF>D'[)GI!^R9Z0?LF>D'[)GO^"$0'_@1L#_X0N#?^4-1;_GCH>_Z0^*/^H
M0C+_K$<[]J]-1.VQ5$WELUM5W+!E8<ZH;''#GW2 N)9\C:Z/AIBEB)&AG8.=
MIY> K:N3@+^KD8'!J8^!PJ>.@<.EC8'%HXV!QJ*,@<B?C('(GXR!R)^,@<B?
MC('(GXR!R)^,@<B?C('(G_^"$0'_@1H#_X8M#?^6-!7_H#D=_Z8\)O^K0"_[
ML$4X\K1+/^FY4T;AO5Q-T[9B8,:M:7"[I7%_L)UYC*65@I>;CXVADXJ9IXR'
MJ:N(A[^LB(? JHB&PJB(A<.FB(7%I(B$QJ*(A,B@B(3(GXB$R)^(A,B?B(3(
MGXB$R)^(A,B?B(3(G_^#$ '_@AH#_X@K#/^9,A3_HC<;_ZDY)/^O/2SWM4(S
M[;M).>7"4C[:PEA,S+I@7[^R9V^SJVY^J*-VBYV<?I>2EXF@B9*6IX*/I:M^
MC[JL@(W JH&+PJB"BL.F@XG%I(.(QJ*$A\B@A(?(GX2'R)^$A\B?A(?(GX2'
MR)^$A\B?A(?(G_^$$ '_@QH#_XLJ#/^<,1+_I30:_ZPV(?ZS.BCSNT MZ<-(
M,>'+43?2QU9+Q<!>7;BX96ZLL6Q]H*ISBI2D>Y6*GX:>@)N2I7F8HJITF+>K
M=Y7!J7J1PJ=\C\.E?8W%HWZ,QJ%_BLB??XK(GW^*R)]_BLB??XK(GW^*R)]_
MBLB??XK(G_^%$ '_A!H#_XXH"_^?,1'_IS(7_[ S'?FY-B+NPCTFYLU')MO3
M3#7+S%1)OL5<6[&^8VRDN&IZF+)QAXRL>9.!J(*<=Z2/HW"BGZ=LHK2H;I_"
MIW*9PZ9UE<2D=Y+&HGB0QZ%ZCLB?>H[)GGJ.R9YZCLF>>H[)GGJ.R9YZCLF>
M>H[)GO^&$ '_A1D#_Y$F"O^A+P__JRX5_[4O&?2_,ASIRSH<W]E$'=':2C/$
MTE)'M\M:6:G&86F<P&=XD+INA(2V=H]YLH"8;Z^-GVBMG:-DK;*D9:K%I&JB
MQ:-MG<:B<)G'H7*6R)]TD\F==9/*G763RIUUD\J==9/*G763RIUUD\J==9/*
MG?^'#P'_AQD#_Y4D"?^D*PW_KRD1^KLI$^S(+!/>V#<0T^%!'LG?23"\VE%$
MK]-85J'-7V:4R&5TB,1L@'S =(IQO7^3:;N,F6*YG)U>NK&>7;C)GF*NR)]F
MILB?::')GFN=RIUNFLN;;IG+FVZ9RYMNF<N;;IG+FVZ9RYMNF<N;;IG+F_^(
M#P'_B1D#_YHC!_^H)PK_M2(,\<0@#.#5) G1X3 4Q^8])+WC1C2RX$Y$IMQ6
M4IG776&,TF-O@,]K>G3,<X1KRGZ+8LB,D5S(G)59R+&65\C.EEN[S9A>LLR9
M8:O,F62FS9EGHLV89Z#-EV>@S9=GH,V79Z#-EV>@S9=GH,V79Z#-E_^*#@'_
MBQ@#_Y\A!?^N( ;XO1@&X]$3!-#A'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@
M5V* W5]L=MMH=6S:<GUCV'Z#7-B,B%?8G8M4U["-5-C-C%7+TX]7P-*16KC1
MDURRT9-?K-&38*K1DV"JT9-@JM&38*K1DV"JT9-@JM&38*K1D_^,#@'_CQ8"
M_Z4> _^U%0/:R@L"T.$. L3K'@VX[RP=K>XW+J+L0#V7ZTA*C.E/5H'H5F!V
MYUYI;.=E<&3F<'=>XWQ\6>")@%;>EX-3W::$4=RXA5'=U(13T-J'5,;8B5:_
MUXI8N-:+6;;6BUFVUHM9MM:+6;;6BUFVUHM9MM:+6;;6B_^.#0#_EQ(!_ZT5
M =F_"0#,S@D P^L.!+;U'A&K]2PAH?0W,);S0#Z+\TA*@?-05'?S5UUM\UUD
M9?!F:E_M<&Y:ZGIR5N>%=E/ED7E1Y)Y[3^.L?$WCO7Q-X]E\4-C@?%'.X']2
MQMZ!4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#
M!P# T@D M?00!JG['Q2?_"PCE/PW,8K\03V!_4E'>/U14&[]5U=E^EY<8/9F
M85OT;V56\7AH4^^":U#NC&U.[)=O3.NC<4KJL'))ZL%R2.K8<DOCY').V.9S
M3M7G=$[5YW1.U>=T3M7G=$[5YW1.U>=T3M7G=/^6"@#>K ( R[H% +W'!@"R
MV @!I_\2")S_(1:2_RXCB?\Y+X#_0CEW_TI";?]0267_5DY?_UY36OYE5E7\
M;5I2^G5<3_A^7TSWAV%*]9%B2/2<9$;SIF5%\K-F1/+!9T/RU&=%[N=G1NOH
M9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9^ZB  #-M ( O+X$ *_-! "DW@<!
MFO\5"9#_)!6'_S @?O\[*G3_0C)K_T@Y8_]./UW_54-8_UU'4_]D2E#_:TU-
M_W)/2O]Y44?_@E-%_XM40_Z45D']GE= _:A8/_RS63[\OUH^^]%:/?O;6CW[
MVUH]^]M:/?O;6CW[VUH]^]M:/?O;6M*M  "]N ( KL4" *'5 @"6]PL"C?\8
M"(3_)A%\_S$:<?\X(FC_/BE@_T4O6O],,U3_4S=0_UHZ3/]@/$G_9CY&_VU
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M<N]FH7;L8ZMYZV"V?.E>Q'[G7MA_V&'??LICWX#!9=Z!N6?>@;1HWH&P:=^
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MVX6@;]N%H&_;A:!OVX6@;]N%H&_;A?]R% '_<!X#_W(H!_^"+@W_CC86_Y5
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M>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z5;+C>O^##@'_E@L W:L$ ,VX!@#"Q 8
MNM0) +'O% .G[B4-GNXS&I3M/2>*[$8S@.M./G;K54=LZEM.9.IC55WJ;5I8
MZG=>4^J#8D[JD65*ZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_
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M=V:2YG=FDN9W9I+F=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD
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M0Z(W_T*J./]!L3K_0+D[_T#!//\_RSW_/MP^_S[H/O\]\S[_/?L__S[_/O]
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M:W2 \&ET@/!I=(#P:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T
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M9%R7\V1<E_-D7)?S9/]P#0#_A 0 W98  ,ZC P#$K@0 N[<$ +3"!0"NS0P
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M'23_S!XC_^T>(O_]'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@
MC\(  (#.  !SW   9^D  %__!@!8_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X
M_SP&-/]"!S'_20@N_U )*_]7"BC_7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_
MLA$9_\@2&/_E$Q?_^A07__H4%__Z%!?_^A07__H4%__Z%)^S  "0OP  @,P
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M_S'Q/?\Q\3W_,?$]_S'Q/?\Q\3W_,?]&(P+_0"T#_T$R _]&,P3_2#@&_TA
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M'/]<82/_66TI_U5Y+O]2A#/_4(\V_4Z9.?M,HCOZ2ZH]^$JT/_=*OD#U2<Q
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M7'YR^EI^<OM9?G+[67YR^UE^<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X
M\940 ..=$0#6HQL RZ$O!L*>/A*YF4H>L)14*ZF073:BBV8_FX=N1Y6$=DZ0
M@']4BWZ(689[DEV!>9YA?7BK9'IXO&5Y>-EE>'GT8GEX]F!Y=_A>>7;Y7'EU
M^EIY=?M:>77[6GEU^UIY=?M:>77[6O]:%0'_:0X _W@, /^$# #OD L W9H*
M -FB"P#0IA@ QJ4L!;VB/!"TGD@=JYE2*:.56S2<D6,^E8UK1H^)<TV)AGQ3
MA(2%6'^!D%UZ?YMA=GZH9'-]N65Q?M-E<7[R8W)]]F!S>_=>='KY7'1Y^EMU
M>?M:=7G[6G5Y^UIU>?M:=7G[6O]=$P'_; T _WL+ /:("0#<DP8 U9T) -&E
M"@#*JA4 P:DJ!+>F.@^NHD8;IIY0*)Z:63.6EF$\CY-I1(F/<4R#C7E2?8J#
M5WB(C5QSAIE@;X2F8VR$MV1JA,]D:H3P8FR"]F!M@/=>;W_Y7&]]^EMP?/M:
M<'S[6G!\^UIP?/M:<'S[6O]?$0'_;PH _WX( .., P#6EP4 SZ ' ,JH" #$
MKA, NZTG [*K-PVIIT09H*1.)IB@5S&1G%\ZBIEG0X.6;TI]DW=0=Y& 5G*/
MBEIMC99>:(NC866+M&-CB\QC8XON866)]U]GAOA>:83Y7&J"^EIK@?M::X'[
M6FN!^UIK@?M::X'[6O]B$ #_<@< ^((# -N/ @#/F@4 R:,& ,.L!@"]LA
MM;(D JRP-0NCK4(7FZI,(Y*F52Z*HUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AF
ME91<8I2A7U^3LF!=D\E@79/M7UZ0^%YAC/E<8XKZ6V2'^UIEAOM998;[666&
M^UEEAOM998;[6?]F#0#_=P, XX<  -.3 0#*G@0 PJ<$ +NO! "UM@T KK<A
M J6V,@F=LS\5E+!*((RM4RN$JELT?:AC/':E:D-PHW)*:J%[3V6@AE1@GI%8
M6YV?6UB=L%U6G<==5IWK7%>:^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?
MC?Q77XW\5_]J"@#_?   W(P  ,V8  ##HP, NJH" +.S 0"LO H IKT= 9Z\
M+P:6NCP1C;A''(6U4"=]LUDP=K%@.&^O:#]IK7!%8ZMY2EZJA$]:J9!25:B>
M55*GKU=1J,974*?J5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y5
M6)7^5?]O! #F@@  TI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-
MPCD-A<!$&'V^3B%UO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVS
MKE!+M,502[/J4$JQ_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_
M4?]V  #=B0  RI<  +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)
M?,E $G7(2AMMQU,C9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'
MP<5&1\'J1D2^_TE%N?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_
M  #1D   PIX  +6G  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\
M#&S31Q1ETE ;7]%9(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[
M0]#J.D#-_3X^R_] 0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'
MF   N*,  *NK  "@M   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@
M0@Y<X$T45^!6&5/@7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E
M+SS?^C$YWO\T.=G_-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H
MK:@  *&Q  "5NP  B<4  '[/ @!TV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2
M[$@/3>Q1$TKM6A9&[6,90^UM'$#M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O
M\R8T[/\F,NO_*#+G_RLSY/\L,^3_+#/D_RPSY/\L,^3_+,&<  "PI@  HZX
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M"1/_^ D3__\*$___"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X
M4>8  $?U  !!_P  //\) #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<
M_SL"&?]" Q;_20,3_U$#$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_
MT 4'_^,%!__C!0?_XP4'_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT
M #K_   U_P  +_\" "K_"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!
M#O\S 0S_.0(*_T$"!_]) @/_4P( _UX" /]L @#_? , _XT# /^= P#_K ,
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M2F\<_T=[(/]%AB/_0Y$E_T*:)_]!HBG_0:HJ_4"R*_Q O"S[/\@M^#_;+?1
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M2XQD_TJ+9/](BV3_2(MD_TB+9/](BV3_2/]0%@'_7!  _V@- /]R#@#_>A
M]H$2 .F&%P#>BB !THHP!,F&0 [!@DT9NGU7([1Y82RN=6HTJ7)R.J1O>T"@
M;(1$G6J-2)EHETR59Z%/DF:M49!EO5*.9=13C&;P48MG_U"(9_].AVC_3(9H
M_TN%9_])A6?_285G_TF%9_])A6?_2?]2% '_7PX _VL+ /]U# #Y?@T \(4.
M ..+$ #6CQH S(XN!,.+/0V[ATH8M(-5(JU^7BNG>V<SHG=O.IUT>$"9<H!%
ME6^)29%MDTV-;)Y0BFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR
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M3'9Q_TQV<?],=G'_3/]9$ #_9@< _W,$ .%_ 0#6B 0 SY & ,J6" #$FA(
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M0DBK]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@
MPY,  +>=  "LI   HJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%I
MOT\88[Y7'EZ]7R-9O&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X
M]3M"MO\]0K/_/D2N_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH
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M'"[D_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0
M=\8  &O/  !?U@  5-X$ %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#!#OS2P4X
M\U0'-O1="#/T: DP]70++O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01)O/_$2;Q
M_Q$E\?\3)?'_$R7Q_Q,E\?\3)?'_$ZVA  "@J0  DK,  (2\  !VQ@  :<\
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M P#_[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P
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M0X<;\4*1'>]"F1_M0:$@[$&I(>I LB+H0+PBYT#*(^1!WR/@0>\DW$#\)]A
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M-Z-2_S:@4_\UGU/_-9]3_S6?4_\UGU/_-?]&%P'_4!$ _U@- /]@$ #_9A,
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M/()C_SR"8_\\@F/_//]0#P#_6P< _V8# .QO @#<=@, U'P' -& "0#*@A0
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M15B([418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0
MSWX  ,.(  "YD0  L)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ% #8"?2A5Y
MG5,<=)M:(V^98BAJF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!4I+)0E*1
MZT%2D/] 4H__/U6+_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #==@  R8,
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M,3ZM_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP
MDJH  (>Q  !\MP  <+X# &C"#@!FPQT 8\,M 5[#.01:PT0(5L).#%+"5Q!/
MP5\42\%I%TC!<QI%P'X=0L",(#_ FR(]P*TC/,'$(SS Z2,ZOOXF.+S_*#>[
M_RDXN/\J.+;_*SBV_RLXMO\K.+;_*\F%  "YDP  K)P  *"B  "4J@  B+$
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M"Q_J_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@
M0=T  #CD   U]@P ,_<4 ##W'@ N^"< *_DP "CY. $F^D !(_M) 2'[4@$>
M_%T"'/UI AK]>0,8_HL#%_^> Q7_LP04_],$%/[T!!/\_P,3^O\#$_G_ Q/Y
M_P,3^?\#$_G_ YVE  "/K@  @+@  '+"  !DRP  5M,  $G:   ^WP  -.0
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M'LHZ_Q_$._\?P#S_'L \_Q[ //\>P#S_'O\Y&P'_0!4 _T41 /]*$P#_3AD
M_U B ?]0+ ']3C<"]DM#!/!)4 ?K2%T*YT9I#>-%=!#@1'X3W4.'%=M"D!?8
M09@8U4"@&=- J1O10+(<ST"]'<U S!W*0>0>QD#T(,) _R*_0/\CO4#_([M
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M*Y12_RN44O\KE%+_*_]&$ #_3@D _U8% /Y>!@#O8@< YV4* .1F#@#69QD
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M/&=PYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@
MV&X  ,EV  "_?0  MX(  +"%  "HAP8 HHD7 )R**0&6B3<&D(=##(N%31.%
M@E49@(!='WQ_921X?6TI='MU+7!Z?C%M>8@T:7>4-V9VH3IC=K [87;$/&%V
MY3MA=OLY8G;_-V-U_S5C<_\T9'+_,V1R_S-D<O\S9'+_,_]8  #F9@  TG$
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M,U")_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD
MHI0  )B8  ",G   A)\* ("@&0!\H2D!=Z V!7*?00IMGDL/:)U3%&2<6QE@
MFV,=7)IK(5B9="55F'XI49>*+$Z6F"Y+EJ@P2I:\,4F6W#!)E/8P29/_,$F2
M_S!*D/\O2XW_+TN-_R]+C?\O2XW_+^)K  #*>0  O(4  +&/  "FE   FYD
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M(#.R_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@
M7[P  %3! P!,Q0T 2\49 $G&* !(QC4 1<=  4/'2@- QU,$/L==!CO'9P@Y
MQW,*-\> ##3'D TRQZ$.,<BU#S#(TP\PQO00+L3_$RW"_Q4LP?\6*\#_%RO
M_Q<KP/\7*\#_%[B-  "JEP  GIX  )&E  "$K   >+(  &NY  !@OP  5,,
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M 9FC  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@
M'/L& !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $
M_VP  O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK
M  !]M0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\
M !#_"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<
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M!^\=_PCO'?\)[QS_">X<_PGN'/\)[AS_"?\J(@'_+AT _S ; /\P' #_,"(
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M&+$[_QBQ._\8L3O_&/\Y$@#_/PT _T,) /](# #_2Q  _TP5 /5,'P#K2BH
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M+W5>XB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50
MWE\  ,UG  ##;   NV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/
M;5@4BVM@&(=I9QR$:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]B
MWS!N8_<N;V/_+&]C_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,
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M+%YP_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P
MJX   **"  "8@0  D8,/ (V%'P"(A2X"@X0[!7Z#10IZ@4X/=8!6%'%_7AAN
M?68<:GQM(&=[=B-C>H G8'F+*EUXF"Q:=Z8N6'>X+U=WT2]7=_$N6';_+%AV
M_RI9=?\I6G3_*%IT_R=:=/\G6G3_)^U9  #79@  Q7$  +EZ  "O@   IH0
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M)$:*_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@
M<)T  &N?#@!HGQP 9J J 6*@-P)?GT$%6Y]*"%B>4@M4GEH.49UB$DZ<:Q5+
MG'482)N!&D6;CQU"FI\?0)JP(#^:R" _F>L?/YC_(#Z6_R$^E?\A/Y3_(3^4
M_R$_E/\A/Y3_(<UP  "\?0  L(@  *2/  "9E   CI@  (.=  !WH   ::0
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MO 4 0+T1 #^]'@ ^OBL /+XV #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_
MA@8MP)<'*\"J""K!P@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_
M#K*,  "EE   F9H  (VA  !_IP  <JT  &:S  !:N   3[L  $2_   ZQ (
M,,D( "[*$0 MRAT +,LI "O+-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$C
MSY$"(<^E B#0O0(@S^0"'\WZ Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4
M  "<F@  D*$  (*H  !TKP  9[8  %N\  !.P   0\,  #G'   OS   )] $
M !_6"@ ;VA  &]L: !K;)@ :W#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4
M%.&: !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2
MH0  A*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?
M!0 4Z0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)
M  ?RH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0
M>+(  &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -
M^0H "_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\
MC   _*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL
M %S$  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,
M ?\)  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0
M_XT  /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/
M   _U@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\
M  #_!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,
M /^,  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_
M$#  _PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\
MH@#_ *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP
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M!=L<_P7;'/\%VQS_!?\J&0#_+1, _RT1 /\M$0#_+AD _RTB /\L+@#_*3H
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M'HE+XAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P
MY5   -56  #*60  PEH  +U8 P"X5PX L5D> *Q:+P&G6CT"HEE)!9Y84PF;
M5UL,EU9D$)55:Q*25',5CU-[%XU2A!J+48T<B%&7'H90HQ^$4+ @@E#!(8!0
MW2%^4?0@?5'_'WU1_QU]4?\<?5'_&WU1_QI]4?\:?5'_&O]"  #P2@  WU0
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M(FI>_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@
MKVP  *=L  "?:@$ F6L1 )1M(@"0;C$!BVT]!(=L1P>#:U +?VI8#WQH8!-X
M9V<6=F=O&7-F>!QP98$>;62,(6ICF"-H8J8E9F*V)F1BS"9D8NPE9&+_(V1B
M_R%E8O\?96+_'F5B_QUE8O\=96+_'?),  #?6   RF(  +UI  "S;@  JW
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M'E5O_QU5;_\=56__'>57  #-9   OFT  +)U  "H>P  GWX  )-]  "'?0
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M%\5N  "V>P  JH4  )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>  !2H X
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M R2YM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0
ME9<  (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  B
MPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(
MK@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX
M 'VE  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H
M$=(1 !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *
MV+X "=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M
M  !DM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+
M  ;?$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH
M .?(  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7
MO@  2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I
M#0  Z1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P
M  #VT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R
M.\P  "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0
M]0L  /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_
ML@  _\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@
M "'=   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P
M /\&  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0
M_Z\  /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\
M00#_ $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J
M /\ L #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_
M $L _P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\
MK0#_ +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_
M /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8
M_P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\
M +  ^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /
M_P#P /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI.
M /\(6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT
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M _\H$ #_*0L _R@& /\K"P#_*Q  _RD7 /TF(@#T(RX ["$[ .8@20#B(%4
MWB!@ -HA:@#6(70 TR%\ = AA '/(HP!S2*3 <LBFP')(J,!R".L L8CM@+$
M(\0"PB3; KXE[@.[)?X$N"7_!;8E_P6U)?\&M27_!K4E_P6U)?\%M27_!?\L
M#0#_+04 _RX! /\Q!0#_,0L _2\0 /$K& #G*24 WR@S -@H0@#1*D\ S2M:
M ,DK90''*VX!Q"QV L(L?@+ +(8#OBR. [TLE@.[+)X$N2RG!+@LL06V++\%
MM2W1!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_
M,0  _S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU
M7P*Z-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*
M"J4UY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0
M]CH  .4^  #<0   U#T$ -(W"0#+.!4 PSHF +T]-@"X/D0!M#Y0 ;$]6@.N
M/6,$K#UK!:D\<P:G/'L(ICR#":0[BPJB.Y0+H#N=#)X[J V=.[0.FSO%#ID[
MX Z6._0/E#S_#Y(\_P^2//\.D3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$
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M%W=,_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6
MM%D  *U6  "G4P< H505 )Q6)0"85S0!E%=  I!72@2-5E,&BE5;"8=48PN$
M5&H.@E-R$(!2>A)]4H,4>U&.%GA0F1AV4*89=%"U&G-0R1IQ4.@:<%'\&'!1
M_Q=P4?\5<%'_%'%0_Q-Q4/\3<5#_$_5   #D2P  SU0  ,%:  "W70  KUX
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M%F!=_Q5@7?\58%W_%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90
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M%-1:  # 9@  LV\  *AV  "=>0  CW@  (1X  !W>0  ;WP  &I]#0!G?AD
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M#3>.LPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0
MI8(  )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$
MF2L 0YDV $&:0 ! FD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9
ML @NF<H(+ICM""Z6_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@
M ).-  "&C@  >(\  &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR(
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M  ^]^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP
M7JP  %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (
MRAT !\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,
M[0  S/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8
M $6Y   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14
M -8>  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0
MW_<  -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"
M   LQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03
M  #E&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,
M ._Y  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?
MT   %=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q
M$   \Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A
M  #_]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0
M#.(   /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P
M_PT  /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_
MT0  _]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9
M /\ 90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +(
M_P"Z /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^
M /\ _@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\
M80#_ &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V
M /P P #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\
M]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_
M &< _P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /(
MNP#Q ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_
M /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &(
M_ !L /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F
M ,, Y #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;
M$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F
M .X"< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<
MU@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_
M'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,
M:@#>#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0
M ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00
M_R   /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-
M%FT RQ9U ,D7?0#'%X4 Q1B, ,08E #"&9P P!FE +X9KP"]&KL NQK+ +@;
MY0&T'/8!LAW_ K =_P*O'?\"KAW_ JX=_P*N'?\"KAW_ O\F!@#_)0  _R8
M /LG  #Q)0, \"$+ .@<$@#>&1T U!LM ,T=/ #('TD Q2!5 ,$A7P"_(F@
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M"(PV_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@
MP$   +LZ 0"V-@X L#D< *H[+ "F/#H HSU& )\]4 &=/5D"FCUA Y@]: 26
M/' %E#QW!I(\@ >1/(@'CSN2"(T[G0F+.ZD*B3NW"X@[R@N%/.@+@SS["X(\
M_PJ!//\*@3S_"8$\_PB!//\(@3S_"/\S  #L.@  VD,  ,I'  "_20  MT<
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M#6I+_PQJ2_\,:DO_#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P
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M#=Y,  #'5@  N%\  *UD  "@90  DV0  (EC  !_80  >6(# '5D$0!R91X
M;V8K &QG-P%J9T "9V9) V5F401B95@&8&5@"%UD9PI;9' ,66-[#E9CAA!4
M8I024F*C$U!BM!-/8LP33V+M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/
M  ##6@  M&,  *EI  ";:   CV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH
M &=L- !D;#T!8FQ& E]K3@1=:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(0
M3&>A$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^
M7@  L6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q
M, !><3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?
M$$5NL!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P
MK6P  *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7
M>#8 57@_ 5-X2 )1>$\#3W=7!$QW7P5*=V@'2'9S"45V?PM#=8T,076=#C]U
MK@X^=<4./77H#CYS_0T^<O\-/G'_##]Q_PP_</\,/W#_#,5>  "U:0  J7$
M )QU  "-=   @'0  '5T  !I=@  7GD  %A\ 0!4?0X 4GX: %%_)@!/?S$
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M R>0^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A
M;X4  &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ J
MG3@ *9U! "B=2P GGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<
M^ (>FO\"'IG_ QZ7_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X
M %N1  !0E0  1ID  #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T
M&Z@W !JI00 9J4P &*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3
MI_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<
M  !(H   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K
M  VU-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\
M"+3_  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  !
MK   -;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"
M*P  PC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_
M  ##_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP
M*;H  !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0
MT"H  -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6
M_P  UO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0
M !3'   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T
M .,G  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@
MZ_\  .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3
M   "V    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9
M  #T)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0
M /WT '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A
MY0   .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_
M%0  _R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4
M /\+( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T
M_P!V /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_
M ,L _P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-
M'0#_"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R
M /\ >@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8
M]@#9 /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_
M#A4 _P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P
M=0#Z 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/
M .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!
M_PP/ /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O
M '@ [0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L
MX #8 /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX)
M /\+# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '(
MX !Z -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#(
M .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0
M!@#_#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T
M ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P
MN O] +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[
M$P8 ^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.
M=@"_#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^
M *D5_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'
MWQ4% -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q
M&7@ KQJ  *X:B "L&Y  JQN9 *D;HP"G'*X IAR\ *0=SP"A'NH!GA[\ 9P?
M_P&;'_\!FA__ 9H>_P&9'O\!F1[_ ?\B  #_(0  ["<  . J  #4*0  S20
M ,H<" #$&1( O1PB +<>,0"S(#X KR%) *TB4P"J(UP J"1D *8D; "D)',
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M!'HV_P1Z-?\$>C7_!/4M  #D-P  T#\  ,)#  "W1   K4   *<Z  "C-@8
MG3<3 )DY(@"5.B\ DCP[ (\\1@",/$\!BCQ7 8@\7@*&/&4"A#QM X(\=02
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M&@"&1B@ @T<T (!(/P!^2$@!>TA0 GE(5P)W2%\#=4AF!'-';@5Q1W8&;T>
M!VU&C EK1I@*:4:F"V=&M@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&
M9$7_!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_
M2R0 ?4PQ 'I-/ !W344!=4U- G--50)Q35P#;TUC!&U,:P5K3',':4M]"&9+
MB0ED2Y8*8DND"V%+M Q?2\H,7DOJ"UY+_@I>2_\)7DK_"%Y*_P=>2O\'7DK_
M!^,_  #+20  O%$  +!5  "A5   EE(  (U0  "'3   @4T( 'U/$P!Z4"$
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M#%!8K@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5
MLEP  *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B
M7SH 8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=
MK Q*7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF
M )]A  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#<
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M!SAN]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P
M=VL  &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !"
M>$0 07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V
M]04Q=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G
M &=Q  !<<P  47<  $IZ  !"?0, /WX. #U_&  \?R, .X M #J -@ Y@3\
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M 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP
M/Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1
MHD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>
M_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL
M "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD
M :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P
MJ_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K
M   <K@  %+$   ZT   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ
M  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\
M +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2
MN@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,
M.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_
M (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0
M LD   #,    T    -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+
MX3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA
M  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8
M  #<    WP   .    #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L
M /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>
ML@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H
M    ZP   .T   #O    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I
M  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D
M_P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_
M (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X
M[ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4
M /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T
M_P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q
M /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\
M$ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_
M /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /
MX@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_
M !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8
M@ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z
M ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X
M_P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2
M (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T
M_P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0
M .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L
MP0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N
M _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T
M$@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =]
M +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\
MGP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#(
M"!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81
M@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_
M )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!
MM!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8
M'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@
M_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@  M2@  + B  "N&PP J!T7
M *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2)6< D"9N (XF=@"-)G\
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M NHP  #3.@  PD$  +-#  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4
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M!EM%K 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P
MM4X  *1.  "63   BTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J
M2SP :$M$ &9+3 %D2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%5TJ:!E5*
MJ@=42KT'4TK<!U)*]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  # 2P  LE$
M *!0  "23P  ATX  'Y,  !X2   <DH  &Y+#0!K31@ :$XD &9.+P!D3SD
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M!D-7\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6
M>U@  '%7  !F5@  85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/
M7DD 35Y1 4Q>6 %*7F$"2%UK T9==@-$78,$0EV2!4!=HP8_7;8&/EW0!CU<
M\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@  H5T  )!<  ""6P  =EL
M &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-8BP 3&,U $IC/@!)8T8
M1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IBH00Y8K0%.&/-!3AB[P0X
M8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&   (M?  !]7P  <E\  &A?
M  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"< 1&DQ $-I.0!":D( 0&I*
M #]J4@ ]:EL!/&IE 3IJ< (X:GX"-FF- S1IGP,S:;(#,6G+ S%H[0,Q9_\#
M,6;_ S)E_P,R9/\#,F3_ [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !9
M90  4&@  $EK  !#;00 0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q
M3@ V<5< -'%A 3)Q;0$Q<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_
M BIL_P(K;/\"*VS_ K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P
M2VX  $-Q   \=   -W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L
M>E( *WI< "IZ:  H>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U
M_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;   96P  %IN  !0<0  174
M #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL
M((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9
M?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!
M   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/
M !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\
M$(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   G
MC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:
M4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_
M )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0
M&)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@
MIU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'
M  ""A@  <H8  &.(  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D
M  NL   $KP   +$&  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T
M +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !Z
MC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y
M    O0   +X   "^!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91
M  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@
M89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]   &P    ,,   #'
MR0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=
M5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T
M $JS   [N   +;L  !^_   4P@  #,8   /)    S    -    #5    V0
M -H   #<    W@   .    #B!0  Y L  .<0  #J&   [20  / R  #Q1
M\E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]
M   MP0  '\8  !/*   +S@   -(   #7    W    .    #E    YP   .D
M  #K    [0   .\   #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<
M /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_
M !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\
MB@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_
M /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !<
M_P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z
M (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P
M_P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P >
M /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8
M[ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#:
M /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L
M)0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "&
M -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\
MQ@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J
M "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8
MAP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_
M +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0
MT0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U
M (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4
M_P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I
M +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0
MI@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7
M"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#
M+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R)
M )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\
MBA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C
M#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5
MCP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_
M /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T
ME!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP"
M'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A
M  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S
M (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*),
M="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0
M,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL
M.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^=
M 6DOK %H,+X!9S#; 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.
MNCT  *@\  ":.@  D3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T
M,SX <C1& ' T3@!O-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$V
MJ0)@-KL"7S;6 ETV\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$
M *)   "5/@  BSP  (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L
M:SI# &HZ2P!H.U( 9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9
M.[@#6#O2 U<[\0)6._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#
M  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]
M &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#
M4D#/ U% [P-00/_B__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1/O\!43[_
M <\[  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\  &M # !G014
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M T5-GP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P
MGD\  (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!1
M42P 3U$U $Y2/0!-4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2
MG0,^4J\#/5+& SQ2Z0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(
M (E1  !\40  <5   &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD
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M 2ICXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P
M95L  %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q
M:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")J
MX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86
M %=@  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\
M)G(W "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :
M<?< &G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F
M  !(:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP
M !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4
M$7G_ !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#
M<   .70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z'
M,0 .ASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_
M  B#_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0
M,GT  "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0
MDC,  ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/
M_P  C_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD
M "*-   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL
M )\U  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P
MG/\  )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:
M   2G@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK
M  "O-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\
M *W_ (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,
MK   !*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^
M*P  P#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_
M 'F-  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP
M +X   #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P
MTRL  -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9
M  !@G@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L
M  #/    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T
M .PJ  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8
MK0  2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
M    XP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<
M  #_+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !(
M_P 2 /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_
M '@ _P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D
MX@#X /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P .
M /\ #P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ',
M^@!Y /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J
M .X Z0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\
M"0#_ !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T
M .L >@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8
MU #X -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_
M  T _  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D
M= #5 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q
M +\ _P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @
M[@ 1 .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#"
M ', P !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\
M_ "M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ ,
M -, %0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T
ML !T *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@">
M /\ G@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,,
M#P"] !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N
M *$ =0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\
MD #_ )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q
M !( K  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"
M< "3 W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_
M (,+_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT
MH@46 )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(
M#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2
M_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0
M ),0&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\
M>Q9X 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M
M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8
M%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T
M ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\
M9"'_ . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![
M(AX >",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H
M>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_
M -@L  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H
M<"HE &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>
M+X0 7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q
M  "].@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A
M &8Q*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8(
M5360 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X
M/0  HSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W
M* !>-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ-
M 4XZG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0
MGC\  (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9
M/"X 5STW %8]/@!4/D8 4SY- %(^50!1/ET 3S]F $T_< !,/WT!2C^+ 4@_
MFP%'/ZP!13_! 40_XP%$/OL!1#[_ 40]_P%$/?\!13S_ <,^  "O0P  FD(
M (I"  !]00  <T   &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5 (@!302L
M4D$T %!"/ !/0D, 3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.) 4-#F0%"
M0ZL!0$/  3]#X0$_0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10  ED4  (9%
M  !Y1   ;T0  &="  !@/P  6T$  %="  !40PT 4405 $]%'P!.12@ 3$8Q
M $M&.0!*1T$ 24=( $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(EP$\2*D!
M.TB^ 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V
M1P  :T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+
M-@!%2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\
M 35,W0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@
M:$H  %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _
M4#L /E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1
MV@$O4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T
M %M-  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53<
M-U8_ #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I
M5O4 *57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1
M  !.4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[
M "Y<0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/,
M(EO_ "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*
M5@  0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C
M/@ E8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_
M !M@_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P
M/EX  #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;
M:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H
M_P 3:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60
M #)G   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L
M$'5&  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,
M<?\ #'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO
M   D<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_
M  1_2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\
M 'O_ (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =
M?   %H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+
M0P  BU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_
M ()M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B
M$(P   N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0
MF4<  )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT
M  !O<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D
M  &<    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T
M *E,  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H
M>P  67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
M    K@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I
M  "Z4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@
M48L  $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[
MO@   +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/
M1   T%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H
M #NA   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0
M ,X   #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@
MZ$D  .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R
M   FN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .
M  #B    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D
M /Y/  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_
M !8 _P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\
M@ #_ (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_
M /, _P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$
M_P = /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T
M (  \@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ .,
M_P#B /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8
M /\ ) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H
MX@"  .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+
M /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$
M'@#M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z
M ,H @ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\
MN #_ +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8
M ", T@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +<
M>@"U ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_
M *4 _P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T
MO@ H +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E
M 'H I "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )<
M_P"7 /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A
M *L + "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4
ME0!] )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"(
M /\ B #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X
M)0"; #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X
M (< @0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\
M>P3_ /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0
M 2D C0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(
M?@!Z"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_
M .@6  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#",
M@PTM ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P
M$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>
M  #&)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H
M '84,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8,
M9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]
M*@  J"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=
M+0!K'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&-
M %HBG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@
MHBX  )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C
M)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,I
MF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(
M (PR  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX
M6RLV %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!+
M+Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U
M  ![-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S
M %,Q.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8
M0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W
M.   ;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV
M. !,-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX
M #TYTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P
M:CH  &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'
M.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]
MT0 W/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT
M %X]  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H
M04!! $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R
M0?  ,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M
M  !4/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^
M #I%1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\
M+47_ "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !0
M0P  2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*
M0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_
M "A)_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P
M1$@  #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L
M4$@ *U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ").
M_P B3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P
M #M.   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4
M)%9. ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;
M4_\ '%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93
M   Q50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU*
M !I=50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\
M%%G_ )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K
M6P  )5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E
M4  095T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_
M (U5  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@
M'V4  !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ '
M;E< !FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:
M  !T6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T
M !-Q   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%
M 'A>  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N
M7P  8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[
M   (?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17
M  "$:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9
M7V,  %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'
MB@   (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "2
M7P  DG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L
M $MM   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F
M )D   ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50
MHVD  **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y
M   W?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@
M  "I    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T
M +5S  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   O
MC@  (Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
M    NP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF
M  #*?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP
M&Z4  !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+
MS    ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E
M;P  YHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8
M  N\    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X
M .(   #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P
M_'H  /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\
M*@#_ #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"'
M /P C0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\
MXP#_ -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_
M #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X
MAP#L (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_
M ,D _P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L
M]P V /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8
M (@ U "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L
M_P"V /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P
M .$ .P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($
MOP") +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J
M /\ IP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,<
M- #$ #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K ""
M *H BP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\
MFP#_ /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P
M #< K0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H
MA "8 (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_
M /P   #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$
MG0 Z )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@")
M (D B "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"
M  #@"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S
M (T / "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0
M>P"0 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/
M$   N1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($
M-@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*-
M &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P
MKA<  )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U
M"#@ <PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-
MF0!B#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X
M )4=  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#,
M:A [ &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9
M$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC
M  "!(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W
M & 7/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0
M3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![
M)P  <B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?
M.@!7'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T
M $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P
M;2H  &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0
M)3X 3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ H
MRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X
M &$M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL
M22M" $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z
M+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ
M  !8+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _
M $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND
M-#+_ #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4
M,P  4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU
M1  \-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^
M # U_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@
M2S0  $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V
M.DH -3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ
M_P K.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@
M $(Z   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T<
M,#]0 "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F
M/?\ )CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^
M   Y/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1-
M "A$6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\
M(4'_ )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T
M10  ,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*
M50 @2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_
M )5"  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20
M*TL  "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 9
M4%T %U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%
M  ![1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E
M "!3 P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD
M$%=H  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V
M2@  9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9
M   57 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB
M  =><P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@
M8DX  %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   0
M8P, #&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G
M;0  9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(
M %12  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$
M!FX)  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@
M<7D  '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6
M  !&5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%
M  !X"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(
M 'V(  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  !
M7P  -6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$
M!@  A0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N
M  "+F0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0
M+FX  "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2
ME 4  )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";
MD0  FZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P
M !N!   2AP  #(P   21    E0   )D   "=    H    *$   "B    I
M *4!  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0
MKJ$  *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2
M   ,F    YT   "B    I@   *H   "N    L    +$   "S    M    +8
M  "X    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,
M ,6O  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #
MJ0   *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
M    S0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A
M  #AO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@
M +\   #$    R    ,X   #1    U    -4   #8    V@   -T   #?
MX@   .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #Y
MJP  ^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^
M /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\
M]P"7 /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#&
M /\ P@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\
M0P#] $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1
M .0 F@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\
MMP#_ /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L
M $8 Z !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L
MDP#( )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_
M /\   #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\
MS@!( ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T
M )8 L@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\
M  #_    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !!
M +4 2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X
MGP": )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
M    Y    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *(
M0@"@ $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3
M (P H0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E
MS0   +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0
M $, C@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X
MFP!\ *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(
M *P!  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T
M@ !# 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O
M *4 ;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,
M  "3"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^
M ', 1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$
M8P"R &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "(
M$0  @ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#
M0 !G T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P
M %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P
M=A8  '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?
M#$( 7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.
MR !-$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP
M &D:  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX
M5A)% %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%
M%>@ 11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?
M  !?'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE"
M $T92 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4
M/1S\ #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9
M(@  5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@
M10!%($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[
M #<B_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@
M42,  $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _
M)4H /293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F
M_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@
M $HF  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@
M."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M
M*O\ +2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K
M  !!*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R].
M #$P6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\
M*"[_ )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \
M,   .C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT
M5@ J-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_
M )@Q  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-
M-#4& #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E
M.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T
M  !_-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH"
M "P["P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP
M'3]I !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z
M.   :CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!
M"  D0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G
M !5$=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/
M9CT  %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =
M2 P &TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*
M=  .2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D
M %9   !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@<
M$U . !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '
M4($ !5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$
M  !*1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*
M  M8$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P
M %B1  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'
M1P  0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?
M#@  7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+
M  !?H@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P
M.TP  #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#
M9P\  &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !J
MG0  :;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,
M "U6   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T
M '(0  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP
M=;$  '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?
M   =8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,
M  "!$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D
M (/)  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5
M<   #G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0
M"P  D0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!
M  "3Z@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P
M!X0   ")    C@   )(   "6    F    )H   ";    G0   )\   "A P
MHP@  *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "G
MW0  I_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8
M  ":    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0
M +@%  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0
MO>\  +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
M    L    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H
M  #- @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D
M -OR $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^
MP@   ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
M    Y@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7=
M /\ !@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T
M_P!5 /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P
M *8 [@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\
M  #_    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/
M /0 5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\
MV0"K -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M    _P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\
M4 #; %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D
M +T L@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_
M_P   /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#
M %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@
MJ@"F +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P
M -\   #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D
MJ !/ *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4
M +( D@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<
M  "Z    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!)
M )0 3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H
M@0"^ (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
M    H    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0
M20"" $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U
M '( SP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7
MD0   (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T
M $D <P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4
MQ@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,
M 'X   ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0
M9P!) &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9
M .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*
M  !O!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!%
M %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L
M3@+T $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E
M#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'
M2 !3"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS
M $4,_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P
M6A$  %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+
M#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1
M_P ]$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8
M %(3  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD
M0Q12 $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V
M%O\ -Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9
M  !+%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/
M #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\
M,!O_ )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%
M' ( 0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@
M5@ S(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_
M )DB  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0
M/2$) #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M
M)5X *R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E
M  " )P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8&
M #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP
M)BII "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\
M*@  ;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K
M#  N+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G
M !\O=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0
M:"X  %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I
M,1  )S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT
M=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$
M %@Q  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T
M(382 " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2
M.80 $3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T
M  !+-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0
M !D]%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$
M##Z5  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(
M-P  03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#
M$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20
M  1#I0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@
M/CH  #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,
M2A0 "TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*
MH0  2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T
M #8]   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$
M %$7  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0
M4;4  %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!
M   J0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3
M  !9&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$
M %C1  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E
M2@  'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B
M%0  8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,
M  !A\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@
M&%4  !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0
M;A8  ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M
M[P  ;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6
M  QD   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!
M 'T6  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0
M>_\  'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M    =@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0
M  "0%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L
M (S_ %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""
MA@   (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B
M#P  I!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__
M $YA  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F
M )T   "A    I    *4   "G    J0   *L   "M    L    +(   "U"
MN X  +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K
M   Y<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +
M  "S    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04
M -$.  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q
M@   (X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
M    R@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%
M  #K#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_
M_P $ /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_
M %X _P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@
MP #F .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P
M /\   #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@
MZP!> .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+
M ,X R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\
M  #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8
M ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$
ML@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D
M    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4
M5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1
M )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V    YP   -,   #&
MO0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"=
M %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D
MZ "( /\ B0#_ (< _P"% /\ @@#_ /,   #C    S    +P   "P    IP
M *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X
MB0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W
M /< > #_ '@ _P!W /\ =0#_ .8   #+    MP   *@   ">    E@   (\
M! "+  P B  2 (< &0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!-
M '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T
M:0#_ &D _P!I /\ :0#_ -(   "X    I0   )<   "-    A@   ($   !\
M  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H
M3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[
M %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0
M;0 , &L $0!I !< :  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!<
M $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$
M_P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P '
M &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L
M40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!'
M /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$
M"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/
M $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\
M/@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0
M"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +
M50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_
M )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@<
M2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X
M$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6
M  ""&0  <1L  &0<  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+
M $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P
M,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]
M'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6
M#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF
M "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P
M:2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R
M'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?
M<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,
M %DD  !/)0  1R4  $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1
M*R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;
M)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G
M  !,)P  1"<  #XG   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283
M "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8
M%"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)
M*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L
M%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2
M  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+
M/RP  #DL   T*P  +RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7
M,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HS
MH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X
M #8N   Q+@  +2X  "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8
M$3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !
M-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q
M   O,   *S   "4R   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9
M  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(
M #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M
M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$
M'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-
M  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P
M(SD  !X[   8/0  $T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0
M2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)
M[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\
M !E!   31   $$<   Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L
M %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0
M4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)
M   /3   "T\   92    5    %<"  !8!P  60L  %H.  !;$0  718  %X=
M  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\
M %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *
M50   UD   !;    7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K
M'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_
M %%(  !(2   048  #='   L2@  (TT  !M1   350  #ED   A=   !80
M &0   !G    :@   &P   !N    <    '(%  !S"0  =0T  '<1  !Z&
M>R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-
M  !'3   .TT  #!/   F4P  '%@  !-<   -80  !F8   !J    ;P   '(
M  !V    >0   'P   !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@
M (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!
M4P  -%4  "E:   >7P  %&4   UJ   %<    '8   ![    ?P   (,   "'
M    B@   (T   ".    D0   ),   "5    F    )H%  "=#   H!$  *,:
M  "C*   HCH  *%.  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7
M+6$  "%G   6;@  #G4   5[    @0   (<   "-    D@   )8   ":
MG0   )\   "A    I    *8   "H    JP   *X   "Q P  M L  +@1  "Y
M'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\
M !AW   /?P  !H<   ".    E    )H   "@    I0   *H   "N    L0
M +(   "U    MP   +H   "\    OP   ,,   #&    R0   ,X*  #2$P
MTB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)
M   (D0   )H   "A    IP   *T   "S    N0   +X   #"    Q0   ,8
M  #)    S    ,X   #2    U0   -H   #>    X0   .4   #J"P  ZQ<
M .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_
M  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L
M9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W
M -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8
M_P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C
M &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,
M_P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_    _0   /H   #X    \  )
M .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T
MPP!C ,  :0"^ '  O !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H
M /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H
M#0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!<
M *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\
MD0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D   "\    M    *\ "@"K
M !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ),
M6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_
M 'P _P![ /\ >0#_ .D   #7    P0   +$   "F    G0   )< !0"4  T
MD@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^
M %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\
M_P!M /\ ; #_ -H   "_    K    )X   "3    C    (4   ""  D ?P /
M 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %,
M; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A
M /\ 8 #_ ,4   "M    FP   (T   "#    ?    '<   !R  4 <  , &X
M$0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5
M %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\
M50#_ +8   "?    C0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@
M !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %(
M6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_
M *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;    60 % %< # !6 !
M5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !'
M %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (
M  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2
M $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H
M/0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "#
M#@  <A   &41  !;$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"
M$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B
M #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0
M;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \
M"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,
M;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8
M %L7  !1&   21<  $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A(
M-0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D
M$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:
M  !-&P  11H  $ :   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5
M "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X
M'161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*
M'0  0AT  #P=   W'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7
M&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/
M !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(
M/R   #D?   T'P  ,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A
M'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>
MH@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(
M #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H
M&R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,
M([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D
M   O(P  *R,  "@C   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<>
M !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$
M!2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M
M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L
M(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)
M   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*
M)R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *
M,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   P
MZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H
M " K   <+   %RX  !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(
M #<J   X,P  .#X  #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@
M-OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO
M   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF
M   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T
M #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4
M-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&
M*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_
M %@T  !+-0  034  #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0
M#4    E"   $10   $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0
M3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y
M  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@
M  )*    30   $\   !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D
M %DV  !91   650  %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#
M/0  /#P  #4[   L/   )#X  !Q!   51   $$@   M+   %3@   %$   !4
M    5P   %D   !;    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N
M  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00
M.C\  #!    F0P  'D8  !5*   03@  "E(   -6    6@   %T   !@
M8P   &4   !G    :0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V
M-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48
M "I(   @3   %U$  !!6   )6@   5\   !C    :    &L   !O    <@
M '4   !W    >0   'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P
MB3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3
M   86   $%X   ED    :0   &\   !T    >    'P   "!    A    (<
M  "(    BP   (X   "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$
M )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   1
M9P  "6T   !T    >P   ($   "&    BP   )    "4    EP   )D   "<
M    GP   *$   "D    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y
M  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>
M (    "'    C@   )4   ":    GP   *0   "H    K    *T   "P
MLP   +4   "X    NP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/
M10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),
M  ";    H@   *@   "N    M    +@   "]    P    ,(   #%    R
M ,L   #.    T0   -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@
MZ50  .=R  #EDP  X[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\
M%P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M
M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\
ML@#_ *H _P"E /\ H@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_
M !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@
M:P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_
M )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R    Z@ % .< #@#B !4
MX0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y
M &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\
M_P"+ /\ B0#_ /D   #O    YP   -\   #/    R    ,$ "@"_ !$ O  8
M +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &,
MG0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!]
M /\ ? #_ .T   #@    T0   +\   "S    J@   *8 !0"B  T H0 3 *
M&P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C
M (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\
M;P#_ -T   #+    M@   *<   "=    E    (X  0"+  H B0 0 (@ %0"'
M !T AP E (0 + "" #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ',
M8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_
M ,H   "T    H0   ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@
M<P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B
M &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D
M  "B    D    (,   !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9
M &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &
M4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4
M    @@   '4   !K    9    &    !=    6@ % %@ # !7 !  5@ 5 %8
M&P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F
M $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")
M> ,  &H$  !A!   6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!*
M !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T
M;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD
M &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@
M00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S
M 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.
M  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 :
M #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '<
M*@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-
M$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%
M'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>'
M "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P
M01,  #L3   W$@  -!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J
M"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-
MG  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18
M #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT
M) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2
M$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08
M   P%P  +!<  "D6   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@
M !T3)P <$RX &A,V !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$
M#13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M
M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8
M)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&
M  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'
M)AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2
M'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=
MY@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X
M "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8
M#2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0
M(/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?
M   <'P  &2   !8A   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J
M  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D
M "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :
M(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L
M,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_
M %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0
M%"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+
M,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG
M  !,*   0"D  #<I   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P
M  XN   +, $ !S(%  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(
M #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(
M+   /2P  #0L   M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT
M   '-@   C@$   Z!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y
M  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P
M.2\  #(O   L+0  )RP  " M   :+P  %3$  !$S   --@  "3@   4[
M/0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)
M0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,
M # Q   J,   (S$  !PS   6-0  $3@   T[   (/@   T$   !#    1@
M $@   !*    3 0  $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/
M5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T
M   F-0  'C<  !<Z   1/0  #$$   =$    2    $H   !-    4    %,
M  !5    5P   %@"  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844
M &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A
M/   &$   !%#   ,1P  !DL   !/    4P   %8   !9    7    %\   !A
M    8P   &4   !G 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/
M  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@
M$DH   Q/   $5    %@   !=    80   &4   !H    :P   &X   !Q
M<P   '4   !X    >P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""
M70  @78  '^6  !^M@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<
M  -=    8P   &@   !M    <0   '8   !Z    ?@   ($   "#    A@
M (D   "+    C@   )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@
MF&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N
M    =    'H   "     A    (H   ".    D@   )4   "7    F@   )T
M  "@    HP   *<   "K    KP   +0)  "X$   MQX  +4P  "S1@  L6
M *]^  "LH   J\$  *GN #%5   D6P  &&$   YI   %<0   'D   "!
MB    (\   "4    F@   )\   "D    J    *D   "L    KP   +,   "U
M    N0   +T   #!    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ
M  #(D@  Q;,  ,/> "EB   <:0  $7$   =[    A    (T   "5    G0
M *,   "I    KP   +0   "Y    O    +X   #"    Q0   ,@   #,
MT    -0   #:    WP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #F
MA@  Y*4  .+& /\   #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F
M /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8
M[0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P":
M /\ E@#_ /\   #[    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /<
M*@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V
M ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\
MB@#_ /H   #Q    Z@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1
M "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X
M=P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_
M .\   #C    V@   -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4
MK@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3
M 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .
M  #0    Q@   +8   "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F
M )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$
M? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^
M    JP   )T   "3    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T
M)@!Z "T =P S '4 . !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U
M &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I
MEP   (D   !^    >    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H
M "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %<
M>P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@
M '@   !N    9P   &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$
M6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !)
M (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P
M  !B    6P   %8   !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A
M $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X
M/0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8
M    40   $P   !)    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $
M(@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P",
M #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P
M208  $,%  !  P  /@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V
M ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H
MG  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L
M #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\
M+@ D "P *@ K #  *@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A
M *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-
M   S#0  , P  "X+   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A
M "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H
M&@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O
M#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " '
M)  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_
M !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0
M*!$  "40   C$   (@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :
M#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,
MX  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,
M "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@
M%! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '
M$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4
M   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N
M  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0
M A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :
M%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8
M,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_
M &$6  !2&   11H  #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P
M%A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $
M'#@  AQ$   =40  '6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8
M  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D"
M !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34
M "%    A3@  (5T  "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+
M'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! =
M @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]
M   F2@  )EH  "9L   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(
M/"$  #(A   K(0  )2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,
M(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L
M1P  +%8  "QI   L@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0
M "\D   H(P  (R(  !\A   <(   %R   !,A   0(P  #B0   LF   (*
M!"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P
M,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF
M   G)0  (B0  !XC   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"
M   S!   -0<  #<*   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX
M #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E
M)P  (28  !LG   5*   $2H   XL   *+P  !C$   $T    -@   #@    [
M 0  /00  #\'  !!"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;
M  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@
M'2H  !<L   1+@  #3$   DT   $-P   #H    \    /P   $$   !$
M1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.
M:@  388  $RD  !*R@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$
M !(S   .-P  "3H   (]    0    $0   !'    20   $P   !/    40
M %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P
M6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]
M   (00   $4   !)    3    %    !3    5@   %D   !;    70   &
M  !B    90   &@%  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4
M &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)
M30   %(   !6    6@   %X   !B    90   &@   !K    ;0   '    !S
M    =@   'D   !]!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*
M  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /2P  !U$   !7    7
M &(   !F    :P   &\   !T    >    'L   !^    @    (,   "&
MB@   (T   "1    E@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0
MH   CL4  (SS #%$   E2   &DT  !!3   (6@   &$   !H    ;@   '0
M  !Y    ?P   (0   ")    C0   )$   "3    E@   )D   "=    H
M *0   "H    K    +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE
MJ;0  *7E "I/   >5   $EL   IB    :@   ',   ![    @@   (D   ".
M    E    )H   "?    I    *8   "I    K0   +    "S    MP   +L
M  #     Q0   ,L   #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD
M ,'+ ");   68@  #&L   %T    ?0   (<   "0    EP   )X   "D
MJP   +$   "V    N@   +P   #     Q    ,@   #+    SP   -0   #:
M    X    .8   #K    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[
M /\   #[    ]@   /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4
M_P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E
M )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H
M  #R    [    .D   #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W
M .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@
MO@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E
M    W@   -H   #;    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,
M-P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "-
M *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3
MR@   ,<   "\    M@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@
M #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@
ME "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0
M *T   "@    F    )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\
MA@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q
M )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(
M  ")    @@   'P   !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M
M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ),
M70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T
M    ;@   &H   !F    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T
M+ !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"?
M $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-    ?    &X   !E
M7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!.
M "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $
MKP _ -< /P#_ #X _P ] /\ /@#_ )0   !_    ;P   &,   !9    40
M $T   !*    2    $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8
M00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U
M ,8 - #U #0 _P T /\ -0#_ (@   !T    90   %@   !/    2    $,
M   _    /0   #P  @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F
M #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L
M*P#J "L _P K /\ + #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W
M    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P
M*  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#>
M "( _P C /\ ) #_ '<   !E!   5@8  $L'  !""   .@@  #4'   P!@
M+04  "P#   K  , *@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D
M "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L
M]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D
M "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8
M'  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4
M /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,
M   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K
M !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X
M$ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;
M#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !()
M,  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_
M &,-  !3#@  1A   #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$
M%@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -
M#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.
M  !0$   0Q$  #@2   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! %
M !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8
M"!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-
M$@  0!,  #84   M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1
M"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^
M  (32P  $UH  !-L   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%
M/14  #,6   K%@  )!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .
M$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   7
M2   %U@  !=J   6@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<
M # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% <
M"Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@
M'%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:
M   F&@  (!D  !L8   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&
M  8:"  "' H  !X-   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(
M "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D
M'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?
M!@  (0@  ",+   E#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@
M   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@
M'1P  !D;   6&@  $AH  ! ;   -'   "QT   @?   $(0   2,"   E!
M)P8  "D)   L#   +@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M
M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X
M !@=   4'0  $!X   X?   +(0  !R,   ,E    )P   "D    L 0  +@,
M # &   S"@  -0T  #81   V%P  -A\  #8I   V-@  -D4  #57   U;0
M-(D  #*H   QSP  ,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@
M   1(0  #B,   HE   &*    BH    M    +P   #(    T    -P   #D#
M   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(
M #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .
M*   "BH   4M    ,    #,    V    .    #L    ^    0    $(   !%
M @  1P8  $H*  !-#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;
M  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;*   %"H   XM   *,
M!#,    W    .@   #T   !     0P   $8   !(    2P   $T   !0
M4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2
MM0  4.H  $__ #,P   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\
M  !"    1@   $D   !,    3P   %(   !5    6    %H   !=    8
M &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP
M7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0
M    5    %@   !;    7P   &(   !E    :    &L   !N    <0   '4
M  !Y    ?08  ((-  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8
M '#W #$V   F.   '#L  !)    +10   DL   !1    5@   %L   !@
M90   &D   !N    <@   '8   !Y    ?    'X   ""    A0   (D   ".
M    DP   )@&  "<#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH
M "L^   @00  %4<   U-   "5    %L   !A    :    &X   !S    >0
M 'X   "#    B    (P   "/    D@   )4   "9    G0   *$   "E
MJ@   +    "W!P  N!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(
M   83@  #E0   1<    9    &T   !U    ?    (,   ")    CP   )4
M  ";    H    *,   "F    J0   *T   "Q    M0   +D   "^    Q
M ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   1
M7   !V4   !N    =P   '\   "(    D    )@   "?    I0   *T   "S
M    N    +H   "^    P@   ,8   #*    S@   -,   #:    X    .<
M  #M    \P   /0.  #R'@  [S8  .Q1  #H;@  Y)   -^Q
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MYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNCH3],="'>C52BO?Y$P_U^Q15LGN66NWXV%\J-AGBYK/:Y>-R6Z@@\1QIWO
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MC,VT<YW"JWFJMZ1^M*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;#
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MXH"5BMU[FI#:=Z"6UG2FFM1QK)[2;[*AT&VYH\]LPZ;%9\.FP&G'H<!IQZ'
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MA:7 GX2OP99^L,&4?[:XDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI.
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MHU16_Z-45O^C5%;_HU39N@4 Q<<' +G9" "L_Q<%HO\K#97_,Q:)_SD>?O]
M)77_2"MM_U P9_]:-&/_93=@_VTY7O]S.US_>#U:_WT^6/^"/U?_AD!6_XM
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M_WXD!O^-)@?_FBT*_Z0U#_^L/1?^LD4B]KA,,.V\5$#DN%U1U[)D8\NI;'/
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MG,V8<)S-F'"<S9APG,V8<)S-F'"<S9C_A1@"_XH>!/^:(@3_J"D&_[4P"/;
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M/TO_LT!*_[E!2O^Y04K_N4%*_[E!2O^Y04K_N4%*_[E!2O^Y04K_N4'(M0(
MN,$$ *O0 P"?ZPD!EO\:!8O_)@I__RT/=?\U%6S_/1IE_T0>7O],(EC_5"55
M_UTG4O]E*5#_;"I._W,K3?]Y+$S_?RU*_X4N2?^,+TC_DC!'_YDP1?^@,43_
MJ3)#_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_KC*XN@( JL@
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M6$-W[6%*<.UI4&KL<55E['E98>R!7%WLBE]:[)-A5^V=8U7MIV52[;-F4>[
M9T_OU&A.Z^9H3>CH:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&C_F0L
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MA/\3 G?_&@1M_R('9/\J"US_,@Y5_SD14/]!$TO_2!5(_T\71?]6&$+_7!E
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MBR<&_Y0O"?^;-P__H#\7^*1'(?"G3R[HHEH]WYMC3=24;%K+C'5EQ(9];[Z
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M<9#C>W&0XWO_<QD"_X(7 O^2&@+_H!\"_ZTD O*X*@3FPS$&V\PU#\S(0B'
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M34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T34CW]$W:HP  Q[$" +B[ P"MR00
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M9%&]]6%1O?5A4;WU85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8
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M96*:]F!BF?=>8IGW7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08
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M34K*_TU*RO]-2LK_34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H
ME.4: 8WE*P:$Y#4->^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0
MWX5 3=^/0TK@FT5(X*A&1N"X1T7AS$=%X.A'1=_V1D7>_T1%WO]$1=[_1$7>
M_T1%WO]$1=[_1$7>_T39EP  QZ8  +BP  "LN0$ HL4" )C1!@"/ZPT B>X?
M H#N*P9X[30,<.T]$VCM1AEB[4X>7>U7(UGM8"=5[6@J4NUQ+4_M>2],[8,R
M2NZ--$?NF#5%[J4W0^^S.$+PQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA
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M7'.&_59SA?]2<X7_4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP
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M4%NA_U!;H?]06Z'_4%NA_U#_=P< \(D  -:8  #+I , P:T$ +FV P"RP 0
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M%R__J1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP
MGK4  )#!  ""S   ==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5
M_SH&//]!!SG_1P@V_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_
MF@\C_Z80(O^S$"'_P1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X
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M0+$;_S^X'/\_P!S_/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?]
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M3X-X_TJ#>/]%@GC_1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T
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M1VR)_T=LB?]';(G_1VR)_T?_:0L _W@$ .6'  #6D@, S9P% ,:D!@#!JP8
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M,#_5PC$_U>$P/]/R,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E
MNZ$  *VI  "BL0  EKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9
MY$$+5>1+#U'D5!)-Y%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OF
MO"0ZYM,D.>7N)#GC^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8
M *.N  "7N   BL(  '[,  !SU@( :>4) &3O% !?\" !6? K U3P-05/\#X'
M2_%&"D?Q3@Q$\5<.0O%?$#_R9Q(]\G 4.O)[%3CSAQ8V\Y08-?2B&3/TL1DR
M]<4:,?7B&C'T\1DQ\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV
M  "+P   ?LH  ''5  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%_3D%0?U
M!C[^2 <[_D\)./]7"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_I! H_[01
M)__'$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^
MR0  <-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_
M/P0P_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q
M"AO_P L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@
M8]X  %7D  !+]0  1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E
M_SL#(O]! Q__1P,=_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__
MJ08._[4&#O^Z!@[_N@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4
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M09)G_SR3:?\XDVK_-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX
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M.GMY_SI[>?\Z>WG_.GMY_SK_7PP _VP$ /5Y @#>@P( TXL% ,V2!P#)EP@
MP)D9 +>8+ .OE3L,IY%'%I^-4!^9B5DGDX9A+HZ#:#2)@6\YA7]V/8%]?D%]
M>X9%>7J/279XF4QS=Z5.<'>R4&YWQ%!M=^!/<'GU2')[_T-T?/\^=7W_.W5]
M_SMU??\[=7W_.W5]_SO_80H _V\" .A\  #9A@$ SXX$ ,B5!@##F@8 NYP6
M +.<*@.JF3D+HI5%%)N13AV4CE<FCHM?+8F(9C.$AFTX@(1T/7N">T%W@(1%
M='^-2'!]ETMM?*-.:GRP3VA\P5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO
M@?\\;X'_/&^!_SS_9 @ _W(  .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@
M)P*EG38)G9I#$Y:731R/DU4DB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+
M1VJ#E4IG@J%-9(*N3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\
M:H;_/&J&_SS_9P0 ]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@
MHC0(F)] $9&<2AJ*F5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*
MDTEAB9]+7HFL35V)O4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_
M/&.,_SS_:@  YGH  -6&  #)D0  P)D! +B? 0"PI0  J*D. **I(0&:J#$&
MDZ4^#XNC2!B$H%$@?IY9)WB<8"USFF<R;YAN-VJ6=3QFE7T_8I2'0U^2D49;
MDIU)69&K2E>1NTM6D=-+5Y+O1UJ2_4)<D_\^79/_.UV3_SM=D_\[79/_.UV3
M_SO_;@  X'X  ,Z+  #$E0  NIT  +&C  "IJ0  H:X+ )NO'0&4KBX$C*P[
M#(6J1A5^J$X<>*96(W*D72IMHF0O::%K-&2?<SA@GGL\7)V%/UF<CT)5FYQ%
M4YNJ1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ
M=   V8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR
M0A%WL$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I
M04NEND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@
MSXD  ,*5  "VGP  K*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUO
MNDD4:KA1&F6W61]@MF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:R
MN3I%LM$Z1K'M.4>P_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY
M +N<  "NHP  I*H  )FQ  "/N0  A, # 'O&#0!XQAX <\8N VW%.@AGQ$4.
M8L-.$UW#5AA9PEX=5<%F(5'!;B1.P'<H2\"!*TB_C"U%OYHO0[^H,4&_NC%!
MP-(Q0;[N,$&]_2]!O/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.B@  OY@  +&@
M  "FJ   F[   )"X  "%OP  >L<$ &_/"0!KT14 9]$F 6/1- 1>T$ (6=!*
M#%7/4Q!1SUL43L]C&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH)CS.NB8\S]0F
M/,WO)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=
MK@  D;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?
M3@E)WU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L
M&C7>^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0
MA;X  'G'  !MSP  8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_
M[$\'/>U8"3KM8 HX[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN
M\1$L[/X1+.O_$"SK_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8
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M PC_P@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[
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M+JA6_RNH5_\HJ%?_):A7_R6H5_\EJ%?_):A7_R7_31, _U8. /]?#0#_9Q
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M#@#A>Q( U'P@ ,I[,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB97@OGV2
M,YQBB#:989 XEE^9.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB_S..9/\P
MCF3_+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9
M?PP S8$= ,1_, .[?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5G
MA#:298PYCV25/(QCGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_
M+H=I_RV':?\MAVG_+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH
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M05J%MT)9A<Q"6H7J/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:
MX'8  ,V"  #"C   N9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_
MFDP7>9A4'7277")PE6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-
MMD!3C<M 5(WI/5:-^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L
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M+T.K^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP
MGJ4  ).L  "(L@  ?;@  '&^!@!NOQ4 :K\F 6:_,P-AOC\'7;Y("UF]40]5
MO5D34;Q@%TZ\:!I+NW$=2+M['T6ZAR)"NI0D0+JB)CZZLR8]NL@F/;KH)CVX
M^24]M_\D/;;_(SVV_R,]MO\C/;;_(SVV_R/'B   N94  *R=  "AI   EJL
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M"B;F_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0
M3]<  $7=   ^[@D //(1 #GS&P V\R4 -/0N #'T-P$N]3\!+/5' 2GV3P(G
M]E<")?=A R/W; ,A^'H$'_B)!![YF@4<^:L%&_K !1KZW@4:^?(%&O?]!1GV
M_P49]O\%&?;_!1GV_P6>I@  D:\  (.Y  !UP@  9\L  %K3  !-V@  0M\
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M&,= _Q?&0?\5Q4'_%,1!_Q3$0?\4Q$'_%,1!_Q3_01< _T<2 /],$ #_4A0
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M(9E7_Q^95_\?F5?_'YE7_Q__30T _U4& /]=!0#[9 < [VD) .EK# #A;!
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M60  ZV4  -MP  #->   Q'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]").
M2 ^.?5$5B7M9&H1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H
M.6AOMSIG;\LZ9W#I-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7
MYV@  -5S  #)>P  P((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)
M@D\4A(!7&7]^7AY[?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-T
MM3EA=,DZ873G.&-V^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP
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M-%*(]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC
MK9(  *.6  ":F@  CIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519E
MF%P:89=C'EZ6:B%;E7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1
M]2U-D?\J3I#_*$Z0_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<
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M&SFP_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP
M;;@  &*] 0!6P@< 4\,4 %+#(P!0Q# !3<0[ DK$10-'Q$X%1<17!T+#7PE
MPV@+/<-R#3O#?@\XPXP1-L.;$C7#JQ,SP\ 3,\/@$S/!]1,RP/\4,K__%#&^
M_Q0QOO\4,;[_%#&^_Q2XD   JYD  )^@  "3IP  AZX  'NT  !NNP  8\
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M A+P_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP
M)O0% "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 .
M_V$ #/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_
M]@&/K   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\
M !G_"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\
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M$;-!_Q"S0?\0LT'_$+-!_Q#_0!  _T8, /]+"@#_40T _U,1 /]4& #S5"(
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M+79>N"YU7LPO=%[I+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@
M[%P  -QF  #.;0  Q'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1
M;E$/C6Q9%(EJ8!>%:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!B
MMB]O8LDO;F+F+F]D^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\
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M+U]Q]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@
MM8   *V$  "DA0  FH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q
M?5X8;GME&VMZ;!YH>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV
M\RI;=O\F7'?_(UQW_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80
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M($J+_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0
M?YP  '6>!0!PGQ, ;9\C &F?, %EGCL$89Y%!UV=30I:G%0-5YM<$52:8Q11
MFFL73IET&4N8?QQ(F(L>19>9($.7J"%"E[HB09?3(D&6[R!"E?X>0I7_'4.4
M_QQ#E/\<0Y3_'$.4_QS,=0  O($  +&,  "FD@  FY<  )&;  "%GP  >:,
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M#BRX_PZSCP  II<  )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^  !'P@$
M/<<& #C)$  WR1L -LHG #7*,P TRST ,\M' #'+40$PRUL!+LQE BS,<0(J
MS'\#*<R0!"?,H00FS;0$)<W.!"7+[@0DR?P&(\C_!R/'_P<CQ_\'(\?_!R/'
M_P>IE@  GIT  )*C  "%JP  >+(  &NX  !?O@  4L(  $?&   ]R@  -,\$
M "O4"0 FV0\ )=D9 "7:)0 DVC  (]L[ "/;10 BW%  (=U; "#=:  >WG8
M'=Z' 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@
MG   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>
M!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW
M !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP
MB:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6
M]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^
M=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0
M &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8
M#?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@
M_W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''
M  !3T   0]8  #;=   JX@  '^8  !;J   0[0  #/H   G_   &_P   O\$
M  #_"0  _PT  /\0  #_%   _QH  /\A  #_*0  _S0  /]   #_3@  _UX
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M'XI-O""(3= @ATWK'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P
M^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY  Z%<2P>=
M6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?@U&J(8%1
MN")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_2@  [E(
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M)FI?]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P
MN6\  +%Q  "J<0  HF\( )MO%P"6<"< D&\U HMN0 6&;$D(@FI2#'YI60][
M:& 2=V9F%'5F;A=R978:<&1^'6UCB!]K8Y,B:6*@)&9BKB5E8K\F9&+:)F1C
M\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E_QCP4P  W5\  ,MH  "_;P  MG,
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M'%=Q_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P
MBX$  (2!#0!_@AH >X(I 7:!-@)R@4 %;G])"&I^4 MG?5<.9'Q>$6%[9A1>
M>FT76WIV&5EY@!Q6>(L?4WB8(5%WIB)0=[<C3W?.(T]W["%0=_T>47?_&U)W
M_QE2=_\94G?_&5)W_QG>8@  R&X  +MW  "P?P  IX0  )V'  "2AP  A(<
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M%3Z/_Q7%<P  MW\  *R)  "ACP  EI,  (N6  !_F0  <YP  &2?  !<H D
M6: 4 %>A(@!5H2\ 4J$Y 5"A0P)-H$L$2J!3!4B@6@=%GV,)0Y]L"T">=@X^
MGH,0.YZ1$3F=H!(XG;(3-Y[($S>=Z!(VF_H2-IK_$C:9_Q$WF?\1-YG_$3>9
M_Q&^>P  L8<  *6/  ";E   D)@  (2<  !WH   :Z0  %^G  !2J@  3:L.
M $NK&@!*JR< 2*LS $:K/0%$JT8!0JM. D"K5@,^JU\%.ZMH!CFJ<P@WJH )
M-*J/"S*JGPPQJK ,,*K'##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVV
MA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV
M$0 ]MAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+
M!2JWG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0
MHI0  )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 M
MPQ( +,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&
MF $?QJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH
M (ZA  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H
M&]$1 !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1
MV*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H
M  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+
M !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4
M!.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !I
MN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS
M#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8
M  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@
M3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!  #\"
M^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_
MF   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(
M #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_    _P0
M /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@
M_Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*
M-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F
M /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_
M#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"
MJ #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_
M /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP
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M \$D_P/_, \ _S(+ /\S" #_-@T _S82 /\U&@#],B4 ]# R .TM/P#G+$P
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M#:8XQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P(
M_SX  /=$  #F1P  WT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41( ;5#4P.Q
M0EP$KD)E!JM!; >I0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40FSZQ$9H^
MOQ&8/M02EC_M$90__ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_/0  _T,
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M&GA.]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7
MOU\  +=?  "Q7   JED, *1:&@">6RH F5LX 91:0P.064P%C%A5"(E77 J&
M5F,,@U5J#H%4<1!_4WD2?5.!%'I2BQ9X4I48=E&A&711KQMS4< ;<5';''%2
M\AEQ4_\5<53_$W)4_Q%R5/\0<E3_$')4_Q#S2   XU,  -!;  #$8   NF,
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M%6%?_Q-B7_\28E__$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@
ME&L  (UJ$ "':QX @VLL 'YK. )Z:D(#=FE*!G-H4@AP9UD*;69@#6ME9P]H
M9&X19F1W%&1C@19A8XP87V*8&EUBIAQ;8K8=6F+,'5IBZAQ;8_P87&/_%EQC
M_Q1=8_\376/_$UUC_Q/F50  SU\  ,%H  "V;@  K'(  *1T  ":<P  CF\
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M$DUR_Q+48   PFL  +5T  "K>P  HG\  )>!  ",@0  >GX  '-_ @!N?Q$
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M#SR-G! ZC:P1.8W!$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@
MLGT  *>&  "<B@  D8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,
MFB< 2IHR $B:/ %&FD0!1)I, D*:5 - F5P$/IEF!3N9< <YF'P(-YB*"C68
MF@LSF*L+,IB_##*8WPLQEO4+,97_"S&4_PLQD_\+,9/_"S&3_PNX>@  K(4
M *&+  "6D   BY0  '^7  !RFP  9IT  %J@  !.H@  1:0) $*D$P! I!\
M/Z0J #ZE-  \I3X .Z5' 3FE3P$WI5@"-:5A C.E; ,QI7D$+Z2'!2VDEP8L
MI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@  I8L  )J1
M  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  SL!4 ,K A
M #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22QE (CL:8"
M(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'
MG   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&]
M(  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V
M !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I
M;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1
MS!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.
MQ@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,
M %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1(
M!=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP
MW\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"
M   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02
M  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<
M ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   O
MS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04  .X+  #P
M$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV
M  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@
M%]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@   #Z!P
M^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_
MK@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!.
M /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X
M_P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[
M /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q
M /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\
M\P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_
M %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4
MM0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_
M .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H
M_PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_
MXO__24-#7U!23T9)3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\
MW0O_ -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_
M&"\ _Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.
MF0#F#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_
M <L3_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@
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M!98T_P7_-0  _S@  .H^  #?0@  U4(  ,\_ P#-. @ Q3@5 +TZ)@"W.S8
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M#W]#KQ!^0\ 0?$3:$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@
MYD@  --/  #'5   O54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&0
M34L"C4U3!(I,6@6'2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(
MK!)U2+P2=$G2$W-)[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P
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M%E]5YQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P
MK68  *1F  ";9   D%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O
M7%8%;%Q<!VI;8PEH6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9
MY15;6OD26UK_$%Q:_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D
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M#TQG_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@
M>7$  '%Q  !K<0\ :'$< &9R* !C<C0 8'(] 5YR10);<4T#67%4!5=P6P94
M<&,(4F]K"E!O= Q-;H .2VZ-$$ENFQ%';:L21FZ^$T5NW!)&;?011FW_#T=M
M_PY';/\-1VS_#4=L_PW,7P  O&D  +!Q  "E=P  G'L  )%\  "&>P  =7@
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M"3.#_PFY<   K7H  **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0
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M !VKBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0
MF8\  (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >
MM08 &;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y
M@P /N9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4
M (:;  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P
M$,,&  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !
MQHL  ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC
M  !MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!
M  '0"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP
M -:2  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !A
ML@  5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #<
M P  W0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!
M  #IF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O
M1\(  #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4   #G
MZ $  .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #Z
MA   ^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L
M "O0   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q    \P
M /4   #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@
M_X4  /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\
M, #_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P">
M /\ I #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\
M^P#_ /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_
M #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X
MH #] *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_
M /  _P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8
M_P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T
M *( \P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4
M_P#E /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^
M /\ 2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X
MYP"D .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5
M ?\ U0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(
M10#X!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@
M -@%J #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\
MQ0S_ ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J
M#DH Y0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.
MI0#(#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_
M ;83_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T,
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M YHKM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,
M\C,  .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D
M,U( H3-: 9\S8@&<,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XR
ML06-,\(&BS/<!HDT\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH
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M#&U$YPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5
ML54  *E4  "A4   F4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y
M2E@#=TI?!'5)9@5S26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)
MY UF2?@+9DG_"69*_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D
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M"U95_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P
M@UP  'M;!@!U6Q( <5L? &Y<*P!K7#8 :%L_ 65;1P%C6TX"85I5 U]:7 1=
M6F,%6UIK!EE9=0A768 *55F,"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9
M_PI16?\)45G_"%%9_PC440  PEH  +1A  "J9@  H&@  )=I  ",9P  ?6
M '5? P!O7Q  :U\< &A@* !F8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%
M5UYI!E5><PA37GX)45V*"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,
M7?\)3%W_"$Q=_PC/5   OEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D
M  !I9 X 9609 &)D)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G
M!5!C<0=.8WL)3&.("DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)
M1V+_"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C
M:0L 7VD5 %QJ(0!::BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II
M;@9(:7D'1FF&"41IE0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_
M"$)G_PC%70  MF8  *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< <
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M S&!C@0P@9\$+H&Q!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@
MJ'@  )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ Y
MBQ< .(PB #>,+  VC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,
MBP(HC)P")HRO B6,Q@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX
M )>%  "-B0  @HP  ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$
M+)<: "N7)  JERT *9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?
MF)D!'9BL 1R8PP$<E^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+
M  "'CP  >I(  &V5  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1
M !ZC&@ =I"0 '*0M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90
M$J6H !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_
ME0  <9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q
M$  0L1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@
M  2PM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0
M9Z(  %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #
MO1(  ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^
MJ@  OL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L
M $^P  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T
M ,D2  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0
MS[,  ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y
M   UO   *;\  !["   5Q@  #LD   C,    T    -,   #5    U@8  -@,
M  #9$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0
M .2Z  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   H
MQ@  ',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y    .4#  #G
M"0  Z0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I
M  #WO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T
M$=4   K;    WP   .(   #E    Z0   .P   #M    \    /$   #S
M]00  /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_
MJ   _[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!*
M /\ 5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8
M_P"L /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z
M /\ ^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\
M4@#_ %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H
M /D KP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\
M[@#_ .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_
M %D _P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X
MJ@#L +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_
M .  _P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %,
M]0!> /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#?
M *X W "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X
M_P#_%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8
M .8 8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H
MRP"S ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_
M&P8 _Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$
M6P#2!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P
M +L'O "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@
M_QL  /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$
M#EX P0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1
MN@"M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R
M / C  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U<
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M X,NZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P
MNS\  +0\  "O-0  J2\+ *,O%P">,28 F3(S )8R/@"2,T@ D#-0 (TS6 "+
M,UX!B3-E 8<S; &&,W,!A#-\ H(SA0* ,X\#?S.: WTSIP-\,[4$>C/)!'DT
MY@1W-?D$=C7_ W4U_P-U-?\#=37_ W4U_P/P,P  W3T  ,I#  "^10  M48
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M!E]$_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P
MBTD  (-'"P!]1Q4 >4<B '9(+@!S2#@ <4A! &Y(20%L2% !:DA6 6A(70)F
M1V0"94=L V-'=@1A1X %8$>-!EY'F@=<1ZD(6TB["%I(U A:2/$'6DG_!EI)
M_P5:2/\%6DC_!%I(_P3;1   QDT  +A3  "M5P  HUD  )I8  "15   ADX
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M!4M4_P7,3@  NU<  *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P
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M!#]CC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P
ML&,  *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+
M:2$ 26HK $AJ- !':CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJ
MC 0W:IP$-FJN!35JQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D
M *%P  "8=0  C7<  ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T
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M 1Z&O $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0
M?H@  '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  A
MD"4 ()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21
MN0 3D=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\
M &F1  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L
M$YTD !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )
MG<P "9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9
M  !4G   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;
M  :J)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$
M *CD  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*
MI@  /:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W
M'0  MR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3
M  "V[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP
M,;$  ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0
MQ!P  ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(
MY   R/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H
M !J]   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1#@  TQ(
M -49  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP
MWN8  -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(
M   )S    ,\   #3    V0   -P   #=    WP   .$   #B!0  Y L  .80
M  #H%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D
M //A  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5
MV@   -X   #B    Y@   .D   #J    [    .X   #P    \@   /0&  #V
M#   ^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!
M  #_P0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\
M_P!J /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_
M +@ _P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$
M_P#_"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E
M /\ ;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +,
M] "^ /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_
M#1$ _PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H
M:0#X '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X
M .4 Q0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT
M_PP+ /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L
M &L Z0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -(
MO@#0 ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT"
M /\'  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4
MV0!M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #
M ,< O0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-
M  #_#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F
M ,4 ;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,(
MKP#8 *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L
M$0  Y@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'
M9P"U!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4
M *$-[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@
MU1H  - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H
M$6@ IA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05
M[ "2%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<
M ,$A  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F(
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M F\O_P)O+_\!;B__ 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.
MES$! )$N$ ",+QP B# H (0Q,P"!,CT ?S)& 'TR30![,E0 >3); '<R80!U
M,FD!=#)P 7(R>0%P,X0!;S.0 FTSG0)L,ZL":C2\ FDTU0-H-?$"9S7_ F<U
M_P)F-?\"9C7_ F8T_P+B-@  S#\  +U$  "R1P  J$<  *!$  "8/P  D#D
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M E1#_P+00@  OTH  +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX
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M DE/C0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3
MM54  *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4
M424 4E(O %%2-P!/4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13
MBP-"4YL#052L!$!4P00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@
M *9>  "<8@  DF4  (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B(
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M B]ENP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0
MB',  'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V
M:S$ -6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2AL
MN0$G;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@
M 'EY  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL
M+70T "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?
M==( 'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_
M  !G?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM
M "%^-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X
M%7[O !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@
MAP  5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*
M+@ 5BC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ
M  V'_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP
M3)   $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +
MER\ "I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4
M]   D_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H
M #B;   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<
M *,Q  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\
MH/L  *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD
M   CI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H
M  "Q,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<
M *__  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8
ML   $+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8  +\>  #
M)P  P3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z
M  #!_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP
M![X   #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'
MTR8  -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9
M] !VGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H
M  #.    T@   -4   #6    V0   -L   #=    WP<  .$,  #C$0  YAD
M .DD  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !J
MJ   6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U    -D   #>
M    X@   .4   #F    Z    .D   #L    [@   / "  #R"0  ]0\  /@7
M  #\(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4
M_P 4 /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_
M '< _P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T
MS@#[ .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0
M /\ $ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '(
M_P!Y /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N
M -X [0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\
M"P#_  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T
M /$ >@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -
MW0#I -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_
M  D _P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .(
M= #@ 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@
M ,8 \P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  ,
M_P + /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#,
M '0 R@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4
M[ "S /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  #
M .< #0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X
MN@!T +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E
M /< I #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H
M!@#0 !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N
M *D =0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0
ME@C_ )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$
M!PH O0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+
M;P";"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_
M (@1_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $
ML0T. *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".
M$W  C!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9
M_P!\&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<(
M )X6$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L
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M 6 N_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1(
M=RX> ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A
M,GD 8#*% 5\RD@%=,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT
M_P'2.   P$   +-%  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0:
M &PT)0!I-2\ 9S4W &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!
M63>" 5@XCP%6.)X!53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-
M/   O$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y
M(@!C.BL 8#HT %XZ/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_
M 5(\C0%0/9P!3SVL DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0
MN$@  *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!<
M/B@ 6CXQ %@^. !7/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!
MB@%+09H"2D&K DE"O@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L
M *E0  ">5   E50  (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4
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M 3E/N0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P
MC6$  (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"
M4#4 05$\ $!11  _44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313
MMP$S5-$!,U/Q 313_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8
M (!E  !T8P  9EX  %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C(
M.U8Y #I700 Y5TD .%=1 #=86@ U6&4 -%AQ #)8@ $Q6) !+UFB 2Y9M0$M
M6<\!+5GO 2Y8_P$N5_\!+E?_ 2Y6_P&R5P  I5\  )ME  "1:0  AVH  'QJ
M  !Q:   8V4  %AB  !-7P  0UT" #Q;#0 Z7!0 .%P= #=<)@ U72X -%TV
M #-=/@ R748 ,5Y. #!>5P O7F( +5YN "Q??0 J7XX *5^@ "A?LP$G7\P
M)U_M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N
M;@  8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD
M.0 K94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K
M "!E_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=
M7'(  $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B
M;3T (6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M
M_  8;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH
M $IY   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S<
M%WA  !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /
M=?\ $'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"
M   X@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y
M  V#1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\
M!G__  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   Q
MC   )HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0
M/0  D$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_
M  "+_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@
M'I<  !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0
MG4   )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8
M_P".B   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(
M  ZD   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8
M *Q$  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")
MC@  >Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P
M    L@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX
M  "]1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0
M<)L  &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\
MOP   ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0
M.@  T4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,
M %:I  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)    S0
M ,\   #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@
MZ#P  .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS
M   [N0  *[P  !W    1Q   "<@   #,    SP   -,   #9    W0   .
M  #A    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X'   ^RL
M /T^  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_
M !, _P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\
M@0#_ (< _P"- /\ DP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S
M /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X
M_P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y
M (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@
M_ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0
M /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P
MZ@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1
M /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H
M%@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\
M -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X
MO@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H
M !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$
M>P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_
M *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\ # #6 !4
MSP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O
M 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P
M_P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  :
M +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4
MGP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"-
M ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X
M'@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V
M ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\
M@ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"=
M"2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.
M>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_
M '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L
MC!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V
M%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;
M_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB
M 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH
M:AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7
M+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B
M)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826!
M %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@
MOCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I
M*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@L
MBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT
M *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@
M7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0
M,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&
M  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M
M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4
M2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<
M30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W
M,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD
M 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94
MCU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)
M/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$ /D"B #U
MM0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "75   C54
M (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9 + !$0#,
M0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@ #A%LP$W
M1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46   BUD  (!8
M  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X
M #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D
M,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S
M6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+
M/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I
M "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P
M8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q
M4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93
M_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$
M %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX
M*5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @
M6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E
M  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y#
M "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\
M&5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!
M:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G
M2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_
M !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P
M,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .
M<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN
M_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP
M "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@
M 7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6
M=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'
M   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.
M  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@
MAX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -
ME   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "6
M50  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH
M '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H
M *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P
MIEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5
M  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K    K0   *\
M  "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU
M +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0
MH@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@   +P   "]
M    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5
M  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP
M-K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L   #+
MS0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E
M7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D
M !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=    WP
M .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30
M^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\
M(P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P")
M /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\
M\@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_
M "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0
MB0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_
M .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4
M_0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B
M (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H
M_P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L
M .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (,
MR@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V
M /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D VP E -4
M,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "#
M +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\
MI #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ? ,( *@"_
M #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4
MA "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_
M )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X
MJP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4
M (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8
M_P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q
M )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (
MA "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J
M$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#
M,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F&
M '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'
MRR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^
M#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0
MCP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH
M +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#
M<10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?
M&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U
M  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS
M &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8
M52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@
M/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB
M-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C
M $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00
MDD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4
M*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8M
MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4
M (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38
M3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _
M,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(
M  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y
M $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8
M.3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U
M2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V
M/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF
M #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30
M9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y
M.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_
M^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P
M %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T
M,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J
M0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.
M  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45&
M "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\
M)4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+
M40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+
M3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_
M "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6
M/%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >
M4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1
M_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P
M "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665
M%5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?
M7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC
M   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8
M  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@
MDFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;
M:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K
M80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,
M (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@
M#W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7
M=6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^
M  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(
M  *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64
M (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !N
MA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0
M P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P
M  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0
M5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T   "=
MG0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?
M>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD
M #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J    J@
M *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P
ML8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F
M   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W    N    +D
M  "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH
M ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6
ML0  #;0   .W    N@   +T   #     Q    ,8   #&    R    ,D   #+
M    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%
M  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O
M ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P   #?
MX0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #X
MCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y
M /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )
M_ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#<
M /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\
M/P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1
M .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\
MQ0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S
M $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@
MD@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_
M +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X
MW0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #
M )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D
M_P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!!
M ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T
MJP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_
M    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$
M0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0
M )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X
MZ0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T *$ / ">
M $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D
ME0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X
M ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X
MC@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y
M )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9
M  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^
M 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@
M:P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K
M(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()
M/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD
M %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P
MFBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E
M$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43
MM !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$
M (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L
M6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+
M&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T
M  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP]
M %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0
M0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y
M-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB
M0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C
M #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P
M;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!"
M)T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L
M^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L
M %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$
M.RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R
M,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[
M  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\
M+33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !.
M/   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U
M3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_
M "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@
M0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I
M.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\
M_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0
M #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%(
M(D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E
M30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'
M   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9:
M !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@
MEU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F
M2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,
M90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T
M (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $
M&E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -
M5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH
M  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L%
M !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT
M UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![
M<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE
M"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[
M  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P
M;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"
M< T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !N
MB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X
M %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L
M 'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA
M>IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&
M  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*    B08  (D,
M  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0
M (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   X
MD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP   )<%  "7
M"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC
M  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@
M'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4   "F @
MIP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "J
MLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4
M  NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U    M@
M +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@
MP,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S
M    M0   +@   "\    OP   ,$   #!    PP   ,0   #&    QP   ,D
M  #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+
M -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L   "_
MPP   ,8   #+    S@   -$   #1    U    -8   #9    VP   -X   #@
M    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V
M  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P
M_P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V
M *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0
M_P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0
M /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P
MXP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_
M    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8
M4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "?
M ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_
M_P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #,
M %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4
MHP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P
M /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T
MM@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@
M *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4
M  #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !-
M *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *(
MC0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%
M    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )(
M3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I
M 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#
MK@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@""
M $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X
MM !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(
M )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8
M<P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@
M ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7
M  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-&
M &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$
M50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#
M&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,
M1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C
M $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])
M=!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0
M$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6
M^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8
M &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0
M1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \
M'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G
M  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q(
M #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\
M-2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4
M*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B
M30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_
M # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@
M2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q
M)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ
M_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X
M #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U(
M*RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I
M/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O
M!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!;
M "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P
MFDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N
M,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V
M90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T
M (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D
M)3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8
M.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5
M  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X-
M !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207
M$4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  "
M70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$
M#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_
M  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@
M<V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /
M3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).
MCP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D
M &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X
M!U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP
M5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N
M  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1
M  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P
M %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/
M<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J
M%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N
M  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@
M.WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-  !V$
M=A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !R
MQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0
M "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "##0  @Q
M (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0
M?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-
M   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P  D@P  )(0
M  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@
M (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )
MF0   )L   "<    G@   *    "@    H    *    "A    H00  *()  "C
M#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K
M  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC    I0
M *<   "I    K    *X   "N    K@   *\   "P    L0   +(   "S!@
MM0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y
M\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0
M  "X    NP   +P   "\    O@   +\   #     P@   ,0   #&    R ,
M ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;
MG0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'
M    R@   ,P   #,    S@   -    #2    U0   -@   #;    WP   .(
M  #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  ,
M_P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_
M &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X
MLP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P
M /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L
M[@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8
M +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\
M  #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!;
M -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +(
MO@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U
M    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,
M6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[
M *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E
MV    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J
M %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8
MQP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@
M +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %,
MEP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O ""
M -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X
M  "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2
M (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P
M<0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";
M  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '<
M4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D
M &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P
MB0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I
M %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@
M] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D
M '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P
M7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-
M!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X-
M @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409.
M % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\
M0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?
M#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-
M40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_
M #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@
M41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]
M$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06
M_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$
M $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U,
M-1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L
M,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :
M"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU;
M "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@
MG3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V
M'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B
M90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\
M (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP
M+B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A
M)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'
M  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\
M&BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""
M30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L
M$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_
M !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40
M=E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;
M,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \V
MD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58
M &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!(
M%#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )
M/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:
M  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5
M  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\
M $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=
M7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='
M&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ
M  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99
M3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1  !0%@
M4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.
MR0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<
M #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD
M %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0
M5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M
M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<
M  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8
M %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @
M=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P
M'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX
M  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@
M#WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P
M?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W
M_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH
M  "+    C    (T   "-    C    (P   ", P  C @  (T-  "-$0  C1<
M (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![
MA0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8
M    F@   )L   ";    FP   )L   ";    G    )T%  "="P  GA   )\7
M  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC
M88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,   "E
MJ    *D   "I    J0   *H   "K    K    *T   "N 0  L D  +(/  "S
M&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<
M $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T    M@
M +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'  #)#P
MRAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE
M   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##    Q@   ,@
M  #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A!0  Y@\
M .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_
M  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@
M: #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8
M .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_
M_P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D
M &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D
MZ0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  %
M /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &(
MR@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S
M /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\
M"P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A
M +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X
MG0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#
M  \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *
M7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z
M (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4  0"N  L
MJ0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"-
M %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@
M_P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@  8 F@ .
M )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@
M>P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H
M /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@
M$ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8
M &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\
M6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W
M !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\
M60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_
M %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X
M9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2
M %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4
M_P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0
M %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5<
M1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R
M(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%
M$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E=
M #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P
MH"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!#
M#!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.
M9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$
M )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \
M.1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J
M$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y
M  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1
M #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\
M(QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#
M/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8
M%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^
M !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@
M=T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C
M'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8B
MCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48
M &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14
M'"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1
M)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)
M  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8
M !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\
M#"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>
M2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M
M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q
M  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4
M4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -
M,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   V
MR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(
M $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX
M!3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0
M.^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4
M   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C
M  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8
M $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R
M6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+
M*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX
M  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P
M(5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P
M5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/
M_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E:   &F8
M !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@
M %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$
M;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN
M   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM
M  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0
M>GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z
M>@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X
M,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8
M &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&    AP
M (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0
MB#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(
M  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3    E0   )8
M  "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":'P  FBT
M )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!
MDP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I    *4   "D
M    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS
M  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG
M)I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0   "S
MM    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&
M.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@
M  VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##    Q0
M ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8  #C*P
MY$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\
M$@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O
M .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\
MV0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\
M !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D
M;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_
M +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T # #H !,
MXP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_
M &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D
M_P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #. !  R0 8
M ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8
MJ0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2
M /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T LP 3 *\
M' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F
M )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\
M?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0 )X %P":
M !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? ((
M90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_
M &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X $@"* !D
MAP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q
M &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$
M_P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ;
M '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &
M80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!
M#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@
M'0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D
M %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@
MJA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !:
M !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $<
M:0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X
M )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D
M3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \
M '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F
M  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  :
M $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X
M,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&
M+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'
M&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\
M "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@
M>3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O
M#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0
MC@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8
M &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@
M)Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8
M%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX
M  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X
M$ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?
M.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ
M  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@
M4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4
M'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DB
MQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\
M $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B
M#R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $
M)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!
M   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E
M  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,
M "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^
M1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O
M*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U
M   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20
M+T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0
M-C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U
M_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL
M "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\
M #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*
M5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0
M   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W
M  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70
M?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .
M5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !/
M/P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D
M '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P
M %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@
M64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S
M  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ    :@   &D
M  !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,
M &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?
M>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0   '8   !U
M    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,
M  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P
M1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,   "#
M@@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!
M5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D
M "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1    D0
M )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43
MDV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4
M   4E0  "I8   "7    F0   )L   "=    GP   *    "@    H    *
M  "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I0   J58
M *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *
MGP   *$   "C    I@   *@   "L    K@   *\   "O    L    +    "R
M    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B
M  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@
M *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(   #$
MQ@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@
M;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D
M /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4
MY@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X
M /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4 \P ? .\
M*0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U
M ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\
MH@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  : -< (P#0
M "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0
M=0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_
M )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "<
MM0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@">
M '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (,
M_P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I
M )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\
MB0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F
M    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L D  C (P
M*P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q
M '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3
MPP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z
M "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8
M= !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(
M *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4
M:0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6
M 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -
M  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E
M %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4
M2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".
M$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\
M)0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^
M #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'
M?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$
M "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #(
MC  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$
M '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$
M.0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H
M )P )P"P "8 R0 E .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE
M  !D(   6QL  %(5  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B
M "\")P M BT + ,T "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH
M'P>N !X'Q@ =!^< '0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A
M)@  6"$  $\<  !'%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<(
M(P E""D ) DP ",)-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM
M !8,Q@ 5#>8 %0WY !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+
M52<  $PC  !$'0  /!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >
M#24 '0TL !L--  :#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0
MQ@ 0$.@ $!#[ !$0_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT
M $HH  !")   .1\  #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$
M%A I !40,0 4$3H $Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +
M%., #!3Z  T3_P"7-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN
M  ! *@  -R4  "\A   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F
M !$4+@ 0%#@ #Q5"  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.
M!QCU  D8_P"5.   BCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^
M,   -BL  "XG   G(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9
M+  ,&C4 "QI   H;3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR
M  ,<_P"3/   B$$  ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@
M-3(  "XN   E*@  '24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ '
M'S, !B ^  0@2@ #(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @
M_@"00   AD4  'U(  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D
M "LT   B+P  &2L  !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$
M "4\   E2   )E4  "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".
M10  A$D  'M-  !S3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y
M   >-0  %3(   \N P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY
M   K10  +%,  "QB   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20
M@DX  'I2  !Q5   :%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :
M/   $C@   PV P &,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R
M0P  ,E   #)@   R<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0
M 'A7  !O60  9ED  %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@
M#D    @] @ !/ @  #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0
M.4X  #E=   Y;P  .(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=
M  !M7P  95\  %U?  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@
M  -& 0  108  $0*  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H
M $%:  !!;   0($  #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L
M90  9&8  %ED  !+80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/
M    3@,  $T(  !,#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6
M  !):   27X  $B6  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;
M8&L  %)I  !$9@  -V0  "IB   ?8   %5X   U=   &6P   %H   !9
M6    %<$  !6"   5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !3
M9   4GD  %*2  !1JP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'
M $IO   \;0  +VP  ")J   7:0  #F<   9F    90   &4   !E    8P
M &(   !B!   80@  &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@
M7G0  %V-  !<IP  6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U
M   S=0  )G0  !ES   0<@  !W$   !Q    <0   '$   !Q    ;P   &\
M  !N    ;@(  &X(  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT
M &J&  !IH0  :+X  &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H
M?@  &WT  !!]   '?0   'T   !]    ?@   '\   !^    ?0   'T   !\
M    ?    'P   !\!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^
M  !ZF@  >;8  'C?  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP
M$8<   >(    B    (D   "*    C    (T   "-    C    (P   ",
MC    (P   "-    C00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-
MD   C*T  (O.  "*\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(
M  "3    E0   )<   "9    FP   )P   ";    FP   )P   "<    G0
M )X   ">    GP   *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@
MHJ(  *+   "AZ !<C0  39   #^3   PE@  (9D  !*:   'FP   )T   "@
M    H@   *0   "H    J@   *L   "J    JP   *P   "M    K@   *\
M  "Q    L@   +0   "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0
M +NQ  "YT@!0E0  09@  #*<   CH   $Z(   BD    IP   *H   "L
MKP   +(   "W    N0   +L   "Z    O    +T   "_    P    ,(   #$
M    Q@   ,D   #-    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C
M  #6O0#_    _P   /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4
M]  _ /  1P#N $X ZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#;
M (< V "1 -, G0#/ *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *,
M_P#_    _P   /\   #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y
M -H 00#5 $@ T0!. ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\
MO@"* +L E0"X *, M@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_
M    _P   /H   #Q    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,
M.@"] $$ N@!( +@ 30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J ""
M *8 C@"D )L H0"K )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_
M]@   .@   #<    S@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H
M #L I0!! *, 1P"A $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )(
MA@"0 ), C0"B (L M0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP
M -(   #%    N@   +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0
MD@ Z )  0 ". $4 C0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!]
M (L >P": '@ JP!V ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\
M  "T    JP   *$   ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S
M '\ .0!] #\ >P!$ 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (,
M:@"2 &@ HP!F +@ 9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E
M    G0   )0   ",    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\
M,@!M #@ :P ] &H 0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"*
M %D FP!7 *\ 5@#+ %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9
MD    (@   "!    >0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !?
M #( 7@ W %P / !; $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P
ME0!* *@ 20#  $@ Z !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4
M 'X   !V    ;P   &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P
M40 Q %  -@!. #P 30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _
M *( /0"X #T W0 \ /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,
M  !N!0  9@   &   0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K
M $4 ,0!# #8 0@ \ $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P
M,P"Q #( S@ R /$ ,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H
M#@  7PH  %@#  !1  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H
M+  Y #$ -P W #8 /@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M
M "D Q@ H .H * #^ "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@
M6A$  %(-  !+!P  1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P
M "P +@ S "T .@ K $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "
MP0 @ .0 'P#Y !\ _P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@
M $X3  !&#@  /PL  #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@
M)@ N "0 -@ C #X (@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7
M -\ %P'U !<"_P":)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:
M  !#%   .Q   #0- @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J
M !T#,@ ;!#H &@5$ !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L
M$ CR ! )_P"7*P  C"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  !
M&P  .!8  #$2   I#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)
M+@ 5"C< $PI! !(+30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ
M  P-_P"5+P  BC,  '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0
M-AT  "X8   G$P  (! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /
M#30 #@X_  T.2@ ,#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80
M_P"2,P  B#<  'XZ  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,
M "T?   F&@  'A8! !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3(
M"A$\  @22  '$E4 !A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0
M-@  ACL  'P^  !S/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF
M   E(@  'AX  !8: @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z
M  ,61@ !%U,  !=B   8=   &(D  !B?   8M0  %]   !?M   7^P"..@
MA#\  'M"  !R0P  :$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D
M*0  &R0  !,? @ -&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;
M1   '%$  !Q@   =<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,
M 'E&  !P2   :$@  %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0
M%RD  ! E @ +(@D !2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00
M(4\  "%>   B<   (H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+
M  !O3   9DT  %U+  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\
M  TL @ '*0@  2<,   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT
M "=<   G;0  )X(  ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N
M40  95(  %Q1  !33P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR
M 0 #, <  "\+   N#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9
M   M:P  +8   "R7   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P
M8U<  %M6  !350  1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z
M. 4  #<)   V#0  -0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T
M:   -'T  #.5   RK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET
M %M=  !/6@  0E8  #92   J3P  ($P  !9)   .1P  "$0   !"    00,
M #\'   ^"P  /0X  #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90
M.WH  #J2   ZJP  .<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B
M  !)7@  /%L  "]8   D50  &5,  !!1   *3P   4T   !,    2@   $D$
M  !("   1PP  $8/  !&%   11P  $4G  !%,P  14   $50  !$80  1'8
M $./  !"J   0<8  $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"
M9   -&$  "A?   =70  $EL   M9   "6    %8   !6    5    %,   !2
M!   40D  % -  !0$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+
M  !,I0  2\(  $GJ  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@
M+&D  "!G   490  #60   -B    8@   &$   !@    7P   %X   !=
M7 0  %P)  !;#0  6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7
MH   5KT  %7H  !3_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$
M !9O   -;@  !&T   !M    ;0   &T   !L    :P   &H   !I    :0
M &D#  !H"0  : X  &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@
M8[<  &+A  !A_ !W>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY
M   $>0   'D   !Y    >@   'H   !Z    >    '@   !W    =P   '<
M  !W 0  =P@  '<.  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\
M '+3  !Q]P!Q?@  8W\  %2   !%@@  -H,  "B$   :A   #H,   2$
MA    (4   "&    B    (D   "(    AP   (<   "'    AP   (<   "(
M    B    (@'  ")$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'
M  "$[P!FA   5X8  $B(   YB@  *HP  !N-   /C0  !(X   "0    D0
M ),   "5    EP   )@   "6    EP   )<   "7    F    )@   "9
MF@   )L   "=!P  G1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";
MX@!:BP  2XX  #R1   MDP  'I4  !"6   $F    )H   "<    G@   *$
M  "D    I@   *<   "F    IP   *<   "H    J0   *H   "L    K0
M *\   "Q    LPD  +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-
MD@  /Y8  "^:   @G0  $9\   6A    HP   *8   "I    K    *\   "S
M    M0   +<   "V    MP   +@   "Z    NP   +T   "_    P0   ,0
M  #'    RP   ,T,  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
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[encoded data, 4270 characters]
M_______________________B@0Y)0T-?4%)/1DE,10 )"?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________3_________________________________________Z]'_____
M____________________________________]^G^____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________X<W7____________________
M___________________=KY:W]/__________________________________
M___%C&BGY______________________________________,G(FDY_______
M_______________________________ZSKO&]?______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____W,6]]?____________________________________^_DWJ%Q?______
M_____________________________]N06SUEJ/;_____________________
M_____________KQU- !4F^O_________________________________TY1^
M22Q.FNS________________________________8U,JS?F5MI?G_________
M___________________________TQ:ZOR?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________\-;&[/______________________
M_____________^:[D71CJ_?________________________________VQ)IS
M128T?<S_______________________________^U@%4P"@ 98++_________
M_____________________\]T-0L    *4J?_________________________
M_____Y8T        3Z?_____________________________]FD=   )# 8)
M4K'_____________________________RSL.$S5,6TU,7L/_____________
M________________J6 V8(:?MJRIN-G_____________________________
MX)>-ON7______________________________________^WY____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MV<J\Q___________________________________SYJ!;5I&B.K_________
M_______________________$?#XF$   5+#_________________________
M_____^"#/       +H?M_____________________________ZQ3$
M%VW6____________________________^X Q        "6',____________
M________________TEH"         %W,____________________________
MJ#4          %S3____________________________?0T          %36
M___________________________N?44          $34________________
M___________\JF0O @  !"(W25C.____________________________Z:1K
M02@_8W^5I[K:_______________________________5LJRRS.3Z________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________ENY=W8LC_________________________
M________VYYG-@H  HS________________________________(?S\%
M %[/_____________________________]F!.0       #RJ____________
M_________________YY,         ".0____________________________
MW&\:         !!]^?__________________________KT@           !O
M[O__________________________A!,           !DYO______________
M___________L40            !7WO________________________^X%0
M          !(UO________________________]T%              XS___
M______________________FB6A,            CQ?__________________
M_______?FUPL           -NO__________________________[[%]53DB
M$0<! A$BLO______________________________W[^EF9B:H*R]VO______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________X[Z=
M@'S[________________________________\K>$5S . !VL____________
M___________________2BDP5      !R\___________________________
M_]9_-@        !+R?__________________________^I$^           O
MJ___________________________P%H            :E?______________
M____________C20            (A/_________________________G7@
M            =_________________________^T)0              :O__
M______________________]]                6_3_________________
M______TK                3.O______________________Z4
M        /.'______________________S ,                +=G_____
M________________F8IA)P              )]?_____________________
M_^V^B54G            )=S__________________________LJ==EU*/#(M
M+# Y1][_______________________________WFW=;2T-/9Y/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________OU+O6____________________________
M_____^>XCVI++Q5O_______________________________DH6<T!P     \
MR?___________________________]:".P         2E_______________
M____________[84Q            ;___________________________ID(
M            4.'________________________L:0              -\G_
M______________________^S+P              (K;_________________
M______]Y                $*?_______________________(T
M         )G______________________ZD                  (S_____
M_________________T8                  '______________________
MWP                   '3_____________________EP
M     &K_____________________S@                   &/_________
M_____________RDB 0               &'______________________[FC
M@%<W%P           &C___________________________K3KI2&?'5Q<')W
M@93_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________V[J=@FEIT_______________
M________________R)-E/1D    =GO___________________________]N.
M3!,         ;O__________________________VWPL            1=?_
M________________________BRH             (K3_________________
M_______"1                Y?_______________________]] 0
M         '_______________________^<V                 &K_____
M_________________YT                  %C_____________________
M_T8                  $?X____________________Z0
M     #7I____________________E@                   "7;________
M____________O                    !C.____________________ZP
M                  _"_____________________P
M  JY_____________________R<                   JU____________
M_________W                    VY_____________________^"<C'!5
M0C,F&Q0/#0X2&B:_____________________________^>38TL[,R\S/UN#\
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________Z].\X________________________________]*IA65(+!(!A?__
M__________________________&K<3P/        3^#_________________
M________U7\U            '[+________________________C=1T
M         (G_______________________^0(P               &?_____
M_________________]5#                 $CV____________________
M_XH                  "[=_____________________S@
M     !?(____________________O@                    2V________
M____________G                     "E____________________N@
M                  "3____________________W
M  ""_____________________P                    !T____________
M_________Q,                   !H_____________________T(
M              !@_____________________WH                   !=
M_____________________]$                   !A________________
M______\D                  !F_______________________)K)F)?79Q
M;&EG9F=K<'J,________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________XL6JD7EA=______________________________=IG=0
M+ P     ,<3_________________________X)).$P           (______
M___________________2<!T              &#_____________________
M_^YO#P               #?B_____________________Y8<
M     !3 _____________________T                    "C________
M____________K@                    ")____________________G@
M                  !R____________________O
M  !?____________________V@                    !-____________
M________^@                     [_____________________PX
M               J^?___________________S,                    ;
MZ?___________________UX                    /V_______________
M_____X\                    &T/___________________]
M            RO____________________\K                    R/__
M__________________^                     R___________________
M___W%@$%!0,!       !!@T8R________________________.OAV,_,S<_0
MTM37W.+J____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________':QO______
M________________________\<:CA&A-,A@ %:O_____________________
M_____[E\1A@          ''________________________7?"\
M     #OC_____________________]]D"0                RU________
M_____________W0#                  "-____________________Q14
M                  !J____________________F0
M  !+____________________M@                     P_?__________
M________UP                     9Y___________________]@
M               %T____________________PX
MP?___________________R\                     K_______________
M_____U(                     GO___________________WD
M            CO___________________Z4                     @/__
M_________________]@                     =/__________________
M__\V                    ;?____________________]\
M        :?_____________________7#0                  :/______
M________________<                   8?______________________
M_U \1DY465UA9&AL<'9^B?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[]6[
MHXMS6I7___________________________B_CF1!(04      %+\________
M_______________WG588             !?!_____________________^5L
M%@                "-_____________________V,
M  !>____________________G0                     U_/__________
M________H0                     1V?__________________R@
M                N___________________[@
MH?___________________PP                     BO______________
M_____RT                     =O___________________TT
M            9/___________________V\                     4O__
M_________________Y0                     0/__________________
M_[P                     ,/___________________^H.
M        (O____________________]$                    %?______
M______________^!                    "_7____________________(
M"P                   NS_____________________7@
M     .7_____________________R1P                  -K_________
M_____________YT!              <.%\7________________________5
MN;S!Q\[5V^'F[?3[____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________XW\__________________________
M____[,:EB&U4.R$' #+>________________________UY)9*0
M  "@______________________^)-@                !G____________
M_________V8                    R]O__________________E0
M               #R/__________________IP
MH/__________________UP                      ?/______________
M_____P                      7O___________________R4
M            0____________________T@                     +/__
M_________________VH                     &/__________________
M_XL                     !?/__________________Z\
M         .'__________________]4                      ,______
M______________\D                     +[___________________]4
M                     *[___________________^+
M     )_____________________+#@                   )+_________
M____________5P                   (;_____________________J@H
M                 'G______________________VT
M &;_______________________=5                 $7_____________
M____________:B,K-3]*56!J=7Z'D9S_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^C/MIV#:4ZY____________
M_____________^RR@UPZ'0(       ![_______________________%;2D
M              ! _____________________X,;                   '
MR___________________D@                      F/______________
M____I                       :O__________________W0
M            0?___________________PX                     '?__
M_________________SD                      .C_________________
M_V                       ,[__________________X4
M         +?__________________Z@                      */_____
M_____________\L                      )#__________________^\6
M                     'W___________________\^
M     &S___________________]I                     %K_________
M__________^9                     $G____________________2%@
M                 #G_____________________6
M "G_____________________H@                   !G_____________
M________]58                   3______________________[LO
M              #X______________________^K*0                #/
M________________________R4<     !Q,@+CY2:(3M________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________]-7)____________________________^M*PDG==0B@,  !*
M________________________Q7U%%P             1V/______________
M_____\10                    G___________________H@P
M            :/__________________E                       -O__
M________________V@                      !^S_________________
M_Q4                      ,3__________________T@
M         *+__________________W4                      (/_____
M_____________YT                      &G__________________\,
M                     %+__________________^</
M     #[___________________\S                     "O_________
M__________]8                     !C___________________^!
M                  7___________________^L
M  #____________________>(@                    #R____________
M________7                     #?____________________GP
M              #,____________________Z$H                   "W
M_____________________Z 6                  "<________________
M______]Z @                !W________________________>@L
M          5,_________________________Z)7:'2 C9RKO-#G________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^WC___________________________2HWI8
M.BDC'!8.!@  G_____________________^L4@X                 :?__
M________________Y$,                     -/__________________
M>0                       ./_________________S0
M         ++__________________Q,                      (7_____
M_____________T\                      %W__________________X,
M                     #K__________________[(
M     !S__________________]L#                      +_________
M__________\J                      #[__________________]/
M                  #G__________________]T
M  #4__________________^;                      # ____________
M_______$!P                    "M___________________P,P
M              ":____________________9P                    "&
M____________________HP                    !R________________
M____XT0                   !<_____________________Y$&
M          !!_____________________^M?                   =____
M___________________*2P                  ____________________
M____RU<   P8)#$_3F!TBZ?'___________________________7Y_+_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______KU,W'PKZZM[.PK:FHI?___________________]U^4S\P(QD1"0(
M         -O_________________=@                       *?_____
M____________N@                       '7__________________P<
M                     $;__________________TX
M     !K__________________XP                       #]________
M_________\$                       #;__________________$9
M                  "^__________________]$
M  "D__________________]K                      "-____________
M______^1                      !Y__________________^W
M              !F___________________>(0                    !3
M____________________2@                     _________________
M____=P                     K____________________K H
M           6____________________YT4                     ____
M_________________XH                     ____________________
M_]9-                    _?____________________^G+@
M        U?______________________F"H           88+45@X/______
M_________________ZAC=(&/G*N[S>+Z____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________G
MR[>IG96.B82 ?'AT<&QH99#_________________O&I(+1D*
M     #'__________________P                        /_________
M_________T(                       #<_________________XX
M                  "R_________________\X
M  "-__________________\I                      !K____________
M______]:                      !.__________________^&
M               T__________________^N                       >
M___________________4%P                     *________________
M___Z/0                      ____________________90
M            ____________________C@                      ____
M________________O!D                     [___________________
M\4X                     V/___________________XL
M        O____________________\Q#                    H?______
M______________^1&0                  >O_____________________R
M= H                17_______________________Z'03'RPX15-B<H6;
MM-+U___________________________7Z/3_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________OW\_'N[.OK[/'__________________]FRF8=Y
M;61=5E%+1D$\.#(M*"/$_________________TLE"P
M  "2_________________X@                       !F____________
M_____]<                        ]__________________\S
M               8__________________]L
M__________________^=                        ________________
M___)#                       ]O_________________Q-0
M            W___________________6P                      R___
M________________@@                      M___________________
MJ08                     H___________________TR\
M        C?___________________UX                     =_______
M_____________Y,'                    7O___________________\U#
M                    0/____________________^'$
M    '/_____________________87@                   /__________
M____________OTX       X<+#Y2:H:ER/_______________________\)\
MC)JGML76Z/W_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^[AU\_)P[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O
M*"(<%A +!      4_________________]<%
M__________________\T                        ]O______________
M__]V                        TO________________^P
M            LO_________________A)                       EO__
M________________40                      ?/__________________
M>0                      9O__________________H
M        4?__________________QR,                     //______
M____________[DL                     )____________________W0
M                    $/___________________Z,6
M     /___________________]A,                     /__________
M__________^(#P                   /_____________________+4P
M                 /______________________I3@           D=-$YK
MC/_______________________YDY0U%?;GV.H+7+Y?__________________
M___________K^?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___KS+FLH9F1BX:!?'AT<&MH9F9H\?________________]A13(C& X&
M            GO________________]^                        =?__
M_______________#                        4O_________________[
M-P                      ,O__________________:@
M        %O__________________E@                       /______
M____________OQL                      /__________________YD(
M                     /___________________VD
M     /___________________Y "                     /__________
M_________[DL                     /3__________________^A<
M                 -G___________________^1&
M +S____________________*4P                   )W_____________
M________F"X             $"E&9L3_____________________[G\=#!HH
M-T97:7Z5K\SN_________________________^>@JKG(V.G\____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________?7PZ^;BW]O8U-+1T-+7X/_________________.
MGHI\<6EA6U913$A#/CHV,B\N,?_________________2)1$#
M         /__________________0@                       /______
M____________?0                       /__________________L L
M                     /;_________________W3D
M     -S__________________V(                      ,7_________
M_________XD                      *___________________Z\B
M                 )G__________________]9(
M (+___________________]R                     &G_____________
M______^A*                    $[____________________37
M             #/_____________________EBX              !4R4G?_
M____________________X'(3   !#Q\O0EAPBZC([/__________________
M_____\IO;GZ.GK##V.__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________^>#2R,"ZM;"LJ*6BGYV;FYR@I___________________@F16
M2T,\-C K)R(=&!,."00  -3_________________D@
M     *W_________________S!X                      (O_________
M________^U(                      &W__________________X
M                 %'__________________ZD;
M #K__________________]!"                     "/_____________
M______5H                      S___________________^/%
M              #___________________^X/@                    #_
M___________________E;0,                   #_________________
M____GS<              ! O4'3_____________________W7(4      87
M*D%:=92VVO_______________________[Q81%1D=8::K\CC____________
M___________________2S>'Q____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________\^_K[_?______________
M________[KFHG9:/BH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A
M&Q40"P<"         "/__________________VD
M  #__________________YL*                      #_____________
M_____\@Y                      #___________________!C
M              #___________________^*#@                    #_
M__________________^P-                     #_________________
M___56P                    #_____________________A1H
M          /L____________________L4D              !@Y78'_____
M________________Y7L>       ,(3A2;X^SV?______________________
M_[M8*3E)6FR E[#-[?____________________________^SGK3%U^O_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________Z[^?AW-G6U-+0T-#1T]G@Z_?_____________
M_____[B*?G=Q;&AD85Y;65A75UE>97'__________________[\Q'Q80"@4
M              #__________________^U6                      #H
M__________________^"!                     #,________________
M__^K+P                    "S___________________25P
M          ";___________________W?!                    "%____
M________________HC<                 !2N4____________________
MRV$"            #"Q0=I[1____________________]8TP       -(SM7
M=IF^Y?_______________________\-C&"H[3%]TC:?&Y_______________
M______________^H?Y:HN]#G____________________________________
M_?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________=SL6_O+FVM+.QLK*UN<#)U>/_________________
M__^7;&1>65513TQ*2$=&2$M066:A__________________^G)@X' @
M          !6___________________.4                      Z____
M_______________T>0L                    A____________________
MGS(                    .____________________Q%@
M   (,5J$____________________Z7\?           &)TMQFL+I________
M_____________Z=)      (7+TIHBJ[5_/_______________________]-U
M'B8X2EYUCZO+[_____________________________^N<H68K,+;]O______
M____________________________W^______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________O[*JIJ.AH)^?H:.FK+3 S=WL____________________
MBEI33TM(1D1#0D%"0T=.66E]____________________GBX&
M        ____________________PU8                  !5!________
M____________YWL:              DT8(NT_____________________Y\_
M          0E2G&9PNO______________________\9F#P   !,J1&*#I\WU
M_________________________^N.-2L^46B!G;S>____________________
M__________^^=G^4J<'<^?__________________________________TMCS
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________V\O#O[^_Q\_C]________________
M____________^+"?FI>6EI:8FY^DK+;"T>'N_____________________HY0
M2D=%1$1$149'2U%::(.I_____________________Z9! 0          !S9C
MC[KA_____________________\9E"@      !"=,<YS$[/______________
M_________^6(+P  $RI$8H*FS/3___________________________^K4#9*
M87N6M-;Z_______________________________2AWR8L<OI____________
M________________________U,[M________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________MY>/CY.;H[?'Y____________________
M__________VQE)*2E9F=HZFRO-#M__________________________^=4T=)
M35%68'.*K];\__________________________^R5@ :-5!MBZ[2]_______
M_______________________-;SY?>YFWU_G_________________________
M_______NGX.FPN'_____________________________________X\[K____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________
M
M
M                                      #_____________________
M____________________________________________________________
M____________________________________________________________
M_____________________________P    #_X4(+:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P
M," W.2XQ8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&9X/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9G@O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO=&EF9B\Q+C O(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P
M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QP9&9X.D%0
M5$M615(^,3$N,2XP+C(R,3,Y(%!R;R!0<F]D=6-T:6]N+3,R/"]P9&9X.D%0
M5$M615(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(R+3$Q+3 S5# Q
M.C,R.C(X+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y4;V]L:VET(&AT=' Z+R]W=W<N86-T:79E<&1F+F-O;3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,BTQ,2TP,U0R,CHS-SHP-RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,3$M,#-4,C(Z,S<Z,#<K,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV97!D9BYC;VT\+W!D9CI0<F]D=6-E
M<CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/F-G,#(R.#<T/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O
M<V]F="!7;W)D("T@5FES:6]N("T@0V]N<V]L:61A=&5D($8M-"Y$3T-8/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#!E9F0R
M9#8M-39E,BUC,31F+3EE93<M-&%F-3)C-F%B-#)C/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP
M:&]T;W-H;W Z8S5B-60S9F$M-S(Y,BUD,S0Y+3@R-C<M86$W-S0U8S8X96,V
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/GAM<"YD:60Z865C.35D-64M-# Y-2TQ8C1F+3DS,#8M.38Y
M.#8T9F%A-S$W/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#IA96,Y-60U92TT,#DU+3%B-&8M.3,P-BTY-CDX-C1F86$W,3<\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C(M,3$M,#-4,C$Z-#0Z-3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z83@W83=D
M-S4M,#<U-BTQ8S0X+3@V,C M960P-V)F-&4Q,3,S/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q+3 S
M5#(R.C,W.C W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,#!E9F0R9#8M-39E,BUC,31F+3EE93<M-&%F-3)C
M-F%B-#)C/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(R+3$Q+3 S5#(R.C,W.C W*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#IA
M.#=A-V0W-2TP-S4V+3%C-#@M.#8R,"UE9# W8F8T93$Q,S,\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z865C.35D-64M-# Y-2TQ8C1F+3DS,#8M.38Y.#8T9F%A-S$W/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z865C.35D-64M-# Y-2TQ8C1F+3DS,#8M.38Y.#8T
M9F%A-S$W/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H
M;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T
M;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I
M;VX^,34P,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z65)E<V]L=71I;VX^,34P,# P,"\Q,# P,#PO=&EF9CI94F5S;VQU
M=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI2
M97-O;'5T:6]N56YI=#X*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S
M-3PO97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE
M;G-I;VX^-38S/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X
M:68Z4&EX96Q91&EM96YS:6]N/C(R-CPO97AI9CI0:7AE;%E$:6UE;G-I;VX^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ D0%H P$1  (1 0,1 ?_$ !\   $#
M! ,!               '" D"! 8* 0,%"__$ $(0  $#! $# @4" P8$! 8#
M  $" P0%!@<1  @2(1,Q"10B05$582,R<0H6@9&A\!="4K$E,T/1&B0TP>'Q
M8G*2_\0 '0$!  $$ P$               $%!@<( @,$"?_$ #T1  $"! 0#
M!@0& @$$ @,   $"$0 #!"$%$C%!!E%A!Q,B<8'P,I&AL0@40L'1\2/A4A46
M,W(78C138__:  P# 0 "$0,1 #\ W^.(0<0@XA!Q"#B$'$(.(0<0@XA!Q"#B
M$'$(.(0<0@XA!Q"#B$'$(.(0<0@XA!Q"#B$'$(.(0<0@XA!Q"#B$'$(X5HI(
M/MH\0BU?;0XTD$CM\@;.O?P=$;U^Y\@#[_E'!2,XM>W73TO_ &8\21(C4Z,X
M[(E)A--MJ+CSKS:&66 APH<6Z_\ PD@! *W%;"$D$]H^H<9<B?.L,Q+GX05&
MU[@)))8W(VTY1Q5,IJ4$J6R4@,5'*->I:QW/JUHBFS#\9OH!PID>#BZO9B_O
M%<;57%)N6=8T)^[+;M).DJ=>KU>B%R$E#<CL9EI@N2)<19<2XA#392FIT^"U
M;&8$,"+ YA<,Y( O<?+9H\,S%J";-($T7+'0 .G07V+M9M 3$D-HY/QYDBS8
MM^8^O.A71:-4I::G&N6AUJ%-IK<9R.F7W.3&7'8\5;;!"Y4>4&GV #ZB$:)Y
MXIM)-5,,J8A0*R$@)"G=V)',&UQOJ4FY]<J;)[N;-ES00A(4HE09KD/=PUG<
M;AX@SZLOC^=/^$*G5+.PM;%2S]==%J$>G2:G"K$>AX[;>94ZS56D7(VS/G3Y
M-.4R%E,6"Y$>=);1+2//+EP[A*8M"43'0E9T;,H,S.64EF>Q!N;G5['K^T.G
MI9LR3+29BV83-$DZ$@$A3$EMB0 6(8Q!WDWX^'Q LNU>10<;U*S</-5>L.N0
M9%H6RS7*[3:8"5I:G5&Z6JI3WAZ8*5.MTAE2U#N20""*U68!24%.HS"D94@
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MW[D_CP0?^W#'1K\HAPSN&C@.()("DDCWT0?]_P!.&/*)-@YTM?:^EXJV!Y)
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MJ;D-K2HMJU]34EGN*V_44"D+42$^Y!UYP_7X)4TBB9R2 E1)LWAS6Z _)SR
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MH:WY[A[#\^W)'ZAS21OY[<F?TVU'7-^$?^R?O&MM\>^JBER,".(7VJ>BWJT
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M:5!SE.5@$)))2@. ZG):RDYL!3A[*&AW!./+S#RE)24K]2VJD#Y]U#N "^\
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M%;UQN1:I0T.B5:5Q5B,RR['JK\=R&@5*3';E-LJDR ZAM;/8A9" 16<7$[
MJ1*4HYG1X2H6 N"D,&!VL.6C1C'@K!.'^T[$_P#N;$</*>[F)G)14(E3*::%
M@S$+5+FA;3"/C2%'-J"',3!4^D1(GR[<)AJ/'CM,MAAIL)90I*5EOTD)3Z:4
MM(4I*"D (\@$;.['GI7431.6HN7-S<[N2SN'ZGEK&Q=/)DTAR4>5,F2.[2$@
M!(2!8)2+ ,68,D7Y-%[Z2%L.(]=O:7PI&D*T&@0>WM[?/D$Z\C?G\$]LM>1L
MSD ,P87Z/<=3]-!';-(J6[EI<VSD6) /B+B]P=_M<Z[?Q,.CN/8UY2,YV-2P
MNU;ZG+3>%/AM=K%#N,I; JWHQVDLLTZM)'IR&U)[6JB#*.B\ZX+]X=Q1+]W.
M6I64).59)W(L[AVU+#E&!^TGA92:V7BQ [H!86SF[!9"@ Q! ]&'_%X@9RQ%
M8G/FVX\9$RD1F4O55*D(6U(?>*BJ ^A0[7&T)^E#;B2V-(4D$)!3D-4S\P.[
M0K<$I=@P=PUMN3N+.!&#,5QVFGHDRZ$]S/DJ20N6E,I8*1<YD7;<@ *>[6AC
MU^]/R[59;N7&B)33$F9Z-T45"E.,MTA[M4R]2XNT--O,K2I+JF4> HH5I!V*
M=BG#DNMI.\*4*)?-F *F!-R "2  ^EQ>[%LK]G_;CB?"AD2:JLJU2Y*60HU,
MQ222HDI!*V2[D!R!FL][XG6[*KE!@4VJR8X7 JJ>V%*[O3>]9'=ZK3C0(2E:
M2>U2E #:3KW&\=8GPW+I):#*R()*\W=!LP #!64 EB2SDL22!J8W7X#[:L%X
MPIC+F *JF *YDM*YB%*!N%^(V(V/4V$6]LU=-M7-1[@DPOU1%&FA\4U#X9[N
MYI)2KY@J2I1*D:^HGM_F4-;YY\)DSY2NZ0E2<Q *T6WU!#%P.; >4>SM0JL"
MKN$54E35OWO>)4F:53$D*2EQE.8$;MOS$2T8#ZE<4W3*@Q<AT2Y[?NANY"+9
MI%M4ZF7#19<5,3O8D56HS)].D1G4K47'6HD9X$H [SO8R;3RDS*!,I24E1'B
MS $DLSD96+[ON#<ZQ\^N)N%.%<+E4V)RS2K$BJ3-F 2$DY,ZB=0"1XAN 'T=
MC"Y_$"I'38,4TK)M?B?WDOZNKCT^Q7K9FQK>KLUI*B:H;C<*#\K#@/?PR9+<
MB6VIM+,/O;*NW''$5))DK43(EAE:Y$[$]-WZDAP+WC<WL:XK.*8%3TF F?*7
MW4N4A=,HR2$A*4AE2U)+91<:; %F,9_3QEVS\83!1Z_C>A+@3WY#B[QF0YE2
MN.FTYQ;JHM.J28[SAG4]+B0J+)AQH[*?4)>90I"DBEX762922I.5)[P@%( )
M\*3\3 [MMT>,J=H'916XYA=/78RFHJ)(D.9:UKGH(SS%DKEJ44%;EE*()( <
MLF+RW\<L9NJ=R7_>U7JM-AW%<503;EO4:8RS#B4J,N2RM*(4\K2VPR^P &VV
MT))4'0D*<43?M%)->@S'604V))<!PQZOJ3TWUC3+&NT;!>RW$A189P[(4I)*
M)A1A],@$@@YE$H!*QEL3X@Y8L3'KR.DMY$-2;2O1"Y?J?P8%<BI9'8%#0,N.
MVL;*=^=@:_EW[<H.*<+S*A:B"6)-B2QL>=NFCEB"XTRAPG^,M% ) FX5/DI2
M9>8B3* 2D*0%. JR0 +.; ,UQ#:,BTF[L7250+KI$J*Y)4MJ-4F0A^C/^B>T
MJA.MH+CBR=:"]-K5]*R#XY;DOA69(J&,I.7,!H&9N3$;<O(.[;1X9^*+!,<P
M<XE35<R7.3+4I*4$RUI ?PC*H%+\AS:[@%N-0GUB\Y*%UIAZFT>,XIRC49Q9
M2)C[*0I52G?4IMOOT%QX[@3I6O33W>.7[@N"2Y"^\F2Y>4$$ I#!M@"  Q+D
M :_^Q;7GC_M7Q'CN>N5)GU29224I*ITQ(4%'4CO"X)<N;];!E1P_A'(/4=DN
MTL,XLMY5T7S=]1;IU.@-E\1HD9U8^?N"L5!L*73:+16$./3)7<A*W5-Q0YZB
M@A5PXE6R)-(L&<V0'( ;)\))8 AM [ 6%[7.'D8)65%1WLU 6G,GQ$YLW-@0
MI[L+ZFVKM]%/X='27&Z)NEW'F 4UQRX*I;[E7K5Q5)06F&NX[ED&JUZ/2TK
M<73XM2==9@O/ ..,-]ZU*4O9PM75:)]4IA<DL6V!40IR'N''K>[/DS#91D4J
M)2@'2D"P8 V?['1KNP%Q#].>>/=%N^@+ !\_L" 3H[U^V]:W]N<2LIT 8@@D
M_P!B(*0I@20'!<=(UM/[0M1'(>*L-7NF&J0BFWE4;61/[])CNUBEO36XKB!K
M0?-+>"GU_2D(VKQKF0N!YHE3)K%(*0D^)RY*\H=F>P9(MN3J8POVL8?,K54<
MU*242Q-19FRY$$#Q;NZM=#E:P;56M"X%LFIN;4"8(BH7HCM5WI5X.]'2DG]C
MLD#9',F3@5)F3%6"D95@%P!<G=]]#TTC&. 87WLXH4H).8,V4;A(V86)/F2X
MM'CW!<+FU[=*@0HD$GSK0\C>_;R1]B/;?GE,* 2!G-R=&_;8G3S?F^2).# H
M8K8 !E#*39QR)L.E]-Q";-UIQFKQI =_]99UW*T \@H(\'>NT@*]B0G[??ME
M)2DV)\RU[A_3KRL8HW$6$S9M N2,ZT(2$N!=D'4-:X&M]3KNZK'5K&[[4FRC
M'6\N+6G&/4;20HH1&B%*>_15K:BH@?=7[CE1DLD]XX*AX<I=F%P[,06/EIU,
M:^8U-.#U,J7X@9RA+R$#*0I9#@ NY+L]K#2S/8^!O;4ZY/BA4@PHBZA%QM9N
M2ZO6)*/X;-&C2H4JV&BX .V27:C*0TE6R0IP@>3RR.,:XKHILGNY>7O4 75F
M%U -=B;GF YY1L;V68=*69=4912H2DK"@]R4A0=R2 0--?(:[YA894'5]HWL
M$@I2.Y2?8DE/</ \@'6C[>.8C0PS)"0+O8G['_6NEXSZWCS[L1<)N_.S\[N_
M6(-NLKI?S%E#J<I5V6=;1J-EU*#:L>?5C(C-T^*8<QY=0$DI493O8D(4 T$?
MQ D*/;O>1<)Q:GDX5^75D*^[()*E!9!.MO,7;=[$ QJCVI]F^.X[Q[28Q0(G
M)I45,HF9+1*[M"4("25%0) <$.00 P9KQ-';=*=@T6 E947&HK25DH;'JJ2-
M;7VI^HIT$@@I/: /QJR:F;FGS"+I*G%R=AH[,.8\]8V>P^0).'TLM@J8F5E4
MI2$A1()N2SG0#5V;32/;=ALNH:2_&8=2H/!2'F4. )6D^HDA:22EWO7WI]E
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MXM2TYE@Y4J45)#+) L;A@'^F4.'.U3C;#,#IZ7"L"E2Z>33R1*,BCFD3$I2
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M2FNQ$AUI(<=8BT)N4:G*F>D6&PPTVHI4L%59PB7,FU#RR62 [-N7LXU+,=P
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MWY_"-PE^4X>D5"J<J6EBGO ^C!+FSG*YS$AR]GC'DPW$0VTH:0I!"RG8&P'
MD*((^H=P'=Y)2"I12D;.[$6E--*.28HO_F)40"ZF2SBP "1UN0]X^C$_AZJQ
M+#J="Y23)F2S+7*4A&4!\SAQF.K%R02 0(R'&-Z55K+EJV.7RN)&H-=J+0!)
M3^G.OM%U_9^G0FK+97OP ->=\RYP95S:JASE*!W:;J3OH+N[WT;RY/\ &?\
M%'P348+QC5K_ "W=4N=8EJ3*2 25J.K979+:"Y)OK#_8-P,LI$92^\ITCU%#
M?:4JT27""2-#?E0\>-Z3XO"G2F?,4%#X23H&/F&9CI87<B[D#17&:FIDU$V2
MBJF)E,H!DH&;8I*DH#.7!#C5P=X;YU35EB5;-MP9#3+DV?4I+J5("%*B-0FW
M%I2P//H^NE([@  L$JT5 $]=72R0H3%@HNY LVNFFNEB7<ABY;)'9M58B2)
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M*O'CABF)IF4<Y"P4E"5*LE0=PS N'UTY7L8\G"Z556-4AERTSGGRTADL2HJ
M=[DD@:, Y!O&WC:M,70[1M^@A,81*50X-**0L)0J'!BHC*<[0-G:4*))\'>_
M8^<'S9J/S$]:5*&116"!<'5PW(_#MH#UW^PV34)H*.294E2<DN4H[* "4E@3
M\)W?GN"!$6_6WT0?WS8EY6Q72HK=_!#DFK4!I'9$O.#'9"VBQ'0@B/<4;L/R
MKB%I^;4E+3RD!3:DWGPUQ%.0%)JB9B !D*G+&[%3DL#SZ V OKIVN=C=)CH&
M(X7(1*Q,35+FRY80E,X$#QRP$D=ZEB3E(S@K(\;!2G=!] RJ<;(AYGM1%/6Q
M,]*W#7:0W"N!=$998[(U;B.*>]-UISU41EI<4LL-H2[W*))H_$F*SJB?..'3
M"E8G+"M4H#%0(278A]"G4 *O>+I[)>'\7H\,-#Q!ADM2*;+*I9JI6>=,D2TI
M2.\\+E(2$E)4Y"BI/PI!B12GV_28SGK0J'3XSJ=]KL9A#)[23K:@ 3[_ )T/
M<:T0;674XLN7DF+2IW!_R%P!YG4N;\^H,9FDX?ATB852J.3*6"W@EA)OMH#8
M$WV/*,DD(>]% ;*$+0I/\Q';VC14-#PKQO0.@=:T-^>U&<(\9 4U]QJ"Q/*Q
MO_4>F8%&Z+-H+Z7Y=&]M&F3_ &EJQLLTS*6 \J/5JNSL-U2UJW:5(I@898H5
MGWTU.I\B7&8>B%+GZI>$0*E*D3GTEN)%7%BC?<D7YP?*E5,R8$E)4EB4E0 (
MNVK$L0;WOZ/9'$O?H2F>_P#@2"21<@@.72+N^C;'UC7WQ'FB^[&GR*+;#%/<
M_7G8SL]BM1)TNGH7'[-R6UT]]#OKK0D(;?42X2OM*"E6Q=F,UR*&E6HDI(&B
M07WT2W34#3<O%N<+]F5-VL8G3R*H*3F6%3"A24N-VSI4_P 1^)CIY%WTS+U[
MWPTQ3JK6F*-"2"V]"H,-^EK<"D^6I+KZW5O(4GZ5A9VON4=)[@$X@Q#BBH7+
MF)DYRS@!2"Y9^9?G]!UCZC=@'X3>S/A250FNIC6U4M*U+34F64J7-F+F)_0+
M#.G+T9F8/@]3HKS#CBX4<NL*3W.*&E  J]UZ'DJ4>]1^^SY\>;5-?45%YJP%
MDV2"Q<[$*)]=1]8W'JN#*/!Z:9(P'"Y,NE5+ 7D "4H39(<"USY;7U+0<R.H
MI%:@S6%I1*FA4=R"I.G)2F]H[P"//H>?IV3VZ(\>>9BX'FS4TJUS/@0E)4=2
MS[ '0G8ON=(^47XKJ"5AV(2B4I0I2IQ6RDDBZ"^7J6=_0C?R+:JIC-+=6\ ^
M4AYY[?\ (4'N2!Y^W\J@G1 \'[<R30H(E35%F6Y3<'4C+;J+@-\S&CJZ%-75
M2EY<TLD6%R7N24ASO?740M]KNFIAN>5>HY+6)25'7\WW6@J]MI420/W'WY@;
MCNI'YY2"3F$U05JSA1#;/< N-1?2/J#^&_#D4_"U/W4IDJ"!\)?5'($@D!CJ
M3>VL+;!I[4B$L**TK0"4]J04D: 202#KR"-;'@#_ !LRLJRA,M'Q=XE@2^KM
M<:"Q>[ZEG=H^A^!X5)JL+E]XE29B)8-DAB,O474[[N6V9H2^HRG[6S-AFI4X
M,(>F5>HT.>^I.B_29B ZY#*O 2REP^IZ9V5.(;(\@\S/V>I6,-F9LMTA@DZ#
MDVIUZZCS'S5_'7P;A])A,K$Z=(-1,FS'46 RIDS%*8L'5F*2D.[. Y$/KJD2
M33I:WVW%OT]Y2T_PP=,K(( <4=#L2HZ.]GLV#L@ZO^@7+[U256\5F3I<!G!V
M\WL=1K\6*W DS*,UDT$3)D\E"00ZLRW!*4CPVU<$\W\1+5\ZU>77KCM>B48R
M:E/4TB%!ID.&:A.G5ZI=K+4>&R@EQQTM2$.16V@7%N%(0E0&N>'B&I1("BE0
M! .YU+!@ 39@#H"P;6XRCV:82M,Q ,HOG# OL;.3J79R"0"2#HQVO?@]_"KI
MO3!;]&ZA,WTR%4>H.\J8V[;E)>*'VL76Q58K,ANGA,D=[EXU!IUY59JAVN.R
M$4YEM&E\Q3B>+3YQ5)0298)#CPY@Y<.]Q=BQOIHXC:##L*ER<DQ22%E(5J"Q
MOLP9Q<%K* +?#&P.W'2TGL;0AMM(TA*?8 DJ/Y.R22K\D[V>6^L$D$"^YWVW
MBX-@.7^OX$=P3HC_ !WY_;0^P_V3SBE)!!(^HY0BOG;"..T;*@-*(T3]]<.=
M'MRB&#NU^<=#L5A[_P UAMT>0>](.M[]M@ZV?QH_Z\D$AV)'E^[$0)-K.!?7
M0]/F?K'!B,*;])339;[5)[" 4]JO<=O: 1]M>VOW\\9E N"0K5[O]X@AQE*0
M4D,;[>3?;YPD&0.G?!64&2C(F'\<7QV,.--?WEL^@U9U*%@@I;?F0776B?LM
MM25H.E-J0H CO16U<IN[GS!?92AK9]2S;\]^4=7Y:1_^M/FP?>_FQ8<K,T14
MY5^!+\/_ "1%99H%@7#BNILU,RI-=Q[=E4CSG$.F0IZD2857>J=);IR5.-E"
M8\=,I)"!MOM 3[Y/$-9)5XE%;&Y.9O(L&).Q%RPT+QX:K Y%0"2/C=5LKEV9
M@X+!V;;4O:(Q\F?V7.!7[H?F6!U;5&AVG*G-#]$N+&[%:JL6G A;S+M=;NVG
M*G2/324MK1#AE*UH5VZ1]5<E\8GNE#N\ITS9WN1Y.G5K\SL(H<SA&F$Q)*7L
M/TY6#J;4W((>Q =N<;(W25TW8\Z1<+6;@7%],;IEI6#3?D8\Q:G7)-7J3Z@]
M4ZW5E.+=4[6*U-+\V4E4B0J$E;,9+A2A.[5K:V=7U)GS"6(9G=MQL-'^9/,@
M7+24DFBD"5+&A!-@'WYVMH!X7#7,.PYYH]D<$ ZV ='8W]C^1Q".>(0<0@XA
M!Q"#B$'$(X(!]QO[^>&?[PBE2$%)':G7D^P]]>^O&^&%K::=/+E#SBS3#:2"
MEMIE+:MJ6D-I'<3Y.T^WD[V/(/CVUR7.I4<VQ_V[QQO;3+^VH8:-_;"+I#;8
M ^E)V-?R@#0UXT/ 'CV]OM[<B)"1:P<;LT<A"$*^E*05#S]M_P!1KW^P\^?;
MG$J U^T223UUU/\ >N_[QY\RF1);2VY,:.\V3W%+S+3B5$>$J(*- @$^1HD;
M"B=G?),R:&R**0Q8N7'HXL^G3SCK7)DS TV6E:;6(#6+[@[^S"(7]TVX+R1%
MG-7CBRR:Q*J,<,/S7*+3H]76T"I*2U5$,(E,;.R%-O(5M2MGR3SURJ^MDL43
M5,+,5'+]G+:Z_.*=681AE6@RYM.@N 0R0%:WY@#;0@ZL-F:WA\+OIRK:X\JS
MX5P6(\TAPO,T:IKD07'2--&2Q6)$[U4I5I13"+"2 0I0)!%3I\=J)*GF**@;
M_&?DW36YUUBR,8[,,'JDD2 J22+&6E+ G0D*(+G<!086L+PW&X_A873&@NBV
MK]I]9?2I:FFZA3%TH>"HE*'&9L\CN'@DI2E7OL#EQT?%=./_ "!S=R[NQV9)
M + !_4QBS%^Q*MGRYGY6L2NPLI)00PN+K.;F 0 #9^2G])?0Q<5BWFU?.4S2
MP_;A*K6H\)Q$@0Y@#K3L]R0\H*=6M*SZ#7DM*6H@G8[?%C'$,NI29<H .JY!
MU=-GMY&S;<HKG9]V6KP6=*G5K&9(45(9*<V?.0E3@FP9*K 9K:!P9=8:8Q ;
M0V@);1Z;9T#I!V -$?CP=_Z<LI1#J4S.75;5SZ<]>7I&PW=&2A" X"; /H0!
M<#7UZ]8N5Q(P24K;0M)UI"P"@$;(4$J"@% GN2?!!!T1L[Y)61=*B.H)'2.I
M0S:@*O\ JNS:'?D(!$8)"W&V=_3VZ0DDZ'T_5K?CR-C6_/MO@WO<G4_N=/+R
MB4*5+! 44"[ $@-RY'30A[#E%TTV&P>T["CL#6@D:UH?MO9_;>N#M9F'SZQ"
M4L2HG,3O[YQRXGO24^//@[_'G?\ L>>=<Q)4D@1RMN''+G#2NK?IDQUU=8*O
M+"62*:S,H-?B?,4Z;VE4ZV[E@)DJHMQTU(?8<$FDSU1Y:?3>:]4(++A6VK0]
MF&54[#)PF)6Q! )!RV<$AWW 8:BY+C4TW&,/364*I1<$NI)9TCP6.K,2HA0
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ME6KM3AAF!4R7/0 EBP-Q=0.PTNS.6 +[#$=7Q!BV.$SL4J%SE2\Q*9BEJ/C
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M*UJG)F)2 /"@(RN2V66<P4^A;2W*+-J> J&HFB8JK5*2DDA$N6E&:U@K*0%
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MAQX%20XID[^_6)]Z6]]'C';OZPL[8-ZM<Q6Q4:?;5Z9+RBKH%PO8]G2\@W1
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M[:DU*WG+&IESW-7J@[:5>HL2RGH#-0K#3T)HLN/?RARMO\M;^^<=%2ZG^KG
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70@XA!Q"#B$'$(.(0<0@XA!Q"#B$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g389734g99c02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389734g99c02.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ ]0&& P$1  (1 0,1 ?_$ !\  0 " @,  P$            &!P@)! 4*
M @,+ ?_$ %(0  (" @(!  8#"0L(" 8#  0% P8"!P !" D1$A,4%19WMA<A
M-CA6=I6UU"(U-SE3='63LK32&2,Q5)*6M]$8&E%55WB7UB0E)C*4UT%A<?_$
M !T! 0 !! ,!               ! @8'" 0%"0/_Q !6$0 ! P, !@0&#08*
M"04!   !  (#! 41!A(A,4%1!Q-Q\!1A@9&QM @B,C4V-W1U=J&UP=$5%C-S
ML^$8(S1"4U22E++Q%U)55I.5TM35)&*6PM-D_]H # ,!  (1 Q$ /P#W\<(G
M")PB<(G")PBU:^D:\EMT^)5E\=-V5"PP?]'JHV@UEYA4LRN(VG<^C6ERU?JT
M[8Z1QDMSM2=IJ=UME9?&L"MK"L95I"TZ9CX#"D23%4T Y!WX]J?&.'E&P>/"
MQOIGI+-@4SR6\Q$FX9V5GHH&\_ W2OBUK-%505<J<WS"U\?<U,]R:I*N]OA)
M^"@6!U88>HK68$TB8UNKU\XDI2-@4ZN0,;\.)SXOP'G^I7_AZ5"M0[*UYJU]
MH795*MFQ$YF,-=NC2OJ[?3;H)XKO/*O.J['JJW-V718<:]5[+1?B; 2)9S;<
MGF:(:0[U].-=)2C5.">7FQG&_MX<CE69X.^D&0>;&=O'5ZKLVN3:SI'Q=W^&
M,W?)K%VZH?E;3+C;:/#C(JC&Z!L2F2A6-<[5YXD#8QY)C1F,DIYB]7(&2!D#
M) R=PSQ/B'%4RYC8]V"_5#_:L&7N+!DM:#C+G; T9VG9E7OHVV7S<&K:1M$R
MU_(2+6R>,&5;#4I)E:U'@Y>)0T"XDM;*TB<*^A%\I#)B6?@6S@90R+8!2QQU
MW=76GI+=7U5"VGZUM.R)C)G22B1\ICBE=,]K7B,QR:SP(V-;JQEA#W.:YS\9
M:#7:_:8Z+632F6[> 27:IKJBIML-)0R4M-0MK*ZBAM]/)-3.JFUE+U-.^6IJ
M)IVRU4=3&ZF9%-''3X[&>1>VP-/6< ]L&/MS7]YH@=BL."%;T(SH.P[538ZD
M['5YC3J SGZ"Y_!CX>XDBP+JMASZZ^(@Z]?<MLUO?<H'LC<;=64M6Z&$RO+H
MZNC@J?"(G2!PD<V*6FUW;02VHA_FE8ZFZ1M+:?0VZ05%7#'I?H_?;##<;@V@
MIA#56#2*ZV86FMBI71/I(9Z^WWKJ(QU;F-FM5Q</XR,:UYLGVSH/(15JR#89
M6"ASJZY[#BS[KM4S^%/6[!3K42KO+M'V3(K@0,?EK+OLCX\PCWK <T23N&.'
MJF0T)L[Z\T;>LCKZ:C(ZZH]LQ]'))+)^EU1(9F:[-FHUN&%KADF^JJX:3LZ0
MZ316/2&5M'6Z+7K2)KC;K23%44VD%'34%*2:$R.I8Z"H\&J?XSPB:37J(YX7
M%C6=GNW=SK7(6W"D*G!B5JO4:._=#$19R0-FES>VM"FQ)]WW@1BHKW5//:..
MA)892X"HX\3!.A)?>T6NUQ5KK>V:0L;7W&6DU@0#''314\TI;G+3)-X2R.+6
M!#2TDL=K-QR=-].*W1R'2^6WTC:F7171"AT@$4C'.CJZJ]5]VH*(2ZI;(*2W
M"S5%76")['31RM:V:+J7ZW=O[JUU@@JEOLMK-MZY[%4ZEVHP3J()&%UNU@K*
M=,[!+1JX" T0WQ[*1D)\,W)^$D&R C-/BB%,^45-'735%-!3LIY(345'6&20
MZE-2PSR21/;+(6NE=J,#':T;=8$/+&$N;SKA>ZO1>WVF\7.[3W>GKVVFT>!B
MCI(S47N]W"V4=%6P34-(R2&@BZ^J=4Q&.LDZET1IVS5#&13Q3#RA@PM 598:
MZLJ<B5SJ-"Q^;$P 'J6&X"[(J28$J21HRLHP'%:)C,S]K#N162,T@QRDR^7]
M\@V(]0Z=E9!(!%<9F=6TO9(RW-@?*1(UQ:"^.=I:,'$C71NP!KKJATHQMND-
MLJ-'+G1R.K=$:"H\+ECIYZ2ITQFN5)0B6DEB;*6P5ELE;,[+2ZEDBJHVEQ\'
M77T'R2M%I!UQ 1KF-C8=DP[(<@!H+,% $J04'8 -6.S/(?C*\9"A5C88SKL;
M//MI, 1W' OR-B%%KJ[+3P/K2VM+(:(T4;W30.+I):ND?.S4;$Z0@.?&YI#@
M.K#Q[9X87.X^C_25<[K!HW&_1QM3<=)6:25L$-!<X(X:2WZ/Z006J=T\EPCI
M0^6*FJXY1U9)JGT\A;'3F9L470L?)\NSDU0&HA$UPW':6A%;_HB1,^"95#;9
M]@%E70GCX%!?,A>Z\Q&/*1E&@CDQ#YJG["*2?J/[,L38!4.J'-F9X!=I(=42
MQ.94VYD+@\L<6NU'==&YC96M>YI/61,(&>OJ>E&:YRVFGM$$ENF&E6@%)<.M
M=15\-59]+ZBX1/IV3QB6 5,1MU3%/+0RS01R,C=2U]0UT@;.-J;1M.K]L4H\
MX[(C4+>%95K6NP5B3FI;1;>[1U3GH1D V#+(8QI6(ZV6(25*)\2]"EBQPF]W
MAWQ*"@@K[?5-8W5N,9?/3O+W!DL%/X/X3$YI<6:S63F9KFM#L1.!.,D=[I7I
M3==%]+;)//.9-$*QE-:[M3-I8I)Z*Z7<W06:N@FCC;4F*:JM;;;-#)*^+K:^
M%S0U^J#7]6\C;16ZWM1]L2'JQFUO<6U*DM6+I4:<=6CU[2,+I*L!PA'R;O#<
MHH& 0TV(K23O#&)@Y,5*Q3V6/,J++!-/;XJ,]2V>VV^H>]XED,DM95&E$CR2
M(XFY+'.!=&,Y9$R21S(U;UJZ1[I;;;I77Z1,%QGMNF.E=IIJ6F?0T<=+0Z.V
M-M[?2TX9'X97S%K*B")XBJG$!E16S4E+%45+9LS\IE4-0O%_1TAZ]J% ZS&?
M,OF2A:4.VP14FQ] 9K2)I"?<D+[I$*(:/V3U*U4,8)H!EN838KBLL+S4TM'-
M510U-7@Q1ZDCVNC,U5!KA[0&Y#Z4N<UVKB.5A#G/#HV]Y4]*E*RSWS2"AL=?
M76>P9BKZGPFDII8ZL4%DN(@--(]TA9)3WML4,\9E#JNCJ8WQQ4Q@K)8Y9O))
MD)>TT*\"<2O5RR^0%8NB:0A#UG8Y]4T!9;%YBYRW[6CIL)YSL<,<S&*\3#UR
M=,9NQ\,9<?M!98W4DKGO#IIH+1/32ALV(1<*M].]KXH]=TI:&'W+'N.S4&3A
M=;<^DFIBOM(RG@DAMULN?2!:[U1.DH,W*3131^FNU/+35M9X-'1-D?.&@S5%
M/$TZPJ']6 \2,?R>Q;&*T]:UZVL-@;7B^T$19 \6+(2'5&IPEYRG%8.X5T.2
MQND,BQ&*,C SA-]<>4$PN6!F?Q=8^K:^2>LCAACI*2L<\Q/>1'55+J75<R(O
M.O'*TZS6%X+-H((+5V4?2@*N:EH[9H]5W&XU=\O^C\5+'74M*R2ML5FAOI?%
M4US*9AIJRBF8V*69M.YD_M2Q\1$QRJZ[[[ZZ[[Z[Z[[ZZ[[Z[]7??7?_ &=^
MKOOKU]?Z/O=]]?\ 9WWSH%E8;MV/%R\2_O")PB<(G")PB<(G"* ;7(*$U=L@
MP TQ8<'0[<8"Q7%2A'@&"(&! I@9<&6$HY(L\<<T,N&7KQDPQ[[Z[Q]?79%Y
MNKCYC^9-4T#AHFU[0NR_>?C/Z0GQXT;N7=T:1,H:[LT1Y![HUZ5I$^$N)%%7
M12-BZ+V8SAN,],P'?5>SZW'DG(4QV8*1@7T &<X!!:XXY$-.>1'MALX8._8M
M@"KTI;AW/<#@-$1IZ"I\EW?BM6+K9]E*QCV&RJGY*K_'=VDGU[ M)V#8;:>"
MP@VG5Z534[UFV1=XUUBP4MR!#BBI+<8V_P W6V9.\9_ 'D3XE0F/IN+"92]7
M[#6^,R7*L7#QY\=?(*VPF[F.A>UY?NWS+$\.7-9K@@^JB5]G+J[XV&Z+&C)G
M587R?J1:4$E-QQES*=3;C.W;PY-SS[^/<=DWD[>-@U>^T]51W;0#IKI_?-@F
M!#/"$@R>4E$D/K+G/IC#.))FD*8EER!3=8!-\.L V>! ^$6,=SV*EHYZ2I?5
M11OZNXVF$/<QSG=552RLGB&H0X"5K&M#QET9)<S!))P=TGWS2&UW^STEBKJJ
MG\+T.T]N#X(9X8HS7V2AHJBV5CA4LDA<ZBEJ9970O AJVXAJA)&U@9SM2;(L
MNVKVX2M[.U7H5&C]/V^J'K L:L5:V-]5,3;%L&0">,COW2IB".J$0%]L*V#-
M(1&>"RSEBSQHN-%!;Z6.6."-\LETN5/4,D=X0VG922,9#1AX+=KV.=(Z9NI,
M\!I:Y@!"^^B.DMSTMOM915=TJJ>@H]!]#KQ::BE@;:IKM4W^DJ9[CI"ZGD;)
M[2EJ8(Z2&WR^$6V![I&U$%2YS'#Y&.;]5-Q+J =;[!:JWN76JK"@V0?+"+"O
M76I3 PWYD%VNPR#AB;5AA%?PNV9!(79JPE"K[P"+[$)-BI*BVOJV4T,$]LK9
M#5PN!)FI:@/-(Q^O[8F.=AHW=6UKPU[9I,O;KB9JV_VG3*FT?GO%PNMMTTT9
MI&Z/W*,M8VW7NT/@9I!4PFF!A8VKM<[=(8/"I98#-32V^EU8)3#+);AMMY4M
MZZW3S9R]:LL93;5;(J9<?U /LUD"LL-3/^D$D&8!\1F )U.B"B.[+&=SL?CH
M,LL8LXOA36^*IM5;( /#X6QU[&A[,NH6.DAJ&=2"'L+"]E27%FJZ(,U"!D'M
M+QI=76C3K1JC>YXT5N4M9HI4ROIJCJX])ZF"EN-IJ/R@Z-T$[9FP3V=D+9S+
M'7/J3.PD-<V6;)N+D6POZLNG)60*=*W:_P"+$7/N(DAT*1 J31P3==?N8E/7
MQQQ<'JRZG)+4Y2>S#!)$3QZ*FB,,-0\-D,ESI:34<,M$1:9)2X<Y/:,:=F&M
MD VD$=MI+>:V*X7"UTTDE+'2:%7O2 5,1U9)*V*1E)1-C?C8RDQ//,S;UDLM
M(789&YDN)&L_):YU5<L-OS%K99+#IWQWM*=09@%-!.TV59XZ4_NY=E$&QS1@
M9.#8,R*F9#ECZ@>IDF0<!DV,5Q5UDIJA[V4C(X.IN5XIY)&ZP<&44!JH:5L#
MG8E=U;2&U##GVY$NL6#.(M&>DR\VJEI9K_4U5R?<=#NCJZT=',V%\;ZK26Z-
MLEPODMRAC#J*!U;.QTEIF81_$=90NA9,]K+AN_DW;*PFMD)FO/HI9E.N;A:$
M^3X^=PB8V*H5.QV1N@';5T(Q7\T5PIPSI*^X9(6YB-AVSCPA^'R&DZVEL=//
M)3EM9X1!)6TT$HB:(IF0U%1#!'*8YG-?J2&1S1-$R6-LK-0YUM87C?.DZ[6N
MBN[)M'OR5<Z31N\76B-?/)64%3<;1:;C<JN@CJ[;#-2&JI64<-0^W5=505DU
M#4>$M#.K+#)]H;&N:>CZ%E#+C6S;,V3K*GWBRKL8INDJ>QCD$->P2)A<8%Q;
MI@*-78&,@D?2V9KET'\.S[7S1_"@HJ:6JNP<PO%#15U12P/)!DDA(;'K@'6>
MV)CG3.8#[<1^VRS7![32C22\T5CT!?#,RF?I-I+HQ9[Y<Z<,>**CN,<DE48)
M'Q".FFK:B*.W1U+HFBF?5$0]74^#O;RMD;6FTJR+!'S/O';2L[$OL"QPWB&@
MJ:75E.!?MD.#C !@R*-LTQD$ZG)[\22+B2R*S.(6K@%?*:*WBYL:XAE+U<]'
M2.DCC+C425]2^&.8QE[&-; &D2=3JM=JQM#&O>^1?7232M^A-3-!&ZHOAJK7
MI'?XZ6LK&QQVFBT5LT%?5T#:QM/454LUS?/')2&OZV2(2U,IGDIJ:GI5$F?E
M#:8*[M2Z+-;*2:MK M2$1DRN9JJP,R+ DU]84\7:?&GFC+\N@+J3 Q]XT([%
M-5X1QXS1E99P<B.Q0.FH*5];(VHKFR. 93-DA8(9:R&4B7PAKG@/I6N9B,:S
M)"201MZBJZ4;K';M*KU2Z-4DMJT7EI(9#57J>EN%3)<*#1ZY4;31BSSQ4Y%/
M>Y8ZD.JI#%/2M:T/;*7,[1]Y)V6I,KVLL.LL2"-6UH>U7OZ,VF-E"*F:*[^X
M4,$LKA-796P\D-21+BH_@QRL&UF-ACAR@K6<SFB*RP5$=+)#7%HKIC!2=?3E
MA=+&^CCE9*(I9A&0ZHF>TZQ;U<#279FQ%RZ_I)N=IJK]2W'1@22:+6V.ZWW\
MF79M2V*BJJ32&LHZBB=64=N?5QN9:*"FE;U,<K:NYSM;&66POK>GN?D;<Z@9
M1V[*M5["JMJ'MG9!T*1_F[.L"&B4BI6=3$I,R5BQ 2L)[5,)U"0/W(5*L%/Z
M*$7F9"R?2FLM-4MJHV3S&>.KM]$PRPB)L,U755$$AD:)'%P:*<.RUQ#6O<S5
M<]FL.%>ND>]6B:Q5E3;+<+35V'2W22=E#<#73W"@L-CM%SHVTDQI(F0.J'W6
M2+4DCUI74L-0)8J>8Q/ANV?)B[Y:_MB]'5^Z=9_N17;:"NT]V8:46-'7HJ3V
ME:5S 9:=VQ.8&W.'VU+J)7UB(H(FFCG!;@R\Y-OLE+X73OEG\)A_*-+0/@$!
M!,LQJA*R?6>W48QE,2)(]?VT@ (?$\+IM+>DR^_F_=J>AM7Y&NGYH7S2BENI
MN<3XFT-N99#155M;%33FIGJ)KTS-)6MI0(J21[VR05<+EGL#)G*"'+)E[6<@
MH\F>7?J]>6><.&667?J]77W^^^^_O===??\ O<M-XPYPW8<1CE@E9[IW.?!
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MV+-87^TM:NZ4H.L5DL;JR[3['#POUC&['D KQ3K-X?\ OX 9!: T;"=QVXV
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M%F6=20OPR8&J';?=$>8 _?CZ_$I[X,[/WWMK2;&R>1 -%RMRW:NUZC5KIK=
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M=+?!G=3#;M%T7!:6-=VJ15]TL=C5O35CU70VQ++78^YDFNK=;:M6_@&OT*V
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M>1&/CL32P*[5I,X)%-1L-9U^TJC#:K]=5D/=N1V>VV'.L_=$(A[*O([<%OE
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ME)_9L7K3T&_%+H-\S#UJI65W.@65TX1.$3A$X1.$3A$X1.$6E[TCNV_&2R[
MHNK'=Z\8W&T:C7-GRF![;WOXETH+5!I,^JYP\G:S>^L-UMA+BZ^+6,4-<$K*
M!19ZJNM6%OE<KHE 4<9',*H []N-FX'?MY$<B-_%;0?'H84/06CA 2\#PA=/
MZT&#.B?IK7&:+!2TL0Y<=IKJQ)7[)@1#CA-@_1)E"9QCGTQ6+  B8!(I4'><
M\U<'"A.$3A%%:1^":+^8X?V\^2[>>T^E4L]R/+Z2I5R%4G"*J=[_ ,!^Y?JI
MV)]D''.?:O?2V_+Z/UB-6GI[\!=-/HGI']CUB\9O-D5XUIPB<(O1EZ(3\6^\
M_7=8?L'KCF&^D/WZI?FN#UNM7HO[$/XM[Y]-[C]@Z-K:MRPUM2G")PB<(G")
MPB<(G")PB<(G")PB<(M.?F^RLJWR=6KTKHK'"W:9H*R,!/Y8^0GCY)7YEUWV
MWC,_N:O2'C5MNI85IG\Y$!16S>^Q:#42F:MXB1S"QC6D_LJAC!.[QX!SR&TC
MQ[LE9F>7D6Q)HO'C#5 6M6-_Z\A I:Z%ME)>W=-R*@TWN>?,TGJ@@&FJCDL,
M<CY<[<R+DBXA7CGB?B]S1B%E X]GWCOL]&5R/'ZH^12_9^W+OY#1>/L32TTK
M3Z!!WHW.\]$3PT]SN MB1<8;O'B3WEWC;5@U?+#SDPGB%:C3^ST#!UPF=F/&
M3Y\?@LN.%"<(HKW^&^/YJY?K?#D\#VCT.4<1V'TM4JY"E.$3A%I0],I^\>@/
MZ5V1_=*7S)G1O^ENWZNC_P 52M*?9D?R+H_^5:2?L;(M$W,J+15.$3A%ZVO!
MK\4K1?YEQ_K-CS7[2GX077Y2?V;%ZT]!OQ2Z#?,P]:J5E=SH%E=.$3A$X1.$
M3A$X1.$3A%C%O:F;8F9)[;I:JTJWMX$%Y1N*;<]K6G3-::MK8/5@TMT</:5K
M38[5VQJHJ$Q>''*O".5@N2F*0_YJ&%!D4C''T9_#T^3E<^M4=EK&N:!6KH\
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@1(%1P#A1I\B"Q92R89SS_5A-PA.>_C)^]7;PH3A%_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
